{
  "file_name": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
  "total_pages": 80,
  "pdf_type": "normal",
  "font_analysis": {
    "font_sizes_frequency": {
      "14.028532981872559": 1,
      "21.333560943603516": 4,
      "21.94206428527832": 1,
      "8.992650032043457": 2,
      "17.02608299255371": 1,
      "15.0": 2,
      "9.960000038146973": 517,
      "17.03999900817871": 1,
      "11.039999961853027": 1121,
      "8.039999961853027": 643,
      "12.0": 35,
      "18.0": 5,
      "12.960000038146973": 27,
      "14.039999961853027": 3,
      "21.959999084472656": 10,
      "12.72218132019043": 9,
      "12.829745292663574": 9,
      "11.879393577575684": 53,
      "8.759956359863281": 74,
      "17.758378982543945": 4,
      "9.725613594055176": 17,
      "9.840714454650879": 18,
      "15.719986915588379": 1,
      "13.799982070922852": 48,
      "10.797332763671875": 39,
      "5.159999847412109": 4,
      "8.519999504089355": 8,
      "9.0": 57,
      "12.839439392089844": 2,
      "5.759999752044678": 2,
      "9.719964981079102": 11,
      "15.718777656555176": 3
    },
    "heading_sizes": [
      21.959999084472656,
      21.333560943603516,
      18.0,
      17.758378982543945,
      15.718777656555176,
      15.0,
      14.039999961853027,
      13.799982070922852,
      12.960000038146973,
      12.839439392089844,
      12.829745292663574,
      12.72218132019043,
      12.0,
      11.879393577575684
    ]
  },
  "table_analysis": {
    "total_tables": 9,
    "tables_info": [
      {
        "bbox": [
          118.19999694824219,
          345.3599853515625,
          461.7582092285156,
          491.4903259277344
        ],
        "num_rows": 4,
        "num_cols": 2
      },
      {
        "bbox": [
          125.04000091552734,
          248.64942932128906,
          488.10614013671875,
          571.1032104492188
        ],
        "num_rows": 9,
        "num_cols": 2
      },
      {
        "bbox": [
          121.79999542236328,
          206.8184814453125,
          473.0145263671875,
          603.178466796875
        ],
        "num_rows": 10,
        "num_cols": 2
      },
      {
        "bbox": [
          130.44000244140625,
          576.6903686523438,
          481.3980712890625,
          618.6903076171875
        ],
        "num_rows": 3,
        "num_cols": 3
      },
      {
        "bbox": [
          159.47999572753906,
          542.6103515625,
          470.0706787109375,
          641.698486328125
        ],
        "num_rows": 5,
        "num_cols": 4
      },
      {
        "bbox": [
          159.47999572753906,
          406.61846923828125,
          466.9274597167969,
          483.9303283691406
        ],
        "num_rows": 3,
        "num_cols": 3
      },
      {
        "bbox": [
          114.36000061035156,
          276.9303283691406,
          474.9179992675781,
          526.1703491210938
        ],
        "num_rows": 8,
        "num_cols": 2
      },
      {
        "bbox": [
          118.68000030517578,
          210.9303436279297,
          483.1668395996094,
          631.1703491210938
        ],
        "num_rows": 10,
        "num_cols": 2
      },
      {
        "bbox": [
          120.23999786376953,
          219.33033752441406,
          483.1668395996094,
          413.4903259277344
        ],
        "num_rows": 6,
        "num_cols": 2
      }
    ]
  },
  "text_blocks": [
    {
      "text": "체외진단용 의료기기",
      "font_size": 14.028532981872559,
      "font_name": "H2hdrM",
      "bbox": [
        110.46013641357422,
        204.4446563720703,
        243.94769287109375,
        218.46932983398438
      ],
      "page_num": 1,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단용 의료기기 중",
      "font_size": 21.333560943603516,
      "font_name": "H2hdrM",
      "bbox": [
        166.34983825683594,
        324.81866455078125,
        435.8717346191406,
        345.7957458496094
      ],
      "page_num": 1,
      "block_type": "heading",
      "level": 2,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "뇌나트륨이뇨펩티드 검사제품의",
      "font_size": 21.333560943603516,
      "font_name": "H2hdrM",
      "bbox": [
        137.80531311035156,
        358.3819885253906,
        464.41717529296875,
        379.35906982421875
      ],
      "page_num": 1,
      "block_type": "heading",
      "level": 2,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "허가․심사 가이드라인",
      "font_size": 21.333560943603516,
      "font_name": "H2hdrM",
      "bbox": [
        180.50216674804688,
        391.9453125,
        414.24322509765625,
        412.9223937988281
      ],
      "page_num": 1,
      "block_type": "heading",
      "level": 2,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[민원인 안내서]",
      "font_size": 21.333560943603516,
      "font_name": "H2hdrM",
      "bbox": [
        210.36598205566406,
        425.50860595703125,
        384.6604309082031,
        446.4856872558594
      ],
      "page_num": 1,
      "block_type": "heading",
      "level": 2,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2018. 7.",
      "font_size": 21.94206428527832,
      "font_name": "H2hdrM",
      "bbox": [
        255.34161376953125,
        538.920654296875,
        339.5438232421875,
        560.856689453125
      ],
      "page_num": 1,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발간등록번호",
      "font_size": 8.992650032043457,
      "font_name": "Haansoft Batang",
      "bbox": [
        151.7177734375,
        161.2981414794922,
        205.68850708007812,
        170.28831481933594
      ],
      "page_num": 1,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안내서-0638-02",
      "font_size": 8.992650032043457,
      "font_name": "Haansoft Batang",
      "bbox": [
        142.00303649902344,
        175.9221649169922,
        215.37179565429688,
        184.91233825683594
      ],
      "page_num": 1,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제·개정 이력서",
      "font_size": 17.02608299255371,
      "font_name": "H2gtrE",
      "bbox": [
        233.75331115722656,
        167.58973693847656,
        361.125,
        184.61114501953125
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단용 의료기기 중 뇌나트륨이뇨펩티드",
      "font_size": 15.0,
      "font_name": "T4",
      "bbox": [
        136.8000030517578,
        208.3199920654297,
        457.91998291015625,
        226.3199920654297
      ],
      "page_num": 2,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검사제품 허가․심사 가이드라인 [민원인 안내서]",
      "font_size": 15.0,
      "font_name": "T4",
      "bbox": [
        120.5999984741211,
        232.3199920654297,
        474.07501220703125,
        250.3199920654297
      ],
      "page_num": 2,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제․개정번호",
      "font_size": 9.960000038146973,
      "font_name": "T4",
      "bbox": [
        122.15999603271484,
        279.8399963378906,
        397.7995910644531,
        291.7919921875
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "승인일자",
      "font_size": 9.960000038146973,
      "font_name": "T4",
      "bbox": [
        122.15999603271484,
        279.8399963378906,
        397.7995910644531,
        291.7919921875
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주요 내용",
      "font_size": 9.960000038146973,
      "font_name": "T4",
      "bbox": [
        122.15999603271484,
        279.8399963378906,
        397.7995910644531,
        291.7919921875
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "뇌나트륨이뇨펩티드 검사제품의 허가․심사",
      "font_size": 9.960000038146973,
      "font_name": "T5",
      "bbox": [
        285.7200012207031,
        306.9599914550781,
        462.8398132324219,
        318.9119873046875
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가이드라인 제정",
      "font_size": 9.960000038146973,
      "font_name": "T5",
      "bbox": [
        340.67999267578125,
        323.0400085449219,
        407.88031005859375,
        334.99200439453125
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안내서-0638-01",
      "font_size": 9.960000038146973,
      "font_name": "T6",
      "bbox": [
        118.19999694824219,
        385.44000244140625,
        246.52145385742188,
        397.3919982910156
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2017.5.",
      "font_size": 9.960000038146973,
      "font_name": "T6",
      "bbox": [
        118.19999694824219,
        385.44000244140625,
        246.52145385742188,
        397.3919982910156
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "｢",
      "font_size": 9.960000038146973,
      "font_name": "T7",
      "bbox": [
        315.1199951171875,
        345.3599853515625,
        320.1000061035156,
        357.3119812011719
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "체외진단용 의료기기 중",
      "font_size": 9.960000038146973,
      "font_name": "T6",
      "bbox": [
        320.2799987792969,
        345.3599853515625,
        433.4399719238281,
        357.3119812011719
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "뇌나트륨이뇨펩티드 검사제품 허가․심사",
      "font_size": 9.960000038146973,
      "font_name": "T6",
      "bbox": [
        276.3599853515625,
        361.44000244140625,
        472.07952880859375,
        373.3919982910156
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가이드라인 [민원인 안내서]｣",
      "font_size": 9.960000038146973,
      "font_name": "T7",
      "bbox": [
        307.32000732421875,
        377.3999938964844,
        441.29998779296875,
        389.35198974609375
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "명칭 변경 및 제·개정 점검표 등 추가",
      "font_size": 9.960000038146973,
      "font_name": "T6",
      "bbox": [
        284.7599792480469,
        393.3599853515625,
        463.7995300292969,
        405.3119812011719
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[근거: ｢",
      "font_size": 9.960000038146973,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        409.44000244140625,
        322.6199951171875,
        421.3919982910156
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "식품의약품안전처 지침서등의",
      "font_size": 9.960000038146973,
      "font_name": "T6",
      "bbox": [
        322.79998779296875,
        409.44000244140625,
        461.7582092285156,
        421.3919982910156
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "관리에 관한 규정｣",
      "font_size": 9.960000038146973,
      "font_name": "T7",
      "bbox": [
        298.44000244140625,
        425.3999938964844,
        385.9800109863281,
        437.35198974609375
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "개정, ‘17.5.1]",
      "font_size": 9.960000038146973,
      "font_name": "T6",
      "bbox": [
        391.3199768066406,
        425.3999938964844,
        450.12054443359375,
        437.35198974609375
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안내서-0638-02",
      "font_size": 9.960000038146973,
      "font_name": "T6",
      "bbox": [
        118.19999694824219,
        478.67999267578125,
        249.85411071777344,
        490.6319885253906
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2018.7.",
      "font_size": 9.960000038146973,
      "font_name": "Dotum",
      "bbox": [
        118.19999694824219,
        478.67999267578125,
        249.85411071777344,
        490.6319885253906
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "｢체외진단용 의료기기 중",
      "font_size": 9.960000038146973,
      "font_name": "Dotum",
      "bbox": [
        317.03997802734375,
        449.4903259277344,
        434.84600830078125,
        459.4503173828125
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "뇌나트륨이뇨펩티드 검사제품 허가․심사",
      "font_size": 9.960000038146973,
      "font_name": "Dotum",
      "bbox": [
        283.44000244140625,
        465.5703430175781,
        468.44647216796875,
        475.53033447265625
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가이드라인 [민원인 안내서]｣ 개정",
      "font_size": 9.960000038146973,
      "font_name": "Dotum",
      "bbox": [
        300.7200012207031,
        481.53033447265625,
        447.8401794433594,
        491.4903259277344
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(현재 적용중인 의료기기 허가규정의 개정내용을",
      "font_size": 9.960000038146973,
      "font_name": "Dotum",
      "bbox": [
        278.6399841308594,
        497.4903259277344,
        473.2461242675781,
        507.4503173828125
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "반영)",
      "font_size": 9.960000038146973,
      "font_name": "Dotum",
      "bbox": [
        363.9599914550781,
        510.5703430175781,
        384.614990234375,
        520.5303344726562
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지침서ᆞ안내서 제ᆞ개정 점검표",
      "font_size": 17.03999900817871,
      "font_name": "H2hdrM",
      "bbox": [
        174.36000061035156,
        165.61288452148438,
        429.3607177734375,
        182.6528778076172
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "명칭",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        130.9199981689453,
        202.66429138183594,
        151.3197021484375,
        217.34835815429688
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단용 의료기기 중 뇌나트륨이뇨펩티드 검사제품 허가·심사",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        175.9199981689453,
        193.78428649902344,
        487.1211242675781,
        208.46835327148438
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가이드라인 [민원인 안내서]",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        264.47998046875,
        211.42430114746094,
        394.8037414550781,
        226.10836791992188
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "아래에 해당하는 사항에 체크하여 주시기 바랍니다.",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        171.47999572753906,
        228.9442901611328,
        432.7293701171875,
        243.62835693359375
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등록대상",
      "font_size": 8.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        125.04000091552734,
        348.4894104003906,
        157.0802001953125,
        359.1832580566406
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "여부",
      "font_size": 8.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        133.0800018310547,
        361.20941162109375,
        149.1599884033203,
        371.90325927734375
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의",
      "font_size": 8.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        173.87998962402344,
        248.64942932128906,
        384.7867736816406,
        259.34326171875
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "지침서ㆍ안내서가 있습니까?",
      "font_size": 8.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        191.1599884033203,
        260.6494140625,
        297.6666564941406,
        271.34326171875
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 8.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        426.0,
        249.1294403076172,
        462.0002136230469,
        270.9832763671875
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 8.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        426.0,
        249.1294403076172,
        462.0002136230469,
        270.9832763671875
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적으로",
      "font_size": 8.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        173.87998962402344,
        274.32940673828125,
        488.1063537597656,
        285.02325439453125
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고려하시기 바랍니다. 그럼에도 불구하고 동 지침서ㆍ안내서의 제정이 필요한 경",
      "font_size": 8.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        190.44000244140625,
        286.32940673828125,
        485.2799987792969,
        309.02325439453125
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "우 그 사유를 아래에 기재해 주시기 바랍니다.",
      "font_size": 8.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        190.44000244140625,
        286.32940673828125,
        485.2799987792969,
        309.02325439453125
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(사유 :                                                                 )",
      "font_size": 8.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        173.87998962402344,
        310.32940673828125,
        460.60968017578125,
        321.02325439453125
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 법령(법ㆍ시행령ㆍ시행규칙) 또는 행정규칙(고시ㆍ훈령ㆍ예규)의",
      "font_size": 8.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        173.87998962402344,
        324.0093994140625,
        415.7465515136719,
        334.7032470703125
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "내용을 단순 편집 또는 나열한 것입니까?",
      "font_size": 8.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        191.1599884033203,
        336.0093994140625,
        339.6668395996094,
        346.7032470703125
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 8.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        426.0,
        324.3694152832031,
        462.0002136230469,
        346.2232666015625
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 8.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        426.0,
        324.3694152832031,
        462.0002136230469,
        346.2232666015625
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?",
      "font_size": 8.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        173.87998962402344,
        349.56939697265625,
        462.0002136230469,
        371.54327392578125
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 8.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        173.87998962402344,
        349.56939697265625,
        462.0002136230469,
        371.54327392578125
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 8.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        173.87998962402344,
        349.56939697265625,
        462.0002136230469,
        371.54327392578125
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 1년 이내 한시적 적용 또는 일회성 지시ㆍ명령에 해당하는",
      "font_size": 8.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        173.87998962402344,
        374.5294189453125,
        405.186767578125,
        385.2232666015625
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "내용입니까?",
      "font_size": 8.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        190.44000244140625,
        385.6894226074219,
        234.09808349609375,
        396.3832702636719
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 8.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        426.0,
        374.5294189453125,
        462.0002136230469,
        396.3832702636719
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 8.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        426.0,
        374.5294189453125,
        462.0002136230469,
        396.3832702636719
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 외국 규정을 번역하거나 설명하는 내용입니까?",
      "font_size": 8.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        173.87998962402344,
        399.3694152832031,
        462.0002136230469,
        421.2232666015625
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 8.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        173.87998962402344,
        399.3694152832031,
        462.0002136230469,
        421.2232666015625
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 8.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        173.87998962402344,
        399.3694152832031,
        462.0002136230469,
        421.2232666015625
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게",
      "font_size": 8.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        173.87998962402344,
        424.20941162109375,
        396.78656005859375,
        434.90325927734375
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정리한 자료입니까?",
      "font_size": 8.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        190.44000244140625,
        435.3694152832031,
        264.9066467285156,
        446.0632629394531
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 8.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        426.0,
        424.20941162109375,
        462.0002136230469,
        446.0632629394531
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 8.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        426.0,
        424.20941162109375,
        462.0002136230469,
        446.0632629394531
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다.",
      "font_size": 8.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        173.87998962402344,
        449.0494079589844,
        460.9866943359375,
        471.7432556152344
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.",
      "font_size": 8.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        173.87998962402344,
        449.0494079589844,
        460.9866943359375,
        471.7432556152344
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "지침서ㆍ안내서",
      "font_size": 8.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        119.5199966430664,
        491.889404296875,
        165.42486572265625,
        502.583251953125
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구분",
      "font_size": 8.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        134.16000366210938,
        504.7294006347656,
        148.0796356201172,
        515.4232177734375
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정사무",
      "font_size": 8.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        173.87998962402344,
        474.7294006347656,
        415.8006286621094,
        485.4232482910156
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의 세부기준이나 절차를 제시하는 것입니까? (공무원용)",
      "font_size": 8.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        190.44000244140625,
        485.889404296875,
        380.9296569824219,
        496.583251953125
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예(☞지침서)",
      "font_size": 8.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        426.0,
        474.7294006347656,
        481.50628662109375,
        496.583251953125
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 8.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        426.0,
        474.7294006347656,
        481.50628662109375,
        496.583251953125
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 설",
      "font_size": 8.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        173.87998962402344,
        499.56939697265625,
        415.79998779296875,
        510.26324462890625
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는",
      "font_size": 8.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        190.44000244140625,
        510.7294006347656,
        418.6263732910156,
        532.583251953125
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "것입니까? (민원인용)",
      "font_size": 8.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        190.44000244140625,
        510.7294006347656,
        418.6263732910156,
        532.583251953125
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 예(☞안내서)",
      "font_size": 8.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        426.0,
        505.0893859863281,
        482.22650146484375,
        527.063232421875
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 아니오",
      "font_size": 8.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        426.0,
        505.0893859863281,
        482.22650146484375,
        527.063232421875
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기타 확인사",
      "font_size": 8.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        119.04000091552734,
        547.5694580078125,
        163.0802001953125,
        558.2632446289062
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "항",
      "font_size": 8.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        137.0399932861328,
        560.409423828125,
        145.07998657226562,
        571.1032104492188
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나",
      "font_size": 8.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        173.87998962402344,
        535.5694580078125,
        392.7071838378906,
        546.2632446289062
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "민원인을 구속하는 내용이 있습니까?",
      "font_size": 8.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        190.44000244140625,
        546.7294311523438,
        326.1380920410156,
        557.4232177734375
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 8.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        426.0,
        535.5694580078125,
        462.0002136230469,
        557.4232177734375
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 8.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        426.0,
        535.5694580078125,
        462.0002136230469,
        557.4232177734375
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ안내서",
      "font_size": 8.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        173.87998962402344,
        560.409423828125,
        488.10614013671875,
        571.1032104492188
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제ㆍ개정 절차를 진행하시기 바랍니다.",
      "font_size": 8.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        190.44000244140625,
        572.409423828125,
        325.15875244140625,
        583.1032104492188
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상기 사항에 대하여 확인하였음.",
      "font_size": 8.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        242.39999389648438,
        588.8494262695312,
        362.82421875,
        599.543212890625
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2018 년    7 월   31  일",
      "font_size": 8.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        237.47999572753906,
        629.409423828125,
        356.2799987792969,
        640.1032104492188
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "담당자",
      "font_size": 8.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        342.1199951171875,
        668.5294189453125,
        396.3575744628906,
        689.6632080078125
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "확  인(부서장)",
      "font_size": 8.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        342.1199951171875,
        668.5294189453125,
        396.3575744628906,
        689.6632080078125
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "우 승 민",
      "font_size": 8.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        423.8399963378906,
        667.3294067382812,
        455.8800048828125,
        678.023193359375
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이 원 규",
      "font_size": 8.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        423.5999755859375,
        680.16943359375,
        456.1199951171875,
        690.8632202148438
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 본 민원인 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        119.63999938964844,
        508.939453125,
        484.67999267578125,
        524.900390625
      ],
      "page_num": 4,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안전평가원 의료기기심사부 체외진단기기과에 문의하시기 바랍니다.",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        136.8000030517578,
        528.1394653320312,
        481.54498291015625,
        544.1004028320312
      ],
      "page_num": 4,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 전화번호 : 043-719-4652~4665",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        120.47999572753906,
        555.3794555664062,
        310.6893615722656,
        571.3403930664062
      ],
      "page_num": 4,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 팩스번호 : 043-719-4650",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        120.47999572753906,
        581.659423828125,
        275.8893737792969,
        597.620361328125
      ],
      "page_num": 4,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이 안내서는 체외진단용 의료기기 중 뇌나트륨이뇨펩티드 검사제품  허가",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        119.63999938964844,
        182.89944458007812,
        478.0802917480469,
        198.86038208007812
      ],
      "page_num": 4,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "심사 시 요구되는 신청서 작성 방법 및 제출자료 요건에 대하여 알기 쉽게",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        119.63999938964844,
        208.30429077148438,
        481.961181640625,
        222.9883575439453
      ],
      "page_num": 4,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "설명하거나 식품의약품안전처의 입장을 기술한 것입니다.",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        119.63999938964844,
        231.46429443359375,
        397.121337890625,
        246.1483612060547
      ],
      "page_num": 4,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        119.63999938964844,
        264.58428955078125,
        478.0796203613281,
        279.26837158203125
      ],
      "page_num": 4,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        119.63999938964844,
        287.624267578125,
        481.84124755859375,
        302.308349609375
      ],
      "page_num": 4,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사항이 아님을 알려드립니다. 또한, 본 안내서는 현재의 과학적ㆍ기술적 사실 및",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        119.63999938964844,
        310.7842712402344,
        481.96124267578125,
        325.4683532714844
      ],
      "page_num": 4,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유효한 법규를 토대로 작성되었으므로 이후 최신 개정 법규 내용 및 구체적인",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        119.63999938964844,
        333.94427490234375,
        481.8400573730469,
        348.62835693359375
      ],
      "page_num": 4,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        119.63999938964844,
        356.9842834472656,
        373.7213439941406,
        371.6683654785156
      ],
      "page_num": 4,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        119.63999938964844,
        397.7842712402344,
        481.8406982421875,
        412.4683532714844
      ],
      "page_num": 4,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "알기 쉽게 풀어서 설명하거나 특정한 사안에 대하여 식품의약품안전처",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        143.75999450683594,
        412.06427001953125,
        481.9611511230469,
        455.4283447265625
      ],
      "page_num": 4,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의 입장을 기술하는 것(식품의약품안전처 지침서등의 관리에 관한",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        143.75999450683594,
        412.06427001953125,
        481.9611511230469,
        455.4283447265625
      ],
      "page_num": 4,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "규정 제2조)",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        143.75999450683594,
        412.06427001953125,
        481.9611511230469,
        455.4283447265625
      ],
      "page_num": 4,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "머 리 말",
      "font_size": 18.0,
      "font_name": "T12",
      "bbox": [
        260.2799987792969,
        153.239990234375,
        334.0799865722656,
        174.83999633789062
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "질병관리 패러다임이 치료중심에서 조기진단을",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        121.55999755859375,
        201.50250244140625,
        396.4793701171875,
        215.17124938964844
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "통한 예방중심으로 전환됨에 따라 진단검사",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.5199966430664,
        215.78250122070312,
        396.4798889160156,
        344.0990295410156
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결과의 신뢰성 확보의 중요성이 부각되고 있고,",
      "font_size": 12.960000038146973,
      "font_name": "T13",
      "bbox": [
        110.5199966430664,
        215.78250122070312,
        396.4798889160156,
        344.0990295410156
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "과거 진단기기의 보조적 역할로 인식되던 체외",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.5199966430664,
        215.78250122070312,
        396.4798889160156,
        344.0990295410156
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "진단용 의료기기가 진단검사 결과의 판정에 결정",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.5199966430664,
        215.78250122070312,
        396.4798889160156,
        344.0990295410156
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적인 영향을 주는 제품으로 개발되고 있습니다.",
      "font_size": 12.960000038146973,
      "font_name": "T13",
      "bbox": [
        110.5199966430664,
        215.78250122070312,
        396.4798889160156,
        344.0990295410156
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또한 최근 IT․BT․NT의 눈부신 발달로 민감",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.5199966430664,
        215.78250122070312,
        396.4798889160156,
        344.0990295410156
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "도와 특이도가 향상된 체외진단용 의료기기가",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.5199966430664,
        215.78250122070312,
        396.4798889160156,
        344.0990295410156
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개발되면서 질병의 신속․정확한 진단도 가능",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.5199966430664,
        215.78250122070312,
        396.4798889160156,
        344.0990295410156
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하게 되었습니다.",
      "font_size": 12.960000038146973,
      "font_name": "T13",
      "bbox": [
        110.5199966430664,
        215.78250122070312,
        396.4798889160156,
        344.0990295410156
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "식약처에서는 국민보건, 산업육성 및 국제조화 측면에서 자율",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        123.47999572753906,
        349.44000244140625,
        484.67999267578125,
        364.9790344238281
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관리되던 체외진단용 의료기기의 국가관리 필요성을 인지하여 ‘12년",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.5199966430664,
        363.8399963378906,
        491.1605224609375,
        407.93902587890625
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "부터 단계적으로 허가를 추진해왔으며 금년에 전 등급에 대한",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.5199966430664,
        363.8399963378906,
        491.1605224609375,
        407.93902587890625
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "허가 의무화가 완료되었습니다.",
      "font_size": 12.960000038146973,
      "font_name": "T13",
      "bbox": [
        110.5199966430664,
        363.8399963378906,
        491.1605224609375,
        407.93902587890625
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단용 의료기기를 의료기기로 관리하기 시작한 이래, 식품의",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        123.0,
        413.3999938964844,
        484.6803894042969,
        428.93902587890625
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "약품안전평가원에서는 허가․심사 규정 해설서 발간, 민원설명회",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.5199966430664,
        427.67999267578125,
        491.1610107421875,
        500.47198486328125
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등을 통하여 민원편의 제공 및 허가․심사의 공정성 확보를 위해 지속",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.5199966430664,
        427.67999267578125,
        491.1610107421875,
        500.47198486328125
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적으로 노력해 왔습니다. 이에 지난 ‘12~’13년 까지 총 19종의 가이",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.5199966430664,
        427.67999267578125,
        491.1610107421875,
        500.47198486328125
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "드라인을 발간한 바 있으며, 금번 심질환표지자 검사 시약 2종의",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.5199966430664,
        427.67999267578125,
        491.1610107421875,
        500.47198486328125
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "허가․심사 가이드라인을 추가로 개발하였습니다.",
      "font_size": 12.960000038146973,
      "font_name": "T13",
      "bbox": [
        110.5199966430664,
        427.67999267578125,
        491.1610107421875,
        500.47198486328125
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동 가이드라인이 해당 제품의 허가․심사를 준비하시는 업체에",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        123.47999572753906,
        505.9200134277344,
        484.67938232421875,
        521.4719848632812
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "많은 도움이 되기를 바라며 앞으로도 우리 원에서는 체외진단",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.5199966430664,
        522.0224609375,
        491.1614685058594,
        578.6990356445312
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료기기의 허가․심사에 공정성 및 투명성을 확보함과 동시에",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.5199966430664,
        522.0224609375,
        491.1614685058594,
        578.6990356445312
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "신속한 허가․심사 지원을 통하여 관련 산업의 발전을 위하여 지",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.5199966430664,
        522.0224609375,
        491.1614685058594,
        578.6990356445312
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "속적으로 노력할 것입니다.",
      "font_size": 12.960000038146973,
      "font_name": "T13",
      "bbox": [
        110.5199966430664,
        522.0224609375,
        491.1614685058594,
        578.6990356445312
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "감사합니다.",
      "font_size": 12.960000038146973,
      "font_name": "T13",
      "bbox": [
        110.5199966430664,
        584.0399780273438,
        178.77407836914062,
        599.5790405273438
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2014년 5월",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        413.7599792480469,
        598.43994140625,
        478.67999267578125,
        613.97900390625
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "식품의약품안전평가원장",
      "font_size": 14.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.55999755859375,
        643.1343994140625,
        371.64202880859375,
        657.9421997070312
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "목  차",
      "font_size": 21.959999084472656,
      "font_name": "MalgunGothic",
      "bbox": [
        374.1600036621094,
        161.3791961669922,
        440.15997314453125,
        190.58770751953125
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 1,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅰ. 개요",
      "font_size": 12.72218132019043,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        151.55999755859375,
        218.1599884033203,
        442.885009765625,
        233.7119903564453
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 12,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2",
      "font_size": 12.829745292663574,
      "font_name": "T15",
      "bbox": [
        151.55999755859375,
        218.1599884033203,
        442.885009765625,
        233.7119903564453
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 11,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅱ. 용어의 정의",
      "font_size": 12.72218132019043,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        151.55999755859375,
        247.5599822998047,
        442.885009765625,
        263.11199951171875
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 12,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4",
      "font_size": 12.829745292663574,
      "font_name": "T15",
      "bbox": [
        151.55999755859375,
        247.5599822998047,
        442.885009765625,
        263.11199951171875
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 11,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅲ. 관련 규정",
      "font_size": 12.72218132019043,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        151.55999755859375,
        276.9599914550781,
        442.6454772949219,
        292.5119934082031
      ],
      "page_num": 6,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "14",
      "font_size": 12.829745292663574,
      "font_name": "T15",
      "bbox": [
        151.55999755859375,
        276.9599914550781,
        442.6454772949219,
        292.5119934082031
      ],
      "page_num": 6,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ⅳ. 신청서 기재 항목 및 기술문서 제출자료",
      "font_size": 12.72218132019043,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        151.55999755859375,
        306.3600158691406,
        442.6454772949219,
        321.9120178222656
      ],
      "page_num": 6,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "15",
      "font_size": 12.829745292663574,
      "font_name": "T15",
      "bbox": [
        151.55999755859375,
        306.3600158691406,
        442.6454772949219,
        321.9120178222656
      ],
      "page_num": 6,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1. 제조․수입허가신청서",
      "font_size": 11.879393577575684,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        156.83999633789062,
        329.8800048828125,
        442.6566162109375,
        344.2799987792969
      ],
      "page_num": 6,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "15",
      "font_size": 11.879393577575684,
      "font_name": "T13",
      "bbox": [
        156.83999633789062,
        329.8800048828125,
        442.6566162109375,
        344.2799987792969
      ],
      "page_num": 6,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 기술문서에 관한 자료",
      "font_size": 11.879393577575684,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        156.83999633789062,
        351.47998046875,
        442.6566162109375,
        365.86798095703125
      ],
      "page_num": 6,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "16",
      "font_size": 11.879393577575684,
      "font_name": "T13",
      "bbox": [
        156.83999633789062,
        351.47998046875,
        442.6566162109375,
        365.86798095703125
      ],
      "page_num": 6,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ⅴ. 제조․수입허가 신청서 기재항목",
      "font_size": 12.72218132019043,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        151.55999755859375,
        378.9599914550781,
        442.6454772949219,
        394.5119934082031
      ],
      "page_num": 6,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "17",
      "font_size": 12.829745292663574,
      "font_name": "T15",
      "bbox": [
        151.55999755859375,
        378.9599914550781,
        442.6454772949219,
        394.5119934082031
      ],
      "page_num": 6,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1. 명칭(제품명, 품목명, 모델명)",
      "font_size": 11.879393577575684,
      "font_name": "T13",
      "bbox": [
        156.83999633789062,
        402.47998046875,
        442.6566162109375,
        416.86798095703125
      ],
      "page_num": 6,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "17",
      "font_size": 11.879393577575684,
      "font_name": "T13",
      "bbox": [
        156.83999633789062,
        402.47998046875,
        442.6566162109375,
        416.86798095703125
      ],
      "page_num": 6,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 모양 및 구조",
      "font_size": 11.879393577575684,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        156.83999633789062,
        424.0799865722656,
        442.6566162109375,
        438.4679870605469
      ],
      "page_num": 6,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "18",
      "font_size": 11.879393577575684,
      "font_name": "T13",
      "bbox": [
        156.83999633789062,
        424.0799865722656,
        442.6566162109375,
        438.4679870605469
      ],
      "page_num": 6,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3. 원재료",
      "font_size": 11.879393577575684,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        156.83999633789062,
        445.67999267578125,
        442.6566162109375,
        460.0679931640625
      ],
      "page_num": 6,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "22",
      "font_size": 11.879393577575684,
      "font_name": "T13",
      "bbox": [
        156.83999633789062,
        445.67999267578125,
        442.6566162109375,
        460.0679931640625
      ],
      "page_num": 6,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4. 제조방법",
      "font_size": 11.879393577575684,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        156.83999633789062,
        467.2799987792969,
        442.6566162109375,
        481.6679992675781
      ],
      "page_num": 6,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "24",
      "font_size": 11.879393577575684,
      "font_name": "T13",
      "bbox": [
        156.83999633789062,
        467.2799987792969,
        442.6566162109375,
        481.6679992675781
      ],
      "page_num": 6,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5. 사용목적(성능)",
      "font_size": 11.879393577575684,
      "font_name": "T13",
      "bbox": [
        156.83999633789062,
        488.8799743652344,
        442.6566162109375,
        503.2679748535156
      ],
      "page_num": 6,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "24",
      "font_size": 11.879393577575684,
      "font_name": "T13",
      "bbox": [
        156.83999633789062,
        488.8799743652344,
        442.6566162109375,
        503.2679748535156
      ],
      "page_num": 6,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6. 사용방법",
      "font_size": 11.879393577575684,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        156.83999633789062,
        510.47998046875,
        442.6566162109375,
        524.8679809570312
      ],
      "page_num": 6,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "32",
      "font_size": 11.879393577575684,
      "font_name": "T13",
      "bbox": [
        156.83999633789062,
        510.47998046875,
        442.6566162109375,
        524.8679809570312
      ],
      "page_num": 6,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "7. 사용시 주의사항",
      "font_size": 11.879393577575684,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        156.83999633789062,
        532.0800170898438,
        442.6566162109375,
        546.468017578125
      ],
      "page_num": 6,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "34",
      "font_size": 11.879393577575684,
      "font_name": "T13",
      "bbox": [
        156.83999633789062,
        532.0800170898438,
        442.6566162109375,
        546.468017578125
      ],
      "page_num": 6,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "8. 포장단위",
      "font_size": 11.879393577575684,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        156.83999633789062,
        553.6799926757812,
        442.6566162109375,
        568.0679931640625
      ],
      "page_num": 6,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "34",
      "font_size": 11.879393577575684,
      "font_name": "T13",
      "bbox": [
        156.83999633789062,
        553.6799926757812,
        442.6566162109375,
        568.0679931640625
      ],
      "page_num": 6,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "9. 저장방법 및 사용기간",
      "font_size": 11.879393577575684,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        156.83999633789062,
        575.2799682617188,
        442.6566162109375,
        589.66796875
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 14,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "35",
      "font_size": 11.879393577575684,
      "font_name": "T13",
      "bbox": [
        156.83999633789062,
        575.2799682617188,
        442.6566162109375,
        589.66796875
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 14,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "10. 시험규격",
      "font_size": 11.879393577575684,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        156.83999633789062,
        596.8800048828125,
        442.6566162109375,
        611.2680053710938
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 14,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "36",
      "font_size": 11.879393577575684,
      "font_name": "T13",
      "bbox": [
        156.83999633789062,
        596.8800048828125,
        442.6566162109375,
        611.2680053710938
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 14,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "11. 제조원",
      "font_size": 11.879393577575684,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        156.83999633789062,
        618.47998046875,
        442.6566162109375,
        632.8679809570312
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 14,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "38",
      "font_size": 11.879393577575684,
      "font_name": "T13",
      "bbox": [
        156.83999633789062,
        618.47998046875,
        442.6566162109375,
        632.8679809570312
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 14,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅵ. 기술문서 등의 심사를 위한 제출자료",
      "font_size": 12.72218132019043,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        151.55999755859375,
        216.47999572753906,
        442.28546142578125,
        232.03199768066406
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 12,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "39",
      "font_size": 12.829745292663574,
      "font_name": "T15",
      "bbox": [
        151.55999755859375,
        216.47999572753906,
        442.28546142578125,
        232.03199768066406
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 11,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 개발경위, 측정원리·방법 및 국내․외 사용현황에",
      "font_size": 11.879393577575684,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        156.83999633789062,
        240.0,
        448.2005920410156,
        254.39999389648438
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 14,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관한 자료",
      "font_size": 11.879393577575684,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        171.0,
        261.6000061035156,
        442.2966003417969,
        275.9880065917969
      ],
      "page_num": 7,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "41",
      "font_size": 11.879393577575684,
      "font_name": "T13",
      "bbox": [
        171.0,
        261.6000061035156,
        442.2966003417969,
        275.9880065917969
      ],
      "page_num": 7,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 원재료 및 제조방법에 관한 자료",
      "font_size": 11.879393577575684,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        156.83999633789062,
        283.1999816894531,
        442.2966003417969,
        297.5879821777344
      ],
      "page_num": 7,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "42",
      "font_size": 11.879393577575684,
      "font_name": "T13",
      "bbox": [
        156.83999633789062,
        283.1999816894531,
        442.2966003417969,
        297.5879821777344
      ],
      "page_num": 7,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3. 사용목적에 관한 자료",
      "font_size": 11.879393577575684,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        156.83999633789062,
        304.79998779296875,
        442.2966003417969,
        319.18798828125
      ],
      "page_num": 7,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "42",
      "font_size": 11.879393577575684,
      "font_name": "T13",
      "bbox": [
        156.83999633789062,
        304.79998779296875,
        442.2966003417969,
        319.18798828125
      ],
      "page_num": 7,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4. 저장방법 및 사용기간(유효기간)에 관한 자료",
      "font_size": 11.879393577575684,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        156.83999633789062,
        326.3999938964844,
        442.2966003417969,
        340.7879943847656
      ],
      "page_num": 7,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "43",
      "font_size": 11.879393577575684,
      "font_name": "T13",
      "bbox": [
        156.83999633789062,
        326.3999938964844,
        442.2966003417969,
        340.7879943847656
      ],
      "page_num": 7,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5. 제품의 성능을 확인하기 위한 자료",
      "font_size": 11.879393577575684,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        156.83999633789062,
        348.0,
        442.2966003417969,
        362.38800048828125
      ],
      "page_num": 7,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "44",
      "font_size": 11.879393577575684,
      "font_name": "T13",
      "bbox": [
        156.83999633789062,
        348.0,
        442.2966003417969,
        362.38800048828125
      ],
      "page_num": 7,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6. 체외진단용 의료기기의 취급자 안전에 관한 자료",
      "font_size": 11.879393577575684,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        156.83999633789062,
        369.6000061035156,
        442.2958984375,
        383.9880065917969
      ],
      "page_num": 7,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "44",
      "font_size": 11.879393577575684,
      "font_name": "T13",
      "bbox": [
        156.83999633789062,
        369.6000061035156,
        442.2958984375,
        383.9880065917969
      ],
      "page_num": 7,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "7. 이미 허가·인증받은 제품과 비교한 자료..................45",
      "font_size": 11.879393577575684,
      "font_name": "T13",
      "bbox": [
        156.83999633789062,
        391.1999816894531,
        442.0564270019531,
        405.5999755859375
      ],
      "page_num": 7,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ⅶ. 성능시험에 대한 상세사항",
      "font_size": 12.72218132019043,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        151.0800018310547,
        418.67999267578125,
        442.28546142578125,
        434.23199462890625
      ],
      "page_num": 7,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "46",
      "font_size": 12.829745292663574,
      "font_name": "T15",
      "bbox": [
        151.0800018310547,
        418.67999267578125,
        442.28546142578125,
        434.23199462890625
      ],
      "page_num": 7,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1. 분석적 성능시험에 관한 자료",
      "font_size": 11.879393577575684,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        156.83999633789062,
        442.1999816894531,
        442.2966003417969,
        456.5879821777344
      ],
      "page_num": 7,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "47",
      "font_size": 11.879393577575684,
      "font_name": "T13",
      "bbox": [
        156.83999633789062,
        442.1999816894531,
        442.2966003417969,
        456.5879821777344
      ],
      "page_num": 7,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 임상적 성능시험에 관한 자료",
      "font_size": 11.879393577575684,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        156.83999633789062,
        463.79998779296875,
        442.2966003417969,
        478.18798828125
      ],
      "page_num": 7,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "57",
      "font_size": 11.879393577575684,
      "font_name": "T13",
      "bbox": [
        156.83999633789062,
        463.79998779296875,
        442.2966003417969,
        478.18798828125
      ],
      "page_num": 7,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3. 완제품의 품질관리 시험성적서 또는 시험에 관한 자료",
      "font_size": 11.879393577575684,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        156.83999633789062,
        485.3999938964844,
        442.2966003417969,
        499.7879943847656
      ],
      "page_num": 7,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "64",
      "font_size": 11.879393577575684,
      "font_name": "T13",
      "bbox": [
        156.83999633789062,
        485.3999938964844,
        442.2966003417969,
        499.7879943847656
      ],
      "page_num": 7,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4. 완제품 품질관리 시험에 사용된 표준물질에 관한 자료",
      "font_size": 11.879393577575684,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        156.83999633789062,
        507.0,
        442.2966003417969,
        521.3880004882812
      ],
      "page_num": 7,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "65",
      "font_size": 11.879393577575684,
      "font_name": "T13",
      "bbox": [
        156.83999633789062,
        507.0,
        442.2966003417969,
        521.3880004882812
      ],
      "page_num": 7,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5. 검체보관 및 취급상(온도, 습도 등)의 조건 설정",
      "font_size": 11.879393577575684,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        156.83999633789062,
        528.5999755859375,
        421.20013427734375,
        542.9879760742188
      ],
      "page_num": 7,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "근거자료",
      "font_size": 11.879393577575684,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        171.0,
        550.2000122070312,
        442.2966003417969,
        564.5880126953125
      ],
      "page_num": 7,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "65",
      "font_size": 11.879393577575684,
      "font_name": "T13",
      "bbox": [
        171.0,
        550.2000122070312,
        442.2966003417969,
        564.5880126953125
      ],
      "page_num": 7,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6. 상관성 평가",
      "font_size": 11.879393577575684,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        156.83999633789062,
        571.7999877929688,
        442.2966003417969,
        586.18798828125
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 14,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "66",
      "font_size": 11.879393577575684,
      "font_name": "T13",
      "bbox": [
        156.83999633789062,
        571.7999877929688,
        442.2966003417969,
        586.18798828125
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 14,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅷ. 참고문헌",
      "font_size": 12.72218132019043,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        151.55999755859375,
        599.2799682617188,
        442.28546142578125,
        614.8319702148438
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 12,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "68",
      "font_size": 12.829745292663574,
      "font_name": "T15",
      "bbox": [
        151.55999755859375,
        599.2799682617188,
        442.28546142578125,
        614.8319702148438
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 11,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅸ. 부록",
      "font_size": 12.72218132019043,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        151.55999755859375,
        628.6799926757812,
        442.28546142578125,
        644.2319946289062
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 12,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "70",
      "font_size": 12.829745292663574,
      "font_name": "T15",
      "bbox": [
        151.55999755859375,
        628.6799926757812,
        442.28546142578125,
        644.2319946289062
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 11,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        98.04000091552734,
        117.91441345214844,
        448.0853271484375,
        126.91441345214844
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 2 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        283.44000244140625,
        721.2903442382812,
        311.7449951171875,
        731.2503051757812
      ],
      "page_num": 8,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅰ",
      "font_size": 21.959999084472656,
      "font_name": "T12",
      "bbox": [
        117.36000061035156,
        160.07998657226562,
        216.83999633789062,
        186.43199157714844
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 1,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개  요",
      "font_size": 17.758378982543945,
      "font_name": "H2hdrM",
      "bbox": [
        117.36000061035156,
        160.07998657226562,
        216.83999633789062,
        186.43199157714844
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 4,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 가이드라인은 심근혈관표지자인 뇌나트륨이뇨펩티드(NT-proBNP,",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        124.43999481201172,
        226.4399871826172,
        476.8559875488281,
        240.82798767089844
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "BNP) 검사 제품의 허가․심사 시에 요구되는 신청서 작성 방법 및",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        118.43999481201172,
        245.63998413085938,
        476.7599792480469,
        260.03997802734375
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제출자료 요건을 예시를 들어 구체적이고 알기 쉽게 설명하였습니다.",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        118.43999481201172,
        264.8399963378906,
        476.8559875488281,
        279.2279968261719
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다만, 가이드라인에 기술한 사항은 현재까지의 경험과 과학적",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        118.43999481201172,
        284.0400085449219,
        476.8799743652344,
        298.4280090332031
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사실을 근거로 작성된 바, 새로운 과학적 사실이 밝혀지거나 관련",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        118.43999481201172,
        303.239990234375,
        476.7599792480469,
        317.62799072265625
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "규정이 개정될 경우 추후 변경될 수 있습니다.",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        118.43999481201172,
        322.44000244140625,
        373.416015625,
        336.8280029296875
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또한 본 가이드라인은 뇌나트륨이뇨펩티드 검사 제품의 허가․심사",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        124.43999481201172,
        351.239990234375,
        476.8799743652344,
        365.6399841308594
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시에 요구되는 사항에 대한 일반적인 해석을 기술하고 있는 것으로서",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        118.43999481201172,
        372.12750244140625,
        482.7599792480469,
        384.78375244140625
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "법적 효력이 있는 사항이 아니며, 개별 사항에 따라 다르게 해석할",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        118.43999481201172,
        389.6399841308594,
        476.7599792480469,
        404.0279846191406
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수 있음을 알려드립니다.",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        118.43999481201172,
        408.8399963378906,
        253.41598510742188,
        423.2279968261719
      ],
      "page_num": 8,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1. 목적",
      "font_size": 12.0,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        476.0592041015625,
        150.95999145507812,
        488.0592041015625
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 가이드라인은 심장질환 진단에 도움을 주는 뇌나트륨이뇨펩티드",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        500.04327392578125,
        484.681640625,
        511.0832824707031
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(NT-proBNP, BNP) 측정시약의 허가․심사 시 요구되는 신청서 및 제출자료",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        522.0032348632812,
        488.35638427734375,
        533.0432739257812
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "준비를 위한 참고자료로 활용하는 것을 목적으로 한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        544.083251953125,
        389.35638427734375,
        555.123291015625
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 알림 : 본 가이드라인에 따라 정상적인 서류와 첨부자료를 제대로",
      "font_size": 11.039999961853027,
      "font_name": "Dotum",
      "bbox": [
        110.5199966430664,
        588.0032348632812,
        488.2459716796875,
        599.0432739257812
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "갖추어 접수한 민원에 대하여 신속처리가 진행될 수 있으니 민원 신청시",
      "font_size": 11.039999961853027,
      "font_name": "Dotum",
      "bbox": [
        110.5199966430664,
        610.083251953125,
        488.3668518066406,
        621.123291015625
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "참고하시기 바랍니다.",
      "font_size": 11.039999961853027,
      "font_name": "Dotum",
      "bbox": [
        110.5199966430664,
        632.043212890625,
        219.17999267578125,
        643.083251953125
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅰ. 개 요",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        446.7599792480469,
        117.55441284179688,
        481.4462890625,
        126.55441284179688
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 3 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        283.44000244140625,
        721.2903442382812,
        311.7449951171875,
        731.2503051757812
      ],
      "page_num": 9,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2. 적용범위",
      "font_size": 12.0,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        155.8992156982422,
        174.95999145507812,
        167.8992156982422
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 가이드라인은 인체에서 유래하는 시료를 검체로 뇌나트륨이뇨펩티드",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        179.76327514648438,
        488.360595703125,
        190.8032684326172
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(NT-proBNP, BNP)를 측정하는 체외진단용 의료기기에 적용되는 허가․심",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        201.72328186035156,
        484.67999267578125,
        212.76327514648438
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사 가이드라인이다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        223.80328369140625,
        211.5164031982422,
        234.84327697753906
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "뇌나트륨이뇨펩티드는 심장에 대한 혈역학적 부하를 알 수 있는 바이오",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        245.76327514648438,
        484.67987060546875,
        256.80328369140625
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "마커로 심장근육층의 호르몬 활성화를 보여준다. NT-proBNP와 BNP는",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        267.7232666015625,
        488.35638427734375,
        278.7632751464844
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혈역학적 부하로 좌심실이 비대해질 때 1:1의 비율로 나눠진다. 이들",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        289.80328369140625,
        488.35638427734375,
        300.8432922363281
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "펩타이드 수치의 증가는 심부전과 연관이 있으며 두 물질 모두 울혈성심부전",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        311.7632751464844,
        488.35638427734375,
        322.80328369140625
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "진단에 유용하게 사용된다. 뇌나트륨이뇨펩티드는 심실근에서 생성되나",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        333.7232666015625,
        488.35540771484375,
        344.7632751464844
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "저장되지 않고 심실 부하에 반응하여 분비되면서 강력한 혈관 확장작용과",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        355.80328369140625,
        488.35638427734375,
        366.8432922363281
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나트륨 이뇨작용을 한다. 또한 심실의 용적이 확장되거나 혈압이 과도하게",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        377.7632751464844,
        488.3560485839844,
        388.80328369140625
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "증가될 때 지속적으로 배출된다. 정상인의 말초혈액 내에서는 20 pg/mL",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        399.7232666015625,
        488.35638427734375,
        410.7632751464844
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "미만의 양으로 존재하지만 심부전 환자의 혈장 내 농도는 질환의 중증도에",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        421.80328369140625,
        488.2357482910156,
        432.8432922363281
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "따라 비례하고, 무증상 좌심기능부전 단계에도 상승한다. 특히 심장기능의",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        443.7632751464844,
        488.3572082519531,
        454.80328369140625
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "약화에 민감하게 상승한다. 뇌나트륨이뇨펩티드는 심정지와 상관없이 심장",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        465.7232666015625,
        488.3560485839844,
        476.7632751464844
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기능에 문제가 있을 경우 혈관 벽에서 말초혈액으로 분비되므로 심부전을",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        487.80328369140625,
        488.3560485839844,
        498.8432922363281
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "진단하는 중요 표지자로 진단에 활용된다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        509.7632751464844,
        326.35662841796875,
        520.8032836914062
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        98.04000091552734,
        117.91441345214844,
        448.0853271484375,
        126.91441345214844
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 4 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        283.44000244140625,
        721.2903442382812,
        311.7449951171875,
        731.2503051757812
      ],
      "page_num": 10,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅱ",
      "font_size": 21.959999084472656,
      "font_name": "T12",
      "bbox": [
        116.15999603271484,
        160.67999267578125,
        255.23989868164062,
        187.03199768066406
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 1,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "용어의 정의",
      "font_size": 17.758378982543945,
      "font_name": "H2hdrM",
      "bbox": [
        116.15999603271484,
        160.67999267578125,
        255.23989868164062,
        187.03199768066406
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 4,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 본 가이드라인에서 사용되는 용어의 정의는 본 가이드라인의 이해를",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        206.88328552246094,
        499.2756652832031,
        217.92327880859375
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "돕기 위해 사용되는 것이므로 단순 참고용임",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        228.84327697753906,
        352.4396667480469,
        239.88327026367188
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "간섭 (Interference)",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        260.8832702636719,
        211.29251098632812,
        271.92327880859375
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분석물질의 농도나 강도가 명백함에도 검출시약이나 신호 자체에 비특이적",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        282.8432922363281,
        484.68096923828125,
        293.88330078125
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "으로 반응하는 물질의 존재로 인해 일어나는 인위적인 증가나 감소",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        304.92327880859375,
        444.2404479980469,
        315.9632873535156
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☞ 검출 시스템의 비특이성에서 기인하기도 하고, 지시약 반응의 억제, 분",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        326.8832702636719,
        484.67999267578125,
        337.92327880859375
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "석 대상(효소)의 억제 또는 검체에 의해 발생하는 바이어스의 다른 원",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        127.55999755859375,
        348.84326171875,
        484.67999267578125,
        359.8832702636719
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인에 기인하기도 한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        127.55999755859375,
        370.92327880859375,
        238.29281616210938,
        381.9632873535156
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검출한계 (Limit of detection, LoD)",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        402.84326171875,
        288.69232177734375,
        413.8832702636719
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검출될 수 있는 분석 물질의 최소량",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        424.92327880859375,
        291.9596862792969,
        435.9632873535156
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "공란한계 (Limit of blank, LoB)",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        456.84326171875,
        269.3558349609375,
        467.8832702636719
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "blank 검체에서 관찰 가능할 수 있는 가장 높은 측정치",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        478.92327880859375,
        389.9996643066406,
        489.9632873535156
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "교차반응 (Cross-reactivity)",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        510.8432922363281,
        252.572509765625,
        521.88330078125
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "항원 이외에 공유되었거나, 유사한 또는 동일한 항원결정기를 가진 항원과",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        532.9232177734375,
        488.35638427734375,
        543.9632568359375
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "항체가 반응하는 현상",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        554.8832397460938,
        220.5599822998047,
        565.9232788085938
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기질효과 (Matrix effect)",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        586.9232177734375,
        236.4944305419922,
        597.9632568359375
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정하고자 하는 분석물질 이외에 검체의 특성이 분석물질의 측정에 영향을",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        608.8832397460938,
        488.3565673828125,
        619.9232788085938
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "미치는 경우",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        630.84326171875,
        169.56008911132812,
        641.88330078125
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☞ 검체의 점성, 표면장력, 혼탁도, 이온 강도, pH 등이 기질효과의 주된",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        652.9232177734375,
        488.35638427734375,
        663.9632568359375
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "요인이다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        127.55999755859375,
        674.8832397460938,
        174.69281005859375,
        685.9232788085938
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅱ. 용어의 정의",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        422.1600036621094,
        117.55441284179688,
        481.4460144042969,
        126.55441284179688
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 5 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        283.44000244140625,
        721.2903442382812,
        311.7449951171875,
        731.2503051757812
      ],
      "page_num": 11,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대조물질 (Control / Control material)",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        165.72328186035156,
        310.6365966796875,
        176.76327514648438
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정도 관리를 위해 이용되는 물질",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.5199966430664,
        187.79249572753906,
        280.91998291015625,
        199.43624877929688
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "면역분석법, 면역측정법 (Immunoassay)",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        219.72328186035156,
        314.8388977050781,
        230.76327514648438
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분석물질에 결합 가능한 특이 항원이나 항체를 이용하는 리간드-결합 분석",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        241.80328369140625,
        482.76007080078125,
        252.84327697753906
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☞ 항체를 사용하여 물질을 측정하는 검사법으로 면역분석법은 경쟁적 또는",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        263.7632751464844,
        488.35638427734375,
        274.80328369140625
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비경쟁적, 고체상 또는 액체상, 동위원소 또는 비동위원소, 항원표지",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        127.55999755859375,
        285.7232666015625,
        488.3560485839844,
        296.7632751464844
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는 항체표지, 단일 또는 이중 부위, 균질적 또는 비균질적 방법일 수",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        127.55999755859375,
        307.80328369140625,
        488.35638427734375,
        318.8432922363281
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        127.55999755859375,
        329.7632751464844,
        156.43663024902344,
        340.80328369140625
      ],
      "page_num": 11,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "바이어스 (Bias)",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        361.80328369140625,
        192.0765380859375,
        372.8432922363281
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검사 결과의 예상치와 허용된 기준치 사이의 차이",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        383.7632751464844,
        363.4800109863281,
        394.80328369140625
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "간섭물질 (Interfering substances)",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        415.80328369140625,
        292.2780456542969,
        426.8432922363281
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상검체에 존재하는 내부물질(예 : 혈액 구성요소, acidic polysaccharides)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        437.7632751464844,
        488.3568115234375,
        448.80328369140625
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는 외부물질(예 : talc, 항응고제 등)으로 위양성 또는 위음성 결과를 야기",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        459.7232666015625,
        484.67974853515625,
        470.7632751464844
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "할 수 있는 물질",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        481.80328369140625,
        190.1997528076172,
        492.8432922363281
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보관 시 안정성 (Storage stability)",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        513.7232666015625,
        287.2533264160156,
        524.7633056640625
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "최종 디자인(포장) 상태에서 시약의 유효기간",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        535.80322265625,
        341.5196838378906,
        546.84326171875
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보정 (Calibration)",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        567.7232666015625,
        200.73277282714844,
        578.7633056640625
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특별한 조건하에서 측정 기기나 측정 시스템이 나타내는 값 또는 물질",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        589.80322265625,
        484.6803283691406,
        600.84326171875
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정이나 참고물질에 의한 값과 표준물질에 상응하는 값 사이의 관계를",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        611.7632446289062,
        488.3560485839844,
        622.8032836914062
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "확립하는 일련의 조작",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        633.7232666015625,
        220.5599822998047,
        644.7633056640625
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보정물질 (Calibrator / Calibration material)",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        665.7632446289062,
        338.1330871582031,
        676.8032836914062
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정과정을 보정하기 위해서 또는 검체의 반응을 비교하기 위해서 사용되는",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        687.7232666015625,
        488.3566589355469,
        698.7633056640625
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        98.04000091552734,
        117.91441345214844,
        448.0853271484375,
        126.91441345214844
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 6 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        283.44000244140625,
        721.2903442382812,
        311.7449951171875,
        731.2503051757812
      ],
      "page_num": 12,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "알려진 정량적/정성적 특성(예 : 농도, 활성도, 강도, 반응성)을 갖는 물질",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        155.76327514648438,
        474.3600769042969,
        166.8032684326172
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☞ a) 보정물질에서 분석물질 양은 그의 제조과정에서 확인된 한계",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        177.72328186035156,
        484.6796875,
        188.76327514648438
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(limit) 내에 있으며, 분석법의 반응과 측정되는 특성과의 관계를",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        151.8000030517578,
        199.80328369140625,
        488.3560485839844,
        210.84327697753906
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "설정하는데 사용될 수 있다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        151.8000030517578,
        221.76327514648438,
        292.5328063964844,
        232.8032684326172
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "b) 보정물질은 국가 또는 국제 표준물질이나 참고물질에 소급성을",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        131.39999389648438,
        243.72328186035156,
        488.35638427734375,
        254.76327514648438
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가져야 한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        149.87998962402344,
        265.80328369140625,
        213.57281494140625,
        276.8432922363281
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "c) 분석물질의 다른 양을 갖는 보정물질은 보정 곡선을 설정하는데",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        131.39999389648438,
        287.7632751464844,
        488.3560485839844,
        298.80328369140625
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용될 수 있다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        149.52000427246094,
        309.7232666015625,
        229.65281677246094,
        320.7632751464844
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "d) “일차”와 “이차표준”이란 용어는 보정물질을 지칭하는 용어로",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        131.39999389648438,
        331.80328369140625,
        488.35638427734375,
        342.8432922363281
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "WHO와 ISO에서 사용되고 있다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        150.1199951171875,
        353.7632751464844,
        314.1327819824219,
        364.80328369140625
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분석물질 (Analyte)",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        385.80328369140625,
        204.93382263183594,
        396.8432922363281
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검사실이 수행하는 검사의 물질 또는 구성요소",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        407.7632751464844,
        346.919677734375,
        418.80328369140625
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분석적 특이도 (Analytical specificity)",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        439.80328369140625,
        307.0365905761719,
        450.8432922363281
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정량검사에서 측정하고자 하는 물질만 측정되고 검체 내 다른 물질은 측정",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        461.7632751464844,
        484.6800842285156,
        472.80328369140625
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "되지 않는 분석법의 능력",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        483.7232666015625,
        234.48040771484375,
        494.7632751464844
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비정밀도 (Imprecision)",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        515.7632446289062,
        227.37481689453125,
        526.8032836914062
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특별한 조건 하에서 얻어진 측정값의 독립적 결과들의 분산",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        537.7232666015625,
        416.59637451171875,
        548.7633056640625
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☞ 표준편차나 변이계수 등의 숫자로 표시된다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        559.80322265625,
        350.1327819824219,
        570.84326171875
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비특이도 (Nonspecificity)",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        591.7232666015625,
        243.79783630371094,
        602.7633056640625
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분석하려는 물질 외에 다른 물질과 항원이 반응하는 정도",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        613.80322265625,
        401.8796691894531,
        624.84326171875
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☞ 비특이도는 보통 분석물질이 아닌 물질에 결합하고, 반응하는 항체,",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        635.7632446289062,
        488.35662841796875,
        646.8032836914062
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "효소, ionophore, 시약에 의해 발생한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        129.0,
        657.7232666015625,
        331.05279541015625,
        668.7633056640625
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅱ. 용어의 정의",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        422.1600036621094,
        117.55441284179688,
        481.4460144042969,
        126.55441284179688
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 7 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        283.44000244140625,
        721.2903442382812,
        311.7449951171875,
        731.2503051757812
      ],
      "page_num": 13,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용 시 안정성 (in–use stability)",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        165.72328186035156,
        282.4371337890625,
        176.76327514648438
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조사에서 제공한 용기를 개봉한 이후에 사용자의 작동 조건에서 시약의",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        187.80328369140625,
        488.3560485839844,
        198.84327697753906
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유효기간내의 검사수행능",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        209.76327514648438,
        236.9993133544922,
        220.8032684326172
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상관계수 (Correlation coefficient, r)",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        241.80328369140625,
        304.6358337402344,
        252.84327697753906
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정된 데이터에 대한 두개의 무작위 변수의 공분산(covariance)과 그들의",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        263.7632751464844,
        488.35638427734375,
        274.80328369140625
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표준편차의 곱의 비(ratio)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        285.7232666015625,
        243.83892822265625,
        296.7632751464844
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수송 안정성 실험 (Transport stability test)",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        317.7632751464844,
        334.0523376464844,
        328.80328369140625
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품 운송 도중 발생 가능한 환경변화가 제품 성능에 미치는 영향을 평가",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        339.7232666015625,
        484.67999267578125,
        350.7632751464844
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하는 것",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        361.80328369140625,
        149.0399932861328,
        372.8432922363281
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☞ 최악의 상황을 시험해야 한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        383.7632751464844,
        278.61279296875,
        394.80328369140625
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "신뢰구간 (Confidence interval)",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        415.80328369140625,
        275.3563537597656,
        426.8432922363281
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평균, 분율, 비율 등의 변수의 참값이 정해진 확률 범위 내에서 분포할",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        437.7632751464844,
        488.3560485839844,
        448.80328369140625
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "것으로 예상되는 계산된 구간",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        459.7232666015625,
        258.9596862792969,
        470.7632751464844
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "실시간 안정성 실험 (Real time stability)",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        491.7632751464844,
        318.45330810546875,
        502.80328369140625
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시약을 추천하는 정상적인 보관과 사용 환경에 두고 그 안정성을 평가하는 실험",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        513.7232666015625,
        481.9201965332031,
        524.7633056640625
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "양성 예측도 (Predictive value of positive result, PPV)",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        545.7632446289062,
        399.5574645996094,
        556.8032836914062
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표적 질환(진단 정확도 기준에 의해 결정되는)을 가지고 있는 환자에서",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        567.7232666015625,
        488.3560485839844,
        578.7633056640625
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "양성 결과를 보이는 비율(100을 곱한 값)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        589.80322265625,
        322.1999816894531,
        600.84326171875
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☞ a) 양성 예측도(PPV)는 반드시 관심대상 조건(진단 정확도 기준에 의해",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        611.7632446289062,
        488.35638427734375,
        622.8032836914062
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결정되는)의 유병률에 맞추어 해석해야 한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        144.239990234375,
        633.7232666015625,
        376.51629638671875,
        644.7633056640625
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "b) PPV의 추정값[추정 유병률은 100x(TP+FN)/(TP+FP+FN+TN)]은",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        127.43999481201172,
        655.80322265625,
        488.35638427734375,
        666.84326171875
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "100xTP/(TP+FP)로 계산된다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        144.72000122070312,
        677.7632446289062,
        302.0127868652344,
        688.8032836914062
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        98.04000091552734,
        117.91441345214844,
        448.0853271484375,
        126.91441345214844
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 8 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        283.44000244140625,
        721.2903442382812,
        311.7449951171875,
        731.2503051757812
      ],
      "page_num": 14,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "진단정확도기준",
      "font_size": 9.725613594055176,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        272.2799987792969,
        160.04061889648438,
        440.828369140625,
        170.54530334472656
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "양성",
      "font_size": 9.725613594055176,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        250.1999969482422,
        175.7606201171875,
        447.8564147949219,
        186.2653045654297
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "음성",
      "font_size": 9.725613594055176,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        250.1999969482422,
        175.7606201171875,
        447.8564147949219,
        186.2653045654297
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전체",
      "font_size": 9.725613594055176,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        250.1999969482422,
        175.7606201171875,
        447.8564147949219,
        186.2653045654297
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "방법 X",
      "font_size": 9.725613594055176,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        119.75999450683594,
        191.36062622070312,
        471.843017578125,
        208.22531127929688
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "양성",
      "font_size": 9.725613594055176,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        119.75999450683594,
        191.36062622070312,
        471.843017578125,
        208.22531127929688
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "# 진양성 TP",
      "font_size": 9.840714454650879,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        119.75999450683594,
        191.36062622070312,
        471.843017578125,
        208.22531127929688
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "# 위양성 FP",
      "font_size": 9.840714454650879,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        119.75999450683594,
        191.36062622070312,
        471.843017578125,
        208.22531127929688
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "진양성+ 위양성",
      "font_size": 9.840714454650879,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        119.75999450683594,
        191.36062622070312,
        471.843017578125,
        208.22531127929688
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "음성",
      "font_size": 9.725613594055176,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        178.55999755859375,
        205.640625,
        474.2430114746094,
        216.1453094482422
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "# 위음성 FN",
      "font_size": 9.840714454650879,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        178.55999755859375,
        205.640625,
        474.2430114746094,
        216.1453094482422
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "# 진음성 TN",
      "font_size": 9.840714454650879,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        178.55999755859375,
        205.640625,
        474.2430114746094,
        216.1453094482422
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위음성 + 진음성",
      "font_size": 9.840714454650879,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        178.55999755859375,
        205.640625,
        474.2430114746094,
        216.1453094482422
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전체",
      "font_size": 9.725613594055176,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        132.72000122070312,
        219.80062866210938,
        441.8424377441406,
        230.30531311035156
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "진양성 + 위음성",
      "font_size": 9.840714454650879,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        132.72000122070312,
        219.80062866210938,
        441.8424377441406,
        230.30531311035156
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위양성 + 진음성",
      "font_size": 9.840714454650879,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        132.72000122070312,
        219.80062866210938,
        441.8424377441406,
        230.30531311035156
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "N",
      "font_size": 9.840714454650879,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        132.72000122070312,
        219.80062866210938,
        441.8424377441406,
        230.30531311035156
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비교방법",
      "font_size": 9.725613594055176,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        316.79998779296875,
        254.24061584472656,
        446.4683837890625,
        264.74530029296875
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "양성",
      "font_size": 9.725613594055176,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        291.1199951171875,
        276.2005920410156,
        453.49639892578125,
        286.7052917480469
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "음성",
      "font_size": 9.725613594055176,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        291.1199951171875,
        276.2005920410156,
        453.49639892578125,
        286.7052917480469
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전체",
      "font_size": 9.725613594055176,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        291.1199951171875,
        276.2005920410156,
        453.49639892578125,
        286.7052917480469
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "후보",
      "font_size": 9.725613594055176,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        144.47999572753906,
        302.6006164550781,
        168.54759216308594,
        313.1053161621094
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검사법",
      "font_size": 9.725613594055176,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        139.67999267578125,
        318.68060302734375,
        168.25665283203125,
        329.185302734375
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "양성",
      "font_size": 9.725613594055176,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        221.51998901367188,
        299.12060546875,
        456.35919189453125,
        309.62530517578125
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "a",
      "font_size": 9.840714454650879,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        221.51998901367188,
        299.12060546875,
        456.35919189453125,
        309.62530517578125
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "b",
      "font_size": 9.840714454650879,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        221.51998901367188,
        299.12060546875,
        456.35919189453125,
        309.62530517578125
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "a + b",
      "font_size": 9.840714454650879,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        221.51998901367188,
        299.12060546875,
        456.35919189453125,
        309.62530517578125
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "음성",
      "font_size": 9.725613594055176,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        221.51998901367188,
        322.5205993652344,
        456.0173645019531,
        333.0252990722656
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "c",
      "font_size": 9.840714454650879,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        221.51998901367188,
        322.5205993652344,
        456.0173645019531,
        333.0252990722656
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "d",
      "font_size": 9.840714454650879,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        221.51998901367188,
        322.5205993652344,
        456.0173645019531,
        333.0252990722656
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "c + d",
      "font_size": 9.840714454650879,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        221.51998901367188,
        322.5205993652344,
        456.0173645019531,
        333.0252990722656
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전체",
      "font_size": 9.725613594055176,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        151.67999267578125,
        345.0805969238281,
        446.83514404296875,
        355.5852966308594
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "a + c",
      "font_size": 9.840714454650879,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        151.67999267578125,
        345.0805969238281,
        446.83514404296875,
        355.5852966308594
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "b + d",
      "font_size": 9.840714454650879,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        151.67999267578125,
        345.0805969238281,
        446.83514404296875,
        355.5852966308594
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "n",
      "font_size": 9.840714454650879,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        151.67999267578125,
        345.0805969238281,
        446.83514404296875,
        355.5852966308594
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "양성 일치율(Percent positive agreement, PPA)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        373.4432678222656,
        473.7608337402344,
        384.4832763671875
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "= 100×a/(a+c)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        373.4432678222656,
        473.7608337402344,
        384.4832763671875
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "음성 일치율(Percent negative agreement, PNA)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        395.4032897949219,
        475.0812072753906,
        406.44329833984375
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "= 100×d/(b+d)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        395.4032897949219,
        475.0812072753906,
        406.44329833984375
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "총 일치율(Overall percent agreement)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        417.36328125,
        474.6942443847656,
        428.4032897949219
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "= 100×(a+d)/n",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        417.36328125,
        474.6942443847656,
        428.4032897949219
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "음성 예측도 (Predictive value of negative result, NPV)",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        449.4032897949219,
        403.9963073730469,
        460.44329833984375
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표적 질환을 가지지 않은 정상인에서 음성 결과를 보이는 비율(100을",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        471.36328125,
        488.35638427734375,
        482.4032897949219
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "곱한 값)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        493.4432678222656,
        154.6800079345703,
        504.4832763671875
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☞ NPV의 추정값은 100×TN/(TN+FN)로 계산된다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        515.4032592773438,
        379.7727966308594,
        526.4432983398438
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위양성 (False positive, FP)",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        547.4432373046875,
        248.37246704101562,
        558.4832763671875
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "질병이나 증상이 없는 상태에서 이를 시사하는 양성검사 결과",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        569.4032592773438,
        427.51605224609375,
        580.4432983398438
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☞ 예시 : 질환에 이환되지 않은 개체에서 비정상 결과",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        591.3632202148438,
        389.0396728515625,
        602.4032592773438
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위음성 (False negative, FN)",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        623.4032592773438,
        256.63763427734375,
        634.4432983398438
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "양성 환자나 양성 검체에서의 음성검사 결과",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        645.3632202148438,
        336.0,
        656.4032592773438
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅱ. 용어의 정의",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        422.1600036621094,
        117.55441284179688,
        481.4460144042969,
        126.55441284179688
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 9 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        283.44000244140625,
        721.2903442382812,
        311.7449951171875,
        731.2503051757812
      ],
      "page_num": 15,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상적 민감도 (Clinical sensitivity)",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        187.80328369140625,
        289.6526184082031,
        198.84327697753906
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특정질환을 가지고 있는 사람들 중 검사 결과가 양성으로 나오는 비율",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        209.76327514648438,
        467.8800048828125,
        220.8032684326172
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상적 보고가능범위 (Clinically reportable range, CCR)",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        241.80328369140625,
        401.35675048828125,
        252.84327697753906
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분석측정범위를 연장하기 위해 검체에 대한 희석, 농축, 또는 기타",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        263.7632751464844,
        488.35638427734375,
        274.80328369140625
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전처리를 하여 정량 결과 값으로 보고할 수 있는 분석물질 값의 범위",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        285.7232666015625,
        462.3599853515625,
        296.7632751464844
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상적 특이도 (Clinical specificity)",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        317.7632751464844,
        290.6141662597656,
        328.80328369140625
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특정질환을 가지고 있지 않은 사람들 중 검사 결과가 음성으로 나오는 비율",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        339.7232666015625,
        484.4400939941406,
        350.7632751464844
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "재현성 조건 (Reproducibility condition)",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        371.7632751464844,
        318.43682861328125,
        382.80328369140625
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동일한 방법과 동일한 검사 품목으로 다른 검사실에서 다른 사용자가 다른",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        393.7232666015625,
        488.35638427734375,
        404.7632751464844
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "장비를 사용하여 검사 결과를 얻는 조건",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        415.80328369140625,
        313.919677734375,
        426.8432922363281
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "재현성 (Reproducibility)",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        447.7232666015625,
        236.4779815673828,
        458.7632751464844
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다른 측정조건에서 수행된 동일한 측정물의 결과값 사이의 일치도의 근접성",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        469.80328369140625,
        484.5601806640625,
        480.8432922363281
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정규분포 (Normal distribution)",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        501.7232666015625,
        267.5716857910156,
        512.7632446289062
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가우스 분포라고 표현되며 측정값을 곡선의 x축에, 관측치의 빈도를 곡선의",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        523.80322265625,
        488.35638427734375,
        534.84326171875
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "y축에 표시",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        545.7632446289062,
        166.4399871826172,
        556.8032836914062
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☞ 관측치가 평균의 양측에 균일하게 분포하면 결과그래프는 전형적인",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        567.7232666015625,
        488.35638427734375,
        578.7633056640625
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "종형곡선을 갖는다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        128.87998962402344,
        589.80322265625,
        225.57281494140625,
        600.84326171875
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정량분석 (Quantitative assay)",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        621.7232666015625,
        264.93389892578125,
        632.7633056640625
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검체에서 분석물질의 농도를 측정할 수 있는 시스템",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        643.80322265625,
        374.3996887207031,
        654.84326171875
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☞ 정량 분석은 표준 참고 물질에 맞춘 보정곡선으로부터 동종 또는 이종",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        665.7632446289062,
        488.35638427734375,
        676.8032836914062
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보간법(Interpolation)1)을 통해 이루어진다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        127.55999755859375,
        687.7232666015625,
        347.2527770996094,
        698.7633056640625
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        98.04000091552734,
        117.91441345214844,
        448.0853271484375,
        126.91441345214844
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 10 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 16,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정밀도 (Precision)",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        165.72328186035156,
        203.97299194335938,
        176.76327514648438
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "규정된 조건 하에서 얻어진 독립적인 검사결과들 가운데 일치도의 근접성",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        187.80328369140625,
        484.44000244140625,
        198.84327697753906
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☞ 정밀도는 전형적으로 수치로 표현되지 않지만 비정밀도는 반복 측정값",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        209.76327514648438,
        488.3560485839844,
        220.8032684326172
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결과들의 ‘표준편차’ 또는 ‘변이계수’라는 용어로 정량적으로 표현",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        127.55999755859375,
        231.72328186035156,
        458.2799987792969,
        242.76327514648438
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정성분석 (Qualitative assay)",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        263.7632751464844,
        257.1335754394531,
        274.80328369140625
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분석물질의 농도가 아니라 단지 분석물질이 있고 없음을 알려주는 검사",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        285.7232666015625,
        488.35638427734375,
        296.7632751464844
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시스템",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        307.80328369140625,
        147.19606018066406,
        318.8432922363281
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☞ 양성 검사 결과는 검사신호가 분석 역치를 넘는 것만을 의미하고 판정",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        329.7632751464844,
        484.67999267578125,
        340.80328369140625
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기준치(cut-off value)는 진단 민감도와 특이도의 인위적 조합에 의해",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        127.55999755859375,
        351.7232666015625,
        488.35638427734375,
        362.7632751464844
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구해진다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        127.55999755859375,
        373.80328369140625,
        178.39663696289062,
        384.8432922363281
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정확도 (Accuracy)",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        405.7232666015625,
        203.85377502441406,
        416.7632751464844
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정치와 참값 사이의 일치도",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        427.80328369140625,
        258.9596862792969,
        438.8432922363281
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☞ 평가대상 검사법에 의한 다수의 연속적인 결과값들에서 얻은 평균값과",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        449.7632751464844,
        488.3566589355469,
        460.80328369140625
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "공인된 참고값(accepted reference value)사이의 일치 근접도(closeness",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        127.07999420166016,
        471.7232666015625,
        488.35546875,
        482.7632751464844
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "of agreement)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        127.07999420166016,
        493.80328369140625,
        199.43792724609375,
        504.8432922363281
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "직선성 (Linearity)",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        525.7232666015625,
        199.41236877441406,
        536.7633056640625
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "실험 검체에 있는 분석물질의 농도[양]에 정비례하는 결과를 제공할 수",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        547.80322265625,
        488.35638427734375,
        558.84326171875
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있는 능력",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        569.7632446289062,
        160.07998657226562,
        580.8032836914062
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "진단검사 (Diagnostic test)",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        601.80322265625,
        248.0123291015625,
        612.84326171875
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특정 질환의 진단, 예방, 치료 또는 개개의 환자에서의 건강이나 건강의",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        623.7632446289062,
        488.3560485839844,
        634.8032836914062
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "손상 정도를 평가하기 위한 목적",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        645.7232666015625,
        275.5199890136719,
        656.7633056640625
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☞ 진단적 검체의 측정 또는 검사를 칭한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        667.80322265625,
        337.276611328125,
        678.84326171875
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 보간법 : 내삽이라고도 하며 그래프상의 알려진 두 값 사이의 특정값을 평균하여 추정하는 것을 의미",
      "font_size": 8.759956359863281,
      "font_name": "Batang",
      "bbox": [
        110.5199966430664,
        699.5543823242188,
        483.0066223144531,
        708.5543823242188
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅱ. 용어의 정의",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        422.1600036621094,
        117.55441284179688,
        481.4460144042969,
        126.55441284179688
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 11 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 17,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "진양성 (True positive, TP)",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        165.72328186035156,
        248.83653259277344,
        176.76327514648438
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "환자의 질병 상태와 검사의 양성판정이 일치하는 결과",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        187.80328369140625,
        385.44000244140625,
        198.84327697753906
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "진음성 (True negative, TN)",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        219.72328186035156,
        253.39678955078125,
        230.76327514648438
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "환자의 질병 상태와 검사의 음성판정이 일치하는 결과",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        241.80328369140625,
        385.44000244140625,
        252.84327697753906
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "참고구간 (Reference interval)",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        273.7232666015625,
        267.0928649902344,
        284.7632751464844
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상하 두 개의 참고 한계치 내의 간격",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        295.80328369140625,
        297.4800109863281,
        306.8432922363281
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☞ 하한 참고치와 상한 참고치 간의 간격으로 명시되어 있다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        317.7632751464844,
        421.53277587890625,
        328.80328369140625
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "참고물질 / 참고제작 (Reference material / Reference preparation, RM)",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        349.80328369140625,
        478.8929138183594,
        360.8432922363281
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 하나 또는 그 이상의 특성값이 충분히 균일하고 기구의 보정, 측정방",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        371.7632751464844,
        484.6796875,
        382.80328369140625
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "법의 평가 또는 물질에 값을 할당하기 위해서 사용되는 물질",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        129.47999572753906,
        393.7232666015625,
        437.3999938964844,
        404.7632751464844
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 인증참고물질(CRM) – 기술적으로 입증된 과정에 의해 공인되었고 인",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        415.80328369140625,
        484.67999267578125,
        426.8432922363281
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "증서나 다른 인증기관에 의해 발행된 서류가 있거나 추적 가능한 하",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        129.47999572753906,
        437.7632751464844,
        484.67999267578125,
        448.80328369140625
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나 또는 그 이상의 값을 갖는 참고물질",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        129.47999572753906,
        459.7232666015625,
        327.47967529296875,
        470.7632751464844
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "☞ a) 인증참고물질(CRM)은 “인증서가 있는 참고물질로서 하나 또는 그",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        481.80328369140625,
        488.35638427734375,
        492.8432922363281
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이상의 특성값이 절차에 따라 공인되며, 그 절차는 특성값이 표현",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        142.55999755859375,
        503.7632751464844,
        484.6796875,
        514.8032836914062
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "되는 단위의 정확한 구현에 대한 추적을 할 수 있고, 그것에 대해",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        142.55999755859375,
        525.7232666015625,
        488.35638427734375,
        536.7633056640625
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "각 공인된 값은 신뢰의 명시된 수준에서의 불확실성과 함께 한다”",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        142.55999755859375,
        547.80322265625,
        484.6860656738281,
        558.84326171875
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라고 정의한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        142.55999755859375,
        569.7632446289062,
        220.8766326904297,
        580.8032836914062
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "b) 표준참고물질(SRM)은 인증참고물질(CRM)의 한 이름으로서 과거에",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        591.7232666015625,
        488.35638427734375,
        602.7633056640625
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "국립표준원(NBS)으로 알려졌던 미국정부기관으로, 국립표준기술",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        142.55999755859375,
        613.80322265625,
        484.68096923828125,
        624.84326171875
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연구소(NIST)에 의해 인증되고 배포되는 인증참고물질의 상품명이다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        142.55999755859375,
        635.7632446289062,
        487.3966064453125,
        646.8032836914062
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "참고치 (Reference value)",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        667.80322265625,
        248.3575439453125,
        678.84326171875
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개체에서 관측 또는 측정으로 얻은 특정 형태의 정량값",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        689.7632446289062,
        390.9599914550781,
        700.8032836914062
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        98.04000091552734,
        117.91441345214844,
        448.0853271484375,
        126.91441345214844
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 12 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 18,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "총 분석 오차 (Total analytical error)",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        165.72328186035156,
        306.0752258300781,
        176.76327514648438
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특정 구성요소들로 구성되어 있으며 90% 또는 95% 신뢰구간으로 정량",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        187.80328369140625,
        484.67999267578125,
        198.84327697753906
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "화된다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        209.76327514648438,
        150.4366455078125,
        220.8032684326172
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정가능범위 (Analytical measurement range, AMR)",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        241.80328369140625,
        385.63714599609375,
        252.84327697753906
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일상적인 측정 과정의 일부가 아닌 희석, 농축 또는 기타 전처리 없이 어떤",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        263.7632751464844,
        488.3564758300781,
        274.80328369140625
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검사법이 검체에서 직접 측정할 수 있는 분석물질 값의 범위",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        285.7232666015625,
        409.8000793457031,
        296.7632751464844
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정 시스템의 민감도 (Sensitivity of a measuring system)",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        317.7632751464844,
        417.8130798339844,
        328.80328369140625
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정 시스템 표시 도수의 변화 및 측정된 양의 값의 변화계수",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        339.7232666015625,
        423.8396911621094,
        350.7632751464844
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☞ 측정시스템의 민감도는 측정된 양의 크기에 의존하며 측정된 양의 값",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        361.80328369140625,
        488.2360534667969,
        372.8432922363281
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "변경은 반드시 분해능(resolution)에 비하여 큰 차이여야 한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        127.55999755859375,
        383.7632751464844,
        445.05279541015625,
        394.80328369140625
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "친화력, 친화성 (Affinity)",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        415.80328369140625,
        235.99644470214844,
        426.8432922363281
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "면역학에서 한 개의 항원결정기 부위와 한 개의 항체 사이에 작용하는 힘",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        437.7632751464844,
        484.32000732421875,
        448.80328369140625
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "판정기준치 (Cut-off value)",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        469.80328369140625,
        250.17372131347656,
        480.8432922363281
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정성검사에서는 경계치 이상을 양성으로, 경계치 미만을 음성으로 보고할",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        491.7632751464844,
        488.3569030761719,
        502.80328369140625
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수 있는 경계값을 말한다. 정량검사에서는 측정 결과가 임상적 또는 분석",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        513.7232666015625,
        484.6804504394531,
        524.7633056640625
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적 결정점(Decision point)의 위 또는 아래에 있는지(양성 또는 음성) 결정",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        535.80322265625,
        484.6800842285156,
        546.84326171875
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하는데 사용되는 측정물질의 정량값",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        557.7632446289062,
        288.24053955078125,
        568.8032836914062
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "항원 (Antigen)",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        589.80322265625,
        187.3974609375,
        600.84326171875
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "생체 내 항체 생성을 유발하고 그들과 특이적으로 결합할 수 있는 물질",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        611.7632446289062,
        476.9560546875,
        622.8032836914062
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "항원결정인자 / 에피토프 (Antigenic determinant / epitope)",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        643.80322265625,
        421.05230712890625,
        654.84326171875
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "항원 분자 중 항체가 결합할 수 있는 모든 부위의 총칭으로 특정 항체군을",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        665.7632446289062,
        488.35736083984375,
        676.8032836914062
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결정하는 부위의 화학적 구조",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        687.7232666015625,
        255.9600830078125,
        698.7633056640625
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅱ. 용어의 정의",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        422.1600036621094,
        117.55441284179688,
        481.4460144042969,
        126.55441284179688
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 13 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 19,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "항원항체결합력 (Avidity)",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        165.72328186035156,
        233.37318420410156,
        176.76327514648438
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "항혈청 또는 항체의 복합적인 반응 강도",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        187.80328369140625,
        313.919677734375,
        198.84327697753906
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☞ 항원항체결합력은 항혈청 내 모든 항체의 항체결합부위와 가용한 마크",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        209.76327514648438,
        484.6796875,
        220.8032684326172
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "로분자의 항원결정기와의 친화력 함수",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        127.55999755859375,
        231.72328186035156,
        323.5960693359375,
        242.76327514648438
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "항체 (Antibody)",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        263.7632751464844,
        192.91744995117188,
        274.80328369140625
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "면역계 내에서 항원의 자극에 의하여 혈청이나 조직에 만들어지는 물질",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        285.7232666015625,
        473.3999938964844,
        296.7632751464844
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☞ 면역원 노출에 반응하여 B림프구에서 생산되는 특이 면역글로불린으",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        307.80328369140625,
        484.6793518066406,
        318.8432922363281
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "로 면역원(immunogen)과 결합한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        127.55999755859375,
        329.7632751464844,
        308.9727783203125,
        340.80328369140625
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허용 오차 (Allowable error)",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        361.80328369140625,
        254.85137939453125,
        372.8432922363281
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모든 가능한 요소들로부터 발생할 수 있는 분석적 변이의 정도 또는 검사",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        383.7632751464844,
        484.67999267578125,
        394.80328369140625
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시스템에서 사용자가 허용할 수 있는 정도로 검사의 임상적 요구사항을",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        405.7232666015625,
        488.3560485839844,
        416.7632751464844
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "만족시킬 수 있는 변이의 정도",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        427.80328369140625,
        264.47998046875,
        438.8432922363281
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "후크효과 (Hook effect)",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        459.7232666015625,
        231.0925750732422,
        470.7632751464844
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "항체 또는 항원 과다로 최적 반응을 방해하여 항원-항체 반응이 최적",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        481.80328369140625,
        488.35638427734375,
        492.8432922363281
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이하로 나타나는 현상",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        503.7632751464844,
        220.5599822998047,
        514.8032836914062
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "회복, 회수 (Recovery)",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        535.80322265625,
        227.3583984375,
        546.84326171875
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동일 물질의 검체에 알고 있는 양을 첨가한 후 분석물질 농도의 증가를",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        557.7632446289062,
        488.3560485839844,
        568.8032836914062
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "확인",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        579.7232666015625,
        132.59999084472656,
        590.7633056640625
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☞ 분석물질이 첨가되지 않은 혈청 검체와 첨가된 혈청 검체로 분석물질",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        601.80322265625,
        484.6796875,
        612.84326171875
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의 증가가 첨가된 양과 동등한 지 분석한다. 첨가된 물질의 양을 확인",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        127.55999755859375,
        623.7632446289062,
        484.67999267578125,
        634.8032836914062
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하는 정확도는 회수 실험에 필수적이며 100% 회수가 이상적이다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        127.55999755859375,
        645.7232666015625,
        466.03662109375,
        656.7633056640625
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☞ 회수실험의 다른 형태는 희석-회수분석이다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        667.80322265625,
        353.852783203125,
        678.84326171875
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        98.04000091552734,
        117.91441345214844,
        448.0853271484375,
        126.91441345214844
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 14 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 20,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅲ",
      "font_size": 21.959999084472656,
      "font_name": "T12",
      "bbox": [
        117.47999572753906,
        160.67999267578125,
        232.5596923828125,
        187.03199768066406
      ],
      "page_num": 20,
      "block_type": "heading",
      "level": 1,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관련규정",
      "font_size": 17.758378982543945,
      "font_name": "H2hdrM",
      "bbox": [
        117.47999572753906,
        160.67999267578125,
        232.5596923828125,
        187.03199768066406
      ],
      "page_num": 20,
      "block_type": "heading",
      "level": 4,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "■ 「의료기기법」제3조 (제조업의 허가의 신청절차)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        224.88328552246094,
        380.8799743652344,
        235.92327880859375
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "■ 「의료기기법」제10조 (임상시험계획의 승인 등)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        246.84329223632812,
        376.3199768066406,
        257.88330078125
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "■ 「의료기기법」제29조 (수입업 허가신청 등)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        268.92327880859375,
        354.239990234375,
        279.9632873535156
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "■ 「의료기기법 시행규칙」제5조 (제조허가의 절차)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        290.8832702636719,
        380.8799743652344,
        301.92327880859375
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "■ 「의료기기법 시행규칙」제6조 (제조인증의 절차)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        312.8432922363281,
        380.8799743652344,
        323.88330078125
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "■ 「의료기기법 시행규칙」제7조 (제조신고의 절차)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        334.92327880859375,
        380.8799743652344,
        345.9632873535156
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "■ 「의료기기법 시행규칙」제9조 (기술문서 등의 심사)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        356.8832702636719,
        397.3199768066406,
        367.92327880859375
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "■ 「의료기기법 시행규칙」제20조 (임상시험계획의 승인 등)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        378.84326171875,
        425.7599792480469,
        389.8832702636719
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "■ 「의료기기법 시행규칙」제21조 (임상시험기관 지정기준 및 절차 등)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        400.92327880859375,
        480.719970703125,
        411.9632873535156
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "■ 「의료기기법 시행규칙」제30조 (수입허가 신청 등)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        422.8832702636719,
        392.7599792480469,
        433.92327880859375
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "■ 「의료기기법 시행규칙」제42조 (용기 등의 기재사항)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        444.84326171875,
        403.79998779296875,
        455.8832702636719
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "■ 「의료기기법 시행규칙」제43조 (첨부문서의 기재사항)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        466.92327880859375,
        409.3199768066406,
        477.9632873535156
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "■ 「의료기기법 시행규칙」제44조 (기재사항의 표시방법)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        488.8832702636719,
        409.3199768066406,
        499.92327880859375
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "■ 「의료기기 허가․신고․심사 등에 관한 규정」",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        510.8432922363281,
        350.760009765625,
        521.88330078125
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "■ 「의료기기 품목 및 품목별 등급에 관한 규정」",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        532.9232177734375,
        368.8800048828125,
        543.9632568359375
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "■ 「의료기기 안정성시험 기준」",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        554.8832397460938,
        281.0400085449219,
        565.9232788085938
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅳ. 신청서 기재 항목 및 기술문서 제출자료",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        315.6000061035156,
        117.55441284179688,
        481.44561767578125,
        126.55441284179688
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 15 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 21,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅳ",
      "font_size": 21.959999084472656,
      "font_name": "T12",
      "bbox": [
        117.23999786376953,
        160.07998657226562,
        427.56353759765625,
        186.43199157714844
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 1,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "신청서 기재 항목 및 기술문서 제출자료",
      "font_size": 15.719986915588379,
      "font_name": "H2hdrM",
      "bbox": [
        117.23999786376953,
        160.07998657226562,
        427.56353759765625,
        186.43199157714844
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1",
      "font_size": 13.799982070922852,
      "font_name": "H2hdrM",
      "bbox": [
        121.91999816894531,
        248.94808959960938,
        271.3235168457031,
        263.7080993652344
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조․수입허가신청서",
      "font_size": 13.799982070922852,
      "font_name": "HYwulM",
      "bbox": [
        121.91999816894531,
        248.94808959960938,
        271.3235168457031,
        263.7080993652344
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "❍ 명칭(제품명, 품목명, 모델명)",
      "font_size": 10.797332763671875,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        295.80328369140625,
        278.03997802734375,
        306.8432922363281
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "❍ 분류번호(등급)",
      "font_size": 10.797332763671875,
      "font_name": "Haansoft Batang",
      "bbox": [
        123.83999633789062,
        317.7632751464844,
        210.0,
        328.80328369140625
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "❍ 모양 및 구조",
      "font_size": 10.797332763671875,
      "font_name": "Haansoft Batang",
      "bbox": [
        123.83999633789062,
        339.8432922363281,
        200.40017700195312,
        350.88330078125
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "❍ 원재료",
      "font_size": 10.797332763671875,
      "font_name": "Haansoft Batang",
      "bbox": [
        123.83999633789062,
        361.80328369140625,
        170.7603759765625,
        372.8432922363281
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ 제조방법",
      "font_size": 10.797332763671875,
      "font_name": "Haansoft Batang",
      "bbox": [
        123.83999633789062,
        383.7632751464844,
        180.60018920898438,
        394.80328369140625
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ 사용목적(성능)",
      "font_size": 10.797332763671875,
      "font_name": "Haansoft Batang",
      "bbox": [
        123.83999633789062,
        405.84326171875,
        210.0,
        416.8832702636719
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ 사용방법",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        123.83999633789062,
        427.80328369140625,
        184.3196563720703,
        438.8432922363281
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ 사용 시 주의사항",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        123.83999633789062,
        449.7632751464844,
        228.35964965820312,
        460.80328369140625
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ 포장단위",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        123.83999633789062,
        471.84326171875,
        184.3196563720703,
        482.8832702636719
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ 저장방법 및 사용기간",
      "font_size": 10.797332763671875,
      "font_name": "Haansoft Batang",
      "bbox": [
        123.83999633789062,
        493.80328369140625,
        240.12017822265625,
        504.8432922363281
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "❍ 시험규격",
      "font_size": 10.797332763671875,
      "font_name": "Haansoft Batang",
      "bbox": [
        123.83999633789062,
        515.7632446289062,
        180.60018920898438,
        526.8032836914062
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "❍ 제조원(수입 또는 제조공정 전부 위탁의 경우)",
      "font_size": 10.797332763671875,
      "font_name": "Haansoft Batang",
      "bbox": [
        123.83999633789062,
        537.84326171875,
        350.1600036621094,
        548.88330078125
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "❍ 허가조건",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        123.83999633789062,
        559.80322265625,
        184.3196563720703,
        570.84326171875
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "❍ 비고",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        123.83999633789062,
        581.7632446289062,
        162.3599853515625,
        592.8032836914062
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        98.04000091552734,
        117.91441345214844,
        448.0853271484375,
        126.91441345214844
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 16 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 22,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2",
      "font_size": 13.799982070922852,
      "font_name": "H2hdrM",
      "bbox": [
        121.91999816894531,
        205.14808654785156,
        282.36395263671875,
        219.9080810546875
      ],
      "page_num": 22,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기술문서에 관한 자료",
      "font_size": 13.799982070922852,
      "font_name": "HYwulM",
      "bbox": [
        121.91999816894531,
        205.14808654785156,
        282.36395263671875,
        219.9080810546875
      ],
      "page_num": 22,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "❍ 개발경위, 측정원리․방법 및 국내·외 사용현황에 관한 자료",
      "font_size": 11.039999961853027,
      "font_name": "Batang",
      "bbox": [
        110.5199966430664,
        251.88327026367188,
        421.6796875,
        262.92327880859375
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "❍ 원재료 및 제조방법에 관한 자료",
      "font_size": 11.039999961853027,
      "font_name": "Batang",
      "bbox": [
        110.5199966430664,
        283.92327880859375,
        291.9599914550781,
        294.9632873535156
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "❍ 사용목적에 관한 자료",
      "font_size": 11.039999961853027,
      "font_name": "Batang",
      "bbox": [
        110.5199966430664,
        311.5232849121094,
        236.99998474121094,
        322.56329345703125
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "❍ 저장방법과 사용기간(유효기간)에 관한 자료",
      "font_size": 11.039999961853027,
      "font_name": "Batang",
      "bbox": [
        110.5199966430664,
        339.123291015625,
        349.79998779296875,
        350.1632995605469
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "❍ 성능시험에 관한 자료",
      "font_size": 11.039999961853027,
      "font_name": "Batang",
      "bbox": [
        110.5199966430664,
        366.7232666015625,
        236.99998474121094,
        377.7632751464844
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "❍ 체외진단용 의료기기의 취급자 안전에 관한 자료",
      "font_size": 11.039999961853027,
      "font_name": "Batang",
      "bbox": [
        110.5199966430664,
        394.3232727050781,
        374.3996887207031,
        405.36328125
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "❍ 이미 허가·인증받은 제품과 비교한 자료(별지제3호서식)",
      "font_size": 11.039999961853027,
      "font_name": "Batang",
      "bbox": [
        110.5199966430664,
        421.92327880859375,
        409.52154541015625,
        432.9632873535156
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅴ. 제조․수입허가 신청서 기재 항목",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        346.91998291015625,
        117.55441284179688,
        481.4460144042969,
        126.55441284179688
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 17 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 23,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅴ",
      "font_size": 21.959999084472656,
      "font_name": "T12",
      "bbox": [
        117.47999572753906,
        160.07998657226562,
        422.1600036621094,
        186.43199157714844
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 1,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조․수입허가 신청서 기재항목",
      "font_size": 18.0,
      "font_name": "H2hdrM",
      "bbox": [
        117.47999572753906,
        160.07998657226562,
        422.1600036621094,
        186.43199157714844
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1",
      "font_size": 13.799982070922852,
      "font_name": "H2hdrM",
      "bbox": [
        121.91999816894531,
        235.62808227539062,
        343.0067443847656,
        255.66807556152344
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "명칭 (제품명, 품목명, 모델명)",
      "font_size": 14.039999961853027,
      "font_name": "HYwulM",
      "bbox": [
        121.91999816894531,
        235.62808227539062,
        343.0067443847656,
        255.66807556152344
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 제조(수입)업소명·제품명, 품목류명, 모델명을 각각 기재한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        289.56329345703125,
        435.8127746582031,
        300.6033020019531
      ],
      "page_num": 23,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 제품명을 기재하는 경우에는 “제조(수입)업소명·제품명”, “품목명”,",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        311.5232849121094,
        488.35699462890625,
        322.56329345703125
      ],
      "page_num": 23,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "“모델명”을 각각 기재한다. 이대 제조(수입)업소명은 생략할 수 있",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        142.55999755859375,
        333.4832763671875,
        484.67999267578125,
        344.5232849121094
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "고 제품명은 두 개 이상 인정한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        142.55999755859375,
        355.5632629394531,
        316.17279052734375,
        366.603271484375
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 제품명을 기재하지 아니하는 경우에는 “제조(수입)업소명·품목명”, “모",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        377.5232849121094,
        484.67999267578125,
        388.56329345703125
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "델명”을 각각 기재한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        144.47999572753906,
        399.4832763671875,
        261.81280517578125,
        410.5232849121094
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다. 동일제품에 대하여 두개 이상의 다른 상품명(또는 모델명) 부여는",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        421.5632629394531,
        488.3560485839844,
        432.603271484375
      ],
      "page_num": 23,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(수출용 의료기기 제외) 불가",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        144.47999572753906,
        443.5232849121094,
        293.0400085449219,
        454.56329345703125
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 제품명은 이미 허가(신고)를 받거나 받았었던 의료기기의 제품명과 동",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        475.5632629394531,
        484.67999267578125,
        486.603271484375
      ],
      "page_num": 23,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일하여서는 아니 된다. 다만, 다음의 어느 하나에 해당하는 경우에는",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        127.55999755859375,
        497.5232849121094,
        488.3560485839844,
        508.56329345703125
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그러하지 아니하다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        127.55999755859375,
        519.4832153320312,
        224.2528076171875,
        530.5232543945312
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가. 허가(신고)가 최소된 의료기기와 사용목적, 작용원리 및 원재료 등",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        541.563232421875,
        484.67999267578125,
        552.603271484375
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이 동일한 의료기기로서 취소된 날로부터 1년이 지난 경우",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        142.55999755859375,
        563.5232543945312,
        440.2796630859375,
        574.5632934570312
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나. 동일한 제조(수입)업자가 허가(신고) 취하 후 동일한 제품을 허가(신",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        585.4832153320312,
        484.67999267578125,
        596.5232543945312
      ],
      "page_num": 23,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고)하는 경우",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        144.47999572753906,
        607.563232421875,
        206.7601776123047,
        618.603271484375
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다. 서로 다른 수입업자가 제조원이 같은 동일한 제품을 수입하는 경",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        629.5232543945312,
        484.67999267578125,
        640.5632934570312
      ],
      "page_num": 23,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "우에 수입업소명을 병기하여 구분하는 경우",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        144.47999572753906,
        651.4832153320312,
        364.4396667480469,
        662.5232543945312
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 다만, 기허가 제품과 사용목적이 유사하여 허가받은 제품의 제품명",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        120.47999572753906,
        673.563232421875,
        484.6796875,
        684.603271484375
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "에 문자, 단어, 숫자 등을 덧붙이거나 교체한 제품명 기재 가능함.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        145.44000244140625,
        695.5232543945312,
        479.372802734375,
        706.5632934570312
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        98.04000091552734,
        117.91441345214844,
        448.0853271484375,
        126.91441345214844
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 18 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 24,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(주)오송진단",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        153.59999084472656,
        164.2799835205078,
        449.5072937011719,
        176.22203063964844
      ],
      "page_num": 24,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "심질환표지자검사시약",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        153.59999084472656,
        164.2799835205078,
        449.5072937011719,
        176.22203063964844
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "BNP Test",
      "font_size": 9.960000038146973,
      "font_name": "T13",
      "bbox": [
        153.59999084472656,
        164.2799835205078,
        449.5072937011719,
        176.22203063964844
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "⇩",
      "font_size": 9.960000038146973,
      "font_name": "T7",
      "bbox": [
        177.0,
        188.51998901367188,
        432.5999755859375,
        200.4720001220703
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "⇩",
      "font_size": 9.960000038146973,
      "font_name": "T7",
      "bbox": [
        177.0,
        188.51998901367188,
        432.5999755859375,
        200.4720001220703
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "⇩",
      "font_size": 9.960000038146973,
      "font_name": "T7",
      "bbox": [
        177.0,
        188.51998901367188,
        432.5999755859375,
        200.4720001220703
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(제조․수입업소명)",
      "font_size": 9.960000038146973,
      "font_name": "T13",
      "bbox": [
        138.59999084472656,
        212.63998413085938,
        447.6600036621094,
        224.5919952392578
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(품목명)",
      "font_size": 9.960000038146973,
      "font_name": "T13",
      "bbox": [
        138.59999084472656,
        212.63998413085938,
        447.6600036621094,
        224.5919952392578
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(모델명)",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        138.59999084472656,
        212.63998413085938,
        447.6600036621094,
        224.5919952392578
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(주)오송진단",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        143.87998962402344,
        253.4399871826172,
        470.5072937011719,
        265.38201904296875
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "오송IVD",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        143.87998962402344,
        253.4399871826172,
        470.5072937011719,
        265.38201904296875
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "심질환표지자검사시약",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        143.87998962402344,
        253.4399871826172,
        470.5072937011719,
        265.38201904296875
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "BNP Test",
      "font_size": 9.960000038146973,
      "font_name": "T13",
      "bbox": [
        143.87998962402344,
        253.4399871826172,
        470.5072937011719,
        265.38201904296875
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "⇩",
      "font_size": 9.960000038146973,
      "font_name": "T7",
      "bbox": [
        167.27999877929688,
        277.55999755859375,
        453.5999755859375,
        289.5119934082031
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "⇩",
      "font_size": 9.960000038146973,
      "font_name": "T7",
      "bbox": [
        167.27999877929688,
        277.55999755859375,
        453.5999755859375,
        289.5119934082031
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "⇩",
      "font_size": 9.960000038146973,
      "font_name": "T7",
      "bbox": [
        167.27999877929688,
        277.55999755859375,
        453.5999755859375,
        289.5119934082031
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "⇩",
      "font_size": 9.960000038146973,
      "font_name": "T7",
      "bbox": [
        167.27999877929688,
        277.55999755859375,
        453.5999755859375,
        289.5119934082031
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(제조․수입업소명)",
      "font_size": 9.960000038146973,
      "font_name": "T13",
      "bbox": [
        128.87998962402344,
        301.67999267578125,
        468.6600036621094,
        313.6319885253906
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(제품명)",
      "font_size": 9.960000038146973,
      "font_name": "T13",
      "bbox": [
        128.87998962402344,
        301.67999267578125,
        468.6600036621094,
        313.6319885253906
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(품목명)",
      "font_size": 9.960000038146973,
      "font_name": "T13",
      "bbox": [
        128.87998962402344,
        301.67999267578125,
        468.6600036621094,
        313.6319885253906
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(모델명)",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        128.87998962402344,
        301.67999267578125,
        468.6600036621094,
        313.6319885253906
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 별첨 기재시의 예",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        120.47999572753906,
        333.9632873535156,
        222.3599853515625,
        345.0032958984375
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "<제품명>",
      "font_size": 9.960000038146973,
      "font_name": "T13",
      "bbox": [
        125.63999938964844,
        363.1199951171875,
        167.66580200195312,
        375.06201171875
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1. 품목류명 : 심질환표지자검사시약",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        125.63999938964844,
        379.0799865722656,
        290.5185546875,
        391.0220031738281
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 모델명 : BNP Test",
      "font_size": 9.960000038146973,
      "font_name": "T13",
      "bbox": [
        125.63999938964844,
        395.0400085449219,
        224.38731384277344,
        406.9820251464844
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3. 품목분류번호 : D04030.01",
      "font_size": 9.960000038146973,
      "font_name": "T13",
      "bbox": [
        125.63999938964844,
        411.1199951171875,
        255.75961303710938,
        423.06201171875
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4. 등급 : 3등급",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        125.63999938964844,
        427.0799865722656,
        200.5795135498047,
        439.0220031738281
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 13.799982070922852,
      "font_name": "H2hdrM",
      "bbox": [
        121.91999816894531,
        507.1880798339844,
        229.083984375,
        522.068115234375
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모양 및 구조",
      "font_size": 13.799982070922852,
      "font_name": "HYwulM",
      "bbox": [
        121.91999816894531,
        507.1880798339844,
        229.083984375,
        522.068115234375
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 모양 및 구조 - 작용원리",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        554.043212890625,
        255.7196502685547,
        565.083251953125
      ],
      "page_num": 24,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품의 용도 및 배경을 포함하여, 해당 제품을 개발하기 위하여 적용한",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        576.1232299804688,
        488.3560485839844,
        587.1632690429688
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정원리, 적용되는 체외진단의료기기, 필요한 경우 검사 결과의 임상적",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        598.083251953125,
        488.35650634765625,
        609.123291015625
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의의 등을 포함하여 기재한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        620.043212890625,
        265.7566223144531,
        631.083251953125
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 임상적 의의(배경) : 필요에 따라 해당 검사의 임상적 의의(배경)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        664.083251953125,
        488.35638427734375,
        675.123291015625
      ],
      "page_num": 24,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등을 기재할 수 있다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        257.0400085449219,
        686.043212890625,
        363.2127990722656,
        697.083251953125
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅴ. 제조․수입허가 신청서 기재 항목",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        346.91998291015625,
        117.55441284179688,
        481.4460144042969,
        126.55441284179688
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 19 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 25,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 예시",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        143.87998962402344,
        164.2832794189453,
        179.75965881347656,
        175.32327270507812
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이 NT-proBNP 및 BNP 검사는 심장에 대한 혈역학적 부하를",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        153.239990234375,
        186.2432861328125,
        483.196044921875,
        197.2832794189453
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "알 수 있는 바이오마커로 심장 근육층의 호르몬 활성화를 보여준다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        153.239990234375,
        208.20327758789062,
        483.1963806152344,
        219.24327087402344
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "NT-proBNP과 BNP 물질은 혈역학적 부하로 좌심실이 비대해",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        153.239990234375,
        230.2832794189453,
        479.5196838378906,
        241.32327270507812
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "질 때 1:1의 비율로 나눠진다. 이들 펩타이드 수치가 증가하면",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        153.239990234375,
        252.2432861328125,
        483.196044921875,
        263.2832946777344
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "심부전과 연관이 있게 되며 두 물질 모두 울혈성심부전 진단에",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        153.239990234375,
        274.2032775878906,
        483.196044921875,
        285.2432861328125
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유용하게 사용된다. 이러한 뇌나트륨이뇨펩티드는 심정지와",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        153.239990234375,
        296.28326416015625,
        483.19610595703125,
        307.3232727050781
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상관없이 심장 기능에 문제가 있을 경우 혈관 벽에서 말초혈액으로",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        153.239990234375,
        318.2432861328125,
        483.1963806152344,
        329.2832946777344
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분비되므로 심부전을 진단하는 중요 표지자로 활용된다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        153.239990234375,
        340.2032775878906,
        436.8927917480469,
        351.2432861328125
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 작용원리 : 해당 진단의 측정 원리를 아래의 예와 같이 작성한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        392.7632751464844,
        476.372802734375,
        403.80328369140625
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 모양 및 구조 - 외형",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        662.6432495117188,
        233.75999450683594,
        673.6832885742188
      ],
      "page_num": 25,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 외형사진 : 제품을 육안으로 식별할 수 있도록 제품의 전체 및",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        684.7232666015625,
        488.2360534667969,
        695.7633056640625
      ],
      "page_num": 25,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 예시",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        143.87998962402344,
        423.2432861328125,
        179.75965881347656,
        434.2832946777344
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "본 제품에는 면역형광법이 사용되며 다음과 같은 반응으로 이루어진다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        153.239990234375,
        445.2032775878906,
        477.4527893066406,
        456.2432861328125
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 투입구에 검체를 주입한 뒤, 혈구 세포는 디바이스에 내장",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        165.0,
        467.16326904296875,
        479.6399841308594,
        478.2032775878906
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "되어 있는 필터에서 혈장과 분리된다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        182.75999450683594,
        489.2432861328125,
        372.81280517578125,
        500.2832946777344
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 일정량의 혈장이 반응부분 내에서 형광 접합된 polyclonal",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        165.0,
        511.2032775878906,
        483.197509765625,
        522.2432861328125
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "antibody against BNP와 반응을 한다. 화합물이 충분히",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        183.0,
        533.1632690429688,
        483.196044921875,
        544.2033081054688
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "반응이 일어 난 뒤, 반응물은 디바이스의 고정체로 이동하고",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        183.0,
        555.2432250976562,
        483.3163757324219,
        566.2832641601562
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "각각의 반응 영역에서는 측정하고자 하는 물질과 형광 항체",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        183.0,
        577.2032470703125,
        483.3163757324219,
        588.2432861328125
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "접합체의 혼합물이 검출된다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        183.0,
        599.1632690429688,
        329.2527770996094,
        610.2033081054688
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3) 형광 발색량은 검체 중 분석물의 농도와 정비례 한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        165.0,
        621.2432250976562,
        458.5962829589844,
        632.2832641601562
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        98.04000091552734,
        117.91441345214844,
        448.0853271484375,
        126.91441345214844
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 20 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 26,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구성하는 시약을 확인할 수 있는 컬러사진을 첨부한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        208.44000244140625,
        155.76327514648438,
        484.05279541015625,
        166.8032684326172
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나. 외관설명 : 고형의 구성제품에 대해서는 모양․구조․중량 등을, 액상",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        177.72328186035156,
        488.3560485839844,
        188.76327514648438
      ],
      "page_num": 26,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는 분말의 시약에 대해서는 색, 성상, 액성, 냄새 등을",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        205.44000244140625,
        199.80328369140625,
        488.35638427734375,
        210.84327697753906
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기재한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        205.44000244140625,
        221.76327514648438,
        252.69281005859375,
        232.8032684326172
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다. 구성 : 만일 체외진단용 의료기기와 별도의 구성품을 포함하고자 할",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        243.72328186035156,
        488.35638427734375,
        254.76327514648438
      ],
      "page_num": 26,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우, 별도판매구성품에 대하여 추가로 외관사진 및 구성표를",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        186.239990234375,
        265.80328369140625,
        488.35638427734375,
        276.8432922363281
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제시한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        186.239990234375,
        287.7632751464844,
        233.49281311035156,
        298.80328369140625
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "본 제품은 체외진단용 의료기기(proBNP test kit)와 별도판매구",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        143.75999450683594,
        339.2432861328125,
        479.3999938964844,
        350.2832946777344
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "성품(proBNP Calset)으로 구성된다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        143.75999450683594,
        361.3232727050781,
        322.05279541015625,
        372.36328125
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1. 체외진단용 의료기기 - proBNP test kit",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        143.75999450683594,
        393.2432861328125,
        358.4994812011719,
        404.2832946777344
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일련번호",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        155.0399932861328,
        422.3703308105469,
        452.8795166015625,
        432.330322265625
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "명 칭",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        155.0399932861328,
        422.3703308105469,
        452.8795166015625,
        432.330322265625
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "세부 구성",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        155.0399932861328,
        422.3703308105469,
        452.8795166015625,
        432.330322265625
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "외관상 특징",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        155.0399932861328,
        422.3703308105469,
        452.8795166015625,
        432.330322265625
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        172.0800018310547,
        440.850341796875,
        465.3599853515625,
        450.8103332519531
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Reagent 1",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        172.0800018310547,
        440.850341796875,
        465.3599853515625,
        450.8103332519531
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "단일구성",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        172.0800018310547,
        440.850341796875,
        465.3599853515625,
        450.8103332519531
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "투명한 액상 시약",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        172.0800018310547,
        440.850341796875,
        465.3599853515625,
        450.8103332519531
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        172.0800018310547,
        459.330322265625,
        465.3599853515625,
        469.2903137207031
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Reagent 2",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        172.0800018310547,
        459.330322265625,
        465.3599853515625,
        469.2903137207031
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "단일구성",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        172.0800018310547,
        459.330322265625,
        465.3599853515625,
        469.2903137207031
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "투명한 액상 시약",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        172.0800018310547,
        459.330322265625,
        465.3599853515625,
        469.2903137207031
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        172.0800018310547,
        477.8103332519531,
        465.3599853515625,
        487.77032470703125
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Reagent 3",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        172.0800018310547,
        477.8103332519531,
        465.3599853515625,
        487.77032470703125
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "단일구성",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        172.0800018310547,
        477.8103332519531,
        465.3599853515625,
        487.77032470703125
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "투명한 액상 시약",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        172.0800018310547,
        477.8103332519531,
        465.3599853515625,
        487.77032470703125
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "<외관사진>",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        154.8000030517578,
        527.8832397460938,
        213.4364013671875,
        538.9232788085938
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ⅴ. 제조․수입허가 신청서 기재 항목",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        346.91998291015625,
        117.55441284179688,
        481.4460144042969,
        126.55441284179688
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 21 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 27,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그림 1. 외관사진 작성의 예",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        226.79998779296875,
        668.5232543945312,
        368.3999938964844,
        679.5632934570312
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2. 별도판매구성품 - proBNP CalSet",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        143.75999450683594,
        355.2032775878906,
        320.3409423828125,
        366.2432861328125
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일련번호",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        157.9199981689453,
        383.0103454589844,
        455.6399841308594,
        392.9703369140625
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "명 칭",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        157.9199981689453,
        383.0103454589844,
        455.6399841308594,
        392.9703369140625
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "세부 구성",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        157.9199981689453,
        383.0103454589844,
        455.6399841308594,
        392.9703369140625
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "외관상 특징",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        157.9199981689453,
        383.0103454589844,
        455.6399841308594,
        392.9703369140625
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        174.95999145507812,
        398.6103515625,
        460.67999267578125,
        408.5703430175781
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Cal 1",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        174.95999145507812,
        398.6103515625,
        460.67999267578125,
        408.5703430175781
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "단일구성",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        174.95999145507812,
        398.6103515625,
        460.67999267578125,
        408.5703430175781
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "동결건조 시약",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        174.95999145507812,
        398.6103515625,
        460.67999267578125,
        408.5703430175781
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        174.95999145507812,
        414.3303527832031,
        460.67999267578125,
        424.29034423828125
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Cal 2",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        174.95999145507812,
        414.3303527832031,
        460.67999267578125,
        424.29034423828125
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "단일구성",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        174.95999145507812,
        414.3303527832031,
        460.67999267578125,
        424.29034423828125
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "동결건조 시약",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        174.95999145507812,
        414.3303527832031,
        460.67999267578125,
        424.29034423828125
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        174.95999145507812,
        429.9303283691406,
        450.7195129394531,
        439.89031982421875
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Bottle 1",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        174.95999145507812,
        429.9303283691406,
        450.7195129394531,
        439.89031982421875
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "단일구성",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        174.95999145507812,
        429.9303283691406,
        450.7195129394531,
        439.89031982421875
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "액상 시약",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        174.95999145507812,
        429.9303283691406,
        450.7195129394531,
        439.89031982421875
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        174.95999145507812,
        445.53033447265625,
        450.7195129394531,
        455.4903259277344
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Bottle 2",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        174.95999145507812,
        445.53033447265625,
        450.7195129394531,
        455.4903259277344
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "단일구성",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        174.95999145507812,
        445.53033447265625,
        450.7195129394531,
        455.4903259277344
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "액상 시약",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        174.95999145507812,
        445.53033447265625,
        450.7195129394531,
        455.4903259277344
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "<외관사진>",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        143.75999450683594,
        472.2032775878906,
        207.4364013671875,
        483.2432861328125
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        98.04000091552734,
        117.91441345214844,
        448.0853271484375,
        126.91441345214844
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 22 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 28,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3",
      "font_size": 13.799982070922852,
      "font_name": "H2hdrM",
      "bbox": [
        121.91999816894531,
        161.10809326171875,
        189.12388610839844,
        175.86807250976562
      ],
      "page_num": 28,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "원재료",
      "font_size": 13.799982070922852,
      "font_name": "HYwulM",
      "bbox": [
        121.91999816894531,
        161.10809326171875,
        189.12388610839844,
        175.86807250976562
      ],
      "page_num": 28,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 원재료는 다음 양식의 표를 사용하여 기재한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        207.96328735351562,
        365.2527770996094,
        219.00328063964844
      ],
      "page_num": 28,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 별도판매구성품이 있을 경우에는 원재료를 함께 기재한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        316.68328857421875,
        419.0127868652344,
        327.7232971191406
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 명칭 : 보조시약을 포함하여 해당 구성시약별로 일반명칭을 기재한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        338.6432800292969,
        488.35638427734375,
        349.68328857421875
      ],
      "page_num": 28,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "두 세트 이상이 함께 사용되어 하나의 사용목적을 달성하는",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        182.63999938964844,
        360.603271484375,
        488.35638427734375,
        371.6432800292969
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우에는 세트별로 구분하여 기재한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        182.63999938964844,
        382.68328857421875,
        378.3327941894531,
        393.7232971191406
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 배합목적 : 체외진단용 의료기기의 특성에 맞게 각 성분의 배합목",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        404.6432800292969,
        484.6796875,
        415.68328857421875
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적을 기재한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        205.55999755859375,
        426.603271484375,
        280.17279052734375,
        437.6432800292969
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다. 원재료명 또는 성분명 : 각 구성 시약의 원재료명 또는 성분명을",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        448.68328857421875,
        488.2357482910156,
        459.7232971191406
      ],
      "page_num": 28,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기재한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        275.5199890136719,
        470.6432800292969,
        322.7727966308594,
        481.68328857421875
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라. 분량",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        492.603271484375,
        167.2799835205078,
        503.6432800292969
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 반응주성분에 대하여 해당 분량을 명시하고 항체의 경우 가급적",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        514.6832275390625,
        488.3560485839844,
        525.7232666015625
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "역가를 기재한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        157.55999755859375,
        536.6432495117188,
        243.2128143310547,
        547.6832885742188
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 제품의 특성에 따라 그 외의(반응보조제, 보존제, 반응안정제,",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        558.603271484375,
        488.35662841796875,
        569.643310546875
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "반응정지제, 희석액 등) 성분은 적량으로 표시 가능",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        160.0800018310547,
        580.6832275390625,
        421.67999267578125,
        591.7232666015625
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3) 단위는 ml, v/v, w/v, w/w 등으로 기재하고 범위의 설정도 가능",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        602.6432495117188,
        482.2796630859375,
        613.6832885742188
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "마. 규격 : 원재료에 대한 규격이 있는 경우 당해 규격(KP, USP 등)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        624.6032104492188,
        484.5599670410156,
        635.6432495117188
      ],
      "page_num": 28,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "을 기재하고 규격이 없는 경우 자사규격 등을 기재한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        184.44000244140625,
        646.6832275390625,
        467.9727783203125,
        657.7232666015625
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "바. 비고 : 비고란에는 각 구성 시약의 총량 및 수량 등을 기재한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        668.6432495117188,
        470.852783203125,
        679.6832885742188
      ],
      "page_num": 28,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일련",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        117.5999984741211,
        237.09034729003906,
        137.27996826171875,
        247.05035400390625
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "번호",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        117.5999984741211,
        245.13034057617188,
        241.5171356201172,
        263.0103454589844
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "명칭",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        117.5999984741211,
        245.13034057617188,
        241.5171356201172,
        263.0103454589844
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "배합목적",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        117.5999984741211,
        245.13034057617188,
        241.5171356201172,
        263.0103454589844
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "원재료명 또는",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        260.3999938964844,
        237.09034729003906,
        326.95672607421875,
        247.05035400390625
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성분명",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        277.32000732421875,
        245.13034057617188,
        473.2804260253906,
        263.0103454589844
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분량",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        277.32000732421875,
        245.13034057617188,
        473.2804260253906,
        263.0103454589844
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "규격",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        277.32000732421875,
        245.13034057617188,
        473.2804260253906,
        263.0103454589844
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비고",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        277.32000732421875,
        245.13034057617188,
        473.2804260253906,
        263.0103454589844
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅴ. 제조․수입허가 신청서 기재 항목",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        346.91998291015625,
        117.55441284179688,
        481.4460144042969,
        126.55441284179688
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 23 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 29,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표 1. 원재료 작성의 예",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        155.76327514648438,
        235.5599822998047,
        166.8032684326172
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 체외진단용 의료기기 - proBNP test kit",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        117.0,
        180.60328674316406,
        331.8594665527344,
        191.64328002929688
      ],
      "page_num": 29,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2. 별도판매구성품 - proBNP CalSet",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        117.0,
        483.36328125,
        293.7001953125,
        494.4032897949219
      ],
      "page_num": 29,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일련",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        121.79999542236328,
        206.8184814453125,
        137.87998962402344,
        214.8584747314453
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "번호",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        121.79999542236328,
        213.29847717285156,
        342.8402099609375,
        227.69847106933594
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "명칭",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        121.79999542236328,
        213.29847717285156,
        342.8402099609375,
        227.69847106933594
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "배합목적",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        121.79999542236328,
        213.29847717285156,
        342.8402099609375,
        227.69847106933594
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "원재료명 또는 성분명",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        121.79999542236328,
        213.29847717285156,
        342.8402099609375,
        227.69847106933594
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분량",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        372.0,
        206.8184814453125,
        387.960205078125,
        214.8584747314453
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "w/v",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        372.9599914550781,
        213.29847717285156,
        462.3599853515625,
        227.69847106933594
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "규격",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        372.9599914550781,
        213.29847717285156,
        462.3599853515625,
        227.69847106933594
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비고",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        372.9599914550781,
        213.29847717285156,
        462.3599853515625,
        227.69847106933594
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        127.43999481201172,
        258.7784729003906,
        183.22946166992188,
        266.8184814453125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Reagent 1",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        127.43999481201172,
        258.7784729003906,
        183.22946166992188,
        266.8184814453125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "주성분",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        201.0,
        231.89846801757812,
        343.8382873535156,
        246.2984619140625
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Streptavidin-coated",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        201.0,
        231.89846801757812,
        343.8382873535156,
        246.2984619140625
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "microparticles",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        275.5199890136719,
        238.2584686279297,
        429.8402099609375,
        252.65846252441406
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        275.5199890136719,
        238.2584686279297,
        429.8402099609375,
        252.65846252441406
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자사규격",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        275.5199890136719,
        238.2584686279297,
        429.8402099609375,
        252.65846252441406
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1x6.5 mL",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        196.9199981689453,
        258.2984619140625,
        473.0145263671875,
        266.8184814453125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보조성분",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        196.9199981689453,
        258.2984619140625,
        473.0145263671875,
        266.8184814453125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "HEPES Buffer",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        196.9199981689453,
        258.2984619140625,
        473.0145263671875,
        266.8184814453125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적량",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        196.9199981689453,
        258.2984619140625,
        473.0145263671875,
        266.8184814453125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자사규격",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        196.9199981689453,
        258.2984619140625,
        473.0145263671875,
        266.8184814453125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보조성분",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        196.9199981689453,
        270.9706726074219,
        429.8402099609375,
        280.01849365234375
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Oxypyrion1)",
      "font_size": 5.159999847412109,
      "font_name": "Batang",
      "bbox": [
        196.9199981689453,
        270.9706726074219,
        429.8402099609375,
        280.01849365234375
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적량",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        196.9199981689453,
        270.9706726074219,
        429.8402099609375,
        280.01849365234375
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자사규격",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        196.9199981689453,
        270.9706726074219,
        429.8402099609375,
        280.01849365234375
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보조성분",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        196.9199981689453,
        285.6584777832031,
        429.8402099609375,
        293.698486328125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Bovine serum albumin",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        196.9199981689453,
        285.6584777832031,
        429.8402099609375,
        293.698486328125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적량",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        196.9199981689453,
        285.6584777832031,
        429.8402099609375,
        293.698486328125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자사규격",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        196.9199981689453,
        285.6584777832031,
        429.8402099609375,
        293.698486328125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        129.83999633789062,
        332.9384765625,
        183.22946166992188,
        340.9784851074219
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Reagent 2",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        129.83999633789062,
        332.9384765625,
        183.22946166992188,
        340.9784851074219
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "주성분",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        201.0,
        305.698486328125,
        225.0001983642578,
        313.7384948730469
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Mouse monoclonal cardiac",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        252.239990234375,
        299.2184753417969,
        370.9566955566406,
        307.25848388671875
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "NT-proBNP antibody",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        262.32000732421875,
        305.698486328125,
        429.8402099609375,
        320.0984802246094
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "0.5",
      "font_size": 8.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        262.32000732421875,
        305.698486328125,
        429.8402099609375,
        320.0984802246094
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자사규격",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        262.32000732421875,
        305.698486328125,
        429.8402099609375,
        320.0984802246094
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1x10mL",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        439.44000244140625,
        332.9384765625,
        469.17486572265625,
        340.9784851074219
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보조성분",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        196.9199981689453,
        325.73846435546875,
        429.8402099609375,
        333.7784729003906
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Buffer",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        196.9199981689453,
        325.73846435546875,
        429.8402099609375,
        333.7784729003906
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적량",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        196.9199981689453,
        325.73846435546875,
        429.8402099609375,
        333.7784729003906
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자사규격",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        196.9199981689453,
        325.73846435546875,
        429.8402099609375,
        333.7784729003906
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보조성분",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        196.9199981689453,
        339.4184875488281,
        429.8402099609375,
        347.45849609375
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Oxypyrion",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        196.9199981689453,
        339.4184875488281,
        429.8402099609375,
        347.45849609375
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적량",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        196.9199981689453,
        339.4184875488281,
        429.8402099609375,
        347.45849609375
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자사규격",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        196.9199981689453,
        339.4184875488281,
        429.8402099609375,
        347.45849609375
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보조성분",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        196.9199981689453,
        352.9784851074219,
        429.8402099609375,
        361.01849365234375
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Bovine serum albumin",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        196.9199981689453,
        352.9784851074219,
        429.8402099609375,
        361.01849365234375
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적량",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        196.9199981689453,
        352.9784851074219,
        429.8402099609375,
        361.01849365234375
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자사규격",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        196.9199981689453,
        352.9784851074219,
        429.8402099609375,
        361.01849365234375
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보조성분",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        196.9199981689453,
        366.6584777832031,
        429.8402099609375,
        374.698486328125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Mouse IgG",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        196.9199981689453,
        366.6584777832031,
        429.8402099609375,
        374.698486328125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적량",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        196.9199981689453,
        366.6584777832031,
        429.8402099609375,
        374.698486328125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자사규격",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        196.9199981689453,
        366.6584777832031,
        429.8402099609375,
        374.698486328125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        129.83999633789062,
        414.0584716796875,
        183.22946166992188,
        422.0984802246094
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Reagent 3",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        129.83999633789062,
        414.0584716796875,
        183.22946166992188,
        422.0984802246094
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "주성분",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        201.0,
        380.3384704589844,
        369.5166931152344,
        394.7384948730469
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Mouse monoclonal cardiac",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        201.0,
        380.3384704589844,
        369.5166931152344,
        394.7384948730469
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "NT-proBNP antibody fragment",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        246.47999572753906,
        393.178466796875,
        359.1694641113281,
        401.2184753417969
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        377.5199890136719,
        386.698486328125,
        429.8402099609375,
        394.7384948730469
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자사규격",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        377.5199890136719,
        386.698486328125,
        429.8402099609375,
        394.7384948730469
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1x10mL",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        439.44000244140625,
        414.0584716796875,
        469.17486572265625,
        422.0984802246094
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보조성분",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        196.9199981689453,
        406.73846435546875,
        429.8402099609375,
        414.7784729003906
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "HEPES Buffer",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        196.9199981689453,
        406.73846435546875,
        429.8402099609375,
        414.7784729003906
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적량",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        196.9199981689453,
        406.73846435546875,
        429.8402099609375,
        414.7784729003906
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자사규격",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        196.9199981689453,
        406.73846435546875,
        429.8402099609375,
        414.7784729003906
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보조성분",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        196.9199981689453,
        420.41845703125,
        429.8402099609375,
        428.4584655761719
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Oxypyrion",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        196.9199981689453,
        420.41845703125,
        429.8402099609375,
        428.4584655761719
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적량",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        196.9199981689453,
        420.41845703125,
        429.8402099609375,
        428.4584655761719
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자사규격",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        196.9199981689453,
        420.41845703125,
        429.8402099609375,
        428.4584655761719
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보조성분",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        196.9199981689453,
        434.0984802246094,
        429.8402099609375,
        442.13848876953125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Mouse IgG",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        196.9199981689453,
        434.0984802246094,
        429.8402099609375,
        442.13848876953125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적량",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        196.9199981689453,
        434.0984802246094,
        429.8402099609375,
        442.13848876953125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자사규격",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        196.9199981689453,
        434.0984802246094,
        429.8402099609375,
        442.13848876953125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보조성분",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        196.9199981689453,
        447.7784729003906,
        429.8402099609375,
        455.8184814453125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Bovine serum albumin",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        196.9199981689453,
        447.7784729003906,
        429.8402099609375,
        455.8184814453125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적량",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        196.9199981689453,
        447.7784729003906,
        429.8402099609375,
        455.8184814453125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자사규격",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        196.9199981689453,
        447.7784729003906,
        429.8402099609375,
        455.8184814453125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일련",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        124.91999816894531,
        509.5784606933594,
        140.88018798828125,
        517.6184692382812
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "번호",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        124.91999816894531,
        516.0584106445312,
        327.3600158691406,
        530.45849609375
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "명칭",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        124.91999816894531,
        516.0584106445312,
        327.3600158691406,
        530.45849609375
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "배합목적",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        124.91999816894531,
        516.0584106445312,
        327.3600158691406,
        530.45849609375
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "원재료명 또는 성분명",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        124.91999816894531,
        516.0584106445312,
        327.3600158691406,
        530.45849609375
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분량",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        361.0799865722656,
        509.5784606933594,
        377.1600036621094,
        517.6184692382812
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㎍/L",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        360.9599914550781,
        516.0584106445312,
        463.6802062988281,
        530.45849609375
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "규격",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        360.9599914550781,
        516.0584106445312,
        463.6802062988281,
        530.45849609375
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비고",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        360.9599914550781,
        516.0584106445312,
        463.6802062988281,
        530.45849609375
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        130.44000244140625,
        550.2584228515625,
        175.189453125,
        558.2984619140625
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Cal 1",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        130.44000244140625,
        550.2584228515625,
        175.189453125,
        558.2984619140625
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보정물질",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        192.1199951171875,
        535.37841796875,
        432.72021484375,
        543.41845703125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "proBNP (recombinant)",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        192.1199951171875,
        535.37841796875,
        432.72021484375,
        543.41845703125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "approx. 0.6",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        192.1199951171875,
        535.37841796875,
        432.72021484375,
        543.41845703125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자사규격",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        192.1199951171875,
        535.37841796875,
        432.72021484375,
        543.41845703125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2.5x",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        447.3599853515625,
        543.8984375,
        463.98809814453125,
        551.9384765625
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1mL",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        447.3599853515625,
        556.7384643554688,
        464.0146179199219,
        564.7785034179688
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보조성분",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        192.1199951171875,
        549.7784423828125,
        432.72021484375,
        557.8184814453125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Human serum",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        192.1199951171875,
        549.7784423828125,
        432.72021484375,
        557.8184814453125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적량",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        192.1199951171875,
        549.7784423828125,
        432.72021484375,
        557.8184814453125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자사규격",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        192.1199951171875,
        549.7784423828125,
        432.72021484375,
        557.8184814453125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보조성분",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        192.1199951171875,
        564.658447265625,
        432.72021484375,
        572.698486328125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Buffer",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        192.1199951171875,
        564.658447265625,
        432.72021484375,
        572.698486328125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적량",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        192.1199951171875,
        564.658447265625,
        432.72021484375,
        572.698486328125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자사규격",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        192.1199951171875,
        564.658447265625,
        432.72021484375,
        572.698486328125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        130.44000244140625,
        595.138427734375,
        175.189453125,
        603.178466796875
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Cal 2",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        130.44000244140625,
        595.138427734375,
        175.189453125,
        603.178466796875
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보정물질",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        192.1199951171875,
        580.2584228515625,
        432.72021484375,
        588.2984619140625
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "proBNP (recombinant)",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        192.1199951171875,
        580.2584228515625,
        432.72021484375,
        588.2984619140625
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "approx. 40",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        192.1199951171875,
        580.2584228515625,
        432.72021484375,
        588.2984619140625
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자사규격",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        192.1199951171875,
        580.2584228515625,
        432.72021484375,
        588.2984619140625
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2.5x",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        447.3599853515625,
        588.7784423828125,
        463.98809814453125,
        596.8184814453125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1mL",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        447.3599853515625,
        601.618408203125,
        464.0146179199219,
        609.658447265625
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보조성분",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        192.1199951171875,
        594.658447265625,
        432.72021484375,
        602.698486328125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Human serum",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        192.1199951171875,
        594.658447265625,
        432.72021484375,
        602.698486328125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적량",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        192.1199951171875,
        594.658447265625,
        432.72021484375,
        602.698486328125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자사규격",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        192.1199951171875,
        594.658447265625,
        432.72021484375,
        602.698486328125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보조성분",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        192.1199951171875,
        609.5384521484375,
        432.72021484375,
        617.5784912109375
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Phosphate buffer",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        192.1199951171875,
        609.5384521484375,
        432.72021484375,
        617.5784912109375
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적량",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        192.1199951171875,
        609.5384521484375,
        432.72021484375,
        617.5784912109375
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "자사규격",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        192.1199951171875,
        609.5384521484375,
        432.72021484375,
        617.5784912109375
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        98.04000091552734,
        117.91441345214844,
        448.0853271484375,
        126.91441345214844
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 24 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 30,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4",
      "font_size": 13.799982070922852,
      "font_name": "H2hdrM",
      "bbox": [
        121.91999816894531,
        161.10809326171875,
        202.4438018798828,
        175.86807250976562
      ],
      "page_num": 30,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조방법",
      "font_size": 13.799982070922852,
      "font_name": "HYwulM",
      "bbox": [
        121.91999816894531,
        161.10809326171875,
        202.4438018798828,
        175.86807250976562
      ],
      "page_num": 30,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. '제조원의 제조방법에 따른다.’라고 기재한다. 다만, 다음 각 호에 해당",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        207.96328735351562,
        484.67999267578125,
        219.00328063964844
      ],
      "page_num": 30,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하는 경우에는 해당사항을 부가하여 기재한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        127.55999755859375,
        229.92327880859375,
        361.6528015136719,
        240.96327209472656
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가. 멸균의료기기의 제조방법의 경우 멸균방법은 식약처장이 인정하는",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        127.55999755859375,
        251.88327026367188,
        493.8761901855469,
        262.92327880859375
      ],
      "page_num": 30,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "멸균의료기기의 멸균방법 [의료기기 허가신고심사 등에 관한 규정,",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        127.55999755859375,
        273.9632873535156,
        493.8766174316406,
        285.0032958984375
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "별표 2] 또는 이와 동등이상 규격의 멸균방법을 기재한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        127.55999755859375,
        295.92327880859375,
        441.6927795410156,
        306.9632873535156
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5",
      "font_size": 13.799982070922852,
      "font_name": "H2hdrM",
      "bbox": [
        121.91999816894531,
        345.3080749511719,
        238.5543212890625,
        360.0680847167969
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사용목적(성능)",
      "font_size": 13.799982070922852,
      "font_name": "HYwulM",
      "bbox": [
        121.91999816894531,
        345.3080749511719,
        238.5543212890625,
        360.0680847167969
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1. 사용목적은 성능을 포함하여 다음에 따라 기재한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        392.16326904296875,
        387.2127990722656,
        403.2032775878906
      ],
      "page_num": 30,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2. 사용목적은 근거자료에 따라 검사대상, 검체종류, 검사항목, 측정원리",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        413.16326904296875,
        488.3560485839844,
        424.2032775878906
      ],
      "page_num": 30,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 정성, 반정량 또는 정량 등을 구체적으로 기재한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        127.55999755859375,
        435.1232604980469,
        403.29278564453125,
        446.16326904296875
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 예시 : 사람의 전혈 또는 혈장에서 pro Brain-type natriuretic",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        134.0399932861328,
        464.8832702636719,
        481.7559814453125,
        475.92327880859375
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "peptide(proBNP)를 면역형광측정법으로 정량하는 체외",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        188.63999938964844,
        486.9632873535156,
        478.20001220703125,
        498.0032958984375
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "진단용 의료기기이다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        188.63999938964844,
        508.9232482910156,
        293.1327819824219,
        519.9632568359375
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가. 검사대상",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        535.2032470703125,
        189.23965454101562,
        546.2432861328125
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 검체종류 : 해당 제품의 적용이 가능한 검체의 종류를 기술한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        557.1632690429688,
        470.9727783203125,
        568.2033081054688
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사람의 혈청, 혈장, 전혈(정맥, 모세관) 등을 포함한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        204.95999145507812,
        579.1232299804688,
        481.6528015136719,
        590.1632690429688
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다. 검사항목 : 검출대상이 되는 물질",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        601.2032470703125,
        311.64007568359375,
        612.2432861328125
      ],
      "page_num": 30,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "라. 측정원리 : 측정에 사용된 검사 원리",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        623.1632690429688,
        330.3600158691406,
        634.2033081054688
      ],
      "page_num": 30,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "마. 정성 또는 정량 : 검사 목적 및 해당 제품의 특성에 따라 정성, 정량,",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        645.1232299804688,
        488.2366027832031,
        656.1632690429688
      ],
      "page_num": 30,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "반정량 검사용 등을 명확하게 기재한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        237.36000061035156,
        667.2032470703125,
        442.1562805175781,
        678.2432861328125
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅴ. 제조․수입허가 신청서 기재 항목",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        346.91998291015625,
        117.55441284179688,
        481.4460144042969,
        126.55441284179688
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 25 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 31,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3. 성능",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        155.76327514648438,
        147.5996551513672,
        166.8032684326172
      ],
      "page_num": 31,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 근거자료를 바탕으로 사용설명서(Instruction for user, IFU)에",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        177.72328186035156,
        488.35638427734375,
        188.76327514648438
      ],
      "page_num": 31,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수치적으로 제시된 성능 기재",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        147.83999633789062,
        199.80328369140625,
        296.2799987792969,
        210.84327697753906
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "❍ 당해 제품의 특성에 맞는 성능을 기재하되, 추상적이고 명확하지",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        130.55999755859375,
        221.76327514648438,
        488.3560485839844,
        232.8032684326172
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "않는 성능 배제, 구체적 근거 자료로 제시",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        148.3199920654297,
        243.72328186035156,
        360.35968017578125,
        254.76327514648438
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "표 2. 성능 작성의 예",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        265.80328369140625,
        224.51998901367188,
        276.8432922363281
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "번호",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        123.36000061035156,
        289.8903503417969,
        370.0799865722656,
        299.850341796875
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "성능항목",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        123.36000061035156,
        289.8903503417969,
        370.0799865722656,
        299.850341796875
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "방법 및 결과",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        123.36000061035156,
        289.8903503417969,
        370.0799865722656,
        299.850341796875
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        130.44000244140625,
        313.41033935546875,
        136.24676513671875,
        323.3703308105469
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분석적",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        159.47999572753906,
        305.3703308105469,
        192.7962646484375,
        315.330322265625
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "민감도",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        159.47999572753906,
        321.4503479003906,
        189.47952270507812,
        331.41033935546875
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "・측정범위(Measuring range) : 5-30000 pg/mL",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        304.53033447265625,
        430.6648864746094,
        314.4903259277344
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "・검출한계(Limits of measurement) : 5pg/mL",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        322.53033447265625,
        419.7447204589844,
        332.4903259277344
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        130.44000244140625,
        512.0103759765625,
        136.24676513671875,
        521.9703369140625
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분석적",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        159.47999572753906,
        496.0503234863281,
        192.7962646484375,
        506.01031494140625
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "특이도",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        159.47999572753906,
        512.0103759765625,
        189.47952270507812,
        521.9703369140625
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(교차반응성)",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        149.75999450683594,
        528.0903930664062,
        199.25999450683594,
        538.0503540039062
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 간섭 약물",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        335.2503356933594,
        262.91998291015625,
        345.2103271484375
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "BNP Test에서의 잠재적 교차반응 및 간섭에 대하여 다음",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        353.2503356933594,
        481.39630126953125,
        363.2103271484375
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "약품을 평가하였다. 모든 약품은 최대 치료 용량 및 최대",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        369.3303527832031,
        481.397216796875,
        379.29034423828125
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "치료 용량에 의한 혈중 농도의 2배 이상에서 간섭반응을",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        385.29034423828125,
        481.3967590332031,
        395.2503356933594
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보이지 않았다.",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        401.2503356933594,
        270.0185241699219,
        411.2103271484375
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아브시심아브",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        226.9199981689453,
        424.37847900390625,
        457.3204040527344,
        432.4184875488281
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "도파민",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        226.9199981689453,
        424.37847900390625,
        457.3204040527344,
        432.4184875488281
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "니트로글리세린",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        226.9199981689453,
        424.37847900390625,
        457.3204040527344,
        432.4184875488281
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아세트아미노펜",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        222.83999633789062,
        440.0984802246094,
        449.40020751953125,
        448.13848876953125
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "말레인산에날라프릴",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        222.83999633789062,
        440.0984802246094,
        449.40020751953125,
        448.13848876953125
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "노라민피린",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        222.83999633789062,
        440.0984802246094,
        449.40020751953125,
        448.13848876953125
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아세틸살리실산",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        222.83999633789062,
        455.8184814453125,
        445.3201904296875,
        463.8584899902344
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "디피리다몰",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        222.83999633789062,
        455.8184814453125,
        445.3201904296875,
        463.8584899902344
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "옥사제팜",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        222.83999633789062,
        455.8184814453125,
        445.3201904296875,
        463.8584899902344
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "액티베이즈",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        230.87998962402344,
        471.5384826660156,
        465.3606262207031,
        479.5784912109375
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "에리스로마이신",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        230.87998962402344,
        471.5384826660156,
        465.3606262207031,
        479.5784912109375
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "옥시테트라사이클린",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        230.87998962402344,
        471.5384826660156,
        465.3606262207031,
        479.5784912109375
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "알로퓨리놀",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        230.87998962402344,
        487.1384582519531,
        453.36041259765625,
        495.178466796875
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "푸로세미드",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        230.87998962402344,
        487.1384582519531,
        453.36041259765625,
        495.178466796875
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "페노바르비탈",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        230.87998962402344,
        487.1384582519531,
        453.36041259765625,
        495.178466796875
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아미오다론",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        230.87998962402344,
        502.85845947265625,
        445.3201904296875,
        510.8984680175781
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "엡티피바티드",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        230.87998962402344,
        502.85845947265625,
        445.3201904296875,
        510.8984680175781
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "페니토인",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        230.87998962402344,
        502.85845947265625,
        445.3201904296875,
        510.8984680175781
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "암피실린",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        234.83999633789062,
        518.5784301757812,
        453.36041259765625,
        526.6184692382812
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "히드랄라진",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        234.83999633789062,
        518.5784301757812,
        453.36041259765625,
        526.6184692382812
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "프로베네시드",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        234.83999633789062,
        518.5784301757812,
        453.36041259765625,
        526.6184692382812
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아스코르빈산",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        226.9199981689453,
        534.2984619140625,
        461.4004211425781,
        542.3385009765625
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하이드로클로로티아지드",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        226.9199981689453,
        534.2984619140625,
        461.4004211425781,
        542.3385009765625
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "프로카이나마이드",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        226.9199981689453,
        534.2984619140625,
        461.4004211425781,
        542.3385009765625
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "암로디핀베실산염",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        218.87998962402344,
        549.8984375,
        449.40020751953125,
        557.9384765625
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "헤파린",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        218.87998962402344,
        549.8984375,
        449.40020751953125,
        557.9384765625
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "프로파놀올",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        218.87998962402344,
        549.8984375,
        449.40020751953125,
        557.9384765625
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아테놀롤",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        234.83999633789062,
        563.2184448242188,
        441.3601989746094,
        581.5784912109375
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이소소르비드",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        234.83999633789062,
        563.2184448242188,
        441.3601989746094,
        581.5784912109375
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "디나이트레이트",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        234.83999633789062,
        563.2184448242188,
        441.3601989746094,
        581.5784912109375
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "퀴니딘",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        234.83999633789062,
        563.2184448242188,
        441.3601989746094,
        581.5784912109375
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "황산수소클로피도그렐",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.55999755859375,
        586.8584594726562,
        453.36041259765625,
        594.8984985351562
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "밀리논유산염",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.55999755859375,
        586.8584594726562,
        453.36041259765625,
        594.8984985351562
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "트리메소프림",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.55999755859375,
        586.8584594726562,
        453.36041259765625,
        594.8984985351562
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "디클로페낙",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        230.87998962402344,
        602.5784301757812,
        445.3201904296875,
        610.6184692382812
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "니코틴",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        230.87998962402344,
        602.5784301757812,
        445.3201904296875,
        610.6184692382812
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "베라파밀",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        230.87998962402344,
        602.5784301757812,
        445.3201904296875,
        610.6184692382812
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "디곡신",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        238.9199981689453,
        618.1784057617188,
        441.3601989746094,
        626.2184448242188
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "니코틴산",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        238.9199981689453,
        618.1784057617188,
        441.3601989746094,
        626.2184448242188
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "와파린",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        238.9199981689453,
        618.1784057617188,
        441.3601989746094,
        626.2184448242188
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "딜티아젬",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        234.83999633789062,
        633.8984375,
        445.3201904296875,
        641.9384765625
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "니페디핀",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        234.83999633789062,
        633.8984375,
        445.3201904296875,
        641.9384765625
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "디기톡신",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        234.83999633789062,
        633.8984375,
        445.3201904296875,
        641.9384765625
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나이트로후란토인",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        218.87998962402344,
        649.618408203125,
        282.9604187011719,
        657.658447265625
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2) 교차반응",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        670.890380859375,
        257.8795166015625,
        680.850341796875
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "아래에 제시된 농도에서 BNP Test와의 잠재적 교차반응에",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        688.890380859375,
        481.3979187011719,
        698.850341796875
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        98.04000091552734,
        117.91441345214844,
        448.0853271484375,
        126.91441345214844
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 26 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 32,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대하여 다음 단백질 및 펩티드를 평가하였다.",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        161.6103515625,
        400.9967346191406,
        171.5703582763672
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "-관련 단백질 및 펩티드와의 반응-",
      "font_size": 8.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        273.47998046875,
        179.45848083496094,
        406.7773742675781,
        187.49847412109375
      ],
      "page_num": 32,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "물질",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        270.7200012207031,
        202.2584686279297,
        464.07000732421875,
        210.2984619140625
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "물질 농도",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        270.7200012207031,
        202.2584686279297,
        464.07000732421875,
        210.2984619140625
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "회수율(%)",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        270.7200012207031,
        202.2584686279297,
        464.07000732421875,
        210.2984619140625
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "레닌",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        270.7200012207031,
        223.49847412109375,
        456.1578063964844,
        231.53846740722656
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "50ng/mL",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        270.7200012207031,
        223.49847412109375,
        456.1578063964844,
        231.53846740722656
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "104%",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        270.7200012207031,
        223.49847412109375,
        456.1578063964844,
        231.53846740722656
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "알도스테론",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        258.7200012207031,
        244.7384796142578,
        456.1578063964844,
        252.77847290039062
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1μg/ml",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        258.7200012207031,
        244.7384796142578,
        456.1578063964844,
        252.77847290039062
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "104%",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        258.7200012207031,
        244.7384796142578,
        456.1578063964844,
        252.77847290039062
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안지오텐신 I",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        255.36000061035156,
        265.85845947265625,
        456.1578063964844,
        273.8984680175781
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "600pg/ml",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        255.36000061035156,
        265.85845947265625,
        456.1578063964844,
        273.8984680175781
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "108%",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        255.36000061035156,
        265.85845947265625,
        456.1578063964844,
        273.8984680175781
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안지오텐신 II",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        254.0399932861328,
        287.0984802246094,
        456.1578063964844,
        295.13848876953125
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "600pg/ml",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        254.0399932861328,
        287.0984802246094,
        456.1578063964844,
        295.13848876953125
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "108%",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        254.0399932861328,
        287.0984802246094,
        456.1578063964844,
        295.13848876953125
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "엔도텔린 I",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        259.32000732421875,
        308.3384704589844,
        456.1578063964844,
        316.37847900390625
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "20pg/ml",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        259.32000732421875,
        308.3384704589844,
        456.1578063964844,
        316.37847900390625
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "101%",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        259.32000732421875,
        308.3384704589844,
        456.1578063964844,
        316.37847900390625
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아드레노메둘린(ADM)",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        238.1999969482422,
        329.5784606933594,
        453.7579345703125,
        337.61846923828125
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,000pg/mL",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        238.1999969482422,
        329.5784606933594,
        453.7579345703125,
        337.61846923828125
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "97%",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        238.1999969482422,
        329.5784606933594,
        453.7579345703125,
        337.61846923828125
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "알파 심방성 나트륨 이뇨",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        230.0399932861328,
        345.5384826660156,
        456.1578063964844,
        364.01849365234375
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "펩티드(Alpha-ANP) 1-28",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        230.0399932861328,
        345.5384826660156,
        456.1578063964844,
        364.01849365234375
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,000pg/mL",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        230.0399932861328,
        345.5384826660156,
        456.1578063964844,
        364.01849365234375
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "104%",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        230.0399932861328,
        345.5384826660156,
        456.1578063964844,
        364.01849365234375
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Prepro BNP 22-46",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        240.95999145507812,
        372.0584716796875,
        456.1578063964844,
        380.0984802246094
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,000pg/mL",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        240.95999145507812,
        372.0584716796875,
        456.1578063964844,
        380.0984802246094
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "104%",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        240.95999145507812,
        372.0584716796875,
        456.1578063964844,
        380.0984802246094
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Prepro BNP 1-21",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        243.36000061035156,
        393.178466796875,
        456.1578063964844,
        401.2184753417969
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,000pg/mL",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        243.36000061035156,
        393.178466796875,
        456.1578063964844,
        401.2184753417969
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "106%",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        243.36000061035156,
        393.178466796875,
        456.1578063964844,
        401.2184753417969
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "알기닌 바소프레신(AVP)",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        233.1599884033203,
        414.41845703125,
        453.7579345703125,
        422.4584655761719
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,000pg/mL",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        233.1599884033203,
        414.41845703125,
        453.7579345703125,
        422.4584655761719
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "96%",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        233.1599884033203,
        414.41845703125,
        453.7579345703125,
        422.4584655761719
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "C형 나트륨 이뇨 펩티드(CNP) 53",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        215.51998901367188,
        435.6584777832031,
        456.1578063964844,
        443.698486328125
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,000pg/mL",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        215.51998901367188,
        435.6584777832031,
        456.1578063964844,
        443.698486328125
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "106%",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        215.51998901367188,
        435.6584777832031,
        456.1578063964844,
        443.698486328125
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Prepro-ANF 56-92",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        240.47999572753906,
        456.8984680175781,
        456.1578063964844,
        464.9384765625
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,000pg/mL",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        240.47999572753906,
        456.8984680175781,
        456.1578063964844,
        464.9384765625
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "104%",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        240.47999572753906,
        456.8984680175781,
        456.1578063964844,
        464.9384765625
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Prepro-ANF 104-123",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        235.67999267578125,
        478.1384582519531,
        453.7579345703125,
        486.178466796875
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,000pg/mL",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        235.67999267578125,
        478.1384582519531,
        453.7579345703125,
        486.178466796875
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "97%",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        235.67999267578125,
        478.1384582519531,
        453.7579345703125,
        486.178466796875
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유로딜라틴(CCD/ANP) 95-126",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        220.44000244140625,
        499.37847900390625,
        456.1578063964844,
        507.4184875488281
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,000pg/mL",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        220.44000244140625,
        499.37847900390625,
        456.1578063964844,
        507.4184875488281
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "100%",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        220.44000244140625,
        499.37847900390625,
        456.1578063964844,
        507.4184875488281
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안지오텐신 III",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        252.72000122070312,
        520.4984130859375,
        456.1578063964844,
        528.5384521484375
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,000pg/mL",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        252.72000122070312,
        520.4984130859375,
        456.1578063964844,
        528.5384521484375
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "108%",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        252.72000122070312,
        520.4984130859375,
        456.1578063964844,
        528.5384521484375
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Prepro-ANF 26-55",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        240.47999572753906,
        541.7384643554688,
        456.1578063964844,
        549.7785034179688
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,000pg/mL",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        240.47999572753906,
        541.7384643554688,
        456.1578063964844,
        549.7785034179688
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "107%",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        240.47999572753906,
        541.7384643554688,
        456.1578063964844,
        549.7785034179688
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        130.44000244140625,
        592.650390625,
        136.24676513671875,
        602.6103515625
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정밀도",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        159.47999572753906,
        576.6903686523438,
        189.47952270507812,
        586.6503295898438
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(반복,",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        161.39999389648438,
        592.650390625,
        190.87718200683594,
        602.6103515625
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "재현성 등)",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        151.0800018310547,
        608.6103515625,
        197.8199920654297,
        618.5703125
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정밀도는",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        560.7303466796875,
        481.3986511230469,
        570.6903076171875
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "CLSI(Clinical",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        560.7303466796875,
        481.3986511230469,
        570.6903076171875
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "and",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        560.7303466796875,
        481.3986511230469,
        570.6903076171875
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Laboratory",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        560.7303466796875,
        481.3986511230469,
        570.6903076171875
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Standards",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        560.7303466796875,
        481.3986511230469,
        570.6903076171875
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Institute)의 프로토콜(EP5-A2)에 따라 본 제품, 사람 혈청",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        576.6903686523438,
        478.0799865722656,
        586.6503295898438
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "풀(pooled human sera) 및 관리물질(controls)을 사용하여",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        592.7703857421875,
        481.3980712890625,
        602.7303466796875
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "결정되었다. 본 연구는 20일 동안 수행되었고, 1일 2회를",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        608.7303466796875,
        481.3967590332031,
        618.6903076171875
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2회씩 반복하여(n=80) 다음의 결과를 얻었다.",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        624.6903686523438,
        421.8185119628906,
        634.6503295898438
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅴ. 제조․수입허가 신청서 기재 항목",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        346.91998291015625,
        117.55441284179688,
        481.4460144042969,
        126.55441284179688
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 27 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 33,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Repeatability",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        352.0799865722656,
        164.45848083496094,
        401.92718505859375,
        172.49847412109375
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Mean",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        308.5199890136719,
        176.57847595214844,
        462.5098571777344,
        184.61846923828125
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "SD",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        308.5199890136719,
        176.57847595214844,
        462.5098571777344,
        184.61846923828125
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "CV",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        308.5199890136719,
        176.57847595214844,
        462.5098571777344,
        184.61846923828125
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "pg/mL",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        286.79998779296875,
        190.7384796142578,
        460.1179504394531,
        198.77847290039062
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "pmol/L",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        286.79998779296875,
        190.7384796142578,
        460.1179504394531,
        198.77847290039062
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "pg/mL",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        286.79998779296875,
        190.7384796142578,
        460.1179504394531,
        198.77847290039062
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "pmol/L",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        286.79998779296875,
        190.7384796142578,
        460.1179504394531,
        198.77847290039062
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "%",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        286.79998779296875,
        190.7384796142578,
        460.1179504394531,
        198.77847290039062
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Human Serum 1",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        205.0184783935547,
        462.5894775390625,
        213.0584716796875
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "50",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        205.0184783935547,
        462.5894775390625,
        213.0584716796875
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "5.9",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        205.0184783935547,
        462.5894775390625,
        213.0584716796875
      ],
      "page_num": 33,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1.7",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        205.0184783935547,
        462.5894775390625,
        213.0584716796875
      ],
      "page_num": 33,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "0.21",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        205.0184783935547,
        462.5894775390625,
        213.0584716796875
      ],
      "page_num": 33,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3.5",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        205.0184783935547,
        462.5894775390625,
        213.0584716796875
      ],
      "page_num": 33,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Human Serum 2",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        217.8584747314453,
        462.5894775390625,
        225.89846801757812
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "120.7",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        217.8584747314453,
        462.5894775390625,
        225.89846801757812
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "14.2",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        217.8584747314453,
        462.5894775390625,
        225.89846801757812
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2.4",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        217.8584747314453,
        462.5894775390625,
        225.89846801757812
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "0.28",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        217.8584747314453,
        462.5894775390625,
        225.89846801757812
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2.0",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        217.8584747314453,
        462.5894775390625,
        225.89846801757812
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Human Serum 3",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        230.69847106933594,
        462.5894775390625,
        238.73846435546875
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "358.7",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        230.69847106933594,
        462.5894775390625,
        238.73846435546875
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "42",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        230.69847106933594,
        462.5894775390625,
        238.73846435546875
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6.43",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        230.69847106933594,
        462.5894775390625,
        238.73846435546875
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "0.75",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        230.69847106933594,
        462.5894775390625,
        238.73846435546875
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1.8",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        230.69847106933594,
        462.5894775390625,
        238.73846435546875
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Human Serum 4",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        242.45848083496094,
        462.5894775390625,
        250.49847412109375
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "794.7",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        242.45848083496094,
        462.5894775390625,
        250.49847412109375
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "93.5",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        242.45848083496094,
        462.5894775390625,
        250.49847412109375
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "14.9",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        242.45848083496094,
        462.5894775390625,
        250.49847412109375
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1.76",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        242.45848083496094,
        462.5894775390625,
        250.49847412109375
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1.9",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        242.45848083496094,
        462.5894775390625,
        250.49847412109375
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Human Serum 5",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        253.25848388671875,
        462.5894775390625,
        261.2984924316406
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5569.2",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        253.25848388671875,
        462.5894775390625,
        261.2984924316406
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "657",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        253.25848388671875,
        462.5894775390625,
        261.2984924316406
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "113",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        253.25848388671875,
        462.5894775390625,
        261.2984924316406
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "13.3",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        253.25848388671875,
        462.5894775390625,
        261.2984924316406
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2.0",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        253.25848388671875,
        462.5894775390625,
        261.2984924316406
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Control 1",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        265.13848876953125,
        462.5894775390625,
        273.1784973144531
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "110",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        265.13848876953125,
        462.5894775390625,
        273.1784973144531
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "13.03",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        265.13848876953125,
        462.5894775390625,
        273.1784973144531
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2.62",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        265.13848876953125,
        462.5894775390625,
        273.1784973144531
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2.8",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        265.13848876953125,
        462.5894775390625,
        273.1784973144531
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2.4",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        265.13848876953125,
        462.5894775390625,
        273.1784973144531
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Control 2",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        277.9784851074219,
        462.5894775390625,
        286.01849365234375
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4200",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        277.9784851074219,
        462.5894775390625,
        286.01849365234375
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "495",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        277.9784851074219,
        462.5894775390625,
        286.01849365234375
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "91",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        277.9784851074219,
        462.5894775390625,
        286.01849365234375
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "10.7",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        277.9784851074219,
        462.5894775390625,
        286.01849365234375
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2.2",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        277.9784851074219,
        462.5894775390625,
        286.01849365234375
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Intermediate precision",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        333.3599853515625,
        301.61846923828125,
        420.6266174316406,
        309.6584777832031
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Mean",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        308.5199890136719,
        314.4584655761719,
        462.5098571777344,
        322.49847412109375
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SD",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        308.5199890136719,
        314.4584655761719,
        462.5098571777344,
        322.49847412109375
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "CV",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        308.5199890136719,
        314.4584655761719,
        462.5098571777344,
        322.49847412109375
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "pg/mL",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        286.79998779296875,
        328.61846923828125,
        460.1179504394531,
        336.6584777832031
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "pmol/L",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        286.79998779296875,
        328.61846923828125,
        460.1179504394531,
        336.6584777832031
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "pg/mL",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        286.79998779296875,
        328.61846923828125,
        460.1179504394531,
        336.6584777832031
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "pmol/L",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        286.79998779296875,
        328.61846923828125,
        460.1179504394531,
        336.6584777832031
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "%",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        286.79998779296875,
        328.61846923828125,
        460.1179504394531,
        336.6584777832031
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Human Serum 1",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        342.8984680175781,
        462.5894775390625,
        350.9384765625
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "50",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        342.8984680175781,
        462.5894775390625,
        350.9384765625
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5.95",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        342.8984680175781,
        462.5894775390625,
        350.9384765625
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1.7",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        342.8984680175781,
        462.5894775390625,
        350.9384765625
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "0.21",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        342.8984680175781,
        462.5894775390625,
        350.9384765625
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3.5",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        342.8984680175781,
        462.5894775390625,
        350.9384765625
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Human Serum 2",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        355.73846435546875,
        462.5894775390625,
        363.7784729003906
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "120.7",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        355.73846435546875,
        462.5894775390625,
        363.7784729003906
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "14.2",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        355.73846435546875,
        462.5894775390625,
        363.7784729003906
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3.03",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        355.73846435546875,
        462.5894775390625,
        363.7784729003906
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "0.35",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        355.73846435546875,
        462.5894775390625,
        363.7784729003906
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2.5",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        355.73846435546875,
        462.5894775390625,
        363.7784729003906
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Human Serum 3",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        368.5784606933594,
        462.5894775390625,
        376.61846923828125
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "358.7",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        368.5784606933594,
        462.5894775390625,
        376.61846923828125
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "42.3",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        368.5784606933594,
        462.5894775390625,
        376.61846923828125
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "7.27",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        368.5784606933594,
        462.5894775390625,
        376.61846923828125
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "0.85",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        368.5784606933594,
        462.5894775390625,
        376.61846923828125
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2.0",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        368.5784606933594,
        462.5894775390625,
        376.61846923828125
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Human Serum 4",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        380.3384704589844,
        462.5894775390625,
        388.37847900390625
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "794",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        380.3384704589844,
        462.5894775390625,
        388.37847900390625
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "93.5",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        380.3384704589844,
        462.5894775390625,
        388.37847900390625
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "19.5",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        380.3384704589844,
        462.5894775390625,
        388.37847900390625
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2.30",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        380.3384704589844,
        462.5894775390625,
        388.37847900390625
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2.5",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        380.3384704589844,
        462.5894775390625,
        388.37847900390625
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Human Serum 5",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        391.1384582519531,
        462.5894775390625,
        399.178466796875
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5569",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        391.1384582519531,
        462.5894775390625,
        399.178466796875
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "657",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        391.1384582519531,
        462.5894775390625,
        399.178466796875
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "130",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        391.1384582519531,
        462.5894775390625,
        399.178466796875
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "15.3",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        391.1384582519531,
        462.5894775390625,
        399.178466796875
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2.3",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        391.1384582519531,
        462.5894775390625,
        399.178466796875
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Control 1",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        403.0184631347656,
        462.5894775390625,
        411.0584716796875
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "110",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        403.0184631347656,
        462.5894775390625,
        411.0584716796875
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "13",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        403.0184631347656,
        462.5894775390625,
        411.0584716796875
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2.72",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        403.0184631347656,
        462.5894775390625,
        411.0584716796875
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "0.3",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        403.0184631347656,
        462.5894775390625,
        411.0584716796875
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2.5",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        403.0184631347656,
        462.5894775390625,
        411.0584716796875
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Control 2",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        415.85845947265625,
        462.5894775390625,
        423.8984680175781
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4200",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        415.85845947265625,
        462.5894775390625,
        423.8984680175781
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "495",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        415.85845947265625,
        462.5894775390625,
        423.8984680175781
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "107.1",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        415.85845947265625,
        462.5894775390625,
        423.8984680175781
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "12.6",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        415.85845947265625,
        462.5894775390625,
        423.8984680175781
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2.6",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        208.67999267578125,
        415.85845947265625,
        462.5894775390625,
        423.8984680175781
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        130.44000244140625,
        555.3303833007812,
        136.24676513671875,
        565.2903442382812
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상관성",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        159.47999572753906,
        547.2903442382812,
        192.7962646484375,
        557.2503051757812
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        164.51998901367188,
        563.370361328125,
        184.44000244140625,
        573.330322265625
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "타 제품과의 비교한 결과 상관계수(r)는 ≥ 0.90이었고",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        430.53033447265625,
        481.3967590332031,
        440.4903259277344
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일치도는 ≥ 90%이었다. NCCLS 프로토콜 EP9- A41을",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        446.6103515625,
        481.3967590332031,
        456.5703430175781
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "따라 상업적으로 유용한 진단검사와 본 제품을 이용한 검사를",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        462.5703430175781,
        481.3967590332031,
        472.53033447265625
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비교하였다. 총 300명(심장 질환 환자 200명, 비심장 질환",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        478.53033447265625,
        481.3967590332031,
        488.4903259277344
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "환자 100명)의 혈장 검체를 두 검사로 시험하였다. 이들",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        494.6103515625,
        481.3967590332031,
        504.5703430175781
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검체는 심장 질환 환자와 비심장 질환자로부터 채취하였다.",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        510.5703430175781,
        481.3971862792969,
        520.5303344726562
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Passing-Bablok 선형회귀 분석과 조화 분석으로부터 얻은",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        526.5303955078125,
        481.3967590332031,
        536.4903564453125
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "결과는 아래 표에 나타내었다.",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        542.6103515625,
        339.978515625,
        552.5703125
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비교방법과 본 제품의 검사의 결정 역치인 125pg/mL를",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        560.6103515625,
        481.3967590332031,
        570.5703125
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이용하여 일치성을 결정하였다.",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        576.5703735351562,
        345.0185241699219,
        586.5303344726562
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "회귀방법",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        213.239990234375,
        597.2984619140625,
        281.3999938964844,
        611.698486328125
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검체",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        213.239990234375,
        597.2984619140625,
        281.3999938964844,
        611.698486328125
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유형",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        265.32000732421875,
        597.2984619140625,
        345.6000061035156,
        618.0584716796875
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "n",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        265.32000732421875,
        597.2984619140625,
        345.6000061035156,
        618.0584716796875
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상관",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        265.32000732421875,
        597.2984619140625,
        345.6000061035156,
        618.0584716796875
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "계수",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        329.5199890136719,
        610.0184326171875,
        345.6000061035156,
        618.0584716796875
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "절편",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        375.0,
        597.2984619140625,
        391.0799865722656,
        605.3385009765625
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(95% CI)",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        365.7599792480469,
        610.0184326171875,
        400.3511047363281,
        618.0584716796875
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기울기",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        431.5199890136719,
        597.2984619140625,
        455.52020263671875,
        605.3385009765625
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(95% CI)",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        426.1199951171875,
        610.0184326171875,
        460.83111572265625,
        618.0584716796875
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Passing-",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        212.0399932861328,
        620.9384155273438,
        246.4656524658203,
        628.9784545898438
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Bablok*1",
      "font_size": 5.159999847412109,
      "font_name": "Batang",
      "bbox": [
        213.36000061035156,
        632.650634765625,
        245.23367309570312,
        641.698486328125
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "EDTA",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        261.7200012207031,
        620.9384155273438,
        284.9196472167969,
        628.9784545898438
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "혈장",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        265.32000732421875,
        620.9384155273438,
        387.94970703125,
        641.698486328125
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "300",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        265.32000732421875,
        620.9384155273438,
        387.94970703125,
        641.698486328125
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "0.96",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        265.32000732421875,
        620.9384155273438,
        387.94970703125,
        641.698486328125
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-8",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        265.32000732421875,
        620.9384155273438,
        387.94970703125,
        641.698486328125
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(-6 ~ -9)",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        363.239990234375,
        633.658447265625,
        402.870849609375,
        641.698486328125
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1.12",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        435.1199951171875,
        620.9384155273438,
        451.78936767578125,
        628.9784545898438
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(1.08 ~ 1.18)",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        416.8800048828125,
        633.658447265625,
        470.0706787109375,
        641.698486328125
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "*1 검체의 분산과 측정 에러에 대한 특별한 가정이 없는 선형회귀 방법",
      "font_size": 8.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        651.4906616210938,
        448.55999755859375,
        660.658447265625
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "샘플범위(해당제품): 0 - 3400pg/mL",
      "font_size": 8.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        209.87998962402344,
        667.37841796875,
        349.66534423828125,
        675.41845703125
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "샘플범위(비교방법): 5 - 3500pg/mL",
      "font_size": 8.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        209.87998962402344,
        682.138427734375,
        349.66534423828125,
        690.178466796875
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        98.04000091552734,
        117.91441345214844,
        448.0853271484375,
        126.91441345214844
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 28 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 34,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해당제품 분석방법*2",
      "font_size": 5.159999847412109,
      "font_name": "Batang",
      "bbox": [
        216.1199951171875,
        165.9706573486328,
        407.23394775390625,
        183.2984619140625
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비교방법*2",
      "font_size": 5.159999847412109,
      "font_name": "Batang",
      "bbox": [
        216.1199951171875,
        165.9706573486328,
        407.23394775390625,
        183.2984619140625
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "양성",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        337.32000732421875,
        183.53848266601562,
        439.55999755859375,
        191.57847595214844
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "음성",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        337.32000732421875,
        183.53848266601562,
        439.55999755859375,
        191.57847595214844
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "양성",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        244.9199981689453,
        199.9784698486328,
        436.0691223144531,
        208.01846313476562
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "130",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        244.9199981689453,
        199.9784698486328,
        436.0691223144531,
        208.01846313476562
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "15",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        244.9199981689453,
        199.9784698486328,
        436.0691223144531,
        208.01846313476562
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "음성",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        244.9199981689453,
        216.53848266601562,
        438.709228515625,
        224.57847595214844
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "10",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        244.9199981689453,
        216.53848266601562,
        438.709228515625,
        224.57847595214844
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "145",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        244.9199981689453,
        216.53848266601562,
        438.709228515625,
        224.57847595214844
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "*2 일치도는 비교 방법과 해당제품 분석방법의 125pg/mL의 결정 역치를",
      "font_size": 8.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        237.1306610107422,
        480.757568359375,
        246.2984619140625
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이용하여 결정하였다.",
      "font_size": 8.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        212.87998962402344,
        250.97848510742188,
        291.17974853515625,
        259.01849365234375
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        130.44000244140625,
        474.9303283691406,
        136.24676513671875,
        484.89031982421875
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상적",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        159.47999572753906,
        461.0103454589844,
        192.7962646484375,
        483.9303283691406
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "민감도",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        159.47999572753906,
        461.0103454589844,
        192.7962646484375,
        483.9303283691406
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "및 특이도",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        152.0399932861328,
        493.0503234863281,
        196.9199981689453,
        503.01031494140625
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 비심장질환 집단",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        261.9303283691406,
        290.39996337890625,
        271.89031982421875
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "심장질환으로 진단되지 않은 900명(465 여성, 435 남성)의",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        279.9303283691406,
        481.3967590332031,
        289.89031982421875
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "혈장 검체를 본 제품으로 검사로 시험하였다. 이 모집단은",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        295.8903503417969,
        481.3967590332031,
        305.850341796875
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "병원에 입원하지 않은 신장병(투석 치료를 받지 않는 환자),",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        311.9703369140625,
        481.3969421386719,
        321.9303283691406
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "당뇨병, 고혈압, 그리고 만성폐쇄성 폐질환을 가진 환자를",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        327.9303283691406,
        481.3967590332031,
        337.89031982421875
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "포함한다. 신장병(투석 치료를 받지 않는 환자), 당뇨병, 고혈압,",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        343.8903503417969,
        481.3967590332031,
        353.850341796875
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "그리고  만성폐쇄성 폐질환을 가진 환자들에 대한 BNP농도는",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        359.9703369140625,
        481.3967590332031,
        369.9303283691406
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "건강한 사람 집단과 통계적인 차이가 없었다.",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        375.9303283691406,
        403.4585266113281,
        385.89031982421875
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-비심장 질환 모집단(전체)-",
      "font_size": 8.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        285.47998046875,
        393.8984680175781,
        394.8976745605469,
        401.9384765625
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전체",
      "font_size": 8.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        288.6000061035156,
        406.61846923828125,
        388.08746337890625,
        418.73846435546875
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "<45세",
      "font_size": 8.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        288.6000061035156,
        406.61846923828125,
        388.08746337890625,
        418.73846435546875
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "45-54",
      "font_size": 8.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        288.6000061035156,
        406.61846923828125,
        388.08746337890625,
        418.73846435546875
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "세",
      "font_size": 8.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        371.3999938964844,
        414.6584777832031,
        379.44000244140625,
        422.698486328125
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "55-64",
      "font_size": 8.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        402.1199951171875,
        406.61846923828125,
        427.4476623535156,
        414.6584777832031
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "세",
      "font_size": 8.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        410.7599792480469,
        414.6584777832031,
        418.79998779296875,
        422.698486328125
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "65-74",
      "font_size": 8.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        441.47998046875,
        406.61846923828125,
        466.9274597167969,
        414.6584777832031
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "세",
      "font_size": 8.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        450.239990234375,
        414.6584777832031,
        458.2799987792969,
        422.698486328125
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검체수 (N)",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        425.4584655761719,
        461.38922119140625,
        433.49847412109375
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "900",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        425.4584655761719,
        461.38922119140625,
        433.49847412109375
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "210",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        425.4584655761719,
        461.38922119140625,
        433.49847412109375
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "140",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        425.4584655761719,
        461.38922119140625,
        433.49847412109375
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "170",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        425.4584655761719,
        461.38922119140625,
        433.49847412109375
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "250",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        425.4584655761719,
        461.38922119140625,
        433.49847412109375
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "메디안 (pg/mL)",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        436.25848388671875,
        458.98931884765625,
        444.2984924316406
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "20",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        436.25848388671875,
        458.98931884765625,
        444.2984924316406
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "20",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        436.25848388671875,
        458.98931884765625,
        444.2984924316406
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "10",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        436.25848388671875,
        458.98931884765625,
        444.2984924316406
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "25",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        436.25848388671875,
        458.98931884765625,
        444.2984924316406
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "20",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        436.25848388671875,
        458.98931884765625,
        444.2984924316406
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "평균 (pg/mL)",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        447.0584716796875,
        458.98931884765625,
        455.0984802246094
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "40",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        447.0584716796875,
        458.98931884765625,
        455.0984802246094
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "30",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        447.0584716796875,
        458.98931884765625,
        455.0984802246094
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "20",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        447.0584716796875,
        458.98931884765625,
        455.0984802246094
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "40",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        447.0584716796875,
        458.98931884765625,
        455.0984802246094
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "50",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        447.0584716796875,
        458.98931884765625,
        455.0984802246094
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SD (pg/mL)",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        457.85845947265625,
        458.98931884765625,
        465.8984680175781
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "70",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        457.85845947265625,
        458.98931884765625,
        465.8984680175781
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "40",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        457.85845947265625,
        458.98931884765625,
        465.8984680175781
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "30",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        457.85845947265625,
        458.98931884765625,
        465.8984680175781
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "50",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        457.85845947265625,
        458.98931884765625,
        465.8984680175781
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "80",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        457.85845947265625,
        458.98931884765625,
        465.8984680175781
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "95th Percentile",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        468.6584777832031,
        461.38922119140625,
        476.698486328125
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "140",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        468.6584777832031,
        461.38922119140625,
        476.698486328125
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "90",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        468.6584777832031,
        461.38922119140625,
        476.698486328125
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "80",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        468.6584777832031,
        461.38922119140625,
        476.698486328125
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "120",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        468.6584777832031,
        461.38922119140625,
        476.698486328125
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "160",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        468.6584777832031,
        461.38922119140625,
        476.698486328125
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "퍼센트 ≥100 pg/mL",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        479.5784606933594,
        468.27783203125,
        487.61846923828125
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "90.50%",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        479.5784606933594,
        468.27783203125,
        487.61846923828125
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "91.50%",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        479.5784606933594,
        468.27783203125,
        487.61846923828125
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "92.00%",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        479.5784606933594,
        468.27783203125,
        487.61846923828125
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "95.00%",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        479.5784606933594,
        468.27783203125,
        487.61846923828125
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "85.10%",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        479.5784606933594,
        468.27783203125,
        487.61846923828125
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "최소 (pg/mL)",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        490.37847900390625,
        456.5894470214844,
        498.4184875488281
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "0",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        490.37847900390625,
        456.5894470214844,
        498.4184875488281
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "0",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        490.37847900390625,
        456.5894470214844,
        498.4184875488281
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "0",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        490.37847900390625,
        456.5894470214844,
        498.4184875488281
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "0",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        490.37847900390625,
        456.5894470214844,
        498.4184875488281
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "0",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        490.37847900390625,
        456.5894470214844,
        498.4184875488281
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "최대 (pg/mL)",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        501.178466796875,
        461.38922119140625,
        509.2184753417969
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "910",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        501.178466796875,
        461.38922119140625,
        509.2184753417969
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "260",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        501.178466796875,
        461.38922119140625,
        509.2184753417969
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "140",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        501.178466796875,
        461.38922119140625,
        509.2184753417969
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "400",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        501.178466796875,
        461.38922119140625,
        509.2184753417969
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "900",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        501.178466796875,
        461.38922119140625,
        509.2184753417969
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "심장 질환으로 진단된 환자 800명의 혈장 검체를 본 제품을",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        520.1703491210938,
        481.3967590332031,
        530.1303100585938
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이용하여 시험하였다. 이 환자들을 New York Heart",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        536.13037109375,
        481.3971862792969,
        546.09033203125
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Association(NYHA)의 기능적인 분류 시스템에 따라서",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        552.0903930664062,
        481.3967590332031,
        562.0503540039062
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류하였다. 이 시스템은 심장 질환 환자를 환자의 임상적인",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        568.1703491210938,
        481.3967590332031,
        578.1303100585938
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "징후와 증상을 평가하여 질병의 진행단계를 4개의 카테고리",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        584.13037109375,
        478.0794982910156,
        594.09033203125
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(class I ~ IV)로 분류한다. 연구로부터 얻은 데이터는",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        600.0903930664062,
        481.3967590332031,
        610.0503540039062
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아래에 요약되었다.",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        616.1703491210938,
        290.05853271484375,
        626.1303100585938
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ⅴ. 제조․수입허가 신청서 기재 항목",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        346.91998291015625,
        117.55441284179688,
        481.4460144042969,
        126.55441284179688
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 29 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 35,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "-심장 질환 모집단(전체)-",
      "font_size": 8.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        289.44000244140625,
        161.45848083496094,
        390.81707763671875,
        169.49847412109375
      ],
      "page_num": 35,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "NYHA Functional Class",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        329.3999938964844,
        179.09848022460938,
        421.2972412109375,
        187.1384735107422
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전체",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        288.6000061035156,
        189.8984832763672,
        458.55035400390625,
        197.9384765625
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "I",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        288.6000061035156,
        189.8984832763672,
        458.55035400390625,
        197.9384765625
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "II",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        288.6000061035156,
        189.8984832763672,
        458.55035400390625,
        197.9384765625
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "III",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        288.6000061035156,
        189.8984832763672,
        458.55035400390625,
        197.9384765625
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "IV",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        288.6000061035156,
        189.8984832763672,
        458.55035400390625,
        197.9384765625
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검체수 (N)",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        200.69847106933594,
        458.98931884765625,
        208.73846435546875
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "800",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        200.69847106933594,
        458.98931884765625,
        208.73846435546875
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "150",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        200.69847106933594,
        458.98931884765625,
        208.73846435546875
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "350",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        200.69847106933594,
        458.98931884765625,
        208.73846435546875
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "240",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        200.69847106933594,
        458.98931884765625,
        208.73846435546875
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "60",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        200.69847106933594,
        458.98931884765625,
        208.73846435546875
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "메디안 (pg/mL)",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        211.49847412109375,
        463.789306640625,
        219.53846740722656
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "300",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        211.49847412109375,
        463.789306640625,
        219.53846740722656
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "130",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        211.49847412109375,
        463.789306640625,
        219.53846740722656
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "250",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        211.49847412109375,
        463.789306640625,
        219.53846740722656
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "330",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        211.49847412109375,
        463.789306640625,
        219.53846740722656
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1530",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        211.49847412109375,
        463.789306640625,
        219.53846740722656
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "평균 (pg/mL)",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        222.29847717285156,
        463.789306640625,
        230.33847045898438
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "570",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        222.29847717285156,
        463.789306640625,
        230.33847045898438
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "300",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        222.29847717285156,
        463.789306640625,
        230.33847045898438
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "430",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        222.29847717285156,
        463.789306640625,
        230.33847045898438
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "650",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        222.29847717285156,
        463.789306640625,
        230.33847045898438
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1630",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        222.29847717285156,
        463.789306640625,
        230.33847045898438
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SD (pg/mL)",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        233.09848022460938,
        463.789306640625,
        241.1384735107422
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "770",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        233.09848022460938,
        463.789306640625,
        241.1384735107422
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "380",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        233.09848022460938,
        463.789306640625,
        241.1384735107422
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "540",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        233.09848022460938,
        463.789306640625,
        241.1384735107422
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "830",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        233.09848022460938,
        463.789306640625,
        241.1384735107422
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1050",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        233.09848022460938,
        463.789306640625,
        241.1384735107422
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5th Percentile",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        244.0184783935547,
        461.38922119140625,
        252.0584716796875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "14",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        244.0184783935547,
        461.38922119140625,
        252.0584716796875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "9",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        244.0184783935547,
        461.38922119140625,
        252.0584716796875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "15",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        244.0184783935547,
        461.38922119140625,
        252.0584716796875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "12",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        244.0184783935547,
        461.38922119140625,
        252.0584716796875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "188",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        244.0184783935547,
        461.38922119140625,
        252.0584716796875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "95th Percentile",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        254.8184814453125,
        466.1889953613281,
        262.8584899902344
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2200",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        254.8184814453125,
        466.1889953613281,
        262.8584899902344
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1300",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        254.8184814453125,
        466.1889953613281,
        262.8584899902344
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1600",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        254.8184814453125,
        466.1889953613281,
        262.8584899902344
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2600",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        254.8184814453125,
        466.1889953613281,
        262.8584899902344
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": ">4000",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        254.8184814453125,
        466.1889953613281,
        262.8584899902344
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "퍼센트 ≥100 pg/mL",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        265.61846923828125,
        468.27783203125,
        273.6584777832031
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "70.50%",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        265.61846923828125,
        468.27783203125,
        273.6584777832031
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "58.50%",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        265.61846923828125,
        468.27783203125,
        273.6584777832031
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "73.00%",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        265.61846923828125,
        468.27783203125,
        273.6584777832031
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "79.00%",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        265.61846923828125,
        468.27783203125,
        273.6584777832031
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "98.50%",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        265.61846923828125,
        468.27783203125,
        273.6584777832031
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "최소 (pg/mL)",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        276.4184875488281,
        458.98931884765625,
        284.45849609375
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "0",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        276.4184875488281,
        458.98931884765625,
        284.45849609375
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        276.4184875488281,
        458.98931884765625,
        284.45849609375
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "0",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        276.4184875488281,
        458.98931884765625,
        284.45849609375
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "0",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        276.4184875488281,
        458.98931884765625,
        284.45849609375
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "14",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        276.4184875488281,
        458.98931884765625,
        284.45849609375
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "최대 (pg/mL)",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        287.2184753417969,
        466.1889953613281,
        295.25848388671875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": ">4000",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        287.2184753417969,
        466.1889953613281,
        295.25848388671875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1650",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        287.2184753417969,
        466.1889953613281,
        295.25848388671875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": ">4000",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        287.2184753417969,
        466.1889953613281,
        295.25848388671875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": ">4000",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        287.2184753417969,
        466.1889953613281,
        295.25848388671875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": ">4000",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        287.2184753417969,
        466.1889953613281,
        295.25848388671875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-심장 질환 모집단(남성)-",
      "font_size": 8.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        289.44000244140625,
        306.178466796875,
        390.81707763671875,
        314.2184753417969
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "NYHA Functional Class",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        329.3999938964844,
        318.8984680175781,
        421.2972412109375,
        326.9384765625
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전체",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        288.6000061035156,
        329.698486328125,
        458.55035400390625,
        337.7384948730469
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "I",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        288.6000061035156,
        329.698486328125,
        458.55035400390625,
        337.7384948730469
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "II",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        288.6000061035156,
        329.698486328125,
        458.55035400390625,
        337.7384948730469
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "III",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        288.6000061035156,
        329.698486328125,
        458.55035400390625,
        337.7384948730469
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "IV",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        288.6000061035156,
        329.698486328125,
        458.55035400390625,
        337.7384948730469
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검체수 (N)",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        340.49847412109375,
        458.98931884765625,
        348.5384826660156
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "480",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        340.49847412109375,
        458.98931884765625,
        348.5384826660156
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "90",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        340.49847412109375,
        458.98931884765625,
        348.5384826660156
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "210",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        340.49847412109375,
        458.98931884765625,
        348.5384826660156
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "144",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        340.49847412109375,
        458.98931884765625,
        348.5384826660156
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "36",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        340.49847412109375,
        458.98931884765625,
        348.5384826660156
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "메디안 (pg/mL)",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        351.2984619140625,
        463.789306640625,
        359.3384704589844
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "270",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        351.2984619140625,
        463.789306640625,
        359.3384704589844
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "120",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        351.2984619140625,
        463.789306640625,
        359.3384704589844
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "260",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        351.2984619140625,
        463.789306640625,
        359.3384704589844
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "290",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        351.2984619140625,
        463.789306640625,
        359.3384704589844
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1650",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        351.2984619140625,
        463.789306640625,
        359.3384704589844
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "평균 (pg/mL)",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        362.2184753417969,
        463.789306640625,
        370.25848388671875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "500",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        362.2184753417969,
        463.789306640625,
        370.25848388671875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "300",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        362.2184753417969,
        463.789306640625,
        370.25848388671875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "400",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        362.2184753417969,
        463.789306640625,
        370.25848388671875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "600",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        362.2184753417969,
        463.789306640625,
        370.25848388671875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1650",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        362.2184753417969,
        463.789306640625,
        370.25848388671875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SD (pg/mL)",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        373.0184631347656,
        463.789306640625,
        381.0584716796875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "700",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        373.0184631347656,
        463.789306640625,
        381.0584716796875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "350",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        373.0184631347656,
        463.789306640625,
        381.0584716796875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "520",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        373.0184631347656,
        463.789306640625,
        381.0584716796875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "820",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        373.0184631347656,
        463.789306640625,
        381.0584716796875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1000",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        373.0184631347656,
        463.789306640625,
        381.0584716796875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5th Percentile",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        383.8184814453125,
        461.38922119140625,
        391.8584899902344
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "12",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        383.8184814453125,
        461.38922119140625,
        391.8584899902344
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "9",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        383.8184814453125,
        461.38922119140625,
        391.8584899902344
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "14",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        383.8184814453125,
        461.38922119140625,
        391.8584899902344
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "22",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        383.8184814453125,
        461.38922119140625,
        391.8584899902344
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "270",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        383.8184814453125,
        461.38922119140625,
        391.8584899902344
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "95th Percentile",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        394.61846923828125,
        463.789306640625,
        402.6584777832031
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2000",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        394.61846923828125,
        463.789306640625,
        402.6584777832031
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1200",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        394.61846923828125,
        463.789306640625,
        402.6584777832031
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1300",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        394.61846923828125,
        463.789306640625,
        402.6584777832031
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2300",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        394.61846923828125,
        463.789306640625,
        402.6584777832031
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3700",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        394.61846923828125,
        463.789306640625,
        402.6584777832031
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "퍼센트 ≥100 pg/mL",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        405.41845703125,
        468.27783203125,
        413.4584655761719
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "71.00%",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        405.41845703125,
        468.27783203125,
        413.4584655761719
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "56.00%",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        405.41845703125,
        468.27783203125,
        413.4584655761719
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "65.70%",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        405.41845703125,
        468.27783203125,
        413.4584655761719
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "70.00%",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        405.41845703125,
        468.27783203125,
        413.4584655761719
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "95.00%",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        405.41845703125,
        468.27783203125,
        413.4584655761719
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "최소 (pg/mL)",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        416.2184753417969,
        458.98931884765625,
        424.25848388671875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "0",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        416.2184753417969,
        458.98931884765625,
        424.25848388671875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        416.2184753417969,
        458.98931884765625,
        424.25848388671875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "0",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        416.2184753417969,
        458.98931884765625,
        424.25848388671875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "0",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        416.2184753417969,
        458.98931884765625,
        424.25848388671875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "14",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        416.2184753417969,
        458.98931884765625,
        424.25848388671875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "최대 (pg/mL)",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        427.1384582519531,
        466.1889953613281,
        435.178466796875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": ">4000",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        427.1384582519531,
        466.1889953613281,
        435.178466796875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1400",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        427.1384582519531,
        466.1889953613281,
        435.178466796875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3800",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        427.1384582519531,
        466.1889953613281,
        435.178466796875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": ">4000",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        427.1384582519531,
        466.1889953613281,
        435.178466796875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": ">4000",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        427.1384582519531,
        466.1889953613281,
        435.178466796875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-심장 질환 모집단(여성)-",
      "font_size": 8.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        289.44000244140625,
        445.9784851074219,
        390.81707763671875,
        454.01849365234375
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "NYHA Functional Class",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        329.3999938964844,
        458.6984558105469,
        421.2972412109375,
        466.73846435546875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전체",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        288.6000061035156,
        469.49847412109375,
        458.55035400390625,
        477.5384826660156
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "I",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        288.6000061035156,
        469.49847412109375,
        458.55035400390625,
        477.5384826660156
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "II",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        288.6000061035156,
        469.49847412109375,
        458.55035400390625,
        477.5384826660156
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "III",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        288.6000061035156,
        469.49847412109375,
        458.55035400390625,
        477.5384826660156
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "IV",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        288.6000061035156,
        469.49847412109375,
        458.55035400390625,
        477.5384826660156
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검체수 (N)",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        480.41845703125,
        458.98931884765625,
        488.4584655761719
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "320",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        480.41845703125,
        458.98931884765625,
        488.4584655761719
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "60",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        480.41845703125,
        458.98931884765625,
        488.4584655761719
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "140",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        480.41845703125,
        458.98931884765625,
        488.4584655761719
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "96",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        480.41845703125,
        458.98931884765625,
        488.4584655761719
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "24",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        480.41845703125,
        458.98931884765625,
        488.4584655761719
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "메디안 (pg/mL)",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        491.2184753417969,
        463.789306640625,
        499.25848388671875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "400",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        491.2184753417969,
        463.789306640625,
        499.25848388671875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "170",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        491.2184753417969,
        463.789306640625,
        499.25848388671875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "300",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        491.2184753417969,
        463.789306640625,
        499.25848388671875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "450",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        491.2184753417969,
        463.789306640625,
        499.25848388671875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1400",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        491.2184753417969,
        463.789306640625,
        499.25848388671875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "평균 (pg/mL)",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        502.0184631347656,
        463.789306640625,
        510.0584716796875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "670",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        502.0184631347656,
        463.789306640625,
        510.0584716796875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "340",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        502.0184631347656,
        463.789306640625,
        510.0584716796875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "450",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        502.0184631347656,
        463.789306640625,
        510.0584716796875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "750",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        502.0184631347656,
        463.789306640625,
        510.0584716796875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1630",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        502.0184631347656,
        463.789306640625,
        510.0584716796875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SD (pg/mL)",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        512.8184204101562,
        463.789306640625,
        520.8584594726562
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "850",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        512.8184204101562,
        463.789306640625,
        520.8584594726562
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "380",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        512.8184204101562,
        463.789306640625,
        520.8584594726562
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "620",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        512.8184204101562,
        463.789306640625,
        520.8584594726562
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "870",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        512.8184204101562,
        463.789306640625,
        520.8584594726562
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1100",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        512.8184204101562,
        463.789306640625,
        520.8584594726562
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5th Percentile",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        523.618408203125,
        461.38922119140625,
        531.658447265625
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "16",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        523.618408203125,
        461.38922119140625,
        531.658447265625
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "14",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        523.618408203125,
        461.38922119140625,
        531.658447265625
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "21",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        523.618408203125,
        461.38922119140625,
        531.658447265625
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "12",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        523.618408203125,
        461.38922119140625,
        531.658447265625
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "250",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        523.618408203125,
        461.38922119140625,
        531.658447265625
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "95th Percentile",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        534.41845703125,
        466.1889953613281,
        542.45849609375
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2600",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        534.41845703125,
        466.1889953613281,
        542.45849609375
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1000",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        534.41845703125,
        466.1889953613281,
        542.45849609375
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2000",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        534.41845703125,
        466.1889953613281,
        542.45849609375
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2700",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        534.41845703125,
        466.1889953613281,
        542.45849609375
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": ">4000",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        534.41845703125,
        466.1889953613281,
        542.45849609375
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "퍼센트 ≥100 pg/mL",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        545.3384399414062,
        468.7587890625,
        553.3784790039062
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "70.50%",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        545.3384399414062,
        468.7587890625,
        553.3784790039062
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "60.50%",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        545.3384399414062,
        468.7587890625,
        553.3784790039062
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "75.20%",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        545.3384399414062,
        468.7587890625,
        553.3784790039062
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "80.30%",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        545.3384399414062,
        468.7587890625,
        553.3784790039062
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "100.00%",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        545.3384399414062,
        468.7587890625,
        553.3784790039062
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "최소 (pg/mL)",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        556.138427734375,
        461.38922119140625,
        564.178466796875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "0",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        556.138427734375,
        461.38922119140625,
        564.178466796875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "10",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        556.138427734375,
        461.38922119140625,
        564.178466796875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "0",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        556.138427734375,
        461.38922119140625,
        564.178466796875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "0",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        556.138427734375,
        461.38922119140625,
        564.178466796875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "173",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        556.138427734375,
        461.38922119140625,
        564.178466796875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "최대 (pg/mL)",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        566.9384155273438,
        466.1889953613281,
        574.9784545898438
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": ">4000",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        566.9384155273438,
        466.1889953613281,
        574.9784545898438
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1600",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        566.9384155273438,
        466.1889953613281,
        574.9784545898438
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": ">4000",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        566.9384155273438,
        466.1889953613281,
        574.9784545898438
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": ">4000",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        566.9384155273438,
        466.1889953613281,
        574.9784545898438
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": ">4000",
      "font_size": 8.039999961853027,
      "font_name": "Batang",
      "bbox": [
        211.44000244140625,
        566.9384155273438,
        466.1889953613281,
        574.9784545898438
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상연구 모집단에 대한 Box and whiskers 표가 NYHA",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        585.9303588867188,
        481.39666748046875,
        595.8903198242188
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "등급에 따라 분류되었고 아래에 제시되었다. 점선은 본",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        601.890380859375,
        481.3967590332031,
        611.850341796875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제품 검사에서 권장하는 결정 역치인 125 pg/mL을 의미한다.",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        617.850341796875,
        481.3967590332031,
        627.810302734375
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이전의 보고자료와 같이 이 결과가 BNP 농도의 증가와",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        633.9303588867188,
        481.39630126953125,
        643.8903198242188
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "NYHA 분류 증가를 나타내고 있다. 이 분석은 BNP 측정이",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        649.890380859375,
        481.39630126953125,
        659.850341796875
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "심장 질환의 심각성 평가에 사용되어 객관적인 정보를 제공",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        665.850341796875,
        478.0799865722656,
        675.810302734375
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하는 것을 시사한다.",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        681.9303588867188,
        294.978515625,
        691.8903198242188
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        98.04000091552734,
        117.91441345214844,
        448.0853271484375,
        126.91441345214844
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 30 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 36,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위의 임상 연구로부터 얻은 데이터는 아래와 같이 임상",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        359.9703369140625,
        481.3967590332031,
        369.9303283691406
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "민감도와 임상 특이도에 대한 BNP 결정 역치의 Receiver",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        376.05035400390625,
        481.3971862792969,
        386.0103454589844
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Operating Characteristic(ROC) 곡선을 생성하는데 사용되었다.",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        392.0103454589844,
        481.3967590332031,
        401.9703369140625
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "본 연구에서 결정 역치인 125pg/mL에서, BNP 검사는 임상적",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        407.9703369140625,
        481.3966979980469,
        417.9303283691406
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "민감도와 특이도에 대하여 각각 70.5% 및 90.5%로 나타났다.",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        424.0503234863281,
        481.3967590332031,
        434.01031494140625
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "곡선 아래 부분은 0.90(0.86 ~ 0.92, 95% 신뢰구간)이다.",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        440.0103454589844,
        464.7785339355469,
        449.9703369140625
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ⅴ. 제조․수입허가 신청서 기재 항목",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        346.91998291015625,
        117.55441284179688,
        481.4460144042969,
        126.55441284179688
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 31 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 37,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 상기 성능은 예시(참고용)에 해당되므로 제품의 특성에 따라 일부",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        313.92327880859375,
        488.3559265136719,
        324.9632873535156
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해당 성능 항목을 가감할 수 있음",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        126.23999786376953,
        335.8832702636719,
        297.8399963378906,
        346.92327880859375
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "심장 질환과 비-심장 질환 모집단에 대한 연령별 분석이",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        161.6103515625,
        481.3966979980469,
        171.5703582763672
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "American Heart Association에 의해 2000 Heart and Stroke",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        177.57034301757812,
        481.396728515625,
        187.5303497314453
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Statistical Update에 발표된 자료와 미국 인구 집단의 연령별",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        193.5303497314453,
        481.3966979980469,
        203.4903564453125
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구조에 근거하여 수행되었다. 사용 목적 집단의 연령 분포는",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        209.61033630371094,
        481.3966979980469,
        219.57034301757812
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대략 다음과 같다 : 45세 미만 9%, 45-54세는 11%,",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        225.57034301757812,
        481.39776611328125,
        235.5303497314453
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "55-64세는 22%, 65-74세는 26%, 그리고 75세 이상은",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        241.5303497314453,
        481.3966979980469,
        251.4903564453125
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "32%로 구성되었다. AUC 결과는 0.87(0.85 ~ 0.90, 95%",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        257.6103515625,
        481.3967590332031,
        267.5703430175781
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "신뢰구간) 이었다.",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        202.0800018310547,
        273.5703430175781,
        285.7972106933594,
        283.53033447265625
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        98.04000091552734,
        117.91441345214844,
        448.0853271484375,
        126.91441345214844
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 32 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 38,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "6",
      "font_size": 13.799982070922852,
      "font_name": "H2hdrM",
      "bbox": [
        121.91999816894531,
        161.10809326171875,
        202.4438018798828,
        175.86807250976562
      ],
      "page_num": 38,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용방법",
      "font_size": 13.799982070922852,
      "font_name": "HYwulM",
      "bbox": [
        121.91999816894531,
        161.10809326171875,
        202.4438018798828,
        175.86807250976562
      ],
      "page_num": 38,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 검체준비 및 저장방법, 검사 전 준비사항, 검사과정, 결과판정 및 정도",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        207.96328735351562,
        484.67999267578125,
        219.00328063964844
      ],
      "page_num": 38,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관리, 장비(해당 장비의 제조사, 모델명) 등을 아래와 같이 포함하여",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        127.55999755859375,
        229.92327880859375,
        488.3560485839844,
        240.96327209472656
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단용 의료기기를 중심으로 사용방법을 기술한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        127.55999755859375,
        251.88327026367188,
        402.2127990722656,
        262.92327880859375
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가. 검체준비 및 저장방법",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        273.9632873535156,
        255.23965454101562,
        285.0032958984375
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 검체대상 및 채취방법 등",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        295.92327880859375,
        288.0763854980469,
        306.9632873535156
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 검체 종류별 사용 가능한 항응고제",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        317.8832702636719,
        337.51605224609375,
        328.92327880859375
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 사용되는 검체의 종류별 필요 분량",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        339.9632873535156,
        333.8396911621094,
        351.0032958984375
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 검체 보관조건, 방법 및 사용기간 등",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        361.92327880859375,
        342.6000061035156,
        372.9632873535156
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5) 냉동 및 해동된 검체의 사용 가능성 및 제한점",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        383.8832702636719,
        397.9960632324219,
        394.92327880859375
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6) 원심분리 조건 등을 포함한 검체 전처리과정 등",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        405.9632873535156,
        399.8399963378906,
        417.0032958984375
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 검사 전 준비사항",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        427.92327880859375,
        233.15965270996094,
        438.9632873535156
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험 전 시약 조제가 필요한 경우 조제 방법 및 조건, 검사에 필요한",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        135.47999572753906,
        449.8832702636719,
        488.23541259765625,
        460.92327880859375
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기구 및 조건 등을 기재한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        135.47999572753906,
        471.9632873535156,
        280.17279052734375,
        483.0032958984375
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 적용되는 체외진단분석기의 제조사 및 모델명을 기재한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        493.92327880859375,
        452.4927978515625,
        504.9632873535156
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 검사 키트의 사용조건(온도 또는 습도 등)을 기재한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        515.8832397460938,
        436.05279541015625,
        526.9232788085938
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 필요한 경우, 시약의 성능과 판정에 영향을 줄 수 있는 기기 및",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        537.9632568359375,
        488.35638427734375,
        549.0032958984375
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "소프트웨어의 회사명, 모델명 등을 기재한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        158.39999389648438,
        559.9232177734375,
        384.6927795410156,
        570.9632568359375
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 필요한 경우, 보정물질에 대한 설명 및 방법에 대하여 기재한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        581.8832397460938,
        483.2127990722656,
        592.9232788085938
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다. 검사과정",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        603.9632568359375,
        189.23965454101562,
        615.0032958984375
      ],
      "page_num": 38,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단 의료기기 장비의 매뉴얼 및 사용방법에 대하여 상세하게",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        135.47999572753906,
        625.9232177734375,
        488.3560485839844,
        636.9632568359375
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기재한다. 환자의 검체를 첨가하는 과정(검체 전처리, 반응시간,",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        135.47999572753906,
        647.8832397460938,
        488.35662841796875,
        658.9232788085938
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "실험실 온도 조건 등), 시험검사 단계(장비의 운용 방법 및 반응시간 등)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        135.47999572753906,
        669.9632568359375,
        488.35638427734375,
        681.0032958984375
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 결과판독과정(판독시간, 결과 출력 방법 등)을 상세하게 기재한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        135.47999572753906,
        691.9232177734375,
        484.3966064453125,
        702.9632568359375
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅴ. 제조․수입허가 신청서 기재 항목",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        346.91998291015625,
        117.55441284179688,
        481.4460144042969,
        126.55441284179688
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 33 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 39,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "라. 결과판정",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        155.76327514648438,
        189.23965454101562,
        166.8032684326172
      ],
      "page_num": 39,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "양성, 음성, 경계값(equivocal), 미확정(indeterminate), 무효(invalid)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        135.47999572753906,
        177.72328186035156,
        488.35638427734375,
        188.76327514648438
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등의 예측되는 모든 경우의 시험 결과를 판정하는 기준과 해석을",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        135.47999572753906,
        199.80328369140625,
        488.35638427734375,
        210.84327697753906
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제시한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        135.47999572753906,
        221.76327514648438,
        182.73280334472656,
        232.8032684326172
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 경계값(equivocal), 미확정(indeterminate) 또는 무효(invalid) 결과를",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        130.55999755859375,
        243.72328186035156,
        488.35638427734375,
        254.76327514648438
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "어떻게 처리해야 하는지에 대한 지침을 제시한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        148.44000244140625,
        265.80328369140625,
        399.0928039550781,
        276.8432922363281
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가) 그대로 보고하는지 재검사가 필요한지 여부",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        287.7632751464844,
        382.4396667480469,
        298.80328369140625
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 환자 검체의 검사 결과를 판독하기 전에 확인해야 할 대조물질 및",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        130.55999755859375,
        309.7232666015625,
        488.35638427734375,
        320.7632751464844
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보정결과 확인 절차에 대해 제시한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        148.0800018310547,
        331.80328369140625,
        338.2527770996094,
        342.8432922363281
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 검사의 검출한계 또는 정량한계 등에 따른 보고가능범위에 대하여",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        130.55999755859375,
        353.7632751464844,
        488.3560485839844,
        364.80328369140625
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제시하고, 정량값 판정 등의 기준을 제시한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        148.0800018310547,
        375.7232666015625,
        379.8927917480469,
        386.7632751464844
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "마. 정도관리",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        397.80328369140625,
        189.23965454101562,
        408.8432922363281
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 사용자가 정도 관리를 할 수 있는 방법을 제시한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        419.7632751464844,
        413.5962829589844,
        430.80328369140625
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 제공하는 정도관리물질과 그 물질의 목표값이 있을 경우, 제시된",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        441.7232666015625,
        488.35638427734375,
        452.7632751464844
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기준 값에 적합함을 확인하는 과정을 제공한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        149.0399932861328,
        463.80328369140625,
        395.61279296875,
        474.8432922363281
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 정도 관리 결과가 적합하지 않을 때 제시할 수 있는 대책을",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        485.7632751464844,
        499.2756042480469,
        496.80328369140625
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기술한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        150.36000061035156,
        507.7232971191406,
        202.51663208007812,
        518.7633056640625
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        98.04000091552734,
        117.91441345214844,
        448.0853271484375,
        126.91441345214844
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 34 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 40,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "7",
      "font_size": 13.799982070922852,
      "font_name": "H2hdrM",
      "bbox": [
        121.91999816894531,
        161.10809326171875,
        249.12380981445312,
        175.86807250976562
      ],
      "page_num": 40,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용시 주의사항",
      "font_size": 13.799982070922852,
      "font_name": "HYwulM",
      "bbox": [
        121.91999816894531,
        161.10809326171875,
        249.12380981445312,
        175.86807250976562
      ],
      "page_num": 40,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 다음의 사항을 포함하여 기재한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        207.96328735351562,
        299.2528076171875,
        219.00328063964844
      ],
      "page_num": 40,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 체외진단용으로 사용해야 함을 명시한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        229.92327880859375,
        351.81280517578125,
        240.96327209472656
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 일반적인 실험실 안전지침 및 생물학적 위험물질(검체, 감염 가능성",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        251.88327026367188,
        488.3569030761719,
        262.92327880859375
      ],
      "page_num": 40,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "물질 및 폐기물 등) 취급 시 안전 등의 주의사항을 기재한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        145.1999969482422,
        273.9632873535156,
        449.4927978515625,
        285.0032958984375
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다. 구성시약 중 유해물질이 포함될 경우 이에 대한 경고사항을 기재한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        295.92327880859375,
        481.29278564453125,
        306.9632873535156
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라. 사용한 검체 및 키트의 처리 및 폐기방법 및 주의사항을 기재한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        317.8832702636719,
        483.6927795410156,
        328.92327880859375
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "마. 경고사항을 포함하여 검체 및 키트 취급 및 보관상의 주의사항(온도,",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        339.9632873535156,
        488.35638427734375,
        351.0032958984375
      ],
      "page_num": 40,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "습도의 영향 등)을 명시한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        145.1999969482422,
        361.92327880859375,
        291.3327941894531,
        372.9632873535156
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "바. 임상 적용 대상 및 미적용 대상을 포함하여 적용상의 주의사항 및",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        383.8832702636719,
        488.35638427734375,
        394.92327880859375
      ],
      "page_num": 40,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결과판정 상 주의사항을 기재한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        145.55999755859375,
        405.9632873535156,
        319.29278564453125,
        417.0032958984375
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사. 검사에 영향을 미치는 내용(예 : 간섭 및 교차반응 물질, 위양성",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        427.92327880859375,
        488.3560485839844,
        438.9632873535156
      ],
      "page_num": 40,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 위음성도) 등을 기재한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        146.52000427246094,
        449.8832702636719,
        292.7727966308594,
        460.92327880859375
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아. 다른 의료기기와 결합하여 사용하는 경우 적절한 조합에 대한",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        471.9632873535156,
        488.35638427734375,
        483.0032958984375
      ],
      "page_num": 40,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정보를 제공한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        147.0,
        493.92327880859375,
        232.65281677246094,
        504.9632873535156
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자. 일회용의 경우 재사용하지 않도록 주의사항을 기재한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        515.8832397460938,
        428.852783203125,
        526.9232788085938
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "8",
      "font_size": 13.799982070922852,
      "font_name": "H2hdrM",
      "bbox": [
        121.91999816894531,
        587.22802734375,
        202.4438018798828,
        602.1080932617188
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "포장단위",
      "font_size": 13.799982070922852,
      "font_name": "HYwulM",
      "bbox": [
        121.91999816894531,
        587.22802734375,
        202.4438018798828,
        602.1080932617188
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1. 체외진단용 의료기기의 포장단위는 취급상 용이한 최소 단위로 기재하되,",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        634.083251953125,
        488.35662841796875,
        645.123291015625
      ],
      "page_num": 40,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조의 경우 “자사포장단위”, 수입의 경우는 “제조원포장단위”로 기재한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.63999938964844,
        656.1632690429688,
        481.41278076171875,
        667.2033081054688
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅴ. 제조․수입허가 신청서 기재 항목",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        346.91998291015625,
        117.55441284179688,
        481.4460144042969,
        126.55441284179688
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 35 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 41,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "9",
      "font_size": 13.799982070922852,
      "font_name": "H2hdrM",
      "bbox": [
        121.91999816894531,
        171.06808471679688,
        282.3638000488281,
        185.9480743408203
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "저장방법 및 사용기간",
      "font_size": 13.799982070922852,
      "font_name": "HYwulM",
      "bbox": [
        121.91999816894531,
        171.06808471679688,
        282.3638000488281,
        185.9480743408203
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 저장방법은 체외진단용 의료기기의 특성을 고려하여 안정성이 보장될 수",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        217.92327880859375,
        488.35638427734375,
        228.96327209472656
      ],
      "page_num": 41,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있도록 검증된 자료에 의한 구체적인 보관 조건(온도, 습도, 차광,",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        127.55999755859375,
        239.88328552246094,
        488.35638427734375,
        250.92327880859375
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "밀폐 등), 사용기간(유효기간) 등을 병기하여야 한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        127.55999755859375,
        261.9632873535156,
        397.8927917480469,
        273.0032958984375
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가. 키트 또는 세트의 제품인 경우, 구성품별로 보관조건을 기재하고,",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        283.92327880859375,
        488.35662841796875,
        294.9632873535156
      ],
      "page_num": 41,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용기간(유효기간)이 서로 다른 경우 가장 짧은 기한으로 기재한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        145.9199981689453,
        305.8832702636719,
        481.7727966308594,
        316.92327880859375
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 일회용 체외진단용 시약이 아닐 경우, 개봉 후 시약의 저장방법(온",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        327.9632873535156,
        484.67999267578125,
        339.0032958984375
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "도, 습도, 차광, 밀폐, 보관용기 등) 및 사용기간(유효기간)등이 포",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        145.9199981689453,
        349.92327880859375,
        484.67999267578125,
        360.9632873535156
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "함되도록 한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        145.9199981689453,
        371.8832702636719,
        220.65281677246094,
        382.92327880859375
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다. 시약의 조제가 필요할 경우 조제 후 보관 조건 및 사용기간(유효",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        393.9632873535156,
        484.67999267578125,
        405.0032958984375
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기간)을 기재한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        146.16000366210938,
        415.92327880859375,
        237.3328094482422,
        426.9632873535156
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라. 전자민원 접수 시 ‘저장방법’ 항은 ‘사용기간에 따름’으로 표기하고",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        437.8832702636719,
        488.3560485839844,
        448.92327880859375
      ],
      "page_num": 41,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "‘사용기간’ 항에 아래 표와 같이 저장방법과 사용기간을 기재한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        145.55999755859375,
        459.9632873535156,
        479.1327819824219,
        471.0032958984375
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "표 3. 저장방법 및 사용기간(유효기간) 작성의 예",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        503.8832702636719,
        367.55999755859375,
        514.9232788085938
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구성시약",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        165.239990234375,
        543.9303588867188,
        478.3199768066406,
        553.8903198242188
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "개봉여부 보관조건",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        165.239990234375,
        543.9303588867188,
        478.3199768066406,
        553.8903198242188
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사용기간",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        165.239990234375,
        543.9303588867188,
        478.3199768066406,
        553.8903198242188
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비고",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        165.239990234375,
        543.9303588867188,
        478.3199768066406,
        553.8903198242188
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "BNP Test",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        111.72000122070312,
        574.5303955078125,
        449.8795166015625,
        584.6103515625
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "미개봉",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        111.72000122070312,
        574.5303955078125,
        449.8795166015625,
        584.6103515625
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2~8℃",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        111.72000122070312,
        574.5303955078125,
        449.8795166015625,
        584.6103515625
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조일로부터 12개월",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        111.72000122070312,
        574.5303955078125,
        449.8795166015625,
        584.6103515625
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일회용",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        111.72000122070312,
        593.0103759765625,
        483.3594970703125,
        603.09033203125
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "BNP Calibration Verification A",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        111.72000122070312,
        593.0103759765625,
        483.3594970703125,
        603.09033203125
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "미개봉",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        111.72000122070312,
        593.0103759765625,
        483.3594970703125,
        603.09033203125
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2~8℃",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        111.72000122070312,
        593.0103759765625,
        483.3594970703125,
        603.09033203125
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조일로부터 11개월",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        111.72000122070312,
        593.0103759765625,
        483.3594970703125,
        603.09033203125
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "BNP Control 1",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        111.72000122070312,
        611.4903564453125,
        449.8795166015625,
        621.5703125
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "미개봉",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        111.72000122070312,
        611.4903564453125,
        449.8795166015625,
        621.5703125
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2~8℃",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        111.72000122070312,
        611.4903564453125,
        449.8795166015625,
        621.5703125
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조일로부터 11개월",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        111.72000122070312,
        611.4903564453125,
        449.8795166015625,
        621.5703125
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        98.04000091552734,
        117.91441345214844,
        448.0853271484375,
        126.91441345214844
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 36 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 42,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "10",
      "font_size": 13.799982070922852,
      "font_name": "H2hdrM",
      "bbox": [
        118.19999694824219,
        161.10809326171875,
        202.4438018798828,
        175.86807250976562
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험규격",
      "font_size": 13.799982070922852,
      "font_name": "HYwulM",
      "bbox": [
        118.19999694824219,
        161.10809326171875,
        202.4438018798828,
        175.86807250976562
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 시약의 품질관리에 적정을 기할 수 있도록 제품의 특성에 따라 성능",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        207.96328735351562,
        488.35638427734375,
        219.00328063964844
      ],
      "page_num": 42,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등을 고려하여, 제조단위별·제조단계별로 안전성·성능을 검증하기 위하여",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        126.83999633789062,
        229.92327880859375,
        488.35638427734375,
        240.96327209472656
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적용할 수 있는 시험규격을 명시한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        126.83999633789062,
        251.88327026367188,
        317.0127868652344,
        262.92327880859375
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 시험규격은 제조사의 품질관리시험 자료에 따라 자사가 설정한 시험",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        295.92327880859375,
        484.67999267578125,
        306.9632873535156
      ],
      "page_num": 42,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "항목, 시험기준, 시험방법을 기재한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        126.7199935913086,
        317.8832702636719,
        317.9727783203125,
        328.92327880859375
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가. 시험항목",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        339.9632873535156,
        189.23965454101562,
        351.0032958984375
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 완제품의 최종 품질관리에 따른 성능시험을 포함한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        361.92327880859375,
        430.53277587890625,
        372.9632873535156
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 분석적 성능시험(민감도, 특이도, 재현성 등)을 포함하는 것을",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        383.8832702636719,
        488.35638427734375,
        394.92327880859375
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "권장하고, 그 외 자사가 설정한 시험항목을 설정할 수 있다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        159.72000122070312,
        405.9632873535156,
        462.93280029296875,
        417.0032958984375
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 시험기준",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        427.92327880859375,
        192.9160614013672,
        438.9632873535156
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 시험결과의 적부판정의 기준이 되는 기준치의 허용범위를 명확히",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        449.8832702636719,
        488.35638427734375,
        460.92327880859375
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기재하여야 하며, 시험결과가 온도, 습도 등 주위조건에 영향을",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        157.9199981689453,
        471.9632873535156,
        488.3560485839844,
        483.0032958984375
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "받는 경우에는 그 조건을 명시하여야 한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        157.9199981689453,
        493.92327880859375,
        375.5727844238281,
        504.9632873535156
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다. 시험방법",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        515.8832397460938,
        189.23965454101562,
        526.9232788085938
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 시험방법은 순서에 따라 시험결과를 정확히 산출할 수 있도록",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        537.9632568359375,
        488.3560485839844,
        549.0032958984375
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구체적, 개조식으로 기재한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        159.59999084472656,
        559.9232177734375,
        308.9727783203125,
        570.9632568359375
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 표준물질이 사용된 경우, 고, 중, 저 역가를 포함한 각각 최소",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        581.8832397460938,
        488.35638427734375,
        592.9232788085938
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3개 이상의 표준물질을 사용할 것을 권장하고 해당 표준물질명을",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        159.1199951171875,
        603.9632568359375,
        488.35638427734375,
        615.0032958984375
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기재한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        159.1199951171875,
        625.9232177734375,
        209.95663452148438,
        636.9632568359375
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가) 저농도 표준물질인 경우, 정량 및 정성검출한계를 근거로",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        150.47999572753906,
        647.8832397460938,
        488.3554992675781,
        658.9232788085938
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하여 설정한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        174.72000122070312,
        669.9632568359375,
        249.69281005859375,
        681.0032958984375
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나) 표준물질의 농도는 재현성, 직선성, 최소검출한계를 고려하여",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        150.47999572753906,
        691.9232177734375,
        488.3560485839844,
        702.9632568359375
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅴ. 제조․수입허가 신청서 기재 항목",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        346.91998291015625,
        117.55441284179688,
        481.4460144042969,
        126.55441284179688
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 37 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 43,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "설정한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        173.0399932861328,
        155.76327514648438,
        220.29281616210938,
        166.8032684326172
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다) 표준물질 농도는 가능하면 임상적으로 중요한 농도여야 한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        150.47999572753906,
        177.72328186035156,
        483.5727844238281,
        188.76327514648438
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표 4. 시험규격 작성의 예",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        221.76327514648438,
        241.07998657226562,
        232.8032684326172
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험항목",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        127.43999481201172,
        252.33035278320312,
        468.3595275878906,
        262.29034423828125
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험기준",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        127.43999481201172,
        252.33035278320312,
        468.3595275878906,
        262.29034423828125
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험방법",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        127.43999481201172,
        252.33035278320312,
        468.3595275878906,
        262.29034423828125
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1. 외관검사",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        121.55999755859375,
        277.41033935546875,
        402.5558166503906,
        294.8103332519531
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "카트리지의 라벨 인쇄상태, 구성품 누락여부를",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        121.55999755859375,
        277.41033935546875,
        402.5558166503906,
        294.8103332519531
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "확인한다.",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        186.239990234375,
        292.41033935546875,
        229.218505859375,
        302.3703308105469
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "육안으로",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        428.5199890136719,
        276.9303283691406,
        471.7962951660156,
        286.89031982421875
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "확인한다.",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        434.5199890136719,
        292.8903503417969,
        477.3785095214844,
        302.850341796875
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2.Timing",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        126.83999633789062,
        320.0103454589844,
        171.3184051513672,
        329.9703369140625
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Mode와 Batch",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        114.36000061035156,
        336.09033203125,
        183.79713439941406,
        346.0503234863281
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Mode간의",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        124.68000030517578,
        352.05035400390625,
        173.35675048828125,
        362.0103454589844
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비교",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        137.39999389648438,
        368.0103454589844,
        157.32000732421875,
        377.9703369140625
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Calibrator H를 이용하여 Timing Mode와 Batch",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        184.3199920654297,
        328.05035400390625,
        409.27716064453125,
        338.0103454589844
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Mode의 평균농도는 Batch Mode ± Range",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        186.1199951171875,
        344.0103454589844,
        386.95751953125,
        353.9703369140625
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Factor(18.7)내에 들어와야 한다.",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        186.1199951171875,
        360.09033203125,
        339.0185241699219,
        370.0503234863281
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "WI-6612",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        426.5999755859375,
        320.0103454589844,
        474.9179992675781,
        329.9703369140625
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "절차서에",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        429.1199951171875,
        336.09033203125,
        472.39630126953125,
        346.0503234863281
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "따라서",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        434.03997802734375,
        352.05035400390625,
        467.3562927246094,
        362.0103454589844
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험한다.",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        427.55999755859375,
        368.0103454589844,
        470.53851318359375,
        377.9703369140625
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3. 정밀도",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        428.0103454589844,
        169.1999969482422,
        437.9703369140625
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Calibrator H, E, C를 이용하여 측정하였을 때",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        184.3199920654297,
        393.8103332519531,
        399.7967529296875,
        403.77032470703125
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "CV 값이 다음의 기준을 만족해야 한다.",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        186.1199951171875,
        409.8903503417969,
        376.0369567871094,
        419.850341796875
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "테스트",
      "font_size": 8.519999504089355,
      "font_name": "Haansoft Batang",
      "bbox": [
        192.83999633789062,
        435.9664306640625,
        400.47442626953125,
        444.4864501953125
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Calibrator H",
      "font_size": 8.519999504089355,
      "font_name": "Haansoft Batang",
      "bbox": [
        192.83999633789062,
        435.9664306640625,
        400.47442626953125,
        444.4864501953125
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Calibrator E",
      "font_size": 8.519999504089355,
      "font_name": "Haansoft Batang",
      "bbox": [
        192.83999633789062,
        435.9664306640625,
        400.47442626953125,
        444.4864501953125
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Calibrator C",
      "font_size": 8.519999504089355,
      "font_name": "Haansoft Batang",
      "bbox": [
        192.83999633789062,
        435.9664306640625,
        400.47442626953125,
        444.4864501953125
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "BNP",
      "font_size": 8.519999504089355,
      "font_name": "Haansoft Batang",
      "bbox": [
        196.9199981689453,
        457.6864318847656,
        394.3248596191406,
        466.2064514160156
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "≤12.5%",
      "font_size": 8.519999504089355,
      "font_name": "Haansoft Batang",
      "bbox": [
        196.9199981689453,
        457.6864318847656,
        394.3248596191406,
        466.2064514160156
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "≤15.2%",
      "font_size": 8.519999504089355,
      "font_name": "Haansoft Batang",
      "bbox": [
        196.9199981689453,
        457.6864318847656,
        394.3248596191406,
        466.2064514160156
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "≤20.9%",
      "font_size": 8.519999504089355,
      "font_name": "Haansoft Batang",
      "bbox": [
        196.9199981689453,
        457.6864318847656,
        394.3248596191406,
        466.2064514160156
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "WI-6612",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        426.5999755859375,
        404.0103454589844,
        474.9179992675781,
        413.9703369140625
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "절차서에",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        429.1199951171875,
        419.9703369140625,
        472.39630126953125,
        429.9303283691406
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "따라서",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        434.03997802734375,
        435.9303283691406,
        467.3562927246094,
        445.89031982421875
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험한다.",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        427.55999755859375,
        452.0103454589844,
        470.53851318359375,
        461.9703369140625
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4. 위양성도",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        120.47999572753906,
        524.2503662109375,
        174.23951721191406,
        534.2103271484375
      ],
      "page_num": 43,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Zero Control을 이용하여 측정하였을 때 다음의",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        184.3199920654297,
        483.9303283691406,
        407.4762878417969,
        493.89031982421875
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기준을 만족해야 한다.",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        184.3199920654297,
        499.8903503417969,
        290.4772033691406,
        509.850341796875
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1. 항목별 시험기준",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        184.3199920654297,
        515.9703369140625,
        273.1195068359375,
        525.9302978515625
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "항 목",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        197.63999938964844,
        539.0103759765625,
        296.8799743652344,
        548.9703369140625
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기 준",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        197.63999938964844,
        539.0103759765625,
        296.8799743652344,
        548.9703369140625
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "BNP",
      "font_size": 9.0,
      "font_name": "Haansoft Batang",
      "bbox": [
        201.0,
        559.3944091796875,
        311.026611328125,
        568.3944091796875
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "≤10.0pg/mL",
      "font_size": 9.0,
      "font_name": "Haansoft Batang",
      "bbox": [
        201.0,
        559.3944091796875,
        311.026611328125,
        568.3944091796875
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "WI-6612",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        426.5999755859375,
        500.2503356933594,
        474.9179992675781,
        510.2103271484375
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "절차서에",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        429.1199951171875,
        516.2103881835938,
        472.39630126953125,
        526.1703491210938
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "따라서",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        434.03997802734375,
        532.2903442382812,
        467.3562927246094,
        542.2503051757812
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험한다.",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        427.55999755859375,
        548.2503662109375,
        470.53851318359375,
        558.2103271484375
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        98.04000091552734,
        117.91441345214844,
        448.0853271484375,
        126.91441345214844
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 38 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 44,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "11",
      "font_size": 13.799982070922852,
      "font_name": "H2hdrM",
      "bbox": [
        118.19999694824219,
        161.10809326171875,
        450.7667541503906,
        175.86807250976562
      ],
      "page_num": 44,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조원 (수입 또는 제조공정 전부 위탁의 경우)",
      "font_size": 14.039999961853027,
      "font_name": "HYwulM",
      "bbox": [
        118.19999694824219,
        161.10809326171875,
        450.7667541503906,
        175.86807250976562
      ],
      "page_num": 44,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "<작성요령>",
      "font_size": 12.0,
      "font_name": "Batang",
      "bbox": [
        110.5199966430664,
        207.97921752929688,
        173.5800018310547,
        219.97921752929688
      ],
      "page_num": 44,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 수입제품은 제조원을 기재하여야 한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        236.1632843017578,
        325.8927917480469,
        247.20327758789062
      ],
      "page_num": 44,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나. 제조제품 중 제조공정을 전부 위탁하는 경우 해당 제조소를 기재한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        262.3232727050781,
        477.0927734375,
        273.36328125
      ],
      "page_num": 44,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조의뢰자와 제조자의 상호와 주소를 모두 기재한다. 다만, 제조자가",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        130.55999755859375,
        284.28326416015625,
        488.35736083984375,
        295.3232727050781
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "외국회사일 경우에는 제조국을 추가로 기재한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        130.55999755859375,
        306.36328125,
        370.41278076171875,
        317.4032897949219
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 예시",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        328.3232727050781,
        162.83999633789062,
        339.36328125
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 국내 A 제조업체가 B 제조업체에게 유전질환검사시약 제조를 전면",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        350.28326416015625,
        488.3560485839844,
        361.3232727050781
      ],
      "page_num": 44,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위탁 시",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        372.36328125,
        149.0399932861328,
        383.4032897949219
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조원은 다음과 같이 기재한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        394.3232727050781,
        278.61279296875,
        405.36328125
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상호 (제조사 주소)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        416.28326416015625,
        220.44000244140625,
        427.3232727050781
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "․ 제조의뢰자 : A (A사 주소)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        438.36328125,
        269.9999694824219,
        449.4032897949219
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "․ 제조자 : B (B사 주소)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        460.3232727050781,
        246.1199951171875,
        471.36328125
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 수입제품의 경우, 미국에 있는 C사가 아일랜드에 있는 D사에 OOO검",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        504.3632507324219,
        484.67999267578125,
        515.4032592773438
      ],
      "page_num": 44,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사시약 제조를 전면 위탁 시 제조원은 다음과 같이 기재한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        131.16000366210938,
        526.3232421875,
        442.17279052734375,
        537.36328125
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상호 (제조국/제조사 주소)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        548.2832641601562,
        257.1600036621094,
        559.3233032226562
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "․ 제조의뢰자 : C (미국 C사 주소)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        570.3632202148438,
        299.35638427734375,
        581.4032592773438
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "․ 제조자 : D (아일랜드 D사 주소)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        592.3232421875,
        311.23602294921875,
        603.36328125
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅵ. 기술문서 등의 심사를 위한 제출자료",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        327.8399963378906,
        117.55441284179688,
        481.44561767578125,
        126.55441284179688
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 39 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 45,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅵ",
      "font_size": 21.959999084472656,
      "font_name": "T12",
      "bbox": [
        117.23999786376953,
        160.07998657226562,
        488.11639404296875,
        188.76327514648438
      ],
      "page_num": 45,
      "block_type": "heading",
      "level": 1,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기술문서 등의 심사를 위한 제출자료",
      "font_size": 18.0,
      "font_name": "H2hdrM",
      "bbox": [
        117.23999786376953,
        160.07998657226562,
        488.11639404296875,
        188.76327514648438
      ],
      "page_num": 45,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 원칙",
      "font_size": 12.0,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        223.69921875,
        150.0,
        235.69921875
      ],
      "page_num": 45,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 기술문서 등의 심사를 받고자 하는 자는 시행규칙 별지 제7호",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        247.68328857421875,
        488.35638427734375,
        258.7232971191406
      ],
      "page_num": 45,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "서식에 따라 작성하여야 한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        147.0,
        269.6432800292969,
        298.6528015136719,
        280.68328857421875
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 첨부자료 등을 식품의약품안전처장이 정한 전용프로그램으로 작성된",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        291.603271484375,
        488.35638427734375,
        302.6432800292969
      ],
      "page_num": 45,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전자적 기록매체(CD·디스켓 등)와 함께 제출한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        145.3199920654297,
        313.68328857421875,
        401.95660400390625,
        324.7232971191406
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다. 해당 제품의 특성상 첨부자료의 일부가 불필요한 경우, 그 사유를",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        335.6432800292969,
        488.3560485839844,
        346.68328857421875
      ],
      "page_num": 45,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구체적으로 기재하여야 한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        145.9199981689453,
        357.603271484375,
        295.7566223144531,
        368.6432800292969
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라. 외국의 자료는 주요사항을 발췌한 한글 요약문 및 원문을 첨부",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        379.68328857421875,
        484.68023681640625,
        390.7232971191406
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하여야 하며, 필요한 경우에 한하여 번역물을 요구할 수 있다. 다만,",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        145.8000030517578,
        401.6432800292969,
        488.35662841796875,
        412.68328857421875
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "영어 외의 외국어 자료는 공증된 전체 번역문을 첨부하여야 한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        145.8000030517578,
        423.603271484375,
        478.7727966308594,
        434.6432800292969
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 시험 자료의 요건 (분석적 성능, 품질관리 시험성적서, 검체 조건 설정 자료)",
      "font_size": 9.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        467.6592102050781,
        482.53851318359375,
        479.6592102050781
      ],
      "page_num": 45,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 임상적 성능시험 자료 요건은 별도 제시",
      "font_size": 9.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        491.7303466796875,
        312.4804382324219,
        501.6903381347656
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 인정범위",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        125.5199966430664,
        531.603271484375,
        188.27964782714844,
        542.643310546875
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 식약처장이 지정한 시험검사기관에서 발급한 시험성적서",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        563.6432495117188,
        447.5560607910156,
        574.6832885742188
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 해당 의료기기에 대하여 경제협력기구(OECD) 회원국에 허가",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        585.603271484375,
        488.3560485839844,
        596.643310546875
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "당시 제출되어 평가된 시험에 관한 자료로서 해당 정부 또는",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        160.55999755859375,
        607.6832275390625,
        488.3560485839844,
        618.7232666015625
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정부가 허가 업무를 위임한 등록기관이 제출받아 승인하였음을",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        160.55999755859375,
        629.6432495117188,
        488.3557434082031,
        640.6832885742188
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "확인한 자료 또는 이를 공증한 자료",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        160.55999755859375,
        651.6032104492188,
        341.9996643066406,
        662.6432495117188
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3) 「의료기기 제조·수입 및 품질관리기준」또는 이와 동등 이상의",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        673.6832275390625,
        488.3560485839844,
        684.7232666015625
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "규격에 따른 제조사의 품질관리시스템 하에서 실시된 시험성적서",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        158.51998901367188,
        695.6432495117188,
        481.4410400390625,
        706.6832885742188
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        98.04000091552734,
        117.91441345214844,
        448.0853271484375,
        126.91441345214844
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 40 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 46,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4) 대학 또는 연구기관 등 국내·외의 전문기관에서 시험한 것으로서",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        155.76327514648438,
        488.35638427734375,
        166.8032684326172
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해당 전문기관의 장이 발급하고 그 내용(전문기관의 시험시설",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        158.63999938964844,
        177.72328186035156,
        488.3560485839844,
        188.76327514648438
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개요, 주요설비, 연구인력 구성, 시험자의 연구경력 등을 포함한다)을",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        158.63999938964844,
        199.80328369140625,
        488.35638427734375,
        210.84327697753906
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검토하여 타당하다고 인정할 수 있는 시험성적서",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        158.63999938964844,
        221.76327514648438,
        406.0796813964844,
        232.8032684326172
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 기재내용",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        125.5199966430664,
        265.80328369140625,
        188.27964782714844,
        276.8432922363281
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 업체명 및 주소",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        297.7232666015625,
        234.95999145507812,
        308.7632751464844
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 시험성적서 일련번호 및 각 페이지와 전체 페이지번호",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        319.80328369140625,
        432.8396911621094,
        330.8432922363281
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 시험검사품의 모델명, 상품명(해당 경우에 한함)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        341.7632751464844,
        403.0799865722656,
        352.80328369140625
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 시험일자 및 시험성적서 발급일자",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        363.7232666015625,
        328.4396667480469,
        374.7632751464844
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5) 시험 책임자의 서명 또는 직인",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        385.80328369140625,
        311.8800048828125,
        396.8432922363281
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6) 시험기준 및 시험방법 단, 규격이 없는 경우 이에 대한 설정 사유",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        407.7632751464844,
        483.6004333496094,
        418.80328369140625
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "7) 시험 검사품 채취 및 방법에 대한 사항(시험을 위한 별도의",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        429.7232666015625,
        488.35638427734375,
        440.7632751464844
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전처리가 필요한 경우에 한함)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        158.0399932861328,
        451.80328369140625,
        311.9999694824219,
        462.8432922363281
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "8) 시험환경요인(시험결과에 영향을 주는 경우에 한함)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        473.7632751464844,
        421.91998291015625,
        484.80328369140625
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다. 추가 기재내용 (대학 또는 연구기관 등 국내외 전문기관에서 시험한",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        125.5199966430664,
        517.80322265625,
        488.35638427734375,
        528.84326171875
      ],
      "page_num": 46,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "자료의 경우)",
      "font_size": 11.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        144.72000122070312,
        539.7632446289062,
        208.41281127929688,
        550.8032836914062
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 시험시설개요",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        571.80322265625,
        227.59573364257812,
        582.84326171875
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전문기관의 명칭, 주소, 인증현황, 검사기능 분야, 연구인력구성,",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        592.80322265625,
        488.35662841796875,
        603.84326171875
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주요설비 목록 등이 기재되어 있어야 함",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        156.95999145507812,
        614.7632446289062,
        360.3600158691406,
        625.8032836914062
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2) 주요설비",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        636.7232666015625,
        205.6360626220703,
        647.7633056640625
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험검사에 사용된 장비명칭, 장비사양, 검·교정 기록서 등에 대한",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        658.80322265625,
        488.35638427734375,
        669.84326171875
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사항이 기재되고 관련 증빙자료를 함께 제출하여야 함",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        156.95999145507812,
        680.7632446289062,
        431.8800048828125,
        691.8032836914062
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅵ. 기술문서 등의 심사를 위한 제출자료",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        327.8399963378906,
        117.55441284179688,
        481.44561767578125,
        126.55441284179688
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 41 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 47,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3) 연구인력구성",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        177.72328186035156,
        223.9193115234375,
        188.76327514648438
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험검사를 실시한 전문기관 담당부서에 속한 연구인력들에 대한",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        199.80328369140625,
        488.3568115234375,
        210.84327697753906
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정보가 기재되어야 함",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        156.95999145507812,
        221.76327514648438,
        265.91998291015625,
        232.8032684326172
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 시험자의 연구경력",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        243.72328186035156,
        255.0760498046875,
        254.76327514648438
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험검사를 실시한 시험자가 해당 검사를 하기에 적합한 전공, 경력",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        265.80328369140625,
        488.35638427734375,
        276.8432922363281
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등을 가지고 있는지에 대해 기재하고, 해당 전문기관에서 규정한",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        156.95999145507812,
        287.7632751464844,
        488.3569030761719,
        298.80328369140625
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "요건에 적합한 시험자가 시험하였는지에 대한 자료를 제출",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        156.95999145507812,
        309.7232666015625,
        447.60009765625,
        320.7632751464844
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1",
      "font_size": 13.799982070922852,
      "font_name": "H2hdrM",
      "bbox": [
        121.91999816894531,
        359.10809326171875,
        472.07965087890625,
        373.3551330566406
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "개발경위, 측정원리·방법 및 국내․외 사용현황에 관한 자료",
      "font_size": 12.839439392089844,
      "font_name": "HYwulM",
      "bbox": [
        121.91999816894531,
        359.10809326171875,
        472.07965087890625,
        373.3551330566406
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1. 개발경위",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        405.9632873535156,
        169.67965698242188,
        417.0032958984375
      ],
      "page_num": 47,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 측정하고자 하는 대상 또는 질병이나 증후군의 설명 및 개발배경이",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        427.92327880859375,
        488.35638427734375,
        438.9632873535156
      ],
      "page_num": 47,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함된 논문, 문헌 등의 자료를 제출한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        145.44000244140625,
        449.8832702636719,
        355.29278564453125,
        460.92327880859375
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 측정원리 ․ 방법",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        493.92327880859375,
        204.47964477539062,
        504.9632873535156
      ],
      "page_num": 47,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 해당제품의 측정 및 질병진단 목적을 달성하기 위하여 적용된 원리에",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        515.8832397460938,
        488.35638427734375,
        526.9232788085938
      ],
      "page_num": 47,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관한 자료",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        144.95999145507812,
        537.9632568359375,
        193.56008911132812,
        549.0032958984375
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3. 국내․외에서 사용현황",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        581.8832397460938,
        232.07965087890625,
        592.9232788085938
      ],
      "page_num": 47,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 국내․외에서 사용현황에 관해 제출할 자료는 다음의 사항을 포함한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        603.9632568359375,
        482.1327819824219,
        615.0032958984375
      ],
      "page_num": 47,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1)국내외의 판매 또는 허가현황 및 제조허가 경위 등과 관련된 자료",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        625.9232177734375,
        470.0401916503906,
        636.9632568359375
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2) 사용 시 보고된 측정오류 : 외국에서 시판 중인 제품의 경우, 제품",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        647.8832397460938,
        488.35638427734375,
        658.9232788085938
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안전성 및 성능과 관련된 유해사례보고 요약",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        158.16000366210938,
        669.9632568359375,
        383.6400146484375,
        681.0032958984375
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3) 제조국에서 사용되지 않는 경우는 그 사유",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        691.9232177734375,
        376.036376953125,
        702.9632568359375
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        98.04000091552734,
        117.91441345214844,
        448.0853271484375,
        126.91441345214844
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 42 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 48,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2",
      "font_size": 13.799982070922852,
      "font_name": "H2hdrM",
      "bbox": [
        121.91999816894531,
        161.10809326171875,
        349.0839538574219,
        175.86807250976562
      ],
      "page_num": 48,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "원재료 및 제조방법에 관한 자료",
      "font_size": 13.799982070922852,
      "font_name": "HYwulM",
      "bbox": [
        121.91999816894531,
        161.10809326171875,
        349.0839538574219,
        175.86807250976562
      ],
      "page_num": 48,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 원재료의 성분 또는 분량을 확인할 수 있는 근거자료",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        207.96328735351562,
        395.0396728515625,
        219.00328063964844
      ],
      "page_num": 48,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 해당시약의 성분과 분량을 확인할 수 있는 자료",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        229.92327880859375,
        387.1199951171875,
        240.96327209472656
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 원료물질(항원)이 재조합, 합성인 경우, 아미노산서열을 확인할 수",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        251.88327026367188,
        488.35638427734375,
        262.92327880859375
      ],
      "page_num": 48,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있는 자료 포함",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        145.67999267578125,
        273.9632873535156,
        222.5996551513672,
        285.0032958984375
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다. 원료물질(단클론항체)의 기원에 관한 자료-기원 생물체, 클론번호",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        295.92327880859375,
        482.0396728515625,
        306.9632873535156
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라. 원료물질의 품질 확인 근거자료",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        317.8832702636719,
        304.6796875,
        328.92327880859375
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 제조공정의 흐름도를 포함한 제조공정에 관한 자료",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        361.92327880859375,
        383.9996643066406,
        372.9632873535156
      ],
      "page_num": 48,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 제조공정의 흐름을 파악할 수 있는 자료를 제출(제조공정상의 제조",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        383.8832702636719,
        488.35638427734375,
        394.92327880859375
      ],
      "page_num": 48,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "단계별 시험 및 완제품 품질관리 시험의 단계를 확인할 수 있는 자료)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        145.8000030517578,
        405.9632873535156,
        481.5599670410156,
        417.0032958984375
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 원료물질의 제조방법을 간략하게 기술하고, 이를 구매한 경우, 이를",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        427.92327880859375,
        488.35638427734375,
        438.9632873535156
      ],
      "page_num": 48,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "확인할 수 있는 자료를 제출한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        145.3199920654297,
        449.8832702636719,
        313.5328063964844,
        460.92327880859375
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다. 일부 구성제품이 OEM제조품인 경우, 구성품의 제조원(제조자의",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        471.9632873535156,
        488.3560485839844,
        483.0032958984375
      ],
      "page_num": 48,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상호와 주소)을 확인할 수 있는 자료도 포함한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        147.59999084472656,
        493.92327880859375,
        398.1327819824219,
        504.9632873535156
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3",
      "font_size": 13.799982070922852,
      "font_name": "H2hdrM",
      "bbox": [
        121.91999816894531,
        543.3080444335938,
        282.36395263671875,
        558.068115234375
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사용목적에 관한 자료",
      "font_size": 13.799982070922852,
      "font_name": "HYwulM",
      "bbox": [
        121.91999816894531,
        543.3080444335938,
        282.36395263671875,
        558.068115234375
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1. 허가신청서에 기재한 해당 제품의 사용목적의 세부 사항(검사대상,",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        590.1632690429688,
        488.35638427734375,
        601.2033081054688
      ],
      "page_num": 48,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검체종류, 검사항목, 측정원리 및 결과판정방법(정성, 정량 등))에 대한",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        127.43999481201172,
        612.1232299804688,
        488.35614013671875,
        623.1632690429688
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "근거자료를 제출한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        127.43999481201172,
        634.083251953125,
        232.77281188964844,
        645.123291015625
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2. 해당제품의 제품설명서(instructions for user)를 제출한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        656.1632690429688,
        426.6763000488281,
        667.2033081054688
      ],
      "page_num": 48,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅵ. 기술문서 등의 심사를 위한 제출자료",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        327.8399963378906,
        117.55441284179688,
        481.44561767578125,
        126.55441284179688
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 43 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 49,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4",
      "font_size": 13.799982070922852,
      "font_name": "H2hdrM",
      "bbox": [
        121.91999816894531,
        183.06808471679688,
        418.56396484375,
        197.9480743408203
      ],
      "page_num": 49,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "저장방법과 사용기간(유효기간)에 관한 자료",
      "font_size": 13.799982070922852,
      "font_name": "HYwulM",
      "bbox": [
        121.91999816894531,
        183.06808471679688,
        418.56396484375,
        197.9480743408203
      ],
      "page_num": 49,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 완제품 및 개봉 후 시약의 안정성에 관한 자료로서 저장방법, 사용기간",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        229.92327880859375,
        488.35638427734375,
        240.96327209472656
      ],
      "page_num": 49,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등에 대한 시험성적서를 제출한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.87999725341797,
        251.88327026367188,
        303.1966247558594,
        262.92327880859375
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 구성 제품별로 구분하여 안정성 시험 자료를 제출한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        273.9632873535156,
        403.6528015136719,
        285.0032958984375
      ],
      "page_num": 49,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3. 시험성적서는 평가계획, 시험간격, 허용기준, 결과 등의 내용을 포함한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        295.92327880859375,
        484.6528015136719,
        306.9632873535156
      ],
      "page_num": 49,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4. 안정성 시험 시에는 식약처「의료기기의 안정성 시험 기준」의 내용을",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        317.8832702636719,
        488.3560485839844,
        328.92327880859375
      ],
      "page_num": 49,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "참고한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        127.55999755859375,
        339.9632873535156,
        174.69281005859375,
        351.0032958984375
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5. 저장 및 사용기간(유효기간)에 대한 시험은 완제품 3 lots, 개봉 후 1",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        361.92327880859375,
        488.2365417480469,
        372.9632873535156
      ],
      "page_num": 49,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "lot 이상의 시험성적서를 제출한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        127.55999755859375,
        383.8832702636719,
        303.4527893066406,
        394.92327880859375
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6. 일회용으로 낱개 포장되어 있는 체외진단용 의료기기를 제외하고, 개",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        405.9632873535156,
        484.67999267578125,
        417.0032958984375
      ],
      "page_num": 49,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "봉 후(on-board, reconstitution, open vial/bottle stability) 안정성 자",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        127.55999755859375,
        427.92327880859375,
        484.67999267578125,
        438.9632873535156
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "료를 포함한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        127.55999755859375,
        449.8832702636719,
        202.1728057861328,
        460.92327880859375
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "7. 수송 조건(환경 및 운반조건 변화)을 고려한 안정성 자료의 제출을 권장한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        471.9632873535156,
        486.1963806152344,
        483.0032958984375
      ],
      "page_num": 49,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "8. 저장방법 및 사용기간(유효기간)에 대한 시험자료는 시험성적서의",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        493.92327880859375,
        488.35638427734375,
        504.9632873535156
      ],
      "page_num": 49,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인정범위내의 자료이어야 한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        128.39999389648438,
        515.8832397460938,
        285.5727844238281,
        526.9232788085938
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        98.04000091552734,
        117.91441345214844,
        448.0853271484375,
        126.91441345214844
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 44 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 50,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "5",
      "font_size": 13.799982070922852,
      "font_name": "H2hdrM",
      "bbox": [
        121.91999816894531,
        161.10809326171875,
        362.4039611816406,
        175.86807250976562
      ],
      "page_num": 50,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품의 성능을 확인하기 위한 자료",
      "font_size": 13.799982070922852,
      "font_name": "HYwulM",
      "bbox": [
        121.91999816894531,
        161.10809326171875,
        362.4039611816406,
        175.86807250976562
      ],
      "page_num": 50,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 제품의 성능을 확인하기 위한 자료는 다음의 자료를 포함한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        207.96328735351562,
        442.17279052734375,
        219.00328063964844
      ],
      "page_num": 50,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 분석적 성능시험에 관한 자료(시험성적서)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        229.92327880859375,
        359.6399841308594,
        240.96327209472656
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 분석적 성능시험에 관한 자료에는 다음의 평가항목을 포함한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        247.56329345703125,
        467.2527770996094,
        258.6033020019531
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 분석적 민감도(판정기준치(cut-off value), 최소검출한계, 측정",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        265.0832824707031,
        484.6796875,
        276.123291015625
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "범위 등)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        159.36000061035156,
        282.7232666015625,
        203.39999389648438,
        293.7632751464844
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 분석적 특이도",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        300.36328125,
        229.4396514892578,
        311.4032897949219
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 정밀도(반복, 재현성 등)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        317.8832702636719,
        282.1199951171875,
        328.92327880859375
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 정확도",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        335.5232849121094,
        190.91964721679688,
        346.56329345703125
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5) 교차반응",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        353.16326904296875,
        201.95965576171875,
        364.2032775878906
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다. 임상적 성능시험에 관한 자료",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        370.68328857421875,
        293.6396789550781,
        381.7232971191406
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "민족적 차이",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        388.3232727050781,
        185.99964904785156,
        399.36328125
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 임상적 민감도",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        405.9632873535156,
        229.4396514892578,
        417.0032958984375
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 임상적 특이도",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        423.4832763671875,
        229.4396514892578,
        434.5232849121094
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라. 완제품의 품질관리 시험성적서 또는 시험에 관한 자료(3배치 1회 이상",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        441.1232604980469,
        488.23638916015625,
        452.16326904296875
      ],
      "page_num": 50,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는 1배치 3회 이상)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        142.55999755859375,
        458.7632751464844,
        248.8800048828125,
        469.80328369140625
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "마. 완제품 품질관리 시험에 사용된 표준물질에 관한 자료",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        476.28326416015625,
        420.1199951171875,
        487.3232727050781
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "바. 검체 보관 및 취급상(온도, 습도 등)의 조건 설정 근거 자료",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        493.92327880859375,
        450.8399963378906,
        504.9632873535156
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사. 국내·외 허가제품과의 상관성 시험에 대한 시험성적서",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        511.5632629394531,
        421.9960632324219,
        522.603271484375
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6",
      "font_size": 13.799982070922852,
      "font_name": "H2hdrM",
      "bbox": [
        121.91999816894531,
        552.0680541992188,
        448.9239501953125,
        566.8280639648438
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "체외진단용 의료기기의 취급자 안전에 관한 자료",
      "font_size": 13.799982070922852,
      "font_name": "HYwulM",
      "bbox": [
        121.91999816894531,
        552.0680541992188,
        448.9239501953125,
        566.8280639648438
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1. 구성시약 중 인간혈액 유래물질이 포함되었을 경우에는 사람면역결핍",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        598.9232177734375,
        484.6793518066406,
        609.9632568359375
      ],
      "page_num": 50,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "바이러스(HIV),",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        127.55999755859375,
        620.8832397460938,
        488.35638427734375,
        631.9232788085938
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "C형간염바이러스(HCV),",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        127.55999755859375,
        620.8832397460938,
        488.35638427734375,
        631.9232788085938
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "B형간염바이러스(HBV)가",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        127.55999755859375,
        620.8832397460938,
        488.35638427734375,
        631.9232788085938
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "음성 또는 불활성화하여 감염력이 없음을 입증하는 자료를 제출한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        127.55999755859375,
        642.9632568359375,
        480.7966003417969,
        654.0032958984375
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2. 유해물질(독성, 가연성 등) 등 취급자 안전 및 적합성을 확인한 자료를",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        664.9232177734375,
        488.2360534667969,
        675.9632568359375
      ],
      "page_num": 50,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제출한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        127.55999755859375,
        686.8832397460938,
        174.69281005859375,
        697.9232788085938
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅵ. 기술문서 등의 심사를 위한 제출자료",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        327.8399963378906,
        117.55441284179688,
        481.44561767578125,
        126.55441284179688
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 45 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 51,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "7",
      "font_size": 13.799982070922852,
      "font_name": "H2hdrM",
      "bbox": [
        121.91999816894531,
        161.10809326171875,
        402.36395263671875,
        175.86807250976562
      ],
      "page_num": 51,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이미 허가·인증받은 제품과 비교한 자료",
      "font_size": 13.799982070922852,
      "font_name": "HYwulM",
      "bbox": [
        121.91999816894531,
        161.10809326171875,
        402.36395263671875,
        175.86807250976562
      ],
      "page_num": 51,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 이미 허가·인증받은 제품과 명칭(제품명, 품목명, 모델명), 제조(수입)업",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        207.96328735351562,
        484.67999267578125,
        219.00328063964844
      ],
      "page_num": 51,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "소명, 제조원 및 소재지, 허가(인증)번호, 사용목적, 작용원리, 원재료,",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        127.55999755859375,
        229.92327880859375,
        488.35662841796875,
        240.96327209472656
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성능, 시험규격, 사용방법을 비교한 별제 제3호서식의 비교표",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        127.55999755859375,
        251.88327026367188,
        437.2799987792969,
        262.92327880859375
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[별지 제3호서식]",
      "font_size": 11.039999961853027,
      "font_name": "DotumChe",
      "bbox": [
        110.5199966430664,
        278.16326904296875,
        209.52000427246094,
        289.2032775878906
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "<본질적 동등품목 비교표>",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        213.72000122070312,
        301.0391540527344,
        381.7108459472656,
        319.7134704589844
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 기허가된 의료기기와의 차이가 명확하게 입증도록 필요한 항목을 기재하여야 한다.",
      "font_size": 9.0,
      "font_name": "DotumChe",
      "bbox": [
        111.47999572753906,
        666.7943725585938,
        481.86029052734375,
        675.7943725585938
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2) 각 항목에 대한 정보가 기 허가된 의료기기와 동등한 경우 ‘예’에 체크하고, 동",
      "font_size": 9.0,
      "font_name": "DotumChe",
      "bbox": [
        111.47999572753906,
        681.6743774414062,
        484.67999267578125,
        690.6743774414062
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등하지 않을 경우 ‘아니오’란에 체크한다.",
      "font_size": 9.0,
      "font_name": "DotumChe",
      "bbox": [
        134.75999450683594,
        691.6343994140625,
        319.1399841308594,
        700.6343994140625
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "번호",
      "font_size": 9.0,
      "font_name": "DotumChe",
      "bbox": [
        120.95999908447266,
        330.81561279296875,
        464.2799987792969,
        340.9944152832031
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비교항목1)",
      "font_size": 5.759999752044678,
      "font_name": "DotumChe",
      "bbox": [
        120.95999908447266,
        330.81561279296875,
        464.2799987792969,
        340.9944152832031
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기허가 제품",
      "font_size": 9.0,
      "font_name": "DotumChe",
      "bbox": [
        120.95999908447266,
        330.81561279296875,
        464.2799987792969,
        340.9944152832031
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "신청제품",
      "font_size": 9.0,
      "font_name": "DotumChe",
      "bbox": [
        120.95999908447266,
        330.81561279296875,
        464.2799987792969,
        340.9944152832031
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "동등여부2)",
      "font_size": 5.759999752044678,
      "font_name": "DotumChe",
      "bbox": [
        120.95999908447266,
        330.81561279296875,
        464.2799987792969,
        340.9944152832031
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1",
      "font_size": 9.0,
      "font_name": "DotumChe",
      "bbox": [
        127.68000030517578,
        352.514404296875,
        212.40028381347656,
        367.3944091796875
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "품목명",
      "font_size": 9.0,
      "font_name": "DotumChe",
      "bbox": [
        127.68000030517578,
        352.514404296875,
        212.40028381347656,
        367.3944091796875
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(분류번호 및 등급)",
      "font_size": 9.0,
      "font_name": "DotumChe",
      "bbox": [
        159.36000061035156,
        364.1544189453125,
        238.6199951171875,
        373.1544189453125
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 9.0,
      "font_name": "DotumChe",
      "bbox": [
        127.68000030517578,
        382.3944091796875,
        226.01998901367188,
        391.3944091796875
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "명칭(모델명)",
      "font_size": 9.0,
      "font_name": "DotumChe",
      "bbox": [
        127.68000030517578,
        382.3944091796875,
        226.01998901367188,
        391.3944091796875
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3",
      "font_size": 9.0,
      "font_name": "DotumChe",
      "bbox": [
        127.68000030517578,
        404.71441650390625,
        234.95999145507812,
        413.71441650390625
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제조(수입)업소명",
      "font_size": 9.0,
      "font_name": "DotumChe",
      "bbox": [
        127.68000030517578,
        404.71441650390625,
        234.95999145507812,
        413.71441650390625
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4",
      "font_size": 9.0,
      "font_name": "DotumChe",
      "bbox": [
        127.68000030517578,
        426.9143981933594,
        234.95999145507812,
        435.9143981933594
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제조원 및 소재지",
      "font_size": 9.0,
      "font_name": "DotumChe",
      "bbox": [
        127.68000030517578,
        426.9143981933594,
        234.95999145507812,
        435.9143981933594
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5",
      "font_size": 9.0,
      "font_name": "DotumChe",
      "bbox": [
        127.68000030517578,
        449.2344055175781,
        216.95999145507812,
        458.2344055175781
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허가번호",
      "font_size": 9.0,
      "font_name": "DotumChe",
      "bbox": [
        127.68000030517578,
        449.2344055175781,
        216.95999145507812,
        458.2344055175781
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6",
      "font_size": 9.0,
      "font_name": "DotumChe",
      "bbox": [
        127.68000030517578,
        466.75439453125,
        468.1199951171875,
        482.2344055175781
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사용목적",
      "font_size": 9.0,
      "font_name": "DotumChe",
      "bbox": [
        127.68000030517578,
        466.75439453125,
        468.1199951171875,
        482.2344055175781
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예",
      "font_size": 9.0,
      "font_name": "DotumChe",
      "bbox": [
        127.68000030517578,
        466.75439453125,
        468.1199951171875,
        482.2344055175781
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□",
      "font_size": 9.0,
      "font_name": "DotumChe",
      "bbox": [
        127.68000030517578,
        466.75439453125,
        468.1199951171875,
        482.2344055175781
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아니오",
      "font_size": 9.0,
      "font_name": "DotumChe",
      "bbox": [
        409.55999755859375,
        479.5943908691406,
        468.1199951171875,
        488.5943908691406
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□",
      "font_size": 9.0,
      "font_name": "DotumChe",
      "bbox": [
        409.55999755859375,
        479.5943908691406,
        468.1199951171875,
        488.5943908691406
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "7",
      "font_size": 9.0,
      "font_name": "DotumChe",
      "bbox": [
        127.68000030517578,
        492.4344177246094,
        468.1199951171875,
        507.7944030761719
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "작용원리",
      "font_size": 9.0,
      "font_name": "DotumChe",
      "bbox": [
        127.68000030517578,
        492.4344177246094,
        468.1199951171875,
        507.7944030761719
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예",
      "font_size": 9.0,
      "font_name": "DotumChe",
      "bbox": [
        127.68000030517578,
        492.4344177246094,
        468.1199951171875,
        507.7944030761719
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□",
      "font_size": 9.0,
      "font_name": "DotumChe",
      "bbox": [
        127.68000030517578,
        492.4344177246094,
        468.1199951171875,
        507.7944030761719
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아니오",
      "font_size": 9.0,
      "font_name": "DotumChe",
      "bbox": [
        409.55999755859375,
        505.2744140625,
        468.1199951171875,
        514.2744140625
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□",
      "font_size": 9.0,
      "font_name": "DotumChe",
      "bbox": [
        409.55999755859375,
        505.2744140625,
        468.1199951171875,
        514.2744140625
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "8",
      "font_size": 9.0,
      "font_name": "DotumChe",
      "bbox": [
        127.68000030517578,
        518.1143798828125,
        468.1199951171875,
        533.4744262695312
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "원재료",
      "font_size": 9.0,
      "font_name": "DotumChe",
      "bbox": [
        127.68000030517578,
        518.1143798828125,
        468.1199951171875,
        533.4744262695312
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예",
      "font_size": 9.0,
      "font_name": "DotumChe",
      "bbox": [
        127.68000030517578,
        518.1143798828125,
        468.1199951171875,
        533.4744262695312
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□",
      "font_size": 9.0,
      "font_name": "DotumChe",
      "bbox": [
        127.68000030517578,
        518.1143798828125,
        468.1199951171875,
        533.4744262695312
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아니오",
      "font_size": 9.0,
      "font_name": "DotumChe",
      "bbox": [
        409.55999755859375,
        530.8344116210938,
        468.1199951171875,
        539.8344116210938
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□",
      "font_size": 9.0,
      "font_name": "DotumChe",
      "bbox": [
        409.55999755859375,
        530.8344116210938,
        468.1199951171875,
        539.8344116210938
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "9",
      "font_size": 9.0,
      "font_name": "DotumChe",
      "bbox": [
        127.68000030517578,
        543.6743774414062,
        468.1199951171875,
        559.1544189453125
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "성능",
      "font_size": 9.0,
      "font_name": "DotumChe",
      "bbox": [
        127.68000030517578,
        543.6743774414062,
        468.1199951171875,
        559.1544189453125
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예",
      "font_size": 9.0,
      "font_name": "DotumChe",
      "bbox": [
        127.68000030517578,
        543.6743774414062,
        468.1199951171875,
        559.1544189453125
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□",
      "font_size": 9.0,
      "font_name": "DotumChe",
      "bbox": [
        127.68000030517578,
        543.6743774414062,
        468.1199951171875,
        559.1544189453125
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아니오",
      "font_size": 9.0,
      "font_name": "DotumChe",
      "bbox": [
        409.55999755859375,
        556.514404296875,
        468.1199951171875,
        565.514404296875
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□",
      "font_size": 9.0,
      "font_name": "DotumChe",
      "bbox": [
        409.55999755859375,
        556.514404296875,
        468.1199951171875,
        565.514404296875
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "10",
      "font_size": 9.0,
      "font_name": "DotumChe",
      "bbox": [
        125.39999389648438,
        569.3544311523438,
        468.1199951171875,
        584.7144165039062
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험규격",
      "font_size": 9.0,
      "font_name": "DotumChe",
      "bbox": [
        125.39999389648438,
        569.3544311523438,
        468.1199951171875,
        584.7144165039062
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예",
      "font_size": 9.0,
      "font_name": "DotumChe",
      "bbox": [
        125.39999389648438,
        569.3544311523438,
        468.1199951171875,
        584.7144165039062
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□",
      "font_size": 9.0,
      "font_name": "DotumChe",
      "bbox": [
        125.39999389648438,
        569.3544311523438,
        468.1199951171875,
        584.7144165039062
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아니오",
      "font_size": 9.0,
      "font_name": "DotumChe",
      "bbox": [
        409.55999755859375,
        582.1943969726562,
        468.1199951171875,
        591.1943969726562
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□",
      "font_size": 9.0,
      "font_name": "DotumChe",
      "bbox": [
        409.55999755859375,
        582.1943969726562,
        468.1199951171875,
        591.1943969726562
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "11",
      "font_size": 9.0,
      "font_name": "DotumChe",
      "bbox": [
        125.39999389648438,
        595.034423828125,
        468.1199951171875,
        610.3944091796875
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용방법",
      "font_size": 9.0,
      "font_name": "DotumChe",
      "bbox": [
        125.39999389648438,
        595.034423828125,
        468.1199951171875,
        610.3944091796875
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예",
      "font_size": 9.0,
      "font_name": "DotumChe",
      "bbox": [
        125.39999389648438,
        595.034423828125,
        468.1199951171875,
        610.3944091796875
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "□",
      "font_size": 9.0,
      "font_name": "DotumChe",
      "bbox": [
        125.39999389648438,
        595.034423828125,
        468.1199951171875,
        610.3944091796875
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "아니오",
      "font_size": 9.0,
      "font_name": "DotumChe",
      "bbox": [
        409.55999755859375,
        607.75439453125,
        468.1199951171875,
        616.75439453125
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□",
      "font_size": 9.0,
      "font_name": "DotumChe",
      "bbox": [
        409.55999755859375,
        607.75439453125,
        468.1199951171875,
        616.75439453125
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위와 같이 동등함을 확인하였음.",
      "font_size": 9.0,
      "font_name": "DotumChe",
      "bbox": [
        119.15999603271484,
        630.0744018554688,
        482.0993957519531,
        650.8344116210938
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "년     월      일            신청자            (서명 또는 인)",
      "font_size": 9.0,
      "font_name": "DotumChe",
      "bbox": [
        119.15999603271484,
        630.0744018554688,
        482.0993957519531,
        650.8344116210938
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        98.04000091552734,
        117.91441345214844,
        448.0853271484375,
        126.91441345214844
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 46 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 52,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅶ",
      "font_size": 21.959999084472656,
      "font_name": "T12",
      "bbox": [
        117.47999572753906,
        160.07998657226562,
        365.9997253417969,
        186.43199157714844
      ],
      "page_num": 52,
      "block_type": "heading",
      "level": 1,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성능시험에 대한 상세사항",
      "font_size": 17.758378982543945,
      "font_name": "H2hdrM",
      "bbox": [
        117.47999572753906,
        160.07998657226562,
        365.9997253417969,
        186.43199157714844
      ],
      "page_num": 52,
      "block_type": "heading",
      "level": 4,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일반요건",
      "font_size": 12.0,
      "font_name": "H2hdrM",
      "bbox": [
        110.5199966430664,
        227.65921020507812,
        158.52000427246094,
        239.65921020507812
      ],
      "page_num": 52,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "❍ 시험성적서에 다음의 항목이 포함되어야 한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        251.64328002929688,
        361.17279052734375,
        262.68328857421875
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 업체명 및 주소",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        273.603271484375,
        217.5596466064453,
        284.6432800292969
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 시험성적서의 일련번호 및 각 페이지와 전체 페이지 번호",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        295.68328857421875,
        432.0,
        306.7232971191406
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3. 시험검사품에 대한 모델명, 상품명",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        317.6432800292969,
        314.2796936035156,
        328.68328857421875
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4. 시험일자",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        339.603271484375,
        184.67965698242188,
        350.6432800292969
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5. 시험성적서 발급일자",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        361.68328857421875,
        245.15965270996094,
        372.7232971191406
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6. 시험성적서에 대한 책임 있는 자의 서명 또는 직인",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        383.6432800292969,
        399.0,
        394.68328857421875
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "7. 시험기준 및 시험방법. 단, 규격이 없는 경우 이에 대한 설정 사유",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        405.603271484375,
        476.8800048828125,
        416.6432800292969
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "8. 시험검사 결과",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        427.68328857421875,
        212.1599884033203,
        438.7232971191406
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "9. 시험검사품 채취 및 방법에 대한 사항(시험을 위한 별도의 전처리가",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        449.6432800292969,
        488.35638427734375,
        460.68328857421875
      ],
      "page_num": 52,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "필요한 경우에 한함)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.75999450683594,
        471.603271484375,
        245.16000366210938,
        482.6432800292969
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "10. 시험 환경요인(시험결과에 영향을 주는 경우에 한함)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        493.68328857421875,
        416.3999938964844,
        504.7232971191406
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ 대학 또는 연구기관 등 국내․외 전문기관에서 시험한 자료는 다음의",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        537.603271484375,
        488.2360534667969,
        548.643310546875
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "항목이 추가로 포함되어야 한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        128.63999938964844,
        559.6832275390625,
        291.3327941894531,
        570.7232666015625
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1. 시험시설개요",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        581.6432495117188,
        206.63931274414062,
        592.6832885742188
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전문기관의 명칭, 주소, 인증현황, 검사기능 분야, 연구인력구성,",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        603.6032104492188,
        488.35638427734375,
        614.6432495117188
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주요설비 목록 등이 기재되어 있어야 함",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        625.6832275390625,
        343.9200134277344,
        636.7232666015625
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2. 주요설비",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        647.6432495117188,
        184.67965698242188,
        658.6832885742188
      ],
      "page_num": 52,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험검사에 사용된 장비명칭, 장비사양, 검·교정 기록서 등에 대한",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        669.6032104492188,
        488.35638427734375,
        680.6432495117188
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사항이 기재되고 관련 증빙자료를 함께 제출하여야 함",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        691.6832275390625,
        415.44000244140625,
        702.7232666015625
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅶ. 성능시험에 대한 상세사항",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        368.8800048828125,
        117.55441284179688,
        481.44561767578125,
        126.55441284179688
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 47 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 53,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3. 연구인력구성",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        155.76327514648438,
        206.63931274414062,
        166.8032684326172
      ],
      "page_num": 53,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험검사를 실시한 전문기관 담당부서에 속한 연구인력들에 대한",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        177.72328186035156,
        488.3560485839844,
        188.76327514648438
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정보가 기재되어야 함",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        199.80328369140625,
        250.5599822998047,
        210.84327697753906
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4. 시험자의 연구경력",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        221.76327514648438,
        234.11964416503906,
        232.8032684326172
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험검사를 실시한 시험자가 해당 검사를 하기에 적합한 전공, 경력",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        243.72328186035156,
        488.35638427734375,
        254.76327514648438
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등을 가지고 있는지에 대해 기재하고, 해당 전문기관에서 규정한 요",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        265.80328369140625,
        484.67999267578125,
        276.8432922363281
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "건에 적합한 시험자가 시험하였는지에 대한 자료를 제출",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        287.7632751464844,
        426.4800109863281,
        298.80328369140625
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1",
      "font_size": 13.799982070922852,
      "font_name": "H2hdrM",
      "bbox": [
        121.91999816894531,
        337.1480712890625,
        329.0439758300781,
        351.9080810546875
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분석적 성능시험에 관한 자료",
      "font_size": 13.799982070922852,
      "font_name": "HYwulM",
      "bbox": [
        121.91999816894531,
        337.1480712890625,
        329.0439758300781,
        351.9080810546875
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1. 분석적 민감도 (최소검출한계, 측정범위, 컷오프농도 등)",
      "font_size": 12.0,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        397.939208984375,
        443.91607666015625,
        409.939208984375
      ],
      "page_num": 53,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "최소검출한계, 최소정량한계 및 측정범위를 평가하고, 판정기준치의 설정",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        443.8832702636719,
        488.35638427734375,
        454.92327880859375
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "배경을 제시한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        465.9632873535156,
        214.8766326904297,
        477.0032958984375
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가. 최소검출한계(Limit of detection, LoD)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        509.8832702636719,
        349.63677978515625,
        520.9232788085938
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "확률적으로 검체에서 검출될 수 있는 최저 분석물질의 양",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        135.47999572753906,
        531.9632568359375,
        426.9599914550781,
        543.0032958984375
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 시험물질",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        575.8832397460938,
        201.95965576171875,
        586.9232788085938
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가) 사람의 검체(혈청, 혈장, 전혈 등)를 사용한다. 호환되는 기질",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        150.47999572753906,
        597.9632568359375,
        484.6796875,
        609.0032958984375
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(matrix)로 희석하거나 분석 대상 물질을 일정량 첨가한 검체를",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        172.8000030517578,
        619.9232177734375,
        488.35638427734375,
        630.9632568359375
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "낮은 농도 검체로 이용할 수 있다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        172.8000030517578,
        641.8832397460938,
        344.61279296875,
        652.9232788085938
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나) 공백검체와 추정되는 검출한계 농도 근처의 검체는 최소 각",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        150.47999572753906,
        663.9632568359375,
        488.35638427734375,
        675.0032958984375
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4개씩 준비한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        173.51998901367188,
        685.9232177734375,
        257.47662353515625,
        696.9632568359375
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        98.04000091552734,
        117.91441345214844,
        448.0853271484375,
        126.91441345214844
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 48 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 54,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다) 측정 가능한 검체(혈청, 혈장, 전혈 등)의 종류별 시험 결과를",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        150.47999572753906,
        155.76327514648438,
        488.35650634765625,
        166.8032684326172
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제시한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        172.44000244140625,
        177.72328186035156,
        219.2128143310547,
        188.76327514648438
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "라) 희석을 위해 만약 인공(simulated)기질을 사용하거나 제품",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        150.47999572753906,
        199.80328369140625,
        484.6795654296875,
        210.84327697753906
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "설명서에 이를 권장한다면 적절한 수의 시험물질로 자연기질과의",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        174.0,
        221.76327514648438,
        488.35638427734375,
        232.8032684326172
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동등성을 먼저 확인해야 한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        174.0,
        243.72328186035156,
        324.0928039550781,
        254.76327514648438
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "마) 희석을 위해 분석대상물질이 포함되어 있지 않은 사람 유래",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        150.47999572753906,
        265.80328369140625,
        488.3568115234375,
        276.8432922363281
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검체를 찾는 것이 어려울 경우에는 제조사에서 제시 또는",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        174.0,
        287.7632751464844,
        488.35638427734375,
        298.80328369140625
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "권장하는 물질로 희석할 수도 있으나 되도록이면 사람 유래",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        174.0,
        309.7232666015625,
        488.3568115234375,
        320.7632751464844
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검체를 사용한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        174.0,
        331.80328369140625,
        258.81280517578125,
        342.8432922363281
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 시험방법",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        353.7632751464844,
        205.6360626220703,
        364.80328369140625
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가) 검체 종류와 검체 준비 과정(검체종류, 기질, 검체의 수, 측정",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        150.47999572753906,
        375.7232666015625,
        484.6796875,
        386.7632751464844
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "횟수, 분석물질의 농도, 농도를 확인한 방법 등)을 기술한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        172.55999755859375,
        397.80328369140625,
        479.0127868652344,
        408.8432922363281
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나) 시험방법은 참고한 부분에 한해서 문헌 기호를 인용하여 실험",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        150.47999572753906,
        419.7632751464844,
        488.35638427734375,
        430.80328369140625
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "방법을 요약 제출할 수 있다. 아래의 참고방법을 참조할 수",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        172.8000030517578,
        441.7232666015625,
        488.35638427734375,
        452.7632751464844
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        172.8000030517578,
        463.80328369140625,
        201.6766357421875,
        474.8432922363281
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다) 검체에서 검출될 수 있는 최소 검출한계치를 제시한다. 검출",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        150.47999572753906,
        485.7632751464844,
        484.67999267578125,
        496.80328369140625
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한계에 영향을 줄 수 있는 여러 변수를 고려하기 위해 검사일은",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        173.39999389648438,
        507.7232971191406,
        488.35797119140625,
        518.7633056640625
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3-5일 이상, 측정 시 2번 이상 반복검사를 권장한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        173.39999389648438,
        529.80322265625,
        444.4527893066406,
        540.84326171875
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라) 참고",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        150.47999572753906,
        551.7632446289062,
        194.5196533203125,
        562.8032836914062
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "CLSI 지침(EP17-A2)에서는 LOB (limit of blank), LoD",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        160.55999755859375,
        573.7232666015625,
        488.35675048828125,
        584.7633056640625
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(limit of detection), LOQ (limit of quantitation)를 확립하기",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        160.55999755859375,
        595.80322265625,
        488.3560485839844,
        606.84326171875
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위한 방법이 기술되어 있으며, LoD 측정에 3가지 방법",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        160.55999755859375,
        617.7632446289062,
        484.6796875,
        628.8032836914062
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(classical",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        160.55999755859375,
        639.7232666015625,
        488.3569030761719,
        650.7633056640625
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "approach,",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        160.55999755859375,
        639.7232666015625,
        488.3569030761719,
        650.7633056640625
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "precision",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        160.55999755859375,
        639.7232666015625,
        488.3569030761719,
        650.7633056640625
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "profile",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        160.55999755859375,
        639.7232666015625,
        488.3569030761719,
        650.7633056640625
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "approach,",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        160.55999755859375,
        639.7232666015625,
        488.3569030761719,
        650.7633056640625
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "probit",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        160.55999755859375,
        639.7232666015625,
        488.3569030761719,
        650.7633056640625
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "approach)이 있다. 심혈관표지자의 LoD 측정을 위해서는 전통",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        160.55999755859375,
        661.80322265625,
        484.67999267578125,
        672.84326171875
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적인 방법 또는 정밀도 profile 방법을 이용한다. 전통적인 방법",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        160.55999755859375,
        683.7632446289062,
        484.6796875,
        694.8032836914062
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅶ. 성능시험에 대한 상세사항",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        368.8800048828125,
        117.55441284179688,
        481.44561767578125,
        126.55441284179688
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 49 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 55,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(classical approach)은 blank 검체와 검출한계 근처의 low",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        160.55999755859375,
        155.76327514648438,
        488.35675048828125,
        166.8032684326172
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "level 검체의 반복 측정 수가 각각 최소 60회가 될 것을 권장한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        160.55999755859375,
        177.72328186035156,
        484.53277587890625,
        188.76327514648438
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3) 결과제시",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        199.80328369140625,
        201.95965576171875,
        210.84327697753906
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가) 통계적으로 유효한 최소검출한계치와 설정에 사용된 검체의",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        150.47999572753906,
        221.76327514648438,
        488.3560485839844,
        232.8032684326172
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "종류, 검체수, 반복회수, 계산법을 함께 제시한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        174.1199951171875,
        243.72328186035156,
        427.036376953125,
        254.76327514648438
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 판정기준치(cut-off value)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        287.7632751464844,
        282.360595703125,
        298.80328369140625
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 일반사항",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        309.7232666015625,
        201.95965576171875,
        320.7632751464844
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가) 임상적 성능시험(다른 검사 결과, 치료에 대한 반응, 임상적",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        150.47999572753906,
        331.80328369140625,
        488.3560485839844,
        342.8432922363281
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "진단 등)에 의해 판정기준치의 적절성을 평가할 수 있다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        173.63999938964844,
        353.7632751464844,
        462.6927795410156,
        364.80328369140625
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나) 측정항목, 측정원리, 판독방법 등에 따라 판정기준치(cut-off",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        150.47999572753906,
        375.7232666015625,
        488.3573913574219,
        386.7632751464844
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "value)의 설정 방법이 달라질 수 있으므로 전문가 그룹의 자문",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        173.0399932861328,
        397.80328369140625,
        488.35638427734375,
        408.8432922363281
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등을 거칠 것을 권장한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        173.0399932861328,
        419.7632751464844,
        306.3166198730469,
        430.80328369140625
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 판정기준치 혹은 판정기준치와 연계된 기대값(Expected",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        160.55999755859375,
        441.7232666015625,
        488.3573913574219,
        452.7632751464844
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Value)의 설정이 임상적 성능(임상적 민감도와 임상적 특이도)을",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        179.63999938964844,
        463.80328369140625,
        488.35638427734375,
        474.8432922363281
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "바탕으로 한 경우, 타당한 임상적 근거를 제시한다(임상적",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        179.63999938964844,
        485.7632751464844,
        488.3560485839844,
        496.80328369140625
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "민감도 참고).",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        179.63999938964844,
        507.7232971191406,
        248.85281372070312,
        518.7633056640625
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 결과제시",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        551.7632446289062,
        201.95965576171875,
        562.8032836914062
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가) 판정기준치(농도)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        150.47999572753906,
        573.84326171875,
        260.5199890136719,
        584.88330078125
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나) 판정기준치에서의 임상적 민감도 및 특이도",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        150.47999572753906,
        595.80322265625,
        392.5199890136719,
        606.84326171875
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다. 측정범위(Measurement range)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        639.7232666015625,
        302.39990234375,
        650.7633056640625
      ],
      "page_num": 55,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 일반사항",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        672.4832153320312,
        201.95965576171875,
        683.5232543945312
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가) 측정범위는 기존의 알려진 농도값을 해당 검사가 정확하게",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        150.47999572753906,
        694.4432373046875,
        488.3560485839844,
        705.4832763671875
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        98.04000091552734,
        117.91441345214844,
        448.0853271484375,
        126.91441345214844
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 50 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 56,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "재현해 낼 수 있는 농도 범위를 말한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        174.72000122070312,
        155.76327514648438,
        375.81280517578125,
        166.8032684326172
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나) 측정항목, 측정원리, 결과산출방법 등에 따라 측정범위를",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        150.47999572753906,
        177.72328186035156,
        488.35638427734375,
        188.76327514648438
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가할 때 사용하는 물질과 희석방법, 결과평가방법이 달라질",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        174.95999145507812,
        199.80328369140625,
        488.35638427734375,
        210.84327697753906
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수 있으므로 시험을 고려할 때 전문가 그룹의 자문 등을",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        174.95999145507812,
        221.76327514648438,
        488.35638427734375,
        232.8032684326172
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "거칠 것을 권장한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        174.95999145507812,
        243.72328186035156,
        277.05279541015625,
        254.76327514648438
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다) 측정범위 이상의 값을 희석하여 보고할 수 있는지 여부와 희석에",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        150.47999572753906,
        265.80328369140625,
        488.35638427734375,
        276.8432922363281
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용할 수 있는 희석액을 명시하고, 그 근거를 제시해야 한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        171.72000122070312,
        287.7632751464844,
        482.7327880859375,
        298.80328369140625
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라) 고역가 검체에 의한 전지대효과(prozone effect) 등에 대한",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        150.47999572753906,
        309.7232666015625,
        488.3560485839844,
        320.7632751464844
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "자료를 포함해야 한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        174.239990234375,
        331.80328369140625,
        287.372802734375,
        342.8432922363281
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 시험물질",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        353.7632751464844,
        201.95965576171875,
        364.80328369140625
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가) 시험물질은 측정법에 적합한 기질(matrix)을 가진 물질이어야",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        150.47999572753906,
        375.7232666015625,
        488.35638427734375,
        386.7632751464844
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        172.8000030517578,
        397.80328369140625,
        198.09280395507812,
        408.8432922363281
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나) 표준품에 비교된 참고물질로 적합한 기질 성상과 목표치를",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        150.47999572753906,
        419.7632751464844,
        488.3560485839844,
        430.80328369140625
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "알고 있는 물질의 사용을 권장한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        174.72000122070312,
        441.7232666015625,
        353.852783203125,
        452.7632751464844
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다) 참고물질을 구할 수 없는 경우, 측정하고자 하는 물질에 대한",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        150.47999572753906,
        463.80328369140625,
        488.35638427734375,
        474.8432922363281
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "농도가 알려진 고농도의 임상검체를 이용한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        172.67999267578125,
        485.7632751464844,
        406.7727966308594,
        496.80328369140625
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라) 희석에 사용하는 음성 검체나 혼합할 음성검체는 기질효과를",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        150.47999572753906,
        507.7232971191406,
        488.3557434082031,
        518.7633056640625
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고려하여, 해당 제품의 대상이 되는 사람의 음성검체(혈청,",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        173.16000366210938,
        529.80322265625,
        488.35662841796875,
        540.84326171875
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혈장, 전혈 등)를 사용하여야 한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        173.16000366210938,
        551.7632446289062,
        350.0127868652344,
        562.8032836914062
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 시험방법",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        595.80322265625,
        201.95965576171875,
        606.84326171875
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가) 고농도검체와 음성검체를 혼합하여 제조하거나, 고농도의",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        150.47999572753906,
        617.7632446289062,
        488.35638427734375,
        628.8032836914062
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검체를 단계 희석하여 시험물질을 제조한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        175.55999755859375,
        639.7232666015625,
        402.3166198730469,
        650.7633056640625
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나) 제시하는 직선성 범위를 포괄하는(예상되는 측정범위보다",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        150.47999572753906,
        661.80322265625,
        488.3557434082031,
        672.84326171875
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "20-30% 더 넓은 범위를 포함할 것을 권장한다) 최소 5개",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        176.63999938964844,
        683.7632446289062,
        488.35638427734375,
        694.8032836914062
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅶ. 성능시험에 대한 상세사항",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        368.8800048828125,
        117.55441284179688,
        481.44561767578125,
        126.55441284179688
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 51 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 57,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이상의 알려진 농도를 가지는 검체를 이용하거나 희석을 통해",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        176.63999938964844,
        155.76327514648438,
        488.35638427734375,
        166.8032684326172
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "농도가 확립된 검체를 이용한다. 희석은 고농도와 저농도",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        176.63999938964844,
        177.72328186035156,
        488.356689453125,
        188.76327514648438
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검체를 비율적으로 혼합하여 같은 간격으로 중간 농도의",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        176.63999938964844,
        199.80328369140625,
        488.35638427734375,
        210.84327697753906
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검체를 만드는 것이 권장되나  농도간의 간격이 일정하지 않을",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        176.63999938964844,
        221.76327514648438,
        488.35638427734375,
        232.8032684326172
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수도 있다. 측정은 각 농도별로 2-4회 반복 측정한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        176.63999938964844,
        243.72328186035156,
        452.372802734375,
        254.76327514648438
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 결과제시",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        287.7632751464844,
        201.95965576171875,
        298.80328369140625
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가) 직선성 범위의 농도 구간을 제시한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        150.47999572753906,
        309.7232666015625,
        362.61279296875,
        320.7632751464844
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나) 비선형 calibration 모델을 사용하는 제품에 대하여는 근거자료를",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        150.47999572753906,
        331.80328369140625,
        488.35638427734375,
        342.8432922363281
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제시한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        172.55999755859375,
        353.7632751464844,
        219.81280517578125,
        364.80328369140625
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 분석적 특이도",
      "font_size": 12.0,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        397.8192138671875,
        204.95999145507812,
        409.8192138671875
      ],
      "page_num": 57,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 시험물질",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        443.7632751464844,
        189.23965454101562,
        454.80328369140625
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 측정 대상이 되는 검체와 호환되는 기질의 검체를 이용한다. 사용",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        465.7232666015625,
        488.35638427734375,
        476.7632751464844
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검체의 종류가 두 가지 이상인 경우 검체의 종류별로 시험한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        158.0399932861328,
        487.80328369140625,
        480.0927734375,
        498.8432922363281
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 간섭물질은 내부 또는 외부 요인일 수 있고 측정법에 따라 다양",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        509.7632751464844,
        484.67999267578125,
        520.8032836914062
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하므로, 검사법에 따라 결과에 영향을 미칠 것으로 예측되는",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        158.16000366210938,
        531.7232666015625,
        488.35638427734375,
        542.7633056640625
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다음과 같은 물질에 대한 간섭 평가 자료를 제출해야 한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        158.16000366210938,
        553.80322265625,
        458.2527770996094,
        564.84326171875
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가) 검체 처치에 첨가된 물질(보존제, 안정제 등)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        150.47999572753906,
        575.7632446289062,
        401.15997314453125,
        586.8032836914062
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나) 검체에 포함될 수 있는 물질(혈색소, 지질, 빌리루빈, heterophile",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        150.47999572753906,
        597.7125244140625,
        490.1999816894531,
        609.3562622070312
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "항체, rheumatoid factors, human anti-mouse 항체 등)",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        172.67999267578125,
        619.79248046875,
        444.45001220703125,
        631.4362182617188
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        98.04000091552734,
        117.91441345214844,
        448.0853271484375,
        126.91441345214844
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 52 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 58,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표 5. 간섭물질 예",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        155.76327514648438,
        211.75640869140625,
        166.8032684326172
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "간섭물질",
      "font_size": 9.719964981079102,
      "font_name": "Haansoft Batang",
      "bbox": [
        183.36000061035156,
        184.89035034179688,
        396.9657287597656,
        194.85035705566406
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예시",
      "font_size": 9.719964981079102,
      "font_name": "Haansoft Batang",
      "bbox": [
        183.36000061035156,
        184.89035034179688,
        396.9657287597656,
        194.85035705566406
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "외인성 물질",
      "font_size": 9.719964981079102,
      "font_name": "Haansoft Batang",
      "bbox": [
        115.31999969482422,
        214.7703399658203,
        166.2052764892578,
        224.7303466796875
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일반의약품, 고혈압, 협심증, 심부전 등",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        295.44000244140625,
        204.8103485107422,
        478.3967590332031,
        214.77035522460938
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "심장질환 치료제 등",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        295.44000244140625,
        224.850341796875,
        385.3199768066406,
        234.8103485107422
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검체 처리 과정에 통상적으로 첨가될 수",
      "font_size": 9.719964981079102,
      "font_name": "Haansoft Batang",
      "bbox": [
        115.31999969482422,
        240.45034790039062,
        289.2388000488281,
        250.4103546142578
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있는 물질",
      "font_size": 9.719964981079102,
      "font_name": "Haansoft Batang",
      "bbox": [
        115.31999969482422,
        258.4503479003906,
        160.35838317871094,
        268.41033935546875
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보존제, 안정제 등",
      "font_size": 9.719964981079102,
      "font_name": "Haansoft Batang",
      "bbox": [
        295.44000244140625,
        249.45034790039062,
        371.8857116699219,
        259.41033935546875
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "드물지 않게 볼 수 있는 특이 검체에",
      "font_size": 9.719964981079102,
      "font_name": "Haansoft Batang",
      "bbox": [
        115.31999969482422,
        280.29034423828125,
        275.4388122558594,
        290.2503356933594
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "포함된 물질",
      "font_size": 9.719964981079102,
      "font_name": "Haansoft Batang",
      "bbox": [
        115.31999969482422,
        298.29034423828125,
        166.80526733398438,
        308.2503356933594
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "혈색소, 지질(콜레스테롤,",
      "font_size": 9.719964981079102,
      "font_name": "Haansoft Batang",
      "bbox": [
        295.44000244140625,
        271.29034423828125,
        408.399169921875,
        281.2503356933594
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "트리글리세리드), 빌리루빈, 이상 단백질",
      "font_size": 9.719964981079102,
      "font_name": "Haansoft Batang",
      "bbox": [
        295.44000244140625,
        289.29034423828125,
        474.9988708496094,
        299.2503356933594
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "및 펩타이드 등",
      "font_size": 9.719964981079102,
      "font_name": "Haansoft Batang",
      "bbox": [
        295.44000244140625,
        307.29034423828125,
        361.80572509765625,
        317.2503356933594
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 각 분석물질에 대한 각 간섭물질의 영향을 평가하기 위해 다음과",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        354.4832763671875,
        488.35638427734375,
        365.5232849121094
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "같은 4가지 형태의 세트를 준비한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        157.9199981689453,
        376.4432678222656,
        343.5328063964844,
        387.4832763671875
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가) 분석물질 양성(판정기준치 이상)인 검체(간섭물질 없음)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        150.47999572753906,
        398.5232849121094,
        458.5199890136719,
        409.56329345703125
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나) 분석물질 양성(판정기준치 이상)인 검체 + 간섭물질",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        150.47999572753906,
        420.4832763671875,
        440.15966796875,
        431.5232849121094
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다) 분석물질 음성(판정기준치 이하)인 검체(간섭물질 없음)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        150.47999572753906,
        442.5632629394531,
        458.5199890136719,
        453.603271484375
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라) 분석물질 음성(판정기준치 이하)인 검체 + 간섭물질",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        150.47999572753906,
        464.5232849121094,
        440.15966796875,
        475.56329345703125
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 시험방법",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        508.4432678222656,
        192.9160614013672,
        519.4832763671875
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 시험할 간섭물질의 목록을 작성한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        530.4032592773438,
        342.5727844238281,
        541.4432983398438
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 검체의 종류, 간섭물질의 종류, 간섭물질의 농도, 분석물질의 농도,",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        552.4832153320312,
        488.35638427734375,
        563.5232543945312
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검체의 제조 방법(예: 간섭물질을 혼합한 검체, 자연적으로 높은",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        158.27999877929688,
        574.4432373046875,
        488.3560485839844,
        585.4832763671875
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "간섭물질을 함유한 검체 등) 등에 대한 실험방법을 제공한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        158.27999877929688,
        596.4032592773438,
        469.41278076171875,
        607.4432983398438
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 간섭물질의 농도는 임상검체에서 보일 수 있는 최대농도의 3배",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        618.4832153320312,
        488.35638427734375,
        629.5232543945312
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이상이 되도록 한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        158.75999450683594,
        640.4432373046875,
        260.9727783203125,
        651.4832763671875
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4) 간섭물질이 포함된 검체와 포함되지 않은 검체 간의 결과 차이의",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        662.4032592773438,
        488.35650634765625,
        673.4432983398438
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "허용범위(dmax)를 결정한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        157.9199981689453,
        684.4832153320312,
        296.1327819824219,
        696.2825317382812
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅶ. 성능시험에 대한 상세사항",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        368.8800048828125,
        117.55441284179688,
        481.44561767578125,
        126.55441284179688
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 53 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 59,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "5) 각 검체를 3회 이상 반복 검사한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        155.76327514648438,
        337.8927917480469,
        166.8032684326172
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "6) 간섭물질을 함유한 검체와 간섭물질을 함유하지 않은 검체의",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        177.72328186035156,
        488.35638427734375,
        188.76327514648438
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결과를 비교한다. 정량검사의 경우는 바이어스를 구한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        160.1999969482422,
        199.80328369140625,
        446.9727783203125,
        210.84327697753906
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "7) 높은 농도의 간섭물질에 영향을 받지 않는 경우는 더 이상의",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        221.76327514648438,
        488.35638427734375,
        232.8032684326172
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가를 시행하지 않아도 되고, 영향을 받는 경우는 간섭물질의",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        159.72000122070312,
        243.72328186035156,
        488.3560485839844,
        254.76327514648438
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "농도에 따른 영향을 보기 위해 용량-반응검사(dose-response",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        159.72000122070312,
        265.80328369140625,
        488.3583679199219,
        276.8432922363281
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "test)를 실시한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        159.72000122070312,
        287.7632751464844,
        248.61280822753906,
        298.80328369140625
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다. 결과제시",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        331.80328369140625,
        189.23965454101562,
        342.8432922363281
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 간섭물질을 함유한 검체와 간섭물질을 함유하지 않은 검체의 결과",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        353.7632751464844,
        488.35638427734375,
        364.80328369140625
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "값을 제시하고, 정량검사의 경우는 결과를 비교하여 바이어스가",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        158.0399932861328,
        375.7232666015625,
        488.3557434082031,
        386.7632751464844
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있는지 확인하고 두 값의 차이가 허용범위(dmax)보다 작은지",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        158.0399932861328,
        397.80328369140625,
        488.35638427734375,
        409.6025390625
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "판단한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        158.0399932861328,
        419.7632751464844,
        208.8762969970703,
        430.80328369140625
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 간섭이 확인된 물질의 경우 간섭을 보이는 구체적 농도와 결과",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        441.7232666015625,
        488.3560485839844,
        452.7632751464844
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "차이를 기술한다. 대상측정물질을 함유하지 않고 간섭 가능한",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        158.75999450683594,
        463.80328369140625,
        488.3560485839844,
        474.8432922363281
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "물질만 포함된 검체의 실측한 자료를 바탕으로 배경한계와 검출",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        158.75999450683594,
        485.7632751464844,
        484.67999267578125,
        496.80328369140625
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한계를 넘지 않는 결과를 보인 최대 간섭물질 농도를 기재한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        158.75999450683594,
        507.7232971191406,
        480.8127746582031,
        518.7633056640625
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 간섭물질에 대한 분석물질 결과에 경향이 있다면 경향을 기술한다",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        529.80322265625,
        484.6802673339844,
        540.84326171875
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(예 : 높은 농도의 물질 X는 분석물질의 결과를 감소시킴).",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        158.0399932861328,
        551.7632446289062,
        458.1327819824219,
        562.8032836914062
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3. 정밀도 (반복성, 재현성 등)",
      "font_size": 12.0,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        595.8192138671875,
        280.44000244140625,
        607.8192138671875
      ],
      "page_num": 59,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 일반사항",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        643.80322265625,
        189.23965454101562,
        654.84326171875
      ],
      "page_num": 59,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 동일 검체를 일정기간 동안 반복 측정한 결과를 분석하여 정밀도",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        665.7632446289062,
        488.35638427734375,
        676.8032836914062
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "자료를 제시한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        157.9199981689453,
        687.7232666015625,
        243.69281005859375,
        698.7633056640625
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        98.04000091552734,
        117.91441345214844,
        448.0853271484375,
        126.91441345214844
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 54 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 60,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2) 단일 기관에서 실시한 정밀도(반복성)와 다수의 기관에서 실시한",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        155.76327514648438,
        488.35650634765625,
        166.8032684326172
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "재현성으로 구분하여 평가한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        157.9199981689453,
        177.72328186035156,
        315.0928039550781,
        188.76327514648438
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3) 각 평가 수행기관은 평가를 시행하기 전에 검사방법에 익숙해지는",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        199.80328369140625,
        488.35638427734375,
        210.84327697753906
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시기를 거친 다음 평가를 수행하도록 한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        158.0399932861328,
        221.76327514648438,
        375.6927795410156,
        232.8032684326172
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 시험물질",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        265.80328369140625,
        189.23965454101562,
        276.8432922363281
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 3개 이상의 농도(컷오프 근처의 검체 포함)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        287.7632751464844,
        378.719970703125,
        298.80328369140625
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 환자검체 또는 정도관리검체",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        309.7232666015625,
        300.9596862792969,
        320.7632751464844
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 시험방법",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        353.7632751464844,
        192.9160614013672,
        364.80328369140625
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 검체의 종류, 검체 수, 측정방법, 측정횟수 등에 대한 실험프로",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        375.7232666015625,
        484.6796875,
        386.7632751464844
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "토콜을 제시한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        159.0,
        397.80328369140625,
        244.65280151367188,
        408.8432922363281
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 반복성(repeatability, within laboratory precision) 평가는 3가지",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        419.7632751464844,
        488.35638427734375,
        430.80328369140625
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "농도 이상의 검체를 1회(run)마다 2~3회 반복(duplicate or",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        158.16000366210938,
        441.7232666015625,
        488.35614013671875,
        452.7632751464844
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "triplicate) 측정하기를, 1일마다 2회(run) 이상, 최소 10일 동안",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        158.16000366210938,
        463.80328369140625,
        484.67999267578125,
        474.8432922363281
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(20일 이상 권장) 시행하기를 권장한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        158.16000366210938,
        485.7632751464844,
        370.276611328125,
        496.80328369140625
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 최소 3개의 시약 로트를 이용하여 로트 간 정밀도(lot-to-lot",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        507.7232971191406,
        488.3568115234375,
        518.7633056640625
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "precision)를 평가한다. 로트 간 정밀도 평가는 별도의 평가로",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        159.47999572753906,
        529.80322265625,
        488.3560485839844,
        540.84326171875
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "계획되거나 반복성이나 재현성 평가의 일부로 계획될 수 있다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        159.47999572753906,
        551.7632446289062,
        476.0127868652344,
        562.8032836914062
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 재현성(reproducibility) 평가는 2곳 이상의 검사실에서 3가지",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        573.7232666015625,
        488.35638427734375,
        584.7633056640625
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "농도 이상의 검체를 1회(run)마다 2회 이상 반복(duplicate or",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        160.44000244140625,
        595.80322265625,
        488.35614013671875,
        606.84326171875
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "more) 측정하기를, 1일에 2회(run) 이상, 5일 이상 동안 실시할",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        160.44000244140625,
        617.7632446289062,
        488.35638427734375,
        628.8032836914062
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "것을 권장한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        160.44000244140625,
        639.7232666015625,
        235.0528106689453,
        650.7633056640625
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅶ. 성능시험에 대한 상세사항",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        368.8800048828125,
        117.55441284179688,
        481.44561767578125,
        126.55441284179688
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 55 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 61,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다. 결과제시",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        155.76327514648438,
        189.23965454101562,
        166.8032684326172
      ],
      "page_num": 61,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 반복성 : 검사 내 정밀도(within-run), 검사 간 정밀도(between-run),",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        177.72328186035156,
        488.35662841796875,
        188.76327514648438
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "날짜 간 정밀도(between-day), 검사실 내 정밀도(within-",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        158.16000366210938,
        199.80328369140625,
        488.3577575683594,
        210.84327697753906
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "laboratory) 자료를 제시한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        158.16000366210938,
        221.76327514648438,
        306.6927795410156,
        232.8032684326172
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 재현성 : 각 검사실 별로 반복성 결과를 기재하고, 모든 검사실",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        243.72328186035156,
        488.3560485839844,
        254.76327514648438
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결과를 합한 반복성 결과와 검사기관간(between-site) 결과를",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        158.51998901367188,
        265.80328369140625,
        488.3560485839844,
        276.8432922363281
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제시한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        158.51998901367188,
        287.7632751464844,
        205.77281188964844,
        298.80328369140625
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 정량검사는 각 정밀도 항목에 대해 농도별로 표준편차 또는",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        309.7232666015625,
        488.35638427734375,
        320.7632751464844
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "변이계수를 산출하여 기재한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        159.95999145507812,
        331.80328369140625,
        317.1327819824219,
        342.8432922363281
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 해당하는 경우 다음의 사항들을 기술한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        353.7632751464844,
        370.05279541015625,
        364.80328369140625
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가) 검사를 시행한 검체의 농도",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        150.47999572753906,
        375.7232666015625,
        309.9596862792969,
        386.7632751464844
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나) 각각의 농도에서의 반복정밀도 표준편차",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        150.47999572753906,
        397.80328369140625,
        375.9596862792969,
        408.8432922363281
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다) 각각의 농도에서의 검사실내 정밀도 표준편차",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        150.47999572753906,
        419.7632751464844,
        403.4396667480469,
        430.80328369140625
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라) 반복정밀도 및 검사실내 정밀도 표준편차의 신뢰구간",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        150.47999572753906,
        441.7232666015625,
        441.9596862792969,
        452.7632751464844
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "마) 실제 검사일수, 검사실의 수",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        150.47999572753906,
        463.80328369140625,
        313.20001220703125,
        474.8432922363281
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "바) 총 run의 수(해당되는 경우 제시)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        150.47999572753906,
        485.7632751464844,
        342.9599914550781,
        496.80328369140625
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사) 총 관찰치의 수 : optional",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        150.47999572753906,
        507.7232971191406,
        304.0529479980469,
        518.7633056640625
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아) 시약 lot의 수",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        150.47999572753906,
        529.80322265625,
        240.83998107910156,
        540.84326171875
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자) Calibration 시행 횟수와 calibrator lot의 수",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        150.47999572753906,
        551.7632446289062,
        392.8800048828125,
        562.8032836914062
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4. 정확도",
      "font_size": 12.0,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        595.8192138671875,
        162.95999145507812,
        607.8192138671875
      ],
      "page_num": 61,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. WHO international reference standard 물질, NIST standard",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        643.80322265625,
        488.3559265136719,
        654.84326171875
      ],
      "page_num": 61,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "reference material 등 국제표준품 등 특성이 명시되어 있는 물질이",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        149.39999389648438,
        665.7632446289062,
        488.35638427734375,
        676.8032836914062
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "존재할 경우에는 이를 사용하여 평가할 것을 권장하며 최소 2회",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        149.39999389648438,
        687.7232666015625,
        488.35638427734375,
        698.7633056640625
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        98.04000091552734,
        117.91441345214844,
        448.0853271484375,
        126.91441345214844
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 56 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 62,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "반복 측정한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        149.39999389648438,
        155.76327514648438,
        227.71629333496094,
        166.8032684326172
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나. 표준물질의 목표 결과와 실측 결과(정량검사의 경우 결과 값과",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        177.72328186035156,
        488.35638427734375,
        188.76327514648438
      ],
      "page_num": 62,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "바이어스)를 제시한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        146.87998962402344,
        199.80328369140625,
        263.83660888671875,
        210.84327697753906
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다. 시약의 표준화(standardization)를 위해 사용된 방법을 기술한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        221.76327514648438,
        471.93280029296875,
        232.8032684326172
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라. 보정물질(calibrator)의 설정농도, 소급성(traceability)에 대해",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        243.72328186035156,
        488.35638427734375,
        254.76327514648438
      ],
      "page_num": 62,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기술한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        145.3199920654297,
        265.80328369140625,
        192.57281494140625,
        276.8432922363281
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "마. 대조물질의 제조방법, 설정 농도 및 반복 측정 결과를 기술한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        287.7632751464844,
        470.4927978515625,
        298.80328369140625
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5. 교차반응",
      "font_size": 12.0,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        331.8192138671875,
        174.95999145507812,
        343.8192138671875
      ],
      "page_num": 62,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 일반사항",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        377.7632751464844,
        189.23965454101562,
        388.80328369140625
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유사한 분자구조를 가지고 있는 단백질 등에 대한 교차반응을 시험하여",
      "font_size": 10.797332763671875,
      "font_name": "Haansoft Batang",
      "bbox": [
        135.47999572753906,
        399.7232666015625,
        488.19732666015625,
        410.7632751464844
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검사의 특이도에 대한 자료를 제공해야 한다.",
      "font_size": 10.797332763671875,
      "font_name": "Haansoft Batang",
      "bbox": [
        135.47999572753906,
        421.80328369140625,
        357.0731201171875,
        432.8432922363281
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 시험물질",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        443.7632751464844,
        189.23965454101562,
        454.80328369140625
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 다양한 교차 반응 가능 물질이 포함된 검체",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        465.7232666015625,
        377.8800048828125,
        476.7632751464844
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 뇌나트륨이뇨펩티드(NT-proBNP, BNP) 항원과의 교차반응을",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        125.5199966430664,
        487.7925109863281,
        490.1993408203125,
        499.4362487792969
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위한 평가에 이용될 수 있는 물질은 atrial natriuretic peptide,",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        161.75999450683594,
        509.75250244140625,
        490.1992492675781,
        521.396240234375
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "NT-proANP, C-type natriuretic peptide이다.",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        161.75999450683594,
        531.7125244140625,
        382.8955993652344,
        543.3562622070312
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 예시",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        130.55999755859375,
        553.80322265625,
        166.4399871826172,
        564.84326171875
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "알파 심방성 나트륨 이뇨 펩티드(alpha-ANP) 1-28, prepro BNP",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        575.7632446289062,
        488.3551940917969,
        586.8032836914062
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "22-46 등.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        597.7232666015625,
        194.97280883789062,
        608.7633056640625
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다. 시험방법",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        641.7632446289062,
        189.23965454101562,
        652.8032836914062
      ],
      "page_num": 62,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 교차반응물질의 종류, 교차반응물질의 농도, 검체종류(예 : 교차",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        663.7232666015625,
        484.67999267578125,
        674.7633056640625
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "반응 예상 물질을 인위적으로 첨가한 검체, 자연적으로 높은 교차",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        158.39999389648438,
        685.80322265625,
        488.35638427734375,
        696.84326171875
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅶ. 성능시험에 대한 상세사항",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        368.8800048828125,
        117.55441284179688,
        481.44561767578125,
        126.55441284179688
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 57 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 63,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "반응 예상물질을 함유한 검체 등), 비교검체(예 : 교차반응물질이",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        158.39999389648438,
        155.76327514648438,
        488.35638427734375,
        166.8032684326172
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "없는 검체 등), 분석물질의 농도 및 결과 등에 대한 실험프로토콜을",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        158.39999389648438,
        177.72328186035156,
        488.35638427734375,
        188.76327514648438
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제공한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        158.39999389648438,
        199.80328369140625,
        205.65281677246094,
        210.84327697753906
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2) 최소 5회 이상 교차 반응 예상물질을 함유한 검체(T)와 교차",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        221.76327514648438,
        484.6795654296875,
        232.8032684326172
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "반응물질을 함유하지 않은 비교검체(C)를 교대로 검사한다(예,",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        158.87998962402344,
        243.72328186035156,
        488.35662841796875,
        254.76327514648438
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "C1T1C2T2C3T3C4T4C5T5).",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        158.87998962402344,
        265.80328369140625,
        309.4536437988281,
        276.8432922363281
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 교차반응평가를 위해 준비된 검체는 최소 3회 반복 측정하기를",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        287.7632751464844,
        488.3560485839844,
        298.80328369140625
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "권장한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        158.75999450683594,
        309.7232666015625,
        206.0128173828125,
        320.7632751464844
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라. 결과제시",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        353.7632751464844,
        189.23965454101562,
        364.80328369140625
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 교차반응 평가에 사용된 물질의 종류, 농도, 측정한 raw data를",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        375.7232666015625,
        488.35638427734375,
        386.7632751464844
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제시한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        158.51998901367188,
        397.80328369140625,
        205.77281188964844,
        408.8432922363281
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 교차반응을 보이는 물질의 종류와 빈도를 제시한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        419.7632751464844,
        419.4927978515625,
        430.80328369140625
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 13.799982070922852,
      "font_name": "H2hdrM",
      "bbox": [
        121.91999816894531,
        491.10809326171875,
        329.0439758300781,
        505.8680725097656
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상적 성능시험에 관한 자료",
      "font_size": 13.799982070922852,
      "font_name": "HYwulM",
      "bbox": [
        121.91999816894531,
        491.10809326171875,
        329.0439758300781,
        505.8680725097656
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 임상적 성능시험에 관한 자료의 작성 시 준수사항",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        532.9232177734375,
        377.2796630859375,
        543.9632568359375
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "❍ 체외진단용 의료기기의 성능 및 유효성을 증명하기 위하여 사람에서 유",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        120.47999572753906,
        554.8832397460938,
        484.67999267578125,
        565.9232788085938
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "래된 검체를 대상으로 시험한 자료를 제출한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        137.16000366210938,
        576.9632568359375,
        376.29278564453125,
        588.0032958984375
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ 외국에서 외국인을 대상으로 시험한 임상시험 성적도 제출할 수",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        120.47999572753906,
        598.9232177734375,
        488.35638427734375,
        609.9632568359375
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있으나 수출용이 아닌 내수용일 경우는 국내에서 우리나라 사람을",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        139.0800018310547,
        620.8832397460938,
        488.3560485839844,
        631.9232788085938
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대상으로 한 자료를 제출하는 것을 원칙으로 한다. 이는 인종 및",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        139.0800018310547,
        642.9632568359375,
        488.35638427734375,
        654.0032958984375
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지역에 따라 유병률이 다를 수 있기 때문이다. 민족적 요인의 차이가",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        139.0800018310547,
        664.9232177734375,
        488.35638427734375,
        675.9632568359375
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있어 외국 임상적 성능시험을 그대로 적용하기가 어렵다고 판단되는",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        139.0800018310547,
        686.8832397460938,
        488.3561706542969,
        697.9232788085938
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        98.04000091552734,
        117.91441345214844,
        448.0853271484375,
        126.91441345214844
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 58 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 64,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우, 처장은 국내에 거주하는 한국인으로부터 유래한 검체를 대상으로",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        139.0800018310547,
        155.76327514648438,
        488.35638427734375,
        166.8032684326172
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한 자료를 추가 제출할 것을 요구 할 수 있다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        139.0800018310547,
        177.72328186035156,
        373.17279052734375,
        188.76327514648438
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "❍ 임상기관에서 임상시험이 수행되어야 하며, 임상시험 수행기관에서",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        120.47999572753906,
        199.80328369140625,
        488.3557434082031,
        210.84327697753906
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수행한 결과를 포함하여야 한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        138.47999572753906,
        221.76327514648438,
        301.17279052734375,
        232.8032684326172
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ 질환이 있음과 없음(“임상적 참값”)을 규명한 방법, 대상군(환자",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        120.47999572753906,
        243.72328186035156,
        488.356689453125,
        254.76327514648438
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "선택기준/배제기준, 환자 수), 검체종류, 검사방법, 통계 방법 등에",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        139.3199920654297,
        265.80328369140625,
        488.35638427734375,
        276.8432922363281
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대한 자세한 실험프로토콜을 제공해야한다. 질환이 있음을 규명한",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        139.3199920654297,
        287.7632751464844,
        488.3560485839844,
        298.80328369140625
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "참고표준방법은 표적물질의 유무를 알기 위해 시행되는 한 가지 방",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        139.3199920654297,
        309.7232666015625,
        484.67999267578125,
        320.7632751464844
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "법일 수도 있고 여러 방법(진단검사의학 검사, 영상의학 검사, 병리",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        139.3199920654297,
        331.80328369140625,
        488.35638427734375,
        342.8432922363281
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검사, 임상 소견, 두 가지 이상의 기허가 제품으로 확인 등)을 종합한",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        139.3199920654297,
        353.7632751464844,
        488.2360534667969,
        364.80328369140625
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "방법일 수도 있다. 종합한 방법일 경우 참값으로 규정한 알고리즘을",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        139.3199920654297,
        375.7232666015625,
        488.2357482910156,
        386.7632751464844
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기술한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        139.3199920654297,
        397.80328369140625,
        186.4528045654297,
        408.8432922363281
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "표6. 진단기준의 예",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        120.47999572753906,
        419.7632751464844,
        218.1599884033203,
        430.80328369140625
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ESC Guidelines for the diagnosis and treatment of acute and",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        120.47999572753906,
        441.7232666015625,
        488.3565368652344,
        452.7632751464844
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "chronic heart failure 2012",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        137.52000427246094,
        463.80328369140625,
        274.8771667480469,
        474.8432922363281
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Eur Heart J 2012;33:1787-847.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        120.47999572753906,
        485.7632751464844,
        291.2171325683594,
        496.80328369140625
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "심부전의 진단",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        120.47999572753906,
        507.7232971191406,
        191.99964904785156,
        518.7633056640625
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "HF-REF의 진단을 위해서는 3개의 조건이 충족되어야 한다:",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        123.47999572753906,
        527.8832397460938,
        432.1963806152344,
        538.9232788085938
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1. HF에 전형적인 증상들",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        123.47999572753906,
        545.4032592773438,
        252.71998596191406,
        556.4432983398438
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. HF에 전형적인 증후들",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        123.47999572753906,
        563.043212890625,
        252.71998596191406,
        574.083251953125
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3. LVEF의 감소",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        123.47999572753906,
        580.6832275390625,
        431.8363952636719,
        605.5232543945312
      ],
      "page_num": 64,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "HF-PEF의 진단을 위해서는 4개의 조건이 충족되어야 한다:",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        123.47999572753906,
        580.6832275390625,
        431.8363952636719,
        605.5232543945312
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. HF에 전형적인 증상들",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        123.47999572753906,
        612.0032348632812,
        252.71998596191406,
        623.0432739257812
      ],
      "page_num": 64,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2. HF에 전형적인 증후들",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        123.47999572753906,
        629.6432495117188,
        252.71998596191406,
        640.6832885742188
      ],
      "page_num": 64,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3. 정상이거나 약간 저하된 LVEF과 확장되지 않은 LV",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        123.47999572753906,
        647.2832641601562,
        405.6765441894531,
        658.3233032226562
      ],
      "page_num": 64,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4. 관련 있는 심장의 구조적 질환 (LV 비대/LA 확장) 및/또는 확장기",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        123.47999572753906,
        664.80322265625,
        475.5163879394531,
        675.84326171875
      ],
      "page_num": 64,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기능장애 (diastolic dysfunction)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        138.59999084472656,
        682.4432373046875,
        305.52197265625,
        693.4832763671875
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅶ. 성능시험에 대한 상세사항",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        368.8800048828125,
        117.55441284179688,
        481.44561767578125,
        126.55441284179688
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 59 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 65,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "❍ 신선 검체를 사용하는 것을 원칙으로 하나, 충분한 수의 신선 검체를",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        120.47999572753906,
        155.76327514648438,
        488.23638916015625,
        166.8032684326172
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "확보하기 어려울 경우, 냉동검체를 사용할 수 있다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        137.16000366210938,
        177.72328186035156,
        396.4527893066406,
        188.76327514648438
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "❍ 아래의 1)부터 4)중 어느 하나에 해당하는 경우, 임상적 성능시험에 관한",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        225.96327209472656,
        488.3562316894531,
        237.00326538085938
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "자료를 제출하여야 한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        136.0800018310547,
        247.92327880859375,
        251.85281372070312,
        258.9632873535156
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 4등급 체외진단용 의료기기의 시험",
      "font_size": 10.797332763671875,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        278.4032897949219,
        312.4803771972656,
        289.44329833984375
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2) 인체로부터 검체를 채취하는 방법의 위해도가 큰 시험(검체의 채취방",
      "font_size": 10.797332763671875,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        304.5632629394531,
        484.56036376953125,
        315.603271484375
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "법이 인체의 피부, 점막, 안구, 요도를 침투 또는 관통하거나, 외이도,",
      "font_size": 10.797332763671875,
      "font_name": "Haansoft Batang",
      "bbox": [
        135.83999633789062,
        326.5232849121094,
        488.197021484375,
        337.56329345703125
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "외비공, 인두, 직장 또는 자궁경부를 넘어서 귀, 코, 입, 항문관 또는",
      "font_size": 10.797332763671875,
      "font_name": "Haansoft Batang",
      "bbox": [
        135.83999633789062,
        348.603271484375,
        488.0769348144531,
        359.6432800292969
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "질에 들어가는 침습적인 시험. 다만, 정맥채혈 등 피험자에게 중대한",
      "font_size": 10.797332763671875,
      "font_name": "Haansoft Batang",
      "bbox": [
        135.83999633789062,
        370.5632629394531,
        488.07733154296875,
        381.603271484375
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위험을 미치지 않는 시험 및 잔여검체로 실시하는 시험은 제외)",
      "font_size": 10.797332763671875,
      "font_name": "Haansoft Batang",
      "bbox": [
        135.83999633789062,
        392.5232849121094,
        449.6399841308594,
        403.56329345703125
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 이미 확립된 의학적 진단방법 또는 허가·인증받은 체외진단용 의료기",
      "font_size": 10.797332763671875,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        414.603271484375,
        484.56036376953125,
        425.6432800292969
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기로 임상적 성능시험의 결과를 확인할 수 없는 시험",
      "font_size": 10.797332763671875,
      "font_name": "Haansoft Batang",
      "bbox": [
        135.83999633789062,
        436.5632629394531,
        396.3599853515625,
        447.603271484375
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 의약품 등과 함께 동반하여 진단하는 시험(다만, 이미 허가·인증받은",
      "font_size": 10.797332763671875,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        458.5232849121094,
        488.19769287109375,
        469.56329345703125
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료기기와 사용목적, 작용원리 등이 동등하지 아니한 체외진단용 의",
      "font_size": 10.797332763671875,
      "font_name": "Haansoft Batang",
      "bbox": [
        137.0399932861328,
        480.603271484375,
        484.55999755859375,
        491.6432800292969
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "료기기의 시험에 한함)",
      "font_size": 10.797332763671875,
      "font_name": "Haansoft Batang",
      "bbox": [
        137.0399932861328,
        502.5632629394531,
        248.63999938964844,
        513.603271484375
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(※ 상기의 1)부터 4)까지는 식약처장의 임상시험계획승인 및 임상시험",
      "font_size": 10.797332763671875,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        524.5232543945312,
        484.5607604980469,
        535.5632934570312
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기관의 임상시험계획승인을 받고 실시해야함)",
      "font_size": 10.797332763671875,
      "font_name": "Haansoft Batang",
      "bbox": [
        151.9199981689453,
        546.603271484375,
        372.239990234375,
        557.643310546875
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ 상기의 1)부터 4)까지에 해당하지 않는 임상시험의 경우에는 아래의 가)부터",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        583.80322265625,
        488.235595703125,
        594.84326171875
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다)까지 중 어느 하나에 해당하는 임상적 성능시험에 관한 자료로 제출하여야 한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.87999725341797,
        605.7632446289062,
        483.4527893066406,
        616.8032836914062
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(※ 하기의 가)부터 나)까지는 식약처장의 임상시험계획승인은 제외되고,",
      "font_size": 10.797332763671875,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        631.9232177734375,
        488.197021484375,
        642.9632568359375
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상적 성능시험 실시기관의 임상시험계획승인을 받고 실시해야함)",
      "font_size": 10.797332763671875,
      "font_name": "Haansoft Batang",
      "bbox": [
        147.239990234375,
        654.0032348632812,
        463.91998291015625,
        665.0432739257812
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가) 다음 각 단의 어느 하나에 해당하는 기관에서 별표 14 임상적 성능시험",
      "font_size": 10.797332763671875,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        675.9632568359375,
        488.07745361328125,
        687.0032958984375
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        98.04000091552734,
        117.91441345214844,
        448.0853271484375,
        126.91441345214844
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 60 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 66,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관리기준에 의하여 실시한 자료",
      "font_size": 10.797332763671875,
      "font_name": "Haansoft Batang",
      "bbox": [
        136.8000030517578,
        155.76327514648438,
        289.8003845214844,
        166.8032684326172
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "➀「감염병의 예방 및 관리에 관한 시행규칙」 제4조제9호에 해당하는 기관",
      "font_size": 10.797332763671875,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        177.72328186035156,
        492.636474609375,
        188.76327514648438
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "➁「혈액관리법」 제6조제3항에 따라 허가받은 공급혈액원",
      "font_size": 10.797332763671875,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        199.80328369140625,
        422.40081787109375,
        210.84327697753906
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "➂ 법 제10조제3항에 따라 식약처장이 지정한 임상시험기관",
      "font_size": 10.797332763671875,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        221.76327514648438,
        433.4410095214844,
        232.8032684326172
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나) 외국 자료로서 그 내용을 검토하여 실시기관의 신뢰성이 인정되고 별표 14",
      "font_size": 10.797332763671875,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        254.76327514648438,
        488.1963806152344,
        265.80328369140625
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상적 성능시험 관리기준에 의하여 실시한 시험자료 또는 이에 준하는",
      "font_size": 10.797332763671875,
      "font_name": "Haansoft Batang",
      "bbox": [
        135.0,
        276.7232666015625,
        488.196533203125,
        287.7632751464844
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "것으로 인정되는 시험자료",
      "font_size": 10.797332763671875,
      "font_name": "Haansoft Batang",
      "bbox": [
        135.0,
        298.80328369140625,
        254.27980041503906,
        309.8432922363281
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다) 임상적 성능시험에 관한 자료 요건( 상기의 1)에서~ 4)까지) 중 어느",
      "font_size": 10.797332763671875,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        320.7632751464844,
        488.1969299316406,
        331.80328369140625
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하나에 해당하는 자료",
      "font_size": 10.797332763671875,
      "font_name": "Haansoft Batang",
      "bbox": [
        136.8000030517578,
        342.7232666015625,
        246.75730895996094,
        353.7632751464844
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ 임상적 성능시험에 관한 자료는 다음 중 어느 하나에 해당하는 자료 요건",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        379.92327880859375,
        484.6805114746094,
        390.9632873535156
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "으로 제출하여야 한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        126.47999572753906,
        402.0032653808594,
        233.97280883789062,
        413.04327392578125
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가. 식품의약품안전처장이 지정한 임상시험기관에서 시험한 자료",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        432.36328125,
        454.5596618652344,
        443.4032897949219
      ],
      "page_num": 66,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나. 외국자료로서 그 내용을 검토하여 실시기관의 신뢰성이 인정되고 시행규",
      "font_size": 10.797332763671875,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        462.7232666015625,
        484.56036376953125,
        473.7632751464844
      ],
      "page_num": 66,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "칙 별표 3 의료기기 임상시험 관리기준에 의하여 실시한 시험자료",
      "font_size": 10.797332763671875,
      "font_name": "Haansoft Batang",
      "bbox": [
        146.87998962402344,
        484.80328369140625,
        488.1965637207031,
        495.8432922363281
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는 이에 준하는 것으로 인정되는 시험자료",
      "font_size": 10.797332763671875,
      "font_name": "Haansoft Batang",
      "bbox": [
        146.87998962402344,
        506.7632751464844,
        362.7596130371094,
        517.8032836914062
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다. 해당 의료기기에 대하여 경제협력개발기구(OECD) 회원국에 허가 당시",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        537.1232299804688,
        488.3562316894531,
        548.1632690429688
      ],
      "page_num": 66,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제출되어 평가된 임상시험에 관한 자료로서 해당 정부 또는 정부가",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        145.3199920654297,
        559.2032470703125,
        488.3565673828125,
        570.2432861328125
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "허가 업무를 위임한 등록기관이 제출받아 승인하였음을 확인한 자료",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        145.3199920654297,
        581.1632690429688,
        488.35614013671875,
        592.2033081054688
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는 이를 공증한 자료",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        145.3199920654297,
        603.1232299804688,
        256.67974853515625,
        614.1632690429688
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라. 과학논문인용색인(Science Citation Index)에 등재된 전문학회지에",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        633.6032104492188,
        488.3557434082031,
        644.6432495117188
      ],
      "page_num": 66,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "게재된 자료",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        145.55999755859375,
        655.563232421875,
        206.03965759277344,
        666.603271484375
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅶ. 성능시험에 대한 상세사항",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        368.8800048828125,
        117.55441284179688,
        481.44561767578125,
        126.55441284179688
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 61 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 67,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 임상적 민감도",
      "font_size": 12.0,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        155.7792205810547,
        204.95999145507812,
        167.7792205810547
      ],
      "page_num": 67,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 실험물질",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        201.72328186035156,
        189.23965454101562,
        212.76327514648438
      ],
      "page_num": 67,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 다양한 농도를 포함한 양성 임상검체를 이용하여 평가한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        223.80328369140625,
        461.71661376953125,
        234.84327697753906
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 임상검체가 양성 또는 음성임을 확인한 방법을 기술한 자료를",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        245.76327514648438,
        488.3560485839844,
        256.80328369140625
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제출한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        159.59999084472656,
        267.7232666015625,
        210.43629455566406,
        278.7632751464844
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 예시",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        134.0399932861328,
        292.5632629394531,
        169.91998291015625,
        303.603271484375
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기허가 진단제품 또는 확진검사방법 등으로 확인하였음을 기술한",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        141.95999145507812,
        314.5232849121094,
        481.7569274902344,
        325.56329345703125
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자료 또는 양성임을 증명하는 임상자료 등. 평가대상 제품의 결과와",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        141.95999145507812,
        336.603271484375,
        481.8763732910156,
        347.6432800292969
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "관계없는 기준이여야 함",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        141.95999145507812,
        358.5632629394531,
        262.91998291015625,
        369.603271484375
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 양성 검체는 각 질환의 다양한 임상단계가 포함되도록 한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        384.84326171875,
        472.63629150390625,
        395.8832702636719
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 검사의 목적, 유병률과 제품의 분석능에 따라 통계적으로 의미",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        406.80328369140625,
        488.35638427734375,
        417.8432922363281
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있는 검체수가 다르므로 검사의 목적, 유병률, 제품의 분석능에",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        159.239990234375,
        428.7632751464844,
        488.3560485839844,
        439.80328369140625
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "따라 통계적으로 의미 있는 검체수를 산정한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        159.239990234375,
        450.84326171875,
        402.4363098144531,
        461.8832702636719
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 뇌나트륨이뇨펩티드(NT-proBNP, BNP) 검사의 목표 질환을",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        150.47999572753906,
        472.80328369140625,
        488.3560485839844,
        483.8432922363281
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가지고 있는 양성 검체 50개 이상을 포함하여 평가하기를",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        166.44000244140625,
        494.7632751464844,
        488.35638427734375,
        505.80328369140625
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "권장한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        166.44000244140625,
        516.84326171875,
        222.79640197753906,
        527.88330078125
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5) 신선한 검체를 이용할 것을 권장하지만, 제조사에서 냉동검체의",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        538.80322265625,
        488.3560485839844,
        549.84326171875
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안정성을 보장한다면 냉동검체를 일부 이용할 수도 있다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        158.63999938964844,
        560.7632446289062,
        447.6927795410156,
        571.8032836914062
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 시험방법",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        604.80322265625,
        189.23965454101562,
        615.84326171875
      ],
      "page_num": 67,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 피험자 선정/제외 기준, 검체 종류와 수, 시험 상 주의사항, 통계",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        626.7632446289062,
        484.67999267578125,
        637.8032836914062
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분석법 등에 대한 자세한 실험프로토콜을 제공한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        157.9199981689453,
        648.84326171875,
        423.1966247558594,
        659.88330078125
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2) 신선한 검체를 이용할 것을 권장하지만, 확진된 보관검체로",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        670.80322265625,
        488.35638427734375,
        681.84326171875
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검사할 경우도 최소 5일 이상 검체를 나누어서 검사한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        159.239990234375,
        692.7632446289062,
        449.1327819824219,
        703.8032836914062
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        98.04000091552734,
        117.91441345214844,
        448.0853271484375,
        126.91441345214844
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 62 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 68,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3) 2개 이상의 독립된 검사실에서 검사를 시행할 것을 권장한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        155.76327514648438,
        478.99627685546875,
        166.8032684326172
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4) 평가 전에 결과 해석에 대한 알고리즘 및 불일치한 경우 추가",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        177.72328186035156,
        488.35638427734375,
        188.76327514648438
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검사 등의 원인 분석 방법을 미리 확립하고 이를 명시한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        159.239990234375,
        199.80328369140625,
        459.3327941894531,
        210.84327697753906
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "5) 검사를 시행할 집단에서의 유병률을 평가할 것을 권장한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        221.76327514648438,
        458.0127868652344,
        232.8032684326172
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다. 결과제시",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        287.7632751464844,
        192.9160614013672,
        298.80328369140625
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 임상적 민감도 및 95% 신뢰구간을 제시한다. 임상적 민감도란",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        309.7232666015625,
        488.3561706542969,
        320.7632751464844
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "질병이나 특정 상태를 가지는 대상군에서 검사 결과가 양성",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        159.36000061035156,
        331.80328369140625,
        484.6803283691406,
        342.8432922363281
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(판정기준치 이상)으로 나오는 환자의 비율이다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        159.36000061035156,
        353.7632751464844,
        401.9727783203125,
        364.80328369140625
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 전체 결과, 특이 결과, 구별되는 소견이 있는 세부 집단별 결과",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        375.7232666015625,
        488.35638427734375,
        386.7632751464844
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등을 제시한다. 유병률을 구한 경우는 유병률도 제시한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        158.63999938964844,
        397.80328369140625,
        450.93280029296875,
        408.8432922363281
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 불일치한 검체에 대해 원인을 분석한 자료를 제출하고 해석을",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        419.7632751464844,
        488.3560485839844,
        430.80328369140625
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제시한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        159.59999084472656,
        441.7232666015625,
        206.85281372070312,
        452.7632751464844
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 전향적으로 목표하는 검체 수가 될 때까지 모든 양성 및 음성",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        463.80328369140625,
        488.35638427734375,
        474.8432922363281
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검체를 수집하였을 경우 유병률, 양성예측도, 음성예측도를 구할",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        159.0,
        483.603271484375,
        488.3564758300781,
        494.6432800292969
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수 있으므로 임상적 민감도, 임상적 특이도와 함께 유병률, 양성",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        159.0,
        503.4032897949219,
        484.6800842285156,
        514.4432983398438
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예측도, 음성예측도 제시를 권장한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        159.0,
        523.2032470703125,
        342.81280517578125,
        534.2432861328125
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ⅶ. 성능시험에 대한 상세사항",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        368.8800048828125,
        117.55441284179688,
        481.44561767578125,
        126.55441284179688
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 63 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 69,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2. 임상적 특이도",
      "font_size": 12.0,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        155.7792205810547,
        204.95999145507812,
        167.7792205810547
      ],
      "page_num": 69,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 시험물질",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        201.72328186035156,
        189.23965454101562,
        212.76327514648438
      ],
      "page_num": 69,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 진단의 목표가 되는 질환이 없음이 확인된 임상검체를 이용하여",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        223.80328369140625,
        488.3560485839844,
        234.84327697753906
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        158.27999877929688,
        245.76327514648438,
        209.11663818359375,
        256.80328369140625
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 검체는 적용하고자 하는 대상 인구집단을 반영하여야 한다(예 :",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        267.7232666015625,
        488.3568420410156,
        278.7632751464844
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "호흡곤란으로 응급실 내원한 환자, 입원환자 등).",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        158.39999389648438,
        289.80328369140625,
        410.47662353515625,
        300.8432922363281
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 뇌나트륨이뇨펩티드(NT-proBNP, BNP)에 대한 목표 질환을",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        311.7632751464844,
        488.35638427734375,
        322.80328369140625
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가지지 않은 음성 검체 100개 이상 평가할 것을 권장한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        157.0800018310547,
        333.7232666015625,
        457.9963073730469,
        344.7632751464844
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 시험방법",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        377.7632751464844,
        189.23965454101562,
        388.80328369140625
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 임상적 특이도란 질환이 없는 환자군에서 음성결과를 보이는",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        399.7232666015625,
        488.35638427734375,
        410.7632751464844
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "환자의 비율이다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        160.1999969482422,
        421.80328369140625,
        245.85281372070312,
        432.8432922363281
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 음성예측도와 양성예측도는 질환 유병률과 상관이 있으므로,",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        443.7632751464844,
        488.35662841796875,
        454.80328369140625
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검사가 이용될 인구집단을 대상으로 산출되어야 한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        159.95999145507812,
        465.7232666015625,
        432.5727844238281,
        476.7632751464844
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 양성 결과를 보인 경우 임상소견 확인 및 확진 검사를 시행하여",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        487.80328369140625,
        488.3560485839844,
        498.8432922363281
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "진양성 유무를 확인토록 한다. 진양성인 검체는 특이도 분석에서",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        158.16000366210938,
        509.7632751464844,
        488.35638427734375,
        520.8032836914062
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제외한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        158.16000366210938,
        531.7232666015625,
        208.9962921142578,
        542.7633056640625
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 피험자 선정/제외 기준, 검체 종류와 수, 시험 상 주의사항, 통계",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        553.80322265625,
        484.67999267578125,
        564.84326171875
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분석법 등을 미리 확립한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        157.9199981689453,
        575.7632446289062,
        298.5328063964844,
        586.8032836914062
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5) 평가 전에 결과 해석에 대한 알고리즘 및 불일치한 경우 추가",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        597.7232666015625,
        488.35638427734375,
        608.7633056640625
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검사 등의 원인 분석 방법을 미리 확립하고 이를 명시한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        159.239990234375,
        619.80322265625,
        463.03662109375,
        630.84326171875
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "6) 선택한 비교평가 방법을 명시하고, 선택한 사유를 기술한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        641.7632446289062,
        464.8363037109375,
        652.8032836914062
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "7) 2개 이상의 독립된 검사실에서 검사를 시행할 것을 권장한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        663.7232666015625,
        478.99627685546875,
        674.7633056640625
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        98.04000091552734,
        117.91441345214844,
        448.0853271484375,
        126.91441345214844
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 64 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 70,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다. 결과제시",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        155.76327514648438,
        189.23965454101562,
        166.8032684326172
      ],
      "page_num": 70,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 임상적 특이도 및 95% 신뢰구간을 제시한다. 임상적 특이도란",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        177.72328186035156,
        488.3560485839844,
        188.76327514648438
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "질병이나 특정 상태가 아닌 대상군에서 검사 결과가 음성(판정",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        159.1199951171875,
        199.80328369140625,
        484.6796875,
        210.84327697753906
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기준치 미만)으로 나오는 환자의 비율이다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        159.1199951171875,
        221.76327514648438,
        376.7727966308594,
        232.8032684326172
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 산출된 특이도의 95% 신뢰구간의 최하위값이 적합기준을 넘어서면",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        243.72328186035156,
        488.35638427734375,
        254.76327514648438
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인정할 수 있다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        158.16000366210938,
        265.80328369140625,
        238.41281127929688,
        276.8432922363281
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 전체 결과, 특이 결과, 구별되는 소견이 있는 세부 집단별 결과",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        287.7632751464844,
        488.35638427734375,
        298.80328369140625
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등을 제시한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        158.63999938964844,
        309.7232666015625,
        233.372802734375,
        320.7632751464844
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 불일치한 검체에 대해 원인을 분석한 자료를 제출하고, 해석을",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        140.52000427246094,
        331.80328369140625,
        488.3560485839844,
        342.8432922363281
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제시한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        159.239990234375,
        353.7632751464844,
        210.07662963867188,
        364.80328369140625
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3",
      "font_size": 13.799982070922852,
      "font_name": "H2hdrM",
      "bbox": [
        121.91999816894531,
        425.10809326171875,
        482.2839660644531,
        439.86810302734375
      ],
      "page_num": 70,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "완제품의 품질관리 시험성적서 또는 시험에 관한 자료",
      "font_size": 13.799982070922852,
      "font_name": "HYwulM",
      "bbox": [
        121.91999816894531,
        425.10809326171875,
        482.2839660644531,
        439.86810302734375
      ],
      "page_num": 70,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 3배치 각 1회 이상 또는 1배치 3회 이상의 시험규격에 따른 시험성적서",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        471.9632873535156,
        484.6820983886719,
        483.0032958984375
      ],
      "page_num": 70,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는 시험에 관한 자료를 제출하여 제품의 균일성을 제시한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        127.07999420166016,
        493.92327880859375,
        441.436279296875,
        504.9632873535156
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 시험규격 설정에 따른 시험 기준 및 방법에 관한 자료와 표준물질이",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        537.9632568359375,
        488.3560485839844,
        549.0032958984375
      ],
      "page_num": 70,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용된 경우, 이에 관한 자료를 제출한다(단, 표준물질에 관한 자료와",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        126.83999633789062,
        559.9232177734375,
        488.3560485839844,
        570.9632568359375
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중복될 경우 이를 생략한다).",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        126.83999633789062,
        581.8832397460938,
        272.97247314453125,
        592.9232788085938
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3. 시험 항목은 품질의 동등성을 입증할 수 있는 항목(민감도, 특이도,",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        625.9232177734375,
        488.35638427734375,
        636.9632568359375
      ],
      "page_num": 70,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정밀도 등)을 설정한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        127.07999420166016,
        647.8832397460938,
        245.85281372070312,
        658.9232788085938
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅶ. 성능시험에 대한 상세사항",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        368.8800048828125,
        117.55441284179688,
        481.44561767578125,
        126.55441284179688
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 65 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 71,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4",
      "font_size": 13.799982070922852,
      "font_name": "H2hdrM",
      "bbox": [
        121.91999816894531,
        161.10809326171875,
        482.2839660644531,
        175.86807250976562
      ],
      "page_num": 71,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "완제품 품질관리 시험에 사용된 표준물질에 관한 자료",
      "font_size": 13.799982070922852,
      "font_name": "HYwulM",
      "bbox": [
        121.91999816894531,
        161.10809326171875,
        482.2839660644531,
        175.86807250976562
      ],
      "page_num": 71,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 표준물질 혹은 타사 표준물질을 구매하여 사용한 경우, 아래의 자료를",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        207.96328735351562,
        488.2360534667969,
        219.00328063964844
      ],
      "page_num": 71,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제출한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        126.0,
        229.92327880859375,
        176.95663452148438,
        240.96327209472656
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가. 표준품 또는 기타 사용된 표준물질의 확인서(certificate)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        251.88327026367188,
        437.11798095703125,
        262.92327880859375
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 출처 및 근거 자료",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        273.9632873535156,
        242.3563995361328,
        285.0032958984375
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 자사 표준물질을 제작하여 사용할 경우, 다음의 자료를 제출한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        317.8832702636719,
        456.3327941894531,
        328.92327880859375
      ],
      "page_num": 71,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 표준물질의 농도별 설정 기준을 입증할 수 있는 시험 자료 및 결과",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        339.9632873535156,
        488.23638916015625,
        351.0032958984375
      ],
      "page_num": 71,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분석 자료",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        145.44000244140625,
        361.92327880859375,
        198.55606079101562,
        372.9632873535156
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 표준물질 관리방법 및 관리기록서(정도관리 포함)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        383.8832702636719,
        401.8363952636719,
        394.92327880859375
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5",
      "font_size": 13.799982070922852,
      "font_name": "H2hdrM",
      "bbox": [
        121.91999816894531,
        433.26806640625,
        460.9193420410156,
        447.51513671875
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검체보관 및 취급상(온도, 습도 등)의 조건 설정 근거자료",
      "font_size": 12.839439392089844,
      "font_name": "HYwulM",
      "bbox": [
        121.91999816894531,
        433.26806640625,
        460.9193420410156,
        447.51513671875
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1. 시험결과를 근거로 하여, 검사에 이용할 수 있는 검체의 취급방법,",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        480.1232604980469,
        488.2362976074219,
        491.16326904296875
      ],
      "page_num": 71,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보관조건 및 방법, 사용기간, 주의사항 등에 대하여 기재한다. 이는",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        127.31999969482422,
        502.0832824707031,
        488.356689453125,
        513.123291015625
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "원심분리 조건 등을 포함한 검체 전처리과정 및 냉동 및 해동된",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        127.31999969482422,
        524.1632690429688,
        488.23638916015625,
        535.2033081054688
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검체의 사용 가능성 및 제한점 등을 포함한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        127.31999969482422,
        546.1232299804688,
        366.4527893066406,
        557.1632690429688
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 검체 취급 및 보관조건에 대한 시험 결과를 제시한다. 이는 제시된 시간,",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        590.1632690429688,
        488.23638916015625,
        601.2033081054688
      ],
      "page_num": 71,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "온도, 습도 등의 항목에 대해 유효하다고 제시된 구간 중 몇 단계에",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.63999938964844,
        612.1232299804688,
        488.3560485839844,
        623.1632690429688
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대해 동일한 검사 결과를 보임을 입증해야 한다. 이 시험은 제시된",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.63999938964844,
        634.083251953125,
        488.35626220703125,
        645.123291015625
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구간의 양측 한계치 이상에서 평가된 결과여야 하며, 조건 변화에 따른",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.63999938964844,
        656.1632690429688,
        488.35638427734375,
        667.2033081054688
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결과의 변화를 제시하고 평가에 사용된 만족기준을 함께 기록한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.63999938964844,
        678.1232299804688,
        467.8363037109375,
        689.1632690429688
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        98.04000091552734,
        117.91441345214844,
        448.0853271484375,
        126.91441345214844
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 66 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 72,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3. 시험에 사용된 방법, 검체 수, 검체 범위, 표준 농도, 계산법, 통계처리법,",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        177.72328186035156,
        488.35662841796875,
        188.76327514648438
      ],
      "page_num": 72,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "허용기준, 결과 등을 요약하여 제시한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.87999725341797,
        199.80328369140625,
        330.2127990722656,
        210.84327697753906
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "6",
      "font_size": 13.799982070922852,
      "font_name": "H2hdrM",
      "bbox": [
        121.91999816894531,
        271.1480712890625,
        222.48397827148438,
        285.9080810546875
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상관성 평가",
      "font_size": 13.799982070922852,
      "font_name": "HYwulM",
      "bbox": [
        121.91999816894531,
        271.1480712890625,
        222.48397827148438,
        285.9080810546875
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1. 일반사항",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        317.8832702636719,
        169.67965698242188,
        328.92327880859375
      ],
      "page_num": 72,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 국내‧외 허가된 체외진단용 의료기기와의 상관성을 확인할 수 있는",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        339.9632873535156,
        488.35638427734375,
        351.0032958984375
      ],
      "page_num": 72,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비교시험 성적서를 포함하여야 한다. 다만, 측정원리 및 측정항목이",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        146.63999938964844,
        361.92327880859375,
        488.35638427734375,
        372.9632873535156
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "새로운 경우 동일목적으로 사용되는 제품과 비교할 수 있다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        146.63999938964844,
        383.8832702636719,
        452.2527770996094,
        394.92327880859375
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 임상적 민감도와 임상적 특이도를 산출하기 위해 시행한 검사에서",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        405.9632873535156,
        488.3560485839844,
        417.0032958984375
      ],
      "page_num": 72,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기존검사법(기허가 제품)을 병행하여 검사하였을 경우, 도출된",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        145.67999267578125,
        427.92327880859375,
        488.35638427734375,
        438.9632873535156
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "두 검사 결과를 정리하여 상관성의 자료로 제시할 수 있다. 분석적",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        145.67999267578125,
        449.8832702636719,
        488.2360534667969,
        460.92327880859375
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성능시험 과정에서 기존검사법과의 비교 자료가 있을 경우에도",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        145.67999267578125,
        471.9632873535156,
        488.35638427734375,
        483.0032958984375
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상관성의 추가 자료로 제시할 수 있다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        145.67999267578125,
        493.92327880859375,
        341.372802734375,
        504.9632873535156
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 시험물질",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        515.8832397460938,
        169.67965698242188,
        526.9232788085938
      ],
      "page_num": 72,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 통계적으로 해석 가능한 수의 임상검체를 포함하여 비교시험을",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        537.9632568359375,
        488.35638427734375,
        549.0032958984375
      ],
      "page_num": 72,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수행한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        147.239990234375,
        559.9232177734375,
        198.07662963867188,
        570.9632568359375
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 임상검체는 기 허가된 방법이거나 여타 검증된 방법으로 검사되어",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        581.8832397460938,
        488.3560485839844,
        592.9232788085938
      ],
      "page_num": 72,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검체의 이력 등이 밝혀진 검체를 사용할 것을 권장한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        145.67999267578125,
        603.9632568359375,
        429.3327941894531,
        615.0032958984375
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다. 다양한 임상상을 포함하는 검체를 포함하여 비교하도록 한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        625.9232177734375,
        459.9162902832031,
        636.9632568359375
      ],
      "page_num": 72,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "라. 정량검사의 임상검체는 측정범위 내의 다양한 농도가 포함되도록 하고,",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        647.8832397460938,
        488.35638427734375,
        658.9232788085938
      ],
      "page_num": 72,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "최소 100개 이상의 검체를 시험하도록 권장한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        145.3199920654297,
        669.9632568359375,
        393.0928039550781,
        681.0032958984375
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅶ. 성능시험에 대한 상세사항",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        368.8800048828125,
        117.55441284179688,
        481.44561767578125,
        126.55441284179688
      ],
      "page_num": 73,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 67 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 73,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3. 시험방법",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        155.76327514648438,
        169.67965698242188,
        166.8032684326172
      ],
      "page_num": 73,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 해당 제품과 측정 원리 및 항목이 가장 유사한 국내 허가 제품 또는",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        177.72328186035156,
        488.35638427734375,
        188.76327514648438
      ],
      "page_num": 73,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "외국 허가 제품(국내 허가 제품이 없을 시)과의 비교시험을 실시",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        145.1999969482422,
        199.80328369140625,
        484.67999267578125,
        210.84327697753906
      ],
      "page_num": 73,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        145.1999969482422,
        221.76327514648438,
        170.49281311035156,
        232.8032684326172
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 가능한 2개 이상의 회사 제품과 비교시험 할 것을 권장한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        243.72328186035156,
        451.6528015136719,
        254.76327514648438
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다. 비교 제품은 각 제품의 사용방법에 따라서 시험한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        265.80328369140625,
        412.29278564453125,
        276.8432922363281
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라. 정량검사의 경우 각 검사를 2회 이상 반복 측정을 권장한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        287.7632751464844,
        451.6528015136719,
        298.80328369140625
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "마. 결과가 불일치하는 경우, 다른 검사를 통해 불일치의 원인을 분석하고",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        309.7232666015625,
        488.23638916015625,
        320.7632751464844
      ],
      "page_num": 73,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이에 대한 자료를 제공하여야 한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        145.44000244140625,
        331.80328369140625,
        328.15631103515625,
        342.8432922363281
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4. 결과제시",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        397.80328369140625,
        169.67965698242188,
        408.8432922363281
      ],
      "page_num": 73,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 전체 결과 및 특이 환자 그룹이 있다면 그룹별 결과를 제시한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        419.7632751464844,
        472.7727966308594,
        430.80328369140625
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 정량검사에 대해서는 기울기, 절편(신뢰구간과 함께), 상관계수 및",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        441.7232666015625,
        488.35638427734375,
        452.7632751464844
      ],
      "page_num": 73,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의학적 결정치(medical decision point)에서의 바이어스를 제시한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        145.67999267578125,
        463.80328369140625,
        486.5563049316406,
        474.8432922363281
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다. 판정기준치(cut-off value)를 적용한 정성적 검사결과(양성과 음성)에",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        485.7632751464844,
        488.35638427734375,
        496.80328369140625
      ],
      "page_num": 73,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대해서는 비교검사와의 일치도(신뢰구간과 함께)를 제시한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        145.8000030517578,
        507.7232971191406,
        456.93280029296875,
        518.7633056640625
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라. 결과가 불일치하는 경우, 불일치의 원인 분석에 대한 자료를 제출",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        125.5199966430664,
        529.80322265625,
        484.67999267578125,
        540.84326171875
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한다.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        145.9199981689453,
        551.7632446289062,
        171.09280395507812,
        562.8032836914062
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        98.04000091552734,
        117.91441345214844,
        448.0853271484375,
        126.91441345214844
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 68 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 74,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅷ",
      "font_size": 21.959999084472656,
      "font_name": "T12",
      "bbox": [
        117.23999786376953,
        160.07998657226562,
        238.55999755859375,
        186.43199157714844
      ],
      "page_num": 74,
      "block_type": "heading",
      "level": 1,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "참고문헌",
      "font_size": 18.0,
      "font_name": "H2hdrM",
      "bbox": [
        117.23999786376953,
        160.07998657226562,
        238.55999755859375,
        186.43199157714844
      ],
      "page_num": 74,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. CLSI. Evaluation of Stability of In Vitro Diagnostic Reagents;",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        225.72328186035156,
        488.3562927246094,
        236.76327514648438
      ],
      "page_num": 74,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Approved Guideline. CLSI document EP25-A. Wayne, PA: Cinical",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        129.239990234375,
        247.68328857421875,
        488.3565368652344,
        258.7232971191406
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "and Laboratory Standard Institute; 2009",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        129.239990234375,
        269.7632751464844,
        340.8771667480469,
        280.80328369140625
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        313.68328857421875,
        488.3594665527344,
        324.7232971191406
      ],
      "page_num": 74,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "CLSI.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        313.68328857421875,
        488.3594665527344,
        324.7232971191406
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Evaluation",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        313.68328857421875,
        488.3594665527344,
        324.7232971191406
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "of",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        313.68328857421875,
        488.3594665527344,
        324.7232971191406
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Precision",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        313.68328857421875,
        488.3594665527344,
        324.7232971191406
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Performance",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        313.68328857421875,
        488.3594665527344,
        324.7232971191406
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "of",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        313.68328857421875,
        488.3594665527344,
        324.7232971191406
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Quantitative",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        313.68328857421875,
        488.3594665527344,
        324.7232971191406
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Measurement Methods; Approved Guideline - Second Edition.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        133.0800018310547,
        335.7632751464844,
        488.3570556640625,
        346.80328369140625
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "CLSI document EP5-A2. Wayne, PA: Cinical and Laboratory",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        133.0800018310547,
        357.7232666015625,
        488.3570556640625,
        368.7632751464844
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Standard Institute; 2004",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        133.0800018310547,
        379.68328857421875,
        260.9571533203125,
        390.7232971191406
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        423.7232666015625,
        488.3559265136719,
        434.7632751464844
      ],
      "page_num": 74,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "CLSI.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        423.7232666015625,
        488.3559265136719,
        434.7632751464844
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "User",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        423.7232666015625,
        488.3559265136719,
        434.7632751464844
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Protocol",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        423.7232666015625,
        488.3559265136719,
        434.7632751464844
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "for",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        423.7232666015625,
        488.3559265136719,
        434.7632751464844
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Evaluation",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        423.7232666015625,
        488.3559265136719,
        434.7632751464844
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "of",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        423.7232666015625,
        488.3559265136719,
        434.7632751464844
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Qualitative",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        423.7232666015625,
        488.3559265136719,
        434.7632751464844
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Test",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        423.7232666015625,
        488.3559265136719,
        434.7632751464844
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Performance;",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        134.39999389648438,
        445.68328857421875,
        488.3562927246094,
        456.7232971191406
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Approved",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        134.39999389648438,
        445.68328857421875,
        488.3562927246094,
        456.7232971191406
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Guideline",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        134.39999389648438,
        445.68328857421875,
        488.3562927246094,
        456.7232971191406
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        134.39999389648438,
        445.68328857421875,
        488.3562927246094,
        456.7232971191406
      ],
      "page_num": 74,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Second",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        134.39999389648438,
        445.68328857421875,
        488.3562927246094,
        456.7232971191406
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Edition.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        134.39999389648438,
        445.68328857421875,
        488.3562927246094,
        456.7232971191406
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "CLSI",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        134.39999389648438,
        445.68328857421875,
        488.3562927246094,
        456.7232971191406
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "document EP12-A2. Wayne, PA: Cinical and Laboratory Standard",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        134.39999389648438,
        467.7632751464844,
        488.3562927246094,
        478.80328369140625
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Institute; 2008",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        134.39999389648438,
        489.7232666015625,
        212.23716735839844,
        500.7632751464844
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4. CLSI. Protocols for Determination of Limits of Detection and",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        533.7632446289062,
        488.3565368652344,
        544.8032836914062
      ],
      "page_num": 74,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Limits",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        129.47999572753906,
        555.7232666015625,
        488.3577575683594,
        566.7633056640625
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "of Quantitation; Approved Guideline.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        129.47999572753906,
        555.7232666015625,
        488.3577575683594,
        566.7633056640625
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "CLSI document",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        129.47999572753906,
        555.7232666015625,
        488.3577575683594,
        566.7633056640625
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "EP17-A. Wayne, PA: Cinical and Laboratory Standard Institute; 2004",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        129.47999572753906,
        577.6832275390625,
        482.8355712890625,
        588.7232666015625
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "5. CLSI. Evaluation of the Linearity of Quantitative Measurement",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        621.7232666015625,
        488.3557434082031,
        632.7633056640625
      ],
      "page_num": 74,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Procedures: A Statistical Approach; Approved Guideline. CLSI",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        129.0,
        643.6832275390625,
        488.3562927246094,
        654.7232666015625
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "document EP6-A. Wayne, PA: Cinical and Laboratory Standard",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        129.0,
        665.7632446289062,
        488.3562927246094,
        676.8032836914062
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Institute; 2003",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        129.0,
        687.7232666015625,
        206.95716857910156,
        698.7633056640625
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅷ. 참고문헌",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        434.3999938964844,
        117.55441284179688,
        481.44561767578125,
        126.55441284179688
      ],
      "page_num": 75,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 69 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 75,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "6. CLSI. Method Comparison and Bias Estimation Using Patient",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        177.84327697753906,
        488.3560485839844,
        188.88327026367188
      ],
      "page_num": 75,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Samples;",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        130.3199920654297,
        199.80328369140625,
        488.3575134277344,
        210.84327697753906
      ],
      "page_num": 75,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Approved",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        130.3199920654297,
        199.80328369140625,
        488.3575134277344,
        210.84327697753906
      ],
      "page_num": 75,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Guideline",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        130.3199920654297,
        199.80328369140625,
        488.3575134277344,
        210.84327697753906
      ],
      "page_num": 75,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        130.3199920654297,
        199.80328369140625,
        488.3575134277344,
        210.84327697753906
      ],
      "page_num": 75,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Second",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        130.3199920654297,
        199.80328369140625,
        488.3575134277344,
        210.84327697753906
      ],
      "page_num": 75,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Edition",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        130.3199920654297,
        199.80328369140625,
        488.3575134277344,
        210.84327697753906
      ],
      "page_num": 75,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(Interim",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        130.3199920654297,
        199.80328369140625,
        488.3575134277344,
        210.84327697753906
      ],
      "page_num": 75,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Revision). CLSI document EP9-A2-IR. Wayne, PA: Cinical and",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        130.3199920654297,
        221.88328552246094,
        488.3568420410156,
        232.92327880859375
      ],
      "page_num": 75,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Laboratory Standard Institute; 2010",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        130.3199920654297,
        243.84327697753906,
        319.03717041015625,
        254.88327026367188
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "7. CLSI. Interference Testing in Clinical Chemistry; Approved",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        287.8832702636719,
        488.3577575683594,
        298.92327880859375
      ],
      "page_num": 75,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Guideline - Second Edition. CLSI document EP7-A. Wayne, PA:",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        132.1199951171875,
        309.8432922363281,
        488.35614013671875,
        320.88330078125
      ],
      "page_num": 75,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Cinical and Laboratory Standard Institute; 2005",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        132.1199951171875,
        331.80328369140625,
        383.1171569824219,
        342.8432922363281
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "8. Guidance for Industry and FDA Staff: In Vitro Diagnostic (IVD)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        375.84326171875,
        488.3551940917969,
        386.8832702636719
      ],
      "page_num": 75,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Device Studies -Frequently Asked Questions, 2010",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        127.43999481201172,
        397.80328369140625,
        405.0773010253906,
        408.8432922363281
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "9. Guidance for industry and FDA staff/ Format for traditional and",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        441.84326171875,
        488.3565368652344,
        452.8832702636719
      ],
      "page_num": 75,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "abbreviated 510(k)s, 2005.",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        127.68000030517578,
        463.80328369140625,
        271.05401611328125,
        474.8432922363281
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "10. Linnet, K and Kondratovich, M. A Partly Noparametric Approach",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        507.8432922363281,
        488.3565368652344,
        518.88330078125
      ],
      "page_num": 75,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "for Determination of the Llimit of Detection. Clinical Chemistry",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        133.0800018310547,
        529.80322265625,
        488.3568115234375,
        540.84326171875
      ],
      "page_num": 75,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2004:50;732-740",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        133.0800018310547,
        551.8832397460938,
        226.40013122558594,
        562.9232788085938
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        98.04000091552734,
        117.91441345214844,
        448.0853271484375,
        126.91441345214844
      ],
      "page_num": 76,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 70 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 76,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅸ",
      "font_size": 21.959999084472656,
      "font_name": "T12",
      "bbox": [
        116.39999389648438,
        160.67999267578125,
        202.0800018310547,
        187.03199768066406
      ],
      "page_num": 76,
      "block_type": "heading",
      "level": 1,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "부록",
      "font_size": 18.0,
      "font_name": "H2hdrM",
      "bbox": [
        116.39999389648438,
        160.67999267578125,
        202.0800018310547,
        187.03199768066406
      ],
      "page_num": 76,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 뇌나트륨이뇨펩티드 제품 국내 제조 및 수입 현황",
      "font_size": 12.0,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        248.89920043945312,
        402.9599914550781,
        260.8992004394531
      ],
      "page_num": 76,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검사법",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        141.239990234375,
        286.65032958984375,
        171.23951721191406,
        296.6103210449219
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "BNP / NT-proBNP",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        295.32000732421875,
        275.9703369140625,
        387.825439453125,
        285.9303283691406
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시약명",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        265.0799865722656,
        297.3303527832031,
        483.4200134277344,
        307.29034423828125
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제조사",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        265.0799865722656,
        297.3303527832031,
        483.4200134277344,
        307.29034423828125
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제조국",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        265.0799865722656,
        297.3303527832031,
        483.4200134277344,
        307.29034423828125
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "MEIA",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        121.79999542236328,
        316.53033447265625,
        453.9901123046875,
        326.4903259277344
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AxSYM BNP  IMMUNOASSAY",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        121.79999542236328,
        316.53033447265625,
        453.9901123046875,
        326.4903259277344
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Abbott",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        121.79999542236328,
        316.53033447265625,
        453.9901123046875,
        326.4903259277344
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "UK",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        121.79999542236328,
        316.53033447265625,
        453.9901123046875,
        326.4903259277344
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "면역분석법",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        121.79999542236328,
        333.9303283691406,
        483.55548095703125,
        350.2503356933594
      ],
      "page_num": 76,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Roche CARDIAC proBNP+",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        121.79999542236328,
        333.9303283691406,
        483.55548095703125,
        350.2503356933594
      ],
      "page_num": 76,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Roche",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        121.79999542236328,
        333.9303283691406,
        483.55548095703125,
        350.2503356933594
      ],
      "page_num": 76,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Germany",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        121.79999542236328,
        333.9303283691406,
        483.55548095703125,
        350.2503356933594
      ],
      "page_num": 76,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Roche CARDIAC proBNP",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        195.59999084472656,
        349.17034912109375,
        483.55548095703125,
        359.1303405761719
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Roche",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        195.59999084472656,
        349.17034912109375,
        483.55548095703125,
        359.1303405761719
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Germany",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        195.59999084472656,
        349.17034912109375,
        483.55548095703125,
        359.1303405761719
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "고형상 면역",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        121.79999542236328,
        363.9303283691406,
        180.19627380371094,
        373.89031982421875
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "크로마토그래",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        121.79999542236328,
        380.0103454589844,
        181.79904174804688,
        389.9703369140625
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "피",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        121.79999542236328,
        395.9703369140625,
        131.75999450683594,
        405.9303283691406
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "StatusFirst™ CHF NT-proBNP",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        195.59999084472656,
        380.0103454589844,
        345.9454345703125,
        389.9703369140625
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Princeton",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        369.47998046875,
        362.0103454589844,
        416.4774169921875,
        371.9703369140625
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "BioMeditech",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        369.47998046875,
        380.0103454589844,
        430.15948486328125,
        389.9703369140625
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Corporation",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        369.47998046875,
        398.0103454589844,
        423.10986328125,
        407.9703369140625
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "USA",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        439.0799865722656,
        380.0103454589844,
        460.23004150390625,
        389.9703369140625
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ELFA",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        121.79999542236328,
        410.7303466796875,
        470.2689208984375,
        420.6903381347656
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "VIDAS NT-proBNP",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        121.79999542236328,
        410.7303466796875,
        470.2689208984375,
        420.6903381347656
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "bioMerieux",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        121.79999542236328,
        410.7303466796875,
        470.2689208984375,
        420.6903381347656
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "France",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        121.79999542236328,
        410.7303466796875,
        470.2689208984375,
        420.6903381347656
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "FIA",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        121.79999542236328,
        423.5703430175781,
        460.23004150390625,
        433.53033447265625
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Alere Triage BNP/NT-proBNP",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        121.79999542236328,
        423.5703430175781,
        460.23004150390625,
        433.53033447265625
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Alere",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        121.79999542236328,
        423.5703430175781,
        460.23004150390625,
        433.53033447265625
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "USA",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        121.79999542236328,
        423.5703430175781,
        460.23004150390625,
        433.53033447265625
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Beckman Coulter Immunoassay",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        193.55999755859375,
        436.3232727050781,
        359.4779052734375,
        447.36328125
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "System BNP Test",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        193.55999755859375,
        445.2032775878906,
        460.23004150390625,
        465.0032958984375
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Alere",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        193.55999755859375,
        445.2032775878906,
        460.23004150390625,
        465.0032958984375
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "USA",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        193.55999755859375,
        445.2032775878906,
        460.23004150390625,
        465.0032958984375
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ADVIA Centaur B-type",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        193.55999755859375,
        467.7632751464844,
        322.75628662109375,
        478.80328369140625
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Natriuretic Peptide (BNP)",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        193.55999755859375,
        485.40325927734375,
        340.15631103515625,
        496.4432678222656
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Siemens",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        369.47998046875,
        476.5232849121094,
        483.55548095703125,
        487.56329345703125
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Germany",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        369.47998046875,
        476.5232849121094,
        483.55548095703125,
        487.56329345703125
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ARCHITECT BNP",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        193.55999755859375,
        499.2032775878906,
        460.23004150390625,
        510.2432861328125
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Abbott",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        193.55999755859375,
        499.2032775878906,
        460.23004150390625,
        510.2432861328125
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "USA",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        193.55999755859375,
        499.2032775878906,
        460.23004150390625,
        510.2432861328125
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AIA BNP",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        193.55999755859375,
        513.0032348632812,
        464.3885192871094,
        524.0432739257812
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Tosoh",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        193.55999755859375,
        513.0032348632812,
        464.3885192871094,
        524.0432739257812
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Japan",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        193.55999755859375,
        513.0032348632812,
        464.3885192871094,
        524.0432739257812
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Elecsys ProBNP II",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        193.55999755859375,
        526.80322265625,
        483.55548095703125,
        537.84326171875
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Roche",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        193.55999755859375,
        526.80322265625,
        483.55548095703125,
        537.84326171875
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Germany",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        193.55999755859375,
        526.80322265625,
        483.55548095703125,
        537.84326171875
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Dimension Vista System Flex",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        193.55999755859375,
        540.603271484375,
        352.9963073730469,
        551.643310546875
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Reagent cartridge N-terminal",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        193.55999755859375,
        558.2432250976562,
        353.4775390625,
        569.2832641601562
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "pro-Brain Natriuretic Peptide",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        193.55999755859375,
        575.8832397460938,
        358.8758239746094,
        586.9232788085938
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Siemens",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        369.47998046875,
        558.2432250976562,
        483.55548095703125,
        569.2832641601562
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Germany",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        369.47998046875,
        558.2432250976562,
        483.55548095703125,
        569.2832641601562
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Vitros  NT-proBNP",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        193.55999755859375,
        589.6832275390625,
        460.23004150390625,
        600.7232666015625
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "J&J",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        193.55999755859375,
        589.6832275390625,
        460.23004150390625,
        600.7232666015625
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "USA",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        193.55999755859375,
        589.6832275390625,
        460.23004150390625,
        600.7232666015625
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "VIDAS NT-proBNP",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        193.55999755859375,
        603.4832153320312,
        470.2689208984375,
        614.5232543945312
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "bioMerieux",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        193.55999755859375,
        603.4832153320312,
        470.2689208984375,
        614.5232543945312
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "France",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        193.55999755859375,
        603.4832153320312,
        470.2689208984375,
        614.5232543945312
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Pathfast NT-proBNP",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        193.55999755859375,
        617.2832641601562,
        464.3885192871094,
        628.3233032226562
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Mitsubishi",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        193.55999755859375,
        617.2832641601562,
        464.3885192871094,
        628.3233032226562
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Japan",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        193.55999755859375,
        617.2832641601562,
        464.3885192871094,
        628.3233032226562
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AQT90 FLEX NT-proBNP",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        193.55999755859375,
        631.083251953125,
        479.74884033203125,
        642.123291015625
      ],
      "page_num": 76,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Radiometer",
      "font_size": 11.039999961853027,
      "font_name": "Haansoft Batang",
      "bbox": [
        193.55999755859375,
        631.083251953125,
        479.74884033203125,
        642.123291015625
      ],
      "page_num": 76,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Denmark",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        193.55999755859375,
        631.083251953125,
        479.74884033203125,
        642.123291015625
      ],
      "page_num": 76,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅸ. 부록",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        450.8399963378906,
        117.55441284179688,
        481.4460144042969,
        126.55441284179688
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 71 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 77,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3. 미국 FDA에 등록되어 있는 뇌나트륨이뇨펩티드(NT-proBNP,",
      "font_size": 12.0,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        155.7792205810547,
        488.67608642578125,
        167.7792205810547
      ],
      "page_num": 77,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "BNP) 제품 목록 (2013년 9월 현재)",
      "font_size": 12.0,
      "font_name": "Haansoft Batang",
      "bbox": [
        110.5199966430664,
        179.7792205810547,
        314.03997802734375,
        191.7792205810547
      ],
      "page_num": 77,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Document",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        118.68000030517578,
        210.9303436279297,
        167.7171173095703,
        220.89035034179688
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "No",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        135.1199951171875,
        210.9303436279297,
        470.4764709472656,
        230.85035705566406
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Device name",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        135.1199951171875,
        210.9303436279297,
        470.4764709472656,
        230.85035705566406
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Company",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        135.1199951171875,
        210.9303436279297,
        470.4764709472656,
        230.85035705566406
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Date",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        135.1199951171875,
        210.9303436279297,
        470.4764709472656,
        230.85035705566406
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "approved",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        435.8399963378906,
        220.89035034179688,
        477.3504943847656,
        230.85035705566406
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "K092649",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        120.23999786376953,
        252.45034790039062,
        162.76731872558594,
        262.41033935546875
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ELECSYS PROBNP II STAT",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        174.72000122070312,
        242.49034118652344,
        334.0391540527344,
        272.4903259277344
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "IMMUNOASSAY AND ELECSYS",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        174.72000122070312,
        242.49034118652344,
        334.0391540527344,
        272.4903259277344
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "PROBNP II CALSET",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        174.72000122070312,
        242.49034118652344,
        334.0391540527344,
        272.4903259277344
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ROCHE",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        344.6399841308594,
        242.49034118652344,
        418.3948974609375,
        272.4903259277344
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "DIAGNOSTICS",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        344.6399841308594,
        242.49034118652344,
        418.3948974609375,
        272.4903259277344
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "CORP",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        344.6399841308594,
        242.49034118652344,
        418.3948974609375,
        272.4903259277344
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "02/04/2010",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        429.8399963378906,
        252.45034790039062,
        483.1668395996094,
        262.41033935546875
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "K063662",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        120.23999786376953,
        289.17034912109375,
        312.2731628417969,
        299.1303405761719
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "RAMP NT-PROBNP ASSAY",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        120.23999786376953,
        289.17034912109375,
        312.2731628417969,
        299.1303405761719
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "RESPONSE",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        344.6399841308594,
        279.09033203125,
        412.6370544433594,
        309.09033203125
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "BIOMEDICAL",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        344.6399841308594,
        279.09033203125,
        412.6370544433594,
        309.09033203125
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "CORP",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        344.6399841308594,
        279.09033203125,
        412.6370544433594,
        309.09033203125
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "07/21/2008",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        429.8399963378906,
        289.17034912109375,
        483.1668395996094,
        299.1303405761719
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "K080578",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        120.23999786376953,
        336.9303283691406,
        162.76731872558594,
        346.89031982421875
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "DIMENSION VISTA",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        174.72000122070312,
        311.9703369140625,
        314.4768981933594,
        371.9703369140625
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-TERMINAL PRO-BRAIN",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        174.72000122070312,
        311.9703369140625,
        314.4768981933594,
        371.9703369140625
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "NATRIURETIC PEPTIDE",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        174.72000122070312,
        311.9703369140625,
        314.4768981933594,
        371.9703369140625
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(PBNP) FLEX REAGENT",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        174.72000122070312,
        311.9703369140625,
        314.4768981933594,
        371.9703369140625
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "CARTRIDGE (K6423A),",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        174.72000122070312,
        311.9703369140625,
        314.4768981933594,
        371.9703369140625
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "DIMENSION VISTA",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        174.72000122070312,
        311.9703369140625,
        314.4768981933594,
        371.9703369140625
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SIEMENS",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        344.6399841308594,
        317.0103454589844,
        418.5164794921875,
        356.9703369140625
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "HEALTHCARE",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        344.6399841308594,
        317.0103454589844,
        418.5164794921875,
        356.9703369140625
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "DIAGNOSTICS",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        344.6399841308594,
        317.0103454589844,
        418.5164794921875,
        356.9703369140625
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "INC",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        344.6399841308594,
        317.0103454589844,
        418.5164794921875,
        356.9703369140625
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "05/16/2008",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        429.8399963378906,
        336.9303283691406,
        483.1668395996094,
        346.89031982421875
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "K073091",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        120.23999786376953,
        376.8903503417969,
        483.1668395996094,
        396.8103332519531
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "VIDAS NT-PROBNP ASSAY",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        120.23999786376953,
        376.8903503417969,
        483.1668395996094,
        396.8103332519531
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "BIOMERIEUX,",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        120.23999786376953,
        376.8903503417969,
        483.1668395996094,
        396.8103332519531
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "INC.",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        120.23999786376953,
        376.8903503417969,
        483.1668395996094,
        396.8103332519531
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "02/29/2008",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        120.23999786376953,
        376.8903503417969,
        483.1668395996094,
        396.8103332519531
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "K072189",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        120.23999786376953,
        401.7303466796875,
        483.1668395996094,
        421.77032470703125
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "PATHFAST NTPROBNP AND",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        120.23999786376953,
        401.7303466796875,
        483.1668395996094,
        421.77032470703125
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "D-DIMER TESTS",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        120.23999786376953,
        401.7303466796875,
        483.1668395996094,
        421.77032470703125
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "helen landicho",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        120.23999786376953,
        401.7303466796875,
        483.1668395996094,
        421.77032470703125
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "02/05/2008",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        120.23999786376953,
        401.7303466796875,
        483.1668395996094,
        421.77032470703125
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "K071834",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        120.23999786376953,
        425.1303405761719,
        318.6769714355469,
        445.0503234863281
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "STRATUS CS ACUTE CARE",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        120.23999786376953,
        425.1303405761719,
        318.6769714355469,
        445.0503234863281
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "NT-PROBNP TESTPAK",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        120.23999786376953,
        425.1303405761719,
        318.6769714355469,
        445.0503234863281
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "DADE BEHRING,",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        344.6399841308594,
        425.1303405761719,
        483.1668395996094,
        445.0503234863281
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "INC.",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        344.6399841308594,
        425.1303405761719,
        483.1668395996094,
        445.0503234863281
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "08/17/2007",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        344.6399841308594,
        425.1303405761719,
        483.1668395996094,
        445.0503234863281
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "K071767",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        120.23999786376953,
        452.4903259277344,
        305.59716796875,
        472.41033935546875
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "DIMENSIONS PBNP FLEX",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        120.23999786376953,
        452.4903259277344,
        305.59716796875,
        472.41033935546875
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "REAGENT CARTRIDGE",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        120.23999786376953,
        452.4903259277344,
        305.59716796875,
        472.41033935546875
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "DADE BEHRING,",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        344.6399841308594,
        452.4903259277344,
        483.1668395996094,
        472.41033935546875
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "INC",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        344.6399841308594,
        452.4903259277344,
        483.1668395996094,
        472.41033935546875
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "08/04/2007",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        344.6399841308594,
        452.4903259277344,
        483.1668395996094,
        472.41033935546875
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "K053597",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        120.23999786376953,
        479.2503356933594,
        331.1408386230469,
        499.2903137207031
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "I-STAT B-TYPE",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        120.23999786376953,
        479.2503356933594,
        331.1408386230469,
        499.2903137207031
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "NATRIURETIC PEPTIDE (BNP)",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        120.23999786376953,
        479.2503356933594,
        331.1408386230469,
        499.2903137207031
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "I-STAT",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        344.6399841308594,
        479.2503356933594,
        483.1668395996094,
        499.2903137207031
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "CORPORATION",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        344.6399841308594,
        479.2503356933594,
        483.1668395996094,
        499.2903137207031
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "07/21/2006",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        344.6399841308594,
        479.2503356933594,
        483.1668395996094,
        499.2903137207031
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "K060632",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        120.23999786376953,
        522.0903930664062,
        162.76731872558594,
        532.0503540039062
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "VITROS IMMUNODIAGNOSTIC",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        174.72000122070312,
        502.17034912109375,
        329.8350830078125,
        552.09033203125
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "PRODUCTS NT PRO-BNP",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        174.72000122070312,
        502.17034912109375,
        329.8350830078125,
        552.09033203125
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "REAGENT",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        174.72000122070312,
        502.17034912109375,
        329.8350830078125,
        552.09033203125
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "PACK,CALIBRATORS,RANGE",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        174.72000122070312,
        502.17034912109375,
        329.8350830078125,
        552.09033203125
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "VERIFIERS",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        174.72000122070312,
        502.17034912109375,
        329.8350830078125,
        552.09033203125
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ORTHO-CLINIC",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        344.6399841308594,
        507.0903625488281,
        423.5124206542969,
        547.0503540039062
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AL",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        344.6399841308594,
        507.0903625488281,
        423.5124206542969,
        547.0503540039062
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "DIAGNOSTICS,",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        344.6399841308594,
        507.0903625488281,
        423.5124206542969,
        547.0503540039062
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "INC",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        344.6399841308594,
        507.0903625488281,
        423.5124206542969,
        547.0503540039062
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "06/06/2006",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        429.8399963378906,
        522.0903930664062,
        483.1668395996094,
        532.0503540039062
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "K060964",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        120.23999786376953,
        555.3303833007812,
        483.1668395996094,
        565.2903442382812
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ARCHITECT BNP ASSAY",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        120.23999786376953,
        555.3303833007812,
        483.1668395996094,
        565.2903442382812
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "diana l wolaniuk",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        120.23999786376953,
        555.3303833007812,
        483.1668395996094,
        565.2903442382812
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "05/25/2006",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        120.23999786376953,
        555.3303833007812,
        483.1668395996094,
        565.2903442382812
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "K060548",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        120.23999786376953,
        583.4103393554688,
        162.76731872558594,
        593.3703002929688
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "STRATUS CS ACUTE CARE",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        174.72000122070312,
        568.4103393554688,
        329.0696716308594,
        608.3703002929688
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "BETAHCG AND NT-PROBNP",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        174.72000122070312,
        568.4103393554688,
        329.0696716308594,
        608.3703002929688
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "TESTPAK AND TESTPAK",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        174.72000122070312,
        568.4103393554688,
        329.0696716308594,
        608.3703002929688
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ASSAY, CALPAK AND DILPAK",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        174.72000122070312,
        568.4103393554688,
        329.0696716308594,
        608.3703002929688
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "DADE BEHRING,",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        344.6399841308594,
        578.4903564453125,
        483.1668395996094,
        598.4103393554688
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "INC.",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        344.6399841308594,
        578.4903564453125,
        483.1668395996094,
        598.4103393554688
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "04/06/2006",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        344.6399841308594,
        578.4903564453125,
        483.1668395996094,
        598.4103393554688
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "K051596",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        120.23999786376953,
        621.2103881835938,
        162.76731872558594,
        631.1703491210938
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "STATUSFIRST CHF",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        174.72000122070312,
        611.2503662109375,
        293.1446838378906,
        641.2503051757812
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(CONGESTIVE HEART",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        174.72000122070312,
        611.2503662109375,
        293.1446838378906,
        641.2503051757812
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "FAILURE) NT-PROBNP",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        174.72000122070312,
        611.2503662109375,
        293.1446838378906,
        641.2503051757812
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "NANOGEN, INC. 03/13/2006",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        344.6399841308594,
        621.2103881835938,
        483.1668395996094,
        631.1703491210938
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "K052789",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        120.23999786376953,
        654.0903930664062,
        162.76731872558594,
        664.0503540039062
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "TRIAGE BNP TEST FOR",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        174.72000122070312,
        644.13037109375,
        306.825439453125,
        674.0103149414062
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "BECKMAN COULTER",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        174.72000122070312,
        644.13037109375,
        306.825439453125,
        674.0103149414062
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "IMMUNOASSAY SYSTEMS",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        174.72000122070312,
        644.13037109375,
        306.825439453125,
        674.0103149414062
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "BIOSITE",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        344.6399841308594,
        649.0503540039062,
        483.1668395996094,
        669.09033203125
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "INCORPORATED 01/23/2006",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        344.6399841308594,
        649.0503540039062,
        483.1668395996094,
        669.09033203125
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        98.04000091552734,
        117.91441345214844,
        448.0853271484375,
        126.91441345214844
      ],
      "page_num": 78,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 72 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        721.2903442382812,
        314.625,
        731.2503051757812
      ],
      "page_num": 78,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "K051787",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        120.23999786376953,
        170.13034057617188,
        483.1668395996094,
        190.05035400390625
      ],
      "page_num": 78,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "TRIAGE BNP TEST",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        120.23999786376953,
        170.13034057617188,
        483.1668395996094,
        190.05035400390625
      ],
      "page_num": 78,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "BIOSITE",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        120.23999786376953,
        170.13034057617188,
        483.1668395996094,
        190.05035400390625
      ],
      "page_num": 78,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "INCORPORATED 09/22/2005",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        120.23999786376953,
        170.13034057617188,
        483.1668395996094,
        190.05035400390625
      ],
      "page_num": 78,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "K051265",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        120.23999786376953,
        219.33033752441406,
        162.76731872558594,
        229.29034423828125
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ADVIA IMMUNO MODULAR",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        174.72000122070312,
        204.33033752441406,
        334.5173645019531,
        244.29034423828125
      ],
      "page_num": 78,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "SYSTEM (IMS) B-TYPE",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        174.72000122070312,
        204.33033752441406,
        334.5173645019531,
        244.29034423828125
      ],
      "page_num": 78,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "NATRIURETIC PEPTIDE (BNP)",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        174.72000122070312,
        204.33033752441406,
        334.5173645019531,
        244.29034423828125
      ],
      "page_num": 78,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "ASSAY",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        174.72000122070312,
        204.33033752441406,
        334.5173645019531,
        244.29034423828125
      ],
      "page_num": 78,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "BAYER",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        344.6399841308594,
        209.37034606933594,
        421.39691162109375,
        239.37034606933594
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "HEALTHCARE,",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        344.6399841308594,
        209.37034606933594,
        421.39691162109375,
        239.37034606933594
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "LLC",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        344.6399841308594,
        209.37034606933594,
        421.39691162109375,
        239.37034606933594
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "06/13/2005",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        429.8399963378906,
        219.33033752441406,
        483.1668395996094,
        229.29034423828125
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "K043584",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        120.23999786376953,
        257.2503356933594,
        310.6643981933594,
        267.2103271484375
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "LIQUICHEK BNP CONTROL",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        120.23999786376953,
        257.2503356933594,
        310.6643981933594,
        267.2103271484375
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "BIO-RAD",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        344.6399841308594,
        247.17034912109375,
        424.3061218261719,
        277.1703186035156
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "LABORATORIES",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        344.6399841308594,
        247.17034912109375,
        424.3061218261719,
        277.1703186035156
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": ", INC.",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        344.6399841308594,
        247.17034912109375,
        424.3061218261719,
        277.1703186035156
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "02/08/2005",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        429.8399963378906,
        257.2503356933594,
        483.1668395996094,
        267.2103271484375
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "K033606",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        120.23999786376953,
        295.05035400390625,
        162.76731872558594,
        305.0103454589844
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ABBOTT AXSYM B-TYPE",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        174.72000122070312,
        280.05035400390625,
        334.5173645019531,
        320.0103454589844
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "NATRIURETIC PEPTIDE (BNP)",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        174.72000122070312,
        280.05035400390625,
        334.5173645019531,
        320.0103454589844
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "MICROPARTICLE ENZYME",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        174.72000122070312,
        280.05035400390625,
        334.5173645019531,
        320.0103454589844
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "IMMUNOASSAY (MEIA) TEST",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        174.72000122070312,
        280.05035400390625,
        334.5173645019531,
        320.0103454589844
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AXIS-SHIELD",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        344.6399841308594,
        284.9703369140625,
        421.3948669433594,
        314.9703369140625
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "DIAGNOSTICS,",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        344.6399841308594,
        284.9703369140625,
        421.3948669433594,
        314.9703369140625
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "LTD.",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        344.6399841308594,
        284.9703369140625,
        421.3948669433594,
        314.9703369140625
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "01/30/2004",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        429.8399963378906,
        295.05035400390625,
        483.1668395996094,
        305.0103454589844
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "K032335",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        120.23999786376953,
        327.8103332519531,
        336.9178161621094,
        347.850341796875
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "MAS CARDIOIMMUNE PROBNP,",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        120.23999786376953,
        327.8103332519531,
        336.9178161621094,
        347.850341796875
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "MAS CARDIOIMMUNE TL",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        120.23999786376953,
        327.8103332519531,
        336.9178161621094,
        347.850341796875
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "MEDICAL",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        344.6399841308594,
        322.8903503417969,
        419.1932067871094,
        352.77032470703125
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ANALYSIS",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        344.6399841308594,
        322.8903503417969,
        419.1932067871094,
        352.77032470703125
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SYSTEMS, INC",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        344.6399841308594,
        322.8903503417969,
        419.1932067871094,
        352.77032470703125
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "08/19/2003",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        429.8399963378906,
        332.850341796875,
        483.1668395996094,
        342.8103332519531
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "K031038",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        120.23999786376953,
        365.6103515625,
        162.76731872558594,
        375.5703430175781
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ADVIA CENTAUR B-TYPE",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        174.72000122070312,
        355.65032958984375,
        334.5173645019531,
        385.65032958984375
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "NATRIURETIC PEPTIDE (BNP)",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        174.72000122070312,
        355.65032958984375,
        334.5173645019531,
        385.65032958984375
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ASSAY",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        174.72000122070312,
        355.65032958984375,
        334.5173645019531,
        385.65032958984375
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "BAYER",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        344.6399841308594,
        355.65032958984375,
        421.39691162109375,
        385.65032958984375
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "HEALTHCARE,",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        344.6399841308594,
        355.65032958984375,
        421.39691162109375,
        385.65032958984375
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "LLC",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        344.6399841308594,
        355.65032958984375,
        421.39691162109375,
        385.65032958984375
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "06/23/2003",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        429.8399963378906,
        365.6103515625,
        483.1668395996094,
        375.5703430175781
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "K031364",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        120.23999786376953,
        403.53033447265625,
        162.76731872558594,
        413.4903259277344
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "MAS CARDIOLMMUNE PROBNP",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        174.72000122070312,
        388.53033447265625,
        338.5971374511719,
        428.4903259277344
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "LIQUID ASSAYED CARDIAC",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        174.72000122070312,
        388.53033447265625,
        338.5971374511719,
        428.4903259277344
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "MARKER CONTROL LEVEL 1, 2",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        174.72000122070312,
        388.53033447265625,
        338.5971374511719,
        428.4903259277344
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AND 3",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        174.72000122070312,
        388.53033447265625,
        338.5971374511719,
        428.4903259277344
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "MEDICAL",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        344.6399841308594,
        393.4503479003906,
        419.1932067871094,
        423.4503173828125
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ANALYSIS",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        344.6399841308594,
        393.4503479003906,
        419.1932067871094,
        423.4503173828125
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SYSTEMS, INC",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        344.6399841308594,
        393.4503479003906,
        419.1932067871094,
        423.4503173828125
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "05/30/2003",
      "font_size": 9.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        429.8399963378906,
        403.53033447265625,
        483.1668395996094,
        413.4903259277344
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ⅸ. 부록",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        450.8399963378906,
        117.55441284179688,
        481.4460144042969,
        126.55441284179688
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단용 의료기기 중 심근혈관표지자",
      "font_size": 15.718777656555176,
      "font_name": "T4",
      "bbox": [
        158.51998901367188,
        322.79998779296875,
        438.1225891113281,
        341.95196533203125
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "뇌나트륨이뇨펩티드 검사제품의 허가․심사",
      "font_size": 15.718777656555176,
      "font_name": "T4",
      "bbox": [
        147.0,
        348.3599853515625,
        449.7608947753906,
        367.511962890625
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가이드라인 [민원인 안내서]",
      "font_size": 15.718777656555176,
      "font_name": "T4",
      "bbox": [
        203.63999938964844,
        373.9200134277344,
        393.0767517089844,
        393.0719909667969
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        117.0,
        398.479736328125,
        279.1190490722656,
        411.727294921875
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "행",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        117.0,
        398.479736328125,
        279.1190490722656,
        411.727294921875
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "처 식품의약품안전처",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        117.0,
        398.479736328125,
        279.1190490722656,
        411.727294921875
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        117.0,
        422.5997619628906,
        251.75999450683594,
        435.8473205566406
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "행",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        117.0,
        422.5997619628906,
        251.75999450683594,
        435.8473205566406
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일 2014년 5월",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        117.0,
        422.5997619628906,
        251.75999450683594,
        435.8473205566406
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        117.0,
        446.7197570800781,
        229.0800018310547,
        459.9673156738281
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "행",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        117.0,
        446.7197570800781,
        229.0800018310547,
        459.9673156738281
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        117.0,
        446.7197570800781,
        229.0800018310547,
        459.9673156738281
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "왕진호",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        117.0,
        446.7197570800781,
        229.0800018310547,
        459.9673156738281
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "편 집 위 원 장 정희교",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        117.0,
        470.8397521972656,
        229.0800018310547,
        484.0873107910156
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "편 집 위 원",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        117.0,
        498.79974365234375,
        442.68084716796875,
        512.0473022460938
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "오현주, 이원규, 김정환, 안영욱, 우승민, 김수영, 김현준",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        117.0,
        498.79974365234375,
        442.68084716796875,
        512.0473022460938
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "문",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        117.0,
        535.0397338867188,
        481.7017822265625,
        549.4873657226562
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        117.0,
        535.0397338867188,
        481.7017822265625,
        549.4873657226562
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "처",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        117.0,
        535.0397338867188,
        481.7017822265625,
        549.4873657226562
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187.",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        117.0,
        535.0397338867188,
        481.7017822265625,
        549.4873657226562
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "오송보건의료행정타운 식품의약품안전평가원",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        199.1999969482422,
        557.479736328125,
        407.66015625,
        570.7273559570312
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기심사부 체외진단기기과",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        199.1999969482422,
        574.7597045898438,
        344.1590576171875,
        588.00732421875
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전화: 043-719-4652~4665",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        199.1999969482422,
        592.1597290039062,
        318.8033447265625,
        605.4073486328125
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "팩스: 043-719-4650",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        199.1999969482422,
        609.439697265625,
        289.76397705078125,
        622.6873168945312
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인",
      "font_size": 8.759956359863281,
      "font_name": "H2hdrM",
      "bbox": [
        98.04000091552734,
        117.91441345214844,
        448.0853271484375,
        126.91441345214844
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187.",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        124.91999816894531,
        520.8194580078125,
        470.2649841308594,
        536.7803955078125
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "식품의약품안전평가원 의료기기심사부 체외진단기기과",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        147.59999084472656,
        540.0194702148438,
        447.5999755859375,
        555.9804077148438
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "TEL : 043-719-4652~4665  FAX : 043-719-4650",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        164.0399932861328,
        559.2194213867188,
        431.16937255859375,
        575.1803588867188
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "http://www.mfds.go.kr",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        237.36000061035156,
        578.41943359375,
        357.8821716308594,
        594.38037109375
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "“내가 지킨 청렴실천 모아지면 청렴사회”",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        184.3199920654297,
        607.8194580078125,
        410.5401611328125,
        623.7803955078125
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    }
  ],
  "markdown_content": "체외진단용 의료기기\n\n<!-- PAGE_1 -->\n## 체외진단용 의료기기 중\n\n<!-- PAGE_1 -->\n## 뇌나트륨이뇨펩티드 검사제품의\n\n<!-- PAGE_1 -->\n## 허가․심사 가이드라인\n\n<!-- PAGE_1 -->\n## [민원인 안내서]\n\n- 2018. 7.\n발간등록번호\n\n안내서-0638-02\n\n제·개정 이력서\n\n<!-- PAGE_2 -->\n###### 체외진단용 의료기기 중 뇌나트륨이뇨펩티드\n\n<!-- PAGE_2 -->\n###### 검사제품 허가․심사 가이드라인 [민원인 안내서]\n\n제․개정번호\n\n승인일자\n\n주요 내용\n\n뇌나트륨이뇨펩티드 검사제품의 허가․심사\n\n가이드라인 제정\n\n**[표 시작]**\n\n| 알파 심방성 나트륨 이뇨 | 펩티드(Alpha-ANP) 1-28 | 1,000pg/mL | 104% | ｢ | 체외진단용 의료기기 중 |\n| --- | --- | --- | --- | --- | --- |\n| Mode간의 | 등록대상 | 뇌나트륨이뇨펩티드 검사제품의 허가․심사 | 2. 기술문서에 관한 자료 | 16 | 5. 제품의 성능을 확인하기 위한 자료 | 44 |\n| 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다. | 나. 시험방법 | 라. 결과제시 | 1 | 품목명 | 5) 교차반응 | 2) 시험방법 | 2) 시험물질 | 4) 해당하는 경우 다음의 사항들을 기술한다. | 고 제품명은 두 개 이상 인정한다. | 2. 별도판매구성품 - proBNP CalSet | WHO와 ISO에서 사용되고 있다. | 제시한다. | (판정기준치 이상)으로 나오는 환자의 비율이다. | 제시한다. | ADVIA CENTAUR B-TYPE | NATRIURETIC PEPTIDE (BNP) | ASSAY | 보조성분 | Bovine serum albumin | 적량 | 자사규격 | BAYER | HEALTHCARE, | LLC |\n| ❍ 원재료 | 5. 시험성적서 발급일자 | 여부 | 4) 검체 보관조건, 방법 및 사용기간 등 | 1) 완제품의 최종 품질관리에 따른 성능시험을 포함한다. | 관계없는 기준이여야 함 | 성품(proBNP Calset)으로 구성된다. | 습도의 영향 등)을 명시한다. | 분석 자료 | 구체적으로 기재하여야 한다. | Factor(18.7)내에 들어와야 한다. | Princeton |\n| K031038 | 고형상 면역 | <제품명> | 4) 시험일자 및 시험성적서 발급일자 | (분류번호 및 등급) | 보조성분 | Mouse IgG | 적량 | 자사규격 |\n| 다. 임상적 성능시험에 관한 자료 | 인에 기인하기도 한다. | 비교 | 함되도록 한다. | 6. 체외진단용 의료기기의 취급자 안전에 관한 자료 | 44 | Prepro BNP 22-46 | 1,000pg/mL | 104% |\n| 구해진다. | 제시하고, 정량값 판정 등의 기준을 제시한다. | 가) 검사를 시행한 검체의 농도 | 같은 4가지 형태의 세트를 준비한다. | □ 1년 이내 한시적 적용 또는 일회성 지시ㆍ명령에 해당하는 | 건강한 사람 집단과 통계적인 차이가 없었다. | 가이드라인 [민원인 안내서] | 가이드라인 [민원인 안내서]｣ |\n| 크로마토그래 | 가. 일반사항 | 나. 시험방법 | 1. 품목류명 : 심질환표지자검사시약 | 2 | 명칭(모델명) | Standard Institute; 2004 | Ⅴ. 제조․수입허가 신청서 기재항목 | 17 | StatusFirst™ CHF NT-proBNP | 주성분 | Mouse monoclonal cardiac | BioMeditech | USA |\n| 안내서-0638-01 | 2017.5. | ❍ 제조방법 | 6. 시험성적서에 대한 책임 있는 자의 서명 또는 직인 | 나. 표준물질 관리방법 및 관리기록서(정도관리 포함) | 변경은 반드시 분해능(resolution)에 비하여 큰 차이여야 한다. | lot 이상의 시험성적서를 제출한다. | 5) 냉동 및 해동된 검체의 사용 가능성 및 제한점 | 5) 시험 책임자의 서명 또는 직인 | 새로운 경우 동일목적으로 사용되는 제품과 비교할 수 있다. | 일련번호 | 명 칭 | 세부 구성 | 외관상 특징 | 경우에는 세트별로 구분하여 기재한다. | 내용입니까? | 5th Percentile | 12 | 9 | 14 | 22 | 270 | 2 | 자사규격 |\n| 민족적 차이 | 7. 이미 허가·인증받은 제품과 비교한 자료..................45 | MAS CARDIOLMMUNE PROBNP | LIQUID ASSAYED CARDIAC | MARKER CONTROL LEVEL 1, 2 | AND 3 |\n| 피 | 2. 모델명 : BNP Test | 법의 평가 또는 물질에 값을 할당하기 위해서 사용되는 물질 | 위험을 미치지 않는 시험 및 잔여검체로 실시하는 시험은 제외) | 1. 체외진단용 의료기기 - proBNP test kit | Calibrator H, E, C를 이용하여 측정하였을 때 | Prepro BNP 1-21 | 1,000pg/mL | 106% | NT-proBNP antibody fragment | -비심장 질환 모집단(전체)- | MEDICAL | ANALYSIS | SYSTEMS, INC |\n| 마. 정도관리 | 으로 제출하여야 한다. | Device Studies -Frequently Asked Questions, 2010 | 기술한다. | 델명”을 각각 기재한다. | 가) 분석물질 양성(판정기준치 이상)인 검체(간섭물질 없음) | 나) 각각의 농도에서의 반복정밀도 표준편차 | 1. 명칭(제품명, 품목명, 모델명) | 17 | 제시한다. | 등을 제시한다. 유병률을 구한 경우는 유병률도 제시한다. | 토콜을 제시한다. | 한다. | 1 | Cal 1 | 단일구성 | 동결건조 시약 | 보이지 않았다. | Corporation |\n| K031364 | ❍ 사용목적(성능) | 3 | 제조(수입)업소명 | 6) 원심분리 조건 등을 포함한 검체 전처리과정 등 | 1) 임상적 민감도 | 결과판정 상 주의사항을 기재한다. | 보조성분 | HEPES Buffer | 적량 | 자사규격 | 전체 | <45세 | 45-54 | 55-64 |\n| 수 있음을 알려드립니다. | 3. 품목분류번호 : D04030.01 | CV 값이 다음의 기준을 만족해야 한다. | [근거: ｢ | 식품의약품안전처 지침서등의 |\n| 3 | Reagent 3 | 기간)을 기재한다. | 2 | Cal 2 | 단일구성 | 동결건조 시약 | 최소 (pg/mL) | 0 | 3 | 0 | 0 | 14 | 알기닌 바소프레신(AVP) | 1,000pg/mL | 96% | 세 | 세 | 세 |\n| 표6. 진단기준의 예 | 1) 사용자가 정도 관리를 할 수 있는 방법을 제시한다. | 검사의 특이도에 대한 자료를 제공해야 한다. | 2) 교차반응을 보이는 물질의 종류와 빈도를 제시한다. | 나) 분석물질 양성(판정기준치 이상)인 검체 + 간섭물질 | 다) 각각의 농도에서의 검사실내 정밀도 표준편차 | Ⅶ. 성능시험에 대한 상세사항 | 46 | 일련번호 | 명 칭 | 세부 구성 | 외관상 특징 | 판단한다. | 환자의 비율이다. | 등을 거칠 것을 권장한다. | 보조성분 | Oxypyrion | 적량 | 자사규격 |\n| K071834 | STRATUS CS ACUTE CARE | NT-PROBNP TESTPAK | FIA | Alere Triage BNP/NT-proBNP | Alere | USA | 4. 등급 : 3등급 | 4 | 제조원 및 소재지 | 2) 임상적 특이도 | ※ 예시 | 2. 모양 및 구조 | 18 | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | 적을 기재한다. | 검체수 (N) | 900 | 210 | 140 | 170 | 250 | 아브시심아브 | 도파민 | 니트로글리세린 | 관리에 관한 규정｣ | 개정, ‘17.5.1] |\n| ❍ 사용방법 | 나. 검사 전 준비사항 | 나. 시험기준 | 3. 정밀도 | 8. 시험검사 결과 | 3 | Bottle 1 | 단일구성 | 액상 시약 |\n| 5 | 검체보관 및 취급상(온도, 습도 등)의 조건 설정 근거자료 | 및 정성, 반정량 또는 정량 등을 구체적으로 기재한다. | 기로 임상적 성능시험의 결과를 확인할 수 없는 시험 | 정리한 자료입니까? | 테스트 | Calibrator H | Calibrator E | Calibrator C | Beckman Coulter Immunoassay | 보조성분 | Mouse IgG | 적량 | 자사규격 | 메디안 (pg/mL) | 20 | 20 | 10 | 25 | 20 | C형 나트륨 이뇨 펩티드(CNP) 53 | 1,000pg/mL | 106% |\n| 라) 반복정밀도 및 검사실내 정밀도 표준편차의 신뢰구간 | 1. 분석적 성능시험에 관한 자료 | 47 | 제시한다. | 알고 있는 물질의 사용을 권장한다. | 아세트아미노펜 | 말레인산에날라프릴 | 노라민피린 |\n| 가. 시험물질 | 나. 시험물질 | (수출용 의료기기 제외) 불가 | 다) 분석물질 음성(판정기준치 이하)인 검체(간섭물질 없음) | 3. 원재료 | 22 | 4 | Bottle 2 | 단일구성 | 액상 시약 | System BNP Test | Alere | USA | 평균 (pg/mL) | 40 | 30 | 20 | 40 | 50 | -심장 질환 모집단(여성)- |\n| K071767 | DIMENSIONS PBNP FLEX | REAGENT CARTRIDGE | ❍ 사용 시 주의사항 | 료를 포함한다. | 5 | 허가번호 | 확인할 수 있는 자료를 제출한다. | 포함된 논문, 문헌 등의 자료를 제출한다. | 및 위음성도) 등을 기재한다. | 전처리가 필요한 경우에 한함) | 따라 통계적으로 의미 있는 검체수를 산정한다. | ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다. | 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다. | 보조성분 | Bovine serum albumin | 적량 | 자사규격 | ｢체외진단용 의료기기 중 |\n| 아세틸살리실산 | 디피리다몰 | 옥사제팜 | Prepro-ANF 56-92 | 1,000pg/mL | 104% |\n| 나 또는 그 이상의 값을 갖는 참고물질 | 또는 1배치 3회 이상) | 임상적 | 민감도 | BNP | ≤12.5% | ≤15.2% | ≤20.9% | SD (pg/mL) | 70 | 40 | 30 | 50 | 80 | NYHA Functional Class |\n| 배경을 제시한다. | abbreviated 510(k)s, 2005. | chronic heart failure 2012 | 1) 다양한 교차 반응 가능 물질이 포함된 검체 | 기준 값에 적합함을 확인하는 과정을 제공한다. | 라) 분석물질 음성(판정기준치 이하)인 검체 + 간섭물질 | 마) 실제 검사일수, 검사실의 수 | 4. 제조방법 | 24 | 2. 임상적 성능시험에 관한 자료 | 57 | 검사가 이용될 인구집단을 대상으로 산출되어야 한다. | 있다. |\n| ❍ 포장단위 | 기구 및 조건 등을 기재한다. | 필요한 경우에 한함) | <외관사진> | ADVIA Centaur B-type | 95th Percentile | 140 | 90 | 80 | 120 | 160 | 기재한다. | 전체 | I | II | III | IV |\n| 마. 완제품 품질관리 시험에 사용된 표준물질에 관한 자료 | 5 | 8) 시험환경요인(시험결과에 영향을 주는 경우에 한함) | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정사무 |\n| 안내서-0638-02 | 2018.7. | 검체수 (N) | 320 | 60 | 140 | 96 | 24 | Prepro-ANF 104-123 | 1,000pg/mL | 97% | 가이드라인 [민원인 안내서]｣ 개정 |\n\n**[표 끝]**\n\n뇌나트륨이뇨펩티드 검사제품 허가․심사\n\n명칭 변경 및 제·개정 점검표 등 추가\n\n뇌나트륨이뇨펩티드 검사제품 허가․심사\n\n(현재 적용중인 의료기기 허가규정의 개정내용을\n\n반영)\n\n지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n체외진단용 의료기기 중 뇌나트륨이뇨펩티드 검사제품 허가·심사\n\n가이드라인 [민원인 안내서]\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n**[표 시작]**\n\n| 가. 표준품 또는 기타 사용된 표준물질의 확인서(certificate) | 등에 대한 시험성적서를 제출한다. | 적용할 수 있는 시험규격을 명시한다. | 시험항목 | 시험기준 | 시험방법 | 체외진단용 의료기기를 중심으로 사용방법을 기술한다. | 성능, 시험규격, 사용방법을 비교한 별제 제3호서식의 비교표 | 질 때 1:1의 비율로 나눠진다. 이들 펩타이드 수치가 증가하면 | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | 이용하여 결정하였다. | 보존제, 안정제 등 | □ 예 | ■ 아니오 | 02/04/2010 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| (주)오송진단 | 오송IVD | 심질환표지자검사시약 | BNP Test | Human Serum 5 | 5569.2 | 657 | 113 | 13.3 | 2.0 | 95th Percentile | 2200 | 1300 | 1600 | 2600 | >4000 | 비교방법 | 02/08/2005 |\n| 1 | Reagent 1 | 밀폐 등), 사용기간(유효기간) 등을 병기하여야 한다. | 관한 자료 | 41 | 지침서ㆍ안내서가 있습니까? | 1x6.5 mL | 보조성분 | HEPES Buffer | 적량 | 자사규격 | 1) 비심장질환 집단 | 32%로 구성되었다. AUC 결과는 0.87(0.85 ~ 0.90, 95% |\n| 나. 기재내용 | 나. 시험물질 | 다. 비교 제품은 각 제품의 사용방법에 따라서 시험한다. | 1) 분석적 민감도(판정기준치(cut-off value), 최소검출한계, 측정 | 등을 가지고 있는지에 대해 기재하고, 해당 전문기관에서 규정한 요 | 기술한다. | 어떻게 처리해야 하는지에 대한 지침을 제시한다. | 가져야 한다. | 인정할 수 있다. | C1T1C2T2C3T3C4T4C5T5). | Control 1 | 110 | 13.03 | 2.62 | 2.8 | 2.4 | 퍼센트 ≥100 pg/mL | 70.50% | 58.50% | 73.00% | 79.00% | 98.50% | 안지오텐신 I | 600pg/ml | 108% |\n| and Laboratory Standard Institute; 2009 | 서식에 따라 작성하여야 한다. | 제출한다. | 보조성분 | Oxypyrion1) | 적량 | 자사규격 | 혈색소, 지질(콜레스테롤, |\n| 가. 검체준비 및 저장방법 | 1. 업체명 및 주소 | 나. 출처 및 근거 자료 | 물질 및 폐기물 등) 취급 시 안전 등의 주의사항을 기재한다. | 있는 자료 포함 | Ⅲ. 관련 규정 | 14 | 심부전과 연관이 있게 되며 두 물질 모두 울혈성심부전 진단에 | 신뢰구간) 이었다. | 최소 (pg/mL) | 0 | 3 | 0 | 0 | 14 | 양성 | 음성 | 전체 | BNP / NT-proBNP | 육안으로 |\n| ⇩ | ⇩ | ⇩ | ⇩ | ABBOTT AXSYM B-TYPE | NATRIURETIC PEPTIDE (BNP) | MICROPARTICLE ENZYME | IMMUNOASSAY (MEIA) TEST | 심장질환으로 진단되지 않은 900명(465 여성, 435 남성)의 | Control 2 | 4200 | 495 | 91 | 10.7 | 2.2 | RESPONSE | BIOMEDICAL | CORP |\n| 검사법 | 2. 원재료 및 제조방법에 관한 자료 | 42 | 범위 등) | 고려하시기 바랍니다. 그럼에도 불구하고 동 지침서ㆍ안내서의 제정이 필요한 경 | 우 그 사유를 아래에 기재해 주시기 바랍니다. | 보조성분 | Bovine serum albumin | 적량 | 자사규격 | 최대 (pg/mL) | >4000 | 1650 | >4000 | >4000 | >4000 | 안지오텐신 II | 600pg/ml | 108% | AXIS-SHIELD | DIAGNOSTICS, | LTD. |\n| 나. 판정기준치(cut-off value) | 마. 대조물질의 제조방법, 설정 농도 및 반복 측정 결과를 기술한다. | 다. 결과제시 | 라. 정량검사의 경우 각 검사를 2회 이상 반복 측정을 권장한다. | 가) 그대로 보고하는지 재검사가 필요한지 여부 | 건에 적합한 시험자가 시험하였는지에 대한 자료를 제출 | 4) 결과제시 | 1) 3개 이상의 농도(컷오프 근처의 검체 포함) | 호흡곤란으로 응급실 내원한 환자, 입원환자 등). | 제시한다. | test)를 실시한다. | 사용할 수 있는 희석액을 명시하고, 그 근거를 제시해야 한다. | 제시한다. | 확인한다. | 트리글리세리드), 빌리루빈, 이상 단백질 | 07/21/2008 |\n| 다. 구성시약 중 유해물질이 포함될 경우 이에 대한 경고사항을 기재한다. | 다. 원료물질(단클론항체)의 기원에 관한 자료-기원 생물체, 클론번호 | 2. 시험성적서의 일련번호 및 각 페이지와 전체 페이지 번호 | 별표 2] 또는 이와 동등이상 규격의 멸균방법을 기재한다. | ※ 예시 | 1) 검체대상 및 채취방법 등 | 유용하게 사용된다. 이러한 뇌나트륨이뇨펩티드는 심정지와 | 혈장 검체를 본 제품으로 검사로 시험하였다. 이 모집단은 | 시약명 | 제조사 | 제조국 | 01/30/2004 | 확인한다. |\n| (제조․수입업소명) | (제품명) | (품목명) | (모델명) | 것으로 인정되는 시험자료 | 1) 업체명 및 주소 | 2) 분석적 특이도 | <본질적 동등품목 비교표> | 양성 | a | b | a + b | Mouse monoclonal cardiac | Intermediate precision |\n| 외국회사일 경우에는 제조국을 추가로 기재한다. | 후보 | 사용기간(유효기간)이 서로 다른 경우 가장 짧은 기한으로 기재한다. | Ⅳ. 신청서 기재 항목 및 기술문서 제출자료 | 15 | 3. 사용목적에 관한 자료 | 42 | 분석적 | 주성분 | ・측정범위(Measuring range) : 5-30000 pg/mL | NT-proBNP antibody | 0.5 | 자사규격 | -심장 질환 모집단(남성)- | 및 펩타이드 등 |\n| 참고표준방법은 표적물질의 유무를 알기 위해 시행되는 한 가지 방 | 1) 일반사항 | 2) 환자검체 또는 정도관리검체 | 사용될 수 있다. | 가) 직선성 범위의 농도 구간을 제시한다. | 요건에 적합한 시험자가 시험하였는지에 대한 자료를 제출 | 등을 제시한다. | 권장한다. | (사유 :                                                                 ) | DIMENSION VISTA | N-TERMINAL PRO-BRAIN | NATRIURETIC PEPTIDE | (PBNP) FLEX REAGENT | CARTRIDGE (K6423A), | DIMENSION VISTA | 병원에 입원하지 않은 신장병(투석 치료를 받지 않는 환자), | 엔도텔린 I | 20pg/ml | 101% |\n| 1 | 기허가 진단제품 또는 확진검사방법 등으로 확인하였음을 기술한 | 전자적 기록매체(CD·디스켓 등)와 함께 제출한다. | Mean | SD | CV | SIEMENS | HEALTHCARE | DIAGNOSTICS | INC |\n| 라. 사용한 검체 및 키트의 처리 및 폐기방법 및 주의사항을 기재한다. | 라. 원료물질의 품질 확인 근거자료 | 3. 시험검사품에 대한 모델명, 상품명 | 항목, 시험기준, 시험방법을 기재한다. | 2.Timing | 검사법 | 2) 검체 종류별 사용 가능한 항응고제 | 2) 시험성적서 일련번호 및 각 페이지와 전체 페이지번호 | 3) 정밀도(반복, 재현성 등) | 상관없이 심장 기능에 문제가 있을 경우 혈관 벽에서 말초혈액으로 | 민감도 | NYHA Functional Class | WI-6612 |\n| 4. 저장방법 및 사용기간(유효기간)에 관한 자료 | 43 | 체외진단용 의료기기 중 심근혈관표지자 | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 행정규칙(고시ㆍ훈령ㆍ예규)의 | 보조성분 | Buffer | 적량 | 자사규격 | ・검출한계(Limits of measurement) : 5pg/mL | 음성 | c | d | c + d | MEDICAL | ANALYSIS | SYSTEMS, INC | □ 예 | ■ 아니오 |\n| 나. 일회용 체외진단용 시약이 아닐 경우, 개봉 후 시약의 저장방법(온 | 다. 결과제시 | 있다. | 로 면역원(immunogen)과 결합한다. | Cinical and Laboratory Standard Institute; 2005 | 이에 대한 자료를 제공하여야 한다. | 보정결과 확인 절차에 대해 제시한다. | 1. 제조․수입허가신청서 | 15 | 질병이나 특정 상태를 가지는 대상군에서 검사 결과가 양성 | 변이계수를 산출하여 기재한다. | 검체를 사용한다. | 자료를 포함해야 한다. | Calibrator H를 이용하여 Timing Mode와 Batch | 당뇨병, 고혈압, 그리고 만성폐쇄성 폐질환을 가진 환자를 | 아드레노메둘린(ADM) | 1,000pg/mL | 97% | pg/mL | pmol/L | pg/mL | pmol/L | % | 전체 | I | II | III | IV |\n| 해당 성능 항목을 가감할 수 있음 | 2 | Reagent 2 | 4) 정확도 | 자료 또는 양성임을 증명하는 임상자료 등. 평가대상 제품의 결과와 | “모델명”을 각각 기재한다. 이대 제조(수입)업소명은 생략할 수 있 | 가지지 않은 음성 검체 100개 이상 평가할 것을 권장한다. | 내용을 단순 편집 또는 나열한 것입니까? | 1) 간섭 약물 | 절차서에 | 05/16/2008 | 08/19/2003 | 1x10mL |\n| 가. 시험항목 | 4. 시험일자 | 참고한다. | 3) 사용되는 검체의 종류별 필요 분량 | 3) 시험검사품의 모델명, 상품명(해당 경우에 한함) | 본 제품은 체외진단용 의료기기(proBNP test kit)와 별도판매구 | 분비되므로 심부전을 진단하는 중요 표지자로 활용된다. | 보조성분 | Oxypyrion | 적량 | 자사규격 | 검체수 (N) | 480 | 90 | 210 | 144 | 36 |\n| 하나에 해당하는 자료 | 전체 | a + c | b + d | n | Mode의 평균농도는 Batch Mode ± Range | 포함한다. 신장병(투석 치료를 받지 않는 환자), 당뇨병, 고혈압, | Human Serum 1 | 50 | 5.95 | 1.7 | 0.21 | 3.5 |\n| 석 대상(효소)의 억제 또는 검체에 의해 발생하는 바이어스의 다른 원 | 외비공, 인두, 직장 또는 자궁경부를 넘어서 귀, 코, 입, 항문관 또는 | 도, 습도, 차광, 밀폐, 보관용기 등) 및 사용기간(유효기간)등이 포 | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까? | □ 예 | ■ 아니오 | Roche CARDIAC proBNP | Roche | Germany | 메디안 (pg/mL) | 270 | 120 | 260 | 290 | 1650 | 따라서 |\n| 진단 등)에 의해 판정기준치의 적절성을 평가할 수 있다. | BNP Test에서의 잠재적 교차반응 및 간섭에 대하여 다음 | Human Serum 2 | 120.7 | 14.2 | 3.03 | 0.35 | 2.5 |\n| 그리고  만성폐쇄성 폐질환을 가진 환자들에 대한 BNP농도는 | 위의 임상 연구로부터 얻은 데이터는 아래와 같이 임상 | 평균 (pg/mL) | 500 | 300 | 400 | 600 | 1650 |\n**06/23/2003**\n| 질에 들어가는 침습적인 시험. 다만, 정맥채혈 등 피험자에게 중대한 | 약품을 평가하였다. 모든 약품은 최대 치료 용량 및 최대 | Human Serum 3 | 358.7 | 42.3 | 7.27 | 0.85 | 2.0 | 시험한다. |\n| 1) 검체의 종류, 검체 수, 측정방법, 측정횟수 등에 대한 실험프로 | 가) 검체 종류와 검체 준비 과정(검체종류, 기질, 검체의 수, 측정 | 민감도와 임상 특이도에 대한 BNP 결정 역치의 Receiver | SD (pg/mL) | 700 | 350 | 520 | 820 | 1000 | □ 예 | ■ 아니오 |\n| 나. 제품명을 기재하지 아니하는 경우에는 “제조(수입)업소명·품목명”, “모 | 라. 외국의 자료는 주요사항을 발췌한 한글 요약문 및 원문을 첨부 | Human Serum 4 | 794 | 93.5 | 19.5 | 2.30 | 2.5 |\n| 3) 양성 검체는 각 질환의 다양한 임상단계가 포함되도록 한다. | 치료 용량에 의한 혈중 농도의 2배 이상에서 간섭반응을 |\n| Operating Characteristic(ROC) 곡선을 생성하는데 사용되었다. | Human Serum 5 | 5569 | 657 | 130 | 15.3 | 2.3 |\n| 나. 작용원리 : 해당 진단의 측정 원리를 아래의 예와 같이 작성한다. | 다. 시약의 조제가 필요할 경우 조제 후 보관 조건 및 사용기간(유효 | 95th Percentile | 2000 | 1200 | 1300 | 2300 | 3700 |\n| 횟수, 분석물질의 농도, 농도를 확인한 방법 등)을 기술한다. | □ 외국 규정을 번역하거나 설명하는 내용입니까? | □ 예 | ■ 아니오 |\n| 나. 배합목적 : 체외진단용 의료기기의 특성에 맞게 각 성분의 배합목 | 7. 시험기준 및 시험방법. 단, 규격이 없는 경우 이에 대한 설정 사유 | 단계별 시험 및 완제품 품질관리 시험의 단계를 확인할 수 있는 자료) | 권장하고, 그 외 자사가 설정한 시험항목을 설정할 수 있다. | Control 1 | 110 | 13 | 2.72 | 0.3 | 2.5 | 퍼센트 ≥100 pg/mL | 71.00% | 56.00% | 65.70% | 70.00% | 95.00% | WI-6612 | 05/30/2003 | 65-74 |\n| 6) 시험기준 및 시험방법 단, 규격이 없는 경우 이에 대한 설정 사유 | 알기 쉽게 풀어서 설명하거나 특정한 사안에 대하여 식품의약품안전처 | 의 입장을 기술하는 것(식품의약품안전처 지침서등의 관리에 관한 | 규정 제2조) | 본 연구에서 결정 역치인 125pg/mL에서, BNP 검사는 임상적 |\n| Control 2 | 4200 | 495 | 107.1 | 12.6 | 2.6 | 1x10mL |\n| 가. 전체 결과 및 특이 환자 그룹이 있다면 그룹별 결과를 제시한다. | 절차서에 |\n| 영어 외의 외국어 자료는 공증된 전체 번역문을 첨부하여야 한다. | 민감도와 특이도에 대하여 각각 70.5% 및 90.5%로 나타났다. | 최대 (pg/mL) | >4000 | 1400 | 3800 | >4000 | >4000 | DADE BEHRING, | INC. | 08/17/2007 | □ 예 | ■ 아니오 |\n| 봉 후(on-board, reconstitution, open vial/bottle stability) 안정성 자 | 타 제품과의 비교한 결과 상관계수(r)는 ≥ 0.90이었고 |\n**따라서**\n| 증서나 다른 인증기관에 의해 발행된 서류가 있거나 추적 가능한 하 | 1 | Reagent 1 | 단일구성 | 투명한 액상 시약 | 곡선 아래 부분은 0.90(0.86 ~ 0.92, 95% 신뢰구간)이다. |\n| 본 제품에는 면역형광법이 사용되며 다음과 같은 반응으로 이루어진다. | 일치도는 ≥ 90%이었다. NCCLS 프로토콜 EP9- A41을 |\n| DADE BEHRING, | INC | 08/04/2007 | 시험한다. |\n| ‘사용기간’ 항에 아래 표와 같이 저장방법과 사용기간을 기재한다. | 2 | Reagent 2 | 단일구성 | 투명한 액상 시약 |\n| 6 | 사용목적 | 예 | □ | ※ 예시 : 사람의 전혈 또는 혈장에서 pro Brain-type natriuretic | 의학적 결정치(medical decision point)에서의 바이어스를 제시한다. | triplicate) 측정하기를, 1일마다 2회(run) 이상, 최소 10일 동안 | 1) 투입구에 검체를 주입한 뒤, 혈구 세포는 디바이스에 내장 | 따라 상업적으로 유용한 진단검사와 본 제품을 이용한 검사를 |\n| 액티베이즈 | 에리스로마이신 | 옥시테트라사이클린 |\n| Siemens | Germany | □ 예(☞지침서) | ■ 아니오 |\n| 의료기기와 사용목적, 작용원리 등이 동등하지 아니한 체외진단용 의 | 3 | Reagent 3 | 단일구성 | 투명한 액상 시약 | 비교하였다. 총 300명(심장 질환 환자 200명, 비심장 질환 | 퍼센트 ≥100 pg/mL | 90.50% | 91.50% | 92.00% | 95.00% | 85.10% | I-STAT | CORPORATION | 07/21/2006 | 아니오 | □ |\n| 다) 검체에서 검출될 수 있는 최소 검출한계치를 제시한다. 검출 | 바) 총 run의 수(해당되는 경우 제시) | 3. 완제품의 품질관리 시험성적서 또는 시험에 관한 자료 | 64 | (20일 이상 권장) 시행하기를 권장한다. | 물질만 포함된 검체의 실측한 자료를 바탕으로 배경한계와 검출 | 농도가 알려진 고농도의 임상검체를 이용한다. | Zero Control을 이용하여 측정하였을 때 다음의 | peptide(proBNP)를 면역형광측정법으로 정량하는 체외 | 의 세부기준이나 절차를 제시하는 것입니까? (공무원용) | Natriuretic Peptide (BNP) | 알로퓨리놀 | 푸로세미드 | 페노바르비탈 |\n| 7 | 작용원리 | 예 | □ | Institute; 2008 | 5. 사용목적(성능) | 24 | 검체의 종류가 두 가지 이상인 경우 검체의 종류별로 시험한다. | 되어 있는 필터에서 혈장과 분리된다. | 최소 (pg/mL) | 0 | 0 | 0 | 0 | 0 | 메디안 (pg/mL) | 400 | 170 | 300 | 450 | 1400 |\n| 라. 분량 | 바. 검체 보관 및 취급상(온도, 습도 등)의 조건 설정 근거 자료 | 10. 시험 환경요인(시험결과에 영향을 주는 경우에 한함) | of agreement) | 또는 시험에 관한 자료를 제출하여 제품의 균일성을 제시한다. | 1) 적용되는 체외진단분석기의 제조사 및 모델명을 기재한다. | 상관성의 추가 자료로 제시할 수 있다. | 정보를 제공한다. | 상호와 주소)을 확인할 수 있는 자료도 포함한다. | 및 특이도 | 받는 경우에는 그 조건을 명시하여야 한다. | 분석적 | 환자 100명)의 혈장 검체를 두 검사로 시험하였다. 이들 |\n| □ 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 설 | VITROS IMMUNODIAGNOSTIC | PRODUCTS NT PRO-BNP | REAGENT | PACK,CALIBRATORS,RANGE | VERIFIERS | 기준을 만족해야 한다. | ARCHITECT BNP | Abbott | USA | 최대 (pg/mL) | 910 | 260 | 140 | 400 | 900 | 평균 (pg/mL) | 670 | 340 | 450 | 750 | 1630 | 유로딜라틴(CCD/ANP) 95-126 | 1,000pg/mL | 100% | WI-6612 |\n| 구분 | 료기기의 시험에 한함) | 이상의 특성값이 절차에 따라 공인되며, 그 절차는 특성값이 표현 | 또는 이에 준하는 것으로 인정되는 시험자료 | 4. 완제품 품질관리 시험에 사용된 표준물질에 관한 자료 | 65 | 수 있으므로 임상적 민감도, 임상적 특이도와 함께 유병률, 양성 | 아미오다론 | 엡티피바티드 | 페니토인 | ORTHO-CLINIC | AL | DIAGNOSTICS, | INC | 아니오 | □ | ■ 예(☞안내서) | □ 아니오 |\n| 사. 국내·외 허가제품과의 상관성 시험에 대한 시험성적서 | 가. 최소검출한계(Limit of detection, LoD) | 나. 시험방법 | 2 | 2) 간섭물질은 내부 또는 외부 요인일 수 있고 측정법에 따라 다양 | 대해서는 비교검사와의 일치도(신뢰구간과 함께)를 제시한다. | 기술한다. | 사) 총 관찰치의 수 : optional | 6. 사용방법 | 32 | 한계를 넘지 않는 결과를 보인 최대 간섭물질 농도를 기재한다. | 특이도 | 2) 일정량의 혈장이 반응부분 내에서 형광 접합된 polyclonal | 민감도 참고). | 진단용 의료기기이다. | 명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 | 것입니까? (민원인용) | 검체는 심장 질환 환자와 비심장 질환자로부터 채취하였다. | 분량 |\n| 자. 일회용의 경우 재사용하지 않도록 주의사항을 기재한다. | 다. 시험방법 | 인정범위내의 자료이어야 한다. | 2) 검사 키트의 사용조건(온도 또는 습도 등)을 기재한다. | 권장한다. | 1. 항목별 시험기준 | AIA BNP | Tosoh | Japan | SD (pg/mL) | 850 | 380 | 620 | 870 | 1100 | ㎍/L | 규격 | 비고 | 절차서에 |\n| 그러하지 아니하다. | 8 | 원재료 | 예 | □ | 심장 질환으로 진단된 환자 800명의 혈장 검체를 본 제품을 | 암피실린 | 히드랄라진 | 프로베네시드 | 안지오텐신 III | 1,000pg/mL | 108% | 06/06/2006 |\n| 사시약 제조를 전면 위탁 시 제조원은 다음과 같이 기재한다. | 예측도, 음성예측도 제시를 권장한다. | Elecsys ProBNP II | Roche | Germany | Passing-Bablok 선형회귀 분석과 조화 분석으로부터 얻은 | 5th Percentile | 16 | 14 | 21 | 12 | 250 |\n| 가. 인정범위 | 라. 결과가 불일치하는 경우, 불일치의 원인 분석에 대한 자료를 제출 | 확률적으로 검체에서 검출될 수 있는 최저 분석물질의 양 | 안전평가원 의료기기심사부 체외진단기기과에 문의하시기 바랍니다. | 1) 시험할 간섭물질의 목록을 작성한다. | 3) 간섭물질에 대한 분석물질 결과에 경향이 있다면 경향을 기술한다 | (교차반응성) | 아) 시약 lot의 수 | <외관사진> | 7. 사용시 주의사항 | 34 | 5. 검체보관 및 취급상(온도, 습도 등)의 조건 설정 | 제외한다. | NT-proANP, C-type natriuretic peptide이다. | 3-5일 이상, 측정 시 2번 이상 반복검사를 권장한다. | 아니오 | □ | 따라서 |\n| 가. 검사대상 | 역가를 기재한다. | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | antibody against BNP와 반응을 한다. 화합물이 충분히 | 보정물질 | proBNP (recombinant) | approx. 0.6 | 자사규격 | 이용하여 시험하였다. 이 환자들을 New York Heart | 95th Percentile | 2600 | 1000 | 2000 | 2700 | >4000 | 아스코르빈산 | 하이드로클로로티아지드 | 프로카이나마이드 | □ 예 | ■ 아니오 |\n| 가. 허가(신고)가 최소된 의료기기와 사용목적, 작용원리 및 원재료 등 | 자료의 경우) | 관한 자료 | 식품의약품안전평가원 의료기기심사부 체외진단기기과 | Dimension Vista System Flex | 항 목 | 기 준 | Prepro-ANF 26-55 | 1,000pg/mL | 107% |\n| 검체의 사용 가능성 및 제한점 등을 포함한다. | 9 | 성능 | 예 | □ | 기관의 임상시험계획승인을 받고 실시해야함) | 상관성 | 구성시약 | 개봉여부 보관조건 | 사용기간 | 비고 | 민원인을 구속하는 내용이 있습니까? | 결과는 아래 표에 나타내었다. | 퍼센트 ≥100 pg/mL | 70.50% | 60.50% | 75.20% | 80.30% | 100.00% | 2.5x |\n| 1 | Cal 1 | 2004:50;732-740 | 2) 결과제시 | 각 공인된 값은 신뢰의 명시된 수준에서의 불확실성과 함께 한다” | 한다. | 라) 참고 | 자) Calibration 시행 횟수와 calibrator lot의 수 | (예 : 높은 농도의 물질 X는 분석물질의 결과를 감소시킴). | 계획되거나 반복성이나 재현성 평가의 일부로 계획될 수 있다. | 근거자료 | 65 | 혈장, 전혈 등)를 사용하여야 한다. | 보조성분 | Human serum | 적량 | 자사규격 | Association(NYHA)의 기능적인 분류 시스템에 따라서 | 암로디핀베실산염 | 헤파린 | 프로파놀올 | 시험한다. |\n| 나. 검체종류 : 해당 제품의 적용이 가능한 검체의 종류를 기술한다. | 4 | ※ 예시 | 4) 피험자 선정/제외 기준, 검체 종류와 수, 시험 상 주의사항, 통계 | 8. 포장단위 | 34 | 다음과 같은 물질에 대한 간섭 평가 자료를 제출해야 한다. | 반응이 일어 난 뒤, 반응물은 디바이스의 고정체로 이동하고 | 오송보건의료행정타운 식품의약품안전평가원 | 최소 (pg/mL) | 0 | 10 | 0 | 0 | 173 | 아니오 | □ | 1mL |\n| 항목이 추가로 포함되어야 한다. | 항 | 수행한다. | 소프트웨어의 회사명, 모델명 등을 기재한다. | 구체적, 개조식으로 기재한다. | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ안내서 | Reagent cartridge N-terminal | BNP | ≤10.0pg/mL | 정밀도는 | CLSI(Clinical | and | Laboratory | Standards | 비교방법과 본 제품의 검사의 결정 역치인 125pg/mL를 | Siemens | Germany |\n\n**[표 끝]**\n\n☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적으로\n\n지침서ㆍ안내서\n\n기타 확인사\n\n제ㆍ개정 절차를 진행하시기 바랍니다.\n\n상기 사항에 대하여 확인하였음.\n\n2018 년    7 월   31  일\n\n담당자\n\n확  인(부서장)\n\n우 승 민\n\n이 원 규\n\n<!-- PAGE_4 -->\n###### ※ 본 민원인 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품\n\n<!-- PAGE_4 -->\n###### - 전화번호 : 043-719-4652~4665\n\n<!-- PAGE_4 -->\n###### - 팩스번호 : 043-719-4650\n\n이 안내서는 체외진단용 의료기기 중 뇌나트륨이뇨펩티드 검사제품  허가\n\n심사 시 요구되는 신청서 작성 방법 및 제출자료 요건에 대하여 알기 쉽게\n\n설명하거나 식품의약품안전처의 입장을 기술한 것입니다.\n\n본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식\n\n(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는\n\n사항이 아님을 알려드립니다. 또한, 본 안내서는 현재의 과학적ㆍ기술적 사실 및\n\n유효한 법규를 토대로 작성되었으므로 이후 최신 개정 법규 내용 및 구체적인\n\n※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을\n\n<!-- PAGE_5 -->\n### 머 리 말\n\n<!-- PAGE_5 -->\n###### 질병관리 패러다임이 치료중심에서 조기진단을\n\n<!-- PAGE_5 -->\n###### 통한 예방중심으로 전환됨에 따라 진단검사\n\n<!-- PAGE_5 -->\n###### 결과의 신뢰성 확보의 중요성이 부각되고 있고,\n\n<!-- PAGE_5 -->\n###### 과거 진단기기의 보조적 역할로 인식되던 체외\n\n<!-- PAGE_5 -->\n###### 진단용 의료기기가 진단검사 결과의 판정에 결정\n\n<!-- PAGE_5 -->\n###### 적인 영향을 주는 제품으로 개발되고 있습니다.\n\n<!-- PAGE_5 -->\n###### 또한 최근 IT․BT․NT의 눈부신 발달로 민감\n\n<!-- PAGE_5 -->\n###### 도와 특이도가 향상된 체외진단용 의료기기가\n\n<!-- PAGE_5 -->\n###### 개발되면서 질병의 신속․정확한 진단도 가능\n\n<!-- PAGE_5 -->\n###### 하게 되었습니다.\n\n<!-- PAGE_5 -->\n###### 식약처에서는 국민보건, 산업육성 및 국제조화 측면에서 자율\n\n<!-- PAGE_5 -->\n###### 관리되던 체외진단용 의료기기의 국가관리 필요성을 인지하여 ‘12년\n\n<!-- PAGE_5 -->\n###### 부터 단계적으로 허가를 추진해왔으며 금년에 전 등급에 대한\n\n<!-- PAGE_5 -->\n###### 허가 의무화가 완료되었습니다.\n\n<!-- PAGE_5 -->\n###### 체외진단용 의료기기를 의료기기로 관리하기 시작한 이래, 식품의\n\n<!-- PAGE_5 -->\n###### 약품안전평가원에서는 허가․심사 규정 해설서 발간, 민원설명회\n\n<!-- PAGE_5 -->\n###### 등을 통하여 민원편의 제공 및 허가․심사의 공정성 확보를 위해 지속\n\n<!-- PAGE_5 -->\n###### 적으로 노력해 왔습니다. 이에 지난 ‘12~’13년 까지 총 19종의 가이\n\n<!-- PAGE_5 -->\n###### 드라인을 발간한 바 있으며, 금번 심질환표지자 검사 시약 2종의\n\n<!-- PAGE_5 -->\n###### 허가․심사 가이드라인을 추가로 개발하였습니다.\n\n<!-- PAGE_5 -->\n###### 동 가이드라인이 해당 제품의 허가․심사를 준비하시는 업체에\n\n<!-- PAGE_5 -->\n###### 많은 도움이 되기를 바라며 앞으로도 우리 원에서는 체외진단\n\n<!-- PAGE_5 -->\n###### 의료기기의 허가․심사에 공정성 및 투명성을 확보함과 동시에\n\n<!-- PAGE_5 -->\n###### 신속한 허가․심사 지원을 통하여 관련 산업의 발전을 위하여 지\n\n<!-- PAGE_5 -->\n###### 속적으로 노력할 것입니다.\n\n<!-- PAGE_5 -->\n###### 감사합니다.\n\n<!-- PAGE_5 -->\n###### 2014년 5월\n\n<!-- PAGE_5 -->\n###### 식품의약품안전평가원장\n\n<!-- PAGE_6 -->\n# 목  차\n\n<!-- PAGE_6 -->\n###### Ⅰ. 개요\n\n<!-- PAGE_6 -->\n###### 2\n\n<!-- PAGE_6 -->\n###### Ⅱ. 용어의 정의\n\n<!-- PAGE_6 -->\n###### 4\n\n<!-- PAGE_6 -->\n###### 9. 저장방법 및 사용기간\n\n<!-- PAGE_6 -->\n###### 35\n\n<!-- PAGE_6 -->\n###### 10. 시험규격\n\n<!-- PAGE_6 -->\n###### 36\n\n<!-- PAGE_6 -->\n###### 11. 제조원\n\n<!-- PAGE_6 -->\n###### 38\n\n<!-- PAGE_7 -->\n###### Ⅵ. 기술문서 등의 심사를 위한 제출자료\n\n<!-- PAGE_7 -->\n###### 39\n\n<!-- PAGE_7 -->\n###### 1. 개발경위, 측정원리·방법 및 국내․외 사용현황에\n\n<!-- PAGE_7 -->\n###### 6. 상관성 평가\n\n<!-- PAGE_7 -->\n###### 66\n\n<!-- PAGE_7 -->\n###### Ⅷ. 참고문헌\n\n<!-- PAGE_7 -->\n###### 68\n\n<!-- PAGE_7 -->\n###### Ⅸ. 부록\n\n<!-- PAGE_7 -->\n###### 70\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 2 -\n<!-- PAGE_8 -->\n# Ⅰ\n\n<!-- PAGE_8 -->\n#### 개  요\n\n<!-- PAGE_8 -->\n###### 본 가이드라인은 심근혈관표지자인 뇌나트륨이뇨펩티드(NT-proBNP,\n\n<!-- PAGE_8 -->\n###### BNP) 검사 제품의 허가․심사 시에 요구되는 신청서 작성 방법 및\n\n<!-- PAGE_8 -->\n###### 제출자료 요건을 예시를 들어 구체적이고 알기 쉽게 설명하였습니다.\n\n<!-- PAGE_8 -->\n###### 다만, 가이드라인에 기술한 사항은 현재까지의 경험과 과학적\n\n<!-- PAGE_8 -->\n###### 사실을 근거로 작성된 바, 새로운 과학적 사실이 밝혀지거나 관련\n\n<!-- PAGE_8 -->\n###### 규정이 개정될 경우 추후 변경될 수 있습니다.\n\n<!-- PAGE_8 -->\n###### 또한 본 가이드라인은 뇌나트륨이뇨펩티드 검사 제품의 허가․심사\n\n<!-- PAGE_8 -->\n###### 시에 요구되는 사항에 대한 일반적인 해석을 기술하고 있는 것으로서\n\n<!-- PAGE_8 -->\n###### 법적 효력이 있는 사항이 아니며, 개별 사항에 따라 다르게 해석할\n\n<!-- PAGE_8 -->\n###### 1. 목적\n\n본 가이드라인은 심장질환 진단에 도움을 주는 뇌나트륨이뇨펩티드\n\n(NT-proBNP, BNP) 측정시약의 허가․심사 시 요구되는 신청서 및 제출자료\n\n준비를 위한 참고자료로 활용하는 것을 목적으로 한다.\n\n※ 알림 : 본 가이드라인에 따라 정상적인 서류와 첨부자료를 제대로\n\n갖추어 접수한 민원에 대하여 신속처리가 진행될 수 있으니 민원 신청시\n\n참고하시기 바랍니다.\n\nⅠ. 개 요\n\n- - 3 -\n<!-- PAGE_9 -->\n###### 2. 적용범위\n\n본 가이드라인은 인체에서 유래하는 시료를 검체로 뇌나트륨이뇨펩티드\n\n(NT-proBNP, BNP)를 측정하는 체외진단용 의료기기에 적용되는 허가․심\n\n사 가이드라인이다.\n\n뇌나트륨이뇨펩티드는 심장에 대한 혈역학적 부하를 알 수 있는 바이오\n\n마커로 심장근육층의 호르몬 활성화를 보여준다. NT-proBNP와 BNP는\n\n혈역학적 부하로 좌심실이 비대해질 때 1:1의 비율로 나눠진다. 이들\n\n펩타이드 수치의 증가는 심부전과 연관이 있으며 두 물질 모두 울혈성심부전\n\n진단에 유용하게 사용된다. 뇌나트륨이뇨펩티드는 심실근에서 생성되나\n\n저장되지 않고 심실 부하에 반응하여 분비되면서 강력한 혈관 확장작용과\n\n나트륨 이뇨작용을 한다. 또한 심실의 용적이 확장되거나 혈압이 과도하게\n\n증가될 때 지속적으로 배출된다. 정상인의 말초혈액 내에서는 20 pg/mL\n\n미만의 양으로 존재하지만 심부전 환자의 혈장 내 농도는 질환의 중증도에\n\n따라 비례하고, 무증상 좌심기능부전 단계에도 상승한다. 특히 심장기능의\n\n약화에 민감하게 상승한다. 뇌나트륨이뇨펩티드는 심정지와 상관없이 심장\n\n기능에 문제가 있을 경우 혈관 벽에서 말초혈액으로 분비되므로 심부전을\n\n진단하는 중요 표지자로 진단에 활용된다.\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 4 -\n<!-- PAGE_10 -->\n# Ⅱ\n\n<!-- PAGE_10 -->\n#### 용어의 정의\n\n※ 본 가이드라인에서 사용되는 용어의 정의는 본 가이드라인의 이해를\n\n돕기 위해 사용되는 것이므로 단순 참고용임\n\n간섭 (Interference)\n\n분석물질의 농도나 강도가 명백함에도 검출시약이나 신호 자체에 비특이적\n\n으로 반응하는 물질의 존재로 인해 일어나는 인위적인 증가나 감소\n\n☞ 검출 시스템의 비특이성에서 기인하기도 하고, 지시약 반응의 억제, 분\n\n검출한계 (Limit of detection, LoD)\n\n검출될 수 있는 분석 물질의 최소량\n\n공란한계 (Limit of blank, LoB)\n\nblank 검체에서 관찰 가능할 수 있는 가장 높은 측정치\n\n교차반응 (Cross-reactivity)\n\n항원 이외에 공유되었거나, 유사한 또는 동일한 항원결정기를 가진 항원과\n\n항체가 반응하는 현상\n\n기질효과 (Matrix effect)\n\n측정하고자 하는 분석물질 이외에 검체의 특성이 분석물질의 측정에 영향을\n\n미치는 경우\n\n☞ 검체의 점성, 표면장력, 혼탁도, 이온 강도, pH 등이 기질효과의 주된\n\n요인이다.\n\nⅡ. 용어의 정의\n\n- - 5 -\n대조물질 (Control / Control material)\n\n정도 관리를 위해 이용되는 물질\n\n면역분석법, 면역측정법 (Immunoassay)\n\n분석물질에 결합 가능한 특이 항원이나 항체를 이용하는 리간드-결합 분석\n\n☞ 항체를 사용하여 물질을 측정하는 검사법으로 면역분석법은 경쟁적 또는\n\n비경쟁적, 고체상 또는 액체상, 동위원소 또는 비동위원소, 항원표지\n\n또는 항체표지, 단일 또는 이중 부위, 균질적 또는 비균질적 방법일 수\n\n바이어스 (Bias)\n\n검사 결과의 예상치와 허용된 기준치 사이의 차이\n\n간섭물질 (Interfering substances)\n\n임상검체에 존재하는 내부물질(예 : 혈액 구성요소, acidic polysaccharides)\n\n또는 외부물질(예 : talc, 항응고제 등)으로 위양성 또는 위음성 결과를 야기\n\n할 수 있는 물질\n\n보관 시 안정성 (Storage stability)\n\n최종 디자인(포장) 상태에서 시약의 유효기간\n\n보정 (Calibration)\n\n특별한 조건하에서 측정 기기나 측정 시스템이 나타내는 값 또는 물질\n\n측정이나 참고물질에 의한 값과 표준물질에 상응하는 값 사이의 관계를\n\n확립하는 일련의 조작\n\n보정물질 (Calibrator / Calibration material)\n\n측정과정을 보정하기 위해서 또는 검체의 반응을 비교하기 위해서 사용되는\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 6 -\n알려진 정량적/정성적 특성(예 : 농도, 활성도, 강도, 반응성)을 갖는 물질\n\n☞ a) 보정물질에서 분석물질 양은 그의 제조과정에서 확인된 한계\n\n(limit) 내에 있으며, 분석법의 반응과 측정되는 특성과의 관계를\n\n설정하는데 사용될 수 있다.\n\nb) 보정물질은 국가 또는 국제 표준물질이나 참고물질에 소급성을\n\nc) 분석물질의 다른 양을 갖는 보정물질은 보정 곡선을 설정하는데\n\nd) “일차”와 “이차표준”이란 용어는 보정물질을 지칭하는 용어로\n\n분석물질 (Analyte)\n\n검사실이 수행하는 검사의 물질 또는 구성요소\n\n분석적 특이도 (Analytical specificity)\n\n정량검사에서 측정하고자 하는 물질만 측정되고 검체 내 다른 물질은 측정\n\n되지 않는 분석법의 능력\n\n비정밀도 (Imprecision)\n\n특별한 조건 하에서 얻어진 측정값의 독립적 결과들의 분산\n\n☞ 표준편차나 변이계수 등의 숫자로 표시된다.\n\n비특이도 (Nonspecificity)\n\n분석하려는 물질 외에 다른 물질과 항원이 반응하는 정도\n\n☞ 비특이도는 보통 분석물질이 아닌 물질에 결합하고, 반응하는 항체,\n\n효소, ionophore, 시약에 의해 발생한다.\n\nⅡ. 용어의 정의\n\n- - 7 -\n사용 시 안정성 (in–use stability)\n\n제조사에서 제공한 용기를 개봉한 이후에 사용자의 작동 조건에서 시약의\n\n유효기간내의 검사수행능\n\n상관계수 (Correlation coefficient, r)\n\n측정된 데이터에 대한 두개의 무작위 변수의 공분산(covariance)과 그들의\n\n표준편차의 곱의 비(ratio)\n\n수송 안정성 실험 (Transport stability test)\n\n제품 운송 도중 발생 가능한 환경변화가 제품 성능에 미치는 영향을 평가\n\n하는 것\n\n☞ 최악의 상황을 시험해야 한다.\n\n신뢰구간 (Confidence interval)\n\n평균, 분율, 비율 등의 변수의 참값이 정해진 확률 범위 내에서 분포할\n\n것으로 예상되는 계산된 구간\n\n실시간 안정성 실험 (Real time stability)\n\n시약을 추천하는 정상적인 보관과 사용 환경에 두고 그 안정성을 평가하는 실험\n\n양성 예측도 (Predictive value of positive result, PPV)\n\n표적 질환(진단 정확도 기준에 의해 결정되는)을 가지고 있는 환자에서\n\n양성 결과를 보이는 비율(100을 곱한 값)\n\n☞ a) 양성 예측도(PPV)는 반드시 관심대상 조건(진단 정확도 기준에 의해\n\n결정되는)의 유병률에 맞추어 해석해야 한다.\n\nb) PPV의 추정값[추정 유병률은 100x(TP+FN)/(TP+FP+FN+TN)]은\n\n100xTP/(TP+FP)로 계산된다.\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 8 -\n진단정확도기준\n\n양성\n\n음성\n\n전체\n\n방법 X\n\n양성\n\n# 진양성 TP\n\n# 위양성 FP\n\n진양성+ 위양성\n\n음성\n\n# 위음성 FN\n\n# 진음성 TN\n\n위음성 + 진음성\n\n전체\n\n진양성 + 위음성\n\n위양성 + 진음성\n\nN\n\n양성 일치율(Percent positive agreement, PPA)\n\n= 100×a/(a+c)\n\n음성 일치율(Percent negative agreement, PNA)\n\n= 100×d/(b+d)\n\n총 일치율(Overall percent agreement)\n\n= 100×(a+d)/n\n\n음성 예측도 (Predictive value of negative result, NPV)\n\n표적 질환을 가지지 않은 정상인에서 음성 결과를 보이는 비율(100을\n\n곱한 값)\n\n☞ NPV의 추정값은 100×TN/(TN+FN)로 계산된다.\n\n위양성 (False positive, FP)\n\n질병이나 증상이 없는 상태에서 이를 시사하는 양성검사 결과\n\n☞ 예시 : 질환에 이환되지 않은 개체에서 비정상 결과\n\n위음성 (False negative, FN)\n\n양성 환자나 양성 검체에서의 음성검사 결과\n\nⅡ. 용어의 정의\n\n- - 9 -\n임상적 민감도 (Clinical sensitivity)\n\n특정질환을 가지고 있는 사람들 중 검사 결과가 양성으로 나오는 비율\n\n임상적 보고가능범위 (Clinically reportable range, CCR)\n\n분석측정범위를 연장하기 위해 검체에 대한 희석, 농축, 또는 기타\n\n전처리를 하여 정량 결과 값으로 보고할 수 있는 분석물질 값의 범위\n\n임상적 특이도 (Clinical specificity)\n\n특정질환을 가지고 있지 않은 사람들 중 검사 결과가 음성으로 나오는 비율\n\n재현성 조건 (Reproducibility condition)\n\n동일한 방법과 동일한 검사 품목으로 다른 검사실에서 다른 사용자가 다른\n\n장비를 사용하여 검사 결과를 얻는 조건\n\n재현성 (Reproducibility)\n\n다른 측정조건에서 수행된 동일한 측정물의 결과값 사이의 일치도의 근접성\n\n정규분포 (Normal distribution)\n\n가우스 분포라고 표현되며 측정값을 곡선의 x축에, 관측치의 빈도를 곡선의\n\ny축에 표시\n\n☞ 관측치가 평균의 양측에 균일하게 분포하면 결과그래프는 전형적인\n\n종형곡선을 갖는다.\n\n정량분석 (Quantitative assay)\n\n검체에서 분석물질의 농도를 측정할 수 있는 시스템\n\n☞ 정량 분석은 표준 참고 물질에 맞춘 보정곡선으로부터 동종 또는 이종\n\n보간법(Interpolation)1)을 통해 이루어진다.\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 10 -\n정밀도 (Precision)\n\n규정된 조건 하에서 얻어진 독립적인 검사결과들 가운데 일치도의 근접성\n\n☞ 정밀도는 전형적으로 수치로 표현되지 않지만 비정밀도는 반복 측정값\n\n결과들의 ‘표준편차’ 또는 ‘변이계수’라는 용어로 정량적으로 표현\n\n정성분석 (Qualitative assay)\n\n분석물질의 농도가 아니라 단지 분석물질이 있고 없음을 알려주는 검사\n\n시스템\n\n☞ 양성 검사 결과는 검사신호가 분석 역치를 넘는 것만을 의미하고 판정\n\n기준치(cut-off value)는 진단 민감도와 특이도의 인위적 조합에 의해\n\n정확도 (Accuracy)\n\n측정치와 참값 사이의 일치도\n\n☞ 평가대상 검사법에 의한 다수의 연속적인 결과값들에서 얻은 평균값과\n\n공인된 참고값(accepted reference value)사이의 일치 근접도(closeness\n\n직선성 (Linearity)\n\n실험 검체에 있는 분석물질의 농도[양]에 정비례하는 결과를 제공할 수\n\n있는 능력\n\n진단검사 (Diagnostic test)\n\n특정 질환의 진단, 예방, 치료 또는 개개의 환자에서의 건강이나 건강의\n\n손상 정도를 평가하기 위한 목적\n\n☞ 진단적 검체의 측정 또는 검사를 칭한다.\n\n1) 보간법 : 내삽이라고도 하며 그래프상의 알려진 두 값 사이의 특정값을 평균하여 추정하는 것을 의미\n\nⅡ. 용어의 정의\n\n- - 11 -\n진양성 (True positive, TP)\n\n환자의 질병 상태와 검사의 양성판정이 일치하는 결과\n\n진음성 (True negative, TN)\n\n환자의 질병 상태와 검사의 음성판정이 일치하는 결과\n\n참고구간 (Reference interval)\n\n상하 두 개의 참고 한계치 내의 간격\n\n☞ 하한 참고치와 상한 참고치 간의 간격으로 명시되어 있다.\n\n참고물질 / 참고제작 (Reference material / Reference preparation, RM)\n\n1) 하나 또는 그 이상의 특성값이 충분히 균일하고 기구의 보정, 측정방\n\n2) 인증참고물질(CRM) – 기술적으로 입증된 과정에 의해 공인되었고 인\n\n☞ a) 인증참고물질(CRM)은 “인증서가 있는 참고물질로서 하나 또는 그\n\n되는 단위의 정확한 구현에 대한 추적을 할 수 있고, 그것에 대해\n\n라고 정의한다.\n\nb) 표준참고물질(SRM)은 인증참고물질(CRM)의 한 이름으로서 과거에\n\n국립표준원(NBS)으로 알려졌던 미국정부기관으로, 국립표준기술\n\n연구소(NIST)에 의해 인증되고 배포되는 인증참고물질의 상품명이다.\n\n참고치 (Reference value)\n\n개체에서 관측 또는 측정으로 얻은 특정 형태의 정량값\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 12 -\n총 분석 오차 (Total analytical error)\n\n특정 구성요소들로 구성되어 있으며 90% 또는 95% 신뢰구간으로 정량\n\n화된다.\n\n측정가능범위 (Analytical measurement range, AMR)\n\n일상적인 측정 과정의 일부가 아닌 희석, 농축 또는 기타 전처리 없이 어떤\n\n검사법이 검체에서 직접 측정할 수 있는 분석물질 값의 범위\n\n측정 시스템의 민감도 (Sensitivity of a measuring system)\n\n측정 시스템 표시 도수의 변화 및 측정된 양의 값의 변화계수\n\n☞ 측정시스템의 민감도는 측정된 양의 크기에 의존하며 측정된 양의 값\n\n친화력, 친화성 (Affinity)\n\n면역학에서 한 개의 항원결정기 부위와 한 개의 항체 사이에 작용하는 힘\n\n판정기준치 (Cut-off value)\n\n정성검사에서는 경계치 이상을 양성으로, 경계치 미만을 음성으로 보고할\n\n수 있는 경계값을 말한다. 정량검사에서는 측정 결과가 임상적 또는 분석\n\n적 결정점(Decision point)의 위 또는 아래에 있는지(양성 또는 음성) 결정\n\n하는데 사용되는 측정물질의 정량값\n\n항원 (Antigen)\n\n생체 내 항체 생성을 유발하고 그들과 특이적으로 결합할 수 있는 물질\n\n항원결정인자 / 에피토프 (Antigenic determinant / epitope)\n\n항원 분자 중 항체가 결합할 수 있는 모든 부위의 총칭으로 특정 항체군을\n\n결정하는 부위의 화학적 구조\n\nⅡ. 용어의 정의\n\n- - 13 -\n항원항체결합력 (Avidity)\n\n항혈청 또는 항체의 복합적인 반응 강도\n\n☞ 항원항체결합력은 항혈청 내 모든 항체의 항체결합부위와 가용한 마크\n\n로분자의 항원결정기와의 친화력 함수\n\n항체 (Antibody)\n\n면역계 내에서 항원의 자극에 의하여 혈청이나 조직에 만들어지는 물질\n\n☞ 면역원 노출에 반응하여 B림프구에서 생산되는 특이 면역글로불린으\n\n허용 오차 (Allowable error)\n\n모든 가능한 요소들로부터 발생할 수 있는 분석적 변이의 정도 또는 검사\n\n시스템에서 사용자가 허용할 수 있는 정도로 검사의 임상적 요구사항을\n\n만족시킬 수 있는 변이의 정도\n\n후크효과 (Hook effect)\n\n항체 또는 항원 과다로 최적 반응을 방해하여 항원-항체 반응이 최적\n\n이하로 나타나는 현상\n\n회복, 회수 (Recovery)\n\n동일 물질의 검체에 알고 있는 양을 첨가한 후 분석물질 농도의 증가를\n\n확인\n\n☞ 분석물질이 첨가되지 않은 혈청 검체와 첨가된 혈청 검체로 분석물질\n\n의 증가가 첨가된 양과 동등한 지 분석한다. 첨가된 물질의 양을 확인\n\n하는 정확도는 회수 실험에 필수적이며 100% 회수가 이상적이다.\n\n☞ 회수실험의 다른 형태는 희석-회수분석이다.\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 14 -\n<!-- PAGE_20 -->\n# Ⅲ\n\n<!-- PAGE_20 -->\n#### 관련규정\n\n■ 「의료기기법」제3조 (제조업의 허가의 신청절차)\n\n■ 「의료기기법」제10조 (임상시험계획의 승인 등)\n\n■ 「의료기기법」제29조 (수입업 허가신청 등)\n\n■ 「의료기기법 시행규칙」제5조 (제조허가의 절차)\n\n■ 「의료기기법 시행규칙」제6조 (제조인증의 절차)\n\n■ 「의료기기법 시행규칙」제7조 (제조신고의 절차)\n\n■ 「의료기기법 시행규칙」제9조 (기술문서 등의 심사)\n\n■ 「의료기기법 시행규칙」제20조 (임상시험계획의 승인 등)\n\n■ 「의료기기법 시행규칙」제21조 (임상시험기관 지정기준 및 절차 등)\n\n■ 「의료기기법 시행규칙」제30조 (수입허가 신청 등)\n\n■ 「의료기기법 시행규칙」제42조 (용기 등의 기재사항)\n\n■ 「의료기기법 시행규칙」제43조 (첨부문서의 기재사항)\n\n■ 「의료기기법 시행규칙」제44조 (기재사항의 표시방법)\n\n■ 「의료기기 허가․신고․심사 등에 관한 규정」\n\n■ 「의료기기 품목 및 품목별 등급에 관한 규정」\n\n■ 「의료기기 안정성시험 기준」\n\nⅣ. 신청서 기재 항목 및 기술문서 제출자료\n\n- - 15 -\n<!-- PAGE_21 -->\n# Ⅳ\n\n신청서 기재 항목 및 기술문서 제출자료\n\n<!-- PAGE_21 -->\n###### 1\n\n<!-- PAGE_21 -->\n###### 제조․수입허가신청서\n\n❍ 명칭(제품명, 품목명, 모델명)\n\n❍ 분류번호(등급)\n\n❍ 모양 및 구조\n\n❍ 저장방법 및 사용기간\n\n❍ 시험규격\n\n❍ 제조원(수입 또는 제조공정 전부 위탁의 경우)\n\n❍ 허가조건\n\n❍ 비고\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 16 -\n<!-- PAGE_22 -->\n###### 2\n\n<!-- PAGE_22 -->\n###### 기술문서에 관한 자료\n\n❍ 개발경위, 측정원리․방법 및 국내·외 사용현황에 관한 자료\n\n❍ 원재료 및 제조방법에 관한 자료\n\n❍ 사용목적에 관한 자료\n\n❍ 저장방법과 사용기간(유효기간)에 관한 자료\n\n❍ 성능시험에 관한 자료\n\n❍ 체외진단용 의료기기의 취급자 안전에 관한 자료\n\n❍ 이미 허가·인증받은 제품과 비교한 자료(별지제3호서식)\n\nⅤ. 제조․수입허가 신청서 기재 항목\n\n- - 17 -\n<!-- PAGE_23 -->\n# Ⅴ\n\n<!-- PAGE_23 -->\n### 제조․수입허가 신청서 기재항목\n\n<!-- PAGE_23 -->\n###### 1\n\n<!-- PAGE_23 -->\n###### 명칭 (제품명, 품목명, 모델명)\n\n- 1. 제조(수입)업소명·제품명, 품목류명, 모델명을 각각 기재한다.\n- 가. 제품명을 기재하는 경우에는 “제조(수입)업소명·제품명”, “품목명”,\n- 다. 동일제품에 대하여 두개 이상의 다른 상품명(또는 모델명) 부여는\n- 2. 제품명은 이미 허가(신고)를 받거나 받았었던 의료기기의 제품명과 동\n일하여서는 아니 된다. 다만, 다음의 어느 하나에 해당하는 경우에는\n\n이 동일한 의료기기로서 취소된 날로부터 1년이 지난 경우\n\n- 나. 동일한 제조(수입)업자가 허가(신고) 취하 후 동일한 제품을 허가(신\n고)하는 경우\n\n- 다. 서로 다른 수입업자가 제조원이 같은 동일한 제품을 수입하는 경\n우에 수입업소명을 병기하여 구분하는 경우\n\n※ 다만, 기허가 제품과 사용목적이 유사하여 허가받은 제품의 제품명\n\n에 문자, 단어, 숫자 등을 덧붙이거나 교체한 제품명 기재 가능함.\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 18 -\n- (주)오송진단\n심질환표지자검사시약\n\nBNP Test\n\n⇩\n\n⇩\n\n⇩\n\n(제조․수입업소명)\n\n(품목명)\n\n(모델명)\n\n※ 별첨 기재시의 예\n\n<!-- PAGE_24 -->\n###### 2\n\n<!-- PAGE_24 -->\n###### 모양 및 구조\n\n- 1. 모양 및 구조 - 작용원리\n제품의 용도 및 배경을 포함하여, 해당 제품을 개발하기 위하여 적용한\n\n측정원리, 적용되는 체외진단의료기기, 필요한 경우 검사 결과의 임상적\n\n의의 등을 포함하여 기재한다.\n\n- 가. 임상적 의의(배경) : 필요에 따라 해당 검사의 임상적 의의(배경)\n등을 기재할 수 있다.\n\nⅤ. 제조․수입허가 신청서 기재 항목\n\n- - 19 -\n※ 예시\n\n이 NT-proBNP 및 BNP 검사는 심장에 대한 혈역학적 부하를\n\n알 수 있는 바이오마커로 심장 근육층의 호르몬 활성화를 보여준다.\n\nNT-proBNP과 BNP 물질은 혈역학적 부하로 좌심실이 비대해\n\n- 2. 모양 및 구조 - 외형\n- 가. 외형사진 : 제품을 육안으로 식별할 수 있도록 제품의 전체 및\n각각의 반응 영역에서는 측정하고자 하는 물질과 형광 항체\n\n접합체의 혼합물이 검출된다.\n\n3) 형광 발색량은 검체 중 분석물의 농도와 정비례 한다.\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 20 -\n구성하는 시약을 확인할 수 있는 컬러사진을 첨부한다.\n\n- 나. 외관설명 : 고형의 구성제품에 대해서는 모양․구조․중량 등을, 액상\n또는 분말의 시약에 대해서는 색, 성상, 액성, 냄새 등을\n\n기재한다.\n\n- 다. 구성 : 만일 체외진단용 의료기기와 별도의 구성품을 포함하고자 할\n경우, 별도판매구성품에 대하여 추가로 외관사진 및 구성표를\n\nⅤ. 제조․수입허가 신청서 기재 항목\n\n- - 21 -\n그림 1. 외관사진 작성의 예\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 22 -\n<!-- PAGE_28 -->\n###### 3\n\n<!-- PAGE_28 -->\n###### 원재료\n\n- 1. 원재료는 다음 양식의 표를 사용하여 기재한다.\n※ 별도판매구성품이 있을 경우에는 원재료를 함께 기재한다.\n\n- 가. 명칭 : 보조시약을 포함하여 해당 구성시약별로 일반명칭을 기재한다.\n두 세트 이상이 함께 사용되어 하나의 사용목적을 달성하는\n\n- 다. 원재료명 또는 성분명 : 각 구성 시약의 원재료명 또는 성분명을\n1) 반응주성분에 대하여 해당 분량을 명시하고 항체의 경우 가급적\n\n2) 제품의 특성에 따라 그 외의(반응보조제, 보존제, 반응안정제,\n\n반응정지제, 희석액 등) 성분은 적량으로 표시 가능\n\n3) 단위는 ml, v/v, w/v, w/w 등으로 기재하고 범위의 설정도 가능\n\n- 마. 규격 : 원재료에 대한 규격이 있는 경우 당해 규격(KP, USP 등)\n을 기재하고 규격이 없는 경우 자사규격 등을 기재한다.\n\n- 바. 비고 : 비고란에는 각 구성 시약의 총량 및 수량 등을 기재한다.\n일련\n\n번호\n\n명칭\n\n배합목적\n\n원재료명 또는\n\n성분명\n\n분량\n\n규격\n\n비고\n\nⅤ. 제조․수입허가 신청서 기재 항목\n\n- - 23 -\n표 1. 원재료 작성의 예\n\n- 1. 체외진단용 의료기기 - proBNP test kit\n- 2. 별도판매구성품 - proBNP CalSet\n**[표 시작]**\n\n| 일련 | 분량 |\n| --- | --- |\n| No | Device name | Company | Date | 메디안 (pg/mL) | 300 | 130 | 250 | 330 | 1530 | BAYER | HEALTHCARE, | LLC |\n| 번호 | 명칭 | 배합목적 | 원재료명 또는 성분명 | 음성 | 10 | 145 | w/v | 규격 | 비고 |\n| 4. 시험자의 연구경력 | 다. 시약의 표준화(standardization)를 위해 사용된 방법을 기술한다. | 제시한다. | 수행한 결과를 포함하여야 한다. | 5) 검사를 시행할 집단에서의 유병률을 평가할 것을 권장한다. | 한다. | 정보가 기재되어야 함 | 시기를 거친 다음 평가를 수행하도록 한다. | laboratory) 자료를 제시한다. | 검토하여 타당하다고 인정할 수 있는 시험성적서 | 기준치 미만)으로 나오는 환자의 비율이다. | Human Serum 2 | 120.7 | 14.2 | 2.4 | 0.28 | 2.0 | 평균 (pg/mL) | 570 | 300 | 430 | 650 | 1630 |\n| 1) 다양한 농도를 포함한 양성 임상검체를 이용하여 평가한다. | 레닌 | 50ng/mL | 104% | 심장질환 치료제 등 |\n| 가. 체외진단용으로 사용해야 함을 명시한다. | 가. 해당시약의 성분과 분량을 확인할 수 있는 자료 | 가. 분석적 성능시험에 관한 자료(시험성적서) | 제출한다. | 하는 경우에는 해당사항을 부가하여 기재한다. | 주성분 | Streptavidin-coated | Human Serum 3 | 358.7 | 42 | 6.43 | 0.75 | 1.8 |\n| SD (pg/mL) | 770 | 380 | 540 | 830 | 1050 |\n| ELECSYS PROBNP II STAT | IMMUNOASSAY AND ELECSYS | PROBNP II CALSET | Human Serum 4 | 794.7 | 93.5 | 14.9 | 1.76 | 1.9 | microparticles | 2 | 자사규격 | ROCHE | DIAGNOSTICS | CORP |\n| 나. 가능한 2개 이상의 회사 제품과 비교시험 할 것을 권장한다. | Laboratory Standard Institute; 2010 | 4) 시험자의 연구경력 | 않는 성능 배제, 구체적 근거 자료로 제시 | 평가한다. | 동등성을 먼저 확인해야 한다. | 종류, 검체수, 반복회수, 계산법을 함께 제시한다. | 거칠 것을 권장한다. | 수도 있다. 측정은 각 농도별로 2-4회 반복 측정한다. | 5th Percentile | 14 | 9 | 15 | 12 | 188 | 알도스테론 | 1μg/ml | 104% | BIO-RAD | LABORATORIES | , INC. |\n| 나. 분석적 성능시험에 관한 자료에는 다음의 평가항목을 포함한다. | 자료를 제출하여야 한다. |\n| 6 | 상관성 평가 |\n| 번호 | 성능항목 | 방법 및 결과 |\n| MEIA | AxSYM BNP  IMMUNOASSAY | Abbott | UK |\n| 1 | 분석적 성능시험에 관한 자료 |\n| 5 | 사용목적(성능) |\n| 1 | 개발경위, 측정원리·방법 및 국내․외 사용현황에 관한 자료 |\n| ELFA | VIDAS NT-proBNP | bioMerieux | France |\n| 2 | 임상적 성능시험에 관한 자료 |\n**일련**\n| 번호 | 명칭 | 배합목적 | 원재료명 또는 성분명 |\n**(우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187.**\n**HF-REF의 진단을 위해서는 3개의 조건이 충족되어야 한다:**\n| 3 | 사용목적에 관한 자료 | 1. HF에 전형적인 증상들 |\n| 6 | 체외진단용 의료기기의 취급자 안전에 관한 자료 |\n| 안정성을 보장한다면 냉동검체를 일부 이용할 수도 있다. | TEL : 043-719-4652~4665  FAX : 043-719-4650 |\n| 2. HF에 전형적인 증후들 | 1) 식약처장이 지정한 시험검사기관에서 발급한 시험성적서 | 시험 | 보조성분 | Buffer | 적량 | 자사규격 | 최대 (pg/mL) | >4000 | 1600 | >4000 | >4000 | >4000 | 아테놀롤 | 이소소르비드 | 디나이트레이트 | 퀴니딘 |\n| 10 | 시험규격 | 예 | □ | 1) 시험시설개요 |\n| 래된 검체를 대상으로 시험한 자료를 제출한다. | 1) 시험물질 | 가) 판정기준치(농도) | 가) 검체 처치에 첨가된 물질(보존제, 안정제 등) | 분석법 등을 미리 확립한다. | 정밀도 | pro-Brain Natriuretic Peptide | 의료기기심사부 체외진단기기과 | 이용하여 일치성을 결정하였다. |\n| 1. 시험시설개요 | 중복될 경우 이를 생략한다). | 보정물질 | proBNP (recombinant) | approx. 40 | 자사규격 | http://www.mfds.go.kr | 아니오 | □ |\n| 8 | 포장단위 | 황산수소클로피도그렐 | 밀리논유산염 | 트리메소프림 |\n| Vitros  NT-proBNP | J&J | USA | 2.5x |\n| 2 | Cal 2 | 3 | (반복, | 보조성분 | Human serum | 적량 | 자사규격 |\n\n**[표 끝]**\n\n1mL\n\n보조성분\n\nPhosphate buffer\n\n적량\n\n자사규격\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 24 -\n<!-- PAGE_30 -->\n###### 4\n\n<!-- PAGE_30 -->\n###### 제조방법\n\n- 1. '제조원의 제조방법에 따른다.’라고 기재한다. 다만, 다음 각 호에 해당\n- 가. 멸균의료기기의 제조방법의 경우 멸균방법은 식약처장이 인정하는\n멸균의료기기의 멸균방법 [의료기기 허가신고심사 등에 관한 규정,\n\n- 1. 사용목적은 성능을 포함하여 다음에 따라 기재한다.\n- 2. 사용목적은 근거자료에 따라 검사대상, 검체종류, 검사항목, 측정원리\n사람의 혈청, 혈장, 전혈(정맥, 모세관) 등을 포함한다.\n\n- 다. 검사항목 : 검출대상이 되는 물질\n- 라. 측정원리 : 측정에 사용된 검사 원리\n- 마. 정성 또는 정량 : 검사 목적 및 해당 제품의 특성에 따라 정성, 정량,\n반정량 검사용 등을 명확하게 기재한다.\n\nⅤ. 제조․수입허가 신청서 기재 항목\n\n- - 25 -\n- 3. 성능\n- 가. 근거자료를 바탕으로 사용설명서(Instruction for user, IFU)에\n수치적으로 제시된 성능 기재\n\n❍ 당해 제품의 특성에 맞는 성능을 기재하되, 추상적이고 명확하지\n\n표 2. 성능 작성의 예\n\n디클로페낙\n\n니코틴\n\n베라파밀\n\n디곡신\n\n니코틴산\n\n와파린\n\n딜티아젬\n\n니페디핀\n\n디기톡신\n\n나이트로후란토인\n\n2) 교차반응\n\n아래에 제시된 농도에서 BNP Test와의 잠재적 교차반응에\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 26 -\n대하여 다음 단백질 및 펩티드를 평가하였다.\n\n- -관련 단백질 및 펩티드와의 반응-\n물질\n\n물질 농도\n\n회수율(%)\n\n**[표 시작]**\n\n**Institute)의 프로토콜(EP5-A2)에 따라 본 제품, 사람 혈청**\n| 징후와 증상을 평가하여 질병의 진행단계를 4개의 카테고리 | 임상연구 모집단에 대한 Box and whiskers 표가 NYHA |\n**전화: 043-719-4652~4665**\n| 3) 시험방법 | 나) 판정기준치에서의 임상적 민감도 및 특이도 | 간섭물질을 함유한 검체 등) 등에 대한 실험방법을 제공한다. | 풀(pooled human sera) 및 관리물질(controls)을 사용하여 | 회귀방법 | 검체 | 유형 | n | 상관 | 절편 | 기울기 |\n| 22-46 등. | (class I ~ IV)로 분류한다. 연구로부터 얻은 데이터는 | 등급에 따라 분류되었고 아래에 제시되었다. 점선은 본 |\n| 또는 이를 공증한 자료 | 검체의 이력 등이 밝혀진 검체를 사용할 것을 권장한다. | VIDAS NT-proBNP | bioMerieux | France |\n| 재현성 등) | 결정되었다. 본 연구는 20일 동안 수행되었고, 1일 2회를 | 계수 | (95% CI) | 아니오 | □ | (95% CI) |\n\n**[표 끝]**\n\n2회씩 반복하여(n=80) 다음의 결과를 얻었다.\n\nⅤ. 제조․수입허가 신청서 기재 항목\n\n- - 27 -\nRepeatability\n\nMean\n\nSD\n\nCV\n\npg/mL\n\npmol/L\n\npg/mL\n\npmol/L\n\n%\n\nHuman Serum 1\n\n50\n\n- 5.9\n- 1.7\n- 0.21\n- 3.5\n**[표 시작]**\n\n| STRATUS CS ACUTE CARE | BETAHCG AND NT-PROBNP | TESTPAK AND TESTPAK | ASSAY, CALPAK AND DILPAK |\n| --- | --- | --- | --- |\n| STATUSFIRST CHF | (CONGESTIVE HEART | FAILURE) NT-PROBNP | “내가 지킨 청렴실천 모아지면 청렴사회” | 팩스: 043-719-4650 |\n| Pathfast NT-proBNP | Mitsubishi | Japan | 아래에 요약되었다. |\n| 항체, rheumatoid factors, human anti-mouse 항체 등) | Passing- | EDTA | 혈장 | 300 | 0.96 | -8 | 1.12 |\n| Bablok*1 | (-6 ~ -9) | (1.08 ~ 1.18) |\n\n**[표 끝]**\n\n*1 검체의 분산과 측정 에러에 대한 특별한 가정이 없는 선형회귀 방법\n\n샘플범위(해당제품): 0 - 3400pg/mL\n\n샘플범위(비교방법): 5 - 3500pg/mL\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 28 -\n해당제품 분석방법*2\n\n비교방법*2\n\n양성\n\n음성\n\n양성\n\n130\n\n15\n\n*2 일치도는 비교 방법과 해당제품 분석방법의 125pg/mL의 결정 역치를\n\n분류하였다. 이 시스템은 심장 질환 환자를 환자의 임상적인\n\nⅤ. 제조․수입허가 신청서 기재 항목\n\n- - 29 -\n- -심장 질환 모집단(전체)-\nNYHA Functional Class\n\n전체\n\nI\n\nII\n\nIII\n\nIV\n\n검체수 (N)\n\n800\n\n150\n\n350\n\n240\n\n60\n\n제품 검사에서 권장하는 결정 역치인 125 pg/mL을 의미한다.\n\n이전의 보고자료와 같이 이 결과가 BNP 농도의 증가와\n\nNYHA 분류 증가를 나타내고 있다. 이 분석은 BNP 측정이\n\n심장 질환의 심각성 평가에 사용되어 객관적인 정보를 제공\n\n하는 것을 시사한다.\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 30 -\nⅤ. 제조․수입허가 신청서 기재 항목\n\n- - 31 -\n※ 상기 성능은 예시(참고용)에 해당되므로 제품의 특성에 따라 일부\n\n심장 질환과 비-심장 질환 모집단에 대한 연령별 분석이\n\nAmerican Heart Association에 의해 2000 Heart and Stroke\n\nStatistical Update에 발표된 자료와 미국 인구 집단의 연령별\n\n구조에 근거하여 수행되었다. 사용 목적 집단의 연령 분포는\n\n대략 다음과 같다 : 45세 미만 9%, 45-54세는 11%,\n\n55-64세는 22%, 65-74세는 26%, 그리고 75세 이상은\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 32 -\n<!-- PAGE_38 -->\n###### 6\n\n<!-- PAGE_38 -->\n###### 사용방법\n\n- 1. 검체준비 및 저장방법, 검사 전 준비사항, 검사과정, 결과판정 및 정도\n관리, 장비(해당 장비의 제조사, 모델명) 등을 아래와 같이 포함하여\n\n시험 전 시약 조제가 필요한 경우 조제 방법 및 조건, 검사에 필요한\n\n3) 필요한 경우, 시약의 성능과 판정에 영향을 줄 수 있는 기기 및\n\n4) 필요한 경우, 보정물질에 대한 설명 및 방법에 대하여 기재한다.\n\n- 다. 검사과정\n체외진단 의료기기 장비의 매뉴얼 및 사용방법에 대하여 상세하게\n\n기재한다. 환자의 검체를 첨가하는 과정(검체 전처리, 반응시간,\n\n실험실 온도 조건 등), 시험검사 단계(장비의 운용 방법 및 반응시간 등)\n\n및 결과판독과정(판독시간, 결과 출력 방법 등)을 상세하게 기재한다.\n\nⅤ. 제조․수입허가 신청서 기재 항목\n\n- - 33 -\n- 라. 결과판정\n양성, 음성, 경계값(equivocal), 미확정(indeterminate), 무효(invalid)\n\n등의 예측되는 모든 경우의 시험 결과를 판정하는 기준과 해석을\n\n1) 경계값(equivocal), 미확정(indeterminate) 또는 무효(invalid) 결과를\n\n2) 환자 검체의 검사 결과를 판독하기 전에 확인해야 할 대조물질 및\n\n3) 검사의 검출한계 또는 정량한계 등에 따른 보고가능범위에 대하여\n\n2) 제공하는 정도관리물질과 그 물질의 목표값이 있을 경우, 제시된\n\n3) 정도 관리 결과가 적합하지 않을 때 제시할 수 있는 대책을\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 34 -\n<!-- PAGE_40 -->\n###### 7\n\n<!-- PAGE_40 -->\n###### 사용시 주의사항\n\n- 1. 다음의 사항을 포함하여 기재한다.\n- 나. 일반적인 실험실 안전지침 및 생물학적 위험물질(검체, 감염 가능성\n- 마. 경고사항을 포함하여 검체 및 키트 취급 및 보관상의 주의사항(온도,\n- 바. 임상 적용 대상 및 미적용 대상을 포함하여 적용상의 주의사항 및\n- 사. 검사에 영향을 미치는 내용(예 : 간섭 및 교차반응 물질, 위양성\n- 아. 다른 의료기기와 결합하여 사용하는 경우 적절한 조합에 대한\n- 1. 체외진단용 의료기기의 포장단위는 취급상 용이한 최소 단위로 기재하되,\n제조의 경우 “자사포장단위”, 수입의 경우는 “제조원포장단위”로 기재한다.\n\nⅤ. 제조․수입허가 신청서 기재 항목\n\n- - 35 -\n<!-- PAGE_41 -->\n###### 9\n\n<!-- PAGE_41 -->\n###### 저장방법 및 사용기간\n\n- 1. 저장방법은 체외진단용 의료기기의 특성을 고려하여 안정성이 보장될 수\n있도록 검증된 자료에 의한 구체적인 보관 조건(온도, 습도, 차광,\n\n- 가. 키트 또는 세트의 제품인 경우, 구성품별로 보관조건을 기재하고,\n- 라. 전자민원 접수 시 ‘저장방법’ 항은 ‘사용기간에 따름’으로 표기하고\n표 3. 저장방법 및 사용기간(유효기간) 작성의 예\n\nBNP Test\n\n미개봉\n\n2~8℃\n\n제조일로부터 12개월\n\n일회용\n\nBNP Calibration Verification A\n\n미개봉\n\n2~8℃\n\n제조일로부터 11개월\n\nBNP Control 1\n\n미개봉\n\n2~8℃\n\n제조일로부터 11개월\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 36 -\n<!-- PAGE_42 -->\n###### 10\n\n<!-- PAGE_42 -->\n###### 시험규격\n\n- 1. 시약의 품질관리에 적정을 기할 수 있도록 제품의 특성에 따라 성능\n등을 고려하여, 제조단위별·제조단계별로 안전성·성능을 검증하기 위하여\n\n- 2. 시험규격은 제조사의 품질관리시험 자료에 따라 자사가 설정한 시험\n2) 분석적 성능시험(민감도, 특이도, 재현성 등)을 포함하는 것을\n\n1) 시험결과의 적부판정의 기준이 되는 기준치의 허용범위를 명확히\n\n기재하여야 하며, 시험결과가 온도, 습도 등 주위조건에 영향을\n\n1) 시험방법은 순서에 따라 시험결과를 정확히 산출할 수 있도록\n\n2) 표준물질이 사용된 경우, 고, 중, 저 역가를 포함한 각각 최소\n\n3개 이상의 표준물질을 사용할 것을 권장하고 해당 표준물질명을\n\n기재한다.\n\n가) 저농도 표준물질인 경우, 정량 및 정성검출한계를 근거로\n\n하여 설정한다.\n\n나) 표준물질의 농도는 재현성, 직선성, 최소검출한계를 고려하여\n\nⅤ. 제조․수입허가 신청서 기재 항목\n\n- - 37 -\n설정한다.\n\n다) 표준물질 농도는 가능하면 임상적으로 중요한 농도여야 한다.\n\n표 4. 시험규격 작성의 예\n\n**[표 시작]**\n\n| 1. 외관검사 | 카트리지의 라벨 인쇄상태, 구성품 누락여부를 |\n| --- | --- |\n**드물지 않게 볼 수 있는 특이 검체에**\n| K063662 | RAMP NT-PROBNP ASSAY |\n**K033606**\n**포함된 물질**\n| K032335 | MAS CARDIOIMMUNE PROBNP, | MAS CARDIOIMMUNE TL | 번호 | 비교항목1) | 기허가 제품 | 신청제품 | 동등여부2) |\n| Mode와 Batch | K080578 |\n| 발 | 행 | 처 식품의약품안전처 |\n| 발 | 행 | 일 2014년 5월 |\n| 발 | 행 | 인 | 왕진호 |\n**편 집 위 원 장 정희교**\n| K053597 | I-STAT B-TYPE | NATRIURETIC PEPTIDE (BNP) |\n**Eur Heart J 2012;33:1787-847.**\n| 편 집 위 원 | 오현주, 이원규, 김정환, 안영욱, 우승민, 김수영, 김현준 |\n**심부전의 진단**\n\n**[표 끝]**\n\n- 4. 위양성도\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 38 -\n<!-- PAGE_44 -->\n###### 11\n\n<!-- PAGE_44 -->\n###### 제조원 (수입 또는 제조공정 전부 위탁의 경우)\n\n<!-- PAGE_44 -->\n###### <작성요령>\n\n- 가. 수입제품은 제조원을 기재하여야 한다.\n- 나. 제조제품 중 제조공정을 전부 위탁하는 경우 해당 제조소를 기재한다.\n제조의뢰자와 제조자의 상호와 주소를 모두 기재한다. 다만, 제조자가\n\n※ 예시\n\n- - 국내 A 제조업체가 B 제조업체에게 유전질환검사시약 제조를 전면\n위탁 시\n\n제조원은 다음과 같이 기재한다.\n\n상호 (제조사 주소)\n\n․ 제조의뢰자 : A (A사 주소)\n\n․ 제조자 : B (B사 주소)\n\n- - 수입제품의 경우, 미국에 있는 C사가 아일랜드에 있는 D사에 OOO검\n상호 (제조국/제조사 주소)\n\n․ 제조의뢰자 : C (미국 C사 주소)\n\n․ 제조자 : D (아일랜드 D사 주소)\n\nⅥ. 기술문서 등의 심사를 위한 제출자료\n\n- - 39 -\n<!-- PAGE_45 -->\n# Ⅵ\n\n<!-- PAGE_45 -->\n### 기술문서 등의 심사를 위한 제출자료\n\n<!-- PAGE_45 -->\n###### 1. 원칙\n\n- 가. 기술문서 등의 심사를 받고자 하는 자는 시행규칙 별지 제7호\n- 나. 첨부자료 등을 식품의약품안전처장이 정한 전용프로그램으로 작성된\n- 다. 해당 제품의 특성상 첨부자료의 일부가 불필요한 경우, 그 사유를\n하여야 하며, 필요한 경우에 한하여 번역물을 요구할 수 있다. 다만,\n\n- 2. 시험 자료의 요건 (분석적 성능, 품질관리 시험성적서, 검체 조건 설정 자료)\n※ 임상적 성능시험 자료 요건은 별도 제시\n\n2) 해당 의료기기에 대하여 경제협력기구(OECD) 회원국에 허가\n\n당시 제출되어 평가된 시험에 관한 자료로서 해당 정부 또는\n\n정부가 허가 업무를 위임한 등록기관이 제출받아 승인하였음을\n\n확인한 자료 또는 이를 공증한 자료\n\n3) 「의료기기 제조·수입 및 품질관리기준」또는 이와 동등 이상의\n\n규격에 따른 제조사의 품질관리시스템 하에서 실시된 시험성적서\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 40 -\n4) 대학 또는 연구기관 등 국내·외의 전문기관에서 시험한 것으로서\n\n해당 전문기관의 장이 발급하고 그 내용(전문기관의 시험시설\n\n개요, 주요설비, 연구인력 구성, 시험자의 연구경력 등을 포함한다)을\n\n7) 시험 검사품 채취 및 방법에 대한 사항(시험을 위한 별도의\n\n- 다. 추가 기재내용 (대학 또는 연구기관 등 국내외 전문기관에서 시험한\n전문기관의 명칭, 주소, 인증현황, 검사기능 분야, 연구인력구성,\n\n주요설비 목록 등이 기재되어 있어야 함\n\n2) 주요설비\n\n시험검사에 사용된 장비명칭, 장비사양, 검·교정 기록서 등에 대한\n\n사항이 기재되고 관련 증빙자료를 함께 제출하여야 함\n\nⅥ. 기술문서 등의 심사를 위한 제출자료\n\n- - 41 -\n3) 연구인력구성\n\n시험검사를 실시한 전문기관 담당부서에 속한 연구인력들에 대한\n\n시험검사를 실시한 시험자가 해당 검사를 하기에 적합한 전공, 경력\n\n등을 가지고 있는지에 대해 기재하고, 해당 전문기관에서 규정한\n\n- 1. 개발경위\n- 가. 측정하고자 하는 대상 또는 질병이나 증후군의 설명 및 개발배경이\n- 2. 측정원리 ․ 방법\n- 가. 해당제품의 측정 및 질병진단 목적을 달성하기 위하여 적용된 원리에\n- 3. 국내․외에서 사용현황\n- 가. 국내․외에서 사용현황에 관해 제출할 자료는 다음의 사항을 포함한다.\n1)국내외의 판매 또는 허가현황 및 제조허가 경위 등과 관련된 자료\n\n2) 사용 시 보고된 측정오류 : 외국에서 시판 중인 제품의 경우, 제품\n\n안전성 및 성능과 관련된 유해사례보고 요약\n\n3) 제조국에서 사용되지 않는 경우는 그 사유\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 42 -\n<!-- PAGE_48 -->\n###### 2\n\n<!-- PAGE_48 -->\n###### 원재료 및 제조방법에 관한 자료\n\n- 1. 원재료의 성분 또는 분량을 확인할 수 있는 근거자료\n- 나. 원료물질(항원)이 재조합, 합성인 경우, 아미노산서열을 확인할 수\n- 2. 제조공정의 흐름도를 포함한 제조공정에 관한 자료\n- 가. 제조공정의 흐름을 파악할 수 있는 자료를 제출(제조공정상의 제조\n- 나. 원료물질의 제조방법을 간략하게 기술하고, 이를 구매한 경우, 이를\n- 다. 일부 구성제품이 OEM제조품인 경우, 구성품의 제조원(제조자의\n- 1. 허가신청서에 기재한 해당 제품의 사용목적의 세부 사항(검사대상,\n검체종류, 검사항목, 측정원리 및 결과판정방법(정성, 정량 등))에 대한\n\n근거자료를 제출한다.\n\n- 2. 해당제품의 제품설명서(instructions for user)를 제출한다.\nⅥ. 기술문서 등의 심사를 위한 제출자료\n\n- - 43 -\n<!-- PAGE_49 -->\n###### 4\n\n<!-- PAGE_49 -->\n###### 저장방법과 사용기간(유효기간)에 관한 자료\n\n- 1. 완제품 및 개봉 후 시약의 안정성에 관한 자료로서 저장방법, 사용기간\n- 2. 구성 제품별로 구분하여 안정성 시험 자료를 제출한다.\n- 3. 시험성적서는 평가계획, 시험간격, 허용기준, 결과 등의 내용을 포함한다.\n- 4. 안정성 시험 시에는 식약처「의료기기의 안정성 시험 기준」의 내용을\n- 5. 저장 및 사용기간(유효기간)에 대한 시험은 완제품 3 lots, 개봉 후 1\n- 6. 일회용으로 낱개 포장되어 있는 체외진단용 의료기기를 제외하고, 개\n- 7. 수송 조건(환경 및 운반조건 변화)을 고려한 안정성 자료의 제출을 권장한다.\n- 8. 저장방법 및 사용기간(유효기간)에 대한 시험자료는 시험성적서의\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 44 -\n<!-- PAGE_50 -->\n###### 5\n\n<!-- PAGE_50 -->\n###### 제품의 성능을 확인하기 위한 자료\n\n- 1. 제품의 성능을 확인하기 위한 자료는 다음의 자료를 포함한다.\n- 라. 완제품의 품질관리 시험성적서 또는 시험에 관한 자료(3배치 1회 이상\n- 1. 구성시약 중 인간혈액 유래물질이 포함되었을 경우에는 사람면역결핍\n바이러스(HIV),\n\nC형간염바이러스(HCV),\n\nB형간염바이러스(HBV)가\n\n음성 또는 불활성화하여 감염력이 없음을 입증하는 자료를 제출한다.\n\n- 2. 유해물질(독성, 가연성 등) 등 취급자 안전 및 적합성을 확인한 자료를\n제출한다.\n\nⅥ. 기술문서 등의 심사를 위한 제출자료\n\n- - 45 -\n<!-- PAGE_51 -->\n###### 7\n\n<!-- PAGE_51 -->\n###### 이미 허가·인증받은 제품과 비교한 자료\n\n- 1. 이미 허가·인증받은 제품과 명칭(제품명, 품목명, 모델명), 제조(수입)업\n소명, 제조원 및 소재지, 허가(인증)번호, 사용목적, 작용원리, 원재료,\n\n[별지 제3호서식]\n\n1) 기허가된 의료기기와의 차이가 명확하게 입증도록 필요한 항목을 기재하여야 한다.\n\n2) 각 항목에 대한 정보가 기 허가된 의료기기와 동등한 경우 ‘예’에 체크하고, 동\n\n등하지 않을 경우 ‘아니오’란에 체크한다.\n\n11\n\n사용방법\n\n예\n\n□\n\n위와 같이 동등함을 확인하였음.\n\n년     월      일            신청자            (서명 또는 인)\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 46 -\n<!-- PAGE_52 -->\n# Ⅶ\n\n<!-- PAGE_52 -->\n#### 성능시험에 대한 상세사항\n\n<!-- PAGE_52 -->\n###### 일반요건\n\n❍ 시험성적서에 다음의 항목이 포함되어야 한다.\n\n- 9. 시험검사품 채취 및 방법에 대한 사항(시험을 위한 별도의 전처리가\n❍ 대학 또는 연구기관 등 국내․외 전문기관에서 시험한 자료는 다음의\n\n전문기관의 명칭, 주소, 인증현황, 검사기능 분야, 연구인력구성,\n\n주요설비 목록 등이 기재되어 있어야 함\n\n- 2. 주요설비\n시험검사에 사용된 장비명칭, 장비사양, 검·교정 기록서 등에 대한\n\n사항이 기재되고 관련 증빙자료를 함께 제출하여야 함\n\nⅦ. 성능시험에 대한 상세사항\n\n- - 47 -\n- 3. 연구인력구성\n시험검사를 실시한 전문기관 담당부서에 속한 연구인력들에 대한\n\n정보가 기재되어야 함\n\n시험검사를 실시한 시험자가 해당 검사를 하기에 적합한 전공, 경력\n\n<!-- PAGE_53 -->\n###### 1. 분석적 민감도 (최소검출한계, 측정범위, 컷오프농도 등)\n\n최소검출한계, 최소정량한계 및 측정범위를 평가하고, 판정기준치의 설정\n\n가) 사람의 검체(혈청, 혈장, 전혈 등)를 사용한다. 호환되는 기질\n\n(matrix)로 희석하거나 분석 대상 물질을 일정량 첨가한 검체를\n\n낮은 농도 검체로 이용할 수 있다.\n\n나) 공백검체와 추정되는 검출한계 농도 근처의 검체는 최소 각\n\n4개씩 준비한다.\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 48 -\n다) 측정 가능한 검체(혈청, 혈장, 전혈 등)의 종류별 시험 결과를\n\n제시한다.\n\n라) 희석을 위해 만약 인공(simulated)기질을 사용하거나 제품\n\n설명서에 이를 권장한다면 적절한 수의 시험물질로 자연기질과의\n\n마) 희석을 위해 분석대상물질이 포함되어 있지 않은 사람 유래\n\n검체를 찾는 것이 어려울 경우에는 제조사에서 제시 또는\n\n권장하는 물질로 희석할 수도 있으나 되도록이면 사람 유래\n\n나) 시험방법은 참고한 부분에 한해서 문헌 기호를 인용하여 실험\n\n방법을 요약 제출할 수 있다. 아래의 참고방법을 참조할 수\n\n한계에 영향을 줄 수 있는 여러 변수를 고려하기 위해 검사일은\n\nCLSI 지침(EP17-A2)에서는 LOB (limit of blank), LoD\n\n(limit of detection), LOQ (limit of quantitation)를 확립하기\n\n위한 방법이 기술되어 있으며, LoD 측정에 3가지 방법\n\n(classical\n\napproach,\n\nprecision\n\nprofile\n\napproach,\n\nprobit\n\napproach)이 있다. 심혈관표지자의 LoD 측정을 위해서는 전통\n\n적인 방법 또는 정밀도 profile 방법을 이용한다. 전통적인 방법\n\nⅦ. 성능시험에 대한 상세사항\n\n- - 49 -\n(classical approach)은 blank 검체와 검출한계 근처의 low\n\nlevel 검체의 반복 측정 수가 각각 최소 60회가 될 것을 권장한다.\n\n3) 결과제시\n\n가) 통계적으로 유효한 최소검출한계치와 설정에 사용된 검체의\n\n가) 임상적 성능시험(다른 검사 결과, 치료에 대한 반응, 임상적\n\n나) 측정항목, 측정원리, 판독방법 등에 따라 판정기준치(cut-off\n\nvalue)의 설정 방법이 달라질 수 있으므로 전문가 그룹의 자문\n\n※ 판정기준치 혹은 판정기준치와 연계된 기대값(Expected\n\nValue)의 설정이 임상적 성능(임상적 민감도와 임상적 특이도)을\n\n바탕으로 한 경우, 타당한 임상적 근거를 제시한다(임상적\n\n- 다. 측정범위(Measurement range)\n1) 일반사항\n\n가) 측정범위는 기존의 알려진 농도값을 해당 검사가 정확하게\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 50 -\n재현해 낼 수 있는 농도 범위를 말한다.\n\n나) 측정항목, 측정원리, 결과산출방법 등에 따라 측정범위를\n\n평가할 때 사용하는 물질과 희석방법, 결과평가방법이 달라질\n\n수 있으므로 시험을 고려할 때 전문가 그룹의 자문 등을\n\n다) 측정범위 이상의 값을 희석하여 보고할 수 있는지 여부와 희석에\n\n라) 고역가 검체에 의한 전지대효과(prozone effect) 등에 대한\n\n가) 시험물질은 측정법에 적합한 기질(matrix)을 가진 물질이어야\n\n나) 표준품에 비교된 참고물질로 적합한 기질 성상과 목표치를\n\n다) 참고물질을 구할 수 없는 경우, 측정하고자 하는 물질에 대한\n\n라) 희석에 사용하는 음성 검체나 혼합할 음성검체는 기질효과를\n\n고려하여, 해당 제품의 대상이 되는 사람의 음성검체(혈청,\n\n가) 고농도검체와 음성검체를 혼합하여 제조하거나, 고농도의\n\n검체를 단계 희석하여 시험물질을 제조한다.\n\n나) 제시하는 직선성 범위를 포괄하는(예상되는 측정범위보다\n\n20-30% 더 넓은 범위를 포함할 것을 권장한다) 최소 5개\n\nⅦ. 성능시험에 대한 상세사항\n\n- - 51 -\n이상의 알려진 농도를 가지는 검체를 이용하거나 희석을 통해\n\n농도가 확립된 검체를 이용한다. 희석은 고농도와 저농도\n\n검체를 비율적으로 혼합하여 같은 간격으로 중간 농도의\n\n검체를 만드는 것이 권장되나  농도간의 간격이 일정하지 않을\n\n나) 비선형 calibration 모델을 사용하는 제품에 대하여는 근거자료를\n\n<!-- PAGE_57 -->\n###### 2. 분석적 특이도\n\n1) 측정 대상이 되는 검체와 호환되는 기질의 검체를 이용한다. 사용\n\n하므로, 검사법에 따라 결과에 영향을 미칠 것으로 예측되는\n\n나) 검체에 포함될 수 있는 물질(혈색소, 지질, 빌리루빈, heterophile\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 52 -\n표 5. 간섭물질 예\n\n간섭물질\n\n예시\n\n외인성 물질\n\n일반의약품, 고혈압, 협심증, 심부전 등\n\n검체 처리 과정에 통상적으로 첨가될 수\n\n있는 물질\n\n3) 각 분석물질에 대한 각 간섭물질의 영향을 평가하기 위해 다음과\n\n2) 검체의 종류, 간섭물질의 종류, 간섭물질의 농도, 분석물질의 농도,\n\n검체의 제조 방법(예: 간섭물질을 혼합한 검체, 자연적으로 높은\n\n3) 간섭물질의 농도는 임상검체에서 보일 수 있는 최대농도의 3배\n\n이상이 되도록 한다.\n\n4) 간섭물질이 포함된 검체와 포함되지 않은 검체 간의 결과 차이의\n\n허용범위(dmax)를 결정한다.\n\nⅦ. 성능시험에 대한 상세사항\n\n- - 53 -\n5) 각 검체를 3회 이상 반복 검사한다.\n\n6) 간섭물질을 함유한 검체와 간섭물질을 함유하지 않은 검체의\n\n결과를 비교한다. 정량검사의 경우는 바이어스를 구한다.\n\n7) 높은 농도의 간섭물질에 영향을 받지 않는 경우는 더 이상의\n\n평가를 시행하지 않아도 되고, 영향을 받는 경우는 간섭물질의\n\n농도에 따른 영향을 보기 위해 용량-반응검사(dose-response\n\n1) 간섭물질을 함유한 검체와 간섭물질을 함유하지 않은 검체의 결과\n\n값을 제시하고, 정량검사의 경우는 결과를 비교하여 바이어스가\n\n있는지 확인하고 두 값의 차이가 허용범위(dmax)보다 작은지\n\n2) 간섭이 확인된 물질의 경우 간섭을 보이는 구체적 농도와 결과\n\n차이를 기술한다. 대상측정물질을 함유하지 않고 간섭 가능한\n\n<!-- PAGE_59 -->\n###### 3. 정밀도 (반복성, 재현성 등)\n\n- 가. 일반사항\n1) 동일 검체를 일정기간 동안 반복 측정한 결과를 분석하여 정밀도\n\n자료를 제시한다.\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 54 -\n2) 단일 기관에서 실시한 정밀도(반복성)와 다수의 기관에서 실시한\n\n재현성으로 구분하여 평가한다.\n\n3) 각 평가 수행기관은 평가를 시행하기 전에 검사방법에 익숙해지는\n\n2) 반복성(repeatability, within laboratory precision) 평가는 3가지\n\n농도 이상의 검체를 1회(run)마다 2~3회 반복(duplicate or\n\n3) 최소 3개의 시약 로트를 이용하여 로트 간 정밀도(lot-to-lot\n\nprecision)를 평가한다. 로트 간 정밀도 평가는 별도의 평가로\n\n4) 재현성(reproducibility) 평가는 2곳 이상의 검사실에서 3가지\n\n농도 이상의 검체를 1회(run)마다 2회 이상 반복(duplicate or\n\nmore) 측정하기를, 1일에 2회(run) 이상, 5일 이상 동안 실시할\n\n것을 권장한다.\n\nⅦ. 성능시험에 대한 상세사항\n\n- - 55 -\n- 다. 결과제시\n1) 반복성 : 검사 내 정밀도(within-run), 검사 간 정밀도(between-run),\n\n날짜 간 정밀도(between-day), 검사실 내 정밀도(within-\n\n2) 재현성 : 각 검사실 별로 반복성 결과를 기재하고, 모든 검사실\n\n결과를 합한 반복성 결과와 검사기관간(between-site) 결과를\n\n3) 정량검사는 각 정밀도 항목에 대해 농도별로 표준편차 또는\n\n<!-- PAGE_61 -->\n###### 4. 정확도\n\n- 가. WHO international reference standard 물질, NIST standard\nreference material 등 국제표준품 등 특성이 명시되어 있는 물질이\n\n존재할 경우에는 이를 사용하여 평가할 것을 권장하며 최소 2회\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 56 -\n반복 측정한다.\n\n- 나. 표준물질의 목표 결과와 실측 결과(정량검사의 경우 결과 값과\n바이어스)를 제시한다.\n\n- 라. 보정물질(calibrator)의 설정농도, 소급성(traceability)에 대해\n<!-- PAGE_62 -->\n###### 5. 교차반응\n\n유사한 분자구조를 가지고 있는 단백질 등에 대한 교차반응을 시험하여\n\n2) 뇌나트륨이뇨펩티드(NT-proBNP, BNP) 항원과의 교차반응을\n\n위한 평가에 이용될 수 있는 물질은 atrial natriuretic peptide,\n\n알파 심방성 나트륨 이뇨 펩티드(alpha-ANP) 1-28, prepro BNP\n\n- 다. 시험방법\n1) 교차반응물질의 종류, 교차반응물질의 농도, 검체종류(예 : 교차\n\n반응 예상 물질을 인위적으로 첨가한 검체, 자연적으로 높은 교차\n\nⅦ. 성능시험에 대한 상세사항\n\n- - 57 -\n반응 예상물질을 함유한 검체 등), 비교검체(예 : 교차반응물질이\n\n없는 검체 등), 분석물질의 농도 및 결과 등에 대한 실험프로토콜을\n\n제공한다.\n\n2) 최소 5회 이상 교차 반응 예상물질을 함유한 검체(T)와 교차\n\n반응물질을 함유하지 않은 비교검체(C)를 교대로 검사한다(예,\n\n3) 교차반응평가를 위해 준비된 검체는 최소 3회 반복 측정하기를\n\n1) 교차반응 평가에 사용된 물질의 종류, 농도, 측정한 raw data를\n\n※ 임상적 성능시험에 관한 자료의 작성 시 준수사항\n\n❍ 체외진단용 의료기기의 성능 및 유효성을 증명하기 위하여 사람에서 유\n\n❍ 외국에서 외국인을 대상으로 시험한 임상시험 성적도 제출할 수\n\n있으나 수출용이 아닌 내수용일 경우는 국내에서 우리나라 사람을\n\n대상으로 한 자료를 제출하는 것을 원칙으로 한다. 이는 인종 및\n\n지역에 따라 유병률이 다를 수 있기 때문이다. 민족적 요인의 차이가\n\n있어 외국 임상적 성능시험을 그대로 적용하기가 어렵다고 판단되는\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 58 -\n경우, 처장은 국내에 거주하는 한국인으로부터 유래한 검체를 대상으로\n\n한 자료를 추가 제출할 것을 요구 할 수 있다.\n\n❍ 임상기관에서 임상시험이 수행되어야 하며, 임상시험 수행기관에서\n\n❍ 질환이 있음과 없음(“임상적 참값”)을 규명한 방법, 대상군(환자\n\n선택기준/배제기준, 환자 수), 검체종류, 검사방법, 통계 방법 등에\n\n대한 자세한 실험프로토콜을 제공해야한다. 질환이 있음을 규명한\n\n법일 수도 있고 여러 방법(진단검사의학 검사, 영상의학 검사, 병리\n\n검사, 임상 소견, 두 가지 이상의 기허가 제품으로 확인 등)을 종합한\n\n방법일 수도 있다. 종합한 방법일 경우 참값으로 규정한 알고리즘을\n\nESC Guidelines for the diagnosis and treatment of acute and\n\n- 3. LVEF의 감소\nHF-PEF의 진단을 위해서는 4개의 조건이 충족되어야 한다:\n\n- 1. HF에 전형적인 증상들\n- 2. HF에 전형적인 증후들\n- 3. 정상이거나 약간 저하된 LVEF과 확장되지 않은 LV\n- 4. 관련 있는 심장의 구조적 질환 (LV 비대/LA 확장) 및/또는 확장기\n기능장애 (diastolic dysfunction)\n\nⅦ. 성능시험에 대한 상세사항\n\n- - 59 -\n❍ 신선 검체를 사용하는 것을 원칙으로 하나, 충분한 수의 신선 검체를\n\n확보하기 어려울 경우, 냉동검체를 사용할 수 있다.\n\n❍ 아래의 1)부터 4)중 어느 하나에 해당하는 경우, 임상적 성능시험에 관한\n\n1) 4등급 체외진단용 의료기기의 시험\n\n2) 인체로부터 검체를 채취하는 방법의 위해도가 큰 시험(검체의 채취방\n\n법이 인체의 피부, 점막, 안구, 요도를 침투 또는 관통하거나, 외이도,\n\n3) 이미 확립된 의학적 진단방법 또는 허가·인증받은 체외진단용 의료기\n\n4) 의약품 등과 함께 동반하여 진단하는 시험(다만, 이미 허가·인증받은\n\n(※ 상기의 1)부터 4)까지는 식약처장의 임상시험계획승인 및 임상시험\n\n❍ 상기의 1)부터 4)까지에 해당하지 않는 임상시험의 경우에는 아래의 가)부터\n\n다)까지 중 어느 하나에 해당하는 임상적 성능시험에 관한 자료로 제출하여야 한다.\n\n(※ 하기의 가)부터 나)까지는 식약처장의 임상시험계획승인은 제외되고,\n\n임상적 성능시험 실시기관의 임상시험계획승인을 받고 실시해야함)\n\n가) 다음 각 단의 어느 하나에 해당하는 기관에서 별표 14 임상적 성능시험\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 60 -\n관리기준에 의하여 실시한 자료\n\n➀「감염병의 예방 및 관리에 관한 시행규칙」 제4조제9호에 해당하는 기관\n\n➁「혈액관리법」 제6조제3항에 따라 허가받은 공급혈액원\n\n➂ 법 제10조제3항에 따라 식약처장이 지정한 임상시험기관\n\n나) 외국 자료로서 그 내용을 검토하여 실시기관의 신뢰성이 인정되고 별표 14\n\n임상적 성능시험 관리기준에 의하여 실시한 시험자료 또는 이에 준하는\n\n다) 임상적 성능시험에 관한 자료 요건( 상기의 1)에서~ 4)까지) 중 어느\n\n❍ 임상적 성능시험에 관한 자료는 다음 중 어느 하나에 해당하는 자료 요건\n\n- 가. 식품의약품안전처장이 지정한 임상시험기관에서 시험한 자료\n- 나. 외국자료로서 그 내용을 검토하여 실시기관의 신뢰성이 인정되고 시행규\n칙 별표 3 의료기기 임상시험 관리기준에 의하여 실시한 시험자료\n\n- 다. 해당 의료기기에 대하여 경제협력개발기구(OECD) 회원국에 허가 당시\n제출되어 평가된 임상시험에 관한 자료로서 해당 정부 또는 정부가\n\n허가 업무를 위임한 등록기관이 제출받아 승인하였음을 확인한 자료\n\n- 라. 과학논문인용색인(Science Citation Index)에 등재된 전문학회지에\n게재된 자료\n\nⅦ. 성능시험에 대한 상세사항\n\n- - 61 -\n<!-- PAGE_67 -->\n###### 1. 임상적 민감도\n\n- 가. 실험물질\n2) 임상검체가 양성 또는 음성임을 확인한 방법을 기술한 자료를\n\n4) 검사의 목적, 유병률과 제품의 분석능에 따라 통계적으로 의미\n\n있는 검체수가 다르므로 검사의 목적, 유병률, 제품의 분석능에\n\n※ 뇌나트륨이뇨펩티드(NT-proBNP, BNP) 검사의 목표 질환을\n\n가지고 있는 양성 검체 50개 이상을 포함하여 평가하기를\n\n5) 신선한 검체를 이용할 것을 권장하지만, 제조사에서 냉동검체의\n\n- 나. 시험방법\n1) 피험자 선정/제외 기준, 검체 종류와 수, 시험 상 주의사항, 통계\n\n분석법 등에 대한 자세한 실험프로토콜을 제공한다.\n\n2) 신선한 검체를 이용할 것을 권장하지만, 확진된 보관검체로\n\n검사할 경우도 최소 5일 이상 검체를 나누어서 검사한다.\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 62 -\n3) 2개 이상의 독립된 검사실에서 검사를 시행할 것을 권장한다.\n\n4) 평가 전에 결과 해석에 대한 알고리즘 및 불일치한 경우 추가\n\n검사 등의 원인 분석 방법을 미리 확립하고 이를 명시한다.\n\n1) 임상적 민감도 및 95% 신뢰구간을 제시한다. 임상적 민감도란\n\n2) 전체 결과, 특이 결과, 구별되는 소견이 있는 세부 집단별 결과\n\n3) 불일치한 검체에 대해 원인을 분석한 자료를 제출하고 해석을\n\n4) 전향적으로 목표하는 검체 수가 될 때까지 모든 양성 및 음성\n\n검체를 수집하였을 경우 유병률, 양성예측도, 음성예측도를 구할\n\nⅦ. 성능시험에 대한 상세사항\n\n- - 63 -\n<!-- PAGE_69 -->\n###### 2. 임상적 특이도\n\n- 가. 시험물질\n1) 진단의 목표가 되는 질환이 없음이 확인된 임상검체를 이용하여\n\n2) 검체는 적용하고자 하는 대상 인구집단을 반영하여야 한다(예 :\n\n※ 뇌나트륨이뇨펩티드(NT-proBNP, BNP)에 대한 목표 질환을\n\n1) 임상적 특이도란 질환이 없는 환자군에서 음성결과를 보이는\n\n2) 음성예측도와 양성예측도는 질환 유병률과 상관이 있으므로,\n\n3) 양성 결과를 보인 경우 임상소견 확인 및 확진 검사를 시행하여\n\n진양성 유무를 확인토록 한다. 진양성인 검체는 특이도 분석에서\n\n5) 평가 전에 결과 해석에 대한 알고리즘 및 불일치한 경우 추가\n\n검사 등의 원인 분석 방법을 미리 확립하고 이를 명시한다.\n\n6) 선택한 비교평가 방법을 명시하고, 선택한 사유를 기술한다.\n\n7) 2개 이상의 독립된 검사실에서 검사를 시행할 것을 권장한다.\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 64 -\n- 다. 결과제시\n1) 임상적 특이도 및 95% 신뢰구간을 제시한다. 임상적 특이도란\n\n질병이나 특정 상태가 아닌 대상군에서 검사 결과가 음성(판정\n\n2) 산출된 특이도의 95% 신뢰구간의 최하위값이 적합기준을 넘어서면\n\n3) 전체 결과, 특이 결과, 구별되는 소견이 있는 세부 집단별 결과\n\n4) 불일치한 검체에 대해 원인을 분석한 자료를 제출하고, 해석을\n\n<!-- PAGE_70 -->\n###### 3\n\n<!-- PAGE_70 -->\n###### 완제품의 품질관리 시험성적서 또는 시험에 관한 자료\n\n- 1. 3배치 각 1회 이상 또는 1배치 3회 이상의 시험규격에 따른 시험성적서\n- 2. 시험규격 설정에 따른 시험 기준 및 방법에 관한 자료와 표준물질이\n사용된 경우, 이에 관한 자료를 제출한다(단, 표준물질에 관한 자료와\n\n- 3. 시험 항목은 품질의 동등성을 입증할 수 있는 항목(민감도, 특이도,\n정밀도 등)을 설정한다.\n\nⅦ. 성능시험에 대한 상세사항\n\n- - 65 -\n<!-- PAGE_71 -->\n###### 4\n\n<!-- PAGE_71 -->\n###### 완제품 품질관리 시험에 사용된 표준물질에 관한 자료\n\n- 1. 표준물질 혹은 타사 표준물질을 구매하여 사용한 경우, 아래의 자료를\n- 2. 자사 표준물질을 제작하여 사용할 경우, 다음의 자료를 제출한다.\n- 가. 표준물질의 농도별 설정 기준을 입증할 수 있는 시험 자료 및 결과\n- 1. 시험결과를 근거로 하여, 검사에 이용할 수 있는 검체의 취급방법,\n보관조건 및 방법, 사용기간, 주의사항 등에 대하여 기재한다. 이는\n\n원심분리 조건 등을 포함한 검체 전처리과정 및 냉동 및 해동된\n\n- 2. 검체 취급 및 보관조건에 대한 시험 결과를 제시한다. 이는 제시된 시간,\n온도, 습도 등의 항목에 대해 유효하다고 제시된 구간 중 몇 단계에\n\n대해 동일한 검사 결과를 보임을 입증해야 한다. 이 시험은 제시된\n\n구간의 양측 한계치 이상에서 평가된 결과여야 하며, 조건 변화에 따른\n\n결과의 변화를 제시하고 평가에 사용된 만족기준을 함께 기록한다.\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 66 -\n- 3. 시험에 사용된 방법, 검체 수, 검체 범위, 표준 농도, 계산법, 통계처리법,\n허용기준, 결과 등을 요약하여 제시한다.\n\n- 1. 일반사항\n- 가. 국내‧외 허가된 체외진단용 의료기기와의 상관성을 확인할 수 있는\n비교시험 성적서를 포함하여야 한다. 다만, 측정원리 및 측정항목이\n\n- 나. 임상적 민감도와 임상적 특이도를 산출하기 위해 시행한 검사에서\n기존검사법(기허가 제품)을 병행하여 검사하였을 경우, 도출된\n\n두 검사 결과를 정리하여 상관성의 자료로 제시할 수 있다. 분석적\n\n성능시험 과정에서 기존검사법과의 비교 자료가 있을 경우에도\n\n- 2. 시험물질\n- 가. 통계적으로 해석 가능한 수의 임상검체를 포함하여 비교시험을\n- 나. 임상검체는 기 허가된 방법이거나 여타 검증된 방법으로 검사되어\n- 다. 다양한 임상상을 포함하는 검체를 포함하여 비교하도록 한다.\n- 라. 정량검사의 임상검체는 측정범위 내의 다양한 농도가 포함되도록 하고,\n최소 100개 이상의 검체를 시험하도록 권장한다.\n\nⅦ. 성능시험에 대한 상세사항\n\n- - 67 -\n- 3. 시험방법\n- 가. 해당 제품과 측정 원리 및 항목이 가장 유사한 국내 허가 제품 또는\n외국 허가 제품(국내 허가 제품이 없을 시)과의 비교시험을 실시\n\n- 마. 결과가 불일치하는 경우, 다른 검사를 통해 불일치의 원인을 분석하고\n- 4. 결과제시\n- 나. 정량검사에 대해서는 기울기, 절편(신뢰구간과 함께), 상관계수 및\n- 다. 판정기준치(cut-off value)를 적용한 정성적 검사결과(양성과 음성)에\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 68 -\n<!-- PAGE_74 -->\n# Ⅷ\n\n<!-- PAGE_74 -->\n### 참고문헌\n\n- 1. CLSI. Evaluation of Stability of In Vitro Diagnostic Reagents;\nApproved Guideline. CLSI document EP25-A. Wayne, PA: Cinical\n\n- 2.\nCLSI.\n\nEvaluation\n\nof\n\nPrecision\n\nPerformance\n\nof\n\nQuantitative\n\nMeasurement Methods; Approved Guideline - Second Edition.\n\nCLSI document EP5-A2. Wayne, PA: Cinical and Laboratory\n\n- 3.\nCLSI.\n\nUser\n\nProtocol\n\nfor\n\nEvaluation\n\nof\n\nQualitative\n\nTest\n\nPerformance;\n\nApproved\n\nGuideline\n\n- -\nSecond\n\nEdition.\n\nCLSI\n\ndocument EP12-A2. Wayne, PA: Cinical and Laboratory Standard\n\n- 4. CLSI. Protocols for Determination of Limits of Detection and\nLimits\n\nof Quantitation; Approved Guideline.\n\nCLSI document\n\nEP17-A. Wayne, PA: Cinical and Laboratory Standard Institute; 2004\n\n- 5. CLSI. Evaluation of the Linearity of Quantitative Measurement\nProcedures: A Statistical Approach; Approved Guideline. CLSI\n\ndocument EP6-A. Wayne, PA: Cinical and Laboratory Standard\n\nInstitute; 2003\n\nⅧ. 참고문헌\n\n- - 69 -\n- 6. CLSI. Method Comparison and Bias Estimation Using Patient\nSamples;\n\nApproved\n\nGuideline\n\n- -\nSecond\n\nEdition\n\n(Interim\n\nRevision). CLSI document EP9-A2-IR. Wayne, PA: Cinical and\n\n- 7. CLSI. Interference Testing in Clinical Chemistry; Approved\nGuideline - Second Edition. CLSI document EP7-A. Wayne, PA:\n\n- 8. Guidance for Industry and FDA Staff: In Vitro Diagnostic (IVD)\n- 9. Guidance for industry and FDA staff/ Format for traditional and\n- 10. Linnet, K and Kondratovich, M. A Partly Noparametric Approach\nfor Determination of the Llimit of Detection. Clinical Chemistry\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 70 -\n<!-- PAGE_76 -->\n# Ⅸ\n\n<!-- PAGE_76 -->\n### 부록\n\n<!-- PAGE_76 -->\n###### 1. 뇌나트륨이뇨펩티드 제품 국내 제조 및 수입 현황\n\n면역분석법\n\nRoche CARDIAC proBNP+\n\nRoche\n\nGermany\n\nAQT90 FLEX NT-proBNP\n\nRadiometer\n\nDenmark\n\nⅨ. 부록\n\n- - 71 -\n<!-- PAGE_77 -->\n###### 3. 미국 FDA에 등록되어 있는 뇌나트륨이뇨펩티드(NT-proBNP,\n\n<!-- PAGE_77 -->\n###### BNP) 제품 목록 (2013년 9월 현재)\n\n**[표 시작]**\n\n**Document**\n| K051265 | 06/13/2005 | approved |\n**K092649**\n| K043584 | LIQUICHEK BNP CONTROL |\n| K073091 | VIDAS NT-PROBNP ASSAY | BIOMERIEUX, | INC. | 02/29/2008 |\n| K072189 | PATHFAST NTPROBNP AND | D-DIMER TESTS | helen landicho | 02/05/2008 |\n**K060632**\n| K060964 | ARCHITECT BNP ASSAY | diana l wolaniuk | 05/25/2006 |\n| DADE BEHRING, | INC. | 04/06/2006 |\n**K060548**\n| K051596 | NANOGEN, INC. 03/13/2006 |\n\n**[표 끝]**\n\nK052789\n\nTRIAGE BNP TEST FOR\n\nBECKMAN COULTER\n\nIMMUNOASSAY SYSTEMS\n\nBIOSITE\n\nINCORPORATED 01/23/2006\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 72 -\nK051787\n\nTRIAGE BNP TEST\n\nBIOSITE\n\nINCORPORATED 09/22/2005\n\nADVIA IMMUNO MODULAR\n\nSYSTEM (IMS) B-TYPE\n\nNATRIURETIC PEPTIDE (BNP)\n\nASSAY\n\nⅨ. 부록\n\n문\n\n의\n\n처\n\n(우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187.\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n",
  "chunks": [
    {
      "chunk_id": "chunk_001",
      "text": "체외진단용 의료기기\n\n<!-- PAGE_1 -->\n## 체외진단용 의료기기 중\n\n<!-- PAGE_1 -->\n## 뇌나트륨이뇨펩티드 검사제품의\n\n<!-- PAGE_1 -->\n## 허가․심사 가이드라인\n\n<!-- PAGE_1 -->\n## [민원인 안내서]\n\n- 2018. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 0,
        "window_size": 3,
        "char_count": 151,
        "word_count": 29,
        "page_number": 1,
        "window_text": "체외진단용 의료기기\n\n<!-- PAGE_1 -->\n## 체외진단용 의료기기 중\n\n<!-- PAGE_1 -->\n## 뇌나트륨이뇨펩티드 검사제품의\n\n<!-- PAGE_1 -->\n## 허가․심사 가이드라인\n\n<!-- PAGE_1 -->\n## [민원인 안내서]\n\n- 2018.  7.\n 발간등록번호\n\n안내서-0638-02\n\n제·개정 이력서\n\n<!-- PAGE_2 -->\n###### 체외진단용 의료기기 중 뇌나트륨이뇨펩티드\n\n<!-- PAGE_2 -->\n###### 검사제품 허가․심사 가이드라인 [민원인 안내서]\n\n제․개정번호\n\n승인일자\n\n주요 내용\n\n뇌나트륨이뇨펩티드 검사제품의 허가․심사\n\n가이드라인 제정\n\n**[표 시작]**\n\n| 알파 심방성 나트륨 이뇨 | 펩티드(Alpha-ANP) 1-28 | 1,000pg/mL | 104% | ｢ | 체외진단용 의료기기 중 |\n| --- | --- | --- | --- | --- | --- |\n| Mode간의 | 등록대상 | 뇌나트륨이뇨펩티드 검사제품의 허가․심사 | 2.  기술문서에 관한 자료 | 16 | 5. ",
        "original_sentence": "체외진단용 의료기기\n\n<!-- PAGE_1 -->\n## 체외진단용 의료기기 중\n\n<!-- PAGE_1 -->\n## 뇌나트륨이뇨펩티드 검사제품의\n\n<!-- PAGE_1 -->\n## 허가․심사 가이드라인\n\n<!-- PAGE_1 -->\n## [민원인 안내서]\n\n- 2018. "
      }
    },
    {
      "chunk_id": "chunk_002",
      "text": "7.\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 1,
        "window_size": 3,
        "char_count": 3,
        "word_count": 1,
        "page_number": 1,
        "window_text": "체외진단용 의료기기\n\n<!-- PAGE_1 -->\n## 체외진단용 의료기기 중\n\n<!-- PAGE_1 -->\n## 뇌나트륨이뇨펩티드 검사제품의\n\n<!-- PAGE_1 -->\n## 허가․심사 가이드라인\n\n<!-- PAGE_1 -->\n## [민원인 안내서]\n\n- 2018.  7.\n 발간등록번호\n\n안내서-0638-02\n\n제·개정 이력서\n\n<!-- PAGE_2 -->\n###### 체외진단용 의료기기 중 뇌나트륨이뇨펩티드\n\n<!-- PAGE_2 -->\n###### 검사제품 허가․심사 가이드라인 [민원인 안내서]\n\n제․개정번호\n\n승인일자\n\n주요 내용\n\n뇌나트륨이뇨펩티드 검사제품의 허가․심사\n\n가이드라인 제정\n\n**[표 시작]**\n\n| 알파 심방성 나트륨 이뇨 | 펩티드(Alpha-ANP) 1-28 | 1,000pg/mL | 104% | ｢ | 체외진단용 의료기기 중 |\n| --- | --- | --- | --- | --- | --- |\n| Mode간의 | 등록대상 | 뇌나트륨이뇨펩티드 검사제품의 허가․심사 | 2.  기술문서에 관한 자료 | 16 | 5.  제품의 성능을 확인하기 위한 자료 | 44 |\n| 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다. ",
        "original_sentence": "7.\n"
      }
    },
    {
      "chunk_id": "chunk_003",
      "text": "발간등록번호\n\n안내서-0638-02\n\n제·개정 이력서\n\n<!-- PAGE_2 -->\n###### 체외진단용 의료기기 중 뇌나트륨이뇨펩티드\n\n<!-- PAGE_2 -->\n###### 검사제품 허가․심사 가이드라인 [민원인 안내서]\n\n제․개정번호\n\n승인일자\n\n주요 내용\n\n뇌나트륨이뇨펩티드 검사제품의 허가․심사\n\n가이드라인 제정\n\n**[표 시작]**\n\n| 알파 심방성 나트륨 이뇨 | 펩티드(Alpha-ANP) 1-28 | 1,000pg/mL | 104% | ｢ | 체외진단용 의료기기 중 |\n| --- | --- | --- | --- | --- | --- |\n| Mode간의 | 등록대상 | 뇌나트륨이뇨펩티드 검사제품의 허가․심사 | 2. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 2,
        "window_size": 3,
        "char_count": 357,
        "word_count": 74,
        "page_number": 2,
        "window_text": "체외진단용 의료기기\n\n<!-- PAGE_1 -->\n## 체외진단용 의료기기 중\n\n<!-- PAGE_1 -->\n## 뇌나트륨이뇨펩티드 검사제품의\n\n<!-- PAGE_1 -->\n## 허가․심사 가이드라인\n\n<!-- PAGE_1 -->\n## [민원인 안내서]\n\n- 2018.  7.\n 발간등록번호\n\n안내서-0638-02\n\n제·개정 이력서\n\n<!-- PAGE_2 -->\n###### 체외진단용 의료기기 중 뇌나트륨이뇨펩티드\n\n<!-- PAGE_2 -->\n###### 검사제품 허가․심사 가이드라인 [민원인 안내서]\n\n제․개정번호\n\n승인일자\n\n주요 내용\n\n뇌나트륨이뇨펩티드 검사제품의 허가․심사\n\n가이드라인 제정\n\n**[표 시작]**\n\n| 알파 심방성 나트륨 이뇨 | 펩티드(Alpha-ANP) 1-28 | 1,000pg/mL | 104% | ｢ | 체외진단용 의료기기 중 |\n| --- | --- | --- | --- | --- | --- |\n| Mode간의 | 등록대상 | 뇌나트륨이뇨펩티드 검사제품의 허가․심사 | 2.  기술문서에 관한 자료 | 16 | 5.  제품의 성능을 확인하기 위한 자료 | 44 |\n| 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.  | 나. ",
        "original_sentence": "발간등록번호\n\n안내서-0638-02\n\n제·개정 이력서\n\n<!-- PAGE_2 -->\n###### 체외진단용 의료기기 중 뇌나트륨이뇨펩티드\n\n<!-- PAGE_2 -->\n###### 검사제품 허가․심사 가이드라인 [민원인 안내서]\n\n제․개정번호\n\n승인일자\n\n주요 내용\n\n뇌나트륨이뇨펩티드 검사제품의 허가․심사\n\n가이드라인 제정\n\n**[표 시작]**\n\n| 알파 심방성 나트륨 이뇨 | 펩티드(Alpha-ANP) 1-28 | 1,000pg/mL | 104% | ｢ | 체외진단용 의료기기 중 |\n| --- | --- | --- | --- | --- | --- |\n| Mode간의 | 등록대상 | 뇌나트륨이뇨펩티드 검사제품의 허가․심사 | 2. "
      }
    },
    {
      "chunk_id": "chunk_004",
      "text": "기술문서에 관한 자료 | 16 | 5. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 3,
        "window_size": 3,
        "char_count": 22,
        "word_count": 7,
        "page_number": 6,
        "window_text": "체외진단용 의료기기\n\n<!-- PAGE_1 -->\n## 체외진단용 의료기기 중\n\n<!-- PAGE_1 -->\n## 뇌나트륨이뇨펩티드 검사제품의\n\n<!-- PAGE_1 -->\n## 허가․심사 가이드라인\n\n<!-- PAGE_1 -->\n## [민원인 안내서]\n\n- 2018.  7.\n 발간등록번호\n\n안내서-0638-02\n\n제·개정 이력서\n\n<!-- PAGE_2 -->\n###### 체외진단용 의료기기 중 뇌나트륨이뇨펩티드\n\n<!-- PAGE_2 -->\n###### 검사제품 허가․심사 가이드라인 [민원인 안내서]\n\n제․개정번호\n\n승인일자\n\n주요 내용\n\n뇌나트륨이뇨펩티드 검사제품의 허가․심사\n\n가이드라인 제정\n\n**[표 시작]**\n\n| 알파 심방성 나트륨 이뇨 | 펩티드(Alpha-ANP) 1-28 | 1,000pg/mL | 104% | ｢ | 체외진단용 의료기기 중 |\n| --- | --- | --- | --- | --- | --- |\n| Mode간의 | 등록대상 | 뇌나트륨이뇨펩티드 검사제품의 허가․심사 | 2.  기술문서에 관한 자료 | 16 | 5.  제품의 성능을 확인하기 위한 자료 | 44 |\n| 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.  | 나.  시험방법 | 라. ",
        "original_sentence": "기술문서에 관한 자료 | 16 | 5. "
      }
    },
    {
      "chunk_id": "chunk_005",
      "text": "제품의 성능을 확인하기 위한 자료 | 44 |\n| 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 4,
        "window_size": 3,
        "char_count": 60,
        "word_count": 17,
        "page_number": 6,
        "window_text": "7.\n 발간등록번호\n\n안내서-0638-02\n\n제·개정 이력서\n\n<!-- PAGE_2 -->\n###### 체외진단용 의료기기 중 뇌나트륨이뇨펩티드\n\n<!-- PAGE_2 -->\n###### 검사제품 허가․심사 가이드라인 [민원인 안내서]\n\n제․개정번호\n\n승인일자\n\n주요 내용\n\n뇌나트륨이뇨펩티드 검사제품의 허가․심사\n\n가이드라인 제정\n\n**[표 시작]**\n\n| 알파 심방성 나트륨 이뇨 | 펩티드(Alpha-ANP) 1-28 | 1,000pg/mL | 104% | ｢ | 체외진단용 의료기기 중 |\n| --- | --- | --- | --- | --- | --- |\n| Mode간의 | 등록대상 | 뇌나트륨이뇨펩티드 검사제품의 허가․심사 | 2.  기술문서에 관한 자료 | 16 | 5.  제품의 성능을 확인하기 위한 자료 | 44 |\n| 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.  | 나.  시험방법 | 라.  결과제시 | 1 | 품목명 | 5) 교차반응 | 2) 시험방법 | 2) 시험물질 | 4) 해당하는 경우 다음의 사항들을 기술한다. ",
        "original_sentence": "제품의 성능을 확인하기 위한 자료 | 44 |\n| 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다. "
      }
    },
    {
      "chunk_id": "chunk_006",
      "text": "| 나. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 5,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 1,
        "window_text": "발간등록번호\n\n안내서-0638-02\n\n제·개정 이력서\n\n<!-- PAGE_2 -->\n###### 체외진단용 의료기기 중 뇌나트륨이뇨펩티드\n\n<!-- PAGE_2 -->\n###### 검사제품 허가․심사 가이드라인 [민원인 안내서]\n\n제․개정번호\n\n승인일자\n\n주요 내용\n\n뇌나트륨이뇨펩티드 검사제품의 허가․심사\n\n가이드라인 제정\n\n**[표 시작]**\n\n| 알파 심방성 나트륨 이뇨 | 펩티드(Alpha-ANP) 1-28 | 1,000pg/mL | 104% | ｢ | 체외진단용 의료기기 중 |\n| --- | --- | --- | --- | --- | --- |\n| Mode간의 | 등록대상 | 뇌나트륨이뇨펩티드 검사제품의 허가․심사 | 2.  기술문서에 관한 자료 | 16 | 5.  제품의 성능을 확인하기 위한 자료 | 44 |\n| 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.  | 나.  시험방법 | 라.  결과제시 | 1 | 품목명 | 5) 교차반응 | 2) 시험방법 | 2) 시험물질 | 4) 해당하는 경우 다음의 사항들을 기술한다.  | 고 제품명은 두 개 이상 인정한다. ",
        "original_sentence": "| 나. "
      }
    },
    {
      "chunk_id": "chunk_007",
      "text": "시험방법 | 라. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 6,
        "window_size": 3,
        "char_count": 10,
        "word_count": 3,
        "page_number": 33,
        "window_text": "기술문서에 관한 자료 | 16 | 5.  제품의 성능을 확인하기 위한 자료 | 44 |\n| 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.  | 나.  시험방법 | 라.  결과제시 | 1 | 품목명 | 5) 교차반응 | 2) 시험방법 | 2) 시험물질 | 4) 해당하는 경우 다음의 사항들을 기술한다.  | 고 제품명은 두 개 이상 인정한다.  | 2. ",
        "original_sentence": "시험방법 | 라. "
      }
    },
    {
      "chunk_id": "chunk_008",
      "text": "결과제시 | 1 | 품목명 | 5) 교차반응 | 2) 시험방법 | 2) 시험물질 | 4) 해당하는 경우 다음의 사항들을 기술한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 7,
        "window_size": 3,
        "char_count": 73,
        "word_count": 21,
        "page_number": 6,
        "window_text": "제품의 성능을 확인하기 위한 자료 | 44 |\n| 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.  | 나.  시험방법 | 라.  결과제시 | 1 | 품목명 | 5) 교차반응 | 2) 시험방법 | 2) 시험물질 | 4) 해당하는 경우 다음의 사항들을 기술한다.  | 고 제품명은 두 개 이상 인정한다.  | 2.  별도판매구성품 - proBNP CalSet | WHO와 ISO에서 사용되고 있다. ",
        "original_sentence": "결과제시 | 1 | 품목명 | 5) 교차반응 | 2) 시험방법 | 2) 시험물질 | 4) 해당하는 경우 다음의 사항들을 기술한다. "
      }
    },
    {
      "chunk_id": "chunk_009",
      "text": "| 고 제품명은 두 개 이상 인정한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 8,
        "window_size": 3,
        "char_count": 22,
        "word_count": 7,
        "page_number": 23,
        "window_text": "| 나.  시험방법 | 라.  결과제시 | 1 | 품목명 | 5) 교차반응 | 2) 시험방법 | 2) 시험물질 | 4) 해당하는 경우 다음의 사항들을 기술한다.  | 고 제품명은 두 개 이상 인정한다.  | 2.  별도판매구성품 - proBNP CalSet | WHO와 ISO에서 사용되고 있다.  | 제시한다. ",
        "original_sentence": "| 고 제품명은 두 개 이상 인정한다. "
      }
    },
    {
      "chunk_id": "chunk_010",
      "text": "| 2. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 9,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 6,
        "window_text": "시험방법 | 라.  결과제시 | 1 | 품목명 | 5) 교차반응 | 2) 시험방법 | 2) 시험물질 | 4) 해당하는 경우 다음의 사항들을 기술한다.  | 고 제품명은 두 개 이상 인정한다.  | 2.  별도판매구성품 - proBNP CalSet | WHO와 ISO에서 사용되고 있다.  | 제시한다.  | (판정기준치 이상)으로 나오는 환자의 비율이다. ",
        "original_sentence": "| 2. "
      }
    },
    {
      "chunk_id": "chunk_011",
      "text": "별도판매구성품 - proBNP CalSet | WHO와 ISO에서 사용되고 있다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 10,
        "window_size": 3,
        "char_count": 46,
        "word_count": 9,
        "page_number": 11,
        "window_text": "결과제시 | 1 | 품목명 | 5) 교차반응 | 2) 시험방법 | 2) 시험물질 | 4) 해당하는 경우 다음의 사항들을 기술한다.  | 고 제품명은 두 개 이상 인정한다.  | 2.  별도판매구성품 - proBNP CalSet | WHO와 ISO에서 사용되고 있다.  | 제시한다.  | (판정기준치 이상)으로 나오는 환자의 비율이다.  | 제시한다. ",
        "original_sentence": "별도판매구성품 - proBNP CalSet | WHO와 ISO에서 사용되고 있다. "
      }
    },
    {
      "chunk_id": "chunk_012",
      "text": "| 제시한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 11,
        "window_size": 3,
        "char_count": 8,
        "word_count": 2,
        "page_number": 26,
        "window_text": "| 고 제품명은 두 개 이상 인정한다.  | 2.  별도판매구성품 - proBNP CalSet | WHO와 ISO에서 사용되고 있다.  | 제시한다.  | (판정기준치 이상)으로 나오는 환자의 비율이다.  | 제시한다.  | ADVIA CENTAUR B-TYPE | NATRIURETIC PEPTIDE (BNP) | ASSAY | 보조성분 | Bovine serum albumin | 적량 | 자사규격 | BAYER | HEALTHCARE, | LLC |\n| ❍ 원재료 | 5. ",
        "original_sentence": "| 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_013",
      "text": "| (판정기준치 이상)으로 나오는 환자의 비율이다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 12,
        "window_size": 3,
        "char_count": 29,
        "word_count": 6,
        "page_number": 68,
        "window_text": "| 2.  별도판매구성품 - proBNP CalSet | WHO와 ISO에서 사용되고 있다.  | 제시한다.  | (판정기준치 이상)으로 나오는 환자의 비율이다.  | 제시한다.  | ADVIA CENTAUR B-TYPE | NATRIURETIC PEPTIDE (BNP) | ASSAY | 보조성분 | Bovine serum albumin | 적량 | 자사규격 | BAYER | HEALTHCARE, | LLC |\n| ❍ 원재료 | 5.  시험성적서 발급일자 | 여부 | 4) 검체 보관조건, 방법 및 사용기간 등 | 1) 완제품의 최종 품질관리에 따른 성능시험을 포함한다. ",
        "original_sentence": "| (판정기준치 이상)으로 나오는 환자의 비율이다. "
      }
    },
    {
      "chunk_id": "chunk_014",
      "text": "| 제시한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 13,
        "window_size": 3,
        "char_count": 8,
        "word_count": 2,
        "page_number": 26,
        "window_text": "별도판매구성품 - proBNP CalSet | WHO와 ISO에서 사용되고 있다.  | 제시한다.  | (판정기준치 이상)으로 나오는 환자의 비율이다.  | 제시한다.  | ADVIA CENTAUR B-TYPE | NATRIURETIC PEPTIDE (BNP) | ASSAY | 보조성분 | Bovine serum albumin | 적량 | 자사규격 | BAYER | HEALTHCARE, | LLC |\n| ❍ 원재료 | 5.  시험성적서 발급일자 | 여부 | 4) 검체 보관조건, 방법 및 사용기간 등 | 1) 완제품의 최종 품질관리에 따른 성능시험을 포함한다.  | 관계없는 기준이여야 함 | 성품(proBNP Calset)으로 구성된다. ",
        "original_sentence": "| 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_015",
      "text": "| ADVIA CENTAUR B-TYPE | NATRIURETIC PEPTIDE (BNP) | ASSAY | 보조성분 | Bovine serum albumin | 적량 | 자사규격 | BAYER | HEALTHCARE, | LLC |\n| ❍ 원재료 | 5. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 14,
        "window_size": 3,
        "char_count": 144,
        "word_count": 32,
        "page_number": 14,
        "window_text": "| 제시한다.  | (판정기준치 이상)으로 나오는 환자의 비율이다.  | 제시한다.  | ADVIA CENTAUR B-TYPE | NATRIURETIC PEPTIDE (BNP) | ASSAY | 보조성분 | Bovine serum albumin | 적량 | 자사규격 | BAYER | HEALTHCARE, | LLC |\n| ❍ 원재료 | 5.  시험성적서 발급일자 | 여부 | 4) 검체 보관조건, 방법 및 사용기간 등 | 1) 완제품의 최종 품질관리에 따른 성능시험을 포함한다.  | 관계없는 기준이여야 함 | 성품(proBNP Calset)으로 구성된다.  | 습도의 영향 등)을 명시한다. ",
        "original_sentence": "| ADVIA CENTAUR B-TYPE | NATRIURETIC PEPTIDE (BNP) | ASSAY | 보조성분 | Bovine serum albumin | 적량 | 자사규격 | BAYER | HEALTHCARE, | LLC |\n| ❍ 원재료 | 5. "
      }
    },
    {
      "chunk_id": "chunk_016",
      "text": "시험성적서 발급일자 | 여부 | 4) 검체 보관조건, 방법 및 사용기간 등 | 1) 완제품의 최종 품질관리에 따른 성능시험을 포함한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 15,
        "window_size": 3,
        "char_count": 76,
        "word_count": 20,
        "page_number": 3,
        "window_text": "| (판정기준치 이상)으로 나오는 환자의 비율이다.  | 제시한다.  | ADVIA CENTAUR B-TYPE | NATRIURETIC PEPTIDE (BNP) | ASSAY | 보조성분 | Bovine serum albumin | 적량 | 자사규격 | BAYER | HEALTHCARE, | LLC |\n| ❍ 원재료 | 5.  시험성적서 발급일자 | 여부 | 4) 검체 보관조건, 방법 및 사용기간 등 | 1) 완제품의 최종 품질관리에 따른 성능시험을 포함한다.  | 관계없는 기준이여야 함 | 성품(proBNP Calset)으로 구성된다.  | 습도의 영향 등)을 명시한다.  | 분석 자료 | 구체적으로 기재하여야 한다. ",
        "original_sentence": "시험성적서 발급일자 | 여부 | 4) 검체 보관조건, 방법 및 사용기간 등 | 1) 완제품의 최종 품질관리에 따른 성능시험을 포함한다. "
      }
    },
    {
      "chunk_id": "chunk_017",
      "text": "| 관계없는 기준이여야 함 | 성품(proBNP Calset)으로 구성된다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 16,
        "window_size": 3,
        "char_count": 43,
        "word_count": 8,
        "page_number": 14,
        "window_text": "| 제시한다.  | ADVIA CENTAUR B-TYPE | NATRIURETIC PEPTIDE (BNP) | ASSAY | 보조성분 | Bovine serum albumin | 적량 | 자사규격 | BAYER | HEALTHCARE, | LLC |\n| ❍ 원재료 | 5.  시험성적서 발급일자 | 여부 | 4) 검체 보관조건, 방법 및 사용기간 등 | 1) 완제품의 최종 품질관리에 따른 성능시험을 포함한다.  | 관계없는 기준이여야 함 | 성품(proBNP Calset)으로 구성된다.  | 습도의 영향 등)을 명시한다.  | 분석 자료 | 구체적으로 기재하여야 한다.  | Factor(18.7)내에 들어와야 한다. ",
        "original_sentence": "| 관계없는 기준이여야 함 | 성품(proBNP Calset)으로 구성된다. "
      }
    },
    {
      "chunk_id": "chunk_018",
      "text": "| 습도의 영향 등)을 명시한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 17,
        "window_size": 3,
        "char_count": 19,
        "word_count": 5,
        "page_number": 40,
        "window_text": "| ADVIA CENTAUR B-TYPE | NATRIURETIC PEPTIDE (BNP) | ASSAY | 보조성분 | Bovine serum albumin | 적량 | 자사규격 | BAYER | HEALTHCARE, | LLC |\n| ❍ 원재료 | 5.  시험성적서 발급일자 | 여부 | 4) 검체 보관조건, 방법 및 사용기간 등 | 1) 완제품의 최종 품질관리에 따른 성능시험을 포함한다.  | 관계없는 기준이여야 함 | 성품(proBNP Calset)으로 구성된다.  | 습도의 영향 등)을 명시한다.  | 분석 자료 | 구체적으로 기재하여야 한다.  | Factor(18.7)내에 들어와야 한다.  | Princeton |\n| K031038 | 고형상 면역 | <제품명> | 4) 시험일자 및 시험성적서 발급일자 | (분류번호 및 등급) | 보조성분 | Mouse IgG | 적량 | 자사규격 |\n| 다. ",
        "original_sentence": "| 습도의 영향 등)을 명시한다. "
      }
    },
    {
      "chunk_id": "chunk_019",
      "text": "| 분석 자료 | 구체적으로 기재하여야 한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 18,
        "window_size": 3,
        "char_count": 26,
        "word_count": 7,
        "page_number": 45,
        "window_text": "시험성적서 발급일자 | 여부 | 4) 검체 보관조건, 방법 및 사용기간 등 | 1) 완제품의 최종 품질관리에 따른 성능시험을 포함한다.  | 관계없는 기준이여야 함 | 성품(proBNP Calset)으로 구성된다.  | 습도의 영향 등)을 명시한다.  | 분석 자료 | 구체적으로 기재하여야 한다.  | Factor(18.7)내에 들어와야 한다.  | Princeton |\n| K031038 | 고형상 면역 | <제품명> | 4) 시험일자 및 시험성적서 발급일자 | (분류번호 및 등급) | 보조성분 | Mouse IgG | 적량 | 자사규격 |\n| 다.  임상적 성능시험에 관한 자료 | 인에 기인하기도 한다. ",
        "original_sentence": "| 분석 자료 | 구체적으로 기재하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_020",
      "text": "| Factor(18.7)내에 들어와야 한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 19,
        "window_size": 3,
        "char_count": 26,
        "word_count": 4,
        "page_number": 6,
        "window_text": "| 관계없는 기준이여야 함 | 성품(proBNP Calset)으로 구성된다.  | 습도의 영향 등)을 명시한다.  | 분석 자료 | 구체적으로 기재하여야 한다.  | Factor(18.7)내에 들어와야 한다.  | Princeton |\n| K031038 | 고형상 면역 | <제품명> | 4) 시험일자 및 시험성적서 발급일자 | (분류번호 및 등급) | 보조성분 | Mouse IgG | 적량 | 자사규격 |\n| 다.  임상적 성능시험에 관한 자료 | 인에 기인하기도 한다.  | 비교 | 함되도록 한다. ",
        "original_sentence": "| Factor(18.7)내에 들어와야 한다. "
      }
    },
    {
      "chunk_id": "chunk_021",
      "text": "| Princeton |\n| K031038 | 고형상 면역 | <제품명> | 4) 시험일자 및 시험성적서 발급일자 | (분류번호 및 등급) | 보조성분 | Mouse IgG | 적량 | 자사규격 |\n| 다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 20,
        "window_size": 3,
        "char_count": 116,
        "word_count": 32,
        "page_number": 6,
        "window_text": "| 습도의 영향 등)을 명시한다.  | 분석 자료 | 구체적으로 기재하여야 한다.  | Factor(18.7)내에 들어와야 한다.  | Princeton |\n| K031038 | 고형상 면역 | <제품명> | 4) 시험일자 및 시험성적서 발급일자 | (분류번호 및 등급) | 보조성분 | Mouse IgG | 적량 | 자사규격 |\n| 다.  임상적 성능시험에 관한 자료 | 인에 기인하기도 한다.  | 비교 | 함되도록 한다.  | 6. ",
        "original_sentence": "| Princeton |\n| K031038 | 고형상 면역 | <제품명> | 4) 시험일자 및 시험성적서 발급일자 | (분류번호 및 등급) | 보조성분 | Mouse IgG | 적량 | 자사규격 |\n| 다. "
      }
    },
    {
      "chunk_id": "chunk_022",
      "text": "임상적 성능시험에 관한 자료 | 인에 기인하기도 한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 21,
        "window_size": 3,
        "char_count": 31,
        "word_count": 8,
        "page_number": 7,
        "window_text": "| 분석 자료 | 구체적으로 기재하여야 한다.  | Factor(18.7)내에 들어와야 한다.  | Princeton |\n| K031038 | 고형상 면역 | <제품명> | 4) 시험일자 및 시험성적서 발급일자 | (분류번호 및 등급) | 보조성분 | Mouse IgG | 적량 | 자사규격 |\n| 다.  임상적 성능시험에 관한 자료 | 인에 기인하기도 한다.  | 비교 | 함되도록 한다.  | 6.  체외진단용 의료기기의 취급자 안전에 관한 자료 | 44 | Prepro BNP 22-46 | 1,000pg/mL | 104% |\n| 구해진다. ",
        "original_sentence": "임상적 성능시험에 관한 자료 | 인에 기인하기도 한다. "
      }
    },
    {
      "chunk_id": "chunk_023",
      "text": "| 비교 | 함되도록 한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 22,
        "window_size": 3,
        "char_count": 16,
        "word_count": 5,
        "page_number": 41,
        "window_text": "| Factor(18.7)내에 들어와야 한다.  | Princeton |\n| K031038 | 고형상 면역 | <제품명> | 4) 시험일자 및 시험성적서 발급일자 | (분류번호 및 등급) | 보조성분 | Mouse IgG | 적량 | 자사규격 |\n| 다.  임상적 성능시험에 관한 자료 | 인에 기인하기도 한다.  | 비교 | 함되도록 한다.  | 6.  체외진단용 의료기기의 취급자 안전에 관한 자료 | 44 | Prepro BNP 22-46 | 1,000pg/mL | 104% |\n| 구해진다.  | 제시하고, 정량값 판정 등의 기준을 제시한다. ",
        "original_sentence": "| 비교 | 함되도록 한다. "
      }
    },
    {
      "chunk_id": "chunk_024",
      "text": "| 6. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 23,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 38,
        "window_text": "| Princeton |\n| K031038 | 고형상 면역 | <제품명> | 4) 시험일자 및 시험성적서 발급일자 | (분류번호 및 등급) | 보조성분 | Mouse IgG | 적량 | 자사규격 |\n| 다.  임상적 성능시험에 관한 자료 | 인에 기인하기도 한다.  | 비교 | 함되도록 한다.  | 6.  체외진단용 의료기기의 취급자 안전에 관한 자료 | 44 | Prepro BNP 22-46 | 1,000pg/mL | 104% |\n| 구해진다.  | 제시하고, 정량값 판정 등의 기준을 제시한다.  | 가) 검사를 시행한 검체의 농도 | 같은 4가지 형태의 세트를 준비한다. ",
        "original_sentence": "| 6. "
      }
    },
    {
      "chunk_id": "chunk_025",
      "text": "체외진단용 의료기기의 취급자 안전에 관한 자료 | 44 | Prepro BNP 22-46 | 1,000pg/mL | 104% |\n| 구해진다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 24,
        "window_size": 3,
        "char_count": 80,
        "word_count": 19,
        "page_number": 1,
        "window_text": "임상적 성능시험에 관한 자료 | 인에 기인하기도 한다.  | 비교 | 함되도록 한다.  | 6.  체외진단용 의료기기의 취급자 안전에 관한 자료 | 44 | Prepro BNP 22-46 | 1,000pg/mL | 104% |\n| 구해진다.  | 제시하고, 정량값 판정 등의 기준을 제시한다.  | 가) 검사를 시행한 검체의 농도 | 같은 4가지 형태의 세트를 준비한다.  | □ 1년 이내 한시적 적용 또는 일회성 지시ㆍ명령에 해당하는 | 건강한 사람 집단과 통계적인 차이가 없었다. ",
        "original_sentence": "체외진단용 의료기기의 취급자 안전에 관한 자료 | 44 | Prepro BNP 22-46 | 1,000pg/mL | 104% |\n| 구해진다. "
      }
    },
    {
      "chunk_id": "chunk_026",
      "text": "| 제시하고, 정량값 판정 등의 기준을 제시한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 25,
        "window_size": 3,
        "char_count": 28,
        "word_count": 7,
        "page_number": 26,
        "window_text": "| 비교 | 함되도록 한다.  | 6.  체외진단용 의료기기의 취급자 안전에 관한 자료 | 44 | Prepro BNP 22-46 | 1,000pg/mL | 104% |\n| 구해진다.  | 제시하고, 정량값 판정 등의 기준을 제시한다.  | 가) 검사를 시행한 검체의 농도 | 같은 4가지 형태의 세트를 준비한다.  | □ 1년 이내 한시적 적용 또는 일회성 지시ㆍ명령에 해당하는 | 건강한 사람 집단과 통계적인 차이가 없었다.  | 가이드라인 [민원인 안내서] | 가이드라인 [민원인 안내서]｣ |\n| 크로마토그래 | 가. ",
        "original_sentence": "| 제시하고, 정량값 판정 등의 기준을 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_027",
      "text": "| 가) 검사를 시행한 검체의 농도 | 같은 4가지 형태의 세트를 준비한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 26,
        "window_size": 3,
        "char_count": 43,
        "word_count": 12,
        "page_number": 6,
        "window_text": "| 6.  체외진단용 의료기기의 취급자 안전에 관한 자료 | 44 | Prepro BNP 22-46 | 1,000pg/mL | 104% |\n| 구해진다.  | 제시하고, 정량값 판정 등의 기준을 제시한다.  | 가) 검사를 시행한 검체의 농도 | 같은 4가지 형태의 세트를 준비한다.  | □ 1년 이내 한시적 적용 또는 일회성 지시ㆍ명령에 해당하는 | 건강한 사람 집단과 통계적인 차이가 없었다.  | 가이드라인 [민원인 안내서] | 가이드라인 [민원인 안내서]｣ |\n| 크로마토그래 | 가.  일반사항 | 나. ",
        "original_sentence": "| 가) 검사를 시행한 검체의 농도 | 같은 4가지 형태의 세트를 준비한다. "
      }
    },
    {
      "chunk_id": "chunk_028",
      "text": "| □ 1년 이내 한시적 적용 또는 일회성 지시ㆍ명령에 해당하는 | 건강한 사람 집단과 통계적인 차이가 없었다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 27,
        "window_size": 3,
        "char_count": 63,
        "word_count": 17,
        "page_number": 3,
        "window_text": "체외진단용 의료기기의 취급자 안전에 관한 자료 | 44 | Prepro BNP 22-46 | 1,000pg/mL | 104% |\n| 구해진다.  | 제시하고, 정량값 판정 등의 기준을 제시한다.  | 가) 검사를 시행한 검체의 농도 | 같은 4가지 형태의 세트를 준비한다.  | □ 1년 이내 한시적 적용 또는 일회성 지시ㆍ명령에 해당하는 | 건강한 사람 집단과 통계적인 차이가 없었다.  | 가이드라인 [민원인 안내서] | 가이드라인 [민원인 안내서]｣ |\n| 크로마토그래 | 가.  일반사항 | 나.  시험방법 | 1. ",
        "original_sentence": "| □ 1년 이내 한시적 적용 또는 일회성 지시ㆍ명령에 해당하는 | 건강한 사람 집단과 통계적인 차이가 없었다. "
      }
    },
    {
      "chunk_id": "chunk_029",
      "text": "| 가이드라인 [민원인 안내서] | 가이드라인 [민원인 안내서]｣ |\n| 크로마토그래 | 가. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 28,
        "window_size": 3,
        "char_count": 53,
        "word_count": 13,
        "page_number": 1,
        "window_text": "| 제시하고, 정량값 판정 등의 기준을 제시한다.  | 가) 검사를 시행한 검체의 농도 | 같은 4가지 형태의 세트를 준비한다.  | □ 1년 이내 한시적 적용 또는 일회성 지시ㆍ명령에 해당하는 | 건강한 사람 집단과 통계적인 차이가 없었다.  | 가이드라인 [민원인 안내서] | 가이드라인 [민원인 안내서]｣ |\n| 크로마토그래 | 가.  일반사항 | 나.  시험방법 | 1.  품목류명 : 심질환표지자검사시약 | 2 | 명칭(모델명) | Standard Institute; 2004 | Ⅴ. ",
        "original_sentence": "| 가이드라인 [민원인 안내서] | 가이드라인 [민원인 안내서]｣ |\n| 크로마토그래 | 가. "
      }
    },
    {
      "chunk_id": "chunk_030",
      "text": "일반사항 | 나. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 29,
        "window_size": 3,
        "char_count": 10,
        "word_count": 3,
        "page_number": 3,
        "window_text": "| 가) 검사를 시행한 검체의 농도 | 같은 4가지 형태의 세트를 준비한다.  | □ 1년 이내 한시적 적용 또는 일회성 지시ㆍ명령에 해당하는 | 건강한 사람 집단과 통계적인 차이가 없었다.  | 가이드라인 [민원인 안내서] | 가이드라인 [민원인 안내서]｣ |\n| 크로마토그래 | 가.  일반사항 | 나.  시험방법 | 1.  품목류명 : 심질환표지자검사시약 | 2 | 명칭(모델명) | Standard Institute; 2004 | Ⅴ.  제조․수입허가 신청서 기재항목 | 17 | StatusFirst™ CHF NT-proBNP | 주성분 | Mouse monoclonal cardiac | BioMeditech | USA |\n| 안내서-0638-01 | 2017.5. ",
        "original_sentence": "일반사항 | 나. "
      }
    },
    {
      "chunk_id": "chunk_031",
      "text": "시험방법 | 1. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 30,
        "window_size": 3,
        "char_count": 10,
        "word_count": 3,
        "page_number": 21,
        "window_text": "| □ 1년 이내 한시적 적용 또는 일회성 지시ㆍ명령에 해당하는 | 건강한 사람 집단과 통계적인 차이가 없었다.  | 가이드라인 [민원인 안내서] | 가이드라인 [민원인 안내서]｣ |\n| 크로마토그래 | 가.  일반사항 | 나.  시험방법 | 1.  품목류명 : 심질환표지자검사시약 | 2 | 명칭(모델명) | Standard Institute; 2004 | Ⅴ.  제조․수입허가 신청서 기재항목 | 17 | StatusFirst™ CHF NT-proBNP | 주성분 | Mouse monoclonal cardiac | BioMeditech | USA |\n| 안내서-0638-01 | 2017.5.  | ❍ 제조방법 | 6. ",
        "original_sentence": "시험방법 | 1. "
      }
    },
    {
      "chunk_id": "chunk_032",
      "text": "품목류명 : 심질환표지자검사시약 | 2 | 명칭(모델명) | Standard Institute; 2004 | Ⅴ. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 31,
        "window_size": 3,
        "char_count": 64,
        "word_count": 13,
        "page_number": 3,
        "window_text": "| 가이드라인 [민원인 안내서] | 가이드라인 [민원인 안내서]｣ |\n| 크로마토그래 | 가.  일반사항 | 나.  시험방법 | 1.  품목류명 : 심질환표지자검사시약 | 2 | 명칭(모델명) | Standard Institute; 2004 | Ⅴ.  제조․수입허가 신청서 기재항목 | 17 | StatusFirst™ CHF NT-proBNP | 주성분 | Mouse monoclonal cardiac | BioMeditech | USA |\n| 안내서-0638-01 | 2017.5.  | ❍ 제조방법 | 6.  시험성적서에 대한 책임 있는 자의 서명 또는 직인 | 나. ",
        "original_sentence": "품목류명 : 심질환표지자검사시약 | 2 | 명칭(모델명) | Standard Institute; 2004 | Ⅴ. "
      }
    },
    {
      "chunk_id": "chunk_033",
      "text": "제조․수입허가 신청서 기재항목 | 17 | StatusFirst™ CHF NT-proBNP | 주성분 | Mouse monoclonal cardiac | BioMeditech | USA |\n| 안내서-0638-01 | 2017.5. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 32,
        "window_size": 3,
        "char_count": 130,
        "word_count": 24,
        "page_number": 3,
        "window_text": "일반사항 | 나.  시험방법 | 1.  품목류명 : 심질환표지자검사시약 | 2 | 명칭(모델명) | Standard Institute; 2004 | Ⅴ.  제조․수입허가 신청서 기재항목 | 17 | StatusFirst™ CHF NT-proBNP | 주성분 | Mouse monoclonal cardiac | BioMeditech | USA |\n| 안내서-0638-01 | 2017.5.  | ❍ 제조방법 | 6.  시험성적서에 대한 책임 있는 자의 서명 또는 직인 | 나.  표준물질 관리방법 및 관리기록서(정도관리 포함) | 변경은 반드시 분해능(resolution)에 비하여 큰 차이여야 한다. ",
        "original_sentence": "제조․수입허가 신청서 기재항목 | 17 | StatusFirst™ CHF NT-proBNP | 주성분 | Mouse monoclonal cardiac | BioMeditech | USA |\n| 안내서-0638-01 | 2017.5. "
      }
    },
    {
      "chunk_id": "chunk_034",
      "text": "| ❍ 제조방법 | 6. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 33,
        "window_size": 3,
        "char_count": 14,
        "word_count": 5,
        "page_number": 21,
        "window_text": "시험방법 | 1.  품목류명 : 심질환표지자검사시약 | 2 | 명칭(모델명) | Standard Institute; 2004 | Ⅴ.  제조․수입허가 신청서 기재항목 | 17 | StatusFirst™ CHF NT-proBNP | 주성분 | Mouse monoclonal cardiac | BioMeditech | USA |\n| 안내서-0638-01 | 2017.5.  | ❍ 제조방법 | 6.  시험성적서에 대한 책임 있는 자의 서명 또는 직인 | 나.  표준물질 관리방법 및 관리기록서(정도관리 포함) | 변경은 반드시 분해능(resolution)에 비하여 큰 차이여야 한다.  | lot 이상의 시험성적서를 제출한다. ",
        "original_sentence": "| ❍ 제조방법 | 6. "
      }
    },
    {
      "chunk_id": "chunk_035",
      "text": "시험성적서에 대한 책임 있는 자의 서명 또는 직인 | 나. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 34,
        "window_size": 3,
        "char_count": 33,
        "word_count": 10,
        "page_number": 33,
        "window_text": "품목류명 : 심질환표지자검사시약 | 2 | 명칭(모델명) | Standard Institute; 2004 | Ⅴ.  제조․수입허가 신청서 기재항목 | 17 | StatusFirst™ CHF NT-proBNP | 주성분 | Mouse monoclonal cardiac | BioMeditech | USA |\n| 안내서-0638-01 | 2017.5.  | ❍ 제조방법 | 6.  시험성적서에 대한 책임 있는 자의 서명 또는 직인 | 나.  표준물질 관리방법 및 관리기록서(정도관리 포함) | 변경은 반드시 분해능(resolution)에 비하여 큰 차이여야 한다.  | lot 이상의 시험성적서를 제출한다.  | 5) 냉동 및 해동된 검체의 사용 가능성 및 제한점 | 5) 시험 책임자의 서명 또는 직인 | 새로운 경우 동일목적으로 사용되는 제품과 비교할 수 있다. ",
        "original_sentence": "시험성적서에 대한 책임 있는 자의 서명 또는 직인 | 나. "
      }
    },
    {
      "chunk_id": "chunk_036",
      "text": "표준물질 관리방법 및 관리기록서(정도관리 포함) | 변경은 반드시 분해능(resolution)에 비하여 큰 차이여야 한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 35,
        "window_size": 3,
        "char_count": 69,
        "word_count": 13,
        "page_number": 32,
        "window_text": "제조․수입허가 신청서 기재항목 | 17 | StatusFirst™ CHF NT-proBNP | 주성분 | Mouse monoclonal cardiac | BioMeditech | USA |\n| 안내서-0638-01 | 2017.5.  | ❍ 제조방법 | 6.  시험성적서에 대한 책임 있는 자의 서명 또는 직인 | 나.  표준물질 관리방법 및 관리기록서(정도관리 포함) | 변경은 반드시 분해능(resolution)에 비하여 큰 차이여야 한다.  | lot 이상의 시험성적서를 제출한다.  | 5) 냉동 및 해동된 검체의 사용 가능성 및 제한점 | 5) 시험 책임자의 서명 또는 직인 | 새로운 경우 동일목적으로 사용되는 제품과 비교할 수 있다.  | 일련번호 | 명 칭 | 세부 구성 | 외관상 특징 | 경우에는 세트별로 구분하여 기재한다. ",
        "original_sentence": "표준물질 관리방법 및 관리기록서(정도관리 포함) | 변경은 반드시 분해능(resolution)에 비하여 큰 차이여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_037",
      "text": "| lot 이상의 시험성적서를 제출한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 36,
        "window_size": 3,
        "char_count": 23,
        "word_count": 5,
        "page_number": 33,
        "window_text": "| ❍ 제조방법 | 6.  시험성적서에 대한 책임 있는 자의 서명 또는 직인 | 나.  표준물질 관리방법 및 관리기록서(정도관리 포함) | 변경은 반드시 분해능(resolution)에 비하여 큰 차이여야 한다.  | lot 이상의 시험성적서를 제출한다.  | 5) 냉동 및 해동된 검체의 사용 가능성 및 제한점 | 5) 시험 책임자의 서명 또는 직인 | 새로운 경우 동일목적으로 사용되는 제품과 비교할 수 있다.  | 일련번호 | 명 칭 | 세부 구성 | 외관상 특징 | 경우에는 세트별로 구분하여 기재한다.  | 내용입니까? ",
        "original_sentence": "| lot 이상의 시험성적서를 제출한다. "
      }
    },
    {
      "chunk_id": "chunk_038",
      "text": "| 5) 냉동 및 해동된 검체의 사용 가능성 및 제한점 | 5) 시험 책임자의 서명 또는 직인 | 새로운 경우 동일목적으로 사용되는 제품과 비교할 수 있다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 37,
        "window_size": 3,
        "char_count": 88,
        "word_count": 26,
        "page_number": 30,
        "window_text": "시험성적서에 대한 책임 있는 자의 서명 또는 직인 | 나.  표준물질 관리방법 및 관리기록서(정도관리 포함) | 변경은 반드시 분해능(resolution)에 비하여 큰 차이여야 한다.  | lot 이상의 시험성적서를 제출한다.  | 5) 냉동 및 해동된 검체의 사용 가능성 및 제한점 | 5) 시험 책임자의 서명 또는 직인 | 새로운 경우 동일목적으로 사용되는 제품과 비교할 수 있다.  | 일련번호 | 명 칭 | 세부 구성 | 외관상 특징 | 경우에는 세트별로 구분하여 기재한다.  | 내용입니까?  | 5th Percentile | 12 | 9 | 14 | 22 | 270 | 2 | 자사규격 |\n| 민족적 차이 | 7. ",
        "original_sentence": "| 5) 냉동 및 해동된 검체의 사용 가능성 및 제한점 | 5) 시험 책임자의 서명 또는 직인 | 새로운 경우 동일목적으로 사용되는 제품과 비교할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_039",
      "text": "| 일련번호 | 명 칭 | 세부 구성 | 외관상 특징 | 경우에는 세트별로 구분하여 기재한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 38,
        "window_size": 3,
        "char_count": 53,
        "word_count": 16,
        "page_number": 3,
        "window_text": "표준물질 관리방법 및 관리기록서(정도관리 포함) | 변경은 반드시 분해능(resolution)에 비하여 큰 차이여야 한다.  | lot 이상의 시험성적서를 제출한다.  | 5) 냉동 및 해동된 검체의 사용 가능성 및 제한점 | 5) 시험 책임자의 서명 또는 직인 | 새로운 경우 동일목적으로 사용되는 제품과 비교할 수 있다.  | 일련번호 | 명 칭 | 세부 구성 | 외관상 특징 | 경우에는 세트별로 구분하여 기재한다.  | 내용입니까?  | 5th Percentile | 12 | 9 | 14 | 22 | 270 | 2 | 자사규격 |\n| 민족적 차이 | 7.  이미 허가·인증받은 제품과 비교한 자료..................45 | MAS CARDIOLMMUNE PROBNP | LIQUID ASSAYED CARDIAC | MARKER CONTROL LEVEL 1, 2 | AND 3 |\n| 피 | 2. ",
        "original_sentence": "| 일련번호 | 명 칭 | 세부 구성 | 외관상 특징 | 경우에는 세트별로 구분하여 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_040",
      "text": "| 내용입니까? ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 39,
        "window_size": 3,
        "char_count": 9,
        "word_count": 2,
        "page_number": 3,
        "window_text": "| lot 이상의 시험성적서를 제출한다.  | 5) 냉동 및 해동된 검체의 사용 가능성 및 제한점 | 5) 시험 책임자의 서명 또는 직인 | 새로운 경우 동일목적으로 사용되는 제품과 비교할 수 있다.  | 일련번호 | 명 칭 | 세부 구성 | 외관상 특징 | 경우에는 세트별로 구분하여 기재한다.  | 내용입니까?  | 5th Percentile | 12 | 9 | 14 | 22 | 270 | 2 | 자사규격 |\n| 민족적 차이 | 7.  이미 허가·인증받은 제품과 비교한 자료..................45 | MAS CARDIOLMMUNE PROBNP | LIQUID ASSAYED CARDIAC | MARKER CONTROL LEVEL 1, 2 | AND 3 |\n| 피 | 2.  모델명 : BNP Test | 법의 평가 또는 물질에 값을 할당하기 위해서 사용되는 물질 | 위험을 미치지 않는 시험 및 잔여검체로 실시하는 시험은 제외) | 1. ",
        "original_sentence": "| 내용입니까? "
      }
    },
    {
      "chunk_id": "chunk_041",
      "text": "| 5th Percentile | 12 | 9 | 14 | 22 | 270 | 2 | 자사규격 |\n| 민족적 차이 | 7. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 40,
        "window_size": 3,
        "char_count": 69,
        "word_count": 23,
        "page_number": 6,
        "window_text": "| 5) 냉동 및 해동된 검체의 사용 가능성 및 제한점 | 5) 시험 책임자의 서명 또는 직인 | 새로운 경우 동일목적으로 사용되는 제품과 비교할 수 있다.  | 일련번호 | 명 칭 | 세부 구성 | 외관상 특징 | 경우에는 세트별로 구분하여 기재한다.  | 내용입니까?  | 5th Percentile | 12 | 9 | 14 | 22 | 270 | 2 | 자사규격 |\n| 민족적 차이 | 7.  이미 허가·인증받은 제품과 비교한 자료..................45 | MAS CARDIOLMMUNE PROBNP | LIQUID ASSAYED CARDIAC | MARKER CONTROL LEVEL 1, 2 | AND 3 |\n| 피 | 2.  모델명 : BNP Test | 법의 평가 또는 물질에 값을 할당하기 위해서 사용되는 물질 | 위험을 미치지 않는 시험 및 잔여검체로 실시하는 시험은 제외) | 1.  체외진단용 의료기기 - proBNP test kit | Calibrator H, E, C를 이용하여 측정하였을 때 | Prepro BNP 1-21 | 1,000pg/mL | 106% | NT-proBNP antibody fragment | -비심장 질환 모집단(전체)- | MEDICAL | ANALYSIS | SYSTEMS, INC |\n| 마. ",
        "original_sentence": "| 5th Percentile | 12 | 9 | 14 | 22 | 270 | 2 | 자사규격 |\n| 민족적 차이 | 7. "
      }
    },
    {
      "chunk_id": "chunk_042",
      "text": "이미 허가·인증받은 제품과 비교한 자료..................45 | MAS CARDIOLMMUNE PROBNP | LIQUID ASSAYED CARDIAC | MARKER CONTROL LEVEL 1, 2 | AND 3 |\n| 피 | 2. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 41,
        "window_size": 3,
        "char_count": 140,
        "word_count": 27,
        "page_number": 6,
        "window_text": "| 일련번호 | 명 칭 | 세부 구성 | 외관상 특징 | 경우에는 세트별로 구분하여 기재한다.  | 내용입니까?  | 5th Percentile | 12 | 9 | 14 | 22 | 270 | 2 | 자사규격 |\n| 민족적 차이 | 7.  이미 허가·인증받은 제품과 비교한 자료..................45 | MAS CARDIOLMMUNE PROBNP | LIQUID ASSAYED CARDIAC | MARKER CONTROL LEVEL 1, 2 | AND 3 |\n| 피 | 2.  모델명 : BNP Test | 법의 평가 또는 물질에 값을 할당하기 위해서 사용되는 물질 | 위험을 미치지 않는 시험 및 잔여검체로 실시하는 시험은 제외) | 1.  체외진단용 의료기기 - proBNP test kit | Calibrator H, E, C를 이용하여 측정하였을 때 | Prepro BNP 1-21 | 1,000pg/mL | 106% | NT-proBNP antibody fragment | -비심장 질환 모집단(전체)- | MEDICAL | ANALYSIS | SYSTEMS, INC |\n| 마.  정도관리 | 으로 제출하여야 한다. ",
        "original_sentence": "이미 허가·인증받은 제품과 비교한 자료..................45 | MAS CARDIOLMMUNE PROBNP | LIQUID ASSAYED CARDIAC | MARKER CONTROL LEVEL 1, 2 | AND 3 |\n| 피 | 2. "
      }
    },
    {
      "chunk_id": "chunk_043",
      "text": "모델명 : BNP Test | 법의 평가 또는 물질에 값을 할당하기 위해서 사용되는 물질 | 위험을 미치지 않는 시험 및 잔여검체로 실시하는 시험은 제외) | 1. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 42,
        "window_size": 3,
        "char_count": 92,
        "word_count": 26,
        "page_number": 14,
        "window_text": "| 내용입니까?  | 5th Percentile | 12 | 9 | 14 | 22 | 270 | 2 | 자사규격 |\n| 민족적 차이 | 7.  이미 허가·인증받은 제품과 비교한 자료..................45 | MAS CARDIOLMMUNE PROBNP | LIQUID ASSAYED CARDIAC | MARKER CONTROL LEVEL 1, 2 | AND 3 |\n| 피 | 2.  모델명 : BNP Test | 법의 평가 또는 물질에 값을 할당하기 위해서 사용되는 물질 | 위험을 미치지 않는 시험 및 잔여검체로 실시하는 시험은 제외) | 1.  체외진단용 의료기기 - proBNP test kit | Calibrator H, E, C를 이용하여 측정하였을 때 | Prepro BNP 1-21 | 1,000pg/mL | 106% | NT-proBNP antibody fragment | -비심장 질환 모집단(전체)- | MEDICAL | ANALYSIS | SYSTEMS, INC |\n| 마.  정도관리 | 으로 제출하여야 한다.  | Device Studies -Frequently Asked Questions, 2010 | 기술한다. ",
        "original_sentence": "모델명 : BNP Test | 법의 평가 또는 물질에 값을 할당하기 위해서 사용되는 물질 | 위험을 미치지 않는 시험 및 잔여검체로 실시하는 시험은 제외) | 1. "
      }
    },
    {
      "chunk_id": "chunk_044",
      "text": "체외진단용 의료기기 - proBNP test kit | Calibrator H, E, C를 이용하여 측정하였을 때 | Prepro BNP 1-21 | 1,000pg/mL | 106% | NT-proBNP antibody fragment | -비심장 질환 모집단(전체)- | MEDICAL | ANALYSIS | SYSTEMS, INC |\n| 마. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 43,
        "window_size": 3,
        "char_count": 194,
        "word_count": 40,
        "page_number": 1,
        "window_text": "| 5th Percentile | 12 | 9 | 14 | 22 | 270 | 2 | 자사규격 |\n| 민족적 차이 | 7.  이미 허가·인증받은 제품과 비교한 자료..................45 | MAS CARDIOLMMUNE PROBNP | LIQUID ASSAYED CARDIAC | MARKER CONTROL LEVEL 1, 2 | AND 3 |\n| 피 | 2.  모델명 : BNP Test | 법의 평가 또는 물질에 값을 할당하기 위해서 사용되는 물질 | 위험을 미치지 않는 시험 및 잔여검체로 실시하는 시험은 제외) | 1.  체외진단용 의료기기 - proBNP test kit | Calibrator H, E, C를 이용하여 측정하였을 때 | Prepro BNP 1-21 | 1,000pg/mL | 106% | NT-proBNP antibody fragment | -비심장 질환 모집단(전체)- | MEDICAL | ANALYSIS | SYSTEMS, INC |\n| 마.  정도관리 | 으로 제출하여야 한다.  | Device Studies -Frequently Asked Questions, 2010 | 기술한다.  | 델명”을 각각 기재한다. ",
        "original_sentence": "체외진단용 의료기기 - proBNP test kit | Calibrator H, E, C를 이용하여 측정하였을 때 | Prepro BNP 1-21 | 1,000pg/mL | 106% | NT-proBNP antibody fragment | -비심장 질환 모집단(전체)- | MEDICAL | ANALYSIS | SYSTEMS, INC |\n| 마. "
      }
    },
    {
      "chunk_id": "chunk_045",
      "text": "정도관리 | 으로 제출하여야 한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 44,
        "window_size": 3,
        "char_count": 20,
        "word_count": 5,
        "page_number": 56,
        "window_text": "이미 허가·인증받은 제품과 비교한 자료..................45 | MAS CARDIOLMMUNE PROBNP | LIQUID ASSAYED CARDIAC | MARKER CONTROL LEVEL 1, 2 | AND 3 |\n| 피 | 2.  모델명 : BNP Test | 법의 평가 또는 물질에 값을 할당하기 위해서 사용되는 물질 | 위험을 미치지 않는 시험 및 잔여검체로 실시하는 시험은 제외) | 1.  체외진단용 의료기기 - proBNP test kit | Calibrator H, E, C를 이용하여 측정하였을 때 | Prepro BNP 1-21 | 1,000pg/mL | 106% | NT-proBNP antibody fragment | -비심장 질환 모집단(전체)- | MEDICAL | ANALYSIS | SYSTEMS, INC |\n| 마.  정도관리 | 으로 제출하여야 한다.  | Device Studies -Frequently Asked Questions, 2010 | 기술한다.  | 델명”을 각각 기재한다.  | 가) 분석물질 양성(판정기준치 이상)인 검체(간섭물질 없음) | 나) 각각의 농도에서의 반복정밀도 표준편차 | 1. ",
        "original_sentence": "정도관리 | 으로 제출하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_046",
      "text": "| Device Studies -Frequently Asked Questions, 2010 | 기술한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 45,
        "window_size": 3,
        "char_count": 59,
        "word_count": 9,
        "page_number": 6,
        "window_text": "모델명 : BNP Test | 법의 평가 또는 물질에 값을 할당하기 위해서 사용되는 물질 | 위험을 미치지 않는 시험 및 잔여검체로 실시하는 시험은 제외) | 1.  체외진단용 의료기기 - proBNP test kit | Calibrator H, E, C를 이용하여 측정하였을 때 | Prepro BNP 1-21 | 1,000pg/mL | 106% | NT-proBNP antibody fragment | -비심장 질환 모집단(전체)- | MEDICAL | ANALYSIS | SYSTEMS, INC |\n| 마.  정도관리 | 으로 제출하여야 한다.  | Device Studies -Frequently Asked Questions, 2010 | 기술한다.  | 델명”을 각각 기재한다.  | 가) 분석물질 양성(판정기준치 이상)인 검체(간섭물질 없음) | 나) 각각의 농도에서의 반복정밀도 표준편차 | 1.  명칭(제품명, 품목명, 모델명) | 17 | 제시한다. ",
        "original_sentence": "| Device Studies -Frequently Asked Questions, 2010 | 기술한다. "
      }
    },
    {
      "chunk_id": "chunk_047",
      "text": "| 델명”을 각각 기재한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 46,
        "window_size": 3,
        "char_count": 16,
        "word_count": 4,
        "page_number": 23,
        "window_text": "체외진단용 의료기기 - proBNP test kit | Calibrator H, E, C를 이용하여 측정하였을 때 | Prepro BNP 1-21 | 1,000pg/mL | 106% | NT-proBNP antibody fragment | -비심장 질환 모집단(전체)- | MEDICAL | ANALYSIS | SYSTEMS, INC |\n| 마.  정도관리 | 으로 제출하여야 한다.  | Device Studies -Frequently Asked Questions, 2010 | 기술한다.  | 델명”을 각각 기재한다.  | 가) 분석물질 양성(판정기준치 이상)인 검체(간섭물질 없음) | 나) 각각의 농도에서의 반복정밀도 표준편차 | 1.  명칭(제품명, 품목명, 모델명) | 17 | 제시한다.  | 등을 제시한다. ",
        "original_sentence": "| 델명”을 각각 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_048",
      "text": "| 가) 분석물질 양성(판정기준치 이상)인 검체(간섭물질 없음) | 나) 각각의 농도에서의 반복정밀도 표준편차 | 1. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 47,
        "window_size": 3,
        "char_count": 67,
        "word_count": 15,
        "page_number": 14,
        "window_text": "정도관리 | 으로 제출하여야 한다.  | Device Studies -Frequently Asked Questions, 2010 | 기술한다.  | 델명”을 각각 기재한다.  | 가) 분석물질 양성(판정기준치 이상)인 검체(간섭물질 없음) | 나) 각각의 농도에서의 반복정밀도 표준편차 | 1.  명칭(제품명, 품목명, 모델명) | 17 | 제시한다.  | 등을 제시한다.  유병률을 구한 경우는 유병률도 제시한다. ",
        "original_sentence": "| 가) 분석물질 양성(판정기준치 이상)인 검체(간섭물질 없음) | 나) 각각의 농도에서의 반복정밀도 표준편차 | 1. "
      }
    },
    {
      "chunk_id": "chunk_049",
      "text": "명칭(제품명, 품목명, 모델명) | 17 | 제시한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 48,
        "window_size": 3,
        "char_count": 31,
        "word_count": 7,
        "page_number": 3,
        "window_text": "| Device Studies -Frequently Asked Questions, 2010 | 기술한다.  | 델명”을 각각 기재한다.  | 가) 분석물질 양성(판정기준치 이상)인 검체(간섭물질 없음) | 나) 각각의 농도에서의 반복정밀도 표준편차 | 1.  명칭(제품명, 품목명, 모델명) | 17 | 제시한다.  | 등을 제시한다.  유병률을 구한 경우는 유병률도 제시한다.  | 토콜을 제시한다. ",
        "original_sentence": "명칭(제품명, 품목명, 모델명) | 17 | 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_050",
      "text": "| 등을 제시한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 49,
        "window_size": 3,
        "char_count": 11,
        "word_count": 3,
        "page_number": 26,
        "window_text": "| 델명”을 각각 기재한다.  | 가) 분석물질 양성(판정기준치 이상)인 검체(간섭물질 없음) | 나) 각각의 농도에서의 반복정밀도 표준편차 | 1.  명칭(제품명, 품목명, 모델명) | 17 | 제시한다.  | 등을 제시한다.  유병률을 구한 경우는 유병률도 제시한다.  | 토콜을 제시한다.  | 한다. ",
        "original_sentence": "| 등을 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_051",
      "text": "유병률을 구한 경우는 유병률도 제시한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 50,
        "window_size": 3,
        "char_count": 23,
        "word_count": 5,
        "page_number": 26,
        "window_text": "| 가) 분석물질 양성(판정기준치 이상)인 검체(간섭물질 없음) | 나) 각각의 농도에서의 반복정밀도 표준편차 | 1.  명칭(제품명, 품목명, 모델명) | 17 | 제시한다.  | 등을 제시한다.  유병률을 구한 경우는 유병률도 제시한다.  | 토콜을 제시한다.  | 한다.  | 1 | Cal 1 | 단일구성 | 동결건조 시약 | 보이지 않았다. ",
        "original_sentence": "유병률을 구한 경우는 유병률도 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_052",
      "text": "| 토콜을 제시한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 51,
        "window_size": 3,
        "char_count": 12,
        "word_count": 3,
        "page_number": 26,
        "window_text": "명칭(제품명, 품목명, 모델명) | 17 | 제시한다.  | 등을 제시한다.  유병률을 구한 경우는 유병률도 제시한다.  | 토콜을 제시한다.  | 한다.  | 1 | Cal 1 | 단일구성 | 동결건조 시약 | 보이지 않았다.  | Corporation |\n| K031364 | ❍ 사용목적(성능) | 3 | 제조(수입)업소명 | 6) 원심분리 조건 등을 포함한 검체 전처리과정 등 | 1) 임상적 민감도 | 결과판정 상 주의사항을 기재한다. ",
        "original_sentence": "| 토콜을 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_053",
      "text": "| 한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 52,
        "window_size": 3,
        "char_count": 6,
        "word_count": 2,
        "page_number": 56,
        "window_text": "| 등을 제시한다.  유병률을 구한 경우는 유병률도 제시한다.  | 토콜을 제시한다.  | 한다.  | 1 | Cal 1 | 단일구성 | 동결건조 시약 | 보이지 않았다.  | Corporation |\n| K031364 | ❍ 사용목적(성능) | 3 | 제조(수입)업소명 | 6) 원심분리 조건 등을 포함한 검체 전처리과정 등 | 1) 임상적 민감도 | 결과판정 상 주의사항을 기재한다.  | 보조성분 | HEPES Buffer | 적량 | 자사규격 | 전체 | <45세 | 45-54 | 55-64 |\n| 수 있음을 알려드립니다. ",
        "original_sentence": "| 한다. "
      }
    },
    {
      "chunk_id": "chunk_054",
      "text": "| 1 | Cal 1 | 단일구성 | 동결건조 시약 | 보이지 않았다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 53,
        "window_size": 3,
        "char_count": 40,
        "word_count": 13,
        "page_number": 14,
        "window_text": "유병률을 구한 경우는 유병률도 제시한다.  | 토콜을 제시한다.  | 한다.  | 1 | Cal 1 | 단일구성 | 동결건조 시약 | 보이지 않았다.  | Corporation |\n| K031364 | ❍ 사용목적(성능) | 3 | 제조(수입)업소명 | 6) 원심분리 조건 등을 포함한 검체 전처리과정 등 | 1) 임상적 민감도 | 결과판정 상 주의사항을 기재한다.  | 보조성분 | HEPES Buffer | 적량 | 자사규격 | 전체 | <45세 | 45-54 | 55-64 |\n| 수 있음을 알려드립니다.  | 3. ",
        "original_sentence": "| 1 | Cal 1 | 단일구성 | 동결건조 시약 | 보이지 않았다. "
      }
    },
    {
      "chunk_id": "chunk_055",
      "text": "| Corporation |\n| K031364 | ❍ 사용목적(성능) | 3 | 제조(수입)업소명 | 6) 원심분리 조건 등을 포함한 검체 전처리과정 등 | 1) 임상적 민감도 | 결과판정 상 주의사항을 기재한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 54,
        "window_size": 3,
        "char_count": 120,
        "word_count": 30,
        "page_number": 6,
        "window_text": "| 토콜을 제시한다.  | 한다.  | 1 | Cal 1 | 단일구성 | 동결건조 시약 | 보이지 않았다.  | Corporation |\n| K031364 | ❍ 사용목적(성능) | 3 | 제조(수입)업소명 | 6) 원심분리 조건 등을 포함한 검체 전처리과정 등 | 1) 임상적 민감도 | 결과판정 상 주의사항을 기재한다.  | 보조성분 | HEPES Buffer | 적량 | 자사규격 | 전체 | <45세 | 45-54 | 55-64 |\n| 수 있음을 알려드립니다.  | 3.  품목분류번호 : D04030.01 | CV 값이 다음의 기준을 만족해야 한다. ",
        "original_sentence": "| Corporation |\n| K031364 | ❍ 사용목적(성능) | 3 | 제조(수입)업소명 | 6) 원심분리 조건 등을 포함한 검체 전처리과정 등 | 1) 임상적 민감도 | 결과판정 상 주의사항을 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_056",
      "text": "| 보조성분 | HEPES Buffer | 적량 | 자사규격 | 전체 | <45세 | 45-54 | 55-64 |\n| 수 있음을 알려드립니다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 55,
        "window_size": 3,
        "char_count": 80,
        "word_count": 22,
        "page_number": 6,
        "window_text": "| 한다.  | 1 | Cal 1 | 단일구성 | 동결건조 시약 | 보이지 않았다.  | Corporation |\n| K031364 | ❍ 사용목적(성능) | 3 | 제조(수입)업소명 | 6) 원심분리 조건 등을 포함한 검체 전처리과정 등 | 1) 임상적 민감도 | 결과판정 상 주의사항을 기재한다.  | 보조성분 | HEPES Buffer | 적량 | 자사규격 | 전체 | <45세 | 45-54 | 55-64 |\n| 수 있음을 알려드립니다.  | 3.  품목분류번호 : D04030.01 | CV 값이 다음의 기준을 만족해야 한다.  | [근거: ｢ | 식품의약품안전처 지침서등의 |\n| 3 | Reagent 3 | 기간)을 기재한다. ",
        "original_sentence": "| 보조성분 | HEPES Buffer | 적량 | 자사규격 | 전체 | <45세 | 45-54 | 55-64 |\n| 수 있음을 알려드립니다. "
      }
    },
    {
      "chunk_id": "chunk_057",
      "text": "| 3. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 56,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 26,
        "window_text": "| 1 | Cal 1 | 단일구성 | 동결건조 시약 | 보이지 않았다.  | Corporation |\n| K031364 | ❍ 사용목적(성능) | 3 | 제조(수입)업소명 | 6) 원심분리 조건 등을 포함한 검체 전처리과정 등 | 1) 임상적 민감도 | 결과판정 상 주의사항을 기재한다.  | 보조성분 | HEPES Buffer | 적량 | 자사규격 | 전체 | <45세 | 45-54 | 55-64 |\n| 수 있음을 알려드립니다.  | 3.  품목분류번호 : D04030.01 | CV 값이 다음의 기준을 만족해야 한다.  | [근거: ｢ | 식품의약품안전처 지침서등의 |\n| 3 | Reagent 3 | 기간)을 기재한다.  | 2 | Cal 2 | 단일구성 | 동결건조 시약 | 최소 (pg/mL) | 0 | 3 | 0 | 0 | 14 | 알기닌 바소프레신(AVP) | 1,000pg/mL | 96% | 세 | 세 | 세 |\n| 표6. ",
        "original_sentence": "| 3. "
      }
    },
    {
      "chunk_id": "chunk_058",
      "text": "품목분류번호 : D04030.01 | CV 값이 다음의 기준을 만족해야 한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 57,
        "window_size": 3,
        "char_count": 44,
        "word_count": 10,
        "page_number": 6,
        "window_text": "| Corporation |\n| K031364 | ❍ 사용목적(성능) | 3 | 제조(수입)업소명 | 6) 원심분리 조건 등을 포함한 검체 전처리과정 등 | 1) 임상적 민감도 | 결과판정 상 주의사항을 기재한다.  | 보조성분 | HEPES Buffer | 적량 | 자사규격 | 전체 | <45세 | 45-54 | 55-64 |\n| 수 있음을 알려드립니다.  | 3.  품목분류번호 : D04030.01 | CV 값이 다음의 기준을 만족해야 한다.  | [근거: ｢ | 식품의약품안전처 지침서등의 |\n| 3 | Reagent 3 | 기간)을 기재한다.  | 2 | Cal 2 | 단일구성 | 동결건조 시약 | 최소 (pg/mL) | 0 | 3 | 0 | 0 | 14 | 알기닌 바소프레신(AVP) | 1,000pg/mL | 96% | 세 | 세 | 세 |\n| 표6.  진단기준의 예 | 1) 사용자가 정도 관리를 할 수 있는 방법을 제시한다. ",
        "original_sentence": "품목분류번호 : D04030.01 | CV 값이 다음의 기준을 만족해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_059",
      "text": "| [근거: ｢ | 식품의약품안전처 지침서등의 |\n| 3 | Reagent 3 | 기간)을 기재한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 58,
        "window_size": 3,
        "char_count": 57,
        "word_count": 15,
        "page_number": 2,
        "window_text": "| 보조성분 | HEPES Buffer | 적량 | 자사규격 | 전체 | <45세 | 45-54 | 55-64 |\n| 수 있음을 알려드립니다.  | 3.  품목분류번호 : D04030.01 | CV 값이 다음의 기준을 만족해야 한다.  | [근거: ｢ | 식품의약품안전처 지침서등의 |\n| 3 | Reagent 3 | 기간)을 기재한다.  | 2 | Cal 2 | 단일구성 | 동결건조 시약 | 최소 (pg/mL) | 0 | 3 | 0 | 0 | 14 | 알기닌 바소프레신(AVP) | 1,000pg/mL | 96% | 세 | 세 | 세 |\n| 표6.  진단기준의 예 | 1) 사용자가 정도 관리를 할 수 있는 방법을 제시한다.  | 검사의 특이도에 대한 자료를 제공해야 한다. ",
        "original_sentence": "| [근거: ｢ | 식품의약품안전처 지침서등의 |\n| 3 | Reagent 3 | 기간)을 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_060",
      "text": "| 2 | Cal 2 | 단일구성 | 동결건조 시약 | 최소 (pg/mL) | 0 | 3 | 0 | 0 | 14 | 알기닌 바소프레신(AVP) | 1,000pg/mL | 96% | 세 | 세 | 세 |\n| 표6. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 59,
        "window_size": 3,
        "char_count": 119,
        "word_count": 39,
        "page_number": 6,
        "window_text": "| 3.  품목분류번호 : D04030.01 | CV 값이 다음의 기준을 만족해야 한다.  | [근거: ｢ | 식품의약품안전처 지침서등의 |\n| 3 | Reagent 3 | 기간)을 기재한다.  | 2 | Cal 2 | 단일구성 | 동결건조 시약 | 최소 (pg/mL) | 0 | 3 | 0 | 0 | 14 | 알기닌 바소프레신(AVP) | 1,000pg/mL | 96% | 세 | 세 | 세 |\n| 표6.  진단기준의 예 | 1) 사용자가 정도 관리를 할 수 있는 방법을 제시한다.  | 검사의 특이도에 대한 자료를 제공해야 한다.  | 2) 교차반응을 보이는 물질의 종류와 빈도를 제시한다. ",
        "original_sentence": "| 2 | Cal 2 | 단일구성 | 동결건조 시약 | 최소 (pg/mL) | 0 | 3 | 0 | 0 | 14 | 알기닌 바소프레신(AVP) | 1,000pg/mL | 96% | 세 | 세 | 세 |\n| 표6. "
      }
    },
    {
      "chunk_id": "chunk_061",
      "text": "진단기준의 예 | 1) 사용자가 정도 관리를 할 수 있는 방법을 제시한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 60,
        "window_size": 3,
        "char_count": 42,
        "word_count": 12,
        "page_number": 21,
        "window_text": "품목분류번호 : D04030.01 | CV 값이 다음의 기준을 만족해야 한다.  | [근거: ｢ | 식품의약품안전처 지침서등의 |\n| 3 | Reagent 3 | 기간)을 기재한다.  | 2 | Cal 2 | 단일구성 | 동결건조 시약 | 최소 (pg/mL) | 0 | 3 | 0 | 0 | 14 | 알기닌 바소프레신(AVP) | 1,000pg/mL | 96% | 세 | 세 | 세 |\n| 표6.  진단기준의 예 | 1) 사용자가 정도 관리를 할 수 있는 방법을 제시한다.  | 검사의 특이도에 대한 자료를 제공해야 한다.  | 2) 교차반응을 보이는 물질의 종류와 빈도를 제시한다.  | 나) 분석물질 양성(판정기준치 이상)인 검체 + 간섭물질 | 다) 각각의 농도에서의 검사실내 정밀도 표준편차 | Ⅶ. ",
        "original_sentence": "진단기준의 예 | 1) 사용자가 정도 관리를 할 수 있는 방법을 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_062",
      "text": "| 검사의 특이도에 대한 자료를 제공해야 한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 61,
        "window_size": 3,
        "char_count": 27,
        "word_count": 7,
        "page_number": 31,
        "window_text": "| [근거: ｢ | 식품의약품안전처 지침서등의 |\n| 3 | Reagent 3 | 기간)을 기재한다.  | 2 | Cal 2 | 단일구성 | 동결건조 시약 | 최소 (pg/mL) | 0 | 3 | 0 | 0 | 14 | 알기닌 바소프레신(AVP) | 1,000pg/mL | 96% | 세 | 세 | 세 |\n| 표6.  진단기준의 예 | 1) 사용자가 정도 관리를 할 수 있는 방법을 제시한다.  | 검사의 특이도에 대한 자료를 제공해야 한다.  | 2) 교차반응을 보이는 물질의 종류와 빈도를 제시한다.  | 나) 분석물질 양성(판정기준치 이상)인 검체 + 간섭물질 | 다) 각각의 농도에서의 검사실내 정밀도 표준편차 | Ⅶ.  성능시험에 대한 상세사항 | 46 | 일련번호 | 명 칭 | 세부 구성 | 외관상 특징 | 판단한다. ",
        "original_sentence": "| 검사의 특이도에 대한 자료를 제공해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_063",
      "text": "| 2) 교차반응을 보이는 물질의 종류와 빈도를 제시한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 62,
        "window_size": 3,
        "char_count": 33,
        "word_count": 8,
        "page_number": 6,
        "window_text": "| 2 | Cal 2 | 단일구성 | 동결건조 시약 | 최소 (pg/mL) | 0 | 3 | 0 | 0 | 14 | 알기닌 바소프레신(AVP) | 1,000pg/mL | 96% | 세 | 세 | 세 |\n| 표6.  진단기준의 예 | 1) 사용자가 정도 관리를 할 수 있는 방법을 제시한다.  | 검사의 특이도에 대한 자료를 제공해야 한다.  | 2) 교차반응을 보이는 물질의 종류와 빈도를 제시한다.  | 나) 분석물질 양성(판정기준치 이상)인 검체 + 간섭물질 | 다) 각각의 농도에서의 검사실내 정밀도 표준편차 | Ⅶ.  성능시험에 대한 상세사항 | 46 | 일련번호 | 명 칭 | 세부 구성 | 외관상 특징 | 판단한다.  | 환자의 비율이다. ",
        "original_sentence": "| 2) 교차반응을 보이는 물질의 종류와 빈도를 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_064",
      "text": "| 나) 분석물질 양성(판정기준치 이상)인 검체 + 간섭물질 | 다) 각각의 농도에서의 검사실내 정밀도 표준편차 | Ⅶ. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 63,
        "window_size": 3,
        "char_count": 68,
        "word_count": 17,
        "page_number": 14,
        "window_text": "진단기준의 예 | 1) 사용자가 정도 관리를 할 수 있는 방법을 제시한다.  | 검사의 특이도에 대한 자료를 제공해야 한다.  | 2) 교차반응을 보이는 물질의 종류와 빈도를 제시한다.  | 나) 분석물질 양성(판정기준치 이상)인 검체 + 간섭물질 | 다) 각각의 농도에서의 검사실내 정밀도 표준편차 | Ⅶ.  성능시험에 대한 상세사항 | 46 | 일련번호 | 명 칭 | 세부 구성 | 외관상 특징 | 판단한다.  | 환자의 비율이다.  | 등을 거칠 것을 권장한다. ",
        "original_sentence": "| 나) 분석물질 양성(판정기준치 이상)인 검체 + 간섭물질 | 다) 각각의 농도에서의 검사실내 정밀도 표준편차 | Ⅶ. "
      }
    },
    {
      "chunk_id": "chunk_065",
      "text": "성능시험에 대한 상세사항 | 46 | 일련번호 | 명 칭 | 세부 구성 | 외관상 특징 | 판단한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 64,
        "window_size": 3,
        "char_count": 57,
        "word_count": 18,
        "page_number": 3,
        "window_text": "| 검사의 특이도에 대한 자료를 제공해야 한다.  | 2) 교차반응을 보이는 물질의 종류와 빈도를 제시한다.  | 나) 분석물질 양성(판정기준치 이상)인 검체 + 간섭물질 | 다) 각각의 농도에서의 검사실내 정밀도 표준편차 | Ⅶ.  성능시험에 대한 상세사항 | 46 | 일련번호 | 명 칭 | 세부 구성 | 외관상 특징 | 판단한다.  | 환자의 비율이다.  | 등을 거칠 것을 권장한다.  | 보조성분 | Oxypyrion | 적량 | 자사규격 |\n| K071834 | STRATUS CS ACUTE CARE | NT-PROBNP TESTPAK | FIA | Alere Triage BNP/NT-proBNP | Alere | USA | 4. ",
        "original_sentence": "성능시험에 대한 상세사항 | 46 | 일련번호 | 명 칭 | 세부 구성 | 외관상 특징 | 판단한다. "
      }
    },
    {
      "chunk_id": "chunk_066",
      "text": "| 환자의 비율이다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 65,
        "window_size": 3,
        "char_count": 12,
        "word_count": 3,
        "page_number": 69,
        "window_text": "| 2) 교차반응을 보이는 물질의 종류와 빈도를 제시한다.  | 나) 분석물질 양성(판정기준치 이상)인 검체 + 간섭물질 | 다) 각각의 농도에서의 검사실내 정밀도 표준편차 | Ⅶ.  성능시험에 대한 상세사항 | 46 | 일련번호 | 명 칭 | 세부 구성 | 외관상 특징 | 판단한다.  | 환자의 비율이다.  | 등을 거칠 것을 권장한다.  | 보조성분 | Oxypyrion | 적량 | 자사규격 |\n| K071834 | STRATUS CS ACUTE CARE | NT-PROBNP TESTPAK | FIA | Alere Triage BNP/NT-proBNP | Alere | USA | 4.  등급 : 3등급 | 4 | 제조원 및 소재지 | 2) 임상적 특이도 | ※ 예시 | 2. ",
        "original_sentence": "| 환자의 비율이다. "
      }
    },
    {
      "chunk_id": "chunk_067",
      "text": "| 등을 거칠 것을 권장한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 66,
        "window_size": 3,
        "char_count": 17,
        "word_count": 5,
        "page_number": 55,
        "window_text": "| 나) 분석물질 양성(판정기준치 이상)인 검체 + 간섭물질 | 다) 각각의 농도에서의 검사실내 정밀도 표준편차 | Ⅶ.  성능시험에 대한 상세사항 | 46 | 일련번호 | 명 칭 | 세부 구성 | 외관상 특징 | 판단한다.  | 환자의 비율이다.  | 등을 거칠 것을 권장한다.  | 보조성분 | Oxypyrion | 적량 | 자사규격 |\n| K071834 | STRATUS CS ACUTE CARE | NT-PROBNP TESTPAK | FIA | Alere Triage BNP/NT-proBNP | Alere | USA | 4.  등급 : 3등급 | 4 | 제조원 및 소재지 | 2) 임상적 특이도 | ※ 예시 | 2.  모양 및 구조 | 18 | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | 적을 기재한다. ",
        "original_sentence": "| 등을 거칠 것을 권장한다. "
      }
    },
    {
      "chunk_id": "chunk_068",
      "text": "| 보조성분 | Oxypyrion | 적량 | 자사규격 |\n| K071834 | STRATUS CS ACUTE CARE | NT-PROBNP TESTPAK | FIA | Alere Triage BNP/NT-proBNP | Alere | USA | 4. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 67,
        "window_size": 3,
        "char_count": 141,
        "word_count": 31,
        "page_number": 6,
        "window_text": "성능시험에 대한 상세사항 | 46 | 일련번호 | 명 칭 | 세부 구성 | 외관상 특징 | 판단한다.  | 환자의 비율이다.  | 등을 거칠 것을 권장한다.  | 보조성분 | Oxypyrion | 적량 | 자사규격 |\n| K071834 | STRATUS CS ACUTE CARE | NT-PROBNP TESTPAK | FIA | Alere Triage BNP/NT-proBNP | Alere | USA | 4.  등급 : 3등급 | 4 | 제조원 및 소재지 | 2) 임상적 특이도 | ※ 예시 | 2.  모양 및 구조 | 18 | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | 적을 기재한다.  | 검체수 (N) | 900 | 210 | 140 | 170 | 250 | 아브시심아브 | 도파민 | 니트로글리세린 | 관리에 관한 규정｣ | 개정, ‘17.5.1] |\n| ❍ 사용방법 | 나. ",
        "original_sentence": "| 보조성분 | Oxypyrion | 적량 | 자사규격 |\n| K071834 | STRATUS CS ACUTE CARE | NT-PROBNP TESTPAK | FIA | Alere Triage BNP/NT-proBNP | Alere | USA | 4. "
      }
    },
    {
      "chunk_id": "chunk_069",
      "text": "등급 : 3등급 | 4 | 제조원 및 소재지 | 2) 임상적 특이도 | ※ 예시 | 2. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 68,
        "window_size": 3,
        "char_count": 50,
        "word_count": 18,
        "page_number": 6,
        "window_text": "| 환자의 비율이다.  | 등을 거칠 것을 권장한다.  | 보조성분 | Oxypyrion | 적량 | 자사규격 |\n| K071834 | STRATUS CS ACUTE CARE | NT-PROBNP TESTPAK | FIA | Alere Triage BNP/NT-proBNP | Alere | USA | 4.  등급 : 3등급 | 4 | 제조원 및 소재지 | 2) 임상적 특이도 | ※ 예시 | 2.  모양 및 구조 | 18 | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | 적을 기재한다.  | 검체수 (N) | 900 | 210 | 140 | 170 | 250 | 아브시심아브 | 도파민 | 니트로글리세린 | 관리에 관한 규정｣ | 개정, ‘17.5.1] |\n| ❍ 사용방법 | 나.  검사 전 준비사항 | 나. ",
        "original_sentence": "등급 : 3등급 | 4 | 제조원 및 소재지 | 2) 임상적 특이도 | ※ 예시 | 2. "
      }
    },
    {
      "chunk_id": "chunk_070",
      "text": "모양 및 구조 | 18 | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | 적을 기재한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 69,
        "window_size": 3,
        "char_count": 59,
        "word_count": 19,
        "page_number": 3,
        "window_text": "| 등을 거칠 것을 권장한다.  | 보조성분 | Oxypyrion | 적량 | 자사규격 |\n| K071834 | STRATUS CS ACUTE CARE | NT-PROBNP TESTPAK | FIA | Alere Triage BNP/NT-proBNP | Alere | USA | 4.  등급 : 3등급 | 4 | 제조원 및 소재지 | 2) 임상적 특이도 | ※ 예시 | 2.  모양 및 구조 | 18 | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | 적을 기재한다.  | 검체수 (N) | 900 | 210 | 140 | 170 | 250 | 아브시심아브 | 도파민 | 니트로글리세린 | 관리에 관한 규정｣ | 개정, ‘17.5.1] |\n| ❍ 사용방법 | 나.  검사 전 준비사항 | 나.  시험기준 | 3. ",
        "original_sentence": "모양 및 구조 | 18 | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | 적을 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_071",
      "text": "| 검체수 (N) | 900 | 210 | 140 | 170 | 250 | 아브시심아브 | 도파민 | 니트로글리세린 | 관리에 관한 규정｣ | 개정, ‘17.5.1] |\n| ❍ 사용방법 | 나. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 70,
        "window_size": 3,
        "char_count": 109,
        "word_count": 32,
        "page_number": 6,
        "window_text": "| 보조성분 | Oxypyrion | 적량 | 자사규격 |\n| K071834 | STRATUS CS ACUTE CARE | NT-PROBNP TESTPAK | FIA | Alere Triage BNP/NT-proBNP | Alere | USA | 4.  등급 : 3등급 | 4 | 제조원 및 소재지 | 2) 임상적 특이도 | ※ 예시 | 2.  모양 및 구조 | 18 | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | 적을 기재한다.  | 검체수 (N) | 900 | 210 | 140 | 170 | 250 | 아브시심아브 | 도파민 | 니트로글리세린 | 관리에 관한 규정｣ | 개정, ‘17.5.1] |\n| ❍ 사용방법 | 나.  검사 전 준비사항 | 나.  시험기준 | 3.  정밀도 | 8. ",
        "original_sentence": "| 검체수 (N) | 900 | 210 | 140 | 170 | 250 | 아브시심아브 | 도파민 | 니트로글리세린 | 관리에 관한 규정｣ | 개정, ‘17.5.1] |\n| ❍ 사용방법 | 나. "
      }
    },
    {
      "chunk_id": "chunk_072",
      "text": "검사 전 준비사항 | 나. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 71,
        "window_size": 3,
        "char_count": 15,
        "word_count": 5,
        "page_number": 3,
        "window_text": "등급 : 3등급 | 4 | 제조원 및 소재지 | 2) 임상적 특이도 | ※ 예시 | 2.  모양 및 구조 | 18 | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | 적을 기재한다.  | 검체수 (N) | 900 | 210 | 140 | 170 | 250 | 아브시심아브 | 도파민 | 니트로글리세린 | 관리에 관한 규정｣ | 개정, ‘17.5.1] |\n| ❍ 사용방법 | 나.  검사 전 준비사항 | 나.  시험기준 | 3.  정밀도 | 8.  시험검사 결과 | 3 | Bottle 1 | 단일구성 | 액상 시약 |\n| 5 | 검체보관 및 취급상(온도, 습도 등)의 조건 설정 근거자료 | 및 정성, 반정량 또는 정량 등을 구체적으로 기재한다. ",
        "original_sentence": "검사 전 준비사항 | 나. "
      }
    },
    {
      "chunk_id": "chunk_073",
      "text": "시험기준 | 3. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 72,
        "window_size": 3,
        "char_count": 10,
        "word_count": 3,
        "page_number": 26,
        "window_text": "모양 및 구조 | 18 | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | 적을 기재한다.  | 검체수 (N) | 900 | 210 | 140 | 170 | 250 | 아브시심아브 | 도파민 | 니트로글리세린 | 관리에 관한 규정｣ | 개정, ‘17.5.1] |\n| ❍ 사용방법 | 나.  검사 전 준비사항 | 나.  시험기준 | 3.  정밀도 | 8.  시험검사 결과 | 3 | Bottle 1 | 단일구성 | 액상 시약 |\n| 5 | 검체보관 및 취급상(온도, 습도 등)의 조건 설정 근거자료 | 및 정성, 반정량 또는 정량 등을 구체적으로 기재한다.  | 기로 임상적 성능시험의 결과를 확인할 수 없는 시험 | 정리한 자료입니까? ",
        "original_sentence": "시험기준 | 3. "
      }
    },
    {
      "chunk_id": "chunk_074",
      "text": "정밀도 | 8. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 73,
        "window_size": 3,
        "char_count": 9,
        "word_count": 3,
        "page_number": 32,
        "window_text": "| 검체수 (N) | 900 | 210 | 140 | 170 | 250 | 아브시심아브 | 도파민 | 니트로글리세린 | 관리에 관한 규정｣ | 개정, ‘17.5.1] |\n| ❍ 사용방법 | 나.  검사 전 준비사항 | 나.  시험기준 | 3.  정밀도 | 8.  시험검사 결과 | 3 | Bottle 1 | 단일구성 | 액상 시약 |\n| 5 | 검체보관 및 취급상(온도, 습도 등)의 조건 설정 근거자료 | 및 정성, 반정량 또는 정량 등을 구체적으로 기재한다.  | 기로 임상적 성능시험의 결과를 확인할 수 없는 시험 | 정리한 자료입니까?  | 테스트 | Calibrator H | Calibrator E | Calibrator C | Beckman Coulter Immunoassay | 보조성분 | Mouse IgG | 적량 | 자사규격 | 메디안 (pg/mL) | 20 | 20 | 10 | 25 | 20 | C형 나트륨 이뇨 펩티드(CNP) 53 | 1,000pg/mL | 106% |\n| 라) 반복정밀도 및 검사실내 정밀도 표준편차의 신뢰구간 | 1. ",
        "original_sentence": "정밀도 | 8. "
      }
    },
    {
      "chunk_id": "chunk_075",
      "text": "시험검사 결과 | 3 | Bottle 1 | 단일구성 | 액상 시약 |\n| 5 | 검체보관 및 취급상(온도, 습도 등)의 조건 설정 근거자료 | 및 정성, 반정량 또는 정량 등을 구체적으로 기재한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 74,
        "window_size": 3,
        "char_count": 112,
        "word_count": 33,
        "page_number": 21,
        "window_text": "검사 전 준비사항 | 나.  시험기준 | 3.  정밀도 | 8.  시험검사 결과 | 3 | Bottle 1 | 단일구성 | 액상 시약 |\n| 5 | 검체보관 및 취급상(온도, 습도 등)의 조건 설정 근거자료 | 및 정성, 반정량 또는 정량 등을 구체적으로 기재한다.  | 기로 임상적 성능시험의 결과를 확인할 수 없는 시험 | 정리한 자료입니까?  | 테스트 | Calibrator H | Calibrator E | Calibrator C | Beckman Coulter Immunoassay | 보조성분 | Mouse IgG | 적량 | 자사규격 | 메디안 (pg/mL) | 20 | 20 | 10 | 25 | 20 | C형 나트륨 이뇨 펩티드(CNP) 53 | 1,000pg/mL | 106% |\n| 라) 반복정밀도 및 검사실내 정밀도 표준편차의 신뢰구간 | 1.  분석적 성능시험에 관한 자료 | 47 | 제시한다. ",
        "original_sentence": "시험검사 결과 | 3 | Bottle 1 | 단일구성 | 액상 시약 |\n| 5 | 검체보관 및 취급상(온도, 습도 등)의 조건 설정 근거자료 | 및 정성, 반정량 또는 정량 등을 구체적으로 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_076",
      "text": "| 기로 임상적 성능시험의 결과를 확인할 수 없는 시험 | 정리한 자료입니까? ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 75,
        "window_size": 3,
        "char_count": 44,
        "word_count": 12,
        "page_number": 3,
        "window_text": "시험기준 | 3.  정밀도 | 8.  시험검사 결과 | 3 | Bottle 1 | 단일구성 | 액상 시약 |\n| 5 | 검체보관 및 취급상(온도, 습도 등)의 조건 설정 근거자료 | 및 정성, 반정량 또는 정량 등을 구체적으로 기재한다.  | 기로 임상적 성능시험의 결과를 확인할 수 없는 시험 | 정리한 자료입니까?  | 테스트 | Calibrator H | Calibrator E | Calibrator C | Beckman Coulter Immunoassay | 보조성분 | Mouse IgG | 적량 | 자사규격 | 메디안 (pg/mL) | 20 | 20 | 10 | 25 | 20 | C형 나트륨 이뇨 펩티드(CNP) 53 | 1,000pg/mL | 106% |\n| 라) 반복정밀도 및 검사실내 정밀도 표준편차의 신뢰구간 | 1.  분석적 성능시험에 관한 자료 | 47 | 제시한다.  | 알고 있는 물질의 사용을 권장한다. ",
        "original_sentence": "| 기로 임상적 성능시험의 결과를 확인할 수 없는 시험 | 정리한 자료입니까? "
      }
    },
    {
      "chunk_id": "chunk_077",
      "text": "| 테스트 | Calibrator H | Calibrator E | Calibrator C | Beckman Coulter Immunoassay | 보조성분 | Mouse IgG | 적량 | 자사규격 | 메디안 (pg/mL) | 20 | 20 | 10 | 25 | 20 | C형 나트륨 이뇨 펩티드(CNP) 53 | 1,000pg/mL | 106% |\n| 라) 반복정밀도 및 검사실내 정밀도 표준편차의 신뢰구간 | 1. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 76,
        "window_size": 3,
        "char_count": 235,
        "word_count": 58,
        "page_number": 14,
        "window_text": "정밀도 | 8.  시험검사 결과 | 3 | Bottle 1 | 단일구성 | 액상 시약 |\n| 5 | 검체보관 및 취급상(온도, 습도 등)의 조건 설정 근거자료 | 및 정성, 반정량 또는 정량 등을 구체적으로 기재한다.  | 기로 임상적 성능시험의 결과를 확인할 수 없는 시험 | 정리한 자료입니까?  | 테스트 | Calibrator H | Calibrator E | Calibrator C | Beckman Coulter Immunoassay | 보조성분 | Mouse IgG | 적량 | 자사규격 | 메디안 (pg/mL) | 20 | 20 | 10 | 25 | 20 | C형 나트륨 이뇨 펩티드(CNP) 53 | 1,000pg/mL | 106% |\n| 라) 반복정밀도 및 검사실내 정밀도 표준편차의 신뢰구간 | 1.  분석적 성능시험에 관한 자료 | 47 | 제시한다.  | 알고 있는 물질의 사용을 권장한다.  | 아세트아미노펜 | 말레인산에날라프릴 | 노라민피린 |\n| 가. ",
        "original_sentence": "| 테스트 | Calibrator H | Calibrator E | Calibrator C | Beckman Coulter Immunoassay | 보조성분 | Mouse IgG | 적량 | 자사규격 | 메디안 (pg/mL) | 20 | 20 | 10 | 25 | 20 | C형 나트륨 이뇨 펩티드(CNP) 53 | 1,000pg/mL | 106% |\n| 라) 반복정밀도 및 검사실내 정밀도 표준편차의 신뢰구간 | 1. "
      }
    },
    {
      "chunk_id": "chunk_078",
      "text": "분석적 성능시험에 관한 자료 | 47 | 제시한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 77,
        "window_size": 3,
        "char_count": 29,
        "word_count": 8,
        "page_number": 6,
        "window_text": "시험검사 결과 | 3 | Bottle 1 | 단일구성 | 액상 시약 |\n| 5 | 검체보관 및 취급상(온도, 습도 등)의 조건 설정 근거자료 | 및 정성, 반정량 또는 정량 등을 구체적으로 기재한다.  | 기로 임상적 성능시험의 결과를 확인할 수 없는 시험 | 정리한 자료입니까?  | 테스트 | Calibrator H | Calibrator E | Calibrator C | Beckman Coulter Immunoassay | 보조성분 | Mouse IgG | 적량 | 자사규격 | 메디안 (pg/mL) | 20 | 20 | 10 | 25 | 20 | C형 나트륨 이뇨 펩티드(CNP) 53 | 1,000pg/mL | 106% |\n| 라) 반복정밀도 및 검사실내 정밀도 표준편차의 신뢰구간 | 1.  분석적 성능시험에 관한 자료 | 47 | 제시한다.  | 알고 있는 물질의 사용을 권장한다.  | 아세트아미노펜 | 말레인산에날라프릴 | 노라민피린 |\n| 가.  시험물질 | 나. ",
        "original_sentence": "분석적 성능시험에 관한 자료 | 47 | 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_079",
      "text": "| 알고 있는 물질의 사용을 권장한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 78,
        "window_size": 3,
        "char_count": 22,
        "word_count": 6,
        "page_number": 32,
        "window_text": "| 기로 임상적 성능시험의 결과를 확인할 수 없는 시험 | 정리한 자료입니까?  | 테스트 | Calibrator H | Calibrator E | Calibrator C | Beckman Coulter Immunoassay | 보조성분 | Mouse IgG | 적량 | 자사규격 | 메디안 (pg/mL) | 20 | 20 | 10 | 25 | 20 | C형 나트륨 이뇨 펩티드(CNP) 53 | 1,000pg/mL | 106% |\n| 라) 반복정밀도 및 검사실내 정밀도 표준편차의 신뢰구간 | 1.  분석적 성능시험에 관한 자료 | 47 | 제시한다.  | 알고 있는 물질의 사용을 권장한다.  | 아세트아미노펜 | 말레인산에날라프릴 | 노라민피린 |\n| 가.  시험물질 | 나.  시험물질 | (수출용 의료기기 제외) 불가 | 다) 분석물질 음성(판정기준치 이하)인 검체(간섭물질 없음) | 3. ",
        "original_sentence": "| 알고 있는 물질의 사용을 권장한다. "
      }
    },
    {
      "chunk_id": "chunk_080",
      "text": "| 아세트아미노펜 | 말레인산에날라프릴 | 노라민피린 |\n| 가. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 79,
        "window_size": 3,
        "char_count": 37,
        "word_count": 9,
        "page_number": 31,
        "window_text": "| 테스트 | Calibrator H | Calibrator E | Calibrator C | Beckman Coulter Immunoassay | 보조성분 | Mouse IgG | 적량 | 자사규격 | 메디안 (pg/mL) | 20 | 20 | 10 | 25 | 20 | C형 나트륨 이뇨 펩티드(CNP) 53 | 1,000pg/mL | 106% |\n| 라) 반복정밀도 및 검사실내 정밀도 표준편차의 신뢰구간 | 1.  분석적 성능시험에 관한 자료 | 47 | 제시한다.  | 알고 있는 물질의 사용을 권장한다.  | 아세트아미노펜 | 말레인산에날라프릴 | 노라민피린 |\n| 가.  시험물질 | 나.  시험물질 | (수출용 의료기기 제외) 불가 | 다) 분석물질 음성(판정기준치 이하)인 검체(간섭물질 없음) | 3.  원재료 | 22 | 4 | Bottle 2 | 단일구성 | 액상 시약 | System BNP Test | Alere | USA | 평균 (pg/mL) | 40 | 30 | 20 | 40 | 50 | -심장 질환 모집단(여성)- |\n| K071767 | DIMENSIONS PBNP FLEX | REAGENT CARTRIDGE | ❍ 사용 시 주의사항 | 료를 포함한다. ",
        "original_sentence": "| 아세트아미노펜 | 말레인산에날라프릴 | 노라민피린 |\n| 가. "
      }
    },
    {
      "chunk_id": "chunk_081",
      "text": "시험물질 | 나. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 80,
        "window_size": 3,
        "char_count": 10,
        "word_count": 3,
        "page_number": 32,
        "window_text": "분석적 성능시험에 관한 자료 | 47 | 제시한다.  | 알고 있는 물질의 사용을 권장한다.  | 아세트아미노펜 | 말레인산에날라프릴 | 노라민피린 |\n| 가.  시험물질 | 나.  시험물질 | (수출용 의료기기 제외) 불가 | 다) 분석물질 음성(판정기준치 이하)인 검체(간섭물질 없음) | 3.  원재료 | 22 | 4 | Bottle 2 | 단일구성 | 액상 시약 | System BNP Test | Alere | USA | 평균 (pg/mL) | 40 | 30 | 20 | 40 | 50 | -심장 질환 모집단(여성)- |\n| K071767 | DIMENSIONS PBNP FLEX | REAGENT CARTRIDGE | ❍ 사용 시 주의사항 | 료를 포함한다.  | 5 | 허가번호 | 확인할 수 있는 자료를 제출한다. ",
        "original_sentence": "시험물질 | 나. "
      }
    },
    {
      "chunk_id": "chunk_082",
      "text": "시험물질 | (수출용 의료기기 제외) 불가 | 다) 분석물질 음성(판정기준치 이하)인 검체(간섭물질 없음) | 3. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 81,
        "window_size": 3,
        "char_count": 65,
        "word_count": 15,
        "page_number": 14,
        "window_text": "| 알고 있는 물질의 사용을 권장한다.  | 아세트아미노펜 | 말레인산에날라프릴 | 노라민피린 |\n| 가.  시험물질 | 나.  시험물질 | (수출용 의료기기 제외) 불가 | 다) 분석물질 음성(판정기준치 이하)인 검체(간섭물질 없음) | 3.  원재료 | 22 | 4 | Bottle 2 | 단일구성 | 액상 시약 | System BNP Test | Alere | USA | 평균 (pg/mL) | 40 | 30 | 20 | 40 | 50 | -심장 질환 모집단(여성)- |\n| K071767 | DIMENSIONS PBNP FLEX | REAGENT CARTRIDGE | ❍ 사용 시 주의사항 | 료를 포함한다.  | 5 | 허가번호 | 확인할 수 있는 자료를 제출한다.  | 포함된 논문, 문헌 등의 자료를 제출한다. ",
        "original_sentence": "시험물질 | (수출용 의료기기 제외) 불가 | 다) 분석물질 음성(판정기준치 이하)인 검체(간섭물질 없음) | 3. "
      }
    },
    {
      "chunk_id": "chunk_083",
      "text": "원재료 | 22 | 4 | Bottle 2 | 단일구성 | 액상 시약 | System BNP Test | Alere | USA | 평균 (pg/mL) | 40 | 30 | 20 | 40 | 50 | -심장 질환 모집단(여성)- |\n| K071767 | DIMENSIONS PBNP FLEX | REAGENT CARTRIDGE | ❍ 사용 시 주의사항 | 료를 포함한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 82,
        "window_size": 3,
        "char_count": 207,
        "word_count": 56,
        "page_number": 6,
        "window_text": "| 아세트아미노펜 | 말레인산에날라프릴 | 노라민피린 |\n| 가.  시험물질 | 나.  시험물질 | (수출용 의료기기 제외) 불가 | 다) 분석물질 음성(판정기준치 이하)인 검체(간섭물질 없음) | 3.  원재료 | 22 | 4 | Bottle 2 | 단일구성 | 액상 시약 | System BNP Test | Alere | USA | 평균 (pg/mL) | 40 | 30 | 20 | 40 | 50 | -심장 질환 모집단(여성)- |\n| K071767 | DIMENSIONS PBNP FLEX | REAGENT CARTRIDGE | ❍ 사용 시 주의사항 | 료를 포함한다.  | 5 | 허가번호 | 확인할 수 있는 자료를 제출한다.  | 포함된 논문, 문헌 등의 자료를 제출한다.  | 및 위음성도) 등을 기재한다. ",
        "original_sentence": "원재료 | 22 | 4 | Bottle 2 | 단일구성 | 액상 시약 | System BNP Test | Alere | USA | 평균 (pg/mL) | 40 | 30 | 20 | 40 | 50 | -심장 질환 모집단(여성)- |\n| K071767 | DIMENSIONS PBNP FLEX | REAGENT CARTRIDGE | ❍ 사용 시 주의사항 | 료를 포함한다. "
      }
    },
    {
      "chunk_id": "chunk_084",
      "text": "| 5 | 허가번호 | 확인할 수 있는 자료를 제출한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 83,
        "window_size": 3,
        "char_count": 32,
        "word_count": 10,
        "page_number": 19,
        "window_text": "시험물질 | 나.  시험물질 | (수출용 의료기기 제외) 불가 | 다) 분석물질 음성(판정기준치 이하)인 검체(간섭물질 없음) | 3.  원재료 | 22 | 4 | Bottle 2 | 단일구성 | 액상 시약 | System BNP Test | Alere | USA | 평균 (pg/mL) | 40 | 30 | 20 | 40 | 50 | -심장 질환 모집단(여성)- |\n| K071767 | DIMENSIONS PBNP FLEX | REAGENT CARTRIDGE | ❍ 사용 시 주의사항 | 료를 포함한다.  | 5 | 허가번호 | 확인할 수 있는 자료를 제출한다.  | 포함된 논문, 문헌 등의 자료를 제출한다.  | 및 위음성도) 등을 기재한다.  | 전처리가 필요한 경우에 한함) | 따라 통계적으로 의미 있는 검체수를 산정한다. ",
        "original_sentence": "| 5 | 허가번호 | 확인할 수 있는 자료를 제출한다. "
      }
    },
    {
      "chunk_id": "chunk_085",
      "text": "| 포함된 논문, 문헌 등의 자료를 제출한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 84,
        "window_size": 3,
        "char_count": 26,
        "word_count": 7,
        "page_number": 47,
        "window_text": "시험물질 | (수출용 의료기기 제외) 불가 | 다) 분석물질 음성(판정기준치 이하)인 검체(간섭물질 없음) | 3.  원재료 | 22 | 4 | Bottle 2 | 단일구성 | 액상 시약 | System BNP Test | Alere | USA | 평균 (pg/mL) | 40 | 30 | 20 | 40 | 50 | -심장 질환 모집단(여성)- |\n| K071767 | DIMENSIONS PBNP FLEX | REAGENT CARTRIDGE | ❍ 사용 시 주의사항 | 료를 포함한다.  | 5 | 허가번호 | 확인할 수 있는 자료를 제출한다.  | 포함된 논문, 문헌 등의 자료를 제출한다.  | 및 위음성도) 등을 기재한다.  | 전처리가 필요한 경우에 한함) | 따라 통계적으로 의미 있는 검체수를 산정한다.  | ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다. ",
        "original_sentence": "| 포함된 논문, 문헌 등의 자료를 제출한다. "
      }
    },
    {
      "chunk_id": "chunk_086",
      "text": "| 및 위음성도) 등을 기재한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 85,
        "window_size": 3,
        "char_count": 19,
        "word_count": 5,
        "page_number": 14,
        "window_text": "원재료 | 22 | 4 | Bottle 2 | 단일구성 | 액상 시약 | System BNP Test | Alere | USA | 평균 (pg/mL) | 40 | 30 | 20 | 40 | 50 | -심장 질환 모집단(여성)- |\n| K071767 | DIMENSIONS PBNP FLEX | REAGENT CARTRIDGE | ❍ 사용 시 주의사항 | 료를 포함한다.  | 5 | 허가번호 | 확인할 수 있는 자료를 제출한다.  | 포함된 논문, 문헌 등의 자료를 제출한다.  | 및 위음성도) 등을 기재한다.  | 전처리가 필요한 경우에 한함) | 따라 통계적으로 의미 있는 검체수를 산정한다.  | ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다.  | 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다. ",
        "original_sentence": "| 및 위음성도) 등을 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_087",
      "text": "| 전처리가 필요한 경우에 한함) | 따라 통계적으로 의미 있는 검체수를 산정한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 86,
        "window_size": 3,
        "char_count": 47,
        "word_count": 12,
        "page_number": 33,
        "window_text": "| 5 | 허가번호 | 확인할 수 있는 자료를 제출한다.  | 포함된 논문, 문헌 등의 자료를 제출한다.  | 및 위음성도) 등을 기재한다.  | 전처리가 필요한 경우에 한함) | 따라 통계적으로 의미 있는 검체수를 산정한다.  | ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다.  | 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.  | 보조성분 | Bovine serum albumin | 적량 | 자사규격 | ｢체외진단용 의료기기 중 |\n| 아세틸살리실산 | 디피리다몰 | 옥사제팜 | Prepro-ANF 56-92 | 1,000pg/mL | 104% |\n| 나 또는 그 이상의 값을 갖는 참고물질 | 또는 1배치 3회 이상) | 임상적 | 민감도 | BNP | ≤12.5% | ≤15.2% | ≤20.9% | SD (pg/mL) | 70 | 40 | 30 | 50 | 80 | NYHA Functional Class |\n| 배경을 제시한다. ",
        "original_sentence": "| 전처리가 필요한 경우에 한함) | 따라 통계적으로 의미 있는 검체수를 산정한다. "
      }
    },
    {
      "chunk_id": "chunk_088",
      "text": "| ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 87,
        "window_size": 3,
        "char_count": 55,
        "word_count": 14,
        "page_number": 3,
        "window_text": "| 포함된 논문, 문헌 등의 자료를 제출한다.  | 및 위음성도) 등을 기재한다.  | 전처리가 필요한 경우에 한함) | 따라 통계적으로 의미 있는 검체수를 산정한다.  | ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다.  | 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.  | 보조성분 | Bovine serum albumin | 적량 | 자사규격 | ｢체외진단용 의료기기 중 |\n| 아세틸살리실산 | 디피리다몰 | 옥사제팜 | Prepro-ANF 56-92 | 1,000pg/mL | 104% |\n| 나 또는 그 이상의 값을 갖는 참고물질 | 또는 1배치 3회 이상) | 임상적 | 민감도 | BNP | ≤12.5% | ≤15.2% | ≤20.9% | SD (pg/mL) | 70 | 40 | 30 | 50 | 80 | NYHA Functional Class |\n| 배경을 제시한다.  | abbreviated 510(k)s, 2005. ",
        "original_sentence": "| ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다. "
      }
    },
    {
      "chunk_id": "chunk_089",
      "text": "| 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 88,
        "window_size": 3,
        "char_count": 34,
        "word_count": 7,
        "page_number": 3,
        "window_text": "| 및 위음성도) 등을 기재한다.  | 전처리가 필요한 경우에 한함) | 따라 통계적으로 의미 있는 검체수를 산정한다.  | ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다.  | 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.  | 보조성분 | Bovine serum albumin | 적량 | 자사규격 | ｢체외진단용 의료기기 중 |\n| 아세틸살리실산 | 디피리다몰 | 옥사제팜 | Prepro-ANF 56-92 | 1,000pg/mL | 104% |\n| 나 또는 그 이상의 값을 갖는 참고물질 | 또는 1배치 3회 이상) | 임상적 | 민감도 | BNP | ≤12.5% | ≤15.2% | ≤20.9% | SD (pg/mL) | 70 | 40 | 30 | 50 | 80 | NYHA Functional Class |\n| 배경을 제시한다.  | abbreviated 510(k)s, 2005.  | chronic heart failure 2012 | 1) 다양한 교차 반응 가능 물질이 포함된 검체 | 기준 값에 적합함을 확인하는 과정을 제공한다. ",
        "original_sentence": "| 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다. "
      }
    },
    {
      "chunk_id": "chunk_090",
      "text": "| 보조성분 | Bovine serum albumin | 적량 | 자사규격 | ｢체외진단용 의료기기 중 |\n| 아세틸살리실산 | 디피리다몰 | 옥사제팜 | Prepro-ANF 56-92 | 1,000pg/mL | 104% |\n| 나 또는 그 이상의 값을 갖는 참고물질 | 또는 1배치 3회 이상) | 임상적 | 민감도 | BNP | ≤12.5% | ≤15.2% | ≤20.9% | SD (pg/mL) | 70 | 40 | 30 | 50 | 80 | NYHA Functional Class |\n| 배경을 제시한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 89,
        "window_size": 3,
        "char_count": 287,
        "word_count": 75,
        "page_number": 2,
        "window_text": "| 전처리가 필요한 경우에 한함) | 따라 통계적으로 의미 있는 검체수를 산정한다.  | ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다.  | 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.  | 보조성분 | Bovine serum albumin | 적량 | 자사규격 | ｢체외진단용 의료기기 중 |\n| 아세틸살리실산 | 디피리다몰 | 옥사제팜 | Prepro-ANF 56-92 | 1,000pg/mL | 104% |\n| 나 또는 그 이상의 값을 갖는 참고물질 | 또는 1배치 3회 이상) | 임상적 | 민감도 | BNP | ≤12.5% | ≤15.2% | ≤20.9% | SD (pg/mL) | 70 | 40 | 30 | 50 | 80 | NYHA Functional Class |\n| 배경을 제시한다.  | abbreviated 510(k)s, 2005.  | chronic heart failure 2012 | 1) 다양한 교차 반응 가능 물질이 포함된 검체 | 기준 값에 적합함을 확인하는 과정을 제공한다.  | 라) 분석물질 음성(판정기준치 이하)인 검체 + 간섭물질 | 마) 실제 검사일수, 검사실의 수 | 4. ",
        "original_sentence": "| 보조성분 | Bovine serum albumin | 적량 | 자사규격 | ｢체외진단용 의료기기 중 |\n| 아세틸살리실산 | 디피리다몰 | 옥사제팜 | Prepro-ANF 56-92 | 1,000pg/mL | 104% |\n| 나 또는 그 이상의 값을 갖는 참고물질 | 또는 1배치 3회 이상) | 임상적 | 민감도 | BNP | ≤12.5% | ≤15.2% | ≤20.9% | SD (pg/mL) | 70 | 40 | 30 | 50 | 80 | NYHA Functional Class |\n| 배경을 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_091",
      "text": "| abbreviated 510(k)s, 2005. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 90,
        "window_size": 3,
        "char_count": 29,
        "word_count": 4,
        "page_number": 6,
        "window_text": "| ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다.  | 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.  | 보조성분 | Bovine serum albumin | 적량 | 자사규격 | ｢체외진단용 의료기기 중 |\n| 아세틸살리실산 | 디피리다몰 | 옥사제팜 | Prepro-ANF 56-92 | 1,000pg/mL | 104% |\n| 나 또는 그 이상의 값을 갖는 참고물질 | 또는 1배치 3회 이상) | 임상적 | 민감도 | BNP | ≤12.5% | ≤15.2% | ≤20.9% | SD (pg/mL) | 70 | 40 | 30 | 50 | 80 | NYHA Functional Class |\n| 배경을 제시한다.  | abbreviated 510(k)s, 2005.  | chronic heart failure 2012 | 1) 다양한 교차 반응 가능 물질이 포함된 검체 | 기준 값에 적합함을 확인하는 과정을 제공한다.  | 라) 분석물질 음성(판정기준치 이하)인 검체 + 간섭물질 | 마) 실제 검사일수, 검사실의 수 | 4.  제조방법 | 24 | 2. ",
        "original_sentence": "| abbreviated 510(k)s, 2005. "
      }
    },
    {
      "chunk_id": "chunk_092",
      "text": "| chronic heart failure 2012 | 1) 다양한 교차 반응 가능 물질이 포함된 검체 | 기준 값에 적합함을 확인하는 과정을 제공한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 91,
        "window_size": 3,
        "char_count": 86,
        "word_count": 21,
        "page_number": 6,
        "window_text": "| 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.  | 보조성분 | Bovine serum albumin | 적량 | 자사규격 | ｢체외진단용 의료기기 중 |\n| 아세틸살리실산 | 디피리다몰 | 옥사제팜 | Prepro-ANF 56-92 | 1,000pg/mL | 104% |\n| 나 또는 그 이상의 값을 갖는 참고물질 | 또는 1배치 3회 이상) | 임상적 | 민감도 | BNP | ≤12.5% | ≤15.2% | ≤20.9% | SD (pg/mL) | 70 | 40 | 30 | 50 | 80 | NYHA Functional Class |\n| 배경을 제시한다.  | abbreviated 510(k)s, 2005.  | chronic heart failure 2012 | 1) 다양한 교차 반응 가능 물질이 포함된 검체 | 기준 값에 적합함을 확인하는 과정을 제공한다.  | 라) 분석물질 음성(판정기준치 이하)인 검체 + 간섭물질 | 마) 실제 검사일수, 검사실의 수 | 4.  제조방법 | 24 | 2.  임상적 성능시험에 관한 자료 | 57 | 검사가 이용될 인구집단을 대상으로 산출되어야 한다. ",
        "original_sentence": "| chronic heart failure 2012 | 1) 다양한 교차 반응 가능 물질이 포함된 검체 | 기준 값에 적합함을 확인하는 과정을 제공한다. "
      }
    },
    {
      "chunk_id": "chunk_093",
      "text": "| 라) 분석물질 음성(판정기준치 이하)인 검체 + 간섭물질 | 마) 실제 검사일수, 검사실의 수 | 4. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 92,
        "window_size": 3,
        "char_count": 60,
        "word_count": 16,
        "page_number": 14,
        "window_text": "| 보조성분 | Bovine serum albumin | 적량 | 자사규격 | ｢체외진단용 의료기기 중 |\n| 아세틸살리실산 | 디피리다몰 | 옥사제팜 | Prepro-ANF 56-92 | 1,000pg/mL | 104% |\n| 나 또는 그 이상의 값을 갖는 참고물질 | 또는 1배치 3회 이상) | 임상적 | 민감도 | BNP | ≤12.5% | ≤15.2% | ≤20.9% | SD (pg/mL) | 70 | 40 | 30 | 50 | 80 | NYHA Functional Class |\n| 배경을 제시한다.  | abbreviated 510(k)s, 2005.  | chronic heart failure 2012 | 1) 다양한 교차 반응 가능 물질이 포함된 검체 | 기준 값에 적합함을 확인하는 과정을 제공한다.  | 라) 분석물질 음성(판정기준치 이하)인 검체 + 간섭물질 | 마) 실제 검사일수, 검사실의 수 | 4.  제조방법 | 24 | 2.  임상적 성능시험에 관한 자료 | 57 | 검사가 이용될 인구집단을 대상으로 산출되어야 한다.  | 있다. ",
        "original_sentence": "| 라) 분석물질 음성(판정기준치 이하)인 검체 + 간섭물질 | 마) 실제 검사일수, 검사실의 수 | 4. "
      }
    },
    {
      "chunk_id": "chunk_094",
      "text": "제조방법 | 24 | 2. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 93,
        "window_size": 3,
        "char_count": 15,
        "word_count": 5,
        "page_number": 6,
        "window_text": "| abbreviated 510(k)s, 2005.  | chronic heart failure 2012 | 1) 다양한 교차 반응 가능 물질이 포함된 검체 | 기준 값에 적합함을 확인하는 과정을 제공한다.  | 라) 분석물질 음성(판정기준치 이하)인 검체 + 간섭물질 | 마) 실제 검사일수, 검사실의 수 | 4.  제조방법 | 24 | 2.  임상적 성능시험에 관한 자료 | 57 | 검사가 이용될 인구집단을 대상으로 산출되어야 한다.  | 있다.  |\n| ❍ 포장단위 | 기구 및 조건 등을 기재한다. ",
        "original_sentence": "제조방법 | 24 | 2. "
      }
    },
    {
      "chunk_id": "chunk_095",
      "text": "임상적 성능시험에 관한 자료 | 57 | 검사가 이용될 인구집단을 대상으로 산출되어야 한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 94,
        "window_size": 3,
        "char_count": 52,
        "word_count": 13,
        "page_number": 7,
        "window_text": "| chronic heart failure 2012 | 1) 다양한 교차 반응 가능 물질이 포함된 검체 | 기준 값에 적합함을 확인하는 과정을 제공한다.  | 라) 분석물질 음성(판정기준치 이하)인 검체 + 간섭물질 | 마) 실제 검사일수, 검사실의 수 | 4.  제조방법 | 24 | 2.  임상적 성능시험에 관한 자료 | 57 | 검사가 이용될 인구집단을 대상으로 산출되어야 한다.  | 있다.  |\n| ❍ 포장단위 | 기구 및 조건 등을 기재한다.  | 필요한 경우에 한함) | <외관사진> | ADVIA Centaur B-type | 95th Percentile | 140 | 90 | 80 | 120 | 160 | 기재한다. ",
        "original_sentence": "임상적 성능시험에 관한 자료 | 57 | 검사가 이용될 인구집단을 대상으로 산출되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_096",
      "text": "| 있다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 95,
        "window_size": 3,
        "char_count": 6,
        "word_count": 2,
        "page_number": 11,
        "window_text": "| 라) 분석물질 음성(판정기준치 이하)인 검체 + 간섭물질 | 마) 실제 검사일수, 검사실의 수 | 4.  제조방법 | 24 | 2.  임상적 성능시험에 관한 자료 | 57 | 검사가 이용될 인구집단을 대상으로 산출되어야 한다.  | 있다.  |\n| ❍ 포장단위 | 기구 및 조건 등을 기재한다.  | 필요한 경우에 한함) | <외관사진> | ADVIA Centaur B-type | 95th Percentile | 140 | 90 | 80 | 120 | 160 | 기재한다.  | 전체 | I | II | III | IV |\n| 마. ",
        "original_sentence": "| 있다. "
      }
    },
    {
      "chunk_id": "chunk_097",
      "text": "|\n| ❍ 포장단위 | 기구 및 조건 등을 기재한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 96,
        "window_size": 3,
        "char_count": 30,
        "word_count": 10,
        "page_number": 21,
        "window_text": "제조방법 | 24 | 2.  임상적 성능시험에 관한 자료 | 57 | 검사가 이용될 인구집단을 대상으로 산출되어야 한다.  | 있다.  |\n| ❍ 포장단위 | 기구 및 조건 등을 기재한다.  | 필요한 경우에 한함) | <외관사진> | ADVIA Centaur B-type | 95th Percentile | 140 | 90 | 80 | 120 | 160 | 기재한다.  | 전체 | I | II | III | IV |\n| 마.  완제품 품질관리 시험에 사용된 표준물질에 관한 자료 | 5 | 8) 시험환경요인(시험결과에 영향을 주는 경우에 한함) | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정사무 |\n| 안내서-0638-02 | 2018.7. ",
        "original_sentence": "|\n| ❍ 포장단위 | 기구 및 조건 등을 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_098",
      "text": "| 필요한 경우에 한함) | <외관사진> | ADVIA Centaur B-type | 95th Percentile | 140 | 90 | 80 | 120 | 160 | 기재한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 97,
        "window_size": 3,
        "char_count": 100,
        "word_count": 25,
        "page_number": 14,
        "window_text": "임상적 성능시험에 관한 자료 | 57 | 검사가 이용될 인구집단을 대상으로 산출되어야 한다.  | 있다.  |\n| ❍ 포장단위 | 기구 및 조건 등을 기재한다.  | 필요한 경우에 한함) | <외관사진> | ADVIA Centaur B-type | 95th Percentile | 140 | 90 | 80 | 120 | 160 | 기재한다.  | 전체 | I | II | III | IV |\n| 마.  완제품 품질관리 시험에 사용된 표준물질에 관한 자료 | 5 | 8) 시험환경요인(시험결과에 영향을 주는 경우에 한함) | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정사무 |\n| 안내서-0638-02 | 2018.7.  | 검체수 (N) | 320 | 60 | 140 | 96 | 24 | Prepro-ANF 104-123 | 1,000pg/mL | 97% | 가이드라인 [민원인 안내서]｣ 개정 |\n\n**[표 끝]**\n\n뇌나트륨이뇨펩티드 검사제품 허가․심사\n\n명칭 변경 및 제·개정 점검표 등 추가\n\n뇌나트륨이뇨펩티드 검사제품 허가․심사\n\n(현재 적용중인 의료기기 허가규정의 개정내용을\n\n반영)\n\n지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n체외진단용 의료기기 중 뇌나트륨이뇨펩티드 검사제품 허가·심사\n\n가이드라인 [민원인 안내서]\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n",
        "original_sentence": "| 필요한 경우에 한함) | <외관사진> | ADVIA Centaur B-type | 95th Percentile | 140 | 90 | 80 | 120 | 160 | 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_099",
      "text": "| 전체 | I | II | III | IV |\n| 마. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 98,
        "window_size": 3,
        "char_count": 32,
        "word_count": 13,
        "page_number": 14,
        "window_text": "| 있다.  |\n| ❍ 포장단위 | 기구 및 조건 등을 기재한다.  | 필요한 경우에 한함) | <외관사진> | ADVIA Centaur B-type | 95th Percentile | 140 | 90 | 80 | 120 | 160 | 기재한다.  | 전체 | I | II | III | IV |\n| 마.  완제품 품질관리 시험에 사용된 표준물질에 관한 자료 | 5 | 8) 시험환경요인(시험결과에 영향을 주는 경우에 한함) | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정사무 |\n| 안내서-0638-02 | 2018.7.  | 검체수 (N) | 320 | 60 | 140 | 96 | 24 | Prepro-ANF 104-123 | 1,000pg/mL | 97% | 가이드라인 [민원인 안내서]｣ 개정 |\n\n**[표 끝]**\n\n뇌나트륨이뇨펩티드 검사제품 허가․심사\n\n명칭 변경 및 제·개정 점검표 등 추가\n\n뇌나트륨이뇨펩티드 검사제품 허가․심사\n\n(현재 적용중인 의료기기 허가규정의 개정내용을\n\n반영)\n\n지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n체외진단용 의료기기 중 뇌나트륨이뇨펩티드 검사제품 허가·심사\n\n가이드라인 [민원인 안내서]\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n **[표 시작]**\n\n| 가. ",
        "original_sentence": "| 전체 | I | II | III | IV |\n| 마. "
      }
    },
    {
      "chunk_id": "chunk_100",
      "text": "완제품 품질관리 시험에 사용된 표준물질에 관한 자료 | 5 | 8) 시험환경요인(시험결과에 영향을 주는 경우에 한함) | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정사무 |\n| 안내서-0638-02 | 2018.7. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 99,
        "window_size": 3,
        "char_count": 131,
        "word_count": 30,
        "page_number": 7,
        "window_text": "|\n| ❍ 포장단위 | 기구 및 조건 등을 기재한다.  | 필요한 경우에 한함) | <외관사진> | ADVIA Centaur B-type | 95th Percentile | 140 | 90 | 80 | 120 | 160 | 기재한다.  | 전체 | I | II | III | IV |\n| 마.  완제품 품질관리 시험에 사용된 표준물질에 관한 자료 | 5 | 8) 시험환경요인(시험결과에 영향을 주는 경우에 한함) | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정사무 |\n| 안내서-0638-02 | 2018.7.  | 검체수 (N) | 320 | 60 | 140 | 96 | 24 | Prepro-ANF 104-123 | 1,000pg/mL | 97% | 가이드라인 [민원인 안내서]｣ 개정 |\n\n**[표 끝]**\n\n뇌나트륨이뇨펩티드 검사제품 허가․심사\n\n명칭 변경 및 제·개정 점검표 등 추가\n\n뇌나트륨이뇨펩티드 검사제품 허가․심사\n\n(현재 적용중인 의료기기 허가규정의 개정내용을\n\n반영)\n\n지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n체외진단용 의료기기 중 뇌나트륨이뇨펩티드 검사제품 허가·심사\n\n가이드라인 [민원인 안내서]\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n **[표 시작]**\n\n| 가.  표준품 또는 기타 사용된 표준물질의 확인서(certificate) | 등에 대한 시험성적서를 제출한다. ",
        "original_sentence": "완제품 품질관리 시험에 사용된 표준물질에 관한 자료 | 5 | 8) 시험환경요인(시험결과에 영향을 주는 경우에 한함) | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정사무 |\n| 안내서-0638-02 | 2018.7. "
      }
    },
    {
      "chunk_id": "chunk_101",
      "text": "| 검체수 (N) | 320 | 60 | 140 | 96 | 24 | Prepro-ANF 104-123 | 1,000pg/mL | 97% | 가이드라인 [민원인 안내서]｣ 개정 |\n\n**[표 끝]**\n\n뇌나트륨이뇨펩티드 검사제품 허가․심사\n\n명칭 변경 및 제·개정 점검표 등 추가\n\n뇌나트륨이뇨펩티드 검사제품 허가․심사\n\n(현재 적용중인 의료기기 허가규정의 개정내용을\n\n반영)\n\n지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n체외진단용 의료기기 중 뇌나트륨이뇨펩티드 검사제품 허가·심사\n\n가이드라인 [민원인 안내서]\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 100,
        "window_size": 3,
        "char_count": 315,
        "word_count": 66,
        "page_number": 6,
        "window_text": "| 필요한 경우에 한함) | <외관사진> | ADVIA Centaur B-type | 95th Percentile | 140 | 90 | 80 | 120 | 160 | 기재한다.  | 전체 | I | II | III | IV |\n| 마.  완제품 품질관리 시험에 사용된 표준물질에 관한 자료 | 5 | 8) 시험환경요인(시험결과에 영향을 주는 경우에 한함) | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정사무 |\n| 안내서-0638-02 | 2018.7.  | 검체수 (N) | 320 | 60 | 140 | 96 | 24 | Prepro-ANF 104-123 | 1,000pg/mL | 97% | 가이드라인 [민원인 안내서]｣ 개정 |\n\n**[표 끝]**\n\n뇌나트륨이뇨펩티드 검사제품 허가․심사\n\n명칭 변경 및 제·개정 점검표 등 추가\n\n뇌나트륨이뇨펩티드 검사제품 허가․심사\n\n(현재 적용중인 의료기기 허가규정의 개정내용을\n\n반영)\n\n지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n체외진단용 의료기기 중 뇌나트륨이뇨펩티드 검사제품 허가·심사\n\n가이드라인 [민원인 안내서]\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n **[표 시작]**\n\n| 가.  표준품 또는 기타 사용된 표준물질의 확인서(certificate) | 등에 대한 시험성적서를 제출한다.  | 적용할 수 있는 시험규격을 명시한다. ",
        "original_sentence": "| 검체수 (N) | 320 | 60 | 140 | 96 | 24 | Prepro-ANF 104-123 | 1,000pg/mL | 97% | 가이드라인 [민원인 안내서]｣ 개정 |\n\n**[표 끝]**\n\n뇌나트륨이뇨펩티드 검사제품 허가․심사\n\n명칭 변경 및 제·개정 점검표 등 추가\n\n뇌나트륨이뇨펩티드 검사제품 허가․심사\n\n(현재 적용중인 의료기기 허가규정의 개정내용을\n\n반영)\n\n지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n체외진단용 의료기기 중 뇌나트륨이뇨펩티드 검사제품 허가·심사\n\n가이드라인 [민원인 안내서]\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_102",
      "text": "**[표 시작]**\n\n| 가. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 101,
        "window_size": 3,
        "char_count": 17,
        "word_count": 4,
        "page_number": 1,
        "window_text": "| 전체 | I | II | III | IV |\n| 마.  완제품 품질관리 시험에 사용된 표준물질에 관한 자료 | 5 | 8) 시험환경요인(시험결과에 영향을 주는 경우에 한함) | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정사무 |\n| 안내서-0638-02 | 2018.7.  | 검체수 (N) | 320 | 60 | 140 | 96 | 24 | Prepro-ANF 104-123 | 1,000pg/mL | 97% | 가이드라인 [민원인 안내서]｣ 개정 |\n\n**[표 끝]**\n\n뇌나트륨이뇨펩티드 검사제품 허가․심사\n\n명칭 변경 및 제·개정 점검표 등 추가\n\n뇌나트륨이뇨펩티드 검사제품 허가․심사\n\n(현재 적용중인 의료기기 허가규정의 개정내용을\n\n반영)\n\n지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n체외진단용 의료기기 중 뇌나트륨이뇨펩티드 검사제품 허가·심사\n\n가이드라인 [민원인 안내서]\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n **[표 시작]**\n\n| 가.  표준품 또는 기타 사용된 표준물질의 확인서(certificate) | 등에 대한 시험성적서를 제출한다.  | 적용할 수 있는 시험규격을 명시한다.  | 시험항목 | 시험기준 | 시험방법 | 체외진단용 의료기기를 중심으로 사용방법을 기술한다. ",
        "original_sentence": "**[표 시작]**\n\n| 가. "
      }
    },
    {
      "chunk_id": "chunk_103",
      "text": "표준품 또는 기타 사용된 표준물질의 확인서(certificate) | 등에 대한 시험성적서를 제출한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 102,
        "window_size": 3,
        "char_count": 58,
        "word_count": 11,
        "page_number": 14,
        "window_text": "완제품 품질관리 시험에 사용된 표준물질에 관한 자료 | 5 | 8) 시험환경요인(시험결과에 영향을 주는 경우에 한함) | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정사무 |\n| 안내서-0638-02 | 2018.7.  | 검체수 (N) | 320 | 60 | 140 | 96 | 24 | Prepro-ANF 104-123 | 1,000pg/mL | 97% | 가이드라인 [민원인 안내서]｣ 개정 |\n\n**[표 끝]**\n\n뇌나트륨이뇨펩티드 검사제품 허가․심사\n\n명칭 변경 및 제·개정 점검표 등 추가\n\n뇌나트륨이뇨펩티드 검사제품 허가․심사\n\n(현재 적용중인 의료기기 허가규정의 개정내용을\n\n반영)\n\n지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n체외진단용 의료기기 중 뇌나트륨이뇨펩티드 검사제품 허가·심사\n\n가이드라인 [민원인 안내서]\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n **[표 시작]**\n\n| 가.  표준품 또는 기타 사용된 표준물질의 확인서(certificate) | 등에 대한 시험성적서를 제출한다.  | 적용할 수 있는 시험규격을 명시한다.  | 시험항목 | 시험기준 | 시험방법 | 체외진단용 의료기기를 중심으로 사용방법을 기술한다.  | 성능, 시험규격, 사용방법을 비교한 별제 제3호서식의 비교표 | 질 때 1:1의 비율로 나눠진다. ",
        "original_sentence": "표준품 또는 기타 사용된 표준물질의 확인서(certificate) | 등에 대한 시험성적서를 제출한다. "
      }
    },
    {
      "chunk_id": "chunk_104",
      "text": "| 적용할 수 있는 시험규격을 명시한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 103,
        "window_size": 3,
        "char_count": 23,
        "word_count": 6,
        "page_number": 28,
        "window_text": "| 검체수 (N) | 320 | 60 | 140 | 96 | 24 | Prepro-ANF 104-123 | 1,000pg/mL | 97% | 가이드라인 [민원인 안내서]｣ 개정 |\n\n**[표 끝]**\n\n뇌나트륨이뇨펩티드 검사제품 허가․심사\n\n명칭 변경 및 제·개정 점검표 등 추가\n\n뇌나트륨이뇨펩티드 검사제품 허가․심사\n\n(현재 적용중인 의료기기 허가규정의 개정내용을\n\n반영)\n\n지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n체외진단용 의료기기 중 뇌나트륨이뇨펩티드 검사제품 허가·심사\n\n가이드라인 [민원인 안내서]\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n **[표 시작]**\n\n| 가.  표준품 또는 기타 사용된 표준물질의 확인서(certificate) | 등에 대한 시험성적서를 제출한다.  | 적용할 수 있는 시험규격을 명시한다.  | 시험항목 | 시험기준 | 시험방법 | 체외진단용 의료기기를 중심으로 사용방법을 기술한다.  | 성능, 시험규격, 사용방법을 비교한 별제 제3호서식의 비교표 | 질 때 1:1의 비율로 나눠진다.  이들 펩타이드 수치가 증가하면 | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | 이용하여 결정하였다. ",
        "original_sentence": "| 적용할 수 있는 시험규격을 명시한다. "
      }
    },
    {
      "chunk_id": "chunk_105",
      "text": "| 시험항목 | 시험기준 | 시험방법 | 체외진단용 의료기기를 중심으로 사용방법을 기술한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 104,
        "window_size": 3,
        "char_count": 52,
        "word_count": 12,
        "page_number": 1,
        "window_text": "**[표 시작]**\n\n| 가.  표준품 또는 기타 사용된 표준물질의 확인서(certificate) | 등에 대한 시험성적서를 제출한다.  | 적용할 수 있는 시험규격을 명시한다.  | 시험항목 | 시험기준 | 시험방법 | 체외진단용 의료기기를 중심으로 사용방법을 기술한다.  | 성능, 시험규격, 사용방법을 비교한 별제 제3호서식의 비교표 | 질 때 1:1의 비율로 나눠진다.  이들 펩타이드 수치가 증가하면 | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | 이용하여 결정하였다.  | 보존제, 안정제 등 | □ 예 | ■ 아니오 | 02/04/2010 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| (주)오송진단 | 오송IVD | 심질환표지자검사시약 | BNP Test | Human Serum 5 | 5569.2 | 657 | 113 | 13.3 | 2.0 | 95th Percentile | 2200 | 1300 | 1600 | 2600 | >4000 | 비교방법 | 02/08/2005 |\n| 1 | Reagent 1 | 밀폐 등), 사용기간(유효기간) 등을 병기하여야 한다. ",
        "original_sentence": "| 시험항목 | 시험기준 | 시험방법 | 체외진단용 의료기기를 중심으로 사용방법을 기술한다. "
      }
    },
    {
      "chunk_id": "chunk_106",
      "text": "| 성능, 시험규격, 사용방법을 비교한 별제 제3호서식의 비교표 | 질 때 1:1의 비율로 나눠진다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 105,
        "window_size": 3,
        "char_count": 57,
        "word_count": 14,
        "page_number": 21,
        "window_text": "표준품 또는 기타 사용된 표준물질의 확인서(certificate) | 등에 대한 시험성적서를 제출한다.  | 적용할 수 있는 시험규격을 명시한다.  | 시험항목 | 시험기준 | 시험방법 | 체외진단용 의료기기를 중심으로 사용방법을 기술한다.  | 성능, 시험규격, 사용방법을 비교한 별제 제3호서식의 비교표 | 질 때 1:1의 비율로 나눠진다.  이들 펩타이드 수치가 증가하면 | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | 이용하여 결정하였다.  | 보존제, 안정제 등 | □ 예 | ■ 아니오 | 02/04/2010 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| (주)오송진단 | 오송IVD | 심질환표지자검사시약 | BNP Test | Human Serum 5 | 5569.2 | 657 | 113 | 13.3 | 2.0 | 95th Percentile | 2200 | 1300 | 1600 | 2600 | >4000 | 비교방법 | 02/08/2005 |\n| 1 | Reagent 1 | 밀폐 등), 사용기간(유효기간) 등을 병기하여야 한다.  | 관한 자료 | 41 | 지침서ㆍ안내서가 있습니까? ",
        "original_sentence": "| 성능, 시험규격, 사용방법을 비교한 별제 제3호서식의 비교표 | 질 때 1:1의 비율로 나눠진다. "
      }
    },
    {
      "chunk_id": "chunk_107",
      "text": "이들 펩타이드 수치가 증가하면 | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | 이용하여 결정하였다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 106,
        "window_size": 3,
        "char_count": 63,
        "word_count": 15,
        "page_number": 3,
        "window_text": "| 적용할 수 있는 시험규격을 명시한다.  | 시험항목 | 시험기준 | 시험방법 | 체외진단용 의료기기를 중심으로 사용방법을 기술한다.  | 성능, 시험규격, 사용방법을 비교한 별제 제3호서식의 비교표 | 질 때 1:1의 비율로 나눠진다.  이들 펩타이드 수치가 증가하면 | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | 이용하여 결정하였다.  | 보존제, 안정제 등 | □ 예 | ■ 아니오 | 02/04/2010 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| (주)오송진단 | 오송IVD | 심질환표지자검사시약 | BNP Test | Human Serum 5 | 5569.2 | 657 | 113 | 13.3 | 2.0 | 95th Percentile | 2200 | 1300 | 1600 | 2600 | >4000 | 비교방법 | 02/08/2005 |\n| 1 | Reagent 1 | 밀폐 등), 사용기간(유효기간) 등을 병기하여야 한다.  | 관한 자료 | 41 | 지침서ㆍ안내서가 있습니까?  | 1x6.5 mL | 보조성분 | HEPES Buffer | 적량 | 자사규격 | 1) 비심장질환 집단 | 32%로 구성되었다. ",
        "original_sentence": "이들 펩타이드 수치가 증가하면 | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | 이용하여 결정하였다. "
      }
    },
    {
      "chunk_id": "chunk_108",
      "text": "| 보존제, 안정제 등 | □ 예 | ■ 아니오 | 02/04/2010 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| (주)오송진단 | 오송IVD | 심질환표지자검사시약 | BNP Test | Human Serum 5 | 5569.2 | 657 | 113 | 13.3 | 2.0 | 95th Percentile | 2200 | 1300 | 1600 | 2600 | >4000 | 비교방법 | 02/08/2005 |\n| 1 | Reagent 1 | 밀폐 등), 사용기간(유효기간) 등을 병기하여야 한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 107,
        "window_size": 3,
        "char_count": 351,
        "word_count": 97,
        "page_number": 3,
        "window_text": "| 시험항목 | 시험기준 | 시험방법 | 체외진단용 의료기기를 중심으로 사용방법을 기술한다.  | 성능, 시험규격, 사용방법을 비교한 별제 제3호서식의 비교표 | 질 때 1:1의 비율로 나눠진다.  이들 펩타이드 수치가 증가하면 | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | 이용하여 결정하였다.  | 보존제, 안정제 등 | □ 예 | ■ 아니오 | 02/04/2010 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| (주)오송진단 | 오송IVD | 심질환표지자검사시약 | BNP Test | Human Serum 5 | 5569.2 | 657 | 113 | 13.3 | 2.0 | 95th Percentile | 2200 | 1300 | 1600 | 2600 | >4000 | 비교방법 | 02/08/2005 |\n| 1 | Reagent 1 | 밀폐 등), 사용기간(유효기간) 등을 병기하여야 한다.  | 관한 자료 | 41 | 지침서ㆍ안내서가 있습니까?  | 1x6.5 mL | 보조성분 | HEPES Buffer | 적량 | 자사규격 | 1) 비심장질환 집단 | 32%로 구성되었다.  AUC 결과는 0.87(0.85 ~ 0.90, 95% |\n| 나. ",
        "original_sentence": "| 보존제, 안정제 등 | □ 예 | ■ 아니오 | 02/04/2010 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| (주)오송진단 | 오송IVD | 심질환표지자검사시약 | BNP Test | Human Serum 5 | 5569.2 | 657 | 113 | 13.3 | 2.0 | 95th Percentile | 2200 | 1300 | 1600 | 2600 | >4000 | 비교방법 | 02/08/2005 |\n| 1 | Reagent 1 | 밀폐 등), 사용기간(유효기간) 등을 병기하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_109",
      "text": "| 관한 자료 | 41 | 지침서ㆍ안내서가 있습니까? ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 108,
        "window_size": 3,
        "char_count": 30,
        "word_count": 8,
        "page_number": 3,
        "window_text": "| 성능, 시험규격, 사용방법을 비교한 별제 제3호서식의 비교표 | 질 때 1:1의 비율로 나눠진다.  이들 펩타이드 수치가 증가하면 | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | 이용하여 결정하였다.  | 보존제, 안정제 등 | □ 예 | ■ 아니오 | 02/04/2010 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| (주)오송진단 | 오송IVD | 심질환표지자검사시약 | BNP Test | Human Serum 5 | 5569.2 | 657 | 113 | 13.3 | 2.0 | 95th Percentile | 2200 | 1300 | 1600 | 2600 | >4000 | 비교방법 | 02/08/2005 |\n| 1 | Reagent 1 | 밀폐 등), 사용기간(유효기간) 등을 병기하여야 한다.  | 관한 자료 | 41 | 지침서ㆍ안내서가 있습니까?  | 1x6.5 mL | 보조성분 | HEPES Buffer | 적량 | 자사규격 | 1) 비심장질환 집단 | 32%로 구성되었다.  AUC 결과는 0.87(0.85 ~ 0.90, 95% |\n| 나.  기재내용 | 나. ",
        "original_sentence": "| 관한 자료 | 41 | 지침서ㆍ안내서가 있습니까? "
      }
    },
    {
      "chunk_id": "chunk_110",
      "text": "| 1x6.5 mL | 보조성분 | HEPES Buffer | 적량 | 자사규격 | 1) 비심장질환 집단 | 32%로 구성되었다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 109,
        "window_size": 3,
        "char_count": 73,
        "word_count": 19,
        "page_number": 21,
        "window_text": "이들 펩타이드 수치가 증가하면 | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | 이용하여 결정하였다.  | 보존제, 안정제 등 | □ 예 | ■ 아니오 | 02/04/2010 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| (주)오송진단 | 오송IVD | 심질환표지자검사시약 | BNP Test | Human Serum 5 | 5569.2 | 657 | 113 | 13.3 | 2.0 | 95th Percentile | 2200 | 1300 | 1600 | 2600 | >4000 | 비교방법 | 02/08/2005 |\n| 1 | Reagent 1 | 밀폐 등), 사용기간(유효기간) 등을 병기하여야 한다.  | 관한 자료 | 41 | 지침서ㆍ안내서가 있습니까?  | 1x6.5 mL | 보조성분 | HEPES Buffer | 적량 | 자사규격 | 1) 비심장질환 집단 | 32%로 구성되었다.  AUC 결과는 0.87(0.85 ~ 0.90, 95% |\n| 나.  기재내용 | 나.  시험물질 | 다. ",
        "original_sentence": "| 1x6.5 mL | 보조성분 | HEPES Buffer | 적량 | 자사규격 | 1) 비심장질환 집단 | 32%로 구성되었다. "
      }
    },
    {
      "chunk_id": "chunk_111",
      "text": "AUC 결과는 0.87(0.85 ~ 0.90, 95% |\n| 나. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 110,
        "window_size": 3,
        "char_count": 37,
        "word_count": 9,
        "page_number": 30,
        "window_text": "| 보존제, 안정제 등 | □ 예 | ■ 아니오 | 02/04/2010 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| (주)오송진단 | 오송IVD | 심질환표지자검사시약 | BNP Test | Human Serum 5 | 5569.2 | 657 | 113 | 13.3 | 2.0 | 95th Percentile | 2200 | 1300 | 1600 | 2600 | >4000 | 비교방법 | 02/08/2005 |\n| 1 | Reagent 1 | 밀폐 등), 사용기간(유효기간) 등을 병기하여야 한다.  | 관한 자료 | 41 | 지침서ㆍ안내서가 있습니까?  | 1x6.5 mL | 보조성분 | HEPES Buffer | 적량 | 자사규격 | 1) 비심장질환 집단 | 32%로 구성되었다.  AUC 결과는 0.87(0.85 ~ 0.90, 95% |\n| 나.  기재내용 | 나.  시험물질 | 다.  비교 제품은 각 제품의 사용방법에 따라서 시험한다. ",
        "original_sentence": "AUC 결과는 0.87(0.85 ~ 0.90, 95% |\n| 나. "
      }
    },
    {
      "chunk_id": "chunk_112",
      "text": "기재내용 | 나. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 111,
        "window_size": 3,
        "char_count": 10,
        "word_count": 3,
        "page_number": 1,
        "window_text": "| 관한 자료 | 41 | 지침서ㆍ안내서가 있습니까?  | 1x6.5 mL | 보조성분 | HEPES Buffer | 적량 | 자사규격 | 1) 비심장질환 집단 | 32%로 구성되었다.  AUC 결과는 0.87(0.85 ~ 0.90, 95% |\n| 나.  기재내용 | 나.  시험물질 | 다.  비교 제품은 각 제품의 사용방법에 따라서 시험한다.  | 1) 분석적 민감도(판정기준치(cut-off value), 최소검출한계, 측정 | 등을 가지고 있는지에 대해 기재하고, 해당 전문기관에서 규정한 요 | 기술한다. ",
        "original_sentence": "기재내용 | 나. "
      }
    },
    {
      "chunk_id": "chunk_113",
      "text": "시험물질 | 다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 112,
        "window_size": 3,
        "char_count": 10,
        "word_count": 3,
        "page_number": 32,
        "window_text": "| 1x6.5 mL | 보조성분 | HEPES Buffer | 적량 | 자사규격 | 1) 비심장질환 집단 | 32%로 구성되었다.  AUC 결과는 0.87(0.85 ~ 0.90, 95% |\n| 나.  기재내용 | 나.  시험물질 | 다.  비교 제품은 각 제품의 사용방법에 따라서 시험한다.  | 1) 분석적 민감도(판정기준치(cut-off value), 최소검출한계, 측정 | 등을 가지고 있는지에 대해 기재하고, 해당 전문기관에서 규정한 요 | 기술한다.  | 어떻게 처리해야 하는지에 대한 지침을 제시한다. ",
        "original_sentence": "시험물질 | 다. "
      }
    },
    {
      "chunk_id": "chunk_114",
      "text": "비교 제품은 각 제품의 사용방법에 따라서 시험한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 113,
        "window_size": 3,
        "char_count": 29,
        "word_count": 7,
        "page_number": 33,
        "window_text": "AUC 결과는 0.87(0.85 ~ 0.90, 95% |\n| 나.  기재내용 | 나.  시험물질 | 다.  비교 제품은 각 제품의 사용방법에 따라서 시험한다.  | 1) 분석적 민감도(판정기준치(cut-off value), 최소검출한계, 측정 | 등을 가지고 있는지에 대해 기재하고, 해당 전문기관에서 규정한 요 | 기술한다.  | 어떻게 처리해야 하는지에 대한 지침을 제시한다.  | 가져야 한다. ",
        "original_sentence": "비교 제품은 각 제품의 사용방법에 따라서 시험한다. "
      }
    },
    {
      "chunk_id": "chunk_115",
      "text": "| 1) 분석적 민감도(판정기준치(cut-off value), 최소검출한계, 측정 | 등을 가지고 있는지에 대해 기재하고, 해당 전문기관에서 규정한 요 | 기술한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 114,
        "window_size": 3,
        "char_count": 93,
        "word_count": 19,
        "page_number": 14,
        "window_text": "기재내용 | 나.  시험물질 | 다.  비교 제품은 각 제품의 사용방법에 따라서 시험한다.  | 1) 분석적 민감도(판정기준치(cut-off value), 최소검출한계, 측정 | 등을 가지고 있는지에 대해 기재하고, 해당 전문기관에서 규정한 요 | 기술한다.  | 어떻게 처리해야 하는지에 대한 지침을 제시한다.  | 가져야 한다.  | 인정할 수 있다. ",
        "original_sentence": "| 1) 분석적 민감도(판정기준치(cut-off value), 최소검출한계, 측정 | 등을 가지고 있는지에 대해 기재하고, 해당 전문기관에서 규정한 요 | 기술한다. "
      }
    },
    {
      "chunk_id": "chunk_116",
      "text": "| 어떻게 처리해야 하는지에 대한 지침을 제시한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 115,
        "window_size": 3,
        "char_count": 29,
        "word_count": 7,
        "page_number": 26,
        "window_text": "시험물질 | 다.  비교 제품은 각 제품의 사용방법에 따라서 시험한다.  | 1) 분석적 민감도(판정기준치(cut-off value), 최소검출한계, 측정 | 등을 가지고 있는지에 대해 기재하고, 해당 전문기관에서 규정한 요 | 기술한다.  | 어떻게 처리해야 하는지에 대한 지침을 제시한다.  | 가져야 한다.  | 인정할 수 있다.  | C1T1C2T2C3T3C4T4C5T5). ",
        "original_sentence": "| 어떻게 처리해야 하는지에 대한 지침을 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_117",
      "text": "| 가져야 한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 116,
        "window_size": 3,
        "char_count": 10,
        "word_count": 3,
        "page_number": 12,
        "window_text": "비교 제품은 각 제품의 사용방법에 따라서 시험한다.  | 1) 분석적 민감도(판정기준치(cut-off value), 최소검출한계, 측정 | 등을 가지고 있는지에 대해 기재하고, 해당 전문기관에서 규정한 요 | 기술한다.  | 어떻게 처리해야 하는지에 대한 지침을 제시한다.  | 가져야 한다.  | 인정할 수 있다.  | C1T1C2T2C3T3C4T4C5T5).  | Control 1 | 110 | 13.03 | 2.62 | 2.8 | 2.4 | 퍼센트 ≥100 pg/mL | 70.50% | 58.50% | 73.00% | 79.00% | 98.50% | 안지오텐신 I | 600pg/ml | 108% |\n| and Laboratory Standard Institute; 2009 | 서식에 따라 작성하여야 한다. ",
        "original_sentence": "| 가져야 한다. "
      }
    },
    {
      "chunk_id": "chunk_118",
      "text": "| 인정할 수 있다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 117,
        "window_size": 3,
        "char_count": 12,
        "word_count": 4,
        "page_number": 11,
        "window_text": "| 1) 분석적 민감도(판정기준치(cut-off value), 최소검출한계, 측정 | 등을 가지고 있는지에 대해 기재하고, 해당 전문기관에서 규정한 요 | 기술한다.  | 어떻게 처리해야 하는지에 대한 지침을 제시한다.  | 가져야 한다.  | 인정할 수 있다.  | C1T1C2T2C3T3C4T4C5T5).  | Control 1 | 110 | 13.03 | 2.62 | 2.8 | 2.4 | 퍼센트 ≥100 pg/mL | 70.50% | 58.50% | 73.00% | 79.00% | 98.50% | 안지오텐신 I | 600pg/ml | 108% |\n| and Laboratory Standard Institute; 2009 | 서식에 따라 작성하여야 한다.  | 제출한다. ",
        "original_sentence": "| 인정할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_119",
      "text": "| C1T1C2T2C3T3C4T4C5T5). ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 118,
        "window_size": 3,
        "char_count": 25,
        "word_count": 2,
        "page_number": 6,
        "window_text": "| 어떻게 처리해야 하는지에 대한 지침을 제시한다.  | 가져야 한다.  | 인정할 수 있다.  | C1T1C2T2C3T3C4T4C5T5).  | Control 1 | 110 | 13.03 | 2.62 | 2.8 | 2.4 | 퍼센트 ≥100 pg/mL | 70.50% | 58.50% | 73.00% | 79.00% | 98.50% | 안지오텐신 I | 600pg/ml | 108% |\n| and Laboratory Standard Institute; 2009 | 서식에 따라 작성하여야 한다.  | 제출한다.  | 보조성분 | Oxypyrion1) | 적량 | 자사규격 | 혈색소, 지질(콜레스테롤, |\n| 가. ",
        "original_sentence": "| C1T1C2T2C3T3C4T4C5T5). "
      }
    },
    {
      "chunk_id": "chunk_120",
      "text": "| Control 1 | 110 | 13.03 | 2.62 | 2.8 | 2.4 | 퍼센트 ≥100 pg/mL | 70.50% | 58.50% | 73.00% | 79.00% | 98.50% | 안지오텐신 I | 600pg/ml | 108% |\n| and Laboratory Standard Institute; 2009 | 서식에 따라 작성하여야 한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 119,
        "window_size": 3,
        "char_count": 198,
        "word_count": 46,
        "page_number": 6,
        "window_text": "| 가져야 한다.  | 인정할 수 있다.  | C1T1C2T2C3T3C4T4C5T5).  | Control 1 | 110 | 13.03 | 2.62 | 2.8 | 2.4 | 퍼센트 ≥100 pg/mL | 70.50% | 58.50% | 73.00% | 79.00% | 98.50% | 안지오텐신 I | 600pg/ml | 108% |\n| and Laboratory Standard Institute; 2009 | 서식에 따라 작성하여야 한다.  | 제출한다.  | 보조성분 | Oxypyrion1) | 적량 | 자사규격 | 혈색소, 지질(콜레스테롤, |\n| 가.  검체준비 및 저장방법 | 1. ",
        "original_sentence": "| Control 1 | 110 | 13.03 | 2.62 | 2.8 | 2.4 | 퍼센트 ≥100 pg/mL | 70.50% | 58.50% | 73.00% | 79.00% | 98.50% | 안지오텐신 I | 600pg/ml | 108% |\n| and Laboratory Standard Institute; 2009 | 서식에 따라 작성하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_121",
      "text": "| 제출한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 120,
        "window_size": 3,
        "char_count": 8,
        "word_count": 2,
        "page_number": 50,
        "window_text": "| 인정할 수 있다.  | C1T1C2T2C3T3C4T4C5T5).  | Control 1 | 110 | 13.03 | 2.62 | 2.8 | 2.4 | 퍼센트 ≥100 pg/mL | 70.50% | 58.50% | 73.00% | 79.00% | 98.50% | 안지오텐신 I | 600pg/ml | 108% |\n| and Laboratory Standard Institute; 2009 | 서식에 따라 작성하여야 한다.  | 제출한다.  | 보조성분 | Oxypyrion1) | 적량 | 자사규격 | 혈색소, 지질(콜레스테롤, |\n| 가.  검체준비 및 저장방법 | 1.  업체명 및 주소 | 나. ",
        "original_sentence": "| 제출한다. "
      }
    },
    {
      "chunk_id": "chunk_122",
      "text": "| 보조성분 | Oxypyrion1) | 적량 | 자사규격 | 혈색소, 지질(콜레스테롤, |\n| 가. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 121,
        "window_size": 3,
        "char_count": 57,
        "word_count": 14,
        "page_number": 14,
        "window_text": "| C1T1C2T2C3T3C4T4C5T5).  | Control 1 | 110 | 13.03 | 2.62 | 2.8 | 2.4 | 퍼센트 ≥100 pg/mL | 70.50% | 58.50% | 73.00% | 79.00% | 98.50% | 안지오텐신 I | 600pg/ml | 108% |\n| and Laboratory Standard Institute; 2009 | 서식에 따라 작성하여야 한다.  | 제출한다.  | 보조성분 | Oxypyrion1) | 적량 | 자사규격 | 혈색소, 지질(콜레스테롤, |\n| 가.  검체준비 및 저장방법 | 1.  업체명 및 주소 | 나.  출처 및 근거 자료 | 물질 및 폐기물 등) 취급 시 안전 등의 주의사항을 기재한다. ",
        "original_sentence": "| 보조성분 | Oxypyrion1) | 적량 | 자사규격 | 혈색소, 지질(콜레스테롤, |\n| 가. "
      }
    },
    {
      "chunk_id": "chunk_123",
      "text": "검체준비 및 저장방법 | 1. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 122,
        "window_size": 3,
        "char_count": 17,
        "word_count": 5,
        "page_number": 21,
        "window_text": "| Control 1 | 110 | 13.03 | 2.62 | 2.8 | 2.4 | 퍼센트 ≥100 pg/mL | 70.50% | 58.50% | 73.00% | 79.00% | 98.50% | 안지오텐신 I | 600pg/ml | 108% |\n| and Laboratory Standard Institute; 2009 | 서식에 따라 작성하여야 한다.  | 제출한다.  | 보조성분 | Oxypyrion1) | 적량 | 자사규격 | 혈색소, 지질(콜레스테롤, |\n| 가.  검체준비 및 저장방법 | 1.  업체명 및 주소 | 나.  출처 및 근거 자료 | 물질 및 폐기물 등) 취급 시 안전 등의 주의사항을 기재한다.  | 있는 자료 포함 | Ⅲ. ",
        "original_sentence": "검체준비 및 저장방법 | 1. "
      }
    },
    {
      "chunk_id": "chunk_124",
      "text": "업체명 및 주소 | 나. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 123,
        "window_size": 3,
        "char_count": 14,
        "word_count": 5,
        "page_number": 1,
        "window_text": "| 제출한다.  | 보조성분 | Oxypyrion1) | 적량 | 자사규격 | 혈색소, 지질(콜레스테롤, |\n| 가.  검체준비 및 저장방법 | 1.  업체명 및 주소 | 나.  출처 및 근거 자료 | 물질 및 폐기물 등) 취급 시 안전 등의 주의사항을 기재한다.  | 있는 자료 포함 | Ⅲ.  관련 규정 | 14 | 심부전과 연관이 있게 되며 두 물질 모두 울혈성심부전 진단에 | 신뢰구간) 이었다. ",
        "original_sentence": "업체명 및 주소 | 나. "
      }
    },
    {
      "chunk_id": "chunk_125",
      "text": "출처 및 근거 자료 | 물질 및 폐기물 등) 취급 시 안전 등의 주의사항을 기재한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 124,
        "window_size": 3,
        "char_count": 48,
        "word_count": 15,
        "page_number": 3,
        "window_text": "| 보조성분 | Oxypyrion1) | 적량 | 자사규격 | 혈색소, 지질(콜레스테롤, |\n| 가.  검체준비 및 저장방법 | 1.  업체명 및 주소 | 나.  출처 및 근거 자료 | 물질 및 폐기물 등) 취급 시 안전 등의 주의사항을 기재한다.  | 있는 자료 포함 | Ⅲ.  관련 규정 | 14 | 심부전과 연관이 있게 되며 두 물질 모두 울혈성심부전 진단에 | 신뢰구간) 이었다.  | 최소 (pg/mL) | 0 | 3 | 0 | 0 | 14 | 양성 | 음성 | 전체 | BNP / NT-proBNP | 육안으로 |\n| ⇩ | ⇩ | ⇩ | ⇩ | ABBOTT AXSYM B-TYPE | NATRIURETIC PEPTIDE (BNP) | MICROPARTICLE ENZYME | IMMUNOASSAY (MEIA) TEST | 심장질환으로 진단되지 않은 900명(465 여성, 435 남성)의 | Control 2 | 4200 | 495 | 91 | 10.7 | 2.2 | RESPONSE | BIOMEDICAL | CORP |\n| 검사법 | 2. ",
        "original_sentence": "출처 및 근거 자료 | 물질 및 폐기물 등) 취급 시 안전 등의 주의사항을 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_126",
      "text": "| 있는 자료 포함 | Ⅲ. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 125,
        "window_size": 3,
        "char_count": 16,
        "word_count": 6,
        "page_number": 20,
        "window_text": "검체준비 및 저장방법 | 1.  업체명 및 주소 | 나.  출처 및 근거 자료 | 물질 및 폐기물 등) 취급 시 안전 등의 주의사항을 기재한다.  | 있는 자료 포함 | Ⅲ.  관련 규정 | 14 | 심부전과 연관이 있게 되며 두 물질 모두 울혈성심부전 진단에 | 신뢰구간) 이었다.  | 최소 (pg/mL) | 0 | 3 | 0 | 0 | 14 | 양성 | 음성 | 전체 | BNP / NT-proBNP | 육안으로 |\n| ⇩ | ⇩ | ⇩ | ⇩ | ABBOTT AXSYM B-TYPE | NATRIURETIC PEPTIDE (BNP) | MICROPARTICLE ENZYME | IMMUNOASSAY (MEIA) TEST | 심장질환으로 진단되지 않은 900명(465 여성, 435 남성)의 | Control 2 | 4200 | 495 | 91 | 10.7 | 2.2 | RESPONSE | BIOMEDICAL | CORP |\n| 검사법 | 2.  원재료 및 제조방법에 관한 자료 | 42 | 범위 등) | 고려하시기 바랍니다. ",
        "original_sentence": "| 있는 자료 포함 | Ⅲ. "
      }
    },
    {
      "chunk_id": "chunk_127",
      "text": "관련 규정 | 14 | 심부전과 연관이 있게 되며 두 물질 모두 울혈성심부전 진단에 | 신뢰구간) 이었다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 126,
        "window_size": 3,
        "char_count": 60,
        "word_count": 17,
        "page_number": 6,
        "window_text": "업체명 및 주소 | 나.  출처 및 근거 자료 | 물질 및 폐기물 등) 취급 시 안전 등의 주의사항을 기재한다.  | 있는 자료 포함 | Ⅲ.  관련 규정 | 14 | 심부전과 연관이 있게 되며 두 물질 모두 울혈성심부전 진단에 | 신뢰구간) 이었다.  | 최소 (pg/mL) | 0 | 3 | 0 | 0 | 14 | 양성 | 음성 | 전체 | BNP / NT-proBNP | 육안으로 |\n| ⇩ | ⇩ | ⇩ | ⇩ | ABBOTT AXSYM B-TYPE | NATRIURETIC PEPTIDE (BNP) | MICROPARTICLE ENZYME | IMMUNOASSAY (MEIA) TEST | 심장질환으로 진단되지 않은 900명(465 여성, 435 남성)의 | Control 2 | 4200 | 495 | 91 | 10.7 | 2.2 | RESPONSE | BIOMEDICAL | CORP |\n| 검사법 | 2.  원재료 및 제조방법에 관한 자료 | 42 | 범위 등) | 고려하시기 바랍니다.  그럼에도 불구하고 동 지침서ㆍ안내서의 제정이 필요한 경 | 우 그 사유를 아래에 기재해 주시기 바랍니다. ",
        "original_sentence": "관련 규정 | 14 | 심부전과 연관이 있게 되며 두 물질 모두 울혈성심부전 진단에 | 신뢰구간) 이었다. "
      }
    },
    {
      "chunk_id": "chunk_128",
      "text": "| 최소 (pg/mL) | 0 | 3 | 0 | 0 | 14 | 양성 | 음성 | 전체 | BNP / NT-proBNP | 육안으로 |\n| ⇩ | ⇩ | ⇩ | ⇩ | ABBOTT AXSYM B-TYPE | NATRIURETIC PEPTIDE (BNP) | MICROPARTICLE ENZYME | IMMUNOASSAY (MEIA) TEST | 심장질환으로 진단되지 않은 900명(465 여성, 435 남성)의 | Control 2 | 4200 | 495 | 91 | 10.7 | 2.2 | RESPONSE | BIOMEDICAL | CORP |\n| 검사법 | 2. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 127,
        "window_size": 3,
        "char_count": 317,
        "word_count": 81,
        "page_number": 6,
        "window_text": "출처 및 근거 자료 | 물질 및 폐기물 등) 취급 시 안전 등의 주의사항을 기재한다.  | 있는 자료 포함 | Ⅲ.  관련 규정 | 14 | 심부전과 연관이 있게 되며 두 물질 모두 울혈성심부전 진단에 | 신뢰구간) 이었다.  | 최소 (pg/mL) | 0 | 3 | 0 | 0 | 14 | 양성 | 음성 | 전체 | BNP / NT-proBNP | 육안으로 |\n| ⇩ | ⇩ | ⇩ | ⇩ | ABBOTT AXSYM B-TYPE | NATRIURETIC PEPTIDE (BNP) | MICROPARTICLE ENZYME | IMMUNOASSAY (MEIA) TEST | 심장질환으로 진단되지 않은 900명(465 여성, 435 남성)의 | Control 2 | 4200 | 495 | 91 | 10.7 | 2.2 | RESPONSE | BIOMEDICAL | CORP |\n| 검사법 | 2.  원재료 및 제조방법에 관한 자료 | 42 | 범위 등) | 고려하시기 바랍니다.  그럼에도 불구하고 동 지침서ㆍ안내서의 제정이 필요한 경 | 우 그 사유를 아래에 기재해 주시기 바랍니다.  | 보조성분 | Bovine serum albumin | 적량 | 자사규격 | 최대 (pg/mL) | >4000 | 1650 | >4000 | >4000 | >4000 | 안지오텐신 II | 600pg/ml | 108% | AXIS-SHIELD | DIAGNOSTICS, | LTD. ",
        "original_sentence": "| 최소 (pg/mL) | 0 | 3 | 0 | 0 | 14 | 양성 | 음성 | 전체 | BNP / NT-proBNP | 육안으로 |\n| ⇩ | ⇩ | ⇩ | ⇩ | ABBOTT AXSYM B-TYPE | NATRIURETIC PEPTIDE (BNP) | MICROPARTICLE ENZYME | IMMUNOASSAY (MEIA) TEST | 심장질환으로 진단되지 않은 900명(465 여성, 435 남성)의 | Control 2 | 4200 | 495 | 91 | 10.7 | 2.2 | RESPONSE | BIOMEDICAL | CORP |\n| 검사법 | 2. "
      }
    },
    {
      "chunk_id": "chunk_129",
      "text": "원재료 및 제조방법에 관한 자료 | 42 | 범위 등) | 고려하시기 바랍니다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 128,
        "window_size": 3,
        "char_count": 45,
        "word_count": 13,
        "page_number": 6,
        "window_text": "| 있는 자료 포함 | Ⅲ.  관련 규정 | 14 | 심부전과 연관이 있게 되며 두 물질 모두 울혈성심부전 진단에 | 신뢰구간) 이었다.  | 최소 (pg/mL) | 0 | 3 | 0 | 0 | 14 | 양성 | 음성 | 전체 | BNP / NT-proBNP | 육안으로 |\n| ⇩ | ⇩ | ⇩ | ⇩ | ABBOTT AXSYM B-TYPE | NATRIURETIC PEPTIDE (BNP) | MICROPARTICLE ENZYME | IMMUNOASSAY (MEIA) TEST | 심장질환으로 진단되지 않은 900명(465 여성, 435 남성)의 | Control 2 | 4200 | 495 | 91 | 10.7 | 2.2 | RESPONSE | BIOMEDICAL | CORP |\n| 검사법 | 2.  원재료 및 제조방법에 관한 자료 | 42 | 범위 등) | 고려하시기 바랍니다.  그럼에도 불구하고 동 지침서ㆍ안내서의 제정이 필요한 경 | 우 그 사유를 아래에 기재해 주시기 바랍니다.  | 보조성분 | Bovine serum albumin | 적량 | 자사규격 | 최대 (pg/mL) | >4000 | 1650 | >4000 | >4000 | >4000 | 안지오텐신 II | 600pg/ml | 108% | AXIS-SHIELD | DIAGNOSTICS, | LTD.  |\n| 나. ",
        "original_sentence": "원재료 및 제조방법에 관한 자료 | 42 | 범위 등) | 고려하시기 바랍니다. "
      }
    },
    {
      "chunk_id": "chunk_130",
      "text": "그럼에도 불구하고 동 지침서ㆍ안내서의 제정이 필요한 경 | 우 그 사유를 아래에 기재해 주시기 바랍니다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 129,
        "window_size": 3,
        "char_count": 59,
        "word_count": 15,
        "page_number": 3,
        "window_text": "관련 규정 | 14 | 심부전과 연관이 있게 되며 두 물질 모두 울혈성심부전 진단에 | 신뢰구간) 이었다.  | 최소 (pg/mL) | 0 | 3 | 0 | 0 | 14 | 양성 | 음성 | 전체 | BNP / NT-proBNP | 육안으로 |\n| ⇩ | ⇩ | ⇩ | ⇩ | ABBOTT AXSYM B-TYPE | NATRIURETIC PEPTIDE (BNP) | MICROPARTICLE ENZYME | IMMUNOASSAY (MEIA) TEST | 심장질환으로 진단되지 않은 900명(465 여성, 435 남성)의 | Control 2 | 4200 | 495 | 91 | 10.7 | 2.2 | RESPONSE | BIOMEDICAL | CORP |\n| 검사법 | 2.  원재료 및 제조방법에 관한 자료 | 42 | 범위 등) | 고려하시기 바랍니다.  그럼에도 불구하고 동 지침서ㆍ안내서의 제정이 필요한 경 | 우 그 사유를 아래에 기재해 주시기 바랍니다.  | 보조성분 | Bovine serum albumin | 적량 | 자사규격 | 최대 (pg/mL) | >4000 | 1650 | >4000 | >4000 | >4000 | 안지오텐신 II | 600pg/ml | 108% | AXIS-SHIELD | DIAGNOSTICS, | LTD.  |\n| 나.  판정기준치(cut-off value) | 마. ",
        "original_sentence": "그럼에도 불구하고 동 지침서ㆍ안내서의 제정이 필요한 경 | 우 그 사유를 아래에 기재해 주시기 바랍니다. "
      }
    },
    {
      "chunk_id": "chunk_131",
      "text": "| 보조성분 | Bovine serum albumin | 적량 | 자사규격 | 최대 (pg/mL) | >4000 | 1650 | >4000 | >4000 | >4000 | 안지오텐신 II | 600pg/ml | 108% | AXIS-SHIELD | DIAGNOSTICS, | LTD. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 130,
        "window_size": 3,
        "char_count": 159,
        "word_count": 36,
        "page_number": 14,
        "window_text": "| 최소 (pg/mL) | 0 | 3 | 0 | 0 | 14 | 양성 | 음성 | 전체 | BNP / NT-proBNP | 육안으로 |\n| ⇩ | ⇩ | ⇩ | ⇩ | ABBOTT AXSYM B-TYPE | NATRIURETIC PEPTIDE (BNP) | MICROPARTICLE ENZYME | IMMUNOASSAY (MEIA) TEST | 심장질환으로 진단되지 않은 900명(465 여성, 435 남성)의 | Control 2 | 4200 | 495 | 91 | 10.7 | 2.2 | RESPONSE | BIOMEDICAL | CORP |\n| 검사법 | 2.  원재료 및 제조방법에 관한 자료 | 42 | 범위 등) | 고려하시기 바랍니다.  그럼에도 불구하고 동 지침서ㆍ안내서의 제정이 필요한 경 | 우 그 사유를 아래에 기재해 주시기 바랍니다.  | 보조성분 | Bovine serum albumin | 적량 | 자사규격 | 최대 (pg/mL) | >4000 | 1650 | >4000 | >4000 | >4000 | 안지오텐신 II | 600pg/ml | 108% | AXIS-SHIELD | DIAGNOSTICS, | LTD.  |\n| 나.  판정기준치(cut-off value) | 마.  대조물질의 제조방법, 설정 농도 및 반복 측정 결과를 기술한다. ",
        "original_sentence": "| 보조성분 | Bovine serum albumin | 적량 | 자사규격 | 최대 (pg/mL) | >4000 | 1650 | >4000 | >4000 | >4000 | 안지오텐신 II | 600pg/ml | 108% | AXIS-SHIELD | DIAGNOSTICS, | LTD. "
      }
    },
    {
      "chunk_id": "chunk_132",
      "text": "|\n| 나. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 131,
        "window_size": 3,
        "char_count": 7,
        "word_count": 3,
        "page_number": 1,
        "window_text": "원재료 및 제조방법에 관한 자료 | 42 | 범위 등) | 고려하시기 바랍니다.  그럼에도 불구하고 동 지침서ㆍ안내서의 제정이 필요한 경 | 우 그 사유를 아래에 기재해 주시기 바랍니다.  | 보조성분 | Bovine serum albumin | 적량 | 자사규격 | 최대 (pg/mL) | >4000 | 1650 | >4000 | >4000 | >4000 | 안지오텐신 II | 600pg/ml | 108% | AXIS-SHIELD | DIAGNOSTICS, | LTD.  |\n| 나.  판정기준치(cut-off value) | 마.  대조물질의 제조방법, 설정 농도 및 반복 측정 결과를 기술한다.  | 다. ",
        "original_sentence": "|\n| 나. "
      }
    },
    {
      "chunk_id": "chunk_133",
      "text": "판정기준치(cut-off value) | 마. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 132,
        "window_size": 3,
        "char_count": 26,
        "word_count": 4,
        "page_number": 14,
        "window_text": "그럼에도 불구하고 동 지침서ㆍ안내서의 제정이 필요한 경 | 우 그 사유를 아래에 기재해 주시기 바랍니다.  | 보조성분 | Bovine serum albumin | 적량 | 자사규격 | 최대 (pg/mL) | >4000 | 1650 | >4000 | >4000 | >4000 | 안지오텐신 II | 600pg/ml | 108% | AXIS-SHIELD | DIAGNOSTICS, | LTD.  |\n| 나.  판정기준치(cut-off value) | 마.  대조물질의 제조방법, 설정 농도 및 반복 측정 결과를 기술한다.  | 다.  결과제시 | 라. ",
        "original_sentence": "판정기준치(cut-off value) | 마. "
      }
    },
    {
      "chunk_id": "chunk_134",
      "text": "대조물질의 제조방법, 설정 농도 및 반복 측정 결과를 기술한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 133,
        "window_size": 3,
        "char_count": 36,
        "word_count": 9,
        "page_number": 30,
        "window_text": "| 보조성분 | Bovine serum albumin | 적량 | 자사규격 | 최대 (pg/mL) | >4000 | 1650 | >4000 | >4000 | >4000 | 안지오텐신 II | 600pg/ml | 108% | AXIS-SHIELD | DIAGNOSTICS, | LTD.  |\n| 나.  판정기준치(cut-off value) | 마.  대조물질의 제조방법, 설정 농도 및 반복 측정 결과를 기술한다.  | 다.  결과제시 | 라.  정량검사의 경우 각 검사를 2회 이상 반복 측정을 권장한다. ",
        "original_sentence": "대조물질의 제조방법, 설정 농도 및 반복 측정 결과를 기술한다. "
      }
    },
    {
      "chunk_id": "chunk_135",
      "text": "| 다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 134,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 1,
        "window_text": "|\n| 나.  판정기준치(cut-off value) | 마.  대조물질의 제조방법, 설정 농도 및 반복 측정 결과를 기술한다.  | 다.  결과제시 | 라.  정량검사의 경우 각 검사를 2회 이상 반복 측정을 권장한다.  | 가) 그대로 보고하는지 재검사가 필요한지 여부 | 건에 적합한 시험자가 시험하였는지에 대한 자료를 제출 | 4) 결과제시 | 1) 3개 이상의 농도(컷오프 근처의 검체 포함) | 호흡곤란으로 응급실 내원한 환자, 입원환자 등). ",
        "original_sentence": "| 다. "
      }
    },
    {
      "chunk_id": "chunk_136",
      "text": "결과제시 | 라. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 135,
        "window_size": 3,
        "char_count": 10,
        "word_count": 3,
        "page_number": 1,
        "window_text": "판정기준치(cut-off value) | 마.  대조물질의 제조방법, 설정 농도 및 반복 측정 결과를 기술한다.  | 다.  결과제시 | 라.  정량검사의 경우 각 검사를 2회 이상 반복 측정을 권장한다.  | 가) 그대로 보고하는지 재검사가 필요한지 여부 | 건에 적합한 시험자가 시험하였는지에 대한 자료를 제출 | 4) 결과제시 | 1) 3개 이상의 농도(컷오프 근처의 검체 포함) | 호흡곤란으로 응급실 내원한 환자, 입원환자 등).  | 제시한다. ",
        "original_sentence": "결과제시 | 라. "
      }
    },
    {
      "chunk_id": "chunk_137",
      "text": "정량검사의 경우 각 검사를 2회 이상 반복 측정을 권장한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 136,
        "window_size": 3,
        "char_count": 34,
        "word_count": 9,
        "page_number": 6,
        "window_text": "대조물질의 제조방법, 설정 농도 및 반복 측정 결과를 기술한다.  | 다.  결과제시 | 라.  정량검사의 경우 각 검사를 2회 이상 반복 측정을 권장한다.  | 가) 그대로 보고하는지 재검사가 필요한지 여부 | 건에 적합한 시험자가 시험하였는지에 대한 자료를 제출 | 4) 결과제시 | 1) 3개 이상의 농도(컷오프 근처의 검체 포함) | 호흡곤란으로 응급실 내원한 환자, 입원환자 등).  | 제시한다.  | test)를 실시한다. ",
        "original_sentence": "정량검사의 경우 각 검사를 2회 이상 반복 측정을 권장한다. "
      }
    },
    {
      "chunk_id": "chunk_138",
      "text": "| 가) 그대로 보고하는지 재검사가 필요한지 여부 | 건에 적합한 시험자가 시험하였는지에 대한 자료를 제출 | 4) 결과제시 | 1) 3개 이상의 농도(컷오프 근처의 검체 포함) | 호흡곤란으로 응급실 내원한 환자, 입원환자 등). ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 137,
        "window_size": 3,
        "char_count": 130,
        "word_count": 33,
        "page_number": 3,
        "window_text": "| 다.  결과제시 | 라.  정량검사의 경우 각 검사를 2회 이상 반복 측정을 권장한다.  | 가) 그대로 보고하는지 재검사가 필요한지 여부 | 건에 적합한 시험자가 시험하였는지에 대한 자료를 제출 | 4) 결과제시 | 1) 3개 이상의 농도(컷오프 근처의 검체 포함) | 호흡곤란으로 응급실 내원한 환자, 입원환자 등).  | 제시한다.  | test)를 실시한다.  | 사용할 수 있는 희석액을 명시하고, 그 근거를 제시해야 한다. ",
        "original_sentence": "| 가) 그대로 보고하는지 재검사가 필요한지 여부 | 건에 적합한 시험자가 시험하였는지에 대한 자료를 제출 | 4) 결과제시 | 1) 3개 이상의 농도(컷오프 근처의 검체 포함) | 호흡곤란으로 응급실 내원한 환자, 입원환자 등). "
      }
    },
    {
      "chunk_id": "chunk_139",
      "text": "| 제시한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 138,
        "window_size": 3,
        "char_count": 8,
        "word_count": 2,
        "page_number": 26,
        "window_text": "결과제시 | 라.  정량검사의 경우 각 검사를 2회 이상 반복 측정을 권장한다.  | 가) 그대로 보고하는지 재검사가 필요한지 여부 | 건에 적합한 시험자가 시험하였는지에 대한 자료를 제출 | 4) 결과제시 | 1) 3개 이상의 농도(컷오프 근처의 검체 포함) | 호흡곤란으로 응급실 내원한 환자, 입원환자 등).  | 제시한다.  | test)를 실시한다.  | 사용할 수 있는 희석액을 명시하고, 그 근거를 제시해야 한다.  | 제시한다. ",
        "original_sentence": "| 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_140",
      "text": "| test)를 실시한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 139,
        "window_size": 3,
        "char_count": 15,
        "word_count": 3,
        "page_number": 56,
        "window_text": "정량검사의 경우 각 검사를 2회 이상 반복 측정을 권장한다.  | 가) 그대로 보고하는지 재검사가 필요한지 여부 | 건에 적합한 시험자가 시험하였는지에 대한 자료를 제출 | 4) 결과제시 | 1) 3개 이상의 농도(컷오프 근처의 검체 포함) | 호흡곤란으로 응급실 내원한 환자, 입원환자 등).  | 제시한다.  | test)를 실시한다.  | 사용할 수 있는 희석액을 명시하고, 그 근거를 제시해야 한다.  | 제시한다.  | 확인한다. ",
        "original_sentence": "| test)를 실시한다. "
      }
    },
    {
      "chunk_id": "chunk_141",
      "text": "| 사용할 수 있는 희석액을 명시하고, 그 근거를 제시해야 한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 140,
        "window_size": 3,
        "char_count": 37,
        "word_count": 10,
        "page_number": 56,
        "window_text": "| 가) 그대로 보고하는지 재검사가 필요한지 여부 | 건에 적합한 시험자가 시험하였는지에 대한 자료를 제출 | 4) 결과제시 | 1) 3개 이상의 농도(컷오프 근처의 검체 포함) | 호흡곤란으로 응급실 내원한 환자, 입원환자 등).  | 제시한다.  | test)를 실시한다.  | 사용할 수 있는 희석액을 명시하고, 그 근거를 제시해야 한다.  | 제시한다.  | 확인한다.  | 트리글리세리드), 빌리루빈, 이상 단백질 | 07/21/2008 |\n| 다. ",
        "original_sentence": "| 사용할 수 있는 희석액을 명시하고, 그 근거를 제시해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_142",
      "text": "| 제시한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 141,
        "window_size": 3,
        "char_count": 8,
        "word_count": 2,
        "page_number": 26,
        "window_text": "| 제시한다.  | test)를 실시한다.  | 사용할 수 있는 희석액을 명시하고, 그 근거를 제시해야 한다.  | 제시한다.  | 확인한다.  | 트리글리세리드), 빌리루빈, 이상 단백질 | 07/21/2008 |\n| 다.  구성시약 중 유해물질이 포함될 경우 이에 대한 경고사항을 기재한다. ",
        "original_sentence": "| 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_143",
      "text": "| 확인한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 142,
        "window_size": 3,
        "char_count": 8,
        "word_count": 2,
        "page_number": 19,
        "window_text": "| test)를 실시한다.  | 사용할 수 있는 희석액을 명시하고, 그 근거를 제시해야 한다.  | 제시한다.  | 확인한다.  | 트리글리세리드), 빌리루빈, 이상 단백질 | 07/21/2008 |\n| 다.  구성시약 중 유해물질이 포함될 경우 이에 대한 경고사항을 기재한다.  | 다. ",
        "original_sentence": "| 확인한다. "
      }
    },
    {
      "chunk_id": "chunk_144",
      "text": "| 트리글리세리드), 빌리루빈, 이상 단백질 | 07/21/2008 |\n| 다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 143,
        "window_size": 3,
        "char_count": 45,
        "word_count": 10,
        "page_number": 6,
        "window_text": "| 사용할 수 있는 희석액을 명시하고, 그 근거를 제시해야 한다.  | 제시한다.  | 확인한다.  | 트리글리세리드), 빌리루빈, 이상 단백질 | 07/21/2008 |\n| 다.  구성시약 중 유해물질이 포함될 경우 이에 대한 경고사항을 기재한다.  | 다.  원료물질(단클론항체)의 기원에 관한 자료-기원 생물체, 클론번호 | 2. ",
        "original_sentence": "| 트리글리세리드), 빌리루빈, 이상 단백질 | 07/21/2008 |\n| 다. "
      }
    },
    {
      "chunk_id": "chunk_145",
      "text": "구성시약 중 유해물질이 포함될 경우 이에 대한 경고사항을 기재한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 144,
        "window_size": 3,
        "char_count": 38,
        "word_count": 9,
        "page_number": 3,
        "window_text": "| 제시한다.  | 확인한다.  | 트리글리세리드), 빌리루빈, 이상 단백질 | 07/21/2008 |\n| 다.  구성시약 중 유해물질이 포함될 경우 이에 대한 경고사항을 기재한다.  | 다.  원료물질(단클론항체)의 기원에 관한 자료-기원 생물체, 클론번호 | 2.  시험성적서의 일련번호 및 각 페이지와 전체 페이지 번호 | 별표 2] 또는 이와 동등이상 규격의 멸균방법을 기재한다. ",
        "original_sentence": "구성시약 중 유해물질이 포함될 경우 이에 대한 경고사항을 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_146",
      "text": "| 다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 145,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 1,
        "window_text": "| 확인한다.  | 트리글리세리드), 빌리루빈, 이상 단백질 | 07/21/2008 |\n| 다.  구성시약 중 유해물질이 포함될 경우 이에 대한 경고사항을 기재한다.  | 다.  원료물질(단클론항체)의 기원에 관한 자료-기원 생물체, 클론번호 | 2.  시험성적서의 일련번호 및 각 페이지와 전체 페이지 번호 | 별표 2] 또는 이와 동등이상 규격의 멸균방법을 기재한다.  | ※ 예시 | 1) 검체대상 및 채취방법 등 | 유용하게 사용된다. ",
        "original_sentence": "| 다. "
      }
    },
    {
      "chunk_id": "chunk_147",
      "text": "원료물질(단클론항체)의 기원에 관한 자료-기원 생물체, 클론번호 | 2. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 146,
        "window_size": 3,
        "char_count": 41,
        "word_count": 8,
        "page_number": 3,
        "window_text": "| 트리글리세리드), 빌리루빈, 이상 단백질 | 07/21/2008 |\n| 다.  구성시약 중 유해물질이 포함될 경우 이에 대한 경고사항을 기재한다.  | 다.  원료물질(단클론항체)의 기원에 관한 자료-기원 생물체, 클론번호 | 2.  시험성적서의 일련번호 및 각 페이지와 전체 페이지 번호 | 별표 2] 또는 이와 동등이상 규격의 멸균방법을 기재한다.  | ※ 예시 | 1) 검체대상 및 채취방법 등 | 유용하게 사용된다.  이러한 뇌나트륨이뇨펩티드는 심정지와 | 혈장 검체를 본 제품으로 검사로 시험하였다. ",
        "original_sentence": "원료물질(단클론항체)의 기원에 관한 자료-기원 생물체, 클론번호 | 2. "
      }
    },
    {
      "chunk_id": "chunk_148",
      "text": "시험성적서의 일련번호 및 각 페이지와 전체 페이지 번호 | 별표 2] 또는 이와 동등이상 규격의 멸균방법을 기재한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 147,
        "window_size": 3,
        "char_count": 66,
        "word_count": 17,
        "page_number": 6,
        "window_text": "구성시약 중 유해물질이 포함될 경우 이에 대한 경고사항을 기재한다.  | 다.  원료물질(단클론항체)의 기원에 관한 자료-기원 생물체, 클론번호 | 2.  시험성적서의 일련번호 및 각 페이지와 전체 페이지 번호 | 별표 2] 또는 이와 동등이상 규격의 멸균방법을 기재한다.  | ※ 예시 | 1) 검체대상 및 채취방법 등 | 유용하게 사용된다.  이러한 뇌나트륨이뇨펩티드는 심정지와 | 혈장 검체를 본 제품으로 검사로 시험하였다.  이 모집단은 | 시약명 | 제조사 | 제조국 | 01/30/2004 | 확인한다. ",
        "original_sentence": "시험성적서의 일련번호 및 각 페이지와 전체 페이지 번호 | 별표 2] 또는 이와 동등이상 규격의 멸균방법을 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_149",
      "text": "| ※ 예시 | 1) 검체대상 및 채취방법 등 | 유용하게 사용된다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 148,
        "window_size": 3,
        "char_count": 39,
        "word_count": 12,
        "page_number": 21,
        "window_text": "| 다.  원료물질(단클론항체)의 기원에 관한 자료-기원 생물체, 클론번호 | 2.  시험성적서의 일련번호 및 각 페이지와 전체 페이지 번호 | 별표 2] 또는 이와 동등이상 규격의 멸균방법을 기재한다.  | ※ 예시 | 1) 검체대상 및 채취방법 등 | 유용하게 사용된다.  이러한 뇌나트륨이뇨펩티드는 심정지와 | 혈장 검체를 본 제품으로 검사로 시험하였다.  이 모집단은 | 시약명 | 제조사 | 제조국 | 01/30/2004 | 확인한다.  |\n| (제조․수입업소명) | (제품명) | (품목명) | (모델명) | 것으로 인정되는 시험자료 | 1) 업체명 및 주소 | 2) 분석적 특이도 | <본질적 동등품목 비교표> | 양성 | a | b | a + b | Mouse monoclonal cardiac | Intermediate precision |\n| 외국회사일 경우에는 제조국을 추가로 기재한다. ",
        "original_sentence": "| ※ 예시 | 1) 검체대상 및 채취방법 등 | 유용하게 사용된다. "
      }
    },
    {
      "chunk_id": "chunk_150",
      "text": "이러한 뇌나트륨이뇨펩티드는 심정지와 | 혈장 검체를 본 제품으로 검사로 시험하였다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 149,
        "window_size": 3,
        "char_count": 47,
        "word_count": 10,
        "page_number": 33,
        "window_text": "원료물질(단클론항체)의 기원에 관한 자료-기원 생물체, 클론번호 | 2.  시험성적서의 일련번호 및 각 페이지와 전체 페이지 번호 | 별표 2] 또는 이와 동등이상 규격의 멸균방법을 기재한다.  | ※ 예시 | 1) 검체대상 및 채취방법 등 | 유용하게 사용된다.  이러한 뇌나트륨이뇨펩티드는 심정지와 | 혈장 검체를 본 제품으로 검사로 시험하였다.  이 모집단은 | 시약명 | 제조사 | 제조국 | 01/30/2004 | 확인한다.  |\n| (제조․수입업소명) | (제품명) | (품목명) | (모델명) | 것으로 인정되는 시험자료 | 1) 업체명 및 주소 | 2) 분석적 특이도 | <본질적 동등품목 비교표> | 양성 | a | b | a + b | Mouse monoclonal cardiac | Intermediate precision |\n| 외국회사일 경우에는 제조국을 추가로 기재한다.  | 후보 | 사용기간(유효기간)이 서로 다른 경우 가장 짧은 기한으로 기재한다. ",
        "original_sentence": "이러한 뇌나트륨이뇨펩티드는 심정지와 | 혈장 검체를 본 제품으로 검사로 시험하였다. "
      }
    },
    {
      "chunk_id": "chunk_151",
      "text": "이 모집단은 | 시약명 | 제조사 | 제조국 | 01/30/2004 | 확인한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 150,
        "window_size": 3,
        "char_count": 46,
        "word_count": 12,
        "page_number": 6,
        "window_text": "시험성적서의 일련번호 및 각 페이지와 전체 페이지 번호 | 별표 2] 또는 이와 동등이상 규격의 멸균방법을 기재한다.  | ※ 예시 | 1) 검체대상 및 채취방법 등 | 유용하게 사용된다.  이러한 뇌나트륨이뇨펩티드는 심정지와 | 혈장 검체를 본 제품으로 검사로 시험하였다.  이 모집단은 | 시약명 | 제조사 | 제조국 | 01/30/2004 | 확인한다.  |\n| (제조․수입업소명) | (제품명) | (품목명) | (모델명) | 것으로 인정되는 시험자료 | 1) 업체명 및 주소 | 2) 분석적 특이도 | <본질적 동등품목 비교표> | 양성 | a | b | a + b | Mouse monoclonal cardiac | Intermediate precision |\n| 외국회사일 경우에는 제조국을 추가로 기재한다.  | 후보 | 사용기간(유효기간)이 서로 다른 경우 가장 짧은 기한으로 기재한다.  | Ⅳ. ",
        "original_sentence": "이 모집단은 | 시약명 | 제조사 | 제조국 | 01/30/2004 | 확인한다. "
      }
    },
    {
      "chunk_id": "chunk_152",
      "text": "|\n| (제조․수입업소명) | (제품명) | (품목명) | (모델명) | 것으로 인정되는 시험자료 | 1) 업체명 및 주소 | 2) 분석적 특이도 | <본질적 동등품목 비교표> | 양성 | a | b | a + b | Mouse monoclonal cardiac | Intermediate precision |\n| 외국회사일 경우에는 제조국을 추가로 기재한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 151,
        "window_size": 3,
        "char_count": 202,
        "word_count": 50,
        "page_number": 24,
        "window_text": "| ※ 예시 | 1) 검체대상 및 채취방법 등 | 유용하게 사용된다.  이러한 뇌나트륨이뇨펩티드는 심정지와 | 혈장 검체를 본 제품으로 검사로 시험하였다.  이 모집단은 | 시약명 | 제조사 | 제조국 | 01/30/2004 | 확인한다.  |\n| (제조․수입업소명) | (제품명) | (품목명) | (모델명) | 것으로 인정되는 시험자료 | 1) 업체명 및 주소 | 2) 분석적 특이도 | <본질적 동등품목 비교표> | 양성 | a | b | a + b | Mouse monoclonal cardiac | Intermediate precision |\n| 외국회사일 경우에는 제조국을 추가로 기재한다.  | 후보 | 사용기간(유효기간)이 서로 다른 경우 가장 짧은 기한으로 기재한다.  | Ⅳ.  신청서 기재 항목 및 기술문서 제출자료 | 15 | 3. ",
        "original_sentence": "|\n| (제조․수입업소명) | (제품명) | (품목명) | (모델명) | 것으로 인정되는 시험자료 | 1) 업체명 및 주소 | 2) 분석적 특이도 | <본질적 동등품목 비교표> | 양성 | a | b | a + b | Mouse monoclonal cardiac | Intermediate precision |\n| 외국회사일 경우에는 제조국을 추가로 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_153",
      "text": "| 후보 | 사용기간(유효기간)이 서로 다른 경우 가장 짧은 기한으로 기재한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 152,
        "window_size": 3,
        "char_count": 45,
        "word_count": 11,
        "page_number": 14,
        "window_text": "이러한 뇌나트륨이뇨펩티드는 심정지와 | 혈장 검체를 본 제품으로 검사로 시험하였다.  이 모집단은 | 시약명 | 제조사 | 제조국 | 01/30/2004 | 확인한다.  |\n| (제조․수입업소명) | (제품명) | (품목명) | (모델명) | 것으로 인정되는 시험자료 | 1) 업체명 및 주소 | 2) 분석적 특이도 | <본질적 동등품목 비교표> | 양성 | a | b | a + b | Mouse monoclonal cardiac | Intermediate precision |\n| 외국회사일 경우에는 제조국을 추가로 기재한다.  | 후보 | 사용기간(유효기간)이 서로 다른 경우 가장 짧은 기한으로 기재한다.  | Ⅳ.  신청서 기재 항목 및 기술문서 제출자료 | 15 | 3.  사용목적에 관한 자료 | 42 | 분석적 | 주성분 | ・측정범위(Measuring range) : 5-30000 pg/mL | NT-proBNP antibody | 0.5 | 자사규격 | -심장 질환 모집단(남성)- | 및 펩타이드 등 |\n| 참고표준방법은 표적물질의 유무를 알기 위해 시행되는 한 가지 방 | 1) 일반사항 | 2) 환자검체 또는 정도관리검체 | 사용될 수 있다. ",
        "original_sentence": "| 후보 | 사용기간(유효기간)이 서로 다른 경우 가장 짧은 기한으로 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_154",
      "text": "| Ⅳ. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 153,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 21,
        "window_text": "이 모집단은 | 시약명 | 제조사 | 제조국 | 01/30/2004 | 확인한다.  |\n| (제조․수입업소명) | (제품명) | (품목명) | (모델명) | 것으로 인정되는 시험자료 | 1) 업체명 및 주소 | 2) 분석적 특이도 | <본질적 동등품목 비교표> | 양성 | a | b | a + b | Mouse monoclonal cardiac | Intermediate precision |\n| 외국회사일 경우에는 제조국을 추가로 기재한다.  | 후보 | 사용기간(유효기간)이 서로 다른 경우 가장 짧은 기한으로 기재한다.  | Ⅳ.  신청서 기재 항목 및 기술문서 제출자료 | 15 | 3.  사용목적에 관한 자료 | 42 | 분석적 | 주성분 | ・측정범위(Measuring range) : 5-30000 pg/mL | NT-proBNP antibody | 0.5 | 자사규격 | -심장 질환 모집단(남성)- | 및 펩타이드 등 |\n| 참고표준방법은 표적물질의 유무를 알기 위해 시행되는 한 가지 방 | 1) 일반사항 | 2) 환자검체 또는 정도관리검체 | 사용될 수 있다.  | 가) 직선성 범위의 농도 구간을 제시한다. ",
        "original_sentence": "| Ⅳ. "
      }
    },
    {
      "chunk_id": "chunk_155",
      "text": "신청서 기재 항목 및 기술문서 제출자료 | 15 | 3. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 154,
        "window_size": 3,
        "char_count": 32,
        "word_count": 10,
        "page_number": 3,
        "window_text": "|\n| (제조․수입업소명) | (제품명) | (품목명) | (모델명) | 것으로 인정되는 시험자료 | 1) 업체명 및 주소 | 2) 분석적 특이도 | <본질적 동등품목 비교표> | 양성 | a | b | a + b | Mouse monoclonal cardiac | Intermediate precision |\n| 외국회사일 경우에는 제조국을 추가로 기재한다.  | 후보 | 사용기간(유효기간)이 서로 다른 경우 가장 짧은 기한으로 기재한다.  | Ⅳ.  신청서 기재 항목 및 기술문서 제출자료 | 15 | 3.  사용목적에 관한 자료 | 42 | 분석적 | 주성분 | ・측정범위(Measuring range) : 5-30000 pg/mL | NT-proBNP antibody | 0.5 | 자사규격 | -심장 질환 모집단(남성)- | 및 펩타이드 등 |\n| 참고표준방법은 표적물질의 유무를 알기 위해 시행되는 한 가지 방 | 1) 일반사항 | 2) 환자검체 또는 정도관리검체 | 사용될 수 있다.  | 가) 직선성 범위의 농도 구간을 제시한다.  | 요건에 적합한 시험자가 시험하였는지에 대한 자료를 제출 | 등을 제시한다. ",
        "original_sentence": "신청서 기재 항목 및 기술문서 제출자료 | 15 | 3. "
      }
    },
    {
      "chunk_id": "chunk_156",
      "text": "사용목적에 관한 자료 | 42 | 분석적 | 주성분 | ・측정범위(Measuring range) : 5-30000 pg/mL | NT-proBNP antibody | 0.5 | 자사규격 | -심장 질환 모집단(남성)- | 및 펩타이드 등 |\n| 참고표준방법은 표적물질의 유무를 알기 위해 시행되는 한 가지 방 | 1) 일반사항 | 2) 환자검체 또는 정도관리검체 | 사용될 수 있다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 155,
        "window_size": 3,
        "char_count": 215,
        "word_count": 53,
        "page_number": 6,
        "window_text": "| 후보 | 사용기간(유효기간)이 서로 다른 경우 가장 짧은 기한으로 기재한다.  | Ⅳ.  신청서 기재 항목 및 기술문서 제출자료 | 15 | 3.  사용목적에 관한 자료 | 42 | 분석적 | 주성분 | ・측정범위(Measuring range) : 5-30000 pg/mL | NT-proBNP antibody | 0.5 | 자사규격 | -심장 질환 모집단(남성)- | 및 펩타이드 등 |\n| 참고표준방법은 표적물질의 유무를 알기 위해 시행되는 한 가지 방 | 1) 일반사항 | 2) 환자검체 또는 정도관리검체 | 사용될 수 있다.  | 가) 직선성 범위의 농도 구간을 제시한다.  | 요건에 적합한 시험자가 시험하였는지에 대한 자료를 제출 | 등을 제시한다.  | 권장한다. ",
        "original_sentence": "사용목적에 관한 자료 | 42 | 분석적 | 주성분 | ・측정범위(Measuring range) : 5-30000 pg/mL | NT-proBNP antibody | 0.5 | 자사규격 | -심장 질환 모집단(남성)- | 및 펩타이드 등 |\n| 참고표준방법은 표적물질의 유무를 알기 위해 시행되는 한 가지 방 | 1) 일반사항 | 2) 환자검체 또는 정도관리검체 | 사용될 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_157",
      "text": "| 가) 직선성 범위의 농도 구간을 제시한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 156,
        "window_size": 3,
        "char_count": 26,
        "word_count": 7,
        "page_number": 26,
        "window_text": "| Ⅳ.  신청서 기재 항목 및 기술문서 제출자료 | 15 | 3.  사용목적에 관한 자료 | 42 | 분석적 | 주성분 | ・측정범위(Measuring range) : 5-30000 pg/mL | NT-proBNP antibody | 0.5 | 자사규격 | -심장 질환 모집단(남성)- | 및 펩타이드 등 |\n| 참고표준방법은 표적물질의 유무를 알기 위해 시행되는 한 가지 방 | 1) 일반사항 | 2) 환자검체 또는 정도관리검체 | 사용될 수 있다.  | 가) 직선성 범위의 농도 구간을 제시한다.  | 요건에 적합한 시험자가 시험하였는지에 대한 자료를 제출 | 등을 제시한다.  | 권장한다.  | (사유 :                                                                 ) | DIMENSION VISTA | N-TERMINAL PRO-BRAIN | NATRIURETIC PEPTIDE | (PBNP) FLEX REAGENT | CARTRIDGE (K6423A), | DIMENSION VISTA | 병원에 입원하지 않은 신장병(투석 치료를 받지 않는 환자), | 엔도텔린 I | 20pg/ml | 101% |\n| 1 | 기허가 진단제품 또는 확진검사방법 등으로 확인하였음을 기술한 | 전자적 기록매체(CD·디스켓 등)와 함께 제출한다. ",
        "original_sentence": "| 가) 직선성 범위의 농도 구간을 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_158",
      "text": "| 요건에 적합한 시험자가 시험하였는지에 대한 자료를 제출 | 등을 제시한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 157,
        "window_size": 3,
        "char_count": 44,
        "word_count": 11,
        "page_number": 26,
        "window_text": "신청서 기재 항목 및 기술문서 제출자료 | 15 | 3.  사용목적에 관한 자료 | 42 | 분석적 | 주성분 | ・측정범위(Measuring range) : 5-30000 pg/mL | NT-proBNP antibody | 0.5 | 자사규격 | -심장 질환 모집단(남성)- | 및 펩타이드 등 |\n| 참고표준방법은 표적물질의 유무를 알기 위해 시행되는 한 가지 방 | 1) 일반사항 | 2) 환자검체 또는 정도관리검체 | 사용될 수 있다.  | 가) 직선성 범위의 농도 구간을 제시한다.  | 요건에 적합한 시험자가 시험하였는지에 대한 자료를 제출 | 등을 제시한다.  | 권장한다.  | (사유 :                                                                 ) | DIMENSION VISTA | N-TERMINAL PRO-BRAIN | NATRIURETIC PEPTIDE | (PBNP) FLEX REAGENT | CARTRIDGE (K6423A), | DIMENSION VISTA | 병원에 입원하지 않은 신장병(투석 치료를 받지 않는 환자), | 엔도텔린 I | 20pg/ml | 101% |\n| 1 | 기허가 진단제품 또는 확진검사방법 등으로 확인하였음을 기술한 | 전자적 기록매체(CD·디스켓 등)와 함께 제출한다.  | Mean | SD | CV | SIEMENS | HEALTHCARE | DIAGNOSTICS | INC |\n| 라. ",
        "original_sentence": "| 요건에 적합한 시험자가 시험하였는지에 대한 자료를 제출 | 등을 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_159",
      "text": "| 권장한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 158,
        "window_size": 3,
        "char_count": 8,
        "word_count": 2,
        "page_number": 56,
        "window_text": "사용목적에 관한 자료 | 42 | 분석적 | 주성분 | ・측정범위(Measuring range) : 5-30000 pg/mL | NT-proBNP antibody | 0.5 | 자사규격 | -심장 질환 모집단(남성)- | 및 펩타이드 등 |\n| 참고표준방법은 표적물질의 유무를 알기 위해 시행되는 한 가지 방 | 1) 일반사항 | 2) 환자검체 또는 정도관리검체 | 사용될 수 있다.  | 가) 직선성 범위의 농도 구간을 제시한다.  | 요건에 적합한 시험자가 시험하였는지에 대한 자료를 제출 | 등을 제시한다.  | 권장한다.  | (사유 :                                                                 ) | DIMENSION VISTA | N-TERMINAL PRO-BRAIN | NATRIURETIC PEPTIDE | (PBNP) FLEX REAGENT | CARTRIDGE (K6423A), | DIMENSION VISTA | 병원에 입원하지 않은 신장병(투석 치료를 받지 않는 환자), | 엔도텔린 I | 20pg/ml | 101% |\n| 1 | 기허가 진단제품 또는 확진검사방법 등으로 확인하였음을 기술한 | 전자적 기록매체(CD·디스켓 등)와 함께 제출한다.  | Mean | SD | CV | SIEMENS | HEALTHCARE | DIAGNOSTICS | INC |\n| 라.  사용한 검체 및 키트의 처리 및 폐기방법 및 주의사항을 기재한다. ",
        "original_sentence": "| 권장한다. "
      }
    },
    {
      "chunk_id": "chunk_160",
      "text": "| (사유 :                                                                 ) | DIMENSION VISTA | N-TERMINAL PRO-BRAIN | NATRIURETIC PEPTIDE | (PBNP) FLEX REAGENT | CARTRIDGE (K6423A), | DIMENSION VISTA | 병원에 입원하지 않은 신장병(투석 치료를 받지 않는 환자), | 엔도텔린 I | 20pg/ml | 101% |\n| 1 | 기허가 진단제품 또는 확진검사방법 등으로 확인하였음을 기술한 | 전자적 기록매체(CD·디스켓 등)와 함께 제출한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 159,
        "window_size": 3,
        "char_count": 334,
        "word_count": 56,
        "page_number": 1,
        "window_text": "| 가) 직선성 범위의 농도 구간을 제시한다.  | 요건에 적합한 시험자가 시험하였는지에 대한 자료를 제출 | 등을 제시한다.  | 권장한다.  | (사유 :                                                                 ) | DIMENSION VISTA | N-TERMINAL PRO-BRAIN | NATRIURETIC PEPTIDE | (PBNP) FLEX REAGENT | CARTRIDGE (K6423A), | DIMENSION VISTA | 병원에 입원하지 않은 신장병(투석 치료를 받지 않는 환자), | 엔도텔린 I | 20pg/ml | 101% |\n| 1 | 기허가 진단제품 또는 확진검사방법 등으로 확인하였음을 기술한 | 전자적 기록매체(CD·디스켓 등)와 함께 제출한다.  | Mean | SD | CV | SIEMENS | HEALTHCARE | DIAGNOSTICS | INC |\n| 라.  사용한 검체 및 키트의 처리 및 폐기방법 및 주의사항을 기재한다.  | 라. ",
        "original_sentence": "| (사유 :                                                                 ) | DIMENSION VISTA | N-TERMINAL PRO-BRAIN | NATRIURETIC PEPTIDE | (PBNP) FLEX REAGENT | CARTRIDGE (K6423A), | DIMENSION VISTA | 병원에 입원하지 않은 신장병(투석 치료를 받지 않는 환자), | 엔도텔린 I | 20pg/ml | 101% |\n| 1 | 기허가 진단제품 또는 확진검사방법 등으로 확인하였음을 기술한 | 전자적 기록매체(CD·디스켓 등)와 함께 제출한다. "
      }
    },
    {
      "chunk_id": "chunk_161",
      "text": "| Mean | SD | CV | SIEMENS | HEALTHCARE | DIAGNOSTICS | INC |\n| 라. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 160,
        "window_size": 3,
        "char_count": 67,
        "word_count": 17,
        "page_number": 14,
        "window_text": "| 요건에 적합한 시험자가 시험하였는지에 대한 자료를 제출 | 등을 제시한다.  | 권장한다.  | (사유 :                                                                 ) | DIMENSION VISTA | N-TERMINAL PRO-BRAIN | NATRIURETIC PEPTIDE | (PBNP) FLEX REAGENT | CARTRIDGE (K6423A), | DIMENSION VISTA | 병원에 입원하지 않은 신장병(투석 치료를 받지 않는 환자), | 엔도텔린 I | 20pg/ml | 101% |\n| 1 | 기허가 진단제품 또는 확진검사방법 등으로 확인하였음을 기술한 | 전자적 기록매체(CD·디스켓 등)와 함께 제출한다.  | Mean | SD | CV | SIEMENS | HEALTHCARE | DIAGNOSTICS | INC |\n| 라.  사용한 검체 및 키트의 처리 및 폐기방법 및 주의사항을 기재한다.  | 라.  원료물질의 품질 확인 근거자료 | 3. ",
        "original_sentence": "| Mean | SD | CV | SIEMENS | HEALTHCARE | DIAGNOSTICS | INC |\n| 라. "
      }
    },
    {
      "chunk_id": "chunk_162",
      "text": "사용한 검체 및 키트의 처리 및 폐기방법 및 주의사항을 기재한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 161,
        "window_size": 3,
        "char_count": 37,
        "word_count": 10,
        "page_number": 3,
        "window_text": "| 권장한다.  | (사유 :                                                                 ) | DIMENSION VISTA | N-TERMINAL PRO-BRAIN | NATRIURETIC PEPTIDE | (PBNP) FLEX REAGENT | CARTRIDGE (K6423A), | DIMENSION VISTA | 병원에 입원하지 않은 신장병(투석 치료를 받지 않는 환자), | 엔도텔린 I | 20pg/ml | 101% |\n| 1 | 기허가 진단제품 또는 확진검사방법 등으로 확인하였음을 기술한 | 전자적 기록매체(CD·디스켓 등)와 함께 제출한다.  | Mean | SD | CV | SIEMENS | HEALTHCARE | DIAGNOSTICS | INC |\n| 라.  사용한 검체 및 키트의 처리 및 폐기방법 및 주의사항을 기재한다.  | 라.  원료물질의 품질 확인 근거자료 | 3.  시험검사품에 대한 모델명, 상품명 | 항목, 시험기준, 시험방법을 기재한다. ",
        "original_sentence": "사용한 검체 및 키트의 처리 및 폐기방법 및 주의사항을 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_163",
      "text": "| 라. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 162,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 1,
        "window_text": "| (사유 :                                                                 ) | DIMENSION VISTA | N-TERMINAL PRO-BRAIN | NATRIURETIC PEPTIDE | (PBNP) FLEX REAGENT | CARTRIDGE (K6423A), | DIMENSION VISTA | 병원에 입원하지 않은 신장병(투석 치료를 받지 않는 환자), | 엔도텔린 I | 20pg/ml | 101% |\n| 1 | 기허가 진단제품 또는 확진검사방법 등으로 확인하였음을 기술한 | 전자적 기록매체(CD·디스켓 등)와 함께 제출한다.  | Mean | SD | CV | SIEMENS | HEALTHCARE | DIAGNOSTICS | INC |\n| 라.  사용한 검체 및 키트의 처리 및 폐기방법 및 주의사항을 기재한다.  | 라.  원료물질의 품질 확인 근거자료 | 3.  시험검사품에 대한 모델명, 상품명 | 항목, 시험기준, 시험방법을 기재한다.  | 2.Timing | 검사법 | 2) 검체 종류별 사용 가능한 항응고제 | 2) 시험성적서 일련번호 및 각 페이지와 전체 페이지번호 | 3) 정밀도(반복, 재현성 등) | 상관없이 심장 기능에 문제가 있을 경우 혈관 벽에서 말초혈액으로 | 민감도 | NYHA Functional Class | WI-6612 |\n| 4. ",
        "original_sentence": "| 라. "
      }
    },
    {
      "chunk_id": "chunk_164",
      "text": "원료물질의 품질 확인 근거자료 | 3. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 163,
        "window_size": 3,
        "char_count": 22,
        "word_count": 6,
        "page_number": 7,
        "window_text": "| Mean | SD | CV | SIEMENS | HEALTHCARE | DIAGNOSTICS | INC |\n| 라.  사용한 검체 및 키트의 처리 및 폐기방법 및 주의사항을 기재한다.  | 라.  원료물질의 품질 확인 근거자료 | 3.  시험검사품에 대한 모델명, 상품명 | 항목, 시험기준, 시험방법을 기재한다.  | 2.Timing | 검사법 | 2) 검체 종류별 사용 가능한 항응고제 | 2) 시험성적서 일련번호 및 각 페이지와 전체 페이지번호 | 3) 정밀도(반복, 재현성 등) | 상관없이 심장 기능에 문제가 있을 경우 혈관 벽에서 말초혈액으로 | 민감도 | NYHA Functional Class | WI-6612 |\n| 4.  저장방법 및 사용기간(유효기간)에 관한 자료 | 43 | 체외진단용 의료기기 중 심근혈관표지자 | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 행정규칙(고시ㆍ훈령ㆍ예규)의 | 보조성분 | Buffer | 적량 | 자사규격 | ・검출한계(Limits of measurement) : 5pg/mL | 음성 | c | d | c + d | MEDICAL | ANALYSIS | SYSTEMS, INC | □ 예 | ■ 아니오 |\n| 나. ",
        "original_sentence": "원료물질의 품질 확인 근거자료 | 3. "
      }
    },
    {
      "chunk_id": "chunk_165",
      "text": "시험검사품에 대한 모델명, 상품명 | 항목, 시험기준, 시험방법을 기재한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 164,
        "window_size": 3,
        "char_count": 43,
        "word_count": 9,
        "page_number": 3,
        "window_text": "사용한 검체 및 키트의 처리 및 폐기방법 및 주의사항을 기재한다.  | 라.  원료물질의 품질 확인 근거자료 | 3.  시험검사품에 대한 모델명, 상품명 | 항목, 시험기준, 시험방법을 기재한다.  | 2.Timing | 검사법 | 2) 검체 종류별 사용 가능한 항응고제 | 2) 시험성적서 일련번호 및 각 페이지와 전체 페이지번호 | 3) 정밀도(반복, 재현성 등) | 상관없이 심장 기능에 문제가 있을 경우 혈관 벽에서 말초혈액으로 | 민감도 | NYHA Functional Class | WI-6612 |\n| 4.  저장방법 및 사용기간(유효기간)에 관한 자료 | 43 | 체외진단용 의료기기 중 심근혈관표지자 | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 행정규칙(고시ㆍ훈령ㆍ예규)의 | 보조성분 | Buffer | 적량 | 자사규격 | ・검출한계(Limits of measurement) : 5pg/mL | 음성 | c | d | c + d | MEDICAL | ANALYSIS | SYSTEMS, INC | □ 예 | ■ 아니오 |\n| 나.  일회용 체외진단용 시약이 아닐 경우, 개봉 후 시약의 저장방법(온 | 다. ",
        "original_sentence": "시험검사품에 대한 모델명, 상품명 | 항목, 시험기준, 시험방법을 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_166",
      "text": "| 2.Timing | 검사법 | 2) 검체 종류별 사용 가능한 항응고제 | 2) 시험성적서 일련번호 및 각 페이지와 전체 페이지번호 | 3) 정밀도(반복, 재현성 등) | 상관없이 심장 기능에 문제가 있을 경우 혈관 벽에서 말초혈액으로 | 민감도 | NYHA Functional Class | WI-6612 |\n| 4. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 165,
        "window_size": 3,
        "char_count": 180,
        "word_count": 46,
        "page_number": 3,
        "window_text": "| 라.  원료물질의 품질 확인 근거자료 | 3.  시험검사품에 대한 모델명, 상품명 | 항목, 시험기준, 시험방법을 기재한다.  | 2.Timing | 검사법 | 2) 검체 종류별 사용 가능한 항응고제 | 2) 시험성적서 일련번호 및 각 페이지와 전체 페이지번호 | 3) 정밀도(반복, 재현성 등) | 상관없이 심장 기능에 문제가 있을 경우 혈관 벽에서 말초혈액으로 | 민감도 | NYHA Functional Class | WI-6612 |\n| 4.  저장방법 및 사용기간(유효기간)에 관한 자료 | 43 | 체외진단용 의료기기 중 심근혈관표지자 | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 행정규칙(고시ㆍ훈령ㆍ예규)의 | 보조성분 | Buffer | 적량 | 자사규격 | ・검출한계(Limits of measurement) : 5pg/mL | 음성 | c | d | c + d | MEDICAL | ANALYSIS | SYSTEMS, INC | □ 예 | ■ 아니오 |\n| 나.  일회용 체외진단용 시약이 아닐 경우, 개봉 후 시약의 저장방법(온 | 다.  결과제시 | 있다. ",
        "original_sentence": "| 2.Timing | 검사법 | 2) 검체 종류별 사용 가능한 항응고제 | 2) 시험성적서 일련번호 및 각 페이지와 전체 페이지번호 | 3) 정밀도(반복, 재현성 등) | 상관없이 심장 기능에 문제가 있을 경우 혈관 벽에서 말초혈액으로 | 민감도 | NYHA Functional Class | WI-6612 |\n| 4. "
      }
    },
    {
      "chunk_id": "chunk_167",
      "text": "저장방법 및 사용기간(유효기간)에 관한 자료 | 43 | 체외진단용 의료기기 중 심근혈관표지자 | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 행정규칙(고시ㆍ훈령ㆍ예규)의 | 보조성분 | Buffer | 적량 | 자사규격 | ・검출한계(Limits of measurement) : 5pg/mL | 음성 | c | d | c + d | MEDICAL | ANALYSIS | SYSTEMS, INC | □ 예 | ■ 아니오 |\n| 나. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 166,
        "window_size": 3,
        "char_count": 237,
        "word_count": 57,
        "page_number": 1,
        "window_text": "원료물질의 품질 확인 근거자료 | 3.  시험검사품에 대한 모델명, 상품명 | 항목, 시험기준, 시험방법을 기재한다.  | 2.Timing | 검사법 | 2) 검체 종류별 사용 가능한 항응고제 | 2) 시험성적서 일련번호 및 각 페이지와 전체 페이지번호 | 3) 정밀도(반복, 재현성 등) | 상관없이 심장 기능에 문제가 있을 경우 혈관 벽에서 말초혈액으로 | 민감도 | NYHA Functional Class | WI-6612 |\n| 4.  저장방법 및 사용기간(유효기간)에 관한 자료 | 43 | 체외진단용 의료기기 중 심근혈관표지자 | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 행정규칙(고시ㆍ훈령ㆍ예규)의 | 보조성분 | Buffer | 적량 | 자사규격 | ・검출한계(Limits of measurement) : 5pg/mL | 음성 | c | d | c + d | MEDICAL | ANALYSIS | SYSTEMS, INC | □ 예 | ■ 아니오 |\n| 나.  일회용 체외진단용 시약이 아닐 경우, 개봉 후 시약의 저장방법(온 | 다.  결과제시 | 있다.  | 로 면역원(immunogen)과 결합한다. ",
        "original_sentence": "저장방법 및 사용기간(유효기간)에 관한 자료 | 43 | 체외진단용 의료기기 중 심근혈관표지자 | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 행정규칙(고시ㆍ훈령ㆍ예규)의 | 보조성분 | Buffer | 적량 | 자사규격 | ・검출한계(Limits of measurement) : 5pg/mL | 음성 | c | d | c + d | MEDICAL | ANALYSIS | SYSTEMS, INC | □ 예 | ■ 아니오 |\n| 나. "
      }
    },
    {
      "chunk_id": "chunk_168",
      "text": "일회용 체외진단용 시약이 아닐 경우, 개봉 후 시약의 저장방법(온 | 다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 167,
        "window_size": 3,
        "char_count": 42,
        "word_count": 11,
        "page_number": 41,
        "window_text": "시험검사품에 대한 모델명, 상품명 | 항목, 시험기준, 시험방법을 기재한다.  | 2.Timing | 검사법 | 2) 검체 종류별 사용 가능한 항응고제 | 2) 시험성적서 일련번호 및 각 페이지와 전체 페이지번호 | 3) 정밀도(반복, 재현성 등) | 상관없이 심장 기능에 문제가 있을 경우 혈관 벽에서 말초혈액으로 | 민감도 | NYHA Functional Class | WI-6612 |\n| 4.  저장방법 및 사용기간(유효기간)에 관한 자료 | 43 | 체외진단용 의료기기 중 심근혈관표지자 | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 행정규칙(고시ㆍ훈령ㆍ예규)의 | 보조성분 | Buffer | 적량 | 자사규격 | ・검출한계(Limits of measurement) : 5pg/mL | 음성 | c | d | c + d | MEDICAL | ANALYSIS | SYSTEMS, INC | □ 예 | ■ 아니오 |\n| 나.  일회용 체외진단용 시약이 아닐 경우, 개봉 후 시약의 저장방법(온 | 다.  결과제시 | 있다.  | 로 면역원(immunogen)과 결합한다.  | Cinical and Laboratory Standard Institute; 2005 | 이에 대한 자료를 제공하여야 한다. ",
        "original_sentence": "일회용 체외진단용 시약이 아닐 경우, 개봉 후 시약의 저장방법(온 | 다. "
      }
    },
    {
      "chunk_id": "chunk_169",
      "text": "결과제시 | 있다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 168,
        "window_size": 3,
        "char_count": 11,
        "word_count": 3,
        "page_number": 11,
        "window_text": "| 2.Timing | 검사법 | 2) 검체 종류별 사용 가능한 항응고제 | 2) 시험성적서 일련번호 및 각 페이지와 전체 페이지번호 | 3) 정밀도(반복, 재현성 등) | 상관없이 심장 기능에 문제가 있을 경우 혈관 벽에서 말초혈액으로 | 민감도 | NYHA Functional Class | WI-6612 |\n| 4.  저장방법 및 사용기간(유효기간)에 관한 자료 | 43 | 체외진단용 의료기기 중 심근혈관표지자 | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 행정규칙(고시ㆍ훈령ㆍ예규)의 | 보조성분 | Buffer | 적량 | 자사규격 | ・검출한계(Limits of measurement) : 5pg/mL | 음성 | c | d | c + d | MEDICAL | ANALYSIS | SYSTEMS, INC | □ 예 | ■ 아니오 |\n| 나.  일회용 체외진단용 시약이 아닐 경우, 개봉 후 시약의 저장방법(온 | 다.  결과제시 | 있다.  | 로 면역원(immunogen)과 결합한다.  | Cinical and Laboratory Standard Institute; 2005 | 이에 대한 자료를 제공하여야 한다.  | 보정결과 확인 절차에 대해 제시한다. ",
        "original_sentence": "결과제시 | 있다. "
      }
    },
    {
      "chunk_id": "chunk_170",
      "text": "| 로 면역원(immunogen)과 결합한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 169,
        "window_size": 3,
        "char_count": 26,
        "word_count": 4,
        "page_number": 14,
        "window_text": "저장방법 및 사용기간(유효기간)에 관한 자료 | 43 | 체외진단용 의료기기 중 심근혈관표지자 | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 행정규칙(고시ㆍ훈령ㆍ예규)의 | 보조성분 | Buffer | 적량 | 자사규격 | ・검출한계(Limits of measurement) : 5pg/mL | 음성 | c | d | c + d | MEDICAL | ANALYSIS | SYSTEMS, INC | □ 예 | ■ 아니오 |\n| 나.  일회용 체외진단용 시약이 아닐 경우, 개봉 후 시약의 저장방법(온 | 다.  결과제시 | 있다.  | 로 면역원(immunogen)과 결합한다.  | Cinical and Laboratory Standard Institute; 2005 | 이에 대한 자료를 제공하여야 한다.  | 보정결과 확인 절차에 대해 제시한다.  | 1. ",
        "original_sentence": "| 로 면역원(immunogen)과 결합한다. "
      }
    },
    {
      "chunk_id": "chunk_171",
      "text": "| Cinical and Laboratory Standard Institute; 2005 | 이에 대한 자료를 제공하여야 한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 170,
        "window_size": 3,
        "char_count": 72,
        "word_count": 13,
        "page_number": 6,
        "window_text": "일회용 체외진단용 시약이 아닐 경우, 개봉 후 시약의 저장방법(온 | 다.  결과제시 | 있다.  | 로 면역원(immunogen)과 결합한다.  | Cinical and Laboratory Standard Institute; 2005 | 이에 대한 자료를 제공하여야 한다.  | 보정결과 확인 절차에 대해 제시한다.  | 1.  제조․수입허가신청서 | 15 | 질병이나 특정 상태를 가지는 대상군에서 검사 결과가 양성 | 변이계수를 산출하여 기재한다. ",
        "original_sentence": "| Cinical and Laboratory Standard Institute; 2005 | 이에 대한 자료를 제공하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_172",
      "text": "| 보정결과 확인 절차에 대해 제시한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 171,
        "window_size": 3,
        "char_count": 23,
        "word_count": 6,
        "page_number": 19,
        "window_text": "결과제시 | 있다.  | 로 면역원(immunogen)과 결합한다.  | Cinical and Laboratory Standard Institute; 2005 | 이에 대한 자료를 제공하여야 한다.  | 보정결과 확인 절차에 대해 제시한다.  | 1.  제조․수입허가신청서 | 15 | 질병이나 특정 상태를 가지는 대상군에서 검사 결과가 양성 | 변이계수를 산출하여 기재한다.  | 검체를 사용한다. ",
        "original_sentence": "| 보정결과 확인 절차에 대해 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_173",
      "text": "| 1. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 172,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 21,
        "window_text": "| 로 면역원(immunogen)과 결합한다.  | Cinical and Laboratory Standard Institute; 2005 | 이에 대한 자료를 제공하여야 한다.  | 보정결과 확인 절차에 대해 제시한다.  | 1.  제조․수입허가신청서 | 15 | 질병이나 특정 상태를 가지는 대상군에서 검사 결과가 양성 | 변이계수를 산출하여 기재한다.  | 검체를 사용한다.  | 자료를 포함해야 한다. ",
        "original_sentence": "| 1. "
      }
    },
    {
      "chunk_id": "chunk_174",
      "text": "제조․수입허가신청서 | 15 | 질병이나 특정 상태를 가지는 대상군에서 검사 결과가 양성 | 변이계수를 산출하여 기재한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 173,
        "window_size": 3,
        "char_count": 69,
        "word_count": 16,
        "page_number": 6,
        "window_text": "| Cinical and Laboratory Standard Institute; 2005 | 이에 대한 자료를 제공하여야 한다.  | 보정결과 확인 절차에 대해 제시한다.  | 1.  제조․수입허가신청서 | 15 | 질병이나 특정 상태를 가지는 대상군에서 검사 결과가 양성 | 변이계수를 산출하여 기재한다.  | 검체를 사용한다.  | 자료를 포함해야 한다.  | Calibrator H를 이용하여 Timing Mode와 Batch | 당뇨병, 고혈압, 그리고 만성폐쇄성 폐질환을 가진 환자를 | 아드레노메둘린(ADM) | 1,000pg/mL | 97% | pg/mL | pmol/L | pg/mL | pmol/L | % | 전체 | I | II | III | IV |\n| 해당 성능 항목을 가감할 수 있음 | 2 | Reagent 2 | 4) 정확도 | 자료 또는 양성임을 증명하는 임상자료 등. ",
        "original_sentence": "제조․수입허가신청서 | 15 | 질병이나 특정 상태를 가지는 대상군에서 검사 결과가 양성 | 변이계수를 산출하여 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_175",
      "text": "| 검체를 사용한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 174,
        "window_size": 3,
        "char_count": 12,
        "word_count": 3,
        "page_number": 33,
        "window_text": "| 보정결과 확인 절차에 대해 제시한다.  | 1.  제조․수입허가신청서 | 15 | 질병이나 특정 상태를 가지는 대상군에서 검사 결과가 양성 | 변이계수를 산출하여 기재한다.  | 검체를 사용한다.  | 자료를 포함해야 한다.  | Calibrator H를 이용하여 Timing Mode와 Batch | 당뇨병, 고혈압, 그리고 만성폐쇄성 폐질환을 가진 환자를 | 아드레노메둘린(ADM) | 1,000pg/mL | 97% | pg/mL | pmol/L | pg/mL | pmol/L | % | 전체 | I | II | III | IV |\n| 해당 성능 항목을 가감할 수 있음 | 2 | Reagent 2 | 4) 정확도 | 자료 또는 양성임을 증명하는 임상자료 등.  평가대상 제품의 결과와 | “모델명”을 각각 기재한다. ",
        "original_sentence": "| 검체를 사용한다. "
      }
    },
    {
      "chunk_id": "chunk_176",
      "text": "| 자료를 포함해야 한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 175,
        "window_size": 3,
        "char_count": 15,
        "word_count": 4,
        "page_number": 56,
        "window_text": "| 1.  제조․수입허가신청서 | 15 | 질병이나 특정 상태를 가지는 대상군에서 검사 결과가 양성 | 변이계수를 산출하여 기재한다.  | 검체를 사용한다.  | 자료를 포함해야 한다.  | Calibrator H를 이용하여 Timing Mode와 Batch | 당뇨병, 고혈압, 그리고 만성폐쇄성 폐질환을 가진 환자를 | 아드레노메둘린(ADM) | 1,000pg/mL | 97% | pg/mL | pmol/L | pg/mL | pmol/L | % | 전체 | I | II | III | IV |\n| 해당 성능 항목을 가감할 수 있음 | 2 | Reagent 2 | 4) 정확도 | 자료 또는 양성임을 증명하는 임상자료 등.  평가대상 제품의 결과와 | “모델명”을 각각 기재한다.  이대 제조(수입)업소명은 생략할 수 있 | 가지지 않은 음성 검체 100개 이상 평가할 것을 권장한다. ",
        "original_sentence": "| 자료를 포함해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_177",
      "text": "| Calibrator H를 이용하여 Timing Mode와 Batch | 당뇨병, 고혈압, 그리고 만성폐쇄성 폐질환을 가진 환자를 | 아드레노메둘린(ADM) | 1,000pg/mL | 97% | pg/mL | pmol/L | pg/mL | pmol/L | % | 전체 | I | II | III | IV |\n| 해당 성능 항목을 가감할 수 있음 | 2 | Reagent 2 | 4) 정확도 | 자료 또는 양성임을 증명하는 임상자료 등. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 176,
        "window_size": 3,
        "char_count": 245,
        "word_count": 64,
        "page_number": 14,
        "window_text": "제조․수입허가신청서 | 15 | 질병이나 특정 상태를 가지는 대상군에서 검사 결과가 양성 | 변이계수를 산출하여 기재한다.  | 검체를 사용한다.  | 자료를 포함해야 한다.  | Calibrator H를 이용하여 Timing Mode와 Batch | 당뇨병, 고혈압, 그리고 만성폐쇄성 폐질환을 가진 환자를 | 아드레노메둘린(ADM) | 1,000pg/mL | 97% | pg/mL | pmol/L | pg/mL | pmol/L | % | 전체 | I | II | III | IV |\n| 해당 성능 항목을 가감할 수 있음 | 2 | Reagent 2 | 4) 정확도 | 자료 또는 양성임을 증명하는 임상자료 등.  평가대상 제품의 결과와 | “모델명”을 각각 기재한다.  이대 제조(수입)업소명은 생략할 수 있 | 가지지 않은 음성 검체 100개 이상 평가할 것을 권장한다.  | 내용을 단순 편집 또는 나열한 것입니까? ",
        "original_sentence": "| Calibrator H를 이용하여 Timing Mode와 Batch | 당뇨병, 고혈압, 그리고 만성폐쇄성 폐질환을 가진 환자를 | 아드레노메둘린(ADM) | 1,000pg/mL | 97% | pg/mL | pmol/L | pg/mL | pmol/L | % | 전체 | I | II | III | IV |\n| 해당 성능 항목을 가감할 수 있음 | 2 | Reagent 2 | 4) 정확도 | 자료 또는 양성임을 증명하는 임상자료 등. "
      }
    },
    {
      "chunk_id": "chunk_178",
      "text": "평가대상 제품의 결과와 | “모델명”을 각각 기재한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 177,
        "window_size": 3,
        "char_count": 31,
        "word_count": 7,
        "page_number": 23,
        "window_text": "| 검체를 사용한다.  | 자료를 포함해야 한다.  | Calibrator H를 이용하여 Timing Mode와 Batch | 당뇨병, 고혈압, 그리고 만성폐쇄성 폐질환을 가진 환자를 | 아드레노메둘린(ADM) | 1,000pg/mL | 97% | pg/mL | pmol/L | pg/mL | pmol/L | % | 전체 | I | II | III | IV |\n| 해당 성능 항목을 가감할 수 있음 | 2 | Reagent 2 | 4) 정확도 | 자료 또는 양성임을 증명하는 임상자료 등.  평가대상 제품의 결과와 | “모델명”을 각각 기재한다.  이대 제조(수입)업소명은 생략할 수 있 | 가지지 않은 음성 검체 100개 이상 평가할 것을 권장한다.  | 내용을 단순 편집 또는 나열한 것입니까?  | 1) 간섭 약물 | 절차서에 | 05/16/2008 | 08/19/2003 | 1x10mL |\n| 가. ",
        "original_sentence": "평가대상 제품의 결과와 | “모델명”을 각각 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_179",
      "text": "이대 제조(수입)업소명은 생략할 수 있 | 가지지 않은 음성 검체 100개 이상 평가할 것을 권장한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 178,
        "window_size": 3,
        "char_count": 58,
        "word_count": 15,
        "page_number": 14,
        "window_text": "| 자료를 포함해야 한다.  | Calibrator H를 이용하여 Timing Mode와 Batch | 당뇨병, 고혈압, 그리고 만성폐쇄성 폐질환을 가진 환자를 | 아드레노메둘린(ADM) | 1,000pg/mL | 97% | pg/mL | pmol/L | pg/mL | pmol/L | % | 전체 | I | II | III | IV |\n| 해당 성능 항목을 가감할 수 있음 | 2 | Reagent 2 | 4) 정확도 | 자료 또는 양성임을 증명하는 임상자료 등.  평가대상 제품의 결과와 | “모델명”을 각각 기재한다.  이대 제조(수입)업소명은 생략할 수 있 | 가지지 않은 음성 검체 100개 이상 평가할 것을 권장한다.  | 내용을 단순 편집 또는 나열한 것입니까?  | 1) 간섭 약물 | 절차서에 | 05/16/2008 | 08/19/2003 | 1x10mL |\n| 가.  시험항목 | 4. ",
        "original_sentence": "이대 제조(수입)업소명은 생략할 수 있 | 가지지 않은 음성 검체 100개 이상 평가할 것을 권장한다. "
      }
    },
    {
      "chunk_id": "chunk_180",
      "text": "| 내용을 단순 편집 또는 나열한 것입니까? ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 179,
        "window_size": 3,
        "char_count": 25,
        "word_count": 7,
        "page_number": 3,
        "window_text": "| Calibrator H를 이용하여 Timing Mode와 Batch | 당뇨병, 고혈압, 그리고 만성폐쇄성 폐질환을 가진 환자를 | 아드레노메둘린(ADM) | 1,000pg/mL | 97% | pg/mL | pmol/L | pg/mL | pmol/L | % | 전체 | I | II | III | IV |\n| 해당 성능 항목을 가감할 수 있음 | 2 | Reagent 2 | 4) 정확도 | 자료 또는 양성임을 증명하는 임상자료 등.  평가대상 제품의 결과와 | “모델명”을 각각 기재한다.  이대 제조(수입)업소명은 생략할 수 있 | 가지지 않은 음성 검체 100개 이상 평가할 것을 권장한다.  | 내용을 단순 편집 또는 나열한 것입니까?  | 1) 간섭 약물 | 절차서에 | 05/16/2008 | 08/19/2003 | 1x10mL |\n| 가.  시험항목 | 4.  시험일자 | 참고한다. ",
        "original_sentence": "| 내용을 단순 편집 또는 나열한 것입니까? "
      }
    },
    {
      "chunk_id": "chunk_181",
      "text": "| 1) 간섭 약물 | 절차서에 | 05/16/2008 | 08/19/2003 | 1x10mL |\n| 가. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 180,
        "window_size": 3,
        "char_count": 60,
        "word_count": 15,
        "page_number": 6,
        "window_text": "평가대상 제품의 결과와 | “모델명”을 각각 기재한다.  이대 제조(수입)업소명은 생략할 수 있 | 가지지 않은 음성 검체 100개 이상 평가할 것을 권장한다.  | 내용을 단순 편집 또는 나열한 것입니까?  | 1) 간섭 약물 | 절차서에 | 05/16/2008 | 08/19/2003 | 1x10mL |\n| 가.  시험항목 | 4.  시험일자 | 참고한다.  | 3) 사용되는 검체의 종류별 필요 분량 | 3) 시험검사품의 모델명, 상품명(해당 경우에 한함) | 본 제품은 체외진단용 의료기기(proBNP test kit)와 별도판매구 | 분비되므로 심부전을 진단하는 중요 표지자로 활용된다. ",
        "original_sentence": "| 1) 간섭 약물 | 절차서에 | 05/16/2008 | 08/19/2003 | 1x10mL |\n| 가. "
      }
    },
    {
      "chunk_id": "chunk_182",
      "text": "시험항목 | 4. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 181,
        "window_size": 3,
        "char_count": 10,
        "word_count": 3,
        "page_number": 3,
        "window_text": "이대 제조(수입)업소명은 생략할 수 있 | 가지지 않은 음성 검체 100개 이상 평가할 것을 권장한다.  | 내용을 단순 편집 또는 나열한 것입니까?  | 1) 간섭 약물 | 절차서에 | 05/16/2008 | 08/19/2003 | 1x10mL |\n| 가.  시험항목 | 4.  시험일자 | 참고한다.  | 3) 사용되는 검체의 종류별 필요 분량 | 3) 시험검사품의 모델명, 상품명(해당 경우에 한함) | 본 제품은 체외진단용 의료기기(proBNP test kit)와 별도판매구 | 분비되므로 심부전을 진단하는 중요 표지자로 활용된다.  | 보조성분 | Oxypyrion | 적량 | 자사규격 | 검체수 (N) | 480 | 90 | 210 | 144 | 36 |\n| 하나에 해당하는 자료 | 전체 | a + c | b + d | n | Mode의 평균농도는 Batch Mode ± Range | 포함한다. ",
        "original_sentence": "시험항목 | 4. "
      }
    },
    {
      "chunk_id": "chunk_183",
      "text": "시험일자 | 참고한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 182,
        "window_size": 3,
        "char_count": 13,
        "word_count": 3,
        "page_number": 33,
        "window_text": "| 내용을 단순 편집 또는 나열한 것입니까?  | 1) 간섭 약물 | 절차서에 | 05/16/2008 | 08/19/2003 | 1x10mL |\n| 가.  시험항목 | 4.  시험일자 | 참고한다.  | 3) 사용되는 검체의 종류별 필요 분량 | 3) 시험검사품의 모델명, 상품명(해당 경우에 한함) | 본 제품은 체외진단용 의료기기(proBNP test kit)와 별도판매구 | 분비되므로 심부전을 진단하는 중요 표지자로 활용된다.  | 보조성분 | Oxypyrion | 적량 | 자사규격 | 검체수 (N) | 480 | 90 | 210 | 144 | 36 |\n| 하나에 해당하는 자료 | 전체 | a + c | b + d | n | Mode의 평균농도는 Batch Mode ± Range | 포함한다.  신장병(투석 치료를 받지 않는 환자), 당뇨병, 고혈압, | Human Serum 1 | 50 | 5.95 | 1.7 | 0.21 | 3.5 |\n| 석 대상(효소)의 억제 또는 검체에 의해 발생하는 바이어스의 다른 원 | 외비공, 인두, 직장 또는 자궁경부를 넘어서 귀, 코, 입, 항문관 또는 | 도, 습도, 차광, 밀폐, 보관용기 등) 및 사용기간(유효기간)등이 포 | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까? ",
        "original_sentence": "시험일자 | 참고한다. "
      }
    },
    {
      "chunk_id": "chunk_184",
      "text": "| 3) 사용되는 검체의 종류별 필요 분량 | 3) 시험검사품의 모델명, 상품명(해당 경우에 한함) | 본 제품은 체외진단용 의료기기(proBNP test kit)와 별도판매구 | 분비되므로 심부전을 진단하는 중요 표지자로 활용된다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 183,
        "window_size": 3,
        "char_count": 131,
        "word_count": 29,
        "page_number": 26,
        "window_text": "| 1) 간섭 약물 | 절차서에 | 05/16/2008 | 08/19/2003 | 1x10mL |\n| 가.  시험항목 | 4.  시험일자 | 참고한다.  | 3) 사용되는 검체의 종류별 필요 분량 | 3) 시험검사품의 모델명, 상품명(해당 경우에 한함) | 본 제품은 체외진단용 의료기기(proBNP test kit)와 별도판매구 | 분비되므로 심부전을 진단하는 중요 표지자로 활용된다.  | 보조성분 | Oxypyrion | 적량 | 자사규격 | 검체수 (N) | 480 | 90 | 210 | 144 | 36 |\n| 하나에 해당하는 자료 | 전체 | a + c | b + d | n | Mode의 평균농도는 Batch Mode ± Range | 포함한다.  신장병(투석 치료를 받지 않는 환자), 당뇨병, 고혈압, | Human Serum 1 | 50 | 5.95 | 1.7 | 0.21 | 3.5 |\n| 석 대상(효소)의 억제 또는 검체에 의해 발생하는 바이어스의 다른 원 | 외비공, 인두, 직장 또는 자궁경부를 넘어서 귀, 코, 입, 항문관 또는 | 도, 습도, 차광, 밀폐, 보관용기 등) 및 사용기간(유효기간)등이 포 | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?  | □ 예 | ■ 아니오 | Roche CARDIAC proBNP | Roche | Germany | 메디안 (pg/mL) | 270 | 120 | 260 | 290 | 1650 | 따라서 |\n| 진단 등)에 의해 판정기준치의 적절성을 평가할 수 있다. ",
        "original_sentence": "| 3) 사용되는 검체의 종류별 필요 분량 | 3) 시험검사품의 모델명, 상품명(해당 경우에 한함) | 본 제품은 체외진단용 의료기기(proBNP test kit)와 별도판매구 | 분비되므로 심부전을 진단하는 중요 표지자로 활용된다. "
      }
    },
    {
      "chunk_id": "chunk_185",
      "text": "| 보조성분 | Oxypyrion | 적량 | 자사규격 | 검체수 (N) | 480 | 90 | 210 | 144 | 36 |\n| 하나에 해당하는 자료 | 전체 | a + c | b + d | n | Mode의 평균농도는 Batch Mode ± Range | 포함한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 184,
        "window_size": 3,
        "char_count": 151,
        "word_count": 47,
        "page_number": 6,
        "window_text": "시험항목 | 4.  시험일자 | 참고한다.  | 3) 사용되는 검체의 종류별 필요 분량 | 3) 시험검사품의 모델명, 상품명(해당 경우에 한함) | 본 제품은 체외진단용 의료기기(proBNP test kit)와 별도판매구 | 분비되므로 심부전을 진단하는 중요 표지자로 활용된다.  | 보조성분 | Oxypyrion | 적량 | 자사규격 | 검체수 (N) | 480 | 90 | 210 | 144 | 36 |\n| 하나에 해당하는 자료 | 전체 | a + c | b + d | n | Mode의 평균농도는 Batch Mode ± Range | 포함한다.  신장병(투석 치료를 받지 않는 환자), 당뇨병, 고혈압, | Human Serum 1 | 50 | 5.95 | 1.7 | 0.21 | 3.5 |\n| 석 대상(효소)의 억제 또는 검체에 의해 발생하는 바이어스의 다른 원 | 외비공, 인두, 직장 또는 자궁경부를 넘어서 귀, 코, 입, 항문관 또는 | 도, 습도, 차광, 밀폐, 보관용기 등) 및 사용기간(유효기간)등이 포 | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?  | □ 예 | ■ 아니오 | Roche CARDIAC proBNP | Roche | Germany | 메디안 (pg/mL) | 270 | 120 | 260 | 290 | 1650 | 따라서 |\n| 진단 등)에 의해 판정기준치의 적절성을 평가할 수 있다.  | BNP Test에서의 잠재적 교차반응 및 간섭에 대하여 다음 | Human Serum 2 | 120.7 | 14.2 | 3.03 | 0.35 | 2.5 |\n| 그리고  만성폐쇄성 폐질환을 가진 환자들에 대한 BNP농도는 | 위의 임상 연구로부터 얻은 데이터는 아래와 같이 임상 | 평균 (pg/mL) | 500 | 300 | 400 | 600 | 1650 |\n**06/23/2003**\n| 질에 들어가는 침습적인 시험. ",
        "original_sentence": "| 보조성분 | Oxypyrion | 적량 | 자사규격 | 검체수 (N) | 480 | 90 | 210 | 144 | 36 |\n| 하나에 해당하는 자료 | 전체 | a + c | b + d | n | Mode의 평균농도는 Batch Mode ± Range | 포함한다. "
      }
    },
    {
      "chunk_id": "chunk_186",
      "text": "신장병(투석 치료를 받지 않는 환자), 당뇨병, 고혈압, | Human Serum 1 | 50 | 5.95 | 1.7 | 0.21 | 3.5 |\n| 석 대상(효소)의 억제 또는 검체에 의해 발생하는 바이어스의 다른 원 | 외비공, 인두, 직장 또는 자궁경부를 넘어서 귀, 코, 입, 항문관 또는 | 도, 습도, 차광, 밀폐, 보관용기 등) 및 사용기간(유효기간)등이 포 | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까? ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 185,
        "window_size": 3,
        "char_count": 240,
        "word_count": 63,
        "page_number": 14,
        "window_text": "시험일자 | 참고한다.  | 3) 사용되는 검체의 종류별 필요 분량 | 3) 시험검사품의 모델명, 상품명(해당 경우에 한함) | 본 제품은 체외진단용 의료기기(proBNP test kit)와 별도판매구 | 분비되므로 심부전을 진단하는 중요 표지자로 활용된다.  | 보조성분 | Oxypyrion | 적량 | 자사규격 | 검체수 (N) | 480 | 90 | 210 | 144 | 36 |\n| 하나에 해당하는 자료 | 전체 | a + c | b + d | n | Mode의 평균농도는 Batch Mode ± Range | 포함한다.  신장병(투석 치료를 받지 않는 환자), 당뇨병, 고혈압, | Human Serum 1 | 50 | 5.95 | 1.7 | 0.21 | 3.5 |\n| 석 대상(효소)의 억제 또는 검체에 의해 발생하는 바이어스의 다른 원 | 외비공, 인두, 직장 또는 자궁경부를 넘어서 귀, 코, 입, 항문관 또는 | 도, 습도, 차광, 밀폐, 보관용기 등) 및 사용기간(유효기간)등이 포 | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?  | □ 예 | ■ 아니오 | Roche CARDIAC proBNP | Roche | Germany | 메디안 (pg/mL) | 270 | 120 | 260 | 290 | 1650 | 따라서 |\n| 진단 등)에 의해 판정기준치의 적절성을 평가할 수 있다.  | BNP Test에서의 잠재적 교차반응 및 간섭에 대하여 다음 | Human Serum 2 | 120.7 | 14.2 | 3.03 | 0.35 | 2.5 |\n| 그리고  만성폐쇄성 폐질환을 가진 환자들에 대한 BNP농도는 | 위의 임상 연구로부터 얻은 데이터는 아래와 같이 임상 | 평균 (pg/mL) | 500 | 300 | 400 | 600 | 1650 |\n**06/23/2003**\n| 질에 들어가는 침습적인 시험.  다만, 정맥채혈 등 피험자에게 중대한 | 약품을 평가하였다. ",
        "original_sentence": "신장병(투석 치료를 받지 않는 환자), 당뇨병, 고혈압, | Human Serum 1 | 50 | 5.95 | 1.7 | 0.21 | 3.5 |\n| 석 대상(효소)의 억제 또는 검체에 의해 발생하는 바이어스의 다른 원 | 외비공, 인두, 직장 또는 자궁경부를 넘어서 귀, 코, 입, 항문관 또는 | 도, 습도, 차광, 밀폐, 보관용기 등) 및 사용기간(유효기간)등이 포 | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까? "
      }
    },
    {
      "chunk_id": "chunk_187",
      "text": "| □ 예 | ■ 아니오 | Roche CARDIAC proBNP | Roche | Germany | 메디안 (pg/mL) | 270 | 120 | 260 | 290 | 1650 | 따라서 |\n| 진단 등)에 의해 판정기준치의 적절성을 평가할 수 있다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 186,
        "window_size": 3,
        "char_count": 142,
        "word_count": 39,
        "page_number": 3,
        "window_text": "| 3) 사용되는 검체의 종류별 필요 분량 | 3) 시험검사품의 모델명, 상품명(해당 경우에 한함) | 본 제품은 체외진단용 의료기기(proBNP test kit)와 별도판매구 | 분비되므로 심부전을 진단하는 중요 표지자로 활용된다.  | 보조성분 | Oxypyrion | 적량 | 자사규격 | 검체수 (N) | 480 | 90 | 210 | 144 | 36 |\n| 하나에 해당하는 자료 | 전체 | a + c | b + d | n | Mode의 평균농도는 Batch Mode ± Range | 포함한다.  신장병(투석 치료를 받지 않는 환자), 당뇨병, 고혈압, | Human Serum 1 | 50 | 5.95 | 1.7 | 0.21 | 3.5 |\n| 석 대상(효소)의 억제 또는 검체에 의해 발생하는 바이어스의 다른 원 | 외비공, 인두, 직장 또는 자궁경부를 넘어서 귀, 코, 입, 항문관 또는 | 도, 습도, 차광, 밀폐, 보관용기 등) 및 사용기간(유효기간)등이 포 | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?  | □ 예 | ■ 아니오 | Roche CARDIAC proBNP | Roche | Germany | 메디안 (pg/mL) | 270 | 120 | 260 | 290 | 1650 | 따라서 |\n| 진단 등)에 의해 판정기준치의 적절성을 평가할 수 있다.  | BNP Test에서의 잠재적 교차반응 및 간섭에 대하여 다음 | Human Serum 2 | 120.7 | 14.2 | 3.03 | 0.35 | 2.5 |\n| 그리고  만성폐쇄성 폐질환을 가진 환자들에 대한 BNP농도는 | 위의 임상 연구로부터 얻은 데이터는 아래와 같이 임상 | 평균 (pg/mL) | 500 | 300 | 400 | 600 | 1650 |\n**06/23/2003**\n| 질에 들어가는 침습적인 시험.  다만, 정맥채혈 등 피험자에게 중대한 | 약품을 평가하였다.  모든 약품은 최대 치료 용량 및 최대 | Human Serum 3 | 358.7 | 42.3 | 7.27 | 0.85 | 2.0 | 시험한다. ",
        "original_sentence": "| □ 예 | ■ 아니오 | Roche CARDIAC proBNP | Roche | Germany | 메디안 (pg/mL) | 270 | 120 | 260 | 290 | 1650 | 따라서 |\n| 진단 등)에 의해 판정기준치의 적절성을 평가할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_188",
      "text": "| BNP Test에서의 잠재적 교차반응 및 간섭에 대하여 다음 | Human Serum 2 | 120.7 | 14.2 | 3.03 | 0.35 | 2.5 |\n| 그리고  만성폐쇄성 폐질환을 가진 환자들에 대한 BNP농도는 | 위의 임상 연구로부터 얻은 데이터는 아래와 같이 임상 | 평균 (pg/mL) | 500 | 300 | 400 | 600 | 1650 |\n**06/23/2003**\n| 질에 들어가는 침습적인 시험. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 187,
        "window_size": 3,
        "char_count": 237,
        "word_count": 61,
        "page_number": 14,
        "window_text": "| 보조성분 | Oxypyrion | 적량 | 자사규격 | 검체수 (N) | 480 | 90 | 210 | 144 | 36 |\n| 하나에 해당하는 자료 | 전체 | a + c | b + d | n | Mode의 평균농도는 Batch Mode ± Range | 포함한다.  신장병(투석 치료를 받지 않는 환자), 당뇨병, 고혈압, | Human Serum 1 | 50 | 5.95 | 1.7 | 0.21 | 3.5 |\n| 석 대상(효소)의 억제 또는 검체에 의해 발생하는 바이어스의 다른 원 | 외비공, 인두, 직장 또는 자궁경부를 넘어서 귀, 코, 입, 항문관 또는 | 도, 습도, 차광, 밀폐, 보관용기 등) 및 사용기간(유효기간)등이 포 | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?  | □ 예 | ■ 아니오 | Roche CARDIAC proBNP | Roche | Germany | 메디안 (pg/mL) | 270 | 120 | 260 | 290 | 1650 | 따라서 |\n| 진단 등)에 의해 판정기준치의 적절성을 평가할 수 있다.  | BNP Test에서의 잠재적 교차반응 및 간섭에 대하여 다음 | Human Serum 2 | 120.7 | 14.2 | 3.03 | 0.35 | 2.5 |\n| 그리고  만성폐쇄성 폐질환을 가진 환자들에 대한 BNP농도는 | 위의 임상 연구로부터 얻은 데이터는 아래와 같이 임상 | 평균 (pg/mL) | 500 | 300 | 400 | 600 | 1650 |\n**06/23/2003**\n| 질에 들어가는 침습적인 시험.  다만, 정맥채혈 등 피험자에게 중대한 | 약품을 평가하였다.  모든 약품은 최대 치료 용량 및 최대 | Human Serum 3 | 358.7 | 42.3 | 7.27 | 0.85 | 2.0 | 시험한다.  |\n| 1) 검체의 종류, 검체 수, 측정방법, 측정횟수 등에 대한 실험프로 | 가) 검체 종류와 검체 준비 과정(검체종류, 기질, 검체의 수, 측정 | 민감도와 임상 특이도에 대한 BNP 결정 역치의 Receiver | SD (pg/mL) | 700 | 350 | 520 | 820 | 1000 | □ 예 | ■ 아니오 |\n| 나. ",
        "original_sentence": "| BNP Test에서의 잠재적 교차반응 및 간섭에 대하여 다음 | Human Serum 2 | 120.7 | 14.2 | 3.03 | 0.35 | 2.5 |\n| 그리고  만성폐쇄성 폐질환을 가진 환자들에 대한 BNP농도는 | 위의 임상 연구로부터 얻은 데이터는 아래와 같이 임상 | 평균 (pg/mL) | 500 | 300 | 400 | 600 | 1650 |\n**06/23/2003**\n| 질에 들어가는 침습적인 시험. "
      }
    },
    {
      "chunk_id": "chunk_189",
      "text": "다만, 정맥채혈 등 피험자에게 중대한 | 약품을 평가하였다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 188,
        "window_size": 3,
        "char_count": 34,
        "word_count": 8,
        "page_number": 76,
        "window_text": "신장병(투석 치료를 받지 않는 환자), 당뇨병, 고혈압, | Human Serum 1 | 50 | 5.95 | 1.7 | 0.21 | 3.5 |\n| 석 대상(효소)의 억제 또는 검체에 의해 발생하는 바이어스의 다른 원 | 외비공, 인두, 직장 또는 자궁경부를 넘어서 귀, 코, 입, 항문관 또는 | 도, 습도, 차광, 밀폐, 보관용기 등) 및 사용기간(유효기간)등이 포 | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?  | □ 예 | ■ 아니오 | Roche CARDIAC proBNP | Roche | Germany | 메디안 (pg/mL) | 270 | 120 | 260 | 290 | 1650 | 따라서 |\n| 진단 등)에 의해 판정기준치의 적절성을 평가할 수 있다.  | BNP Test에서의 잠재적 교차반응 및 간섭에 대하여 다음 | Human Serum 2 | 120.7 | 14.2 | 3.03 | 0.35 | 2.5 |\n| 그리고  만성폐쇄성 폐질환을 가진 환자들에 대한 BNP농도는 | 위의 임상 연구로부터 얻은 데이터는 아래와 같이 임상 | 평균 (pg/mL) | 500 | 300 | 400 | 600 | 1650 |\n**06/23/2003**\n| 질에 들어가는 침습적인 시험.  다만, 정맥채혈 등 피험자에게 중대한 | 약품을 평가하였다.  모든 약품은 최대 치료 용량 및 최대 | Human Serum 3 | 358.7 | 42.3 | 7.27 | 0.85 | 2.0 | 시험한다.  |\n| 1) 검체의 종류, 검체 수, 측정방법, 측정횟수 등에 대한 실험프로 | 가) 검체 종류와 검체 준비 과정(검체종류, 기질, 검체의 수, 측정 | 민감도와 임상 특이도에 대한 BNP 결정 역치의 Receiver | SD (pg/mL) | 700 | 350 | 520 | 820 | 1000 | □ 예 | ■ 아니오 |\n| 나.  제품명을 기재하지 아니하는 경우에는 “제조(수입)업소명·품목명”, “모 | 라. ",
        "original_sentence": "다만, 정맥채혈 등 피험자에게 중대한 | 약품을 평가하였다. "
      }
    },
    {
      "chunk_id": "chunk_190",
      "text": "모든 약품은 최대 치료 용량 및 최대 | Human Serum 3 | 358.7 | 42.3 | 7.27 | 0.85 | 2.0 | 시험한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 189,
        "window_size": 3,
        "char_count": 80,
        "word_count": 23,
        "page_number": 6,
        "window_text": "| □ 예 | ■ 아니오 | Roche CARDIAC proBNP | Roche | Germany | 메디안 (pg/mL) | 270 | 120 | 260 | 290 | 1650 | 따라서 |\n| 진단 등)에 의해 판정기준치의 적절성을 평가할 수 있다.  | BNP Test에서의 잠재적 교차반응 및 간섭에 대하여 다음 | Human Serum 2 | 120.7 | 14.2 | 3.03 | 0.35 | 2.5 |\n| 그리고  만성폐쇄성 폐질환을 가진 환자들에 대한 BNP농도는 | 위의 임상 연구로부터 얻은 데이터는 아래와 같이 임상 | 평균 (pg/mL) | 500 | 300 | 400 | 600 | 1650 |\n**06/23/2003**\n| 질에 들어가는 침습적인 시험.  다만, 정맥채혈 등 피험자에게 중대한 | 약품을 평가하였다.  모든 약품은 최대 치료 용량 및 최대 | Human Serum 3 | 358.7 | 42.3 | 7.27 | 0.85 | 2.0 | 시험한다.  |\n| 1) 검체의 종류, 검체 수, 측정방법, 측정횟수 등에 대한 실험프로 | 가) 검체 종류와 검체 준비 과정(검체종류, 기질, 검체의 수, 측정 | 민감도와 임상 특이도에 대한 BNP 결정 역치의 Receiver | SD (pg/mL) | 700 | 350 | 520 | 820 | 1000 | □ 예 | ■ 아니오 |\n| 나.  제품명을 기재하지 아니하는 경우에는 “제조(수입)업소명·품목명”, “모 | 라.  외국의 자료는 주요사항을 발췌한 한글 요약문 및 원문을 첨부 | Human Serum 4 | 794 | 93.5 | 19.5 | 2.30 | 2.5 |\n| 3) 양성 검체는 각 질환의 다양한 임상단계가 포함되도록 한다. ",
        "original_sentence": "모든 약품은 최대 치료 용량 및 최대 | Human Serum 3 | 358.7 | 42.3 | 7.27 | 0.85 | 2.0 | 시험한다. "
      }
    },
    {
      "chunk_id": "chunk_191",
      "text": "|\n| 1) 검체의 종류, 검체 수, 측정방법, 측정횟수 등에 대한 실험프로 | 가) 검체 종류와 검체 준비 과정(검체종류, 기질, 검체의 수, 측정 | 민감도와 임상 특이도에 대한 BNP 결정 역치의 Receiver | SD (pg/mL) | 700 | 350 | 520 | 820 | 1000 | □ 예 | ■ 아니오 |\n| 나. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 190,
        "window_size": 3,
        "char_count": 187,
        "word_count": 54,
        "page_number": 21,
        "window_text": "| BNP Test에서의 잠재적 교차반응 및 간섭에 대하여 다음 | Human Serum 2 | 120.7 | 14.2 | 3.03 | 0.35 | 2.5 |\n| 그리고  만성폐쇄성 폐질환을 가진 환자들에 대한 BNP농도는 | 위의 임상 연구로부터 얻은 데이터는 아래와 같이 임상 | 평균 (pg/mL) | 500 | 300 | 400 | 600 | 1650 |\n**06/23/2003**\n| 질에 들어가는 침습적인 시험.  다만, 정맥채혈 등 피험자에게 중대한 | 약품을 평가하였다.  모든 약품은 최대 치료 용량 및 최대 | Human Serum 3 | 358.7 | 42.3 | 7.27 | 0.85 | 2.0 | 시험한다.  |\n| 1) 검체의 종류, 검체 수, 측정방법, 측정횟수 등에 대한 실험프로 | 가) 검체 종류와 검체 준비 과정(검체종류, 기질, 검체의 수, 측정 | 민감도와 임상 특이도에 대한 BNP 결정 역치의 Receiver | SD (pg/mL) | 700 | 350 | 520 | 820 | 1000 | □ 예 | ■ 아니오 |\n| 나.  제품명을 기재하지 아니하는 경우에는 “제조(수입)업소명·품목명”, “모 | 라.  외국의 자료는 주요사항을 발췌한 한글 요약문 및 원문을 첨부 | Human Serum 4 | 794 | 93.5 | 19.5 | 2.30 | 2.5 |\n| 3) 양성 검체는 각 질환의 다양한 임상단계가 포함되도록 한다.  | 치료 용량에 의한 혈중 농도의 2배 이상에서 간섭반응을 |\n| Operating Characteristic(ROC) 곡선을 생성하는데 사용되었다. ",
        "original_sentence": "|\n| 1) 검체의 종류, 검체 수, 측정방법, 측정횟수 등에 대한 실험프로 | 가) 검체 종류와 검체 준비 과정(검체종류, 기질, 검체의 수, 측정 | 민감도와 임상 특이도에 대한 BNP 결정 역치의 Receiver | SD (pg/mL) | 700 | 350 | 520 | 820 | 1000 | □ 예 | ■ 아니오 |\n| 나. "
      }
    },
    {
      "chunk_id": "chunk_192",
      "text": "제품명을 기재하지 아니하는 경우에는 “제조(수입)업소명·품목명”, “모 | 라. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 191,
        "window_size": 3,
        "char_count": 45,
        "word_count": 8,
        "page_number": 51,
        "window_text": "다만, 정맥채혈 등 피험자에게 중대한 | 약품을 평가하였다.  모든 약품은 최대 치료 용량 및 최대 | Human Serum 3 | 358.7 | 42.3 | 7.27 | 0.85 | 2.0 | 시험한다.  |\n| 1) 검체의 종류, 검체 수, 측정방법, 측정횟수 등에 대한 실험프로 | 가) 검체 종류와 검체 준비 과정(검체종류, 기질, 검체의 수, 측정 | 민감도와 임상 특이도에 대한 BNP 결정 역치의 Receiver | SD (pg/mL) | 700 | 350 | 520 | 820 | 1000 | □ 예 | ■ 아니오 |\n| 나.  제품명을 기재하지 아니하는 경우에는 “제조(수입)업소명·품목명”, “모 | 라.  외국의 자료는 주요사항을 발췌한 한글 요약문 및 원문을 첨부 | Human Serum 4 | 794 | 93.5 | 19.5 | 2.30 | 2.5 |\n| 3) 양성 검체는 각 질환의 다양한 임상단계가 포함되도록 한다.  | 치료 용량에 의한 혈중 농도의 2배 이상에서 간섭반응을 |\n| Operating Characteristic(ROC) 곡선을 생성하는데 사용되었다.  | Human Serum 5 | 5569 | 657 | 130 | 15.3 | 2.3 |\n| 나. ",
        "original_sentence": "제품명을 기재하지 아니하는 경우에는 “제조(수입)업소명·품목명”, “모 | 라. "
      }
    },
    {
      "chunk_id": "chunk_193",
      "text": "외국의 자료는 주요사항을 발췌한 한글 요약문 및 원문을 첨부 | Human Serum 4 | 794 | 93.5 | 19.5 | 2.30 | 2.5 |\n| 3) 양성 검체는 각 질환의 다양한 임상단계가 포함되도록 한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 192,
        "window_size": 3,
        "char_count": 123,
        "word_count": 34,
        "page_number": 3,
        "window_text": "모든 약품은 최대 치료 용량 및 최대 | Human Serum 3 | 358.7 | 42.3 | 7.27 | 0.85 | 2.0 | 시험한다.  |\n| 1) 검체의 종류, 검체 수, 측정방법, 측정횟수 등에 대한 실험프로 | 가) 검체 종류와 검체 준비 과정(검체종류, 기질, 검체의 수, 측정 | 민감도와 임상 특이도에 대한 BNP 결정 역치의 Receiver | SD (pg/mL) | 700 | 350 | 520 | 820 | 1000 | □ 예 | ■ 아니오 |\n| 나.  제품명을 기재하지 아니하는 경우에는 “제조(수입)업소명·품목명”, “모 | 라.  외국의 자료는 주요사항을 발췌한 한글 요약문 및 원문을 첨부 | Human Serum 4 | 794 | 93.5 | 19.5 | 2.30 | 2.5 |\n| 3) 양성 검체는 각 질환의 다양한 임상단계가 포함되도록 한다.  | 치료 용량에 의한 혈중 농도의 2배 이상에서 간섭반응을 |\n| Operating Characteristic(ROC) 곡선을 생성하는데 사용되었다.  | Human Serum 5 | 5569 | 657 | 130 | 15.3 | 2.3 |\n| 나.  작용원리 : 해당 진단의 측정 원리를 아래의 예와 같이 작성한다. ",
        "original_sentence": "외국의 자료는 주요사항을 발췌한 한글 요약문 및 원문을 첨부 | Human Serum 4 | 794 | 93.5 | 19.5 | 2.30 | 2.5 |\n| 3) 양성 검체는 각 질환의 다양한 임상단계가 포함되도록 한다. "
      }
    },
    {
      "chunk_id": "chunk_194",
      "text": "| 치료 용량에 의한 혈중 농도의 2배 이상에서 간섭반응을 |\n| Operating Characteristic(ROC) 곡선을 생성하는데 사용되었다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 193,
        "window_size": 3,
        "char_count": 84,
        "word_count": 16,
        "page_number": 6,
        "window_text": "|\n| 1) 검체의 종류, 검체 수, 측정방법, 측정횟수 등에 대한 실험프로 | 가) 검체 종류와 검체 준비 과정(검체종류, 기질, 검체의 수, 측정 | 민감도와 임상 특이도에 대한 BNP 결정 역치의 Receiver | SD (pg/mL) | 700 | 350 | 520 | 820 | 1000 | □ 예 | ■ 아니오 |\n| 나.  제품명을 기재하지 아니하는 경우에는 “제조(수입)업소명·품목명”, “모 | 라.  외국의 자료는 주요사항을 발췌한 한글 요약문 및 원문을 첨부 | Human Serum 4 | 794 | 93.5 | 19.5 | 2.30 | 2.5 |\n| 3) 양성 검체는 각 질환의 다양한 임상단계가 포함되도록 한다.  | 치료 용량에 의한 혈중 농도의 2배 이상에서 간섭반응을 |\n| Operating Characteristic(ROC) 곡선을 생성하는데 사용되었다.  | Human Serum 5 | 5569 | 657 | 130 | 15.3 | 2.3 |\n| 나.  작용원리 : 해당 진단의 측정 원리를 아래의 예와 같이 작성한다.  | 다. ",
        "original_sentence": "| 치료 용량에 의한 혈중 농도의 2배 이상에서 간섭반응을 |\n| Operating Characteristic(ROC) 곡선을 생성하는데 사용되었다. "
      }
    },
    {
      "chunk_id": "chunk_195",
      "text": "| Human Serum 5 | 5569 | 657 | 130 | 15.3 | 2.3 |\n| 나. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 194,
        "window_size": 3,
        "char_count": 55,
        "word_count": 17,
        "page_number": 6,
        "window_text": "제품명을 기재하지 아니하는 경우에는 “제조(수입)업소명·품목명”, “모 | 라.  외국의 자료는 주요사항을 발췌한 한글 요약문 및 원문을 첨부 | Human Serum 4 | 794 | 93.5 | 19.5 | 2.30 | 2.5 |\n| 3) 양성 검체는 각 질환의 다양한 임상단계가 포함되도록 한다.  | 치료 용량에 의한 혈중 농도의 2배 이상에서 간섭반응을 |\n| Operating Characteristic(ROC) 곡선을 생성하는데 사용되었다.  | Human Serum 5 | 5569 | 657 | 130 | 15.3 | 2.3 |\n| 나.  작용원리 : 해당 진단의 측정 원리를 아래의 예와 같이 작성한다.  | 다.  시약의 조제가 필요할 경우 조제 후 보관 조건 및 사용기간(유효 | 95th Percentile | 2000 | 1200 | 1300 | 2300 | 3700 |\n| 횟수, 분석물질의 농도, 농도를 확인한 방법 등)을 기술한다. ",
        "original_sentence": "| Human Serum 5 | 5569 | 657 | 130 | 15.3 | 2.3 |\n| 나. "
      }
    },
    {
      "chunk_id": "chunk_196",
      "text": "작용원리 : 해당 진단의 측정 원리를 아래의 예와 같이 작성한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 195,
        "window_size": 3,
        "char_count": 37,
        "word_count": 10,
        "page_number": 25,
        "window_text": "외국의 자료는 주요사항을 발췌한 한글 요약문 및 원문을 첨부 | Human Serum 4 | 794 | 93.5 | 19.5 | 2.30 | 2.5 |\n| 3) 양성 검체는 각 질환의 다양한 임상단계가 포함되도록 한다.  | 치료 용량에 의한 혈중 농도의 2배 이상에서 간섭반응을 |\n| Operating Characteristic(ROC) 곡선을 생성하는데 사용되었다.  | Human Serum 5 | 5569 | 657 | 130 | 15.3 | 2.3 |\n| 나.  작용원리 : 해당 진단의 측정 원리를 아래의 예와 같이 작성한다.  | 다.  시약의 조제가 필요할 경우 조제 후 보관 조건 및 사용기간(유효 | 95th Percentile | 2000 | 1200 | 1300 | 2300 | 3700 |\n| 횟수, 분석물질의 농도, 농도를 확인한 방법 등)을 기술한다.  | □ 외국 규정을 번역하거나 설명하는 내용입니까? ",
        "original_sentence": "작용원리 : 해당 진단의 측정 원리를 아래의 예와 같이 작성한다. "
      }
    },
    {
      "chunk_id": "chunk_197",
      "text": "| 다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 196,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 1,
        "window_text": "| 치료 용량에 의한 혈중 농도의 2배 이상에서 간섭반응을 |\n| Operating Characteristic(ROC) 곡선을 생성하는데 사용되었다.  | Human Serum 5 | 5569 | 657 | 130 | 15.3 | 2.3 |\n| 나.  작용원리 : 해당 진단의 측정 원리를 아래의 예와 같이 작성한다.  | 다.  시약의 조제가 필요할 경우 조제 후 보관 조건 및 사용기간(유효 | 95th Percentile | 2000 | 1200 | 1300 | 2300 | 3700 |\n| 횟수, 분석물질의 농도, 농도를 확인한 방법 등)을 기술한다.  | □ 외국 규정을 번역하거나 설명하는 내용입니까?  | □ 예 | ■ 아니오 |\n| 나. ",
        "original_sentence": "| 다. "
      }
    },
    {
      "chunk_id": "chunk_198",
      "text": "시약의 조제가 필요할 경우 조제 후 보관 조건 및 사용기간(유효 | 95th Percentile | 2000 | 1200 | 1300 | 2300 | 3700 |\n| 횟수, 분석물질의 농도, 농도를 확인한 방법 등)을 기술한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 197,
        "window_size": 3,
        "char_count": 128,
        "word_count": 33,
        "page_number": 14,
        "window_text": "| Human Serum 5 | 5569 | 657 | 130 | 15.3 | 2.3 |\n| 나.  작용원리 : 해당 진단의 측정 원리를 아래의 예와 같이 작성한다.  | 다.  시약의 조제가 필요할 경우 조제 후 보관 조건 및 사용기간(유효 | 95th Percentile | 2000 | 1200 | 1300 | 2300 | 3700 |\n| 횟수, 분석물질의 농도, 농도를 확인한 방법 등)을 기술한다.  | □ 외국 규정을 번역하거나 설명하는 내용입니까?  | □ 예 | ■ 아니오 |\n| 나.  배합목적 : 체외진단용 의료기기의 특성에 맞게 각 성분의 배합목 | 7. ",
        "original_sentence": "시약의 조제가 필요할 경우 조제 후 보관 조건 및 사용기간(유효 | 95th Percentile | 2000 | 1200 | 1300 | 2300 | 3700 |\n| 횟수, 분석물질의 농도, 농도를 확인한 방법 등)을 기술한다. "
      }
    },
    {
      "chunk_id": "chunk_199",
      "text": "| □ 외국 규정을 번역하거나 설명하는 내용입니까? ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 198,
        "window_size": 3,
        "char_count": 29,
        "word_count": 7,
        "page_number": 3,
        "window_text": "작용원리 : 해당 진단의 측정 원리를 아래의 예와 같이 작성한다.  | 다.  시약의 조제가 필요할 경우 조제 후 보관 조건 및 사용기간(유효 | 95th Percentile | 2000 | 1200 | 1300 | 2300 | 3700 |\n| 횟수, 분석물질의 농도, 농도를 확인한 방법 등)을 기술한다.  | □ 외국 규정을 번역하거나 설명하는 내용입니까?  | □ 예 | ■ 아니오 |\n| 나.  배합목적 : 체외진단용 의료기기의 특성에 맞게 각 성분의 배합목 | 7.  시험기준 및 시험방법. ",
        "original_sentence": "| □ 외국 규정을 번역하거나 설명하는 내용입니까? "
      }
    },
    {
      "chunk_id": "chunk_200",
      "text": "| □ 예 | ■ 아니오 |\n| 나. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 199,
        "window_size": 3,
        "char_count": 21,
        "word_count": 9,
        "page_number": 3,
        "window_text": "| 다.  시약의 조제가 필요할 경우 조제 후 보관 조건 및 사용기간(유효 | 95th Percentile | 2000 | 1200 | 1300 | 2300 | 3700 |\n| 횟수, 분석물질의 농도, 농도를 확인한 방법 등)을 기술한다.  | □ 외국 규정을 번역하거나 설명하는 내용입니까?  | □ 예 | ■ 아니오 |\n| 나.  배합목적 : 체외진단용 의료기기의 특성에 맞게 각 성분의 배합목 | 7.  시험기준 및 시험방법.  단, 규격이 없는 경우 이에 대한 설정 사유 | 단계별 시험 및 완제품 품질관리 시험의 단계를 확인할 수 있는 자료) | 권장하고, 그 외 자사가 설정한 시험항목을 설정할 수 있다. ",
        "original_sentence": "| □ 예 | ■ 아니오 |\n| 나. "
      }
    },
    {
      "chunk_id": "chunk_201",
      "text": "배합목적 : 체외진단용 의료기기의 특성에 맞게 각 성분의 배합목 | 7. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 200,
        "window_size": 3,
        "char_count": 41,
        "word_count": 11,
        "page_number": 1,
        "window_text": "시약의 조제가 필요할 경우 조제 후 보관 조건 및 사용기간(유효 | 95th Percentile | 2000 | 1200 | 1300 | 2300 | 3700 |\n| 횟수, 분석물질의 농도, 농도를 확인한 방법 등)을 기술한다.  | □ 외국 규정을 번역하거나 설명하는 내용입니까?  | □ 예 | ■ 아니오 |\n| 나.  배합목적 : 체외진단용 의료기기의 특성에 맞게 각 성분의 배합목 | 7.  시험기준 및 시험방법.  단, 규격이 없는 경우 이에 대한 설정 사유 | 단계별 시험 및 완제품 품질관리 시험의 단계를 확인할 수 있는 자료) | 권장하고, 그 외 자사가 설정한 시험항목을 설정할 수 있다.  | Control 1 | 110 | 13 | 2.72 | 0.3 | 2.5 | 퍼센트 ≥100 pg/mL | 71.00% | 56.00% | 65.70% | 70.00% | 95.00% | WI-6612 | 05/30/2003 | 65-74 |\n| 6) 시험기준 및 시험방법 단, 규격이 없는 경우 이에 대한 설정 사유 | 알기 쉽게 풀어서 설명하거나 특정한 사안에 대하여 식품의약품안전처 | 의 입장을 기술하는 것(식품의약품안전처 지침서등의 관리에 관한 | 규정 제2조) | 본 연구에서 결정 역치인 125pg/mL에서, BNP 검사는 임상적 |\n| Control 2 | 4200 | 495 | 107.1 | 12.6 | 2.6 | 1x10mL |\n| 가. ",
        "original_sentence": "배합목적 : 체외진단용 의료기기의 특성에 맞게 각 성분의 배합목 | 7. "
      }
    },
    {
      "chunk_id": "chunk_202",
      "text": "시험기준 및 시험방법. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 201,
        "window_size": 3,
        "char_count": 13,
        "word_count": 3,
        "page_number": 33,
        "window_text": "| □ 외국 규정을 번역하거나 설명하는 내용입니까?  | □ 예 | ■ 아니오 |\n| 나.  배합목적 : 체외진단용 의료기기의 특성에 맞게 각 성분의 배합목 | 7.  시험기준 및 시험방법.  단, 규격이 없는 경우 이에 대한 설정 사유 | 단계별 시험 및 완제품 품질관리 시험의 단계를 확인할 수 있는 자료) | 권장하고, 그 외 자사가 설정한 시험항목을 설정할 수 있다.  | Control 1 | 110 | 13 | 2.72 | 0.3 | 2.5 | 퍼센트 ≥100 pg/mL | 71.00% | 56.00% | 65.70% | 70.00% | 95.00% | WI-6612 | 05/30/2003 | 65-74 |\n| 6) 시험기준 및 시험방법 단, 규격이 없는 경우 이에 대한 설정 사유 | 알기 쉽게 풀어서 설명하거나 특정한 사안에 대하여 식품의약품안전처 | 의 입장을 기술하는 것(식품의약품안전처 지침서등의 관리에 관한 | 규정 제2조) | 본 연구에서 결정 역치인 125pg/mL에서, BNP 검사는 임상적 |\n| Control 2 | 4200 | 495 | 107.1 | 12.6 | 2.6 | 1x10mL |\n| 가.  전체 결과 및 특이 환자 그룹이 있다면 그룹별 결과를 제시한다. ",
        "original_sentence": "시험기준 및 시험방법. "
      }
    },
    {
      "chunk_id": "chunk_203",
      "text": "단, 규격이 없는 경우 이에 대한 설정 사유 | 단계별 시험 및 완제품 품질관리 시험의 단계를 확인할 수 있는 자료) | 권장하고, 그 외 자사가 설정한 시험항목을 설정할 수 있다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 202,
        "window_size": 3,
        "char_count": 102,
        "word_count": 30,
        "page_number": 28,
        "window_text": "| □ 예 | ■ 아니오 |\n| 나.  배합목적 : 체외진단용 의료기기의 특성에 맞게 각 성분의 배합목 | 7.  시험기준 및 시험방법.  단, 규격이 없는 경우 이에 대한 설정 사유 | 단계별 시험 및 완제품 품질관리 시험의 단계를 확인할 수 있는 자료) | 권장하고, 그 외 자사가 설정한 시험항목을 설정할 수 있다.  | Control 1 | 110 | 13 | 2.72 | 0.3 | 2.5 | 퍼센트 ≥100 pg/mL | 71.00% | 56.00% | 65.70% | 70.00% | 95.00% | WI-6612 | 05/30/2003 | 65-74 |\n| 6) 시험기준 및 시험방법 단, 규격이 없는 경우 이에 대한 설정 사유 | 알기 쉽게 풀어서 설명하거나 특정한 사안에 대하여 식품의약품안전처 | 의 입장을 기술하는 것(식품의약품안전처 지침서등의 관리에 관한 | 규정 제2조) | 본 연구에서 결정 역치인 125pg/mL에서, BNP 검사는 임상적 |\n| Control 2 | 4200 | 495 | 107.1 | 12.6 | 2.6 | 1x10mL |\n| 가.  전체 결과 및 특이 환자 그룹이 있다면 그룹별 결과를 제시한다.  | 절차서에 |\n| 영어 외의 외국어 자료는 공증된 전체 번역문을 첨부하여야 한다. ",
        "original_sentence": "단, 규격이 없는 경우 이에 대한 설정 사유 | 단계별 시험 및 완제품 품질관리 시험의 단계를 확인할 수 있는 자료) | 권장하고, 그 외 자사가 설정한 시험항목을 설정할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_204",
      "text": "| Control 1 | 110 | 13 | 2.72 | 0.3 | 2.5 | 퍼센트 ≥100 pg/mL | 71.00% | 56.00% | 65.70% | 70.00% | 95.00% | WI-6612 | 05/30/2003 | 65-74 |\n| 6) 시험기준 및 시험방법 단, 규격이 없는 경우 이에 대한 설정 사유 | 알기 쉽게 풀어서 설명하거나 특정한 사안에 대하여 식품의약품안전처 | 의 입장을 기술하는 것(식품의약품안전처 지침서등의 관리에 관한 | 규정 제2조) | 본 연구에서 결정 역치인 125pg/mL에서, BNP 검사는 임상적 |\n| Control 2 | 4200 | 495 | 107.1 | 12.6 | 2.6 | 1x10mL |\n| 가. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 203,
        "window_size": 3,
        "char_count": 369,
        "word_count": 95,
        "page_number": 6,
        "window_text": "배합목적 : 체외진단용 의료기기의 특성에 맞게 각 성분의 배합목 | 7.  시험기준 및 시험방법.  단, 규격이 없는 경우 이에 대한 설정 사유 | 단계별 시험 및 완제품 품질관리 시험의 단계를 확인할 수 있는 자료) | 권장하고, 그 외 자사가 설정한 시험항목을 설정할 수 있다.  | Control 1 | 110 | 13 | 2.72 | 0.3 | 2.5 | 퍼센트 ≥100 pg/mL | 71.00% | 56.00% | 65.70% | 70.00% | 95.00% | WI-6612 | 05/30/2003 | 65-74 |\n| 6) 시험기준 및 시험방법 단, 규격이 없는 경우 이에 대한 설정 사유 | 알기 쉽게 풀어서 설명하거나 특정한 사안에 대하여 식품의약품안전처 | 의 입장을 기술하는 것(식품의약품안전처 지침서등의 관리에 관한 | 규정 제2조) | 본 연구에서 결정 역치인 125pg/mL에서, BNP 검사는 임상적 |\n| Control 2 | 4200 | 495 | 107.1 | 12.6 | 2.6 | 1x10mL |\n| 가.  전체 결과 및 특이 환자 그룹이 있다면 그룹별 결과를 제시한다.  | 절차서에 |\n| 영어 외의 외국어 자료는 공증된 전체 번역문을 첨부하여야 한다.  | 민감도와 특이도에 대하여 각각 70.5% 및 90.5%로 나타났다. ",
        "original_sentence": "| Control 1 | 110 | 13 | 2.72 | 0.3 | 2.5 | 퍼센트 ≥100 pg/mL | 71.00% | 56.00% | 65.70% | 70.00% | 95.00% | WI-6612 | 05/30/2003 | 65-74 |\n| 6) 시험기준 및 시험방법 단, 규격이 없는 경우 이에 대한 설정 사유 | 알기 쉽게 풀어서 설명하거나 특정한 사안에 대하여 식품의약품안전처 | 의 입장을 기술하는 것(식품의약품안전처 지침서등의 관리에 관한 | 규정 제2조) | 본 연구에서 결정 역치인 125pg/mL에서, BNP 검사는 임상적 |\n| Control 2 | 4200 | 495 | 107.1 | 12.6 | 2.6 | 1x10mL |\n| 가. "
      }
    },
    {
      "chunk_id": "chunk_205",
      "text": "전체 결과 및 특이 환자 그룹이 있다면 그룹별 결과를 제시한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 204,
        "window_size": 3,
        "char_count": 36,
        "word_count": 10,
        "page_number": 14,
        "window_text": "시험기준 및 시험방법.  단, 규격이 없는 경우 이에 대한 설정 사유 | 단계별 시험 및 완제품 품질관리 시험의 단계를 확인할 수 있는 자료) | 권장하고, 그 외 자사가 설정한 시험항목을 설정할 수 있다.  | Control 1 | 110 | 13 | 2.72 | 0.3 | 2.5 | 퍼센트 ≥100 pg/mL | 71.00% | 56.00% | 65.70% | 70.00% | 95.00% | WI-6612 | 05/30/2003 | 65-74 |\n| 6) 시험기준 및 시험방법 단, 규격이 없는 경우 이에 대한 설정 사유 | 알기 쉽게 풀어서 설명하거나 특정한 사안에 대하여 식품의약품안전처 | 의 입장을 기술하는 것(식품의약품안전처 지침서등의 관리에 관한 | 규정 제2조) | 본 연구에서 결정 역치인 125pg/mL에서, BNP 검사는 임상적 |\n| Control 2 | 4200 | 495 | 107.1 | 12.6 | 2.6 | 1x10mL |\n| 가.  전체 결과 및 특이 환자 그룹이 있다면 그룹별 결과를 제시한다.  | 절차서에 |\n| 영어 외의 외국어 자료는 공증된 전체 번역문을 첨부하여야 한다.  | 민감도와 특이도에 대하여 각각 70.5% 및 90.5%로 나타났다.  | 최대 (pg/mL) | >4000 | 1400 | 3800 | >4000 | >4000 | DADE BEHRING, | INC. ",
        "original_sentence": "전체 결과 및 특이 환자 그룹이 있다면 그룹별 결과를 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_206",
      "text": "| 절차서에 |\n| 영어 외의 외국어 자료는 공증된 전체 번역문을 첨부하여야 한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 205,
        "window_size": 3,
        "char_count": 47,
        "word_count": 13,
        "page_number": 14,
        "window_text": "단, 규격이 없는 경우 이에 대한 설정 사유 | 단계별 시험 및 완제품 품질관리 시험의 단계를 확인할 수 있는 자료) | 권장하고, 그 외 자사가 설정한 시험항목을 설정할 수 있다.  | Control 1 | 110 | 13 | 2.72 | 0.3 | 2.5 | 퍼센트 ≥100 pg/mL | 71.00% | 56.00% | 65.70% | 70.00% | 95.00% | WI-6612 | 05/30/2003 | 65-74 |\n| 6) 시험기준 및 시험방법 단, 규격이 없는 경우 이에 대한 설정 사유 | 알기 쉽게 풀어서 설명하거나 특정한 사안에 대하여 식품의약품안전처 | 의 입장을 기술하는 것(식품의약품안전처 지침서등의 관리에 관한 | 규정 제2조) | 본 연구에서 결정 역치인 125pg/mL에서, BNP 검사는 임상적 |\n| Control 2 | 4200 | 495 | 107.1 | 12.6 | 2.6 | 1x10mL |\n| 가.  전체 결과 및 특이 환자 그룹이 있다면 그룹별 결과를 제시한다.  | 절차서에 |\n| 영어 외의 외국어 자료는 공증된 전체 번역문을 첨부하여야 한다.  | 민감도와 특이도에 대하여 각각 70.5% 및 90.5%로 나타났다.  | 최대 (pg/mL) | >4000 | 1400 | 3800 | >4000 | >4000 | DADE BEHRING, | INC.  | 08/17/2007 | □ 예 | ■ 아니오 |\n| 봉 후(on-board, reconstitution, open vial/bottle stability) 안정성 자 | 타 제품과의 비교한 결과 상관계수(r)는 ≥ 0.90이었고 |\n**따라서**\n| 증서나 다른 인증기관에 의해 발행된 서류가 있거나 추적 가능한 하 | 1 | Reagent 1 | 단일구성 | 투명한 액상 시약 | 곡선 아래 부분은 0.90(0.86 ~ 0.92, 95% 신뢰구간)이다. ",
        "original_sentence": "| 절차서에 |\n| 영어 외의 외국어 자료는 공증된 전체 번역문을 첨부하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_207",
      "text": "| 민감도와 특이도에 대하여 각각 70.5% 및 90.5%로 나타났다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 206,
        "window_size": 3,
        "char_count": 40,
        "word_count": 9,
        "page_number": 7,
        "window_text": "| Control 1 | 110 | 13 | 2.72 | 0.3 | 2.5 | 퍼센트 ≥100 pg/mL | 71.00% | 56.00% | 65.70% | 70.00% | 95.00% | WI-6612 | 05/30/2003 | 65-74 |\n| 6) 시험기준 및 시험방법 단, 규격이 없는 경우 이에 대한 설정 사유 | 알기 쉽게 풀어서 설명하거나 특정한 사안에 대하여 식품의약품안전처 | 의 입장을 기술하는 것(식품의약품안전처 지침서등의 관리에 관한 | 규정 제2조) | 본 연구에서 결정 역치인 125pg/mL에서, BNP 검사는 임상적 |\n| Control 2 | 4200 | 495 | 107.1 | 12.6 | 2.6 | 1x10mL |\n| 가.  전체 결과 및 특이 환자 그룹이 있다면 그룹별 결과를 제시한다.  | 절차서에 |\n| 영어 외의 외국어 자료는 공증된 전체 번역문을 첨부하여야 한다.  | 민감도와 특이도에 대하여 각각 70.5% 및 90.5%로 나타났다.  | 최대 (pg/mL) | >4000 | 1400 | 3800 | >4000 | >4000 | DADE BEHRING, | INC.  | 08/17/2007 | □ 예 | ■ 아니오 |\n| 봉 후(on-board, reconstitution, open vial/bottle stability) 안정성 자 | 타 제품과의 비교한 결과 상관계수(r)는 ≥ 0.90이었고 |\n**따라서**\n| 증서나 다른 인증기관에 의해 발행된 서류가 있거나 추적 가능한 하 | 1 | Reagent 1 | 단일구성 | 투명한 액상 시약 | 곡선 아래 부분은 0.90(0.86 ~ 0.92, 95% 신뢰구간)이다.  |\n| 본 제품에는 면역형광법이 사용되며 다음과 같은 반응으로 이루어진다. ",
        "original_sentence": "| 민감도와 특이도에 대하여 각각 70.5% 및 90.5%로 나타났다. "
      }
    },
    {
      "chunk_id": "chunk_208",
      "text": "| 최대 (pg/mL) | >4000 | 1400 | 3800 | >4000 | >4000 | DADE BEHRING, | INC. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 207,
        "window_size": 3,
        "char_count": 74,
        "word_count": 18,
        "page_number": 6,
        "window_text": "전체 결과 및 특이 환자 그룹이 있다면 그룹별 결과를 제시한다.  | 절차서에 |\n| 영어 외의 외국어 자료는 공증된 전체 번역문을 첨부하여야 한다.  | 민감도와 특이도에 대하여 각각 70.5% 및 90.5%로 나타났다.  | 최대 (pg/mL) | >4000 | 1400 | 3800 | >4000 | >4000 | DADE BEHRING, | INC.  | 08/17/2007 | □ 예 | ■ 아니오 |\n| 봉 후(on-board, reconstitution, open vial/bottle stability) 안정성 자 | 타 제품과의 비교한 결과 상관계수(r)는 ≥ 0.90이었고 |\n**따라서**\n| 증서나 다른 인증기관에 의해 발행된 서류가 있거나 추적 가능한 하 | 1 | Reagent 1 | 단일구성 | 투명한 액상 시약 | 곡선 아래 부분은 0.90(0.86 ~ 0.92, 95% 신뢰구간)이다.  |\n| 본 제품에는 면역형광법이 사용되며 다음과 같은 반응으로 이루어진다.  | 일치도는 ≥ 90%이었다. ",
        "original_sentence": "| 최대 (pg/mL) | >4000 | 1400 | 3800 | >4000 | >4000 | DADE BEHRING, | INC. "
      }
    },
    {
      "chunk_id": "chunk_209",
      "text": "| 08/17/2007 | □ 예 | ■ 아니오 |\n| 봉 후(on-board, reconstitution, open vial/bottle stability) 안정성 자 | 타 제품과의 비교한 결과 상관계수(r)는 ≥ 0.90이었고 |\n**따라서**\n| 증서나 다른 인증기관에 의해 발행된 서류가 있거나 추적 가능한 하 | 1 | Reagent 1 | 단일구성 | 투명한 액상 시약 | 곡선 아래 부분은 0.90(0.86 ~ 0.92, 95% 신뢰구간)이다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 208,
        "window_size": 3,
        "char_count": 257,
        "word_count": 59,
        "page_number": 3,
        "window_text": "| 절차서에 |\n| 영어 외의 외국어 자료는 공증된 전체 번역문을 첨부하여야 한다.  | 민감도와 특이도에 대하여 각각 70.5% 및 90.5%로 나타났다.  | 최대 (pg/mL) | >4000 | 1400 | 3800 | >4000 | >4000 | DADE BEHRING, | INC.  | 08/17/2007 | □ 예 | ■ 아니오 |\n| 봉 후(on-board, reconstitution, open vial/bottle stability) 안정성 자 | 타 제품과의 비교한 결과 상관계수(r)는 ≥ 0.90이었고 |\n**따라서**\n| 증서나 다른 인증기관에 의해 발행된 서류가 있거나 추적 가능한 하 | 1 | Reagent 1 | 단일구성 | 투명한 액상 시약 | 곡선 아래 부분은 0.90(0.86 ~ 0.92, 95% 신뢰구간)이다.  |\n| 본 제품에는 면역형광법이 사용되며 다음과 같은 반응으로 이루어진다.  | 일치도는 ≥ 90%이었다.  NCCLS 프로토콜 EP9- A41을 |\n| DADE BEHRING, | INC | 08/04/2007 | 시험한다. ",
        "original_sentence": "| 08/17/2007 | □ 예 | ■ 아니오 |\n| 봉 후(on-board, reconstitution, open vial/bottle stability) 안정성 자 | 타 제품과의 비교한 결과 상관계수(r)는 ≥ 0.90이었고 |\n**따라서**\n| 증서나 다른 인증기관에 의해 발행된 서류가 있거나 추적 가능한 하 | 1 | Reagent 1 | 단일구성 | 투명한 액상 시약 | 곡선 아래 부분은 0.90(0.86 ~ 0.92, 95% 신뢰구간)이다. "
      }
    },
    {
      "chunk_id": "chunk_210",
      "text": "|\n| 본 제품에는 면역형광법이 사용되며 다음과 같은 반응으로 이루어진다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 209,
        "window_size": 3,
        "char_count": 42,
        "word_count": 10,
        "page_number": 25,
        "window_text": "| 민감도와 특이도에 대하여 각각 70.5% 및 90.5%로 나타났다.  | 최대 (pg/mL) | >4000 | 1400 | 3800 | >4000 | >4000 | DADE BEHRING, | INC.  | 08/17/2007 | □ 예 | ■ 아니오 |\n| 봉 후(on-board, reconstitution, open vial/bottle stability) 안정성 자 | 타 제품과의 비교한 결과 상관계수(r)는 ≥ 0.90이었고 |\n**따라서**\n| 증서나 다른 인증기관에 의해 발행된 서류가 있거나 추적 가능한 하 | 1 | Reagent 1 | 단일구성 | 투명한 액상 시약 | 곡선 아래 부분은 0.90(0.86 ~ 0.92, 95% 신뢰구간)이다.  |\n| 본 제품에는 면역형광법이 사용되며 다음과 같은 반응으로 이루어진다.  | 일치도는 ≥ 90%이었다.  NCCLS 프로토콜 EP9- A41을 |\n| DADE BEHRING, | INC | 08/04/2007 | 시험한다.  |\n| ‘사용기간’ 항에 아래 표와 같이 저장방법과 사용기간을 기재한다. ",
        "original_sentence": "|\n| 본 제품에는 면역형광법이 사용되며 다음과 같은 반응으로 이루어진다. "
      }
    },
    {
      "chunk_id": "chunk_211",
      "text": "| 일치도는 ≥ 90%이었다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 210,
        "window_size": 3,
        "char_count": 17,
        "word_count": 4,
        "page_number": 33,
        "window_text": "| 최대 (pg/mL) | >4000 | 1400 | 3800 | >4000 | >4000 | DADE BEHRING, | INC.  | 08/17/2007 | □ 예 | ■ 아니오 |\n| 봉 후(on-board, reconstitution, open vial/bottle stability) 안정성 자 | 타 제품과의 비교한 결과 상관계수(r)는 ≥ 0.90이었고 |\n**따라서**\n| 증서나 다른 인증기관에 의해 발행된 서류가 있거나 추적 가능한 하 | 1 | Reagent 1 | 단일구성 | 투명한 액상 시약 | 곡선 아래 부분은 0.90(0.86 ~ 0.92, 95% 신뢰구간)이다.  |\n| 본 제품에는 면역형광법이 사용되며 다음과 같은 반응으로 이루어진다.  | 일치도는 ≥ 90%이었다.  NCCLS 프로토콜 EP9- A41을 |\n| DADE BEHRING, | INC | 08/04/2007 | 시험한다.  |\n| ‘사용기간’ 항에 아래 표와 같이 저장방법과 사용기간을 기재한다.  | 2 | Reagent 2 | 단일구성 | 투명한 액상 시약 |\n| 6 | 사용목적 | 예 | □ | ※ 예시 : 사람의 전혈 또는 혈장에서 pro Brain-type natriuretic | 의학적 결정치(medical decision point)에서의 바이어스를 제시한다. ",
        "original_sentence": "| 일치도는 ≥ 90%이었다. "
      }
    },
    {
      "chunk_id": "chunk_212",
      "text": "NCCLS 프로토콜 EP9- A41을 |\n| DADE BEHRING, | INC | 08/04/2007 | 시험한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 211,
        "window_size": 3,
        "char_count": 66,
        "word_count": 14,
        "page_number": 6,
        "window_text": "| 08/17/2007 | □ 예 | ■ 아니오 |\n| 봉 후(on-board, reconstitution, open vial/bottle stability) 안정성 자 | 타 제품과의 비교한 결과 상관계수(r)는 ≥ 0.90이었고 |\n**따라서**\n| 증서나 다른 인증기관에 의해 발행된 서류가 있거나 추적 가능한 하 | 1 | Reagent 1 | 단일구성 | 투명한 액상 시약 | 곡선 아래 부분은 0.90(0.86 ~ 0.92, 95% 신뢰구간)이다.  |\n| 본 제품에는 면역형광법이 사용되며 다음과 같은 반응으로 이루어진다.  | 일치도는 ≥ 90%이었다.  NCCLS 프로토콜 EP9- A41을 |\n| DADE BEHRING, | INC | 08/04/2007 | 시험한다.  |\n| ‘사용기간’ 항에 아래 표와 같이 저장방법과 사용기간을 기재한다.  | 2 | Reagent 2 | 단일구성 | 투명한 액상 시약 |\n| 6 | 사용목적 | 예 | □ | ※ 예시 : 사람의 전혈 또는 혈장에서 pro Brain-type natriuretic | 의학적 결정치(medical decision point)에서의 바이어스를 제시한다.  | triplicate) 측정하기를, 1일마다 2회(run) 이상, 최소 10일 동안 | 1) 투입구에 검체를 주입한 뒤, 혈구 세포는 디바이스에 내장 | 따라 상업적으로 유용한 진단검사와 본 제품을 이용한 검사를 |\n| 액티베이즈 | 에리스로마이신 | 옥시테트라사이클린 |\n| Siemens | Germany | □ 예(☞지침서) | ■ 아니오 |\n| 의료기기와 사용목적, 작용원리 등이 동등하지 아니한 체외진단용 의 | 3 | Reagent 3 | 단일구성 | 투명한 액상 시약 | 비교하였다. ",
        "original_sentence": "NCCLS 프로토콜 EP9- A41을 |\n| DADE BEHRING, | INC | 08/04/2007 | 시험한다. "
      }
    },
    {
      "chunk_id": "chunk_213",
      "text": "|\n| ‘사용기간’ 항에 아래 표와 같이 저장방법과 사용기간을 기재한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 212,
        "window_size": 3,
        "char_count": 41,
        "word_count": 10,
        "page_number": 3,
        "window_text": "|\n| 본 제품에는 면역형광법이 사용되며 다음과 같은 반응으로 이루어진다.  | 일치도는 ≥ 90%이었다.  NCCLS 프로토콜 EP9- A41을 |\n| DADE BEHRING, | INC | 08/04/2007 | 시험한다.  |\n| ‘사용기간’ 항에 아래 표와 같이 저장방법과 사용기간을 기재한다.  | 2 | Reagent 2 | 단일구성 | 투명한 액상 시약 |\n| 6 | 사용목적 | 예 | □ | ※ 예시 : 사람의 전혈 또는 혈장에서 pro Brain-type natriuretic | 의학적 결정치(medical decision point)에서의 바이어스를 제시한다.  | triplicate) 측정하기를, 1일마다 2회(run) 이상, 최소 10일 동안 | 1) 투입구에 검체를 주입한 뒤, 혈구 세포는 디바이스에 내장 | 따라 상업적으로 유용한 진단검사와 본 제품을 이용한 검사를 |\n| 액티베이즈 | 에리스로마이신 | 옥시테트라사이클린 |\n| Siemens | Germany | □ 예(☞지침서) | ■ 아니오 |\n| 의료기기와 사용목적, 작용원리 등이 동등하지 아니한 체외진단용 의 | 3 | Reagent 3 | 단일구성 | 투명한 액상 시약 | 비교하였다.  총 300명(심장 질환 환자 200명, 비심장 질환 | 퍼센트 ≥100 pg/mL | 90.50% | 91.50% | 92.00% | 95.00% | 85.10% | I-STAT | CORPORATION | 07/21/2006 | 아니오 | □ |\n| 다) 검체에서 검출될 수 있는 최소 검출한계치를 제시한다. ",
        "original_sentence": "|\n| ‘사용기간’ 항에 아래 표와 같이 저장방법과 사용기간을 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_214",
      "text": "| 2 | Reagent 2 | 단일구성 | 투명한 액상 시약 |\n| 6 | 사용목적 | 예 | □ | ※ 예시 : 사람의 전혈 또는 혈장에서 pro Brain-type natriuretic | 의학적 결정치(medical decision point)에서의 바이어스를 제시한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 213,
        "window_size": 3,
        "char_count": 156,
        "word_count": 38,
        "page_number": 6,
        "window_text": "| 일치도는 ≥ 90%이었다.  NCCLS 프로토콜 EP9- A41을 |\n| DADE BEHRING, | INC | 08/04/2007 | 시험한다.  |\n| ‘사용기간’ 항에 아래 표와 같이 저장방법과 사용기간을 기재한다.  | 2 | Reagent 2 | 단일구성 | 투명한 액상 시약 |\n| 6 | 사용목적 | 예 | □ | ※ 예시 : 사람의 전혈 또는 혈장에서 pro Brain-type natriuretic | 의학적 결정치(medical decision point)에서의 바이어스를 제시한다.  | triplicate) 측정하기를, 1일마다 2회(run) 이상, 최소 10일 동안 | 1) 투입구에 검체를 주입한 뒤, 혈구 세포는 디바이스에 내장 | 따라 상업적으로 유용한 진단검사와 본 제품을 이용한 검사를 |\n| 액티베이즈 | 에리스로마이신 | 옥시테트라사이클린 |\n| Siemens | Germany | □ 예(☞지침서) | ■ 아니오 |\n| 의료기기와 사용목적, 작용원리 등이 동등하지 아니한 체외진단용 의 | 3 | Reagent 3 | 단일구성 | 투명한 액상 시약 | 비교하였다.  총 300명(심장 질환 환자 200명, 비심장 질환 | 퍼센트 ≥100 pg/mL | 90.50% | 91.50% | 92.00% | 95.00% | 85.10% | I-STAT | CORPORATION | 07/21/2006 | 아니오 | □ |\n| 다) 검체에서 검출될 수 있는 최소 검출한계치를 제시한다.  검출 | 바) 총 run의 수(해당되는 경우 제시) | 3. ",
        "original_sentence": "| 2 | Reagent 2 | 단일구성 | 투명한 액상 시약 |\n| 6 | 사용목적 | 예 | □ | ※ 예시 : 사람의 전혈 또는 혈장에서 pro Brain-type natriuretic | 의학적 결정치(medical decision point)에서의 바이어스를 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_215",
      "text": "| triplicate) 측정하기를, 1일마다 2회(run) 이상, 최소 10일 동안 | 1) 투입구에 검체를 주입한 뒤, 혈구 세포는 디바이스에 내장 | 따라 상업적으로 유용한 진단검사와 본 제품을 이용한 검사를 |\n| 액티베이즈 | 에리스로마이신 | 옥시테트라사이클린 |\n| Siemens | Germany | □ 예(☞지침서) | ■ 아니오 |\n| 의료기기와 사용목적, 작용원리 등이 동등하지 아니한 체외진단용 의 | 3 | Reagent 3 | 단일구성 | 투명한 액상 시약 | 비교하였다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 214,
        "window_size": 3,
        "char_count": 279,
        "word_count": 69,
        "page_number": 6,
        "window_text": "NCCLS 프로토콜 EP9- A41을 |\n| DADE BEHRING, | INC | 08/04/2007 | 시험한다.  |\n| ‘사용기간’ 항에 아래 표와 같이 저장방법과 사용기간을 기재한다.  | 2 | Reagent 2 | 단일구성 | 투명한 액상 시약 |\n| 6 | 사용목적 | 예 | □ | ※ 예시 : 사람의 전혈 또는 혈장에서 pro Brain-type natriuretic | 의학적 결정치(medical decision point)에서의 바이어스를 제시한다.  | triplicate) 측정하기를, 1일마다 2회(run) 이상, 최소 10일 동안 | 1) 투입구에 검체를 주입한 뒤, 혈구 세포는 디바이스에 내장 | 따라 상업적으로 유용한 진단검사와 본 제품을 이용한 검사를 |\n| 액티베이즈 | 에리스로마이신 | 옥시테트라사이클린 |\n| Siemens | Germany | □ 예(☞지침서) | ■ 아니오 |\n| 의료기기와 사용목적, 작용원리 등이 동등하지 아니한 체외진단용 의 | 3 | Reagent 3 | 단일구성 | 투명한 액상 시약 | 비교하였다.  총 300명(심장 질환 환자 200명, 비심장 질환 | 퍼센트 ≥100 pg/mL | 90.50% | 91.50% | 92.00% | 95.00% | 85.10% | I-STAT | CORPORATION | 07/21/2006 | 아니오 | □ |\n| 다) 검체에서 검출될 수 있는 최소 검출한계치를 제시한다.  검출 | 바) 총 run의 수(해당되는 경우 제시) | 3.  완제품의 품질관리 시험성적서 또는 시험에 관한 자료 | 64 | (20일 이상 권장) 시행하기를 권장한다. ",
        "original_sentence": "| triplicate) 측정하기를, 1일마다 2회(run) 이상, 최소 10일 동안 | 1) 투입구에 검체를 주입한 뒤, 혈구 세포는 디바이스에 내장 | 따라 상업적으로 유용한 진단검사와 본 제품을 이용한 검사를 |\n| 액티베이즈 | 에리스로마이신 | 옥시테트라사이클린 |\n| Siemens | Germany | □ 예(☞지침서) | ■ 아니오 |\n| 의료기기와 사용목적, 작용원리 등이 동등하지 아니한 체외진단용 의 | 3 | Reagent 3 | 단일구성 | 투명한 액상 시약 | 비교하였다. "
      }
    },
    {
      "chunk_id": "chunk_216",
      "text": "총 300명(심장 질환 환자 200명, 비심장 질환 | 퍼센트 ≥100 pg/mL | 90.50% | 91.50% | 92.00% | 95.00% | 85.10% | I-STAT | CORPORATION | 07/21/2006 | 아니오 | □ |\n| 다) 검체에서 검출될 수 있는 최소 검출한계치를 제시한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 215,
        "window_size": 3,
        "char_count": 174,
        "word_count": 41,
        "page_number": 6,
        "window_text": "|\n| ‘사용기간’ 항에 아래 표와 같이 저장방법과 사용기간을 기재한다.  | 2 | Reagent 2 | 단일구성 | 투명한 액상 시약 |\n| 6 | 사용목적 | 예 | □ | ※ 예시 : 사람의 전혈 또는 혈장에서 pro Brain-type natriuretic | 의학적 결정치(medical decision point)에서의 바이어스를 제시한다.  | triplicate) 측정하기를, 1일마다 2회(run) 이상, 최소 10일 동안 | 1) 투입구에 검체를 주입한 뒤, 혈구 세포는 디바이스에 내장 | 따라 상업적으로 유용한 진단검사와 본 제품을 이용한 검사를 |\n| 액티베이즈 | 에리스로마이신 | 옥시테트라사이클린 |\n| Siemens | Germany | □ 예(☞지침서) | ■ 아니오 |\n| 의료기기와 사용목적, 작용원리 등이 동등하지 아니한 체외진단용 의 | 3 | Reagent 3 | 단일구성 | 투명한 액상 시약 | 비교하였다.  총 300명(심장 질환 환자 200명, 비심장 질환 | 퍼센트 ≥100 pg/mL | 90.50% | 91.50% | 92.00% | 95.00% | 85.10% | I-STAT | CORPORATION | 07/21/2006 | 아니오 | □ |\n| 다) 검체에서 검출될 수 있는 최소 검출한계치를 제시한다.  검출 | 바) 총 run의 수(해당되는 경우 제시) | 3.  완제품의 품질관리 시험성적서 또는 시험에 관한 자료 | 64 | (20일 이상 권장) 시행하기를 권장한다.  | 물질만 포함된 검체의 실측한 자료를 바탕으로 배경한계와 검출 | 농도가 알려진 고농도의 임상검체를 이용한다. ",
        "original_sentence": "총 300명(심장 질환 환자 200명, 비심장 질환 | 퍼센트 ≥100 pg/mL | 90.50% | 91.50% | 92.00% | 95.00% | 85.10% | I-STAT | CORPORATION | 07/21/2006 | 아니오 | □ |\n| 다) 검체에서 검출될 수 있는 최소 검출한계치를 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_217",
      "text": "검출 | 바) 총 run의 수(해당되는 경우 제시) | 3. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 216,
        "window_size": 3,
        "char_count": 34,
        "word_count": 10,
        "page_number": 14,
        "window_text": "| 2 | Reagent 2 | 단일구성 | 투명한 액상 시약 |\n| 6 | 사용목적 | 예 | □ | ※ 예시 : 사람의 전혈 또는 혈장에서 pro Brain-type natriuretic | 의학적 결정치(medical decision point)에서의 바이어스를 제시한다.  | triplicate) 측정하기를, 1일마다 2회(run) 이상, 최소 10일 동안 | 1) 투입구에 검체를 주입한 뒤, 혈구 세포는 디바이스에 내장 | 따라 상업적으로 유용한 진단검사와 본 제품을 이용한 검사를 |\n| 액티베이즈 | 에리스로마이신 | 옥시테트라사이클린 |\n| Siemens | Germany | □ 예(☞지침서) | ■ 아니오 |\n| 의료기기와 사용목적, 작용원리 등이 동등하지 아니한 체외진단용 의 | 3 | Reagent 3 | 단일구성 | 투명한 액상 시약 | 비교하였다.  총 300명(심장 질환 환자 200명, 비심장 질환 | 퍼센트 ≥100 pg/mL | 90.50% | 91.50% | 92.00% | 95.00% | 85.10% | I-STAT | CORPORATION | 07/21/2006 | 아니오 | □ |\n| 다) 검체에서 검출될 수 있는 최소 검출한계치를 제시한다.  검출 | 바) 총 run의 수(해당되는 경우 제시) | 3.  완제품의 품질관리 시험성적서 또는 시험에 관한 자료 | 64 | (20일 이상 권장) 시행하기를 권장한다.  | 물질만 포함된 검체의 실측한 자료를 바탕으로 배경한계와 검출 | 농도가 알려진 고농도의 임상검체를 이용한다.  | Zero Control을 이용하여 측정하였을 때 다음의 | peptide(proBNP)를 면역형광측정법으로 정량하는 체외 | 의 세부기준이나 절차를 제시하는 것입니까? ",
        "original_sentence": "검출 | 바) 총 run의 수(해당되는 경우 제시) | 3. "
      }
    },
    {
      "chunk_id": "chunk_218",
      "text": "완제품의 품질관리 시험성적서 또는 시험에 관한 자료 | 64 | (20일 이상 권장) 시행하기를 권장한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 217,
        "window_size": 3,
        "char_count": 60,
        "word_count": 15,
        "page_number": 6,
        "window_text": "| triplicate) 측정하기를, 1일마다 2회(run) 이상, 최소 10일 동안 | 1) 투입구에 검체를 주입한 뒤, 혈구 세포는 디바이스에 내장 | 따라 상업적으로 유용한 진단검사와 본 제품을 이용한 검사를 |\n| 액티베이즈 | 에리스로마이신 | 옥시테트라사이클린 |\n| Siemens | Germany | □ 예(☞지침서) | ■ 아니오 |\n| 의료기기와 사용목적, 작용원리 등이 동등하지 아니한 체외진단용 의 | 3 | Reagent 3 | 단일구성 | 투명한 액상 시약 | 비교하였다.  총 300명(심장 질환 환자 200명, 비심장 질환 | 퍼센트 ≥100 pg/mL | 90.50% | 91.50% | 92.00% | 95.00% | 85.10% | I-STAT | CORPORATION | 07/21/2006 | 아니오 | □ |\n| 다) 검체에서 검출될 수 있는 최소 검출한계치를 제시한다.  검출 | 바) 총 run의 수(해당되는 경우 제시) | 3.  완제품의 품질관리 시험성적서 또는 시험에 관한 자료 | 64 | (20일 이상 권장) 시행하기를 권장한다.  | 물질만 포함된 검체의 실측한 자료를 바탕으로 배경한계와 검출 | 농도가 알려진 고농도의 임상검체를 이용한다.  | Zero Control을 이용하여 측정하였을 때 다음의 | peptide(proBNP)를 면역형광측정법으로 정량하는 체외 | 의 세부기준이나 절차를 제시하는 것입니까?  (공무원용) | Natriuretic Peptide (BNP) | 알로퓨리놀 | 푸로세미드 | 페노바르비탈 |\n| 7 | 작용원리 | 예 | □ | Institute; 2008 | 5. ",
        "original_sentence": "완제품의 품질관리 시험성적서 또는 시험에 관한 자료 | 64 | (20일 이상 권장) 시행하기를 권장한다. "
      }
    },
    {
      "chunk_id": "chunk_219",
      "text": "| 물질만 포함된 검체의 실측한 자료를 바탕으로 배경한계와 검출 | 농도가 알려진 고농도의 임상검체를 이용한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 218,
        "window_size": 3,
        "char_count": 63,
        "word_count": 15,
        "page_number": 32,
        "window_text": "총 300명(심장 질환 환자 200명, 비심장 질환 | 퍼센트 ≥100 pg/mL | 90.50% | 91.50% | 92.00% | 95.00% | 85.10% | I-STAT | CORPORATION | 07/21/2006 | 아니오 | □ |\n| 다) 검체에서 검출될 수 있는 최소 검출한계치를 제시한다.  검출 | 바) 총 run의 수(해당되는 경우 제시) | 3.  완제품의 품질관리 시험성적서 또는 시험에 관한 자료 | 64 | (20일 이상 권장) 시행하기를 권장한다.  | 물질만 포함된 검체의 실측한 자료를 바탕으로 배경한계와 검출 | 농도가 알려진 고농도의 임상검체를 이용한다.  | Zero Control을 이용하여 측정하였을 때 다음의 | peptide(proBNP)를 면역형광측정법으로 정량하는 체외 | 의 세부기준이나 절차를 제시하는 것입니까?  (공무원용) | Natriuretic Peptide (BNP) | 알로퓨리놀 | 푸로세미드 | 페노바르비탈 |\n| 7 | 작용원리 | 예 | □ | Institute; 2008 | 5.  사용목적(성능) | 24 | 검체의 종류가 두 가지 이상인 경우 검체의 종류별로 시험한다. ",
        "original_sentence": "| 물질만 포함된 검체의 실측한 자료를 바탕으로 배경한계와 검출 | 농도가 알려진 고농도의 임상검체를 이용한다. "
      }
    },
    {
      "chunk_id": "chunk_220",
      "text": "| Zero Control을 이용하여 측정하였을 때 다음의 | peptide(proBNP)를 면역형광측정법으로 정량하는 체외 | 의 세부기준이나 절차를 제시하는 것입니까? ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 219,
        "window_size": 3,
        "char_count": 96,
        "word_count": 18,
        "page_number": 14,
        "window_text": "검출 | 바) 총 run의 수(해당되는 경우 제시) | 3.  완제품의 품질관리 시험성적서 또는 시험에 관한 자료 | 64 | (20일 이상 권장) 시행하기를 권장한다.  | 물질만 포함된 검체의 실측한 자료를 바탕으로 배경한계와 검출 | 농도가 알려진 고농도의 임상검체를 이용한다.  | Zero Control을 이용하여 측정하였을 때 다음의 | peptide(proBNP)를 면역형광측정법으로 정량하는 체외 | 의 세부기준이나 절차를 제시하는 것입니까?  (공무원용) | Natriuretic Peptide (BNP) | 알로퓨리놀 | 푸로세미드 | 페노바르비탈 |\n| 7 | 작용원리 | 예 | □ | Institute; 2008 | 5.  사용목적(성능) | 24 | 검체의 종류가 두 가지 이상인 경우 검체의 종류별로 시험한다.  | 되어 있는 필터에서 혈장과 분리된다. ",
        "original_sentence": "| Zero Control을 이용하여 측정하였을 때 다음의 | peptide(proBNP)를 면역형광측정법으로 정량하는 체외 | 의 세부기준이나 절차를 제시하는 것입니까? "
      }
    },
    {
      "chunk_id": "chunk_221",
      "text": "(공무원용) | Natriuretic Peptide (BNP) | 알로퓨리놀 | 푸로세미드 | 페노바르비탈 |\n| 7 | 작용원리 | 예 | □ | Institute; 2008 | 5. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 220,
        "window_size": 3,
        "char_count": 104,
        "word_count": 25,
        "page_number": 14,
        "window_text": "완제품의 품질관리 시험성적서 또는 시험에 관한 자료 | 64 | (20일 이상 권장) 시행하기를 권장한다.  | 물질만 포함된 검체의 실측한 자료를 바탕으로 배경한계와 검출 | 농도가 알려진 고농도의 임상검체를 이용한다.  | Zero Control을 이용하여 측정하였을 때 다음의 | peptide(proBNP)를 면역형광측정법으로 정량하는 체외 | 의 세부기준이나 절차를 제시하는 것입니까?  (공무원용) | Natriuretic Peptide (BNP) | 알로퓨리놀 | 푸로세미드 | 페노바르비탈 |\n| 7 | 작용원리 | 예 | □ | Institute; 2008 | 5.  사용목적(성능) | 24 | 검체의 종류가 두 가지 이상인 경우 검체의 종류별로 시험한다.  | 되어 있는 필터에서 혈장과 분리된다.  | 최소 (pg/mL) | 0 | 0 | 0 | 0 | 0 | 메디안 (pg/mL) | 400 | 170 | 300 | 450 | 1400 |\n| 라. ",
        "original_sentence": "(공무원용) | Natriuretic Peptide (BNP) | 알로퓨리놀 | 푸로세미드 | 페노바르비탈 |\n| 7 | 작용원리 | 예 | □ | Institute; 2008 | 5. "
      }
    },
    {
      "chunk_id": "chunk_222",
      "text": "사용목적(성능) | 24 | 검체의 종류가 두 가지 이상인 경우 검체의 종류별로 시험한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 221,
        "window_size": 3,
        "char_count": 51,
        "word_count": 13,
        "page_number": 6,
        "window_text": "| 물질만 포함된 검체의 실측한 자료를 바탕으로 배경한계와 검출 | 농도가 알려진 고농도의 임상검체를 이용한다.  | Zero Control을 이용하여 측정하였을 때 다음의 | peptide(proBNP)를 면역형광측정법으로 정량하는 체외 | 의 세부기준이나 절차를 제시하는 것입니까?  (공무원용) | Natriuretic Peptide (BNP) | 알로퓨리놀 | 푸로세미드 | 페노바르비탈 |\n| 7 | 작용원리 | 예 | □ | Institute; 2008 | 5.  사용목적(성능) | 24 | 검체의 종류가 두 가지 이상인 경우 검체의 종류별로 시험한다.  | 되어 있는 필터에서 혈장과 분리된다.  | 최소 (pg/mL) | 0 | 0 | 0 | 0 | 0 | 메디안 (pg/mL) | 400 | 170 | 300 | 450 | 1400 |\n| 라.  분량 | 바. ",
        "original_sentence": "사용목적(성능) | 24 | 검체의 종류가 두 가지 이상인 경우 검체의 종류별로 시험한다. "
      }
    },
    {
      "chunk_id": "chunk_223",
      "text": "| 되어 있는 필터에서 혈장과 분리된다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 222,
        "window_size": 3,
        "char_count": 23,
        "word_count": 6,
        "page_number": 25,
        "window_text": "| Zero Control을 이용하여 측정하였을 때 다음의 | peptide(proBNP)를 면역형광측정법으로 정량하는 체외 | 의 세부기준이나 절차를 제시하는 것입니까?  (공무원용) | Natriuretic Peptide (BNP) | 알로퓨리놀 | 푸로세미드 | 페노바르비탈 |\n| 7 | 작용원리 | 예 | □ | Institute; 2008 | 5.  사용목적(성능) | 24 | 검체의 종류가 두 가지 이상인 경우 검체의 종류별로 시험한다.  | 되어 있는 필터에서 혈장과 분리된다.  | 최소 (pg/mL) | 0 | 0 | 0 | 0 | 0 | 메디안 (pg/mL) | 400 | 170 | 300 | 450 | 1400 |\n| 라.  분량 | 바.  검체 보관 및 취급상(온도, 습도 등)의 조건 설정 근거 자료 | 10. ",
        "original_sentence": "| 되어 있는 필터에서 혈장과 분리된다. "
      }
    },
    {
      "chunk_id": "chunk_224",
      "text": "| 최소 (pg/mL) | 0 | 0 | 0 | 0 | 0 | 메디안 (pg/mL) | 400 | 170 | 300 | 450 | 1400 |\n| 라. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 223,
        "window_size": 3,
        "char_count": 85,
        "word_count": 29,
        "page_number": 6,
        "window_text": "(공무원용) | Natriuretic Peptide (BNP) | 알로퓨리놀 | 푸로세미드 | 페노바르비탈 |\n| 7 | 작용원리 | 예 | □ | Institute; 2008 | 5.  사용목적(성능) | 24 | 검체의 종류가 두 가지 이상인 경우 검체의 종류별로 시험한다.  | 되어 있는 필터에서 혈장과 분리된다.  | 최소 (pg/mL) | 0 | 0 | 0 | 0 | 0 | 메디안 (pg/mL) | 400 | 170 | 300 | 450 | 1400 |\n| 라.  분량 | 바.  검체 보관 및 취급상(온도, 습도 등)의 조건 설정 근거 자료 | 10.  시험 환경요인(시험결과에 영향을 주는 경우에 한함) | of agreement) | 또는 시험에 관한 자료를 제출하여 제품의 균일성을 제시한다. ",
        "original_sentence": "| 최소 (pg/mL) | 0 | 0 | 0 | 0 | 0 | 메디안 (pg/mL) | 400 | 170 | 300 | 450 | 1400 |\n| 라. "
      }
    },
    {
      "chunk_id": "chunk_225",
      "text": "분량 | 바. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 224,
        "window_size": 3,
        "char_count": 8,
        "word_count": 3,
        "page_number": 28,
        "window_text": "사용목적(성능) | 24 | 검체의 종류가 두 가지 이상인 경우 검체의 종류별로 시험한다.  | 되어 있는 필터에서 혈장과 분리된다.  | 최소 (pg/mL) | 0 | 0 | 0 | 0 | 0 | 메디안 (pg/mL) | 400 | 170 | 300 | 450 | 1400 |\n| 라.  분량 | 바.  검체 보관 및 취급상(온도, 습도 등)의 조건 설정 근거 자료 | 10.  시험 환경요인(시험결과에 영향을 주는 경우에 한함) | of agreement) | 또는 시험에 관한 자료를 제출하여 제품의 균일성을 제시한다.  | 1) 적용되는 체외진단분석기의 제조사 및 모델명을 기재한다. ",
        "original_sentence": "분량 | 바. "
      }
    },
    {
      "chunk_id": "chunk_226",
      "text": "검체 보관 및 취급상(온도, 습도 등)의 조건 설정 근거 자료 | 10. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 225,
        "window_size": 3,
        "char_count": 41,
        "word_count": 12,
        "page_number": 21,
        "window_text": "| 되어 있는 필터에서 혈장과 분리된다.  | 최소 (pg/mL) | 0 | 0 | 0 | 0 | 0 | 메디안 (pg/mL) | 400 | 170 | 300 | 450 | 1400 |\n| 라.  분량 | 바.  검체 보관 및 취급상(온도, 습도 등)의 조건 설정 근거 자료 | 10.  시험 환경요인(시험결과에 영향을 주는 경우에 한함) | of agreement) | 또는 시험에 관한 자료를 제출하여 제품의 균일성을 제시한다.  | 1) 적용되는 체외진단분석기의 제조사 및 모델명을 기재한다.  | 상관성의 추가 자료로 제시할 수 있다. ",
        "original_sentence": "검체 보관 및 취급상(온도, 습도 등)의 조건 설정 근거 자료 | 10. "
      }
    },
    {
      "chunk_id": "chunk_227",
      "text": "시험 환경요인(시험결과에 영향을 주는 경우에 한함) | of agreement) | 또는 시험에 관한 자료를 제출하여 제품의 균일성을 제시한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 226,
        "window_size": 3,
        "char_count": 81,
        "word_count": 18,
        "page_number": 14,
        "window_text": "| 최소 (pg/mL) | 0 | 0 | 0 | 0 | 0 | 메디안 (pg/mL) | 400 | 170 | 300 | 450 | 1400 |\n| 라.  분량 | 바.  검체 보관 및 취급상(온도, 습도 등)의 조건 설정 근거 자료 | 10.  시험 환경요인(시험결과에 영향을 주는 경우에 한함) | of agreement) | 또는 시험에 관한 자료를 제출하여 제품의 균일성을 제시한다.  | 1) 적용되는 체외진단분석기의 제조사 및 모델명을 기재한다.  | 상관성의 추가 자료로 제시할 수 있다.  | 정보를 제공한다. ",
        "original_sentence": "시험 환경요인(시험결과에 영향을 주는 경우에 한함) | of agreement) | 또는 시험에 관한 자료를 제출하여 제품의 균일성을 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_228",
      "text": "| 1) 적용되는 체외진단분석기의 제조사 및 모델명을 기재한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 227,
        "window_size": 3,
        "char_count": 36,
        "word_count": 8,
        "page_number": 21,
        "window_text": "분량 | 바.  검체 보관 및 취급상(온도, 습도 등)의 조건 설정 근거 자료 | 10.  시험 환경요인(시험결과에 영향을 주는 경우에 한함) | of agreement) | 또는 시험에 관한 자료를 제출하여 제품의 균일성을 제시한다.  | 1) 적용되는 체외진단분석기의 제조사 및 모델명을 기재한다.  | 상관성의 추가 자료로 제시할 수 있다.  | 정보를 제공한다.  | 상호와 주소)을 확인할 수 있는 자료도 포함한다. ",
        "original_sentence": "| 1) 적용되는 체외진단분석기의 제조사 및 모델명을 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_229",
      "text": "| 상관성의 추가 자료로 제시할 수 있다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 228,
        "window_size": 3,
        "char_count": 24,
        "word_count": 7,
        "page_number": 11,
        "window_text": "검체 보관 및 취급상(온도, 습도 등)의 조건 설정 근거 자료 | 10.  시험 환경요인(시험결과에 영향을 주는 경우에 한함) | of agreement) | 또는 시험에 관한 자료를 제출하여 제품의 균일성을 제시한다.  | 1) 적용되는 체외진단분석기의 제조사 및 모델명을 기재한다.  | 상관성의 추가 자료로 제시할 수 있다.  | 정보를 제공한다.  | 상호와 주소)을 확인할 수 있는 자료도 포함한다.  | 및 특이도 | 받는 경우에는 그 조건을 명시하여야 한다. ",
        "original_sentence": "| 상관성의 추가 자료로 제시할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_230",
      "text": "| 정보를 제공한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 229,
        "window_size": 3,
        "char_count": 12,
        "word_count": 3,
        "page_number": 40,
        "window_text": "시험 환경요인(시험결과에 영향을 주는 경우에 한함) | of agreement) | 또는 시험에 관한 자료를 제출하여 제품의 균일성을 제시한다.  | 1) 적용되는 체외진단분석기의 제조사 및 모델명을 기재한다.  | 상관성의 추가 자료로 제시할 수 있다.  | 정보를 제공한다.  | 상호와 주소)을 확인할 수 있는 자료도 포함한다.  | 및 특이도 | 받는 경우에는 그 조건을 명시하여야 한다.  | 분석적 | 환자 100명)의 혈장 검체를 두 검사로 시험하였다. ",
        "original_sentence": "| 정보를 제공한다. "
      }
    },
    {
      "chunk_id": "chunk_231",
      "text": "| 상호와 주소)을 확인할 수 있는 자료도 포함한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 230,
        "window_size": 3,
        "char_count": 30,
        "word_count": 8,
        "page_number": 19,
        "window_text": "| 1) 적용되는 체외진단분석기의 제조사 및 모델명을 기재한다.  | 상관성의 추가 자료로 제시할 수 있다.  | 정보를 제공한다.  | 상호와 주소)을 확인할 수 있는 자료도 포함한다.  | 및 특이도 | 받는 경우에는 그 조건을 명시하여야 한다.  | 분석적 | 환자 100명)의 혈장 검체를 두 검사로 시험하였다.  이들 |\n| □ 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 설 | VITROS IMMUNODIAGNOSTIC | PRODUCTS NT PRO-BNP | REAGENT | PACK,CALIBRATORS,RANGE | VERIFIERS | 기준을 만족해야 한다. ",
        "original_sentence": "| 상호와 주소)을 확인할 수 있는 자료도 포함한다. "
      }
    },
    {
      "chunk_id": "chunk_232",
      "text": "| 및 특이도 | 받는 경우에는 그 조건을 명시하여야 한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 231,
        "window_size": 3,
        "char_count": 34,
        "word_count": 10,
        "page_number": 31,
        "window_text": "| 상관성의 추가 자료로 제시할 수 있다.  | 정보를 제공한다.  | 상호와 주소)을 확인할 수 있는 자료도 포함한다.  | 및 특이도 | 받는 경우에는 그 조건을 명시하여야 한다.  | 분석적 | 환자 100명)의 혈장 검체를 두 검사로 시험하였다.  이들 |\n| □ 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 설 | VITROS IMMUNODIAGNOSTIC | PRODUCTS NT PRO-BNP | REAGENT | PACK,CALIBRATORS,RANGE | VERIFIERS | 기준을 만족해야 한다.  | ARCHITECT BNP | Abbott | USA | 최대 (pg/mL) | 910 | 260 | 140 | 400 | 900 | 평균 (pg/mL) | 670 | 340 | 450 | 750 | 1630 | 유로딜라틴(CCD/ANP) 95-126 | 1,000pg/mL | 100% | WI-6612 |\n| 구분 | 료기기의 시험에 한함) | 이상의 특성값이 절차에 따라 공인되며, 그 절차는 특성값이 표현 | 또는 이에 준하는 것으로 인정되는 시험자료 | 4. ",
        "original_sentence": "| 및 특이도 | 받는 경우에는 그 조건을 명시하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_233",
      "text": "| 분석적 | 환자 100명)의 혈장 검체를 두 검사로 시험하였다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 232,
        "window_size": 3,
        "char_count": 38,
        "word_count": 10,
        "page_number": 21,
        "window_text": "| 정보를 제공한다.  | 상호와 주소)을 확인할 수 있는 자료도 포함한다.  | 및 특이도 | 받는 경우에는 그 조건을 명시하여야 한다.  | 분석적 | 환자 100명)의 혈장 검체를 두 검사로 시험하였다.  이들 |\n| □ 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 설 | VITROS IMMUNODIAGNOSTIC | PRODUCTS NT PRO-BNP | REAGENT | PACK,CALIBRATORS,RANGE | VERIFIERS | 기준을 만족해야 한다.  | ARCHITECT BNP | Abbott | USA | 최대 (pg/mL) | 910 | 260 | 140 | 400 | 900 | 평균 (pg/mL) | 670 | 340 | 450 | 750 | 1630 | 유로딜라틴(CCD/ANP) 95-126 | 1,000pg/mL | 100% | WI-6612 |\n| 구분 | 료기기의 시험에 한함) | 이상의 특성값이 절차에 따라 공인되며, 그 절차는 특성값이 표현 | 또는 이에 준하는 것으로 인정되는 시험자료 | 4.  완제품 품질관리 시험에 사용된 표준물질에 관한 자료 | 65 | 수 있으므로 임상적 민감도, 임상적 특이도와 함께 유병률, 양성 | 아미오다론 | 엡티피바티드 | 페니토인 | ORTHO-CLINIC | AL | DIAGNOSTICS, | INC | 아니오 | □ | ■ 예(☞안내서) | □ 아니오 |\n| 사. ",
        "original_sentence": "| 분석적 | 환자 100명)의 혈장 검체를 두 검사로 시험하였다. "
      }
    },
    {
      "chunk_id": "chunk_234",
      "text": "이들 |\n| □ 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 설 | VITROS IMMUNODIAGNOSTIC | PRODUCTS NT PRO-BNP | REAGENT | PACK,CALIBRATORS,RANGE | VERIFIERS | 기준을 만족해야 한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 233,
        "window_size": 3,
        "char_count": 156,
        "word_count": 30,
        "page_number": 3,
        "window_text": "| 상호와 주소)을 확인할 수 있는 자료도 포함한다.  | 및 특이도 | 받는 경우에는 그 조건을 명시하여야 한다.  | 분석적 | 환자 100명)의 혈장 검체를 두 검사로 시험하였다.  이들 |\n| □ 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 설 | VITROS IMMUNODIAGNOSTIC | PRODUCTS NT PRO-BNP | REAGENT | PACK,CALIBRATORS,RANGE | VERIFIERS | 기준을 만족해야 한다.  | ARCHITECT BNP | Abbott | USA | 최대 (pg/mL) | 910 | 260 | 140 | 400 | 900 | 평균 (pg/mL) | 670 | 340 | 450 | 750 | 1630 | 유로딜라틴(CCD/ANP) 95-126 | 1,000pg/mL | 100% | WI-6612 |\n| 구분 | 료기기의 시험에 한함) | 이상의 특성값이 절차에 따라 공인되며, 그 절차는 특성값이 표현 | 또는 이에 준하는 것으로 인정되는 시험자료 | 4.  완제품 품질관리 시험에 사용된 표준물질에 관한 자료 | 65 | 수 있으므로 임상적 민감도, 임상적 특이도와 함께 유병률, 양성 | 아미오다론 | 엡티피바티드 | 페니토인 | ORTHO-CLINIC | AL | DIAGNOSTICS, | INC | 아니오 | □ | ■ 예(☞안내서) | □ 아니오 |\n| 사.  국내·외 허가제품과의 상관성 시험에 대한 시험성적서 | 가. ",
        "original_sentence": "이들 |\n| □ 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 설 | VITROS IMMUNODIAGNOSTIC | PRODUCTS NT PRO-BNP | REAGENT | PACK,CALIBRATORS,RANGE | VERIFIERS | 기준을 만족해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_235",
      "text": "| ARCHITECT BNP | Abbott | USA | 최대 (pg/mL) | 910 | 260 | 140 | 400 | 900 | 평균 (pg/mL) | 670 | 340 | 450 | 750 | 1630 | 유로딜라틴(CCD/ANP) 95-126 | 1,000pg/mL | 100% | WI-6612 |\n| 구분 | 료기기의 시험에 한함) | 이상의 특성값이 절차에 따라 공인되며, 그 절차는 특성값이 표현 | 또는 이에 준하는 것으로 인정되는 시험자료 | 4. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 234,
        "window_size": 3,
        "char_count": 263,
        "word_count": 68,
        "page_number": 14,
        "window_text": "| 및 특이도 | 받는 경우에는 그 조건을 명시하여야 한다.  | 분석적 | 환자 100명)의 혈장 검체를 두 검사로 시험하였다.  이들 |\n| □ 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 설 | VITROS IMMUNODIAGNOSTIC | PRODUCTS NT PRO-BNP | REAGENT | PACK,CALIBRATORS,RANGE | VERIFIERS | 기준을 만족해야 한다.  | ARCHITECT BNP | Abbott | USA | 최대 (pg/mL) | 910 | 260 | 140 | 400 | 900 | 평균 (pg/mL) | 670 | 340 | 450 | 750 | 1630 | 유로딜라틴(CCD/ANP) 95-126 | 1,000pg/mL | 100% | WI-6612 |\n| 구분 | 료기기의 시험에 한함) | 이상의 특성값이 절차에 따라 공인되며, 그 절차는 특성값이 표현 | 또는 이에 준하는 것으로 인정되는 시험자료 | 4.  완제품 품질관리 시험에 사용된 표준물질에 관한 자료 | 65 | 수 있으므로 임상적 민감도, 임상적 특이도와 함께 유병률, 양성 | 아미오다론 | 엡티피바티드 | 페니토인 | ORTHO-CLINIC | AL | DIAGNOSTICS, | INC | 아니오 | □ | ■ 예(☞안내서) | □ 아니오 |\n| 사.  국내·외 허가제품과의 상관성 시험에 대한 시험성적서 | 가.  최소검출한계(Limit of detection, LoD) | 나. ",
        "original_sentence": "| ARCHITECT BNP | Abbott | USA | 최대 (pg/mL) | 910 | 260 | 140 | 400 | 900 | 평균 (pg/mL) | 670 | 340 | 450 | 750 | 1630 | 유로딜라틴(CCD/ANP) 95-126 | 1,000pg/mL | 100% | WI-6612 |\n| 구분 | 료기기의 시험에 한함) | 이상의 특성값이 절차에 따라 공인되며, 그 절차는 특성값이 표현 | 또는 이에 준하는 것으로 인정되는 시험자료 | 4. "
      }
    },
    {
      "chunk_id": "chunk_236",
      "text": "완제품 품질관리 시험에 사용된 표준물질에 관한 자료 | 65 | 수 있으므로 임상적 민감도, 임상적 특이도와 함께 유병률, 양성 | 아미오다론 | 엡티피바티드 | 페니토인 | ORTHO-CLINIC | AL | DIAGNOSTICS, | INC | 아니오 | □ | ■ 예(☞안내서) | □ 아니오 |\n| 사. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 235,
        "window_size": 3,
        "char_count": 174,
        "word_count": 46,
        "page_number": 7,
        "window_text": "| 분석적 | 환자 100명)의 혈장 검체를 두 검사로 시험하였다.  이들 |\n| □ 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 설 | VITROS IMMUNODIAGNOSTIC | PRODUCTS NT PRO-BNP | REAGENT | PACK,CALIBRATORS,RANGE | VERIFIERS | 기준을 만족해야 한다.  | ARCHITECT BNP | Abbott | USA | 최대 (pg/mL) | 910 | 260 | 140 | 400 | 900 | 평균 (pg/mL) | 670 | 340 | 450 | 750 | 1630 | 유로딜라틴(CCD/ANP) 95-126 | 1,000pg/mL | 100% | WI-6612 |\n| 구분 | 료기기의 시험에 한함) | 이상의 특성값이 절차에 따라 공인되며, 그 절차는 특성값이 표현 | 또는 이에 준하는 것으로 인정되는 시험자료 | 4.  완제품 품질관리 시험에 사용된 표준물질에 관한 자료 | 65 | 수 있으므로 임상적 민감도, 임상적 특이도와 함께 유병률, 양성 | 아미오다론 | 엡티피바티드 | 페니토인 | ORTHO-CLINIC | AL | DIAGNOSTICS, | INC | 아니오 | □ | ■ 예(☞안내서) | □ 아니오 |\n| 사.  국내·외 허가제품과의 상관성 시험에 대한 시험성적서 | 가.  최소검출한계(Limit of detection, LoD) | 나.  시험방법 | 2 | 2) 간섭물질은 내부 또는 외부 요인일 수 있고 측정법에 따라 다양 | 대해서는 비교검사와의 일치도(신뢰구간과 함께)를 제시한다. ",
        "original_sentence": "완제품 품질관리 시험에 사용된 표준물질에 관한 자료 | 65 | 수 있으므로 임상적 민감도, 임상적 특이도와 함께 유병률, 양성 | 아미오다론 | 엡티피바티드 | 페니토인 | ORTHO-CLINIC | AL | DIAGNOSTICS, | INC | 아니오 | □ | ■ 예(☞안내서) | □ 아니오 |\n| 사. "
      }
    },
    {
      "chunk_id": "chunk_237",
      "text": "국내·외 허가제품과의 상관성 시험에 대한 시험성적서 | 가. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 236,
        "window_size": 3,
        "char_count": 34,
        "word_count": 8,
        "page_number": 33,
        "window_text": "이들 |\n| □ 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 설 | VITROS IMMUNODIAGNOSTIC | PRODUCTS NT PRO-BNP | REAGENT | PACK,CALIBRATORS,RANGE | VERIFIERS | 기준을 만족해야 한다.  | ARCHITECT BNP | Abbott | USA | 최대 (pg/mL) | 910 | 260 | 140 | 400 | 900 | 평균 (pg/mL) | 670 | 340 | 450 | 750 | 1630 | 유로딜라틴(CCD/ANP) 95-126 | 1,000pg/mL | 100% | WI-6612 |\n| 구분 | 료기기의 시험에 한함) | 이상의 특성값이 절차에 따라 공인되며, 그 절차는 특성값이 표현 | 또는 이에 준하는 것으로 인정되는 시험자료 | 4.  완제품 품질관리 시험에 사용된 표준물질에 관한 자료 | 65 | 수 있으므로 임상적 민감도, 임상적 특이도와 함께 유병률, 양성 | 아미오다론 | 엡티피바티드 | 페니토인 | ORTHO-CLINIC | AL | DIAGNOSTICS, | INC | 아니오 | □ | ■ 예(☞안내서) | □ 아니오 |\n| 사.  국내·외 허가제품과의 상관성 시험에 대한 시험성적서 | 가.  최소검출한계(Limit of detection, LoD) | 나.  시험방법 | 2 | 2) 간섭물질은 내부 또는 외부 요인일 수 있고 측정법에 따라 다양 | 대해서는 비교검사와의 일치도(신뢰구간과 함께)를 제시한다.  | 기술한다. ",
        "original_sentence": "국내·외 허가제품과의 상관성 시험에 대한 시험성적서 | 가. "
      }
    },
    {
      "chunk_id": "chunk_238",
      "text": "최소검출한계(Limit of detection, LoD) | 나. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 237,
        "window_size": 3,
        "char_count": 37,
        "word_count": 6,
        "page_number": 14,
        "window_text": "| ARCHITECT BNP | Abbott | USA | 최대 (pg/mL) | 910 | 260 | 140 | 400 | 900 | 평균 (pg/mL) | 670 | 340 | 450 | 750 | 1630 | 유로딜라틴(CCD/ANP) 95-126 | 1,000pg/mL | 100% | WI-6612 |\n| 구분 | 료기기의 시험에 한함) | 이상의 특성값이 절차에 따라 공인되며, 그 절차는 특성값이 표현 | 또는 이에 준하는 것으로 인정되는 시험자료 | 4.  완제품 품질관리 시험에 사용된 표준물질에 관한 자료 | 65 | 수 있으므로 임상적 민감도, 임상적 특이도와 함께 유병률, 양성 | 아미오다론 | 엡티피바티드 | 페니토인 | ORTHO-CLINIC | AL | DIAGNOSTICS, | INC | 아니오 | □ | ■ 예(☞안내서) | □ 아니오 |\n| 사.  국내·외 허가제품과의 상관성 시험에 대한 시험성적서 | 가.  최소검출한계(Limit of detection, LoD) | 나.  시험방법 | 2 | 2) 간섭물질은 내부 또는 외부 요인일 수 있고 측정법에 따라 다양 | 대해서는 비교검사와의 일치도(신뢰구간과 함께)를 제시한다.  | 기술한다.  | 사) 총 관찰치의 수 : optional | 6. ",
        "original_sentence": "최소검출한계(Limit of detection, LoD) | 나. "
      }
    },
    {
      "chunk_id": "chunk_239",
      "text": "시험방법 | 2 | 2) 간섭물질은 내부 또는 외부 요인일 수 있고 측정법에 따라 다양 | 대해서는 비교검사와의 일치도(신뢰구간과 함께)를 제시한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 238,
        "window_size": 3,
        "char_count": 84,
        "word_count": 21,
        "page_number": 6,
        "window_text": "완제품 품질관리 시험에 사용된 표준물질에 관한 자료 | 65 | 수 있으므로 임상적 민감도, 임상적 특이도와 함께 유병률, 양성 | 아미오다론 | 엡티피바티드 | 페니토인 | ORTHO-CLINIC | AL | DIAGNOSTICS, | INC | 아니오 | □ | ■ 예(☞안내서) | □ 아니오 |\n| 사.  국내·외 허가제품과의 상관성 시험에 대한 시험성적서 | 가.  최소검출한계(Limit of detection, LoD) | 나.  시험방법 | 2 | 2) 간섭물질은 내부 또는 외부 요인일 수 있고 측정법에 따라 다양 | 대해서는 비교검사와의 일치도(신뢰구간과 함께)를 제시한다.  | 기술한다.  | 사) 총 관찰치의 수 : optional | 6.  사용방법 | 32 | 한계를 넘지 않는 결과를 보인 최대 간섭물질 농도를 기재한다. ",
        "original_sentence": "시험방법 | 2 | 2) 간섭물질은 내부 또는 외부 요인일 수 있고 측정법에 따라 다양 | 대해서는 비교검사와의 일치도(신뢰구간과 함께)를 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_240",
      "text": "| 기술한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 239,
        "window_size": 3,
        "char_count": 8,
        "word_count": 2,
        "page_number": 39,
        "window_text": "국내·외 허가제품과의 상관성 시험에 대한 시험성적서 | 가.  최소검출한계(Limit of detection, LoD) | 나.  시험방법 | 2 | 2) 간섭물질은 내부 또는 외부 요인일 수 있고 측정법에 따라 다양 | 대해서는 비교검사와의 일치도(신뢰구간과 함께)를 제시한다.  | 기술한다.  | 사) 총 관찰치의 수 : optional | 6.  사용방법 | 32 | 한계를 넘지 않는 결과를 보인 최대 간섭물질 농도를 기재한다.  | 특이도 | 2) 일정량의 혈장이 반응부분 내에서 형광 접합된 polyclonal | 민감도 참고). ",
        "original_sentence": "| 기술한다. "
      }
    },
    {
      "chunk_id": "chunk_241",
      "text": "| 사) 총 관찰치의 수 : optional | 6. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 240,
        "window_size": 3,
        "char_count": 30,
        "word_count": 9,
        "page_number": 14,
        "window_text": "최소검출한계(Limit of detection, LoD) | 나.  시험방법 | 2 | 2) 간섭물질은 내부 또는 외부 요인일 수 있고 측정법에 따라 다양 | 대해서는 비교검사와의 일치도(신뢰구간과 함께)를 제시한다.  | 기술한다.  | 사) 총 관찰치의 수 : optional | 6.  사용방법 | 32 | 한계를 넘지 않는 결과를 보인 최대 간섭물질 농도를 기재한다.  | 특이도 | 2) 일정량의 혈장이 반응부분 내에서 형광 접합된 polyclonal | 민감도 참고).  | 진단용 의료기기이다. ",
        "original_sentence": "| 사) 총 관찰치의 수 : optional | 6. "
      }
    },
    {
      "chunk_id": "chunk_242",
      "text": "사용방법 | 32 | 한계를 넘지 않는 결과를 보인 최대 간섭물질 농도를 기재한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 241,
        "window_size": 3,
        "char_count": 47,
        "word_count": 13,
        "page_number": 6,
        "window_text": "시험방법 | 2 | 2) 간섭물질은 내부 또는 외부 요인일 수 있고 측정법에 따라 다양 | 대해서는 비교검사와의 일치도(신뢰구간과 함께)를 제시한다.  | 기술한다.  | 사) 총 관찰치의 수 : optional | 6.  사용방법 | 32 | 한계를 넘지 않는 결과를 보인 최대 간섭물질 농도를 기재한다.  | 특이도 | 2) 일정량의 혈장이 반응부분 내에서 형광 접합된 polyclonal | 민감도 참고).  | 진단용 의료기기이다.  | 명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 | 것입니까? ",
        "original_sentence": "사용방법 | 32 | 한계를 넘지 않는 결과를 보인 최대 간섭물질 농도를 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_243",
      "text": "| 특이도 | 2) 일정량의 혈장이 반응부분 내에서 형광 접합된 polyclonal | 민감도 참고). ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 242,
        "window_size": 3,
        "char_count": 58,
        "word_count": 14,
        "page_number": 6,
        "window_text": "| 기술한다.  | 사) 총 관찰치의 수 : optional | 6.  사용방법 | 32 | 한계를 넘지 않는 결과를 보인 최대 간섭물질 농도를 기재한다.  | 특이도 | 2) 일정량의 혈장이 반응부분 내에서 형광 접합된 polyclonal | 민감도 참고).  | 진단용 의료기기이다.  | 명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 | 것입니까?  (민원인용) | 검체는 심장 질환 환자와 비심장 질환자로부터 채취하였다. ",
        "original_sentence": "| 특이도 | 2) 일정량의 혈장이 반응부분 내에서 형광 접합된 polyclonal | 민감도 참고). "
      }
    },
    {
      "chunk_id": "chunk_244",
      "text": "| 진단용 의료기기이다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 243,
        "window_size": 3,
        "char_count": 14,
        "word_count": 3,
        "page_number": 30,
        "window_text": "| 사) 총 관찰치의 수 : optional | 6.  사용방법 | 32 | 한계를 넘지 않는 결과를 보인 최대 간섭물질 농도를 기재한다.  | 특이도 | 2) 일정량의 혈장이 반응부분 내에서 형광 접합된 polyclonal | 민감도 참고).  | 진단용 의료기기이다.  | 명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 | 것입니까?  (민원인용) | 검체는 심장 질환 환자와 비심장 질환자로부터 채취하였다.  | 분량 |\n| 자. ",
        "original_sentence": "| 진단용 의료기기이다. "
      }
    },
    {
      "chunk_id": "chunk_245",
      "text": "| 명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 | 것입니까? ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 244,
        "window_size": 3,
        "char_count": 46,
        "word_count": 10,
        "page_number": 3,
        "window_text": "사용방법 | 32 | 한계를 넘지 않는 결과를 보인 최대 간섭물질 농도를 기재한다.  | 특이도 | 2) 일정량의 혈장이 반응부분 내에서 형광 접합된 polyclonal | 민감도 참고).  | 진단용 의료기기이다.  | 명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 | 것입니까?  (민원인용) | 검체는 심장 질환 환자와 비심장 질환자로부터 채취하였다.  | 분량 |\n| 자.  일회용의 경우 재사용하지 않도록 주의사항을 기재한다. ",
        "original_sentence": "| 명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 | 것입니까? "
      }
    },
    {
      "chunk_id": "chunk_246",
      "text": "(민원인용) | 검체는 심장 질환 환자와 비심장 질환자로부터 채취하였다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 245,
        "window_size": 3,
        "char_count": 41,
        "word_count": 9,
        "page_number": 33,
        "window_text": "| 특이도 | 2) 일정량의 혈장이 반응부분 내에서 형광 접합된 polyclonal | 민감도 참고).  | 진단용 의료기기이다.  | 명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 | 것입니까?  (민원인용) | 검체는 심장 질환 환자와 비심장 질환자로부터 채취하였다.  | 분량 |\n| 자.  일회용의 경우 재사용하지 않도록 주의사항을 기재한다.  | 다. ",
        "original_sentence": "(민원인용) | 검체는 심장 질환 환자와 비심장 질환자로부터 채취하였다. "
      }
    },
    {
      "chunk_id": "chunk_247",
      "text": "| 분량 |\n| 자. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 246,
        "window_size": 3,
        "char_count": 12,
        "word_count": 5,
        "page_number": 28,
        "window_text": "| 진단용 의료기기이다.  | 명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 | 것입니까?  (민원인용) | 검체는 심장 질환 환자와 비심장 질환자로부터 채취하였다.  | 분량 |\n| 자.  일회용의 경우 재사용하지 않도록 주의사항을 기재한다.  | 다.  시험방법 | 인정범위내의 자료이어야 한다. ",
        "original_sentence": "| 분량 |\n| 자. "
      }
    },
    {
      "chunk_id": "chunk_248",
      "text": "일회용의 경우 재사용하지 않도록 주의사항을 기재한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 247,
        "window_size": 3,
        "char_count": 30,
        "word_count": 6,
        "page_number": 3,
        "window_text": "| 명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 | 것입니까?  (민원인용) | 검체는 심장 질환 환자와 비심장 질환자로부터 채취하였다.  | 분량 |\n| 자.  일회용의 경우 재사용하지 않도록 주의사항을 기재한다.  | 다.  시험방법 | 인정범위내의 자료이어야 한다.  | 2) 검사 키트의 사용조건(온도 또는 습도 등)을 기재한다. ",
        "original_sentence": "일회용의 경우 재사용하지 않도록 주의사항을 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_249",
      "text": "| 다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 248,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 1,
        "window_text": "(민원인용) | 검체는 심장 질환 환자와 비심장 질환자로부터 채취하였다.  | 분량 |\n| 자.  일회용의 경우 재사용하지 않도록 주의사항을 기재한다.  | 다.  시험방법 | 인정범위내의 자료이어야 한다.  | 2) 검사 키트의 사용조건(온도 또는 습도 등)을 기재한다.  | 권장한다. ",
        "original_sentence": "| 다. "
      }
    },
    {
      "chunk_id": "chunk_250",
      "text": "시험방법 | 인정범위내의 자료이어야 한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 249,
        "window_size": 3,
        "char_count": 24,
        "word_count": 5,
        "page_number": 33,
        "window_text": "| 분량 |\n| 자.  일회용의 경우 재사용하지 않도록 주의사항을 기재한다.  | 다.  시험방법 | 인정범위내의 자료이어야 한다.  | 2) 검사 키트의 사용조건(온도 또는 습도 등)을 기재한다.  | 권장한다.  | 1. ",
        "original_sentence": "시험방법 | 인정범위내의 자료이어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_251",
      "text": "| 2) 검사 키트의 사용조건(온도 또는 습도 등)을 기재한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 250,
        "window_size": 3,
        "char_count": 36,
        "word_count": 9,
        "page_number": 6,
        "window_text": "일회용의 경우 재사용하지 않도록 주의사항을 기재한다.  | 다.  시험방법 | 인정범위내의 자료이어야 한다.  | 2) 검사 키트의 사용조건(온도 또는 습도 등)을 기재한다.  | 권장한다.  | 1.  항목별 시험기준 | AIA BNP | Tosoh | Japan | SD (pg/mL) | 850 | 380 | 620 | 870 | 1100 | ㎍/L | 규격 | 비고 | 절차서에 |\n| 그러하지 아니하다. ",
        "original_sentence": "| 2) 검사 키트의 사용조건(온도 또는 습도 등)을 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_252",
      "text": "| 권장한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 251,
        "window_size": 3,
        "char_count": 8,
        "word_count": 2,
        "page_number": 56,
        "window_text": "| 다.  시험방법 | 인정범위내의 자료이어야 한다.  | 2) 검사 키트의 사용조건(온도 또는 습도 등)을 기재한다.  | 권장한다.  | 1.  항목별 시험기준 | AIA BNP | Tosoh | Japan | SD (pg/mL) | 850 | 380 | 620 | 870 | 1100 | ㎍/L | 규격 | 비고 | 절차서에 |\n| 그러하지 아니하다.  | 8 | 원재료 | 예 | □ | 심장 질환으로 진단된 환자 800명의 혈장 검체를 본 제품을 | 암피실린 | 히드랄라진 | 프로베네시드 | 안지오텐신 III | 1,000pg/mL | 108% | 06/06/2006 |\n| 사시약 제조를 전면 위탁 시 제조원은 다음과 같이 기재한다. ",
        "original_sentence": "| 권장한다. "
      }
    },
    {
      "chunk_id": "chunk_253",
      "text": "| 1. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 252,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 21,
        "window_text": "시험방법 | 인정범위내의 자료이어야 한다.  | 2) 검사 키트의 사용조건(온도 또는 습도 등)을 기재한다.  | 권장한다.  | 1.  항목별 시험기준 | AIA BNP | Tosoh | Japan | SD (pg/mL) | 850 | 380 | 620 | 870 | 1100 | ㎍/L | 규격 | 비고 | 절차서에 |\n| 그러하지 아니하다.  | 8 | 원재료 | 예 | □ | 심장 질환으로 진단된 환자 800명의 혈장 검체를 본 제품을 | 암피실린 | 히드랄라진 | 프로베네시드 | 안지오텐신 III | 1,000pg/mL | 108% | 06/06/2006 |\n| 사시약 제조를 전면 위탁 시 제조원은 다음과 같이 기재한다.  | 예측도, 음성예측도 제시를 권장한다. ",
        "original_sentence": "| 1. "
      }
    },
    {
      "chunk_id": "chunk_254",
      "text": "항목별 시험기준 | AIA BNP | Tosoh | Japan | SD (pg/mL) | 850 | 380 | 620 | 870 | 1100 | ㎍/L | 규격 | 비고 | 절차서에 |\n| 그러하지 아니하다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 253,
        "window_size": 3,
        "char_count": 117,
        "word_count": 34,
        "page_number": 3,
        "window_text": "| 2) 검사 키트의 사용조건(온도 또는 습도 등)을 기재한다.  | 권장한다.  | 1.  항목별 시험기준 | AIA BNP | Tosoh | Japan | SD (pg/mL) | 850 | 380 | 620 | 870 | 1100 | ㎍/L | 규격 | 비고 | 절차서에 |\n| 그러하지 아니하다.  | 8 | 원재료 | 예 | □ | 심장 질환으로 진단된 환자 800명의 혈장 검체를 본 제품을 | 암피실린 | 히드랄라진 | 프로베네시드 | 안지오텐신 III | 1,000pg/mL | 108% | 06/06/2006 |\n| 사시약 제조를 전면 위탁 시 제조원은 다음과 같이 기재한다.  | 예측도, 음성예측도 제시를 권장한다.  | Elecsys ProBNP II | Roche | Germany | Passing-Bablok 선형회귀 분석과 조화 분석으로부터 얻은 | 5th Percentile | 16 | 14 | 21 | 12 | 250 |\n| 가. ",
        "original_sentence": "항목별 시험기준 | AIA BNP | Tosoh | Japan | SD (pg/mL) | 850 | 380 | 620 | 870 | 1100 | ㎍/L | 규격 | 비고 | 절차서에 |\n| 그러하지 아니하다. "
      }
    },
    {
      "chunk_id": "chunk_255",
      "text": "| 8 | 원재료 | 예 | □ | 심장 질환으로 진단된 환자 800명의 혈장 검체를 본 제품을 | 암피실린 | 히드랄라진 | 프로베네시드 | 안지오텐신 III | 1,000pg/mL | 108% | 06/06/2006 |\n| 사시약 제조를 전면 위탁 시 제조원은 다음과 같이 기재한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 254,
        "window_size": 3,
        "char_count": 161,
        "word_count": 44,
        "page_number": 28,
        "window_text": "| 권장한다.  | 1.  항목별 시험기준 | AIA BNP | Tosoh | Japan | SD (pg/mL) | 850 | 380 | 620 | 870 | 1100 | ㎍/L | 규격 | 비고 | 절차서에 |\n| 그러하지 아니하다.  | 8 | 원재료 | 예 | □ | 심장 질환으로 진단된 환자 800명의 혈장 검체를 본 제품을 | 암피실린 | 히드랄라진 | 프로베네시드 | 안지오텐신 III | 1,000pg/mL | 108% | 06/06/2006 |\n| 사시약 제조를 전면 위탁 시 제조원은 다음과 같이 기재한다.  | 예측도, 음성예측도 제시를 권장한다.  | Elecsys ProBNP II | Roche | Germany | Passing-Bablok 선형회귀 분석과 조화 분석으로부터 얻은 | 5th Percentile | 16 | 14 | 21 | 12 | 250 |\n| 가.  인정범위 | 라. ",
        "original_sentence": "| 8 | 원재료 | 예 | □ | 심장 질환으로 진단된 환자 800명의 혈장 검체를 본 제품을 | 암피실린 | 히드랄라진 | 프로베네시드 | 안지오텐신 III | 1,000pg/mL | 108% | 06/06/2006 |\n| 사시약 제조를 전면 위탁 시 제조원은 다음과 같이 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_256",
      "text": "| 예측도, 음성예측도 제시를 권장한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 255,
        "window_size": 3,
        "char_count": 23,
        "word_count": 5,
        "page_number": 14,
        "window_text": "| 1.  항목별 시험기준 | AIA BNP | Tosoh | Japan | SD (pg/mL) | 850 | 380 | 620 | 870 | 1100 | ㎍/L | 규격 | 비고 | 절차서에 |\n| 그러하지 아니하다.  | 8 | 원재료 | 예 | □ | 심장 질환으로 진단된 환자 800명의 혈장 검체를 본 제품을 | 암피실린 | 히드랄라진 | 프로베네시드 | 안지오텐신 III | 1,000pg/mL | 108% | 06/06/2006 |\n| 사시약 제조를 전면 위탁 시 제조원은 다음과 같이 기재한다.  | 예측도, 음성예측도 제시를 권장한다.  | Elecsys ProBNP II | Roche | Germany | Passing-Bablok 선형회귀 분석과 조화 분석으로부터 얻은 | 5th Percentile | 16 | 14 | 21 | 12 | 250 |\n| 가.  인정범위 | 라.  결과가 불일치하는 경우, 불일치의 원인 분석에 대한 자료를 제출 | 확률적으로 검체에서 검출될 수 있는 최저 분석물질의 양 | 안전평가원 의료기기심사부 체외진단기기과에 문의하시기 바랍니다. ",
        "original_sentence": "| 예측도, 음성예측도 제시를 권장한다. "
      }
    },
    {
      "chunk_id": "chunk_257",
      "text": "| Elecsys ProBNP II | Roche | Germany | Passing-Bablok 선형회귀 분석과 조화 분석으로부터 얻은 | 5th Percentile | 16 | 14 | 21 | 12 | 250 |\n| 가. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 256,
        "window_size": 3,
        "char_count": 127,
        "word_count": 31,
        "page_number": 14,
        "window_text": "항목별 시험기준 | AIA BNP | Tosoh | Japan | SD (pg/mL) | 850 | 380 | 620 | 870 | 1100 | ㎍/L | 규격 | 비고 | 절차서에 |\n| 그러하지 아니하다.  | 8 | 원재료 | 예 | □ | 심장 질환으로 진단된 환자 800명의 혈장 검체를 본 제품을 | 암피실린 | 히드랄라진 | 프로베네시드 | 안지오텐신 III | 1,000pg/mL | 108% | 06/06/2006 |\n| 사시약 제조를 전면 위탁 시 제조원은 다음과 같이 기재한다.  | 예측도, 음성예측도 제시를 권장한다.  | Elecsys ProBNP II | Roche | Germany | Passing-Bablok 선형회귀 분석과 조화 분석으로부터 얻은 | 5th Percentile | 16 | 14 | 21 | 12 | 250 |\n| 가.  인정범위 | 라.  결과가 불일치하는 경우, 불일치의 원인 분석에 대한 자료를 제출 | 확률적으로 검체에서 검출될 수 있는 최저 분석물질의 양 | 안전평가원 의료기기심사부 체외진단기기과에 문의하시기 바랍니다.  | 1) 시험할 간섭물질의 목록을 작성한다. ",
        "original_sentence": "| Elecsys ProBNP II | Roche | Germany | Passing-Bablok 선형회귀 분석과 조화 분석으로부터 얻은 | 5th Percentile | 16 | 14 | 21 | 12 | 250 |\n| 가. "
      }
    },
    {
      "chunk_id": "chunk_258",
      "text": "인정범위 | 라. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 257,
        "window_size": 3,
        "char_count": 10,
        "word_count": 3,
        "page_number": 79,
        "window_text": "| 8 | 원재료 | 예 | □ | 심장 질환으로 진단된 환자 800명의 혈장 검체를 본 제품을 | 암피실린 | 히드랄라진 | 프로베네시드 | 안지오텐신 III | 1,000pg/mL | 108% | 06/06/2006 |\n| 사시약 제조를 전면 위탁 시 제조원은 다음과 같이 기재한다.  | 예측도, 음성예측도 제시를 권장한다.  | Elecsys ProBNP II | Roche | Germany | Passing-Bablok 선형회귀 분석과 조화 분석으로부터 얻은 | 5th Percentile | 16 | 14 | 21 | 12 | 250 |\n| 가.  인정범위 | 라.  결과가 불일치하는 경우, 불일치의 원인 분석에 대한 자료를 제출 | 확률적으로 검체에서 검출될 수 있는 최저 분석물질의 양 | 안전평가원 의료기기심사부 체외진단기기과에 문의하시기 바랍니다.  | 1) 시험할 간섭물질의 목록을 작성한다.  | 3) 간섭물질에 대한 분석물질 결과에 경향이 있다면 경향을 기술한다 | (교차반응성) | 아) 시약 lot의 수 | <외관사진> | 7. ",
        "original_sentence": "인정범위 | 라. "
      }
    },
    {
      "chunk_id": "chunk_259",
      "text": "결과가 불일치하는 경우, 불일치의 원인 분석에 대한 자료를 제출 | 확률적으로 검체에서 검출될 수 있는 최저 분석물질의 양 | 안전평가원 의료기기심사부 체외진단기기과에 문의하시기 바랍니다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 258,
        "window_size": 3,
        "char_count": 106,
        "word_count": 24,
        "page_number": 33,
        "window_text": "| 예측도, 음성예측도 제시를 권장한다.  | Elecsys ProBNP II | Roche | Germany | Passing-Bablok 선형회귀 분석과 조화 분석으로부터 얻은 | 5th Percentile | 16 | 14 | 21 | 12 | 250 |\n| 가.  인정범위 | 라.  결과가 불일치하는 경우, 불일치의 원인 분석에 대한 자료를 제출 | 확률적으로 검체에서 검출될 수 있는 최저 분석물질의 양 | 안전평가원 의료기기심사부 체외진단기기과에 문의하시기 바랍니다.  | 1) 시험할 간섭물질의 목록을 작성한다.  | 3) 간섭물질에 대한 분석물질 결과에 경향이 있다면 경향을 기술한다 | (교차반응성) | 아) 시약 lot의 수 | <외관사진> | 7.  사용시 주의사항 | 34 | 5. ",
        "original_sentence": "결과가 불일치하는 경우, 불일치의 원인 분석에 대한 자료를 제출 | 확률적으로 검체에서 검출될 수 있는 최저 분석물질의 양 | 안전평가원 의료기기심사부 체외진단기기과에 문의하시기 바랍니다. "
      }
    },
    {
      "chunk_id": "chunk_260",
      "text": "| 1) 시험할 간섭물질의 목록을 작성한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 259,
        "window_size": 3,
        "char_count": 25,
        "word_count": 6,
        "page_number": 21,
        "window_text": "| Elecsys ProBNP II | Roche | Germany | Passing-Bablok 선형회귀 분석과 조화 분석으로부터 얻은 | 5th Percentile | 16 | 14 | 21 | 12 | 250 |\n| 가.  인정범위 | 라.  결과가 불일치하는 경우, 불일치의 원인 분석에 대한 자료를 제출 | 확률적으로 검체에서 검출될 수 있는 최저 분석물질의 양 | 안전평가원 의료기기심사부 체외진단기기과에 문의하시기 바랍니다.  | 1) 시험할 간섭물질의 목록을 작성한다.  | 3) 간섭물질에 대한 분석물질 결과에 경향이 있다면 경향을 기술한다 | (교차반응성) | 아) 시약 lot의 수 | <외관사진> | 7.  사용시 주의사항 | 34 | 5.  검체보관 및 취급상(온도, 습도 등)의 조건 설정 | 제외한다. ",
        "original_sentence": "| 1) 시험할 간섭물질의 목록을 작성한다. "
      }
    },
    {
      "chunk_id": "chunk_261",
      "text": "| 3) 간섭물질에 대한 분석물질 결과에 경향이 있다면 경향을 기술한다 | (교차반응성) | 아) 시약 lot의 수 | <외관사진> | 7. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 260,
        "window_size": 3,
        "char_count": 79,
        "word_count": 21,
        "page_number": 26,
        "window_text": "인정범위 | 라.  결과가 불일치하는 경우, 불일치의 원인 분석에 대한 자료를 제출 | 확률적으로 검체에서 검출될 수 있는 최저 분석물질의 양 | 안전평가원 의료기기심사부 체외진단기기과에 문의하시기 바랍니다.  | 1) 시험할 간섭물질의 목록을 작성한다.  | 3) 간섭물질에 대한 분석물질 결과에 경향이 있다면 경향을 기술한다 | (교차반응성) | 아) 시약 lot의 수 | <외관사진> | 7.  사용시 주의사항 | 34 | 5.  검체보관 및 취급상(온도, 습도 등)의 조건 설정 | 제외한다.  | NT-proANP, C-type natriuretic peptide이다. ",
        "original_sentence": "| 3) 간섭물질에 대한 분석물질 결과에 경향이 있다면 경향을 기술한다 | (교차반응성) | 아) 시약 lot의 수 | <외관사진> | 7. "
      }
    },
    {
      "chunk_id": "chunk_262",
      "text": "사용시 주의사항 | 34 | 5. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 261,
        "window_size": 3,
        "char_count": 19,
        "word_count": 6,
        "page_number": 3,
        "window_text": "결과가 불일치하는 경우, 불일치의 원인 분석에 대한 자료를 제출 | 확률적으로 검체에서 검출될 수 있는 최저 분석물질의 양 | 안전평가원 의료기기심사부 체외진단기기과에 문의하시기 바랍니다.  | 1) 시험할 간섭물질의 목록을 작성한다.  | 3) 간섭물질에 대한 분석물질 결과에 경향이 있다면 경향을 기술한다 | (교차반응성) | 아) 시약 lot의 수 | <외관사진> | 7.  사용시 주의사항 | 34 | 5.  검체보관 및 취급상(온도, 습도 등)의 조건 설정 | 제외한다.  | NT-proANP, C-type natriuretic peptide이다.  | 3-5일 이상, 측정 시 2번 이상 반복검사를 권장한다. ",
        "original_sentence": "사용시 주의사항 | 34 | 5. "
      }
    },
    {
      "chunk_id": "chunk_263",
      "text": "검체보관 및 취급상(온도, 습도 등)의 조건 설정 | 제외한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 262,
        "window_size": 3,
        "char_count": 36,
        "word_count": 9,
        "page_number": 33,
        "window_text": "| 1) 시험할 간섭물질의 목록을 작성한다.  | 3) 간섭물질에 대한 분석물질 결과에 경향이 있다면 경향을 기술한다 | (교차반응성) | 아) 시약 lot의 수 | <외관사진> | 7.  사용시 주의사항 | 34 | 5.  검체보관 및 취급상(온도, 습도 등)의 조건 설정 | 제외한다.  | NT-proANP, C-type natriuretic peptide이다.  | 3-5일 이상, 측정 시 2번 이상 반복검사를 권장한다.  | 아니오 | □ | 따라서 |\n| 가. ",
        "original_sentence": "검체보관 및 취급상(온도, 습도 등)의 조건 설정 | 제외한다. "
      }
    },
    {
      "chunk_id": "chunk_264",
      "text": "| NT-proANP, C-type natriuretic peptide이다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 263,
        "window_size": 3,
        "char_count": 43,
        "word_count": 5,
        "page_number": 14,
        "window_text": "| 3) 간섭물질에 대한 분석물질 결과에 경향이 있다면 경향을 기술한다 | (교차반응성) | 아) 시약 lot의 수 | <외관사진> | 7.  사용시 주의사항 | 34 | 5.  검체보관 및 취급상(온도, 습도 등)의 조건 설정 | 제외한다.  | NT-proANP, C-type natriuretic peptide이다.  | 3-5일 이상, 측정 시 2번 이상 반복검사를 권장한다.  | 아니오 | □ | 따라서 |\n| 가.  검사대상 | 역가를 기재한다. ",
        "original_sentence": "| NT-proANP, C-type natriuretic peptide이다. "
      }
    },
    {
      "chunk_id": "chunk_265",
      "text": "| 3-5일 이상, 측정 시 2번 이상 반복검사를 권장한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 264,
        "window_size": 3,
        "char_count": 34,
        "word_count": 9,
        "page_number": 6,
        "window_text": "사용시 주의사항 | 34 | 5.  검체보관 및 취급상(온도, 습도 등)의 조건 설정 | 제외한다.  | NT-proANP, C-type natriuretic peptide이다.  | 3-5일 이상, 측정 시 2번 이상 반복검사를 권장한다.  | 아니오 | □ | 따라서 |\n| 가.  검사대상 | 역가를 기재한다.  | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | antibody against BNP와 반응을 한다. ",
        "original_sentence": "| 3-5일 이상, 측정 시 2번 이상 반복검사를 권장한다. "
      }
    },
    {
      "chunk_id": "chunk_266",
      "text": "| 아니오 | □ | 따라서 |\n| 가. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 265,
        "window_size": 3,
        "char_count": 23,
        "word_count": 9,
        "page_number": 43,
        "window_text": "검체보관 및 취급상(온도, 습도 등)의 조건 설정 | 제외한다.  | NT-proANP, C-type natriuretic peptide이다.  | 3-5일 이상, 측정 시 2번 이상 반복검사를 권장한다.  | 아니오 | □ | 따라서 |\n| 가.  검사대상 | 역가를 기재한다.  | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | antibody against BNP와 반응을 한다.  화합물이 충분히 | 보정물질 | proBNP (recombinant) | approx. ",
        "original_sentence": "| 아니오 | □ | 따라서 |\n| 가. "
      }
    },
    {
      "chunk_id": "chunk_267",
      "text": "검사대상 | 역가를 기재한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 266,
        "window_size": 3,
        "char_count": 17,
        "word_count": 4,
        "page_number": 26,
        "window_text": "| NT-proANP, C-type natriuretic peptide이다.  | 3-5일 이상, 측정 시 2번 이상 반복검사를 권장한다.  | 아니오 | □ | 따라서 |\n| 가.  검사대상 | 역가를 기재한다.  | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | antibody against BNP와 반응을 한다.  화합물이 충분히 | 보정물질 | proBNP (recombinant) | approx.  0.6 | 자사규격 | 이용하여 시험하였다. ",
        "original_sentence": "검사대상 | 역가를 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_268",
      "text": "| □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | antibody against BNP와 반응을 한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 267,
        "window_size": 3,
        "char_count": 65,
        "word_count": 14,
        "page_number": 3,
        "window_text": "| 3-5일 이상, 측정 시 2번 이상 반복검사를 권장한다.  | 아니오 | □ | 따라서 |\n| 가.  검사대상 | 역가를 기재한다.  | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | antibody against BNP와 반응을 한다.  화합물이 충분히 | 보정물질 | proBNP (recombinant) | approx.  0.6 | 자사규격 | 이용하여 시험하였다.  이 환자들을 New York Heart | 95th Percentile | 2600 | 1000 | 2000 | 2700 | >4000 | 아스코르빈산 | 하이드로클로로티아지드 | 프로카이나마이드 | □ 예 | ■ 아니오 |\n| 가. ",
        "original_sentence": "| □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | antibody against BNP와 반응을 한다. "
      }
    },
    {
      "chunk_id": "chunk_269",
      "text": "화합물이 충분히 | 보정물질 | proBNP (recombinant) | approx. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 268,
        "window_size": 3,
        "char_count": 49,
        "word_count": 9,
        "page_number": 14,
        "window_text": "| 아니오 | □ | 따라서 |\n| 가.  검사대상 | 역가를 기재한다.  | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | antibody against BNP와 반응을 한다.  화합물이 충분히 | 보정물질 | proBNP (recombinant) | approx.  0.6 | 자사규격 | 이용하여 시험하였다.  이 환자들을 New York Heart | 95th Percentile | 2600 | 1000 | 2000 | 2700 | >4000 | 아스코르빈산 | 하이드로클로로티아지드 | 프로카이나마이드 | □ 예 | ■ 아니오 |\n| 가.  허가(신고)가 최소된 의료기기와 사용목적, 작용원리 및 원재료 등 | 자료의 경우) | 관한 자료 | 식품의약품안전평가원 의료기기심사부 체외진단기기과 | Dimension Vista System Flex | 항 목 | 기 준 | Prepro-ANF 26-55 | 1,000pg/mL | 107% |\n| 검체의 사용 가능성 및 제한점 등을 포함한다. ",
        "original_sentence": "화합물이 충분히 | 보정물질 | proBNP (recombinant) | approx. "
      }
    },
    {
      "chunk_id": "chunk_270",
      "text": "0.6 | 자사규격 | 이용하여 시험하였다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 269,
        "window_size": 3,
        "char_count": 25,
        "word_count": 6,
        "page_number": 28,
        "window_text": "검사대상 | 역가를 기재한다.  | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | antibody against BNP와 반응을 한다.  화합물이 충분히 | 보정물질 | proBNP (recombinant) | approx.  0.6 | 자사규격 | 이용하여 시험하였다.  이 환자들을 New York Heart | 95th Percentile | 2600 | 1000 | 2000 | 2700 | >4000 | 아스코르빈산 | 하이드로클로로티아지드 | 프로카이나마이드 | □ 예 | ■ 아니오 |\n| 가.  허가(신고)가 최소된 의료기기와 사용목적, 작용원리 및 원재료 등 | 자료의 경우) | 관한 자료 | 식품의약품안전평가원 의료기기심사부 체외진단기기과 | Dimension Vista System Flex | 항 목 | 기 준 | Prepro-ANF 26-55 | 1,000pg/mL | 107% |\n| 검체의 사용 가능성 및 제한점 등을 포함한다.  | 9 | 성능 | 예 | □ | 기관의 임상시험계획승인을 받고 실시해야함) | 상관성 | 구성시약 | 개봉여부 보관조건 | 사용기간 | 비고 | 민원인을 구속하는 내용이 있습니까? ",
        "original_sentence": "0.6 | 자사규격 | 이용하여 시험하였다. "
      }
    },
    {
      "chunk_id": "chunk_271",
      "text": "이 환자들을 New York Heart | 95th Percentile | 2600 | 1000 | 2000 | 2700 | >4000 | 아스코르빈산 | 하이드로클로로티아지드 | 프로카이나마이드 | □ 예 | ■ 아니오 |\n| 가. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 270,
        "window_size": 3,
        "char_count": 131,
        "word_count": 33,
        "page_number": 6,
        "window_text": "| □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | antibody against BNP와 반응을 한다.  화합물이 충분히 | 보정물질 | proBNP (recombinant) | approx.  0.6 | 자사규격 | 이용하여 시험하였다.  이 환자들을 New York Heart | 95th Percentile | 2600 | 1000 | 2000 | 2700 | >4000 | 아스코르빈산 | 하이드로클로로티아지드 | 프로카이나마이드 | □ 예 | ■ 아니오 |\n| 가.  허가(신고)가 최소된 의료기기와 사용목적, 작용원리 및 원재료 등 | 자료의 경우) | 관한 자료 | 식품의약품안전평가원 의료기기심사부 체외진단기기과 | Dimension Vista System Flex | 항 목 | 기 준 | Prepro-ANF 26-55 | 1,000pg/mL | 107% |\n| 검체의 사용 가능성 및 제한점 등을 포함한다.  | 9 | 성능 | 예 | □ | 기관의 임상시험계획승인을 받고 실시해야함) | 상관성 | 구성시약 | 개봉여부 보관조건 | 사용기간 | 비고 | 민원인을 구속하는 내용이 있습니까?  | 결과는 아래 표에 나타내었다. ",
        "original_sentence": "이 환자들을 New York Heart | 95th Percentile | 2600 | 1000 | 2000 | 2700 | >4000 | 아스코르빈산 | 하이드로클로로티아지드 | 프로카이나마이드 | □ 예 | ■ 아니오 |\n| 가. "
      }
    },
    {
      "chunk_id": "chunk_272",
      "text": "허가(신고)가 최소된 의료기기와 사용목적, 작용원리 및 원재료 등 | 자료의 경우) | 관한 자료 | 식품의약품안전평가원 의료기기심사부 체외진단기기과 | Dimension Vista System Flex | 항 목 | 기 준 | Prepro-ANF 26-55 | 1,000pg/mL | 107% |\n| 검체의 사용 가능성 및 제한점 등을 포함한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 271,
        "window_size": 3,
        "char_count": 195,
        "word_count": 45,
        "page_number": 28,
        "window_text": "화합물이 충분히 | 보정물질 | proBNP (recombinant) | approx.  0.6 | 자사규격 | 이용하여 시험하였다.  이 환자들을 New York Heart | 95th Percentile | 2600 | 1000 | 2000 | 2700 | >4000 | 아스코르빈산 | 하이드로클로로티아지드 | 프로카이나마이드 | □ 예 | ■ 아니오 |\n| 가.  허가(신고)가 최소된 의료기기와 사용목적, 작용원리 및 원재료 등 | 자료의 경우) | 관한 자료 | 식품의약품안전평가원 의료기기심사부 체외진단기기과 | Dimension Vista System Flex | 항 목 | 기 준 | Prepro-ANF 26-55 | 1,000pg/mL | 107% |\n| 검체의 사용 가능성 및 제한점 등을 포함한다.  | 9 | 성능 | 예 | □ | 기관의 임상시험계획승인을 받고 실시해야함) | 상관성 | 구성시약 | 개봉여부 보관조건 | 사용기간 | 비고 | 민원인을 구속하는 내용이 있습니까?  | 결과는 아래 표에 나타내었다.  | 퍼센트 ≥100 pg/mL | 70.50% | 60.50% | 75.20% | 80.30% | 100.00% | 2.5x |\n| 1 | Cal 1 | 2004:50;732-740 | 2) 결과제시 | 각 공인된 값은 신뢰의 명시된 수준에서의 불확실성과 함께 한다” | 한다. ",
        "original_sentence": "허가(신고)가 최소된 의료기기와 사용목적, 작용원리 및 원재료 등 | 자료의 경우) | 관한 자료 | 식품의약품안전평가원 의료기기심사부 체외진단기기과 | Dimension Vista System Flex | 항 목 | 기 준 | Prepro-ANF 26-55 | 1,000pg/mL | 107% |\n| 검체의 사용 가능성 및 제한점 등을 포함한다. "
      }
    },
    {
      "chunk_id": "chunk_273",
      "text": "| 9 | 성능 | 예 | □ | 기관의 임상시험계획승인을 받고 실시해야함) | 상관성 | 구성시약 | 개봉여부 보관조건 | 사용기간 | 비고 | 민원인을 구속하는 내용이 있습니까? ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 272,
        "window_size": 3,
        "char_count": 102,
        "word_count": 29,
        "page_number": 33,
        "window_text": "0.6 | 자사규격 | 이용하여 시험하였다.  이 환자들을 New York Heart | 95th Percentile | 2600 | 1000 | 2000 | 2700 | >4000 | 아스코르빈산 | 하이드로클로로티아지드 | 프로카이나마이드 | □ 예 | ■ 아니오 |\n| 가.  허가(신고)가 최소된 의료기기와 사용목적, 작용원리 및 원재료 등 | 자료의 경우) | 관한 자료 | 식품의약품안전평가원 의료기기심사부 체외진단기기과 | Dimension Vista System Flex | 항 목 | 기 준 | Prepro-ANF 26-55 | 1,000pg/mL | 107% |\n| 검체의 사용 가능성 및 제한점 등을 포함한다.  | 9 | 성능 | 예 | □ | 기관의 임상시험계획승인을 받고 실시해야함) | 상관성 | 구성시약 | 개봉여부 보관조건 | 사용기간 | 비고 | 민원인을 구속하는 내용이 있습니까?  | 결과는 아래 표에 나타내었다.  | 퍼센트 ≥100 pg/mL | 70.50% | 60.50% | 75.20% | 80.30% | 100.00% | 2.5x |\n| 1 | Cal 1 | 2004:50;732-740 | 2) 결과제시 | 각 공인된 값은 신뢰의 명시된 수준에서의 불확실성과 함께 한다” | 한다.  | 라) 참고 | 자) Calibration 시행 횟수와 calibrator lot의 수 | (예 : 높은 농도의 물질 X는 분석물질의 결과를 감소시킴). ",
        "original_sentence": "| 9 | 성능 | 예 | □ | 기관의 임상시험계획승인을 받고 실시해야함) | 상관성 | 구성시약 | 개봉여부 보관조건 | 사용기간 | 비고 | 민원인을 구속하는 내용이 있습니까? "
      }
    },
    {
      "chunk_id": "chunk_274",
      "text": "| 결과는 아래 표에 나타내었다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 273,
        "window_size": 3,
        "char_count": 19,
        "word_count": 5,
        "page_number": 33,
        "window_text": "이 환자들을 New York Heart | 95th Percentile | 2600 | 1000 | 2000 | 2700 | >4000 | 아스코르빈산 | 하이드로클로로티아지드 | 프로카이나마이드 | □ 예 | ■ 아니오 |\n| 가.  허가(신고)가 최소된 의료기기와 사용목적, 작용원리 및 원재료 등 | 자료의 경우) | 관한 자료 | 식품의약품안전평가원 의료기기심사부 체외진단기기과 | Dimension Vista System Flex | 항 목 | 기 준 | Prepro-ANF 26-55 | 1,000pg/mL | 107% |\n| 검체의 사용 가능성 및 제한점 등을 포함한다.  | 9 | 성능 | 예 | □ | 기관의 임상시험계획승인을 받고 실시해야함) | 상관성 | 구성시약 | 개봉여부 보관조건 | 사용기간 | 비고 | 민원인을 구속하는 내용이 있습니까?  | 결과는 아래 표에 나타내었다.  | 퍼센트 ≥100 pg/mL | 70.50% | 60.50% | 75.20% | 80.30% | 100.00% | 2.5x |\n| 1 | Cal 1 | 2004:50;732-740 | 2) 결과제시 | 각 공인된 값은 신뢰의 명시된 수준에서의 불확실성과 함께 한다” | 한다.  | 라) 참고 | 자) Calibration 시행 횟수와 calibrator lot의 수 | (예 : 높은 농도의 물질 X는 분석물질의 결과를 감소시킴).  | 계획되거나 반복성이나 재현성 평가의 일부로 계획될 수 있다. ",
        "original_sentence": "| 결과는 아래 표에 나타내었다. "
      }
    },
    {
      "chunk_id": "chunk_275",
      "text": "| 퍼센트 ≥100 pg/mL | 70.50% | 60.50% | 75.20% | 80.30% | 100.00% | 2.5x |\n| 1 | Cal 1 | 2004:50;732-740 | 2) 결과제시 | 각 공인된 값은 신뢰의 명시된 수준에서의 불확실성과 함께 한다” | 한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 274,
        "window_size": 3,
        "char_count": 156,
        "word_count": 39,
        "page_number": 6,
        "window_text": "허가(신고)가 최소된 의료기기와 사용목적, 작용원리 및 원재료 등 | 자료의 경우) | 관한 자료 | 식품의약품안전평가원 의료기기심사부 체외진단기기과 | Dimension Vista System Flex | 항 목 | 기 준 | Prepro-ANF 26-55 | 1,000pg/mL | 107% |\n| 검체의 사용 가능성 및 제한점 등을 포함한다.  | 9 | 성능 | 예 | □ | 기관의 임상시험계획승인을 받고 실시해야함) | 상관성 | 구성시약 | 개봉여부 보관조건 | 사용기간 | 비고 | 민원인을 구속하는 내용이 있습니까?  | 결과는 아래 표에 나타내었다.  | 퍼센트 ≥100 pg/mL | 70.50% | 60.50% | 75.20% | 80.30% | 100.00% | 2.5x |\n| 1 | Cal 1 | 2004:50;732-740 | 2) 결과제시 | 각 공인된 값은 신뢰의 명시된 수준에서의 불확실성과 함께 한다” | 한다.  | 라) 참고 | 자) Calibration 시행 횟수와 calibrator lot의 수 | (예 : 높은 농도의 물질 X는 분석물질의 결과를 감소시킴).  | 계획되거나 반복성이나 재현성 평가의 일부로 계획될 수 있다.  | 근거자료 | 65 | 혈장, 전혈 등)를 사용하여야 한다. ",
        "original_sentence": "| 퍼센트 ≥100 pg/mL | 70.50% | 60.50% | 75.20% | 80.30% | 100.00% | 2.5x |\n| 1 | Cal 1 | 2004:50;732-740 | 2) 결과제시 | 각 공인된 값은 신뢰의 명시된 수준에서의 불확실성과 함께 한다” | 한다. "
      }
    },
    {
      "chunk_id": "chunk_276",
      "text": "| 라) 참고 | 자) Calibration 시행 횟수와 calibrator lot의 수 | (예 : 높은 농도의 물질 X는 분석물질의 결과를 감소시킴). ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 275,
        "window_size": 3,
        "char_count": 87,
        "word_count": 21,
        "page_number": 14,
        "window_text": "| 9 | 성능 | 예 | □ | 기관의 임상시험계획승인을 받고 실시해야함) | 상관성 | 구성시약 | 개봉여부 보관조건 | 사용기간 | 비고 | 민원인을 구속하는 내용이 있습니까?  | 결과는 아래 표에 나타내었다.  | 퍼센트 ≥100 pg/mL | 70.50% | 60.50% | 75.20% | 80.30% | 100.00% | 2.5x |\n| 1 | Cal 1 | 2004:50;732-740 | 2) 결과제시 | 각 공인된 값은 신뢰의 명시된 수준에서의 불확실성과 함께 한다” | 한다.  | 라) 참고 | 자) Calibration 시행 횟수와 calibrator lot의 수 | (예 : 높은 농도의 물질 X는 분석물질의 결과를 감소시킴).  | 계획되거나 반복성이나 재현성 평가의 일부로 계획될 수 있다.  | 근거자료 | 65 | 혈장, 전혈 등)를 사용하여야 한다.  | 보조성분 | Human serum | 적량 | 자사규격 | Association(NYHA)의 기능적인 분류 시스템에 따라서 | 암로디핀베실산염 | 헤파린 | 프로파놀올 | 시험한다. ",
        "original_sentence": "| 라) 참고 | 자) Calibration 시행 횟수와 calibrator lot의 수 | (예 : 높은 농도의 물질 X는 분석물질의 결과를 감소시킴). "
      }
    },
    {
      "chunk_id": "chunk_277",
      "text": "| 계획되거나 반복성이나 재현성 평가의 일부로 계획될 수 있다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 276,
        "window_size": 3,
        "char_count": 36,
        "word_count": 9,
        "page_number": 11,
        "window_text": "| 결과는 아래 표에 나타내었다.  | 퍼센트 ≥100 pg/mL | 70.50% | 60.50% | 75.20% | 80.30% | 100.00% | 2.5x |\n| 1 | Cal 1 | 2004:50;732-740 | 2) 결과제시 | 각 공인된 값은 신뢰의 명시된 수준에서의 불확실성과 함께 한다” | 한다.  | 라) 참고 | 자) Calibration 시행 횟수와 calibrator lot의 수 | (예 : 높은 농도의 물질 X는 분석물질의 결과를 감소시킴).  | 계획되거나 반복성이나 재현성 평가의 일부로 계획될 수 있다.  | 근거자료 | 65 | 혈장, 전혈 등)를 사용하여야 한다.  | 보조성분 | Human serum | 적량 | 자사규격 | Association(NYHA)의 기능적인 분류 시스템에 따라서 | 암로디핀베실산염 | 헤파린 | 프로파놀올 | 시험한다.  |\n| 나. ",
        "original_sentence": "| 계획되거나 반복성이나 재현성 평가의 일부로 계획될 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_278",
      "text": "| 근거자료 | 65 | 혈장, 전혈 등)를 사용하여야 한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 277,
        "window_size": 3,
        "char_count": 35,
        "word_count": 10,
        "page_number": 7,
        "window_text": "| 퍼센트 ≥100 pg/mL | 70.50% | 60.50% | 75.20% | 80.30% | 100.00% | 2.5x |\n| 1 | Cal 1 | 2004:50;732-740 | 2) 결과제시 | 각 공인된 값은 신뢰의 명시된 수준에서의 불확실성과 함께 한다” | 한다.  | 라) 참고 | 자) Calibration 시행 횟수와 calibrator lot의 수 | (예 : 높은 농도의 물질 X는 분석물질의 결과를 감소시킴).  | 계획되거나 반복성이나 재현성 평가의 일부로 계획될 수 있다.  | 근거자료 | 65 | 혈장, 전혈 등)를 사용하여야 한다.  | 보조성분 | Human serum | 적량 | 자사규격 | Association(NYHA)의 기능적인 분류 시스템에 따라서 | 암로디핀베실산염 | 헤파린 | 프로파놀올 | 시험한다.  |\n| 나.  검체종류 : 해당 제품의 적용이 가능한 검체의 종류를 기술한다. ",
        "original_sentence": "| 근거자료 | 65 | 혈장, 전혈 등)를 사용하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_279",
      "text": "| 보조성분 | Human serum | 적량 | 자사규격 | Association(NYHA)의 기능적인 분류 시스템에 따라서 | 암로디핀베실산염 | 헤파린 | 프로파놀올 | 시험한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 278,
        "window_size": 3,
        "char_count": 104,
        "word_count": 23,
        "page_number": 14,
        "window_text": "| 라) 참고 | 자) Calibration 시행 횟수와 calibrator lot의 수 | (예 : 높은 농도의 물질 X는 분석물질의 결과를 감소시킴).  | 계획되거나 반복성이나 재현성 평가의 일부로 계획될 수 있다.  | 근거자료 | 65 | 혈장, 전혈 등)를 사용하여야 한다.  | 보조성분 | Human serum | 적량 | 자사규격 | Association(NYHA)의 기능적인 분류 시스템에 따라서 | 암로디핀베실산염 | 헤파린 | 프로파놀올 | 시험한다.  |\n| 나.  검체종류 : 해당 제품의 적용이 가능한 검체의 종류를 기술한다.  | 4 | ※ 예시 | 4) 피험자 선정/제외 기준, 검체 종류와 수, 시험 상 주의사항, 통계 | 8. ",
        "original_sentence": "| 보조성분 | Human serum | 적량 | 자사규격 | Association(NYHA)의 기능적인 분류 시스템에 따라서 | 암로디핀베실산염 | 헤파린 | 프로파놀올 | 시험한다. "
      }
    },
    {
      "chunk_id": "chunk_280",
      "text": "|\n| 나. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 279,
        "window_size": 3,
        "char_count": 7,
        "word_count": 3,
        "page_number": 1,
        "window_text": "| 계획되거나 반복성이나 재현성 평가의 일부로 계획될 수 있다.  | 근거자료 | 65 | 혈장, 전혈 등)를 사용하여야 한다.  | 보조성분 | Human serum | 적량 | 자사규격 | Association(NYHA)의 기능적인 분류 시스템에 따라서 | 암로디핀베실산염 | 헤파린 | 프로파놀올 | 시험한다.  |\n| 나.  검체종류 : 해당 제품의 적용이 가능한 검체의 종류를 기술한다.  | 4 | ※ 예시 | 4) 피험자 선정/제외 기준, 검체 종류와 수, 시험 상 주의사항, 통계 | 8.  포장단위 | 34 | 다음과 같은 물질에 대한 간섭 평가 자료를 제출해야 한다. ",
        "original_sentence": "|\n| 나. "
      }
    },
    {
      "chunk_id": "chunk_281",
      "text": "검체종류 : 해당 제품의 적용이 가능한 검체의 종류를 기술한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 280,
        "window_size": 3,
        "char_count": 36,
        "word_count": 9,
        "page_number": 30,
        "window_text": "| 근거자료 | 65 | 혈장, 전혈 등)를 사용하여야 한다.  | 보조성분 | Human serum | 적량 | 자사규격 | Association(NYHA)의 기능적인 분류 시스템에 따라서 | 암로디핀베실산염 | 헤파린 | 프로파놀올 | 시험한다.  |\n| 나.  검체종류 : 해당 제품의 적용이 가능한 검체의 종류를 기술한다.  | 4 | ※ 예시 | 4) 피험자 선정/제외 기준, 검체 종류와 수, 시험 상 주의사항, 통계 | 8.  포장단위 | 34 | 다음과 같은 물질에 대한 간섭 평가 자료를 제출해야 한다.  | 반응이 일어 난 뒤, 반응물은 디바이스의 고정체로 이동하고 | 오송보건의료행정타운 식품의약품안전평가원 | 최소 (pg/mL) | 0 | 10 | 0 | 0 | 173 | 아니오 | □ | 1mL |\n| 항목이 추가로 포함되어야 한다. ",
        "original_sentence": "검체종류 : 해당 제품의 적용이 가능한 검체의 종류를 기술한다. "
      }
    },
    {
      "chunk_id": "chunk_282",
      "text": "| 4 | ※ 예시 | 4) 피험자 선정/제외 기준, 검체 종류와 수, 시험 상 주의사항, 통계 | 8. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 281,
        "window_size": 3,
        "char_count": 59,
        "word_count": 19,
        "page_number": 3,
        "window_text": "| 보조성분 | Human serum | 적량 | 자사규격 | Association(NYHA)의 기능적인 분류 시스템에 따라서 | 암로디핀베실산염 | 헤파린 | 프로파놀올 | 시험한다.  |\n| 나.  검체종류 : 해당 제품의 적용이 가능한 검체의 종류를 기술한다.  | 4 | ※ 예시 | 4) 피험자 선정/제외 기준, 검체 종류와 수, 시험 상 주의사항, 통계 | 8.  포장단위 | 34 | 다음과 같은 물질에 대한 간섭 평가 자료를 제출해야 한다.  | 반응이 일어 난 뒤, 반응물은 디바이스의 고정체로 이동하고 | 오송보건의료행정타운 식품의약품안전평가원 | 최소 (pg/mL) | 0 | 10 | 0 | 0 | 173 | 아니오 | □ | 1mL |\n| 항목이 추가로 포함되어야 한다.  | 항 | 수행한다. ",
        "original_sentence": "| 4 | ※ 예시 | 4) 피험자 선정/제외 기준, 검체 종류와 수, 시험 상 주의사항, 통계 | 8. "
      }
    },
    {
      "chunk_id": "chunk_283",
      "text": "포장단위 | 34 | 다음과 같은 물질에 대한 간섭 평가 자료를 제출해야 한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 282,
        "window_size": 3,
        "char_count": 45,
        "word_count": 13,
        "page_number": 6,
        "window_text": "|\n| 나.  검체종류 : 해당 제품의 적용이 가능한 검체의 종류를 기술한다.  | 4 | ※ 예시 | 4) 피험자 선정/제외 기준, 검체 종류와 수, 시험 상 주의사항, 통계 | 8.  포장단위 | 34 | 다음과 같은 물질에 대한 간섭 평가 자료를 제출해야 한다.  | 반응이 일어 난 뒤, 반응물은 디바이스의 고정체로 이동하고 | 오송보건의료행정타운 식품의약품안전평가원 | 최소 (pg/mL) | 0 | 10 | 0 | 0 | 173 | 아니오 | □ | 1mL |\n| 항목이 추가로 포함되어야 한다.  | 항 | 수행한다.  | 소프트웨어의 회사명, 모델명 등을 기재한다. ",
        "original_sentence": "포장단위 | 34 | 다음과 같은 물질에 대한 간섭 평가 자료를 제출해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_284",
      "text": "| 반응이 일어 난 뒤, 반응물은 디바이스의 고정체로 이동하고 | 오송보건의료행정타운 식품의약품안전평가원 | 최소 (pg/mL) | 0 | 10 | 0 | 0 | 173 | 아니오 | □ | 1mL |\n| 항목이 추가로 포함되어야 한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 283,
        "window_size": 3,
        "char_count": 133,
        "word_count": 37,
        "page_number": 25,
        "window_text": "검체종류 : 해당 제품의 적용이 가능한 검체의 종류를 기술한다.  | 4 | ※ 예시 | 4) 피험자 선정/제외 기준, 검체 종류와 수, 시험 상 주의사항, 통계 | 8.  포장단위 | 34 | 다음과 같은 물질에 대한 간섭 평가 자료를 제출해야 한다.  | 반응이 일어 난 뒤, 반응물은 디바이스의 고정체로 이동하고 | 오송보건의료행정타운 식품의약품안전평가원 | 최소 (pg/mL) | 0 | 10 | 0 | 0 | 173 | 아니오 | □ | 1mL |\n| 항목이 추가로 포함되어야 한다.  | 항 | 수행한다.  | 소프트웨어의 회사명, 모델명 등을 기재한다.  | 구체적, 개조식으로 기재한다. ",
        "original_sentence": "| 반응이 일어 난 뒤, 반응물은 디바이스의 고정체로 이동하고 | 오송보건의료행정타운 식품의약품안전평가원 | 최소 (pg/mL) | 0 | 10 | 0 | 0 | 173 | 아니오 | □ | 1mL |\n| 항목이 추가로 포함되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_285",
      "text": "| 항 | 수행한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 284,
        "window_size": 3,
        "char_count": 12,
        "word_count": 4,
        "page_number": 3,
        "window_text": "| 4 | ※ 예시 | 4) 피험자 선정/제외 기준, 검체 종류와 수, 시험 상 주의사항, 통계 | 8.  포장단위 | 34 | 다음과 같은 물질에 대한 간섭 평가 자료를 제출해야 한다.  | 반응이 일어 난 뒤, 반응물은 디바이스의 고정체로 이동하고 | 오송보건의료행정타운 식품의약품안전평가원 | 최소 (pg/mL) | 0 | 10 | 0 | 0 | 173 | 아니오 | □ | 1mL |\n| 항목이 추가로 포함되어야 한다.  | 항 | 수행한다.  | 소프트웨어의 회사명, 모델명 등을 기재한다.  | 구체적, 개조식으로 기재한다.  | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ안내서 | Reagent cartridge N-terminal | BNP | ≤10.0pg/mL | 정밀도는 | CLSI(Clinical | and | Laboratory | Standards | 비교방법과 본 제품의 검사의 결정 역치인 125pg/mL를 | Siemens | Germany |\n\n**[표 끝]**\n\n☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적으로\n\n지침서ㆍ안내서\n\n기타 확인사\n\n제ㆍ개정 절차를 진행하시기 바랍니다.\n\n",
        "original_sentence": "| 항 | 수행한다. "
      }
    },
    {
      "chunk_id": "chunk_286",
      "text": "| 소프트웨어의 회사명, 모델명 등을 기재한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 285,
        "window_size": 3,
        "char_count": 27,
        "word_count": 6,
        "page_number": 26,
        "window_text": "포장단위 | 34 | 다음과 같은 물질에 대한 간섭 평가 자료를 제출해야 한다.  | 반응이 일어 난 뒤, 반응물은 디바이스의 고정체로 이동하고 | 오송보건의료행정타운 식품의약품안전평가원 | 최소 (pg/mL) | 0 | 10 | 0 | 0 | 173 | 아니오 | □ | 1mL |\n| 항목이 추가로 포함되어야 한다.  | 항 | 수행한다.  | 소프트웨어의 회사명, 모델명 등을 기재한다.  | 구체적, 개조식으로 기재한다.  | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ안내서 | Reagent cartridge N-terminal | BNP | ≤10.0pg/mL | 정밀도는 | CLSI(Clinical | and | Laboratory | Standards | 비교방법과 본 제품의 검사의 결정 역치인 125pg/mL를 | Siemens | Germany |\n\n**[표 끝]**\n\n☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적으로\n\n지침서ㆍ안내서\n\n기타 확인사\n\n제ㆍ개정 절차를 진행하시기 바랍니다.\n\n 상기 사항에 대하여 확인하였음.\n\n",
        "original_sentence": "| 소프트웨어의 회사명, 모델명 등을 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_287",
      "text": "| 구체적, 개조식으로 기재한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 286,
        "window_size": 3,
        "char_count": 19,
        "word_count": 4,
        "page_number": 26,
        "window_text": "| 반응이 일어 난 뒤, 반응물은 디바이스의 고정체로 이동하고 | 오송보건의료행정타운 식품의약품안전평가원 | 최소 (pg/mL) | 0 | 10 | 0 | 0 | 173 | 아니오 | □ | 1mL |\n| 항목이 추가로 포함되어야 한다.  | 항 | 수행한다.  | 소프트웨어의 회사명, 모델명 등을 기재한다.  | 구체적, 개조식으로 기재한다.  | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ안내서 | Reagent cartridge N-terminal | BNP | ≤10.0pg/mL | 정밀도는 | CLSI(Clinical | and | Laboratory | Standards | 비교방법과 본 제품의 검사의 결정 역치인 125pg/mL를 | Siemens | Germany |\n\n**[표 끝]**\n\n☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적으로\n\n지침서ㆍ안내서\n\n기타 확인사\n\n제ㆍ개정 절차를 진행하시기 바랍니다.\n\n 상기 사항에 대하여 확인하였음.\n\n 2018 년    7 월   31  일\n\n담당자\n\n확  인(부서장)\n\n우 승 민\n\n이 원 규\n\n<!-- PAGE_4 -->\n###### ※ 본 민원인 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품\n\n<!-- PAGE_4 -->\n###### - 전화번호 : 043-719-4652~4665\n\n<!-- PAGE_4 -->\n###### - 팩스번호 : 043-719-4650\n\n이 안내서는 체외진단용 의료기기 중 뇌나트륨이뇨펩티드 검사제품  허가\n\n심사 시 요구되는 신청서 작성 방법 및 제출자료 요건에 대하여 알기 쉽게\n\n설명하거나 식품의약품안전처의 입장을 기술한 것입니다.\n\n",
        "original_sentence": "| 구체적, 개조식으로 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_288",
      "text": "| ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ안내서 | Reagent cartridge N-terminal | BNP | ≤10.0pg/mL | 정밀도는 | CLSI(Clinical | and | Laboratory | Standards | 비교방법과 본 제품의 검사의 결정 역치인 125pg/mL를 | Siemens | Germany |\n\n**[표 끝]**\n\n☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적으로\n\n지침서ㆍ안내서\n\n기타 확인사\n\n제ㆍ개정 절차를 진행하시기 바랍니다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 287,
        "window_size": 3,
        "char_count": 308,
        "word_count": 62,
        "page_number": 3,
        "window_text": "| 항 | 수행한다.  | 소프트웨어의 회사명, 모델명 등을 기재한다.  | 구체적, 개조식으로 기재한다.  | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ안내서 | Reagent cartridge N-terminal | BNP | ≤10.0pg/mL | 정밀도는 | CLSI(Clinical | and | Laboratory | Standards | 비교방법과 본 제품의 검사의 결정 역치인 125pg/mL를 | Siemens | Germany |\n\n**[표 끝]**\n\n☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적으로\n\n지침서ㆍ안내서\n\n기타 확인사\n\n제ㆍ개정 절차를 진행하시기 바랍니다.\n\n 상기 사항에 대하여 확인하였음.\n\n 2018 년    7 월   31  일\n\n담당자\n\n확  인(부서장)\n\n우 승 민\n\n이 원 규\n\n<!-- PAGE_4 -->\n###### ※ 본 민원인 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품\n\n<!-- PAGE_4 -->\n###### - 전화번호 : 043-719-4652~4665\n\n<!-- PAGE_4 -->\n###### - 팩스번호 : 043-719-4650\n\n이 안내서는 체외진단용 의료기기 중 뇌나트륨이뇨펩티드 검사제품  허가\n\n심사 시 요구되는 신청서 작성 방법 및 제출자료 요건에 대하여 알기 쉽게\n\n설명하거나 식품의약품안전처의 입장을 기술한 것입니다.\n\n 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식\n\n(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는\n\n사항이 아님을 알려드립니다. ",
        "original_sentence": "| ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ안내서 | Reagent cartridge N-terminal | BNP | ≤10.0pg/mL | 정밀도는 | CLSI(Clinical | and | Laboratory | Standards | 비교방법과 본 제품의 검사의 결정 역치인 125pg/mL를 | Siemens | Germany |\n\n**[표 끝]**\n\n☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적으로\n\n지침서ㆍ안내서\n\n기타 확인사\n\n제ㆍ개정 절차를 진행하시기 바랍니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_289",
      "text": "상기 사항에 대하여 확인하였음.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 288,
        "window_size": 3,
        "char_count": 19,
        "word_count": 4,
        "page_number": 3,
        "window_text": "| 소프트웨어의 회사명, 모델명 등을 기재한다.  | 구체적, 개조식으로 기재한다.  | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ안내서 | Reagent cartridge N-terminal | BNP | ≤10.0pg/mL | 정밀도는 | CLSI(Clinical | and | Laboratory | Standards | 비교방법과 본 제품의 검사의 결정 역치인 125pg/mL를 | Siemens | Germany |\n\n**[표 끝]**\n\n☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적으로\n\n지침서ㆍ안내서\n\n기타 확인사\n\n제ㆍ개정 절차를 진행하시기 바랍니다.\n\n 상기 사항에 대하여 확인하였음.\n\n 2018 년    7 월   31  일\n\n담당자\n\n확  인(부서장)\n\n우 승 민\n\n이 원 규\n\n<!-- PAGE_4 -->\n###### ※ 본 민원인 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품\n\n<!-- PAGE_4 -->\n###### - 전화번호 : 043-719-4652~4665\n\n<!-- PAGE_4 -->\n###### - 팩스번호 : 043-719-4650\n\n이 안내서는 체외진단용 의료기기 중 뇌나트륨이뇨펩티드 검사제품  허가\n\n심사 시 요구되는 신청서 작성 방법 및 제출자료 요건에 대하여 알기 쉽게\n\n설명하거나 식품의약품안전처의 입장을 기술한 것입니다.\n\n 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식\n\n(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는\n\n사항이 아님을 알려드립니다.  또한, 본 안내서는 현재의 과학적ㆍ기술적 사실 및\n\n유효한 법규를 토대로 작성되었으므로 이후 최신 개정 법규 내용 및 구체적인\n\n※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을\n\n<!-- PAGE_5 -->\n### 머 리 말\n\n<!-- PAGE_5 -->\n###### 질병관리 패러다임이 치료중심에서 조기진단을\n\n<!-- PAGE_5 -->\n###### 통한 예방중심으로 전환됨에 따라 진단검사\n\n<!-- PAGE_5 -->\n###### 결과의 신뢰성 확보의 중요성이 부각되고 있고,\n\n<!-- PAGE_5 -->\n###### 과거 진단기기의 보조적 역할로 인식되던 체외\n\n<!-- PAGE_5 -->\n###### 진단용 의료기기가 진단검사 결과의 판정에 결정\n\n<!-- PAGE_5 -->\n###### 적인 영향을 주는 제품으로 개발되고 있습니다.\n\n",
        "original_sentence": "상기 사항에 대하여 확인하였음.\n\n"
      }
    },
    {
      "chunk_id": "chunk_290",
      "text": "2018 년    7 월   31  일\n\n담당자\n\n확  인(부서장)\n\n우 승 민\n\n이 원 규\n\n<!-- PAGE_4 -->\n###### ※ 본 민원인 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품\n\n<!-- PAGE_4 -->\n###### - 전화번호 : 043-719-4652~4665\n\n<!-- PAGE_4 -->\n###### - 팩스번호 : 043-719-4650\n\n이 안내서는 체외진단용 의료기기 중 뇌나트륨이뇨펩티드 검사제품  허가\n\n심사 시 요구되는 신청서 작성 방법 및 제출자료 요건에 대하여 알기 쉽게\n\n설명하거나 식품의약품안전처의 입장을 기술한 것입니다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 289,
        "window_size": 3,
        "char_count": 326,
        "word_count": 70,
        "page_number": 4,
        "window_text": "| 구체적, 개조식으로 기재한다.  | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ안내서 | Reagent cartridge N-terminal | BNP | ≤10.0pg/mL | 정밀도는 | CLSI(Clinical | and | Laboratory | Standards | 비교방법과 본 제품의 검사의 결정 역치인 125pg/mL를 | Siemens | Germany |\n\n**[표 끝]**\n\n☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적으로\n\n지침서ㆍ안내서\n\n기타 확인사\n\n제ㆍ개정 절차를 진행하시기 바랍니다.\n\n 상기 사항에 대하여 확인하였음.\n\n 2018 년    7 월   31  일\n\n담당자\n\n확  인(부서장)\n\n우 승 민\n\n이 원 규\n\n<!-- PAGE_4 -->\n###### ※ 본 민원인 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품\n\n<!-- PAGE_4 -->\n###### - 전화번호 : 043-719-4652~4665\n\n<!-- PAGE_4 -->\n###### - 팩스번호 : 043-719-4650\n\n이 안내서는 체외진단용 의료기기 중 뇌나트륨이뇨펩티드 검사제품  허가\n\n심사 시 요구되는 신청서 작성 방법 및 제출자료 요건에 대하여 알기 쉽게\n\n설명하거나 식품의약품안전처의 입장을 기술한 것입니다.\n\n 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식\n\n(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는\n\n사항이 아님을 알려드립니다.  또한, 본 안내서는 현재의 과학적ㆍ기술적 사실 및\n\n유효한 법규를 토대로 작성되었으므로 이후 최신 개정 법규 내용 및 구체적인\n\n※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을\n\n<!-- PAGE_5 -->\n### 머 리 말\n\n<!-- PAGE_5 -->\n###### 질병관리 패러다임이 치료중심에서 조기진단을\n\n<!-- PAGE_5 -->\n###### 통한 예방중심으로 전환됨에 따라 진단검사\n\n<!-- PAGE_5 -->\n###### 결과의 신뢰성 확보의 중요성이 부각되고 있고,\n\n<!-- PAGE_5 -->\n###### 과거 진단기기의 보조적 역할로 인식되던 체외\n\n<!-- PAGE_5 -->\n###### 진단용 의료기기가 진단검사 결과의 판정에 결정\n\n<!-- PAGE_5 -->\n###### 적인 영향을 주는 제품으로 개발되고 있습니다.\n\n <!-- PAGE_5 -->\n###### 또한 최근 IT․BT․NT의 눈부신 발달로 민감\n\n<!-- PAGE_5 -->\n###### 도와 특이도가 향상된 체외진단용 의료기기가\n\n<!-- PAGE_5 -->\n###### 개발되면서 질병의 신속․정확한 진단도 가능\n\n<!-- PAGE_5 -->\n###### 하게 되었습니다.\n\n",
        "original_sentence": "2018 년    7 월   31  일\n\n담당자\n\n확  인(부서장)\n\n우 승 민\n\n이 원 규\n\n<!-- PAGE_4 -->\n###### ※ 본 민원인 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품\n\n<!-- PAGE_4 -->\n###### - 전화번호 : 043-719-4652~4665\n\n<!-- PAGE_4 -->\n###### - 팩스번호 : 043-719-4650\n\n이 안내서는 체외진단용 의료기기 중 뇌나트륨이뇨펩티드 검사제품  허가\n\n심사 시 요구되는 신청서 작성 방법 및 제출자료 요건에 대하여 알기 쉽게\n\n설명하거나 식품의약품안전처의 입장을 기술한 것입니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_291",
      "text": "본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식\n\n(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는\n\n사항이 아님을 알려드립니다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 290,
        "window_size": 3,
        "char_count": 103,
        "word_count": 22,
        "page_number": 4,
        "window_text": "| ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ안내서 | Reagent cartridge N-terminal | BNP | ≤10.0pg/mL | 정밀도는 | CLSI(Clinical | and | Laboratory | Standards | 비교방법과 본 제품의 검사의 결정 역치인 125pg/mL를 | Siemens | Germany |\n\n**[표 끝]**\n\n☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적으로\n\n지침서ㆍ안내서\n\n기타 확인사\n\n제ㆍ개정 절차를 진행하시기 바랍니다.\n\n 상기 사항에 대하여 확인하였음.\n\n 2018 년    7 월   31  일\n\n담당자\n\n확  인(부서장)\n\n우 승 민\n\n이 원 규\n\n<!-- PAGE_4 -->\n###### ※ 본 민원인 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품\n\n<!-- PAGE_4 -->\n###### - 전화번호 : 043-719-4652~4665\n\n<!-- PAGE_4 -->\n###### - 팩스번호 : 043-719-4650\n\n이 안내서는 체외진단용 의료기기 중 뇌나트륨이뇨펩티드 검사제품  허가\n\n심사 시 요구되는 신청서 작성 방법 및 제출자료 요건에 대하여 알기 쉽게\n\n설명하거나 식품의약품안전처의 입장을 기술한 것입니다.\n\n 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식\n\n(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는\n\n사항이 아님을 알려드립니다.  또한, 본 안내서는 현재의 과학적ㆍ기술적 사실 및\n\n유효한 법규를 토대로 작성되었으므로 이후 최신 개정 법규 내용 및 구체적인\n\n※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을\n\n<!-- PAGE_5 -->\n### 머 리 말\n\n<!-- PAGE_5 -->\n###### 질병관리 패러다임이 치료중심에서 조기진단을\n\n<!-- PAGE_5 -->\n###### 통한 예방중심으로 전환됨에 따라 진단검사\n\n<!-- PAGE_5 -->\n###### 결과의 신뢰성 확보의 중요성이 부각되고 있고,\n\n<!-- PAGE_5 -->\n###### 과거 진단기기의 보조적 역할로 인식되던 체외\n\n<!-- PAGE_5 -->\n###### 진단용 의료기기가 진단검사 결과의 판정에 결정\n\n<!-- PAGE_5 -->\n###### 적인 영향을 주는 제품으로 개발되고 있습니다.\n\n <!-- PAGE_5 -->\n###### 또한 최근 IT․BT․NT의 눈부신 발달로 민감\n\n<!-- PAGE_5 -->\n###### 도와 특이도가 향상된 체외진단용 의료기기가\n\n<!-- PAGE_5 -->\n###### 개발되면서 질병의 신속․정확한 진단도 가능\n\n<!-- PAGE_5 -->\n###### 하게 되었습니다.\n\n <!-- PAGE_5 -->\n###### 식약처에서는 국민보건, 산업육성 및 국제조화 측면에서 자율\n\n<!-- PAGE_5 -->\n###### 관리되던 체외진단용 의료기기의 국가관리 필요성을 인지하여 ‘12년\n\n<!-- PAGE_5 -->\n###### 부터 단계적으로 허가를 추진해왔으며 금년에 전 등급에 대한\n\n<!-- PAGE_5 -->\n###### 허가 의무화가 완료되었습니다.\n\n",
        "original_sentence": "본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식\n\n(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는\n\n사항이 아님을 알려드립니다. "
      }
    },
    {
      "chunk_id": "chunk_292",
      "text": "또한, 본 안내서는 현재의 과학적ㆍ기술적 사실 및\n\n유효한 법규를 토대로 작성되었으므로 이후 최신 개정 법규 내용 및 구체적인\n\n※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을\n\n<!-- PAGE_5 -->\n### 머 리 말\n\n<!-- PAGE_5 -->\n###### 질병관리 패러다임이 치료중심에서 조기진단을\n\n<!-- PAGE_5 -->\n###### 통한 예방중심으로 전환됨에 따라 진단검사\n\n<!-- PAGE_5 -->\n###### 결과의 신뢰성 확보의 중요성이 부각되고 있고,\n\n<!-- PAGE_5 -->\n###### 과거 진단기기의 보조적 역할로 인식되던 체외\n\n<!-- PAGE_5 -->\n###### 진단용 의료기기가 진단검사 결과의 판정에 결정\n\n<!-- PAGE_5 -->\n###### 적인 영향을 주는 제품으로 개발되고 있습니다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 291,
        "window_size": 3,
        "char_count": 432,
        "word_count": 90,
        "page_number": 5,
        "window_text": "상기 사항에 대하여 확인하였음.\n\n 2018 년    7 월   31  일\n\n담당자\n\n확  인(부서장)\n\n우 승 민\n\n이 원 규\n\n<!-- PAGE_4 -->\n###### ※ 본 민원인 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품\n\n<!-- PAGE_4 -->\n###### - 전화번호 : 043-719-4652~4665\n\n<!-- PAGE_4 -->\n###### - 팩스번호 : 043-719-4650\n\n이 안내서는 체외진단용 의료기기 중 뇌나트륨이뇨펩티드 검사제품  허가\n\n심사 시 요구되는 신청서 작성 방법 및 제출자료 요건에 대하여 알기 쉽게\n\n설명하거나 식품의약품안전처의 입장을 기술한 것입니다.\n\n 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식\n\n(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는\n\n사항이 아님을 알려드립니다.  또한, 본 안내서는 현재의 과학적ㆍ기술적 사실 및\n\n유효한 법규를 토대로 작성되었으므로 이후 최신 개정 법규 내용 및 구체적인\n\n※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을\n\n<!-- PAGE_5 -->\n### 머 리 말\n\n<!-- PAGE_5 -->\n###### 질병관리 패러다임이 치료중심에서 조기진단을\n\n<!-- PAGE_5 -->\n###### 통한 예방중심으로 전환됨에 따라 진단검사\n\n<!-- PAGE_5 -->\n###### 결과의 신뢰성 확보의 중요성이 부각되고 있고,\n\n<!-- PAGE_5 -->\n###### 과거 진단기기의 보조적 역할로 인식되던 체외\n\n<!-- PAGE_5 -->\n###### 진단용 의료기기가 진단검사 결과의 판정에 결정\n\n<!-- PAGE_5 -->\n###### 적인 영향을 주는 제품으로 개발되고 있습니다.\n\n <!-- PAGE_5 -->\n###### 또한 최근 IT․BT․NT의 눈부신 발달로 민감\n\n<!-- PAGE_5 -->\n###### 도와 특이도가 향상된 체외진단용 의료기기가\n\n<!-- PAGE_5 -->\n###### 개발되면서 질병의 신속․정확한 진단도 가능\n\n<!-- PAGE_5 -->\n###### 하게 되었습니다.\n\n <!-- PAGE_5 -->\n###### 식약처에서는 국민보건, 산업육성 및 국제조화 측면에서 자율\n\n<!-- PAGE_5 -->\n###### 관리되던 체외진단용 의료기기의 국가관리 필요성을 인지하여 ‘12년\n\n<!-- PAGE_5 -->\n###### 부터 단계적으로 허가를 추진해왔으며 금년에 전 등급에 대한\n\n<!-- PAGE_5 -->\n###### 허가 의무화가 완료되었습니다.\n\n <!-- PAGE_5 -->\n###### 체외진단용 의료기기를 의료기기로 관리하기 시작한 이래, 식품의\n\n<!-- PAGE_5 -->\n###### 약품안전평가원에서는 허가․심사 규정 해설서 발간, 민원설명회\n\n<!-- PAGE_5 -->\n###### 등을 통하여 민원편의 제공 및 허가․심사의 공정성 확보를 위해 지속\n\n<!-- PAGE_5 -->\n###### 적으로 노력해 왔습니다. ",
        "original_sentence": "또한, 본 안내서는 현재의 과학적ㆍ기술적 사실 및\n\n유효한 법규를 토대로 작성되었으므로 이후 최신 개정 법규 내용 및 구체적인\n\n※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을\n\n<!-- PAGE_5 -->\n### 머 리 말\n\n<!-- PAGE_5 -->\n###### 질병관리 패러다임이 치료중심에서 조기진단을\n\n<!-- PAGE_5 -->\n###### 통한 예방중심으로 전환됨에 따라 진단검사\n\n<!-- PAGE_5 -->\n###### 결과의 신뢰성 확보의 중요성이 부각되고 있고,\n\n<!-- PAGE_5 -->\n###### 과거 진단기기의 보조적 역할로 인식되던 체외\n\n<!-- PAGE_5 -->\n###### 진단용 의료기기가 진단검사 결과의 판정에 결정\n\n<!-- PAGE_5 -->\n###### 적인 영향을 주는 제품으로 개발되고 있습니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_293",
      "text": "<!-- PAGE_5 -->\n###### 또한 최근 IT․BT․NT의 눈부신 발달로 민감\n\n<!-- PAGE_5 -->\n###### 도와 특이도가 향상된 체외진단용 의료기기가\n\n<!-- PAGE_5 -->\n###### 개발되면서 질병의 신속․정확한 진단도 가능\n\n<!-- PAGE_5 -->\n###### 하게 되었습니다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 292,
        "window_size": 3,
        "char_count": 181,
        "word_count": 34,
        "page_number": 5,
        "window_text": "2018 년    7 월   31  일\n\n담당자\n\n확  인(부서장)\n\n우 승 민\n\n이 원 규\n\n<!-- PAGE_4 -->\n###### ※ 본 민원인 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품\n\n<!-- PAGE_4 -->\n###### - 전화번호 : 043-719-4652~4665\n\n<!-- PAGE_4 -->\n###### - 팩스번호 : 043-719-4650\n\n이 안내서는 체외진단용 의료기기 중 뇌나트륨이뇨펩티드 검사제품  허가\n\n심사 시 요구되는 신청서 작성 방법 및 제출자료 요건에 대하여 알기 쉽게\n\n설명하거나 식품의약품안전처의 입장을 기술한 것입니다.\n\n 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식\n\n(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는\n\n사항이 아님을 알려드립니다.  또한, 본 안내서는 현재의 과학적ㆍ기술적 사실 및\n\n유효한 법규를 토대로 작성되었으므로 이후 최신 개정 법규 내용 및 구체적인\n\n※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을\n\n<!-- PAGE_5 -->\n### 머 리 말\n\n<!-- PAGE_5 -->\n###### 질병관리 패러다임이 치료중심에서 조기진단을\n\n<!-- PAGE_5 -->\n###### 통한 예방중심으로 전환됨에 따라 진단검사\n\n<!-- PAGE_5 -->\n###### 결과의 신뢰성 확보의 중요성이 부각되고 있고,\n\n<!-- PAGE_5 -->\n###### 과거 진단기기의 보조적 역할로 인식되던 체외\n\n<!-- PAGE_5 -->\n###### 진단용 의료기기가 진단검사 결과의 판정에 결정\n\n<!-- PAGE_5 -->\n###### 적인 영향을 주는 제품으로 개발되고 있습니다.\n\n <!-- PAGE_5 -->\n###### 또한 최근 IT․BT․NT의 눈부신 발달로 민감\n\n<!-- PAGE_5 -->\n###### 도와 특이도가 향상된 체외진단용 의료기기가\n\n<!-- PAGE_5 -->\n###### 개발되면서 질병의 신속․정확한 진단도 가능\n\n<!-- PAGE_5 -->\n###### 하게 되었습니다.\n\n <!-- PAGE_5 -->\n###### 식약처에서는 국민보건, 산업육성 및 국제조화 측면에서 자율\n\n<!-- PAGE_5 -->\n###### 관리되던 체외진단용 의료기기의 국가관리 필요성을 인지하여 ‘12년\n\n<!-- PAGE_5 -->\n###### 부터 단계적으로 허가를 추진해왔으며 금년에 전 등급에 대한\n\n<!-- PAGE_5 -->\n###### 허가 의무화가 완료되었습니다.\n\n <!-- PAGE_5 -->\n###### 체외진단용 의료기기를 의료기기로 관리하기 시작한 이래, 식품의\n\n<!-- PAGE_5 -->\n###### 약품안전평가원에서는 허가․심사 규정 해설서 발간, 민원설명회\n\n<!-- PAGE_5 -->\n###### 등을 통하여 민원편의 제공 및 허가․심사의 공정성 확보를 위해 지속\n\n<!-- PAGE_5 -->\n###### 적으로 노력해 왔습니다.  이에 지난 ‘12~’13년 까지 총 19종의 가이\n\n<!-- PAGE_5 -->\n###### 드라인을 발간한 바 있으며, 금번 심질환표지자 검사 시약 2종의\n\n<!-- PAGE_5 -->\n###### 허가․심사 가이드라인을 추가로 개발하였습니다.\n\n",
        "original_sentence": "<!-- PAGE_5 -->\n###### 또한 최근 IT․BT․NT의 눈부신 발달로 민감\n\n<!-- PAGE_5 -->\n###### 도와 특이도가 향상된 체외진단용 의료기기가\n\n<!-- PAGE_5 -->\n###### 개발되면서 질병의 신속․정확한 진단도 가능\n\n<!-- PAGE_5 -->\n###### 하게 되었습니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_294",
      "text": "<!-- PAGE_5 -->\n###### 식약처에서는 국민보건, 산업육성 및 국제조화 측면에서 자율\n\n<!-- PAGE_5 -->\n###### 관리되던 체외진단용 의료기기의 국가관리 필요성을 인지하여 ‘12년\n\n<!-- PAGE_5 -->\n###### 부터 단계적으로 허가를 추진해왔으며 금년에 전 등급에 대한\n\n<!-- PAGE_5 -->\n###### 허가 의무화가 완료되었습니다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 293,
        "window_size": 3,
        "char_count": 216,
        "word_count": 41,
        "page_number": 5,
        "window_text": "본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식\n\n(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는\n\n사항이 아님을 알려드립니다.  또한, 본 안내서는 현재의 과학적ㆍ기술적 사실 및\n\n유효한 법규를 토대로 작성되었으므로 이후 최신 개정 법규 내용 및 구체적인\n\n※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을\n\n<!-- PAGE_5 -->\n### 머 리 말\n\n<!-- PAGE_5 -->\n###### 질병관리 패러다임이 치료중심에서 조기진단을\n\n<!-- PAGE_5 -->\n###### 통한 예방중심으로 전환됨에 따라 진단검사\n\n<!-- PAGE_5 -->\n###### 결과의 신뢰성 확보의 중요성이 부각되고 있고,\n\n<!-- PAGE_5 -->\n###### 과거 진단기기의 보조적 역할로 인식되던 체외\n\n<!-- PAGE_5 -->\n###### 진단용 의료기기가 진단검사 결과의 판정에 결정\n\n<!-- PAGE_5 -->\n###### 적인 영향을 주는 제품으로 개발되고 있습니다.\n\n <!-- PAGE_5 -->\n###### 또한 최근 IT․BT․NT의 눈부신 발달로 민감\n\n<!-- PAGE_5 -->\n###### 도와 특이도가 향상된 체외진단용 의료기기가\n\n<!-- PAGE_5 -->\n###### 개발되면서 질병의 신속․정확한 진단도 가능\n\n<!-- PAGE_5 -->\n###### 하게 되었습니다.\n\n <!-- PAGE_5 -->\n###### 식약처에서는 국민보건, 산업육성 및 국제조화 측면에서 자율\n\n<!-- PAGE_5 -->\n###### 관리되던 체외진단용 의료기기의 국가관리 필요성을 인지하여 ‘12년\n\n<!-- PAGE_5 -->\n###### 부터 단계적으로 허가를 추진해왔으며 금년에 전 등급에 대한\n\n<!-- PAGE_5 -->\n###### 허가 의무화가 완료되었습니다.\n\n <!-- PAGE_5 -->\n###### 체외진단용 의료기기를 의료기기로 관리하기 시작한 이래, 식품의\n\n<!-- PAGE_5 -->\n###### 약품안전평가원에서는 허가․심사 규정 해설서 발간, 민원설명회\n\n<!-- PAGE_5 -->\n###### 등을 통하여 민원편의 제공 및 허가․심사의 공정성 확보를 위해 지속\n\n<!-- PAGE_5 -->\n###### 적으로 노력해 왔습니다.  이에 지난 ‘12~’13년 까지 총 19종의 가이\n\n<!-- PAGE_5 -->\n###### 드라인을 발간한 바 있으며, 금번 심질환표지자 검사 시약 2종의\n\n<!-- PAGE_5 -->\n###### 허가․심사 가이드라인을 추가로 개발하였습니다.\n\n <!-- PAGE_5 -->\n###### 동 가이드라인이 해당 제품의 허가․심사를 준비하시는 업체에\n\n<!-- PAGE_5 -->\n###### 많은 도움이 되기를 바라며 앞으로도 우리 원에서는 체외진단\n\n<!-- PAGE_5 -->\n###### 의료기기의 허가․심사에 공정성 및 투명성을 확보함과 동시에\n\n<!-- PAGE_5 -->\n###### 신속한 허가․심사 지원을 통하여 관련 산업의 발전을 위하여 지\n\n<!-- PAGE_5 -->\n###### 속적으로 노력할 것입니다.\n\n",
        "original_sentence": "<!-- PAGE_5 -->\n###### 식약처에서는 국민보건, 산업육성 및 국제조화 측면에서 자율\n\n<!-- PAGE_5 -->\n###### 관리되던 체외진단용 의료기기의 국가관리 필요성을 인지하여 ‘12년\n\n<!-- PAGE_5 -->\n###### 부터 단계적으로 허가를 추진해왔으며 금년에 전 등급에 대한\n\n<!-- PAGE_5 -->\n###### 허가 의무화가 완료되었습니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_295",
      "text": "<!-- PAGE_5 -->\n###### 체외진단용 의료기기를 의료기기로 관리하기 시작한 이래, 식품의\n\n<!-- PAGE_5 -->\n###### 약품안전평가원에서는 허가․심사 규정 해설서 발간, 민원설명회\n\n<!-- PAGE_5 -->\n###### 등을 통하여 민원편의 제공 및 허가․심사의 공정성 확보를 위해 지속\n\n<!-- PAGE_5 -->\n###### 적으로 노력해 왔습니다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 294,
        "window_size": 3,
        "char_count": 216,
        "word_count": 42,
        "page_number": 5,
        "window_text": "또한, 본 안내서는 현재의 과학적ㆍ기술적 사실 및\n\n유효한 법규를 토대로 작성되었으므로 이후 최신 개정 법규 내용 및 구체적인\n\n※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을\n\n<!-- PAGE_5 -->\n### 머 리 말\n\n<!-- PAGE_5 -->\n###### 질병관리 패러다임이 치료중심에서 조기진단을\n\n<!-- PAGE_5 -->\n###### 통한 예방중심으로 전환됨에 따라 진단검사\n\n<!-- PAGE_5 -->\n###### 결과의 신뢰성 확보의 중요성이 부각되고 있고,\n\n<!-- PAGE_5 -->\n###### 과거 진단기기의 보조적 역할로 인식되던 체외\n\n<!-- PAGE_5 -->\n###### 진단용 의료기기가 진단검사 결과의 판정에 결정\n\n<!-- PAGE_5 -->\n###### 적인 영향을 주는 제품으로 개발되고 있습니다.\n\n <!-- PAGE_5 -->\n###### 또한 최근 IT․BT․NT의 눈부신 발달로 민감\n\n<!-- PAGE_5 -->\n###### 도와 특이도가 향상된 체외진단용 의료기기가\n\n<!-- PAGE_5 -->\n###### 개발되면서 질병의 신속․정확한 진단도 가능\n\n<!-- PAGE_5 -->\n###### 하게 되었습니다.\n\n <!-- PAGE_5 -->\n###### 식약처에서는 국민보건, 산업육성 및 국제조화 측면에서 자율\n\n<!-- PAGE_5 -->\n###### 관리되던 체외진단용 의료기기의 국가관리 필요성을 인지하여 ‘12년\n\n<!-- PAGE_5 -->\n###### 부터 단계적으로 허가를 추진해왔으며 금년에 전 등급에 대한\n\n<!-- PAGE_5 -->\n###### 허가 의무화가 완료되었습니다.\n\n <!-- PAGE_5 -->\n###### 체외진단용 의료기기를 의료기기로 관리하기 시작한 이래, 식품의\n\n<!-- PAGE_5 -->\n###### 약품안전평가원에서는 허가․심사 규정 해설서 발간, 민원설명회\n\n<!-- PAGE_5 -->\n###### 등을 통하여 민원편의 제공 및 허가․심사의 공정성 확보를 위해 지속\n\n<!-- PAGE_5 -->\n###### 적으로 노력해 왔습니다.  이에 지난 ‘12~’13년 까지 총 19종의 가이\n\n<!-- PAGE_5 -->\n###### 드라인을 발간한 바 있으며, 금번 심질환표지자 검사 시약 2종의\n\n<!-- PAGE_5 -->\n###### 허가․심사 가이드라인을 추가로 개발하였습니다.\n\n <!-- PAGE_5 -->\n###### 동 가이드라인이 해당 제품의 허가․심사를 준비하시는 업체에\n\n<!-- PAGE_5 -->\n###### 많은 도움이 되기를 바라며 앞으로도 우리 원에서는 체외진단\n\n<!-- PAGE_5 -->\n###### 의료기기의 허가․심사에 공정성 및 투명성을 확보함과 동시에\n\n<!-- PAGE_5 -->\n###### 신속한 허가․심사 지원을 통하여 관련 산업의 발전을 위하여 지\n\n<!-- PAGE_5 -->\n###### 속적으로 노력할 것입니다.\n\n <!-- PAGE_5 -->\n###### 감사합니다.\n\n",
        "original_sentence": "<!-- PAGE_5 -->\n###### 체외진단용 의료기기를 의료기기로 관리하기 시작한 이래, 식품의\n\n<!-- PAGE_5 -->\n###### 약품안전평가원에서는 허가․심사 규정 해설서 발간, 민원설명회\n\n<!-- PAGE_5 -->\n###### 등을 통하여 민원편의 제공 및 허가․심사의 공정성 확보를 위해 지속\n\n<!-- PAGE_5 -->\n###### 적으로 노력해 왔습니다. "
      }
    },
    {
      "chunk_id": "chunk_296",
      "text": "이에 지난 ‘12~’13년 까지 총 19종의 가이\n\n<!-- PAGE_5 -->\n###### 드라인을 발간한 바 있으며, 금번 심질환표지자 검사 시약 2종의\n\n<!-- PAGE_5 -->\n###### 허가․심사 가이드라인을 추가로 개발하였습니다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 295,
        "window_size": 3,
        "char_count": 139,
        "word_count": 28,
        "page_number": 5,
        "window_text": "<!-- PAGE_5 -->\n###### 또한 최근 IT․BT․NT의 눈부신 발달로 민감\n\n<!-- PAGE_5 -->\n###### 도와 특이도가 향상된 체외진단용 의료기기가\n\n<!-- PAGE_5 -->\n###### 개발되면서 질병의 신속․정확한 진단도 가능\n\n<!-- PAGE_5 -->\n###### 하게 되었습니다.\n\n <!-- PAGE_5 -->\n###### 식약처에서는 국민보건, 산업육성 및 국제조화 측면에서 자율\n\n<!-- PAGE_5 -->\n###### 관리되던 체외진단용 의료기기의 국가관리 필요성을 인지하여 ‘12년\n\n<!-- PAGE_5 -->\n###### 부터 단계적으로 허가를 추진해왔으며 금년에 전 등급에 대한\n\n<!-- PAGE_5 -->\n###### 허가 의무화가 완료되었습니다.\n\n <!-- PAGE_5 -->\n###### 체외진단용 의료기기를 의료기기로 관리하기 시작한 이래, 식품의\n\n<!-- PAGE_5 -->\n###### 약품안전평가원에서는 허가․심사 규정 해설서 발간, 민원설명회\n\n<!-- PAGE_5 -->\n###### 등을 통하여 민원편의 제공 및 허가․심사의 공정성 확보를 위해 지속\n\n<!-- PAGE_5 -->\n###### 적으로 노력해 왔습니다.  이에 지난 ‘12~’13년 까지 총 19종의 가이\n\n<!-- PAGE_5 -->\n###### 드라인을 발간한 바 있으며, 금번 심질환표지자 검사 시약 2종의\n\n<!-- PAGE_5 -->\n###### 허가․심사 가이드라인을 추가로 개발하였습니다.\n\n <!-- PAGE_5 -->\n###### 동 가이드라인이 해당 제품의 허가․심사를 준비하시는 업체에\n\n<!-- PAGE_5 -->\n###### 많은 도움이 되기를 바라며 앞으로도 우리 원에서는 체외진단\n\n<!-- PAGE_5 -->\n###### 의료기기의 허가․심사에 공정성 및 투명성을 확보함과 동시에\n\n<!-- PAGE_5 -->\n###### 신속한 허가․심사 지원을 통하여 관련 산업의 발전을 위하여 지\n\n<!-- PAGE_5 -->\n###### 속적으로 노력할 것입니다.\n\n <!-- PAGE_5 -->\n###### 감사합니다.\n\n <!-- PAGE_5 -->\n###### 2014년 5월\n\n<!-- PAGE_5 -->\n###### 식품의약품안전평가원장\n\n<!-- PAGE_6 -->\n# 목  차\n\n<!-- PAGE_6 -->\n###### Ⅰ. ",
        "original_sentence": "이에 지난 ‘12~’13년 까지 총 19종의 가이\n\n<!-- PAGE_5 -->\n###### 드라인을 발간한 바 있으며, 금번 심질환표지자 검사 시약 2종의\n\n<!-- PAGE_5 -->\n###### 허가․심사 가이드라인을 추가로 개발하였습니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_297",
      "text": "<!-- PAGE_5 -->\n###### 동 가이드라인이 해당 제품의 허가․심사를 준비하시는 업체에\n\n<!-- PAGE_5 -->\n###### 많은 도움이 되기를 바라며 앞으로도 우리 원에서는 체외진단\n\n<!-- PAGE_5 -->\n###### 의료기기의 허가․심사에 공정성 및 투명성을 확보함과 동시에\n\n<!-- PAGE_5 -->\n###### 신속한 허가․심사 지원을 통하여 관련 산업의 발전을 위하여 지\n\n<!-- PAGE_5 -->\n###### 속적으로 노력할 것입니다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 296,
        "window_size": 3,
        "char_count": 269,
        "word_count": 54,
        "page_number": 5,
        "window_text": "<!-- PAGE_5 -->\n###### 식약처에서는 국민보건, 산업육성 및 국제조화 측면에서 자율\n\n<!-- PAGE_5 -->\n###### 관리되던 체외진단용 의료기기의 국가관리 필요성을 인지하여 ‘12년\n\n<!-- PAGE_5 -->\n###### 부터 단계적으로 허가를 추진해왔으며 금년에 전 등급에 대한\n\n<!-- PAGE_5 -->\n###### 허가 의무화가 완료되었습니다.\n\n <!-- PAGE_5 -->\n###### 체외진단용 의료기기를 의료기기로 관리하기 시작한 이래, 식품의\n\n<!-- PAGE_5 -->\n###### 약품안전평가원에서는 허가․심사 규정 해설서 발간, 민원설명회\n\n<!-- PAGE_5 -->\n###### 등을 통하여 민원편의 제공 및 허가․심사의 공정성 확보를 위해 지속\n\n<!-- PAGE_5 -->\n###### 적으로 노력해 왔습니다.  이에 지난 ‘12~’13년 까지 총 19종의 가이\n\n<!-- PAGE_5 -->\n###### 드라인을 발간한 바 있으며, 금번 심질환표지자 검사 시약 2종의\n\n<!-- PAGE_5 -->\n###### 허가․심사 가이드라인을 추가로 개발하였습니다.\n\n <!-- PAGE_5 -->\n###### 동 가이드라인이 해당 제품의 허가․심사를 준비하시는 업체에\n\n<!-- PAGE_5 -->\n###### 많은 도움이 되기를 바라며 앞으로도 우리 원에서는 체외진단\n\n<!-- PAGE_5 -->\n###### 의료기기의 허가․심사에 공정성 및 투명성을 확보함과 동시에\n\n<!-- PAGE_5 -->\n###### 신속한 허가․심사 지원을 통하여 관련 산업의 발전을 위하여 지\n\n<!-- PAGE_5 -->\n###### 속적으로 노력할 것입니다.\n\n <!-- PAGE_5 -->\n###### 감사합니다.\n\n <!-- PAGE_5 -->\n###### 2014년 5월\n\n<!-- PAGE_5 -->\n###### 식품의약품안전평가원장\n\n<!-- PAGE_6 -->\n# 목  차\n\n<!-- PAGE_6 -->\n###### Ⅰ.  개요\n\n<!-- PAGE_6 -->\n###### 2\n\n<!-- PAGE_6 -->\n###### Ⅱ. ",
        "original_sentence": "<!-- PAGE_5 -->\n###### 동 가이드라인이 해당 제품의 허가․심사를 준비하시는 업체에\n\n<!-- PAGE_5 -->\n###### 많은 도움이 되기를 바라며 앞으로도 우리 원에서는 체외진단\n\n<!-- PAGE_5 -->\n###### 의료기기의 허가․심사에 공정성 및 투명성을 확보함과 동시에\n\n<!-- PAGE_5 -->\n###### 신속한 허가․심사 지원을 통하여 관련 산업의 발전을 위하여 지\n\n<!-- PAGE_5 -->\n###### 속적으로 노력할 것입니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_298",
      "text": "<!-- PAGE_5 -->\n###### 감사합니다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 297,
        "window_size": 3,
        "char_count": 31,
        "word_count": 5,
        "page_number": 5,
        "window_text": "<!-- PAGE_5 -->\n###### 체외진단용 의료기기를 의료기기로 관리하기 시작한 이래, 식품의\n\n<!-- PAGE_5 -->\n###### 약품안전평가원에서는 허가․심사 규정 해설서 발간, 민원설명회\n\n<!-- PAGE_5 -->\n###### 등을 통하여 민원편의 제공 및 허가․심사의 공정성 확보를 위해 지속\n\n<!-- PAGE_5 -->\n###### 적으로 노력해 왔습니다.  이에 지난 ‘12~’13년 까지 총 19종의 가이\n\n<!-- PAGE_5 -->\n###### 드라인을 발간한 바 있으며, 금번 심질환표지자 검사 시약 2종의\n\n<!-- PAGE_5 -->\n###### 허가․심사 가이드라인을 추가로 개발하였습니다.\n\n <!-- PAGE_5 -->\n###### 동 가이드라인이 해당 제품의 허가․심사를 준비하시는 업체에\n\n<!-- PAGE_5 -->\n###### 많은 도움이 되기를 바라며 앞으로도 우리 원에서는 체외진단\n\n<!-- PAGE_5 -->\n###### 의료기기의 허가․심사에 공정성 및 투명성을 확보함과 동시에\n\n<!-- PAGE_5 -->\n###### 신속한 허가․심사 지원을 통하여 관련 산업의 발전을 위하여 지\n\n<!-- PAGE_5 -->\n###### 속적으로 노력할 것입니다.\n\n <!-- PAGE_5 -->\n###### 감사합니다.\n\n <!-- PAGE_5 -->\n###### 2014년 5월\n\n<!-- PAGE_5 -->\n###### 식품의약품안전평가원장\n\n<!-- PAGE_6 -->\n# 목  차\n\n<!-- PAGE_6 -->\n###### Ⅰ.  개요\n\n<!-- PAGE_6 -->\n###### 2\n\n<!-- PAGE_6 -->\n###### Ⅱ.  용어의 정의\n\n<!-- PAGE_6 -->\n###### 4\n\n<!-- PAGE_6 -->\n###### 9. ",
        "original_sentence": "<!-- PAGE_5 -->\n###### 감사합니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_299",
      "text": "<!-- PAGE_5 -->\n###### 2014년 5월\n\n<!-- PAGE_5 -->\n###### 식품의약품안전평가원장\n\n<!-- PAGE_6 -->\n# 목  차\n\n<!-- PAGE_6 -->\n###### Ⅰ. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 298,
        "window_size": 3,
        "char_count": 119,
        "word_count": 22,
        "page_number": 5,
        "window_text": "이에 지난 ‘12~’13년 까지 총 19종의 가이\n\n<!-- PAGE_5 -->\n###### 드라인을 발간한 바 있으며, 금번 심질환표지자 검사 시약 2종의\n\n<!-- PAGE_5 -->\n###### 허가․심사 가이드라인을 추가로 개발하였습니다.\n\n <!-- PAGE_5 -->\n###### 동 가이드라인이 해당 제품의 허가․심사를 준비하시는 업체에\n\n<!-- PAGE_5 -->\n###### 많은 도움이 되기를 바라며 앞으로도 우리 원에서는 체외진단\n\n<!-- PAGE_5 -->\n###### 의료기기의 허가․심사에 공정성 및 투명성을 확보함과 동시에\n\n<!-- PAGE_5 -->\n###### 신속한 허가․심사 지원을 통하여 관련 산업의 발전을 위하여 지\n\n<!-- PAGE_5 -->\n###### 속적으로 노력할 것입니다.\n\n <!-- PAGE_5 -->\n###### 감사합니다.\n\n <!-- PAGE_5 -->\n###### 2014년 5월\n\n<!-- PAGE_5 -->\n###### 식품의약품안전평가원장\n\n<!-- PAGE_6 -->\n# 목  차\n\n<!-- PAGE_6 -->\n###### Ⅰ.  개요\n\n<!-- PAGE_6 -->\n###### 2\n\n<!-- PAGE_6 -->\n###### Ⅱ.  용어의 정의\n\n<!-- PAGE_6 -->\n###### 4\n\n<!-- PAGE_6 -->\n###### 9.  저장방법 및 사용기간\n\n<!-- PAGE_6 -->\n###### 35\n\n<!-- PAGE_6 -->\n###### 10. ",
        "original_sentence": "<!-- PAGE_5 -->\n###### 2014년 5월\n\n<!-- PAGE_5 -->\n###### 식품의약품안전평가원장\n\n<!-- PAGE_6 -->\n# 목  차\n\n<!-- PAGE_6 -->\n###### Ⅰ. "
      }
    },
    {
      "chunk_id": "chunk_300",
      "text": "개요\n\n<!-- PAGE_6 -->\n###### 2\n\n<!-- PAGE_6 -->\n###### Ⅱ. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 299,
        "window_size": 3,
        "char_count": 56,
        "word_count": 11,
        "page_number": 6,
        "window_text": "<!-- PAGE_5 -->\n###### 동 가이드라인이 해당 제품의 허가․심사를 준비하시는 업체에\n\n<!-- PAGE_5 -->\n###### 많은 도움이 되기를 바라며 앞으로도 우리 원에서는 체외진단\n\n<!-- PAGE_5 -->\n###### 의료기기의 허가․심사에 공정성 및 투명성을 확보함과 동시에\n\n<!-- PAGE_5 -->\n###### 신속한 허가․심사 지원을 통하여 관련 산업의 발전을 위하여 지\n\n<!-- PAGE_5 -->\n###### 속적으로 노력할 것입니다.\n\n <!-- PAGE_5 -->\n###### 감사합니다.\n\n <!-- PAGE_5 -->\n###### 2014년 5월\n\n<!-- PAGE_5 -->\n###### 식품의약품안전평가원장\n\n<!-- PAGE_6 -->\n# 목  차\n\n<!-- PAGE_6 -->\n###### Ⅰ.  개요\n\n<!-- PAGE_6 -->\n###### 2\n\n<!-- PAGE_6 -->\n###### Ⅱ.  용어의 정의\n\n<!-- PAGE_6 -->\n###### 4\n\n<!-- PAGE_6 -->\n###### 9.  저장방법 및 사용기간\n\n<!-- PAGE_6 -->\n###### 35\n\n<!-- PAGE_6 -->\n###### 10.  시험규격\n\n<!-- PAGE_6 -->\n###### 36\n\n<!-- PAGE_6 -->\n###### 11. ",
        "original_sentence": "개요\n\n<!-- PAGE_6 -->\n###### 2\n\n<!-- PAGE_6 -->\n###### Ⅱ. "
      }
    },
    {
      "chunk_id": "chunk_301",
      "text": "용어의 정의\n\n<!-- PAGE_6 -->\n###### 4\n\n<!-- PAGE_6 -->\n###### 9. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 300,
        "window_size": 3,
        "char_count": 60,
        "word_count": 12,
        "page_number": 6,
        "window_text": "<!-- PAGE_5 -->\n###### 감사합니다.\n\n <!-- PAGE_5 -->\n###### 2014년 5월\n\n<!-- PAGE_5 -->\n###### 식품의약품안전평가원장\n\n<!-- PAGE_6 -->\n# 목  차\n\n<!-- PAGE_6 -->\n###### Ⅰ.  개요\n\n<!-- PAGE_6 -->\n###### 2\n\n<!-- PAGE_6 -->\n###### Ⅱ.  용어의 정의\n\n<!-- PAGE_6 -->\n###### 4\n\n<!-- PAGE_6 -->\n###### 9.  저장방법 및 사용기간\n\n<!-- PAGE_6 -->\n###### 35\n\n<!-- PAGE_6 -->\n###### 10.  시험규격\n\n<!-- PAGE_6 -->\n###### 36\n\n<!-- PAGE_6 -->\n###### 11.  제조원\n\n<!-- PAGE_6 -->\n###### 38\n\n<!-- PAGE_7 -->\n###### Ⅵ. ",
        "original_sentence": "용어의 정의\n\n<!-- PAGE_6 -->\n###### 4\n\n<!-- PAGE_6 -->\n###### 9. "
      }
    },
    {
      "chunk_id": "chunk_302",
      "text": "저장방법 및 사용기간\n\n<!-- PAGE_6 -->\n###### 35\n\n<!-- PAGE_6 -->\n###### 10. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 301,
        "window_size": 3,
        "char_count": 67,
        "word_count": 13,
        "page_number": 6,
        "window_text": "<!-- PAGE_5 -->\n###### 2014년 5월\n\n<!-- PAGE_5 -->\n###### 식품의약품안전평가원장\n\n<!-- PAGE_6 -->\n# 목  차\n\n<!-- PAGE_6 -->\n###### Ⅰ.  개요\n\n<!-- PAGE_6 -->\n###### 2\n\n<!-- PAGE_6 -->\n###### Ⅱ.  용어의 정의\n\n<!-- PAGE_6 -->\n###### 4\n\n<!-- PAGE_6 -->\n###### 9.  저장방법 및 사용기간\n\n<!-- PAGE_6 -->\n###### 35\n\n<!-- PAGE_6 -->\n###### 10.  시험규격\n\n<!-- PAGE_6 -->\n###### 36\n\n<!-- PAGE_6 -->\n###### 11.  제조원\n\n<!-- PAGE_6 -->\n###### 38\n\n<!-- PAGE_7 -->\n###### Ⅵ.  기술문서 등의 심사를 위한 제출자료\n\n<!-- PAGE_7 -->\n###### 39\n\n<!-- PAGE_7 -->\n###### 1. ",
        "original_sentence": "저장방법 및 사용기간\n\n<!-- PAGE_6 -->\n###### 35\n\n<!-- PAGE_6 -->\n###### 10. "
      }
    },
    {
      "chunk_id": "chunk_303",
      "text": "시험규격\n\n<!-- PAGE_6 -->\n###### 36\n\n<!-- PAGE_6 -->\n###### 11. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 302,
        "window_size": 3,
        "char_count": 60,
        "word_count": 11,
        "page_number": 6,
        "window_text": "개요\n\n<!-- PAGE_6 -->\n###### 2\n\n<!-- PAGE_6 -->\n###### Ⅱ.  용어의 정의\n\n<!-- PAGE_6 -->\n###### 4\n\n<!-- PAGE_6 -->\n###### 9.  저장방법 및 사용기간\n\n<!-- PAGE_6 -->\n###### 35\n\n<!-- PAGE_6 -->\n###### 10.  시험규격\n\n<!-- PAGE_6 -->\n###### 36\n\n<!-- PAGE_6 -->\n###### 11.  제조원\n\n<!-- PAGE_6 -->\n###### 38\n\n<!-- PAGE_7 -->\n###### Ⅵ.  기술문서 등의 심사를 위한 제출자료\n\n<!-- PAGE_7 -->\n###### 39\n\n<!-- PAGE_7 -->\n###### 1.  개발경위, 측정원리·방법 및 국내․외 사용현황에\n\n<!-- PAGE_7 -->\n###### 6. ",
        "original_sentence": "시험규격\n\n<!-- PAGE_6 -->\n###### 36\n\n<!-- PAGE_6 -->\n###### 11. "
      }
    },
    {
      "chunk_id": "chunk_304",
      "text": "제조원\n\n<!-- PAGE_6 -->\n###### 38\n\n<!-- PAGE_7 -->\n###### Ⅵ. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 303,
        "window_size": 3,
        "char_count": 58,
        "word_count": 11,
        "page_number": 6,
        "window_text": "용어의 정의\n\n<!-- PAGE_6 -->\n###### 4\n\n<!-- PAGE_6 -->\n###### 9.  저장방법 및 사용기간\n\n<!-- PAGE_6 -->\n###### 35\n\n<!-- PAGE_6 -->\n###### 10.  시험규격\n\n<!-- PAGE_6 -->\n###### 36\n\n<!-- PAGE_6 -->\n###### 11.  제조원\n\n<!-- PAGE_6 -->\n###### 38\n\n<!-- PAGE_7 -->\n###### Ⅵ.  기술문서 등의 심사를 위한 제출자료\n\n<!-- PAGE_7 -->\n###### 39\n\n<!-- PAGE_7 -->\n###### 1.  개발경위, 측정원리·방법 및 국내․외 사용현황에\n\n<!-- PAGE_7 -->\n###### 6.  상관성 평가\n\n<!-- PAGE_7 -->\n###### 66\n\n<!-- PAGE_7 -->\n###### Ⅷ. ",
        "original_sentence": "제조원\n\n<!-- PAGE_6 -->\n###### 38\n\n<!-- PAGE_7 -->\n###### Ⅵ. "
      }
    },
    {
      "chunk_id": "chunk_305",
      "text": "기술문서 등의 심사를 위한 제출자료\n\n<!-- PAGE_7 -->\n###### 39\n\n<!-- PAGE_7 -->\n###### 1. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 304,
        "window_size": 3,
        "char_count": 74,
        "word_count": 15,
        "page_number": 7,
        "window_text": "저장방법 및 사용기간\n\n<!-- PAGE_6 -->\n###### 35\n\n<!-- PAGE_6 -->\n###### 10.  시험규격\n\n<!-- PAGE_6 -->\n###### 36\n\n<!-- PAGE_6 -->\n###### 11.  제조원\n\n<!-- PAGE_6 -->\n###### 38\n\n<!-- PAGE_7 -->\n###### Ⅵ.  기술문서 등의 심사를 위한 제출자료\n\n<!-- PAGE_7 -->\n###### 39\n\n<!-- PAGE_7 -->\n###### 1.  개발경위, 측정원리·방법 및 국내․외 사용현황에\n\n<!-- PAGE_7 -->\n###### 6.  상관성 평가\n\n<!-- PAGE_7 -->\n###### 66\n\n<!-- PAGE_7 -->\n###### Ⅷ.  참고문헌\n\n<!-- PAGE_7 -->\n###### 68\n\n<!-- PAGE_7 -->\n###### Ⅸ. ",
        "original_sentence": "기술문서 등의 심사를 위한 제출자료\n\n<!-- PAGE_7 -->\n###### 39\n\n<!-- PAGE_7 -->\n###### 1. "
      }
    },
    {
      "chunk_id": "chunk_306",
      "text": "개발경위, 측정원리·방법 및 국내․외 사용현황에\n\n<!-- PAGE_7 -->\n###### 6. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 305,
        "window_size": 3,
        "char_count": 54,
        "word_count": 10,
        "page_number": 7,
        "window_text": "시험규격\n\n<!-- PAGE_6 -->\n###### 36\n\n<!-- PAGE_6 -->\n###### 11.  제조원\n\n<!-- PAGE_6 -->\n###### 38\n\n<!-- PAGE_7 -->\n###### Ⅵ.  기술문서 등의 심사를 위한 제출자료\n\n<!-- PAGE_7 -->\n###### 39\n\n<!-- PAGE_7 -->\n###### 1.  개발경위, 측정원리·방법 및 국내․외 사용현황에\n\n<!-- PAGE_7 -->\n###### 6.  상관성 평가\n\n<!-- PAGE_7 -->\n###### 66\n\n<!-- PAGE_7 -->\n###### Ⅷ.  참고문헌\n\n<!-- PAGE_7 -->\n###### 68\n\n<!-- PAGE_7 -->\n###### Ⅸ.  부록\n\n<!-- PAGE_7 -->\n###### 70\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 2 -\n<!-- PAGE_8 -->\n# Ⅰ\n\n<!-- PAGE_8 -->\n#### 개  요\n\n<!-- PAGE_8 -->\n###### 본 가이드라인은 심근혈관표지자인 뇌나트륨이뇨펩티드(NT-proBNP,\n\n<!-- PAGE_8 -->\n###### BNP) 검사 제품의 허가․심사 시에 요구되는 신청서 작성 방법 및\n\n<!-- PAGE_8 -->\n###### 제출자료 요건을 예시를 들어 구체적이고 알기 쉽게 설명하였습니다.\n\n",
        "original_sentence": "개발경위, 측정원리·방법 및 국내․외 사용현황에\n\n<!-- PAGE_7 -->\n###### 6. "
      }
    },
    {
      "chunk_id": "chunk_307",
      "text": "상관성 평가\n\n<!-- PAGE_7 -->\n###### 66\n\n<!-- PAGE_7 -->\n###### Ⅷ. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 306,
        "window_size": 3,
        "char_count": 61,
        "word_count": 12,
        "page_number": 7,
        "window_text": "제조원\n\n<!-- PAGE_6 -->\n###### 38\n\n<!-- PAGE_7 -->\n###### Ⅵ.  기술문서 등의 심사를 위한 제출자료\n\n<!-- PAGE_7 -->\n###### 39\n\n<!-- PAGE_7 -->\n###### 1.  개발경위, 측정원리·방법 및 국내․외 사용현황에\n\n<!-- PAGE_7 -->\n###### 6.  상관성 평가\n\n<!-- PAGE_7 -->\n###### 66\n\n<!-- PAGE_7 -->\n###### Ⅷ.  참고문헌\n\n<!-- PAGE_7 -->\n###### 68\n\n<!-- PAGE_7 -->\n###### Ⅸ.  부록\n\n<!-- PAGE_7 -->\n###### 70\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 2 -\n<!-- PAGE_8 -->\n# Ⅰ\n\n<!-- PAGE_8 -->\n#### 개  요\n\n<!-- PAGE_8 -->\n###### 본 가이드라인은 심근혈관표지자인 뇌나트륨이뇨펩티드(NT-proBNP,\n\n<!-- PAGE_8 -->\n###### BNP) 검사 제품의 허가․심사 시에 요구되는 신청서 작성 방법 및\n\n<!-- PAGE_8 -->\n###### 제출자료 요건을 예시를 들어 구체적이고 알기 쉽게 설명하였습니다.\n\n <!-- PAGE_8 -->\n###### 다만, 가이드라인에 기술한 사항은 현재까지의 경험과 과학적\n\n<!-- PAGE_8 -->\n###### 사실을 근거로 작성된 바, 새로운 과학적 사실이 밝혀지거나 관련\n\n<!-- PAGE_8 -->\n###### 규정이 개정될 경우 추후 변경될 수 있습니다.\n\n",
        "original_sentence": "상관성 평가\n\n<!-- PAGE_7 -->\n###### 66\n\n<!-- PAGE_7 -->\n###### Ⅷ. "
      }
    },
    {
      "chunk_id": "chunk_308",
      "text": "참고문헌\n\n<!-- PAGE_7 -->\n###### 68\n\n<!-- PAGE_7 -->\n###### Ⅸ. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 307,
        "window_size": 3,
        "char_count": 59,
        "word_count": 11,
        "page_number": 7,
        "window_text": "기술문서 등의 심사를 위한 제출자료\n\n<!-- PAGE_7 -->\n###### 39\n\n<!-- PAGE_7 -->\n###### 1.  개발경위, 측정원리·방법 및 국내․외 사용현황에\n\n<!-- PAGE_7 -->\n###### 6.  상관성 평가\n\n<!-- PAGE_7 -->\n###### 66\n\n<!-- PAGE_7 -->\n###### Ⅷ.  참고문헌\n\n<!-- PAGE_7 -->\n###### 68\n\n<!-- PAGE_7 -->\n###### Ⅸ.  부록\n\n<!-- PAGE_7 -->\n###### 70\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 2 -\n<!-- PAGE_8 -->\n# Ⅰ\n\n<!-- PAGE_8 -->\n#### 개  요\n\n<!-- PAGE_8 -->\n###### 본 가이드라인은 심근혈관표지자인 뇌나트륨이뇨펩티드(NT-proBNP,\n\n<!-- PAGE_8 -->\n###### BNP) 검사 제품의 허가․심사 시에 요구되는 신청서 작성 방법 및\n\n<!-- PAGE_8 -->\n###### 제출자료 요건을 예시를 들어 구체적이고 알기 쉽게 설명하였습니다.\n\n <!-- PAGE_8 -->\n###### 다만, 가이드라인에 기술한 사항은 현재까지의 경험과 과학적\n\n<!-- PAGE_8 -->\n###### 사실을 근거로 작성된 바, 새로운 과학적 사실이 밝혀지거나 관련\n\n<!-- PAGE_8 -->\n###### 규정이 개정될 경우 추후 변경될 수 있습니다.\n\n <!-- PAGE_8 -->\n###### 또한 본 가이드라인은 뇌나트륨이뇨펩티드 검사 제품의 허가․심사\n\n<!-- PAGE_8 -->\n###### 시에 요구되는 사항에 대한 일반적인 해석을 기술하고 있는 것으로서\n\n<!-- PAGE_8 -->\n###### 법적 효력이 있는 사항이 아니며, 개별 사항에 따라 다르게 해석할\n\n<!-- PAGE_8 -->\n###### 1. ",
        "original_sentence": "참고문헌\n\n<!-- PAGE_7 -->\n###### 68\n\n<!-- PAGE_7 -->\n###### Ⅸ. "
      }
    },
    {
      "chunk_id": "chunk_309",
      "text": "부록\n\n<!-- PAGE_7 -->\n###### 70\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 2 -\n<!-- PAGE_8 -->\n# Ⅰ\n\n<!-- PAGE_8 -->\n#### 개  요\n\n<!-- PAGE_8 -->\n###### 본 가이드라인은 심근혈관표지자인 뇌나트륨이뇨펩티드(NT-proBNP,\n\n<!-- PAGE_8 -->\n###### BNP) 검사 제품의 허가․심사 시에 요구되는 신청서 작성 방법 및\n\n<!-- PAGE_8 -->\n###### 제출자료 요건을 예시를 들어 구체적이고 알기 쉽게 설명하였습니다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 308,
        "window_size": 3,
        "char_count": 322,
        "word_count": 63,
        "page_number": 7,
        "window_text": "개발경위, 측정원리·방법 및 국내․외 사용현황에\n\n<!-- PAGE_7 -->\n###### 6.  상관성 평가\n\n<!-- PAGE_7 -->\n###### 66\n\n<!-- PAGE_7 -->\n###### Ⅷ.  참고문헌\n\n<!-- PAGE_7 -->\n###### 68\n\n<!-- PAGE_7 -->\n###### Ⅸ.  부록\n\n<!-- PAGE_7 -->\n###### 70\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 2 -\n<!-- PAGE_8 -->\n# Ⅰ\n\n<!-- PAGE_8 -->\n#### 개  요\n\n<!-- PAGE_8 -->\n###### 본 가이드라인은 심근혈관표지자인 뇌나트륨이뇨펩티드(NT-proBNP,\n\n<!-- PAGE_8 -->\n###### BNP) 검사 제품의 허가․심사 시에 요구되는 신청서 작성 방법 및\n\n<!-- PAGE_8 -->\n###### 제출자료 요건을 예시를 들어 구체적이고 알기 쉽게 설명하였습니다.\n\n <!-- PAGE_8 -->\n###### 다만, 가이드라인에 기술한 사항은 현재까지의 경험과 과학적\n\n<!-- PAGE_8 -->\n###### 사실을 근거로 작성된 바, 새로운 과학적 사실이 밝혀지거나 관련\n\n<!-- PAGE_8 -->\n###### 규정이 개정될 경우 추후 변경될 수 있습니다.\n\n <!-- PAGE_8 -->\n###### 또한 본 가이드라인은 뇌나트륨이뇨펩티드 검사 제품의 허가․심사\n\n<!-- PAGE_8 -->\n###### 시에 요구되는 사항에 대한 일반적인 해석을 기술하고 있는 것으로서\n\n<!-- PAGE_8 -->\n###### 법적 효력이 있는 사항이 아니며, 개별 사항에 따라 다르게 해석할\n\n<!-- PAGE_8 -->\n###### 1.  목적\n\n본 가이드라인은 심장질환 진단에 도움을 주는 뇌나트륨이뇨펩티드\n\n(NT-proBNP, BNP) 측정시약의 허가․심사 시 요구되는 신청서 및 제출자료\n\n준비를 위한 참고자료로 활용하는 것을 목적으로 한다.\n\n",
        "original_sentence": "부록\n\n<!-- PAGE_7 -->\n###### 70\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 2 -\n<!-- PAGE_8 -->\n# Ⅰ\n\n<!-- PAGE_8 -->\n#### 개  요\n\n<!-- PAGE_8 -->\n###### 본 가이드라인은 심근혈관표지자인 뇌나트륨이뇨펩티드(NT-proBNP,\n\n<!-- PAGE_8 -->\n###### BNP) 검사 제품의 허가․심사 시에 요구되는 신청서 작성 방법 및\n\n<!-- PAGE_8 -->\n###### 제출자료 요건을 예시를 들어 구체적이고 알기 쉽게 설명하였습니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_310",
      "text": "<!-- PAGE_8 -->\n###### 다만, 가이드라인에 기술한 사항은 현재까지의 경험과 과학적\n\n<!-- PAGE_8 -->\n###### 사실을 근거로 작성된 바, 새로운 과학적 사실이 밝혀지거나 관련\n\n<!-- PAGE_8 -->\n###### 규정이 개정될 경우 추후 변경될 수 있습니다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 309,
        "window_size": 3,
        "char_count": 167,
        "word_count": 35,
        "page_number": 8,
        "window_text": "상관성 평가\n\n<!-- PAGE_7 -->\n###### 66\n\n<!-- PAGE_7 -->\n###### Ⅷ.  참고문헌\n\n<!-- PAGE_7 -->\n###### 68\n\n<!-- PAGE_7 -->\n###### Ⅸ.  부록\n\n<!-- PAGE_7 -->\n###### 70\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 2 -\n<!-- PAGE_8 -->\n# Ⅰ\n\n<!-- PAGE_8 -->\n#### 개  요\n\n<!-- PAGE_8 -->\n###### 본 가이드라인은 심근혈관표지자인 뇌나트륨이뇨펩티드(NT-proBNP,\n\n<!-- PAGE_8 -->\n###### BNP) 검사 제품의 허가․심사 시에 요구되는 신청서 작성 방법 및\n\n<!-- PAGE_8 -->\n###### 제출자료 요건을 예시를 들어 구체적이고 알기 쉽게 설명하였습니다.\n\n <!-- PAGE_8 -->\n###### 다만, 가이드라인에 기술한 사항은 현재까지의 경험과 과학적\n\n<!-- PAGE_8 -->\n###### 사실을 근거로 작성된 바, 새로운 과학적 사실이 밝혀지거나 관련\n\n<!-- PAGE_8 -->\n###### 규정이 개정될 경우 추후 변경될 수 있습니다.\n\n <!-- PAGE_8 -->\n###### 또한 본 가이드라인은 뇌나트륨이뇨펩티드 검사 제품의 허가․심사\n\n<!-- PAGE_8 -->\n###### 시에 요구되는 사항에 대한 일반적인 해석을 기술하고 있는 것으로서\n\n<!-- PAGE_8 -->\n###### 법적 효력이 있는 사항이 아니며, 개별 사항에 따라 다르게 해석할\n\n<!-- PAGE_8 -->\n###### 1.  목적\n\n본 가이드라인은 심장질환 진단에 도움을 주는 뇌나트륨이뇨펩티드\n\n(NT-proBNP, BNP) 측정시약의 허가․심사 시 요구되는 신청서 및 제출자료\n\n준비를 위한 참고자료로 활용하는 것을 목적으로 한다.\n\n ※ 알림 : 본 가이드라인에 따라 정상적인 서류와 첨부자료를 제대로\n\n갖추어 접수한 민원에 대하여 신속처리가 진행될 수 있으니 민원 신청시\n\n참고하시기 바랍니다.\n\n",
        "original_sentence": "<!-- PAGE_8 -->\n###### 다만, 가이드라인에 기술한 사항은 현재까지의 경험과 과학적\n\n<!-- PAGE_8 -->\n###### 사실을 근거로 작성된 바, 새로운 과학적 사실이 밝혀지거나 관련\n\n<!-- PAGE_8 -->\n###### 규정이 개정될 경우 추후 변경될 수 있습니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_311",
      "text": "<!-- PAGE_8 -->\n###### 또한 본 가이드라인은 뇌나트륨이뇨펩티드 검사 제품의 허가․심사\n\n<!-- PAGE_8 -->\n###### 시에 요구되는 사항에 대한 일반적인 해석을 기술하고 있는 것으로서\n\n<!-- PAGE_8 -->\n###### 법적 효력이 있는 사항이 아니며, 개별 사항에 따라 다르게 해석할\n\n<!-- PAGE_8 -->\n###### 1. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 310,
        "window_size": 3,
        "char_count": 207,
        "word_count": 43,
        "page_number": 8,
        "window_text": "참고문헌\n\n<!-- PAGE_7 -->\n###### 68\n\n<!-- PAGE_7 -->\n###### Ⅸ.  부록\n\n<!-- PAGE_7 -->\n###### 70\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 2 -\n<!-- PAGE_8 -->\n# Ⅰ\n\n<!-- PAGE_8 -->\n#### 개  요\n\n<!-- PAGE_8 -->\n###### 본 가이드라인은 심근혈관표지자인 뇌나트륨이뇨펩티드(NT-proBNP,\n\n<!-- PAGE_8 -->\n###### BNP) 검사 제품의 허가․심사 시에 요구되는 신청서 작성 방법 및\n\n<!-- PAGE_8 -->\n###### 제출자료 요건을 예시를 들어 구체적이고 알기 쉽게 설명하였습니다.\n\n <!-- PAGE_8 -->\n###### 다만, 가이드라인에 기술한 사항은 현재까지의 경험과 과학적\n\n<!-- PAGE_8 -->\n###### 사실을 근거로 작성된 바, 새로운 과학적 사실이 밝혀지거나 관련\n\n<!-- PAGE_8 -->\n###### 규정이 개정될 경우 추후 변경될 수 있습니다.\n\n <!-- PAGE_8 -->\n###### 또한 본 가이드라인은 뇌나트륨이뇨펩티드 검사 제품의 허가․심사\n\n<!-- PAGE_8 -->\n###### 시에 요구되는 사항에 대한 일반적인 해석을 기술하고 있는 것으로서\n\n<!-- PAGE_8 -->\n###### 법적 효력이 있는 사항이 아니며, 개별 사항에 따라 다르게 해석할\n\n<!-- PAGE_8 -->\n###### 1.  목적\n\n본 가이드라인은 심장질환 진단에 도움을 주는 뇌나트륨이뇨펩티드\n\n(NT-proBNP, BNP) 측정시약의 허가․심사 시 요구되는 신청서 및 제출자료\n\n준비를 위한 참고자료로 활용하는 것을 목적으로 한다.\n\n ※ 알림 : 본 가이드라인에 따라 정상적인 서류와 첨부자료를 제대로\n\n갖추어 접수한 민원에 대하여 신속처리가 진행될 수 있으니 민원 신청시\n\n참고하시기 바랍니다.\n\n Ⅰ. ",
        "original_sentence": "<!-- PAGE_8 -->\n###### 또한 본 가이드라인은 뇌나트륨이뇨펩티드 검사 제품의 허가․심사\n\n<!-- PAGE_8 -->\n###### 시에 요구되는 사항에 대한 일반적인 해석을 기술하고 있는 것으로서\n\n<!-- PAGE_8 -->\n###### 법적 효력이 있는 사항이 아니며, 개별 사항에 따라 다르게 해석할\n\n<!-- PAGE_8 -->\n###### 1. "
      }
    },
    {
      "chunk_id": "chunk_312",
      "text": "목적\n\n본 가이드라인은 심장질환 진단에 도움을 주는 뇌나트륨이뇨펩티드\n\n(NT-proBNP, BNP) 측정시약의 허가․심사 시 요구되는 신청서 및 제출자료\n\n준비를 위한 참고자료로 활용하는 것을 목적으로 한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 311,
        "window_size": 3,
        "char_count": 119,
        "word_count": 24,
        "page_number": 8,
        "window_text": "부록\n\n<!-- PAGE_7 -->\n###### 70\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 2 -\n<!-- PAGE_8 -->\n# Ⅰ\n\n<!-- PAGE_8 -->\n#### 개  요\n\n<!-- PAGE_8 -->\n###### 본 가이드라인은 심근혈관표지자인 뇌나트륨이뇨펩티드(NT-proBNP,\n\n<!-- PAGE_8 -->\n###### BNP) 검사 제품의 허가․심사 시에 요구되는 신청서 작성 방법 및\n\n<!-- PAGE_8 -->\n###### 제출자료 요건을 예시를 들어 구체적이고 알기 쉽게 설명하였습니다.\n\n <!-- PAGE_8 -->\n###### 다만, 가이드라인에 기술한 사항은 현재까지의 경험과 과학적\n\n<!-- PAGE_8 -->\n###### 사실을 근거로 작성된 바, 새로운 과학적 사실이 밝혀지거나 관련\n\n<!-- PAGE_8 -->\n###### 규정이 개정될 경우 추후 변경될 수 있습니다.\n\n <!-- PAGE_8 -->\n###### 또한 본 가이드라인은 뇌나트륨이뇨펩티드 검사 제품의 허가․심사\n\n<!-- PAGE_8 -->\n###### 시에 요구되는 사항에 대한 일반적인 해석을 기술하고 있는 것으로서\n\n<!-- PAGE_8 -->\n###### 법적 효력이 있는 사항이 아니며, 개별 사항에 따라 다르게 해석할\n\n<!-- PAGE_8 -->\n###### 1.  목적\n\n본 가이드라인은 심장질환 진단에 도움을 주는 뇌나트륨이뇨펩티드\n\n(NT-proBNP, BNP) 측정시약의 허가․심사 시 요구되는 신청서 및 제출자료\n\n준비를 위한 참고자료로 활용하는 것을 목적으로 한다.\n\n ※ 알림 : 본 가이드라인에 따라 정상적인 서류와 첨부자료를 제대로\n\n갖추어 접수한 민원에 대하여 신속처리가 진행될 수 있으니 민원 신청시\n\n참고하시기 바랍니다.\n\n Ⅰ.  개 요\n\n- - 3 -\n<!-- PAGE_9 -->\n###### 2. ",
        "original_sentence": "목적\n\n본 가이드라인은 심장질환 진단에 도움을 주는 뇌나트륨이뇨펩티드\n\n(NT-proBNP, BNP) 측정시약의 허가․심사 시 요구되는 신청서 및 제출자료\n\n준비를 위한 참고자료로 활용하는 것을 목적으로 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_313",
      "text": "※ 알림 : 본 가이드라인에 따라 정상적인 서류와 첨부자료를 제대로\n\n갖추어 접수한 민원에 대하여 신속처리가 진행될 수 있으니 민원 신청시\n\n참고하시기 바랍니다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 312,
        "window_size": 3,
        "char_count": 92,
        "word_count": 22,
        "page_number": 8,
        "window_text": "<!-- PAGE_8 -->\n###### 다만, 가이드라인에 기술한 사항은 현재까지의 경험과 과학적\n\n<!-- PAGE_8 -->\n###### 사실을 근거로 작성된 바, 새로운 과학적 사실이 밝혀지거나 관련\n\n<!-- PAGE_8 -->\n###### 규정이 개정될 경우 추후 변경될 수 있습니다.\n\n <!-- PAGE_8 -->\n###### 또한 본 가이드라인은 뇌나트륨이뇨펩티드 검사 제품의 허가․심사\n\n<!-- PAGE_8 -->\n###### 시에 요구되는 사항에 대한 일반적인 해석을 기술하고 있는 것으로서\n\n<!-- PAGE_8 -->\n###### 법적 효력이 있는 사항이 아니며, 개별 사항에 따라 다르게 해석할\n\n<!-- PAGE_8 -->\n###### 1.  목적\n\n본 가이드라인은 심장질환 진단에 도움을 주는 뇌나트륨이뇨펩티드\n\n(NT-proBNP, BNP) 측정시약의 허가․심사 시 요구되는 신청서 및 제출자료\n\n준비를 위한 참고자료로 활용하는 것을 목적으로 한다.\n\n ※ 알림 : 본 가이드라인에 따라 정상적인 서류와 첨부자료를 제대로\n\n갖추어 접수한 민원에 대하여 신속처리가 진행될 수 있으니 민원 신청시\n\n참고하시기 바랍니다.\n\n Ⅰ.  개 요\n\n- - 3 -\n<!-- PAGE_9 -->\n###### 2.  적용범위\n\n본 가이드라인은 인체에서 유래하는 시료를 검체로 뇌나트륨이뇨펩티드\n\n(NT-proBNP, BNP)를 측정하는 체외진단용 의료기기에 적용되는 허가․심\n\n사 가이드라인이다.\n\n",
        "original_sentence": "※ 알림 : 본 가이드라인에 따라 정상적인 서류와 첨부자료를 제대로\n\n갖추어 접수한 민원에 대하여 신속처리가 진행될 수 있으니 민원 신청시\n\n참고하시기 바랍니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_314",
      "text": "Ⅰ. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 313,
        "window_size": 3,
        "char_count": 3,
        "word_count": 1,
        "page_number": 6,
        "window_text": "<!-- PAGE_8 -->\n###### 또한 본 가이드라인은 뇌나트륨이뇨펩티드 검사 제품의 허가․심사\n\n<!-- PAGE_8 -->\n###### 시에 요구되는 사항에 대한 일반적인 해석을 기술하고 있는 것으로서\n\n<!-- PAGE_8 -->\n###### 법적 효력이 있는 사항이 아니며, 개별 사항에 따라 다르게 해석할\n\n<!-- PAGE_8 -->\n###### 1.  목적\n\n본 가이드라인은 심장질환 진단에 도움을 주는 뇌나트륨이뇨펩티드\n\n(NT-proBNP, BNP) 측정시약의 허가․심사 시 요구되는 신청서 및 제출자료\n\n준비를 위한 참고자료로 활용하는 것을 목적으로 한다.\n\n ※ 알림 : 본 가이드라인에 따라 정상적인 서류와 첨부자료를 제대로\n\n갖추어 접수한 민원에 대하여 신속처리가 진행될 수 있으니 민원 신청시\n\n참고하시기 바랍니다.\n\n Ⅰ.  개 요\n\n- - 3 -\n<!-- PAGE_9 -->\n###### 2.  적용범위\n\n본 가이드라인은 인체에서 유래하는 시료를 검체로 뇌나트륨이뇨펩티드\n\n(NT-proBNP, BNP)를 측정하는 체외진단용 의료기기에 적용되는 허가․심\n\n사 가이드라인이다.\n\n 뇌나트륨이뇨펩티드는 심장에 대한 혈역학적 부하를 알 수 있는 바이오\n\n마커로 심장근육층의 호르몬 활성화를 보여준다. ",
        "original_sentence": "Ⅰ. "
      }
    },
    {
      "chunk_id": "chunk_315",
      "text": "개 요\n\n- - 3 -\n<!-- PAGE_9 -->\n###### 2. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 314,
        "window_size": 3,
        "char_count": 39,
        "word_count": 11,
        "page_number": 9,
        "window_text": "목적\n\n본 가이드라인은 심장질환 진단에 도움을 주는 뇌나트륨이뇨펩티드\n\n(NT-proBNP, BNP) 측정시약의 허가․심사 시 요구되는 신청서 및 제출자료\n\n준비를 위한 참고자료로 활용하는 것을 목적으로 한다.\n\n ※ 알림 : 본 가이드라인에 따라 정상적인 서류와 첨부자료를 제대로\n\n갖추어 접수한 민원에 대하여 신속처리가 진행될 수 있으니 민원 신청시\n\n참고하시기 바랍니다.\n\n Ⅰ.  개 요\n\n- - 3 -\n<!-- PAGE_9 -->\n###### 2.  적용범위\n\n본 가이드라인은 인체에서 유래하는 시료를 검체로 뇌나트륨이뇨펩티드\n\n(NT-proBNP, BNP)를 측정하는 체외진단용 의료기기에 적용되는 허가․심\n\n사 가이드라인이다.\n\n 뇌나트륨이뇨펩티드는 심장에 대한 혈역학적 부하를 알 수 있는 바이오\n\n마커로 심장근육층의 호르몬 활성화를 보여준다.  NT-proBNP와 BNP는\n\n혈역학적 부하로 좌심실이 비대해질 때 1:1의 비율로 나눠진다. ",
        "original_sentence": "개 요\n\n- - 3 -\n<!-- PAGE_9 -->\n###### 2. "
      }
    },
    {
      "chunk_id": "chunk_316",
      "text": "적용범위\n\n본 가이드라인은 인체에서 유래하는 시료를 검체로 뇌나트륨이뇨펩티드\n\n(NT-proBNP, BNP)를 측정하는 체외진단용 의료기기에 적용되는 허가․심\n\n사 가이드라인이다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 315,
        "window_size": 3,
        "char_count": 102,
        "word_count": 17,
        "page_number": 9,
        "window_text": "※ 알림 : 본 가이드라인에 따라 정상적인 서류와 첨부자료를 제대로\n\n갖추어 접수한 민원에 대하여 신속처리가 진행될 수 있으니 민원 신청시\n\n참고하시기 바랍니다.\n\n Ⅰ.  개 요\n\n- - 3 -\n<!-- PAGE_9 -->\n###### 2.  적용범위\n\n본 가이드라인은 인체에서 유래하는 시료를 검체로 뇌나트륨이뇨펩티드\n\n(NT-proBNP, BNP)를 측정하는 체외진단용 의료기기에 적용되는 허가․심\n\n사 가이드라인이다.\n\n 뇌나트륨이뇨펩티드는 심장에 대한 혈역학적 부하를 알 수 있는 바이오\n\n마커로 심장근육층의 호르몬 활성화를 보여준다.  NT-proBNP와 BNP는\n\n혈역학적 부하로 좌심실이 비대해질 때 1:1의 비율로 나눠진다.  이들\n\n펩타이드 수치의 증가는 심부전과 연관이 있으며 두 물질 모두 울혈성심부전\n\n진단에 유용하게 사용된다. ",
        "original_sentence": "적용범위\n\n본 가이드라인은 인체에서 유래하는 시료를 검체로 뇌나트륨이뇨펩티드\n\n(NT-proBNP, BNP)를 측정하는 체외진단용 의료기기에 적용되는 허가․심\n\n사 가이드라인이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_317",
      "text": "뇌나트륨이뇨펩티드는 심장에 대한 혈역학적 부하를 알 수 있는 바이오\n\n마커로 심장근육층의 호르몬 활성화를 보여준다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 316,
        "window_size": 3,
        "char_count": 65,
        "word_count": 14,
        "page_number": 9,
        "window_text": "Ⅰ.  개 요\n\n- - 3 -\n<!-- PAGE_9 -->\n###### 2.  적용범위\n\n본 가이드라인은 인체에서 유래하는 시료를 검체로 뇌나트륨이뇨펩티드\n\n(NT-proBNP, BNP)를 측정하는 체외진단용 의료기기에 적용되는 허가․심\n\n사 가이드라인이다.\n\n 뇌나트륨이뇨펩티드는 심장에 대한 혈역학적 부하를 알 수 있는 바이오\n\n마커로 심장근육층의 호르몬 활성화를 보여준다.  NT-proBNP와 BNP는\n\n혈역학적 부하로 좌심실이 비대해질 때 1:1의 비율로 나눠진다.  이들\n\n펩타이드 수치의 증가는 심부전과 연관이 있으며 두 물질 모두 울혈성심부전\n\n진단에 유용하게 사용된다.  뇌나트륨이뇨펩티드는 심실근에서 생성되나\n\n저장되지 않고 심실 부하에 반응하여 분비되면서 강력한 혈관 확장작용과\n\n나트륨 이뇨작용을 한다. ",
        "original_sentence": "뇌나트륨이뇨펩티드는 심장에 대한 혈역학적 부하를 알 수 있는 바이오\n\n마커로 심장근육층의 호르몬 활성화를 보여준다. "
      }
    },
    {
      "chunk_id": "chunk_318",
      "text": "NT-proBNP와 BNP는\n\n혈역학적 부하로 좌심실이 비대해질 때 1:1의 비율로 나눠진다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 317,
        "window_size": 3,
        "char_count": 53,
        "word_count": 10,
        "page_number": 14,
        "window_text": "개 요\n\n- - 3 -\n<!-- PAGE_9 -->\n###### 2.  적용범위\n\n본 가이드라인은 인체에서 유래하는 시료를 검체로 뇌나트륨이뇨펩티드\n\n(NT-proBNP, BNP)를 측정하는 체외진단용 의료기기에 적용되는 허가․심\n\n사 가이드라인이다.\n\n 뇌나트륨이뇨펩티드는 심장에 대한 혈역학적 부하를 알 수 있는 바이오\n\n마커로 심장근육층의 호르몬 활성화를 보여준다.  NT-proBNP와 BNP는\n\n혈역학적 부하로 좌심실이 비대해질 때 1:1의 비율로 나눠진다.  이들\n\n펩타이드 수치의 증가는 심부전과 연관이 있으며 두 물질 모두 울혈성심부전\n\n진단에 유용하게 사용된다.  뇌나트륨이뇨펩티드는 심실근에서 생성되나\n\n저장되지 않고 심실 부하에 반응하여 분비되면서 강력한 혈관 확장작용과\n\n나트륨 이뇨작용을 한다.  또한 심실의 용적이 확장되거나 혈압이 과도하게\n\n증가될 때 지속적으로 배출된다. ",
        "original_sentence": "NT-proBNP와 BNP는\n\n혈역학적 부하로 좌심실이 비대해질 때 1:1의 비율로 나눠진다. "
      }
    },
    {
      "chunk_id": "chunk_319",
      "text": "이들\n\n펩타이드 수치의 증가는 심부전과 연관이 있으며 두 물질 모두 울혈성심부전\n\n진단에 유용하게 사용된다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 318,
        "window_size": 3,
        "char_count": 61,
        "word_count": 14,
        "page_number": 9,
        "window_text": "적용범위\n\n본 가이드라인은 인체에서 유래하는 시료를 검체로 뇌나트륨이뇨펩티드\n\n(NT-proBNP, BNP)를 측정하는 체외진단용 의료기기에 적용되는 허가․심\n\n사 가이드라인이다.\n\n 뇌나트륨이뇨펩티드는 심장에 대한 혈역학적 부하를 알 수 있는 바이오\n\n마커로 심장근육층의 호르몬 활성화를 보여준다.  NT-proBNP와 BNP는\n\n혈역학적 부하로 좌심실이 비대해질 때 1:1의 비율로 나눠진다.  이들\n\n펩타이드 수치의 증가는 심부전과 연관이 있으며 두 물질 모두 울혈성심부전\n\n진단에 유용하게 사용된다.  뇌나트륨이뇨펩티드는 심실근에서 생성되나\n\n저장되지 않고 심실 부하에 반응하여 분비되면서 강력한 혈관 확장작용과\n\n나트륨 이뇨작용을 한다.  또한 심실의 용적이 확장되거나 혈압이 과도하게\n\n증가될 때 지속적으로 배출된다.  정상인의 말초혈액 내에서는 20 pg/mL\n\n미만의 양으로 존재하지만 심부전 환자의 혈장 내 농도는 질환의 중증도에\n\n따라 비례하고, 무증상 좌심기능부전 단계에도 상승한다. ",
        "original_sentence": "이들\n\n펩타이드 수치의 증가는 심부전과 연관이 있으며 두 물질 모두 울혈성심부전\n\n진단에 유용하게 사용된다. "
      }
    },
    {
      "chunk_id": "chunk_320",
      "text": "뇌나트륨이뇨펩티드는 심실근에서 생성되나\n\n저장되지 않고 심실 부하에 반응하여 분비되면서 강력한 혈관 확장작용과\n\n나트륨 이뇨작용을 한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 319,
        "window_size": 3,
        "char_count": 77,
        "word_count": 15,
        "page_number": 1,
        "window_text": "뇌나트륨이뇨펩티드는 심장에 대한 혈역학적 부하를 알 수 있는 바이오\n\n마커로 심장근육층의 호르몬 활성화를 보여준다.  NT-proBNP와 BNP는\n\n혈역학적 부하로 좌심실이 비대해질 때 1:1의 비율로 나눠진다.  이들\n\n펩타이드 수치의 증가는 심부전과 연관이 있으며 두 물질 모두 울혈성심부전\n\n진단에 유용하게 사용된다.  뇌나트륨이뇨펩티드는 심실근에서 생성되나\n\n저장되지 않고 심실 부하에 반응하여 분비되면서 강력한 혈관 확장작용과\n\n나트륨 이뇨작용을 한다.  또한 심실의 용적이 확장되거나 혈압이 과도하게\n\n증가될 때 지속적으로 배출된다.  정상인의 말초혈액 내에서는 20 pg/mL\n\n미만의 양으로 존재하지만 심부전 환자의 혈장 내 농도는 질환의 중증도에\n\n따라 비례하고, 무증상 좌심기능부전 단계에도 상승한다.  특히 심장기능의\n\n약화에 민감하게 상승한다. ",
        "original_sentence": "뇌나트륨이뇨펩티드는 심실근에서 생성되나\n\n저장되지 않고 심실 부하에 반응하여 분비되면서 강력한 혈관 확장작용과\n\n나트륨 이뇨작용을 한다. "
      }
    },
    {
      "chunk_id": "chunk_321",
      "text": "또한 심실의 용적이 확장되거나 혈압이 과도하게\n\n증가될 때 지속적으로 배출된다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 320,
        "window_size": 3,
        "char_count": 45,
        "word_count": 10,
        "page_number": 79,
        "window_text": "NT-proBNP와 BNP는\n\n혈역학적 부하로 좌심실이 비대해질 때 1:1의 비율로 나눠진다.  이들\n\n펩타이드 수치의 증가는 심부전과 연관이 있으며 두 물질 모두 울혈성심부전\n\n진단에 유용하게 사용된다.  뇌나트륨이뇨펩티드는 심실근에서 생성되나\n\n저장되지 않고 심실 부하에 반응하여 분비되면서 강력한 혈관 확장작용과\n\n나트륨 이뇨작용을 한다.  또한 심실의 용적이 확장되거나 혈압이 과도하게\n\n증가될 때 지속적으로 배출된다.  정상인의 말초혈액 내에서는 20 pg/mL\n\n미만의 양으로 존재하지만 심부전 환자의 혈장 내 농도는 질환의 중증도에\n\n따라 비례하고, 무증상 좌심기능부전 단계에도 상승한다.  특히 심장기능의\n\n약화에 민감하게 상승한다.  뇌나트륨이뇨펩티드는 심정지와 상관없이 심장\n\n기능에 문제가 있을 경우 혈관 벽에서 말초혈액으로 분비되므로 심부전을\n\n진단하는 중요 표지자로 진단에 활용된다.\n\n",
        "original_sentence": "또한 심실의 용적이 확장되거나 혈압이 과도하게\n\n증가될 때 지속적으로 배출된다. "
      }
    },
    {
      "chunk_id": "chunk_322",
      "text": "정상인의 말초혈액 내에서는 20 pg/mL\n\n미만의 양으로 존재하지만 심부전 환자의 혈장 내 농도는 질환의 중증도에\n\n따라 비례하고, 무증상 좌심기능부전 단계에도 상승한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 321,
        "window_size": 3,
        "char_count": 97,
        "word_count": 21,
        "page_number": 6,
        "window_text": "이들\n\n펩타이드 수치의 증가는 심부전과 연관이 있으며 두 물질 모두 울혈성심부전\n\n진단에 유용하게 사용된다.  뇌나트륨이뇨펩티드는 심실근에서 생성되나\n\n저장되지 않고 심실 부하에 반응하여 분비되면서 강력한 혈관 확장작용과\n\n나트륨 이뇨작용을 한다.  또한 심실의 용적이 확장되거나 혈압이 과도하게\n\n증가될 때 지속적으로 배출된다.  정상인의 말초혈액 내에서는 20 pg/mL\n\n미만의 양으로 존재하지만 심부전 환자의 혈장 내 농도는 질환의 중증도에\n\n따라 비례하고, 무증상 좌심기능부전 단계에도 상승한다.  특히 심장기능의\n\n약화에 민감하게 상승한다.  뇌나트륨이뇨펩티드는 심정지와 상관없이 심장\n\n기능에 문제가 있을 경우 혈관 벽에서 말초혈액으로 분비되므로 심부전을\n\n진단하는 중요 표지자로 진단에 활용된다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 4 -\n<!-- PAGE_10 -->\n# Ⅱ\n\n<!-- PAGE_10 -->\n#### 용어의 정의\n\n※ 본 가이드라인에서 사용되는 용어의 정의는 본 가이드라인의 이해를\n\n돕기 위해 사용되는 것이므로 단순 참고용임\n\n간섭 (Interference)\n\n분석물질의 농도나 강도가 명백함에도 검출시약이나 신호 자체에 비특이적\n\n으로 반응하는 물질의 존재로 인해 일어나는 인위적인 증가나 감소\n\n☞ 검출 시스템의 비특이성에서 기인하기도 하고, 지시약 반응의 억제, 분\n\n검출한계 (Limit of detection, LoD)\n\n검출될 수 있는 분석 물질의 최소량\n\n공란한계 (Limit of blank, LoB)\n\nblank 검체에서 관찰 가능할 수 있는 가장 높은 측정치\n\n교차반응 (Cross-reactivity)\n\n항원 이외에 공유되었거나, 유사한 또는 동일한 항원결정기를 가진 항원과\n\n항체가 반응하는 현상\n\n기질효과 (Matrix effect)\n\n측정하고자 하는 분석물질 이외에 검체의 특성이 분석물질의 측정에 영향을\n\n미치는 경우\n\n☞ 검체의 점성, 표면장력, 혼탁도, 이온 강도, pH 등이 기질효과의 주된\n\n요인이다.\n\n",
        "original_sentence": "정상인의 말초혈액 내에서는 20 pg/mL\n\n미만의 양으로 존재하지만 심부전 환자의 혈장 내 농도는 질환의 중증도에\n\n따라 비례하고, 무증상 좌심기능부전 단계에도 상승한다. "
      }
    },
    {
      "chunk_id": "chunk_323",
      "text": "특히 심장기능의\n\n약화에 민감하게 상승한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 322,
        "window_size": 3,
        "char_count": 25,
        "word_count": 5,
        "page_number": 56,
        "window_text": "뇌나트륨이뇨펩티드는 심실근에서 생성되나\n\n저장되지 않고 심실 부하에 반응하여 분비되면서 강력한 혈관 확장작용과\n\n나트륨 이뇨작용을 한다.  또한 심실의 용적이 확장되거나 혈압이 과도하게\n\n증가될 때 지속적으로 배출된다.  정상인의 말초혈액 내에서는 20 pg/mL\n\n미만의 양으로 존재하지만 심부전 환자의 혈장 내 농도는 질환의 중증도에\n\n따라 비례하고, 무증상 좌심기능부전 단계에도 상승한다.  특히 심장기능의\n\n약화에 민감하게 상승한다.  뇌나트륨이뇨펩티드는 심정지와 상관없이 심장\n\n기능에 문제가 있을 경우 혈관 벽에서 말초혈액으로 분비되므로 심부전을\n\n진단하는 중요 표지자로 진단에 활용된다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 4 -\n<!-- PAGE_10 -->\n# Ⅱ\n\n<!-- PAGE_10 -->\n#### 용어의 정의\n\n※ 본 가이드라인에서 사용되는 용어의 정의는 본 가이드라인의 이해를\n\n돕기 위해 사용되는 것이므로 단순 참고용임\n\n간섭 (Interference)\n\n분석물질의 농도나 강도가 명백함에도 검출시약이나 신호 자체에 비특이적\n\n으로 반응하는 물질의 존재로 인해 일어나는 인위적인 증가나 감소\n\n☞ 검출 시스템의 비특이성에서 기인하기도 하고, 지시약 반응의 억제, 분\n\n검출한계 (Limit of detection, LoD)\n\n검출될 수 있는 분석 물질의 최소량\n\n공란한계 (Limit of blank, LoB)\n\nblank 검체에서 관찰 가능할 수 있는 가장 높은 측정치\n\n교차반응 (Cross-reactivity)\n\n항원 이외에 공유되었거나, 유사한 또는 동일한 항원결정기를 가진 항원과\n\n항체가 반응하는 현상\n\n기질효과 (Matrix effect)\n\n측정하고자 하는 분석물질 이외에 검체의 특성이 분석물질의 측정에 영향을\n\n미치는 경우\n\n☞ 검체의 점성, 표면장력, 혼탁도, 이온 강도, pH 등이 기질효과의 주된\n\n요인이다.\n\n Ⅱ. ",
        "original_sentence": "특히 심장기능의\n\n약화에 민감하게 상승한다. "
      }
    },
    {
      "chunk_id": "chunk_324",
      "text": "뇌나트륨이뇨펩티드는 심정지와 상관없이 심장\n\n기능에 문제가 있을 경우 혈관 벽에서 말초혈액으로 분비되므로 심부전을\n\n진단하는 중요 표지자로 진단에 활용된다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 323,
        "window_size": 3,
        "char_count": 89,
        "word_count": 18,
        "page_number": 33,
        "window_text": "또한 심실의 용적이 확장되거나 혈압이 과도하게\n\n증가될 때 지속적으로 배출된다.  정상인의 말초혈액 내에서는 20 pg/mL\n\n미만의 양으로 존재하지만 심부전 환자의 혈장 내 농도는 질환의 중증도에\n\n따라 비례하고, 무증상 좌심기능부전 단계에도 상승한다.  특히 심장기능의\n\n약화에 민감하게 상승한다.  뇌나트륨이뇨펩티드는 심정지와 상관없이 심장\n\n기능에 문제가 있을 경우 혈관 벽에서 말초혈액으로 분비되므로 심부전을\n\n진단하는 중요 표지자로 진단에 활용된다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 4 -\n<!-- PAGE_10 -->\n# Ⅱ\n\n<!-- PAGE_10 -->\n#### 용어의 정의\n\n※ 본 가이드라인에서 사용되는 용어의 정의는 본 가이드라인의 이해를\n\n돕기 위해 사용되는 것이므로 단순 참고용임\n\n간섭 (Interference)\n\n분석물질의 농도나 강도가 명백함에도 검출시약이나 신호 자체에 비특이적\n\n으로 반응하는 물질의 존재로 인해 일어나는 인위적인 증가나 감소\n\n☞ 검출 시스템의 비특이성에서 기인하기도 하고, 지시약 반응의 억제, 분\n\n검출한계 (Limit of detection, LoD)\n\n검출될 수 있는 분석 물질의 최소량\n\n공란한계 (Limit of blank, LoB)\n\nblank 검체에서 관찰 가능할 수 있는 가장 높은 측정치\n\n교차반응 (Cross-reactivity)\n\n항원 이외에 공유되었거나, 유사한 또는 동일한 항원결정기를 가진 항원과\n\n항체가 반응하는 현상\n\n기질효과 (Matrix effect)\n\n측정하고자 하는 분석물질 이외에 검체의 특성이 분석물질의 측정에 영향을\n\n미치는 경우\n\n☞ 검체의 점성, 표면장력, 혼탁도, 이온 강도, pH 등이 기질효과의 주된\n\n요인이다.\n\n Ⅱ.  용어의 정의\n\n- - 5 -\n대조물질 (Control / Control material)\n\n정도 관리를 위해 이용되는 물질\n\n면역분석법, 면역측정법 (Immunoassay)\n\n분석물질에 결합 가능한 특이 항원이나 항체를 이용하는 리간드-결합 분석\n\n☞ 항체를 사용하여 물질을 측정하는 검사법으로 면역분석법은 경쟁적 또는\n\n비경쟁적, 고체상 또는 액체상, 동위원소 또는 비동위원소, 항원표지\n\n또는 항체표지, 단일 또는 이중 부위, 균질적 또는 비균질적 방법일 수\n\n바이어스 (Bias)\n\n검사 결과의 예상치와 허용된 기준치 사이의 차이\n\n간섭물질 (Interfering substances)\n\n임상검체에 존재하는 내부물질(예 : 혈액 구성요소, acidic polysaccharides)\n\n또는 외부물질(예 : talc, 항응고제 등)으로 위양성 또는 위음성 결과를 야기\n\n할 수 있는 물질\n\n보관 시 안정성 (Storage stability)\n\n최종 디자인(포장) 상태에서 시약의 유효기간\n\n보정 (Calibration)\n\n특별한 조건하에서 측정 기기나 측정 시스템이 나타내는 값 또는 물질\n\n측정이나 참고물질에 의한 값과 표준물질에 상응하는 값 사이의 관계를\n\n확립하는 일련의 조작\n\n보정물질 (Calibrator / Calibration material)\n\n측정과정을 보정하기 위해서 또는 검체의 반응을 비교하기 위해서 사용되는\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 6 -\n알려진 정량적/정성적 특성(예 : 농도, 활성도, 강도, 반응성)을 갖는 물질\n\n☞ a) 보정물질에서 분석물질 양은 그의 제조과정에서 확인된 한계\n\n(limit) 내에 있으며, 분석법의 반응과 측정되는 특성과의 관계를\n\n설정하는데 사용될 수 있다.\n\n",
        "original_sentence": "뇌나트륨이뇨펩티드는 심정지와 상관없이 심장\n\n기능에 문제가 있을 경우 혈관 벽에서 말초혈액으로 분비되므로 심부전을\n\n진단하는 중요 표지자로 진단에 활용된다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_325",
      "text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 4 -\n<!-- PAGE_10 -->\n# Ⅱ\n\n<!-- PAGE_10 -->\n#### 용어의 정의\n\n※ 본 가이드라인에서 사용되는 용어의 정의는 본 가이드라인의 이해를\n\n돕기 위해 사용되는 것이므로 단순 참고용임\n\n간섭 (Interference)\n\n분석물질의 농도나 강도가 명백함에도 검출시약이나 신호 자체에 비특이적\n\n으로 반응하는 물질의 존재로 인해 일어나는 인위적인 증가나 감소\n\n☞ 검출 시스템의 비특이성에서 기인하기도 하고, 지시약 반응의 억제, 분\n\n검출한계 (Limit of detection, LoD)\n\n검출될 수 있는 분석 물질의 최소량\n\n공란한계 (Limit of blank, LoB)\n\nblank 검체에서 관찰 가능할 수 있는 가장 높은 측정치\n\n교차반응 (Cross-reactivity)\n\n항원 이외에 공유되었거나, 유사한 또는 동일한 항원결정기를 가진 항원과\n\n항체가 반응하는 현상\n\n기질효과 (Matrix effect)\n\n측정하고자 하는 분석물질 이외에 검체의 특성이 분석물질의 측정에 영향을\n\n미치는 경우\n\n☞ 검체의 점성, 표면장력, 혼탁도, 이온 강도, pH 등이 기질효과의 주된\n\n요인이다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 324,
        "window_size": 3,
        "char_count": 627,
        "word_count": 132,
        "page_number": 10,
        "window_text": "정상인의 말초혈액 내에서는 20 pg/mL\n\n미만의 양으로 존재하지만 심부전 환자의 혈장 내 농도는 질환의 중증도에\n\n따라 비례하고, 무증상 좌심기능부전 단계에도 상승한다.  특히 심장기능의\n\n약화에 민감하게 상승한다.  뇌나트륨이뇨펩티드는 심정지와 상관없이 심장\n\n기능에 문제가 있을 경우 혈관 벽에서 말초혈액으로 분비되므로 심부전을\n\n진단하는 중요 표지자로 진단에 활용된다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 4 -\n<!-- PAGE_10 -->\n# Ⅱ\n\n<!-- PAGE_10 -->\n#### 용어의 정의\n\n※ 본 가이드라인에서 사용되는 용어의 정의는 본 가이드라인의 이해를\n\n돕기 위해 사용되는 것이므로 단순 참고용임\n\n간섭 (Interference)\n\n분석물질의 농도나 강도가 명백함에도 검출시약이나 신호 자체에 비특이적\n\n으로 반응하는 물질의 존재로 인해 일어나는 인위적인 증가나 감소\n\n☞ 검출 시스템의 비특이성에서 기인하기도 하고, 지시약 반응의 억제, 분\n\n검출한계 (Limit of detection, LoD)\n\n검출될 수 있는 분석 물질의 최소량\n\n공란한계 (Limit of blank, LoB)\n\nblank 검체에서 관찰 가능할 수 있는 가장 높은 측정치\n\n교차반응 (Cross-reactivity)\n\n항원 이외에 공유되었거나, 유사한 또는 동일한 항원결정기를 가진 항원과\n\n항체가 반응하는 현상\n\n기질효과 (Matrix effect)\n\n측정하고자 하는 분석물질 이외에 검체의 특성이 분석물질의 측정에 영향을\n\n미치는 경우\n\n☞ 검체의 점성, 표면장력, 혼탁도, 이온 강도, pH 등이 기질효과의 주된\n\n요인이다.\n\n Ⅱ.  용어의 정의\n\n- - 5 -\n대조물질 (Control / Control material)\n\n정도 관리를 위해 이용되는 물질\n\n면역분석법, 면역측정법 (Immunoassay)\n\n분석물질에 결합 가능한 특이 항원이나 항체를 이용하는 리간드-결합 분석\n\n☞ 항체를 사용하여 물질을 측정하는 검사법으로 면역분석법은 경쟁적 또는\n\n비경쟁적, 고체상 또는 액체상, 동위원소 또는 비동위원소, 항원표지\n\n또는 항체표지, 단일 또는 이중 부위, 균질적 또는 비균질적 방법일 수\n\n바이어스 (Bias)\n\n검사 결과의 예상치와 허용된 기준치 사이의 차이\n\n간섭물질 (Interfering substances)\n\n임상검체에 존재하는 내부물질(예 : 혈액 구성요소, acidic polysaccharides)\n\n또는 외부물질(예 : talc, 항응고제 등)으로 위양성 또는 위음성 결과를 야기\n\n할 수 있는 물질\n\n보관 시 안정성 (Storage stability)\n\n최종 디자인(포장) 상태에서 시약의 유효기간\n\n보정 (Calibration)\n\n특별한 조건하에서 측정 기기나 측정 시스템이 나타내는 값 또는 물질\n\n측정이나 참고물질에 의한 값과 표준물질에 상응하는 값 사이의 관계를\n\n확립하는 일련의 조작\n\n보정물질 (Calibrator / Calibration material)\n\n측정과정을 보정하기 위해서 또는 검체의 반응을 비교하기 위해서 사용되는\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 6 -\n알려진 정량적/정성적 특성(예 : 농도, 활성도, 강도, 반응성)을 갖는 물질\n\n☞ a) 보정물질에서 분석물질 양은 그의 제조과정에서 확인된 한계\n\n(limit) 내에 있으며, 분석법의 반응과 측정되는 특성과의 관계를\n\n설정하는데 사용될 수 있다.\n\n b) 보정물질은 국가 또는 국제 표준물질이나 참고물질에 소급성을\n\nc) 분석물질의 다른 양을 갖는 보정물질은 보정 곡선을 설정하는데\n\nd) “일차”와 “이차표준”이란 용어는 보정물질을 지칭하는 용어로\n\n분석물질 (Analyte)\n\n검사실이 수행하는 검사의 물질 또는 구성요소\n\n분석적 특이도 (Analytical specificity)\n\n정량검사에서 측정하고자 하는 물질만 측정되고 검체 내 다른 물질은 측정\n\n되지 않는 분석법의 능력\n\n비정밀도 (Imprecision)\n\n특별한 조건 하에서 얻어진 측정값의 독립적 결과들의 분산\n\n☞ 표준편차나 변이계수 등의 숫자로 표시된다.\n\n",
        "original_sentence": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 4 -\n<!-- PAGE_10 -->\n# Ⅱ\n\n<!-- PAGE_10 -->\n#### 용어의 정의\n\n※ 본 가이드라인에서 사용되는 용어의 정의는 본 가이드라인의 이해를\n\n돕기 위해 사용되는 것이므로 단순 참고용임\n\n간섭 (Interference)\n\n분석물질의 농도나 강도가 명백함에도 검출시약이나 신호 자체에 비특이적\n\n으로 반응하는 물질의 존재로 인해 일어나는 인위적인 증가나 감소\n\n☞ 검출 시스템의 비특이성에서 기인하기도 하고, 지시약 반응의 억제, 분\n\n검출한계 (Limit of detection, LoD)\n\n검출될 수 있는 분석 물질의 최소량\n\n공란한계 (Limit of blank, LoB)\n\nblank 검체에서 관찰 가능할 수 있는 가장 높은 측정치\n\n교차반응 (Cross-reactivity)\n\n항원 이외에 공유되었거나, 유사한 또는 동일한 항원결정기를 가진 항원과\n\n항체가 반응하는 현상\n\n기질효과 (Matrix effect)\n\n측정하고자 하는 분석물질 이외에 검체의 특성이 분석물질의 측정에 영향을\n\n미치는 경우\n\n☞ 검체의 점성, 표면장력, 혼탁도, 이온 강도, pH 등이 기질효과의 주된\n\n요인이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_326",
      "text": "Ⅱ. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 325,
        "window_size": 3,
        "char_count": 3,
        "word_count": 1,
        "page_number": 6,
        "window_text": "특히 심장기능의\n\n약화에 민감하게 상승한다.  뇌나트륨이뇨펩티드는 심정지와 상관없이 심장\n\n기능에 문제가 있을 경우 혈관 벽에서 말초혈액으로 분비되므로 심부전을\n\n진단하는 중요 표지자로 진단에 활용된다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 4 -\n<!-- PAGE_10 -->\n# Ⅱ\n\n<!-- PAGE_10 -->\n#### 용어의 정의\n\n※ 본 가이드라인에서 사용되는 용어의 정의는 본 가이드라인의 이해를\n\n돕기 위해 사용되는 것이므로 단순 참고용임\n\n간섭 (Interference)\n\n분석물질의 농도나 강도가 명백함에도 검출시약이나 신호 자체에 비특이적\n\n으로 반응하는 물질의 존재로 인해 일어나는 인위적인 증가나 감소\n\n☞ 검출 시스템의 비특이성에서 기인하기도 하고, 지시약 반응의 억제, 분\n\n검출한계 (Limit of detection, LoD)\n\n검출될 수 있는 분석 물질의 최소량\n\n공란한계 (Limit of blank, LoB)\n\nblank 검체에서 관찰 가능할 수 있는 가장 높은 측정치\n\n교차반응 (Cross-reactivity)\n\n항원 이외에 공유되었거나, 유사한 또는 동일한 항원결정기를 가진 항원과\n\n항체가 반응하는 현상\n\n기질효과 (Matrix effect)\n\n측정하고자 하는 분석물질 이외에 검체의 특성이 분석물질의 측정에 영향을\n\n미치는 경우\n\n☞ 검체의 점성, 표면장력, 혼탁도, 이온 강도, pH 등이 기질효과의 주된\n\n요인이다.\n\n Ⅱ.  용어의 정의\n\n- - 5 -\n대조물질 (Control / Control material)\n\n정도 관리를 위해 이용되는 물질\n\n면역분석법, 면역측정법 (Immunoassay)\n\n분석물질에 결합 가능한 특이 항원이나 항체를 이용하는 리간드-결합 분석\n\n☞ 항체를 사용하여 물질을 측정하는 검사법으로 면역분석법은 경쟁적 또는\n\n비경쟁적, 고체상 또는 액체상, 동위원소 또는 비동위원소, 항원표지\n\n또는 항체표지, 단일 또는 이중 부위, 균질적 또는 비균질적 방법일 수\n\n바이어스 (Bias)\n\n검사 결과의 예상치와 허용된 기준치 사이의 차이\n\n간섭물질 (Interfering substances)\n\n임상검체에 존재하는 내부물질(예 : 혈액 구성요소, acidic polysaccharides)\n\n또는 외부물질(예 : talc, 항응고제 등)으로 위양성 또는 위음성 결과를 야기\n\n할 수 있는 물질\n\n보관 시 안정성 (Storage stability)\n\n최종 디자인(포장) 상태에서 시약의 유효기간\n\n보정 (Calibration)\n\n특별한 조건하에서 측정 기기나 측정 시스템이 나타내는 값 또는 물질\n\n측정이나 참고물질에 의한 값과 표준물질에 상응하는 값 사이의 관계를\n\n확립하는 일련의 조작\n\n보정물질 (Calibrator / Calibration material)\n\n측정과정을 보정하기 위해서 또는 검체의 반응을 비교하기 위해서 사용되는\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 6 -\n알려진 정량적/정성적 특성(예 : 농도, 활성도, 강도, 반응성)을 갖는 물질\n\n☞ a) 보정물질에서 분석물질 양은 그의 제조과정에서 확인된 한계\n\n(limit) 내에 있으며, 분석법의 반응과 측정되는 특성과의 관계를\n\n설정하는데 사용될 수 있다.\n\n b) 보정물질은 국가 또는 국제 표준물질이나 참고물질에 소급성을\n\nc) 분석물질의 다른 양을 갖는 보정물질은 보정 곡선을 설정하는데\n\nd) “일차”와 “이차표준”이란 용어는 보정물질을 지칭하는 용어로\n\n분석물질 (Analyte)\n\n검사실이 수행하는 검사의 물질 또는 구성요소\n\n분석적 특이도 (Analytical specificity)\n\n정량검사에서 측정하고자 하는 물질만 측정되고 검체 내 다른 물질은 측정\n\n되지 않는 분석법의 능력\n\n비정밀도 (Imprecision)\n\n특별한 조건 하에서 얻어진 측정값의 독립적 결과들의 분산\n\n☞ 표준편차나 변이계수 등의 숫자로 표시된다.\n\n 비특이도 (Nonspecificity)\n\n분석하려는 물질 외에 다른 물질과 항원이 반응하는 정도\n\n☞ 비특이도는 보통 분석물질이 아닌 물질에 결합하고, 반응하는 항체,\n\n효소, ionophore, 시약에 의해 발생한다.\n\n",
        "original_sentence": "Ⅱ. "
      }
    },
    {
      "chunk_id": "chunk_327",
      "text": "용어의 정의\n\n- - 5 -\n대조물질 (Control / Control material)\n\n정도 관리를 위해 이용되는 물질\n\n면역분석법, 면역측정법 (Immunoassay)\n\n분석물질에 결합 가능한 특이 항원이나 항체를 이용하는 리간드-결합 분석\n\n☞ 항체를 사용하여 물질을 측정하는 검사법으로 면역분석법은 경쟁적 또는\n\n비경쟁적, 고체상 또는 액체상, 동위원소 또는 비동위원소, 항원표지\n\n또는 항체표지, 단일 또는 이중 부위, 균질적 또는 비균질적 방법일 수\n\n바이어스 (Bias)\n\n검사 결과의 예상치와 허용된 기준치 사이의 차이\n\n간섭물질 (Interfering substances)\n\n임상검체에 존재하는 내부물질(예 : 혈액 구성요소, acidic polysaccharides)\n\n또는 외부물질(예 : talc, 항응고제 등)으로 위양성 또는 위음성 결과를 야기\n\n할 수 있는 물질\n\n보관 시 안정성 (Storage stability)\n\n최종 디자인(포장) 상태에서 시약의 유효기간\n\n보정 (Calibration)\n\n특별한 조건하에서 측정 기기나 측정 시스템이 나타내는 값 또는 물질\n\n측정이나 참고물질에 의한 값과 표준물질에 상응하는 값 사이의 관계를\n\n확립하는 일련의 조작\n\n보정물질 (Calibrator / Calibration material)\n\n측정과정을 보정하기 위해서 또는 검체의 반응을 비교하기 위해서 사용되는\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 6 -\n알려진 정량적/정성적 특성(예 : 농도, 활성도, 강도, 반응성)을 갖는 물질\n\n☞ a) 보정물질에서 분석물질 양은 그의 제조과정에서 확인된 한계\n\n(limit) 내에 있으며, 분석법의 반응과 측정되는 특성과의 관계를\n\n설정하는데 사용될 수 있다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 326,
        "window_size": 3,
        "char_count": 889,
        "word_count": 182,
        "page_number": 10,
        "window_text": "뇌나트륨이뇨펩티드는 심정지와 상관없이 심장\n\n기능에 문제가 있을 경우 혈관 벽에서 말초혈액으로 분비되므로 심부전을\n\n진단하는 중요 표지자로 진단에 활용된다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 4 -\n<!-- PAGE_10 -->\n# Ⅱ\n\n<!-- PAGE_10 -->\n#### 용어의 정의\n\n※ 본 가이드라인에서 사용되는 용어의 정의는 본 가이드라인의 이해를\n\n돕기 위해 사용되는 것이므로 단순 참고용임\n\n간섭 (Interference)\n\n분석물질의 농도나 강도가 명백함에도 검출시약이나 신호 자체에 비특이적\n\n으로 반응하는 물질의 존재로 인해 일어나는 인위적인 증가나 감소\n\n☞ 검출 시스템의 비특이성에서 기인하기도 하고, 지시약 반응의 억제, 분\n\n검출한계 (Limit of detection, LoD)\n\n검출될 수 있는 분석 물질의 최소량\n\n공란한계 (Limit of blank, LoB)\n\nblank 검체에서 관찰 가능할 수 있는 가장 높은 측정치\n\n교차반응 (Cross-reactivity)\n\n항원 이외에 공유되었거나, 유사한 또는 동일한 항원결정기를 가진 항원과\n\n항체가 반응하는 현상\n\n기질효과 (Matrix effect)\n\n측정하고자 하는 분석물질 이외에 검체의 특성이 분석물질의 측정에 영향을\n\n미치는 경우\n\n☞ 검체의 점성, 표면장력, 혼탁도, 이온 강도, pH 등이 기질효과의 주된\n\n요인이다.\n\n Ⅱ.  용어의 정의\n\n- - 5 -\n대조물질 (Control / Control material)\n\n정도 관리를 위해 이용되는 물질\n\n면역분석법, 면역측정법 (Immunoassay)\n\n분석물질에 결합 가능한 특이 항원이나 항체를 이용하는 리간드-결합 분석\n\n☞ 항체를 사용하여 물질을 측정하는 검사법으로 면역분석법은 경쟁적 또는\n\n비경쟁적, 고체상 또는 액체상, 동위원소 또는 비동위원소, 항원표지\n\n또는 항체표지, 단일 또는 이중 부위, 균질적 또는 비균질적 방법일 수\n\n바이어스 (Bias)\n\n검사 결과의 예상치와 허용된 기준치 사이의 차이\n\n간섭물질 (Interfering substances)\n\n임상검체에 존재하는 내부물질(예 : 혈액 구성요소, acidic polysaccharides)\n\n또는 외부물질(예 : talc, 항응고제 등)으로 위양성 또는 위음성 결과를 야기\n\n할 수 있는 물질\n\n보관 시 안정성 (Storage stability)\n\n최종 디자인(포장) 상태에서 시약의 유효기간\n\n보정 (Calibration)\n\n특별한 조건하에서 측정 기기나 측정 시스템이 나타내는 값 또는 물질\n\n측정이나 참고물질에 의한 값과 표준물질에 상응하는 값 사이의 관계를\n\n확립하는 일련의 조작\n\n보정물질 (Calibrator / Calibration material)\n\n측정과정을 보정하기 위해서 또는 검체의 반응을 비교하기 위해서 사용되는\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 6 -\n알려진 정량적/정성적 특성(예 : 농도, 활성도, 강도, 반응성)을 갖는 물질\n\n☞ a) 보정물질에서 분석물질 양은 그의 제조과정에서 확인된 한계\n\n(limit) 내에 있으며, 분석법의 반응과 측정되는 특성과의 관계를\n\n설정하는데 사용될 수 있다.\n\n b) 보정물질은 국가 또는 국제 표준물질이나 참고물질에 소급성을\n\nc) 분석물질의 다른 양을 갖는 보정물질은 보정 곡선을 설정하는데\n\nd) “일차”와 “이차표준”이란 용어는 보정물질을 지칭하는 용어로\n\n분석물질 (Analyte)\n\n검사실이 수행하는 검사의 물질 또는 구성요소\n\n분석적 특이도 (Analytical specificity)\n\n정량검사에서 측정하고자 하는 물질만 측정되고 검체 내 다른 물질은 측정\n\n되지 않는 분석법의 능력\n\n비정밀도 (Imprecision)\n\n특별한 조건 하에서 얻어진 측정값의 독립적 결과들의 분산\n\n☞ 표준편차나 변이계수 등의 숫자로 표시된다.\n\n 비특이도 (Nonspecificity)\n\n분석하려는 물질 외에 다른 물질과 항원이 반응하는 정도\n\n☞ 비특이도는 보통 분석물질이 아닌 물질에 결합하고, 반응하는 항체,\n\n효소, ionophore, 시약에 의해 발생한다.\n\n Ⅱ. ",
        "original_sentence": "용어의 정의\n\n- - 5 -\n대조물질 (Control / Control material)\n\n정도 관리를 위해 이용되는 물질\n\n면역분석법, 면역측정법 (Immunoassay)\n\n분석물질에 결합 가능한 특이 항원이나 항체를 이용하는 리간드-결합 분석\n\n☞ 항체를 사용하여 물질을 측정하는 검사법으로 면역분석법은 경쟁적 또는\n\n비경쟁적, 고체상 또는 액체상, 동위원소 또는 비동위원소, 항원표지\n\n또는 항체표지, 단일 또는 이중 부위, 균질적 또는 비균질적 방법일 수\n\n바이어스 (Bias)\n\n검사 결과의 예상치와 허용된 기준치 사이의 차이\n\n간섭물질 (Interfering substances)\n\n임상검체에 존재하는 내부물질(예 : 혈액 구성요소, acidic polysaccharides)\n\n또는 외부물질(예 : talc, 항응고제 등)으로 위양성 또는 위음성 결과를 야기\n\n할 수 있는 물질\n\n보관 시 안정성 (Storage stability)\n\n최종 디자인(포장) 상태에서 시약의 유효기간\n\n보정 (Calibration)\n\n특별한 조건하에서 측정 기기나 측정 시스템이 나타내는 값 또는 물질\n\n측정이나 참고물질에 의한 값과 표준물질에 상응하는 값 사이의 관계를\n\n확립하는 일련의 조작\n\n보정물질 (Calibrator / Calibration material)\n\n측정과정을 보정하기 위해서 또는 검체의 반응을 비교하기 위해서 사용되는\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 6 -\n알려진 정량적/정성적 특성(예 : 농도, 활성도, 강도, 반응성)을 갖는 물질\n\n☞ a) 보정물질에서 분석물질 양은 그의 제조과정에서 확인된 한계\n\n(limit) 내에 있으며, 분석법의 반응과 측정되는 특성과의 관계를\n\n설정하는데 사용될 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_328",
      "text": "b) 보정물질은 국가 또는 국제 표준물질이나 참고물질에 소급성을\n\nc) 분석물질의 다른 양을 갖는 보정물질은 보정 곡선을 설정하는데\n\nd) “일차”와 “이차표준”이란 용어는 보정물질을 지칭하는 용어로\n\n분석물질 (Analyte)\n\n검사실이 수행하는 검사의 물질 또는 구성요소\n\n분석적 특이도 (Analytical specificity)\n\n정량검사에서 측정하고자 하는 물질만 측정되고 검체 내 다른 물질은 측정\n\n되지 않는 분석법의 능력\n\n비정밀도 (Imprecision)\n\n특별한 조건 하에서 얻어진 측정값의 독립적 결과들의 분산\n\n☞ 표준편차나 변이계수 등의 숫자로 표시된다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 327,
        "window_size": 3,
        "char_count": 325,
        "word_count": 66,
        "page_number": 12,
        "window_text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 4 -\n<!-- PAGE_10 -->\n# Ⅱ\n\n<!-- PAGE_10 -->\n#### 용어의 정의\n\n※ 본 가이드라인에서 사용되는 용어의 정의는 본 가이드라인의 이해를\n\n돕기 위해 사용되는 것이므로 단순 참고용임\n\n간섭 (Interference)\n\n분석물질의 농도나 강도가 명백함에도 검출시약이나 신호 자체에 비특이적\n\n으로 반응하는 물질의 존재로 인해 일어나는 인위적인 증가나 감소\n\n☞ 검출 시스템의 비특이성에서 기인하기도 하고, 지시약 반응의 억제, 분\n\n검출한계 (Limit of detection, LoD)\n\n검출될 수 있는 분석 물질의 최소량\n\n공란한계 (Limit of blank, LoB)\n\nblank 검체에서 관찰 가능할 수 있는 가장 높은 측정치\n\n교차반응 (Cross-reactivity)\n\n항원 이외에 공유되었거나, 유사한 또는 동일한 항원결정기를 가진 항원과\n\n항체가 반응하는 현상\n\n기질효과 (Matrix effect)\n\n측정하고자 하는 분석물질 이외에 검체의 특성이 분석물질의 측정에 영향을\n\n미치는 경우\n\n☞ 검체의 점성, 표면장력, 혼탁도, 이온 강도, pH 등이 기질효과의 주된\n\n요인이다.\n\n Ⅱ.  용어의 정의\n\n- - 5 -\n대조물질 (Control / Control material)\n\n정도 관리를 위해 이용되는 물질\n\n면역분석법, 면역측정법 (Immunoassay)\n\n분석물질에 결합 가능한 특이 항원이나 항체를 이용하는 리간드-결합 분석\n\n☞ 항체를 사용하여 물질을 측정하는 검사법으로 면역분석법은 경쟁적 또는\n\n비경쟁적, 고체상 또는 액체상, 동위원소 또는 비동위원소, 항원표지\n\n또는 항체표지, 단일 또는 이중 부위, 균질적 또는 비균질적 방법일 수\n\n바이어스 (Bias)\n\n검사 결과의 예상치와 허용된 기준치 사이의 차이\n\n간섭물질 (Interfering substances)\n\n임상검체에 존재하는 내부물질(예 : 혈액 구성요소, acidic polysaccharides)\n\n또는 외부물질(예 : talc, 항응고제 등)으로 위양성 또는 위음성 결과를 야기\n\n할 수 있는 물질\n\n보관 시 안정성 (Storage stability)\n\n최종 디자인(포장) 상태에서 시약의 유효기간\n\n보정 (Calibration)\n\n특별한 조건하에서 측정 기기나 측정 시스템이 나타내는 값 또는 물질\n\n측정이나 참고물질에 의한 값과 표준물질에 상응하는 값 사이의 관계를\n\n확립하는 일련의 조작\n\n보정물질 (Calibrator / Calibration material)\n\n측정과정을 보정하기 위해서 또는 검체의 반응을 비교하기 위해서 사용되는\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 6 -\n알려진 정량적/정성적 특성(예 : 농도, 활성도, 강도, 반응성)을 갖는 물질\n\n☞ a) 보정물질에서 분석물질 양은 그의 제조과정에서 확인된 한계\n\n(limit) 내에 있으며, 분석법의 반응과 측정되는 특성과의 관계를\n\n설정하는데 사용될 수 있다.\n\n b) 보정물질은 국가 또는 국제 표준물질이나 참고물질에 소급성을\n\nc) 분석물질의 다른 양을 갖는 보정물질은 보정 곡선을 설정하는데\n\nd) “일차”와 “이차표준”이란 용어는 보정물질을 지칭하는 용어로\n\n분석물질 (Analyte)\n\n검사실이 수행하는 검사의 물질 또는 구성요소\n\n분석적 특이도 (Analytical specificity)\n\n정량검사에서 측정하고자 하는 물질만 측정되고 검체 내 다른 물질은 측정\n\n되지 않는 분석법의 능력\n\n비정밀도 (Imprecision)\n\n특별한 조건 하에서 얻어진 측정값의 독립적 결과들의 분산\n\n☞ 표준편차나 변이계수 등의 숫자로 표시된다.\n\n 비특이도 (Nonspecificity)\n\n분석하려는 물질 외에 다른 물질과 항원이 반응하는 정도\n\n☞ 비특이도는 보통 분석물질이 아닌 물질에 결합하고, 반응하는 항체,\n\n효소, ionophore, 시약에 의해 발생한다.\n\n Ⅱ.  용어의 정의\n\n- - 7 -\n사용 시 안정성 (in–use stability)\n\n제조사에서 제공한 용기를 개봉한 이후에 사용자의 작동 조건에서 시약의\n\n유효기간내의 검사수행능\n\n상관계수 (Correlation coefficient, r)\n\n측정된 데이터에 대한 두개의 무작위 변수의 공분산(covariance)과 그들의\n\n표준편차의 곱의 비(ratio)\n\n수송 안정성 실험 (Transport stability test)\n\n제품 운송 도중 발생 가능한 환경변화가 제품 성능에 미치는 영향을 평가\n\n하는 것\n\n☞ 최악의 상황을 시험해야 한다.\n\n",
        "original_sentence": "b) 보정물질은 국가 또는 국제 표준물질이나 참고물질에 소급성을\n\nc) 분석물질의 다른 양을 갖는 보정물질은 보정 곡선을 설정하는데\n\nd) “일차”와 “이차표준”이란 용어는 보정물질을 지칭하는 용어로\n\n분석물질 (Analyte)\n\n검사실이 수행하는 검사의 물질 또는 구성요소\n\n분석적 특이도 (Analytical specificity)\n\n정량검사에서 측정하고자 하는 물질만 측정되고 검체 내 다른 물질은 측정\n\n되지 않는 분석법의 능력\n\n비정밀도 (Imprecision)\n\n특별한 조건 하에서 얻어진 측정값의 독립적 결과들의 분산\n\n☞ 표준편차나 변이계수 등의 숫자로 표시된다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_329",
      "text": "비특이도 (Nonspecificity)\n\n분석하려는 물질 외에 다른 물질과 항원이 반응하는 정도\n\n☞ 비특이도는 보통 분석물질이 아닌 물질에 결합하고, 반응하는 항체,\n\n효소, ionophore, 시약에 의해 발생한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 328,
        "window_size": 3,
        "char_count": 124,
        "word_count": 24,
        "page_number": 3,
        "window_text": "Ⅱ.  용어의 정의\n\n- - 5 -\n대조물질 (Control / Control material)\n\n정도 관리를 위해 이용되는 물질\n\n면역분석법, 면역측정법 (Immunoassay)\n\n분석물질에 결합 가능한 특이 항원이나 항체를 이용하는 리간드-결합 분석\n\n☞ 항체를 사용하여 물질을 측정하는 검사법으로 면역분석법은 경쟁적 또는\n\n비경쟁적, 고체상 또는 액체상, 동위원소 또는 비동위원소, 항원표지\n\n또는 항체표지, 단일 또는 이중 부위, 균질적 또는 비균질적 방법일 수\n\n바이어스 (Bias)\n\n검사 결과의 예상치와 허용된 기준치 사이의 차이\n\n간섭물질 (Interfering substances)\n\n임상검체에 존재하는 내부물질(예 : 혈액 구성요소, acidic polysaccharides)\n\n또는 외부물질(예 : talc, 항응고제 등)으로 위양성 또는 위음성 결과를 야기\n\n할 수 있는 물질\n\n보관 시 안정성 (Storage stability)\n\n최종 디자인(포장) 상태에서 시약의 유효기간\n\n보정 (Calibration)\n\n특별한 조건하에서 측정 기기나 측정 시스템이 나타내는 값 또는 물질\n\n측정이나 참고물질에 의한 값과 표준물질에 상응하는 값 사이의 관계를\n\n확립하는 일련의 조작\n\n보정물질 (Calibrator / Calibration material)\n\n측정과정을 보정하기 위해서 또는 검체의 반응을 비교하기 위해서 사용되는\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 6 -\n알려진 정량적/정성적 특성(예 : 농도, 활성도, 강도, 반응성)을 갖는 물질\n\n☞ a) 보정물질에서 분석물질 양은 그의 제조과정에서 확인된 한계\n\n(limit) 내에 있으며, 분석법의 반응과 측정되는 특성과의 관계를\n\n설정하는데 사용될 수 있다.\n\n b) 보정물질은 국가 또는 국제 표준물질이나 참고물질에 소급성을\n\nc) 분석물질의 다른 양을 갖는 보정물질은 보정 곡선을 설정하는데\n\nd) “일차”와 “이차표준”이란 용어는 보정물질을 지칭하는 용어로\n\n분석물질 (Analyte)\n\n검사실이 수행하는 검사의 물질 또는 구성요소\n\n분석적 특이도 (Analytical specificity)\n\n정량검사에서 측정하고자 하는 물질만 측정되고 검체 내 다른 물질은 측정\n\n되지 않는 분석법의 능력\n\n비정밀도 (Imprecision)\n\n특별한 조건 하에서 얻어진 측정값의 독립적 결과들의 분산\n\n☞ 표준편차나 변이계수 등의 숫자로 표시된다.\n\n 비특이도 (Nonspecificity)\n\n분석하려는 물질 외에 다른 물질과 항원이 반응하는 정도\n\n☞ 비특이도는 보통 분석물질이 아닌 물질에 결합하고, 반응하는 항체,\n\n효소, ionophore, 시약에 의해 발생한다.\n\n Ⅱ.  용어의 정의\n\n- - 7 -\n사용 시 안정성 (in–use stability)\n\n제조사에서 제공한 용기를 개봉한 이후에 사용자의 작동 조건에서 시약의\n\n유효기간내의 검사수행능\n\n상관계수 (Correlation coefficient, r)\n\n측정된 데이터에 대한 두개의 무작위 변수의 공분산(covariance)과 그들의\n\n표준편차의 곱의 비(ratio)\n\n수송 안정성 실험 (Transport stability test)\n\n제품 운송 도중 발생 가능한 환경변화가 제품 성능에 미치는 영향을 평가\n\n하는 것\n\n☞ 최악의 상황을 시험해야 한다.\n\n 신뢰구간 (Confidence interval)\n\n평균, 분율, 비율 등의 변수의 참값이 정해진 확률 범위 내에서 분포할\n\n것으로 예상되는 계산된 구간\n\n실시간 안정성 실험 (Real time stability)\n\n시약을 추천하는 정상적인 보관과 사용 환경에 두고 그 안정성을 평가하는 실험\n\n양성 예측도 (Predictive value of positive result, PPV)\n\n표적 질환(진단 정확도 기준에 의해 결정되는)을 가지고 있는 환자에서\n\n양성 결과를 보이는 비율(100을 곱한 값)\n\n☞ a) 양성 예측도(PPV)는 반드시 관심대상 조건(진단 정확도 기준에 의해\n\n결정되는)의 유병률에 맞추어 해석해야 한다.\n\n",
        "original_sentence": "비특이도 (Nonspecificity)\n\n분석하려는 물질 외에 다른 물질과 항원이 반응하는 정도\n\n☞ 비특이도는 보통 분석물질이 아닌 물질에 결합하고, 반응하는 항체,\n\n효소, ionophore, 시약에 의해 발생한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_330",
      "text": "Ⅱ. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 329,
        "window_size": 3,
        "char_count": 3,
        "word_count": 1,
        "page_number": 6,
        "window_text": "용어의 정의\n\n- - 5 -\n대조물질 (Control / Control material)\n\n정도 관리를 위해 이용되는 물질\n\n면역분석법, 면역측정법 (Immunoassay)\n\n분석물질에 결합 가능한 특이 항원이나 항체를 이용하는 리간드-결합 분석\n\n☞ 항체를 사용하여 물질을 측정하는 검사법으로 면역분석법은 경쟁적 또는\n\n비경쟁적, 고체상 또는 액체상, 동위원소 또는 비동위원소, 항원표지\n\n또는 항체표지, 단일 또는 이중 부위, 균질적 또는 비균질적 방법일 수\n\n바이어스 (Bias)\n\n검사 결과의 예상치와 허용된 기준치 사이의 차이\n\n간섭물질 (Interfering substances)\n\n임상검체에 존재하는 내부물질(예 : 혈액 구성요소, acidic polysaccharides)\n\n또는 외부물질(예 : talc, 항응고제 등)으로 위양성 또는 위음성 결과를 야기\n\n할 수 있는 물질\n\n보관 시 안정성 (Storage stability)\n\n최종 디자인(포장) 상태에서 시약의 유효기간\n\n보정 (Calibration)\n\n특별한 조건하에서 측정 기기나 측정 시스템이 나타내는 값 또는 물질\n\n측정이나 참고물질에 의한 값과 표준물질에 상응하는 값 사이의 관계를\n\n확립하는 일련의 조작\n\n보정물질 (Calibrator / Calibration material)\n\n측정과정을 보정하기 위해서 또는 검체의 반응을 비교하기 위해서 사용되는\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 6 -\n알려진 정량적/정성적 특성(예 : 농도, 활성도, 강도, 반응성)을 갖는 물질\n\n☞ a) 보정물질에서 분석물질 양은 그의 제조과정에서 확인된 한계\n\n(limit) 내에 있으며, 분석법의 반응과 측정되는 특성과의 관계를\n\n설정하는데 사용될 수 있다.\n\n b) 보정물질은 국가 또는 국제 표준물질이나 참고물질에 소급성을\n\nc) 분석물질의 다른 양을 갖는 보정물질은 보정 곡선을 설정하는데\n\nd) “일차”와 “이차표준”이란 용어는 보정물질을 지칭하는 용어로\n\n분석물질 (Analyte)\n\n검사실이 수행하는 검사의 물질 또는 구성요소\n\n분석적 특이도 (Analytical specificity)\n\n정량검사에서 측정하고자 하는 물질만 측정되고 검체 내 다른 물질은 측정\n\n되지 않는 분석법의 능력\n\n비정밀도 (Imprecision)\n\n특별한 조건 하에서 얻어진 측정값의 독립적 결과들의 분산\n\n☞ 표준편차나 변이계수 등의 숫자로 표시된다.\n\n 비특이도 (Nonspecificity)\n\n분석하려는 물질 외에 다른 물질과 항원이 반응하는 정도\n\n☞ 비특이도는 보통 분석물질이 아닌 물질에 결합하고, 반응하는 항체,\n\n효소, ionophore, 시약에 의해 발생한다.\n\n Ⅱ.  용어의 정의\n\n- - 7 -\n사용 시 안정성 (in–use stability)\n\n제조사에서 제공한 용기를 개봉한 이후에 사용자의 작동 조건에서 시약의\n\n유효기간내의 검사수행능\n\n상관계수 (Correlation coefficient, r)\n\n측정된 데이터에 대한 두개의 무작위 변수의 공분산(covariance)과 그들의\n\n표준편차의 곱의 비(ratio)\n\n수송 안정성 실험 (Transport stability test)\n\n제품 운송 도중 발생 가능한 환경변화가 제품 성능에 미치는 영향을 평가\n\n하는 것\n\n☞ 최악의 상황을 시험해야 한다.\n\n 신뢰구간 (Confidence interval)\n\n평균, 분율, 비율 등의 변수의 참값이 정해진 확률 범위 내에서 분포할\n\n것으로 예상되는 계산된 구간\n\n실시간 안정성 실험 (Real time stability)\n\n시약을 추천하는 정상적인 보관과 사용 환경에 두고 그 안정성을 평가하는 실험\n\n양성 예측도 (Predictive value of positive result, PPV)\n\n표적 질환(진단 정확도 기준에 의해 결정되는)을 가지고 있는 환자에서\n\n양성 결과를 보이는 비율(100을 곱한 값)\n\n☞ a) 양성 예측도(PPV)는 반드시 관심대상 조건(진단 정확도 기준에 의해\n\n결정되는)의 유병률에 맞추어 해석해야 한다.\n\n b) PPV의 추정값[추정 유병률은 100x(TP+FN)/(TP+FP+FN+TN)]은\n\n100xTP/(TP+FP)로 계산된다.\n\n",
        "original_sentence": "Ⅱ. "
      }
    },
    {
      "chunk_id": "chunk_331",
      "text": "용어의 정의\n\n- - 7 -\n사용 시 안정성 (in–use stability)\n\n제조사에서 제공한 용기를 개봉한 이후에 사용자의 작동 조건에서 시약의\n\n유효기간내의 검사수행능\n\n상관계수 (Correlation coefficient, r)\n\n측정된 데이터에 대한 두개의 무작위 변수의 공분산(covariance)과 그들의\n\n표준편차의 곱의 비(ratio)\n\n수송 안정성 실험 (Transport stability test)\n\n제품 운송 도중 발생 가능한 환경변화가 제품 성능에 미치는 영향을 평가\n\n하는 것\n\n☞ 최악의 상황을 시험해야 한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 330,
        "window_size": 3,
        "char_count": 304,
        "word_count": 61,
        "page_number": 10,
        "window_text": "b) 보정물질은 국가 또는 국제 표준물질이나 참고물질에 소급성을\n\nc) 분석물질의 다른 양을 갖는 보정물질은 보정 곡선을 설정하는데\n\nd) “일차”와 “이차표준”이란 용어는 보정물질을 지칭하는 용어로\n\n분석물질 (Analyte)\n\n검사실이 수행하는 검사의 물질 또는 구성요소\n\n분석적 특이도 (Analytical specificity)\n\n정량검사에서 측정하고자 하는 물질만 측정되고 검체 내 다른 물질은 측정\n\n되지 않는 분석법의 능력\n\n비정밀도 (Imprecision)\n\n특별한 조건 하에서 얻어진 측정값의 독립적 결과들의 분산\n\n☞ 표준편차나 변이계수 등의 숫자로 표시된다.\n\n 비특이도 (Nonspecificity)\n\n분석하려는 물질 외에 다른 물질과 항원이 반응하는 정도\n\n☞ 비특이도는 보통 분석물질이 아닌 물질에 결합하고, 반응하는 항체,\n\n효소, ionophore, 시약에 의해 발생한다.\n\n Ⅱ.  용어의 정의\n\n- - 7 -\n사용 시 안정성 (in–use stability)\n\n제조사에서 제공한 용기를 개봉한 이후에 사용자의 작동 조건에서 시약의\n\n유효기간내의 검사수행능\n\n상관계수 (Correlation coefficient, r)\n\n측정된 데이터에 대한 두개의 무작위 변수의 공분산(covariance)과 그들의\n\n표준편차의 곱의 비(ratio)\n\n수송 안정성 실험 (Transport stability test)\n\n제품 운송 도중 발생 가능한 환경변화가 제품 성능에 미치는 영향을 평가\n\n하는 것\n\n☞ 최악의 상황을 시험해야 한다.\n\n 신뢰구간 (Confidence interval)\n\n평균, 분율, 비율 등의 변수의 참값이 정해진 확률 범위 내에서 분포할\n\n것으로 예상되는 계산된 구간\n\n실시간 안정성 실험 (Real time stability)\n\n시약을 추천하는 정상적인 보관과 사용 환경에 두고 그 안정성을 평가하는 실험\n\n양성 예측도 (Predictive value of positive result, PPV)\n\n표적 질환(진단 정확도 기준에 의해 결정되는)을 가지고 있는 환자에서\n\n양성 결과를 보이는 비율(100을 곱한 값)\n\n☞ a) 양성 예측도(PPV)는 반드시 관심대상 조건(진단 정확도 기준에 의해\n\n결정되는)의 유병률에 맞추어 해석해야 한다.\n\n b) PPV의 추정값[추정 유병률은 100x(TP+FN)/(TP+FP+FN+TN)]은\n\n100xTP/(TP+FP)로 계산된다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 8 -\n진단정확도기준\n\n양성\n\n음성\n\n전체\n\n방법 X\n\n양성\n\n# 진양성 TP\n\n# 위양성 FP\n\n진양성+ 위양성\n\n음성\n\n# 위음성 FN\n\n# 진음성 TN\n\n위음성 + 진음성\n\n전체\n\n진양성 + 위음성\n\n위양성 + 진음성\n\nN\n\n양성 일치율(Percent positive agreement, PPA)\n\n= 100×a/(a+c)\n\n음성 일치율(Percent negative agreement, PNA)\n\n= 100×d/(b+d)\n\n총 일치율(Overall percent agreement)\n\n= 100×(a+d)/n\n\n음성 예측도 (Predictive value of negative result, NPV)\n\n표적 질환을 가지지 않은 정상인에서 음성 결과를 보이는 비율(100을\n\n곱한 값)\n\n☞ NPV의 추정값은 100×TN/(TN+FN)로 계산된다.\n\n",
        "original_sentence": "용어의 정의\n\n- - 7 -\n사용 시 안정성 (in–use stability)\n\n제조사에서 제공한 용기를 개봉한 이후에 사용자의 작동 조건에서 시약의\n\n유효기간내의 검사수행능\n\n상관계수 (Correlation coefficient, r)\n\n측정된 데이터에 대한 두개의 무작위 변수의 공분산(covariance)과 그들의\n\n표준편차의 곱의 비(ratio)\n\n수송 안정성 실험 (Transport stability test)\n\n제품 운송 도중 발생 가능한 환경변화가 제품 성능에 미치는 영향을 평가\n\n하는 것\n\n☞ 최악의 상황을 시험해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_332",
      "text": "신뢰구간 (Confidence interval)\n\n평균, 분율, 비율 등의 변수의 참값이 정해진 확률 범위 내에서 분포할\n\n것으로 예상되는 계산된 구간\n\n실시간 안정성 실험 (Real time stability)\n\n시약을 추천하는 정상적인 보관과 사용 환경에 두고 그 안정성을 평가하는 실험\n\n양성 예측도 (Predictive value of positive result, PPV)\n\n표적 질환(진단 정확도 기준에 의해 결정되는)을 가지고 있는 환자에서\n\n양성 결과를 보이는 비율(100을 곱한 값)\n\n☞ a) 양성 예측도(PPV)는 반드시 관심대상 조건(진단 정확도 기준에 의해\n\n결정되는)의 유병률에 맞추어 해석해야 한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 331,
        "window_size": 3,
        "char_count": 352,
        "word_count": 73,
        "page_number": 13,
        "window_text": "비특이도 (Nonspecificity)\n\n분석하려는 물질 외에 다른 물질과 항원이 반응하는 정도\n\n☞ 비특이도는 보통 분석물질이 아닌 물질에 결합하고, 반응하는 항체,\n\n효소, ionophore, 시약에 의해 발생한다.\n\n Ⅱ.  용어의 정의\n\n- - 7 -\n사용 시 안정성 (in–use stability)\n\n제조사에서 제공한 용기를 개봉한 이후에 사용자의 작동 조건에서 시약의\n\n유효기간내의 검사수행능\n\n상관계수 (Correlation coefficient, r)\n\n측정된 데이터에 대한 두개의 무작위 변수의 공분산(covariance)과 그들의\n\n표준편차의 곱의 비(ratio)\n\n수송 안정성 실험 (Transport stability test)\n\n제품 운송 도중 발생 가능한 환경변화가 제품 성능에 미치는 영향을 평가\n\n하는 것\n\n☞ 최악의 상황을 시험해야 한다.\n\n 신뢰구간 (Confidence interval)\n\n평균, 분율, 비율 등의 변수의 참값이 정해진 확률 범위 내에서 분포할\n\n것으로 예상되는 계산된 구간\n\n실시간 안정성 실험 (Real time stability)\n\n시약을 추천하는 정상적인 보관과 사용 환경에 두고 그 안정성을 평가하는 실험\n\n양성 예측도 (Predictive value of positive result, PPV)\n\n표적 질환(진단 정확도 기준에 의해 결정되는)을 가지고 있는 환자에서\n\n양성 결과를 보이는 비율(100을 곱한 값)\n\n☞ a) 양성 예측도(PPV)는 반드시 관심대상 조건(진단 정확도 기준에 의해\n\n결정되는)의 유병률에 맞추어 해석해야 한다.\n\n b) PPV의 추정값[추정 유병률은 100x(TP+FN)/(TP+FP+FN+TN)]은\n\n100xTP/(TP+FP)로 계산된다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 8 -\n진단정확도기준\n\n양성\n\n음성\n\n전체\n\n방법 X\n\n양성\n\n# 진양성 TP\n\n# 위양성 FP\n\n진양성+ 위양성\n\n음성\n\n# 위음성 FN\n\n# 진음성 TN\n\n위음성 + 진음성\n\n전체\n\n진양성 + 위음성\n\n위양성 + 진음성\n\nN\n\n양성 일치율(Percent positive agreement, PPA)\n\n= 100×a/(a+c)\n\n음성 일치율(Percent negative agreement, PNA)\n\n= 100×d/(b+d)\n\n총 일치율(Overall percent agreement)\n\n= 100×(a+d)/n\n\n음성 예측도 (Predictive value of negative result, NPV)\n\n표적 질환을 가지지 않은 정상인에서 음성 결과를 보이는 비율(100을\n\n곱한 값)\n\n☞ NPV의 추정값은 100×TN/(TN+FN)로 계산된다.\n\n 위양성 (False positive, FP)\n\n질병이나 증상이 없는 상태에서 이를 시사하는 양성검사 결과\n\n☞ 예시 : 질환에 이환되지 않은 개체에서 비정상 결과\n\n위음성 (False negative, FN)\n\n양성 환자나 양성 검체에서의 음성검사 결과\n\nⅡ. ",
        "original_sentence": "신뢰구간 (Confidence interval)\n\n평균, 분율, 비율 등의 변수의 참값이 정해진 확률 범위 내에서 분포할\n\n것으로 예상되는 계산된 구간\n\n실시간 안정성 실험 (Real time stability)\n\n시약을 추천하는 정상적인 보관과 사용 환경에 두고 그 안정성을 평가하는 실험\n\n양성 예측도 (Predictive value of positive result, PPV)\n\n표적 질환(진단 정확도 기준에 의해 결정되는)을 가지고 있는 환자에서\n\n양성 결과를 보이는 비율(100을 곱한 값)\n\n☞ a) 양성 예측도(PPV)는 반드시 관심대상 조건(진단 정확도 기준에 의해\n\n결정되는)의 유병률에 맞추어 해석해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_333",
      "text": "b) PPV의 추정값[추정 유병률은 100x(TP+FN)/(TP+FP+FN+TN)]은\n\n100xTP/(TP+FP)로 계산된다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 332,
        "window_size": 3,
        "char_count": 72,
        "word_count": 7,
        "page_number": 13,
        "window_text": "Ⅱ.  용어의 정의\n\n- - 7 -\n사용 시 안정성 (in–use stability)\n\n제조사에서 제공한 용기를 개봉한 이후에 사용자의 작동 조건에서 시약의\n\n유효기간내의 검사수행능\n\n상관계수 (Correlation coefficient, r)\n\n측정된 데이터에 대한 두개의 무작위 변수의 공분산(covariance)과 그들의\n\n표준편차의 곱의 비(ratio)\n\n수송 안정성 실험 (Transport stability test)\n\n제품 운송 도중 발생 가능한 환경변화가 제품 성능에 미치는 영향을 평가\n\n하는 것\n\n☞ 최악의 상황을 시험해야 한다.\n\n 신뢰구간 (Confidence interval)\n\n평균, 분율, 비율 등의 변수의 참값이 정해진 확률 범위 내에서 분포할\n\n것으로 예상되는 계산된 구간\n\n실시간 안정성 실험 (Real time stability)\n\n시약을 추천하는 정상적인 보관과 사용 환경에 두고 그 안정성을 평가하는 실험\n\n양성 예측도 (Predictive value of positive result, PPV)\n\n표적 질환(진단 정확도 기준에 의해 결정되는)을 가지고 있는 환자에서\n\n양성 결과를 보이는 비율(100을 곱한 값)\n\n☞ a) 양성 예측도(PPV)는 반드시 관심대상 조건(진단 정확도 기준에 의해\n\n결정되는)의 유병률에 맞추어 해석해야 한다.\n\n b) PPV의 추정값[추정 유병률은 100x(TP+FN)/(TP+FP+FN+TN)]은\n\n100xTP/(TP+FP)로 계산된다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 8 -\n진단정확도기준\n\n양성\n\n음성\n\n전체\n\n방법 X\n\n양성\n\n# 진양성 TP\n\n# 위양성 FP\n\n진양성+ 위양성\n\n음성\n\n# 위음성 FN\n\n# 진음성 TN\n\n위음성 + 진음성\n\n전체\n\n진양성 + 위음성\n\n위양성 + 진음성\n\nN\n\n양성 일치율(Percent positive agreement, PPA)\n\n= 100×a/(a+c)\n\n음성 일치율(Percent negative agreement, PNA)\n\n= 100×d/(b+d)\n\n총 일치율(Overall percent agreement)\n\n= 100×(a+d)/n\n\n음성 예측도 (Predictive value of negative result, NPV)\n\n표적 질환을 가지지 않은 정상인에서 음성 결과를 보이는 비율(100을\n\n곱한 값)\n\n☞ NPV의 추정값은 100×TN/(TN+FN)로 계산된다.\n\n 위양성 (False positive, FP)\n\n질병이나 증상이 없는 상태에서 이를 시사하는 양성검사 결과\n\n☞ 예시 : 질환에 이환되지 않은 개체에서 비정상 결과\n\n위음성 (False negative, FN)\n\n양성 환자나 양성 검체에서의 음성검사 결과\n\nⅡ.  용어의 정의\n\n- - 9 -\n임상적 민감도 (Clinical sensitivity)\n\n특정질환을 가지고 있는 사람들 중 검사 결과가 양성으로 나오는 비율\n\n임상적 보고가능범위 (Clinically reportable range, CCR)\n\n분석측정범위를 연장하기 위해 검체에 대한 희석, 농축, 또는 기타\n\n전처리를 하여 정량 결과 값으로 보고할 수 있는 분석물질 값의 범위\n\n임상적 특이도 (Clinical specificity)\n\n특정질환을 가지고 있지 않은 사람들 중 검사 결과가 음성으로 나오는 비율\n\n재현성 조건 (Reproducibility condition)\n\n동일한 방법과 동일한 검사 품목으로 다른 검사실에서 다른 사용자가 다른\n\n장비를 사용하여 검사 결과를 얻는 조건\n\n재현성 (Reproducibility)\n\n다른 측정조건에서 수행된 동일한 측정물의 결과값 사이의 일치도의 근접성\n\n정규분포 (Normal distribution)\n\n가우스 분포라고 표현되며 측정값을 곡선의 x축에, 관측치의 빈도를 곡선의\n\ny축에 표시\n\n☞ 관측치가 평균의 양측에 균일하게 분포하면 결과그래프는 전형적인\n\n종형곡선을 갖는다.\n\n",
        "original_sentence": "b) PPV의 추정값[추정 유병률은 100x(TP+FN)/(TP+FP+FN+TN)]은\n\n100xTP/(TP+FP)로 계산된다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_334",
      "text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 8 -\n진단정확도기준\n\n양성\n\n음성\n\n전체\n\n방법 X\n\n양성\n\n# 진양성 TP\n\n# 위양성 FP\n\n진양성+ 위양성\n\n음성\n\n# 위음성 FN\n\n# 진음성 TN\n\n위음성 + 진음성\n\n전체\n\n진양성 + 위음성\n\n위양성 + 진음성\n\nN\n\n양성 일치율(Percent positive agreement, PPA)\n\n= 100×a/(a+c)\n\n음성 일치율(Percent negative agreement, PNA)\n\n= 100×d/(b+d)\n\n총 일치율(Overall percent agreement)\n\n= 100×(a+d)/n\n\n음성 예측도 (Predictive value of negative result, NPV)\n\n표적 질환을 가지지 않은 정상인에서 음성 결과를 보이는 비율(100을\n\n곱한 값)\n\n☞ NPV의 추정값은 100×TN/(TN+FN)로 계산된다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 333,
        "window_size": 3,
        "char_count": 476,
        "word_count": 89,
        "page_number": 1,
        "window_text": "용어의 정의\n\n- - 7 -\n사용 시 안정성 (in–use stability)\n\n제조사에서 제공한 용기를 개봉한 이후에 사용자의 작동 조건에서 시약의\n\n유효기간내의 검사수행능\n\n상관계수 (Correlation coefficient, r)\n\n측정된 데이터에 대한 두개의 무작위 변수의 공분산(covariance)과 그들의\n\n표준편차의 곱의 비(ratio)\n\n수송 안정성 실험 (Transport stability test)\n\n제품 운송 도중 발생 가능한 환경변화가 제품 성능에 미치는 영향을 평가\n\n하는 것\n\n☞ 최악의 상황을 시험해야 한다.\n\n 신뢰구간 (Confidence interval)\n\n평균, 분율, 비율 등의 변수의 참값이 정해진 확률 범위 내에서 분포할\n\n것으로 예상되는 계산된 구간\n\n실시간 안정성 실험 (Real time stability)\n\n시약을 추천하는 정상적인 보관과 사용 환경에 두고 그 안정성을 평가하는 실험\n\n양성 예측도 (Predictive value of positive result, PPV)\n\n표적 질환(진단 정확도 기준에 의해 결정되는)을 가지고 있는 환자에서\n\n양성 결과를 보이는 비율(100을 곱한 값)\n\n☞ a) 양성 예측도(PPV)는 반드시 관심대상 조건(진단 정확도 기준에 의해\n\n결정되는)의 유병률에 맞추어 해석해야 한다.\n\n b) PPV의 추정값[추정 유병률은 100x(TP+FN)/(TP+FP+FN+TN)]은\n\n100xTP/(TP+FP)로 계산된다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 8 -\n진단정확도기준\n\n양성\n\n음성\n\n전체\n\n방법 X\n\n양성\n\n# 진양성 TP\n\n# 위양성 FP\n\n진양성+ 위양성\n\n음성\n\n# 위음성 FN\n\n# 진음성 TN\n\n위음성 + 진음성\n\n전체\n\n진양성 + 위음성\n\n위양성 + 진음성\n\nN\n\n양성 일치율(Percent positive agreement, PPA)\n\n= 100×a/(a+c)\n\n음성 일치율(Percent negative agreement, PNA)\n\n= 100×d/(b+d)\n\n총 일치율(Overall percent agreement)\n\n= 100×(a+d)/n\n\n음성 예측도 (Predictive value of negative result, NPV)\n\n표적 질환을 가지지 않은 정상인에서 음성 결과를 보이는 비율(100을\n\n곱한 값)\n\n☞ NPV의 추정값은 100×TN/(TN+FN)로 계산된다.\n\n 위양성 (False positive, FP)\n\n질병이나 증상이 없는 상태에서 이를 시사하는 양성검사 결과\n\n☞ 예시 : 질환에 이환되지 않은 개체에서 비정상 결과\n\n위음성 (False negative, FN)\n\n양성 환자나 양성 검체에서의 음성검사 결과\n\nⅡ.  용어의 정의\n\n- - 9 -\n임상적 민감도 (Clinical sensitivity)\n\n특정질환을 가지고 있는 사람들 중 검사 결과가 양성으로 나오는 비율\n\n임상적 보고가능범위 (Clinically reportable range, CCR)\n\n분석측정범위를 연장하기 위해 검체에 대한 희석, 농축, 또는 기타\n\n전처리를 하여 정량 결과 값으로 보고할 수 있는 분석물질 값의 범위\n\n임상적 특이도 (Clinical specificity)\n\n특정질환을 가지고 있지 않은 사람들 중 검사 결과가 음성으로 나오는 비율\n\n재현성 조건 (Reproducibility condition)\n\n동일한 방법과 동일한 검사 품목으로 다른 검사실에서 다른 사용자가 다른\n\n장비를 사용하여 검사 결과를 얻는 조건\n\n재현성 (Reproducibility)\n\n다른 측정조건에서 수행된 동일한 측정물의 결과값 사이의 일치도의 근접성\n\n정규분포 (Normal distribution)\n\n가우스 분포라고 표현되며 측정값을 곡선의 x축에, 관측치의 빈도를 곡선의\n\ny축에 표시\n\n☞ 관측치가 평균의 양측에 균일하게 분포하면 결과그래프는 전형적인\n\n종형곡선을 갖는다.\n\n 정량분석 (Quantitative assay)\n\n검체에서 분석물질의 농도를 측정할 수 있는 시스템\n\n☞ 정량 분석은 표준 참고 물질에 맞춘 보정곡선으로부터 동종 또는 이종\n\n보간법(Interpolation)1)을 통해 이루어진다.\n\n",
        "original_sentence": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 8 -\n진단정확도기준\n\n양성\n\n음성\n\n전체\n\n방법 X\n\n양성\n\n# 진양성 TP\n\n# 위양성 FP\n\n진양성+ 위양성\n\n음성\n\n# 위음성 FN\n\n# 진음성 TN\n\n위음성 + 진음성\n\n전체\n\n진양성 + 위음성\n\n위양성 + 진음성\n\nN\n\n양성 일치율(Percent positive agreement, PPA)\n\n= 100×a/(a+c)\n\n음성 일치율(Percent negative agreement, PNA)\n\n= 100×d/(b+d)\n\n총 일치율(Overall percent agreement)\n\n= 100×(a+d)/n\n\n음성 예측도 (Predictive value of negative result, NPV)\n\n표적 질환을 가지지 않은 정상인에서 음성 결과를 보이는 비율(100을\n\n곱한 값)\n\n☞ NPV의 추정값은 100×TN/(TN+FN)로 계산된다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_335",
      "text": "위양성 (False positive, FP)\n\n질병이나 증상이 없는 상태에서 이를 시사하는 양성검사 결과\n\n☞ 예시 : 질환에 이환되지 않은 개체에서 비정상 결과\n\n위음성 (False negative, FN)\n\n양성 환자나 양성 검체에서의 음성검사 결과\n\nⅡ. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 334,
        "window_size": 3,
        "char_count": 146,
        "word_count": 32,
        "page_number": 14,
        "window_text": "신뢰구간 (Confidence interval)\n\n평균, 분율, 비율 등의 변수의 참값이 정해진 확률 범위 내에서 분포할\n\n것으로 예상되는 계산된 구간\n\n실시간 안정성 실험 (Real time stability)\n\n시약을 추천하는 정상적인 보관과 사용 환경에 두고 그 안정성을 평가하는 실험\n\n양성 예측도 (Predictive value of positive result, PPV)\n\n표적 질환(진단 정확도 기준에 의해 결정되는)을 가지고 있는 환자에서\n\n양성 결과를 보이는 비율(100을 곱한 값)\n\n☞ a) 양성 예측도(PPV)는 반드시 관심대상 조건(진단 정확도 기준에 의해\n\n결정되는)의 유병률에 맞추어 해석해야 한다.\n\n b) PPV의 추정값[추정 유병률은 100x(TP+FN)/(TP+FP+FN+TN)]은\n\n100xTP/(TP+FP)로 계산된다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 8 -\n진단정확도기준\n\n양성\n\n음성\n\n전체\n\n방법 X\n\n양성\n\n# 진양성 TP\n\n# 위양성 FP\n\n진양성+ 위양성\n\n음성\n\n# 위음성 FN\n\n# 진음성 TN\n\n위음성 + 진음성\n\n전체\n\n진양성 + 위음성\n\n위양성 + 진음성\n\nN\n\n양성 일치율(Percent positive agreement, PPA)\n\n= 100×a/(a+c)\n\n음성 일치율(Percent negative agreement, PNA)\n\n= 100×d/(b+d)\n\n총 일치율(Overall percent agreement)\n\n= 100×(a+d)/n\n\n음성 예측도 (Predictive value of negative result, NPV)\n\n표적 질환을 가지지 않은 정상인에서 음성 결과를 보이는 비율(100을\n\n곱한 값)\n\n☞ NPV의 추정값은 100×TN/(TN+FN)로 계산된다.\n\n 위양성 (False positive, FP)\n\n질병이나 증상이 없는 상태에서 이를 시사하는 양성검사 결과\n\n☞ 예시 : 질환에 이환되지 않은 개체에서 비정상 결과\n\n위음성 (False negative, FN)\n\n양성 환자나 양성 검체에서의 음성검사 결과\n\nⅡ.  용어의 정의\n\n- - 9 -\n임상적 민감도 (Clinical sensitivity)\n\n특정질환을 가지고 있는 사람들 중 검사 결과가 양성으로 나오는 비율\n\n임상적 보고가능범위 (Clinically reportable range, CCR)\n\n분석측정범위를 연장하기 위해 검체에 대한 희석, 농축, 또는 기타\n\n전처리를 하여 정량 결과 값으로 보고할 수 있는 분석물질 값의 범위\n\n임상적 특이도 (Clinical specificity)\n\n특정질환을 가지고 있지 않은 사람들 중 검사 결과가 음성으로 나오는 비율\n\n재현성 조건 (Reproducibility condition)\n\n동일한 방법과 동일한 검사 품목으로 다른 검사실에서 다른 사용자가 다른\n\n장비를 사용하여 검사 결과를 얻는 조건\n\n재현성 (Reproducibility)\n\n다른 측정조건에서 수행된 동일한 측정물의 결과값 사이의 일치도의 근접성\n\n정규분포 (Normal distribution)\n\n가우스 분포라고 표현되며 측정값을 곡선의 x축에, 관측치의 빈도를 곡선의\n\ny축에 표시\n\n☞ 관측치가 평균의 양측에 균일하게 분포하면 결과그래프는 전형적인\n\n종형곡선을 갖는다.\n\n 정량분석 (Quantitative assay)\n\n검체에서 분석물질의 농도를 측정할 수 있는 시스템\n\n☞ 정량 분석은 표준 참고 물질에 맞춘 보정곡선으로부터 동종 또는 이종\n\n보간법(Interpolation)1)을 통해 이루어진다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 10 -\n정밀도 (Precision)\n\n규정된 조건 하에서 얻어진 독립적인 검사결과들 가운데 일치도의 근접성\n\n☞ 정밀도는 전형적으로 수치로 표현되지 않지만 비정밀도는 반복 측정값\n\n결과들의 ‘표준편차’ 또는 ‘변이계수’라는 용어로 정량적으로 표현\n\n정성분석 (Qualitative assay)\n\n분석물질의 농도가 아니라 단지 분석물질이 있고 없음을 알려주는 검사\n\n시스템\n\n☞ 양성 검사 결과는 검사신호가 분석 역치를 넘는 것만을 의미하고 판정\n\n기준치(cut-off value)는 진단 민감도와 특이도의 인위적 조합에 의해\n\n정확도 (Accuracy)\n\n측정치와 참값 사이의 일치도\n\n☞ 평가대상 검사법에 의한 다수의 연속적인 결과값들에서 얻은 평균값과\n\n공인된 참고값(accepted reference value)사이의 일치 근접도(closeness\n\n직선성 (Linearity)\n\n실험 검체에 있는 분석물질의 농도[양]에 정비례하는 결과를 제공할 수\n\n있는 능력\n\n진단검사 (Diagnostic test)\n\n특정 질환의 진단, 예방, 치료 또는 개개의 환자에서의 건강이나 건강의\n\n손상 정도를 평가하기 위한 목적\n\n☞ 진단적 검체의 측정 또는 검사를 칭한다.\n\n",
        "original_sentence": "위양성 (False positive, FP)\n\n질병이나 증상이 없는 상태에서 이를 시사하는 양성검사 결과\n\n☞ 예시 : 질환에 이환되지 않은 개체에서 비정상 결과\n\n위음성 (False negative, FN)\n\n양성 환자나 양성 검체에서의 음성검사 결과\n\nⅡ. "
      }
    },
    {
      "chunk_id": "chunk_336",
      "text": "용어의 정의\n\n- - 9 -\n임상적 민감도 (Clinical sensitivity)\n\n특정질환을 가지고 있는 사람들 중 검사 결과가 양성으로 나오는 비율\n\n임상적 보고가능범위 (Clinically reportable range, CCR)\n\n분석측정범위를 연장하기 위해 검체에 대한 희석, 농축, 또는 기타\n\n전처리를 하여 정량 결과 값으로 보고할 수 있는 분석물질 값의 범위\n\n임상적 특이도 (Clinical specificity)\n\n특정질환을 가지고 있지 않은 사람들 중 검사 결과가 음성으로 나오는 비율\n\n재현성 조건 (Reproducibility condition)\n\n동일한 방법과 동일한 검사 품목으로 다른 검사실에서 다른 사용자가 다른\n\n장비를 사용하여 검사 결과를 얻는 조건\n\n재현성 (Reproducibility)\n\n다른 측정조건에서 수행된 동일한 측정물의 결과값 사이의 일치도의 근접성\n\n정규분포 (Normal distribution)\n\n가우스 분포라고 표현되며 측정값을 곡선의 x축에, 관측치의 빈도를 곡선의\n\ny축에 표시\n\n☞ 관측치가 평균의 양측에 균일하게 분포하면 결과그래프는 전형적인\n\n종형곡선을 갖는다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 335,
        "window_size": 3,
        "char_count": 577,
        "word_count": 116,
        "page_number": 10,
        "window_text": "b) PPV의 추정값[추정 유병률은 100x(TP+FN)/(TP+FP+FN+TN)]은\n\n100xTP/(TP+FP)로 계산된다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 8 -\n진단정확도기준\n\n양성\n\n음성\n\n전체\n\n방법 X\n\n양성\n\n# 진양성 TP\n\n# 위양성 FP\n\n진양성+ 위양성\n\n음성\n\n# 위음성 FN\n\n# 진음성 TN\n\n위음성 + 진음성\n\n전체\n\n진양성 + 위음성\n\n위양성 + 진음성\n\nN\n\n양성 일치율(Percent positive agreement, PPA)\n\n= 100×a/(a+c)\n\n음성 일치율(Percent negative agreement, PNA)\n\n= 100×d/(b+d)\n\n총 일치율(Overall percent agreement)\n\n= 100×(a+d)/n\n\n음성 예측도 (Predictive value of negative result, NPV)\n\n표적 질환을 가지지 않은 정상인에서 음성 결과를 보이는 비율(100을\n\n곱한 값)\n\n☞ NPV의 추정값은 100×TN/(TN+FN)로 계산된다.\n\n 위양성 (False positive, FP)\n\n질병이나 증상이 없는 상태에서 이를 시사하는 양성검사 결과\n\n☞ 예시 : 질환에 이환되지 않은 개체에서 비정상 결과\n\n위음성 (False negative, FN)\n\n양성 환자나 양성 검체에서의 음성검사 결과\n\nⅡ.  용어의 정의\n\n- - 9 -\n임상적 민감도 (Clinical sensitivity)\n\n특정질환을 가지고 있는 사람들 중 검사 결과가 양성으로 나오는 비율\n\n임상적 보고가능범위 (Clinically reportable range, CCR)\n\n분석측정범위를 연장하기 위해 검체에 대한 희석, 농축, 또는 기타\n\n전처리를 하여 정량 결과 값으로 보고할 수 있는 분석물질 값의 범위\n\n임상적 특이도 (Clinical specificity)\n\n특정질환을 가지고 있지 않은 사람들 중 검사 결과가 음성으로 나오는 비율\n\n재현성 조건 (Reproducibility condition)\n\n동일한 방법과 동일한 검사 품목으로 다른 검사실에서 다른 사용자가 다른\n\n장비를 사용하여 검사 결과를 얻는 조건\n\n재현성 (Reproducibility)\n\n다른 측정조건에서 수행된 동일한 측정물의 결과값 사이의 일치도의 근접성\n\n정규분포 (Normal distribution)\n\n가우스 분포라고 표현되며 측정값을 곡선의 x축에, 관측치의 빈도를 곡선의\n\ny축에 표시\n\n☞ 관측치가 평균의 양측에 균일하게 분포하면 결과그래프는 전형적인\n\n종형곡선을 갖는다.\n\n 정량분석 (Quantitative assay)\n\n검체에서 분석물질의 농도를 측정할 수 있는 시스템\n\n☞ 정량 분석은 표준 참고 물질에 맞춘 보정곡선으로부터 동종 또는 이종\n\n보간법(Interpolation)1)을 통해 이루어진다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 10 -\n정밀도 (Precision)\n\n규정된 조건 하에서 얻어진 독립적인 검사결과들 가운데 일치도의 근접성\n\n☞ 정밀도는 전형적으로 수치로 표현되지 않지만 비정밀도는 반복 측정값\n\n결과들의 ‘표준편차’ 또는 ‘변이계수’라는 용어로 정량적으로 표현\n\n정성분석 (Qualitative assay)\n\n분석물질의 농도가 아니라 단지 분석물질이 있고 없음을 알려주는 검사\n\n시스템\n\n☞ 양성 검사 결과는 검사신호가 분석 역치를 넘는 것만을 의미하고 판정\n\n기준치(cut-off value)는 진단 민감도와 특이도의 인위적 조합에 의해\n\n정확도 (Accuracy)\n\n측정치와 참값 사이의 일치도\n\n☞ 평가대상 검사법에 의한 다수의 연속적인 결과값들에서 얻은 평균값과\n\n공인된 참고값(accepted reference value)사이의 일치 근접도(closeness\n\n직선성 (Linearity)\n\n실험 검체에 있는 분석물질의 농도[양]에 정비례하는 결과를 제공할 수\n\n있는 능력\n\n진단검사 (Diagnostic test)\n\n특정 질환의 진단, 예방, 치료 또는 개개의 환자에서의 건강이나 건강의\n\n손상 정도를 평가하기 위한 목적\n\n☞ 진단적 검체의 측정 또는 검사를 칭한다.\n\n 1) 보간법 : 내삽이라고도 하며 그래프상의 알려진 두 값 사이의 특정값을 평균하여 추정하는 것을 의미\n\nⅡ. ",
        "original_sentence": "용어의 정의\n\n- - 9 -\n임상적 민감도 (Clinical sensitivity)\n\n특정질환을 가지고 있는 사람들 중 검사 결과가 양성으로 나오는 비율\n\n임상적 보고가능범위 (Clinically reportable range, CCR)\n\n분석측정범위를 연장하기 위해 검체에 대한 희석, 농축, 또는 기타\n\n전처리를 하여 정량 결과 값으로 보고할 수 있는 분석물질 값의 범위\n\n임상적 특이도 (Clinical specificity)\n\n특정질환을 가지고 있지 않은 사람들 중 검사 결과가 음성으로 나오는 비율\n\n재현성 조건 (Reproducibility condition)\n\n동일한 방법과 동일한 검사 품목으로 다른 검사실에서 다른 사용자가 다른\n\n장비를 사용하여 검사 결과를 얻는 조건\n\n재현성 (Reproducibility)\n\n다른 측정조건에서 수행된 동일한 측정물의 결과값 사이의 일치도의 근접성\n\n정규분포 (Normal distribution)\n\n가우스 분포라고 표현되며 측정값을 곡선의 x축에, 관측치의 빈도를 곡선의\n\ny축에 표시\n\n☞ 관측치가 평균의 양측에 균일하게 분포하면 결과그래프는 전형적인\n\n종형곡선을 갖는다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_337",
      "text": "정량분석 (Quantitative assay)\n\n검체에서 분석물질의 농도를 측정할 수 있는 시스템\n\n☞ 정량 분석은 표준 참고 물질에 맞춘 보정곡선으로부터 동종 또는 이종\n\n보간법(Interpolation)1)을 통해 이루어진다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 336,
        "window_size": 3,
        "char_count": 130,
        "word_count": 24,
        "page_number": 14,
        "window_text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 8 -\n진단정확도기준\n\n양성\n\n음성\n\n전체\n\n방법 X\n\n양성\n\n# 진양성 TP\n\n# 위양성 FP\n\n진양성+ 위양성\n\n음성\n\n# 위음성 FN\n\n# 진음성 TN\n\n위음성 + 진음성\n\n전체\n\n진양성 + 위음성\n\n위양성 + 진음성\n\nN\n\n양성 일치율(Percent positive agreement, PPA)\n\n= 100×a/(a+c)\n\n음성 일치율(Percent negative agreement, PNA)\n\n= 100×d/(b+d)\n\n총 일치율(Overall percent agreement)\n\n= 100×(a+d)/n\n\n음성 예측도 (Predictive value of negative result, NPV)\n\n표적 질환을 가지지 않은 정상인에서 음성 결과를 보이는 비율(100을\n\n곱한 값)\n\n☞ NPV의 추정값은 100×TN/(TN+FN)로 계산된다.\n\n 위양성 (False positive, FP)\n\n질병이나 증상이 없는 상태에서 이를 시사하는 양성검사 결과\n\n☞ 예시 : 질환에 이환되지 않은 개체에서 비정상 결과\n\n위음성 (False negative, FN)\n\n양성 환자나 양성 검체에서의 음성검사 결과\n\nⅡ.  용어의 정의\n\n- - 9 -\n임상적 민감도 (Clinical sensitivity)\n\n특정질환을 가지고 있는 사람들 중 검사 결과가 양성으로 나오는 비율\n\n임상적 보고가능범위 (Clinically reportable range, CCR)\n\n분석측정범위를 연장하기 위해 검체에 대한 희석, 농축, 또는 기타\n\n전처리를 하여 정량 결과 값으로 보고할 수 있는 분석물질 값의 범위\n\n임상적 특이도 (Clinical specificity)\n\n특정질환을 가지고 있지 않은 사람들 중 검사 결과가 음성으로 나오는 비율\n\n재현성 조건 (Reproducibility condition)\n\n동일한 방법과 동일한 검사 품목으로 다른 검사실에서 다른 사용자가 다른\n\n장비를 사용하여 검사 결과를 얻는 조건\n\n재현성 (Reproducibility)\n\n다른 측정조건에서 수행된 동일한 측정물의 결과값 사이의 일치도의 근접성\n\n정규분포 (Normal distribution)\n\n가우스 분포라고 표현되며 측정값을 곡선의 x축에, 관측치의 빈도를 곡선의\n\ny축에 표시\n\n☞ 관측치가 평균의 양측에 균일하게 분포하면 결과그래프는 전형적인\n\n종형곡선을 갖는다.\n\n 정량분석 (Quantitative assay)\n\n검체에서 분석물질의 농도를 측정할 수 있는 시스템\n\n☞ 정량 분석은 표준 참고 물질에 맞춘 보정곡선으로부터 동종 또는 이종\n\n보간법(Interpolation)1)을 통해 이루어진다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 10 -\n정밀도 (Precision)\n\n규정된 조건 하에서 얻어진 독립적인 검사결과들 가운데 일치도의 근접성\n\n☞ 정밀도는 전형적으로 수치로 표현되지 않지만 비정밀도는 반복 측정값\n\n결과들의 ‘표준편차’ 또는 ‘변이계수’라는 용어로 정량적으로 표현\n\n정성분석 (Qualitative assay)\n\n분석물질의 농도가 아니라 단지 분석물질이 있고 없음을 알려주는 검사\n\n시스템\n\n☞ 양성 검사 결과는 검사신호가 분석 역치를 넘는 것만을 의미하고 판정\n\n기준치(cut-off value)는 진단 민감도와 특이도의 인위적 조합에 의해\n\n정확도 (Accuracy)\n\n측정치와 참값 사이의 일치도\n\n☞ 평가대상 검사법에 의한 다수의 연속적인 결과값들에서 얻은 평균값과\n\n공인된 참고값(accepted reference value)사이의 일치 근접도(closeness\n\n직선성 (Linearity)\n\n실험 검체에 있는 분석물질의 농도[양]에 정비례하는 결과를 제공할 수\n\n있는 능력\n\n진단검사 (Diagnostic test)\n\n특정 질환의 진단, 예방, 치료 또는 개개의 환자에서의 건강이나 건강의\n\n손상 정도를 평가하기 위한 목적\n\n☞ 진단적 검체의 측정 또는 검사를 칭한다.\n\n 1) 보간법 : 내삽이라고도 하며 그래프상의 알려진 두 값 사이의 특정값을 평균하여 추정하는 것을 의미\n\nⅡ.  용어의 정의\n\n- - 11 -\n진양성 (True positive, TP)\n\n환자의 질병 상태와 검사의 양성판정이 일치하는 결과\n\n진음성 (True negative, TN)\n\n환자의 질병 상태와 검사의 음성판정이 일치하는 결과\n\n참고구간 (Reference interval)\n\n상하 두 개의 참고 한계치 내의 간격\n\n☞ 하한 참고치와 상한 참고치 간의 간격으로 명시되어 있다.\n\n",
        "original_sentence": "정량분석 (Quantitative assay)\n\n검체에서 분석물질의 농도를 측정할 수 있는 시스템\n\n☞ 정량 분석은 표준 참고 물질에 맞춘 보정곡선으로부터 동종 또는 이종\n\n보간법(Interpolation)1)을 통해 이루어진다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_338",
      "text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 10 -\n정밀도 (Precision)\n\n규정된 조건 하에서 얻어진 독립적인 검사결과들 가운데 일치도의 근접성\n\n☞ 정밀도는 전형적으로 수치로 표현되지 않지만 비정밀도는 반복 측정값\n\n결과들의 ‘표준편차’ 또는 ‘변이계수’라는 용어로 정량적으로 표현\n\n정성분석 (Qualitative assay)\n\n분석물질의 농도가 아니라 단지 분석물질이 있고 없음을 알려주는 검사\n\n시스템\n\n☞ 양성 검사 결과는 검사신호가 분석 역치를 넘는 것만을 의미하고 판정\n\n기준치(cut-off value)는 진단 민감도와 특이도의 인위적 조합에 의해\n\n정확도 (Accuracy)\n\n측정치와 참값 사이의 일치도\n\n☞ 평가대상 검사법에 의한 다수의 연속적인 결과값들에서 얻은 평균값과\n\n공인된 참고값(accepted reference value)사이의 일치 근접도(closeness\n\n직선성 (Linearity)\n\n실험 검체에 있는 분석물질의 농도[양]에 정비례하는 결과를 제공할 수\n\n있는 능력\n\n진단검사 (Diagnostic test)\n\n특정 질환의 진단, 예방, 치료 또는 개개의 환자에서의 건강이나 건강의\n\n손상 정도를 평가하기 위한 목적\n\n☞ 진단적 검체의 측정 또는 검사를 칭한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 337,
        "window_size": 3,
        "char_count": 651,
        "word_count": 130,
        "page_number": 1,
        "window_text": "위양성 (False positive, FP)\n\n질병이나 증상이 없는 상태에서 이를 시사하는 양성검사 결과\n\n☞ 예시 : 질환에 이환되지 않은 개체에서 비정상 결과\n\n위음성 (False negative, FN)\n\n양성 환자나 양성 검체에서의 음성검사 결과\n\nⅡ.  용어의 정의\n\n- - 9 -\n임상적 민감도 (Clinical sensitivity)\n\n특정질환을 가지고 있는 사람들 중 검사 결과가 양성으로 나오는 비율\n\n임상적 보고가능범위 (Clinically reportable range, CCR)\n\n분석측정범위를 연장하기 위해 검체에 대한 희석, 농축, 또는 기타\n\n전처리를 하여 정량 결과 값으로 보고할 수 있는 분석물질 값의 범위\n\n임상적 특이도 (Clinical specificity)\n\n특정질환을 가지고 있지 않은 사람들 중 검사 결과가 음성으로 나오는 비율\n\n재현성 조건 (Reproducibility condition)\n\n동일한 방법과 동일한 검사 품목으로 다른 검사실에서 다른 사용자가 다른\n\n장비를 사용하여 검사 결과를 얻는 조건\n\n재현성 (Reproducibility)\n\n다른 측정조건에서 수행된 동일한 측정물의 결과값 사이의 일치도의 근접성\n\n정규분포 (Normal distribution)\n\n가우스 분포라고 표현되며 측정값을 곡선의 x축에, 관측치의 빈도를 곡선의\n\ny축에 표시\n\n☞ 관측치가 평균의 양측에 균일하게 분포하면 결과그래프는 전형적인\n\n종형곡선을 갖는다.\n\n 정량분석 (Quantitative assay)\n\n검체에서 분석물질의 농도를 측정할 수 있는 시스템\n\n☞ 정량 분석은 표준 참고 물질에 맞춘 보정곡선으로부터 동종 또는 이종\n\n보간법(Interpolation)1)을 통해 이루어진다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 10 -\n정밀도 (Precision)\n\n규정된 조건 하에서 얻어진 독립적인 검사결과들 가운데 일치도의 근접성\n\n☞ 정밀도는 전형적으로 수치로 표현되지 않지만 비정밀도는 반복 측정값\n\n결과들의 ‘표준편차’ 또는 ‘변이계수’라는 용어로 정량적으로 표현\n\n정성분석 (Qualitative assay)\n\n분석물질의 농도가 아니라 단지 분석물질이 있고 없음을 알려주는 검사\n\n시스템\n\n☞ 양성 검사 결과는 검사신호가 분석 역치를 넘는 것만을 의미하고 판정\n\n기준치(cut-off value)는 진단 민감도와 특이도의 인위적 조합에 의해\n\n정확도 (Accuracy)\n\n측정치와 참값 사이의 일치도\n\n☞ 평가대상 검사법에 의한 다수의 연속적인 결과값들에서 얻은 평균값과\n\n공인된 참고값(accepted reference value)사이의 일치 근접도(closeness\n\n직선성 (Linearity)\n\n실험 검체에 있는 분석물질의 농도[양]에 정비례하는 결과를 제공할 수\n\n있는 능력\n\n진단검사 (Diagnostic test)\n\n특정 질환의 진단, 예방, 치료 또는 개개의 환자에서의 건강이나 건강의\n\n손상 정도를 평가하기 위한 목적\n\n☞ 진단적 검체의 측정 또는 검사를 칭한다.\n\n 1) 보간법 : 내삽이라고도 하며 그래프상의 알려진 두 값 사이의 특정값을 평균하여 추정하는 것을 의미\n\nⅡ.  용어의 정의\n\n- - 11 -\n진양성 (True positive, TP)\n\n환자의 질병 상태와 검사의 양성판정이 일치하는 결과\n\n진음성 (True negative, TN)\n\n환자의 질병 상태와 검사의 음성판정이 일치하는 결과\n\n참고구간 (Reference interval)\n\n상하 두 개의 참고 한계치 내의 간격\n\n☞ 하한 참고치와 상한 참고치 간의 간격으로 명시되어 있다.\n\n 참고물질 / 참고제작 (Reference material / Reference preparation, RM)\n\n1) 하나 또는 그 이상의 특성값이 충분히 균일하고 기구의 보정, 측정방\n\n2) 인증참고물질(CRM) – 기술적으로 입증된 과정에 의해 공인되었고 인\n\n☞ a) 인증참고물질(CRM)은 “인증서가 있는 참고물질로서 하나 또는 그\n\n되는 단위의 정확한 구현에 대한 추적을 할 수 있고, 그것에 대해\n\n라고 정의한다.\n\n",
        "original_sentence": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 10 -\n정밀도 (Precision)\n\n규정된 조건 하에서 얻어진 독립적인 검사결과들 가운데 일치도의 근접성\n\n☞ 정밀도는 전형적으로 수치로 표현되지 않지만 비정밀도는 반복 측정값\n\n결과들의 ‘표준편차’ 또는 ‘변이계수’라는 용어로 정량적으로 표현\n\n정성분석 (Qualitative assay)\n\n분석물질의 농도가 아니라 단지 분석물질이 있고 없음을 알려주는 검사\n\n시스템\n\n☞ 양성 검사 결과는 검사신호가 분석 역치를 넘는 것만을 의미하고 판정\n\n기준치(cut-off value)는 진단 민감도와 특이도의 인위적 조합에 의해\n\n정확도 (Accuracy)\n\n측정치와 참값 사이의 일치도\n\n☞ 평가대상 검사법에 의한 다수의 연속적인 결과값들에서 얻은 평균값과\n\n공인된 참고값(accepted reference value)사이의 일치 근접도(closeness\n\n직선성 (Linearity)\n\n실험 검체에 있는 분석물질의 농도[양]에 정비례하는 결과를 제공할 수\n\n있는 능력\n\n진단검사 (Diagnostic test)\n\n특정 질환의 진단, 예방, 치료 또는 개개의 환자에서의 건강이나 건강의\n\n손상 정도를 평가하기 위한 목적\n\n☞ 진단적 검체의 측정 또는 검사를 칭한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_339",
      "text": "1) 보간법 : 내삽이라고도 하며 그래프상의 알려진 두 값 사이의 특정값을 평균하여 추정하는 것을 의미\n\nⅡ. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 338,
        "window_size": 3,
        "char_count": 62,
        "word_count": 16,
        "page_number": 16,
        "window_text": "용어의 정의\n\n- - 9 -\n임상적 민감도 (Clinical sensitivity)\n\n특정질환을 가지고 있는 사람들 중 검사 결과가 양성으로 나오는 비율\n\n임상적 보고가능범위 (Clinically reportable range, CCR)\n\n분석측정범위를 연장하기 위해 검체에 대한 희석, 농축, 또는 기타\n\n전처리를 하여 정량 결과 값으로 보고할 수 있는 분석물질 값의 범위\n\n임상적 특이도 (Clinical specificity)\n\n특정질환을 가지고 있지 않은 사람들 중 검사 결과가 음성으로 나오는 비율\n\n재현성 조건 (Reproducibility condition)\n\n동일한 방법과 동일한 검사 품목으로 다른 검사실에서 다른 사용자가 다른\n\n장비를 사용하여 검사 결과를 얻는 조건\n\n재현성 (Reproducibility)\n\n다른 측정조건에서 수행된 동일한 측정물의 결과값 사이의 일치도의 근접성\n\n정규분포 (Normal distribution)\n\n가우스 분포라고 표현되며 측정값을 곡선의 x축에, 관측치의 빈도를 곡선의\n\ny축에 표시\n\n☞ 관측치가 평균의 양측에 균일하게 분포하면 결과그래프는 전형적인\n\n종형곡선을 갖는다.\n\n 정량분석 (Quantitative assay)\n\n검체에서 분석물질의 농도를 측정할 수 있는 시스템\n\n☞ 정량 분석은 표준 참고 물질에 맞춘 보정곡선으로부터 동종 또는 이종\n\n보간법(Interpolation)1)을 통해 이루어진다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 10 -\n정밀도 (Precision)\n\n규정된 조건 하에서 얻어진 독립적인 검사결과들 가운데 일치도의 근접성\n\n☞ 정밀도는 전형적으로 수치로 표현되지 않지만 비정밀도는 반복 측정값\n\n결과들의 ‘표준편차’ 또는 ‘변이계수’라는 용어로 정량적으로 표현\n\n정성분석 (Qualitative assay)\n\n분석물질의 농도가 아니라 단지 분석물질이 있고 없음을 알려주는 검사\n\n시스템\n\n☞ 양성 검사 결과는 검사신호가 분석 역치를 넘는 것만을 의미하고 판정\n\n기준치(cut-off value)는 진단 민감도와 특이도의 인위적 조합에 의해\n\n정확도 (Accuracy)\n\n측정치와 참값 사이의 일치도\n\n☞ 평가대상 검사법에 의한 다수의 연속적인 결과값들에서 얻은 평균값과\n\n공인된 참고값(accepted reference value)사이의 일치 근접도(closeness\n\n직선성 (Linearity)\n\n실험 검체에 있는 분석물질의 농도[양]에 정비례하는 결과를 제공할 수\n\n있는 능력\n\n진단검사 (Diagnostic test)\n\n특정 질환의 진단, 예방, 치료 또는 개개의 환자에서의 건강이나 건강의\n\n손상 정도를 평가하기 위한 목적\n\n☞ 진단적 검체의 측정 또는 검사를 칭한다.\n\n 1) 보간법 : 내삽이라고도 하며 그래프상의 알려진 두 값 사이의 특정값을 평균하여 추정하는 것을 의미\n\nⅡ.  용어의 정의\n\n- - 11 -\n진양성 (True positive, TP)\n\n환자의 질병 상태와 검사의 양성판정이 일치하는 결과\n\n진음성 (True negative, TN)\n\n환자의 질병 상태와 검사의 음성판정이 일치하는 결과\n\n참고구간 (Reference interval)\n\n상하 두 개의 참고 한계치 내의 간격\n\n☞ 하한 참고치와 상한 참고치 간의 간격으로 명시되어 있다.\n\n 참고물질 / 참고제작 (Reference material / Reference preparation, RM)\n\n1) 하나 또는 그 이상의 특성값이 충분히 균일하고 기구의 보정, 측정방\n\n2) 인증참고물질(CRM) – 기술적으로 입증된 과정에 의해 공인되었고 인\n\n☞ a) 인증참고물질(CRM)은 “인증서가 있는 참고물질로서 하나 또는 그\n\n되는 단위의 정확한 구현에 대한 추적을 할 수 있고, 그것에 대해\n\n라고 정의한다.\n\n b) 표준참고물질(SRM)은 인증참고물질(CRM)의 한 이름으로서 과거에\n\n국립표준원(NBS)으로 알려졌던 미국정부기관으로, 국립표준기술\n\n연구소(NIST)에 의해 인증되고 배포되는 인증참고물질의 상품명이다.\n\n",
        "original_sentence": "1) 보간법 : 내삽이라고도 하며 그래프상의 알려진 두 값 사이의 특정값을 평균하여 추정하는 것을 의미\n\nⅡ. "
      }
    },
    {
      "chunk_id": "chunk_340",
      "text": "용어의 정의\n\n- - 11 -\n진양성 (True positive, TP)\n\n환자의 질병 상태와 검사의 양성판정이 일치하는 결과\n\n진음성 (True negative, TN)\n\n환자의 질병 상태와 검사의 음성판정이 일치하는 결과\n\n참고구간 (Reference interval)\n\n상하 두 개의 참고 한계치 내의 간격\n\n☞ 하한 참고치와 상한 참고치 간의 간격으로 명시되어 있다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 339,
        "window_size": 3,
        "char_count": 211,
        "word_count": 47,
        "page_number": 10,
        "window_text": "정량분석 (Quantitative assay)\n\n검체에서 분석물질의 농도를 측정할 수 있는 시스템\n\n☞ 정량 분석은 표준 참고 물질에 맞춘 보정곡선으로부터 동종 또는 이종\n\n보간법(Interpolation)1)을 통해 이루어진다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 10 -\n정밀도 (Precision)\n\n규정된 조건 하에서 얻어진 독립적인 검사결과들 가운데 일치도의 근접성\n\n☞ 정밀도는 전형적으로 수치로 표현되지 않지만 비정밀도는 반복 측정값\n\n결과들의 ‘표준편차’ 또는 ‘변이계수’라는 용어로 정량적으로 표현\n\n정성분석 (Qualitative assay)\n\n분석물질의 농도가 아니라 단지 분석물질이 있고 없음을 알려주는 검사\n\n시스템\n\n☞ 양성 검사 결과는 검사신호가 분석 역치를 넘는 것만을 의미하고 판정\n\n기준치(cut-off value)는 진단 민감도와 특이도의 인위적 조합에 의해\n\n정확도 (Accuracy)\n\n측정치와 참값 사이의 일치도\n\n☞ 평가대상 검사법에 의한 다수의 연속적인 결과값들에서 얻은 평균값과\n\n공인된 참고값(accepted reference value)사이의 일치 근접도(closeness\n\n직선성 (Linearity)\n\n실험 검체에 있는 분석물질의 농도[양]에 정비례하는 결과를 제공할 수\n\n있는 능력\n\n진단검사 (Diagnostic test)\n\n특정 질환의 진단, 예방, 치료 또는 개개의 환자에서의 건강이나 건강의\n\n손상 정도를 평가하기 위한 목적\n\n☞ 진단적 검체의 측정 또는 검사를 칭한다.\n\n 1) 보간법 : 내삽이라고도 하며 그래프상의 알려진 두 값 사이의 특정값을 평균하여 추정하는 것을 의미\n\nⅡ.  용어의 정의\n\n- - 11 -\n진양성 (True positive, TP)\n\n환자의 질병 상태와 검사의 양성판정이 일치하는 결과\n\n진음성 (True negative, TN)\n\n환자의 질병 상태와 검사의 음성판정이 일치하는 결과\n\n참고구간 (Reference interval)\n\n상하 두 개의 참고 한계치 내의 간격\n\n☞ 하한 참고치와 상한 참고치 간의 간격으로 명시되어 있다.\n\n 참고물질 / 참고제작 (Reference material / Reference preparation, RM)\n\n1) 하나 또는 그 이상의 특성값이 충분히 균일하고 기구의 보정, 측정방\n\n2) 인증참고물질(CRM) – 기술적으로 입증된 과정에 의해 공인되었고 인\n\n☞ a) 인증참고물질(CRM)은 “인증서가 있는 참고물질로서 하나 또는 그\n\n되는 단위의 정확한 구현에 대한 추적을 할 수 있고, 그것에 대해\n\n라고 정의한다.\n\n b) 표준참고물질(SRM)은 인증참고물질(CRM)의 한 이름으로서 과거에\n\n국립표준원(NBS)으로 알려졌던 미국정부기관으로, 국립표준기술\n\n연구소(NIST)에 의해 인증되고 배포되는 인증참고물질의 상품명이다.\n\n 참고치 (Reference value)\n\n개체에서 관측 또는 측정으로 얻은 특정 형태의 정량값\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 12 -\n총 분석 오차 (Total analytical error)\n\n특정 구성요소들로 구성되어 있으며 90% 또는 95% 신뢰구간으로 정량\n\n화된다.\n\n",
        "original_sentence": "용어의 정의\n\n- - 11 -\n진양성 (True positive, TP)\n\n환자의 질병 상태와 검사의 양성판정이 일치하는 결과\n\n진음성 (True negative, TN)\n\n환자의 질병 상태와 검사의 음성판정이 일치하는 결과\n\n참고구간 (Reference interval)\n\n상하 두 개의 참고 한계치 내의 간격\n\n☞ 하한 참고치와 상한 참고치 간의 간격으로 명시되어 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_341",
      "text": "참고물질 / 참고제작 (Reference material / Reference preparation, RM)\n\n1) 하나 또는 그 이상의 특성값이 충분히 균일하고 기구의 보정, 측정방\n\n2) 인증참고물질(CRM) – 기술적으로 입증된 과정에 의해 공인되었고 인\n\n☞ a) 인증참고물질(CRM)은 “인증서가 있는 참고물질로서 하나 또는 그\n\n되는 단위의 정확한 구현에 대한 추적을 할 수 있고, 그것에 대해\n\n라고 정의한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 340,
        "window_size": 3,
        "char_count": 238,
        "word_count": 51,
        "page_number": 14,
        "window_text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 10 -\n정밀도 (Precision)\n\n규정된 조건 하에서 얻어진 독립적인 검사결과들 가운데 일치도의 근접성\n\n☞ 정밀도는 전형적으로 수치로 표현되지 않지만 비정밀도는 반복 측정값\n\n결과들의 ‘표준편차’ 또는 ‘변이계수’라는 용어로 정량적으로 표현\n\n정성분석 (Qualitative assay)\n\n분석물질의 농도가 아니라 단지 분석물질이 있고 없음을 알려주는 검사\n\n시스템\n\n☞ 양성 검사 결과는 검사신호가 분석 역치를 넘는 것만을 의미하고 판정\n\n기준치(cut-off value)는 진단 민감도와 특이도의 인위적 조합에 의해\n\n정확도 (Accuracy)\n\n측정치와 참값 사이의 일치도\n\n☞ 평가대상 검사법에 의한 다수의 연속적인 결과값들에서 얻은 평균값과\n\n공인된 참고값(accepted reference value)사이의 일치 근접도(closeness\n\n직선성 (Linearity)\n\n실험 검체에 있는 분석물질의 농도[양]에 정비례하는 결과를 제공할 수\n\n있는 능력\n\n진단검사 (Diagnostic test)\n\n특정 질환의 진단, 예방, 치료 또는 개개의 환자에서의 건강이나 건강의\n\n손상 정도를 평가하기 위한 목적\n\n☞ 진단적 검체의 측정 또는 검사를 칭한다.\n\n 1) 보간법 : 내삽이라고도 하며 그래프상의 알려진 두 값 사이의 특정값을 평균하여 추정하는 것을 의미\n\nⅡ.  용어의 정의\n\n- - 11 -\n진양성 (True positive, TP)\n\n환자의 질병 상태와 검사의 양성판정이 일치하는 결과\n\n진음성 (True negative, TN)\n\n환자의 질병 상태와 검사의 음성판정이 일치하는 결과\n\n참고구간 (Reference interval)\n\n상하 두 개의 참고 한계치 내의 간격\n\n☞ 하한 참고치와 상한 참고치 간의 간격으로 명시되어 있다.\n\n 참고물질 / 참고제작 (Reference material / Reference preparation, RM)\n\n1) 하나 또는 그 이상의 특성값이 충분히 균일하고 기구의 보정, 측정방\n\n2) 인증참고물질(CRM) – 기술적으로 입증된 과정에 의해 공인되었고 인\n\n☞ a) 인증참고물질(CRM)은 “인증서가 있는 참고물질로서 하나 또는 그\n\n되는 단위의 정확한 구현에 대한 추적을 할 수 있고, 그것에 대해\n\n라고 정의한다.\n\n b) 표준참고물질(SRM)은 인증참고물질(CRM)의 한 이름으로서 과거에\n\n국립표준원(NBS)으로 알려졌던 미국정부기관으로, 국립표준기술\n\n연구소(NIST)에 의해 인증되고 배포되는 인증참고물질의 상품명이다.\n\n 참고치 (Reference value)\n\n개체에서 관측 또는 측정으로 얻은 특정 형태의 정량값\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 12 -\n총 분석 오차 (Total analytical error)\n\n특정 구성요소들로 구성되어 있으며 90% 또는 95% 신뢰구간으로 정량\n\n화된다.\n\n 측정가능범위 (Analytical measurement range, AMR)\n\n일상적인 측정 과정의 일부가 아닌 희석, 농축 또는 기타 전처리 없이 어떤\n\n검사법이 검체에서 직접 측정할 수 있는 분석물질 값의 범위\n\n측정 시스템의 민감도 (Sensitivity of a measuring system)\n\n측정 시스템 표시 도수의 변화 및 측정된 양의 값의 변화계수\n\n☞ 측정시스템의 민감도는 측정된 양의 크기에 의존하며 측정된 양의 값\n\n친화력, 친화성 (Affinity)\n\n면역학에서 한 개의 항원결정기 부위와 한 개의 항체 사이에 작용하는 힘\n\n판정기준치 (Cut-off value)\n\n정성검사에서는 경계치 이상을 양성으로, 경계치 미만을 음성으로 보고할\n\n수 있는 경계값을 말한다. ",
        "original_sentence": "참고물질 / 참고제작 (Reference material / Reference preparation, RM)\n\n1) 하나 또는 그 이상의 특성값이 충분히 균일하고 기구의 보정, 측정방\n\n2) 인증참고물질(CRM) – 기술적으로 입증된 과정에 의해 공인되었고 인\n\n☞ a) 인증참고물질(CRM)은 “인증서가 있는 참고물질로서 하나 또는 그\n\n되는 단위의 정확한 구현에 대한 추적을 할 수 있고, 그것에 대해\n\n라고 정의한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_342",
      "text": "b) 표준참고물질(SRM)은 인증참고물질(CRM)의 한 이름으로서 과거에\n\n국립표준원(NBS)으로 알려졌던 미국정부기관으로, 국립표준기술\n\n연구소(NIST)에 의해 인증되고 배포되는 인증참고물질의 상품명이다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 341,
        "window_size": 3,
        "char_count": 118,
        "word_count": 16,
        "page_number": 14,
        "window_text": "1) 보간법 : 내삽이라고도 하며 그래프상의 알려진 두 값 사이의 특정값을 평균하여 추정하는 것을 의미\n\nⅡ.  용어의 정의\n\n- - 11 -\n진양성 (True positive, TP)\n\n환자의 질병 상태와 검사의 양성판정이 일치하는 결과\n\n진음성 (True negative, TN)\n\n환자의 질병 상태와 검사의 음성판정이 일치하는 결과\n\n참고구간 (Reference interval)\n\n상하 두 개의 참고 한계치 내의 간격\n\n☞ 하한 참고치와 상한 참고치 간의 간격으로 명시되어 있다.\n\n 참고물질 / 참고제작 (Reference material / Reference preparation, RM)\n\n1) 하나 또는 그 이상의 특성값이 충분히 균일하고 기구의 보정, 측정방\n\n2) 인증참고물질(CRM) – 기술적으로 입증된 과정에 의해 공인되었고 인\n\n☞ a) 인증참고물질(CRM)은 “인증서가 있는 참고물질로서 하나 또는 그\n\n되는 단위의 정확한 구현에 대한 추적을 할 수 있고, 그것에 대해\n\n라고 정의한다.\n\n b) 표준참고물질(SRM)은 인증참고물질(CRM)의 한 이름으로서 과거에\n\n국립표준원(NBS)으로 알려졌던 미국정부기관으로, 국립표준기술\n\n연구소(NIST)에 의해 인증되고 배포되는 인증참고물질의 상품명이다.\n\n 참고치 (Reference value)\n\n개체에서 관측 또는 측정으로 얻은 특정 형태의 정량값\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 12 -\n총 분석 오차 (Total analytical error)\n\n특정 구성요소들로 구성되어 있으며 90% 또는 95% 신뢰구간으로 정량\n\n화된다.\n\n 측정가능범위 (Analytical measurement range, AMR)\n\n일상적인 측정 과정의 일부가 아닌 희석, 농축 또는 기타 전처리 없이 어떤\n\n검사법이 검체에서 직접 측정할 수 있는 분석물질 값의 범위\n\n측정 시스템의 민감도 (Sensitivity of a measuring system)\n\n측정 시스템 표시 도수의 변화 및 측정된 양의 값의 변화계수\n\n☞ 측정시스템의 민감도는 측정된 양의 크기에 의존하며 측정된 양의 값\n\n친화력, 친화성 (Affinity)\n\n면역학에서 한 개의 항원결정기 부위와 한 개의 항체 사이에 작용하는 힘\n\n판정기준치 (Cut-off value)\n\n정성검사에서는 경계치 이상을 양성으로, 경계치 미만을 음성으로 보고할\n\n수 있는 경계값을 말한다.  정량검사에서는 측정 결과가 임상적 또는 분석\n\n적 결정점(Decision point)의 위 또는 아래에 있는지(양성 또는 음성) 결정\n\n하는데 사용되는 측정물질의 정량값\n\n항원 (Antigen)\n\n생체 내 항체 생성을 유발하고 그들과 특이적으로 결합할 수 있는 물질\n\n항원결정인자 / 에피토프 (Antigenic determinant / epitope)\n\n항원 분자 중 항체가 결합할 수 있는 모든 부위의 총칭으로 특정 항체군을\n\n결정하는 부위의 화학적 구조\n\nⅡ. ",
        "original_sentence": "b) 표준참고물질(SRM)은 인증참고물질(CRM)의 한 이름으로서 과거에\n\n국립표준원(NBS)으로 알려졌던 미국정부기관으로, 국립표준기술\n\n연구소(NIST)에 의해 인증되고 배포되는 인증참고물질의 상품명이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_343",
      "text": "참고치 (Reference value)\n\n개체에서 관측 또는 측정으로 얻은 특정 형태의 정량값\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 12 -\n총 분석 오차 (Total analytical error)\n\n특정 구성요소들로 구성되어 있으며 90% 또는 95% 신뢰구간으로 정량\n\n화된다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 342,
        "window_size": 3,
        "char_count": 193,
        "word_count": 39,
        "page_number": 14,
        "window_text": "용어의 정의\n\n- - 11 -\n진양성 (True positive, TP)\n\n환자의 질병 상태와 검사의 양성판정이 일치하는 결과\n\n진음성 (True negative, TN)\n\n환자의 질병 상태와 검사의 음성판정이 일치하는 결과\n\n참고구간 (Reference interval)\n\n상하 두 개의 참고 한계치 내의 간격\n\n☞ 하한 참고치와 상한 참고치 간의 간격으로 명시되어 있다.\n\n 참고물질 / 참고제작 (Reference material / Reference preparation, RM)\n\n1) 하나 또는 그 이상의 특성값이 충분히 균일하고 기구의 보정, 측정방\n\n2) 인증참고물질(CRM) – 기술적으로 입증된 과정에 의해 공인되었고 인\n\n☞ a) 인증참고물질(CRM)은 “인증서가 있는 참고물질로서 하나 또는 그\n\n되는 단위의 정확한 구현에 대한 추적을 할 수 있고, 그것에 대해\n\n라고 정의한다.\n\n b) 표준참고물질(SRM)은 인증참고물질(CRM)의 한 이름으로서 과거에\n\n국립표준원(NBS)으로 알려졌던 미국정부기관으로, 국립표준기술\n\n연구소(NIST)에 의해 인증되고 배포되는 인증참고물질의 상품명이다.\n\n 참고치 (Reference value)\n\n개체에서 관측 또는 측정으로 얻은 특정 형태의 정량값\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 12 -\n총 분석 오차 (Total analytical error)\n\n특정 구성요소들로 구성되어 있으며 90% 또는 95% 신뢰구간으로 정량\n\n화된다.\n\n 측정가능범위 (Analytical measurement range, AMR)\n\n일상적인 측정 과정의 일부가 아닌 희석, 농축 또는 기타 전처리 없이 어떤\n\n검사법이 검체에서 직접 측정할 수 있는 분석물질 값의 범위\n\n측정 시스템의 민감도 (Sensitivity of a measuring system)\n\n측정 시스템 표시 도수의 변화 및 측정된 양의 값의 변화계수\n\n☞ 측정시스템의 민감도는 측정된 양의 크기에 의존하며 측정된 양의 값\n\n친화력, 친화성 (Affinity)\n\n면역학에서 한 개의 항원결정기 부위와 한 개의 항체 사이에 작용하는 힘\n\n판정기준치 (Cut-off value)\n\n정성검사에서는 경계치 이상을 양성으로, 경계치 미만을 음성으로 보고할\n\n수 있는 경계값을 말한다.  정량검사에서는 측정 결과가 임상적 또는 분석\n\n적 결정점(Decision point)의 위 또는 아래에 있는지(양성 또는 음성) 결정\n\n하는데 사용되는 측정물질의 정량값\n\n항원 (Antigen)\n\n생체 내 항체 생성을 유발하고 그들과 특이적으로 결합할 수 있는 물질\n\n항원결정인자 / 에피토프 (Antigenic determinant / epitope)\n\n항원 분자 중 항체가 결합할 수 있는 모든 부위의 총칭으로 특정 항체군을\n\n결정하는 부위의 화학적 구조\n\nⅡ.  용어의 정의\n\n- - 13 -\n항원항체결합력 (Avidity)\n\n항혈청 또는 항체의 복합적인 반응 강도\n\n☞ 항원항체결합력은 항혈청 내 모든 항체의 항체결합부위와 가용한 마크\n\n로분자의 항원결정기와의 친화력 함수\n\n항체 (Antibody)\n\n면역계 내에서 항원의 자극에 의하여 혈청이나 조직에 만들어지는 물질\n\n☞ 면역원 노출에 반응하여 B림프구에서 생산되는 특이 면역글로불린으\n\n허용 오차 (Allowable error)\n\n모든 가능한 요소들로부터 발생할 수 있는 분석적 변이의 정도 또는 검사\n\n시스템에서 사용자가 허용할 수 있는 정도로 검사의 임상적 요구사항을\n\n만족시킬 수 있는 변이의 정도\n\n후크효과 (Hook effect)\n\n항체 또는 항원 과다로 최적 반응을 방해하여 항원-항체 반응이 최적\n\n이하로 나타나는 현상\n\n회복, 회수 (Recovery)\n\n동일 물질의 검체에 알고 있는 양을 첨가한 후 분석물질 농도의 증가를\n\n확인\n\n☞ 분석물질이 첨가되지 않은 혈청 검체와 첨가된 혈청 검체로 분석물질\n\n의 증가가 첨가된 양과 동등한 지 분석한다. ",
        "original_sentence": "참고치 (Reference value)\n\n개체에서 관측 또는 측정으로 얻은 특정 형태의 정량값\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 12 -\n총 분석 오차 (Total analytical error)\n\n특정 구성요소들로 구성되어 있으며 90% 또는 95% 신뢰구간으로 정량\n\n화된다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_344",
      "text": "측정가능범위 (Analytical measurement range, AMR)\n\n일상적인 측정 과정의 일부가 아닌 희석, 농축 또는 기타 전처리 없이 어떤\n\n검사법이 검체에서 직접 측정할 수 있는 분석물질 값의 범위\n\n측정 시스템의 민감도 (Sensitivity of a measuring system)\n\n측정 시스템 표시 도수의 변화 및 측정된 양의 값의 변화계수\n\n☞ 측정시스템의 민감도는 측정된 양의 크기에 의존하며 측정된 양의 값\n\n친화력, 친화성 (Affinity)\n\n면역학에서 한 개의 항원결정기 부위와 한 개의 항체 사이에 작용하는 힘\n\n판정기준치 (Cut-off value)\n\n정성검사에서는 경계치 이상을 양성으로, 경계치 미만을 음성으로 보고할\n\n수 있는 경계값을 말한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 343,
        "window_size": 3,
        "char_count": 385,
        "word_count": 83,
        "page_number": 14,
        "window_text": "참고물질 / 참고제작 (Reference material / Reference preparation, RM)\n\n1) 하나 또는 그 이상의 특성값이 충분히 균일하고 기구의 보정, 측정방\n\n2) 인증참고물질(CRM) – 기술적으로 입증된 과정에 의해 공인되었고 인\n\n☞ a) 인증참고물질(CRM)은 “인증서가 있는 참고물질로서 하나 또는 그\n\n되는 단위의 정확한 구현에 대한 추적을 할 수 있고, 그것에 대해\n\n라고 정의한다.\n\n b) 표준참고물질(SRM)은 인증참고물질(CRM)의 한 이름으로서 과거에\n\n국립표준원(NBS)으로 알려졌던 미국정부기관으로, 국립표준기술\n\n연구소(NIST)에 의해 인증되고 배포되는 인증참고물질의 상품명이다.\n\n 참고치 (Reference value)\n\n개체에서 관측 또는 측정으로 얻은 특정 형태의 정량값\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 12 -\n총 분석 오차 (Total analytical error)\n\n특정 구성요소들로 구성되어 있으며 90% 또는 95% 신뢰구간으로 정량\n\n화된다.\n\n 측정가능범위 (Analytical measurement range, AMR)\n\n일상적인 측정 과정의 일부가 아닌 희석, 농축 또는 기타 전처리 없이 어떤\n\n검사법이 검체에서 직접 측정할 수 있는 분석물질 값의 범위\n\n측정 시스템의 민감도 (Sensitivity of a measuring system)\n\n측정 시스템 표시 도수의 변화 및 측정된 양의 값의 변화계수\n\n☞ 측정시스템의 민감도는 측정된 양의 크기에 의존하며 측정된 양의 값\n\n친화력, 친화성 (Affinity)\n\n면역학에서 한 개의 항원결정기 부위와 한 개의 항체 사이에 작용하는 힘\n\n판정기준치 (Cut-off value)\n\n정성검사에서는 경계치 이상을 양성으로, 경계치 미만을 음성으로 보고할\n\n수 있는 경계값을 말한다.  정량검사에서는 측정 결과가 임상적 또는 분석\n\n적 결정점(Decision point)의 위 또는 아래에 있는지(양성 또는 음성) 결정\n\n하는데 사용되는 측정물질의 정량값\n\n항원 (Antigen)\n\n생체 내 항체 생성을 유발하고 그들과 특이적으로 결합할 수 있는 물질\n\n항원결정인자 / 에피토프 (Antigenic determinant / epitope)\n\n항원 분자 중 항체가 결합할 수 있는 모든 부위의 총칭으로 특정 항체군을\n\n결정하는 부위의 화학적 구조\n\nⅡ.  용어의 정의\n\n- - 13 -\n항원항체결합력 (Avidity)\n\n항혈청 또는 항체의 복합적인 반응 강도\n\n☞ 항원항체결합력은 항혈청 내 모든 항체의 항체결합부위와 가용한 마크\n\n로분자의 항원결정기와의 친화력 함수\n\n항체 (Antibody)\n\n면역계 내에서 항원의 자극에 의하여 혈청이나 조직에 만들어지는 물질\n\n☞ 면역원 노출에 반응하여 B림프구에서 생산되는 특이 면역글로불린으\n\n허용 오차 (Allowable error)\n\n모든 가능한 요소들로부터 발생할 수 있는 분석적 변이의 정도 또는 검사\n\n시스템에서 사용자가 허용할 수 있는 정도로 검사의 임상적 요구사항을\n\n만족시킬 수 있는 변이의 정도\n\n후크효과 (Hook effect)\n\n항체 또는 항원 과다로 최적 반응을 방해하여 항원-항체 반응이 최적\n\n이하로 나타나는 현상\n\n회복, 회수 (Recovery)\n\n동일 물질의 검체에 알고 있는 양을 첨가한 후 분석물질 농도의 증가를\n\n확인\n\n☞ 분석물질이 첨가되지 않은 혈청 검체와 첨가된 혈청 검체로 분석물질\n\n의 증가가 첨가된 양과 동등한 지 분석한다.  첨가된 물질의 양을 확인\n\n하는 정확도는 회수 실험에 필수적이며 100% 회수가 이상적이다.\n\n",
        "original_sentence": "측정가능범위 (Analytical measurement range, AMR)\n\n일상적인 측정 과정의 일부가 아닌 희석, 농축 또는 기타 전처리 없이 어떤\n\n검사법이 검체에서 직접 측정할 수 있는 분석물질 값의 범위\n\n측정 시스템의 민감도 (Sensitivity of a measuring system)\n\n측정 시스템 표시 도수의 변화 및 측정된 양의 값의 변화계수\n\n☞ 측정시스템의 민감도는 측정된 양의 크기에 의존하며 측정된 양의 값\n\n친화력, 친화성 (Affinity)\n\n면역학에서 한 개의 항원결정기 부위와 한 개의 항체 사이에 작용하는 힘\n\n판정기준치 (Cut-off value)\n\n정성검사에서는 경계치 이상을 양성으로, 경계치 미만을 음성으로 보고할\n\n수 있는 경계값을 말한다. "
      }
    },
    {
      "chunk_id": "chunk_345",
      "text": "정량검사에서는 측정 결과가 임상적 또는 분석\n\n적 결정점(Decision point)의 위 또는 아래에 있는지(양성 또는 음성) 결정\n\n하는데 사용되는 측정물질의 정량값\n\n항원 (Antigen)\n\n생체 내 항체 생성을 유발하고 그들과 특이적으로 결합할 수 있는 물질\n\n항원결정인자 / 에피토프 (Antigenic determinant / epitope)\n\n항원 분자 중 항체가 결합할 수 있는 모든 부위의 총칭으로 특정 항체군을\n\n결정하는 부위의 화학적 구조\n\nⅡ. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 344,
        "window_size": 3,
        "char_count": 261,
        "word_count": 57,
        "page_number": 14,
        "window_text": "b) 표준참고물질(SRM)은 인증참고물질(CRM)의 한 이름으로서 과거에\n\n국립표준원(NBS)으로 알려졌던 미국정부기관으로, 국립표준기술\n\n연구소(NIST)에 의해 인증되고 배포되는 인증참고물질의 상품명이다.\n\n 참고치 (Reference value)\n\n개체에서 관측 또는 측정으로 얻은 특정 형태의 정량값\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 12 -\n총 분석 오차 (Total analytical error)\n\n특정 구성요소들로 구성되어 있으며 90% 또는 95% 신뢰구간으로 정량\n\n화된다.\n\n 측정가능범위 (Analytical measurement range, AMR)\n\n일상적인 측정 과정의 일부가 아닌 희석, 농축 또는 기타 전처리 없이 어떤\n\n검사법이 검체에서 직접 측정할 수 있는 분석물질 값의 범위\n\n측정 시스템의 민감도 (Sensitivity of a measuring system)\n\n측정 시스템 표시 도수의 변화 및 측정된 양의 값의 변화계수\n\n☞ 측정시스템의 민감도는 측정된 양의 크기에 의존하며 측정된 양의 값\n\n친화력, 친화성 (Affinity)\n\n면역학에서 한 개의 항원결정기 부위와 한 개의 항체 사이에 작용하는 힘\n\n판정기준치 (Cut-off value)\n\n정성검사에서는 경계치 이상을 양성으로, 경계치 미만을 음성으로 보고할\n\n수 있는 경계값을 말한다.  정량검사에서는 측정 결과가 임상적 또는 분석\n\n적 결정점(Decision point)의 위 또는 아래에 있는지(양성 또는 음성) 결정\n\n하는데 사용되는 측정물질의 정량값\n\n항원 (Antigen)\n\n생체 내 항체 생성을 유발하고 그들과 특이적으로 결합할 수 있는 물질\n\n항원결정인자 / 에피토프 (Antigenic determinant / epitope)\n\n항원 분자 중 항체가 결합할 수 있는 모든 부위의 총칭으로 특정 항체군을\n\n결정하는 부위의 화학적 구조\n\nⅡ.  용어의 정의\n\n- - 13 -\n항원항체결합력 (Avidity)\n\n항혈청 또는 항체의 복합적인 반응 강도\n\n☞ 항원항체결합력은 항혈청 내 모든 항체의 항체결합부위와 가용한 마크\n\n로분자의 항원결정기와의 친화력 함수\n\n항체 (Antibody)\n\n면역계 내에서 항원의 자극에 의하여 혈청이나 조직에 만들어지는 물질\n\n☞ 면역원 노출에 반응하여 B림프구에서 생산되는 특이 면역글로불린으\n\n허용 오차 (Allowable error)\n\n모든 가능한 요소들로부터 발생할 수 있는 분석적 변이의 정도 또는 검사\n\n시스템에서 사용자가 허용할 수 있는 정도로 검사의 임상적 요구사항을\n\n만족시킬 수 있는 변이의 정도\n\n후크효과 (Hook effect)\n\n항체 또는 항원 과다로 최적 반응을 방해하여 항원-항체 반응이 최적\n\n이하로 나타나는 현상\n\n회복, 회수 (Recovery)\n\n동일 물질의 검체에 알고 있는 양을 첨가한 후 분석물질 농도의 증가를\n\n확인\n\n☞ 분석물질이 첨가되지 않은 혈청 검체와 첨가된 혈청 검체로 분석물질\n\n의 증가가 첨가된 양과 동등한 지 분석한다.  첨가된 물질의 양을 확인\n\n하는 정확도는 회수 실험에 필수적이며 100% 회수가 이상적이다.\n\n ☞ 회수실험의 다른 형태는 희석-회수분석이다.\n\n",
        "original_sentence": "정량검사에서는 측정 결과가 임상적 또는 분석\n\n적 결정점(Decision point)의 위 또는 아래에 있는지(양성 또는 음성) 결정\n\n하는데 사용되는 측정물질의 정량값\n\n항원 (Antigen)\n\n생체 내 항체 생성을 유발하고 그들과 특이적으로 결합할 수 있는 물질\n\n항원결정인자 / 에피토프 (Antigenic determinant / epitope)\n\n항원 분자 중 항체가 결합할 수 있는 모든 부위의 총칭으로 특정 항체군을\n\n결정하는 부위의 화학적 구조\n\nⅡ. "
      }
    },
    {
      "chunk_id": "chunk_346",
      "text": "용어의 정의\n\n- - 13 -\n항원항체결합력 (Avidity)\n\n항혈청 또는 항체의 복합적인 반응 강도\n\n☞ 항원항체결합력은 항혈청 내 모든 항체의 항체결합부위와 가용한 마크\n\n로분자의 항원결정기와의 친화력 함수\n\n항체 (Antibody)\n\n면역계 내에서 항원의 자극에 의하여 혈청이나 조직에 만들어지는 물질\n\n☞ 면역원 노출에 반응하여 B림프구에서 생산되는 특이 면역글로불린으\n\n허용 오차 (Allowable error)\n\n모든 가능한 요소들로부터 발생할 수 있는 분석적 변이의 정도 또는 검사\n\n시스템에서 사용자가 허용할 수 있는 정도로 검사의 임상적 요구사항을\n\n만족시킬 수 있는 변이의 정도\n\n후크효과 (Hook effect)\n\n항체 또는 항원 과다로 최적 반응을 방해하여 항원-항체 반응이 최적\n\n이하로 나타나는 현상\n\n회복, 회수 (Recovery)\n\n동일 물질의 검체에 알고 있는 양을 첨가한 후 분석물질 농도의 증가를\n\n확인\n\n☞ 분석물질이 첨가되지 않은 혈청 검체와 첨가된 혈청 검체로 분석물질\n\n의 증가가 첨가된 양과 동등한 지 분석한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 345,
        "window_size": 3,
        "char_count": 536,
        "word_count": 123,
        "page_number": 3,
        "window_text": "참고치 (Reference value)\n\n개체에서 관측 또는 측정으로 얻은 특정 형태의 정량값\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 12 -\n총 분석 오차 (Total analytical error)\n\n특정 구성요소들로 구성되어 있으며 90% 또는 95% 신뢰구간으로 정량\n\n화된다.\n\n 측정가능범위 (Analytical measurement range, AMR)\n\n일상적인 측정 과정의 일부가 아닌 희석, 농축 또는 기타 전처리 없이 어떤\n\n검사법이 검체에서 직접 측정할 수 있는 분석물질 값의 범위\n\n측정 시스템의 민감도 (Sensitivity of a measuring system)\n\n측정 시스템 표시 도수의 변화 및 측정된 양의 값의 변화계수\n\n☞ 측정시스템의 민감도는 측정된 양의 크기에 의존하며 측정된 양의 값\n\n친화력, 친화성 (Affinity)\n\n면역학에서 한 개의 항원결정기 부위와 한 개의 항체 사이에 작용하는 힘\n\n판정기준치 (Cut-off value)\n\n정성검사에서는 경계치 이상을 양성으로, 경계치 미만을 음성으로 보고할\n\n수 있는 경계값을 말한다.  정량검사에서는 측정 결과가 임상적 또는 분석\n\n적 결정점(Decision point)의 위 또는 아래에 있는지(양성 또는 음성) 결정\n\n하는데 사용되는 측정물질의 정량값\n\n항원 (Antigen)\n\n생체 내 항체 생성을 유발하고 그들과 특이적으로 결합할 수 있는 물질\n\n항원결정인자 / 에피토프 (Antigenic determinant / epitope)\n\n항원 분자 중 항체가 결합할 수 있는 모든 부위의 총칭으로 특정 항체군을\n\n결정하는 부위의 화학적 구조\n\nⅡ.  용어의 정의\n\n- - 13 -\n항원항체결합력 (Avidity)\n\n항혈청 또는 항체의 복합적인 반응 강도\n\n☞ 항원항체결합력은 항혈청 내 모든 항체의 항체결합부위와 가용한 마크\n\n로분자의 항원결정기와의 친화력 함수\n\n항체 (Antibody)\n\n면역계 내에서 항원의 자극에 의하여 혈청이나 조직에 만들어지는 물질\n\n☞ 면역원 노출에 반응하여 B림프구에서 생산되는 특이 면역글로불린으\n\n허용 오차 (Allowable error)\n\n모든 가능한 요소들로부터 발생할 수 있는 분석적 변이의 정도 또는 검사\n\n시스템에서 사용자가 허용할 수 있는 정도로 검사의 임상적 요구사항을\n\n만족시킬 수 있는 변이의 정도\n\n후크효과 (Hook effect)\n\n항체 또는 항원 과다로 최적 반응을 방해하여 항원-항체 반응이 최적\n\n이하로 나타나는 현상\n\n회복, 회수 (Recovery)\n\n동일 물질의 검체에 알고 있는 양을 첨가한 후 분석물질 농도의 증가를\n\n확인\n\n☞ 분석물질이 첨가되지 않은 혈청 검체와 첨가된 혈청 검체로 분석물질\n\n의 증가가 첨가된 양과 동등한 지 분석한다.  첨가된 물질의 양을 확인\n\n하는 정확도는 회수 실험에 필수적이며 100% 회수가 이상적이다.\n\n ☞ 회수실험의 다른 형태는 희석-회수분석이다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 14 -\n<!-- PAGE_20 -->\n# Ⅲ\n\n<!-- PAGE_20 -->\n#### 관련규정\n\n■ 「의료기기법」제3조 (제조업의 허가의 신청절차)\n\n■ 「의료기기법」제10조 (임상시험계획의 승인 등)\n\n■ 「의료기기법」제29조 (수입업 허가신청 등)\n\n■ 「의료기기법 시행규칙」제5조 (제조허가의 절차)\n\n■ 「의료기기법 시행규칙」제6조 (제조인증의 절차)\n\n■ 「의료기기법 시행규칙」제7조 (제조신고의 절차)\n\n■ 「의료기기법 시행규칙」제9조 (기술문서 등의 심사)\n\n■ 「의료기기법 시행규칙」제20조 (임상시험계획의 승인 등)\n\n■ 「의료기기법 시행규칙」제21조 (임상시험기관 지정기준 및 절차 등)\n\n■ 「의료기기법 시행규칙」제30조 (수입허가 신청 등)\n\n■ 「의료기기법 시행규칙」제42조 (용기 등의 기재사항)\n\n■ 「의료기기법 시행규칙」제43조 (첨부문서의 기재사항)\n\n■ 「의료기기법 시행규칙」제44조 (기재사항의 표시방법)\n\n■ 「의료기기 허가․신고․심사 등에 관한 규정」\n\n■ 「의료기기 품목 및 품목별 등급에 관한 규정」\n\n■ 「의료기기 안정성시험 기준」\n\nⅣ. ",
        "original_sentence": "용어의 정의\n\n- - 13 -\n항원항체결합력 (Avidity)\n\n항혈청 또는 항체의 복합적인 반응 강도\n\n☞ 항원항체결합력은 항혈청 내 모든 항체의 항체결합부위와 가용한 마크\n\n로분자의 항원결정기와의 친화력 함수\n\n항체 (Antibody)\n\n면역계 내에서 항원의 자극에 의하여 혈청이나 조직에 만들어지는 물질\n\n☞ 면역원 노출에 반응하여 B림프구에서 생산되는 특이 면역글로불린으\n\n허용 오차 (Allowable error)\n\n모든 가능한 요소들로부터 발생할 수 있는 분석적 변이의 정도 또는 검사\n\n시스템에서 사용자가 허용할 수 있는 정도로 검사의 임상적 요구사항을\n\n만족시킬 수 있는 변이의 정도\n\n후크효과 (Hook effect)\n\n항체 또는 항원 과다로 최적 반응을 방해하여 항원-항체 반응이 최적\n\n이하로 나타나는 현상\n\n회복, 회수 (Recovery)\n\n동일 물질의 검체에 알고 있는 양을 첨가한 후 분석물질 농도의 증가를\n\n확인\n\n☞ 분석물질이 첨가되지 않은 혈청 검체와 첨가된 혈청 검체로 분석물질\n\n의 증가가 첨가된 양과 동등한 지 분석한다. "
      }
    },
    {
      "chunk_id": "chunk_347",
      "text": "첨가된 물질의 양을 확인\n\n하는 정확도는 회수 실험에 필수적이며 100% 회수가 이상적이다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 346,
        "window_size": 3,
        "char_count": 53,
        "word_count": 12,
        "page_number": 19,
        "window_text": "측정가능범위 (Analytical measurement range, AMR)\n\n일상적인 측정 과정의 일부가 아닌 희석, 농축 또는 기타 전처리 없이 어떤\n\n검사법이 검체에서 직접 측정할 수 있는 분석물질 값의 범위\n\n측정 시스템의 민감도 (Sensitivity of a measuring system)\n\n측정 시스템 표시 도수의 변화 및 측정된 양의 값의 변화계수\n\n☞ 측정시스템의 민감도는 측정된 양의 크기에 의존하며 측정된 양의 값\n\n친화력, 친화성 (Affinity)\n\n면역학에서 한 개의 항원결정기 부위와 한 개의 항체 사이에 작용하는 힘\n\n판정기준치 (Cut-off value)\n\n정성검사에서는 경계치 이상을 양성으로, 경계치 미만을 음성으로 보고할\n\n수 있는 경계값을 말한다.  정량검사에서는 측정 결과가 임상적 또는 분석\n\n적 결정점(Decision point)의 위 또는 아래에 있는지(양성 또는 음성) 결정\n\n하는데 사용되는 측정물질의 정량값\n\n항원 (Antigen)\n\n생체 내 항체 생성을 유발하고 그들과 특이적으로 결합할 수 있는 물질\n\n항원결정인자 / 에피토프 (Antigenic determinant / epitope)\n\n항원 분자 중 항체가 결합할 수 있는 모든 부위의 총칭으로 특정 항체군을\n\n결정하는 부위의 화학적 구조\n\nⅡ.  용어의 정의\n\n- - 13 -\n항원항체결합력 (Avidity)\n\n항혈청 또는 항체의 복합적인 반응 강도\n\n☞ 항원항체결합력은 항혈청 내 모든 항체의 항체결합부위와 가용한 마크\n\n로분자의 항원결정기와의 친화력 함수\n\n항체 (Antibody)\n\n면역계 내에서 항원의 자극에 의하여 혈청이나 조직에 만들어지는 물질\n\n☞ 면역원 노출에 반응하여 B림프구에서 생산되는 특이 면역글로불린으\n\n허용 오차 (Allowable error)\n\n모든 가능한 요소들로부터 발생할 수 있는 분석적 변이의 정도 또는 검사\n\n시스템에서 사용자가 허용할 수 있는 정도로 검사의 임상적 요구사항을\n\n만족시킬 수 있는 변이의 정도\n\n후크효과 (Hook effect)\n\n항체 또는 항원 과다로 최적 반응을 방해하여 항원-항체 반응이 최적\n\n이하로 나타나는 현상\n\n회복, 회수 (Recovery)\n\n동일 물질의 검체에 알고 있는 양을 첨가한 후 분석물질 농도의 증가를\n\n확인\n\n☞ 분석물질이 첨가되지 않은 혈청 검체와 첨가된 혈청 검체로 분석물질\n\n의 증가가 첨가된 양과 동등한 지 분석한다.  첨가된 물질의 양을 확인\n\n하는 정확도는 회수 실험에 필수적이며 100% 회수가 이상적이다.\n\n ☞ 회수실험의 다른 형태는 희석-회수분석이다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 14 -\n<!-- PAGE_20 -->\n# Ⅲ\n\n<!-- PAGE_20 -->\n#### 관련규정\n\n■ 「의료기기법」제3조 (제조업의 허가의 신청절차)\n\n■ 「의료기기법」제10조 (임상시험계획의 승인 등)\n\n■ 「의료기기법」제29조 (수입업 허가신청 등)\n\n■ 「의료기기법 시행규칙」제5조 (제조허가의 절차)\n\n■ 「의료기기법 시행규칙」제6조 (제조인증의 절차)\n\n■ 「의료기기법 시행규칙」제7조 (제조신고의 절차)\n\n■ 「의료기기법 시행규칙」제9조 (기술문서 등의 심사)\n\n■ 「의료기기법 시행규칙」제20조 (임상시험계획의 승인 등)\n\n■ 「의료기기법 시행규칙」제21조 (임상시험기관 지정기준 및 절차 등)\n\n■ 「의료기기법 시행규칙」제30조 (수입허가 신청 등)\n\n■ 「의료기기법 시행규칙」제42조 (용기 등의 기재사항)\n\n■ 「의료기기법 시행규칙」제43조 (첨부문서의 기재사항)\n\n■ 「의료기기법 시행규칙」제44조 (기재사항의 표시방법)\n\n■ 「의료기기 허가․신고․심사 등에 관한 규정」\n\n■ 「의료기기 품목 및 품목별 등급에 관한 규정」\n\n■ 「의료기기 안정성시험 기준」\n\nⅣ.  신청서 기재 항목 및 기술문서 제출자료\n\n- - 15 -\n<!-- PAGE_21 -->\n# Ⅳ\n\n신청서 기재 항목 및 기술문서 제출자료\n\n<!-- PAGE_21 -->\n###### 1\n\n<!-- PAGE_21 -->\n###### 제조․수입허가신청서\n\n❍ 명칭(제품명, 품목명, 모델명)\n\n❍ 분류번호(등급)\n\n❍ 모양 및 구조\n\n❍ 저장방법 및 사용기간\n\n❍ 시험규격\n\n❍ 제조원(수입 또는 제조공정 전부 위탁의 경우)\n\n❍ 허가조건\n\n❍ 비고\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 16 -\n<!-- PAGE_22 -->\n###### 2\n\n<!-- PAGE_22 -->\n###### 기술문서에 관한 자료\n\n❍ 개발경위, 측정원리․방법 및 국내·외 사용현황에 관한 자료\n\n❍ 원재료 및 제조방법에 관한 자료\n\n❍ 사용목적에 관한 자료\n\n❍ 저장방법과 사용기간(유효기간)에 관한 자료\n\n❍ 성능시험에 관한 자료\n\n❍ 체외진단용 의료기기의 취급자 안전에 관한 자료\n\n❍ 이미 허가·인증받은 제품과 비교한 자료(별지제3호서식)\n\nⅤ. ",
        "original_sentence": "첨가된 물질의 양을 확인\n\n하는 정확도는 회수 실험에 필수적이며 100% 회수가 이상적이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_348",
      "text": "☞ 회수실험의 다른 형태는 희석-회수분석이다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 347,
        "window_size": 3,
        "char_count": 27,
        "word_count": 5,
        "page_number": 19,
        "window_text": "정량검사에서는 측정 결과가 임상적 또는 분석\n\n적 결정점(Decision point)의 위 또는 아래에 있는지(양성 또는 음성) 결정\n\n하는데 사용되는 측정물질의 정량값\n\n항원 (Antigen)\n\n생체 내 항체 생성을 유발하고 그들과 특이적으로 결합할 수 있는 물질\n\n항원결정인자 / 에피토프 (Antigenic determinant / epitope)\n\n항원 분자 중 항체가 결합할 수 있는 모든 부위의 총칭으로 특정 항체군을\n\n결정하는 부위의 화학적 구조\n\nⅡ.  용어의 정의\n\n- - 13 -\n항원항체결합력 (Avidity)\n\n항혈청 또는 항체의 복합적인 반응 강도\n\n☞ 항원항체결합력은 항혈청 내 모든 항체의 항체결합부위와 가용한 마크\n\n로분자의 항원결정기와의 친화력 함수\n\n항체 (Antibody)\n\n면역계 내에서 항원의 자극에 의하여 혈청이나 조직에 만들어지는 물질\n\n☞ 면역원 노출에 반응하여 B림프구에서 생산되는 특이 면역글로불린으\n\n허용 오차 (Allowable error)\n\n모든 가능한 요소들로부터 발생할 수 있는 분석적 변이의 정도 또는 검사\n\n시스템에서 사용자가 허용할 수 있는 정도로 검사의 임상적 요구사항을\n\n만족시킬 수 있는 변이의 정도\n\n후크효과 (Hook effect)\n\n항체 또는 항원 과다로 최적 반응을 방해하여 항원-항체 반응이 최적\n\n이하로 나타나는 현상\n\n회복, 회수 (Recovery)\n\n동일 물질의 검체에 알고 있는 양을 첨가한 후 분석물질 농도의 증가를\n\n확인\n\n☞ 분석물질이 첨가되지 않은 혈청 검체와 첨가된 혈청 검체로 분석물질\n\n의 증가가 첨가된 양과 동등한 지 분석한다.  첨가된 물질의 양을 확인\n\n하는 정확도는 회수 실험에 필수적이며 100% 회수가 이상적이다.\n\n ☞ 회수실험의 다른 형태는 희석-회수분석이다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 14 -\n<!-- PAGE_20 -->\n# Ⅲ\n\n<!-- PAGE_20 -->\n#### 관련규정\n\n■ 「의료기기법」제3조 (제조업의 허가의 신청절차)\n\n■ 「의료기기법」제10조 (임상시험계획의 승인 등)\n\n■ 「의료기기법」제29조 (수입업 허가신청 등)\n\n■ 「의료기기법 시행규칙」제5조 (제조허가의 절차)\n\n■ 「의료기기법 시행규칙」제6조 (제조인증의 절차)\n\n■ 「의료기기법 시행규칙」제7조 (제조신고의 절차)\n\n■ 「의료기기법 시행규칙」제9조 (기술문서 등의 심사)\n\n■ 「의료기기법 시행규칙」제20조 (임상시험계획의 승인 등)\n\n■ 「의료기기법 시행규칙」제21조 (임상시험기관 지정기준 및 절차 등)\n\n■ 「의료기기법 시행규칙」제30조 (수입허가 신청 등)\n\n■ 「의료기기법 시행규칙」제42조 (용기 등의 기재사항)\n\n■ 「의료기기법 시행규칙」제43조 (첨부문서의 기재사항)\n\n■ 「의료기기법 시행규칙」제44조 (기재사항의 표시방법)\n\n■ 「의료기기 허가․신고․심사 등에 관한 규정」\n\n■ 「의료기기 품목 및 품목별 등급에 관한 규정」\n\n■ 「의료기기 안정성시험 기준」\n\nⅣ.  신청서 기재 항목 및 기술문서 제출자료\n\n- - 15 -\n<!-- PAGE_21 -->\n# Ⅳ\n\n신청서 기재 항목 및 기술문서 제출자료\n\n<!-- PAGE_21 -->\n###### 1\n\n<!-- PAGE_21 -->\n###### 제조․수입허가신청서\n\n❍ 명칭(제품명, 품목명, 모델명)\n\n❍ 분류번호(등급)\n\n❍ 모양 및 구조\n\n❍ 저장방법 및 사용기간\n\n❍ 시험규격\n\n❍ 제조원(수입 또는 제조공정 전부 위탁의 경우)\n\n❍ 허가조건\n\n❍ 비고\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 16 -\n<!-- PAGE_22 -->\n###### 2\n\n<!-- PAGE_22 -->\n###### 기술문서에 관한 자료\n\n❍ 개발경위, 측정원리․방법 및 국내·외 사용현황에 관한 자료\n\n❍ 원재료 및 제조방법에 관한 자료\n\n❍ 사용목적에 관한 자료\n\n❍ 저장방법과 사용기간(유효기간)에 관한 자료\n\n❍ 성능시험에 관한 자료\n\n❍ 체외진단용 의료기기의 취급자 안전에 관한 자료\n\n❍ 이미 허가·인증받은 제품과 비교한 자료(별지제3호서식)\n\nⅤ.  제조․수입허가 신청서 기재 항목\n\n- - 17 -\n<!-- PAGE_23 -->\n# Ⅴ\n\n<!-- PAGE_23 -->\n### 제조․수입허가 신청서 기재항목\n\n<!-- PAGE_23 -->\n###### 1\n\n<!-- PAGE_23 -->\n###### 명칭 (제품명, 품목명, 모델명)\n\n- 1. ",
        "original_sentence": "☞ 회수실험의 다른 형태는 희석-회수분석이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_349",
      "text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 14 -\n<!-- PAGE_20 -->\n# Ⅲ\n\n<!-- PAGE_20 -->\n#### 관련규정\n\n■ 「의료기기법」제3조 (제조업의 허가의 신청절차)\n\n■ 「의료기기법」제10조 (임상시험계획의 승인 등)\n\n■ 「의료기기법」제29조 (수입업 허가신청 등)\n\n■ 「의료기기법 시행규칙」제5조 (제조허가의 절차)\n\n■ 「의료기기법 시행규칙」제6조 (제조인증의 절차)\n\n■ 「의료기기법 시행규칙」제7조 (제조신고의 절차)\n\n■ 「의료기기법 시행규칙」제9조 (기술문서 등의 심사)\n\n■ 「의료기기법 시행규칙」제20조 (임상시험계획의 승인 등)\n\n■ 「의료기기법 시행규칙」제21조 (임상시험기관 지정기준 및 절차 등)\n\n■ 「의료기기법 시행규칙」제30조 (수입허가 신청 등)\n\n■ 「의료기기법 시행규칙」제42조 (용기 등의 기재사항)\n\n■ 「의료기기법 시행규칙」제43조 (첨부문서의 기재사항)\n\n■ 「의료기기법 시행규칙」제44조 (기재사항의 표시방법)\n\n■ 「의료기기 허가․신고․심사 등에 관한 규정」\n\n■ 「의료기기 품목 및 품목별 등급에 관한 규정」\n\n■ 「의료기기 안정성시험 기준」\n\nⅣ. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 348,
        "window_size": 3,
        "char_count": 604,
        "word_count": 113,
        "page_number": 20,
        "window_text": "용어의 정의\n\n- - 13 -\n항원항체결합력 (Avidity)\n\n항혈청 또는 항체의 복합적인 반응 강도\n\n☞ 항원항체결합력은 항혈청 내 모든 항체의 항체결합부위와 가용한 마크\n\n로분자의 항원결정기와의 친화력 함수\n\n항체 (Antibody)\n\n면역계 내에서 항원의 자극에 의하여 혈청이나 조직에 만들어지는 물질\n\n☞ 면역원 노출에 반응하여 B림프구에서 생산되는 특이 면역글로불린으\n\n허용 오차 (Allowable error)\n\n모든 가능한 요소들로부터 발생할 수 있는 분석적 변이의 정도 또는 검사\n\n시스템에서 사용자가 허용할 수 있는 정도로 검사의 임상적 요구사항을\n\n만족시킬 수 있는 변이의 정도\n\n후크효과 (Hook effect)\n\n항체 또는 항원 과다로 최적 반응을 방해하여 항원-항체 반응이 최적\n\n이하로 나타나는 현상\n\n회복, 회수 (Recovery)\n\n동일 물질의 검체에 알고 있는 양을 첨가한 후 분석물질 농도의 증가를\n\n확인\n\n☞ 분석물질이 첨가되지 않은 혈청 검체와 첨가된 혈청 검체로 분석물질\n\n의 증가가 첨가된 양과 동등한 지 분석한다.  첨가된 물질의 양을 확인\n\n하는 정확도는 회수 실험에 필수적이며 100% 회수가 이상적이다.\n\n ☞ 회수실험의 다른 형태는 희석-회수분석이다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 14 -\n<!-- PAGE_20 -->\n# Ⅲ\n\n<!-- PAGE_20 -->\n#### 관련규정\n\n■ 「의료기기법」제3조 (제조업의 허가의 신청절차)\n\n■ 「의료기기법」제10조 (임상시험계획의 승인 등)\n\n■ 「의료기기법」제29조 (수입업 허가신청 등)\n\n■ 「의료기기법 시행규칙」제5조 (제조허가의 절차)\n\n■ 「의료기기법 시행규칙」제6조 (제조인증의 절차)\n\n■ 「의료기기법 시행규칙」제7조 (제조신고의 절차)\n\n■ 「의료기기법 시행규칙」제9조 (기술문서 등의 심사)\n\n■ 「의료기기법 시행규칙」제20조 (임상시험계획의 승인 등)\n\n■ 「의료기기법 시행규칙」제21조 (임상시험기관 지정기준 및 절차 등)\n\n■ 「의료기기법 시행규칙」제30조 (수입허가 신청 등)\n\n■ 「의료기기법 시행규칙」제42조 (용기 등의 기재사항)\n\n■ 「의료기기법 시행규칙」제43조 (첨부문서의 기재사항)\n\n■ 「의료기기법 시행규칙」제44조 (기재사항의 표시방법)\n\n■ 「의료기기 허가․신고․심사 등에 관한 규정」\n\n■ 「의료기기 품목 및 품목별 등급에 관한 규정」\n\n■ 「의료기기 안정성시험 기준」\n\nⅣ.  신청서 기재 항목 및 기술문서 제출자료\n\n- - 15 -\n<!-- PAGE_21 -->\n# Ⅳ\n\n신청서 기재 항목 및 기술문서 제출자료\n\n<!-- PAGE_21 -->\n###### 1\n\n<!-- PAGE_21 -->\n###### 제조․수입허가신청서\n\n❍ 명칭(제품명, 품목명, 모델명)\n\n❍ 분류번호(등급)\n\n❍ 모양 및 구조\n\n❍ 저장방법 및 사용기간\n\n❍ 시험규격\n\n❍ 제조원(수입 또는 제조공정 전부 위탁의 경우)\n\n❍ 허가조건\n\n❍ 비고\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 16 -\n<!-- PAGE_22 -->\n###### 2\n\n<!-- PAGE_22 -->\n###### 기술문서에 관한 자료\n\n❍ 개발경위, 측정원리․방법 및 국내·외 사용현황에 관한 자료\n\n❍ 원재료 및 제조방법에 관한 자료\n\n❍ 사용목적에 관한 자료\n\n❍ 저장방법과 사용기간(유효기간)에 관한 자료\n\n❍ 성능시험에 관한 자료\n\n❍ 체외진단용 의료기기의 취급자 안전에 관한 자료\n\n❍ 이미 허가·인증받은 제품과 비교한 자료(별지제3호서식)\n\nⅤ.  제조․수입허가 신청서 기재 항목\n\n- - 17 -\n<!-- PAGE_23 -->\n# Ⅴ\n\n<!-- PAGE_23 -->\n### 제조․수입허가 신청서 기재항목\n\n<!-- PAGE_23 -->\n###### 1\n\n<!-- PAGE_23 -->\n###### 명칭 (제품명, 품목명, 모델명)\n\n- 1.  제조(수입)업소명·제품명, 품목류명, 모델명을 각각 기재한다.\n",
        "original_sentence": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 14 -\n<!-- PAGE_20 -->\n# Ⅲ\n\n<!-- PAGE_20 -->\n#### 관련규정\n\n■ 「의료기기법」제3조 (제조업의 허가의 신청절차)\n\n■ 「의료기기법」제10조 (임상시험계획의 승인 등)\n\n■ 「의료기기법」제29조 (수입업 허가신청 등)\n\n■ 「의료기기법 시행규칙」제5조 (제조허가의 절차)\n\n■ 「의료기기법 시행규칙」제6조 (제조인증의 절차)\n\n■ 「의료기기법 시행규칙」제7조 (제조신고의 절차)\n\n■ 「의료기기법 시행규칙」제9조 (기술문서 등의 심사)\n\n■ 「의료기기법 시행규칙」제20조 (임상시험계획의 승인 등)\n\n■ 「의료기기법 시행규칙」제21조 (임상시험기관 지정기준 및 절차 등)\n\n■ 「의료기기법 시행규칙」제30조 (수입허가 신청 등)\n\n■ 「의료기기법 시행규칙」제42조 (용기 등의 기재사항)\n\n■ 「의료기기법 시행규칙」제43조 (첨부문서의 기재사항)\n\n■ 「의료기기법 시행규칙」제44조 (기재사항의 표시방법)\n\n■ 「의료기기 허가․신고․심사 등에 관한 규정」\n\n■ 「의료기기 품목 및 품목별 등급에 관한 규정」\n\n■ 「의료기기 안정성시험 기준」\n\nⅣ. "
      }
    },
    {
      "chunk_id": "chunk_350",
      "text": "신청서 기재 항목 및 기술문서 제출자료\n\n- - 15 -\n<!-- PAGE_21 -->\n# Ⅳ\n\n신청서 기재 항목 및 기술문서 제출자료\n\n<!-- PAGE_21 -->\n###### 1\n\n<!-- PAGE_21 -->\n###### 제조․수입허가신청서\n\n❍ 명칭(제품명, 품목명, 모델명)\n\n❍ 분류번호(등급)\n\n❍ 모양 및 구조\n\n❍ 저장방법 및 사용기간\n\n❍ 시험규격\n\n❍ 제조원(수입 또는 제조공정 전부 위탁의 경우)\n\n❍ 허가조건\n\n❍ 비고\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 16 -\n<!-- PAGE_22 -->\n###### 2\n\n<!-- PAGE_22 -->\n###### 기술문서에 관한 자료\n\n❍ 개발경위, 측정원리․방법 및 국내·외 사용현황에 관한 자료\n\n❍ 원재료 및 제조방법에 관한 자료\n\n❍ 사용목적에 관한 자료\n\n❍ 저장방법과 사용기간(유효기간)에 관한 자료\n\n❍ 성능시험에 관한 자료\n\n❍ 체외진단용 의료기기의 취급자 안전에 관한 자료\n\n❍ 이미 허가·인증받은 제품과 비교한 자료(별지제3호서식)\n\nⅤ. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 349,
        "window_size": 3,
        "char_count": 552,
        "word_count": 123,
        "page_number": 21,
        "window_text": "첨가된 물질의 양을 확인\n\n하는 정확도는 회수 실험에 필수적이며 100% 회수가 이상적이다.\n\n ☞ 회수실험의 다른 형태는 희석-회수분석이다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 14 -\n<!-- PAGE_20 -->\n# Ⅲ\n\n<!-- PAGE_20 -->\n#### 관련규정\n\n■ 「의료기기법」제3조 (제조업의 허가의 신청절차)\n\n■ 「의료기기법」제10조 (임상시험계획의 승인 등)\n\n■ 「의료기기법」제29조 (수입업 허가신청 등)\n\n■ 「의료기기법 시행규칙」제5조 (제조허가의 절차)\n\n■ 「의료기기법 시행규칙」제6조 (제조인증의 절차)\n\n■ 「의료기기법 시행규칙」제7조 (제조신고의 절차)\n\n■ 「의료기기법 시행규칙」제9조 (기술문서 등의 심사)\n\n■ 「의료기기법 시행규칙」제20조 (임상시험계획의 승인 등)\n\n■ 「의료기기법 시행규칙」제21조 (임상시험기관 지정기준 및 절차 등)\n\n■ 「의료기기법 시행규칙」제30조 (수입허가 신청 등)\n\n■ 「의료기기법 시행규칙」제42조 (용기 등의 기재사항)\n\n■ 「의료기기법 시행규칙」제43조 (첨부문서의 기재사항)\n\n■ 「의료기기법 시행규칙」제44조 (기재사항의 표시방법)\n\n■ 「의료기기 허가․신고․심사 등에 관한 규정」\n\n■ 「의료기기 품목 및 품목별 등급에 관한 규정」\n\n■ 「의료기기 안정성시험 기준」\n\nⅣ.  신청서 기재 항목 및 기술문서 제출자료\n\n- - 15 -\n<!-- PAGE_21 -->\n# Ⅳ\n\n신청서 기재 항목 및 기술문서 제출자료\n\n<!-- PAGE_21 -->\n###### 1\n\n<!-- PAGE_21 -->\n###### 제조․수입허가신청서\n\n❍ 명칭(제품명, 품목명, 모델명)\n\n❍ 분류번호(등급)\n\n❍ 모양 및 구조\n\n❍ 저장방법 및 사용기간\n\n❍ 시험규격\n\n❍ 제조원(수입 또는 제조공정 전부 위탁의 경우)\n\n❍ 허가조건\n\n❍ 비고\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 16 -\n<!-- PAGE_22 -->\n###### 2\n\n<!-- PAGE_22 -->\n###### 기술문서에 관한 자료\n\n❍ 개발경위, 측정원리․방법 및 국내·외 사용현황에 관한 자료\n\n❍ 원재료 및 제조방법에 관한 자료\n\n❍ 사용목적에 관한 자료\n\n❍ 저장방법과 사용기간(유효기간)에 관한 자료\n\n❍ 성능시험에 관한 자료\n\n❍ 체외진단용 의료기기의 취급자 안전에 관한 자료\n\n❍ 이미 허가·인증받은 제품과 비교한 자료(별지제3호서식)\n\nⅤ.  제조․수입허가 신청서 기재 항목\n\n- - 17 -\n<!-- PAGE_23 -->\n# Ⅴ\n\n<!-- PAGE_23 -->\n### 제조․수입허가 신청서 기재항목\n\n<!-- PAGE_23 -->\n###### 1\n\n<!-- PAGE_23 -->\n###### 명칭 (제품명, 품목명, 모델명)\n\n- 1.  제조(수입)업소명·제품명, 품목류명, 모델명을 각각 기재한다.\n - 가. ",
        "original_sentence": "신청서 기재 항목 및 기술문서 제출자료\n\n- - 15 -\n<!-- PAGE_21 -->\n# Ⅳ\n\n신청서 기재 항목 및 기술문서 제출자료\n\n<!-- PAGE_21 -->\n###### 1\n\n<!-- PAGE_21 -->\n###### 제조․수입허가신청서\n\n❍ 명칭(제품명, 품목명, 모델명)\n\n❍ 분류번호(등급)\n\n❍ 모양 및 구조\n\n❍ 저장방법 및 사용기간\n\n❍ 시험규격\n\n❍ 제조원(수입 또는 제조공정 전부 위탁의 경우)\n\n❍ 허가조건\n\n❍ 비고\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 16 -\n<!-- PAGE_22 -->\n###### 2\n\n<!-- PAGE_22 -->\n###### 기술문서에 관한 자료\n\n❍ 개발경위, 측정원리․방법 및 국내·외 사용현황에 관한 자료\n\n❍ 원재료 및 제조방법에 관한 자료\n\n❍ 사용목적에 관한 자료\n\n❍ 저장방법과 사용기간(유효기간)에 관한 자료\n\n❍ 성능시험에 관한 자료\n\n❍ 체외진단용 의료기기의 취급자 안전에 관한 자료\n\n❍ 이미 허가·인증받은 제품과 비교한 자료(별지제3호서식)\n\nⅤ. "
      }
    },
    {
      "chunk_id": "chunk_351",
      "text": "제조․수입허가 신청서 기재 항목\n\n- - 17 -\n<!-- PAGE_23 -->\n# Ⅴ\n\n<!-- PAGE_23 -->\n### 제조․수입허가 신청서 기재항목\n\n<!-- PAGE_23 -->\n###### 1\n\n<!-- PAGE_23 -->\n###### 명칭 (제품명, 품목명, 모델명)\n\n- 1. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 350,
        "window_size": 3,
        "char_count": 165,
        "word_count": 35,
        "page_number": 23,
        "window_text": "☞ 회수실험의 다른 형태는 희석-회수분석이다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 14 -\n<!-- PAGE_20 -->\n# Ⅲ\n\n<!-- PAGE_20 -->\n#### 관련규정\n\n■ 「의료기기법」제3조 (제조업의 허가의 신청절차)\n\n■ 「의료기기법」제10조 (임상시험계획의 승인 등)\n\n■ 「의료기기법」제29조 (수입업 허가신청 등)\n\n■ 「의료기기법 시행규칙」제5조 (제조허가의 절차)\n\n■ 「의료기기법 시행규칙」제6조 (제조인증의 절차)\n\n■ 「의료기기법 시행규칙」제7조 (제조신고의 절차)\n\n■ 「의료기기법 시행규칙」제9조 (기술문서 등의 심사)\n\n■ 「의료기기법 시행규칙」제20조 (임상시험계획의 승인 등)\n\n■ 「의료기기법 시행규칙」제21조 (임상시험기관 지정기준 및 절차 등)\n\n■ 「의료기기법 시행규칙」제30조 (수입허가 신청 등)\n\n■ 「의료기기법 시행규칙」제42조 (용기 등의 기재사항)\n\n■ 「의료기기법 시행규칙」제43조 (첨부문서의 기재사항)\n\n■ 「의료기기법 시행규칙」제44조 (기재사항의 표시방법)\n\n■ 「의료기기 허가․신고․심사 등에 관한 규정」\n\n■ 「의료기기 품목 및 품목별 등급에 관한 규정」\n\n■ 「의료기기 안정성시험 기준」\n\nⅣ.  신청서 기재 항목 및 기술문서 제출자료\n\n- - 15 -\n<!-- PAGE_21 -->\n# Ⅳ\n\n신청서 기재 항목 및 기술문서 제출자료\n\n<!-- PAGE_21 -->\n###### 1\n\n<!-- PAGE_21 -->\n###### 제조․수입허가신청서\n\n❍ 명칭(제품명, 품목명, 모델명)\n\n❍ 분류번호(등급)\n\n❍ 모양 및 구조\n\n❍ 저장방법 및 사용기간\n\n❍ 시험규격\n\n❍ 제조원(수입 또는 제조공정 전부 위탁의 경우)\n\n❍ 허가조건\n\n❍ 비고\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 16 -\n<!-- PAGE_22 -->\n###### 2\n\n<!-- PAGE_22 -->\n###### 기술문서에 관한 자료\n\n❍ 개발경위, 측정원리․방법 및 국내·외 사용현황에 관한 자료\n\n❍ 원재료 및 제조방법에 관한 자료\n\n❍ 사용목적에 관한 자료\n\n❍ 저장방법과 사용기간(유효기간)에 관한 자료\n\n❍ 성능시험에 관한 자료\n\n❍ 체외진단용 의료기기의 취급자 안전에 관한 자료\n\n❍ 이미 허가·인증받은 제품과 비교한 자료(별지제3호서식)\n\nⅤ.  제조․수입허가 신청서 기재 항목\n\n- - 17 -\n<!-- PAGE_23 -->\n# Ⅴ\n\n<!-- PAGE_23 -->\n### 제조․수입허가 신청서 기재항목\n\n<!-- PAGE_23 -->\n###### 1\n\n<!-- PAGE_23 -->\n###### 명칭 (제품명, 품목명, 모델명)\n\n- 1.  제조(수입)업소명·제품명, 품목류명, 모델명을 각각 기재한다.\n - 가.  제품명을 기재하는 경우에는 “제조(수입)업소명·제품명”, “품목명”,\n- 다. ",
        "original_sentence": "제조․수입허가 신청서 기재 항목\n\n- - 17 -\n<!-- PAGE_23 -->\n# Ⅴ\n\n<!-- PAGE_23 -->\n### 제조․수입허가 신청서 기재항목\n\n<!-- PAGE_23 -->\n###### 1\n\n<!-- PAGE_23 -->\n###### 명칭 (제품명, 품목명, 모델명)\n\n- 1. "
      }
    },
    {
      "chunk_id": "chunk_352",
      "text": "제조(수입)업소명·제품명, 품목류명, 모델명을 각각 기재한다.\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 351,
        "window_size": 3,
        "char_count": 35,
        "word_count": 5,
        "page_number": 23,
        "window_text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 14 -\n<!-- PAGE_20 -->\n# Ⅲ\n\n<!-- PAGE_20 -->\n#### 관련규정\n\n■ 「의료기기법」제3조 (제조업의 허가의 신청절차)\n\n■ 「의료기기법」제10조 (임상시험계획의 승인 등)\n\n■ 「의료기기법」제29조 (수입업 허가신청 등)\n\n■ 「의료기기법 시행규칙」제5조 (제조허가의 절차)\n\n■ 「의료기기법 시행규칙」제6조 (제조인증의 절차)\n\n■ 「의료기기법 시행규칙」제7조 (제조신고의 절차)\n\n■ 「의료기기법 시행규칙」제9조 (기술문서 등의 심사)\n\n■ 「의료기기법 시행규칙」제20조 (임상시험계획의 승인 등)\n\n■ 「의료기기법 시행규칙」제21조 (임상시험기관 지정기준 및 절차 등)\n\n■ 「의료기기법 시행규칙」제30조 (수입허가 신청 등)\n\n■ 「의료기기법 시행규칙」제42조 (용기 등의 기재사항)\n\n■ 「의료기기법 시행규칙」제43조 (첨부문서의 기재사항)\n\n■ 「의료기기법 시행규칙」제44조 (기재사항의 표시방법)\n\n■ 「의료기기 허가․신고․심사 등에 관한 규정」\n\n■ 「의료기기 품목 및 품목별 등급에 관한 규정」\n\n■ 「의료기기 안정성시험 기준」\n\nⅣ.  신청서 기재 항목 및 기술문서 제출자료\n\n- - 15 -\n<!-- PAGE_21 -->\n# Ⅳ\n\n신청서 기재 항목 및 기술문서 제출자료\n\n<!-- PAGE_21 -->\n###### 1\n\n<!-- PAGE_21 -->\n###### 제조․수입허가신청서\n\n❍ 명칭(제품명, 품목명, 모델명)\n\n❍ 분류번호(등급)\n\n❍ 모양 및 구조\n\n❍ 저장방법 및 사용기간\n\n❍ 시험규격\n\n❍ 제조원(수입 또는 제조공정 전부 위탁의 경우)\n\n❍ 허가조건\n\n❍ 비고\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 16 -\n<!-- PAGE_22 -->\n###### 2\n\n<!-- PAGE_22 -->\n###### 기술문서에 관한 자료\n\n❍ 개발경위, 측정원리․방법 및 국내·외 사용현황에 관한 자료\n\n❍ 원재료 및 제조방법에 관한 자료\n\n❍ 사용목적에 관한 자료\n\n❍ 저장방법과 사용기간(유효기간)에 관한 자료\n\n❍ 성능시험에 관한 자료\n\n❍ 체외진단용 의료기기의 취급자 안전에 관한 자료\n\n❍ 이미 허가·인증받은 제품과 비교한 자료(별지제3호서식)\n\nⅤ.  제조․수입허가 신청서 기재 항목\n\n- - 17 -\n<!-- PAGE_23 -->\n# Ⅴ\n\n<!-- PAGE_23 -->\n### 제조․수입허가 신청서 기재항목\n\n<!-- PAGE_23 -->\n###### 1\n\n<!-- PAGE_23 -->\n###### 명칭 (제품명, 품목명, 모델명)\n\n- 1.  제조(수입)업소명·제품명, 품목류명, 모델명을 각각 기재한다.\n - 가.  제품명을 기재하는 경우에는 “제조(수입)업소명·제품명”, “품목명”,\n- 다.  동일제품에 대하여 두개 이상의 다른 상품명(또는 모델명) 부여는\n- 2. ",
        "original_sentence": "제조(수입)업소명·제품명, 품목류명, 모델명을 각각 기재한다.\n"
      }
    },
    {
      "chunk_id": "chunk_353",
      "text": "- 가. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 352,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 74,
        "window_text": "신청서 기재 항목 및 기술문서 제출자료\n\n- - 15 -\n<!-- PAGE_21 -->\n# Ⅳ\n\n신청서 기재 항목 및 기술문서 제출자료\n\n<!-- PAGE_21 -->\n###### 1\n\n<!-- PAGE_21 -->\n###### 제조․수입허가신청서\n\n❍ 명칭(제품명, 품목명, 모델명)\n\n❍ 분류번호(등급)\n\n❍ 모양 및 구조\n\n❍ 저장방법 및 사용기간\n\n❍ 시험규격\n\n❍ 제조원(수입 또는 제조공정 전부 위탁의 경우)\n\n❍ 허가조건\n\n❍ 비고\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 16 -\n<!-- PAGE_22 -->\n###### 2\n\n<!-- PAGE_22 -->\n###### 기술문서에 관한 자료\n\n❍ 개발경위, 측정원리․방법 및 국내·외 사용현황에 관한 자료\n\n❍ 원재료 및 제조방법에 관한 자료\n\n❍ 사용목적에 관한 자료\n\n❍ 저장방법과 사용기간(유효기간)에 관한 자료\n\n❍ 성능시험에 관한 자료\n\n❍ 체외진단용 의료기기의 취급자 안전에 관한 자료\n\n❍ 이미 허가·인증받은 제품과 비교한 자료(별지제3호서식)\n\nⅤ.  제조․수입허가 신청서 기재 항목\n\n- - 17 -\n<!-- PAGE_23 -->\n# Ⅴ\n\n<!-- PAGE_23 -->\n### 제조․수입허가 신청서 기재항목\n\n<!-- PAGE_23 -->\n###### 1\n\n<!-- PAGE_23 -->\n###### 명칭 (제품명, 품목명, 모델명)\n\n- 1.  제조(수입)업소명·제품명, 품목류명, 모델명을 각각 기재한다.\n - 가.  제품명을 기재하는 경우에는 “제조(수입)업소명·제품명”, “품목명”,\n- 다.  동일제품에 대하여 두개 이상의 다른 상품명(또는 모델명) 부여는\n- 2.  제품명은 이미 허가(신고)를 받거나 받았었던 의료기기의 제품명과 동\n일하여서는 아니 된다. ",
        "original_sentence": "- 가. "
      }
    },
    {
      "chunk_id": "chunk_354",
      "text": "제품명을 기재하는 경우에는 “제조(수입)업소명·제품명”, “품목명”,\n- 다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 353,
        "window_size": 3,
        "char_count": 44,
        "word_count": 7,
        "page_number": 51,
        "window_text": "제조․수입허가 신청서 기재 항목\n\n- - 17 -\n<!-- PAGE_23 -->\n# Ⅴ\n\n<!-- PAGE_23 -->\n### 제조․수입허가 신청서 기재항목\n\n<!-- PAGE_23 -->\n###### 1\n\n<!-- PAGE_23 -->\n###### 명칭 (제품명, 품목명, 모델명)\n\n- 1.  제조(수입)업소명·제품명, 품목류명, 모델명을 각각 기재한다.\n - 가.  제품명을 기재하는 경우에는 “제조(수입)업소명·제품명”, “품목명”,\n- 다.  동일제품에 대하여 두개 이상의 다른 상품명(또는 모델명) 부여는\n- 2.  제품명은 이미 허가(신고)를 받거나 받았었던 의료기기의 제품명과 동\n일하여서는 아니 된다.  다만, 다음의 어느 하나에 해당하는 경우에는\n\n이 동일한 의료기기로서 취소된 날로부터 1년이 지난 경우\n\n- 나. ",
        "original_sentence": "제품명을 기재하는 경우에는 “제조(수입)업소명·제품명”, “품목명”,\n- 다. "
      }
    },
    {
      "chunk_id": "chunk_355",
      "text": "동일제품에 대하여 두개 이상의 다른 상품명(또는 모델명) 부여는\n- 2. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 354,
        "window_size": 3,
        "char_count": 41,
        "word_count": 10,
        "page_number": 6,
        "window_text": "제조(수입)업소명·제품명, 품목류명, 모델명을 각각 기재한다.\n - 가.  제품명을 기재하는 경우에는 “제조(수입)업소명·제품명”, “품목명”,\n- 다.  동일제품에 대하여 두개 이상의 다른 상품명(또는 모델명) 부여는\n- 2.  제품명은 이미 허가(신고)를 받거나 받았었던 의료기기의 제품명과 동\n일하여서는 아니 된다.  다만, 다음의 어느 하나에 해당하는 경우에는\n\n이 동일한 의료기기로서 취소된 날로부터 1년이 지난 경우\n\n- 나.  동일한 제조(수입)업자가 허가(신고) 취하 후 동일한 제품을 허가(신\n고)하는 경우\n\n- 다. ",
        "original_sentence": "동일제품에 대하여 두개 이상의 다른 상품명(또는 모델명) 부여는\n- 2. "
      }
    },
    {
      "chunk_id": "chunk_356",
      "text": "제품명은 이미 허가(신고)를 받거나 받았었던 의료기기의 제품명과 동\n일하여서는 아니 된다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 355,
        "window_size": 3,
        "char_count": 51,
        "word_count": 11,
        "page_number": 79,
        "window_text": "- 가.  제품명을 기재하는 경우에는 “제조(수입)업소명·제품명”, “품목명”,\n- 다.  동일제품에 대하여 두개 이상의 다른 상품명(또는 모델명) 부여는\n- 2.  제품명은 이미 허가(신고)를 받거나 받았었던 의료기기의 제품명과 동\n일하여서는 아니 된다.  다만, 다음의 어느 하나에 해당하는 경우에는\n\n이 동일한 의료기기로서 취소된 날로부터 1년이 지난 경우\n\n- 나.  동일한 제조(수입)업자가 허가(신고) 취하 후 동일한 제품을 허가(신\n고)하는 경우\n\n- 다.  서로 다른 수입업자가 제조원이 같은 동일한 제품을 수입하는 경\n우에 수입업소명을 병기하여 구분하는 경우\n\n※ 다만, 기허가 제품과 사용목적이 유사하여 허가받은 제품의 제품명\n\n에 문자, 단어, 숫자 등을 덧붙이거나 교체한 제품명 기재 가능함.\n\n",
        "original_sentence": "제품명은 이미 허가(신고)를 받거나 받았었던 의료기기의 제품명과 동\n일하여서는 아니 된다. "
      }
    },
    {
      "chunk_id": "chunk_357",
      "text": "다만, 다음의 어느 하나에 해당하는 경우에는\n\n이 동일한 의료기기로서 취소된 날로부터 1년이 지난 경우\n\n- 나. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 356,
        "window_size": 3,
        "char_count": 64,
        "word_count": 16,
        "page_number": 21,
        "window_text": "제품명을 기재하는 경우에는 “제조(수입)업소명·제품명”, “품목명”,\n- 다.  동일제품에 대하여 두개 이상의 다른 상품명(또는 모델명) 부여는\n- 2.  제품명은 이미 허가(신고)를 받거나 받았었던 의료기기의 제품명과 동\n일하여서는 아니 된다.  다만, 다음의 어느 하나에 해당하는 경우에는\n\n이 동일한 의료기기로서 취소된 날로부터 1년이 지난 경우\n\n- 나.  동일한 제조(수입)업자가 허가(신고) 취하 후 동일한 제품을 허가(신\n고)하는 경우\n\n- 다.  서로 다른 수입업자가 제조원이 같은 동일한 제품을 수입하는 경\n우에 수입업소명을 병기하여 구분하는 경우\n\n※ 다만, 기허가 제품과 사용목적이 유사하여 허가받은 제품의 제품명\n\n에 문자, 단어, 숫자 등을 덧붙이거나 교체한 제품명 기재 가능함.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 18 -\n- (주)오송진단\n심질환표지자검사시약\n\nBNP Test\n\n⇩\n\n⇩\n\n⇩\n\n(제조․수입업소명)\n\n(품목명)\n\n(모델명)\n\n※ 별첨 기재시의 예\n\n<!-- PAGE_24 -->\n###### 2\n\n<!-- PAGE_24 -->\n###### 모양 및 구조\n\n- 1. ",
        "original_sentence": "다만, 다음의 어느 하나에 해당하는 경우에는\n\n이 동일한 의료기기로서 취소된 날로부터 1년이 지난 경우\n\n- 나. "
      }
    },
    {
      "chunk_id": "chunk_358",
      "text": "동일한 제조(수입)업자가 허가(신고) 취하 후 동일한 제품을 허가(신\n고)하는 경우\n\n- 다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 357,
        "window_size": 3,
        "char_count": 53,
        "word_count": 12,
        "page_number": 23,
        "window_text": "동일제품에 대하여 두개 이상의 다른 상품명(또는 모델명) 부여는\n- 2.  제품명은 이미 허가(신고)를 받거나 받았었던 의료기기의 제품명과 동\n일하여서는 아니 된다.  다만, 다음의 어느 하나에 해당하는 경우에는\n\n이 동일한 의료기기로서 취소된 날로부터 1년이 지난 경우\n\n- 나.  동일한 제조(수입)업자가 허가(신고) 취하 후 동일한 제품을 허가(신\n고)하는 경우\n\n- 다.  서로 다른 수입업자가 제조원이 같은 동일한 제품을 수입하는 경\n우에 수입업소명을 병기하여 구분하는 경우\n\n※ 다만, 기허가 제품과 사용목적이 유사하여 허가받은 제품의 제품명\n\n에 문자, 단어, 숫자 등을 덧붙이거나 교체한 제품명 기재 가능함.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 18 -\n- (주)오송진단\n심질환표지자검사시약\n\nBNP Test\n\n⇩\n\n⇩\n\n⇩\n\n(제조․수입업소명)\n\n(품목명)\n\n(모델명)\n\n※ 별첨 기재시의 예\n\n<!-- PAGE_24 -->\n###### 2\n\n<!-- PAGE_24 -->\n###### 모양 및 구조\n\n- 1.  모양 및 구조 - 작용원리\n제품의 용도 및 배경을 포함하여, 해당 제품을 개발하기 위하여 적용한\n\n측정원리, 적용되는 체외진단의료기기, 필요한 경우 검사 결과의 임상적\n\n의의 등을 포함하여 기재한다.\n\n",
        "original_sentence": "동일한 제조(수입)업자가 허가(신고) 취하 후 동일한 제품을 허가(신\n고)하는 경우\n\n- 다. "
      }
    },
    {
      "chunk_id": "chunk_359",
      "text": "서로 다른 수입업자가 제조원이 같은 동일한 제품을 수입하는 경\n우에 수입업소명을 병기하여 구분하는 경우\n\n※ 다만, 기허가 제품과 사용목적이 유사하여 허가받은 제품의 제품명\n\n에 문자, 단어, 숫자 등을 덧붙이거나 교체한 제품명 기재 가능함.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 358,
        "window_size": 3,
        "char_count": 137,
        "word_count": 33,
        "page_number": 1,
        "window_text": "제품명은 이미 허가(신고)를 받거나 받았었던 의료기기의 제품명과 동\n일하여서는 아니 된다.  다만, 다음의 어느 하나에 해당하는 경우에는\n\n이 동일한 의료기기로서 취소된 날로부터 1년이 지난 경우\n\n- 나.  동일한 제조(수입)업자가 허가(신고) 취하 후 동일한 제품을 허가(신\n고)하는 경우\n\n- 다.  서로 다른 수입업자가 제조원이 같은 동일한 제품을 수입하는 경\n우에 수입업소명을 병기하여 구분하는 경우\n\n※ 다만, 기허가 제품과 사용목적이 유사하여 허가받은 제품의 제품명\n\n에 문자, 단어, 숫자 등을 덧붙이거나 교체한 제품명 기재 가능함.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 18 -\n- (주)오송진단\n심질환표지자검사시약\n\nBNP Test\n\n⇩\n\n⇩\n\n⇩\n\n(제조․수입업소명)\n\n(품목명)\n\n(모델명)\n\n※ 별첨 기재시의 예\n\n<!-- PAGE_24 -->\n###### 2\n\n<!-- PAGE_24 -->\n###### 모양 및 구조\n\n- 1.  모양 및 구조 - 작용원리\n제품의 용도 및 배경을 포함하여, 해당 제품을 개발하기 위하여 적용한\n\n측정원리, 적용되는 체외진단의료기기, 필요한 경우 검사 결과의 임상적\n\n의의 등을 포함하여 기재한다.\n\n - 가. ",
        "original_sentence": "서로 다른 수입업자가 제조원이 같은 동일한 제품을 수입하는 경\n우에 수입업소명을 병기하여 구분하는 경우\n\n※ 다만, 기허가 제품과 사용목적이 유사하여 허가받은 제품의 제품명\n\n에 문자, 단어, 숫자 등을 덧붙이거나 교체한 제품명 기재 가능함.\n\n"
      }
    },
    {
      "chunk_id": "chunk_360",
      "text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 18 -\n- (주)오송진단\n심질환표지자검사시약\n\nBNP Test\n\n⇩\n\n⇩\n\n⇩\n\n(제조․수입업소명)\n\n(품목명)\n\n(모델명)\n\n※ 별첨 기재시의 예\n\n<!-- PAGE_24 -->\n###### 2\n\n<!-- PAGE_24 -->\n###### 모양 및 구조\n\n- 1. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 359,
        "window_size": 3,
        "char_count": 203,
        "word_count": 41,
        "page_number": 24,
        "window_text": "다만, 다음의 어느 하나에 해당하는 경우에는\n\n이 동일한 의료기기로서 취소된 날로부터 1년이 지난 경우\n\n- 나.  동일한 제조(수입)업자가 허가(신고) 취하 후 동일한 제품을 허가(신\n고)하는 경우\n\n- 다.  서로 다른 수입업자가 제조원이 같은 동일한 제품을 수입하는 경\n우에 수입업소명을 병기하여 구분하는 경우\n\n※ 다만, 기허가 제품과 사용목적이 유사하여 허가받은 제품의 제품명\n\n에 문자, 단어, 숫자 등을 덧붙이거나 교체한 제품명 기재 가능함.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 18 -\n- (주)오송진단\n심질환표지자검사시약\n\nBNP Test\n\n⇩\n\n⇩\n\n⇩\n\n(제조․수입업소명)\n\n(품목명)\n\n(모델명)\n\n※ 별첨 기재시의 예\n\n<!-- PAGE_24 -->\n###### 2\n\n<!-- PAGE_24 -->\n###### 모양 및 구조\n\n- 1.  모양 및 구조 - 작용원리\n제품의 용도 및 배경을 포함하여, 해당 제품을 개발하기 위하여 적용한\n\n측정원리, 적용되는 체외진단의료기기, 필요한 경우 검사 결과의 임상적\n\n의의 등을 포함하여 기재한다.\n\n - 가.  임상적 의의(배경) : 필요에 따라 해당 검사의 임상적 의의(배경)\n등을 기재할 수 있다.\n\n",
        "original_sentence": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 18 -\n- (주)오송진단\n심질환표지자검사시약\n\nBNP Test\n\n⇩\n\n⇩\n\n⇩\n\n(제조․수입업소명)\n\n(품목명)\n\n(모델명)\n\n※ 별첨 기재시의 예\n\n<!-- PAGE_24 -->\n###### 2\n\n<!-- PAGE_24 -->\n###### 모양 및 구조\n\n- 1. "
      }
    },
    {
      "chunk_id": "chunk_361",
      "text": "모양 및 구조 - 작용원리\n제품의 용도 및 배경을 포함하여, 해당 제품을 개발하기 위하여 적용한\n\n측정원리, 적용되는 체외진단의료기기, 필요한 경우 검사 결과의 임상적\n\n의의 등을 포함하여 기재한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 360,
        "window_size": 3,
        "char_count": 113,
        "word_count": 27,
        "page_number": 24,
        "window_text": "동일한 제조(수입)업자가 허가(신고) 취하 후 동일한 제품을 허가(신\n고)하는 경우\n\n- 다.  서로 다른 수입업자가 제조원이 같은 동일한 제품을 수입하는 경\n우에 수입업소명을 병기하여 구분하는 경우\n\n※ 다만, 기허가 제품과 사용목적이 유사하여 허가받은 제품의 제품명\n\n에 문자, 단어, 숫자 등을 덧붙이거나 교체한 제품명 기재 가능함.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 18 -\n- (주)오송진단\n심질환표지자검사시약\n\nBNP Test\n\n⇩\n\n⇩\n\n⇩\n\n(제조․수입업소명)\n\n(품목명)\n\n(모델명)\n\n※ 별첨 기재시의 예\n\n<!-- PAGE_24 -->\n###### 2\n\n<!-- PAGE_24 -->\n###### 모양 및 구조\n\n- 1.  모양 및 구조 - 작용원리\n제품의 용도 및 배경을 포함하여, 해당 제품을 개발하기 위하여 적용한\n\n측정원리, 적용되는 체외진단의료기기, 필요한 경우 검사 결과의 임상적\n\n의의 등을 포함하여 기재한다.\n\n - 가.  임상적 의의(배경) : 필요에 따라 해당 검사의 임상적 의의(배경)\n등을 기재할 수 있다.\n\n Ⅴ. ",
        "original_sentence": "모양 및 구조 - 작용원리\n제품의 용도 및 배경을 포함하여, 해당 제품을 개발하기 위하여 적용한\n\n측정원리, 적용되는 체외진단의료기기, 필요한 경우 검사 결과의 임상적\n\n의의 등을 포함하여 기재한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_362",
      "text": "- 가. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 361,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 74,
        "window_text": "서로 다른 수입업자가 제조원이 같은 동일한 제품을 수입하는 경\n우에 수입업소명을 병기하여 구분하는 경우\n\n※ 다만, 기허가 제품과 사용목적이 유사하여 허가받은 제품의 제품명\n\n에 문자, 단어, 숫자 등을 덧붙이거나 교체한 제품명 기재 가능함.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 18 -\n- (주)오송진단\n심질환표지자검사시약\n\nBNP Test\n\n⇩\n\n⇩\n\n⇩\n\n(제조․수입업소명)\n\n(품목명)\n\n(모델명)\n\n※ 별첨 기재시의 예\n\n<!-- PAGE_24 -->\n###### 2\n\n<!-- PAGE_24 -->\n###### 모양 및 구조\n\n- 1.  모양 및 구조 - 작용원리\n제품의 용도 및 배경을 포함하여, 해당 제품을 개발하기 위하여 적용한\n\n측정원리, 적용되는 체외진단의료기기, 필요한 경우 검사 결과의 임상적\n\n의의 등을 포함하여 기재한다.\n\n - 가.  임상적 의의(배경) : 필요에 따라 해당 검사의 임상적 의의(배경)\n등을 기재할 수 있다.\n\n Ⅴ.  제조․수입허가 신청서 기재 항목\n\n- - 19 -\n※ 예시\n\n이 NT-proBNP 및 BNP 검사는 심장에 대한 혈역학적 부하를\n\n알 수 있는 바이오마커로 심장 근육층의 호르몬 활성화를 보여준다.\n\n",
        "original_sentence": "- 가. "
      }
    },
    {
      "chunk_id": "chunk_363",
      "text": "임상적 의의(배경) : 필요에 따라 해당 검사의 임상적 의의(배경)\n등을 기재할 수 있다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 362,
        "window_size": 3,
        "char_count": 52,
        "word_count": 13,
        "page_number": 11,
        "window_text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 18 -\n- (주)오송진단\n심질환표지자검사시약\n\nBNP Test\n\n⇩\n\n⇩\n\n⇩\n\n(제조․수입업소명)\n\n(품목명)\n\n(모델명)\n\n※ 별첨 기재시의 예\n\n<!-- PAGE_24 -->\n###### 2\n\n<!-- PAGE_24 -->\n###### 모양 및 구조\n\n- 1.  모양 및 구조 - 작용원리\n제품의 용도 및 배경을 포함하여, 해당 제품을 개발하기 위하여 적용한\n\n측정원리, 적용되는 체외진단의료기기, 필요한 경우 검사 결과의 임상적\n\n의의 등을 포함하여 기재한다.\n\n - 가.  임상적 의의(배경) : 필요에 따라 해당 검사의 임상적 의의(배경)\n등을 기재할 수 있다.\n\n Ⅴ.  제조․수입허가 신청서 기재 항목\n\n- - 19 -\n※ 예시\n\n이 NT-proBNP 및 BNP 검사는 심장에 대한 혈역학적 부하를\n\n알 수 있는 바이오마커로 심장 근육층의 호르몬 활성화를 보여준다.\n\n NT-proBNP과 BNP 물질은 혈역학적 부하로 좌심실이 비대해\n\n- 2. ",
        "original_sentence": "임상적 의의(배경) : 필요에 따라 해당 검사의 임상적 의의(배경)\n등을 기재할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_364",
      "text": "Ⅴ. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 363,
        "window_size": 3,
        "char_count": 3,
        "word_count": 1,
        "page_number": 6,
        "window_text": "모양 및 구조 - 작용원리\n제품의 용도 및 배경을 포함하여, 해당 제품을 개발하기 위하여 적용한\n\n측정원리, 적용되는 체외진단의료기기, 필요한 경우 검사 결과의 임상적\n\n의의 등을 포함하여 기재한다.\n\n - 가.  임상적 의의(배경) : 필요에 따라 해당 검사의 임상적 의의(배경)\n등을 기재할 수 있다.\n\n Ⅴ.  제조․수입허가 신청서 기재 항목\n\n- - 19 -\n※ 예시\n\n이 NT-proBNP 및 BNP 검사는 심장에 대한 혈역학적 부하를\n\n알 수 있는 바이오마커로 심장 근육층의 호르몬 활성화를 보여준다.\n\n NT-proBNP과 BNP 물질은 혈역학적 부하로 좌심실이 비대해\n\n- 2.  모양 및 구조 - 외형\n- 가. ",
        "original_sentence": "Ⅴ. "
      }
    },
    {
      "chunk_id": "chunk_365",
      "text": "제조․수입허가 신청서 기재 항목\n\n- - 19 -\n※ 예시\n\n이 NT-proBNP 및 BNP 검사는 심장에 대한 혈역학적 부하를\n\n알 수 있는 바이오마커로 심장 근육층의 호르몬 활성화를 보여준다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 364,
        "window_size": 3,
        "char_count": 111,
        "word_count": 28,
        "page_number": 3,
        "window_text": "- 가.  임상적 의의(배경) : 필요에 따라 해당 검사의 임상적 의의(배경)\n등을 기재할 수 있다.\n\n Ⅴ.  제조․수입허가 신청서 기재 항목\n\n- - 19 -\n※ 예시\n\n이 NT-proBNP 및 BNP 검사는 심장에 대한 혈역학적 부하를\n\n알 수 있는 바이오마커로 심장 근육층의 호르몬 활성화를 보여준다.\n\n NT-proBNP과 BNP 물질은 혈역학적 부하로 좌심실이 비대해\n\n- 2.  모양 및 구조 - 외형\n- 가.  외형사진 : 제품을 육안으로 식별할 수 있도록 제품의 전체 및\n각각의 반응 영역에서는 측정하고자 하는 물질과 형광 항체\n\n접합체의 혼합물이 검출된다.\n\n",
        "original_sentence": "제조․수입허가 신청서 기재 항목\n\n- - 19 -\n※ 예시\n\n이 NT-proBNP 및 BNP 검사는 심장에 대한 혈역학적 부하를\n\n알 수 있는 바이오마커로 심장 근육층의 호르몬 활성화를 보여준다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_366",
      "text": "NT-proBNP과 BNP 물질은 혈역학적 부하로 좌심실이 비대해\n\n- 2. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 365,
        "window_size": 3,
        "char_count": 43,
        "word_count": 9,
        "page_number": 6,
        "window_text": "임상적 의의(배경) : 필요에 따라 해당 검사의 임상적 의의(배경)\n등을 기재할 수 있다.\n\n Ⅴ.  제조․수입허가 신청서 기재 항목\n\n- - 19 -\n※ 예시\n\n이 NT-proBNP 및 BNP 검사는 심장에 대한 혈역학적 부하를\n\n알 수 있는 바이오마커로 심장 근육층의 호르몬 활성화를 보여준다.\n\n NT-proBNP과 BNP 물질은 혈역학적 부하로 좌심실이 비대해\n\n- 2.  모양 및 구조 - 외형\n- 가.  외형사진 : 제품을 육안으로 식별할 수 있도록 제품의 전체 및\n각각의 반응 영역에서는 측정하고자 하는 물질과 형광 항체\n\n접합체의 혼합물이 검출된다.\n\n 3) 형광 발색량은 검체 중 분석물의 농도와 정비례 한다.\n\n",
        "original_sentence": "NT-proBNP과 BNP 물질은 혈역학적 부하로 좌심실이 비대해\n\n- 2. "
      }
    },
    {
      "chunk_id": "chunk_367",
      "text": "모양 및 구조 - 외형\n- 가. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 366,
        "window_size": 3,
        "char_count": 18,
        "word_count": 7,
        "page_number": 24,
        "window_text": "Ⅴ.  제조․수입허가 신청서 기재 항목\n\n- - 19 -\n※ 예시\n\n이 NT-proBNP 및 BNP 검사는 심장에 대한 혈역학적 부하를\n\n알 수 있는 바이오마커로 심장 근육층의 호르몬 활성화를 보여준다.\n\n NT-proBNP과 BNP 물질은 혈역학적 부하로 좌심실이 비대해\n\n- 2.  모양 및 구조 - 외형\n- 가.  외형사진 : 제품을 육안으로 식별할 수 있도록 제품의 전체 및\n각각의 반응 영역에서는 측정하고자 하는 물질과 형광 항체\n\n접합체의 혼합물이 검출된다.\n\n 3) 형광 발색량은 검체 중 분석물의 농도와 정비례 한다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 20 -\n구성하는 시약을 확인할 수 있는 컬러사진을 첨부한다.\n\n",
        "original_sentence": "모양 및 구조 - 외형\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_368",
      "text": "외형사진 : 제품을 육안으로 식별할 수 있도록 제품의 전체 및\n각각의 반응 영역에서는 측정하고자 하는 물질과 형광 항체\n\n접합체의 혼합물이 검출된다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 367,
        "window_size": 3,
        "char_count": 85,
        "word_count": 21,
        "page_number": 14,
        "window_text": "제조․수입허가 신청서 기재 항목\n\n- - 19 -\n※ 예시\n\n이 NT-proBNP 및 BNP 검사는 심장에 대한 혈역학적 부하를\n\n알 수 있는 바이오마커로 심장 근육층의 호르몬 활성화를 보여준다.\n\n NT-proBNP과 BNP 물질은 혈역학적 부하로 좌심실이 비대해\n\n- 2.  모양 및 구조 - 외형\n- 가.  외형사진 : 제품을 육안으로 식별할 수 있도록 제품의 전체 및\n각각의 반응 영역에서는 측정하고자 하는 물질과 형광 항체\n\n접합체의 혼합물이 검출된다.\n\n 3) 형광 발색량은 검체 중 분석물의 농도와 정비례 한다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 20 -\n구성하는 시약을 확인할 수 있는 컬러사진을 첨부한다.\n\n - 나. ",
        "original_sentence": "외형사진 : 제품을 육안으로 식별할 수 있도록 제품의 전체 및\n각각의 반응 영역에서는 측정하고자 하는 물질과 형광 항체\n\n접합체의 혼합물이 검출된다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_369",
      "text": "3) 형광 발색량은 검체 중 분석물의 농도와 정비례 한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 368,
        "window_size": 3,
        "char_count": 34,
        "word_count": 9,
        "page_number": 25,
        "window_text": "NT-proBNP과 BNP 물질은 혈역학적 부하로 좌심실이 비대해\n\n- 2.  모양 및 구조 - 외형\n- 가.  외형사진 : 제품을 육안으로 식별할 수 있도록 제품의 전체 및\n각각의 반응 영역에서는 측정하고자 하는 물질과 형광 항체\n\n접합체의 혼합물이 검출된다.\n\n 3) 형광 발색량은 검체 중 분석물의 농도와 정비례 한다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 20 -\n구성하는 시약을 확인할 수 있는 컬러사진을 첨부한다.\n\n - 나.  외관설명 : 고형의 구성제품에 대해서는 모양․구조․중량 등을, 액상\n또는 분말의 시약에 대해서는 색, 성상, 액성, 냄새 등을\n\n기재한다.\n\n",
        "original_sentence": "3) 형광 발색량은 검체 중 분석물의 농도와 정비례 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_370",
      "text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 20 -\n구성하는 시약을 확인할 수 있는 컬러사진을 첨부한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 369,
        "window_size": 3,
        "char_count": 89,
        "word_count": 19,
        "page_number": 1,
        "window_text": "모양 및 구조 - 외형\n- 가.  외형사진 : 제품을 육안으로 식별할 수 있도록 제품의 전체 및\n각각의 반응 영역에서는 측정하고자 하는 물질과 형광 항체\n\n접합체의 혼합물이 검출된다.\n\n 3) 형광 발색량은 검체 중 분석물의 농도와 정비례 한다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 20 -\n구성하는 시약을 확인할 수 있는 컬러사진을 첨부한다.\n\n - 나.  외관설명 : 고형의 구성제품에 대해서는 모양․구조․중량 등을, 액상\n또는 분말의 시약에 대해서는 색, 성상, 액성, 냄새 등을\n\n기재한다.\n\n - 다. ",
        "original_sentence": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 20 -\n구성하는 시약을 확인할 수 있는 컬러사진을 첨부한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_371",
      "text": "- 나. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 370,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 74,
        "window_text": "외형사진 : 제품을 육안으로 식별할 수 있도록 제품의 전체 및\n각각의 반응 영역에서는 측정하고자 하는 물질과 형광 항체\n\n접합체의 혼합물이 검출된다.\n\n 3) 형광 발색량은 검체 중 분석물의 농도와 정비례 한다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 20 -\n구성하는 시약을 확인할 수 있는 컬러사진을 첨부한다.\n\n - 나.  외관설명 : 고형의 구성제품에 대해서는 모양․구조․중량 등을, 액상\n또는 분말의 시약에 대해서는 색, 성상, 액성, 냄새 등을\n\n기재한다.\n\n - 다.  구성 : 만일 체외진단용 의료기기와 별도의 구성품을 포함하고자 할\n경우, 별도판매구성품에 대하여 추가로 외관사진 및 구성표를\n\nⅤ. ",
        "original_sentence": "- 나. "
      }
    },
    {
      "chunk_id": "chunk_372",
      "text": "외관설명 : 고형의 구성제품에 대해서는 모양․구조․중량 등을, 액상\n또는 분말의 시약에 대해서는 색, 성상, 액성, 냄새 등을\n\n기재한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 371,
        "window_size": 3,
        "char_count": 79,
        "word_count": 18,
        "page_number": 79,
        "window_text": "3) 형광 발색량은 검체 중 분석물의 농도와 정비례 한다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 20 -\n구성하는 시약을 확인할 수 있는 컬러사진을 첨부한다.\n\n - 나.  외관설명 : 고형의 구성제품에 대해서는 모양․구조․중량 등을, 액상\n또는 분말의 시약에 대해서는 색, 성상, 액성, 냄새 등을\n\n기재한다.\n\n - 다.  구성 : 만일 체외진단용 의료기기와 별도의 구성품을 포함하고자 할\n경우, 별도판매구성품에 대하여 추가로 외관사진 및 구성표를\n\nⅤ.  제조․수입허가 신청서 기재 항목\n\n- - 21 -\n그림 1. ",
        "original_sentence": "외관설명 : 고형의 구성제품에 대해서는 모양․구조․중량 등을, 액상\n또는 분말의 시약에 대해서는 색, 성상, 액성, 냄새 등을\n\n기재한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_373",
      "text": "- 다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 372,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 74,
        "window_text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 20 -\n구성하는 시약을 확인할 수 있는 컬러사진을 첨부한다.\n\n - 나.  외관설명 : 고형의 구성제품에 대해서는 모양․구조․중량 등을, 액상\n또는 분말의 시약에 대해서는 색, 성상, 액성, 냄새 등을\n\n기재한다.\n\n - 다.  구성 : 만일 체외진단용 의료기기와 별도의 구성품을 포함하고자 할\n경우, 별도판매구성품에 대하여 추가로 외관사진 및 구성표를\n\nⅤ.  제조․수입허가 신청서 기재 항목\n\n- - 21 -\n그림 1.  외관사진 작성의 예\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 22 -\n<!-- PAGE_28 -->\n###### 3\n\n<!-- PAGE_28 -->\n###### 원재료\n\n- 1. ",
        "original_sentence": "- 다. "
      }
    },
    {
      "chunk_id": "chunk_374",
      "text": "구성 : 만일 체외진단용 의료기기와 별도의 구성품을 포함하고자 할\n경우, 별도판매구성품에 대하여 추가로 외관사진 및 구성표를\n\nⅤ. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 373,
        "window_size": 3,
        "char_count": 74,
        "word_count": 17,
        "page_number": 1,
        "window_text": "- 나.  외관설명 : 고형의 구성제품에 대해서는 모양․구조․중량 등을, 액상\n또는 분말의 시약에 대해서는 색, 성상, 액성, 냄새 등을\n\n기재한다.\n\n - 다.  구성 : 만일 체외진단용 의료기기와 별도의 구성품을 포함하고자 할\n경우, 별도판매구성품에 대하여 추가로 외관사진 및 구성표를\n\nⅤ.  제조․수입허가 신청서 기재 항목\n\n- - 21 -\n그림 1.  외관사진 작성의 예\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 22 -\n<!-- PAGE_28 -->\n###### 3\n\n<!-- PAGE_28 -->\n###### 원재료\n\n- 1.  원재료는 다음 양식의 표를 사용하여 기재한다.\n",
        "original_sentence": "구성 : 만일 체외진단용 의료기기와 별도의 구성품을 포함하고자 할\n경우, 별도판매구성품에 대하여 추가로 외관사진 및 구성표를\n\nⅤ. "
      }
    },
    {
      "chunk_id": "chunk_375",
      "text": "제조․수입허가 신청서 기재 항목\n\n- - 21 -\n그림 1. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 374,
        "window_size": 3,
        "char_count": 34,
        "word_count": 10,
        "page_number": 3,
        "window_text": "외관설명 : 고형의 구성제품에 대해서는 모양․구조․중량 등을, 액상\n또는 분말의 시약에 대해서는 색, 성상, 액성, 냄새 등을\n\n기재한다.\n\n - 다.  구성 : 만일 체외진단용 의료기기와 별도의 구성품을 포함하고자 할\n경우, 별도판매구성품에 대하여 추가로 외관사진 및 구성표를\n\nⅤ.  제조․수입허가 신청서 기재 항목\n\n- - 21 -\n그림 1.  외관사진 작성의 예\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 22 -\n<!-- PAGE_28 -->\n###### 3\n\n<!-- PAGE_28 -->\n###### 원재료\n\n- 1.  원재료는 다음 양식의 표를 사용하여 기재한다.\n ※ 별도판매구성품이 있을 경우에는 원재료를 함께 기재한다.\n\n",
        "original_sentence": "제조․수입허가 신청서 기재 항목\n\n- - 21 -\n그림 1. "
      }
    },
    {
      "chunk_id": "chunk_376",
      "text": "외관사진 작성의 예\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 22 -\n<!-- PAGE_28 -->\n###### 3\n\n<!-- PAGE_28 -->\n###### 원재료\n\n- 1. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 375,
        "window_size": 3,
        "char_count": 131,
        "word_count": 27,
        "page_number": 28,
        "window_text": "- 다.  구성 : 만일 체외진단용 의료기기와 별도의 구성품을 포함하고자 할\n경우, 별도판매구성품에 대하여 추가로 외관사진 및 구성표를\n\nⅤ.  제조․수입허가 신청서 기재 항목\n\n- - 21 -\n그림 1.  외관사진 작성의 예\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 22 -\n<!-- PAGE_28 -->\n###### 3\n\n<!-- PAGE_28 -->\n###### 원재료\n\n- 1.  원재료는 다음 양식의 표를 사용하여 기재한다.\n ※ 별도판매구성품이 있을 경우에는 원재료를 함께 기재한다.\n\n - 가. ",
        "original_sentence": "외관사진 작성의 예\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 22 -\n<!-- PAGE_28 -->\n###### 3\n\n<!-- PAGE_28 -->\n###### 원재료\n\n- 1. "
      }
    },
    {
      "chunk_id": "chunk_377",
      "text": "원재료는 다음 양식의 표를 사용하여 기재한다.\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 376,
        "window_size": 3,
        "char_count": 26,
        "word_count": 6,
        "page_number": 26,
        "window_text": "구성 : 만일 체외진단용 의료기기와 별도의 구성품을 포함하고자 할\n경우, 별도판매구성품에 대하여 추가로 외관사진 및 구성표를\n\nⅤ.  제조․수입허가 신청서 기재 항목\n\n- - 21 -\n그림 1.  외관사진 작성의 예\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 22 -\n<!-- PAGE_28 -->\n###### 3\n\n<!-- PAGE_28 -->\n###### 원재료\n\n- 1.  원재료는 다음 양식의 표를 사용하여 기재한다.\n ※ 별도판매구성품이 있을 경우에는 원재료를 함께 기재한다.\n\n - 가.  명칭 : 보조시약을 포함하여 해당 구성시약별로 일반명칭을 기재한다.\n",
        "original_sentence": "원재료는 다음 양식의 표를 사용하여 기재한다.\n"
      }
    },
    {
      "chunk_id": "chunk_378",
      "text": "※ 별도판매구성품이 있을 경우에는 원재료를 함께 기재한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 377,
        "window_size": 3,
        "char_count": 34,
        "word_count": 7,
        "page_number": 28,
        "window_text": "제조․수입허가 신청서 기재 항목\n\n- - 21 -\n그림 1.  외관사진 작성의 예\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 22 -\n<!-- PAGE_28 -->\n###### 3\n\n<!-- PAGE_28 -->\n###### 원재료\n\n- 1.  원재료는 다음 양식의 표를 사용하여 기재한다.\n ※ 별도판매구성품이 있을 경우에는 원재료를 함께 기재한다.\n\n - 가.  명칭 : 보조시약을 포함하여 해당 구성시약별로 일반명칭을 기재한다.\n 두 세트 이상이 함께 사용되어 하나의 사용목적을 달성하는\n\n- 다. ",
        "original_sentence": "※ 별도판매구성품이 있을 경우에는 원재료를 함께 기재한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_379",
      "text": "- 가. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 378,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 74,
        "window_text": "외관사진 작성의 예\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 22 -\n<!-- PAGE_28 -->\n###### 3\n\n<!-- PAGE_28 -->\n###### 원재료\n\n- 1.  원재료는 다음 양식의 표를 사용하여 기재한다.\n ※ 별도판매구성품이 있을 경우에는 원재료를 함께 기재한다.\n\n - 가.  명칭 : 보조시약을 포함하여 해당 구성시약별로 일반명칭을 기재한다.\n 두 세트 이상이 함께 사용되어 하나의 사용목적을 달성하는\n\n- 다.  원재료명 또는 성분명 : 각 구성 시약의 원재료명 또는 성분명을\n1) 반응주성분에 대하여 해당 분량을 명시하고 항체의 경우 가급적\n\n2) 제품의 특성에 따라 그 외의(반응보조제, 보존제, 반응안정제,\n\n반응정지제, 희석액 등) 성분은 적량으로 표시 가능\n\n3) 단위는 ml, v/v, w/v, w/w 등으로 기재하고 범위의 설정도 가능\n\n- 마. ",
        "original_sentence": "- 가. "
      }
    },
    {
      "chunk_id": "chunk_380",
      "text": "명칭 : 보조시약을 포함하여 해당 구성시약별로 일반명칭을 기재한다.\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 379,
        "window_size": 3,
        "char_count": 38,
        "word_count": 8,
        "page_number": 3,
        "window_text": "원재료는 다음 양식의 표를 사용하여 기재한다.\n ※ 별도판매구성품이 있을 경우에는 원재료를 함께 기재한다.\n\n - 가.  명칭 : 보조시약을 포함하여 해당 구성시약별로 일반명칭을 기재한다.\n 두 세트 이상이 함께 사용되어 하나의 사용목적을 달성하는\n\n- 다.  원재료명 또는 성분명 : 각 구성 시약의 원재료명 또는 성분명을\n1) 반응주성분에 대하여 해당 분량을 명시하고 항체의 경우 가급적\n\n2) 제품의 특성에 따라 그 외의(반응보조제, 보존제, 반응안정제,\n\n반응정지제, 희석액 등) 성분은 적량으로 표시 가능\n\n3) 단위는 ml, v/v, w/v, w/w 등으로 기재하고 범위의 설정도 가능\n\n- 마.  규격 : 원재료에 대한 규격이 있는 경우 당해 규격(KP, USP 등)\n을 기재하고 규격이 없는 경우 자사규격 등을 기재한다.\n\n",
        "original_sentence": "명칭 : 보조시약을 포함하여 해당 구성시약별로 일반명칭을 기재한다.\n"
      }
    },
    {
      "chunk_id": "chunk_381",
      "text": "두 세트 이상이 함께 사용되어 하나의 사용목적을 달성하는\n\n- 다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 380,
        "window_size": 3,
        "char_count": 38,
        "word_count": 10,
        "page_number": 28,
        "window_text": "※ 별도판매구성품이 있을 경우에는 원재료를 함께 기재한다.\n\n - 가.  명칭 : 보조시약을 포함하여 해당 구성시약별로 일반명칭을 기재한다.\n 두 세트 이상이 함께 사용되어 하나의 사용목적을 달성하는\n\n- 다.  원재료명 또는 성분명 : 각 구성 시약의 원재료명 또는 성분명을\n1) 반응주성분에 대하여 해당 분량을 명시하고 항체의 경우 가급적\n\n2) 제품의 특성에 따라 그 외의(반응보조제, 보존제, 반응안정제,\n\n반응정지제, 희석액 등) 성분은 적량으로 표시 가능\n\n3) 단위는 ml, v/v, w/v, w/w 등으로 기재하고 범위의 설정도 가능\n\n- 마.  규격 : 원재료에 대한 규격이 있는 경우 당해 규격(KP, USP 등)\n을 기재하고 규격이 없는 경우 자사규격 등을 기재한다.\n\n - 바. ",
        "original_sentence": "두 세트 이상이 함께 사용되어 하나의 사용목적을 달성하는\n\n- 다. "
      }
    },
    {
      "chunk_id": "chunk_382",
      "text": "원재료명 또는 성분명 : 각 구성 시약의 원재료명 또는 성분명을\n1) 반응주성분에 대하여 해당 분량을 명시하고 항체의 경우 가급적\n\n2) 제품의 특성에 따라 그 외의(반응보조제, 보존제, 반응안정제,\n\n반응정지제, 희석액 등) 성분은 적량으로 표시 가능\n\n3) 단위는 ml, v/v, w/v, w/w 등으로 기재하고 범위의 설정도 가능\n\n- 마. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 381,
        "window_size": 3,
        "char_count": 194,
        "word_count": 47,
        "page_number": 21,
        "window_text": "- 가.  명칭 : 보조시약을 포함하여 해당 구성시약별로 일반명칭을 기재한다.\n 두 세트 이상이 함께 사용되어 하나의 사용목적을 달성하는\n\n- 다.  원재료명 또는 성분명 : 각 구성 시약의 원재료명 또는 성분명을\n1) 반응주성분에 대하여 해당 분량을 명시하고 항체의 경우 가급적\n\n2) 제품의 특성에 따라 그 외의(반응보조제, 보존제, 반응안정제,\n\n반응정지제, 희석액 등) 성분은 적량으로 표시 가능\n\n3) 단위는 ml, v/v, w/v, w/w 등으로 기재하고 범위의 설정도 가능\n\n- 마.  규격 : 원재료에 대한 규격이 있는 경우 당해 규격(KP, USP 등)\n을 기재하고 규격이 없는 경우 자사규격 등을 기재한다.\n\n - 바.  비고 : 비고란에는 각 구성 시약의 총량 및 수량 등을 기재한다.\n",
        "original_sentence": "원재료명 또는 성분명 : 각 구성 시약의 원재료명 또는 성분명을\n1) 반응주성분에 대하여 해당 분량을 명시하고 항체의 경우 가급적\n\n2) 제품의 특성에 따라 그 외의(반응보조제, 보존제, 반응안정제,\n\n반응정지제, 희석액 등) 성분은 적량으로 표시 가능\n\n3) 단위는 ml, v/v, w/v, w/w 등으로 기재하고 범위의 설정도 가능\n\n- 마. "
      }
    },
    {
      "chunk_id": "chunk_383",
      "text": "규격 : 원재료에 대한 규격이 있는 경우 당해 규격(KP, USP 등)\n을 기재하고 규격이 없는 경우 자사규격 등을 기재한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 382,
        "window_size": 3,
        "char_count": 72,
        "word_count": 19,
        "page_number": 28,
        "window_text": "명칭 : 보조시약을 포함하여 해당 구성시약별로 일반명칭을 기재한다.\n 두 세트 이상이 함께 사용되어 하나의 사용목적을 달성하는\n\n- 다.  원재료명 또는 성분명 : 각 구성 시약의 원재료명 또는 성분명을\n1) 반응주성분에 대하여 해당 분량을 명시하고 항체의 경우 가급적\n\n2) 제품의 특성에 따라 그 외의(반응보조제, 보존제, 반응안정제,\n\n반응정지제, 희석액 등) 성분은 적량으로 표시 가능\n\n3) 단위는 ml, v/v, w/v, w/w 등으로 기재하고 범위의 설정도 가능\n\n- 마.  규격 : 원재료에 대한 규격이 있는 경우 당해 규격(KP, USP 등)\n을 기재하고 규격이 없는 경우 자사규격 등을 기재한다.\n\n - 바.  비고 : 비고란에는 각 구성 시약의 총량 및 수량 등을 기재한다.\n 일련\n\n번호\n\n명칭\n\n배합목적\n\n원재료명 또는\n\n성분명\n\n분량\n\n규격\n\n비고\n\nⅤ. ",
        "original_sentence": "규격 : 원재료에 대한 규격이 있는 경우 당해 규격(KP, USP 등)\n을 기재하고 규격이 없는 경우 자사규격 등을 기재한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_384",
      "text": "- 바. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 383,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 74,
        "window_text": "두 세트 이상이 함께 사용되어 하나의 사용목적을 달성하는\n\n- 다.  원재료명 또는 성분명 : 각 구성 시약의 원재료명 또는 성분명을\n1) 반응주성분에 대하여 해당 분량을 명시하고 항체의 경우 가급적\n\n2) 제품의 특성에 따라 그 외의(반응보조제, 보존제, 반응안정제,\n\n반응정지제, 희석액 등) 성분은 적량으로 표시 가능\n\n3) 단위는 ml, v/v, w/v, w/w 등으로 기재하고 범위의 설정도 가능\n\n- 마.  규격 : 원재료에 대한 규격이 있는 경우 당해 규격(KP, USP 등)\n을 기재하고 규격이 없는 경우 자사규격 등을 기재한다.\n\n - 바.  비고 : 비고란에는 각 구성 시약의 총량 및 수량 등을 기재한다.\n 일련\n\n번호\n\n명칭\n\n배합목적\n\n원재료명 또는\n\n성분명\n\n분량\n\n규격\n\n비고\n\nⅤ.  제조․수입허가 신청서 기재 항목\n\n- - 23 -\n표 1. ",
        "original_sentence": "- 바. "
      }
    },
    {
      "chunk_id": "chunk_385",
      "text": "비고 : 비고란에는 각 구성 시약의 총량 및 수량 등을 기재한다.\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 384,
        "window_size": 3,
        "char_count": 37,
        "word_count": 11,
        "page_number": 26,
        "window_text": "원재료명 또는 성분명 : 각 구성 시약의 원재료명 또는 성분명을\n1) 반응주성분에 대하여 해당 분량을 명시하고 항체의 경우 가급적\n\n2) 제품의 특성에 따라 그 외의(반응보조제, 보존제, 반응안정제,\n\n반응정지제, 희석액 등) 성분은 적량으로 표시 가능\n\n3) 단위는 ml, v/v, w/v, w/w 등으로 기재하고 범위의 설정도 가능\n\n- 마.  규격 : 원재료에 대한 규격이 있는 경우 당해 규격(KP, USP 등)\n을 기재하고 규격이 없는 경우 자사규격 등을 기재한다.\n\n - 바.  비고 : 비고란에는 각 구성 시약의 총량 및 수량 등을 기재한다.\n 일련\n\n번호\n\n명칭\n\n배합목적\n\n원재료명 또는\n\n성분명\n\n분량\n\n규격\n\n비고\n\nⅤ.  제조․수입허가 신청서 기재 항목\n\n- - 23 -\n표 1.  원재료 작성의 예\n\n- 1. ",
        "original_sentence": "비고 : 비고란에는 각 구성 시약의 총량 및 수량 등을 기재한다.\n"
      }
    },
    {
      "chunk_id": "chunk_386",
      "text": "일련\n\n번호\n\n명칭\n\n배합목적\n\n원재료명 또는\n\n성분명\n\n분량\n\n규격\n\n비고\n\nⅤ. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 385,
        "window_size": 3,
        "char_count": 47,
        "word_count": 11,
        "page_number": 3,
        "window_text": "규격 : 원재료에 대한 규격이 있는 경우 당해 규격(KP, USP 등)\n을 기재하고 규격이 없는 경우 자사규격 등을 기재한다.\n\n - 바.  비고 : 비고란에는 각 구성 시약의 총량 및 수량 등을 기재한다.\n 일련\n\n번호\n\n명칭\n\n배합목적\n\n원재료명 또는\n\n성분명\n\n분량\n\n규격\n\n비고\n\nⅤ.  제조․수입허가 신청서 기재 항목\n\n- - 23 -\n표 1.  원재료 작성의 예\n\n- 1.  체외진단용 의료기기 - proBNP test kit\n- 2. ",
        "original_sentence": "일련\n\n번호\n\n명칭\n\n배합목적\n\n원재료명 또는\n\n성분명\n\n분량\n\n규격\n\n비고\n\nⅤ. "
      }
    },
    {
      "chunk_id": "chunk_387",
      "text": "제조․수입허가 신청서 기재 항목\n\n- - 23 -\n표 1. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 386,
        "window_size": 3,
        "char_count": 33,
        "word_count": 10,
        "page_number": 3,
        "window_text": "- 바.  비고 : 비고란에는 각 구성 시약의 총량 및 수량 등을 기재한다.\n 일련\n\n번호\n\n명칭\n\n배합목적\n\n원재료명 또는\n\n성분명\n\n분량\n\n규격\n\n비고\n\nⅤ.  제조․수입허가 신청서 기재 항목\n\n- - 23 -\n표 1.  원재료 작성의 예\n\n- 1.  체외진단용 의료기기 - proBNP test kit\n- 2.  별도판매구성품 - proBNP CalSet\n**[표 시작]**\n\n| 일련 | 분량 |\n| --- | --- |\n| No | Device name | Company | Date | 메디안 (pg/mL) | 300 | 130 | 250 | 330 | 1530 | BAYER | HEALTHCARE, | LLC |\n| 번호 | 명칭 | 배합목적 | 원재료명 또는 성분명 | 음성 | 10 | 145 | w/v | 규격 | 비고 |\n| 4. ",
        "original_sentence": "제조․수입허가 신청서 기재 항목\n\n- - 23 -\n표 1. "
      }
    },
    {
      "chunk_id": "chunk_388",
      "text": "원재료 작성의 예\n\n- 1. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 387,
        "window_size": 3,
        "char_count": 16,
        "word_count": 5,
        "page_number": 21,
        "window_text": "비고 : 비고란에는 각 구성 시약의 총량 및 수량 등을 기재한다.\n 일련\n\n번호\n\n명칭\n\n배합목적\n\n원재료명 또는\n\n성분명\n\n분량\n\n규격\n\n비고\n\nⅤ.  제조․수입허가 신청서 기재 항목\n\n- - 23 -\n표 1.  원재료 작성의 예\n\n- 1.  체외진단용 의료기기 - proBNP test kit\n- 2.  별도판매구성품 - proBNP CalSet\n**[표 시작]**\n\n| 일련 | 분량 |\n| --- | --- |\n| No | Device name | Company | Date | 메디안 (pg/mL) | 300 | 130 | 250 | 330 | 1530 | BAYER | HEALTHCARE, | LLC |\n| 번호 | 명칭 | 배합목적 | 원재료명 또는 성분명 | 음성 | 10 | 145 | w/v | 규격 | 비고 |\n| 4.  시험자의 연구경력 | 다. ",
        "original_sentence": "원재료 작성의 예\n\n- 1. "
      }
    },
    {
      "chunk_id": "chunk_389",
      "text": "체외진단용 의료기기 - proBNP test kit\n- 2. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 388,
        "window_size": 3,
        "char_count": 34,
        "word_count": 8,
        "page_number": 1,
        "window_text": "일련\n\n번호\n\n명칭\n\n배합목적\n\n원재료명 또는\n\n성분명\n\n분량\n\n규격\n\n비고\n\nⅤ.  제조․수입허가 신청서 기재 항목\n\n- - 23 -\n표 1.  원재료 작성의 예\n\n- 1.  체외진단용 의료기기 - proBNP test kit\n- 2.  별도판매구성품 - proBNP CalSet\n**[표 시작]**\n\n| 일련 | 분량 |\n| --- | --- |\n| No | Device name | Company | Date | 메디안 (pg/mL) | 300 | 130 | 250 | 330 | 1530 | BAYER | HEALTHCARE, | LLC |\n| 번호 | 명칭 | 배합목적 | 원재료명 또는 성분명 | 음성 | 10 | 145 | w/v | 규격 | 비고 |\n| 4.  시험자의 연구경력 | 다.  시약의 표준화(standardization)를 위해 사용된 방법을 기술한다. ",
        "original_sentence": "체외진단용 의료기기 - proBNP test kit\n- 2. "
      }
    },
    {
      "chunk_id": "chunk_390",
      "text": "별도판매구성품 - proBNP CalSet\n**[표 시작]**\n\n| 일련 | 분량 |\n| --- | --- |\n| No | Device name | Company | Date | 메디안 (pg/mL) | 300 | 130 | 250 | 330 | 1530 | BAYER | HEALTHCARE, | LLC |\n| 번호 | 명칭 | 배합목적 | 원재료명 또는 성분명 | 음성 | 10 | 145 | w/v | 규격 | 비고 |\n| 4. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 389,
        "window_size": 3,
        "char_count": 243,
        "word_count": 70,
        "page_number": 14,
        "window_text": "제조․수입허가 신청서 기재 항목\n\n- - 23 -\n표 1.  원재료 작성의 예\n\n- 1.  체외진단용 의료기기 - proBNP test kit\n- 2.  별도판매구성품 - proBNP CalSet\n**[표 시작]**\n\n| 일련 | 분량 |\n| --- | --- |\n| No | Device name | Company | Date | 메디안 (pg/mL) | 300 | 130 | 250 | 330 | 1530 | BAYER | HEALTHCARE, | LLC |\n| 번호 | 명칭 | 배합목적 | 원재료명 또는 성분명 | 음성 | 10 | 145 | w/v | 규격 | 비고 |\n| 4.  시험자의 연구경력 | 다.  시약의 표준화(standardization)를 위해 사용된 방법을 기술한다.  | 제시한다. ",
        "original_sentence": "별도판매구성품 - proBNP CalSet\n**[표 시작]**\n\n| 일련 | 분량 |\n| --- | --- |\n| No | Device name | Company | Date | 메디안 (pg/mL) | 300 | 130 | 250 | 330 | 1530 | BAYER | HEALTHCARE, | LLC |\n| 번호 | 명칭 | 배합목적 | 원재료명 또는 성분명 | 음성 | 10 | 145 | w/v | 규격 | 비고 |\n| 4. "
      }
    },
    {
      "chunk_id": "chunk_391",
      "text": "시험자의 연구경력 | 다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 390,
        "window_size": 3,
        "char_count": 15,
        "word_count": 4,
        "page_number": 33,
        "window_text": "원재료 작성의 예\n\n- 1.  체외진단용 의료기기 - proBNP test kit\n- 2.  별도판매구성품 - proBNP CalSet\n**[표 시작]**\n\n| 일련 | 분량 |\n| --- | --- |\n| No | Device name | Company | Date | 메디안 (pg/mL) | 300 | 130 | 250 | 330 | 1530 | BAYER | HEALTHCARE, | LLC |\n| 번호 | 명칭 | 배합목적 | 원재료명 또는 성분명 | 음성 | 10 | 145 | w/v | 규격 | 비고 |\n| 4.  시험자의 연구경력 | 다.  시약의 표준화(standardization)를 위해 사용된 방법을 기술한다.  | 제시한다.  | 수행한 결과를 포함하여야 한다. ",
        "original_sentence": "시험자의 연구경력 | 다. "
      }
    },
    {
      "chunk_id": "chunk_392",
      "text": "시약의 표준화(standardization)를 위해 사용된 방법을 기술한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 391,
        "window_size": 3,
        "char_count": 43,
        "word_count": 6,
        "page_number": 14,
        "window_text": "체외진단용 의료기기 - proBNP test kit\n- 2.  별도판매구성품 - proBNP CalSet\n**[표 시작]**\n\n| 일련 | 분량 |\n| --- | --- |\n| No | Device name | Company | Date | 메디안 (pg/mL) | 300 | 130 | 250 | 330 | 1530 | BAYER | HEALTHCARE, | LLC |\n| 번호 | 명칭 | 배합목적 | 원재료명 또는 성분명 | 음성 | 10 | 145 | w/v | 규격 | 비고 |\n| 4.  시험자의 연구경력 | 다.  시약의 표준화(standardization)를 위해 사용된 방법을 기술한다.  | 제시한다.  | 수행한 결과를 포함하여야 한다.  | 5) 검사를 시행할 집단에서의 유병률을 평가할 것을 권장한다. ",
        "original_sentence": "시약의 표준화(standardization)를 위해 사용된 방법을 기술한다. "
      }
    },
    {
      "chunk_id": "chunk_393",
      "text": "| 제시한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 392,
        "window_size": 3,
        "char_count": 8,
        "word_count": 2,
        "page_number": 26,
        "window_text": "별도판매구성품 - proBNP CalSet\n**[표 시작]**\n\n| 일련 | 분량 |\n| --- | --- |\n| No | Device name | Company | Date | 메디안 (pg/mL) | 300 | 130 | 250 | 330 | 1530 | BAYER | HEALTHCARE, | LLC |\n| 번호 | 명칭 | 배합목적 | 원재료명 또는 성분명 | 음성 | 10 | 145 | w/v | 규격 | 비고 |\n| 4.  시험자의 연구경력 | 다.  시약의 표준화(standardization)를 위해 사용된 방법을 기술한다.  | 제시한다.  | 수행한 결과를 포함하여야 한다.  | 5) 검사를 시행할 집단에서의 유병률을 평가할 것을 권장한다.  | 한다. ",
        "original_sentence": "| 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_394",
      "text": "| 수행한 결과를 포함하여야 한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 393,
        "window_size": 3,
        "char_count": 20,
        "word_count": 5,
        "page_number": 56,
        "window_text": "시험자의 연구경력 | 다.  시약의 표준화(standardization)를 위해 사용된 방법을 기술한다.  | 제시한다.  | 수행한 결과를 포함하여야 한다.  | 5) 검사를 시행할 집단에서의 유병률을 평가할 것을 권장한다.  | 한다.  | 정보가 기재되어야 함 | 시기를 거친 다음 평가를 수행하도록 한다. ",
        "original_sentence": "| 수행한 결과를 포함하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_395",
      "text": "| 5) 검사를 시행할 집단에서의 유병률을 평가할 것을 권장한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 394,
        "window_size": 3,
        "char_count": 37,
        "word_count": 9,
        "page_number": 30,
        "window_text": "시약의 표준화(standardization)를 위해 사용된 방법을 기술한다.  | 제시한다.  | 수행한 결과를 포함하여야 한다.  | 5) 검사를 시행할 집단에서의 유병률을 평가할 것을 권장한다.  | 한다.  | 정보가 기재되어야 함 | 시기를 거친 다음 평가를 수행하도록 한다.  | laboratory) 자료를 제시한다. ",
        "original_sentence": "| 5) 검사를 시행할 집단에서의 유병률을 평가할 것을 권장한다. "
      }
    },
    {
      "chunk_id": "chunk_396",
      "text": "| 한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 395,
        "window_size": 3,
        "char_count": 6,
        "word_count": 2,
        "page_number": 56,
        "window_text": "| 제시한다.  | 수행한 결과를 포함하여야 한다.  | 5) 검사를 시행할 집단에서의 유병률을 평가할 것을 권장한다.  | 한다.  | 정보가 기재되어야 함 | 시기를 거친 다음 평가를 수행하도록 한다.  | laboratory) 자료를 제시한다.  | 검토하여 타당하다고 인정할 수 있는 시험성적서 | 기준치 미만)으로 나오는 환자의 비율이다. ",
        "original_sentence": "| 한다. "
      }
    },
    {
      "chunk_id": "chunk_397",
      "text": "| 정보가 기재되어야 함 | 시기를 거친 다음 평가를 수행하도록 한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 396,
        "window_size": 3,
        "char_count": 40,
        "word_count": 11,
        "page_number": 47,
        "window_text": "| 수행한 결과를 포함하여야 한다.  | 5) 검사를 시행할 집단에서의 유병률을 평가할 것을 권장한다.  | 한다.  | 정보가 기재되어야 함 | 시기를 거친 다음 평가를 수행하도록 한다.  | laboratory) 자료를 제시한다.  | 검토하여 타당하다고 인정할 수 있는 시험성적서 | 기준치 미만)으로 나오는 환자의 비율이다.  | Human Serum 2 | 120.7 | 14.2 | 2.4 | 0.28 | 2.0 | 평균 (pg/mL) | 570 | 300 | 430 | 650 | 1630 |\n| 1) 다양한 농도를 포함한 양성 임상검체를 이용하여 평가한다. ",
        "original_sentence": "| 정보가 기재되어야 함 | 시기를 거친 다음 평가를 수행하도록 한다. "
      }
    },
    {
      "chunk_id": "chunk_398",
      "text": "| laboratory) 자료를 제시한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 397,
        "window_size": 3,
        "char_count": 24,
        "word_count": 4,
        "page_number": 14,
        "window_text": "| 5) 검사를 시행할 집단에서의 유병률을 평가할 것을 권장한다.  | 한다.  | 정보가 기재되어야 함 | 시기를 거친 다음 평가를 수행하도록 한다.  | laboratory) 자료를 제시한다.  | 검토하여 타당하다고 인정할 수 있는 시험성적서 | 기준치 미만)으로 나오는 환자의 비율이다.  | Human Serum 2 | 120.7 | 14.2 | 2.4 | 0.28 | 2.0 | 평균 (pg/mL) | 570 | 300 | 430 | 650 | 1630 |\n| 1) 다양한 농도를 포함한 양성 임상검체를 이용하여 평가한다.  | 레닌 | 50ng/mL | 104% | 심장질환 치료제 등 |\n| 가. ",
        "original_sentence": "| laboratory) 자료를 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_399",
      "text": "| 검토하여 타당하다고 인정할 수 있는 시험성적서 | 기준치 미만)으로 나오는 환자의 비율이다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 398,
        "window_size": 3,
        "char_count": 54,
        "word_count": 13,
        "page_number": 33,
        "window_text": "| 한다.  | 정보가 기재되어야 함 | 시기를 거친 다음 평가를 수행하도록 한다.  | laboratory) 자료를 제시한다.  | 검토하여 타당하다고 인정할 수 있는 시험성적서 | 기준치 미만)으로 나오는 환자의 비율이다.  | Human Serum 2 | 120.7 | 14.2 | 2.4 | 0.28 | 2.0 | 평균 (pg/mL) | 570 | 300 | 430 | 650 | 1630 |\n| 1) 다양한 농도를 포함한 양성 임상검체를 이용하여 평가한다.  | 레닌 | 50ng/mL | 104% | 심장질환 치료제 등 |\n| 가.  체외진단용으로 사용해야 함을 명시한다. ",
        "original_sentence": "| 검토하여 타당하다고 인정할 수 있는 시험성적서 | 기준치 미만)으로 나오는 환자의 비율이다. "
      }
    },
    {
      "chunk_id": "chunk_400",
      "text": "| Human Serum 2 | 120.7 | 14.2 | 2.4 | 0.28 | 2.0 | 평균 (pg/mL) | 570 | 300 | 430 | 650 | 1630 |\n| 1) 다양한 농도를 포함한 양성 임상검체를 이용하여 평가한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 399,
        "window_size": 3,
        "char_count": 133,
        "word_count": 37,
        "page_number": 6,
        "window_text": "| 정보가 기재되어야 함 | 시기를 거친 다음 평가를 수행하도록 한다.  | laboratory) 자료를 제시한다.  | 검토하여 타당하다고 인정할 수 있는 시험성적서 | 기준치 미만)으로 나오는 환자의 비율이다.  | Human Serum 2 | 120.7 | 14.2 | 2.4 | 0.28 | 2.0 | 평균 (pg/mL) | 570 | 300 | 430 | 650 | 1630 |\n| 1) 다양한 농도를 포함한 양성 임상검체를 이용하여 평가한다.  | 레닌 | 50ng/mL | 104% | 심장질환 치료제 등 |\n| 가.  체외진단용으로 사용해야 함을 명시한다.  | 가. ",
        "original_sentence": "| Human Serum 2 | 120.7 | 14.2 | 2.4 | 0.28 | 2.0 | 평균 (pg/mL) | 570 | 300 | 430 | 650 | 1630 |\n| 1) 다양한 농도를 포함한 양성 임상검체를 이용하여 평가한다. "
      }
    },
    {
      "chunk_id": "chunk_401",
      "text": "| 레닌 | 50ng/mL | 104% | 심장질환 치료제 등 |\n| 가. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 400,
        "window_size": 3,
        "char_count": 42,
        "word_count": 13,
        "page_number": 6,
        "window_text": "| laboratory) 자료를 제시한다.  | 검토하여 타당하다고 인정할 수 있는 시험성적서 | 기준치 미만)으로 나오는 환자의 비율이다.  | Human Serum 2 | 120.7 | 14.2 | 2.4 | 0.28 | 2.0 | 평균 (pg/mL) | 570 | 300 | 430 | 650 | 1630 |\n| 1) 다양한 농도를 포함한 양성 임상검체를 이용하여 평가한다.  | 레닌 | 50ng/mL | 104% | 심장질환 치료제 등 |\n| 가.  체외진단용으로 사용해야 함을 명시한다.  | 가.  해당시약의 성분과 분량을 확인할 수 있는 자료 | 가. ",
        "original_sentence": "| 레닌 | 50ng/mL | 104% | 심장질환 치료제 등 |\n| 가. "
      }
    },
    {
      "chunk_id": "chunk_402",
      "text": "체외진단용으로 사용해야 함을 명시한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 401,
        "window_size": 3,
        "char_count": 22,
        "word_count": 4,
        "page_number": 40,
        "window_text": "| 검토하여 타당하다고 인정할 수 있는 시험성적서 | 기준치 미만)으로 나오는 환자의 비율이다.  | Human Serum 2 | 120.7 | 14.2 | 2.4 | 0.28 | 2.0 | 평균 (pg/mL) | 570 | 300 | 430 | 650 | 1630 |\n| 1) 다양한 농도를 포함한 양성 임상검체를 이용하여 평가한다.  | 레닌 | 50ng/mL | 104% | 심장질환 치료제 등 |\n| 가.  체외진단용으로 사용해야 함을 명시한다.  | 가.  해당시약의 성분과 분량을 확인할 수 있는 자료 | 가.  분석적 성능시험에 관한 자료(시험성적서) | 제출한다. ",
        "original_sentence": "체외진단용으로 사용해야 함을 명시한다. "
      }
    },
    {
      "chunk_id": "chunk_403",
      "text": "| 가. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 402,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 1,
        "window_text": "| Human Serum 2 | 120.7 | 14.2 | 2.4 | 0.28 | 2.0 | 평균 (pg/mL) | 570 | 300 | 430 | 650 | 1630 |\n| 1) 다양한 농도를 포함한 양성 임상검체를 이용하여 평가한다.  | 레닌 | 50ng/mL | 104% | 심장질환 치료제 등 |\n| 가.  체외진단용으로 사용해야 함을 명시한다.  | 가.  해당시약의 성분과 분량을 확인할 수 있는 자료 | 가.  분석적 성능시험에 관한 자료(시험성적서) | 제출한다.  | 하는 경우에는 해당사항을 부가하여 기재한다. ",
        "original_sentence": "| 가. "
      }
    },
    {
      "chunk_id": "chunk_404",
      "text": "해당시약의 성분과 분량을 확인할 수 있는 자료 | 가. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 403,
        "window_size": 3,
        "char_count": 31,
        "word_count": 9,
        "page_number": 19,
        "window_text": "| 레닌 | 50ng/mL | 104% | 심장질환 치료제 등 |\n| 가.  체외진단용으로 사용해야 함을 명시한다.  | 가.  해당시약의 성분과 분량을 확인할 수 있는 자료 | 가.  분석적 성능시험에 관한 자료(시험성적서) | 제출한다.  | 하는 경우에는 해당사항을 부가하여 기재한다.  | 주성분 | Streptavidin-coated | Human Serum 3 | 358.7 | 42 | 6.43 | 0.75 | 1.8 |\n| SD (pg/mL) | 770 | 380 | 540 | 830 | 1050 |\n| ELECSYS PROBNP II STAT | IMMUNOASSAY AND ELECSYS | PROBNP II CALSET | Human Serum 4 | 794.7 | 93.5 | 14.9 | 1.76 | 1.9 | microparticles | 2 | 자사규격 | ROCHE | DIAGNOSTICS | CORP |\n| 나. ",
        "original_sentence": "해당시약의 성분과 분량을 확인할 수 있는 자료 | 가. "
      }
    },
    {
      "chunk_id": "chunk_405",
      "text": "분석적 성능시험에 관한 자료(시험성적서) | 제출한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 404,
        "window_size": 3,
        "char_count": 31,
        "word_count": 6,
        "page_number": 7,
        "window_text": "체외진단용으로 사용해야 함을 명시한다.  | 가.  해당시약의 성분과 분량을 확인할 수 있는 자료 | 가.  분석적 성능시험에 관한 자료(시험성적서) | 제출한다.  | 하는 경우에는 해당사항을 부가하여 기재한다.  | 주성분 | Streptavidin-coated | Human Serum 3 | 358.7 | 42 | 6.43 | 0.75 | 1.8 |\n| SD (pg/mL) | 770 | 380 | 540 | 830 | 1050 |\n| ELECSYS PROBNP II STAT | IMMUNOASSAY AND ELECSYS | PROBNP II CALSET | Human Serum 4 | 794.7 | 93.5 | 14.9 | 1.76 | 1.9 | microparticles | 2 | 자사규격 | ROCHE | DIAGNOSTICS | CORP |\n| 나.  가능한 2개 이상의 회사 제품과 비교시험 할 것을 권장한다. ",
        "original_sentence": "분석적 성능시험에 관한 자료(시험성적서) | 제출한다. "
      }
    },
    {
      "chunk_id": "chunk_406",
      "text": "| 하는 경우에는 해당사항을 부가하여 기재한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 405,
        "window_size": 3,
        "char_count": 27,
        "word_count": 6,
        "page_number": 3,
        "window_text": "| 가.  해당시약의 성분과 분량을 확인할 수 있는 자료 | 가.  분석적 성능시험에 관한 자료(시험성적서) | 제출한다.  | 하는 경우에는 해당사항을 부가하여 기재한다.  | 주성분 | Streptavidin-coated | Human Serum 3 | 358.7 | 42 | 6.43 | 0.75 | 1.8 |\n| SD (pg/mL) | 770 | 380 | 540 | 830 | 1050 |\n| ELECSYS PROBNP II STAT | IMMUNOASSAY AND ELECSYS | PROBNP II CALSET | Human Serum 4 | 794.7 | 93.5 | 14.9 | 1.76 | 1.9 | microparticles | 2 | 자사규격 | ROCHE | DIAGNOSTICS | CORP |\n| 나.  가능한 2개 이상의 회사 제품과 비교시험 할 것을 권장한다.  | Laboratory Standard Institute; 2010 | 4) 시험자의 연구경력 | 않는 성능 배제, 구체적 근거 자료로 제시 | 평가한다. ",
        "original_sentence": "| 하는 경우에는 해당사항을 부가하여 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_407",
      "text": "| 주성분 | Streptavidin-coated | Human Serum 3 | 358.7 | 42 | 6.43 | 0.75 | 1.8 |\n| SD (pg/mL) | 770 | 380 | 540 | 830 | 1050 |\n| ELECSYS PROBNP II STAT | IMMUNOASSAY AND ELECSYS | PROBNP II CALSET | Human Serum 4 | 794.7 | 93.5 | 14.9 | 1.76 | 1.9 | microparticles | 2 | 자사규격 | ROCHE | DIAGNOSTICS | CORP |\n| 나. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 406,
        "window_size": 3,
        "char_count": 310,
        "word_count": 75,
        "page_number": 6,
        "window_text": "해당시약의 성분과 분량을 확인할 수 있는 자료 | 가.  분석적 성능시험에 관한 자료(시험성적서) | 제출한다.  | 하는 경우에는 해당사항을 부가하여 기재한다.  | 주성분 | Streptavidin-coated | Human Serum 3 | 358.7 | 42 | 6.43 | 0.75 | 1.8 |\n| SD (pg/mL) | 770 | 380 | 540 | 830 | 1050 |\n| ELECSYS PROBNP II STAT | IMMUNOASSAY AND ELECSYS | PROBNP II CALSET | Human Serum 4 | 794.7 | 93.5 | 14.9 | 1.76 | 1.9 | microparticles | 2 | 자사규격 | ROCHE | DIAGNOSTICS | CORP |\n| 나.  가능한 2개 이상의 회사 제품과 비교시험 할 것을 권장한다.  | Laboratory Standard Institute; 2010 | 4) 시험자의 연구경력 | 않는 성능 배제, 구체적 근거 자료로 제시 | 평가한다.  | 동등성을 먼저 확인해야 한다. ",
        "original_sentence": "| 주성분 | Streptavidin-coated | Human Serum 3 | 358.7 | 42 | 6.43 | 0.75 | 1.8 |\n| SD (pg/mL) | 770 | 380 | 540 | 830 | 1050 |\n| ELECSYS PROBNP II STAT | IMMUNOASSAY AND ELECSYS | PROBNP II CALSET | Human Serum 4 | 794.7 | 93.5 | 14.9 | 1.76 | 1.9 | microparticles | 2 | 자사규격 | ROCHE | DIAGNOSTICS | CORP |\n| 나. "
      }
    },
    {
      "chunk_id": "chunk_408",
      "text": "가능한 2개 이상의 회사 제품과 비교시험 할 것을 권장한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 407,
        "window_size": 3,
        "char_count": 34,
        "word_count": 9,
        "page_number": 6,
        "window_text": "분석적 성능시험에 관한 자료(시험성적서) | 제출한다.  | 하는 경우에는 해당사항을 부가하여 기재한다.  | 주성분 | Streptavidin-coated | Human Serum 3 | 358.7 | 42 | 6.43 | 0.75 | 1.8 |\n| SD (pg/mL) | 770 | 380 | 540 | 830 | 1050 |\n| ELECSYS PROBNP II STAT | IMMUNOASSAY AND ELECSYS | PROBNP II CALSET | Human Serum 4 | 794.7 | 93.5 | 14.9 | 1.76 | 1.9 | microparticles | 2 | 자사규격 | ROCHE | DIAGNOSTICS | CORP |\n| 나.  가능한 2개 이상의 회사 제품과 비교시험 할 것을 권장한다.  | Laboratory Standard Institute; 2010 | 4) 시험자의 연구경력 | 않는 성능 배제, 구체적 근거 자료로 제시 | 평가한다.  | 동등성을 먼저 확인해야 한다.  | 종류, 검체수, 반복회수, 계산법을 함께 제시한다. ",
        "original_sentence": "가능한 2개 이상의 회사 제품과 비교시험 할 것을 권장한다. "
      }
    },
    {
      "chunk_id": "chunk_409",
      "text": "| Laboratory Standard Institute; 2010 | 4) 시험자의 연구경력 | 않는 성능 배제, 구체적 근거 자료로 제시 | 평가한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 408,
        "window_size": 3,
        "char_count": 87,
        "word_count": 19,
        "page_number": 6,
        "window_text": "| 하는 경우에는 해당사항을 부가하여 기재한다.  | 주성분 | Streptavidin-coated | Human Serum 3 | 358.7 | 42 | 6.43 | 0.75 | 1.8 |\n| SD (pg/mL) | 770 | 380 | 540 | 830 | 1050 |\n| ELECSYS PROBNP II STAT | IMMUNOASSAY AND ELECSYS | PROBNP II CALSET | Human Serum 4 | 794.7 | 93.5 | 14.9 | 1.76 | 1.9 | microparticles | 2 | 자사규격 | ROCHE | DIAGNOSTICS | CORP |\n| 나.  가능한 2개 이상의 회사 제품과 비교시험 할 것을 권장한다.  | Laboratory Standard Institute; 2010 | 4) 시험자의 연구경력 | 않는 성능 배제, 구체적 근거 자료로 제시 | 평가한다.  | 동등성을 먼저 확인해야 한다.  | 종류, 검체수, 반복회수, 계산법을 함께 제시한다.  | 거칠 것을 권장한다. ",
        "original_sentence": "| Laboratory Standard Institute; 2010 | 4) 시험자의 연구경력 | 않는 성능 배제, 구체적 근거 자료로 제시 | 평가한다. "
      }
    },
    {
      "chunk_id": "chunk_410",
      "text": "| 동등성을 먼저 확인해야 한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 409,
        "window_size": 3,
        "char_count": 19,
        "word_count": 5,
        "page_number": 19,
        "window_text": "| 주성분 | Streptavidin-coated | Human Serum 3 | 358.7 | 42 | 6.43 | 0.75 | 1.8 |\n| SD (pg/mL) | 770 | 380 | 540 | 830 | 1050 |\n| ELECSYS PROBNP II STAT | IMMUNOASSAY AND ELECSYS | PROBNP II CALSET | Human Serum 4 | 794.7 | 93.5 | 14.9 | 1.76 | 1.9 | microparticles | 2 | 자사규격 | ROCHE | DIAGNOSTICS | CORP |\n| 나.  가능한 2개 이상의 회사 제품과 비교시험 할 것을 권장한다.  | Laboratory Standard Institute; 2010 | 4) 시험자의 연구경력 | 않는 성능 배제, 구체적 근거 자료로 제시 | 평가한다.  | 동등성을 먼저 확인해야 한다.  | 종류, 검체수, 반복회수, 계산법을 함께 제시한다.  | 거칠 것을 권장한다.  | 수도 있다. ",
        "original_sentence": "| 동등성을 먼저 확인해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_411",
      "text": "| 종류, 검체수, 반복회수, 계산법을 함께 제시한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 410,
        "window_size": 3,
        "char_count": 31,
        "word_count": 7,
        "page_number": 26,
        "window_text": "가능한 2개 이상의 회사 제품과 비교시험 할 것을 권장한다.  | Laboratory Standard Institute; 2010 | 4) 시험자의 연구경력 | 않는 성능 배제, 구체적 근거 자료로 제시 | 평가한다.  | 동등성을 먼저 확인해야 한다.  | 종류, 검체수, 반복회수, 계산법을 함께 제시한다.  | 거칠 것을 권장한다.  | 수도 있다.  측정은 각 농도별로 2-4회 반복 측정한다. ",
        "original_sentence": "| 종류, 검체수, 반복회수, 계산법을 함께 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_412",
      "text": "| 거칠 것을 권장한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 411,
        "window_size": 3,
        "char_count": 14,
        "word_count": 4,
        "page_number": 56,
        "window_text": "| Laboratory Standard Institute; 2010 | 4) 시험자의 연구경력 | 않는 성능 배제, 구체적 근거 자료로 제시 | 평가한다.  | 동등성을 먼저 확인해야 한다.  | 종류, 검체수, 반복회수, 계산법을 함께 제시한다.  | 거칠 것을 권장한다.  | 수도 있다.  측정은 각 농도별로 2-4회 반복 측정한다.  | 5th Percentile | 14 | 9 | 15 | 12 | 188 | 알도스테론 | 1μg/ml | 104% | BIO-RAD | LABORATORIES | , INC. ",
        "original_sentence": "| 거칠 것을 권장한다. "
      }
    },
    {
      "chunk_id": "chunk_413",
      "text": "| 수도 있다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 412,
        "window_size": 3,
        "char_count": 9,
        "word_count": 3,
        "page_number": 11,
        "window_text": "| 동등성을 먼저 확인해야 한다.  | 종류, 검체수, 반복회수, 계산법을 함께 제시한다.  | 거칠 것을 권장한다.  | 수도 있다.  측정은 각 농도별로 2-4회 반복 측정한다.  | 5th Percentile | 14 | 9 | 15 | 12 | 188 | 알도스테론 | 1μg/ml | 104% | BIO-RAD | LABORATORIES | , INC.  |\n| 나. ",
        "original_sentence": "| 수도 있다. "
      }
    },
    {
      "chunk_id": "chunk_414",
      "text": "측정은 각 농도별로 2-4회 반복 측정한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 413,
        "window_size": 3,
        "char_count": 25,
        "word_count": 6,
        "page_number": 6,
        "window_text": "| 종류, 검체수, 반복회수, 계산법을 함께 제시한다.  | 거칠 것을 권장한다.  | 수도 있다.  측정은 각 농도별로 2-4회 반복 측정한다.  | 5th Percentile | 14 | 9 | 15 | 12 | 188 | 알도스테론 | 1μg/ml | 104% | BIO-RAD | LABORATORIES | , INC.  |\n| 나.  분석적 성능시험에 관한 자료에는 다음의 평가항목을 포함한다. ",
        "original_sentence": "측정은 각 농도별로 2-4회 반복 측정한다. "
      }
    },
    {
      "chunk_id": "chunk_415",
      "text": "| 5th Percentile | 14 | 9 | 15 | 12 | 188 | 알도스테론 | 1μg/ml | 104% | BIO-RAD | LABORATORIES | , INC. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 414,
        "window_size": 3,
        "char_count": 100,
        "word_count": 26,
        "page_number": 6,
        "window_text": "| 거칠 것을 권장한다.  | 수도 있다.  측정은 각 농도별로 2-4회 반복 측정한다.  | 5th Percentile | 14 | 9 | 15 | 12 | 188 | 알도스테론 | 1μg/ml | 104% | BIO-RAD | LABORATORIES | , INC.  |\n| 나.  분석적 성능시험에 관한 자료에는 다음의 평가항목을 포함한다.  | 자료를 제출하여야 한다. ",
        "original_sentence": "| 5th Percentile | 14 | 9 | 15 | 12 | 188 | 알도스테론 | 1μg/ml | 104% | BIO-RAD | LABORATORIES | , INC. "
      }
    },
    {
      "chunk_id": "chunk_416",
      "text": "|\n| 나. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 415,
        "window_size": 3,
        "char_count": 7,
        "word_count": 3,
        "page_number": 1,
        "window_text": "| 수도 있다.  측정은 각 농도별로 2-4회 반복 측정한다.  | 5th Percentile | 14 | 9 | 15 | 12 | 188 | 알도스테론 | 1μg/ml | 104% | BIO-RAD | LABORATORIES | , INC.  |\n| 나.  분석적 성능시험에 관한 자료에는 다음의 평가항목을 포함한다.  | 자료를 제출하여야 한다.  |\n| 6 | 상관성 평가 |\n| 번호 | 성능항목 | 방법 및 결과 |\n| MEIA | AxSYM BNP  IMMUNOASSAY | Abbott | UK |\n| 1 | 분석적 성능시험에 관한 자료 |\n| 5 | 사용목적(성능) |\n| 1 | 개발경위, 측정원리·방법 및 국내․외 사용현황에 관한 자료 |\n| ELFA | VIDAS NT-proBNP | bioMerieux | France |\n| 2 | 임상적 성능시험에 관한 자료 |\n**일련**\n| 번호 | 명칭 | 배합목적 | 원재료명 또는 성분명 |\n**(우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187.",
        "original_sentence": "|\n| 나. "
      }
    },
    {
      "chunk_id": "chunk_417",
      "text": "분석적 성능시험에 관한 자료에는 다음의 평가항목을 포함한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 416,
        "window_size": 3,
        "char_count": 34,
        "word_count": 7,
        "page_number": 3,
        "window_text": "측정은 각 농도별로 2-4회 반복 측정한다.  | 5th Percentile | 14 | 9 | 15 | 12 | 188 | 알도스테론 | 1μg/ml | 104% | BIO-RAD | LABORATORIES | , INC.  |\n| 나.  분석적 성능시험에 관한 자료에는 다음의 평가항목을 포함한다.  | 자료를 제출하여야 한다.  |\n| 6 | 상관성 평가 |\n| 번호 | 성능항목 | 방법 및 결과 |\n| MEIA | AxSYM BNP  IMMUNOASSAY | Abbott | UK |\n| 1 | 분석적 성능시험에 관한 자료 |\n| 5 | 사용목적(성능) |\n| 1 | 개발경위, 측정원리·방법 및 국내․외 사용현황에 관한 자료 |\n| ELFA | VIDAS NT-proBNP | bioMerieux | France |\n| 2 | 임상적 성능시험에 관한 자료 |\n**일련**\n| 번호 | 명칭 | 배합목적 | 원재료명 또는 성분명 |\n**(우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187. **\n**HF-REF의 진단을 위해서는 3개의 조건이 충족되어야 한다:**\n| 3 | 사용목적에 관한 자료 | 1. ",
        "original_sentence": "분석적 성능시험에 관한 자료에는 다음의 평가항목을 포함한다. "
      }
    },
    {
      "chunk_id": "chunk_418",
      "text": "| 자료를 제출하여야 한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 417,
        "window_size": 3,
        "char_count": 16,
        "word_count": 4,
        "page_number": 56,
        "window_text": "| 5th Percentile | 14 | 9 | 15 | 12 | 188 | 알도스테론 | 1μg/ml | 104% | BIO-RAD | LABORATORIES | , INC.  |\n| 나.  분석적 성능시험에 관한 자료에는 다음의 평가항목을 포함한다.  | 자료를 제출하여야 한다.  |\n| 6 | 상관성 평가 |\n| 번호 | 성능항목 | 방법 및 결과 |\n| MEIA | AxSYM BNP  IMMUNOASSAY | Abbott | UK |\n| 1 | 분석적 성능시험에 관한 자료 |\n| 5 | 사용목적(성능) |\n| 1 | 개발경위, 측정원리·방법 및 국내․외 사용현황에 관한 자료 |\n| ELFA | VIDAS NT-proBNP | bioMerieux | France |\n| 2 | 임상적 성능시험에 관한 자료 |\n**일련**\n| 번호 | 명칭 | 배합목적 | 원재료명 또는 성분명 |\n**(우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187. **\n**HF-REF의 진단을 위해서는 3개의 조건이 충족되어야 한다:**\n| 3 | 사용목적에 관한 자료 | 1.  HF에 전형적인 증상들 |\n| 6 | 체외진단용 의료기기의 취급자 안전에 관한 자료 |\n| 안정성을 보장한다면 냉동검체를 일부 이용할 수도 있다. ",
        "original_sentence": "| 자료를 제출하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_419",
      "text": "|\n| 6 | 상관성 평가 |\n| 번호 | 성능항목 | 방법 및 결과 |\n| MEIA | AxSYM BNP  IMMUNOASSAY | Abbott | UK |\n| 1 | 분석적 성능시험에 관한 자료 |\n| 5 | 사용목적(성능) |\n| 1 | 개발경위, 측정원리·방법 및 국내․외 사용현황에 관한 자료 |\n| ELFA | VIDAS NT-proBNP | bioMerieux | France |\n| 2 | 임상적 성능시험에 관한 자료 |\n**일련**\n| 번호 | 명칭 | 배합목적 | 원재료명 또는 성분명 |\n**(우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187.",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 418,
        "window_size": 3,
        "char_count": 325,
        "word_count": 90,
        "page_number": 3,
        "window_text": "|\n| 나.  분석적 성능시험에 관한 자료에는 다음의 평가항목을 포함한다.  | 자료를 제출하여야 한다.  |\n| 6 | 상관성 평가 |\n| 번호 | 성능항목 | 방법 및 결과 |\n| MEIA | AxSYM BNP  IMMUNOASSAY | Abbott | UK |\n| 1 | 분석적 성능시험에 관한 자료 |\n| 5 | 사용목적(성능) |\n| 1 | 개발경위, 측정원리·방법 및 국내․외 사용현황에 관한 자료 |\n| ELFA | VIDAS NT-proBNP | bioMerieux | France |\n| 2 | 임상적 성능시험에 관한 자료 |\n**일련**\n| 번호 | 명칭 | 배합목적 | 원재료명 또는 성분명 |\n**(우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187. **\n**HF-REF의 진단을 위해서는 3개의 조건이 충족되어야 한다:**\n| 3 | 사용목적에 관한 자료 | 1.  HF에 전형적인 증상들 |\n| 6 | 체외진단용 의료기기의 취급자 안전에 관한 자료 |\n| 안정성을 보장한다면 냉동검체를 일부 이용할 수도 있다.  | TEL : 043-719-4652~4665  FAX : 043-719-4650 |\n| 2. ",
        "original_sentence": "|\n| 6 | 상관성 평가 |\n| 번호 | 성능항목 | 방법 및 결과 |\n| MEIA | AxSYM BNP  IMMUNOASSAY | Abbott | UK |\n| 1 | 분석적 성능시험에 관한 자료 |\n| 5 | 사용목적(성능) |\n| 1 | 개발경위, 측정원리·방법 및 국내․외 사용현황에 관한 자료 |\n| ELFA | VIDAS NT-proBNP | bioMerieux | France |\n| 2 | 임상적 성능시험에 관한 자료 |\n**일련**\n| 번호 | 명칭 | 배합목적 | 원재료명 또는 성분명 |\n**(우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187."
      }
    },
    {
      "chunk_id": "chunk_420",
      "text": "**\n**HF-REF의 진단을 위해서는 3개의 조건이 충족되어야 한다:**\n| 3 | 사용목적에 관한 자료 | 1. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 419,
        "window_size": 3,
        "char_count": 65,
        "word_count": 16,
        "page_number": 26,
        "window_text": "분석적 성능시험에 관한 자료에는 다음의 평가항목을 포함한다.  | 자료를 제출하여야 한다.  |\n| 6 | 상관성 평가 |\n| 번호 | 성능항목 | 방법 및 결과 |\n| MEIA | AxSYM BNP  IMMUNOASSAY | Abbott | UK |\n| 1 | 분석적 성능시험에 관한 자료 |\n| 5 | 사용목적(성능) |\n| 1 | 개발경위, 측정원리·방법 및 국내․외 사용현황에 관한 자료 |\n| ELFA | VIDAS NT-proBNP | bioMerieux | France |\n| 2 | 임상적 성능시험에 관한 자료 |\n**일련**\n| 번호 | 명칭 | 배합목적 | 원재료명 또는 성분명 |\n**(우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187. **\n**HF-REF의 진단을 위해서는 3개의 조건이 충족되어야 한다:**\n| 3 | 사용목적에 관한 자료 | 1.  HF에 전형적인 증상들 |\n| 6 | 체외진단용 의료기기의 취급자 안전에 관한 자료 |\n| 안정성을 보장한다면 냉동검체를 일부 이용할 수도 있다.  | TEL : 043-719-4652~4665  FAX : 043-719-4650 |\n| 2.  HF에 전형적인 증후들 | 1) 식약처장이 지정한 시험검사기관에서 발급한 시험성적서 | 시험 | 보조성분 | Buffer | 적량 | 자사규격 | 최대 (pg/mL) | >4000 | 1600 | >4000 | >4000 | >4000 | 아테놀롤 | 이소소르비드 | 디나이트레이트 | 퀴니딘 |\n| 10 | 시험규격 | 예 | □ | 1) 시험시설개요 |\n| 래된 검체를 대상으로 시험한 자료를 제출한다. ",
        "original_sentence": "**\n**HF-REF의 진단을 위해서는 3개의 조건이 충족되어야 한다:**\n| 3 | 사용목적에 관한 자료 | 1. "
      }
    },
    {
      "chunk_id": "chunk_421",
      "text": "HF에 전형적인 증상들 |\n| 6 | 체외진단용 의료기기의 취급자 안전에 관한 자료 |\n| 안정성을 보장한다면 냉동검체를 일부 이용할 수도 있다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 420,
        "window_size": 3,
        "char_count": 82,
        "word_count": 22,
        "page_number": 1,
        "window_text": "| 자료를 제출하여야 한다.  |\n| 6 | 상관성 평가 |\n| 번호 | 성능항목 | 방법 및 결과 |\n| MEIA | AxSYM BNP  IMMUNOASSAY | Abbott | UK |\n| 1 | 분석적 성능시험에 관한 자료 |\n| 5 | 사용목적(성능) |\n| 1 | 개발경위, 측정원리·방법 및 국내․외 사용현황에 관한 자료 |\n| ELFA | VIDAS NT-proBNP | bioMerieux | France |\n| 2 | 임상적 성능시험에 관한 자료 |\n**일련**\n| 번호 | 명칭 | 배합목적 | 원재료명 또는 성분명 |\n**(우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187. **\n**HF-REF의 진단을 위해서는 3개의 조건이 충족되어야 한다:**\n| 3 | 사용목적에 관한 자료 | 1.  HF에 전형적인 증상들 |\n| 6 | 체외진단용 의료기기의 취급자 안전에 관한 자료 |\n| 안정성을 보장한다면 냉동검체를 일부 이용할 수도 있다.  | TEL : 043-719-4652~4665  FAX : 043-719-4650 |\n| 2.  HF에 전형적인 증후들 | 1) 식약처장이 지정한 시험검사기관에서 발급한 시험성적서 | 시험 | 보조성분 | Buffer | 적량 | 자사규격 | 최대 (pg/mL) | >4000 | 1600 | >4000 | >4000 | >4000 | 아테놀롤 | 이소소르비드 | 디나이트레이트 | 퀴니딘 |\n| 10 | 시험규격 | 예 | □ | 1) 시험시설개요 |\n| 래된 검체를 대상으로 시험한 자료를 제출한다.  | 1) 시험물질 | 가) 판정기준치(농도) | 가) 검체 처치에 첨가된 물질(보존제, 안정제 등) | 분석법 등을 미리 확립한다. ",
        "original_sentence": "HF에 전형적인 증상들 |\n| 6 | 체외진단용 의료기기의 취급자 안전에 관한 자료 |\n| 안정성을 보장한다면 냉동검체를 일부 이용할 수도 있다. "
      }
    },
    {
      "chunk_id": "chunk_422",
      "text": "| TEL : 043-719-4652~4665  FAX : 043-719-4650 |\n| 2. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 421,
        "window_size": 3,
        "char_count": 53,
        "word_count": 10,
        "page_number": 6,
        "window_text": "|\n| 6 | 상관성 평가 |\n| 번호 | 성능항목 | 방법 및 결과 |\n| MEIA | AxSYM BNP  IMMUNOASSAY | Abbott | UK |\n| 1 | 분석적 성능시험에 관한 자료 |\n| 5 | 사용목적(성능) |\n| 1 | 개발경위, 측정원리·방법 및 국내․외 사용현황에 관한 자료 |\n| ELFA | VIDAS NT-proBNP | bioMerieux | France |\n| 2 | 임상적 성능시험에 관한 자료 |\n**일련**\n| 번호 | 명칭 | 배합목적 | 원재료명 또는 성분명 |\n**(우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187. **\n**HF-REF의 진단을 위해서는 3개의 조건이 충족되어야 한다:**\n| 3 | 사용목적에 관한 자료 | 1.  HF에 전형적인 증상들 |\n| 6 | 체외진단용 의료기기의 취급자 안전에 관한 자료 |\n| 안정성을 보장한다면 냉동검체를 일부 이용할 수도 있다.  | TEL : 043-719-4652~4665  FAX : 043-719-4650 |\n| 2.  HF에 전형적인 증후들 | 1) 식약처장이 지정한 시험검사기관에서 발급한 시험성적서 | 시험 | 보조성분 | Buffer | 적량 | 자사규격 | 최대 (pg/mL) | >4000 | 1600 | >4000 | >4000 | >4000 | 아테놀롤 | 이소소르비드 | 디나이트레이트 | 퀴니딘 |\n| 10 | 시험규격 | 예 | □ | 1) 시험시설개요 |\n| 래된 검체를 대상으로 시험한 자료를 제출한다.  | 1) 시험물질 | 가) 판정기준치(농도) | 가) 검체 처치에 첨가된 물질(보존제, 안정제 등) | 분석법 등을 미리 확립한다.  | 정밀도 | pro-Brain Natriuretic Peptide | 의료기기심사부 체외진단기기과 | 이용하여 일치성을 결정하였다. ",
        "original_sentence": "| TEL : 043-719-4652~4665  FAX : 043-719-4650 |\n| 2. "
      }
    },
    {
      "chunk_id": "chunk_423",
      "text": "HF에 전형적인 증후들 | 1) 식약처장이 지정한 시험검사기관에서 발급한 시험성적서 | 시험 | 보조성분 | Buffer | 적량 | 자사규격 | 최대 (pg/mL) | >4000 | 1600 | >4000 | >4000 | >4000 | 아테놀롤 | 이소소르비드 | 디나이트레이트 | 퀴니딘 |\n| 10 | 시험규격 | 예 | □ | 1) 시험시설개요 |\n| 래된 검체를 대상으로 시험한 자료를 제출한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 422,
        "window_size": 3,
        "char_count": 228,
        "word_count": 61,
        "page_number": 21,
        "window_text": "**\n**HF-REF의 진단을 위해서는 3개의 조건이 충족되어야 한다:**\n| 3 | 사용목적에 관한 자료 | 1.  HF에 전형적인 증상들 |\n| 6 | 체외진단용 의료기기의 취급자 안전에 관한 자료 |\n| 안정성을 보장한다면 냉동검체를 일부 이용할 수도 있다.  | TEL : 043-719-4652~4665  FAX : 043-719-4650 |\n| 2.  HF에 전형적인 증후들 | 1) 식약처장이 지정한 시험검사기관에서 발급한 시험성적서 | 시험 | 보조성분 | Buffer | 적량 | 자사규격 | 최대 (pg/mL) | >4000 | 1600 | >4000 | >4000 | >4000 | 아테놀롤 | 이소소르비드 | 디나이트레이트 | 퀴니딘 |\n| 10 | 시험규격 | 예 | □ | 1) 시험시설개요 |\n| 래된 검체를 대상으로 시험한 자료를 제출한다.  | 1) 시험물질 | 가) 판정기준치(농도) | 가) 검체 처치에 첨가된 물질(보존제, 안정제 등) | 분석법 등을 미리 확립한다.  | 정밀도 | pro-Brain Natriuretic Peptide | 의료기기심사부 체외진단기기과 | 이용하여 일치성을 결정하였다.  |\n| 1. ",
        "original_sentence": "HF에 전형적인 증후들 | 1) 식약처장이 지정한 시험검사기관에서 발급한 시험성적서 | 시험 | 보조성분 | Buffer | 적량 | 자사규격 | 최대 (pg/mL) | >4000 | 1600 | >4000 | >4000 | >4000 | 아테놀롤 | 이소소르비드 | 디나이트레이트 | 퀴니딘 |\n| 10 | 시험규격 | 예 | □ | 1) 시험시설개요 |\n| 래된 검체를 대상으로 시험한 자료를 제출한다. "
      }
    },
    {
      "chunk_id": "chunk_424",
      "text": "| 1) 시험물질 | 가) 판정기준치(농도) | 가) 검체 처치에 첨가된 물질(보존제, 안정제 등) | 분석법 등을 미리 확립한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 423,
        "window_size": 3,
        "char_count": 74,
        "word_count": 19,
        "page_number": 21,
        "window_text": "HF에 전형적인 증상들 |\n| 6 | 체외진단용 의료기기의 취급자 안전에 관한 자료 |\n| 안정성을 보장한다면 냉동검체를 일부 이용할 수도 있다.  | TEL : 043-719-4652~4665  FAX : 043-719-4650 |\n| 2.  HF에 전형적인 증후들 | 1) 식약처장이 지정한 시험검사기관에서 발급한 시험성적서 | 시험 | 보조성분 | Buffer | 적량 | 자사규격 | 최대 (pg/mL) | >4000 | 1600 | >4000 | >4000 | >4000 | 아테놀롤 | 이소소르비드 | 디나이트레이트 | 퀴니딘 |\n| 10 | 시험규격 | 예 | □ | 1) 시험시설개요 |\n| 래된 검체를 대상으로 시험한 자료를 제출한다.  | 1) 시험물질 | 가) 판정기준치(농도) | 가) 검체 처치에 첨가된 물질(보존제, 안정제 등) | 분석법 등을 미리 확립한다.  | 정밀도 | pro-Brain Natriuretic Peptide | 의료기기심사부 체외진단기기과 | 이용하여 일치성을 결정하였다.  |\n| 1.  시험시설개요 | 중복될 경우 이를 생략한다). ",
        "original_sentence": "| 1) 시험물질 | 가) 판정기준치(농도) | 가) 검체 처치에 첨가된 물질(보존제, 안정제 등) | 분석법 등을 미리 확립한다. "
      }
    },
    {
      "chunk_id": "chunk_425",
      "text": "| 정밀도 | pro-Brain Natriuretic Peptide | 의료기기심사부 체외진단기기과 | 이용하여 일치성을 결정하였다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 424,
        "window_size": 3,
        "char_count": 75,
        "word_count": 13,
        "page_number": 14,
        "window_text": "| TEL : 043-719-4652~4665  FAX : 043-719-4650 |\n| 2.  HF에 전형적인 증후들 | 1) 식약처장이 지정한 시험검사기관에서 발급한 시험성적서 | 시험 | 보조성분 | Buffer | 적량 | 자사규격 | 최대 (pg/mL) | >4000 | 1600 | >4000 | >4000 | >4000 | 아테놀롤 | 이소소르비드 | 디나이트레이트 | 퀴니딘 |\n| 10 | 시험규격 | 예 | □ | 1) 시험시설개요 |\n| 래된 검체를 대상으로 시험한 자료를 제출한다.  | 1) 시험물질 | 가) 판정기준치(농도) | 가) 검체 처치에 첨가된 물질(보존제, 안정제 등) | 분석법 등을 미리 확립한다.  | 정밀도 | pro-Brain Natriuretic Peptide | 의료기기심사부 체외진단기기과 | 이용하여 일치성을 결정하였다.  |\n| 1.  시험시설개요 | 중복될 경우 이를 생략한다).  | 보정물질 | proBNP (recombinant) | approx. ",
        "original_sentence": "| 정밀도 | pro-Brain Natriuretic Peptide | 의료기기심사부 체외진단기기과 | 이용하여 일치성을 결정하였다. "
      }
    },
    {
      "chunk_id": "chunk_426",
      "text": "|\n| 1. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 425,
        "window_size": 3,
        "char_count": 7,
        "word_count": 3,
        "page_number": 21,
        "window_text": "HF에 전형적인 증후들 | 1) 식약처장이 지정한 시험검사기관에서 발급한 시험성적서 | 시험 | 보조성분 | Buffer | 적량 | 자사규격 | 최대 (pg/mL) | >4000 | 1600 | >4000 | >4000 | >4000 | 아테놀롤 | 이소소르비드 | 디나이트레이트 | 퀴니딘 |\n| 10 | 시험규격 | 예 | □ | 1) 시험시설개요 |\n| 래된 검체를 대상으로 시험한 자료를 제출한다.  | 1) 시험물질 | 가) 판정기준치(농도) | 가) 검체 처치에 첨가된 물질(보존제, 안정제 등) | 분석법 등을 미리 확립한다.  | 정밀도 | pro-Brain Natriuretic Peptide | 의료기기심사부 체외진단기기과 | 이용하여 일치성을 결정하였다.  |\n| 1.  시험시설개요 | 중복될 경우 이를 생략한다).  | 보정물질 | proBNP (recombinant) | approx.  40 | 자사규격 | http://www.mfds.go.kr | 아니오 | □ |\n| 8 | 포장단위 | 황산수소클로피도그렐 | 밀리논유산염 | 트리메소프림 |\n| Vitros  NT-proBNP | J&J | USA | 2.5x |\n| 2 | Cal 2 | 3 | (반복, | 보조성분 | Human serum | 적량 | 자사규격 |\n\n**[표 끝]**\n\n1mL\n\n보조성분\n\nPhosphate buffer\n\n적량\n\n자사규격\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 24 -\n<!-- PAGE_30 -->\n###### 4\n\n<!-- PAGE_30 -->\n###### 제조방법\n\n- 1. ",
        "original_sentence": "|\n| 1. "
      }
    },
    {
      "chunk_id": "chunk_427",
      "text": "시험시설개요 | 중복될 경우 이를 생략한다). ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 426,
        "window_size": 3,
        "char_count": 26,
        "word_count": 6,
        "page_number": 33,
        "window_text": "| 1) 시험물질 | 가) 판정기준치(농도) | 가) 검체 처치에 첨가된 물질(보존제, 안정제 등) | 분석법 등을 미리 확립한다.  | 정밀도 | pro-Brain Natriuretic Peptide | 의료기기심사부 체외진단기기과 | 이용하여 일치성을 결정하였다.  |\n| 1.  시험시설개요 | 중복될 경우 이를 생략한다).  | 보정물질 | proBNP (recombinant) | approx.  40 | 자사규격 | http://www.mfds.go.kr | 아니오 | □ |\n| 8 | 포장단위 | 황산수소클로피도그렐 | 밀리논유산염 | 트리메소프림 |\n| Vitros  NT-proBNP | J&J | USA | 2.5x |\n| 2 | Cal 2 | 3 | (반복, | 보조성분 | Human serum | 적량 | 자사규격 |\n\n**[표 끝]**\n\n1mL\n\n보조성분\n\nPhosphate buffer\n\n적량\n\n자사규격\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 24 -\n<!-- PAGE_30 -->\n###### 4\n\n<!-- PAGE_30 -->\n###### 제조방법\n\n- 1.  '제조원의 제조방법에 따른다.’라고 기재한다. ",
        "original_sentence": "시험시설개요 | 중복될 경우 이를 생략한다). "
      }
    },
    {
      "chunk_id": "chunk_428",
      "text": "| 보정물질 | proBNP (recombinant) | approx. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 427,
        "window_size": 3,
        "char_count": 40,
        "word_count": 7,
        "page_number": 14,
        "window_text": "| 정밀도 | pro-Brain Natriuretic Peptide | 의료기기심사부 체외진단기기과 | 이용하여 일치성을 결정하였다.  |\n| 1.  시험시설개요 | 중복될 경우 이를 생략한다).  | 보정물질 | proBNP (recombinant) | approx.  40 | 자사규격 | http://www.mfds.go.kr | 아니오 | □ |\n| 8 | 포장단위 | 황산수소클로피도그렐 | 밀리논유산염 | 트리메소프림 |\n| Vitros  NT-proBNP | J&J | USA | 2.5x |\n| 2 | Cal 2 | 3 | (반복, | 보조성분 | Human serum | 적량 | 자사규격 |\n\n**[표 끝]**\n\n1mL\n\n보조성분\n\nPhosphate buffer\n\n적량\n\n자사규격\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 24 -\n<!-- PAGE_30 -->\n###### 4\n\n<!-- PAGE_30 -->\n###### 제조방법\n\n- 1.  '제조원의 제조방법에 따른다.’라고 기재한다.  다만, 다음 각 호에 해당\n- 가. ",
        "original_sentence": "| 보정물질 | proBNP (recombinant) | approx. "
      }
    },
    {
      "chunk_id": "chunk_429",
      "text": "40 | 자사규격 | http://www.mfds.go.kr | 아니오 | □ |\n| 8 | 포장단위 | 황산수소클로피도그렐 | 밀리논유산염 | 트리메소프림 |\n| Vitros  NT-proBNP | J&J | USA | 2.5x |\n| 2 | Cal 2 | 3 | (반복, | 보조성분 | Human serum | 적량 | 자사규격 |\n\n**[표 끝]**\n\n1mL\n\n보조성분\n\nPhosphate buffer\n\n적량\n\n자사규격\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 24 -\n<!-- PAGE_30 -->\n###### 4\n\n<!-- PAGE_30 -->\n###### 제조방법\n\n- 1. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 428,
        "window_size": 3,
        "char_count": 360,
        "word_count": 82,
        "page_number": 30,
        "window_text": "|\n| 1.  시험시설개요 | 중복될 경우 이를 생략한다).  | 보정물질 | proBNP (recombinant) | approx.  40 | 자사규격 | http://www.mfds.go.kr | 아니오 | □ |\n| 8 | 포장단위 | 황산수소클로피도그렐 | 밀리논유산염 | 트리메소프림 |\n| Vitros  NT-proBNP | J&J | USA | 2.5x |\n| 2 | Cal 2 | 3 | (반복, | 보조성분 | Human serum | 적량 | 자사규격 |\n\n**[표 끝]**\n\n1mL\n\n보조성분\n\nPhosphate buffer\n\n적량\n\n자사규격\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 24 -\n<!-- PAGE_30 -->\n###### 4\n\n<!-- PAGE_30 -->\n###### 제조방법\n\n- 1.  '제조원의 제조방법에 따른다.’라고 기재한다.  다만, 다음 각 호에 해당\n- 가.  멸균의료기기의 제조방법의 경우 멸균방법은 식약처장이 인정하는\n멸균의료기기의 멸균방법 [의료기기 허가신고심사 등에 관한 규정,\n\n- 1. ",
        "original_sentence": "40 | 자사규격 | http://www.mfds.go.kr | 아니오 | □ |\n| 8 | 포장단위 | 황산수소클로피도그렐 | 밀리논유산염 | 트리메소프림 |\n| Vitros  NT-proBNP | J&J | USA | 2.5x |\n| 2 | Cal 2 | 3 | (반복, | 보조성분 | Human serum | 적량 | 자사규격 |\n\n**[표 끝]**\n\n1mL\n\n보조성분\n\nPhosphate buffer\n\n적량\n\n자사규격\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 24 -\n<!-- PAGE_30 -->\n###### 4\n\n<!-- PAGE_30 -->\n###### 제조방법\n\n- 1. "
      }
    },
    {
      "chunk_id": "chunk_430",
      "text": "'제조원의 제조방법에 따른다.’라고 기재한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 429,
        "window_size": 3,
        "char_count": 26,
        "word_count": 4,
        "page_number": 26,
        "window_text": "시험시설개요 | 중복될 경우 이를 생략한다).  | 보정물질 | proBNP (recombinant) | approx.  40 | 자사규격 | http://www.mfds.go.kr | 아니오 | □ |\n| 8 | 포장단위 | 황산수소클로피도그렐 | 밀리논유산염 | 트리메소프림 |\n| Vitros  NT-proBNP | J&J | USA | 2.5x |\n| 2 | Cal 2 | 3 | (반복, | 보조성분 | Human serum | 적량 | 자사규격 |\n\n**[표 끝]**\n\n1mL\n\n보조성분\n\nPhosphate buffer\n\n적량\n\n자사규격\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 24 -\n<!-- PAGE_30 -->\n###### 4\n\n<!-- PAGE_30 -->\n###### 제조방법\n\n- 1.  '제조원의 제조방법에 따른다.’라고 기재한다.  다만, 다음 각 호에 해당\n- 가.  멸균의료기기의 제조방법의 경우 멸균방법은 식약처장이 인정하는\n멸균의료기기의 멸균방법 [의료기기 허가신고심사 등에 관한 규정,\n\n- 1.  사용목적은 성능을 포함하여 다음에 따라 기재한다.\n",
        "original_sentence": "'제조원의 제조방법에 따른다.’라고 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_431",
      "text": "다만, 다음 각 호에 해당\n- 가. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 430,
        "window_size": 3,
        "char_count": 20,
        "word_count": 7,
        "page_number": 74,
        "window_text": "| 보정물질 | proBNP (recombinant) | approx.  40 | 자사규격 | http://www.mfds.go.kr | 아니오 | □ |\n| 8 | 포장단위 | 황산수소클로피도그렐 | 밀리논유산염 | 트리메소프림 |\n| Vitros  NT-proBNP | J&J | USA | 2.5x |\n| 2 | Cal 2 | 3 | (반복, | 보조성분 | Human serum | 적량 | 자사규격 |\n\n**[표 끝]**\n\n1mL\n\n보조성분\n\nPhosphate buffer\n\n적량\n\n자사규격\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 24 -\n<!-- PAGE_30 -->\n###### 4\n\n<!-- PAGE_30 -->\n###### 제조방법\n\n- 1.  '제조원의 제조방법에 따른다.’라고 기재한다.  다만, 다음 각 호에 해당\n- 가.  멸균의료기기의 제조방법의 경우 멸균방법은 식약처장이 인정하는\n멸균의료기기의 멸균방법 [의료기기 허가신고심사 등에 관한 규정,\n\n- 1.  사용목적은 성능을 포함하여 다음에 따라 기재한다.\n - 2. ",
        "original_sentence": "다만, 다음 각 호에 해당\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_432",
      "text": "멸균의료기기의 제조방법의 경우 멸균방법은 식약처장이 인정하는\n멸균의료기기의 멸균방법 [의료기기 허가신고심사 등에 관한 규정,\n\n- 1. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 431,
        "window_size": 3,
        "char_count": 76,
        "word_count": 15,
        "page_number": 30,
        "window_text": "40 | 자사규격 | http://www.mfds.go.kr | 아니오 | □ |\n| 8 | 포장단위 | 황산수소클로피도그렐 | 밀리논유산염 | 트리메소프림 |\n| Vitros  NT-proBNP | J&J | USA | 2.5x |\n| 2 | Cal 2 | 3 | (반복, | 보조성분 | Human serum | 적량 | 자사규격 |\n\n**[표 끝]**\n\n1mL\n\n보조성분\n\nPhosphate buffer\n\n적량\n\n자사규격\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 24 -\n<!-- PAGE_30 -->\n###### 4\n\n<!-- PAGE_30 -->\n###### 제조방법\n\n- 1.  '제조원의 제조방법에 따른다.’라고 기재한다.  다만, 다음 각 호에 해당\n- 가.  멸균의료기기의 제조방법의 경우 멸균방법은 식약처장이 인정하는\n멸균의료기기의 멸균방법 [의료기기 허가신고심사 등에 관한 규정,\n\n- 1.  사용목적은 성능을 포함하여 다음에 따라 기재한다.\n - 2.  사용목적은 근거자료에 따라 검사대상, 검체종류, 검사항목, 측정원리\n사람의 혈청, 혈장, 전혈(정맥, 모세관) 등을 포함한다.\n\n",
        "original_sentence": "멸균의료기기의 제조방법의 경우 멸균방법은 식약처장이 인정하는\n멸균의료기기의 멸균방법 [의료기기 허가신고심사 등에 관한 규정,\n\n- 1. "
      }
    },
    {
      "chunk_id": "chunk_433",
      "text": "사용목적은 성능을 포함하여 다음에 따라 기재한다.\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 432,
        "window_size": 3,
        "char_count": 28,
        "word_count": 6,
        "page_number": 26,
        "window_text": "'제조원의 제조방법에 따른다.’라고 기재한다.  다만, 다음 각 호에 해당\n- 가.  멸균의료기기의 제조방법의 경우 멸균방법은 식약처장이 인정하는\n멸균의료기기의 멸균방법 [의료기기 허가신고심사 등에 관한 규정,\n\n- 1.  사용목적은 성능을 포함하여 다음에 따라 기재한다.\n - 2.  사용목적은 근거자료에 따라 검사대상, 검체종류, 검사항목, 측정원리\n사람의 혈청, 혈장, 전혈(정맥, 모세관) 등을 포함한다.\n\n - 다. ",
        "original_sentence": "사용목적은 성능을 포함하여 다음에 따라 기재한다.\n"
      }
    },
    {
      "chunk_id": "chunk_434",
      "text": "- 2. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 433,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 6,
        "window_text": "다만, 다음 각 호에 해당\n- 가.  멸균의료기기의 제조방법의 경우 멸균방법은 식약처장이 인정하는\n멸균의료기기의 멸균방법 [의료기기 허가신고심사 등에 관한 규정,\n\n- 1.  사용목적은 성능을 포함하여 다음에 따라 기재한다.\n - 2.  사용목적은 근거자료에 따라 검사대상, 검체종류, 검사항목, 측정원리\n사람의 혈청, 혈장, 전혈(정맥, 모세관) 등을 포함한다.\n\n - 다.  검사항목 : 검출대상이 되는 물질\n- 라. ",
        "original_sentence": "- 2. "
      }
    },
    {
      "chunk_id": "chunk_435",
      "text": "사용목적은 근거자료에 따라 검사대상, 검체종류, 검사항목, 측정원리\n사람의 혈청, 혈장, 전혈(정맥, 모세관) 등을 포함한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 434,
        "window_size": 3,
        "char_count": 72,
        "word_count": 14,
        "page_number": 3,
        "window_text": "멸균의료기기의 제조방법의 경우 멸균방법은 식약처장이 인정하는\n멸균의료기기의 멸균방법 [의료기기 허가신고심사 등에 관한 규정,\n\n- 1.  사용목적은 성능을 포함하여 다음에 따라 기재한다.\n - 2.  사용목적은 근거자료에 따라 검사대상, 검체종류, 검사항목, 측정원리\n사람의 혈청, 혈장, 전혈(정맥, 모세관) 등을 포함한다.\n\n - 다.  검사항목 : 검출대상이 되는 물질\n- 라.  측정원리 : 측정에 사용된 검사 원리\n- 마. ",
        "original_sentence": "사용목적은 근거자료에 따라 검사대상, 검체종류, 검사항목, 측정원리\n사람의 혈청, 혈장, 전혈(정맥, 모세관) 등을 포함한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_436",
      "text": "- 다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 435,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 74,
        "window_text": "사용목적은 성능을 포함하여 다음에 따라 기재한다.\n - 2.  사용목적은 근거자료에 따라 검사대상, 검체종류, 검사항목, 측정원리\n사람의 혈청, 혈장, 전혈(정맥, 모세관) 등을 포함한다.\n\n - 다.  검사항목 : 검출대상이 되는 물질\n- 라.  측정원리 : 측정에 사용된 검사 원리\n- 마.  정성 또는 정량 : 검사 목적 및 해당 제품의 특성에 따라 정성, 정량,\n반정량 검사용 등을 명확하게 기재한다.\n\n",
        "original_sentence": "- 다. "
      }
    },
    {
      "chunk_id": "chunk_437",
      "text": "검사항목 : 검출대상이 되는 물질\n- 라. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 436,
        "window_size": 3,
        "char_count": 24,
        "word_count": 7,
        "page_number": 3,
        "window_text": "- 2.  사용목적은 근거자료에 따라 검사대상, 검체종류, 검사항목, 측정원리\n사람의 혈청, 혈장, 전혈(정맥, 모세관) 등을 포함한다.\n\n - 다.  검사항목 : 검출대상이 되는 물질\n- 라.  측정원리 : 측정에 사용된 검사 원리\n- 마.  정성 또는 정량 : 검사 목적 및 해당 제품의 특성에 따라 정성, 정량,\n반정량 검사용 등을 명확하게 기재한다.\n\n Ⅴ. ",
        "original_sentence": "검사항목 : 검출대상이 되는 물질\n- 라. "
      }
    },
    {
      "chunk_id": "chunk_438",
      "text": "측정원리 : 측정에 사용된 검사 원리\n- 마. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 437,
        "window_size": 3,
        "char_count": 26,
        "word_count": 8,
        "page_number": 74,
        "window_text": "사용목적은 근거자료에 따라 검사대상, 검체종류, 검사항목, 측정원리\n사람의 혈청, 혈장, 전혈(정맥, 모세관) 등을 포함한다.\n\n - 다.  검사항목 : 검출대상이 되는 물질\n- 라.  측정원리 : 측정에 사용된 검사 원리\n- 마.  정성 또는 정량 : 검사 목적 및 해당 제품의 특성에 따라 정성, 정량,\n반정량 검사용 등을 명확하게 기재한다.\n\n Ⅴ.  제조․수입허가 신청서 기재 항목\n\n- - 25 -\n- 3. ",
        "original_sentence": "측정원리 : 측정에 사용된 검사 원리\n- 마. "
      }
    },
    {
      "chunk_id": "chunk_439",
      "text": "정성 또는 정량 : 검사 목적 및 해당 제품의 특성에 따라 정성, 정량,\n반정량 검사용 등을 명확하게 기재한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 438,
        "window_size": 3,
        "char_count": 64,
        "word_count": 18,
        "page_number": 79,
        "window_text": "- 다.  검사항목 : 검출대상이 되는 물질\n- 라.  측정원리 : 측정에 사용된 검사 원리\n- 마.  정성 또는 정량 : 검사 목적 및 해당 제품의 특성에 따라 정성, 정량,\n반정량 검사용 등을 명확하게 기재한다.\n\n Ⅴ.  제조․수입허가 신청서 기재 항목\n\n- - 25 -\n- 3.  성능\n- 가. ",
        "original_sentence": "정성 또는 정량 : 검사 목적 및 해당 제품의 특성에 따라 정성, 정량,\n반정량 검사용 등을 명확하게 기재한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_440",
      "text": "Ⅴ. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 439,
        "window_size": 3,
        "char_count": 3,
        "word_count": 1,
        "page_number": 6,
        "window_text": "검사항목 : 검출대상이 되는 물질\n- 라.  측정원리 : 측정에 사용된 검사 원리\n- 마.  정성 또는 정량 : 검사 목적 및 해당 제품의 특성에 따라 정성, 정량,\n반정량 검사용 등을 명확하게 기재한다.\n\n Ⅴ.  제조․수입허가 신청서 기재 항목\n\n- - 25 -\n- 3.  성능\n- 가.  근거자료를 바탕으로 사용설명서(Instruction for user, IFU)에\n수치적으로 제시된 성능 기재\n\n❍ 당해 제품의 특성에 맞는 성능을 기재하되, 추상적이고 명확하지\n\n표 2. ",
        "original_sentence": "Ⅴ. "
      }
    },
    {
      "chunk_id": "chunk_441",
      "text": "제조․수입허가 신청서 기재 항목\n\n- - 25 -\n- 3. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 440,
        "window_size": 3,
        "char_count": 33,
        "word_count": 10,
        "page_number": 3,
        "window_text": "측정원리 : 측정에 사용된 검사 원리\n- 마.  정성 또는 정량 : 검사 목적 및 해당 제품의 특성에 따라 정성, 정량,\n반정량 검사용 등을 명확하게 기재한다.\n\n Ⅴ.  제조․수입허가 신청서 기재 항목\n\n- - 25 -\n- 3.  성능\n- 가.  근거자료를 바탕으로 사용설명서(Instruction for user, IFU)에\n수치적으로 제시된 성능 기재\n\n❍ 당해 제품의 특성에 맞는 성능을 기재하되, 추상적이고 명확하지\n\n표 2.  성능 작성의 예\n\n디클로페낙\n\n니코틴\n\n베라파밀\n\n디곡신\n\n니코틴산\n\n와파린\n\n딜티아젬\n\n니페디핀\n\n디기톡신\n\n나이트로후란토인\n\n2) 교차반응\n\n아래에 제시된 농도에서 BNP Test와의 잠재적 교차반응에\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 26 -\n대하여 다음 단백질 및 펩티드를 평가하였다.\n\n",
        "original_sentence": "제조․수입허가 신청서 기재 항목\n\n- - 25 -\n- 3. "
      }
    },
    {
      "chunk_id": "chunk_442",
      "text": "성능\n- 가. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 441,
        "window_size": 3,
        "char_count": 8,
        "word_count": 3,
        "page_number": 51,
        "window_text": "정성 또는 정량 : 검사 목적 및 해당 제품의 특성에 따라 정성, 정량,\n반정량 검사용 등을 명확하게 기재한다.\n\n Ⅴ.  제조․수입허가 신청서 기재 항목\n\n- - 25 -\n- 3.  성능\n- 가.  근거자료를 바탕으로 사용설명서(Instruction for user, IFU)에\n수치적으로 제시된 성능 기재\n\n❍ 당해 제품의 특성에 맞는 성능을 기재하되, 추상적이고 명확하지\n\n표 2.  성능 작성의 예\n\n디클로페낙\n\n니코틴\n\n베라파밀\n\n디곡신\n\n니코틴산\n\n와파린\n\n딜티아젬\n\n니페디핀\n\n디기톡신\n\n나이트로후란토인\n\n2) 교차반응\n\n아래에 제시된 농도에서 BNP Test와의 잠재적 교차반응에\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 26 -\n대하여 다음 단백질 및 펩티드를 평가하였다.\n\n - -관련 단백질 및 펩티드와의 반응-\n물질\n\n물질 농도\n\n회수율(%)\n\n**[표 시작]**\n\n**Institute)의 프로토콜(EP5-A2)에 따라 본 제품, 사람 혈청**\n| 징후와 증상을 평가하여 질병의 진행단계를 4개의 카테고리 | 임상연구 모집단에 대한 Box and whiskers 표가 NYHA |\n**전화: 043-719-4652~4665**\n| 3) 시험방법 | 나) 판정기준치에서의 임상적 민감도 및 특이도 | 간섭물질을 함유한 검체 등) 등에 대한 실험방법을 제공한다. ",
        "original_sentence": "성능\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_443",
      "text": "근거자료를 바탕으로 사용설명서(Instruction for user, IFU)에\n수치적으로 제시된 성능 기재\n\n❍ 당해 제품의 특성에 맞는 성능을 기재하되, 추상적이고 명확하지\n\n표 2. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 442,
        "window_size": 3,
        "char_count": 105,
        "word_count": 21,
        "page_number": 7,
        "window_text": "Ⅴ.  제조․수입허가 신청서 기재 항목\n\n- - 25 -\n- 3.  성능\n- 가.  근거자료를 바탕으로 사용설명서(Instruction for user, IFU)에\n수치적으로 제시된 성능 기재\n\n❍ 당해 제품의 특성에 맞는 성능을 기재하되, 추상적이고 명확하지\n\n표 2.  성능 작성의 예\n\n디클로페낙\n\n니코틴\n\n베라파밀\n\n디곡신\n\n니코틴산\n\n와파린\n\n딜티아젬\n\n니페디핀\n\n디기톡신\n\n나이트로후란토인\n\n2) 교차반응\n\n아래에 제시된 농도에서 BNP Test와의 잠재적 교차반응에\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 26 -\n대하여 다음 단백질 및 펩티드를 평가하였다.\n\n - -관련 단백질 및 펩티드와의 반응-\n물질\n\n물질 농도\n\n회수율(%)\n\n**[표 시작]**\n\n**Institute)의 프로토콜(EP5-A2)에 따라 본 제품, 사람 혈청**\n| 징후와 증상을 평가하여 질병의 진행단계를 4개의 카테고리 | 임상연구 모집단에 대한 Box and whiskers 표가 NYHA |\n**전화: 043-719-4652~4665**\n| 3) 시험방법 | 나) 판정기준치에서의 임상적 민감도 및 특이도 | 간섭물질을 함유한 검체 등) 등에 대한 실험방법을 제공한다.  | 풀(pooled human sera) 및 관리물질(controls)을 사용하여 | 회귀방법 | 검체 | 유형 | n | 상관 | 절편 | 기울기 |\n| 22-46 등. ",
        "original_sentence": "근거자료를 바탕으로 사용설명서(Instruction for user, IFU)에\n수치적으로 제시된 성능 기재\n\n❍ 당해 제품의 특성에 맞는 성능을 기재하되, 추상적이고 명확하지\n\n표 2. "
      }
    },
    {
      "chunk_id": "chunk_444",
      "text": "성능 작성의 예\n\n디클로페낙\n\n니코틴\n\n베라파밀\n\n디곡신\n\n니코틴산\n\n와파린\n\n딜티아젬\n\n니페디핀\n\n디기톡신\n\n나이트로후란토인\n\n2) 교차반응\n\n아래에 제시된 농도에서 BNP Test와의 잠재적 교차반응에\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 26 -\n대하여 다음 단백질 및 펩티드를 평가하였다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 443,
        "window_size": 3,
        "char_count": 200,
        "word_count": 40,
        "page_number": 31,
        "window_text": "제조․수입허가 신청서 기재 항목\n\n- - 25 -\n- 3.  성능\n- 가.  근거자료를 바탕으로 사용설명서(Instruction for user, IFU)에\n수치적으로 제시된 성능 기재\n\n❍ 당해 제품의 특성에 맞는 성능을 기재하되, 추상적이고 명확하지\n\n표 2.  성능 작성의 예\n\n디클로페낙\n\n니코틴\n\n베라파밀\n\n디곡신\n\n니코틴산\n\n와파린\n\n딜티아젬\n\n니페디핀\n\n디기톡신\n\n나이트로후란토인\n\n2) 교차반응\n\n아래에 제시된 농도에서 BNP Test와의 잠재적 교차반응에\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 26 -\n대하여 다음 단백질 및 펩티드를 평가하였다.\n\n - -관련 단백질 및 펩티드와의 반응-\n물질\n\n물질 농도\n\n회수율(%)\n\n**[표 시작]**\n\n**Institute)의 프로토콜(EP5-A2)에 따라 본 제품, 사람 혈청**\n| 징후와 증상을 평가하여 질병의 진행단계를 4개의 카테고리 | 임상연구 모집단에 대한 Box and whiskers 표가 NYHA |\n**전화: 043-719-4652~4665**\n| 3) 시험방법 | 나) 판정기준치에서의 임상적 민감도 및 특이도 | 간섭물질을 함유한 검체 등) 등에 대한 실험방법을 제공한다.  | 풀(pooled human sera) 및 관리물질(controls)을 사용하여 | 회귀방법 | 검체 | 유형 | n | 상관 | 절편 | 기울기 |\n| 22-46 등.  | (class I ~ IV)로 분류한다. ",
        "original_sentence": "성능 작성의 예\n\n디클로페낙\n\n니코틴\n\n베라파밀\n\n디곡신\n\n니코틴산\n\n와파린\n\n딜티아젬\n\n니페디핀\n\n디기톡신\n\n나이트로후란토인\n\n2) 교차반응\n\n아래에 제시된 농도에서 BNP Test와의 잠재적 교차반응에\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 26 -\n대하여 다음 단백질 및 펩티드를 평가하였다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_445",
      "text": "- -관련 단백질 및 펩티드와의 반응-\n물질\n\n물질 농도\n\n회수율(%)\n\n**[표 시작]**\n\n**Institute)의 프로토콜(EP5-A2)에 따라 본 제품, 사람 혈청**\n| 징후와 증상을 평가하여 질병의 진행단계를 4개의 카테고리 | 임상연구 모집단에 대한 Box and whiskers 표가 NYHA |\n**전화: 043-719-4652~4665**\n| 3) 시험방법 | 나) 판정기준치에서의 임상적 민감도 및 특이도 | 간섭물질을 함유한 검체 등) 등에 대한 실험방법을 제공한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 444,
        "window_size": 3,
        "char_count": 274,
        "word_count": 58,
        "page_number": 32,
        "window_text": "성능\n- 가.  근거자료를 바탕으로 사용설명서(Instruction for user, IFU)에\n수치적으로 제시된 성능 기재\n\n❍ 당해 제품의 특성에 맞는 성능을 기재하되, 추상적이고 명확하지\n\n표 2.  성능 작성의 예\n\n디클로페낙\n\n니코틴\n\n베라파밀\n\n디곡신\n\n니코틴산\n\n와파린\n\n딜티아젬\n\n니페디핀\n\n디기톡신\n\n나이트로후란토인\n\n2) 교차반응\n\n아래에 제시된 농도에서 BNP Test와의 잠재적 교차반응에\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 26 -\n대하여 다음 단백질 및 펩티드를 평가하였다.\n\n - -관련 단백질 및 펩티드와의 반응-\n물질\n\n물질 농도\n\n회수율(%)\n\n**[표 시작]**\n\n**Institute)의 프로토콜(EP5-A2)에 따라 본 제품, 사람 혈청**\n| 징후와 증상을 평가하여 질병의 진행단계를 4개의 카테고리 | 임상연구 모집단에 대한 Box and whiskers 표가 NYHA |\n**전화: 043-719-4652~4665**\n| 3) 시험방법 | 나) 판정기준치에서의 임상적 민감도 및 특이도 | 간섭물질을 함유한 검체 등) 등에 대한 실험방법을 제공한다.  | 풀(pooled human sera) 및 관리물질(controls)을 사용하여 | 회귀방법 | 검체 | 유형 | n | 상관 | 절편 | 기울기 |\n| 22-46 등.  | (class I ~ IV)로 분류한다.  연구로부터 얻은 데이터는 | 등급에 따라 분류되었고 아래에 제시되었다. ",
        "original_sentence": "- -관련 단백질 및 펩티드와의 반응-\n물질\n\n물질 농도\n\n회수율(%)\n\n**[표 시작]**\n\n**Institute)의 프로토콜(EP5-A2)에 따라 본 제품, 사람 혈청**\n| 징후와 증상을 평가하여 질병의 진행단계를 4개의 카테고리 | 임상연구 모집단에 대한 Box and whiskers 표가 NYHA |\n**전화: 043-719-4652~4665**\n| 3) 시험방법 | 나) 판정기준치에서의 임상적 민감도 및 특이도 | 간섭물질을 함유한 검체 등) 등에 대한 실험방법을 제공한다. "
      }
    },
    {
      "chunk_id": "chunk_446",
      "text": "| 풀(pooled human sera) 및 관리물질(controls)을 사용하여 | 회귀방법 | 검체 | 유형 | n | 상관 | 절편 | 기울기 |\n| 22-46 등. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 445,
        "window_size": 3,
        "char_count": 96,
        "word_count": 25,
        "page_number": 14,
        "window_text": "근거자료를 바탕으로 사용설명서(Instruction for user, IFU)에\n수치적으로 제시된 성능 기재\n\n❍ 당해 제품의 특성에 맞는 성능을 기재하되, 추상적이고 명확하지\n\n표 2.  성능 작성의 예\n\n디클로페낙\n\n니코틴\n\n베라파밀\n\n디곡신\n\n니코틴산\n\n와파린\n\n딜티아젬\n\n니페디핀\n\n디기톡신\n\n나이트로후란토인\n\n2) 교차반응\n\n아래에 제시된 농도에서 BNP Test와의 잠재적 교차반응에\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 26 -\n대하여 다음 단백질 및 펩티드를 평가하였다.\n\n - -관련 단백질 및 펩티드와의 반응-\n물질\n\n물질 농도\n\n회수율(%)\n\n**[표 시작]**\n\n**Institute)의 프로토콜(EP5-A2)에 따라 본 제품, 사람 혈청**\n| 징후와 증상을 평가하여 질병의 진행단계를 4개의 카테고리 | 임상연구 모집단에 대한 Box and whiskers 표가 NYHA |\n**전화: 043-719-4652~4665**\n| 3) 시험방법 | 나) 판정기준치에서의 임상적 민감도 및 특이도 | 간섭물질을 함유한 검체 등) 등에 대한 실험방법을 제공한다.  | 풀(pooled human sera) 및 관리물질(controls)을 사용하여 | 회귀방법 | 검체 | 유형 | n | 상관 | 절편 | 기울기 |\n| 22-46 등.  | (class I ~ IV)로 분류한다.  연구로부터 얻은 데이터는 | 등급에 따라 분류되었고 아래에 제시되었다.  점선은 본 |\n| 또는 이를 공증한 자료 | 검체의 이력 등이 밝혀진 검체를 사용할 것을 권장한다. ",
        "original_sentence": "| 풀(pooled human sera) 및 관리물질(controls)을 사용하여 | 회귀방법 | 검체 | 유형 | n | 상관 | 절편 | 기울기 |\n| 22-46 등. "
      }
    },
    {
      "chunk_id": "chunk_447",
      "text": "| (class I ~ IV)로 분류한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 446,
        "window_size": 3,
        "char_count": 24,
        "word_count": 6,
        "page_number": 14,
        "window_text": "성능 작성의 예\n\n디클로페낙\n\n니코틴\n\n베라파밀\n\n디곡신\n\n니코틴산\n\n와파린\n\n딜티아젬\n\n니페디핀\n\n디기톡신\n\n나이트로후란토인\n\n2) 교차반응\n\n아래에 제시된 농도에서 BNP Test와의 잠재적 교차반응에\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 26 -\n대하여 다음 단백질 및 펩티드를 평가하였다.\n\n - -관련 단백질 및 펩티드와의 반응-\n물질\n\n물질 농도\n\n회수율(%)\n\n**[표 시작]**\n\n**Institute)의 프로토콜(EP5-A2)에 따라 본 제품, 사람 혈청**\n| 징후와 증상을 평가하여 질병의 진행단계를 4개의 카테고리 | 임상연구 모집단에 대한 Box and whiskers 표가 NYHA |\n**전화: 043-719-4652~4665**\n| 3) 시험방법 | 나) 판정기준치에서의 임상적 민감도 및 특이도 | 간섭물질을 함유한 검체 등) 등에 대한 실험방법을 제공한다.  | 풀(pooled human sera) 및 관리물질(controls)을 사용하여 | 회귀방법 | 검체 | 유형 | n | 상관 | 절편 | 기울기 |\n| 22-46 등.  | (class I ~ IV)로 분류한다.  연구로부터 얻은 데이터는 | 등급에 따라 분류되었고 아래에 제시되었다.  점선은 본 |\n| 또는 이를 공증한 자료 | 검체의 이력 등이 밝혀진 검체를 사용할 것을 권장한다.  | VIDAS NT-proBNP | bioMerieux | France |\n| 재현성 등) | 결정되었다. ",
        "original_sentence": "| (class I ~ IV)로 분류한다. "
      }
    },
    {
      "chunk_id": "chunk_448",
      "text": "연구로부터 얻은 데이터는 | 등급에 따라 분류되었고 아래에 제시되었다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 447,
        "window_size": 3,
        "char_count": 40,
        "word_count": 9,
        "page_number": 1,
        "window_text": "- -관련 단백질 및 펩티드와의 반응-\n물질\n\n물질 농도\n\n회수율(%)\n\n**[표 시작]**\n\n**Institute)의 프로토콜(EP5-A2)에 따라 본 제품, 사람 혈청**\n| 징후와 증상을 평가하여 질병의 진행단계를 4개의 카테고리 | 임상연구 모집단에 대한 Box and whiskers 표가 NYHA |\n**전화: 043-719-4652~4665**\n| 3) 시험방법 | 나) 판정기준치에서의 임상적 민감도 및 특이도 | 간섭물질을 함유한 검체 등) 등에 대한 실험방법을 제공한다.  | 풀(pooled human sera) 및 관리물질(controls)을 사용하여 | 회귀방법 | 검체 | 유형 | n | 상관 | 절편 | 기울기 |\n| 22-46 등.  | (class I ~ IV)로 분류한다.  연구로부터 얻은 데이터는 | 등급에 따라 분류되었고 아래에 제시되었다.  점선은 본 |\n| 또는 이를 공증한 자료 | 검체의 이력 등이 밝혀진 검체를 사용할 것을 권장한다.  | VIDAS NT-proBNP | bioMerieux | France |\n| 재현성 등) | 결정되었다.  본 연구는 20일 동안 수행되었고, 1일 2회를 | 계수 | (95% CI) | 아니오 | □ | (95% CI) |\n\n**[표 끝]**\n\n2회씩 반복하여(n=80) 다음의 결과를 얻었다.\n\n",
        "original_sentence": "연구로부터 얻은 데이터는 | 등급에 따라 분류되었고 아래에 제시되었다. "
      }
    },
    {
      "chunk_id": "chunk_449",
      "text": "점선은 본 |\n| 또는 이를 공증한 자료 | 검체의 이력 등이 밝혀진 검체를 사용할 것을 권장한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 448,
        "window_size": 3,
        "char_count": 56,
        "word_count": 17,
        "page_number": 33,
        "window_text": "| 풀(pooled human sera) 및 관리물질(controls)을 사용하여 | 회귀방법 | 검체 | 유형 | n | 상관 | 절편 | 기울기 |\n| 22-46 등.  | (class I ~ IV)로 분류한다.  연구로부터 얻은 데이터는 | 등급에 따라 분류되었고 아래에 제시되었다.  점선은 본 |\n| 또는 이를 공증한 자료 | 검체의 이력 등이 밝혀진 검체를 사용할 것을 권장한다.  | VIDAS NT-proBNP | bioMerieux | France |\n| 재현성 등) | 결정되었다.  본 연구는 20일 동안 수행되었고, 1일 2회를 | 계수 | (95% CI) | 아니오 | □ | (95% CI) |\n\n**[표 끝]**\n\n2회씩 반복하여(n=80) 다음의 결과를 얻었다.\n\n Ⅴ. ",
        "original_sentence": "점선은 본 |\n| 또는 이를 공증한 자료 | 검체의 이력 등이 밝혀진 검체를 사용할 것을 권장한다. "
      }
    },
    {
      "chunk_id": "chunk_450",
      "text": "| VIDAS NT-proBNP | bioMerieux | France |\n| 재현성 등) | 결정되었다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 449,
        "window_size": 3,
        "char_count": 60,
        "word_count": 13,
        "page_number": 14,
        "window_text": "| (class I ~ IV)로 분류한다.  연구로부터 얻은 데이터는 | 등급에 따라 분류되었고 아래에 제시되었다.  점선은 본 |\n| 또는 이를 공증한 자료 | 검체의 이력 등이 밝혀진 검체를 사용할 것을 권장한다.  | VIDAS NT-proBNP | bioMerieux | France |\n| 재현성 등) | 결정되었다.  본 연구는 20일 동안 수행되었고, 1일 2회를 | 계수 | (95% CI) | 아니오 | □ | (95% CI) |\n\n**[표 끝]**\n\n2회씩 반복하여(n=80) 다음의 결과를 얻었다.\n\n Ⅴ.  제조․수입허가 신청서 기재 항목\n\n- - 27 -\nRepeatability\n\nMean\n\nSD\n\nCV\n\npg/mL\n\npmol/L\n\npg/mL\n\npmol/L\n\n%\n\nHuman Serum 1\n\n50\n\n- 5.9\n- 1.7\n- 0.21\n- 3.5\n**[표 시작]**\n\n| STRATUS CS ACUTE CARE | BETAHCG AND NT-PROBNP | TESTPAK AND TESTPAK | ASSAY, CALPAK AND DILPAK |\n| --- | --- | --- | --- |\n| STATUSFIRST CHF | (CONGESTIVE HEART | FAILURE) NT-PROBNP | “내가 지킨 청렴실천 모아지면 청렴사회” | 팩스: 043-719-4650 |\n| Pathfast NT-proBNP | Mitsubishi | Japan | 아래에 요약되었다. ",
        "original_sentence": "| VIDAS NT-proBNP | bioMerieux | France |\n| 재현성 등) | 결정되었다. "
      }
    },
    {
      "chunk_id": "chunk_451",
      "text": "본 연구는 20일 동안 수행되었고, 1일 2회를 | 계수 | (95% CI) | 아니오 | □ | (95% CI) |\n\n**[표 끝]**\n\n2회씩 반복하여(n=80) 다음의 결과를 얻었다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 450,
        "window_size": 3,
        "char_count": 107,
        "word_count": 27,
        "page_number": 6,
        "window_text": "연구로부터 얻은 데이터는 | 등급에 따라 분류되었고 아래에 제시되었다.  점선은 본 |\n| 또는 이를 공증한 자료 | 검체의 이력 등이 밝혀진 검체를 사용할 것을 권장한다.  | VIDAS NT-proBNP | bioMerieux | France |\n| 재현성 등) | 결정되었다.  본 연구는 20일 동안 수행되었고, 1일 2회를 | 계수 | (95% CI) | 아니오 | □ | (95% CI) |\n\n**[표 끝]**\n\n2회씩 반복하여(n=80) 다음의 결과를 얻었다.\n\n Ⅴ.  제조․수입허가 신청서 기재 항목\n\n- - 27 -\nRepeatability\n\nMean\n\nSD\n\nCV\n\npg/mL\n\npmol/L\n\npg/mL\n\npmol/L\n\n%\n\nHuman Serum 1\n\n50\n\n- 5.9\n- 1.7\n- 0.21\n- 3.5\n**[표 시작]**\n\n| STRATUS CS ACUTE CARE | BETAHCG AND NT-PROBNP | TESTPAK AND TESTPAK | ASSAY, CALPAK AND DILPAK |\n| --- | --- | --- | --- |\n| STATUSFIRST CHF | (CONGESTIVE HEART | FAILURE) NT-PROBNP | “내가 지킨 청렴실천 모아지면 청렴사회” | 팩스: 043-719-4650 |\n| Pathfast NT-proBNP | Mitsubishi | Japan | 아래에 요약되었다.  |\n| 항체, rheumatoid factors, human anti-mouse 항체 등) | Passing- | EDTA | 혈장 | 300 | 0.96 | -8 | 1.12 |\n| Bablok*1 | (-6 ~ -9) | (1.08 ~ 1.18) |\n\n**[표 끝]**\n\n*1 검체의 분산과 측정 에러에 대한 특별한 가정이 없는 선형회귀 방법\n\n샘플범위(해당제품): 0 - 3400pg/mL\n\n샘플범위(비교방법): 5 - 3500pg/mL\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 28 -\n해당제품 분석방법*2\n\n비교방법*2\n\n양성\n\n음성\n\n양성\n\n130\n\n15\n\n*2 일치도는 비교 방법과 해당제품 분석방법의 125pg/mL의 결정 역치를\n\n분류하였다. ",
        "original_sentence": "본 연구는 20일 동안 수행되었고, 1일 2회를 | 계수 | (95% CI) | 아니오 | □ | (95% CI) |\n\n**[표 끝]**\n\n2회씩 반복하여(n=80) 다음의 결과를 얻었다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_452",
      "text": "Ⅴ. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 451,
        "window_size": 3,
        "char_count": 3,
        "word_count": 1,
        "page_number": 6,
        "window_text": "점선은 본 |\n| 또는 이를 공증한 자료 | 검체의 이력 등이 밝혀진 검체를 사용할 것을 권장한다.  | VIDAS NT-proBNP | bioMerieux | France |\n| 재현성 등) | 결정되었다.  본 연구는 20일 동안 수행되었고, 1일 2회를 | 계수 | (95% CI) | 아니오 | □ | (95% CI) |\n\n**[표 끝]**\n\n2회씩 반복하여(n=80) 다음의 결과를 얻었다.\n\n Ⅴ.  제조․수입허가 신청서 기재 항목\n\n- - 27 -\nRepeatability\n\nMean\n\nSD\n\nCV\n\npg/mL\n\npmol/L\n\npg/mL\n\npmol/L\n\n%\n\nHuman Serum 1\n\n50\n\n- 5.9\n- 1.7\n- 0.21\n- 3.5\n**[표 시작]**\n\n| STRATUS CS ACUTE CARE | BETAHCG AND NT-PROBNP | TESTPAK AND TESTPAK | ASSAY, CALPAK AND DILPAK |\n| --- | --- | --- | --- |\n| STATUSFIRST CHF | (CONGESTIVE HEART | FAILURE) NT-PROBNP | “내가 지킨 청렴실천 모아지면 청렴사회” | 팩스: 043-719-4650 |\n| Pathfast NT-proBNP | Mitsubishi | Japan | 아래에 요약되었다.  |\n| 항체, rheumatoid factors, human anti-mouse 항체 등) | Passing- | EDTA | 혈장 | 300 | 0.96 | -8 | 1.12 |\n| Bablok*1 | (-6 ~ -9) | (1.08 ~ 1.18) |\n\n**[표 끝]**\n\n*1 검체의 분산과 측정 에러에 대한 특별한 가정이 없는 선형회귀 방법\n\n샘플범위(해당제품): 0 - 3400pg/mL\n\n샘플범위(비교방법): 5 - 3500pg/mL\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 28 -\n해당제품 분석방법*2\n\n비교방법*2\n\n양성\n\n음성\n\n양성\n\n130\n\n15\n\n*2 일치도는 비교 방법과 해당제품 분석방법의 125pg/mL의 결정 역치를\n\n분류하였다.  이 시스템은 심장 질환 환자를 환자의 임상적인\n\nⅤ. ",
        "original_sentence": "Ⅴ. "
      }
    },
    {
      "chunk_id": "chunk_453",
      "text": "제조․수입허가 신청서 기재 항목\n\n- - 27 -\nRepeatability\n\nMean\n\nSD\n\nCV\n\npg/mL\n\npmol/L\n\npg/mL\n\npmol/L\n\n%\n\nHuman Serum 1\n\n50\n\n- 5.9\n- 1.7\n- 0.21\n- 3.5\n**[표 시작]**\n\n| STRATUS CS ACUTE CARE | BETAHCG AND NT-PROBNP | TESTPAK AND TESTPAK | ASSAY, CALPAK AND DILPAK |\n| --- | --- | --- | --- |\n| STATUSFIRST CHF | (CONGESTIVE HEART | FAILURE) NT-PROBNP | “내가 지킨 청렴실천 모아지면 청렴사회” | 팩스: 043-719-4650 |\n| Pathfast NT-proBNP | Mitsubishi | Japan | 아래에 요약되었다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 452,
        "window_size": 3,
        "char_count": 431,
        "word_count": 88,
        "page_number": 3,
        "window_text": "| VIDAS NT-proBNP | bioMerieux | France |\n| 재현성 등) | 결정되었다.  본 연구는 20일 동안 수행되었고, 1일 2회를 | 계수 | (95% CI) | 아니오 | □ | (95% CI) |\n\n**[표 끝]**\n\n2회씩 반복하여(n=80) 다음의 결과를 얻었다.\n\n Ⅴ.  제조․수입허가 신청서 기재 항목\n\n- - 27 -\nRepeatability\n\nMean\n\nSD\n\nCV\n\npg/mL\n\npmol/L\n\npg/mL\n\npmol/L\n\n%\n\nHuman Serum 1\n\n50\n\n- 5.9\n- 1.7\n- 0.21\n- 3.5\n**[표 시작]**\n\n| STRATUS CS ACUTE CARE | BETAHCG AND NT-PROBNP | TESTPAK AND TESTPAK | ASSAY, CALPAK AND DILPAK |\n| --- | --- | --- | --- |\n| STATUSFIRST CHF | (CONGESTIVE HEART | FAILURE) NT-PROBNP | “내가 지킨 청렴실천 모아지면 청렴사회” | 팩스: 043-719-4650 |\n| Pathfast NT-proBNP | Mitsubishi | Japan | 아래에 요약되었다.  |\n| 항체, rheumatoid factors, human anti-mouse 항체 등) | Passing- | EDTA | 혈장 | 300 | 0.96 | -8 | 1.12 |\n| Bablok*1 | (-6 ~ -9) | (1.08 ~ 1.18) |\n\n**[표 끝]**\n\n*1 검체의 분산과 측정 에러에 대한 특별한 가정이 없는 선형회귀 방법\n\n샘플범위(해당제품): 0 - 3400pg/mL\n\n샘플범위(비교방법): 5 - 3500pg/mL\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 28 -\n해당제품 분석방법*2\n\n비교방법*2\n\n양성\n\n음성\n\n양성\n\n130\n\n15\n\n*2 일치도는 비교 방법과 해당제품 분석방법의 125pg/mL의 결정 역치를\n\n분류하였다.  이 시스템은 심장 질환 환자를 환자의 임상적인\n\nⅤ.  제조․수입허가 신청서 기재 항목\n\n- - 29 -\n- -심장 질환 모집단(전체)-\nNYHA Functional Class\n\n전체\n\nI\n\nII\n\nIII\n\nIV\n\n검체수 (N)\n\n800\n\n150\n\n350\n\n240\n\n60\n\n제품 검사에서 권장하는 결정 역치인 125 pg/mL을 의미한다.\n\n",
        "original_sentence": "제조․수입허가 신청서 기재 항목\n\n- - 27 -\nRepeatability\n\nMean\n\nSD\n\nCV\n\npg/mL\n\npmol/L\n\npg/mL\n\npmol/L\n\n%\n\nHuman Serum 1\n\n50\n\n- 5.9\n- 1.7\n- 0.21\n- 3.5\n**[표 시작]**\n\n| STRATUS CS ACUTE CARE | BETAHCG AND NT-PROBNP | TESTPAK AND TESTPAK | ASSAY, CALPAK AND DILPAK |\n| --- | --- | --- | --- |\n| STATUSFIRST CHF | (CONGESTIVE HEART | FAILURE) NT-PROBNP | “내가 지킨 청렴실천 모아지면 청렴사회” | 팩스: 043-719-4650 |\n| Pathfast NT-proBNP | Mitsubishi | Japan | 아래에 요약되었다. "
      }
    },
    {
      "chunk_id": "chunk_454",
      "text": "|\n| 항체, rheumatoid factors, human anti-mouse 항체 등) | Passing- | EDTA | 혈장 | 300 | 0.96 | -8 | 1.12 |\n| Bablok*1 | (-6 ~ -9) | (1.08 ~ 1.18) |\n\n**[표 끝]**\n\n*1 검체의 분산과 측정 에러에 대한 특별한 가정이 없는 선형회귀 방법\n\n샘플범위(해당제품): 0 - 3400pg/mL\n\n샘플범위(비교방법): 5 - 3500pg/mL\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 28 -\n해당제품 분석방법*2\n\n비교방법*2\n\n양성\n\n음성\n\n양성\n\n130\n\n15\n\n*2 일치도는 비교 방법과 해당제품 분석방법의 125pg/mL의 결정 역치를\n\n분류하였다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 453,
        "window_size": 3,
        "char_count": 400,
        "word_count": 86,
        "page_number": 3,
        "window_text": "본 연구는 20일 동안 수행되었고, 1일 2회를 | 계수 | (95% CI) | 아니오 | □ | (95% CI) |\n\n**[표 끝]**\n\n2회씩 반복하여(n=80) 다음의 결과를 얻었다.\n\n Ⅴ.  제조․수입허가 신청서 기재 항목\n\n- - 27 -\nRepeatability\n\nMean\n\nSD\n\nCV\n\npg/mL\n\npmol/L\n\npg/mL\n\npmol/L\n\n%\n\nHuman Serum 1\n\n50\n\n- 5.9\n- 1.7\n- 0.21\n- 3.5\n**[표 시작]**\n\n| STRATUS CS ACUTE CARE | BETAHCG AND NT-PROBNP | TESTPAK AND TESTPAK | ASSAY, CALPAK AND DILPAK |\n| --- | --- | --- | --- |\n| STATUSFIRST CHF | (CONGESTIVE HEART | FAILURE) NT-PROBNP | “내가 지킨 청렴실천 모아지면 청렴사회” | 팩스: 043-719-4650 |\n| Pathfast NT-proBNP | Mitsubishi | Japan | 아래에 요약되었다.  |\n| 항체, rheumatoid factors, human anti-mouse 항체 등) | Passing- | EDTA | 혈장 | 300 | 0.96 | -8 | 1.12 |\n| Bablok*1 | (-6 ~ -9) | (1.08 ~ 1.18) |\n\n**[표 끝]**\n\n*1 검체의 분산과 측정 에러에 대한 특별한 가정이 없는 선형회귀 방법\n\n샘플범위(해당제품): 0 - 3400pg/mL\n\n샘플범위(비교방법): 5 - 3500pg/mL\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 28 -\n해당제품 분석방법*2\n\n비교방법*2\n\n양성\n\n음성\n\n양성\n\n130\n\n15\n\n*2 일치도는 비교 방법과 해당제품 분석방법의 125pg/mL의 결정 역치를\n\n분류하였다.  이 시스템은 심장 질환 환자를 환자의 임상적인\n\nⅤ.  제조․수입허가 신청서 기재 항목\n\n- - 29 -\n- -심장 질환 모집단(전체)-\nNYHA Functional Class\n\n전체\n\nI\n\nII\n\nIII\n\nIV\n\n검체수 (N)\n\n800\n\n150\n\n350\n\n240\n\n60\n\n제품 검사에서 권장하는 결정 역치인 125 pg/mL을 의미한다.\n\n 이전의 보고자료와 같이 이 결과가 BNP 농도의 증가와\n\nNYHA 분류 증가를 나타내고 있다. ",
        "original_sentence": "|\n| 항체, rheumatoid factors, human anti-mouse 항체 등) | Passing- | EDTA | 혈장 | 300 | 0.96 | -8 | 1.12 |\n| Bablok*1 | (-6 ~ -9) | (1.08 ~ 1.18) |\n\n**[표 끝]**\n\n*1 검체의 분산과 측정 에러에 대한 특별한 가정이 없는 선형회귀 방법\n\n샘플범위(해당제품): 0 - 3400pg/mL\n\n샘플범위(비교방법): 5 - 3500pg/mL\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 28 -\n해당제품 분석방법*2\n\n비교방법*2\n\n양성\n\n음성\n\n양성\n\n130\n\n15\n\n*2 일치도는 비교 방법과 해당제품 분석방법의 125pg/mL의 결정 역치를\n\n분류하였다. "
      }
    },
    {
      "chunk_id": "chunk_455",
      "text": "이 시스템은 심장 질환 환자를 환자의 임상적인\n\nⅤ. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 454,
        "window_size": 3,
        "char_count": 30,
        "word_count": 8,
        "page_number": 16,
        "window_text": "Ⅴ.  제조․수입허가 신청서 기재 항목\n\n- - 27 -\nRepeatability\n\nMean\n\nSD\n\nCV\n\npg/mL\n\npmol/L\n\npg/mL\n\npmol/L\n\n%\n\nHuman Serum 1\n\n50\n\n- 5.9\n- 1.7\n- 0.21\n- 3.5\n**[표 시작]**\n\n| STRATUS CS ACUTE CARE | BETAHCG AND NT-PROBNP | TESTPAK AND TESTPAK | ASSAY, CALPAK AND DILPAK |\n| --- | --- | --- | --- |\n| STATUSFIRST CHF | (CONGESTIVE HEART | FAILURE) NT-PROBNP | “내가 지킨 청렴실천 모아지면 청렴사회” | 팩스: 043-719-4650 |\n| Pathfast NT-proBNP | Mitsubishi | Japan | 아래에 요약되었다.  |\n| 항체, rheumatoid factors, human anti-mouse 항체 등) | Passing- | EDTA | 혈장 | 300 | 0.96 | -8 | 1.12 |\n| Bablok*1 | (-6 ~ -9) | (1.08 ~ 1.18) |\n\n**[표 끝]**\n\n*1 검체의 분산과 측정 에러에 대한 특별한 가정이 없는 선형회귀 방법\n\n샘플범위(해당제품): 0 - 3400pg/mL\n\n샘플범위(비교방법): 5 - 3500pg/mL\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 28 -\n해당제품 분석방법*2\n\n비교방법*2\n\n양성\n\n음성\n\n양성\n\n130\n\n15\n\n*2 일치도는 비교 방법과 해당제품 분석방법의 125pg/mL의 결정 역치를\n\n분류하였다.  이 시스템은 심장 질환 환자를 환자의 임상적인\n\nⅤ.  제조․수입허가 신청서 기재 항목\n\n- - 29 -\n- -심장 질환 모집단(전체)-\nNYHA Functional Class\n\n전체\n\nI\n\nII\n\nIII\n\nIV\n\n검체수 (N)\n\n800\n\n150\n\n350\n\n240\n\n60\n\n제품 검사에서 권장하는 결정 역치인 125 pg/mL을 의미한다.\n\n 이전의 보고자료와 같이 이 결과가 BNP 농도의 증가와\n\nNYHA 분류 증가를 나타내고 있다.  이 분석은 BNP 측정이\n\n심장 질환의 심각성 평가에 사용되어 객관적인 정보를 제공\n\n하는 것을 시사한다.\n\n",
        "original_sentence": "이 시스템은 심장 질환 환자를 환자의 임상적인\n\nⅤ. "
      }
    },
    {
      "chunk_id": "chunk_456",
      "text": "제조․수입허가 신청서 기재 항목\n\n- - 29 -\n- -심장 질환 모집단(전체)-\nNYHA Functional Class\n\n전체\n\nI\n\nII\n\nIII\n\nIV\n\n검체수 (N)\n\n800\n\n150\n\n350\n\n240\n\n60\n\n제품 검사에서 권장하는 결정 역치인 125 pg/mL을 의미한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 455,
        "window_size": 3,
        "char_count": 160,
        "word_count": 35,
        "page_number": 3,
        "window_text": "제조․수입허가 신청서 기재 항목\n\n- - 27 -\nRepeatability\n\nMean\n\nSD\n\nCV\n\npg/mL\n\npmol/L\n\npg/mL\n\npmol/L\n\n%\n\nHuman Serum 1\n\n50\n\n- 5.9\n- 1.7\n- 0.21\n- 3.5\n**[표 시작]**\n\n| STRATUS CS ACUTE CARE | BETAHCG AND NT-PROBNP | TESTPAK AND TESTPAK | ASSAY, CALPAK AND DILPAK |\n| --- | --- | --- | --- |\n| STATUSFIRST CHF | (CONGESTIVE HEART | FAILURE) NT-PROBNP | “내가 지킨 청렴실천 모아지면 청렴사회” | 팩스: 043-719-4650 |\n| Pathfast NT-proBNP | Mitsubishi | Japan | 아래에 요약되었다.  |\n| 항체, rheumatoid factors, human anti-mouse 항체 등) | Passing- | EDTA | 혈장 | 300 | 0.96 | -8 | 1.12 |\n| Bablok*1 | (-6 ~ -9) | (1.08 ~ 1.18) |\n\n**[표 끝]**\n\n*1 검체의 분산과 측정 에러에 대한 특별한 가정이 없는 선형회귀 방법\n\n샘플범위(해당제품): 0 - 3400pg/mL\n\n샘플범위(비교방법): 5 - 3500pg/mL\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 28 -\n해당제품 분석방법*2\n\n비교방법*2\n\n양성\n\n음성\n\n양성\n\n130\n\n15\n\n*2 일치도는 비교 방법과 해당제품 분석방법의 125pg/mL의 결정 역치를\n\n분류하였다.  이 시스템은 심장 질환 환자를 환자의 임상적인\n\nⅤ.  제조․수입허가 신청서 기재 항목\n\n- - 29 -\n- -심장 질환 모집단(전체)-\nNYHA Functional Class\n\n전체\n\nI\n\nII\n\nIII\n\nIV\n\n검체수 (N)\n\n800\n\n150\n\n350\n\n240\n\n60\n\n제품 검사에서 권장하는 결정 역치인 125 pg/mL을 의미한다.\n\n 이전의 보고자료와 같이 이 결과가 BNP 농도의 증가와\n\nNYHA 분류 증가를 나타내고 있다.  이 분석은 BNP 측정이\n\n심장 질환의 심각성 평가에 사용되어 객관적인 정보를 제공\n\n하는 것을 시사한다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 30 -\nⅤ. ",
        "original_sentence": "제조․수입허가 신청서 기재 항목\n\n- - 29 -\n- -심장 질환 모집단(전체)-\nNYHA Functional Class\n\n전체\n\nI\n\nII\n\nIII\n\nIV\n\n검체수 (N)\n\n800\n\n150\n\n350\n\n240\n\n60\n\n제품 검사에서 권장하는 결정 역치인 125 pg/mL을 의미한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_457",
      "text": "이전의 보고자료와 같이 이 결과가 BNP 농도의 증가와\n\nNYHA 분류 증가를 나타내고 있다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 456,
        "window_size": 3,
        "char_count": 53,
        "word_count": 13,
        "page_number": 14,
        "window_text": "|\n| 항체, rheumatoid factors, human anti-mouse 항체 등) | Passing- | EDTA | 혈장 | 300 | 0.96 | -8 | 1.12 |\n| Bablok*1 | (-6 ~ -9) | (1.08 ~ 1.18) |\n\n**[표 끝]**\n\n*1 검체의 분산과 측정 에러에 대한 특별한 가정이 없는 선형회귀 방법\n\n샘플범위(해당제품): 0 - 3400pg/mL\n\n샘플범위(비교방법): 5 - 3500pg/mL\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 28 -\n해당제품 분석방법*2\n\n비교방법*2\n\n양성\n\n음성\n\n양성\n\n130\n\n15\n\n*2 일치도는 비교 방법과 해당제품 분석방법의 125pg/mL의 결정 역치를\n\n분류하였다.  이 시스템은 심장 질환 환자를 환자의 임상적인\n\nⅤ.  제조․수입허가 신청서 기재 항목\n\n- - 29 -\n- -심장 질환 모집단(전체)-\nNYHA Functional Class\n\n전체\n\nI\n\nII\n\nIII\n\nIV\n\n검체수 (N)\n\n800\n\n150\n\n350\n\n240\n\n60\n\n제품 검사에서 권장하는 결정 역치인 125 pg/mL을 의미한다.\n\n 이전의 보고자료와 같이 이 결과가 BNP 농도의 증가와\n\nNYHA 분류 증가를 나타내고 있다.  이 분석은 BNP 측정이\n\n심장 질환의 심각성 평가에 사용되어 객관적인 정보를 제공\n\n하는 것을 시사한다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 30 -\nⅤ.  제조․수입허가 신청서 기재 항목\n\n- - 31 -\n※ 상기 성능은 예시(참고용)에 해당되므로 제품의 특성에 따라 일부\n\n심장 질환과 비-심장 질환 모집단에 대한 연령별 분석이\n\nAmerican Heart Association에 의해 2000 Heart and Stroke\n\nStatistical Update에 발표된 자료와 미국 인구 집단의 연령별\n\n구조에 근거하여 수행되었다. ",
        "original_sentence": "이전의 보고자료와 같이 이 결과가 BNP 농도의 증가와\n\nNYHA 분류 증가를 나타내고 있다. "
      }
    },
    {
      "chunk_id": "chunk_458",
      "text": "이 분석은 BNP 측정이\n\n심장 질환의 심각성 평가에 사용되어 객관적인 정보를 제공\n\n하는 것을 시사한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 457,
        "window_size": 3,
        "char_count": 61,
        "word_count": 15,
        "page_number": 14,
        "window_text": "이 시스템은 심장 질환 환자를 환자의 임상적인\n\nⅤ.  제조․수입허가 신청서 기재 항목\n\n- - 29 -\n- -심장 질환 모집단(전체)-\nNYHA Functional Class\n\n전체\n\nI\n\nII\n\nIII\n\nIV\n\n검체수 (N)\n\n800\n\n150\n\n350\n\n240\n\n60\n\n제품 검사에서 권장하는 결정 역치인 125 pg/mL을 의미한다.\n\n 이전의 보고자료와 같이 이 결과가 BNP 농도의 증가와\n\nNYHA 분류 증가를 나타내고 있다.  이 분석은 BNP 측정이\n\n심장 질환의 심각성 평가에 사용되어 객관적인 정보를 제공\n\n하는 것을 시사한다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 30 -\nⅤ.  제조․수입허가 신청서 기재 항목\n\n- - 31 -\n※ 상기 성능은 예시(참고용)에 해당되므로 제품의 특성에 따라 일부\n\n심장 질환과 비-심장 질환 모집단에 대한 연령별 분석이\n\nAmerican Heart Association에 의해 2000 Heart and Stroke\n\nStatistical Update에 발표된 자료와 미국 인구 집단의 연령별\n\n구조에 근거하여 수행되었다.  사용 목적 집단의 연령 분포는\n\n대략 다음과 같다 : 45세 미만 9%, 45-54세는 11%,\n\n55-64세는 22%, 65-74세는 26%, 그리고 75세 이상은\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 32 -\n<!-- PAGE_38 -->\n###### 6\n\n<!-- PAGE_38 -->\n###### 사용방법\n\n- 1. ",
        "original_sentence": "이 분석은 BNP 측정이\n\n심장 질환의 심각성 평가에 사용되어 객관적인 정보를 제공\n\n하는 것을 시사한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_459",
      "text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 30 -\nⅤ. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 458,
        "window_size": 3,
        "char_count": 61,
        "word_count": 13,
        "page_number": 1,
        "window_text": "제조․수입허가 신청서 기재 항목\n\n- - 29 -\n- -심장 질환 모집단(전체)-\nNYHA Functional Class\n\n전체\n\nI\n\nII\n\nIII\n\nIV\n\n검체수 (N)\n\n800\n\n150\n\n350\n\n240\n\n60\n\n제품 검사에서 권장하는 결정 역치인 125 pg/mL을 의미한다.\n\n 이전의 보고자료와 같이 이 결과가 BNP 농도의 증가와\n\nNYHA 분류 증가를 나타내고 있다.  이 분석은 BNP 측정이\n\n심장 질환의 심각성 평가에 사용되어 객관적인 정보를 제공\n\n하는 것을 시사한다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 30 -\nⅤ.  제조․수입허가 신청서 기재 항목\n\n- - 31 -\n※ 상기 성능은 예시(참고용)에 해당되므로 제품의 특성에 따라 일부\n\n심장 질환과 비-심장 질환 모집단에 대한 연령별 분석이\n\nAmerican Heart Association에 의해 2000 Heart and Stroke\n\nStatistical Update에 발표된 자료와 미국 인구 집단의 연령별\n\n구조에 근거하여 수행되었다.  사용 목적 집단의 연령 분포는\n\n대략 다음과 같다 : 45세 미만 9%, 45-54세는 11%,\n\n55-64세는 22%, 65-74세는 26%, 그리고 75세 이상은\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 32 -\n<!-- PAGE_38 -->\n###### 6\n\n<!-- PAGE_38 -->\n###### 사용방법\n\n- 1.  검체준비 및 저장방법, 검사 전 준비사항, 검사과정, 결과판정 및 정도\n관리, 장비(해당 장비의 제조사, 모델명) 등을 아래와 같이 포함하여\n\n시험 전 시약 조제가 필요한 경우 조제 방법 및 조건, 검사에 필요한\n\n3) 필요한 경우, 시약의 성능과 판정에 영향을 줄 수 있는 기기 및\n\n4) 필요한 경우, 보정물질에 대한 설명 및 방법에 대하여 기재한다.\n\n",
        "original_sentence": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 30 -\nⅤ. "
      }
    },
    {
      "chunk_id": "chunk_460",
      "text": "제조․수입허가 신청서 기재 항목\n\n- - 31 -\n※ 상기 성능은 예시(참고용)에 해당되므로 제품의 특성에 따라 일부\n\n심장 질환과 비-심장 질환 모집단에 대한 연령별 분석이\n\nAmerican Heart Association에 의해 2000 Heart and Stroke\n\nStatistical Update에 발표된 자료와 미국 인구 집단의 연령별\n\n구조에 근거하여 수행되었다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 459,
        "window_size": 3,
        "char_count": 212,
        "word_count": 44,
        "page_number": 3,
        "window_text": "이전의 보고자료와 같이 이 결과가 BNP 농도의 증가와\n\nNYHA 분류 증가를 나타내고 있다.  이 분석은 BNP 측정이\n\n심장 질환의 심각성 평가에 사용되어 객관적인 정보를 제공\n\n하는 것을 시사한다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 30 -\nⅤ.  제조․수입허가 신청서 기재 항목\n\n- - 31 -\n※ 상기 성능은 예시(참고용)에 해당되므로 제품의 특성에 따라 일부\n\n심장 질환과 비-심장 질환 모집단에 대한 연령별 분석이\n\nAmerican Heart Association에 의해 2000 Heart and Stroke\n\nStatistical Update에 발표된 자료와 미국 인구 집단의 연령별\n\n구조에 근거하여 수행되었다.  사용 목적 집단의 연령 분포는\n\n대략 다음과 같다 : 45세 미만 9%, 45-54세는 11%,\n\n55-64세는 22%, 65-74세는 26%, 그리고 75세 이상은\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 32 -\n<!-- PAGE_38 -->\n###### 6\n\n<!-- PAGE_38 -->\n###### 사용방법\n\n- 1.  검체준비 및 저장방법, 검사 전 준비사항, 검사과정, 결과판정 및 정도\n관리, 장비(해당 장비의 제조사, 모델명) 등을 아래와 같이 포함하여\n\n시험 전 시약 조제가 필요한 경우 조제 방법 및 조건, 검사에 필요한\n\n3) 필요한 경우, 시약의 성능과 판정에 영향을 줄 수 있는 기기 및\n\n4) 필요한 경우, 보정물질에 대한 설명 및 방법에 대하여 기재한다.\n\n - 다. ",
        "original_sentence": "제조․수입허가 신청서 기재 항목\n\n- - 31 -\n※ 상기 성능은 예시(참고용)에 해당되므로 제품의 특성에 따라 일부\n\n심장 질환과 비-심장 질환 모집단에 대한 연령별 분석이\n\nAmerican Heart Association에 의해 2000 Heart and Stroke\n\nStatistical Update에 발표된 자료와 미국 인구 집단의 연령별\n\n구조에 근거하여 수행되었다. "
      }
    },
    {
      "chunk_id": "chunk_461",
      "text": "사용 목적 집단의 연령 분포는\n\n대략 다음과 같다 : 45세 미만 9%, 45-54세는 11%,\n\n55-64세는 22%, 65-74세는 26%, 그리고 75세 이상은\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 32 -\n<!-- PAGE_38 -->\n###### 6\n\n<!-- PAGE_38 -->\n###### 사용방법\n\n- 1. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 460,
        "window_size": 3,
        "char_count": 214,
        "word_count": 45,
        "page_number": 38,
        "window_text": "이 분석은 BNP 측정이\n\n심장 질환의 심각성 평가에 사용되어 객관적인 정보를 제공\n\n하는 것을 시사한다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 30 -\nⅤ.  제조․수입허가 신청서 기재 항목\n\n- - 31 -\n※ 상기 성능은 예시(참고용)에 해당되므로 제품의 특성에 따라 일부\n\n심장 질환과 비-심장 질환 모집단에 대한 연령별 분석이\n\nAmerican Heart Association에 의해 2000 Heart and Stroke\n\nStatistical Update에 발표된 자료와 미국 인구 집단의 연령별\n\n구조에 근거하여 수행되었다.  사용 목적 집단의 연령 분포는\n\n대략 다음과 같다 : 45세 미만 9%, 45-54세는 11%,\n\n55-64세는 22%, 65-74세는 26%, 그리고 75세 이상은\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 32 -\n<!-- PAGE_38 -->\n###### 6\n\n<!-- PAGE_38 -->\n###### 사용방법\n\n- 1.  검체준비 및 저장방법, 검사 전 준비사항, 검사과정, 결과판정 및 정도\n관리, 장비(해당 장비의 제조사, 모델명) 등을 아래와 같이 포함하여\n\n시험 전 시약 조제가 필요한 경우 조제 방법 및 조건, 검사에 필요한\n\n3) 필요한 경우, 시약의 성능과 판정에 영향을 줄 수 있는 기기 및\n\n4) 필요한 경우, 보정물질에 대한 설명 및 방법에 대하여 기재한다.\n\n - 다.  검사과정\n체외진단 의료기기 장비의 매뉴얼 및 사용방법에 대하여 상세하게\n\n기재한다. ",
        "original_sentence": "사용 목적 집단의 연령 분포는\n\n대략 다음과 같다 : 45세 미만 9%, 45-54세는 11%,\n\n55-64세는 22%, 65-74세는 26%, 그리고 75세 이상은\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 32 -\n<!-- PAGE_38 -->\n###### 6\n\n<!-- PAGE_38 -->\n###### 사용방법\n\n- 1. "
      }
    },
    {
      "chunk_id": "chunk_462",
      "text": "검체준비 및 저장방법, 검사 전 준비사항, 검사과정, 결과판정 및 정도\n관리, 장비(해당 장비의 제조사, 모델명) 등을 아래와 같이 포함하여\n\n시험 전 시약 조제가 필요한 경우 조제 방법 및 조건, 검사에 필요한\n\n3) 필요한 경우, 시약의 성능과 판정에 영향을 줄 수 있는 기기 및\n\n4) 필요한 경우, 보정물질에 대한 설명 및 방법에 대하여 기재한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 461,
        "window_size": 3,
        "char_count": 200,
        "word_count": 53,
        "page_number": 3,
        "window_text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 30 -\nⅤ.  제조․수입허가 신청서 기재 항목\n\n- - 31 -\n※ 상기 성능은 예시(참고용)에 해당되므로 제품의 특성에 따라 일부\n\n심장 질환과 비-심장 질환 모집단에 대한 연령별 분석이\n\nAmerican Heart Association에 의해 2000 Heart and Stroke\n\nStatistical Update에 발표된 자료와 미국 인구 집단의 연령별\n\n구조에 근거하여 수행되었다.  사용 목적 집단의 연령 분포는\n\n대략 다음과 같다 : 45세 미만 9%, 45-54세는 11%,\n\n55-64세는 22%, 65-74세는 26%, 그리고 75세 이상은\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 32 -\n<!-- PAGE_38 -->\n###### 6\n\n<!-- PAGE_38 -->\n###### 사용방법\n\n- 1.  검체준비 및 저장방법, 검사 전 준비사항, 검사과정, 결과판정 및 정도\n관리, 장비(해당 장비의 제조사, 모델명) 등을 아래와 같이 포함하여\n\n시험 전 시약 조제가 필요한 경우 조제 방법 및 조건, 검사에 필요한\n\n3) 필요한 경우, 시약의 성능과 판정에 영향을 줄 수 있는 기기 및\n\n4) 필요한 경우, 보정물질에 대한 설명 및 방법에 대하여 기재한다.\n\n - 다.  검사과정\n체외진단 의료기기 장비의 매뉴얼 및 사용방법에 대하여 상세하게\n\n기재한다.  환자의 검체를 첨가하는 과정(검체 전처리, 반응시간,\n\n실험실 온도 조건 등), 시험검사 단계(장비의 운용 방법 및 반응시간 등)\n\n및 결과판독과정(판독시간, 결과 출력 방법 등)을 상세하게 기재한다.\n\n",
        "original_sentence": "검체준비 및 저장방법, 검사 전 준비사항, 검사과정, 결과판정 및 정도\n관리, 장비(해당 장비의 제조사, 모델명) 등을 아래와 같이 포함하여\n\n시험 전 시약 조제가 필요한 경우 조제 방법 및 조건, 검사에 필요한\n\n3) 필요한 경우, 시약의 성능과 판정에 영향을 줄 수 있는 기기 및\n\n4) 필요한 경우, 보정물질에 대한 설명 및 방법에 대하여 기재한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_463",
      "text": "- 다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 462,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 74,
        "window_text": "제조․수입허가 신청서 기재 항목\n\n- - 31 -\n※ 상기 성능은 예시(참고용)에 해당되므로 제품의 특성에 따라 일부\n\n심장 질환과 비-심장 질환 모집단에 대한 연령별 분석이\n\nAmerican Heart Association에 의해 2000 Heart and Stroke\n\nStatistical Update에 발표된 자료와 미국 인구 집단의 연령별\n\n구조에 근거하여 수행되었다.  사용 목적 집단의 연령 분포는\n\n대략 다음과 같다 : 45세 미만 9%, 45-54세는 11%,\n\n55-64세는 22%, 65-74세는 26%, 그리고 75세 이상은\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 32 -\n<!-- PAGE_38 -->\n###### 6\n\n<!-- PAGE_38 -->\n###### 사용방법\n\n- 1.  검체준비 및 저장방법, 검사 전 준비사항, 검사과정, 결과판정 및 정도\n관리, 장비(해당 장비의 제조사, 모델명) 등을 아래와 같이 포함하여\n\n시험 전 시약 조제가 필요한 경우 조제 방법 및 조건, 검사에 필요한\n\n3) 필요한 경우, 시약의 성능과 판정에 영향을 줄 수 있는 기기 및\n\n4) 필요한 경우, 보정물질에 대한 설명 및 방법에 대하여 기재한다.\n\n - 다.  검사과정\n체외진단 의료기기 장비의 매뉴얼 및 사용방법에 대하여 상세하게\n\n기재한다.  환자의 검체를 첨가하는 과정(검체 전처리, 반응시간,\n\n실험실 온도 조건 등), 시험검사 단계(장비의 운용 방법 및 반응시간 등)\n\n및 결과판독과정(판독시간, 결과 출력 방법 등)을 상세하게 기재한다.\n\n Ⅴ. ",
        "original_sentence": "- 다. "
      }
    },
    {
      "chunk_id": "chunk_464",
      "text": "검사과정\n체외진단 의료기기 장비의 매뉴얼 및 사용방법에 대하여 상세하게\n\n기재한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 463,
        "window_size": 3,
        "char_count": 47,
        "word_count": 10,
        "page_number": 26,
        "window_text": "사용 목적 집단의 연령 분포는\n\n대략 다음과 같다 : 45세 미만 9%, 45-54세는 11%,\n\n55-64세는 22%, 65-74세는 26%, 그리고 75세 이상은\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 32 -\n<!-- PAGE_38 -->\n###### 6\n\n<!-- PAGE_38 -->\n###### 사용방법\n\n- 1.  검체준비 및 저장방법, 검사 전 준비사항, 검사과정, 결과판정 및 정도\n관리, 장비(해당 장비의 제조사, 모델명) 등을 아래와 같이 포함하여\n\n시험 전 시약 조제가 필요한 경우 조제 방법 및 조건, 검사에 필요한\n\n3) 필요한 경우, 시약의 성능과 판정에 영향을 줄 수 있는 기기 및\n\n4) 필요한 경우, 보정물질에 대한 설명 및 방법에 대하여 기재한다.\n\n - 다.  검사과정\n체외진단 의료기기 장비의 매뉴얼 및 사용방법에 대하여 상세하게\n\n기재한다.  환자의 검체를 첨가하는 과정(검체 전처리, 반응시간,\n\n실험실 온도 조건 등), 시험검사 단계(장비의 운용 방법 및 반응시간 등)\n\n및 결과판독과정(판독시간, 결과 출력 방법 등)을 상세하게 기재한다.\n\n Ⅴ.  제조․수입허가 신청서 기재 항목\n\n- - 33 -\n- 라. ",
        "original_sentence": "검사과정\n체외진단 의료기기 장비의 매뉴얼 및 사용방법에 대하여 상세하게\n\n기재한다. "
      }
    },
    {
      "chunk_id": "chunk_465",
      "text": "환자의 검체를 첨가하는 과정(검체 전처리, 반응시간,\n\n실험실 온도 조건 등), 시험검사 단계(장비의 운용 방법 및 반응시간 등)\n\n및 결과판독과정(판독시간, 결과 출력 방법 등)을 상세하게 기재한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 464,
        "window_size": 3,
        "char_count": 114,
        "word_count": 25,
        "page_number": 33,
        "window_text": "검체준비 및 저장방법, 검사 전 준비사항, 검사과정, 결과판정 및 정도\n관리, 장비(해당 장비의 제조사, 모델명) 등을 아래와 같이 포함하여\n\n시험 전 시약 조제가 필요한 경우 조제 방법 및 조건, 검사에 필요한\n\n3) 필요한 경우, 시약의 성능과 판정에 영향을 줄 수 있는 기기 및\n\n4) 필요한 경우, 보정물질에 대한 설명 및 방법에 대하여 기재한다.\n\n - 다.  검사과정\n체외진단 의료기기 장비의 매뉴얼 및 사용방법에 대하여 상세하게\n\n기재한다.  환자의 검체를 첨가하는 과정(검체 전처리, 반응시간,\n\n실험실 온도 조건 등), 시험검사 단계(장비의 운용 방법 및 반응시간 등)\n\n및 결과판독과정(판독시간, 결과 출력 방법 등)을 상세하게 기재한다.\n\n Ⅴ.  제조․수입허가 신청서 기재 항목\n\n- - 33 -\n- 라.  결과판정\n양성, 음성, 경계값(equivocal), 미확정(indeterminate), 무효(invalid)\n\n등의 예측되는 모든 경우의 시험 결과를 판정하는 기준과 해석을\n\n1) 경계값(equivocal), 미확정(indeterminate) 또는 무효(invalid) 결과를\n\n2) 환자 검체의 검사 결과를 판독하기 전에 확인해야 할 대조물질 및\n\n3) 검사의 검출한계 또는 정량한계 등에 따른 보고가능범위에 대하여\n\n2) 제공하는 정도관리물질과 그 물질의 목표값이 있을 경우, 제시된\n\n3) 정도 관리 결과가 적합하지 않을 때 제시할 수 있는 대책을\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 34 -\n<!-- PAGE_40 -->\n###### 7\n\n<!-- PAGE_40 -->\n###### 사용시 주의사항\n\n- 1. ",
        "original_sentence": "환자의 검체를 첨가하는 과정(검체 전처리, 반응시간,\n\n실험실 온도 조건 등), 시험검사 단계(장비의 운용 방법 및 반응시간 등)\n\n및 결과판독과정(판독시간, 결과 출력 방법 등)을 상세하게 기재한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_466",
      "text": "Ⅴ. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 465,
        "window_size": 3,
        "char_count": 3,
        "word_count": 1,
        "page_number": 6,
        "window_text": "- 다.  검사과정\n체외진단 의료기기 장비의 매뉴얼 및 사용방법에 대하여 상세하게\n\n기재한다.  환자의 검체를 첨가하는 과정(검체 전처리, 반응시간,\n\n실험실 온도 조건 등), 시험검사 단계(장비의 운용 방법 및 반응시간 등)\n\n및 결과판독과정(판독시간, 결과 출력 방법 등)을 상세하게 기재한다.\n\n Ⅴ.  제조․수입허가 신청서 기재 항목\n\n- - 33 -\n- 라.  결과판정\n양성, 음성, 경계값(equivocal), 미확정(indeterminate), 무효(invalid)\n\n등의 예측되는 모든 경우의 시험 결과를 판정하는 기준과 해석을\n\n1) 경계값(equivocal), 미확정(indeterminate) 또는 무효(invalid) 결과를\n\n2) 환자 검체의 검사 결과를 판독하기 전에 확인해야 할 대조물질 및\n\n3) 검사의 검출한계 또는 정량한계 등에 따른 보고가능범위에 대하여\n\n2) 제공하는 정도관리물질과 그 물질의 목표값이 있을 경우, 제시된\n\n3) 정도 관리 결과가 적합하지 않을 때 제시할 수 있는 대책을\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 34 -\n<!-- PAGE_40 -->\n###### 7\n\n<!-- PAGE_40 -->\n###### 사용시 주의사항\n\n- 1.  다음의 사항을 포함하여 기재한다.\n",
        "original_sentence": "Ⅴ. "
      }
    },
    {
      "chunk_id": "chunk_467",
      "text": "제조․수입허가 신청서 기재 항목\n\n- - 33 -\n- 라. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 466,
        "window_size": 3,
        "char_count": 33,
        "word_count": 10,
        "page_number": 3,
        "window_text": "검사과정\n체외진단 의료기기 장비의 매뉴얼 및 사용방법에 대하여 상세하게\n\n기재한다.  환자의 검체를 첨가하는 과정(검체 전처리, 반응시간,\n\n실험실 온도 조건 등), 시험검사 단계(장비의 운용 방법 및 반응시간 등)\n\n및 결과판독과정(판독시간, 결과 출력 방법 등)을 상세하게 기재한다.\n\n Ⅴ.  제조․수입허가 신청서 기재 항목\n\n- - 33 -\n- 라.  결과판정\n양성, 음성, 경계값(equivocal), 미확정(indeterminate), 무효(invalid)\n\n등의 예측되는 모든 경우의 시험 결과를 판정하는 기준과 해석을\n\n1) 경계값(equivocal), 미확정(indeterminate) 또는 무효(invalid) 결과를\n\n2) 환자 검체의 검사 결과를 판독하기 전에 확인해야 할 대조물질 및\n\n3) 검사의 검출한계 또는 정량한계 등에 따른 보고가능범위에 대하여\n\n2) 제공하는 정도관리물질과 그 물질의 목표값이 있을 경우, 제시된\n\n3) 정도 관리 결과가 적합하지 않을 때 제시할 수 있는 대책을\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 34 -\n<!-- PAGE_40 -->\n###### 7\n\n<!-- PAGE_40 -->\n###### 사용시 주의사항\n\n- 1.  다음의 사항을 포함하여 기재한다.\n - 나. ",
        "original_sentence": "제조․수입허가 신청서 기재 항목\n\n- - 33 -\n- 라. "
      }
    },
    {
      "chunk_id": "chunk_468",
      "text": "결과판정\n양성, 음성, 경계값(equivocal), 미확정(indeterminate), 무효(invalid)\n\n등의 예측되는 모든 경우의 시험 결과를 판정하는 기준과 해석을\n\n1) 경계값(equivocal), 미확정(indeterminate) 또는 무효(invalid) 결과를\n\n2) 환자 검체의 검사 결과를 판독하기 전에 확인해야 할 대조물질 및\n\n3) 검사의 검출한계 또는 정량한계 등에 따른 보고가능범위에 대하여\n\n2) 제공하는 정도관리물질과 그 물질의 목표값이 있을 경우, 제시된\n\n3) 정도 관리 결과가 적합하지 않을 때 제시할 수 있는 대책을\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 34 -\n<!-- PAGE_40 -->\n###### 7\n\n<!-- PAGE_40 -->\n###### 사용시 주의사항\n\n- 1. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 467,
        "window_size": 3,
        "char_count": 435,
        "word_count": 86,
        "page_number": 40,
        "window_text": "환자의 검체를 첨가하는 과정(검체 전처리, 반응시간,\n\n실험실 온도 조건 등), 시험검사 단계(장비의 운용 방법 및 반응시간 등)\n\n및 결과판독과정(판독시간, 결과 출력 방법 등)을 상세하게 기재한다.\n\n Ⅴ.  제조․수입허가 신청서 기재 항목\n\n- - 33 -\n- 라.  결과판정\n양성, 음성, 경계값(equivocal), 미확정(indeterminate), 무효(invalid)\n\n등의 예측되는 모든 경우의 시험 결과를 판정하는 기준과 해석을\n\n1) 경계값(equivocal), 미확정(indeterminate) 또는 무효(invalid) 결과를\n\n2) 환자 검체의 검사 결과를 판독하기 전에 확인해야 할 대조물질 및\n\n3) 검사의 검출한계 또는 정량한계 등에 따른 보고가능범위에 대하여\n\n2) 제공하는 정도관리물질과 그 물질의 목표값이 있을 경우, 제시된\n\n3) 정도 관리 결과가 적합하지 않을 때 제시할 수 있는 대책을\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 34 -\n<!-- PAGE_40 -->\n###### 7\n\n<!-- PAGE_40 -->\n###### 사용시 주의사항\n\n- 1.  다음의 사항을 포함하여 기재한다.\n - 나.  일반적인 실험실 안전지침 및 생물학적 위험물질(검체, 감염 가능성\n- 마. ",
        "original_sentence": "결과판정\n양성, 음성, 경계값(equivocal), 미확정(indeterminate), 무효(invalid)\n\n등의 예측되는 모든 경우의 시험 결과를 판정하는 기준과 해석을\n\n1) 경계값(equivocal), 미확정(indeterminate) 또는 무효(invalid) 결과를\n\n2) 환자 검체의 검사 결과를 판독하기 전에 확인해야 할 대조물질 및\n\n3) 검사의 검출한계 또는 정량한계 등에 따른 보고가능범위에 대하여\n\n2) 제공하는 정도관리물질과 그 물질의 목표값이 있을 경우, 제시된\n\n3) 정도 관리 결과가 적합하지 않을 때 제시할 수 있는 대책을\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 34 -\n<!-- PAGE_40 -->\n###### 7\n\n<!-- PAGE_40 -->\n###### 사용시 주의사항\n\n- 1. "
      }
    },
    {
      "chunk_id": "chunk_469",
      "text": "다음의 사항을 포함하여 기재한다.\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 468,
        "window_size": 3,
        "char_count": 19,
        "word_count": 4,
        "page_number": 3,
        "window_text": "Ⅴ.  제조․수입허가 신청서 기재 항목\n\n- - 33 -\n- 라.  결과판정\n양성, 음성, 경계값(equivocal), 미확정(indeterminate), 무효(invalid)\n\n등의 예측되는 모든 경우의 시험 결과를 판정하는 기준과 해석을\n\n1) 경계값(equivocal), 미확정(indeterminate) 또는 무효(invalid) 결과를\n\n2) 환자 검체의 검사 결과를 판독하기 전에 확인해야 할 대조물질 및\n\n3) 검사의 검출한계 또는 정량한계 등에 따른 보고가능범위에 대하여\n\n2) 제공하는 정도관리물질과 그 물질의 목표값이 있을 경우, 제시된\n\n3) 정도 관리 결과가 적합하지 않을 때 제시할 수 있는 대책을\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 34 -\n<!-- PAGE_40 -->\n###### 7\n\n<!-- PAGE_40 -->\n###### 사용시 주의사항\n\n- 1.  다음의 사항을 포함하여 기재한다.\n - 나.  일반적인 실험실 안전지침 및 생물학적 위험물질(검체, 감염 가능성\n- 마.  경고사항을 포함하여 검체 및 키트 취급 및 보관상의 주의사항(온도,\n- 바. ",
        "original_sentence": "다음의 사항을 포함하여 기재한다.\n"
      }
    },
    {
      "chunk_id": "chunk_470",
      "text": "- 나. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 469,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 74,
        "window_text": "제조․수입허가 신청서 기재 항목\n\n- - 33 -\n- 라.  결과판정\n양성, 음성, 경계값(equivocal), 미확정(indeterminate), 무효(invalid)\n\n등의 예측되는 모든 경우의 시험 결과를 판정하는 기준과 해석을\n\n1) 경계값(equivocal), 미확정(indeterminate) 또는 무효(invalid) 결과를\n\n2) 환자 검체의 검사 결과를 판독하기 전에 확인해야 할 대조물질 및\n\n3) 검사의 검출한계 또는 정량한계 등에 따른 보고가능범위에 대하여\n\n2) 제공하는 정도관리물질과 그 물질의 목표값이 있을 경우, 제시된\n\n3) 정도 관리 결과가 적합하지 않을 때 제시할 수 있는 대책을\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 34 -\n<!-- PAGE_40 -->\n###### 7\n\n<!-- PAGE_40 -->\n###### 사용시 주의사항\n\n- 1.  다음의 사항을 포함하여 기재한다.\n - 나.  일반적인 실험실 안전지침 및 생물학적 위험물질(검체, 감염 가능성\n- 마.  경고사항을 포함하여 검체 및 키트 취급 및 보관상의 주의사항(온도,\n- 바.  임상 적용 대상 및 미적용 대상을 포함하여 적용상의 주의사항 및\n- 사. ",
        "original_sentence": "- 나. "
      }
    },
    {
      "chunk_id": "chunk_471",
      "text": "일반적인 실험실 안전지침 및 생물학적 위험물질(검체, 감염 가능성\n- 마. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 470,
        "window_size": 3,
        "char_count": 42,
        "word_count": 10,
        "page_number": 32,
        "window_text": "결과판정\n양성, 음성, 경계값(equivocal), 미확정(indeterminate), 무효(invalid)\n\n등의 예측되는 모든 경우의 시험 결과를 판정하는 기준과 해석을\n\n1) 경계값(equivocal), 미확정(indeterminate) 또는 무효(invalid) 결과를\n\n2) 환자 검체의 검사 결과를 판독하기 전에 확인해야 할 대조물질 및\n\n3) 검사의 검출한계 또는 정량한계 등에 따른 보고가능범위에 대하여\n\n2) 제공하는 정도관리물질과 그 물질의 목표값이 있을 경우, 제시된\n\n3) 정도 관리 결과가 적합하지 않을 때 제시할 수 있는 대책을\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 34 -\n<!-- PAGE_40 -->\n###### 7\n\n<!-- PAGE_40 -->\n###### 사용시 주의사항\n\n- 1.  다음의 사항을 포함하여 기재한다.\n - 나.  일반적인 실험실 안전지침 및 생물학적 위험물질(검체, 감염 가능성\n- 마.  경고사항을 포함하여 검체 및 키트 취급 및 보관상의 주의사항(온도,\n- 바.  임상 적용 대상 및 미적용 대상을 포함하여 적용상의 주의사항 및\n- 사.  검사에 영향을 미치는 내용(예 : 간섭 및 교차반응 물질, 위양성\n- 아. ",
        "original_sentence": "일반적인 실험실 안전지침 및 생물학적 위험물질(검체, 감염 가능성\n- 마. "
      }
    },
    {
      "chunk_id": "chunk_472",
      "text": "경고사항을 포함하여 검체 및 키트 취급 및 보관상의 주의사항(온도,\n- 바. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 471,
        "window_size": 3,
        "char_count": 43,
        "word_count": 11,
        "page_number": 3,
        "window_text": "다음의 사항을 포함하여 기재한다.\n - 나.  일반적인 실험실 안전지침 및 생물학적 위험물질(검체, 감염 가능성\n- 마.  경고사항을 포함하여 검체 및 키트 취급 및 보관상의 주의사항(온도,\n- 바.  임상 적용 대상 및 미적용 대상을 포함하여 적용상의 주의사항 및\n- 사.  검사에 영향을 미치는 내용(예 : 간섭 및 교차반응 물질, 위양성\n- 아.  다른 의료기기와 결합하여 사용하는 경우 적절한 조합에 대한\n- 1. ",
        "original_sentence": "경고사항을 포함하여 검체 및 키트 취급 및 보관상의 주의사항(온도,\n- 바. "
      }
    },
    {
      "chunk_id": "chunk_473",
      "text": "임상 적용 대상 및 미적용 대상을 포함하여 적용상의 주의사항 및\n- 사. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 472,
        "window_size": 3,
        "char_count": 41,
        "word_count": 12,
        "page_number": 3,
        "window_text": "- 나.  일반적인 실험실 안전지침 및 생물학적 위험물질(검체, 감염 가능성\n- 마.  경고사항을 포함하여 검체 및 키트 취급 및 보관상의 주의사항(온도,\n- 바.  임상 적용 대상 및 미적용 대상을 포함하여 적용상의 주의사항 및\n- 사.  검사에 영향을 미치는 내용(예 : 간섭 및 교차반응 물질, 위양성\n- 아.  다른 의료기기와 결합하여 사용하는 경우 적절한 조합에 대한\n- 1.  체외진단용 의료기기의 포장단위는 취급상 용이한 최소 단위로 기재하되,\n제조의 경우 “자사포장단위”, 수입의 경우는 “제조원포장단위”로 기재한다.\n\n",
        "original_sentence": "임상 적용 대상 및 미적용 대상을 포함하여 적용상의 주의사항 및\n- 사. "
      }
    },
    {
      "chunk_id": "chunk_474",
      "text": "검사에 영향을 미치는 내용(예 : 간섭 및 교차반응 물질, 위양성\n- 아. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 473,
        "window_size": 3,
        "char_count": 42,
        "word_count": 12,
        "page_number": 14,
        "window_text": "일반적인 실험실 안전지침 및 생물학적 위험물질(검체, 감염 가능성\n- 마.  경고사항을 포함하여 검체 및 키트 취급 및 보관상의 주의사항(온도,\n- 바.  임상 적용 대상 및 미적용 대상을 포함하여 적용상의 주의사항 및\n- 사.  검사에 영향을 미치는 내용(예 : 간섭 및 교차반응 물질, 위양성\n- 아.  다른 의료기기와 결합하여 사용하는 경우 적절한 조합에 대한\n- 1.  체외진단용 의료기기의 포장단위는 취급상 용이한 최소 단위로 기재하되,\n제조의 경우 “자사포장단위”, 수입의 경우는 “제조원포장단위”로 기재한다.\n\n Ⅴ. ",
        "original_sentence": "검사에 영향을 미치는 내용(예 : 간섭 및 교차반응 물질, 위양성\n- 아. "
      }
    },
    {
      "chunk_id": "chunk_475",
      "text": "다른 의료기기와 결합하여 사용하는 경우 적절한 조합에 대한\n- 1. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 474,
        "window_size": 3,
        "char_count": 38,
        "word_count": 10,
        "page_number": 21,
        "window_text": "경고사항을 포함하여 검체 및 키트 취급 및 보관상의 주의사항(온도,\n- 바.  임상 적용 대상 및 미적용 대상을 포함하여 적용상의 주의사항 및\n- 사.  검사에 영향을 미치는 내용(예 : 간섭 및 교차반응 물질, 위양성\n- 아.  다른 의료기기와 결합하여 사용하는 경우 적절한 조합에 대한\n- 1.  체외진단용 의료기기의 포장단위는 취급상 용이한 최소 단위로 기재하되,\n제조의 경우 “자사포장단위”, 수입의 경우는 “제조원포장단위”로 기재한다.\n\n Ⅴ.  제조․수입허가 신청서 기재 항목\n\n- - 35 -\n<!-- PAGE_41 -->\n###### 9\n\n<!-- PAGE_41 -->\n###### 저장방법 및 사용기간\n\n- 1. ",
        "original_sentence": "다른 의료기기와 결합하여 사용하는 경우 적절한 조합에 대한\n- 1. "
      }
    },
    {
      "chunk_id": "chunk_476",
      "text": "체외진단용 의료기기의 포장단위는 취급상 용이한 최소 단위로 기재하되,\n제조의 경우 “자사포장단위”, 수입의 경우는 “제조원포장단위”로 기재한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 475,
        "window_size": 3,
        "char_count": 82,
        "word_count": 15,
        "page_number": 1,
        "window_text": "임상 적용 대상 및 미적용 대상을 포함하여 적용상의 주의사항 및\n- 사.  검사에 영향을 미치는 내용(예 : 간섭 및 교차반응 물질, 위양성\n- 아.  다른 의료기기와 결합하여 사용하는 경우 적절한 조합에 대한\n- 1.  체외진단용 의료기기의 포장단위는 취급상 용이한 최소 단위로 기재하되,\n제조의 경우 “자사포장단위”, 수입의 경우는 “제조원포장단위”로 기재한다.\n\n Ⅴ.  제조․수입허가 신청서 기재 항목\n\n- - 35 -\n<!-- PAGE_41 -->\n###### 9\n\n<!-- PAGE_41 -->\n###### 저장방법 및 사용기간\n\n- 1.  저장방법은 체외진단용 의료기기의 특성을 고려하여 안정성이 보장될 수\n있도록 검증된 자료에 의한 구체적인 보관 조건(온도, 습도, 차광,\n\n- 가. ",
        "original_sentence": "체외진단용 의료기기의 포장단위는 취급상 용이한 최소 단위로 기재하되,\n제조의 경우 “자사포장단위”, 수입의 경우는 “제조원포장단위”로 기재한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_477",
      "text": "Ⅴ. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 476,
        "window_size": 3,
        "char_count": 3,
        "word_count": 1,
        "page_number": 6,
        "window_text": "검사에 영향을 미치는 내용(예 : 간섭 및 교차반응 물질, 위양성\n- 아.  다른 의료기기와 결합하여 사용하는 경우 적절한 조합에 대한\n- 1.  체외진단용 의료기기의 포장단위는 취급상 용이한 최소 단위로 기재하되,\n제조의 경우 “자사포장단위”, 수입의 경우는 “제조원포장단위”로 기재한다.\n\n Ⅴ.  제조․수입허가 신청서 기재 항목\n\n- - 35 -\n<!-- PAGE_41 -->\n###### 9\n\n<!-- PAGE_41 -->\n###### 저장방법 및 사용기간\n\n- 1.  저장방법은 체외진단용 의료기기의 특성을 고려하여 안정성이 보장될 수\n있도록 검증된 자료에 의한 구체적인 보관 조건(온도, 습도, 차광,\n\n- 가.  키트 또는 세트의 제품인 경우, 구성품별로 보관조건을 기재하고,\n- 라. ",
        "original_sentence": "Ⅴ. "
      }
    },
    {
      "chunk_id": "chunk_478",
      "text": "제조․수입허가 신청서 기재 항목\n\n- - 35 -\n<!-- PAGE_41 -->\n###### 9\n\n<!-- PAGE_41 -->\n###### 저장방법 및 사용기간\n\n- 1. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 477,
        "window_size": 3,
        "char_count": 97,
        "word_count": 22,
        "page_number": 41,
        "window_text": "다른 의료기기와 결합하여 사용하는 경우 적절한 조합에 대한\n- 1.  체외진단용 의료기기의 포장단위는 취급상 용이한 최소 단위로 기재하되,\n제조의 경우 “자사포장단위”, 수입의 경우는 “제조원포장단위”로 기재한다.\n\n Ⅴ.  제조․수입허가 신청서 기재 항목\n\n- - 35 -\n<!-- PAGE_41 -->\n###### 9\n\n<!-- PAGE_41 -->\n###### 저장방법 및 사용기간\n\n- 1.  저장방법은 체외진단용 의료기기의 특성을 고려하여 안정성이 보장될 수\n있도록 검증된 자료에 의한 구체적인 보관 조건(온도, 습도, 차광,\n\n- 가.  키트 또는 세트의 제품인 경우, 구성품별로 보관조건을 기재하고,\n- 라.  전자민원 접수 시 ‘저장방법’ 항은 ‘사용기간에 따름’으로 표기하고\n표 3. ",
        "original_sentence": "제조․수입허가 신청서 기재 항목\n\n- - 35 -\n<!-- PAGE_41 -->\n###### 9\n\n<!-- PAGE_41 -->\n###### 저장방법 및 사용기간\n\n- 1. "
      }
    },
    {
      "chunk_id": "chunk_479",
      "text": "저장방법은 체외진단용 의료기기의 특성을 고려하여 안정성이 보장될 수\n있도록 검증된 자료에 의한 구체적인 보관 조건(온도, 습도, 차광,\n\n- 가. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 478,
        "window_size": 3,
        "char_count": 82,
        "word_count": 19,
        "page_number": 1,
        "window_text": "체외진단용 의료기기의 포장단위는 취급상 용이한 최소 단위로 기재하되,\n제조의 경우 “자사포장단위”, 수입의 경우는 “제조원포장단위”로 기재한다.\n\n Ⅴ.  제조․수입허가 신청서 기재 항목\n\n- - 35 -\n<!-- PAGE_41 -->\n###### 9\n\n<!-- PAGE_41 -->\n###### 저장방법 및 사용기간\n\n- 1.  저장방법은 체외진단용 의료기기의 특성을 고려하여 안정성이 보장될 수\n있도록 검증된 자료에 의한 구체적인 보관 조건(온도, 습도, 차광,\n\n- 가.  키트 또는 세트의 제품인 경우, 구성품별로 보관조건을 기재하고,\n- 라.  전자민원 접수 시 ‘저장방법’ 항은 ‘사용기간에 따름’으로 표기하고\n표 3.  저장방법 및 사용기간(유효기간) 작성의 예\n\nBNP Test\n\n미개봉\n\n2~8℃\n\n제조일로부터 12개월\n\n일회용\n\nBNP Calibration Verification A\n\n미개봉\n\n2~8℃\n\n제조일로부터 11개월\n\nBNP Control 1\n\n미개봉\n\n2~8℃\n\n제조일로부터 11개월\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 36 -\n<!-- PAGE_42 -->\n###### 10\n\n<!-- PAGE_42 -->\n###### 시험규격\n\n- 1. ",
        "original_sentence": "저장방법은 체외진단용 의료기기의 특성을 고려하여 안정성이 보장될 수\n있도록 검증된 자료에 의한 구체적인 보관 조건(온도, 습도, 차광,\n\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_480",
      "text": "키트 또는 세트의 제품인 경우, 구성품별로 보관조건을 기재하고,\n- 라. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 479,
        "window_size": 3,
        "char_count": 41,
        "word_count": 10,
        "page_number": 34,
        "window_text": "Ⅴ.  제조․수입허가 신청서 기재 항목\n\n- - 35 -\n<!-- PAGE_41 -->\n###### 9\n\n<!-- PAGE_41 -->\n###### 저장방법 및 사용기간\n\n- 1.  저장방법은 체외진단용 의료기기의 특성을 고려하여 안정성이 보장될 수\n있도록 검증된 자료에 의한 구체적인 보관 조건(온도, 습도, 차광,\n\n- 가.  키트 또는 세트의 제품인 경우, 구성품별로 보관조건을 기재하고,\n- 라.  전자민원 접수 시 ‘저장방법’ 항은 ‘사용기간에 따름’으로 표기하고\n표 3.  저장방법 및 사용기간(유효기간) 작성의 예\n\nBNP Test\n\n미개봉\n\n2~8℃\n\n제조일로부터 12개월\n\n일회용\n\nBNP Calibration Verification A\n\n미개봉\n\n2~8℃\n\n제조일로부터 11개월\n\nBNP Control 1\n\n미개봉\n\n2~8℃\n\n제조일로부터 11개월\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 36 -\n<!-- PAGE_42 -->\n###### 10\n\n<!-- PAGE_42 -->\n###### 시험규격\n\n- 1.  시약의 품질관리에 적정을 기할 수 있도록 제품의 특성에 따라 성능\n등을 고려하여, 제조단위별·제조단계별로 안전성·성능을 검증하기 위하여\n\n- 2. ",
        "original_sentence": "키트 또는 세트의 제품인 경우, 구성품별로 보관조건을 기재하고,\n- 라. "
      }
    },
    {
      "chunk_id": "chunk_481",
      "text": "전자민원 접수 시 ‘저장방법’ 항은 ‘사용기간에 따름’으로 표기하고\n표 3. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 480,
        "window_size": 3,
        "char_count": 43,
        "word_count": 10,
        "page_number": 3,
        "window_text": "제조․수입허가 신청서 기재 항목\n\n- - 35 -\n<!-- PAGE_41 -->\n###### 9\n\n<!-- PAGE_41 -->\n###### 저장방법 및 사용기간\n\n- 1.  저장방법은 체외진단용 의료기기의 특성을 고려하여 안정성이 보장될 수\n있도록 검증된 자료에 의한 구체적인 보관 조건(온도, 습도, 차광,\n\n- 가.  키트 또는 세트의 제품인 경우, 구성품별로 보관조건을 기재하고,\n- 라.  전자민원 접수 시 ‘저장방법’ 항은 ‘사용기간에 따름’으로 표기하고\n표 3.  저장방법 및 사용기간(유효기간) 작성의 예\n\nBNP Test\n\n미개봉\n\n2~8℃\n\n제조일로부터 12개월\n\n일회용\n\nBNP Calibration Verification A\n\n미개봉\n\n2~8℃\n\n제조일로부터 11개월\n\nBNP Control 1\n\n미개봉\n\n2~8℃\n\n제조일로부터 11개월\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 36 -\n<!-- PAGE_42 -->\n###### 10\n\n<!-- PAGE_42 -->\n###### 시험규격\n\n- 1.  시약의 품질관리에 적정을 기할 수 있도록 제품의 특성에 따라 성능\n등을 고려하여, 제조단위별·제조단계별로 안전성·성능을 검증하기 위하여\n\n- 2.  시험규격은 제조사의 품질관리시험 자료에 따라 자사가 설정한 시험\n2) 분석적 성능시험(민감도, 특이도, 재현성 등)을 포함하는 것을\n\n1) 시험결과의 적부판정의 기준이 되는 기준치의 허용범위를 명확히\n\n기재하여야 하며, 시험결과가 온도, 습도 등 주위조건에 영향을\n\n1) 시험방법은 순서에 따라 시험결과를 정확히 산출할 수 있도록\n\n2) 표준물질이 사용된 경우, 고, 중, 저 역가를 포함한 각각 최소\n\n3개 이상의 표준물질을 사용할 것을 권장하고 해당 표준물질명을\n\n기재한다.\n\n",
        "original_sentence": "전자민원 접수 시 ‘저장방법’ 항은 ‘사용기간에 따름’으로 표기하고\n표 3. "
      }
    },
    {
      "chunk_id": "chunk_482",
      "text": "저장방법 및 사용기간(유효기간) 작성의 예\n\nBNP Test\n\n미개봉\n\n2~8℃\n\n제조일로부터 12개월\n\n일회용\n\nBNP Calibration Verification A\n\n미개봉\n\n2~8℃\n\n제조일로부터 11개월\n\nBNP Control 1\n\n미개봉\n\n2~8℃\n\n제조일로부터 11개월\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 36 -\n<!-- PAGE_42 -->\n###### 10\n\n<!-- PAGE_42 -->\n###### 시험규격\n\n- 1. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 481,
        "window_size": 3,
        "char_count": 280,
        "word_count": 51,
        "page_number": 42,
        "window_text": "저장방법은 체외진단용 의료기기의 특성을 고려하여 안정성이 보장될 수\n있도록 검증된 자료에 의한 구체적인 보관 조건(온도, 습도, 차광,\n\n- 가.  키트 또는 세트의 제품인 경우, 구성품별로 보관조건을 기재하고,\n- 라.  전자민원 접수 시 ‘저장방법’ 항은 ‘사용기간에 따름’으로 표기하고\n표 3.  저장방법 및 사용기간(유효기간) 작성의 예\n\nBNP Test\n\n미개봉\n\n2~8℃\n\n제조일로부터 12개월\n\n일회용\n\nBNP Calibration Verification A\n\n미개봉\n\n2~8℃\n\n제조일로부터 11개월\n\nBNP Control 1\n\n미개봉\n\n2~8℃\n\n제조일로부터 11개월\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 36 -\n<!-- PAGE_42 -->\n###### 10\n\n<!-- PAGE_42 -->\n###### 시험규격\n\n- 1.  시약의 품질관리에 적정을 기할 수 있도록 제품의 특성에 따라 성능\n등을 고려하여, 제조단위별·제조단계별로 안전성·성능을 검증하기 위하여\n\n- 2.  시험규격은 제조사의 품질관리시험 자료에 따라 자사가 설정한 시험\n2) 분석적 성능시험(민감도, 특이도, 재현성 등)을 포함하는 것을\n\n1) 시험결과의 적부판정의 기준이 되는 기준치의 허용범위를 명확히\n\n기재하여야 하며, 시험결과가 온도, 습도 등 주위조건에 영향을\n\n1) 시험방법은 순서에 따라 시험결과를 정확히 산출할 수 있도록\n\n2) 표준물질이 사용된 경우, 고, 중, 저 역가를 포함한 각각 최소\n\n3개 이상의 표준물질을 사용할 것을 권장하고 해당 표준물질명을\n\n기재한다.\n\n 가) 저농도 표준물질인 경우, 정량 및 정성검출한계를 근거로\n\n하여 설정한다.\n\n",
        "original_sentence": "저장방법 및 사용기간(유효기간) 작성의 예\n\nBNP Test\n\n미개봉\n\n2~8℃\n\n제조일로부터 12개월\n\n일회용\n\nBNP Calibration Verification A\n\n미개봉\n\n2~8℃\n\n제조일로부터 11개월\n\nBNP Control 1\n\n미개봉\n\n2~8℃\n\n제조일로부터 11개월\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 36 -\n<!-- PAGE_42 -->\n###### 10\n\n<!-- PAGE_42 -->\n###### 시험규격\n\n- 1. "
      }
    },
    {
      "chunk_id": "chunk_483",
      "text": "시약의 품질관리에 적정을 기할 수 있도록 제품의 특성에 따라 성능\n등을 고려하여, 제조단위별·제조단계별로 안전성·성능을 검증하기 위하여\n\n- 2. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 482,
        "window_size": 3,
        "char_count": 82,
        "word_count": 18,
        "page_number": 51,
        "window_text": "키트 또는 세트의 제품인 경우, 구성품별로 보관조건을 기재하고,\n- 라.  전자민원 접수 시 ‘저장방법’ 항은 ‘사용기간에 따름’으로 표기하고\n표 3.  저장방법 및 사용기간(유효기간) 작성의 예\n\nBNP Test\n\n미개봉\n\n2~8℃\n\n제조일로부터 12개월\n\n일회용\n\nBNP Calibration Verification A\n\n미개봉\n\n2~8℃\n\n제조일로부터 11개월\n\nBNP Control 1\n\n미개봉\n\n2~8℃\n\n제조일로부터 11개월\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 36 -\n<!-- PAGE_42 -->\n###### 10\n\n<!-- PAGE_42 -->\n###### 시험규격\n\n- 1.  시약의 품질관리에 적정을 기할 수 있도록 제품의 특성에 따라 성능\n등을 고려하여, 제조단위별·제조단계별로 안전성·성능을 검증하기 위하여\n\n- 2.  시험규격은 제조사의 품질관리시험 자료에 따라 자사가 설정한 시험\n2) 분석적 성능시험(민감도, 특이도, 재현성 등)을 포함하는 것을\n\n1) 시험결과의 적부판정의 기준이 되는 기준치의 허용범위를 명확히\n\n기재하여야 하며, 시험결과가 온도, 습도 등 주위조건에 영향을\n\n1) 시험방법은 순서에 따라 시험결과를 정확히 산출할 수 있도록\n\n2) 표준물질이 사용된 경우, 고, 중, 저 역가를 포함한 각각 최소\n\n3개 이상의 표준물질을 사용할 것을 권장하고 해당 표준물질명을\n\n기재한다.\n\n 가) 저농도 표준물질인 경우, 정량 및 정성검출한계를 근거로\n\n하여 설정한다.\n\n 나) 표준물질의 농도는 재현성, 직선성, 최소검출한계를 고려하여\n\nⅤ. ",
        "original_sentence": "시약의 품질관리에 적정을 기할 수 있도록 제품의 특성에 따라 성능\n등을 고려하여, 제조단위별·제조단계별로 안전성·성능을 검증하기 위하여\n\n- 2. "
      }
    },
    {
      "chunk_id": "chunk_484",
      "text": "시험규격은 제조사의 품질관리시험 자료에 따라 자사가 설정한 시험\n2) 분석적 성능시험(민감도, 특이도, 재현성 등)을 포함하는 것을\n\n1) 시험결과의 적부판정의 기준이 되는 기준치의 허용범위를 명확히\n\n기재하여야 하며, 시험결과가 온도, 습도 등 주위조건에 영향을\n\n1) 시험방법은 순서에 따라 시험결과를 정확히 산출할 수 있도록\n\n2) 표준물질이 사용된 경우, 고, 중, 저 역가를 포함한 각각 최소\n\n3개 이상의 표준물질을 사용할 것을 권장하고 해당 표준물질명을\n\n기재한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 483,
        "window_size": 3,
        "char_count": 269,
        "word_count": 61,
        "page_number": 6,
        "window_text": "전자민원 접수 시 ‘저장방법’ 항은 ‘사용기간에 따름’으로 표기하고\n표 3.  저장방법 및 사용기간(유효기간) 작성의 예\n\nBNP Test\n\n미개봉\n\n2~8℃\n\n제조일로부터 12개월\n\n일회용\n\nBNP Calibration Verification A\n\n미개봉\n\n2~8℃\n\n제조일로부터 11개월\n\nBNP Control 1\n\n미개봉\n\n2~8℃\n\n제조일로부터 11개월\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 36 -\n<!-- PAGE_42 -->\n###### 10\n\n<!-- PAGE_42 -->\n###### 시험규격\n\n- 1.  시약의 품질관리에 적정을 기할 수 있도록 제품의 특성에 따라 성능\n등을 고려하여, 제조단위별·제조단계별로 안전성·성능을 검증하기 위하여\n\n- 2.  시험규격은 제조사의 품질관리시험 자료에 따라 자사가 설정한 시험\n2) 분석적 성능시험(민감도, 특이도, 재현성 등)을 포함하는 것을\n\n1) 시험결과의 적부판정의 기준이 되는 기준치의 허용범위를 명확히\n\n기재하여야 하며, 시험결과가 온도, 습도 등 주위조건에 영향을\n\n1) 시험방법은 순서에 따라 시험결과를 정확히 산출할 수 있도록\n\n2) 표준물질이 사용된 경우, 고, 중, 저 역가를 포함한 각각 최소\n\n3개 이상의 표준물질을 사용할 것을 권장하고 해당 표준물질명을\n\n기재한다.\n\n 가) 저농도 표준물질인 경우, 정량 및 정성검출한계를 근거로\n\n하여 설정한다.\n\n 나) 표준물질의 농도는 재현성, 직선성, 최소검출한계를 고려하여\n\nⅤ.  제조․수입허가 신청서 기재 항목\n\n- - 37 -\n설정한다.\n\n",
        "original_sentence": "시험규격은 제조사의 품질관리시험 자료에 따라 자사가 설정한 시험\n2) 분석적 성능시험(민감도, 특이도, 재현성 등)을 포함하는 것을\n\n1) 시험결과의 적부판정의 기준이 되는 기준치의 허용범위를 명확히\n\n기재하여야 하며, 시험결과가 온도, 습도 등 주위조건에 영향을\n\n1) 시험방법은 순서에 따라 시험결과를 정확히 산출할 수 있도록\n\n2) 표준물질이 사용된 경우, 고, 중, 저 역가를 포함한 각각 최소\n\n3개 이상의 표준물질을 사용할 것을 권장하고 해당 표준물질명을\n\n기재한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_485",
      "text": "가) 저농도 표준물질인 경우, 정량 및 정성검출한계를 근거로\n\n하여 설정한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 484,
        "window_size": 3,
        "char_count": 45,
        "word_count": 10,
        "page_number": 32,
        "window_text": "저장방법 및 사용기간(유효기간) 작성의 예\n\nBNP Test\n\n미개봉\n\n2~8℃\n\n제조일로부터 12개월\n\n일회용\n\nBNP Calibration Verification A\n\n미개봉\n\n2~8℃\n\n제조일로부터 11개월\n\nBNP Control 1\n\n미개봉\n\n2~8℃\n\n제조일로부터 11개월\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 36 -\n<!-- PAGE_42 -->\n###### 10\n\n<!-- PAGE_42 -->\n###### 시험규격\n\n- 1.  시약의 품질관리에 적정을 기할 수 있도록 제품의 특성에 따라 성능\n등을 고려하여, 제조단위별·제조단계별로 안전성·성능을 검증하기 위하여\n\n- 2.  시험규격은 제조사의 품질관리시험 자료에 따라 자사가 설정한 시험\n2) 분석적 성능시험(민감도, 특이도, 재현성 등)을 포함하는 것을\n\n1) 시험결과의 적부판정의 기준이 되는 기준치의 허용범위를 명확히\n\n기재하여야 하며, 시험결과가 온도, 습도 등 주위조건에 영향을\n\n1) 시험방법은 순서에 따라 시험결과를 정확히 산출할 수 있도록\n\n2) 표준물질이 사용된 경우, 고, 중, 저 역가를 포함한 각각 최소\n\n3개 이상의 표준물질을 사용할 것을 권장하고 해당 표준물질명을\n\n기재한다.\n\n 가) 저농도 표준물질인 경우, 정량 및 정성검출한계를 근거로\n\n하여 설정한다.\n\n 나) 표준물질의 농도는 재현성, 직선성, 최소검출한계를 고려하여\n\nⅤ.  제조․수입허가 신청서 기재 항목\n\n- - 37 -\n설정한다.\n\n 다) 표준물질 농도는 가능하면 임상적으로 중요한 농도여야 한다.\n\n",
        "original_sentence": "가) 저농도 표준물질인 경우, 정량 및 정성검출한계를 근거로\n\n하여 설정한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_486",
      "text": "나) 표준물질의 농도는 재현성, 직선성, 최소검출한계를 고려하여\n\nⅤ. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 485,
        "window_size": 3,
        "char_count": 40,
        "word_count": 8,
        "page_number": 23,
        "window_text": "시약의 품질관리에 적정을 기할 수 있도록 제품의 특성에 따라 성능\n등을 고려하여, 제조단위별·제조단계별로 안전성·성능을 검증하기 위하여\n\n- 2.  시험규격은 제조사의 품질관리시험 자료에 따라 자사가 설정한 시험\n2) 분석적 성능시험(민감도, 특이도, 재현성 등)을 포함하는 것을\n\n1) 시험결과의 적부판정의 기준이 되는 기준치의 허용범위를 명확히\n\n기재하여야 하며, 시험결과가 온도, 습도 등 주위조건에 영향을\n\n1) 시험방법은 순서에 따라 시험결과를 정확히 산출할 수 있도록\n\n2) 표준물질이 사용된 경우, 고, 중, 저 역가를 포함한 각각 최소\n\n3개 이상의 표준물질을 사용할 것을 권장하고 해당 표준물질명을\n\n기재한다.\n\n 가) 저농도 표준물질인 경우, 정량 및 정성검출한계를 근거로\n\n하여 설정한다.\n\n 나) 표준물질의 농도는 재현성, 직선성, 최소검출한계를 고려하여\n\nⅤ.  제조․수입허가 신청서 기재 항목\n\n- - 37 -\n설정한다.\n\n 다) 표준물질 농도는 가능하면 임상적으로 중요한 농도여야 한다.\n\n 표 4. ",
        "original_sentence": "나) 표준물질의 농도는 재현성, 직선성, 최소검출한계를 고려하여\n\nⅤ. "
      }
    },
    {
      "chunk_id": "chunk_487",
      "text": "제조․수입허가 신청서 기재 항목\n\n- - 37 -\n설정한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 486,
        "window_size": 3,
        "char_count": 35,
        "word_count": 9,
        "page_number": 3,
        "window_text": "시험규격은 제조사의 품질관리시험 자료에 따라 자사가 설정한 시험\n2) 분석적 성능시험(민감도, 특이도, 재현성 등)을 포함하는 것을\n\n1) 시험결과의 적부판정의 기준이 되는 기준치의 허용범위를 명확히\n\n기재하여야 하며, 시험결과가 온도, 습도 등 주위조건에 영향을\n\n1) 시험방법은 순서에 따라 시험결과를 정확히 산출할 수 있도록\n\n2) 표준물질이 사용된 경우, 고, 중, 저 역가를 포함한 각각 최소\n\n3개 이상의 표준물질을 사용할 것을 권장하고 해당 표준물질명을\n\n기재한다.\n\n 가) 저농도 표준물질인 경우, 정량 및 정성검출한계를 근거로\n\n하여 설정한다.\n\n 나) 표준물질의 농도는 재현성, 직선성, 최소검출한계를 고려하여\n\nⅤ.  제조․수입허가 신청서 기재 항목\n\n- - 37 -\n설정한다.\n\n 다) 표준물질 농도는 가능하면 임상적으로 중요한 농도여야 한다.\n\n 표 4.  시험규격 작성의 예\n\n**[표 시작]**\n\n| 1. ",
        "original_sentence": "제조․수입허가 신청서 기재 항목\n\n- - 37 -\n설정한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_488",
      "text": "다) 표준물질 농도는 가능하면 임상적으로 중요한 농도여야 한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 487,
        "window_size": 3,
        "char_count": 37,
        "word_count": 8,
        "page_number": 43,
        "window_text": "가) 저농도 표준물질인 경우, 정량 및 정성검출한계를 근거로\n\n하여 설정한다.\n\n 나) 표준물질의 농도는 재현성, 직선성, 최소검출한계를 고려하여\n\nⅤ.  제조․수입허가 신청서 기재 항목\n\n- - 37 -\n설정한다.\n\n 다) 표준물질 농도는 가능하면 임상적으로 중요한 농도여야 한다.\n\n 표 4.  시험규격 작성의 예\n\n**[표 시작]**\n\n| 1.  외관검사 | 카트리지의 라벨 인쇄상태, 구성품 누락여부를 |\n| --- | --- |\n**드물지 않게 볼 수 있는 특이 검체에**\n| K063662 | RAMP NT-PROBNP ASSAY |\n**K033606**\n**포함된 물질**\n| K032335 | MAS CARDIOIMMUNE PROBNP, | MAS CARDIOIMMUNE TL | 번호 | 비교항목1) | 기허가 제품 | 신청제품 | 동등여부2) |\n| Mode와 Batch | K080578 |\n| 발 | 행 | 처 식품의약품안전처 |\n| 발 | 행 | 일 2014년 5월 |\n| 발 | 행 | 인 | 왕진호 |\n**편 집 위 원 장 정희교**\n| K053597 | I-STAT B-TYPE | NATRIURETIC PEPTIDE (BNP) |\n**Eur Heart J 2012;33:1787-847.",
        "original_sentence": "다) 표준물질 농도는 가능하면 임상적으로 중요한 농도여야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_489",
      "text": "표 4. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 488,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 6,
        "window_text": "나) 표준물질의 농도는 재현성, 직선성, 최소검출한계를 고려하여\n\nⅤ.  제조․수입허가 신청서 기재 항목\n\n- - 37 -\n설정한다.\n\n 다) 표준물질 농도는 가능하면 임상적으로 중요한 농도여야 한다.\n\n 표 4.  시험규격 작성의 예\n\n**[표 시작]**\n\n| 1.  외관검사 | 카트리지의 라벨 인쇄상태, 구성품 누락여부를 |\n| --- | --- |\n**드물지 않게 볼 수 있는 특이 검체에**\n| K063662 | RAMP NT-PROBNP ASSAY |\n**K033606**\n**포함된 물질**\n| K032335 | MAS CARDIOIMMUNE PROBNP, | MAS CARDIOIMMUNE TL | 번호 | 비교항목1) | 기허가 제품 | 신청제품 | 동등여부2) |\n| Mode와 Batch | K080578 |\n| 발 | 행 | 처 식품의약품안전처 |\n| 발 | 행 | 일 2014년 5월 |\n| 발 | 행 | 인 | 왕진호 |\n**편 집 위 원 장 정희교**\n| K053597 | I-STAT B-TYPE | NATRIURETIC PEPTIDE (BNP) |\n**Eur Heart J 2012;33:1787-847. **\n| 편 집 위 원 | 오현주, 이원규, 김정환, 안영욱, 우승민, 김수영, 김현준 |\n**심부전의 진단**\n\n**[표 끝]**\n\n- 4. ",
        "original_sentence": "표 4. "
      }
    },
    {
      "chunk_id": "chunk_490",
      "text": "시험규격 작성의 예\n\n**[표 시작]**\n\n| 1. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 489,
        "window_size": 3,
        "char_count": 29,
        "word_count": 7,
        "page_number": 21,
        "window_text": "제조․수입허가 신청서 기재 항목\n\n- - 37 -\n설정한다.\n\n 다) 표준물질 농도는 가능하면 임상적으로 중요한 농도여야 한다.\n\n 표 4.  시험규격 작성의 예\n\n**[표 시작]**\n\n| 1.  외관검사 | 카트리지의 라벨 인쇄상태, 구성품 누락여부를 |\n| --- | --- |\n**드물지 않게 볼 수 있는 특이 검체에**\n| K063662 | RAMP NT-PROBNP ASSAY |\n**K033606**\n**포함된 물질**\n| K032335 | MAS CARDIOIMMUNE PROBNP, | MAS CARDIOIMMUNE TL | 번호 | 비교항목1) | 기허가 제품 | 신청제품 | 동등여부2) |\n| Mode와 Batch | K080578 |\n| 발 | 행 | 처 식품의약품안전처 |\n| 발 | 행 | 일 2014년 5월 |\n| 발 | 행 | 인 | 왕진호 |\n**편 집 위 원 장 정희교**\n| K053597 | I-STAT B-TYPE | NATRIURETIC PEPTIDE (BNP) |\n**Eur Heart J 2012;33:1787-847. **\n| 편 집 위 원 | 오현주, 이원규, 김정환, 안영욱, 우승민, 김수영, 김현준 |\n**심부전의 진단**\n\n**[표 끝]**\n\n- 4.  위양성도\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 38 -\n<!-- PAGE_44 -->\n###### 11\n\n<!-- PAGE_44 -->\n###### 제조원 (수입 또는 제조공정 전부 위탁의 경우)\n\n<!-- PAGE_44 -->\n###### <작성요령>\n\n- 가. ",
        "original_sentence": "시험규격 작성의 예\n\n**[표 시작]**\n\n| 1. "
      }
    },
    {
      "chunk_id": "chunk_491",
      "text": "외관검사 | 카트리지의 라벨 인쇄상태, 구성품 누락여부를 |\n| --- | --- |\n**드물지 않게 볼 수 있는 특이 검체에**\n| K063662 | RAMP NT-PROBNP ASSAY |\n**K033606**\n**포함된 물질**\n| K032335 | MAS CARDIOIMMUNE PROBNP, | MAS CARDIOIMMUNE TL | 번호 | 비교항목1) | 기허가 제품 | 신청제품 | 동등여부2) |\n| Mode와 Batch | K080578 |\n| 발 | 행 | 처 식품의약품안전처 |\n| 발 | 행 | 일 2014년 5월 |\n| 발 | 행 | 인 | 왕진호 |\n**편 집 위 원 장 정희교**\n| K053597 | I-STAT B-TYPE | NATRIURETIC PEPTIDE (BNP) |\n**Eur Heart J 2012;33:1787-847.",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 490,
        "window_size": 3,
        "char_count": 428,
        "word_count": 104,
        "page_number": 3,
        "window_text": "다) 표준물질 농도는 가능하면 임상적으로 중요한 농도여야 한다.\n\n 표 4.  시험규격 작성의 예\n\n**[표 시작]**\n\n| 1.  외관검사 | 카트리지의 라벨 인쇄상태, 구성품 누락여부를 |\n| --- | --- |\n**드물지 않게 볼 수 있는 특이 검체에**\n| K063662 | RAMP NT-PROBNP ASSAY |\n**K033606**\n**포함된 물질**\n| K032335 | MAS CARDIOIMMUNE PROBNP, | MAS CARDIOIMMUNE TL | 번호 | 비교항목1) | 기허가 제품 | 신청제품 | 동등여부2) |\n| Mode와 Batch | K080578 |\n| 발 | 행 | 처 식품의약품안전처 |\n| 발 | 행 | 일 2014년 5월 |\n| 발 | 행 | 인 | 왕진호 |\n**편 집 위 원 장 정희교**\n| K053597 | I-STAT B-TYPE | NATRIURETIC PEPTIDE (BNP) |\n**Eur Heart J 2012;33:1787-847. **\n| 편 집 위 원 | 오현주, 이원규, 김정환, 안영욱, 우승민, 김수영, 김현준 |\n**심부전의 진단**\n\n**[표 끝]**\n\n- 4.  위양성도\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 38 -\n<!-- PAGE_44 -->\n###### 11\n\n<!-- PAGE_44 -->\n###### 제조원 (수입 또는 제조공정 전부 위탁의 경우)\n\n<!-- PAGE_44 -->\n###### <작성요령>\n\n- 가.  수입제품은 제조원을 기재하여야 한다.\n",
        "original_sentence": "외관검사 | 카트리지의 라벨 인쇄상태, 구성품 누락여부를 |\n| --- | --- |\n**드물지 않게 볼 수 있는 특이 검체에**\n| K063662 | RAMP NT-PROBNP ASSAY |\n**K033606**\n**포함된 물질**\n| K032335 | MAS CARDIOIMMUNE PROBNP, | MAS CARDIOIMMUNE TL | 번호 | 비교항목1) | 기허가 제품 | 신청제품 | 동등여부2) |\n| Mode와 Batch | K080578 |\n| 발 | 행 | 처 식품의약품안전처 |\n| 발 | 행 | 일 2014년 5월 |\n| 발 | 행 | 인 | 왕진호 |\n**편 집 위 원 장 정희교**\n| K053597 | I-STAT B-TYPE | NATRIURETIC PEPTIDE (BNP) |\n**Eur Heart J 2012;33:1787-847."
      }
    },
    {
      "chunk_id": "chunk_492",
      "text": "**\n| 편 집 위 원 | 오현주, 이원규, 김정환, 안영욱, 우승민, 김수영, 김현준 |\n**심부전의 진단**\n\n**[표 끝]**\n\n- 4. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 491,
        "window_size": 3,
        "char_count": 80,
        "word_count": 21,
        "page_number": 79,
        "window_text": "표 4.  시험규격 작성의 예\n\n**[표 시작]**\n\n| 1.  외관검사 | 카트리지의 라벨 인쇄상태, 구성품 누락여부를 |\n| --- | --- |\n**드물지 않게 볼 수 있는 특이 검체에**\n| K063662 | RAMP NT-PROBNP ASSAY |\n**K033606**\n**포함된 물질**\n| K032335 | MAS CARDIOIMMUNE PROBNP, | MAS CARDIOIMMUNE TL | 번호 | 비교항목1) | 기허가 제품 | 신청제품 | 동등여부2) |\n| Mode와 Batch | K080578 |\n| 발 | 행 | 처 식품의약품안전처 |\n| 발 | 행 | 일 2014년 5월 |\n| 발 | 행 | 인 | 왕진호 |\n**편 집 위 원 장 정희교**\n| K053597 | I-STAT B-TYPE | NATRIURETIC PEPTIDE (BNP) |\n**Eur Heart J 2012;33:1787-847. **\n| 편 집 위 원 | 오현주, 이원규, 김정환, 안영욱, 우승민, 김수영, 김현준 |\n**심부전의 진단**\n\n**[표 끝]**\n\n- 4.  위양성도\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 38 -\n<!-- PAGE_44 -->\n###### 11\n\n<!-- PAGE_44 -->\n###### 제조원 (수입 또는 제조공정 전부 위탁의 경우)\n\n<!-- PAGE_44 -->\n###### <작성요령>\n\n- 가.  수입제품은 제조원을 기재하여야 한다.\n - 나. ",
        "original_sentence": "**\n| 편 집 위 원 | 오현주, 이원규, 김정환, 안영욱, 우승민, 김수영, 김현준 |\n**심부전의 진단**\n\n**[표 끝]**\n\n- 4. "
      }
    },
    {
      "chunk_id": "chunk_493",
      "text": "위양성도\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 38 -\n<!-- PAGE_44 -->\n###### 11\n\n<!-- PAGE_44 -->\n###### 제조원 (수입 또는 제조공정 전부 위탁의 경우)\n\n<!-- PAGE_44 -->\n###### <작성요령>\n\n- 가. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 492,
        "window_size": 3,
        "char_count": 180,
        "word_count": 36,
        "page_number": 44,
        "window_text": "시험규격 작성의 예\n\n**[표 시작]**\n\n| 1.  외관검사 | 카트리지의 라벨 인쇄상태, 구성품 누락여부를 |\n| --- | --- |\n**드물지 않게 볼 수 있는 특이 검체에**\n| K063662 | RAMP NT-PROBNP ASSAY |\n**K033606**\n**포함된 물질**\n| K032335 | MAS CARDIOIMMUNE PROBNP, | MAS CARDIOIMMUNE TL | 번호 | 비교항목1) | 기허가 제품 | 신청제품 | 동등여부2) |\n| Mode와 Batch | K080578 |\n| 발 | 행 | 처 식품의약품안전처 |\n| 발 | 행 | 일 2014년 5월 |\n| 발 | 행 | 인 | 왕진호 |\n**편 집 위 원 장 정희교**\n| K053597 | I-STAT B-TYPE | NATRIURETIC PEPTIDE (BNP) |\n**Eur Heart J 2012;33:1787-847. **\n| 편 집 위 원 | 오현주, 이원규, 김정환, 안영욱, 우승민, 김수영, 김현준 |\n**심부전의 진단**\n\n**[표 끝]**\n\n- 4.  위양성도\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 38 -\n<!-- PAGE_44 -->\n###### 11\n\n<!-- PAGE_44 -->\n###### 제조원 (수입 또는 제조공정 전부 위탁의 경우)\n\n<!-- PAGE_44 -->\n###### <작성요령>\n\n- 가.  수입제품은 제조원을 기재하여야 한다.\n - 나.  제조제품 중 제조공정을 전부 위탁하는 경우 해당 제조소를 기재한다.\n",
        "original_sentence": "위양성도\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 38 -\n<!-- PAGE_44 -->\n###### 11\n\n<!-- PAGE_44 -->\n###### 제조원 (수입 또는 제조공정 전부 위탁의 경우)\n\n<!-- PAGE_44 -->\n###### <작성요령>\n\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_494",
      "text": "수입제품은 제조원을 기재하여야 한다.\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 493,
        "window_size": 3,
        "char_count": 21,
        "word_count": 4,
        "page_number": 44,
        "window_text": "외관검사 | 카트리지의 라벨 인쇄상태, 구성품 누락여부를 |\n| --- | --- |\n**드물지 않게 볼 수 있는 특이 검체에**\n| K063662 | RAMP NT-PROBNP ASSAY |\n**K033606**\n**포함된 물질**\n| K032335 | MAS CARDIOIMMUNE PROBNP, | MAS CARDIOIMMUNE TL | 번호 | 비교항목1) | 기허가 제품 | 신청제품 | 동등여부2) |\n| Mode와 Batch | K080578 |\n| 발 | 행 | 처 식품의약품안전처 |\n| 발 | 행 | 일 2014년 5월 |\n| 발 | 행 | 인 | 왕진호 |\n**편 집 위 원 장 정희교**\n| K053597 | I-STAT B-TYPE | NATRIURETIC PEPTIDE (BNP) |\n**Eur Heart J 2012;33:1787-847. **\n| 편 집 위 원 | 오현주, 이원규, 김정환, 안영욱, 우승민, 김수영, 김현준 |\n**심부전의 진단**\n\n**[표 끝]**\n\n- 4.  위양성도\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 38 -\n<!-- PAGE_44 -->\n###### 11\n\n<!-- PAGE_44 -->\n###### 제조원 (수입 또는 제조공정 전부 위탁의 경우)\n\n<!-- PAGE_44 -->\n###### <작성요령>\n\n- 가.  수입제품은 제조원을 기재하여야 한다.\n - 나.  제조제품 중 제조공정을 전부 위탁하는 경우 해당 제조소를 기재한다.\n 제조의뢰자와 제조자의 상호와 주소를 모두 기재한다. ",
        "original_sentence": "수입제품은 제조원을 기재하여야 한다.\n"
      }
    },
    {
      "chunk_id": "chunk_495",
      "text": "- 나. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 494,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 74,
        "window_text": "**\n| 편 집 위 원 | 오현주, 이원규, 김정환, 안영욱, 우승민, 김수영, 김현준 |\n**심부전의 진단**\n\n**[표 끝]**\n\n- 4.  위양성도\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 38 -\n<!-- PAGE_44 -->\n###### 11\n\n<!-- PAGE_44 -->\n###### 제조원 (수입 또는 제조공정 전부 위탁의 경우)\n\n<!-- PAGE_44 -->\n###### <작성요령>\n\n- 가.  수입제품은 제조원을 기재하여야 한다.\n - 나.  제조제품 중 제조공정을 전부 위탁하는 경우 해당 제조소를 기재한다.\n 제조의뢰자와 제조자의 상호와 주소를 모두 기재한다.  다만, 제조자가\n\n※ 예시\n\n- - 국내 A 제조업체가 B 제조업체에게 유전질환검사시약 제조를 전면\n위탁 시\n\n제조원은 다음과 같이 기재한다.\n\n",
        "original_sentence": "- 나. "
      }
    },
    {
      "chunk_id": "chunk_496",
      "text": "제조제품 중 제조공정을 전부 위탁하는 경우 해당 제조소를 기재한다.\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 495,
        "window_size": 3,
        "char_count": 38,
        "word_count": 9,
        "page_number": 26,
        "window_text": "위양성도\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 38 -\n<!-- PAGE_44 -->\n###### 11\n\n<!-- PAGE_44 -->\n###### 제조원 (수입 또는 제조공정 전부 위탁의 경우)\n\n<!-- PAGE_44 -->\n###### <작성요령>\n\n- 가.  수입제품은 제조원을 기재하여야 한다.\n - 나.  제조제품 중 제조공정을 전부 위탁하는 경우 해당 제조소를 기재한다.\n 제조의뢰자와 제조자의 상호와 주소를 모두 기재한다.  다만, 제조자가\n\n※ 예시\n\n- - 국내 A 제조업체가 B 제조업체에게 유전질환검사시약 제조를 전면\n위탁 시\n\n제조원은 다음과 같이 기재한다.\n\n 상호 (제조사 주소)\n\n․ 제조의뢰자 : A (A사 주소)\n\n․ 제조자 : B (B사 주소)\n\n- - 수입제품의 경우, 미국에 있는 C사가 아일랜드에 있는 D사에 OOO검\n상호 (제조국/제조사 주소)\n\n․ 제조의뢰자 : C (미국 C사 주소)\n\n․ 제조자 : D (아일랜드 D사 주소)\n\nⅥ. ",
        "original_sentence": "제조제품 중 제조공정을 전부 위탁하는 경우 해당 제조소를 기재한다.\n"
      }
    },
    {
      "chunk_id": "chunk_497",
      "text": "제조의뢰자와 제조자의 상호와 주소를 모두 기재한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 496,
        "window_size": 3,
        "char_count": 29,
        "word_count": 6,
        "page_number": 26,
        "window_text": "수입제품은 제조원을 기재하여야 한다.\n - 나.  제조제품 중 제조공정을 전부 위탁하는 경우 해당 제조소를 기재한다.\n 제조의뢰자와 제조자의 상호와 주소를 모두 기재한다.  다만, 제조자가\n\n※ 예시\n\n- - 국내 A 제조업체가 B 제조업체에게 유전질환검사시약 제조를 전면\n위탁 시\n\n제조원은 다음과 같이 기재한다.\n\n 상호 (제조사 주소)\n\n․ 제조의뢰자 : A (A사 주소)\n\n․ 제조자 : B (B사 주소)\n\n- - 수입제품의 경우, 미국에 있는 C사가 아일랜드에 있는 D사에 OOO검\n상호 (제조국/제조사 주소)\n\n․ 제조의뢰자 : C (미국 C사 주소)\n\n․ 제조자 : D (아일랜드 D사 주소)\n\nⅥ.  기술문서 등의 심사를 위한 제출자료\n\n- - 39 -\n<!-- PAGE_45 -->\n# Ⅵ\n\n<!-- PAGE_45 -->\n### 기술문서 등의 심사를 위한 제출자료\n\n<!-- PAGE_45 -->\n###### 1. ",
        "original_sentence": "제조의뢰자와 제조자의 상호와 주소를 모두 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_498",
      "text": "다만, 제조자가\n\n※ 예시\n\n- - 국내 A 제조업체가 B 제조업체에게 유전질환검사시약 제조를 전면\n위탁 시\n\n제조원은 다음과 같이 기재한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 497,
        "window_size": 3,
        "char_count": 81,
        "word_count": 20,
        "page_number": 25,
        "window_text": "- 나.  제조제품 중 제조공정을 전부 위탁하는 경우 해당 제조소를 기재한다.\n 제조의뢰자와 제조자의 상호와 주소를 모두 기재한다.  다만, 제조자가\n\n※ 예시\n\n- - 국내 A 제조업체가 B 제조업체에게 유전질환검사시약 제조를 전면\n위탁 시\n\n제조원은 다음과 같이 기재한다.\n\n 상호 (제조사 주소)\n\n․ 제조의뢰자 : A (A사 주소)\n\n․ 제조자 : B (B사 주소)\n\n- - 수입제품의 경우, 미국에 있는 C사가 아일랜드에 있는 D사에 OOO검\n상호 (제조국/제조사 주소)\n\n․ 제조의뢰자 : C (미국 C사 주소)\n\n․ 제조자 : D (아일랜드 D사 주소)\n\nⅥ.  기술문서 등의 심사를 위한 제출자료\n\n- - 39 -\n<!-- PAGE_45 -->\n# Ⅵ\n\n<!-- PAGE_45 -->\n### 기술문서 등의 심사를 위한 제출자료\n\n<!-- PAGE_45 -->\n###### 1.  원칙\n\n- 가. ",
        "original_sentence": "다만, 제조자가\n\n※ 예시\n\n- - 국내 A 제조업체가 B 제조업체에게 유전질환검사시약 제조를 전면\n위탁 시\n\n제조원은 다음과 같이 기재한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_499",
      "text": "상호 (제조사 주소)\n\n․ 제조의뢰자 : A (A사 주소)\n\n․ 제조자 : B (B사 주소)\n\n- - 수입제품의 경우, 미국에 있는 C사가 아일랜드에 있는 D사에 OOO검\n상호 (제조국/제조사 주소)\n\n․ 제조의뢰자 : C (미국 C사 주소)\n\n․ 제조자 : D (아일랜드 D사 주소)\n\nⅥ. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 498,
        "window_size": 3,
        "char_count": 164,
        "word_count": 44,
        "page_number": 44,
        "window_text": "제조제품 중 제조공정을 전부 위탁하는 경우 해당 제조소를 기재한다.\n 제조의뢰자와 제조자의 상호와 주소를 모두 기재한다.  다만, 제조자가\n\n※ 예시\n\n- - 국내 A 제조업체가 B 제조업체에게 유전질환검사시약 제조를 전면\n위탁 시\n\n제조원은 다음과 같이 기재한다.\n\n 상호 (제조사 주소)\n\n․ 제조의뢰자 : A (A사 주소)\n\n․ 제조자 : B (B사 주소)\n\n- - 수입제품의 경우, 미국에 있는 C사가 아일랜드에 있는 D사에 OOO검\n상호 (제조국/제조사 주소)\n\n․ 제조의뢰자 : C (미국 C사 주소)\n\n․ 제조자 : D (아일랜드 D사 주소)\n\nⅥ.  기술문서 등의 심사를 위한 제출자료\n\n- - 39 -\n<!-- PAGE_45 -->\n# Ⅵ\n\n<!-- PAGE_45 -->\n### 기술문서 등의 심사를 위한 제출자료\n\n<!-- PAGE_45 -->\n###### 1.  원칙\n\n- 가.  기술문서 등의 심사를 받고자 하는 자는 시행규칙 별지 제7호\n- 나. ",
        "original_sentence": "상호 (제조사 주소)\n\n․ 제조의뢰자 : A (A사 주소)\n\n․ 제조자 : B (B사 주소)\n\n- - 수입제품의 경우, 미국에 있는 C사가 아일랜드에 있는 D사에 OOO검\n상호 (제조국/제조사 주소)\n\n․ 제조의뢰자 : C (미국 C사 주소)\n\n․ 제조자 : D (아일랜드 D사 주소)\n\nⅥ. "
      }
    },
    {
      "chunk_id": "chunk_500",
      "text": "기술문서 등의 심사를 위한 제출자료\n\n- - 39 -\n<!-- PAGE_45 -->\n# Ⅵ\n\n<!-- PAGE_45 -->\n### 기술문서 등의 심사를 위한 제출자료\n\n<!-- PAGE_45 -->\n###### 1. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 499,
        "window_size": 3,
        "char_count": 121,
        "word_count": 28,
        "page_number": 45,
        "window_text": "제조의뢰자와 제조자의 상호와 주소를 모두 기재한다.  다만, 제조자가\n\n※ 예시\n\n- - 국내 A 제조업체가 B 제조업체에게 유전질환검사시약 제조를 전면\n위탁 시\n\n제조원은 다음과 같이 기재한다.\n\n 상호 (제조사 주소)\n\n․ 제조의뢰자 : A (A사 주소)\n\n․ 제조자 : B (B사 주소)\n\n- - 수입제품의 경우, 미국에 있는 C사가 아일랜드에 있는 D사에 OOO검\n상호 (제조국/제조사 주소)\n\n․ 제조의뢰자 : C (미국 C사 주소)\n\n․ 제조자 : D (아일랜드 D사 주소)\n\nⅥ.  기술문서 등의 심사를 위한 제출자료\n\n- - 39 -\n<!-- PAGE_45 -->\n# Ⅵ\n\n<!-- PAGE_45 -->\n### 기술문서 등의 심사를 위한 제출자료\n\n<!-- PAGE_45 -->\n###### 1.  원칙\n\n- 가.  기술문서 등의 심사를 받고자 하는 자는 시행규칙 별지 제7호\n- 나.  첨부자료 등을 식품의약품안전처장이 정한 전용프로그램으로 작성된\n- 다. ",
        "original_sentence": "기술문서 등의 심사를 위한 제출자료\n\n- - 39 -\n<!-- PAGE_45 -->\n# Ⅵ\n\n<!-- PAGE_45 -->\n### 기술문서 등의 심사를 위한 제출자료\n\n<!-- PAGE_45 -->\n###### 1. "
      }
    },
    {
      "chunk_id": "chunk_501",
      "text": "원칙\n\n- 가. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 500,
        "window_size": 3,
        "char_count": 9,
        "word_count": 3,
        "page_number": 74,
        "window_text": "다만, 제조자가\n\n※ 예시\n\n- - 국내 A 제조업체가 B 제조업체에게 유전질환검사시약 제조를 전면\n위탁 시\n\n제조원은 다음과 같이 기재한다.\n\n 상호 (제조사 주소)\n\n․ 제조의뢰자 : A (A사 주소)\n\n․ 제조자 : B (B사 주소)\n\n- - 수입제품의 경우, 미국에 있는 C사가 아일랜드에 있는 D사에 OOO검\n상호 (제조국/제조사 주소)\n\n․ 제조의뢰자 : C (미국 C사 주소)\n\n․ 제조자 : D (아일랜드 D사 주소)\n\nⅥ.  기술문서 등의 심사를 위한 제출자료\n\n- - 39 -\n<!-- PAGE_45 -->\n# Ⅵ\n\n<!-- PAGE_45 -->\n### 기술문서 등의 심사를 위한 제출자료\n\n<!-- PAGE_45 -->\n###### 1.  원칙\n\n- 가.  기술문서 등의 심사를 받고자 하는 자는 시행규칙 별지 제7호\n- 나.  첨부자료 등을 식품의약품안전처장이 정한 전용프로그램으로 작성된\n- 다.  해당 제품의 특성상 첨부자료의 일부가 불필요한 경우, 그 사유를\n하여야 하며, 필요한 경우에 한하여 번역물을 요구할 수 있다. ",
        "original_sentence": "원칙\n\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_502",
      "text": "기술문서 등의 심사를 받고자 하는 자는 시행규칙 별지 제7호\n- 나. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 501,
        "window_size": 3,
        "char_count": 39,
        "word_count": 11,
        "page_number": 40,
        "window_text": "상호 (제조사 주소)\n\n․ 제조의뢰자 : A (A사 주소)\n\n․ 제조자 : B (B사 주소)\n\n- - 수입제품의 경우, 미국에 있는 C사가 아일랜드에 있는 D사에 OOO검\n상호 (제조국/제조사 주소)\n\n․ 제조의뢰자 : C (미국 C사 주소)\n\n․ 제조자 : D (아일랜드 D사 주소)\n\nⅥ.  기술문서 등의 심사를 위한 제출자료\n\n- - 39 -\n<!-- PAGE_45 -->\n# Ⅵ\n\n<!-- PAGE_45 -->\n### 기술문서 등의 심사를 위한 제출자료\n\n<!-- PAGE_45 -->\n###### 1.  원칙\n\n- 가.  기술문서 등의 심사를 받고자 하는 자는 시행규칙 별지 제7호\n- 나.  첨부자료 등을 식품의약품안전처장이 정한 전용프로그램으로 작성된\n- 다.  해당 제품의 특성상 첨부자료의 일부가 불필요한 경우, 그 사유를\n하여야 하며, 필요한 경우에 한하여 번역물을 요구할 수 있다.  다만,\n\n- 2. ",
        "original_sentence": "기술문서 등의 심사를 받고자 하는 자는 시행규칙 별지 제7호\n- 나. "
      }
    },
    {
      "chunk_id": "chunk_503",
      "text": "첨부자료 등을 식품의약품안전처장이 정한 전용프로그램으로 작성된\n- 다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 502,
        "window_size": 3,
        "char_count": 40,
        "word_count": 8,
        "page_number": 74,
        "window_text": "기술문서 등의 심사를 위한 제출자료\n\n- - 39 -\n<!-- PAGE_45 -->\n# Ⅵ\n\n<!-- PAGE_45 -->\n### 기술문서 등의 심사를 위한 제출자료\n\n<!-- PAGE_45 -->\n###### 1.  원칙\n\n- 가.  기술문서 등의 심사를 받고자 하는 자는 시행규칙 별지 제7호\n- 나.  첨부자료 등을 식품의약품안전처장이 정한 전용프로그램으로 작성된\n- 다.  해당 제품의 특성상 첨부자료의 일부가 불필요한 경우, 그 사유를\n하여야 하며, 필요한 경우에 한하여 번역물을 요구할 수 있다.  다만,\n\n- 2.  시험 자료의 요건 (분석적 성능, 품질관리 시험성적서, 검체 조건 설정 자료)\n※ 임상적 성능시험 자료 요건은 별도 제시\n\n2) 해당 의료기기에 대하여 경제협력기구(OECD) 회원국에 허가\n\n당시 제출되어 평가된 시험에 관한 자료로서 해당 정부 또는\n\n정부가 허가 업무를 위임한 등록기관이 제출받아 승인하였음을\n\n확인한 자료 또는 이를 공증한 자료\n\n3) 「의료기기 제조·수입 및 품질관리기준」또는 이와 동등 이상의\n\n규격에 따른 제조사의 품질관리시스템 하에서 실시된 시험성적서\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 40 -\n4) 대학 또는 연구기관 등 국내·외의 전문기관에서 시험한 것으로서\n\n해당 전문기관의 장이 발급하고 그 내용(전문기관의 시험시설\n\n개요, 주요설비, 연구인력 구성, 시험자의 연구경력 등을 포함한다)을\n\n7) 시험 검사품 채취 및 방법에 대한 사항(시험을 위한 별도의\n\n- 다. ",
        "original_sentence": "첨부자료 등을 식품의약품안전처장이 정한 전용프로그램으로 작성된\n- 다. "
      }
    },
    {
      "chunk_id": "chunk_504",
      "text": "해당 제품의 특성상 첨부자료의 일부가 불필요한 경우, 그 사유를\n하여야 하며, 필요한 경우에 한하여 번역물을 요구할 수 있다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 503,
        "window_size": 3,
        "char_count": 71,
        "word_count": 18,
        "page_number": 79,
        "window_text": "원칙\n\n- 가.  기술문서 등의 심사를 받고자 하는 자는 시행규칙 별지 제7호\n- 나.  첨부자료 등을 식품의약품안전처장이 정한 전용프로그램으로 작성된\n- 다.  해당 제품의 특성상 첨부자료의 일부가 불필요한 경우, 그 사유를\n하여야 하며, 필요한 경우에 한하여 번역물을 요구할 수 있다.  다만,\n\n- 2.  시험 자료의 요건 (분석적 성능, 품질관리 시험성적서, 검체 조건 설정 자료)\n※ 임상적 성능시험 자료 요건은 별도 제시\n\n2) 해당 의료기기에 대하여 경제협력기구(OECD) 회원국에 허가\n\n당시 제출되어 평가된 시험에 관한 자료로서 해당 정부 또는\n\n정부가 허가 업무를 위임한 등록기관이 제출받아 승인하였음을\n\n확인한 자료 또는 이를 공증한 자료\n\n3) 「의료기기 제조·수입 및 품질관리기준」또는 이와 동등 이상의\n\n규격에 따른 제조사의 품질관리시스템 하에서 실시된 시험성적서\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 40 -\n4) 대학 또는 연구기관 등 국내·외의 전문기관에서 시험한 것으로서\n\n해당 전문기관의 장이 발급하고 그 내용(전문기관의 시험시설\n\n개요, 주요설비, 연구인력 구성, 시험자의 연구경력 등을 포함한다)을\n\n7) 시험 검사품 채취 및 방법에 대한 사항(시험을 위한 별도의\n\n- 다.  추가 기재내용 (대학 또는 연구기관 등 국내외 전문기관에서 시험한\n전문기관의 명칭, 주소, 인증현황, 검사기능 분야, 연구인력구성,\n\n주요설비 목록 등이 기재되어 있어야 함\n\n2) 주요설비\n\n시험검사에 사용된 장비명칭, 장비사양, 검·교정 기록서 등에 대한\n\n사항이 기재되고 관련 증빙자료를 함께 제출하여야 함\n\nⅥ. ",
        "original_sentence": "해당 제품의 특성상 첨부자료의 일부가 불필요한 경우, 그 사유를\n하여야 하며, 필요한 경우에 한하여 번역물을 요구할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_505",
      "text": "다만,\n\n- 2. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 504,
        "window_size": 3,
        "char_count": 10,
        "word_count": 3,
        "page_number": 6,
        "window_text": "기술문서 등의 심사를 받고자 하는 자는 시행규칙 별지 제7호\n- 나.  첨부자료 등을 식품의약품안전처장이 정한 전용프로그램으로 작성된\n- 다.  해당 제품의 특성상 첨부자료의 일부가 불필요한 경우, 그 사유를\n하여야 하며, 필요한 경우에 한하여 번역물을 요구할 수 있다.  다만,\n\n- 2.  시험 자료의 요건 (분석적 성능, 품질관리 시험성적서, 검체 조건 설정 자료)\n※ 임상적 성능시험 자료 요건은 별도 제시\n\n2) 해당 의료기기에 대하여 경제협력기구(OECD) 회원국에 허가\n\n당시 제출되어 평가된 시험에 관한 자료로서 해당 정부 또는\n\n정부가 허가 업무를 위임한 등록기관이 제출받아 승인하였음을\n\n확인한 자료 또는 이를 공증한 자료\n\n3) 「의료기기 제조·수입 및 품질관리기준」또는 이와 동등 이상의\n\n규격에 따른 제조사의 품질관리시스템 하에서 실시된 시험성적서\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 40 -\n4) 대학 또는 연구기관 등 국내·외의 전문기관에서 시험한 것으로서\n\n해당 전문기관의 장이 발급하고 그 내용(전문기관의 시험시설\n\n개요, 주요설비, 연구인력 구성, 시험자의 연구경력 등을 포함한다)을\n\n7) 시험 검사품 채취 및 방법에 대한 사항(시험을 위한 별도의\n\n- 다.  추가 기재내용 (대학 또는 연구기관 등 국내외 전문기관에서 시험한\n전문기관의 명칭, 주소, 인증현황, 검사기능 분야, 연구인력구성,\n\n주요설비 목록 등이 기재되어 있어야 함\n\n2) 주요설비\n\n시험검사에 사용된 장비명칭, 장비사양, 검·교정 기록서 등에 대한\n\n사항이 기재되고 관련 증빙자료를 함께 제출하여야 함\n\nⅥ.  기술문서 등의 심사를 위한 제출자료\n\n- - 41 -\n3) 연구인력구성\n\n시험검사를 실시한 전문기관 담당부서에 속한 연구인력들에 대한\n\n시험검사를 실시한 시험자가 해당 검사를 하기에 적합한 전공, 경력\n\n등을 가지고 있는지에 대해 기재하고, 해당 전문기관에서 규정한\n\n- 1. ",
        "original_sentence": "다만,\n\n- 2. "
      }
    },
    {
      "chunk_id": "chunk_506",
      "text": "시험 자료의 요건 (분석적 성능, 품질관리 시험성적서, 검체 조건 설정 자료)\n※ 임상적 성능시험 자료 요건은 별도 제시\n\n2) 해당 의료기기에 대하여 경제협력기구(OECD) 회원국에 허가\n\n당시 제출되어 평가된 시험에 관한 자료로서 해당 정부 또는\n\n정부가 허가 업무를 위임한 등록기관이 제출받아 승인하였음을\n\n확인한 자료 또는 이를 공증한 자료\n\n3) 「의료기기 제조·수입 및 품질관리기준」또는 이와 동등 이상의\n\n규격에 따른 제조사의 품질관리시스템 하에서 실시된 시험성적서\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 40 -\n4) 대학 또는 연구기관 등 국내·외의 전문기관에서 시험한 것으로서\n\n해당 전문기관의 장이 발급하고 그 내용(전문기관의 시험시설\n\n개요, 주요설비, 연구인력 구성, 시험자의 연구경력 등을 포함한다)을\n\n7) 시험 검사품 채취 및 방법에 대한 사항(시험을 위한 별도의\n\n- 다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 505,
        "window_size": 3,
        "char_count": 482,
        "word_count": 110,
        "page_number": 31,
        "window_text": "첨부자료 등을 식품의약품안전처장이 정한 전용프로그램으로 작성된\n- 다.  해당 제품의 특성상 첨부자료의 일부가 불필요한 경우, 그 사유를\n하여야 하며, 필요한 경우에 한하여 번역물을 요구할 수 있다.  다만,\n\n- 2.  시험 자료의 요건 (분석적 성능, 품질관리 시험성적서, 검체 조건 설정 자료)\n※ 임상적 성능시험 자료 요건은 별도 제시\n\n2) 해당 의료기기에 대하여 경제협력기구(OECD) 회원국에 허가\n\n당시 제출되어 평가된 시험에 관한 자료로서 해당 정부 또는\n\n정부가 허가 업무를 위임한 등록기관이 제출받아 승인하였음을\n\n확인한 자료 또는 이를 공증한 자료\n\n3) 「의료기기 제조·수입 및 품질관리기준」또는 이와 동등 이상의\n\n규격에 따른 제조사의 품질관리시스템 하에서 실시된 시험성적서\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 40 -\n4) 대학 또는 연구기관 등 국내·외의 전문기관에서 시험한 것으로서\n\n해당 전문기관의 장이 발급하고 그 내용(전문기관의 시험시설\n\n개요, 주요설비, 연구인력 구성, 시험자의 연구경력 등을 포함한다)을\n\n7) 시험 검사품 채취 및 방법에 대한 사항(시험을 위한 별도의\n\n- 다.  추가 기재내용 (대학 또는 연구기관 등 국내외 전문기관에서 시험한\n전문기관의 명칭, 주소, 인증현황, 검사기능 분야, 연구인력구성,\n\n주요설비 목록 등이 기재되어 있어야 함\n\n2) 주요설비\n\n시험검사에 사용된 장비명칭, 장비사양, 검·교정 기록서 등에 대한\n\n사항이 기재되고 관련 증빙자료를 함께 제출하여야 함\n\nⅥ.  기술문서 등의 심사를 위한 제출자료\n\n- - 41 -\n3) 연구인력구성\n\n시험검사를 실시한 전문기관 담당부서에 속한 연구인력들에 대한\n\n시험검사를 실시한 시험자가 해당 검사를 하기에 적합한 전공, 경력\n\n등을 가지고 있는지에 대해 기재하고, 해당 전문기관에서 규정한\n\n- 1.  개발경위\n- 가. ",
        "original_sentence": "시험 자료의 요건 (분석적 성능, 품질관리 시험성적서, 검체 조건 설정 자료)\n※ 임상적 성능시험 자료 요건은 별도 제시\n\n2) 해당 의료기기에 대하여 경제협력기구(OECD) 회원국에 허가\n\n당시 제출되어 평가된 시험에 관한 자료로서 해당 정부 또는\n\n정부가 허가 업무를 위임한 등록기관이 제출받아 승인하였음을\n\n확인한 자료 또는 이를 공증한 자료\n\n3) 「의료기기 제조·수입 및 품질관리기준」또는 이와 동등 이상의\n\n규격에 따른 제조사의 품질관리시스템 하에서 실시된 시험성적서\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 40 -\n4) 대학 또는 연구기관 등 국내·외의 전문기관에서 시험한 것으로서\n\n해당 전문기관의 장이 발급하고 그 내용(전문기관의 시험시설\n\n개요, 주요설비, 연구인력 구성, 시험자의 연구경력 등을 포함한다)을\n\n7) 시험 검사품 채취 및 방법에 대한 사항(시험을 위한 별도의\n\n- 다. "
      }
    },
    {
      "chunk_id": "chunk_507",
      "text": "추가 기재내용 (대학 또는 연구기관 등 국내외 전문기관에서 시험한\n전문기관의 명칭, 주소, 인증현황, 검사기능 분야, 연구인력구성,\n\n주요설비 목록 등이 기재되어 있어야 함\n\n2) 주요설비\n\n시험검사에 사용된 장비명칭, 장비사양, 검·교정 기록서 등에 대한\n\n사항이 기재되고 관련 증빙자료를 함께 제출하여야 함\n\nⅥ. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 506,
        "window_size": 3,
        "char_count": 178,
        "word_count": 40,
        "page_number": 3,
        "window_text": "해당 제품의 특성상 첨부자료의 일부가 불필요한 경우, 그 사유를\n하여야 하며, 필요한 경우에 한하여 번역물을 요구할 수 있다.  다만,\n\n- 2.  시험 자료의 요건 (분석적 성능, 품질관리 시험성적서, 검체 조건 설정 자료)\n※ 임상적 성능시험 자료 요건은 별도 제시\n\n2) 해당 의료기기에 대하여 경제협력기구(OECD) 회원국에 허가\n\n당시 제출되어 평가된 시험에 관한 자료로서 해당 정부 또는\n\n정부가 허가 업무를 위임한 등록기관이 제출받아 승인하였음을\n\n확인한 자료 또는 이를 공증한 자료\n\n3) 「의료기기 제조·수입 및 품질관리기준」또는 이와 동등 이상의\n\n규격에 따른 제조사의 품질관리시스템 하에서 실시된 시험성적서\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 40 -\n4) 대학 또는 연구기관 등 국내·외의 전문기관에서 시험한 것으로서\n\n해당 전문기관의 장이 발급하고 그 내용(전문기관의 시험시설\n\n개요, 주요설비, 연구인력 구성, 시험자의 연구경력 등을 포함한다)을\n\n7) 시험 검사품 채취 및 방법에 대한 사항(시험을 위한 별도의\n\n- 다.  추가 기재내용 (대학 또는 연구기관 등 국내외 전문기관에서 시험한\n전문기관의 명칭, 주소, 인증현황, 검사기능 분야, 연구인력구성,\n\n주요설비 목록 등이 기재되어 있어야 함\n\n2) 주요설비\n\n시험검사에 사용된 장비명칭, 장비사양, 검·교정 기록서 등에 대한\n\n사항이 기재되고 관련 증빙자료를 함께 제출하여야 함\n\nⅥ.  기술문서 등의 심사를 위한 제출자료\n\n- - 41 -\n3) 연구인력구성\n\n시험검사를 실시한 전문기관 담당부서에 속한 연구인력들에 대한\n\n시험검사를 실시한 시험자가 해당 검사를 하기에 적합한 전공, 경력\n\n등을 가지고 있는지에 대해 기재하고, 해당 전문기관에서 규정한\n\n- 1.  개발경위\n- 가.  측정하고자 하는 대상 또는 질병이나 증후군의 설명 및 개발배경이\n- 2. ",
        "original_sentence": "추가 기재내용 (대학 또는 연구기관 등 국내외 전문기관에서 시험한\n전문기관의 명칭, 주소, 인증현황, 검사기능 분야, 연구인력구성,\n\n주요설비 목록 등이 기재되어 있어야 함\n\n2) 주요설비\n\n시험검사에 사용된 장비명칭, 장비사양, 검·교정 기록서 등에 대한\n\n사항이 기재되고 관련 증빙자료를 함께 제출하여야 함\n\nⅥ. "
      }
    },
    {
      "chunk_id": "chunk_508",
      "text": "기술문서 등의 심사를 위한 제출자료\n\n- - 41 -\n3) 연구인력구성\n\n시험검사를 실시한 전문기관 담당부서에 속한 연구인력들에 대한\n\n시험검사를 실시한 시험자가 해당 검사를 하기에 적합한 전공, 경력\n\n등을 가지고 있는지에 대해 기재하고, 해당 전문기관에서 규정한\n\n- 1. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 507,
        "window_size": 3,
        "char_count": 155,
        "word_count": 37,
        "page_number": 6,
        "window_text": "다만,\n\n- 2.  시험 자료의 요건 (분석적 성능, 품질관리 시험성적서, 검체 조건 설정 자료)\n※ 임상적 성능시험 자료 요건은 별도 제시\n\n2) 해당 의료기기에 대하여 경제협력기구(OECD) 회원국에 허가\n\n당시 제출되어 평가된 시험에 관한 자료로서 해당 정부 또는\n\n정부가 허가 업무를 위임한 등록기관이 제출받아 승인하였음을\n\n확인한 자료 또는 이를 공증한 자료\n\n3) 「의료기기 제조·수입 및 품질관리기준」또는 이와 동등 이상의\n\n규격에 따른 제조사의 품질관리시스템 하에서 실시된 시험성적서\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 40 -\n4) 대학 또는 연구기관 등 국내·외의 전문기관에서 시험한 것으로서\n\n해당 전문기관의 장이 발급하고 그 내용(전문기관의 시험시설\n\n개요, 주요설비, 연구인력 구성, 시험자의 연구경력 등을 포함한다)을\n\n7) 시험 검사품 채취 및 방법에 대한 사항(시험을 위한 별도의\n\n- 다.  추가 기재내용 (대학 또는 연구기관 등 국내외 전문기관에서 시험한\n전문기관의 명칭, 주소, 인증현황, 검사기능 분야, 연구인력구성,\n\n주요설비 목록 등이 기재되어 있어야 함\n\n2) 주요설비\n\n시험검사에 사용된 장비명칭, 장비사양, 검·교정 기록서 등에 대한\n\n사항이 기재되고 관련 증빙자료를 함께 제출하여야 함\n\nⅥ.  기술문서 등의 심사를 위한 제출자료\n\n- - 41 -\n3) 연구인력구성\n\n시험검사를 실시한 전문기관 담당부서에 속한 연구인력들에 대한\n\n시험검사를 실시한 시험자가 해당 검사를 하기에 적합한 전공, 경력\n\n등을 가지고 있는지에 대해 기재하고, 해당 전문기관에서 규정한\n\n- 1.  개발경위\n- 가.  측정하고자 하는 대상 또는 질병이나 증후군의 설명 및 개발배경이\n- 2.  측정원리 ․ 방법\n- 가. ",
        "original_sentence": "기술문서 등의 심사를 위한 제출자료\n\n- - 41 -\n3) 연구인력구성\n\n시험검사를 실시한 전문기관 담당부서에 속한 연구인력들에 대한\n\n시험검사를 실시한 시험자가 해당 검사를 하기에 적합한 전공, 경력\n\n등을 가지고 있는지에 대해 기재하고, 해당 전문기관에서 규정한\n\n- 1. "
      }
    },
    {
      "chunk_id": "chunk_509",
      "text": "개발경위\n- 가. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 508,
        "window_size": 3,
        "char_count": 10,
        "word_count": 3,
        "page_number": 74,
        "window_text": "시험 자료의 요건 (분석적 성능, 품질관리 시험성적서, 검체 조건 설정 자료)\n※ 임상적 성능시험 자료 요건은 별도 제시\n\n2) 해당 의료기기에 대하여 경제협력기구(OECD) 회원국에 허가\n\n당시 제출되어 평가된 시험에 관한 자료로서 해당 정부 또는\n\n정부가 허가 업무를 위임한 등록기관이 제출받아 승인하였음을\n\n확인한 자료 또는 이를 공증한 자료\n\n3) 「의료기기 제조·수입 및 품질관리기준」또는 이와 동등 이상의\n\n규격에 따른 제조사의 품질관리시스템 하에서 실시된 시험성적서\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 40 -\n4) 대학 또는 연구기관 등 국내·외의 전문기관에서 시험한 것으로서\n\n해당 전문기관의 장이 발급하고 그 내용(전문기관의 시험시설\n\n개요, 주요설비, 연구인력 구성, 시험자의 연구경력 등을 포함한다)을\n\n7) 시험 검사품 채취 및 방법에 대한 사항(시험을 위한 별도의\n\n- 다.  추가 기재내용 (대학 또는 연구기관 등 국내외 전문기관에서 시험한\n전문기관의 명칭, 주소, 인증현황, 검사기능 분야, 연구인력구성,\n\n주요설비 목록 등이 기재되어 있어야 함\n\n2) 주요설비\n\n시험검사에 사용된 장비명칭, 장비사양, 검·교정 기록서 등에 대한\n\n사항이 기재되고 관련 증빙자료를 함께 제출하여야 함\n\nⅥ.  기술문서 등의 심사를 위한 제출자료\n\n- - 41 -\n3) 연구인력구성\n\n시험검사를 실시한 전문기관 담당부서에 속한 연구인력들에 대한\n\n시험검사를 실시한 시험자가 해당 검사를 하기에 적합한 전공, 경력\n\n등을 가지고 있는지에 대해 기재하고, 해당 전문기관에서 규정한\n\n- 1.  개발경위\n- 가.  측정하고자 하는 대상 또는 질병이나 증후군의 설명 및 개발배경이\n- 2.  측정원리 ․ 방법\n- 가.  해당제품의 측정 및 질병진단 목적을 달성하기 위하여 적용된 원리에\n- 3. ",
        "original_sentence": "개발경위\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_510",
      "text": "측정하고자 하는 대상 또는 질병이나 증후군의 설명 및 개발배경이\n- 2. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 509,
        "window_size": 3,
        "char_count": 41,
        "word_count": 11,
        "page_number": 6,
        "window_text": "추가 기재내용 (대학 또는 연구기관 등 국내외 전문기관에서 시험한\n전문기관의 명칭, 주소, 인증현황, 검사기능 분야, 연구인력구성,\n\n주요설비 목록 등이 기재되어 있어야 함\n\n2) 주요설비\n\n시험검사에 사용된 장비명칭, 장비사양, 검·교정 기록서 등에 대한\n\n사항이 기재되고 관련 증빙자료를 함께 제출하여야 함\n\nⅥ.  기술문서 등의 심사를 위한 제출자료\n\n- - 41 -\n3) 연구인력구성\n\n시험검사를 실시한 전문기관 담당부서에 속한 연구인력들에 대한\n\n시험검사를 실시한 시험자가 해당 검사를 하기에 적합한 전공, 경력\n\n등을 가지고 있는지에 대해 기재하고, 해당 전문기관에서 규정한\n\n- 1.  개발경위\n- 가.  측정하고자 하는 대상 또는 질병이나 증후군의 설명 및 개발배경이\n- 2.  측정원리 ․ 방법\n- 가.  해당제품의 측정 및 질병진단 목적을 달성하기 위하여 적용된 원리에\n- 3.  국내․외에서 사용현황\n- 가. ",
        "original_sentence": "측정하고자 하는 대상 또는 질병이나 증후군의 설명 및 개발배경이\n- 2. "
      }
    },
    {
      "chunk_id": "chunk_511",
      "text": "측정원리 ․ 방법\n- 가. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 510,
        "window_size": 3,
        "char_count": 15,
        "word_count": 5,
        "page_number": 74,
        "window_text": "기술문서 등의 심사를 위한 제출자료\n\n- - 41 -\n3) 연구인력구성\n\n시험검사를 실시한 전문기관 담당부서에 속한 연구인력들에 대한\n\n시험검사를 실시한 시험자가 해당 검사를 하기에 적합한 전공, 경력\n\n등을 가지고 있는지에 대해 기재하고, 해당 전문기관에서 규정한\n\n- 1.  개발경위\n- 가.  측정하고자 하는 대상 또는 질병이나 증후군의 설명 및 개발배경이\n- 2.  측정원리 ․ 방법\n- 가.  해당제품의 측정 및 질병진단 목적을 달성하기 위하여 적용된 원리에\n- 3.  국내․외에서 사용현황\n- 가.  국내․외에서 사용현황에 관해 제출할 자료는 다음의 사항을 포함한다.\n",
        "original_sentence": "측정원리 ․ 방법\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_512",
      "text": "해당제품의 측정 및 질병진단 목적을 달성하기 위하여 적용된 원리에\n- 3. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 511,
        "window_size": 3,
        "char_count": 42,
        "word_count": 11,
        "page_number": 26,
        "window_text": "개발경위\n- 가.  측정하고자 하는 대상 또는 질병이나 증후군의 설명 및 개발배경이\n- 2.  측정원리 ․ 방법\n- 가.  해당제품의 측정 및 질병진단 목적을 달성하기 위하여 적용된 원리에\n- 3.  국내․외에서 사용현황\n- 가.  국내․외에서 사용현황에 관해 제출할 자료는 다음의 사항을 포함한다.\n 1)국내외의 판매 또는 허가현황 및 제조허가 경위 등과 관련된 자료\n\n2) 사용 시 보고된 측정오류 : 외국에서 시판 중인 제품의 경우, 제품\n\n안전성 및 성능과 관련된 유해사례보고 요약\n\n3) 제조국에서 사용되지 않는 경우는 그 사유\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 42 -\n<!-- PAGE_48 -->\n###### 2\n\n<!-- PAGE_48 -->\n###### 원재료 및 제조방법에 관한 자료\n\n- 1. ",
        "original_sentence": "해당제품의 측정 및 질병진단 목적을 달성하기 위하여 적용된 원리에\n- 3. "
      }
    },
    {
      "chunk_id": "chunk_513",
      "text": "국내․외에서 사용현황\n- 가. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 512,
        "window_size": 3,
        "char_count": 17,
        "word_count": 4,
        "page_number": 74,
        "window_text": "측정하고자 하는 대상 또는 질병이나 증후군의 설명 및 개발배경이\n- 2.  측정원리 ․ 방법\n- 가.  해당제품의 측정 및 질병진단 목적을 달성하기 위하여 적용된 원리에\n- 3.  국내․외에서 사용현황\n- 가.  국내․외에서 사용현황에 관해 제출할 자료는 다음의 사항을 포함한다.\n 1)국내외의 판매 또는 허가현황 및 제조허가 경위 등과 관련된 자료\n\n2) 사용 시 보고된 측정오류 : 외국에서 시판 중인 제품의 경우, 제품\n\n안전성 및 성능과 관련된 유해사례보고 요약\n\n3) 제조국에서 사용되지 않는 경우는 그 사유\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 42 -\n<!-- PAGE_48 -->\n###### 2\n\n<!-- PAGE_48 -->\n###### 원재료 및 제조방법에 관한 자료\n\n- 1.  원재료의 성분 또는 분량을 확인할 수 있는 근거자료\n- 나. ",
        "original_sentence": "국내․외에서 사용현황\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_514",
      "text": "국내․외에서 사용현황에 관해 제출할 자료는 다음의 사항을 포함한다.\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 513,
        "window_size": 3,
        "char_count": 38,
        "word_count": 8,
        "page_number": 3,
        "window_text": "측정원리 ․ 방법\n- 가.  해당제품의 측정 및 질병진단 목적을 달성하기 위하여 적용된 원리에\n- 3.  국내․외에서 사용현황\n- 가.  국내․외에서 사용현황에 관해 제출할 자료는 다음의 사항을 포함한다.\n 1)국내외의 판매 또는 허가현황 및 제조허가 경위 등과 관련된 자료\n\n2) 사용 시 보고된 측정오류 : 외국에서 시판 중인 제품의 경우, 제품\n\n안전성 및 성능과 관련된 유해사례보고 요약\n\n3) 제조국에서 사용되지 않는 경우는 그 사유\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 42 -\n<!-- PAGE_48 -->\n###### 2\n\n<!-- PAGE_48 -->\n###### 원재료 및 제조방법에 관한 자료\n\n- 1.  원재료의 성분 또는 분량을 확인할 수 있는 근거자료\n- 나.  원료물질(항원)이 재조합, 합성인 경우, 아미노산서열을 확인할 수\n- 2. ",
        "original_sentence": "국내․외에서 사용현황에 관해 제출할 자료는 다음의 사항을 포함한다.\n"
      }
    },
    {
      "chunk_id": "chunk_515",
      "text": "1)국내외의 판매 또는 허가현황 및 제조허가 경위 등과 관련된 자료\n\n2) 사용 시 보고된 측정오류 : 외국에서 시판 중인 제품의 경우, 제품\n\n안전성 및 성능과 관련된 유해사례보고 요약\n\n3) 제조국에서 사용되지 않는 경우는 그 사유\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 42 -\n<!-- PAGE_48 -->\n###### 2\n\n<!-- PAGE_48 -->\n###### 원재료 및 제조방법에 관한 자료\n\n- 1. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 514,
        "window_size": 3,
        "char_count": 266,
        "word_count": 63,
        "page_number": 48,
        "window_text": "해당제품의 측정 및 질병진단 목적을 달성하기 위하여 적용된 원리에\n- 3.  국내․외에서 사용현황\n- 가.  국내․외에서 사용현황에 관해 제출할 자료는 다음의 사항을 포함한다.\n 1)국내외의 판매 또는 허가현황 및 제조허가 경위 등과 관련된 자료\n\n2) 사용 시 보고된 측정오류 : 외국에서 시판 중인 제품의 경우, 제품\n\n안전성 및 성능과 관련된 유해사례보고 요약\n\n3) 제조국에서 사용되지 않는 경우는 그 사유\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 42 -\n<!-- PAGE_48 -->\n###### 2\n\n<!-- PAGE_48 -->\n###### 원재료 및 제조방법에 관한 자료\n\n- 1.  원재료의 성분 또는 분량을 확인할 수 있는 근거자료\n- 나.  원료물질(항원)이 재조합, 합성인 경우, 아미노산서열을 확인할 수\n- 2.  제조공정의 흐름도를 포함한 제조공정에 관한 자료\n- 가. ",
        "original_sentence": "1)국내외의 판매 또는 허가현황 및 제조허가 경위 등과 관련된 자료\n\n2) 사용 시 보고된 측정오류 : 외국에서 시판 중인 제품의 경우, 제품\n\n안전성 및 성능과 관련된 유해사례보고 요약\n\n3) 제조국에서 사용되지 않는 경우는 그 사유\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 42 -\n<!-- PAGE_48 -->\n###### 2\n\n<!-- PAGE_48 -->\n###### 원재료 및 제조방법에 관한 자료\n\n- 1. "
      }
    },
    {
      "chunk_id": "chunk_516",
      "text": "원재료의 성분 또는 분량을 확인할 수 있는 근거자료\n- 나. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 515,
        "window_size": 3,
        "char_count": 34,
        "word_count": 10,
        "page_number": 7,
        "window_text": "국내․외에서 사용현황\n- 가.  국내․외에서 사용현황에 관해 제출할 자료는 다음의 사항을 포함한다.\n 1)국내외의 판매 또는 허가현황 및 제조허가 경위 등과 관련된 자료\n\n2) 사용 시 보고된 측정오류 : 외국에서 시판 중인 제품의 경우, 제품\n\n안전성 및 성능과 관련된 유해사례보고 요약\n\n3) 제조국에서 사용되지 않는 경우는 그 사유\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 42 -\n<!-- PAGE_48 -->\n###### 2\n\n<!-- PAGE_48 -->\n###### 원재료 및 제조방법에 관한 자료\n\n- 1.  원재료의 성분 또는 분량을 확인할 수 있는 근거자료\n- 나.  원료물질(항원)이 재조합, 합성인 경우, 아미노산서열을 확인할 수\n- 2.  제조공정의 흐름도를 포함한 제조공정에 관한 자료\n- 가.  제조공정의 흐름을 파악할 수 있는 자료를 제출(제조공정상의 제조\n- 나. ",
        "original_sentence": "원재료의 성분 또는 분량을 확인할 수 있는 근거자료\n- 나. "
      }
    },
    {
      "chunk_id": "chunk_517",
      "text": "원료물질(항원)이 재조합, 합성인 경우, 아미노산서열을 확인할 수\n- 2. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 516,
        "window_size": 3,
        "char_count": 42,
        "word_count": 9,
        "page_number": 3,
        "window_text": "국내․외에서 사용현황에 관해 제출할 자료는 다음의 사항을 포함한다.\n 1)국내외의 판매 또는 허가현황 및 제조허가 경위 등과 관련된 자료\n\n2) 사용 시 보고된 측정오류 : 외국에서 시판 중인 제품의 경우, 제품\n\n안전성 및 성능과 관련된 유해사례보고 요약\n\n3) 제조국에서 사용되지 않는 경우는 그 사유\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 42 -\n<!-- PAGE_48 -->\n###### 2\n\n<!-- PAGE_48 -->\n###### 원재료 및 제조방법에 관한 자료\n\n- 1.  원재료의 성분 또는 분량을 확인할 수 있는 근거자료\n- 나.  원료물질(항원)이 재조합, 합성인 경우, 아미노산서열을 확인할 수\n- 2.  제조공정의 흐름도를 포함한 제조공정에 관한 자료\n- 가.  제조공정의 흐름을 파악할 수 있는 자료를 제출(제조공정상의 제조\n- 나.  원료물질의 제조방법을 간략하게 기술하고, 이를 구매한 경우, 이를\n- 다. ",
        "original_sentence": "원료물질(항원)이 재조합, 합성인 경우, 아미노산서열을 확인할 수\n- 2. "
      }
    },
    {
      "chunk_id": "chunk_518",
      "text": "제조공정의 흐름도를 포함한 제조공정에 관한 자료\n- 가. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 517,
        "window_size": 3,
        "char_count": 32,
        "word_count": 8,
        "page_number": 7,
        "window_text": "1)국내외의 판매 또는 허가현황 및 제조허가 경위 등과 관련된 자료\n\n2) 사용 시 보고된 측정오류 : 외국에서 시판 중인 제품의 경우, 제품\n\n안전성 및 성능과 관련된 유해사례보고 요약\n\n3) 제조국에서 사용되지 않는 경우는 그 사유\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 42 -\n<!-- PAGE_48 -->\n###### 2\n\n<!-- PAGE_48 -->\n###### 원재료 및 제조방법에 관한 자료\n\n- 1.  원재료의 성분 또는 분량을 확인할 수 있는 근거자료\n- 나.  원료물질(항원)이 재조합, 합성인 경우, 아미노산서열을 확인할 수\n- 2.  제조공정의 흐름도를 포함한 제조공정에 관한 자료\n- 가.  제조공정의 흐름을 파악할 수 있는 자료를 제출(제조공정상의 제조\n- 나.  원료물질의 제조방법을 간략하게 기술하고, 이를 구매한 경우, 이를\n- 다.  일부 구성제품이 OEM제조품인 경우, 구성품의 제조원(제조자의\n- 1. ",
        "original_sentence": "제조공정의 흐름도를 포함한 제조공정에 관한 자료\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_519",
      "text": "제조공정의 흐름을 파악할 수 있는 자료를 제출(제조공정상의 제조\n- 나. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 518,
        "window_size": 3,
        "char_count": 41,
        "word_count": 10,
        "page_number": 74,
        "window_text": "원재료의 성분 또는 분량을 확인할 수 있는 근거자료\n- 나.  원료물질(항원)이 재조합, 합성인 경우, 아미노산서열을 확인할 수\n- 2.  제조공정의 흐름도를 포함한 제조공정에 관한 자료\n- 가.  제조공정의 흐름을 파악할 수 있는 자료를 제출(제조공정상의 제조\n- 나.  원료물질의 제조방법을 간략하게 기술하고, 이를 구매한 경우, 이를\n- 다.  일부 구성제품이 OEM제조품인 경우, 구성품의 제조원(제조자의\n- 1.  허가신청서에 기재한 해당 제품의 사용목적의 세부 사항(검사대상,\n검체종류, 검사항목, 측정원리 및 결과판정방법(정성, 정량 등))에 대한\n\n근거자료를 제출한다.\n\n",
        "original_sentence": "제조공정의 흐름을 파악할 수 있는 자료를 제출(제조공정상의 제조\n- 나. "
      }
    },
    {
      "chunk_id": "chunk_520",
      "text": "원료물질의 제조방법을 간략하게 기술하고, 이를 구매한 경우, 이를\n- 다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 519,
        "window_size": 3,
        "char_count": 42,
        "word_count": 10,
        "page_number": 30,
        "window_text": "원료물질(항원)이 재조합, 합성인 경우, 아미노산서열을 확인할 수\n- 2.  제조공정의 흐름도를 포함한 제조공정에 관한 자료\n- 가.  제조공정의 흐름을 파악할 수 있는 자료를 제출(제조공정상의 제조\n- 나.  원료물질의 제조방법을 간략하게 기술하고, 이를 구매한 경우, 이를\n- 다.  일부 구성제품이 OEM제조품인 경우, 구성품의 제조원(제조자의\n- 1.  허가신청서에 기재한 해당 제품의 사용목적의 세부 사항(검사대상,\n검체종류, 검사항목, 측정원리 및 결과판정방법(정성, 정량 등))에 대한\n\n근거자료를 제출한다.\n\n - 2. ",
        "original_sentence": "원료물질의 제조방법을 간략하게 기술하고, 이를 구매한 경우, 이를\n- 다. "
      }
    },
    {
      "chunk_id": "chunk_521",
      "text": "일부 구성제품이 OEM제조품인 경우, 구성품의 제조원(제조자의\n- 1. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 520,
        "window_size": 3,
        "char_count": 40,
        "word_count": 8,
        "page_number": 21,
        "window_text": "제조공정의 흐름도를 포함한 제조공정에 관한 자료\n- 가.  제조공정의 흐름을 파악할 수 있는 자료를 제출(제조공정상의 제조\n- 나.  원료물질의 제조방법을 간략하게 기술하고, 이를 구매한 경우, 이를\n- 다.  일부 구성제품이 OEM제조품인 경우, 구성품의 제조원(제조자의\n- 1.  허가신청서에 기재한 해당 제품의 사용목적의 세부 사항(검사대상,\n검체종류, 검사항목, 측정원리 및 결과판정방법(정성, 정량 등))에 대한\n\n근거자료를 제출한다.\n\n - 2.  해당제품의 제품설명서(instructions for user)를 제출한다.\n",
        "original_sentence": "일부 구성제품이 OEM제조품인 경우, 구성품의 제조원(제조자의\n- 1. "
      }
    },
    {
      "chunk_id": "chunk_522",
      "text": "허가신청서에 기재한 해당 제품의 사용목적의 세부 사항(검사대상,\n검체종류, 검사항목, 측정원리 및 결과판정방법(정성, 정량 등))에 대한\n\n근거자료를 제출한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 521,
        "window_size": 3,
        "char_count": 91,
        "word_count": 17,
        "page_number": 3,
        "window_text": "제조공정의 흐름을 파악할 수 있는 자료를 제출(제조공정상의 제조\n- 나.  원료물질의 제조방법을 간략하게 기술하고, 이를 구매한 경우, 이를\n- 다.  일부 구성제품이 OEM제조품인 경우, 구성품의 제조원(제조자의\n- 1.  허가신청서에 기재한 해당 제품의 사용목적의 세부 사항(검사대상,\n검체종류, 검사항목, 측정원리 및 결과판정방법(정성, 정량 등))에 대한\n\n근거자료를 제출한다.\n\n - 2.  해당제품의 제품설명서(instructions for user)를 제출한다.\n Ⅵ. ",
        "original_sentence": "허가신청서에 기재한 해당 제품의 사용목적의 세부 사항(검사대상,\n검체종류, 검사항목, 측정원리 및 결과판정방법(정성, 정량 등))에 대한\n\n근거자료를 제출한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_523",
      "text": "- 2. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 522,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 6,
        "window_text": "원료물질의 제조방법을 간략하게 기술하고, 이를 구매한 경우, 이를\n- 다.  일부 구성제품이 OEM제조품인 경우, 구성품의 제조원(제조자의\n- 1.  허가신청서에 기재한 해당 제품의 사용목적의 세부 사항(검사대상,\n검체종류, 검사항목, 측정원리 및 결과판정방법(정성, 정량 등))에 대한\n\n근거자료를 제출한다.\n\n - 2.  해당제품의 제품설명서(instructions for user)를 제출한다.\n Ⅵ.  기술문서 등의 심사를 위한 제출자료\n\n- - 43 -\n<!-- PAGE_49 -->\n###### 4\n\n<!-- PAGE_49 -->\n###### 저장방법과 사용기간(유효기간)에 관한 자료\n\n- 1. ",
        "original_sentence": "- 2. "
      }
    },
    {
      "chunk_id": "chunk_524",
      "text": "해당제품의 제품설명서(instructions for user)를 제출한다.\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 523,
        "window_size": 3,
        "char_count": 42,
        "word_count": 5,
        "page_number": 14,
        "window_text": "일부 구성제품이 OEM제조품인 경우, 구성품의 제조원(제조자의\n- 1.  허가신청서에 기재한 해당 제품의 사용목적의 세부 사항(검사대상,\n검체종류, 검사항목, 측정원리 및 결과판정방법(정성, 정량 등))에 대한\n\n근거자료를 제출한다.\n\n - 2.  해당제품의 제품설명서(instructions for user)를 제출한다.\n Ⅵ.  기술문서 등의 심사를 위한 제출자료\n\n- - 43 -\n<!-- PAGE_49 -->\n###### 4\n\n<!-- PAGE_49 -->\n###### 저장방법과 사용기간(유효기간)에 관한 자료\n\n- 1.  완제품 및 개봉 후 시약의 안정성에 관한 자료로서 저장방법, 사용기간\n- 2. ",
        "original_sentence": "해당제품의 제품설명서(instructions for user)를 제출한다.\n"
      }
    },
    {
      "chunk_id": "chunk_525",
      "text": "Ⅵ. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 524,
        "window_size": 3,
        "char_count": 3,
        "word_count": 1,
        "page_number": 7,
        "window_text": "허가신청서에 기재한 해당 제품의 사용목적의 세부 사항(검사대상,\n검체종류, 검사항목, 측정원리 및 결과판정방법(정성, 정량 등))에 대한\n\n근거자료를 제출한다.\n\n - 2.  해당제품의 제품설명서(instructions for user)를 제출한다.\n Ⅵ.  기술문서 등의 심사를 위한 제출자료\n\n- - 43 -\n<!-- PAGE_49 -->\n###### 4\n\n<!-- PAGE_49 -->\n###### 저장방법과 사용기간(유효기간)에 관한 자료\n\n- 1.  완제품 및 개봉 후 시약의 안정성에 관한 자료로서 저장방법, 사용기간\n- 2.  구성 제품별로 구분하여 안정성 시험 자료를 제출한다.\n",
        "original_sentence": "Ⅵ. "
      }
    },
    {
      "chunk_id": "chunk_526",
      "text": "기술문서 등의 심사를 위한 제출자료\n\n- - 43 -\n<!-- PAGE_49 -->\n###### 4\n\n<!-- PAGE_49 -->\n###### 저장방법과 사용기간(유효기간)에 관한 자료\n\n- 1. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 525,
        "window_size": 3,
        "char_count": 111,
        "word_count": 24,
        "page_number": 49,
        "window_text": "- 2.  해당제품의 제품설명서(instructions for user)를 제출한다.\n Ⅵ.  기술문서 등의 심사를 위한 제출자료\n\n- - 43 -\n<!-- PAGE_49 -->\n###### 4\n\n<!-- PAGE_49 -->\n###### 저장방법과 사용기간(유효기간)에 관한 자료\n\n- 1.  완제품 및 개봉 후 시약의 안정성에 관한 자료로서 저장방법, 사용기간\n- 2.  구성 제품별로 구분하여 안정성 시험 자료를 제출한다.\n - 3. ",
        "original_sentence": "기술문서 등의 심사를 위한 제출자료\n\n- - 43 -\n<!-- PAGE_49 -->\n###### 4\n\n<!-- PAGE_49 -->\n###### 저장방법과 사용기간(유효기간)에 관한 자료\n\n- 1. "
      }
    },
    {
      "chunk_id": "chunk_527",
      "text": "완제품 및 개봉 후 시약의 안정성에 관한 자료로서 저장방법, 사용기간\n- 2. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 526,
        "window_size": 3,
        "char_count": 44,
        "word_count": 12,
        "page_number": 6,
        "window_text": "해당제품의 제품설명서(instructions for user)를 제출한다.\n Ⅵ.  기술문서 등의 심사를 위한 제출자료\n\n- - 43 -\n<!-- PAGE_49 -->\n###### 4\n\n<!-- PAGE_49 -->\n###### 저장방법과 사용기간(유효기간)에 관한 자료\n\n- 1.  완제품 및 개봉 후 시약의 안정성에 관한 자료로서 저장방법, 사용기간\n- 2.  구성 제품별로 구분하여 안정성 시험 자료를 제출한다.\n - 3.  시험성적서는 평가계획, 시험간격, 허용기준, 결과 등의 내용을 포함한다.\n",
        "original_sentence": "완제품 및 개봉 후 시약의 안정성에 관한 자료로서 저장방법, 사용기간\n- 2. "
      }
    },
    {
      "chunk_id": "chunk_528",
      "text": "구성 제품별로 구분하여 안정성 시험 자료를 제출한다.\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 527,
        "window_size": 3,
        "char_count": 30,
        "word_count": 7,
        "page_number": 3,
        "window_text": "Ⅵ.  기술문서 등의 심사를 위한 제출자료\n\n- - 43 -\n<!-- PAGE_49 -->\n###### 4\n\n<!-- PAGE_49 -->\n###### 저장방법과 사용기간(유효기간)에 관한 자료\n\n- 1.  완제품 및 개봉 후 시약의 안정성에 관한 자료로서 저장방법, 사용기간\n- 2.  구성 제품별로 구분하여 안정성 시험 자료를 제출한다.\n - 3.  시험성적서는 평가계획, 시험간격, 허용기준, 결과 등의 내용을 포함한다.\n - 4. ",
        "original_sentence": "구성 제품별로 구분하여 안정성 시험 자료를 제출한다.\n"
      }
    },
    {
      "chunk_id": "chunk_529",
      "text": "- 3. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 528,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 26,
        "window_text": "기술문서 등의 심사를 위한 제출자료\n\n- - 43 -\n<!-- PAGE_49 -->\n###### 4\n\n<!-- PAGE_49 -->\n###### 저장방법과 사용기간(유효기간)에 관한 자료\n\n- 1.  완제품 및 개봉 후 시약의 안정성에 관한 자료로서 저장방법, 사용기간\n- 2.  구성 제품별로 구분하여 안정성 시험 자료를 제출한다.\n - 3.  시험성적서는 평가계획, 시험간격, 허용기준, 결과 등의 내용을 포함한다.\n - 4.  안정성 시험 시에는 식약처「의료기기의 안정성 시험 기준」의 내용을\n- 5. ",
        "original_sentence": "- 3. "
      }
    },
    {
      "chunk_id": "chunk_530",
      "text": "시험성적서는 평가계획, 시험간격, 허용기준, 결과 등의 내용을 포함한다.\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 529,
        "window_size": 3,
        "char_count": 41,
        "word_count": 8,
        "page_number": 33,
        "window_text": "완제품 및 개봉 후 시약의 안정성에 관한 자료로서 저장방법, 사용기간\n- 2.  구성 제품별로 구분하여 안정성 시험 자료를 제출한다.\n - 3.  시험성적서는 평가계획, 시험간격, 허용기준, 결과 등의 내용을 포함한다.\n - 4.  안정성 시험 시에는 식약처「의료기기의 안정성 시험 기준」의 내용을\n- 5.  저장 및 사용기간(유효기간)에 대한 시험은 완제품 3 lots, 개봉 후 1\n- 6. ",
        "original_sentence": "시험성적서는 평가계획, 시험간격, 허용기준, 결과 등의 내용을 포함한다.\n"
      }
    },
    {
      "chunk_id": "chunk_531",
      "text": "- 4. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 530,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 6,
        "window_text": "구성 제품별로 구분하여 안정성 시험 자료를 제출한다.\n - 3.  시험성적서는 평가계획, 시험간격, 허용기준, 결과 등의 내용을 포함한다.\n - 4.  안정성 시험 시에는 식약처「의료기기의 안정성 시험 기준」의 내용을\n- 5.  저장 및 사용기간(유효기간)에 대한 시험은 완제품 3 lots, 개봉 후 1\n- 6.  일회용으로 낱개 포장되어 있는 체외진단용 의료기기를 제외하고, 개\n- 7. ",
        "original_sentence": "- 4. "
      }
    },
    {
      "chunk_id": "chunk_532",
      "text": "안정성 시험 시에는 식약처「의료기기의 안정성 시험 기준」의 내용을\n- 5. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 531,
        "window_size": 3,
        "char_count": 42,
        "word_count": 10,
        "page_number": 30,
        "window_text": "- 3.  시험성적서는 평가계획, 시험간격, 허용기준, 결과 등의 내용을 포함한다.\n - 4.  안정성 시험 시에는 식약처「의료기기의 안정성 시험 기준」의 내용을\n- 5.  저장 및 사용기간(유효기간)에 대한 시험은 완제품 3 lots, 개봉 후 1\n- 6.  일회용으로 낱개 포장되어 있는 체외진단용 의료기기를 제외하고, 개\n- 7.  수송 조건(환경 및 운반조건 변화)을 고려한 안정성 자료의 제출을 권장한다.\n",
        "original_sentence": "안정성 시험 시에는 식약처「의료기기의 안정성 시험 기준」의 내용을\n- 5. "
      }
    },
    {
      "chunk_id": "chunk_533",
      "text": "저장 및 사용기간(유효기간)에 대한 시험은 완제품 3 lots, 개봉 후 1\n- 6. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 532,
        "window_size": 3,
        "char_count": 48,
        "word_count": 13,
        "page_number": 21,
        "window_text": "시험성적서는 평가계획, 시험간격, 허용기준, 결과 등의 내용을 포함한다.\n - 4.  안정성 시험 시에는 식약처「의료기기의 안정성 시험 기준」의 내용을\n- 5.  저장 및 사용기간(유효기간)에 대한 시험은 완제품 3 lots, 개봉 후 1\n- 6.  일회용으로 낱개 포장되어 있는 체외진단용 의료기기를 제외하고, 개\n- 7.  수송 조건(환경 및 운반조건 변화)을 고려한 안정성 자료의 제출을 권장한다.\n - 8. ",
        "original_sentence": "저장 및 사용기간(유효기간)에 대한 시험은 완제품 3 lots, 개봉 후 1\n- 6. "
      }
    },
    {
      "chunk_id": "chunk_534",
      "text": "일회용으로 낱개 포장되어 있는 체외진단용 의료기기를 제외하고, 개\n- 7. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 533,
        "window_size": 3,
        "char_count": 42,
        "word_count": 10,
        "page_number": 1,
        "window_text": "- 4.  안정성 시험 시에는 식약처「의료기기의 안정성 시험 기준」의 내용을\n- 5.  저장 및 사용기간(유효기간)에 대한 시험은 완제품 3 lots, 개봉 후 1\n- 6.  일회용으로 낱개 포장되어 있는 체외진단용 의료기기를 제외하고, 개\n- 7.  수송 조건(환경 및 운반조건 변화)을 고려한 안정성 자료의 제출을 권장한다.\n - 8.  저장방법 및 사용기간(유효기간)에 대한 시험자료는 시험성적서의\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 44 -\n<!-- PAGE_50 -->\n###### 5\n\n<!-- PAGE_50 -->\n###### 제품의 성능을 확인하기 위한 자료\n\n- 1. ",
        "original_sentence": "일회용으로 낱개 포장되어 있는 체외진단용 의료기기를 제외하고, 개\n- 7. "
      }
    },
    {
      "chunk_id": "chunk_535",
      "text": "수송 조건(환경 및 운반조건 변화)을 고려한 안정성 자료의 제출을 권장한다.\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 534,
        "window_size": 3,
        "char_count": 43,
        "word_count": 10,
        "page_number": 49,
        "window_text": "안정성 시험 시에는 식약처「의료기기의 안정성 시험 기준」의 내용을\n- 5.  저장 및 사용기간(유효기간)에 대한 시험은 완제품 3 lots, 개봉 후 1\n- 6.  일회용으로 낱개 포장되어 있는 체외진단용 의료기기를 제외하고, 개\n- 7.  수송 조건(환경 및 운반조건 변화)을 고려한 안정성 자료의 제출을 권장한다.\n - 8.  저장방법 및 사용기간(유효기간)에 대한 시험자료는 시험성적서의\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 44 -\n<!-- PAGE_50 -->\n###### 5\n\n<!-- PAGE_50 -->\n###### 제품의 성능을 확인하기 위한 자료\n\n- 1.  제품의 성능을 확인하기 위한 자료는 다음의 자료를 포함한다.\n",
        "original_sentence": "수송 조건(환경 및 운반조건 변화)을 고려한 안정성 자료의 제출을 권장한다.\n"
      }
    },
    {
      "chunk_id": "chunk_536",
      "text": "- 8. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 535,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 40,
        "window_text": "저장 및 사용기간(유효기간)에 대한 시험은 완제품 3 lots, 개봉 후 1\n- 6.  일회용으로 낱개 포장되어 있는 체외진단용 의료기기를 제외하고, 개\n- 7.  수송 조건(환경 및 운반조건 변화)을 고려한 안정성 자료의 제출을 권장한다.\n - 8.  저장방법 및 사용기간(유효기간)에 대한 시험자료는 시험성적서의\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 44 -\n<!-- PAGE_50 -->\n###### 5\n\n<!-- PAGE_50 -->\n###### 제품의 성능을 확인하기 위한 자료\n\n- 1.  제품의 성능을 확인하기 위한 자료는 다음의 자료를 포함한다.\n - 라. ",
        "original_sentence": "- 8. "
      }
    },
    {
      "chunk_id": "chunk_537",
      "text": "저장방법 및 사용기간(유효기간)에 대한 시험자료는 시험성적서의\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 44 -\n<!-- PAGE_50 -->\n###### 5\n\n<!-- PAGE_50 -->\n###### 제품의 성능을 확인하기 위한 자료\n\n- 1. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 536,
        "window_size": 3,
        "char_count": 169,
        "word_count": 34,
        "page_number": 50,
        "window_text": "일회용으로 낱개 포장되어 있는 체외진단용 의료기기를 제외하고, 개\n- 7.  수송 조건(환경 및 운반조건 변화)을 고려한 안정성 자료의 제출을 권장한다.\n - 8.  저장방법 및 사용기간(유효기간)에 대한 시험자료는 시험성적서의\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 44 -\n<!-- PAGE_50 -->\n###### 5\n\n<!-- PAGE_50 -->\n###### 제품의 성능을 확인하기 위한 자료\n\n- 1.  제품의 성능을 확인하기 위한 자료는 다음의 자료를 포함한다.\n - 라.  완제품의 품질관리 시험성적서 또는 시험에 관한 자료(3배치 1회 이상\n- 1. ",
        "original_sentence": "저장방법 및 사용기간(유효기간)에 대한 시험자료는 시험성적서의\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 44 -\n<!-- PAGE_50 -->\n###### 5\n\n<!-- PAGE_50 -->\n###### 제품의 성능을 확인하기 위한 자료\n\n- 1. "
      }
    },
    {
      "chunk_id": "chunk_538",
      "text": "제품의 성능을 확인하기 위한 자료는 다음의 자료를 포함한다.\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 537,
        "window_size": 3,
        "char_count": 34,
        "word_count": 8,
        "page_number": 19,
        "window_text": "수송 조건(환경 및 운반조건 변화)을 고려한 안정성 자료의 제출을 권장한다.\n - 8.  저장방법 및 사용기간(유효기간)에 대한 시험자료는 시험성적서의\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 44 -\n<!-- PAGE_50 -->\n###### 5\n\n<!-- PAGE_50 -->\n###### 제품의 성능을 확인하기 위한 자료\n\n- 1.  제품의 성능을 확인하기 위한 자료는 다음의 자료를 포함한다.\n - 라.  완제품의 품질관리 시험성적서 또는 시험에 관한 자료(3배치 1회 이상\n- 1.  구성시약 중 인간혈액 유래물질이 포함되었을 경우에는 사람면역결핍\n바이러스(HIV),\n\nC형간염바이러스(HCV),\n\nB형간염바이러스(HBV)가\n\n음성 또는 불활성화하여 감염력이 없음을 입증하는 자료를 제출한다.\n\n",
        "original_sentence": "제품의 성능을 확인하기 위한 자료는 다음의 자료를 포함한다.\n"
      }
    },
    {
      "chunk_id": "chunk_539",
      "text": "- 라. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 538,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 74,
        "window_text": "- 8.  저장방법 및 사용기간(유효기간)에 대한 시험자료는 시험성적서의\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 44 -\n<!-- PAGE_50 -->\n###### 5\n\n<!-- PAGE_50 -->\n###### 제품의 성능을 확인하기 위한 자료\n\n- 1.  제품의 성능을 확인하기 위한 자료는 다음의 자료를 포함한다.\n - 라.  완제품의 품질관리 시험성적서 또는 시험에 관한 자료(3배치 1회 이상\n- 1.  구성시약 중 인간혈액 유래물질이 포함되었을 경우에는 사람면역결핍\n바이러스(HIV),\n\nC형간염바이러스(HCV),\n\nB형간염바이러스(HBV)가\n\n음성 또는 불활성화하여 감염력이 없음을 입증하는 자료를 제출한다.\n\n - 2. ",
        "original_sentence": "- 라. "
      }
    },
    {
      "chunk_id": "chunk_540",
      "text": "완제품의 품질관리 시험성적서 또는 시험에 관한 자료(3배치 1회 이상\n- 1. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 539,
        "window_size": 3,
        "char_count": 44,
        "word_count": 11,
        "page_number": 7,
        "window_text": "저장방법 및 사용기간(유효기간)에 대한 시험자료는 시험성적서의\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 44 -\n<!-- PAGE_50 -->\n###### 5\n\n<!-- PAGE_50 -->\n###### 제품의 성능을 확인하기 위한 자료\n\n- 1.  제품의 성능을 확인하기 위한 자료는 다음의 자료를 포함한다.\n - 라.  완제품의 품질관리 시험성적서 또는 시험에 관한 자료(3배치 1회 이상\n- 1.  구성시약 중 인간혈액 유래물질이 포함되었을 경우에는 사람면역결핍\n바이러스(HIV),\n\nC형간염바이러스(HCV),\n\nB형간염바이러스(HBV)가\n\n음성 또는 불활성화하여 감염력이 없음을 입증하는 자료를 제출한다.\n\n - 2.  유해물질(독성, 가연성 등) 등 취급자 안전 및 적합성을 확인한 자료를\n제출한다.\n\n",
        "original_sentence": "완제품의 품질관리 시험성적서 또는 시험에 관한 자료(3배치 1회 이상\n- 1. "
      }
    },
    {
      "chunk_id": "chunk_541",
      "text": "구성시약 중 인간혈액 유래물질이 포함되었을 경우에는 사람면역결핍\n바이러스(HIV),\n\nC형간염바이러스(HCV),\n\nB형간염바이러스(HBV)가\n\n음성 또는 불활성화하여 감염력이 없음을 입증하는 자료를 제출한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 540,
        "window_size": 3,
        "char_count": 118,
        "word_count": 18,
        "page_number": 32,
        "window_text": "제품의 성능을 확인하기 위한 자료는 다음의 자료를 포함한다.\n - 라.  완제품의 품질관리 시험성적서 또는 시험에 관한 자료(3배치 1회 이상\n- 1.  구성시약 중 인간혈액 유래물질이 포함되었을 경우에는 사람면역결핍\n바이러스(HIV),\n\nC형간염바이러스(HCV),\n\nB형간염바이러스(HBV)가\n\n음성 또는 불활성화하여 감염력이 없음을 입증하는 자료를 제출한다.\n\n - 2.  유해물질(독성, 가연성 등) 등 취급자 안전 및 적합성을 확인한 자료를\n제출한다.\n\n Ⅵ. ",
        "original_sentence": "구성시약 중 인간혈액 유래물질이 포함되었을 경우에는 사람면역결핍\n바이러스(HIV),\n\nC형간염바이러스(HCV),\n\nB형간염바이러스(HBV)가\n\n음성 또는 불활성화하여 감염력이 없음을 입증하는 자료를 제출한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_542",
      "text": "- 2. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 541,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 6,
        "window_text": "- 라.  완제품의 품질관리 시험성적서 또는 시험에 관한 자료(3배치 1회 이상\n- 1.  구성시약 중 인간혈액 유래물질이 포함되었을 경우에는 사람면역결핍\n바이러스(HIV),\n\nC형간염바이러스(HCV),\n\nB형간염바이러스(HBV)가\n\n음성 또는 불활성화하여 감염력이 없음을 입증하는 자료를 제출한다.\n\n - 2.  유해물질(독성, 가연성 등) 등 취급자 안전 및 적합성을 확인한 자료를\n제출한다.\n\n Ⅵ.  기술문서 등의 심사를 위한 제출자료\n\n- - 45 -\n<!-- PAGE_51 -->\n###### 7\n\n<!-- PAGE_51 -->\n###### 이미 허가·인증받은 제품과 비교한 자료\n\n- 1. ",
        "original_sentence": "- 2. "
      }
    },
    {
      "chunk_id": "chunk_543",
      "text": "유해물질(독성, 가연성 등) 등 취급자 안전 및 적합성을 확인한 자료를\n제출한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 542,
        "window_size": 3,
        "char_count": 47,
        "word_count": 11,
        "page_number": 19,
        "window_text": "완제품의 품질관리 시험성적서 또는 시험에 관한 자료(3배치 1회 이상\n- 1.  구성시약 중 인간혈액 유래물질이 포함되었을 경우에는 사람면역결핍\n바이러스(HIV),\n\nC형간염바이러스(HCV),\n\nB형간염바이러스(HBV)가\n\n음성 또는 불활성화하여 감염력이 없음을 입증하는 자료를 제출한다.\n\n - 2.  유해물질(독성, 가연성 등) 등 취급자 안전 및 적합성을 확인한 자료를\n제출한다.\n\n Ⅵ.  기술문서 등의 심사를 위한 제출자료\n\n- - 45 -\n<!-- PAGE_51 -->\n###### 7\n\n<!-- PAGE_51 -->\n###### 이미 허가·인증받은 제품과 비교한 자료\n\n- 1.  이미 허가·인증받은 제품과 명칭(제품명, 품목명, 모델명), 제조(수입)업\n소명, 제조원 및 소재지, 허가(인증)번호, 사용목적, 작용원리, 원재료,\n\n[별지 제3호서식]\n\n1) 기허가된 의료기기와의 차이가 명확하게 입증도록 필요한 항목을 기재하여야 한다.\n\n",
        "original_sentence": "유해물질(독성, 가연성 등) 등 취급자 안전 및 적합성을 확인한 자료를\n제출한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_544",
      "text": "Ⅵ. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 543,
        "window_size": 3,
        "char_count": 3,
        "word_count": 1,
        "page_number": 7,
        "window_text": "구성시약 중 인간혈액 유래물질이 포함되었을 경우에는 사람면역결핍\n바이러스(HIV),\n\nC형간염바이러스(HCV),\n\nB형간염바이러스(HBV)가\n\n음성 또는 불활성화하여 감염력이 없음을 입증하는 자료를 제출한다.\n\n - 2.  유해물질(독성, 가연성 등) 등 취급자 안전 및 적합성을 확인한 자료를\n제출한다.\n\n Ⅵ.  기술문서 등의 심사를 위한 제출자료\n\n- - 45 -\n<!-- PAGE_51 -->\n###### 7\n\n<!-- PAGE_51 -->\n###### 이미 허가·인증받은 제품과 비교한 자료\n\n- 1.  이미 허가·인증받은 제품과 명칭(제품명, 품목명, 모델명), 제조(수입)업\n소명, 제조원 및 소재지, 허가(인증)번호, 사용목적, 작용원리, 원재료,\n\n[별지 제3호서식]\n\n1) 기허가된 의료기기와의 차이가 명확하게 입증도록 필요한 항목을 기재하여야 한다.\n\n 2) 각 항목에 대한 정보가 기 허가된 의료기기와 동등한 경우 ‘예’에 체크하고, 동\n\n등하지 않을 경우 ‘아니오’란에 체크한다.\n\n",
        "original_sentence": "Ⅵ. "
      }
    },
    {
      "chunk_id": "chunk_545",
      "text": "기술문서 등의 심사를 위한 제출자료\n\n- - 45 -\n<!-- PAGE_51 -->\n###### 7\n\n<!-- PAGE_51 -->\n###### 이미 허가·인증받은 제품과 비교한 자료\n\n- 1. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 544,
        "window_size": 3,
        "char_count": 109,
        "word_count": 25,
        "page_number": 51,
        "window_text": "- 2.  유해물질(독성, 가연성 등) 등 취급자 안전 및 적합성을 확인한 자료를\n제출한다.\n\n Ⅵ.  기술문서 등의 심사를 위한 제출자료\n\n- - 45 -\n<!-- PAGE_51 -->\n###### 7\n\n<!-- PAGE_51 -->\n###### 이미 허가·인증받은 제품과 비교한 자료\n\n- 1.  이미 허가·인증받은 제품과 명칭(제품명, 품목명, 모델명), 제조(수입)업\n소명, 제조원 및 소재지, 허가(인증)번호, 사용목적, 작용원리, 원재료,\n\n[별지 제3호서식]\n\n1) 기허가된 의료기기와의 차이가 명확하게 입증도록 필요한 항목을 기재하여야 한다.\n\n 2) 각 항목에 대한 정보가 기 허가된 의료기기와 동등한 경우 ‘예’에 체크하고, 동\n\n등하지 않을 경우 ‘아니오’란에 체크한다.\n\n 11\n\n사용방법\n\n예\n\n□\n\n위와 같이 동등함을 확인하였음.\n\n",
        "original_sentence": "기술문서 등의 심사를 위한 제출자료\n\n- - 45 -\n<!-- PAGE_51 -->\n###### 7\n\n<!-- PAGE_51 -->\n###### 이미 허가·인증받은 제품과 비교한 자료\n\n- 1. "
      }
    },
    {
      "chunk_id": "chunk_546",
      "text": "이미 허가·인증받은 제품과 명칭(제품명, 품목명, 모델명), 제조(수입)업\n소명, 제조원 및 소재지, 허가(인증)번호, 사용목적, 작용원리, 원재료,\n\n[별지 제3호서식]\n\n1) 기허가된 의료기기와의 차이가 명확하게 입증도록 필요한 항목을 기재하여야 한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 545,
        "window_size": 3,
        "char_count": 145,
        "word_count": 27,
        "page_number": 3,
        "window_text": "유해물질(독성, 가연성 등) 등 취급자 안전 및 적합성을 확인한 자료를\n제출한다.\n\n Ⅵ.  기술문서 등의 심사를 위한 제출자료\n\n- - 45 -\n<!-- PAGE_51 -->\n###### 7\n\n<!-- PAGE_51 -->\n###### 이미 허가·인증받은 제품과 비교한 자료\n\n- 1.  이미 허가·인증받은 제품과 명칭(제품명, 품목명, 모델명), 제조(수입)업\n소명, 제조원 및 소재지, 허가(인증)번호, 사용목적, 작용원리, 원재료,\n\n[별지 제3호서식]\n\n1) 기허가된 의료기기와의 차이가 명확하게 입증도록 필요한 항목을 기재하여야 한다.\n\n 2) 각 항목에 대한 정보가 기 허가된 의료기기와 동등한 경우 ‘예’에 체크하고, 동\n\n등하지 않을 경우 ‘아니오’란에 체크한다.\n\n 11\n\n사용방법\n\n예\n\n□\n\n위와 같이 동등함을 확인하였음.\n\n 년     월      일            신청자            (서명 또는 인)\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 46 -\n<!-- PAGE_52 -->\n# Ⅶ\n\n<!-- PAGE_52 -->\n#### 성능시험에 대한 상세사항\n\n<!-- PAGE_52 -->\n###### 일반요건\n\n❍ 시험성적서에 다음의 항목이 포함되어야 한다.\n\n",
        "original_sentence": "이미 허가·인증받은 제품과 명칭(제품명, 품목명, 모델명), 제조(수입)업\n소명, 제조원 및 소재지, 허가(인증)번호, 사용목적, 작용원리, 원재료,\n\n[별지 제3호서식]\n\n1) 기허가된 의료기기와의 차이가 명확하게 입증도록 필요한 항목을 기재하여야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_547",
      "text": "2) 각 항목에 대한 정보가 기 허가된 의료기기와 동등한 경우 ‘예’에 체크하고, 동\n\n등하지 않을 경우 ‘아니오’란에 체크한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 546,
        "window_size": 3,
        "char_count": 74,
        "word_count": 18,
        "page_number": 3,
        "window_text": "Ⅵ.  기술문서 등의 심사를 위한 제출자료\n\n- - 45 -\n<!-- PAGE_51 -->\n###### 7\n\n<!-- PAGE_51 -->\n###### 이미 허가·인증받은 제품과 비교한 자료\n\n- 1.  이미 허가·인증받은 제품과 명칭(제품명, 품목명, 모델명), 제조(수입)업\n소명, 제조원 및 소재지, 허가(인증)번호, 사용목적, 작용원리, 원재료,\n\n[별지 제3호서식]\n\n1) 기허가된 의료기기와의 차이가 명확하게 입증도록 필요한 항목을 기재하여야 한다.\n\n 2) 각 항목에 대한 정보가 기 허가된 의료기기와 동등한 경우 ‘예’에 체크하고, 동\n\n등하지 않을 경우 ‘아니오’란에 체크한다.\n\n 11\n\n사용방법\n\n예\n\n□\n\n위와 같이 동등함을 확인하였음.\n\n 년     월      일            신청자            (서명 또는 인)\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 46 -\n<!-- PAGE_52 -->\n# Ⅶ\n\n<!-- PAGE_52 -->\n#### 성능시험에 대한 상세사항\n\n<!-- PAGE_52 -->\n###### 일반요건\n\n❍ 시험성적서에 다음의 항목이 포함되어야 한다.\n\n - 9. ",
        "original_sentence": "2) 각 항목에 대한 정보가 기 허가된 의료기기와 동등한 경우 ‘예’에 체크하고, 동\n\n등하지 않을 경우 ‘아니오’란에 체크한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_548",
      "text": "11\n\n사용방법\n\n예\n\n□\n\n위와 같이 동등함을 확인하였음.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 547,
        "window_size": 3,
        "char_count": 35,
        "word_count": 8,
        "page_number": 19,
        "window_text": "기술문서 등의 심사를 위한 제출자료\n\n- - 45 -\n<!-- PAGE_51 -->\n###### 7\n\n<!-- PAGE_51 -->\n###### 이미 허가·인증받은 제품과 비교한 자료\n\n- 1.  이미 허가·인증받은 제품과 명칭(제품명, 품목명, 모델명), 제조(수입)업\n소명, 제조원 및 소재지, 허가(인증)번호, 사용목적, 작용원리, 원재료,\n\n[별지 제3호서식]\n\n1) 기허가된 의료기기와의 차이가 명확하게 입증도록 필요한 항목을 기재하여야 한다.\n\n 2) 각 항목에 대한 정보가 기 허가된 의료기기와 동등한 경우 ‘예’에 체크하고, 동\n\n등하지 않을 경우 ‘아니오’란에 체크한다.\n\n 11\n\n사용방법\n\n예\n\n□\n\n위와 같이 동등함을 확인하였음.\n\n 년     월      일            신청자            (서명 또는 인)\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 46 -\n<!-- PAGE_52 -->\n# Ⅶ\n\n<!-- PAGE_52 -->\n#### 성능시험에 대한 상세사항\n\n<!-- PAGE_52 -->\n###### 일반요건\n\n❍ 시험성적서에 다음의 항목이 포함되어야 한다.\n\n - 9.  시험검사품 채취 및 방법에 대한 사항(시험을 위한 별도의 전처리가\n❍ 대학 또는 연구기관 등 국내․외 전문기관에서 시험한 자료는 다음의\n\n전문기관의 명칭, 주소, 인증현황, 검사기능 분야, 연구인력구성,\n\n주요설비 목록 등이 기재되어 있어야 함\n\n- 2. ",
        "original_sentence": "11\n\n사용방법\n\n예\n\n□\n\n위와 같이 동등함을 확인하였음.\n\n"
      }
    },
    {
      "chunk_id": "chunk_549",
      "text": "년     월      일            신청자            (서명 또는 인)\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 46 -\n<!-- PAGE_52 -->\n# Ⅶ\n\n<!-- PAGE_52 -->\n#### 성능시험에 대한 상세사항\n\n<!-- PAGE_52 -->\n###### 일반요건\n\n❍ 시험성적서에 다음의 항목이 포함되어야 한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 548,
        "window_size": 3,
        "char_count": 227,
        "word_count": 42,
        "page_number": 52,
        "window_text": "이미 허가·인증받은 제품과 명칭(제품명, 품목명, 모델명), 제조(수입)업\n소명, 제조원 및 소재지, 허가(인증)번호, 사용목적, 작용원리, 원재료,\n\n[별지 제3호서식]\n\n1) 기허가된 의료기기와의 차이가 명확하게 입증도록 필요한 항목을 기재하여야 한다.\n\n 2) 각 항목에 대한 정보가 기 허가된 의료기기와 동등한 경우 ‘예’에 체크하고, 동\n\n등하지 않을 경우 ‘아니오’란에 체크한다.\n\n 11\n\n사용방법\n\n예\n\n□\n\n위와 같이 동등함을 확인하였음.\n\n 년     월      일            신청자            (서명 또는 인)\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 46 -\n<!-- PAGE_52 -->\n# Ⅶ\n\n<!-- PAGE_52 -->\n#### 성능시험에 대한 상세사항\n\n<!-- PAGE_52 -->\n###### 일반요건\n\n❍ 시험성적서에 다음의 항목이 포함되어야 한다.\n\n - 9.  시험검사품 채취 및 방법에 대한 사항(시험을 위한 별도의 전처리가\n❍ 대학 또는 연구기관 등 국내․외 전문기관에서 시험한 자료는 다음의\n\n전문기관의 명칭, 주소, 인증현황, 검사기능 분야, 연구인력구성,\n\n주요설비 목록 등이 기재되어 있어야 함\n\n- 2.  주요설비\n시험검사에 사용된 장비명칭, 장비사양, 검·교정 기록서 등에 대한\n\n사항이 기재되고 관련 증빙자료를 함께 제출하여야 함\n\nⅦ. ",
        "original_sentence": "년     월      일            신청자            (서명 또는 인)\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 46 -\n<!-- PAGE_52 -->\n# Ⅶ\n\n<!-- PAGE_52 -->\n#### 성능시험에 대한 상세사항\n\n<!-- PAGE_52 -->\n###### 일반요건\n\n❍ 시험성적서에 다음의 항목이 포함되어야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_550",
      "text": "- 9. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 549,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 35,
        "window_text": "2) 각 항목에 대한 정보가 기 허가된 의료기기와 동등한 경우 ‘예’에 체크하고, 동\n\n등하지 않을 경우 ‘아니오’란에 체크한다.\n\n 11\n\n사용방법\n\n예\n\n□\n\n위와 같이 동등함을 확인하였음.\n\n 년     월      일            신청자            (서명 또는 인)\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 46 -\n<!-- PAGE_52 -->\n# Ⅶ\n\n<!-- PAGE_52 -->\n#### 성능시험에 대한 상세사항\n\n<!-- PAGE_52 -->\n###### 일반요건\n\n❍ 시험성적서에 다음의 항목이 포함되어야 한다.\n\n - 9.  시험검사품 채취 및 방법에 대한 사항(시험을 위한 별도의 전처리가\n❍ 대학 또는 연구기관 등 국내․외 전문기관에서 시험한 자료는 다음의\n\n전문기관의 명칭, 주소, 인증현황, 검사기능 분야, 연구인력구성,\n\n주요설비 목록 등이 기재되어 있어야 함\n\n- 2.  주요설비\n시험검사에 사용된 장비명칭, 장비사양, 검·교정 기록서 등에 대한\n\n사항이 기재되고 관련 증빙자료를 함께 제출하여야 함\n\nⅦ.  성능시험에 대한 상세사항\n\n- - 47 -\n- 3. ",
        "original_sentence": "- 9. "
      }
    },
    {
      "chunk_id": "chunk_551",
      "text": "시험검사품 채취 및 방법에 대한 사항(시험을 위한 별도의 전처리가\n❍ 대학 또는 연구기관 등 국내․외 전문기관에서 시험한 자료는 다음의\n\n전문기관의 명칭, 주소, 인증현황, 검사기능 분야, 연구인력구성,\n\n주요설비 목록 등이 기재되어 있어야 함\n\n- 2. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 550,
        "window_size": 3,
        "char_count": 143,
        "word_count": 34,
        "page_number": 3,
        "window_text": "11\n\n사용방법\n\n예\n\n□\n\n위와 같이 동등함을 확인하였음.\n\n 년     월      일            신청자            (서명 또는 인)\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 46 -\n<!-- PAGE_52 -->\n# Ⅶ\n\n<!-- PAGE_52 -->\n#### 성능시험에 대한 상세사항\n\n<!-- PAGE_52 -->\n###### 일반요건\n\n❍ 시험성적서에 다음의 항목이 포함되어야 한다.\n\n - 9.  시험검사품 채취 및 방법에 대한 사항(시험을 위한 별도의 전처리가\n❍ 대학 또는 연구기관 등 국내․외 전문기관에서 시험한 자료는 다음의\n\n전문기관의 명칭, 주소, 인증현황, 검사기능 분야, 연구인력구성,\n\n주요설비 목록 등이 기재되어 있어야 함\n\n- 2.  주요설비\n시험검사에 사용된 장비명칭, 장비사양, 검·교정 기록서 등에 대한\n\n사항이 기재되고 관련 증빙자료를 함께 제출하여야 함\n\nⅦ.  성능시험에 대한 상세사항\n\n- - 47 -\n- 3.  연구인력구성\n시험검사를 실시한 전문기관 담당부서에 속한 연구인력들에 대한\n\n정보가 기재되어야 함\n\n시험검사를 실시한 시험자가 해당 검사를 하기에 적합한 전공, 경력\n\n<!-- PAGE_53 -->\n###### 1. ",
        "original_sentence": "시험검사품 채취 및 방법에 대한 사항(시험을 위한 별도의 전처리가\n❍ 대학 또는 연구기관 등 국내․외 전문기관에서 시험한 자료는 다음의\n\n전문기관의 명칭, 주소, 인증현황, 검사기능 분야, 연구인력구성,\n\n주요설비 목록 등이 기재되어 있어야 함\n\n- 2. "
      }
    },
    {
      "chunk_id": "chunk_552",
      "text": "주요설비\n시험검사에 사용된 장비명칭, 장비사양, 검·교정 기록서 등에 대한\n\n사항이 기재되고 관련 증빙자료를 함께 제출하여야 함\n\nⅦ. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 551,
        "window_size": 3,
        "char_count": 76,
        "word_count": 17,
        "page_number": 3,
        "window_text": "년     월      일            신청자            (서명 또는 인)\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 46 -\n<!-- PAGE_52 -->\n# Ⅶ\n\n<!-- PAGE_52 -->\n#### 성능시험에 대한 상세사항\n\n<!-- PAGE_52 -->\n###### 일반요건\n\n❍ 시험성적서에 다음의 항목이 포함되어야 한다.\n\n - 9.  시험검사품 채취 및 방법에 대한 사항(시험을 위한 별도의 전처리가\n❍ 대학 또는 연구기관 등 국내․외 전문기관에서 시험한 자료는 다음의\n\n전문기관의 명칭, 주소, 인증현황, 검사기능 분야, 연구인력구성,\n\n주요설비 목록 등이 기재되어 있어야 함\n\n- 2.  주요설비\n시험검사에 사용된 장비명칭, 장비사양, 검·교정 기록서 등에 대한\n\n사항이 기재되고 관련 증빙자료를 함께 제출하여야 함\n\nⅦ.  성능시험에 대한 상세사항\n\n- - 47 -\n- 3.  연구인력구성\n시험검사를 실시한 전문기관 담당부서에 속한 연구인력들에 대한\n\n정보가 기재되어야 함\n\n시험검사를 실시한 시험자가 해당 검사를 하기에 적합한 전공, 경력\n\n<!-- PAGE_53 -->\n###### 1.  분석적 민감도 (최소검출한계, 측정범위, 컷오프농도 등)\n\n최소검출한계, 최소정량한계 및 측정범위를 평가하고, 판정기준치의 설정\n\n가) 사람의 검체(혈청, 혈장, 전혈 등)를 사용한다. ",
        "original_sentence": "주요설비\n시험검사에 사용된 장비명칭, 장비사양, 검·교정 기록서 등에 대한\n\n사항이 기재되고 관련 증빙자료를 함께 제출하여야 함\n\nⅦ. "
      }
    },
    {
      "chunk_id": "chunk_553",
      "text": "성능시험에 대한 상세사항\n\n- - 47 -\n- 3. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 552,
        "window_size": 3,
        "char_count": 29,
        "word_count": 9,
        "page_number": 3,
        "window_text": "- 9.  시험검사품 채취 및 방법에 대한 사항(시험을 위한 별도의 전처리가\n❍ 대학 또는 연구기관 등 국내․외 전문기관에서 시험한 자료는 다음의\n\n전문기관의 명칭, 주소, 인증현황, 검사기능 분야, 연구인력구성,\n\n주요설비 목록 등이 기재되어 있어야 함\n\n- 2.  주요설비\n시험검사에 사용된 장비명칭, 장비사양, 검·교정 기록서 등에 대한\n\n사항이 기재되고 관련 증빙자료를 함께 제출하여야 함\n\nⅦ.  성능시험에 대한 상세사항\n\n- - 47 -\n- 3.  연구인력구성\n시험검사를 실시한 전문기관 담당부서에 속한 연구인력들에 대한\n\n정보가 기재되어야 함\n\n시험검사를 실시한 시험자가 해당 검사를 하기에 적합한 전공, 경력\n\n<!-- PAGE_53 -->\n###### 1.  분석적 민감도 (최소검출한계, 측정범위, 컷오프농도 등)\n\n최소검출한계, 최소정량한계 및 측정범위를 평가하고, 판정기준치의 설정\n\n가) 사람의 검체(혈청, 혈장, 전혈 등)를 사용한다.  호환되는 기질\n\n(matrix)로 희석하거나 분석 대상 물질을 일정량 첨가한 검체를\n\n낮은 농도 검체로 이용할 수 있다.\n\n",
        "original_sentence": "성능시험에 대한 상세사항\n\n- - 47 -\n- 3. "
      }
    },
    {
      "chunk_id": "chunk_554",
      "text": "연구인력구성\n시험검사를 실시한 전문기관 담당부서에 속한 연구인력들에 대한\n\n정보가 기재되어야 함\n\n시험검사를 실시한 시험자가 해당 검사를 하기에 적합한 전공, 경력\n\n<!-- PAGE_53 -->\n###### 1. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 553,
        "window_size": 3,
        "char_count": 120,
        "word_count": 25,
        "page_number": 53,
        "window_text": "시험검사품 채취 및 방법에 대한 사항(시험을 위한 별도의 전처리가\n❍ 대학 또는 연구기관 등 국내․외 전문기관에서 시험한 자료는 다음의\n\n전문기관의 명칭, 주소, 인증현황, 검사기능 분야, 연구인력구성,\n\n주요설비 목록 등이 기재되어 있어야 함\n\n- 2.  주요설비\n시험검사에 사용된 장비명칭, 장비사양, 검·교정 기록서 등에 대한\n\n사항이 기재되고 관련 증빙자료를 함께 제출하여야 함\n\nⅦ.  성능시험에 대한 상세사항\n\n- - 47 -\n- 3.  연구인력구성\n시험검사를 실시한 전문기관 담당부서에 속한 연구인력들에 대한\n\n정보가 기재되어야 함\n\n시험검사를 실시한 시험자가 해당 검사를 하기에 적합한 전공, 경력\n\n<!-- PAGE_53 -->\n###### 1.  분석적 민감도 (최소검출한계, 측정범위, 컷오프농도 등)\n\n최소검출한계, 최소정량한계 및 측정범위를 평가하고, 판정기준치의 설정\n\n가) 사람의 검체(혈청, 혈장, 전혈 등)를 사용한다.  호환되는 기질\n\n(matrix)로 희석하거나 분석 대상 물질을 일정량 첨가한 검체를\n\n낮은 농도 검체로 이용할 수 있다.\n\n 나) 공백검체와 추정되는 검출한계 농도 근처의 검체는 최소 각\n\n4개씩 준비한다.\n\n",
        "original_sentence": "연구인력구성\n시험검사를 실시한 전문기관 담당부서에 속한 연구인력들에 대한\n\n정보가 기재되어야 함\n\n시험검사를 실시한 시험자가 해당 검사를 하기에 적합한 전공, 경력\n\n<!-- PAGE_53 -->\n###### 1. "
      }
    },
    {
      "chunk_id": "chunk_555",
      "text": "분석적 민감도 (최소검출한계, 측정범위, 컷오프농도 등)\n\n최소검출한계, 최소정량한계 및 측정범위를 평가하고, 판정기준치의 설정\n\n가) 사람의 검체(혈청, 혈장, 전혈 등)를 사용한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 554,
        "window_size": 3,
        "char_count": 104,
        "word_count": 20,
        "page_number": 31,
        "window_text": "주요설비\n시험검사에 사용된 장비명칭, 장비사양, 검·교정 기록서 등에 대한\n\n사항이 기재되고 관련 증빙자료를 함께 제출하여야 함\n\nⅦ.  성능시험에 대한 상세사항\n\n- - 47 -\n- 3.  연구인력구성\n시험검사를 실시한 전문기관 담당부서에 속한 연구인력들에 대한\n\n정보가 기재되어야 함\n\n시험검사를 실시한 시험자가 해당 검사를 하기에 적합한 전공, 경력\n\n<!-- PAGE_53 -->\n###### 1.  분석적 민감도 (최소검출한계, 측정범위, 컷오프농도 등)\n\n최소검출한계, 최소정량한계 및 측정범위를 평가하고, 판정기준치의 설정\n\n가) 사람의 검체(혈청, 혈장, 전혈 등)를 사용한다.  호환되는 기질\n\n(matrix)로 희석하거나 분석 대상 물질을 일정량 첨가한 검체를\n\n낮은 농도 검체로 이용할 수 있다.\n\n 나) 공백검체와 추정되는 검출한계 농도 근처의 검체는 최소 각\n\n4개씩 준비한다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 48 -\n다) 측정 가능한 검체(혈청, 혈장, 전혈 등)의 종류별 시험 결과를\n\n제시한다.\n\n",
        "original_sentence": "분석적 민감도 (최소검출한계, 측정범위, 컷오프농도 등)\n\n최소검출한계, 최소정량한계 및 측정범위를 평가하고, 판정기준치의 설정\n\n가) 사람의 검체(혈청, 혈장, 전혈 등)를 사용한다. "
      }
    },
    {
      "chunk_id": "chunk_556",
      "text": "호환되는 기질\n\n(matrix)로 희석하거나 분석 대상 물질을 일정량 첨가한 검체를\n\n낮은 농도 검체로 이용할 수 있다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 555,
        "window_size": 3,
        "char_count": 69,
        "word_count": 16,
        "page_number": 14,
        "window_text": "성능시험에 대한 상세사항\n\n- - 47 -\n- 3.  연구인력구성\n시험검사를 실시한 전문기관 담당부서에 속한 연구인력들에 대한\n\n정보가 기재되어야 함\n\n시험검사를 실시한 시험자가 해당 검사를 하기에 적합한 전공, 경력\n\n<!-- PAGE_53 -->\n###### 1.  분석적 민감도 (최소검출한계, 측정범위, 컷오프농도 등)\n\n최소검출한계, 최소정량한계 및 측정범위를 평가하고, 판정기준치의 설정\n\n가) 사람의 검체(혈청, 혈장, 전혈 등)를 사용한다.  호환되는 기질\n\n(matrix)로 희석하거나 분석 대상 물질을 일정량 첨가한 검체를\n\n낮은 농도 검체로 이용할 수 있다.\n\n 나) 공백검체와 추정되는 검출한계 농도 근처의 검체는 최소 각\n\n4개씩 준비한다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 48 -\n다) 측정 가능한 검체(혈청, 혈장, 전혈 등)의 종류별 시험 결과를\n\n제시한다.\n\n 라) 희석을 위해 만약 인공(simulated)기질을 사용하거나 제품\n\n설명서에 이를 권장한다면 적절한 수의 시험물질로 자연기질과의\n\n마) 희석을 위해 분석대상물질이 포함되어 있지 않은 사람 유래\n\n검체를 찾는 것이 어려울 경우에는 제조사에서 제시 또는\n\n권장하는 물질로 희석할 수도 있으나 되도록이면 사람 유래\n\n나) 시험방법은 참고한 부분에 한해서 문헌 기호를 인용하여 실험\n\n방법을 요약 제출할 수 있다. ",
        "original_sentence": "호환되는 기질\n\n(matrix)로 희석하거나 분석 대상 물질을 일정량 첨가한 검체를\n\n낮은 농도 검체로 이용할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_557",
      "text": "나) 공백검체와 추정되는 검출한계 농도 근처의 검체는 최소 각\n\n4개씩 준비한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 556,
        "window_size": 3,
        "char_count": 47,
        "word_count": 11,
        "page_number": 6,
        "window_text": "연구인력구성\n시험검사를 실시한 전문기관 담당부서에 속한 연구인력들에 대한\n\n정보가 기재되어야 함\n\n시험검사를 실시한 시험자가 해당 검사를 하기에 적합한 전공, 경력\n\n<!-- PAGE_53 -->\n###### 1.  분석적 민감도 (최소검출한계, 측정범위, 컷오프농도 등)\n\n최소검출한계, 최소정량한계 및 측정범위를 평가하고, 판정기준치의 설정\n\n가) 사람의 검체(혈청, 혈장, 전혈 등)를 사용한다.  호환되는 기질\n\n(matrix)로 희석하거나 분석 대상 물질을 일정량 첨가한 검체를\n\n낮은 농도 검체로 이용할 수 있다.\n\n 나) 공백검체와 추정되는 검출한계 농도 근처의 검체는 최소 각\n\n4개씩 준비한다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 48 -\n다) 측정 가능한 검체(혈청, 혈장, 전혈 등)의 종류별 시험 결과를\n\n제시한다.\n\n 라) 희석을 위해 만약 인공(simulated)기질을 사용하거나 제품\n\n설명서에 이를 권장한다면 적절한 수의 시험물질로 자연기질과의\n\n마) 희석을 위해 분석대상물질이 포함되어 있지 않은 사람 유래\n\n검체를 찾는 것이 어려울 경우에는 제조사에서 제시 또는\n\n권장하는 물질로 희석할 수도 있으나 되도록이면 사람 유래\n\n나) 시험방법은 참고한 부분에 한해서 문헌 기호를 인용하여 실험\n\n방법을 요약 제출할 수 있다.  아래의 참고방법을 참조할 수\n\n한계에 영향을 줄 수 있는 여러 변수를 고려하기 위해 검사일은\n\nCLSI 지침(EP17-A2)에서는 LOB (limit of blank), LoD\n\n(limit of detection), LOQ (limit of quantitation)를 확립하기\n\n위한 방법이 기술되어 있으며, LoD 측정에 3가지 방법\n\n(classical\n\napproach,\n\nprecision\n\nprofile\n\napproach,\n\nprobit\n\napproach)이 있다. ",
        "original_sentence": "나) 공백검체와 추정되는 검출한계 농도 근처의 검체는 최소 각\n\n4개씩 준비한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_558",
      "text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 48 -\n다) 측정 가능한 검체(혈청, 혈장, 전혈 등)의 종류별 시험 결과를\n\n제시한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 557,
        "window_size": 3,
        "char_count": 105,
        "word_count": 23,
        "page_number": 1,
        "window_text": "분석적 민감도 (최소검출한계, 측정범위, 컷오프농도 등)\n\n최소검출한계, 최소정량한계 및 측정범위를 평가하고, 판정기준치의 설정\n\n가) 사람의 검체(혈청, 혈장, 전혈 등)를 사용한다.  호환되는 기질\n\n(matrix)로 희석하거나 분석 대상 물질을 일정량 첨가한 검체를\n\n낮은 농도 검체로 이용할 수 있다.\n\n 나) 공백검체와 추정되는 검출한계 농도 근처의 검체는 최소 각\n\n4개씩 준비한다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 48 -\n다) 측정 가능한 검체(혈청, 혈장, 전혈 등)의 종류별 시험 결과를\n\n제시한다.\n\n 라) 희석을 위해 만약 인공(simulated)기질을 사용하거나 제품\n\n설명서에 이를 권장한다면 적절한 수의 시험물질로 자연기질과의\n\n마) 희석을 위해 분석대상물질이 포함되어 있지 않은 사람 유래\n\n검체를 찾는 것이 어려울 경우에는 제조사에서 제시 또는\n\n권장하는 물질로 희석할 수도 있으나 되도록이면 사람 유래\n\n나) 시험방법은 참고한 부분에 한해서 문헌 기호를 인용하여 실험\n\n방법을 요약 제출할 수 있다.  아래의 참고방법을 참조할 수\n\n한계에 영향을 줄 수 있는 여러 변수를 고려하기 위해 검사일은\n\nCLSI 지침(EP17-A2)에서는 LOB (limit of blank), LoD\n\n(limit of detection), LOQ (limit of quantitation)를 확립하기\n\n위한 방법이 기술되어 있으며, LoD 측정에 3가지 방법\n\n(classical\n\napproach,\n\nprecision\n\nprofile\n\napproach,\n\nprobit\n\napproach)이 있다.  심혈관표지자의 LoD 측정을 위해서는 전통\n\n적인 방법 또는 정밀도 profile 방법을 이용한다. ",
        "original_sentence": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 48 -\n다) 측정 가능한 검체(혈청, 혈장, 전혈 등)의 종류별 시험 결과를\n\n제시한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_559",
      "text": "라) 희석을 위해 만약 인공(simulated)기질을 사용하거나 제품\n\n설명서에 이를 권장한다면 적절한 수의 시험물질로 자연기질과의\n\n마) 희석을 위해 분석대상물질이 포함되어 있지 않은 사람 유래\n\n검체를 찾는 것이 어려울 경우에는 제조사에서 제시 또는\n\n권장하는 물질로 희석할 수도 있으나 되도록이면 사람 유래\n\n나) 시험방법은 참고한 부분에 한해서 문헌 기호를 인용하여 실험\n\n방법을 요약 제출할 수 있다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 558,
        "window_size": 3,
        "char_count": 230,
        "word_count": 53,
        "page_number": 14,
        "window_text": "호환되는 기질\n\n(matrix)로 희석하거나 분석 대상 물질을 일정량 첨가한 검체를\n\n낮은 농도 검체로 이용할 수 있다.\n\n 나) 공백검체와 추정되는 검출한계 농도 근처의 검체는 최소 각\n\n4개씩 준비한다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 48 -\n다) 측정 가능한 검체(혈청, 혈장, 전혈 등)의 종류별 시험 결과를\n\n제시한다.\n\n 라) 희석을 위해 만약 인공(simulated)기질을 사용하거나 제품\n\n설명서에 이를 권장한다면 적절한 수의 시험물질로 자연기질과의\n\n마) 희석을 위해 분석대상물질이 포함되어 있지 않은 사람 유래\n\n검체를 찾는 것이 어려울 경우에는 제조사에서 제시 또는\n\n권장하는 물질로 희석할 수도 있으나 되도록이면 사람 유래\n\n나) 시험방법은 참고한 부분에 한해서 문헌 기호를 인용하여 실험\n\n방법을 요약 제출할 수 있다.  아래의 참고방법을 참조할 수\n\n한계에 영향을 줄 수 있는 여러 변수를 고려하기 위해 검사일은\n\nCLSI 지침(EP17-A2)에서는 LOB (limit of blank), LoD\n\n(limit of detection), LOQ (limit of quantitation)를 확립하기\n\n위한 방법이 기술되어 있으며, LoD 측정에 3가지 방법\n\n(classical\n\napproach,\n\nprecision\n\nprofile\n\napproach,\n\nprobit\n\napproach)이 있다.  심혈관표지자의 LoD 측정을 위해서는 전통\n\n적인 방법 또는 정밀도 profile 방법을 이용한다.  전통적인 방법\n\nⅦ. ",
        "original_sentence": "라) 희석을 위해 만약 인공(simulated)기질을 사용하거나 제품\n\n설명서에 이를 권장한다면 적절한 수의 시험물질로 자연기질과의\n\n마) 희석을 위해 분석대상물질이 포함되어 있지 않은 사람 유래\n\n검체를 찾는 것이 어려울 경우에는 제조사에서 제시 또는\n\n권장하는 물질로 희석할 수도 있으나 되도록이면 사람 유래\n\n나) 시험방법은 참고한 부분에 한해서 문헌 기호를 인용하여 실험\n\n방법을 요약 제출할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_560",
      "text": "아래의 참고방법을 참조할 수\n\n한계에 영향을 줄 수 있는 여러 변수를 고려하기 위해 검사일은\n\nCLSI 지침(EP17-A2)에서는 LOB (limit of blank), LoD\n\n(limit of detection), LOQ (limit of quantitation)를 확립하기\n\n위한 방법이 기술되어 있으며, LoD 측정에 3가지 방법\n\n(classical\n\napproach,\n\nprecision\n\nprofile\n\napproach,\n\nprobit\n\napproach)이 있다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 559,
        "window_size": 3,
        "char_count": 267,
        "word_count": 45,
        "page_number": 79,
        "window_text": "나) 공백검체와 추정되는 검출한계 농도 근처의 검체는 최소 각\n\n4개씩 준비한다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 48 -\n다) 측정 가능한 검체(혈청, 혈장, 전혈 등)의 종류별 시험 결과를\n\n제시한다.\n\n 라) 희석을 위해 만약 인공(simulated)기질을 사용하거나 제품\n\n설명서에 이를 권장한다면 적절한 수의 시험물질로 자연기질과의\n\n마) 희석을 위해 분석대상물질이 포함되어 있지 않은 사람 유래\n\n검체를 찾는 것이 어려울 경우에는 제조사에서 제시 또는\n\n권장하는 물질로 희석할 수도 있으나 되도록이면 사람 유래\n\n나) 시험방법은 참고한 부분에 한해서 문헌 기호를 인용하여 실험\n\n방법을 요약 제출할 수 있다.  아래의 참고방법을 참조할 수\n\n한계에 영향을 줄 수 있는 여러 변수를 고려하기 위해 검사일은\n\nCLSI 지침(EP17-A2)에서는 LOB (limit of blank), LoD\n\n(limit of detection), LOQ (limit of quantitation)를 확립하기\n\n위한 방법이 기술되어 있으며, LoD 측정에 3가지 방법\n\n(classical\n\napproach,\n\nprecision\n\nprofile\n\napproach,\n\nprobit\n\napproach)이 있다.  심혈관표지자의 LoD 측정을 위해서는 전통\n\n적인 방법 또는 정밀도 profile 방법을 이용한다.  전통적인 방법\n\nⅦ.  성능시험에 대한 상세사항\n\n- - 49 -\n(classical approach)은 blank 검체와 검출한계 근처의 low\n\nlevel 검체의 반복 측정 수가 각각 최소 60회가 될 것을 권장한다.\n\n",
        "original_sentence": "아래의 참고방법을 참조할 수\n\n한계에 영향을 줄 수 있는 여러 변수를 고려하기 위해 검사일은\n\nCLSI 지침(EP17-A2)에서는 LOB (limit of blank), LoD\n\n(limit of detection), LOQ (limit of quantitation)를 확립하기\n\n위한 방법이 기술되어 있으며, LoD 측정에 3가지 방법\n\n(classical\n\napproach,\n\nprecision\n\nprofile\n\napproach,\n\nprobit\n\napproach)이 있다. "
      }
    },
    {
      "chunk_id": "chunk_561",
      "text": "심혈관표지자의 LoD 측정을 위해서는 전통\n\n적인 방법 또는 정밀도 profile 방법을 이용한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 560,
        "window_size": 3,
        "char_count": 56,
        "word_count": 12,
        "page_number": 32,
        "window_text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 48 -\n다) 측정 가능한 검체(혈청, 혈장, 전혈 등)의 종류별 시험 결과를\n\n제시한다.\n\n 라) 희석을 위해 만약 인공(simulated)기질을 사용하거나 제품\n\n설명서에 이를 권장한다면 적절한 수의 시험물질로 자연기질과의\n\n마) 희석을 위해 분석대상물질이 포함되어 있지 않은 사람 유래\n\n검체를 찾는 것이 어려울 경우에는 제조사에서 제시 또는\n\n권장하는 물질로 희석할 수도 있으나 되도록이면 사람 유래\n\n나) 시험방법은 참고한 부분에 한해서 문헌 기호를 인용하여 실험\n\n방법을 요약 제출할 수 있다.  아래의 참고방법을 참조할 수\n\n한계에 영향을 줄 수 있는 여러 변수를 고려하기 위해 검사일은\n\nCLSI 지침(EP17-A2)에서는 LOB (limit of blank), LoD\n\n(limit of detection), LOQ (limit of quantitation)를 확립하기\n\n위한 방법이 기술되어 있으며, LoD 측정에 3가지 방법\n\n(classical\n\napproach,\n\nprecision\n\nprofile\n\napproach,\n\nprobit\n\napproach)이 있다.  심혈관표지자의 LoD 측정을 위해서는 전통\n\n적인 방법 또는 정밀도 profile 방법을 이용한다.  전통적인 방법\n\nⅦ.  성능시험에 대한 상세사항\n\n- - 49 -\n(classical approach)은 blank 검체와 검출한계 근처의 low\n\nlevel 검체의 반복 측정 수가 각각 최소 60회가 될 것을 권장한다.\n\n 3) 결과제시\n\n가) 통계적으로 유효한 최소검출한계치와 설정에 사용된 검체의\n\n가) 임상적 성능시험(다른 검사 결과, 치료에 대한 반응, 임상적\n\n나) 측정항목, 측정원리, 판독방법 등에 따라 판정기준치(cut-off\n\nvalue)의 설정 방법이 달라질 수 있으므로 전문가 그룹의 자문\n\n※ 판정기준치 혹은 판정기준치와 연계된 기대값(Expected\n\nValue)의 설정이 임상적 성능(임상적 민감도와 임상적 특이도)을\n\n바탕으로 한 경우, 타당한 임상적 근거를 제시한다(임상적\n\n- 다. ",
        "original_sentence": "심혈관표지자의 LoD 측정을 위해서는 전통\n\n적인 방법 또는 정밀도 profile 방법을 이용한다. "
      }
    },
    {
      "chunk_id": "chunk_562",
      "text": "전통적인 방법\n\nⅦ. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 561,
        "window_size": 3,
        "char_count": 12,
        "word_count": 3,
        "page_number": 52,
        "window_text": "라) 희석을 위해 만약 인공(simulated)기질을 사용하거나 제품\n\n설명서에 이를 권장한다면 적절한 수의 시험물질로 자연기질과의\n\n마) 희석을 위해 분석대상물질이 포함되어 있지 않은 사람 유래\n\n검체를 찾는 것이 어려울 경우에는 제조사에서 제시 또는\n\n권장하는 물질로 희석할 수도 있으나 되도록이면 사람 유래\n\n나) 시험방법은 참고한 부분에 한해서 문헌 기호를 인용하여 실험\n\n방법을 요약 제출할 수 있다.  아래의 참고방법을 참조할 수\n\n한계에 영향을 줄 수 있는 여러 변수를 고려하기 위해 검사일은\n\nCLSI 지침(EP17-A2)에서는 LOB (limit of blank), LoD\n\n(limit of detection), LOQ (limit of quantitation)를 확립하기\n\n위한 방법이 기술되어 있으며, LoD 측정에 3가지 방법\n\n(classical\n\napproach,\n\nprecision\n\nprofile\n\napproach,\n\nprobit\n\napproach)이 있다.  심혈관표지자의 LoD 측정을 위해서는 전통\n\n적인 방법 또는 정밀도 profile 방법을 이용한다.  전통적인 방법\n\nⅦ.  성능시험에 대한 상세사항\n\n- - 49 -\n(classical approach)은 blank 검체와 검출한계 근처의 low\n\nlevel 검체의 반복 측정 수가 각각 최소 60회가 될 것을 권장한다.\n\n 3) 결과제시\n\n가) 통계적으로 유효한 최소검출한계치와 설정에 사용된 검체의\n\n가) 임상적 성능시험(다른 검사 결과, 치료에 대한 반응, 임상적\n\n나) 측정항목, 측정원리, 판독방법 등에 따라 판정기준치(cut-off\n\nvalue)의 설정 방법이 달라질 수 있으므로 전문가 그룹의 자문\n\n※ 판정기준치 혹은 판정기준치와 연계된 기대값(Expected\n\nValue)의 설정이 임상적 성능(임상적 민감도와 임상적 특이도)을\n\n바탕으로 한 경우, 타당한 임상적 근거를 제시한다(임상적\n\n- 다.  측정범위(Measurement range)\n1) 일반사항\n\n가) 측정범위는 기존의 알려진 농도값을 해당 검사가 정확하게\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 50 -\n재현해 낼 수 있는 농도 범위를 말한다.\n\n",
        "original_sentence": "전통적인 방법\n\nⅦ. "
      }
    },
    {
      "chunk_id": "chunk_563",
      "text": "성능시험에 대한 상세사항\n\n- - 49 -\n(classical approach)은 blank 검체와 검출한계 근처의 low\n\nlevel 검체의 반복 측정 수가 각각 최소 60회가 될 것을 권장한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 562,
        "window_size": 3,
        "char_count": 112,
        "word_count": 25,
        "page_number": 3,
        "window_text": "아래의 참고방법을 참조할 수\n\n한계에 영향을 줄 수 있는 여러 변수를 고려하기 위해 검사일은\n\nCLSI 지침(EP17-A2)에서는 LOB (limit of blank), LoD\n\n(limit of detection), LOQ (limit of quantitation)를 확립하기\n\n위한 방법이 기술되어 있으며, LoD 측정에 3가지 방법\n\n(classical\n\napproach,\n\nprecision\n\nprofile\n\napproach,\n\nprobit\n\napproach)이 있다.  심혈관표지자의 LoD 측정을 위해서는 전통\n\n적인 방법 또는 정밀도 profile 방법을 이용한다.  전통적인 방법\n\nⅦ.  성능시험에 대한 상세사항\n\n- - 49 -\n(classical approach)은 blank 검체와 검출한계 근처의 low\n\nlevel 검체의 반복 측정 수가 각각 최소 60회가 될 것을 권장한다.\n\n 3) 결과제시\n\n가) 통계적으로 유효한 최소검출한계치와 설정에 사용된 검체의\n\n가) 임상적 성능시험(다른 검사 결과, 치료에 대한 반응, 임상적\n\n나) 측정항목, 측정원리, 판독방법 등에 따라 판정기준치(cut-off\n\nvalue)의 설정 방법이 달라질 수 있으므로 전문가 그룹의 자문\n\n※ 판정기준치 혹은 판정기준치와 연계된 기대값(Expected\n\nValue)의 설정이 임상적 성능(임상적 민감도와 임상적 특이도)을\n\n바탕으로 한 경우, 타당한 임상적 근거를 제시한다(임상적\n\n- 다.  측정범위(Measurement range)\n1) 일반사항\n\n가) 측정범위는 기존의 알려진 농도값을 해당 검사가 정확하게\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 50 -\n재현해 낼 수 있는 농도 범위를 말한다.\n\n 나) 측정항목, 측정원리, 결과산출방법 등에 따라 측정범위를\n\n평가할 때 사용하는 물질과 희석방법, 결과평가방법이 달라질\n\n수 있으므로 시험을 고려할 때 전문가 그룹의 자문 등을\n\n다) 측정범위 이상의 값을 희석하여 보고할 수 있는지 여부와 희석에\n\n라) 고역가 검체에 의한 전지대효과(prozone effect) 등에 대한\n\n가) 시험물질은 측정법에 적합한 기질(matrix)을 가진 물질이어야\n\n나) 표준품에 비교된 참고물질로 적합한 기질 성상과 목표치를\n\n다) 참고물질을 구할 수 없는 경우, 측정하고자 하는 물질에 대한\n\n라) 희석에 사용하는 음성 검체나 혼합할 음성검체는 기질효과를\n\n고려하여, 해당 제품의 대상이 되는 사람의 음성검체(혈청,\n\n가) 고농도검체와 음성검체를 혼합하여 제조하거나, 고농도의\n\n검체를 단계 희석하여 시험물질을 제조한다.\n\n",
        "original_sentence": "성능시험에 대한 상세사항\n\n- - 49 -\n(classical approach)은 blank 검체와 검출한계 근처의 low\n\nlevel 검체의 반복 측정 수가 각각 최소 60회가 될 것을 권장한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_564",
      "text": "3) 결과제시\n\n가) 통계적으로 유효한 최소검출한계치와 설정에 사용된 검체의\n\n가) 임상적 성능시험(다른 검사 결과, 치료에 대한 반응, 임상적\n\n나) 측정항목, 측정원리, 판독방법 등에 따라 판정기준치(cut-off\n\nvalue)의 설정 방법이 달라질 수 있으므로 전문가 그룹의 자문\n\n※ 판정기준치 혹은 판정기준치와 연계된 기대값(Expected\n\nValue)의 설정이 임상적 성능(임상적 민감도와 임상적 특이도)을\n\n바탕으로 한 경우, 타당한 임상적 근거를 제시한다(임상적\n\n- 다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 563,
        "window_size": 3,
        "char_count": 274,
        "word_count": 56,
        "page_number": 26,
        "window_text": "심혈관표지자의 LoD 측정을 위해서는 전통\n\n적인 방법 또는 정밀도 profile 방법을 이용한다.  전통적인 방법\n\nⅦ.  성능시험에 대한 상세사항\n\n- - 49 -\n(classical approach)은 blank 검체와 검출한계 근처의 low\n\nlevel 검체의 반복 측정 수가 각각 최소 60회가 될 것을 권장한다.\n\n 3) 결과제시\n\n가) 통계적으로 유효한 최소검출한계치와 설정에 사용된 검체의\n\n가) 임상적 성능시험(다른 검사 결과, 치료에 대한 반응, 임상적\n\n나) 측정항목, 측정원리, 판독방법 등에 따라 판정기준치(cut-off\n\nvalue)의 설정 방법이 달라질 수 있으므로 전문가 그룹의 자문\n\n※ 판정기준치 혹은 판정기준치와 연계된 기대값(Expected\n\nValue)의 설정이 임상적 성능(임상적 민감도와 임상적 특이도)을\n\n바탕으로 한 경우, 타당한 임상적 근거를 제시한다(임상적\n\n- 다.  측정범위(Measurement range)\n1) 일반사항\n\n가) 측정범위는 기존의 알려진 농도값을 해당 검사가 정확하게\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 50 -\n재현해 낼 수 있는 농도 범위를 말한다.\n\n 나) 측정항목, 측정원리, 결과산출방법 등에 따라 측정범위를\n\n평가할 때 사용하는 물질과 희석방법, 결과평가방법이 달라질\n\n수 있으므로 시험을 고려할 때 전문가 그룹의 자문 등을\n\n다) 측정범위 이상의 값을 희석하여 보고할 수 있는지 여부와 희석에\n\n라) 고역가 검체에 의한 전지대효과(prozone effect) 등에 대한\n\n가) 시험물질은 측정법에 적합한 기질(matrix)을 가진 물질이어야\n\n나) 표준품에 비교된 참고물질로 적합한 기질 성상과 목표치를\n\n다) 참고물질을 구할 수 없는 경우, 측정하고자 하는 물질에 대한\n\n라) 희석에 사용하는 음성 검체나 혼합할 음성검체는 기질효과를\n\n고려하여, 해당 제품의 대상이 되는 사람의 음성검체(혈청,\n\n가) 고농도검체와 음성검체를 혼합하여 제조하거나, 고농도의\n\n검체를 단계 희석하여 시험물질을 제조한다.\n\n 나) 제시하는 직선성 범위를 포괄하는(예상되는 측정범위보다\n\n20-30% 더 넓은 범위를 포함할 것을 권장한다) 최소 5개\n\nⅦ. ",
        "original_sentence": "3) 결과제시\n\n가) 통계적으로 유효한 최소검출한계치와 설정에 사용된 검체의\n\n가) 임상적 성능시험(다른 검사 결과, 치료에 대한 반응, 임상적\n\n나) 측정항목, 측정원리, 판독방법 등에 따라 판정기준치(cut-off\n\nvalue)의 설정 방법이 달라질 수 있으므로 전문가 그룹의 자문\n\n※ 판정기준치 혹은 판정기준치와 연계된 기대값(Expected\n\nValue)의 설정이 임상적 성능(임상적 민감도와 임상적 특이도)을\n\n바탕으로 한 경우, 타당한 임상적 근거를 제시한다(임상적\n\n- 다. "
      }
    },
    {
      "chunk_id": "chunk_565",
      "text": "측정범위(Measurement range)\n1) 일반사항\n\n가) 측정범위는 기존의 알려진 농도값을 해당 검사가 정확하게\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 50 -\n재현해 낼 수 있는 농도 범위를 말한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 564,
        "window_size": 3,
        "char_count": 150,
        "word_count": 31,
        "page_number": 3,
        "window_text": "전통적인 방법\n\nⅦ.  성능시험에 대한 상세사항\n\n- - 49 -\n(classical approach)은 blank 검체와 검출한계 근처의 low\n\nlevel 검체의 반복 측정 수가 각각 최소 60회가 될 것을 권장한다.\n\n 3) 결과제시\n\n가) 통계적으로 유효한 최소검출한계치와 설정에 사용된 검체의\n\n가) 임상적 성능시험(다른 검사 결과, 치료에 대한 반응, 임상적\n\n나) 측정항목, 측정원리, 판독방법 등에 따라 판정기준치(cut-off\n\nvalue)의 설정 방법이 달라질 수 있으므로 전문가 그룹의 자문\n\n※ 판정기준치 혹은 판정기준치와 연계된 기대값(Expected\n\nValue)의 설정이 임상적 성능(임상적 민감도와 임상적 특이도)을\n\n바탕으로 한 경우, 타당한 임상적 근거를 제시한다(임상적\n\n- 다.  측정범위(Measurement range)\n1) 일반사항\n\n가) 측정범위는 기존의 알려진 농도값을 해당 검사가 정확하게\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 50 -\n재현해 낼 수 있는 농도 범위를 말한다.\n\n 나) 측정항목, 측정원리, 결과산출방법 등에 따라 측정범위를\n\n평가할 때 사용하는 물질과 희석방법, 결과평가방법이 달라질\n\n수 있으므로 시험을 고려할 때 전문가 그룹의 자문 등을\n\n다) 측정범위 이상의 값을 희석하여 보고할 수 있는지 여부와 희석에\n\n라) 고역가 검체에 의한 전지대효과(prozone effect) 등에 대한\n\n가) 시험물질은 측정법에 적합한 기질(matrix)을 가진 물질이어야\n\n나) 표준품에 비교된 참고물질로 적합한 기질 성상과 목표치를\n\n다) 참고물질을 구할 수 없는 경우, 측정하고자 하는 물질에 대한\n\n라) 희석에 사용하는 음성 검체나 혼합할 음성검체는 기질효과를\n\n고려하여, 해당 제품의 대상이 되는 사람의 음성검체(혈청,\n\n가) 고농도검체와 음성검체를 혼합하여 제조하거나, 고농도의\n\n검체를 단계 희석하여 시험물질을 제조한다.\n\n 나) 제시하는 직선성 범위를 포괄하는(예상되는 측정범위보다\n\n20-30% 더 넓은 범위를 포함할 것을 권장한다) 최소 5개\n\nⅦ.  성능시험에 대한 상세사항\n\n- - 51 -\n이상의 알려진 농도를 가지는 검체를 이용하거나 희석을 통해\n\n농도가 확립된 검체를 이용한다. ",
        "original_sentence": "측정범위(Measurement range)\n1) 일반사항\n\n가) 측정범위는 기존의 알려진 농도값을 해당 검사가 정확하게\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 50 -\n재현해 낼 수 있는 농도 범위를 말한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_566",
      "text": "나) 측정항목, 측정원리, 결과산출방법 등에 따라 측정범위를\n\n평가할 때 사용하는 물질과 희석방법, 결과평가방법이 달라질\n\n수 있으므로 시험을 고려할 때 전문가 그룹의 자문 등을\n\n다) 측정범위 이상의 값을 희석하여 보고할 수 있는지 여부와 희석에\n\n라) 고역가 검체에 의한 전지대효과(prozone effect) 등에 대한\n\n가) 시험물질은 측정법에 적합한 기질(matrix)을 가진 물질이어야\n\n나) 표준품에 비교된 참고물질로 적합한 기질 성상과 목표치를\n\n다) 참고물질을 구할 수 없는 경우, 측정하고자 하는 물질에 대한\n\n라) 희석에 사용하는 음성 검체나 혼합할 음성검체는 기질효과를\n\n고려하여, 해당 제품의 대상이 되는 사람의 음성검체(혈청,\n\n가) 고농도검체와 음성검체를 혼합하여 제조하거나, 고농도의\n\n검체를 단계 희석하여 시험물질을 제조한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 565,
        "window_size": 3,
        "char_count": 425,
        "word_count": 92,
        "page_number": 3,
        "window_text": "성능시험에 대한 상세사항\n\n- - 49 -\n(classical approach)은 blank 검체와 검출한계 근처의 low\n\nlevel 검체의 반복 측정 수가 각각 최소 60회가 될 것을 권장한다.\n\n 3) 결과제시\n\n가) 통계적으로 유효한 최소검출한계치와 설정에 사용된 검체의\n\n가) 임상적 성능시험(다른 검사 결과, 치료에 대한 반응, 임상적\n\n나) 측정항목, 측정원리, 판독방법 등에 따라 판정기준치(cut-off\n\nvalue)의 설정 방법이 달라질 수 있으므로 전문가 그룹의 자문\n\n※ 판정기준치 혹은 판정기준치와 연계된 기대값(Expected\n\nValue)의 설정이 임상적 성능(임상적 민감도와 임상적 특이도)을\n\n바탕으로 한 경우, 타당한 임상적 근거를 제시한다(임상적\n\n- 다.  측정범위(Measurement range)\n1) 일반사항\n\n가) 측정범위는 기존의 알려진 농도값을 해당 검사가 정확하게\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 50 -\n재현해 낼 수 있는 농도 범위를 말한다.\n\n 나) 측정항목, 측정원리, 결과산출방법 등에 따라 측정범위를\n\n평가할 때 사용하는 물질과 희석방법, 결과평가방법이 달라질\n\n수 있으므로 시험을 고려할 때 전문가 그룹의 자문 등을\n\n다) 측정범위 이상의 값을 희석하여 보고할 수 있는지 여부와 희석에\n\n라) 고역가 검체에 의한 전지대효과(prozone effect) 등에 대한\n\n가) 시험물질은 측정법에 적합한 기질(matrix)을 가진 물질이어야\n\n나) 표준품에 비교된 참고물질로 적합한 기질 성상과 목표치를\n\n다) 참고물질을 구할 수 없는 경우, 측정하고자 하는 물질에 대한\n\n라) 희석에 사용하는 음성 검체나 혼합할 음성검체는 기질효과를\n\n고려하여, 해당 제품의 대상이 되는 사람의 음성검체(혈청,\n\n가) 고농도검체와 음성검체를 혼합하여 제조하거나, 고농도의\n\n검체를 단계 희석하여 시험물질을 제조한다.\n\n 나) 제시하는 직선성 범위를 포괄하는(예상되는 측정범위보다\n\n20-30% 더 넓은 범위를 포함할 것을 권장한다) 최소 5개\n\nⅦ.  성능시험에 대한 상세사항\n\n- - 51 -\n이상의 알려진 농도를 가지는 검체를 이용하거나 희석을 통해\n\n농도가 확립된 검체를 이용한다.  희석은 고농도와 저농도\n\n검체를 비율적으로 혼합하여 같은 간격으로 중간 농도의\n\n검체를 만드는 것이 권장되나  농도간의 간격이 일정하지 않을\n\n나) 비선형 calibration 모델을 사용하는 제품에 대하여는 근거자료를\n\n<!-- PAGE_57 -->\n###### 2. ",
        "original_sentence": "나) 측정항목, 측정원리, 결과산출방법 등에 따라 측정범위를\n\n평가할 때 사용하는 물질과 희석방법, 결과평가방법이 달라질\n\n수 있으므로 시험을 고려할 때 전문가 그룹의 자문 등을\n\n다) 측정범위 이상의 값을 희석하여 보고할 수 있는지 여부와 희석에\n\n라) 고역가 검체에 의한 전지대효과(prozone effect) 등에 대한\n\n가) 시험물질은 측정법에 적합한 기질(matrix)을 가진 물질이어야\n\n나) 표준품에 비교된 참고물질로 적합한 기질 성상과 목표치를\n\n다) 참고물질을 구할 수 없는 경우, 측정하고자 하는 물질에 대한\n\n라) 희석에 사용하는 음성 검체나 혼합할 음성검체는 기질효과를\n\n고려하여, 해당 제품의 대상이 되는 사람의 음성검체(혈청,\n\n가) 고농도검체와 음성검체를 혼합하여 제조하거나, 고농도의\n\n검체를 단계 희석하여 시험물질을 제조한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_567",
      "text": "나) 제시하는 직선성 범위를 포괄하는(예상되는 측정범위보다\n\n20-30% 더 넓은 범위를 포함할 것을 권장한다) 최소 5개\n\nⅦ. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 566,
        "window_size": 3,
        "char_count": 73,
        "word_count": 16,
        "page_number": 6,
        "window_text": "3) 결과제시\n\n가) 통계적으로 유효한 최소검출한계치와 설정에 사용된 검체의\n\n가) 임상적 성능시험(다른 검사 결과, 치료에 대한 반응, 임상적\n\n나) 측정항목, 측정원리, 판독방법 등에 따라 판정기준치(cut-off\n\nvalue)의 설정 방법이 달라질 수 있으므로 전문가 그룹의 자문\n\n※ 판정기준치 혹은 판정기준치와 연계된 기대값(Expected\n\nValue)의 설정이 임상적 성능(임상적 민감도와 임상적 특이도)을\n\n바탕으로 한 경우, 타당한 임상적 근거를 제시한다(임상적\n\n- 다.  측정범위(Measurement range)\n1) 일반사항\n\n가) 측정범위는 기존의 알려진 농도값을 해당 검사가 정확하게\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 50 -\n재현해 낼 수 있는 농도 범위를 말한다.\n\n 나) 측정항목, 측정원리, 결과산출방법 등에 따라 측정범위를\n\n평가할 때 사용하는 물질과 희석방법, 결과평가방법이 달라질\n\n수 있으므로 시험을 고려할 때 전문가 그룹의 자문 등을\n\n다) 측정범위 이상의 값을 희석하여 보고할 수 있는지 여부와 희석에\n\n라) 고역가 검체에 의한 전지대효과(prozone effect) 등에 대한\n\n가) 시험물질은 측정법에 적합한 기질(matrix)을 가진 물질이어야\n\n나) 표준품에 비교된 참고물질로 적합한 기질 성상과 목표치를\n\n다) 참고물질을 구할 수 없는 경우, 측정하고자 하는 물질에 대한\n\n라) 희석에 사용하는 음성 검체나 혼합할 음성검체는 기질효과를\n\n고려하여, 해당 제품의 대상이 되는 사람의 음성검체(혈청,\n\n가) 고농도검체와 음성검체를 혼합하여 제조하거나, 고농도의\n\n검체를 단계 희석하여 시험물질을 제조한다.\n\n 나) 제시하는 직선성 범위를 포괄하는(예상되는 측정범위보다\n\n20-30% 더 넓은 범위를 포함할 것을 권장한다) 최소 5개\n\nⅦ.  성능시험에 대한 상세사항\n\n- - 51 -\n이상의 알려진 농도를 가지는 검체를 이용하거나 희석을 통해\n\n농도가 확립된 검체를 이용한다.  희석은 고농도와 저농도\n\n검체를 비율적으로 혼합하여 같은 간격으로 중간 농도의\n\n검체를 만드는 것이 권장되나  농도간의 간격이 일정하지 않을\n\n나) 비선형 calibration 모델을 사용하는 제품에 대하여는 근거자료를\n\n<!-- PAGE_57 -->\n###### 2.  분석적 특이도\n\n1) 측정 대상이 되는 검체와 호환되는 기질의 검체를 이용한다. ",
        "original_sentence": "나) 제시하는 직선성 범위를 포괄하는(예상되는 측정범위보다\n\n20-30% 더 넓은 범위를 포함할 것을 권장한다) 최소 5개\n\nⅦ. "
      }
    },
    {
      "chunk_id": "chunk_568",
      "text": "성능시험에 대한 상세사항\n\n- - 51 -\n이상의 알려진 농도를 가지는 검체를 이용하거나 희석을 통해\n\n농도가 확립된 검체를 이용한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 567,
        "window_size": 3,
        "char_count": 76,
        "word_count": 19,
        "page_number": 3,
        "window_text": "측정범위(Measurement range)\n1) 일반사항\n\n가) 측정범위는 기존의 알려진 농도값을 해당 검사가 정확하게\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 50 -\n재현해 낼 수 있는 농도 범위를 말한다.\n\n 나) 측정항목, 측정원리, 결과산출방법 등에 따라 측정범위를\n\n평가할 때 사용하는 물질과 희석방법, 결과평가방법이 달라질\n\n수 있으므로 시험을 고려할 때 전문가 그룹의 자문 등을\n\n다) 측정범위 이상의 값을 희석하여 보고할 수 있는지 여부와 희석에\n\n라) 고역가 검체에 의한 전지대효과(prozone effect) 등에 대한\n\n가) 시험물질은 측정법에 적합한 기질(matrix)을 가진 물질이어야\n\n나) 표준품에 비교된 참고물질로 적합한 기질 성상과 목표치를\n\n다) 참고물질을 구할 수 없는 경우, 측정하고자 하는 물질에 대한\n\n라) 희석에 사용하는 음성 검체나 혼합할 음성검체는 기질효과를\n\n고려하여, 해당 제품의 대상이 되는 사람의 음성검체(혈청,\n\n가) 고농도검체와 음성검체를 혼합하여 제조하거나, 고농도의\n\n검체를 단계 희석하여 시험물질을 제조한다.\n\n 나) 제시하는 직선성 범위를 포괄하는(예상되는 측정범위보다\n\n20-30% 더 넓은 범위를 포함할 것을 권장한다) 최소 5개\n\nⅦ.  성능시험에 대한 상세사항\n\n- - 51 -\n이상의 알려진 농도를 가지는 검체를 이용하거나 희석을 통해\n\n농도가 확립된 검체를 이용한다.  희석은 고농도와 저농도\n\n검체를 비율적으로 혼합하여 같은 간격으로 중간 농도의\n\n검체를 만드는 것이 권장되나  농도간의 간격이 일정하지 않을\n\n나) 비선형 calibration 모델을 사용하는 제품에 대하여는 근거자료를\n\n<!-- PAGE_57 -->\n###### 2.  분석적 특이도\n\n1) 측정 대상이 되는 검체와 호환되는 기질의 검체를 이용한다.  사용\n\n하므로, 검사법에 따라 결과에 영향을 미칠 것으로 예측되는\n\n나) 검체에 포함될 수 있는 물질(혈색소, 지질, 빌리루빈, heterophile\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 52 -\n표 5. ",
        "original_sentence": "성능시험에 대한 상세사항\n\n- - 51 -\n이상의 알려진 농도를 가지는 검체를 이용하거나 희석을 통해\n\n농도가 확립된 검체를 이용한다. "
      }
    },
    {
      "chunk_id": "chunk_569",
      "text": "희석은 고농도와 저농도\n\n검체를 비율적으로 혼합하여 같은 간격으로 중간 농도의\n\n검체를 만드는 것이 권장되나  농도간의 간격이 일정하지 않을\n\n나) 비선형 calibration 모델을 사용하는 제품에 대하여는 근거자료를\n\n<!-- PAGE_57 -->\n###### 2. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 568,
        "window_size": 3,
        "char_count": 151,
        "word_count": 31,
        "page_number": 57,
        "window_text": "나) 측정항목, 측정원리, 결과산출방법 등에 따라 측정범위를\n\n평가할 때 사용하는 물질과 희석방법, 결과평가방법이 달라질\n\n수 있으므로 시험을 고려할 때 전문가 그룹의 자문 등을\n\n다) 측정범위 이상의 값을 희석하여 보고할 수 있는지 여부와 희석에\n\n라) 고역가 검체에 의한 전지대효과(prozone effect) 등에 대한\n\n가) 시험물질은 측정법에 적합한 기질(matrix)을 가진 물질이어야\n\n나) 표준품에 비교된 참고물질로 적합한 기질 성상과 목표치를\n\n다) 참고물질을 구할 수 없는 경우, 측정하고자 하는 물질에 대한\n\n라) 희석에 사용하는 음성 검체나 혼합할 음성검체는 기질효과를\n\n고려하여, 해당 제품의 대상이 되는 사람의 음성검체(혈청,\n\n가) 고농도검체와 음성검체를 혼합하여 제조하거나, 고농도의\n\n검체를 단계 희석하여 시험물질을 제조한다.\n\n 나) 제시하는 직선성 범위를 포괄하는(예상되는 측정범위보다\n\n20-30% 더 넓은 범위를 포함할 것을 권장한다) 최소 5개\n\nⅦ.  성능시험에 대한 상세사항\n\n- - 51 -\n이상의 알려진 농도를 가지는 검체를 이용하거나 희석을 통해\n\n농도가 확립된 검체를 이용한다.  희석은 고농도와 저농도\n\n검체를 비율적으로 혼합하여 같은 간격으로 중간 농도의\n\n검체를 만드는 것이 권장되나  농도간의 간격이 일정하지 않을\n\n나) 비선형 calibration 모델을 사용하는 제품에 대하여는 근거자료를\n\n<!-- PAGE_57 -->\n###### 2.  분석적 특이도\n\n1) 측정 대상이 되는 검체와 호환되는 기질의 검체를 이용한다.  사용\n\n하므로, 검사법에 따라 결과에 영향을 미칠 것으로 예측되는\n\n나) 검체에 포함될 수 있는 물질(혈색소, 지질, 빌리루빈, heterophile\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 52 -\n표 5.  간섭물질 예\n\n간섭물질\n\n예시\n\n외인성 물질\n\n일반의약품, 고혈압, 협심증, 심부전 등\n\n검체 처리 과정에 통상적으로 첨가될 수\n\n있는 물질\n\n3) 각 분석물질에 대한 각 간섭물질의 영향을 평가하기 위해 다음과\n\n2) 검체의 종류, 간섭물질의 종류, 간섭물질의 농도, 분석물질의 농도,\n\n검체의 제조 방법(예: 간섭물질을 혼합한 검체, 자연적으로 높은\n\n3) 간섭물질의 농도는 임상검체에서 보일 수 있는 최대농도의 3배\n\n이상이 되도록 한다.\n\n",
        "original_sentence": "희석은 고농도와 저농도\n\n검체를 비율적으로 혼합하여 같은 간격으로 중간 농도의\n\n검체를 만드는 것이 권장되나  농도간의 간격이 일정하지 않을\n\n나) 비선형 calibration 모델을 사용하는 제품에 대하여는 근거자료를\n\n<!-- PAGE_57 -->\n###### 2. "
      }
    },
    {
      "chunk_id": "chunk_570",
      "text": "분석적 특이도\n\n1) 측정 대상이 되는 검체와 호환되는 기질의 검체를 이용한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 569,
        "window_size": 3,
        "char_count": 45,
        "word_count": 11,
        "page_number": 21,
        "window_text": "나) 제시하는 직선성 범위를 포괄하는(예상되는 측정범위보다\n\n20-30% 더 넓은 범위를 포함할 것을 권장한다) 최소 5개\n\nⅦ.  성능시험에 대한 상세사항\n\n- - 51 -\n이상의 알려진 농도를 가지는 검체를 이용하거나 희석을 통해\n\n농도가 확립된 검체를 이용한다.  희석은 고농도와 저농도\n\n검체를 비율적으로 혼합하여 같은 간격으로 중간 농도의\n\n검체를 만드는 것이 권장되나  농도간의 간격이 일정하지 않을\n\n나) 비선형 calibration 모델을 사용하는 제품에 대하여는 근거자료를\n\n<!-- PAGE_57 -->\n###### 2.  분석적 특이도\n\n1) 측정 대상이 되는 검체와 호환되는 기질의 검체를 이용한다.  사용\n\n하므로, 검사법에 따라 결과에 영향을 미칠 것으로 예측되는\n\n나) 검체에 포함될 수 있는 물질(혈색소, 지질, 빌리루빈, heterophile\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 52 -\n표 5.  간섭물질 예\n\n간섭물질\n\n예시\n\n외인성 물질\n\n일반의약품, 고혈압, 협심증, 심부전 등\n\n검체 처리 과정에 통상적으로 첨가될 수\n\n있는 물질\n\n3) 각 분석물질에 대한 각 간섭물질의 영향을 평가하기 위해 다음과\n\n2) 검체의 종류, 간섭물질의 종류, 간섭물질의 농도, 분석물질의 농도,\n\n검체의 제조 방법(예: 간섭물질을 혼합한 검체, 자연적으로 높은\n\n3) 간섭물질의 농도는 임상검체에서 보일 수 있는 최대농도의 3배\n\n이상이 되도록 한다.\n\n 4) 간섭물질이 포함된 검체와 포함되지 않은 검체 간의 결과 차이의\n\n허용범위(dmax)를 결정한다.\n\n",
        "original_sentence": "분석적 특이도\n\n1) 측정 대상이 되는 검체와 호환되는 기질의 검체를 이용한다. "
      }
    },
    {
      "chunk_id": "chunk_571",
      "text": "사용\n\n하므로, 검사법에 따라 결과에 영향을 미칠 것으로 예측되는\n\n나) 검체에 포함될 수 있는 물질(혈색소, 지질, 빌리루빈, heterophile\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 52 -\n표 5. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 570,
        "window_size": 3,
        "char_count": 148,
        "word_count": 32,
        "page_number": 14,
        "window_text": "성능시험에 대한 상세사항\n\n- - 51 -\n이상의 알려진 농도를 가지는 검체를 이용하거나 희석을 통해\n\n농도가 확립된 검체를 이용한다.  희석은 고농도와 저농도\n\n검체를 비율적으로 혼합하여 같은 간격으로 중간 농도의\n\n검체를 만드는 것이 권장되나  농도간의 간격이 일정하지 않을\n\n나) 비선형 calibration 모델을 사용하는 제품에 대하여는 근거자료를\n\n<!-- PAGE_57 -->\n###### 2.  분석적 특이도\n\n1) 측정 대상이 되는 검체와 호환되는 기질의 검체를 이용한다.  사용\n\n하므로, 검사법에 따라 결과에 영향을 미칠 것으로 예측되는\n\n나) 검체에 포함될 수 있는 물질(혈색소, 지질, 빌리루빈, heterophile\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 52 -\n표 5.  간섭물질 예\n\n간섭물질\n\n예시\n\n외인성 물질\n\n일반의약품, 고혈압, 협심증, 심부전 등\n\n검체 처리 과정에 통상적으로 첨가될 수\n\n있는 물질\n\n3) 각 분석물질에 대한 각 간섭물질의 영향을 평가하기 위해 다음과\n\n2) 검체의 종류, 간섭물질의 종류, 간섭물질의 농도, 분석물질의 농도,\n\n검체의 제조 방법(예: 간섭물질을 혼합한 검체, 자연적으로 높은\n\n3) 간섭물질의 농도는 임상검체에서 보일 수 있는 최대농도의 3배\n\n이상이 되도록 한다.\n\n 4) 간섭물질이 포함된 검체와 포함되지 않은 검체 간의 결과 차이의\n\n허용범위(dmax)를 결정한다.\n\n Ⅶ. ",
        "original_sentence": "사용\n\n하므로, 검사법에 따라 결과에 영향을 미칠 것으로 예측되는\n\n나) 검체에 포함될 수 있는 물질(혈색소, 지질, 빌리루빈, heterophile\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 52 -\n표 5. "
      }
    },
    {
      "chunk_id": "chunk_572",
      "text": "간섭물질 예\n\n간섭물질\n\n예시\n\n외인성 물질\n\n일반의약품, 고혈압, 협심증, 심부전 등\n\n검체 처리 과정에 통상적으로 첨가될 수\n\n있는 물질\n\n3) 각 분석물질에 대한 각 간섭물질의 영향을 평가하기 위해 다음과\n\n2) 검체의 종류, 간섭물질의 종류, 간섭물질의 농도, 분석물질의 농도,\n\n검체의 제조 방법(예: 간섭물질을 혼합한 검체, 자연적으로 높은\n\n3) 간섭물질의 농도는 임상검체에서 보일 수 있는 최대농도의 3배\n\n이상이 되도록 한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 571,
        "window_size": 3,
        "char_count": 249,
        "word_count": 58,
        "page_number": 32,
        "window_text": "희석은 고농도와 저농도\n\n검체를 비율적으로 혼합하여 같은 간격으로 중간 농도의\n\n검체를 만드는 것이 권장되나  농도간의 간격이 일정하지 않을\n\n나) 비선형 calibration 모델을 사용하는 제품에 대하여는 근거자료를\n\n<!-- PAGE_57 -->\n###### 2.  분석적 특이도\n\n1) 측정 대상이 되는 검체와 호환되는 기질의 검체를 이용한다.  사용\n\n하므로, 검사법에 따라 결과에 영향을 미칠 것으로 예측되는\n\n나) 검체에 포함될 수 있는 물질(혈색소, 지질, 빌리루빈, heterophile\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 52 -\n표 5.  간섭물질 예\n\n간섭물질\n\n예시\n\n외인성 물질\n\n일반의약품, 고혈압, 협심증, 심부전 등\n\n검체 처리 과정에 통상적으로 첨가될 수\n\n있는 물질\n\n3) 각 분석물질에 대한 각 간섭물질의 영향을 평가하기 위해 다음과\n\n2) 검체의 종류, 간섭물질의 종류, 간섭물질의 농도, 분석물질의 농도,\n\n검체의 제조 방법(예: 간섭물질을 혼합한 검체, 자연적으로 높은\n\n3) 간섭물질의 농도는 임상검체에서 보일 수 있는 최대농도의 3배\n\n이상이 되도록 한다.\n\n 4) 간섭물질이 포함된 검체와 포함되지 않은 검체 간의 결과 차이의\n\n허용범위(dmax)를 결정한다.\n\n Ⅶ.  성능시험에 대한 상세사항\n\n- - 53 -\n5) 각 검체를 3회 이상 반복 검사한다.\n\n",
        "original_sentence": "간섭물질 예\n\n간섭물질\n\n예시\n\n외인성 물질\n\n일반의약품, 고혈압, 협심증, 심부전 등\n\n검체 처리 과정에 통상적으로 첨가될 수\n\n있는 물질\n\n3) 각 분석물질에 대한 각 간섭물질의 영향을 평가하기 위해 다음과\n\n2) 검체의 종류, 간섭물질의 종류, 간섭물질의 농도, 분석물질의 농도,\n\n검체의 제조 방법(예: 간섭물질을 혼합한 검체, 자연적으로 높은\n\n3) 간섭물질의 농도는 임상검체에서 보일 수 있는 최대농도의 3배\n\n이상이 되도록 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_573",
      "text": "4) 간섭물질이 포함된 검체와 포함되지 않은 검체 간의 결과 차이의\n\n허용범위(dmax)를 결정한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 572,
        "window_size": 3,
        "char_count": 58,
        "word_count": 12,
        "page_number": 6,
        "window_text": "분석적 특이도\n\n1) 측정 대상이 되는 검체와 호환되는 기질의 검체를 이용한다.  사용\n\n하므로, 검사법에 따라 결과에 영향을 미칠 것으로 예측되는\n\n나) 검체에 포함될 수 있는 물질(혈색소, 지질, 빌리루빈, heterophile\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 52 -\n표 5.  간섭물질 예\n\n간섭물질\n\n예시\n\n외인성 물질\n\n일반의약품, 고혈압, 협심증, 심부전 등\n\n검체 처리 과정에 통상적으로 첨가될 수\n\n있는 물질\n\n3) 각 분석물질에 대한 각 간섭물질의 영향을 평가하기 위해 다음과\n\n2) 검체의 종류, 간섭물질의 종류, 간섭물질의 농도, 분석물질의 농도,\n\n검체의 제조 방법(예: 간섭물질을 혼합한 검체, 자연적으로 높은\n\n3) 간섭물질의 농도는 임상검체에서 보일 수 있는 최대농도의 3배\n\n이상이 되도록 한다.\n\n 4) 간섭물질이 포함된 검체와 포함되지 않은 검체 간의 결과 차이의\n\n허용범위(dmax)를 결정한다.\n\n Ⅶ.  성능시험에 대한 상세사항\n\n- - 53 -\n5) 각 검체를 3회 이상 반복 검사한다.\n\n 6) 간섭물질을 함유한 검체와 간섭물질을 함유하지 않은 검체의\n\n결과를 비교한다. ",
        "original_sentence": "4) 간섭물질이 포함된 검체와 포함되지 않은 검체 간의 결과 차이의\n\n허용범위(dmax)를 결정한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_574",
      "text": "Ⅶ. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 573,
        "window_size": 3,
        "char_count": 3,
        "word_count": 1,
        "page_number": 7,
        "window_text": "사용\n\n하므로, 검사법에 따라 결과에 영향을 미칠 것으로 예측되는\n\n나) 검체에 포함될 수 있는 물질(혈색소, 지질, 빌리루빈, heterophile\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 52 -\n표 5.  간섭물질 예\n\n간섭물질\n\n예시\n\n외인성 물질\n\n일반의약품, 고혈압, 협심증, 심부전 등\n\n검체 처리 과정에 통상적으로 첨가될 수\n\n있는 물질\n\n3) 각 분석물질에 대한 각 간섭물질의 영향을 평가하기 위해 다음과\n\n2) 검체의 종류, 간섭물질의 종류, 간섭물질의 농도, 분석물질의 농도,\n\n검체의 제조 방법(예: 간섭물질을 혼합한 검체, 자연적으로 높은\n\n3) 간섭물질의 농도는 임상검체에서 보일 수 있는 최대농도의 3배\n\n이상이 되도록 한다.\n\n 4) 간섭물질이 포함된 검체와 포함되지 않은 검체 간의 결과 차이의\n\n허용범위(dmax)를 결정한다.\n\n Ⅶ.  성능시험에 대한 상세사항\n\n- - 53 -\n5) 각 검체를 3회 이상 반복 검사한다.\n\n 6) 간섭물질을 함유한 검체와 간섭물질을 함유하지 않은 검체의\n\n결과를 비교한다.  정량검사의 경우는 바이어스를 구한다.\n\n",
        "original_sentence": "Ⅶ. "
      }
    },
    {
      "chunk_id": "chunk_575",
      "text": "성능시험에 대한 상세사항\n\n- - 53 -\n5) 각 검체를 3회 이상 반복 검사한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 574,
        "window_size": 3,
        "char_count": 49,
        "word_count": 14,
        "page_number": 3,
        "window_text": "간섭물질 예\n\n간섭물질\n\n예시\n\n외인성 물질\n\n일반의약품, 고혈압, 협심증, 심부전 등\n\n검체 처리 과정에 통상적으로 첨가될 수\n\n있는 물질\n\n3) 각 분석물질에 대한 각 간섭물질의 영향을 평가하기 위해 다음과\n\n2) 검체의 종류, 간섭물질의 종류, 간섭물질의 농도, 분석물질의 농도,\n\n검체의 제조 방법(예: 간섭물질을 혼합한 검체, 자연적으로 높은\n\n3) 간섭물질의 농도는 임상검체에서 보일 수 있는 최대농도의 3배\n\n이상이 되도록 한다.\n\n 4) 간섭물질이 포함된 검체와 포함되지 않은 검체 간의 결과 차이의\n\n허용범위(dmax)를 결정한다.\n\n Ⅶ.  성능시험에 대한 상세사항\n\n- - 53 -\n5) 각 검체를 3회 이상 반복 검사한다.\n\n 6) 간섭물질을 함유한 검체와 간섭물질을 함유하지 않은 검체의\n\n결과를 비교한다.  정량검사의 경우는 바이어스를 구한다.\n\n 7) 높은 농도의 간섭물질에 영향을 받지 않는 경우는 더 이상의\n\n평가를 시행하지 않아도 되고, 영향을 받는 경우는 간섭물질의\n\n농도에 따른 영향을 보기 위해 용량-반응검사(dose-response\n\n1) 간섭물질을 함유한 검체와 간섭물질을 함유하지 않은 검체의 결과\n\n값을 제시하고, 정량검사의 경우는 결과를 비교하여 바이어스가\n\n있는지 확인하고 두 값의 차이가 허용범위(dmax)보다 작은지\n\n2) 간섭이 확인된 물질의 경우 간섭을 보이는 구체적 농도와 결과\n\n차이를 기술한다. ",
        "original_sentence": "성능시험에 대한 상세사항\n\n- - 53 -\n5) 각 검체를 3회 이상 반복 검사한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_576",
      "text": "6) 간섭물질을 함유한 검체와 간섭물질을 함유하지 않은 검체의\n\n결과를 비교한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 575,
        "window_size": 3,
        "char_count": 46,
        "word_count": 10,
        "page_number": 32,
        "window_text": "4) 간섭물질이 포함된 검체와 포함되지 않은 검체 간의 결과 차이의\n\n허용범위(dmax)를 결정한다.\n\n Ⅶ.  성능시험에 대한 상세사항\n\n- - 53 -\n5) 각 검체를 3회 이상 반복 검사한다.\n\n 6) 간섭물질을 함유한 검체와 간섭물질을 함유하지 않은 검체의\n\n결과를 비교한다.  정량검사의 경우는 바이어스를 구한다.\n\n 7) 높은 농도의 간섭물질에 영향을 받지 않는 경우는 더 이상의\n\n평가를 시행하지 않아도 되고, 영향을 받는 경우는 간섭물질의\n\n농도에 따른 영향을 보기 위해 용량-반응검사(dose-response\n\n1) 간섭물질을 함유한 검체와 간섭물질을 함유하지 않은 검체의 결과\n\n값을 제시하고, 정량검사의 경우는 결과를 비교하여 바이어스가\n\n있는지 확인하고 두 값의 차이가 허용범위(dmax)보다 작은지\n\n2) 간섭이 확인된 물질의 경우 간섭을 보이는 구체적 농도와 결과\n\n차이를 기술한다.  대상측정물질을 함유하지 않고 간섭 가능한\n\n<!-- PAGE_59 -->\n###### 3. ",
        "original_sentence": "6) 간섭물질을 함유한 검체와 간섭물질을 함유하지 않은 검체의\n\n결과를 비교한다. "
      }
    },
    {
      "chunk_id": "chunk_577",
      "text": "정량검사의 경우는 바이어스를 구한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 576,
        "window_size": 3,
        "char_count": 22,
        "word_count": 4,
        "page_number": 56,
        "window_text": "Ⅶ.  성능시험에 대한 상세사항\n\n- - 53 -\n5) 각 검체를 3회 이상 반복 검사한다.\n\n 6) 간섭물질을 함유한 검체와 간섭물질을 함유하지 않은 검체의\n\n결과를 비교한다.  정량검사의 경우는 바이어스를 구한다.\n\n 7) 높은 농도의 간섭물질에 영향을 받지 않는 경우는 더 이상의\n\n평가를 시행하지 않아도 되고, 영향을 받는 경우는 간섭물질의\n\n농도에 따른 영향을 보기 위해 용량-반응검사(dose-response\n\n1) 간섭물질을 함유한 검체와 간섭물질을 함유하지 않은 검체의 결과\n\n값을 제시하고, 정량검사의 경우는 결과를 비교하여 바이어스가\n\n있는지 확인하고 두 값의 차이가 허용범위(dmax)보다 작은지\n\n2) 간섭이 확인된 물질의 경우 간섭을 보이는 구체적 농도와 결과\n\n차이를 기술한다.  대상측정물질을 함유하지 않고 간섭 가능한\n\n<!-- PAGE_59 -->\n###### 3.  정밀도 (반복성, 재현성 등)\n\n- 가. ",
        "original_sentence": "정량검사의 경우는 바이어스를 구한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_578",
      "text": "7) 높은 농도의 간섭물질에 영향을 받지 않는 경우는 더 이상의\n\n평가를 시행하지 않아도 되고, 영향을 받는 경우는 간섭물질의\n\n농도에 따른 영향을 보기 위해 용량-반응검사(dose-response\n\n1) 간섭물질을 함유한 검체와 간섭물질을 함유하지 않은 검체의 결과\n\n값을 제시하고, 정량검사의 경우는 결과를 비교하여 바이어스가\n\n있는지 확인하고 두 값의 차이가 허용범위(dmax)보다 작은지\n\n2) 간섭이 확인된 물질의 경우 간섭을 보이는 구체적 농도와 결과\n\n차이를 기술한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 577,
        "window_size": 3,
        "char_count": 270,
        "word_count": 59,
        "page_number": 32,
        "window_text": "성능시험에 대한 상세사항\n\n- - 53 -\n5) 각 검체를 3회 이상 반복 검사한다.\n\n 6) 간섭물질을 함유한 검체와 간섭물질을 함유하지 않은 검체의\n\n결과를 비교한다.  정량검사의 경우는 바이어스를 구한다.\n\n 7) 높은 농도의 간섭물질에 영향을 받지 않는 경우는 더 이상의\n\n평가를 시행하지 않아도 되고, 영향을 받는 경우는 간섭물질의\n\n농도에 따른 영향을 보기 위해 용량-반응검사(dose-response\n\n1) 간섭물질을 함유한 검체와 간섭물질을 함유하지 않은 검체의 결과\n\n값을 제시하고, 정량검사의 경우는 결과를 비교하여 바이어스가\n\n있는지 확인하고 두 값의 차이가 허용범위(dmax)보다 작은지\n\n2) 간섭이 확인된 물질의 경우 간섭을 보이는 구체적 농도와 결과\n\n차이를 기술한다.  대상측정물질을 함유하지 않고 간섭 가능한\n\n<!-- PAGE_59 -->\n###### 3.  정밀도 (반복성, 재현성 등)\n\n- 가.  일반사항\n1) 동일 검체를 일정기간 동안 반복 측정한 결과를 분석하여 정밀도\n\n자료를 제시한다.\n\n",
        "original_sentence": "7) 높은 농도의 간섭물질에 영향을 받지 않는 경우는 더 이상의\n\n평가를 시행하지 않아도 되고, 영향을 받는 경우는 간섭물질의\n\n농도에 따른 영향을 보기 위해 용량-반응검사(dose-response\n\n1) 간섭물질을 함유한 검체와 간섭물질을 함유하지 않은 검체의 결과\n\n값을 제시하고, 정량검사의 경우는 결과를 비교하여 바이어스가\n\n있는지 확인하고 두 값의 차이가 허용범위(dmax)보다 작은지\n\n2) 간섭이 확인된 물질의 경우 간섭을 보이는 구체적 농도와 결과\n\n차이를 기술한다. "
      }
    },
    {
      "chunk_id": "chunk_579",
      "text": "대상측정물질을 함유하지 않고 간섭 가능한\n\n<!-- PAGE_59 -->\n###### 3. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 578,
        "window_size": 3,
        "char_count": 51,
        "word_count": 10,
        "page_number": 59,
        "window_text": "6) 간섭물질을 함유한 검체와 간섭물질을 함유하지 않은 검체의\n\n결과를 비교한다.  정량검사의 경우는 바이어스를 구한다.\n\n 7) 높은 농도의 간섭물질에 영향을 받지 않는 경우는 더 이상의\n\n평가를 시행하지 않아도 되고, 영향을 받는 경우는 간섭물질의\n\n농도에 따른 영향을 보기 위해 용량-반응검사(dose-response\n\n1) 간섭물질을 함유한 검체와 간섭물질을 함유하지 않은 검체의 결과\n\n값을 제시하고, 정량검사의 경우는 결과를 비교하여 바이어스가\n\n있는지 확인하고 두 값의 차이가 허용범위(dmax)보다 작은지\n\n2) 간섭이 확인된 물질의 경우 간섭을 보이는 구체적 농도와 결과\n\n차이를 기술한다.  대상측정물질을 함유하지 않고 간섭 가능한\n\n<!-- PAGE_59 -->\n###### 3.  정밀도 (반복성, 재현성 등)\n\n- 가.  일반사항\n1) 동일 검체를 일정기간 동안 반복 측정한 결과를 분석하여 정밀도\n\n자료를 제시한다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 54 -\n2) 단일 기관에서 실시한 정밀도(반복성)와 다수의 기관에서 실시한\n\n재현성으로 구분하여 평가한다.\n\n",
        "original_sentence": "대상측정물질을 함유하지 않고 간섭 가능한\n\n<!-- PAGE_59 -->\n###### 3. "
      }
    },
    {
      "chunk_id": "chunk_580",
      "text": "정밀도 (반복성, 재현성 등)\n\n- 가. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 579,
        "window_size": 3,
        "char_count": 23,
        "word_count": 6,
        "page_number": 32,
        "window_text": "정량검사의 경우는 바이어스를 구한다.\n\n 7) 높은 농도의 간섭물질에 영향을 받지 않는 경우는 더 이상의\n\n평가를 시행하지 않아도 되고, 영향을 받는 경우는 간섭물질의\n\n농도에 따른 영향을 보기 위해 용량-반응검사(dose-response\n\n1) 간섭물질을 함유한 검체와 간섭물질을 함유하지 않은 검체의 결과\n\n값을 제시하고, 정량검사의 경우는 결과를 비교하여 바이어스가\n\n있는지 확인하고 두 값의 차이가 허용범위(dmax)보다 작은지\n\n2) 간섭이 확인된 물질의 경우 간섭을 보이는 구체적 농도와 결과\n\n차이를 기술한다.  대상측정물질을 함유하지 않고 간섭 가능한\n\n<!-- PAGE_59 -->\n###### 3.  정밀도 (반복성, 재현성 등)\n\n- 가.  일반사항\n1) 동일 검체를 일정기간 동안 반복 측정한 결과를 분석하여 정밀도\n\n자료를 제시한다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 54 -\n2) 단일 기관에서 실시한 정밀도(반복성)와 다수의 기관에서 실시한\n\n재현성으로 구분하여 평가한다.\n\n 3) 각 평가 수행기관은 평가를 시행하기 전에 검사방법에 익숙해지는\n\n2) 반복성(repeatability, within laboratory precision) 평가는 3가지\n\n농도 이상의 검체를 1회(run)마다 2~3회 반복(duplicate or\n\n3) 최소 3개의 시약 로트를 이용하여 로트 간 정밀도(lot-to-lot\n\nprecision)를 평가한다. ",
        "original_sentence": "정밀도 (반복성, 재현성 등)\n\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_581",
      "text": "일반사항\n1) 동일 검체를 일정기간 동안 반복 측정한 결과를 분석하여 정밀도\n\n자료를 제시한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 580,
        "window_size": 3,
        "char_count": 55,
        "word_count": 13,
        "page_number": 3,
        "window_text": "7) 높은 농도의 간섭물질에 영향을 받지 않는 경우는 더 이상의\n\n평가를 시행하지 않아도 되고, 영향을 받는 경우는 간섭물질의\n\n농도에 따른 영향을 보기 위해 용량-반응검사(dose-response\n\n1) 간섭물질을 함유한 검체와 간섭물질을 함유하지 않은 검체의 결과\n\n값을 제시하고, 정량검사의 경우는 결과를 비교하여 바이어스가\n\n있는지 확인하고 두 값의 차이가 허용범위(dmax)보다 작은지\n\n2) 간섭이 확인된 물질의 경우 간섭을 보이는 구체적 농도와 결과\n\n차이를 기술한다.  대상측정물질을 함유하지 않고 간섭 가능한\n\n<!-- PAGE_59 -->\n###### 3.  정밀도 (반복성, 재현성 등)\n\n- 가.  일반사항\n1) 동일 검체를 일정기간 동안 반복 측정한 결과를 분석하여 정밀도\n\n자료를 제시한다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 54 -\n2) 단일 기관에서 실시한 정밀도(반복성)와 다수의 기관에서 실시한\n\n재현성으로 구분하여 평가한다.\n\n 3) 각 평가 수행기관은 평가를 시행하기 전에 검사방법에 익숙해지는\n\n2) 반복성(repeatability, within laboratory precision) 평가는 3가지\n\n농도 이상의 검체를 1회(run)마다 2~3회 반복(duplicate or\n\n3) 최소 3개의 시약 로트를 이용하여 로트 간 정밀도(lot-to-lot\n\nprecision)를 평가한다.  로트 간 정밀도 평가는 별도의 평가로\n\n4) 재현성(reproducibility) 평가는 2곳 이상의 검사실에서 3가지\n\n농도 이상의 검체를 1회(run)마다 2회 이상 반복(duplicate or\n\nmore) 측정하기를, 1일에 2회(run) 이상, 5일 이상 동안 실시할\n\n것을 권장한다.\n\n",
        "original_sentence": "일반사항\n1) 동일 검체를 일정기간 동안 반복 측정한 결과를 분석하여 정밀도\n\n자료를 제시한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_582",
      "text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 54 -\n2) 단일 기관에서 실시한 정밀도(반복성)와 다수의 기관에서 실시한\n\n재현성으로 구분하여 평가한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 581,
        "window_size": 3,
        "char_count": 115,
        "word_count": 23,
        "page_number": 1,
        "window_text": "대상측정물질을 함유하지 않고 간섭 가능한\n\n<!-- PAGE_59 -->\n###### 3.  정밀도 (반복성, 재현성 등)\n\n- 가.  일반사항\n1) 동일 검체를 일정기간 동안 반복 측정한 결과를 분석하여 정밀도\n\n자료를 제시한다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 54 -\n2) 단일 기관에서 실시한 정밀도(반복성)와 다수의 기관에서 실시한\n\n재현성으로 구분하여 평가한다.\n\n 3) 각 평가 수행기관은 평가를 시행하기 전에 검사방법에 익숙해지는\n\n2) 반복성(repeatability, within laboratory precision) 평가는 3가지\n\n농도 이상의 검체를 1회(run)마다 2~3회 반복(duplicate or\n\n3) 최소 3개의 시약 로트를 이용하여 로트 간 정밀도(lot-to-lot\n\nprecision)를 평가한다.  로트 간 정밀도 평가는 별도의 평가로\n\n4) 재현성(reproducibility) 평가는 2곳 이상의 검사실에서 3가지\n\n농도 이상의 검체를 1회(run)마다 2회 이상 반복(duplicate or\n\nmore) 측정하기를, 1일에 2회(run) 이상, 5일 이상 동안 실시할\n\n것을 권장한다.\n\n Ⅶ. ",
        "original_sentence": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 54 -\n2) 단일 기관에서 실시한 정밀도(반복성)와 다수의 기관에서 실시한\n\n재현성으로 구분하여 평가한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_583",
      "text": "3) 각 평가 수행기관은 평가를 시행하기 전에 검사방법에 익숙해지는\n\n2) 반복성(repeatability, within laboratory precision) 평가는 3가지\n\n농도 이상의 검체를 1회(run)마다 2~3회 반복(duplicate or\n\n3) 최소 3개의 시약 로트를 이용하여 로트 간 정밀도(lot-to-lot\n\nprecision)를 평가한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 582,
        "window_size": 3,
        "char_count": 203,
        "word_count": 34,
        "page_number": 6,
        "window_text": "정밀도 (반복성, 재현성 등)\n\n- 가.  일반사항\n1) 동일 검체를 일정기간 동안 반복 측정한 결과를 분석하여 정밀도\n\n자료를 제시한다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 54 -\n2) 단일 기관에서 실시한 정밀도(반복성)와 다수의 기관에서 실시한\n\n재현성으로 구분하여 평가한다.\n\n 3) 각 평가 수행기관은 평가를 시행하기 전에 검사방법에 익숙해지는\n\n2) 반복성(repeatability, within laboratory precision) 평가는 3가지\n\n농도 이상의 검체를 1회(run)마다 2~3회 반복(duplicate or\n\n3) 최소 3개의 시약 로트를 이용하여 로트 간 정밀도(lot-to-lot\n\nprecision)를 평가한다.  로트 간 정밀도 평가는 별도의 평가로\n\n4) 재현성(reproducibility) 평가는 2곳 이상의 검사실에서 3가지\n\n농도 이상의 검체를 1회(run)마다 2회 이상 반복(duplicate or\n\nmore) 측정하기를, 1일에 2회(run) 이상, 5일 이상 동안 실시할\n\n것을 권장한다.\n\n Ⅶ.  성능시험에 대한 상세사항\n\n- - 55 -\n- 다. ",
        "original_sentence": "3) 각 평가 수행기관은 평가를 시행하기 전에 검사방법에 익숙해지는\n\n2) 반복성(repeatability, within laboratory precision) 평가는 3가지\n\n농도 이상의 검체를 1회(run)마다 2~3회 반복(duplicate or\n\n3) 최소 3개의 시약 로트를 이용하여 로트 간 정밀도(lot-to-lot\n\nprecision)를 평가한다. "
      }
    },
    {
      "chunk_id": "chunk_584",
      "text": "로트 간 정밀도 평가는 별도의 평가로\n\n4) 재현성(reproducibility) 평가는 2곳 이상의 검사실에서 3가지\n\n농도 이상의 검체를 1회(run)마다 2회 이상 반복(duplicate or\n\nmore) 측정하기를, 1일에 2회(run) 이상, 5일 이상 동안 실시할\n\n것을 권장한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 583,
        "window_size": 3,
        "char_count": 165,
        "word_count": 32,
        "page_number": 6,
        "window_text": "일반사항\n1) 동일 검체를 일정기간 동안 반복 측정한 결과를 분석하여 정밀도\n\n자료를 제시한다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 54 -\n2) 단일 기관에서 실시한 정밀도(반복성)와 다수의 기관에서 실시한\n\n재현성으로 구분하여 평가한다.\n\n 3) 각 평가 수행기관은 평가를 시행하기 전에 검사방법에 익숙해지는\n\n2) 반복성(repeatability, within laboratory precision) 평가는 3가지\n\n농도 이상의 검체를 1회(run)마다 2~3회 반복(duplicate or\n\n3) 최소 3개의 시약 로트를 이용하여 로트 간 정밀도(lot-to-lot\n\nprecision)를 평가한다.  로트 간 정밀도 평가는 별도의 평가로\n\n4) 재현성(reproducibility) 평가는 2곳 이상의 검사실에서 3가지\n\n농도 이상의 검체를 1회(run)마다 2회 이상 반복(duplicate or\n\nmore) 측정하기를, 1일에 2회(run) 이상, 5일 이상 동안 실시할\n\n것을 권장한다.\n\n Ⅶ.  성능시험에 대한 상세사항\n\n- - 55 -\n- 다.  결과제시\n1) 반복성 : 검사 내 정밀도(within-run), 검사 간 정밀도(between-run),\n\n날짜 간 정밀도(between-day), 검사실 내 정밀도(within-\n\n2) 재현성 : 각 검사실 별로 반복성 결과를 기재하고, 모든 검사실\n\n결과를 합한 반복성 결과와 검사기관간(between-site) 결과를\n\n3) 정량검사는 각 정밀도 항목에 대해 농도별로 표준편차 또는\n\n<!-- PAGE_61 -->\n###### 4. ",
        "original_sentence": "로트 간 정밀도 평가는 별도의 평가로\n\n4) 재현성(reproducibility) 평가는 2곳 이상의 검사실에서 3가지\n\n농도 이상의 검체를 1회(run)마다 2회 이상 반복(duplicate or\n\nmore) 측정하기를, 1일에 2회(run) 이상, 5일 이상 동안 실시할\n\n것을 권장한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_585",
      "text": "Ⅶ. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 584,
        "window_size": 3,
        "char_count": 3,
        "word_count": 1,
        "page_number": 7,
        "window_text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 54 -\n2) 단일 기관에서 실시한 정밀도(반복성)와 다수의 기관에서 실시한\n\n재현성으로 구분하여 평가한다.\n\n 3) 각 평가 수행기관은 평가를 시행하기 전에 검사방법에 익숙해지는\n\n2) 반복성(repeatability, within laboratory precision) 평가는 3가지\n\n농도 이상의 검체를 1회(run)마다 2~3회 반복(duplicate or\n\n3) 최소 3개의 시약 로트를 이용하여 로트 간 정밀도(lot-to-lot\n\nprecision)를 평가한다.  로트 간 정밀도 평가는 별도의 평가로\n\n4) 재현성(reproducibility) 평가는 2곳 이상의 검사실에서 3가지\n\n농도 이상의 검체를 1회(run)마다 2회 이상 반복(duplicate or\n\nmore) 측정하기를, 1일에 2회(run) 이상, 5일 이상 동안 실시할\n\n것을 권장한다.\n\n Ⅶ.  성능시험에 대한 상세사항\n\n- - 55 -\n- 다.  결과제시\n1) 반복성 : 검사 내 정밀도(within-run), 검사 간 정밀도(between-run),\n\n날짜 간 정밀도(between-day), 검사실 내 정밀도(within-\n\n2) 재현성 : 각 검사실 별로 반복성 결과를 기재하고, 모든 검사실\n\n결과를 합한 반복성 결과와 검사기관간(between-site) 결과를\n\n3) 정량검사는 각 정밀도 항목에 대해 농도별로 표준편차 또는\n\n<!-- PAGE_61 -->\n###### 4.  정확도\n\n- 가. WHO international reference standard 물질, NIST standard\nreference material 등 국제표준품 등 특성이 명시되어 있는 물질이\n\n존재할 경우에는 이를 사용하여 평가할 것을 권장하며 최소 2회\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 56 -\n반복 측정한다.\n\n",
        "original_sentence": "Ⅶ. "
      }
    },
    {
      "chunk_id": "chunk_586",
      "text": "성능시험에 대한 상세사항\n\n- - 55 -\n- 다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 585,
        "window_size": 3,
        "char_count": 29,
        "word_count": 9,
        "page_number": 3,
        "window_text": "3) 각 평가 수행기관은 평가를 시행하기 전에 검사방법에 익숙해지는\n\n2) 반복성(repeatability, within laboratory precision) 평가는 3가지\n\n농도 이상의 검체를 1회(run)마다 2~3회 반복(duplicate or\n\n3) 최소 3개의 시약 로트를 이용하여 로트 간 정밀도(lot-to-lot\n\nprecision)를 평가한다.  로트 간 정밀도 평가는 별도의 평가로\n\n4) 재현성(reproducibility) 평가는 2곳 이상의 검사실에서 3가지\n\n농도 이상의 검체를 1회(run)마다 2회 이상 반복(duplicate or\n\nmore) 측정하기를, 1일에 2회(run) 이상, 5일 이상 동안 실시할\n\n것을 권장한다.\n\n Ⅶ.  성능시험에 대한 상세사항\n\n- - 55 -\n- 다.  결과제시\n1) 반복성 : 검사 내 정밀도(within-run), 검사 간 정밀도(between-run),\n\n날짜 간 정밀도(between-day), 검사실 내 정밀도(within-\n\n2) 재현성 : 각 검사실 별로 반복성 결과를 기재하고, 모든 검사실\n\n결과를 합한 반복성 결과와 검사기관간(between-site) 결과를\n\n3) 정량검사는 각 정밀도 항목에 대해 농도별로 표준편차 또는\n\n<!-- PAGE_61 -->\n###### 4.  정확도\n\n- 가. WHO international reference standard 물질, NIST standard\nreference material 등 국제표준품 등 특성이 명시되어 있는 물질이\n\n존재할 경우에는 이를 사용하여 평가할 것을 권장하며 최소 2회\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 56 -\n반복 측정한다.\n\n - 나. ",
        "original_sentence": "성능시험에 대한 상세사항\n\n- - 55 -\n- 다. "
      }
    },
    {
      "chunk_id": "chunk_587",
      "text": "결과제시\n1) 반복성 : 검사 내 정밀도(within-run), 검사 간 정밀도(between-run),\n\n날짜 간 정밀도(between-day), 검사실 내 정밀도(within-\n\n2) 재현성 : 각 검사실 별로 반복성 결과를 기재하고, 모든 검사실\n\n결과를 합한 반복성 결과와 검사기관간(between-site) 결과를\n\n3) 정량검사는 각 정밀도 항목에 대해 농도별로 표준편차 또는\n\n<!-- PAGE_61 -->\n###### 4. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 586,
        "window_size": 3,
        "char_count": 245,
        "word_count": 47,
        "page_number": 61,
        "window_text": "로트 간 정밀도 평가는 별도의 평가로\n\n4) 재현성(reproducibility) 평가는 2곳 이상의 검사실에서 3가지\n\n농도 이상의 검체를 1회(run)마다 2회 이상 반복(duplicate or\n\nmore) 측정하기를, 1일에 2회(run) 이상, 5일 이상 동안 실시할\n\n것을 권장한다.\n\n Ⅶ.  성능시험에 대한 상세사항\n\n- - 55 -\n- 다.  결과제시\n1) 반복성 : 검사 내 정밀도(within-run), 검사 간 정밀도(between-run),\n\n날짜 간 정밀도(between-day), 검사실 내 정밀도(within-\n\n2) 재현성 : 각 검사실 별로 반복성 결과를 기재하고, 모든 검사실\n\n결과를 합한 반복성 결과와 검사기관간(between-site) 결과를\n\n3) 정량검사는 각 정밀도 항목에 대해 농도별로 표준편차 또는\n\n<!-- PAGE_61 -->\n###### 4.  정확도\n\n- 가. WHO international reference standard 물질, NIST standard\nreference material 등 국제표준품 등 특성이 명시되어 있는 물질이\n\n존재할 경우에는 이를 사용하여 평가할 것을 권장하며 최소 2회\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 56 -\n반복 측정한다.\n\n - 나.  표준물질의 목표 결과와 실측 결과(정량검사의 경우 결과 값과\n바이어스)를 제시한다.\n\n",
        "original_sentence": "결과제시\n1) 반복성 : 검사 내 정밀도(within-run), 검사 간 정밀도(between-run),\n\n날짜 간 정밀도(between-day), 검사실 내 정밀도(within-\n\n2) 재현성 : 각 검사실 별로 반복성 결과를 기재하고, 모든 검사실\n\n결과를 합한 반복성 결과와 검사기관간(between-site) 결과를\n\n3) 정량검사는 각 정밀도 항목에 대해 농도별로 표준편차 또는\n\n<!-- PAGE_61 -->\n###### 4. "
      }
    },
    {
      "chunk_id": "chunk_588",
      "text": "정확도\n\n- 가. WHO international reference standard 물질, NIST standard\nreference material 등 국제표준품 등 특성이 명시되어 있는 물질이\n\n존재할 경우에는 이를 사용하여 평가할 것을 권장하며 최소 2회\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 56 -\n반복 측정한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 587,
        "window_size": 3,
        "char_count": 215,
        "word_count": 42,
        "page_number": 14,
        "window_text": "Ⅶ.  성능시험에 대한 상세사항\n\n- - 55 -\n- 다.  결과제시\n1) 반복성 : 검사 내 정밀도(within-run), 검사 간 정밀도(between-run),\n\n날짜 간 정밀도(between-day), 검사실 내 정밀도(within-\n\n2) 재현성 : 각 검사실 별로 반복성 결과를 기재하고, 모든 검사실\n\n결과를 합한 반복성 결과와 검사기관간(between-site) 결과를\n\n3) 정량검사는 각 정밀도 항목에 대해 농도별로 표준편차 또는\n\n<!-- PAGE_61 -->\n###### 4.  정확도\n\n- 가. WHO international reference standard 물질, NIST standard\nreference material 등 국제표준품 등 특성이 명시되어 있는 물질이\n\n존재할 경우에는 이를 사용하여 평가할 것을 권장하며 최소 2회\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 56 -\n반복 측정한다.\n\n - 나.  표준물질의 목표 결과와 실측 결과(정량검사의 경우 결과 값과\n바이어스)를 제시한다.\n\n - 라. ",
        "original_sentence": "정확도\n\n- 가. WHO international reference standard 물질, NIST standard\nreference material 등 국제표준품 등 특성이 명시되어 있는 물질이\n\n존재할 경우에는 이를 사용하여 평가할 것을 권장하며 최소 2회\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 56 -\n반복 측정한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_589",
      "text": "- 나. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 588,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 74,
        "window_text": "성능시험에 대한 상세사항\n\n- - 55 -\n- 다.  결과제시\n1) 반복성 : 검사 내 정밀도(within-run), 검사 간 정밀도(between-run),\n\n날짜 간 정밀도(between-day), 검사실 내 정밀도(within-\n\n2) 재현성 : 각 검사실 별로 반복성 결과를 기재하고, 모든 검사실\n\n결과를 합한 반복성 결과와 검사기관간(between-site) 결과를\n\n3) 정량검사는 각 정밀도 항목에 대해 농도별로 표준편차 또는\n\n<!-- PAGE_61 -->\n###### 4.  정확도\n\n- 가. WHO international reference standard 물질, NIST standard\nreference material 등 국제표준품 등 특성이 명시되어 있는 물질이\n\n존재할 경우에는 이를 사용하여 평가할 것을 권장하며 최소 2회\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 56 -\n반복 측정한다.\n\n - 나.  표준물질의 목표 결과와 실측 결과(정량검사의 경우 결과 값과\n바이어스)를 제시한다.\n\n - 라.  보정물질(calibrator)의 설정농도, 소급성(traceability)에 대해\n<!-- PAGE_62 -->\n###### 5. ",
        "original_sentence": "- 나. "
      }
    },
    {
      "chunk_id": "chunk_590",
      "text": "표준물질의 목표 결과와 실측 결과(정량검사의 경우 결과 값과\n바이어스)를 제시한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 589,
        "window_size": 3,
        "char_count": 48,
        "word_count": 10,
        "page_number": 26,
        "window_text": "결과제시\n1) 반복성 : 검사 내 정밀도(within-run), 검사 간 정밀도(between-run),\n\n날짜 간 정밀도(between-day), 검사실 내 정밀도(within-\n\n2) 재현성 : 각 검사실 별로 반복성 결과를 기재하고, 모든 검사실\n\n결과를 합한 반복성 결과와 검사기관간(between-site) 결과를\n\n3) 정량검사는 각 정밀도 항목에 대해 농도별로 표준편차 또는\n\n<!-- PAGE_61 -->\n###### 4.  정확도\n\n- 가. WHO international reference standard 물질, NIST standard\nreference material 등 국제표준품 등 특성이 명시되어 있는 물질이\n\n존재할 경우에는 이를 사용하여 평가할 것을 권장하며 최소 2회\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 56 -\n반복 측정한다.\n\n - 나.  표준물질의 목표 결과와 실측 결과(정량검사의 경우 결과 값과\n바이어스)를 제시한다.\n\n - 라.  보정물질(calibrator)의 설정농도, 소급성(traceability)에 대해\n<!-- PAGE_62 -->\n###### 5.  교차반응\n\n유사한 분자구조를 가지고 있는 단백질 등에 대한 교차반응을 시험하여\n\n2) 뇌나트륨이뇨펩티드(NT-proBNP, BNP) 항원과의 교차반응을\n\n위한 평가에 이용될 수 있는 물질은 atrial natriuretic peptide,\n\n알파 심방성 나트륨 이뇨 펩티드(alpha-ANP) 1-28, prepro BNP\n\n- 다. ",
        "original_sentence": "표준물질의 목표 결과와 실측 결과(정량검사의 경우 결과 값과\n바이어스)를 제시한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_591",
      "text": "- 라. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 590,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 74,
        "window_text": "정확도\n\n- 가. WHO international reference standard 물질, NIST standard\nreference material 등 국제표준품 등 특성이 명시되어 있는 물질이\n\n존재할 경우에는 이를 사용하여 평가할 것을 권장하며 최소 2회\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 56 -\n반복 측정한다.\n\n - 나.  표준물질의 목표 결과와 실측 결과(정량검사의 경우 결과 값과\n바이어스)를 제시한다.\n\n - 라.  보정물질(calibrator)의 설정농도, 소급성(traceability)에 대해\n<!-- PAGE_62 -->\n###### 5.  교차반응\n\n유사한 분자구조를 가지고 있는 단백질 등에 대한 교차반응을 시험하여\n\n2) 뇌나트륨이뇨펩티드(NT-proBNP, BNP) 항원과의 교차반응을\n\n위한 평가에 이용될 수 있는 물질은 atrial natriuretic peptide,\n\n알파 심방성 나트륨 이뇨 펩티드(alpha-ANP) 1-28, prepro BNP\n\n- 다.  시험방법\n1) 교차반응물질의 종류, 교차반응물질의 농도, 검체종류(예 : 교차\n\n반응 예상 물질을 인위적으로 첨가한 검체, 자연적으로 높은 교차\n\nⅦ. ",
        "original_sentence": "- 라. "
      }
    },
    {
      "chunk_id": "chunk_592",
      "text": "보정물질(calibrator)의 설정농도, 소급성(traceability)에 대해\n<!-- PAGE_62 -->\n###### 5. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 591,
        "window_size": 3,
        "char_count": 73,
        "word_count": 9,
        "page_number": 62,
        "window_text": "- 나.  표준물질의 목표 결과와 실측 결과(정량검사의 경우 결과 값과\n바이어스)를 제시한다.\n\n - 라.  보정물질(calibrator)의 설정농도, 소급성(traceability)에 대해\n<!-- PAGE_62 -->\n###### 5.  교차반응\n\n유사한 분자구조를 가지고 있는 단백질 등에 대한 교차반응을 시험하여\n\n2) 뇌나트륨이뇨펩티드(NT-proBNP, BNP) 항원과의 교차반응을\n\n위한 평가에 이용될 수 있는 물질은 atrial natriuretic peptide,\n\n알파 심방성 나트륨 이뇨 펩티드(alpha-ANP) 1-28, prepro BNP\n\n- 다.  시험방법\n1) 교차반응물질의 종류, 교차반응물질의 농도, 검체종류(예 : 교차\n\n반응 예상 물질을 인위적으로 첨가한 검체, 자연적으로 높은 교차\n\nⅦ.  성능시험에 대한 상세사항\n\n- - 57 -\n반응 예상물질을 함유한 검체 등), 비교검체(예 : 교차반응물질이\n\n없는 검체 등), 분석물질의 농도 및 결과 등에 대한 실험프로토콜을\n\n제공한다.\n\n",
        "original_sentence": "보정물질(calibrator)의 설정농도, 소급성(traceability)에 대해\n<!-- PAGE_62 -->\n###### 5. "
      }
    },
    {
      "chunk_id": "chunk_593",
      "text": "교차반응\n\n유사한 분자구조를 가지고 있는 단백질 등에 대한 교차반응을 시험하여\n\n2) 뇌나트륨이뇨펩티드(NT-proBNP, BNP) 항원과의 교차반응을\n\n위한 평가에 이용될 수 있는 물질은 atrial natriuretic peptide,\n\n알파 심방성 나트륨 이뇨 펩티드(alpha-ANP) 1-28, prepro BNP\n\n- 다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 592,
        "window_size": 3,
        "char_count": 187,
        "word_count": 34,
        "page_number": 6,
        "window_text": "표준물질의 목표 결과와 실측 결과(정량검사의 경우 결과 값과\n바이어스)를 제시한다.\n\n - 라.  보정물질(calibrator)의 설정농도, 소급성(traceability)에 대해\n<!-- PAGE_62 -->\n###### 5.  교차반응\n\n유사한 분자구조를 가지고 있는 단백질 등에 대한 교차반응을 시험하여\n\n2) 뇌나트륨이뇨펩티드(NT-proBNP, BNP) 항원과의 교차반응을\n\n위한 평가에 이용될 수 있는 물질은 atrial natriuretic peptide,\n\n알파 심방성 나트륨 이뇨 펩티드(alpha-ANP) 1-28, prepro BNP\n\n- 다.  시험방법\n1) 교차반응물질의 종류, 교차반응물질의 농도, 검체종류(예 : 교차\n\n반응 예상 물질을 인위적으로 첨가한 검체, 자연적으로 높은 교차\n\nⅦ.  성능시험에 대한 상세사항\n\n- - 57 -\n반응 예상물질을 함유한 검체 등), 비교검체(예 : 교차반응물질이\n\n없는 검체 등), 분석물질의 농도 및 결과 등에 대한 실험프로토콜을\n\n제공한다.\n\n 2) 최소 5회 이상 교차 반응 예상물질을 함유한 검체(T)와 교차\n\n반응물질을 함유하지 않은 비교검체(C)를 교대로 검사한다(예,\n\n3) 교차반응평가를 위해 준비된 검체는 최소 3회 반복 측정하기를\n\n1) 교차반응 평가에 사용된 물질의 종류, 농도, 측정한 raw data를\n\n※ 임상적 성능시험에 관한 자료의 작성 시 준수사항\n\n❍ 체외진단용 의료기기의 성능 및 유효성을 증명하기 위하여 사람에서 유\n\n❍ 외국에서 외국인을 대상으로 시험한 임상시험 성적도 제출할 수\n\n있으나 수출용이 아닌 내수용일 경우는 국내에서 우리나라 사람을\n\n대상으로 한 자료를 제출하는 것을 원칙으로 한다. ",
        "original_sentence": "교차반응\n\n유사한 분자구조를 가지고 있는 단백질 등에 대한 교차반응을 시험하여\n\n2) 뇌나트륨이뇨펩티드(NT-proBNP, BNP) 항원과의 교차반응을\n\n위한 평가에 이용될 수 있는 물질은 atrial natriuretic peptide,\n\n알파 심방성 나트륨 이뇨 펩티드(alpha-ANP) 1-28, prepro BNP\n\n- 다. "
      }
    },
    {
      "chunk_id": "chunk_594",
      "text": "시험방법\n1) 교차반응물질의 종류, 교차반응물질의 농도, 검체종류(예 : 교차\n\n반응 예상 물질을 인위적으로 첨가한 검체, 자연적으로 높은 교차\n\nⅦ. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 593,
        "window_size": 3,
        "char_count": 85,
        "word_count": 19,
        "page_number": 21,
        "window_text": "- 라.  보정물질(calibrator)의 설정농도, 소급성(traceability)에 대해\n<!-- PAGE_62 -->\n###### 5.  교차반응\n\n유사한 분자구조를 가지고 있는 단백질 등에 대한 교차반응을 시험하여\n\n2) 뇌나트륨이뇨펩티드(NT-proBNP, BNP) 항원과의 교차반응을\n\n위한 평가에 이용될 수 있는 물질은 atrial natriuretic peptide,\n\n알파 심방성 나트륨 이뇨 펩티드(alpha-ANP) 1-28, prepro BNP\n\n- 다.  시험방법\n1) 교차반응물질의 종류, 교차반응물질의 농도, 검체종류(예 : 교차\n\n반응 예상 물질을 인위적으로 첨가한 검체, 자연적으로 높은 교차\n\nⅦ.  성능시험에 대한 상세사항\n\n- - 57 -\n반응 예상물질을 함유한 검체 등), 비교검체(예 : 교차반응물질이\n\n없는 검체 등), 분석물질의 농도 및 결과 등에 대한 실험프로토콜을\n\n제공한다.\n\n 2) 최소 5회 이상 교차 반응 예상물질을 함유한 검체(T)와 교차\n\n반응물질을 함유하지 않은 비교검체(C)를 교대로 검사한다(예,\n\n3) 교차반응평가를 위해 준비된 검체는 최소 3회 반복 측정하기를\n\n1) 교차반응 평가에 사용된 물질의 종류, 농도, 측정한 raw data를\n\n※ 임상적 성능시험에 관한 자료의 작성 시 준수사항\n\n❍ 체외진단용 의료기기의 성능 및 유효성을 증명하기 위하여 사람에서 유\n\n❍ 외국에서 외국인을 대상으로 시험한 임상시험 성적도 제출할 수\n\n있으나 수출용이 아닌 내수용일 경우는 국내에서 우리나라 사람을\n\n대상으로 한 자료를 제출하는 것을 원칙으로 한다.  이는 인종 및\n\n지역에 따라 유병률이 다를 수 있기 때문이다. ",
        "original_sentence": "시험방법\n1) 교차반응물질의 종류, 교차반응물질의 농도, 검체종류(예 : 교차\n\n반응 예상 물질을 인위적으로 첨가한 검체, 자연적으로 높은 교차\n\nⅦ. "
      }
    },
    {
      "chunk_id": "chunk_595",
      "text": "성능시험에 대한 상세사항\n\n- - 57 -\n반응 예상물질을 함유한 검체 등), 비교검체(예 : 교차반응물질이\n\n없는 검체 등), 분석물질의 농도 및 결과 등에 대한 실험프로토콜을\n\n제공한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 594,
        "window_size": 3,
        "char_count": 108,
        "word_count": 26,
        "page_number": 3,
        "window_text": "보정물질(calibrator)의 설정농도, 소급성(traceability)에 대해\n<!-- PAGE_62 -->\n###### 5.  교차반응\n\n유사한 분자구조를 가지고 있는 단백질 등에 대한 교차반응을 시험하여\n\n2) 뇌나트륨이뇨펩티드(NT-proBNP, BNP) 항원과의 교차반응을\n\n위한 평가에 이용될 수 있는 물질은 atrial natriuretic peptide,\n\n알파 심방성 나트륨 이뇨 펩티드(alpha-ANP) 1-28, prepro BNP\n\n- 다.  시험방법\n1) 교차반응물질의 종류, 교차반응물질의 농도, 검체종류(예 : 교차\n\n반응 예상 물질을 인위적으로 첨가한 검체, 자연적으로 높은 교차\n\nⅦ.  성능시험에 대한 상세사항\n\n- - 57 -\n반응 예상물질을 함유한 검체 등), 비교검체(예 : 교차반응물질이\n\n없는 검체 등), 분석물질의 농도 및 결과 등에 대한 실험프로토콜을\n\n제공한다.\n\n 2) 최소 5회 이상 교차 반응 예상물질을 함유한 검체(T)와 교차\n\n반응물질을 함유하지 않은 비교검체(C)를 교대로 검사한다(예,\n\n3) 교차반응평가를 위해 준비된 검체는 최소 3회 반복 측정하기를\n\n1) 교차반응 평가에 사용된 물질의 종류, 농도, 측정한 raw data를\n\n※ 임상적 성능시험에 관한 자료의 작성 시 준수사항\n\n❍ 체외진단용 의료기기의 성능 및 유효성을 증명하기 위하여 사람에서 유\n\n❍ 외국에서 외국인을 대상으로 시험한 임상시험 성적도 제출할 수\n\n있으나 수출용이 아닌 내수용일 경우는 국내에서 우리나라 사람을\n\n대상으로 한 자료를 제출하는 것을 원칙으로 한다.  이는 인종 및\n\n지역에 따라 유병률이 다를 수 있기 때문이다.  민족적 요인의 차이가\n\n있어 외국 임상적 성능시험을 그대로 적용하기가 어렵다고 판단되는\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 58 -\n경우, 처장은 국내에 거주하는 한국인으로부터 유래한 검체를 대상으로\n\n한 자료를 추가 제출할 것을 요구 할 수 있다.\n\n",
        "original_sentence": "성능시험에 대한 상세사항\n\n- - 57 -\n반응 예상물질을 함유한 검체 등), 비교검체(예 : 교차반응물질이\n\n없는 검체 등), 분석물질의 농도 및 결과 등에 대한 실험프로토콜을\n\n제공한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_596",
      "text": "2) 최소 5회 이상 교차 반응 예상물질을 함유한 검체(T)와 교차\n\n반응물질을 함유하지 않은 비교검체(C)를 교대로 검사한다(예,\n\n3) 교차반응평가를 위해 준비된 검체는 최소 3회 반복 측정하기를\n\n1) 교차반응 평가에 사용된 물질의 종류, 농도, 측정한 raw data를\n\n※ 임상적 성능시험에 관한 자료의 작성 시 준수사항\n\n❍ 체외진단용 의료기기의 성능 및 유효성을 증명하기 위하여 사람에서 유\n\n❍ 외국에서 외국인을 대상으로 시험한 임상시험 성적도 제출할 수\n\n있으나 수출용이 아닌 내수용일 경우는 국내에서 우리나라 사람을\n\n대상으로 한 자료를 제출하는 것을 원칙으로 한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 595,
        "window_size": 3,
        "char_count": 328,
        "word_count": 77,
        "page_number": 6,
        "window_text": "교차반응\n\n유사한 분자구조를 가지고 있는 단백질 등에 대한 교차반응을 시험하여\n\n2) 뇌나트륨이뇨펩티드(NT-proBNP, BNP) 항원과의 교차반응을\n\n위한 평가에 이용될 수 있는 물질은 atrial natriuretic peptide,\n\n알파 심방성 나트륨 이뇨 펩티드(alpha-ANP) 1-28, prepro BNP\n\n- 다.  시험방법\n1) 교차반응물질의 종류, 교차반응물질의 농도, 검체종류(예 : 교차\n\n반응 예상 물질을 인위적으로 첨가한 검체, 자연적으로 높은 교차\n\nⅦ.  성능시험에 대한 상세사항\n\n- - 57 -\n반응 예상물질을 함유한 검체 등), 비교검체(예 : 교차반응물질이\n\n없는 검체 등), 분석물질의 농도 및 결과 등에 대한 실험프로토콜을\n\n제공한다.\n\n 2) 최소 5회 이상 교차 반응 예상물질을 함유한 검체(T)와 교차\n\n반응물질을 함유하지 않은 비교검체(C)를 교대로 검사한다(예,\n\n3) 교차반응평가를 위해 준비된 검체는 최소 3회 반복 측정하기를\n\n1) 교차반응 평가에 사용된 물질의 종류, 농도, 측정한 raw data를\n\n※ 임상적 성능시험에 관한 자료의 작성 시 준수사항\n\n❍ 체외진단용 의료기기의 성능 및 유효성을 증명하기 위하여 사람에서 유\n\n❍ 외국에서 외국인을 대상으로 시험한 임상시험 성적도 제출할 수\n\n있으나 수출용이 아닌 내수용일 경우는 국내에서 우리나라 사람을\n\n대상으로 한 자료를 제출하는 것을 원칙으로 한다.  이는 인종 및\n\n지역에 따라 유병률이 다를 수 있기 때문이다.  민족적 요인의 차이가\n\n있어 외국 임상적 성능시험을 그대로 적용하기가 어렵다고 판단되는\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 58 -\n경우, 처장은 국내에 거주하는 한국인으로부터 유래한 검체를 대상으로\n\n한 자료를 추가 제출할 것을 요구 할 수 있다.\n\n ❍ 임상기관에서 임상시험이 수행되어야 하며, 임상시험 수행기관에서\n\n❍ 질환이 있음과 없음(“임상적 참값”)을 규명한 방법, 대상군(환자\n\n선택기준/배제기준, 환자 수), 검체종류, 검사방법, 통계 방법 등에\n\n대한 자세한 실험프로토콜을 제공해야한다. ",
        "original_sentence": "2) 최소 5회 이상 교차 반응 예상물질을 함유한 검체(T)와 교차\n\n반응물질을 함유하지 않은 비교검체(C)를 교대로 검사한다(예,\n\n3) 교차반응평가를 위해 준비된 검체는 최소 3회 반복 측정하기를\n\n1) 교차반응 평가에 사용된 물질의 종류, 농도, 측정한 raw data를\n\n※ 임상적 성능시험에 관한 자료의 작성 시 준수사항\n\n❍ 체외진단용 의료기기의 성능 및 유효성을 증명하기 위하여 사람에서 유\n\n❍ 외국에서 외국인을 대상으로 시험한 임상시험 성적도 제출할 수\n\n있으나 수출용이 아닌 내수용일 경우는 국내에서 우리나라 사람을\n\n대상으로 한 자료를 제출하는 것을 원칙으로 한다. "
      }
    },
    {
      "chunk_id": "chunk_597",
      "text": "이는 인종 및\n\n지역에 따라 유병률이 다를 수 있기 때문이다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 596,
        "window_size": 3,
        "char_count": 35,
        "word_count": 10,
        "page_number": 79,
        "window_text": "시험방법\n1) 교차반응물질의 종류, 교차반응물질의 농도, 검체종류(예 : 교차\n\n반응 예상 물질을 인위적으로 첨가한 검체, 자연적으로 높은 교차\n\nⅦ.  성능시험에 대한 상세사항\n\n- - 57 -\n반응 예상물질을 함유한 검체 등), 비교검체(예 : 교차반응물질이\n\n없는 검체 등), 분석물질의 농도 및 결과 등에 대한 실험프로토콜을\n\n제공한다.\n\n 2) 최소 5회 이상 교차 반응 예상물질을 함유한 검체(T)와 교차\n\n반응물질을 함유하지 않은 비교검체(C)를 교대로 검사한다(예,\n\n3) 교차반응평가를 위해 준비된 검체는 최소 3회 반복 측정하기를\n\n1) 교차반응 평가에 사용된 물질의 종류, 농도, 측정한 raw data를\n\n※ 임상적 성능시험에 관한 자료의 작성 시 준수사항\n\n❍ 체외진단용 의료기기의 성능 및 유효성을 증명하기 위하여 사람에서 유\n\n❍ 외국에서 외국인을 대상으로 시험한 임상시험 성적도 제출할 수\n\n있으나 수출용이 아닌 내수용일 경우는 국내에서 우리나라 사람을\n\n대상으로 한 자료를 제출하는 것을 원칙으로 한다.  이는 인종 및\n\n지역에 따라 유병률이 다를 수 있기 때문이다.  민족적 요인의 차이가\n\n있어 외국 임상적 성능시험을 그대로 적용하기가 어렵다고 판단되는\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 58 -\n경우, 처장은 국내에 거주하는 한국인으로부터 유래한 검체를 대상으로\n\n한 자료를 추가 제출할 것을 요구 할 수 있다.\n\n ❍ 임상기관에서 임상시험이 수행되어야 하며, 임상시험 수행기관에서\n\n❍ 질환이 있음과 없음(“임상적 참값”)을 규명한 방법, 대상군(환자\n\n선택기준/배제기준, 환자 수), 검체종류, 검사방법, 통계 방법 등에\n\n대한 자세한 실험프로토콜을 제공해야한다.  질환이 있음을 규명한\n\n법일 수도 있고 여러 방법(진단검사의학 검사, 영상의학 검사, 병리\n\n검사, 임상 소견, 두 가지 이상의 기허가 제품으로 확인 등)을 종합한\n\n방법일 수도 있다. ",
        "original_sentence": "이는 인종 및\n\n지역에 따라 유병률이 다를 수 있기 때문이다. "
      }
    },
    {
      "chunk_id": "chunk_598",
      "text": "민족적 요인의 차이가\n\n있어 외국 임상적 성능시험을 그대로 적용하기가 어렵다고 판단되는\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 58 -\n경우, 처장은 국내에 거주하는 한국인으로부터 유래한 검체를 대상으로\n\n한 자료를 추가 제출할 것을 요구 할 수 있다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 597,
        "window_size": 3,
        "char_count": 175,
        "word_count": 40,
        "page_number": 33,
        "window_text": "성능시험에 대한 상세사항\n\n- - 57 -\n반응 예상물질을 함유한 검체 등), 비교검체(예 : 교차반응물질이\n\n없는 검체 등), 분석물질의 농도 및 결과 등에 대한 실험프로토콜을\n\n제공한다.\n\n 2) 최소 5회 이상 교차 반응 예상물질을 함유한 검체(T)와 교차\n\n반응물질을 함유하지 않은 비교검체(C)를 교대로 검사한다(예,\n\n3) 교차반응평가를 위해 준비된 검체는 최소 3회 반복 측정하기를\n\n1) 교차반응 평가에 사용된 물질의 종류, 농도, 측정한 raw data를\n\n※ 임상적 성능시험에 관한 자료의 작성 시 준수사항\n\n❍ 체외진단용 의료기기의 성능 및 유효성을 증명하기 위하여 사람에서 유\n\n❍ 외국에서 외국인을 대상으로 시험한 임상시험 성적도 제출할 수\n\n있으나 수출용이 아닌 내수용일 경우는 국내에서 우리나라 사람을\n\n대상으로 한 자료를 제출하는 것을 원칙으로 한다.  이는 인종 및\n\n지역에 따라 유병률이 다를 수 있기 때문이다.  민족적 요인의 차이가\n\n있어 외국 임상적 성능시험을 그대로 적용하기가 어렵다고 판단되는\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 58 -\n경우, 처장은 국내에 거주하는 한국인으로부터 유래한 검체를 대상으로\n\n한 자료를 추가 제출할 것을 요구 할 수 있다.\n\n ❍ 임상기관에서 임상시험이 수행되어야 하며, 임상시험 수행기관에서\n\n❍ 질환이 있음과 없음(“임상적 참값”)을 규명한 방법, 대상군(환자\n\n선택기준/배제기준, 환자 수), 검체종류, 검사방법, 통계 방법 등에\n\n대한 자세한 실험프로토콜을 제공해야한다.  질환이 있음을 규명한\n\n법일 수도 있고 여러 방법(진단검사의학 검사, 영상의학 검사, 병리\n\n검사, 임상 소견, 두 가지 이상의 기허가 제품으로 확인 등)을 종합한\n\n방법일 수도 있다.  종합한 방법일 경우 참값으로 규정한 알고리즘을\n\nESC Guidelines for the diagnosis and treatment of acute and\n\n- 3. ",
        "original_sentence": "민족적 요인의 차이가\n\n있어 외국 임상적 성능시험을 그대로 적용하기가 어렵다고 판단되는\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 58 -\n경우, 처장은 국내에 거주하는 한국인으로부터 유래한 검체를 대상으로\n\n한 자료를 추가 제출할 것을 요구 할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_599",
      "text": "❍ 임상기관에서 임상시험이 수행되어야 하며, 임상시험 수행기관에서\n\n❍ 질환이 있음과 없음(“임상적 참값”)을 규명한 방법, 대상군(환자\n\n선택기준/배제기준, 환자 수), 검체종류, 검사방법, 통계 방법 등에\n\n대한 자세한 실험프로토콜을 제공해야한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 598,
        "window_size": 3,
        "char_count": 141,
        "word_count": 27,
        "page_number": 33,
        "window_text": "2) 최소 5회 이상 교차 반응 예상물질을 함유한 검체(T)와 교차\n\n반응물질을 함유하지 않은 비교검체(C)를 교대로 검사한다(예,\n\n3) 교차반응평가를 위해 준비된 검체는 최소 3회 반복 측정하기를\n\n1) 교차반응 평가에 사용된 물질의 종류, 농도, 측정한 raw data를\n\n※ 임상적 성능시험에 관한 자료의 작성 시 준수사항\n\n❍ 체외진단용 의료기기의 성능 및 유효성을 증명하기 위하여 사람에서 유\n\n❍ 외국에서 외국인을 대상으로 시험한 임상시험 성적도 제출할 수\n\n있으나 수출용이 아닌 내수용일 경우는 국내에서 우리나라 사람을\n\n대상으로 한 자료를 제출하는 것을 원칙으로 한다.  이는 인종 및\n\n지역에 따라 유병률이 다를 수 있기 때문이다.  민족적 요인의 차이가\n\n있어 외국 임상적 성능시험을 그대로 적용하기가 어렵다고 판단되는\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 58 -\n경우, 처장은 국내에 거주하는 한국인으로부터 유래한 검체를 대상으로\n\n한 자료를 추가 제출할 것을 요구 할 수 있다.\n\n ❍ 임상기관에서 임상시험이 수행되어야 하며, 임상시험 수행기관에서\n\n❍ 질환이 있음과 없음(“임상적 참값”)을 규명한 방법, 대상군(환자\n\n선택기준/배제기준, 환자 수), 검체종류, 검사방법, 통계 방법 등에\n\n대한 자세한 실험프로토콜을 제공해야한다.  질환이 있음을 규명한\n\n법일 수도 있고 여러 방법(진단검사의학 검사, 영상의학 검사, 병리\n\n검사, 임상 소견, 두 가지 이상의 기허가 제품으로 확인 등)을 종합한\n\n방법일 수도 있다.  종합한 방법일 경우 참값으로 규정한 알고리즘을\n\nESC Guidelines for the diagnosis and treatment of acute and\n\n- 3.  LVEF의 감소\nHF-PEF의 진단을 위해서는 4개의 조건이 충족되어야 한다:\n\n- 1. ",
        "original_sentence": "❍ 임상기관에서 임상시험이 수행되어야 하며, 임상시험 수행기관에서\n\n❍ 질환이 있음과 없음(“임상적 참값”)을 규명한 방법, 대상군(환자\n\n선택기준/배제기준, 환자 수), 검체종류, 검사방법, 통계 방법 등에\n\n대한 자세한 실험프로토콜을 제공해야한다. "
      }
    },
    {
      "chunk_id": "chunk_600",
      "text": "질환이 있음을 규명한\n\n법일 수도 있고 여러 방법(진단검사의학 검사, 영상의학 검사, 병리\n\n검사, 임상 소견, 두 가지 이상의 기허가 제품으로 확인 등)을 종합한\n\n방법일 수도 있다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 599,
        "window_size": 3,
        "char_count": 104,
        "word_count": 26,
        "page_number": 64,
        "window_text": "이는 인종 및\n\n지역에 따라 유병률이 다를 수 있기 때문이다.  민족적 요인의 차이가\n\n있어 외국 임상적 성능시험을 그대로 적용하기가 어렵다고 판단되는\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 58 -\n경우, 처장은 국내에 거주하는 한국인으로부터 유래한 검체를 대상으로\n\n한 자료를 추가 제출할 것을 요구 할 수 있다.\n\n ❍ 임상기관에서 임상시험이 수행되어야 하며, 임상시험 수행기관에서\n\n❍ 질환이 있음과 없음(“임상적 참값”)을 규명한 방법, 대상군(환자\n\n선택기준/배제기준, 환자 수), 검체종류, 검사방법, 통계 방법 등에\n\n대한 자세한 실험프로토콜을 제공해야한다.  질환이 있음을 규명한\n\n법일 수도 있고 여러 방법(진단검사의학 검사, 영상의학 검사, 병리\n\n검사, 임상 소견, 두 가지 이상의 기허가 제품으로 확인 등)을 종합한\n\n방법일 수도 있다.  종합한 방법일 경우 참값으로 규정한 알고리즘을\n\nESC Guidelines for the diagnosis and treatment of acute and\n\n- 3.  LVEF의 감소\nHF-PEF의 진단을 위해서는 4개의 조건이 충족되어야 한다:\n\n- 1.  HF에 전형적인 증상들\n- 2. ",
        "original_sentence": "질환이 있음을 규명한\n\n법일 수도 있고 여러 방법(진단검사의학 검사, 영상의학 검사, 병리\n\n검사, 임상 소견, 두 가지 이상의 기허가 제품으로 확인 등)을 종합한\n\n방법일 수도 있다. "
      }
    },
    {
      "chunk_id": "chunk_601",
      "text": "종합한 방법일 경우 참값으로 규정한 알고리즘을\n\nESC Guidelines for the diagnosis and treatment of acute and\n\n- 3. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 600,
        "window_size": 3,
        "char_count": 93,
        "word_count": 18,
        "page_number": 14,
        "window_text": "민족적 요인의 차이가\n\n있어 외국 임상적 성능시험을 그대로 적용하기가 어렵다고 판단되는\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 58 -\n경우, 처장은 국내에 거주하는 한국인으로부터 유래한 검체를 대상으로\n\n한 자료를 추가 제출할 것을 요구 할 수 있다.\n\n ❍ 임상기관에서 임상시험이 수행되어야 하며, 임상시험 수행기관에서\n\n❍ 질환이 있음과 없음(“임상적 참값”)을 규명한 방법, 대상군(환자\n\n선택기준/배제기준, 환자 수), 검체종류, 검사방법, 통계 방법 등에\n\n대한 자세한 실험프로토콜을 제공해야한다.  질환이 있음을 규명한\n\n법일 수도 있고 여러 방법(진단검사의학 검사, 영상의학 검사, 병리\n\n검사, 임상 소견, 두 가지 이상의 기허가 제품으로 확인 등)을 종합한\n\n방법일 수도 있다.  종합한 방법일 경우 참값으로 규정한 알고리즘을\n\nESC Guidelines for the diagnosis and treatment of acute and\n\n- 3.  LVEF의 감소\nHF-PEF의 진단을 위해서는 4개의 조건이 충족되어야 한다:\n\n- 1.  HF에 전형적인 증상들\n- 2.  HF에 전형적인 증후들\n- 3. ",
        "original_sentence": "종합한 방법일 경우 참값으로 규정한 알고리즘을\n\nESC Guidelines for the diagnosis and treatment of acute and\n\n- 3. "
      }
    },
    {
      "chunk_id": "chunk_602",
      "text": "LVEF의 감소\nHF-PEF의 진단을 위해서는 4개의 조건이 충족되어야 한다:\n\n- 1. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 601,
        "window_size": 3,
        "char_count": 50,
        "word_count": 11,
        "page_number": 6,
        "window_text": "❍ 임상기관에서 임상시험이 수행되어야 하며, 임상시험 수행기관에서\n\n❍ 질환이 있음과 없음(“임상적 참값”)을 규명한 방법, 대상군(환자\n\n선택기준/배제기준, 환자 수), 검체종류, 검사방법, 통계 방법 등에\n\n대한 자세한 실험프로토콜을 제공해야한다.  질환이 있음을 규명한\n\n법일 수도 있고 여러 방법(진단검사의학 검사, 영상의학 검사, 병리\n\n검사, 임상 소견, 두 가지 이상의 기허가 제품으로 확인 등)을 종합한\n\n방법일 수도 있다.  종합한 방법일 경우 참값으로 규정한 알고리즘을\n\nESC Guidelines for the diagnosis and treatment of acute and\n\n- 3.  LVEF의 감소\nHF-PEF의 진단을 위해서는 4개의 조건이 충족되어야 한다:\n\n- 1.  HF에 전형적인 증상들\n- 2.  HF에 전형적인 증후들\n- 3.  정상이거나 약간 저하된 LVEF과 확장되지 않은 LV\n- 4. ",
        "original_sentence": "LVEF의 감소\nHF-PEF의 진단을 위해서는 4개의 조건이 충족되어야 한다:\n\n- 1. "
      }
    },
    {
      "chunk_id": "chunk_603",
      "text": "HF에 전형적인 증상들\n- 2. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 602,
        "window_size": 3,
        "char_count": 18,
        "word_count": 5,
        "page_number": 6,
        "window_text": "질환이 있음을 규명한\n\n법일 수도 있고 여러 방법(진단검사의학 검사, 영상의학 검사, 병리\n\n검사, 임상 소견, 두 가지 이상의 기허가 제품으로 확인 등)을 종합한\n\n방법일 수도 있다.  종합한 방법일 경우 참값으로 규정한 알고리즘을\n\nESC Guidelines for the diagnosis and treatment of acute and\n\n- 3.  LVEF의 감소\nHF-PEF의 진단을 위해서는 4개의 조건이 충족되어야 한다:\n\n- 1.  HF에 전형적인 증상들\n- 2.  HF에 전형적인 증후들\n- 3.  정상이거나 약간 저하된 LVEF과 확장되지 않은 LV\n- 4.  관련 있는 심장의 구조적 질환 (LV 비대/LA 확장) 및/또는 확장기\n기능장애 (diastolic dysfunction)\n\nⅦ. ",
        "original_sentence": "HF에 전형적인 증상들\n- 2. "
      }
    },
    {
      "chunk_id": "chunk_604",
      "text": "HF에 전형적인 증후들\n- 3. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 603,
        "window_size": 3,
        "char_count": 18,
        "word_count": 5,
        "page_number": 26,
        "window_text": "종합한 방법일 경우 참값으로 규정한 알고리즘을\n\nESC Guidelines for the diagnosis and treatment of acute and\n\n- 3.  LVEF의 감소\nHF-PEF의 진단을 위해서는 4개의 조건이 충족되어야 한다:\n\n- 1.  HF에 전형적인 증상들\n- 2.  HF에 전형적인 증후들\n- 3.  정상이거나 약간 저하된 LVEF과 확장되지 않은 LV\n- 4.  관련 있는 심장의 구조적 질환 (LV 비대/LA 확장) 및/또는 확장기\n기능장애 (diastolic dysfunction)\n\nⅦ.  성능시험에 대한 상세사항\n\n- - 59 -\n❍ 신선 검체를 사용하는 것을 원칙으로 하나, 충분한 수의 신선 검체를\n\n확보하기 어려울 경우, 냉동검체를 사용할 수 있다.\n\n",
        "original_sentence": "HF에 전형적인 증후들\n- 3. "
      }
    },
    {
      "chunk_id": "chunk_605",
      "text": "정상이거나 약간 저하된 LVEF과 확장되지 않은 LV\n- 4. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 604,
        "window_size": 3,
        "char_count": 35,
        "word_count": 9,
        "page_number": 6,
        "window_text": "LVEF의 감소\nHF-PEF의 진단을 위해서는 4개의 조건이 충족되어야 한다:\n\n- 1.  HF에 전형적인 증상들\n- 2.  HF에 전형적인 증후들\n- 3.  정상이거나 약간 저하된 LVEF과 확장되지 않은 LV\n- 4.  관련 있는 심장의 구조적 질환 (LV 비대/LA 확장) 및/또는 확장기\n기능장애 (diastolic dysfunction)\n\nⅦ.  성능시험에 대한 상세사항\n\n- - 59 -\n❍ 신선 검체를 사용하는 것을 원칙으로 하나, 충분한 수의 신선 검체를\n\n확보하기 어려울 경우, 냉동검체를 사용할 수 있다.\n\n ❍ 아래의 1)부터 4)중 어느 하나에 해당하는 경우, 임상적 성능시험에 관한\n\n1) 4등급 체외진단용 의료기기의 시험\n\n2) 인체로부터 검체를 채취하는 방법의 위해도가 큰 시험(검체의 채취방\n\n법이 인체의 피부, 점막, 안구, 요도를 침투 또는 관통하거나, 외이도,\n\n3) 이미 확립된 의학적 진단방법 또는 허가·인증받은 체외진단용 의료기\n\n4) 의약품 등과 함께 동반하여 진단하는 시험(다만, 이미 허가·인증받은\n\n(※ 상기의 1)부터 4)까지는 식약처장의 임상시험계획승인 및 임상시험\n\n❍ 상기의 1)부터 4)까지에 해당하지 않는 임상시험의 경우에는 아래의 가)부터\n\n다)까지 중 어느 하나에 해당하는 임상적 성능시험에 관한 자료로 제출하여야 한다.\n\n",
        "original_sentence": "정상이거나 약간 저하된 LVEF과 확장되지 않은 LV\n- 4. "
      }
    },
    {
      "chunk_id": "chunk_606",
      "text": "관련 있는 심장의 구조적 질환 (LV 비대/LA 확장) 및/또는 확장기\n기능장애 (diastolic dysfunction)\n\nⅦ. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 605,
        "window_size": 3,
        "char_count": 73,
        "word_count": 14,
        "page_number": 14,
        "window_text": "HF에 전형적인 증상들\n- 2.  HF에 전형적인 증후들\n- 3.  정상이거나 약간 저하된 LVEF과 확장되지 않은 LV\n- 4.  관련 있는 심장의 구조적 질환 (LV 비대/LA 확장) 및/또는 확장기\n기능장애 (diastolic dysfunction)\n\nⅦ.  성능시험에 대한 상세사항\n\n- - 59 -\n❍ 신선 검체를 사용하는 것을 원칙으로 하나, 충분한 수의 신선 검체를\n\n확보하기 어려울 경우, 냉동검체를 사용할 수 있다.\n\n ❍ 아래의 1)부터 4)중 어느 하나에 해당하는 경우, 임상적 성능시험에 관한\n\n1) 4등급 체외진단용 의료기기의 시험\n\n2) 인체로부터 검체를 채취하는 방법의 위해도가 큰 시험(검체의 채취방\n\n법이 인체의 피부, 점막, 안구, 요도를 침투 또는 관통하거나, 외이도,\n\n3) 이미 확립된 의학적 진단방법 또는 허가·인증받은 체외진단용 의료기\n\n4) 의약품 등과 함께 동반하여 진단하는 시험(다만, 이미 허가·인증받은\n\n(※ 상기의 1)부터 4)까지는 식약처장의 임상시험계획승인 및 임상시험\n\n❍ 상기의 1)부터 4)까지에 해당하지 않는 임상시험의 경우에는 아래의 가)부터\n\n다)까지 중 어느 하나에 해당하는 임상적 성능시험에 관한 자료로 제출하여야 한다.\n\n (※ 하기의 가)부터 나)까지는 식약처장의 임상시험계획승인은 제외되고,\n\n임상적 성능시험 실시기관의 임상시험계획승인을 받고 실시해야함)\n\n가) 다음 각 단의 어느 하나에 해당하는 기관에서 별표 14 임상적 성능시험\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 60 -\n관리기준에 의하여 실시한 자료\n\n➀「감염병의 예방 및 관리에 관한 시행규칙」 제4조제9호에 해당하는 기관\n\n➁「혈액관리법」 제6조제3항에 따라 허가받은 공급혈액원\n\n➂ 법 제10조제3항에 따라 식약처장이 지정한 임상시험기관\n\n나) 외국 자료로서 그 내용을 검토하여 실시기관의 신뢰성이 인정되고 별표 14\n\n임상적 성능시험 관리기준에 의하여 실시한 시험자료 또는 이에 준하는\n\n다) 임상적 성능시험에 관한 자료 요건( 상기의 1)에서~ 4)까지) 중 어느\n\n❍ 임상적 성능시험에 관한 자료는 다음 중 어느 하나에 해당하는 자료 요건\n\n- 가. ",
        "original_sentence": "관련 있는 심장의 구조적 질환 (LV 비대/LA 확장) 및/또는 확장기\n기능장애 (diastolic dysfunction)\n\nⅦ. "
      }
    },
    {
      "chunk_id": "chunk_607",
      "text": "성능시험에 대한 상세사항\n\n- - 59 -\n❍ 신선 검체를 사용하는 것을 원칙으로 하나, 충분한 수의 신선 검체를\n\n확보하기 어려울 경우, 냉동검체를 사용할 수 있다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 606,
        "window_size": 3,
        "char_count": 95,
        "word_count": 25,
        "page_number": 3,
        "window_text": "HF에 전형적인 증후들\n- 3.  정상이거나 약간 저하된 LVEF과 확장되지 않은 LV\n- 4.  관련 있는 심장의 구조적 질환 (LV 비대/LA 확장) 및/또는 확장기\n기능장애 (diastolic dysfunction)\n\nⅦ.  성능시험에 대한 상세사항\n\n- - 59 -\n❍ 신선 검체를 사용하는 것을 원칙으로 하나, 충분한 수의 신선 검체를\n\n확보하기 어려울 경우, 냉동검체를 사용할 수 있다.\n\n ❍ 아래의 1)부터 4)중 어느 하나에 해당하는 경우, 임상적 성능시험에 관한\n\n1) 4등급 체외진단용 의료기기의 시험\n\n2) 인체로부터 검체를 채취하는 방법의 위해도가 큰 시험(검체의 채취방\n\n법이 인체의 피부, 점막, 안구, 요도를 침투 또는 관통하거나, 외이도,\n\n3) 이미 확립된 의학적 진단방법 또는 허가·인증받은 체외진단용 의료기\n\n4) 의약품 등과 함께 동반하여 진단하는 시험(다만, 이미 허가·인증받은\n\n(※ 상기의 1)부터 4)까지는 식약처장의 임상시험계획승인 및 임상시험\n\n❍ 상기의 1)부터 4)까지에 해당하지 않는 임상시험의 경우에는 아래의 가)부터\n\n다)까지 중 어느 하나에 해당하는 임상적 성능시험에 관한 자료로 제출하여야 한다.\n\n (※ 하기의 가)부터 나)까지는 식약처장의 임상시험계획승인은 제외되고,\n\n임상적 성능시험 실시기관의 임상시험계획승인을 받고 실시해야함)\n\n가) 다음 각 단의 어느 하나에 해당하는 기관에서 별표 14 임상적 성능시험\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 60 -\n관리기준에 의하여 실시한 자료\n\n➀「감염병의 예방 및 관리에 관한 시행규칙」 제4조제9호에 해당하는 기관\n\n➁「혈액관리법」 제6조제3항에 따라 허가받은 공급혈액원\n\n➂ 법 제10조제3항에 따라 식약처장이 지정한 임상시험기관\n\n나) 외국 자료로서 그 내용을 검토하여 실시기관의 신뢰성이 인정되고 별표 14\n\n임상적 성능시험 관리기준에 의하여 실시한 시험자료 또는 이에 준하는\n\n다) 임상적 성능시험에 관한 자료 요건( 상기의 1)에서~ 4)까지) 중 어느\n\n❍ 임상적 성능시험에 관한 자료는 다음 중 어느 하나에 해당하는 자료 요건\n\n- 가.  식품의약품안전처장이 지정한 임상시험기관에서 시험한 자료\n- 나. ",
        "original_sentence": "성능시험에 대한 상세사항\n\n- - 59 -\n❍ 신선 검체를 사용하는 것을 원칙으로 하나, 충분한 수의 신선 검체를\n\n확보하기 어려울 경우, 냉동검체를 사용할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_608",
      "text": "❍ 아래의 1)부터 4)중 어느 하나에 해당하는 경우, 임상적 성능시험에 관한\n\n1) 4등급 체외진단용 의료기기의 시험\n\n2) 인체로부터 검체를 채취하는 방법의 위해도가 큰 시험(검체의 채취방\n\n법이 인체의 피부, 점막, 안구, 요도를 침투 또는 관통하거나, 외이도,\n\n3) 이미 확립된 의학적 진단방법 또는 허가·인증받은 체외진단용 의료기\n\n4) 의약품 등과 함께 동반하여 진단하는 시험(다만, 이미 허가·인증받은\n\n(※ 상기의 1)부터 4)까지는 식약처장의 임상시험계획승인 및 임상시험\n\n❍ 상기의 1)부터 4)까지에 해당하지 않는 임상시험의 경우에는 아래의 가)부터\n\n다)까지 중 어느 하나에 해당하는 임상적 성능시험에 관한 자료로 제출하여야 한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 607,
        "window_size": 3,
        "char_count": 368,
        "word_count": 82,
        "page_number": 6,
        "window_text": "정상이거나 약간 저하된 LVEF과 확장되지 않은 LV\n- 4.  관련 있는 심장의 구조적 질환 (LV 비대/LA 확장) 및/또는 확장기\n기능장애 (diastolic dysfunction)\n\nⅦ.  성능시험에 대한 상세사항\n\n- - 59 -\n❍ 신선 검체를 사용하는 것을 원칙으로 하나, 충분한 수의 신선 검체를\n\n확보하기 어려울 경우, 냉동검체를 사용할 수 있다.\n\n ❍ 아래의 1)부터 4)중 어느 하나에 해당하는 경우, 임상적 성능시험에 관한\n\n1) 4등급 체외진단용 의료기기의 시험\n\n2) 인체로부터 검체를 채취하는 방법의 위해도가 큰 시험(검체의 채취방\n\n법이 인체의 피부, 점막, 안구, 요도를 침투 또는 관통하거나, 외이도,\n\n3) 이미 확립된 의학적 진단방법 또는 허가·인증받은 체외진단용 의료기\n\n4) 의약품 등과 함께 동반하여 진단하는 시험(다만, 이미 허가·인증받은\n\n(※ 상기의 1)부터 4)까지는 식약처장의 임상시험계획승인 및 임상시험\n\n❍ 상기의 1)부터 4)까지에 해당하지 않는 임상시험의 경우에는 아래의 가)부터\n\n다)까지 중 어느 하나에 해당하는 임상적 성능시험에 관한 자료로 제출하여야 한다.\n\n (※ 하기의 가)부터 나)까지는 식약처장의 임상시험계획승인은 제외되고,\n\n임상적 성능시험 실시기관의 임상시험계획승인을 받고 실시해야함)\n\n가) 다음 각 단의 어느 하나에 해당하는 기관에서 별표 14 임상적 성능시험\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 60 -\n관리기준에 의하여 실시한 자료\n\n➀「감염병의 예방 및 관리에 관한 시행규칙」 제4조제9호에 해당하는 기관\n\n➁「혈액관리법」 제6조제3항에 따라 허가받은 공급혈액원\n\n➂ 법 제10조제3항에 따라 식약처장이 지정한 임상시험기관\n\n나) 외국 자료로서 그 내용을 검토하여 실시기관의 신뢰성이 인정되고 별표 14\n\n임상적 성능시험 관리기준에 의하여 실시한 시험자료 또는 이에 준하는\n\n다) 임상적 성능시험에 관한 자료 요건( 상기의 1)에서~ 4)까지) 중 어느\n\n❍ 임상적 성능시험에 관한 자료는 다음 중 어느 하나에 해당하는 자료 요건\n\n- 가.  식품의약품안전처장이 지정한 임상시험기관에서 시험한 자료\n- 나.  외국자료로서 그 내용을 검토하여 실시기관의 신뢰성이 인정되고 시행규\n칙 별표 3 의료기기 임상시험 관리기준에 의하여 실시한 시험자료\n\n- 다. ",
        "original_sentence": "❍ 아래의 1)부터 4)중 어느 하나에 해당하는 경우, 임상적 성능시험에 관한\n\n1) 4등급 체외진단용 의료기기의 시험\n\n2) 인체로부터 검체를 채취하는 방법의 위해도가 큰 시험(검체의 채취방\n\n법이 인체의 피부, 점막, 안구, 요도를 침투 또는 관통하거나, 외이도,\n\n3) 이미 확립된 의학적 진단방법 또는 허가·인증받은 체외진단용 의료기\n\n4) 의약품 등과 함께 동반하여 진단하는 시험(다만, 이미 허가·인증받은\n\n(※ 상기의 1)부터 4)까지는 식약처장의 임상시험계획승인 및 임상시험\n\n❍ 상기의 1)부터 4)까지에 해당하지 않는 임상시험의 경우에는 아래의 가)부터\n\n다)까지 중 어느 하나에 해당하는 임상적 성능시험에 관한 자료로 제출하여야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_609",
      "text": "(※ 하기의 가)부터 나)까지는 식약처장의 임상시험계획승인은 제외되고,\n\n임상적 성능시험 실시기관의 임상시험계획승인을 받고 실시해야함)\n\n가) 다음 각 단의 어느 하나에 해당하는 기관에서 별표 14 임상적 성능시험\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 60 -\n관리기준에 의하여 실시한 자료\n\n➀「감염병의 예방 및 관리에 관한 시행규칙」 제4조제9호에 해당하는 기관\n\n➁「혈액관리법」 제6조제3항에 따라 허가받은 공급혈액원\n\n➂ 법 제10조제3항에 따라 식약처장이 지정한 임상시험기관\n\n나) 외국 자료로서 그 내용을 검토하여 실시기관의 신뢰성이 인정되고 별표 14\n\n임상적 성능시험 관리기준에 의하여 실시한 시험자료 또는 이에 준하는\n\n다) 임상적 성능시험에 관한 자료 요건( 상기의 1)에서~ 4)까지) 중 어느\n\n❍ 임상적 성능시험에 관한 자료는 다음 중 어느 하나에 해당하는 자료 요건\n\n- 가. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 608,
        "window_size": 3,
        "char_count": 482,
        "word_count": 107,
        "page_number": 33,
        "window_text": "관련 있는 심장의 구조적 질환 (LV 비대/LA 확장) 및/또는 확장기\n기능장애 (diastolic dysfunction)\n\nⅦ.  성능시험에 대한 상세사항\n\n- - 59 -\n❍ 신선 검체를 사용하는 것을 원칙으로 하나, 충분한 수의 신선 검체를\n\n확보하기 어려울 경우, 냉동검체를 사용할 수 있다.\n\n ❍ 아래의 1)부터 4)중 어느 하나에 해당하는 경우, 임상적 성능시험에 관한\n\n1) 4등급 체외진단용 의료기기의 시험\n\n2) 인체로부터 검체를 채취하는 방법의 위해도가 큰 시험(검체의 채취방\n\n법이 인체의 피부, 점막, 안구, 요도를 침투 또는 관통하거나, 외이도,\n\n3) 이미 확립된 의학적 진단방법 또는 허가·인증받은 체외진단용 의료기\n\n4) 의약품 등과 함께 동반하여 진단하는 시험(다만, 이미 허가·인증받은\n\n(※ 상기의 1)부터 4)까지는 식약처장의 임상시험계획승인 및 임상시험\n\n❍ 상기의 1)부터 4)까지에 해당하지 않는 임상시험의 경우에는 아래의 가)부터\n\n다)까지 중 어느 하나에 해당하는 임상적 성능시험에 관한 자료로 제출하여야 한다.\n\n (※ 하기의 가)부터 나)까지는 식약처장의 임상시험계획승인은 제외되고,\n\n임상적 성능시험 실시기관의 임상시험계획승인을 받고 실시해야함)\n\n가) 다음 각 단의 어느 하나에 해당하는 기관에서 별표 14 임상적 성능시험\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 60 -\n관리기준에 의하여 실시한 자료\n\n➀「감염병의 예방 및 관리에 관한 시행규칙」 제4조제9호에 해당하는 기관\n\n➁「혈액관리법」 제6조제3항에 따라 허가받은 공급혈액원\n\n➂ 법 제10조제3항에 따라 식약처장이 지정한 임상시험기관\n\n나) 외국 자료로서 그 내용을 검토하여 실시기관의 신뢰성이 인정되고 별표 14\n\n임상적 성능시험 관리기준에 의하여 실시한 시험자료 또는 이에 준하는\n\n다) 임상적 성능시험에 관한 자료 요건( 상기의 1)에서~ 4)까지) 중 어느\n\n❍ 임상적 성능시험에 관한 자료는 다음 중 어느 하나에 해당하는 자료 요건\n\n- 가.  식품의약품안전처장이 지정한 임상시험기관에서 시험한 자료\n- 나.  외국자료로서 그 내용을 검토하여 실시기관의 신뢰성이 인정되고 시행규\n칙 별표 3 의료기기 임상시험 관리기준에 의하여 실시한 시험자료\n\n- 다.  해당 의료기기에 대하여 경제협력개발기구(OECD) 회원국에 허가 당시\n제출되어 평가된 임상시험에 관한 자료로서 해당 정부 또는 정부가\n\n허가 업무를 위임한 등록기관이 제출받아 승인하였음을 확인한 자료\n\n- 라. ",
        "original_sentence": "(※ 하기의 가)부터 나)까지는 식약처장의 임상시험계획승인은 제외되고,\n\n임상적 성능시험 실시기관의 임상시험계획승인을 받고 실시해야함)\n\n가) 다음 각 단의 어느 하나에 해당하는 기관에서 별표 14 임상적 성능시험\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 60 -\n관리기준에 의하여 실시한 자료\n\n➀「감염병의 예방 및 관리에 관한 시행규칙」 제4조제9호에 해당하는 기관\n\n➁「혈액관리법」 제6조제3항에 따라 허가받은 공급혈액원\n\n➂ 법 제10조제3항에 따라 식약처장이 지정한 임상시험기관\n\n나) 외국 자료로서 그 내용을 검토하여 실시기관의 신뢰성이 인정되고 별표 14\n\n임상적 성능시험 관리기준에 의하여 실시한 시험자료 또는 이에 준하는\n\n다) 임상적 성능시험에 관한 자료 요건( 상기의 1)에서~ 4)까지) 중 어느\n\n❍ 임상적 성능시험에 관한 자료는 다음 중 어느 하나에 해당하는 자료 요건\n\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_610",
      "text": "식품의약품안전처장이 지정한 임상시험기관에서 시험한 자료\n- 나. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 609,
        "window_size": 3,
        "char_count": 36,
        "word_count": 7,
        "page_number": 33,
        "window_text": "성능시험에 대한 상세사항\n\n- - 59 -\n❍ 신선 검체를 사용하는 것을 원칙으로 하나, 충분한 수의 신선 검체를\n\n확보하기 어려울 경우, 냉동검체를 사용할 수 있다.\n\n ❍ 아래의 1)부터 4)중 어느 하나에 해당하는 경우, 임상적 성능시험에 관한\n\n1) 4등급 체외진단용 의료기기의 시험\n\n2) 인체로부터 검체를 채취하는 방법의 위해도가 큰 시험(검체의 채취방\n\n법이 인체의 피부, 점막, 안구, 요도를 침투 또는 관통하거나, 외이도,\n\n3) 이미 확립된 의학적 진단방법 또는 허가·인증받은 체외진단용 의료기\n\n4) 의약품 등과 함께 동반하여 진단하는 시험(다만, 이미 허가·인증받은\n\n(※ 상기의 1)부터 4)까지는 식약처장의 임상시험계획승인 및 임상시험\n\n❍ 상기의 1)부터 4)까지에 해당하지 않는 임상시험의 경우에는 아래의 가)부터\n\n다)까지 중 어느 하나에 해당하는 임상적 성능시험에 관한 자료로 제출하여야 한다.\n\n (※ 하기의 가)부터 나)까지는 식약처장의 임상시험계획승인은 제외되고,\n\n임상적 성능시험 실시기관의 임상시험계획승인을 받고 실시해야함)\n\n가) 다음 각 단의 어느 하나에 해당하는 기관에서 별표 14 임상적 성능시험\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 60 -\n관리기준에 의하여 실시한 자료\n\n➀「감염병의 예방 및 관리에 관한 시행규칙」 제4조제9호에 해당하는 기관\n\n➁「혈액관리법」 제6조제3항에 따라 허가받은 공급혈액원\n\n➂ 법 제10조제3항에 따라 식약처장이 지정한 임상시험기관\n\n나) 외국 자료로서 그 내용을 검토하여 실시기관의 신뢰성이 인정되고 별표 14\n\n임상적 성능시험 관리기준에 의하여 실시한 시험자료 또는 이에 준하는\n\n다) 임상적 성능시험에 관한 자료 요건( 상기의 1)에서~ 4)까지) 중 어느\n\n❍ 임상적 성능시험에 관한 자료는 다음 중 어느 하나에 해당하는 자료 요건\n\n- 가.  식품의약품안전처장이 지정한 임상시험기관에서 시험한 자료\n- 나.  외국자료로서 그 내용을 검토하여 실시기관의 신뢰성이 인정되고 시행규\n칙 별표 3 의료기기 임상시험 관리기준에 의하여 실시한 시험자료\n\n- 다.  해당 의료기기에 대하여 경제협력개발기구(OECD) 회원국에 허가 당시\n제출되어 평가된 임상시험에 관한 자료로서 해당 정부 또는 정부가\n\n허가 업무를 위임한 등록기관이 제출받아 승인하였음을 확인한 자료\n\n- 라.  과학논문인용색인(Science Citation Index)에 등재된 전문학회지에\n게재된 자료\n\nⅦ. ",
        "original_sentence": "식품의약품안전처장이 지정한 임상시험기관에서 시험한 자료\n- 나. "
      }
    },
    {
      "chunk_id": "chunk_611",
      "text": "외국자료로서 그 내용을 검토하여 실시기관의 신뢰성이 인정되고 시행규\n칙 별표 3 의료기기 임상시험 관리기준에 의하여 실시한 시험자료\n\n- 다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 610,
        "window_size": 3,
        "char_count": 80,
        "word_count": 19,
        "page_number": 26,
        "window_text": "❍ 아래의 1)부터 4)중 어느 하나에 해당하는 경우, 임상적 성능시험에 관한\n\n1) 4등급 체외진단용 의료기기의 시험\n\n2) 인체로부터 검체를 채취하는 방법의 위해도가 큰 시험(검체의 채취방\n\n법이 인체의 피부, 점막, 안구, 요도를 침투 또는 관통하거나, 외이도,\n\n3) 이미 확립된 의학적 진단방법 또는 허가·인증받은 체외진단용 의료기\n\n4) 의약품 등과 함께 동반하여 진단하는 시험(다만, 이미 허가·인증받은\n\n(※ 상기의 1)부터 4)까지는 식약처장의 임상시험계획승인 및 임상시험\n\n❍ 상기의 1)부터 4)까지에 해당하지 않는 임상시험의 경우에는 아래의 가)부터\n\n다)까지 중 어느 하나에 해당하는 임상적 성능시험에 관한 자료로 제출하여야 한다.\n\n (※ 하기의 가)부터 나)까지는 식약처장의 임상시험계획승인은 제외되고,\n\n임상적 성능시험 실시기관의 임상시험계획승인을 받고 실시해야함)\n\n가) 다음 각 단의 어느 하나에 해당하는 기관에서 별표 14 임상적 성능시험\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 60 -\n관리기준에 의하여 실시한 자료\n\n➀「감염병의 예방 및 관리에 관한 시행규칙」 제4조제9호에 해당하는 기관\n\n➁「혈액관리법」 제6조제3항에 따라 허가받은 공급혈액원\n\n➂ 법 제10조제3항에 따라 식약처장이 지정한 임상시험기관\n\n나) 외국 자료로서 그 내용을 검토하여 실시기관의 신뢰성이 인정되고 별표 14\n\n임상적 성능시험 관리기준에 의하여 실시한 시험자료 또는 이에 준하는\n\n다) 임상적 성능시험에 관한 자료 요건( 상기의 1)에서~ 4)까지) 중 어느\n\n❍ 임상적 성능시험에 관한 자료는 다음 중 어느 하나에 해당하는 자료 요건\n\n- 가.  식품의약품안전처장이 지정한 임상시험기관에서 시험한 자료\n- 나.  외국자료로서 그 내용을 검토하여 실시기관의 신뢰성이 인정되고 시행규\n칙 별표 3 의료기기 임상시험 관리기준에 의하여 실시한 시험자료\n\n- 다.  해당 의료기기에 대하여 경제협력개발기구(OECD) 회원국에 허가 당시\n제출되어 평가된 임상시험에 관한 자료로서 해당 정부 또는 정부가\n\n허가 업무를 위임한 등록기관이 제출받아 승인하였음을 확인한 자료\n\n- 라.  과학논문인용색인(Science Citation Index)에 등재된 전문학회지에\n게재된 자료\n\nⅦ.  성능시험에 대한 상세사항\n\n- - 61 -\n<!-- PAGE_67 -->\n###### 1. ",
        "original_sentence": "외국자료로서 그 내용을 검토하여 실시기관의 신뢰성이 인정되고 시행규\n칙 별표 3 의료기기 임상시험 관리기준에 의하여 실시한 시험자료\n\n- 다. "
      }
    },
    {
      "chunk_id": "chunk_612",
      "text": "해당 의료기기에 대하여 경제협력개발기구(OECD) 회원국에 허가 당시\n제출되어 평가된 임상시험에 관한 자료로서 해당 정부 또는 정부가\n\n허가 업무를 위임한 등록기관이 제출받아 승인하였음을 확인한 자료\n\n- 라. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 611,
        "window_size": 3,
        "char_count": 118,
        "word_count": 26,
        "page_number": 79,
        "window_text": "(※ 하기의 가)부터 나)까지는 식약처장의 임상시험계획승인은 제외되고,\n\n임상적 성능시험 실시기관의 임상시험계획승인을 받고 실시해야함)\n\n가) 다음 각 단의 어느 하나에 해당하는 기관에서 별표 14 임상적 성능시험\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 60 -\n관리기준에 의하여 실시한 자료\n\n➀「감염병의 예방 및 관리에 관한 시행규칙」 제4조제9호에 해당하는 기관\n\n➁「혈액관리법」 제6조제3항에 따라 허가받은 공급혈액원\n\n➂ 법 제10조제3항에 따라 식약처장이 지정한 임상시험기관\n\n나) 외국 자료로서 그 내용을 검토하여 실시기관의 신뢰성이 인정되고 별표 14\n\n임상적 성능시험 관리기준에 의하여 실시한 시험자료 또는 이에 준하는\n\n다) 임상적 성능시험에 관한 자료 요건( 상기의 1)에서~ 4)까지) 중 어느\n\n❍ 임상적 성능시험에 관한 자료는 다음 중 어느 하나에 해당하는 자료 요건\n\n- 가.  식품의약품안전처장이 지정한 임상시험기관에서 시험한 자료\n- 나.  외국자료로서 그 내용을 검토하여 실시기관의 신뢰성이 인정되고 시행규\n칙 별표 3 의료기기 임상시험 관리기준에 의하여 실시한 시험자료\n\n- 다.  해당 의료기기에 대하여 경제협력개발기구(OECD) 회원국에 허가 당시\n제출되어 평가된 임상시험에 관한 자료로서 해당 정부 또는 정부가\n\n허가 업무를 위임한 등록기관이 제출받아 승인하였음을 확인한 자료\n\n- 라.  과학논문인용색인(Science Citation Index)에 등재된 전문학회지에\n게재된 자료\n\nⅦ.  성능시험에 대한 상세사항\n\n- - 61 -\n<!-- PAGE_67 -->\n###### 1.  임상적 민감도\n\n- 가. ",
        "original_sentence": "해당 의료기기에 대하여 경제협력개발기구(OECD) 회원국에 허가 당시\n제출되어 평가된 임상시험에 관한 자료로서 해당 정부 또는 정부가\n\n허가 업무를 위임한 등록기관이 제출받아 승인하였음을 확인한 자료\n\n- 라. "
      }
    },
    {
      "chunk_id": "chunk_613",
      "text": "과학논문인용색인(Science Citation Index)에 등재된 전문학회지에\n게재된 자료\n\nⅦ. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 612,
        "window_size": 3,
        "char_count": 56,
        "word_count": 8,
        "page_number": 14,
        "window_text": "식품의약품안전처장이 지정한 임상시험기관에서 시험한 자료\n- 나.  외국자료로서 그 내용을 검토하여 실시기관의 신뢰성이 인정되고 시행규\n칙 별표 3 의료기기 임상시험 관리기준에 의하여 실시한 시험자료\n\n- 다.  해당 의료기기에 대하여 경제협력개발기구(OECD) 회원국에 허가 당시\n제출되어 평가된 임상시험에 관한 자료로서 해당 정부 또는 정부가\n\n허가 업무를 위임한 등록기관이 제출받아 승인하였음을 확인한 자료\n\n- 라.  과학논문인용색인(Science Citation Index)에 등재된 전문학회지에\n게재된 자료\n\nⅦ.  성능시험에 대한 상세사항\n\n- - 61 -\n<!-- PAGE_67 -->\n###### 1.  임상적 민감도\n\n- 가.  실험물질\n2) 임상검체가 양성 또는 음성임을 확인한 방법을 기술한 자료를\n\n4) 검사의 목적, 유병률과 제품의 분석능에 따라 통계적으로 의미\n\n있는 검체수가 다르므로 검사의 목적, 유병률, 제품의 분석능에\n\n※ 뇌나트륨이뇨펩티드(NT-proBNP, BNP) 검사의 목표 질환을\n\n가지고 있는 양성 검체 50개 이상을 포함하여 평가하기를\n\n5) 신선한 검체를 이용할 것을 권장하지만, 제조사에서 냉동검체의\n\n- 나. ",
        "original_sentence": "과학논문인용색인(Science Citation Index)에 등재된 전문학회지에\n게재된 자료\n\nⅦ. "
      }
    },
    {
      "chunk_id": "chunk_614",
      "text": "성능시험에 대한 상세사항\n\n- - 61 -\n<!-- PAGE_67 -->\n###### 1. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 613,
        "window_size": 3,
        "char_count": 51,
        "word_count": 12,
        "page_number": 67,
        "window_text": "외국자료로서 그 내용을 검토하여 실시기관의 신뢰성이 인정되고 시행규\n칙 별표 3 의료기기 임상시험 관리기준에 의하여 실시한 시험자료\n\n- 다.  해당 의료기기에 대하여 경제협력개발기구(OECD) 회원국에 허가 당시\n제출되어 평가된 임상시험에 관한 자료로서 해당 정부 또는 정부가\n\n허가 업무를 위임한 등록기관이 제출받아 승인하였음을 확인한 자료\n\n- 라.  과학논문인용색인(Science Citation Index)에 등재된 전문학회지에\n게재된 자료\n\nⅦ.  성능시험에 대한 상세사항\n\n- - 61 -\n<!-- PAGE_67 -->\n###### 1.  임상적 민감도\n\n- 가.  실험물질\n2) 임상검체가 양성 또는 음성임을 확인한 방법을 기술한 자료를\n\n4) 검사의 목적, 유병률과 제품의 분석능에 따라 통계적으로 의미\n\n있는 검체수가 다르므로 검사의 목적, 유병률, 제품의 분석능에\n\n※ 뇌나트륨이뇨펩티드(NT-proBNP, BNP) 검사의 목표 질환을\n\n가지고 있는 양성 검체 50개 이상을 포함하여 평가하기를\n\n5) 신선한 검체를 이용할 것을 권장하지만, 제조사에서 냉동검체의\n\n- 나.  시험방법\n1) 피험자 선정/제외 기준, 검체 종류와 수, 시험 상 주의사항, 통계\n\n분석법 등에 대한 자세한 실험프로토콜을 제공한다.\n\n",
        "original_sentence": "성능시험에 대한 상세사항\n\n- - 61 -\n<!-- PAGE_67 -->\n###### 1. "
      }
    },
    {
      "chunk_id": "chunk_615",
      "text": "임상적 민감도\n\n- 가. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 614,
        "window_size": 3,
        "char_count": 14,
        "word_count": 4,
        "page_number": 31,
        "window_text": "해당 의료기기에 대하여 경제협력개발기구(OECD) 회원국에 허가 당시\n제출되어 평가된 임상시험에 관한 자료로서 해당 정부 또는 정부가\n\n허가 업무를 위임한 등록기관이 제출받아 승인하였음을 확인한 자료\n\n- 라.  과학논문인용색인(Science Citation Index)에 등재된 전문학회지에\n게재된 자료\n\nⅦ.  성능시험에 대한 상세사항\n\n- - 61 -\n<!-- PAGE_67 -->\n###### 1.  임상적 민감도\n\n- 가.  실험물질\n2) 임상검체가 양성 또는 음성임을 확인한 방법을 기술한 자료를\n\n4) 검사의 목적, 유병률과 제품의 분석능에 따라 통계적으로 의미\n\n있는 검체수가 다르므로 검사의 목적, 유병률, 제품의 분석능에\n\n※ 뇌나트륨이뇨펩티드(NT-proBNP, BNP) 검사의 목표 질환을\n\n가지고 있는 양성 검체 50개 이상을 포함하여 평가하기를\n\n5) 신선한 검체를 이용할 것을 권장하지만, 제조사에서 냉동검체의\n\n- 나.  시험방법\n1) 피험자 선정/제외 기준, 검체 종류와 수, 시험 상 주의사항, 통계\n\n분석법 등에 대한 자세한 실험프로토콜을 제공한다.\n\n 2) 신선한 검체를 이용할 것을 권장하지만, 확진된 보관검체로\n\n검사할 경우도 최소 5일 이상 검체를 나누어서 검사한다.\n\n",
        "original_sentence": "임상적 민감도\n\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_616",
      "text": "실험물질\n2) 임상검체가 양성 또는 음성임을 확인한 방법을 기술한 자료를\n\n4) 검사의 목적, 유병률과 제품의 분석능에 따라 통계적으로 의미\n\n있는 검체수가 다르므로 검사의 목적, 유병률, 제품의 분석능에\n\n※ 뇌나트륨이뇨펩티드(NT-proBNP, BNP) 검사의 목표 질환을\n\n가지고 있는 양성 검체 50개 이상을 포함하여 평가하기를\n\n5) 신선한 검체를 이용할 것을 권장하지만, 제조사에서 냉동검체의\n\n- 나. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 615,
        "window_size": 3,
        "char_count": 232,
        "word_count": 51,
        "page_number": 6,
        "window_text": "과학논문인용색인(Science Citation Index)에 등재된 전문학회지에\n게재된 자료\n\nⅦ.  성능시험에 대한 상세사항\n\n- - 61 -\n<!-- PAGE_67 -->\n###### 1.  임상적 민감도\n\n- 가.  실험물질\n2) 임상검체가 양성 또는 음성임을 확인한 방법을 기술한 자료를\n\n4) 검사의 목적, 유병률과 제품의 분석능에 따라 통계적으로 의미\n\n있는 검체수가 다르므로 검사의 목적, 유병률, 제품의 분석능에\n\n※ 뇌나트륨이뇨펩티드(NT-proBNP, BNP) 검사의 목표 질환을\n\n가지고 있는 양성 검체 50개 이상을 포함하여 평가하기를\n\n5) 신선한 검체를 이용할 것을 권장하지만, 제조사에서 냉동검체의\n\n- 나.  시험방법\n1) 피험자 선정/제외 기준, 검체 종류와 수, 시험 상 주의사항, 통계\n\n분석법 등에 대한 자세한 실험프로토콜을 제공한다.\n\n 2) 신선한 검체를 이용할 것을 권장하지만, 확진된 보관검체로\n\n검사할 경우도 최소 5일 이상 검체를 나누어서 검사한다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 62 -\n3) 2개 이상의 독립된 검사실에서 검사를 시행할 것을 권장한다.\n\n",
        "original_sentence": "실험물질\n2) 임상검체가 양성 또는 음성임을 확인한 방법을 기술한 자료를\n\n4) 검사의 목적, 유병률과 제품의 분석능에 따라 통계적으로 의미\n\n있는 검체수가 다르므로 검사의 목적, 유병률, 제품의 분석능에\n\n※ 뇌나트륨이뇨펩티드(NT-proBNP, BNP) 검사의 목표 질환을\n\n가지고 있는 양성 검체 50개 이상을 포함하여 평가하기를\n\n5) 신선한 검체를 이용할 것을 권장하지만, 제조사에서 냉동검체의\n\n- 나. "
      }
    },
    {
      "chunk_id": "chunk_617",
      "text": "시험방법\n1) 피험자 선정/제외 기준, 검체 종류와 수, 시험 상 주의사항, 통계\n\n분석법 등에 대한 자세한 실험프로토콜을 제공한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 616,
        "window_size": 3,
        "char_count": 76,
        "word_count": 18,
        "page_number": 3,
        "window_text": "성능시험에 대한 상세사항\n\n- - 61 -\n<!-- PAGE_67 -->\n###### 1.  임상적 민감도\n\n- 가.  실험물질\n2) 임상검체가 양성 또는 음성임을 확인한 방법을 기술한 자료를\n\n4) 검사의 목적, 유병률과 제품의 분석능에 따라 통계적으로 의미\n\n있는 검체수가 다르므로 검사의 목적, 유병률, 제품의 분석능에\n\n※ 뇌나트륨이뇨펩티드(NT-proBNP, BNP) 검사의 목표 질환을\n\n가지고 있는 양성 검체 50개 이상을 포함하여 평가하기를\n\n5) 신선한 검체를 이용할 것을 권장하지만, 제조사에서 냉동검체의\n\n- 나.  시험방법\n1) 피험자 선정/제외 기준, 검체 종류와 수, 시험 상 주의사항, 통계\n\n분석법 등에 대한 자세한 실험프로토콜을 제공한다.\n\n 2) 신선한 검체를 이용할 것을 권장하지만, 확진된 보관검체로\n\n검사할 경우도 최소 5일 이상 검체를 나누어서 검사한다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 62 -\n3) 2개 이상의 독립된 검사실에서 검사를 시행할 것을 권장한다.\n\n 4) 평가 전에 결과 해석에 대한 알고리즘 및 불일치한 경우 추가\n\n검사 등의 원인 분석 방법을 미리 확립하고 이를 명시한다.\n\n",
        "original_sentence": "시험방법\n1) 피험자 선정/제외 기준, 검체 종류와 수, 시험 상 주의사항, 통계\n\n분석법 등에 대한 자세한 실험프로토콜을 제공한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_618",
      "text": "2) 신선한 검체를 이용할 것을 권장하지만, 확진된 보관검체로\n\n검사할 경우도 최소 5일 이상 검체를 나누어서 검사한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 617,
        "window_size": 3,
        "char_count": 69,
        "word_count": 16,
        "page_number": 6,
        "window_text": "임상적 민감도\n\n- 가.  실험물질\n2) 임상검체가 양성 또는 음성임을 확인한 방법을 기술한 자료를\n\n4) 검사의 목적, 유병률과 제품의 분석능에 따라 통계적으로 의미\n\n있는 검체수가 다르므로 검사의 목적, 유병률, 제품의 분석능에\n\n※ 뇌나트륨이뇨펩티드(NT-proBNP, BNP) 검사의 목표 질환을\n\n가지고 있는 양성 검체 50개 이상을 포함하여 평가하기를\n\n5) 신선한 검체를 이용할 것을 권장하지만, 제조사에서 냉동검체의\n\n- 나.  시험방법\n1) 피험자 선정/제외 기준, 검체 종류와 수, 시험 상 주의사항, 통계\n\n분석법 등에 대한 자세한 실험프로토콜을 제공한다.\n\n 2) 신선한 검체를 이용할 것을 권장하지만, 확진된 보관검체로\n\n검사할 경우도 최소 5일 이상 검체를 나누어서 검사한다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 62 -\n3) 2개 이상의 독립된 검사실에서 검사를 시행할 것을 권장한다.\n\n 4) 평가 전에 결과 해석에 대한 알고리즘 및 불일치한 경우 추가\n\n검사 등의 원인 분석 방법을 미리 확립하고 이를 명시한다.\n\n 1) 임상적 민감도 및 95% 신뢰구간을 제시한다. ",
        "original_sentence": "2) 신선한 검체를 이용할 것을 권장하지만, 확진된 보관검체로\n\n검사할 경우도 최소 5일 이상 검체를 나누어서 검사한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_619",
      "text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 62 -\n3) 2개 이상의 독립된 검사실에서 검사를 시행할 것을 권장한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 618,
        "window_size": 3,
        "char_count": 96,
        "word_count": 21,
        "page_number": 1,
        "window_text": "실험물질\n2) 임상검체가 양성 또는 음성임을 확인한 방법을 기술한 자료를\n\n4) 검사의 목적, 유병률과 제품의 분석능에 따라 통계적으로 의미\n\n있는 검체수가 다르므로 검사의 목적, 유병률, 제품의 분석능에\n\n※ 뇌나트륨이뇨펩티드(NT-proBNP, BNP) 검사의 목표 질환을\n\n가지고 있는 양성 검체 50개 이상을 포함하여 평가하기를\n\n5) 신선한 검체를 이용할 것을 권장하지만, 제조사에서 냉동검체의\n\n- 나.  시험방법\n1) 피험자 선정/제외 기준, 검체 종류와 수, 시험 상 주의사항, 통계\n\n분석법 등에 대한 자세한 실험프로토콜을 제공한다.\n\n 2) 신선한 검체를 이용할 것을 권장하지만, 확진된 보관검체로\n\n검사할 경우도 최소 5일 이상 검체를 나누어서 검사한다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 62 -\n3) 2개 이상의 독립된 검사실에서 검사를 시행할 것을 권장한다.\n\n 4) 평가 전에 결과 해석에 대한 알고리즘 및 불일치한 경우 추가\n\n검사 등의 원인 분석 방법을 미리 확립하고 이를 명시한다.\n\n 1) 임상적 민감도 및 95% 신뢰구간을 제시한다.  임상적 민감도란\n\n2) 전체 결과, 특이 결과, 구별되는 소견이 있는 세부 집단별 결과\n\n3) 불일치한 검체에 대해 원인을 분석한 자료를 제출하고 해석을\n\n4) 전향적으로 목표하는 검체 수가 될 때까지 모든 양성 및 음성\n\n검체를 수집하였을 경우 유병률, 양성예측도, 음성예측도를 구할\n\nⅦ. ",
        "original_sentence": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 62 -\n3) 2개 이상의 독립된 검사실에서 검사를 시행할 것을 권장한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_620",
      "text": "4) 평가 전에 결과 해석에 대한 알고리즘 및 불일치한 경우 추가\n\n검사 등의 원인 분석 방법을 미리 확립하고 이를 명시한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 619,
        "window_size": 3,
        "char_count": 72,
        "word_count": 20,
        "page_number": 6,
        "window_text": "시험방법\n1) 피험자 선정/제외 기준, 검체 종류와 수, 시험 상 주의사항, 통계\n\n분석법 등에 대한 자세한 실험프로토콜을 제공한다.\n\n 2) 신선한 검체를 이용할 것을 권장하지만, 확진된 보관검체로\n\n검사할 경우도 최소 5일 이상 검체를 나누어서 검사한다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 62 -\n3) 2개 이상의 독립된 검사실에서 검사를 시행할 것을 권장한다.\n\n 4) 평가 전에 결과 해석에 대한 알고리즘 및 불일치한 경우 추가\n\n검사 등의 원인 분석 방법을 미리 확립하고 이를 명시한다.\n\n 1) 임상적 민감도 및 95% 신뢰구간을 제시한다.  임상적 민감도란\n\n2) 전체 결과, 특이 결과, 구별되는 소견이 있는 세부 집단별 결과\n\n3) 불일치한 검체에 대해 원인을 분석한 자료를 제출하고 해석을\n\n4) 전향적으로 목표하는 검체 수가 될 때까지 모든 양성 및 음성\n\n검체를 수집하였을 경우 유병률, 양성예측도, 음성예측도를 구할\n\nⅦ.  성능시험에 대한 상세사항\n\n- - 63 -\n<!-- PAGE_69 -->\n###### 2. ",
        "original_sentence": "4) 평가 전에 결과 해석에 대한 알고리즘 및 불일치한 경우 추가\n\n검사 등의 원인 분석 방법을 미리 확립하고 이를 명시한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_621",
      "text": "1) 임상적 민감도 및 95% 신뢰구간을 제시한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 620,
        "window_size": 3,
        "char_count": 29,
        "word_count": 7,
        "page_number": 21,
        "window_text": "2) 신선한 검체를 이용할 것을 권장하지만, 확진된 보관검체로\n\n검사할 경우도 최소 5일 이상 검체를 나누어서 검사한다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 62 -\n3) 2개 이상의 독립된 검사실에서 검사를 시행할 것을 권장한다.\n\n 4) 평가 전에 결과 해석에 대한 알고리즘 및 불일치한 경우 추가\n\n검사 등의 원인 분석 방법을 미리 확립하고 이를 명시한다.\n\n 1) 임상적 민감도 및 95% 신뢰구간을 제시한다.  임상적 민감도란\n\n2) 전체 결과, 특이 결과, 구별되는 소견이 있는 세부 집단별 결과\n\n3) 불일치한 검체에 대해 원인을 분석한 자료를 제출하고 해석을\n\n4) 전향적으로 목표하는 검체 수가 될 때까지 모든 양성 및 음성\n\n검체를 수집하였을 경우 유병률, 양성예측도, 음성예측도를 구할\n\nⅦ.  성능시험에 대한 상세사항\n\n- - 63 -\n<!-- PAGE_69 -->\n###### 2.  임상적 특이도\n\n- 가. ",
        "original_sentence": "1) 임상적 민감도 및 95% 신뢰구간을 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_622",
      "text": "임상적 민감도란\n\n2) 전체 결과, 특이 결과, 구별되는 소견이 있는 세부 집단별 결과\n\n3) 불일치한 검체에 대해 원인을 분석한 자료를 제출하고 해석을\n\n4) 전향적으로 목표하는 검체 수가 될 때까지 모든 양성 및 음성\n\n검체를 수집하였을 경우 유병률, 양성예측도, 음성예측도를 구할\n\nⅦ. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 621,
        "window_size": 3,
        "char_count": 164,
        "word_count": 41,
        "page_number": 6,
        "window_text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 62 -\n3) 2개 이상의 독립된 검사실에서 검사를 시행할 것을 권장한다.\n\n 4) 평가 전에 결과 해석에 대한 알고리즘 및 불일치한 경우 추가\n\n검사 등의 원인 분석 방법을 미리 확립하고 이를 명시한다.\n\n 1) 임상적 민감도 및 95% 신뢰구간을 제시한다.  임상적 민감도란\n\n2) 전체 결과, 특이 결과, 구별되는 소견이 있는 세부 집단별 결과\n\n3) 불일치한 검체에 대해 원인을 분석한 자료를 제출하고 해석을\n\n4) 전향적으로 목표하는 검체 수가 될 때까지 모든 양성 및 음성\n\n검체를 수집하였을 경우 유병률, 양성예측도, 음성예측도를 구할\n\nⅦ.  성능시험에 대한 상세사항\n\n- - 63 -\n<!-- PAGE_69 -->\n###### 2.  임상적 특이도\n\n- 가.  시험물질\n1) 진단의 목표가 되는 질환이 없음이 확인된 임상검체를 이용하여\n\n2) 검체는 적용하고자 하는 대상 인구집단을 반영하여야 한다(예 :\n\n※ 뇌나트륨이뇨펩티드(NT-proBNP, BNP)에 대한 목표 질환을\n\n1) 임상적 특이도란 질환이 없는 환자군에서 음성결과를 보이는\n\n2) 음성예측도와 양성예측도는 질환 유병률과 상관이 있으므로,\n\n3) 양성 결과를 보인 경우 임상소견 확인 및 확진 검사를 시행하여\n\n진양성 유무를 확인토록 한다. ",
        "original_sentence": "임상적 민감도란\n\n2) 전체 결과, 특이 결과, 구별되는 소견이 있는 세부 집단별 결과\n\n3) 불일치한 검체에 대해 원인을 분석한 자료를 제출하고 해석을\n\n4) 전향적으로 목표하는 검체 수가 될 때까지 모든 양성 및 음성\n\n검체를 수집하였을 경우 유병률, 양성예측도, 음성예측도를 구할\n\nⅦ. "
      }
    },
    {
      "chunk_id": "chunk_623",
      "text": "성능시험에 대한 상세사항\n\n- - 63 -\n<!-- PAGE_69 -->\n###### 2. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 622,
        "window_size": 3,
        "char_count": 51,
        "word_count": 12,
        "page_number": 69,
        "window_text": "4) 평가 전에 결과 해석에 대한 알고리즘 및 불일치한 경우 추가\n\n검사 등의 원인 분석 방법을 미리 확립하고 이를 명시한다.\n\n 1) 임상적 민감도 및 95% 신뢰구간을 제시한다.  임상적 민감도란\n\n2) 전체 결과, 특이 결과, 구별되는 소견이 있는 세부 집단별 결과\n\n3) 불일치한 검체에 대해 원인을 분석한 자료를 제출하고 해석을\n\n4) 전향적으로 목표하는 검체 수가 될 때까지 모든 양성 및 음성\n\n검체를 수집하였을 경우 유병률, 양성예측도, 음성예측도를 구할\n\nⅦ.  성능시험에 대한 상세사항\n\n- - 63 -\n<!-- PAGE_69 -->\n###### 2.  임상적 특이도\n\n- 가.  시험물질\n1) 진단의 목표가 되는 질환이 없음이 확인된 임상검체를 이용하여\n\n2) 검체는 적용하고자 하는 대상 인구집단을 반영하여야 한다(예 :\n\n※ 뇌나트륨이뇨펩티드(NT-proBNP, BNP)에 대한 목표 질환을\n\n1) 임상적 특이도란 질환이 없는 환자군에서 음성결과를 보이는\n\n2) 음성예측도와 양성예측도는 질환 유병률과 상관이 있으므로,\n\n3) 양성 결과를 보인 경우 임상소견 확인 및 확진 검사를 시행하여\n\n진양성 유무를 확인토록 한다.  진양성인 검체는 특이도 분석에서\n\n5) 평가 전에 결과 해석에 대한 알고리즘 및 불일치한 경우 추가\n\n검사 등의 원인 분석 방법을 미리 확립하고 이를 명시한다.\n\n",
        "original_sentence": "성능시험에 대한 상세사항\n\n- - 63 -\n<!-- PAGE_69 -->\n###### 2. "
      }
    },
    {
      "chunk_id": "chunk_624",
      "text": "임상적 특이도\n\n- 가. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 623,
        "window_size": 3,
        "char_count": 14,
        "word_count": 4,
        "page_number": 31,
        "window_text": "1) 임상적 민감도 및 95% 신뢰구간을 제시한다.  임상적 민감도란\n\n2) 전체 결과, 특이 결과, 구별되는 소견이 있는 세부 집단별 결과\n\n3) 불일치한 검체에 대해 원인을 분석한 자료를 제출하고 해석을\n\n4) 전향적으로 목표하는 검체 수가 될 때까지 모든 양성 및 음성\n\n검체를 수집하였을 경우 유병률, 양성예측도, 음성예측도를 구할\n\nⅦ.  성능시험에 대한 상세사항\n\n- - 63 -\n<!-- PAGE_69 -->\n###### 2.  임상적 특이도\n\n- 가.  시험물질\n1) 진단의 목표가 되는 질환이 없음이 확인된 임상검체를 이용하여\n\n2) 검체는 적용하고자 하는 대상 인구집단을 반영하여야 한다(예 :\n\n※ 뇌나트륨이뇨펩티드(NT-proBNP, BNP)에 대한 목표 질환을\n\n1) 임상적 특이도란 질환이 없는 환자군에서 음성결과를 보이는\n\n2) 음성예측도와 양성예측도는 질환 유병률과 상관이 있으므로,\n\n3) 양성 결과를 보인 경우 임상소견 확인 및 확진 검사를 시행하여\n\n진양성 유무를 확인토록 한다.  진양성인 검체는 특이도 분석에서\n\n5) 평가 전에 결과 해석에 대한 알고리즘 및 불일치한 경우 추가\n\n검사 등의 원인 분석 방법을 미리 확립하고 이를 명시한다.\n\n 6) 선택한 비교평가 방법을 명시하고, 선택한 사유를 기술한다.\n\n",
        "original_sentence": "임상적 특이도\n\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_625",
      "text": "시험물질\n1) 진단의 목표가 되는 질환이 없음이 확인된 임상검체를 이용하여\n\n2) 검체는 적용하고자 하는 대상 인구집단을 반영하여야 한다(예 :\n\n※ 뇌나트륨이뇨펩티드(NT-proBNP, BNP)에 대한 목표 질환을\n\n1) 임상적 특이도란 질환이 없는 환자군에서 음성결과를 보이는\n\n2) 음성예측도와 양성예측도는 질환 유병률과 상관이 있으므로,\n\n3) 양성 결과를 보인 경우 임상소견 확인 및 확진 검사를 시행하여\n\n진양성 유무를 확인토록 한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 624,
        "window_size": 3,
        "char_count": 250,
        "word_count": 55,
        "page_number": 6,
        "window_text": "임상적 민감도란\n\n2) 전체 결과, 특이 결과, 구별되는 소견이 있는 세부 집단별 결과\n\n3) 불일치한 검체에 대해 원인을 분석한 자료를 제출하고 해석을\n\n4) 전향적으로 목표하는 검체 수가 될 때까지 모든 양성 및 음성\n\n검체를 수집하였을 경우 유병률, 양성예측도, 음성예측도를 구할\n\nⅦ.  성능시험에 대한 상세사항\n\n- - 63 -\n<!-- PAGE_69 -->\n###### 2.  임상적 특이도\n\n- 가.  시험물질\n1) 진단의 목표가 되는 질환이 없음이 확인된 임상검체를 이용하여\n\n2) 검체는 적용하고자 하는 대상 인구집단을 반영하여야 한다(예 :\n\n※ 뇌나트륨이뇨펩티드(NT-proBNP, BNP)에 대한 목표 질환을\n\n1) 임상적 특이도란 질환이 없는 환자군에서 음성결과를 보이는\n\n2) 음성예측도와 양성예측도는 질환 유병률과 상관이 있으므로,\n\n3) 양성 결과를 보인 경우 임상소견 확인 및 확진 검사를 시행하여\n\n진양성 유무를 확인토록 한다.  진양성인 검체는 특이도 분석에서\n\n5) 평가 전에 결과 해석에 대한 알고리즘 및 불일치한 경우 추가\n\n검사 등의 원인 분석 방법을 미리 확립하고 이를 명시한다.\n\n 6) 선택한 비교평가 방법을 명시하고, 선택한 사유를 기술한다.\n\n 7) 2개 이상의 독립된 검사실에서 검사를 시행할 것을 권장한다.\n\n",
        "original_sentence": "시험물질\n1) 진단의 목표가 되는 질환이 없음이 확인된 임상검체를 이용하여\n\n2) 검체는 적용하고자 하는 대상 인구집단을 반영하여야 한다(예 :\n\n※ 뇌나트륨이뇨펩티드(NT-proBNP, BNP)에 대한 목표 질환을\n\n1) 임상적 특이도란 질환이 없는 환자군에서 음성결과를 보이는\n\n2) 음성예측도와 양성예측도는 질환 유병률과 상관이 있으므로,\n\n3) 양성 결과를 보인 경우 임상소견 확인 및 확진 검사를 시행하여\n\n진양성 유무를 확인토록 한다. "
      }
    },
    {
      "chunk_id": "chunk_626",
      "text": "진양성인 검체는 특이도 분석에서\n\n5) 평가 전에 결과 해석에 대한 알고리즘 및 불일치한 경우 추가\n\n검사 등의 원인 분석 방법을 미리 확립하고 이를 명시한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 625,
        "window_size": 3,
        "char_count": 91,
        "word_count": 24,
        "page_number": 14,
        "window_text": "성능시험에 대한 상세사항\n\n- - 63 -\n<!-- PAGE_69 -->\n###### 2.  임상적 특이도\n\n- 가.  시험물질\n1) 진단의 목표가 되는 질환이 없음이 확인된 임상검체를 이용하여\n\n2) 검체는 적용하고자 하는 대상 인구집단을 반영하여야 한다(예 :\n\n※ 뇌나트륨이뇨펩티드(NT-proBNP, BNP)에 대한 목표 질환을\n\n1) 임상적 특이도란 질환이 없는 환자군에서 음성결과를 보이는\n\n2) 음성예측도와 양성예측도는 질환 유병률과 상관이 있으므로,\n\n3) 양성 결과를 보인 경우 임상소견 확인 및 확진 검사를 시행하여\n\n진양성 유무를 확인토록 한다.  진양성인 검체는 특이도 분석에서\n\n5) 평가 전에 결과 해석에 대한 알고리즘 및 불일치한 경우 추가\n\n검사 등의 원인 분석 방법을 미리 확립하고 이를 명시한다.\n\n 6) 선택한 비교평가 방법을 명시하고, 선택한 사유를 기술한다.\n\n 7) 2개 이상의 독립된 검사실에서 검사를 시행할 것을 권장한다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 64 -\n- 다. ",
        "original_sentence": "진양성인 검체는 특이도 분석에서\n\n5) 평가 전에 결과 해석에 대한 알고리즘 및 불일치한 경우 추가\n\n검사 등의 원인 분석 방법을 미리 확립하고 이를 명시한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_627",
      "text": "6) 선택한 비교평가 방법을 명시하고, 선택한 사유를 기술한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 626,
        "window_size": 3,
        "char_count": 37,
        "word_count": 8,
        "page_number": 69,
        "window_text": "임상적 특이도\n\n- 가.  시험물질\n1) 진단의 목표가 되는 질환이 없음이 확인된 임상검체를 이용하여\n\n2) 검체는 적용하고자 하는 대상 인구집단을 반영하여야 한다(예 :\n\n※ 뇌나트륨이뇨펩티드(NT-proBNP, BNP)에 대한 목표 질환을\n\n1) 임상적 특이도란 질환이 없는 환자군에서 음성결과를 보이는\n\n2) 음성예측도와 양성예측도는 질환 유병률과 상관이 있으므로,\n\n3) 양성 결과를 보인 경우 임상소견 확인 및 확진 검사를 시행하여\n\n진양성 유무를 확인토록 한다.  진양성인 검체는 특이도 분석에서\n\n5) 평가 전에 결과 해석에 대한 알고리즘 및 불일치한 경우 추가\n\n검사 등의 원인 분석 방법을 미리 확립하고 이를 명시한다.\n\n 6) 선택한 비교평가 방법을 명시하고, 선택한 사유를 기술한다.\n\n 7) 2개 이상의 독립된 검사실에서 검사를 시행할 것을 권장한다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 64 -\n- 다.  결과제시\n1) 임상적 특이도 및 95% 신뢰구간을 제시한다. ",
        "original_sentence": "6) 선택한 비교평가 방법을 명시하고, 선택한 사유를 기술한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_628",
      "text": "7) 2개 이상의 독립된 검사실에서 검사를 시행할 것을 권장한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 627,
        "window_size": 3,
        "char_count": 38,
        "word_count": 9,
        "page_number": 69,
        "window_text": "시험물질\n1) 진단의 목표가 되는 질환이 없음이 확인된 임상검체를 이용하여\n\n2) 검체는 적용하고자 하는 대상 인구집단을 반영하여야 한다(예 :\n\n※ 뇌나트륨이뇨펩티드(NT-proBNP, BNP)에 대한 목표 질환을\n\n1) 임상적 특이도란 질환이 없는 환자군에서 음성결과를 보이는\n\n2) 음성예측도와 양성예측도는 질환 유병률과 상관이 있으므로,\n\n3) 양성 결과를 보인 경우 임상소견 확인 및 확진 검사를 시행하여\n\n진양성 유무를 확인토록 한다.  진양성인 검체는 특이도 분석에서\n\n5) 평가 전에 결과 해석에 대한 알고리즘 및 불일치한 경우 추가\n\n검사 등의 원인 분석 방법을 미리 확립하고 이를 명시한다.\n\n 6) 선택한 비교평가 방법을 명시하고, 선택한 사유를 기술한다.\n\n 7) 2개 이상의 독립된 검사실에서 검사를 시행할 것을 권장한다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 64 -\n- 다.  결과제시\n1) 임상적 특이도 및 95% 신뢰구간을 제시한다.  임상적 특이도란\n\n질병이나 특정 상태가 아닌 대상군에서 검사 결과가 음성(판정\n\n2) 산출된 특이도의 95% 신뢰구간의 최하위값이 적합기준을 넘어서면\n\n3) 전체 결과, 특이 결과, 구별되는 소견이 있는 세부 집단별 결과\n\n4) 불일치한 검체에 대해 원인을 분석한 자료를 제출하고, 해석을\n\n<!-- PAGE_70 -->\n###### 3\n\n<!-- PAGE_70 -->\n###### 완제품의 품질관리 시험성적서 또는 시험에 관한 자료\n\n- 1. ",
        "original_sentence": "7) 2개 이상의 독립된 검사실에서 검사를 시행할 것을 권장한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_629",
      "text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 64 -\n- 다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 628,
        "window_size": 3,
        "char_count": 63,
        "word_count": 14,
        "page_number": 1,
        "window_text": "진양성인 검체는 특이도 분석에서\n\n5) 평가 전에 결과 해석에 대한 알고리즘 및 불일치한 경우 추가\n\n검사 등의 원인 분석 방법을 미리 확립하고 이를 명시한다.\n\n 6) 선택한 비교평가 방법을 명시하고, 선택한 사유를 기술한다.\n\n 7) 2개 이상의 독립된 검사실에서 검사를 시행할 것을 권장한다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 64 -\n- 다.  결과제시\n1) 임상적 특이도 및 95% 신뢰구간을 제시한다.  임상적 특이도란\n\n질병이나 특정 상태가 아닌 대상군에서 검사 결과가 음성(판정\n\n2) 산출된 특이도의 95% 신뢰구간의 최하위값이 적합기준을 넘어서면\n\n3) 전체 결과, 특이 결과, 구별되는 소견이 있는 세부 집단별 결과\n\n4) 불일치한 검체에 대해 원인을 분석한 자료를 제출하고, 해석을\n\n<!-- PAGE_70 -->\n###### 3\n\n<!-- PAGE_70 -->\n###### 완제품의 품질관리 시험성적서 또는 시험에 관한 자료\n\n- 1.  3배치 각 1회 이상 또는 1배치 3회 이상의 시험규격에 따른 시험성적서\n- 2. ",
        "original_sentence": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 64 -\n- 다. "
      }
    },
    {
      "chunk_id": "chunk_630",
      "text": "결과제시\n1) 임상적 특이도 및 95% 신뢰구간을 제시한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 629,
        "window_size": 3,
        "char_count": 34,
        "word_count": 8,
        "page_number": 21,
        "window_text": "6) 선택한 비교평가 방법을 명시하고, 선택한 사유를 기술한다.\n\n 7) 2개 이상의 독립된 검사실에서 검사를 시행할 것을 권장한다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 64 -\n- 다.  결과제시\n1) 임상적 특이도 및 95% 신뢰구간을 제시한다.  임상적 특이도란\n\n질병이나 특정 상태가 아닌 대상군에서 검사 결과가 음성(판정\n\n2) 산출된 특이도의 95% 신뢰구간의 최하위값이 적합기준을 넘어서면\n\n3) 전체 결과, 특이 결과, 구별되는 소견이 있는 세부 집단별 결과\n\n4) 불일치한 검체에 대해 원인을 분석한 자료를 제출하고, 해석을\n\n<!-- PAGE_70 -->\n###### 3\n\n<!-- PAGE_70 -->\n###### 완제품의 품질관리 시험성적서 또는 시험에 관한 자료\n\n- 1.  3배치 각 1회 이상 또는 1배치 3회 이상의 시험규격에 따른 시험성적서\n- 2.  시험규격 설정에 따른 시험 기준 및 방법에 관한 자료와 표준물질이\n사용된 경우, 이에 관한 자료를 제출한다(단, 표준물질에 관한 자료와\n\n- 3. ",
        "original_sentence": "결과제시\n1) 임상적 특이도 및 95% 신뢰구간을 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_631",
      "text": "임상적 특이도란\n\n질병이나 특정 상태가 아닌 대상군에서 검사 결과가 음성(판정\n\n2) 산출된 특이도의 95% 신뢰구간의 최하위값이 적합기준을 넘어서면\n\n3) 전체 결과, 특이 결과, 구별되는 소견이 있는 세부 집단별 결과\n\n4) 불일치한 검체에 대해 원인을 분석한 자료를 제출하고, 해석을\n\n<!-- PAGE_70 -->\n###### 3\n\n<!-- PAGE_70 -->\n###### 완제품의 품질관리 시험성적서 또는 시험에 관한 자료\n\n- 1. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 630,
        "window_size": 3,
        "char_count": 249,
        "word_count": 56,
        "page_number": 70,
        "window_text": "7) 2개 이상의 독립된 검사실에서 검사를 시행할 것을 권장한다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 64 -\n- 다.  결과제시\n1) 임상적 특이도 및 95% 신뢰구간을 제시한다.  임상적 특이도란\n\n질병이나 특정 상태가 아닌 대상군에서 검사 결과가 음성(판정\n\n2) 산출된 특이도의 95% 신뢰구간의 최하위값이 적합기준을 넘어서면\n\n3) 전체 결과, 특이 결과, 구별되는 소견이 있는 세부 집단별 결과\n\n4) 불일치한 검체에 대해 원인을 분석한 자료를 제출하고, 해석을\n\n<!-- PAGE_70 -->\n###### 3\n\n<!-- PAGE_70 -->\n###### 완제품의 품질관리 시험성적서 또는 시험에 관한 자료\n\n- 1.  3배치 각 1회 이상 또는 1배치 3회 이상의 시험규격에 따른 시험성적서\n- 2.  시험규격 설정에 따른 시험 기준 및 방법에 관한 자료와 표준물질이\n사용된 경우, 이에 관한 자료를 제출한다(단, 표준물질에 관한 자료와\n\n- 3.  시험 항목은 품질의 동등성을 입증할 수 있는 항목(민감도, 특이도,\n정밀도 등)을 설정한다.\n\n",
        "original_sentence": "임상적 특이도란\n\n질병이나 특정 상태가 아닌 대상군에서 검사 결과가 음성(판정\n\n2) 산출된 특이도의 95% 신뢰구간의 최하위값이 적합기준을 넘어서면\n\n3) 전체 결과, 특이 결과, 구별되는 소견이 있는 세부 집단별 결과\n\n4) 불일치한 검체에 대해 원인을 분석한 자료를 제출하고, 해석을\n\n<!-- PAGE_70 -->\n###### 3\n\n<!-- PAGE_70 -->\n###### 완제품의 품질관리 시험성적서 또는 시험에 관한 자료\n\n- 1. "
      }
    },
    {
      "chunk_id": "chunk_632",
      "text": "3배치 각 1회 이상 또는 1배치 3회 이상의 시험규격에 따른 시험성적서\n- 2. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 631,
        "window_size": 3,
        "char_count": 46,
        "word_count": 13,
        "page_number": 6,
        "window_text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 64 -\n- 다.  결과제시\n1) 임상적 특이도 및 95% 신뢰구간을 제시한다.  임상적 특이도란\n\n질병이나 특정 상태가 아닌 대상군에서 검사 결과가 음성(판정\n\n2) 산출된 특이도의 95% 신뢰구간의 최하위값이 적합기준을 넘어서면\n\n3) 전체 결과, 특이 결과, 구별되는 소견이 있는 세부 집단별 결과\n\n4) 불일치한 검체에 대해 원인을 분석한 자료를 제출하고, 해석을\n\n<!-- PAGE_70 -->\n###### 3\n\n<!-- PAGE_70 -->\n###### 완제품의 품질관리 시험성적서 또는 시험에 관한 자료\n\n- 1.  3배치 각 1회 이상 또는 1배치 3회 이상의 시험규격에 따른 시험성적서\n- 2.  시험규격 설정에 따른 시험 기준 및 방법에 관한 자료와 표준물질이\n사용된 경우, 이에 관한 자료를 제출한다(단, 표준물질에 관한 자료와\n\n- 3.  시험 항목은 품질의 동등성을 입증할 수 있는 항목(민감도, 특이도,\n정밀도 등)을 설정한다.\n\n Ⅶ. ",
        "original_sentence": "3배치 각 1회 이상 또는 1배치 3회 이상의 시험규격에 따른 시험성적서\n- 2. "
      }
    },
    {
      "chunk_id": "chunk_633",
      "text": "시험규격 설정에 따른 시험 기준 및 방법에 관한 자료와 표준물질이\n사용된 경우, 이에 관한 자료를 제출한다(단, 표준물질에 관한 자료와\n\n- 3. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 632,
        "window_size": 3,
        "char_count": 82,
        "word_count": 21,
        "page_number": 7,
        "window_text": "결과제시\n1) 임상적 특이도 및 95% 신뢰구간을 제시한다.  임상적 특이도란\n\n질병이나 특정 상태가 아닌 대상군에서 검사 결과가 음성(판정\n\n2) 산출된 특이도의 95% 신뢰구간의 최하위값이 적합기준을 넘어서면\n\n3) 전체 결과, 특이 결과, 구별되는 소견이 있는 세부 집단별 결과\n\n4) 불일치한 검체에 대해 원인을 분석한 자료를 제출하고, 해석을\n\n<!-- PAGE_70 -->\n###### 3\n\n<!-- PAGE_70 -->\n###### 완제품의 품질관리 시험성적서 또는 시험에 관한 자료\n\n- 1.  3배치 각 1회 이상 또는 1배치 3회 이상의 시험규격에 따른 시험성적서\n- 2.  시험규격 설정에 따른 시험 기준 및 방법에 관한 자료와 표준물질이\n사용된 경우, 이에 관한 자료를 제출한다(단, 표준물질에 관한 자료와\n\n- 3.  시험 항목은 품질의 동등성을 입증할 수 있는 항목(민감도, 특이도,\n정밀도 등)을 설정한다.\n\n Ⅶ.  성능시험에 대한 상세사항\n\n- - 65 -\n<!-- PAGE_71 -->\n###### 4\n\n<!-- PAGE_71 -->\n###### 완제품 품질관리 시험에 사용된 표준물질에 관한 자료\n\n- 1. ",
        "original_sentence": "시험규격 설정에 따른 시험 기준 및 방법에 관한 자료와 표준물질이\n사용된 경우, 이에 관한 자료를 제출한다(단, 표준물질에 관한 자료와\n\n- 3. "
      }
    },
    {
      "chunk_id": "chunk_634",
      "text": "시험 항목은 품질의 동등성을 입증할 수 있는 항목(민감도, 특이도,\n정밀도 등)을 설정한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 633,
        "window_size": 3,
        "char_count": 53,
        "word_count": 12,
        "page_number": 3,
        "window_text": "임상적 특이도란\n\n질병이나 특정 상태가 아닌 대상군에서 검사 결과가 음성(판정\n\n2) 산출된 특이도의 95% 신뢰구간의 최하위값이 적합기준을 넘어서면\n\n3) 전체 결과, 특이 결과, 구별되는 소견이 있는 세부 집단별 결과\n\n4) 불일치한 검체에 대해 원인을 분석한 자료를 제출하고, 해석을\n\n<!-- PAGE_70 -->\n###### 3\n\n<!-- PAGE_70 -->\n###### 완제품의 품질관리 시험성적서 또는 시험에 관한 자료\n\n- 1.  3배치 각 1회 이상 또는 1배치 3회 이상의 시험규격에 따른 시험성적서\n- 2.  시험규격 설정에 따른 시험 기준 및 방법에 관한 자료와 표준물질이\n사용된 경우, 이에 관한 자료를 제출한다(단, 표준물질에 관한 자료와\n\n- 3.  시험 항목은 품질의 동등성을 입증할 수 있는 항목(민감도, 특이도,\n정밀도 등)을 설정한다.\n\n Ⅶ.  성능시험에 대한 상세사항\n\n- - 65 -\n<!-- PAGE_71 -->\n###### 4\n\n<!-- PAGE_71 -->\n###### 완제품 품질관리 시험에 사용된 표준물질에 관한 자료\n\n- 1.  표준물질 혹은 타사 표준물질을 구매하여 사용한 경우, 아래의 자료를\n- 2. ",
        "original_sentence": "시험 항목은 품질의 동등성을 입증할 수 있는 항목(민감도, 특이도,\n정밀도 등)을 설정한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_635",
      "text": "Ⅶ. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 634,
        "window_size": 3,
        "char_count": 3,
        "word_count": 1,
        "page_number": 7,
        "window_text": "3배치 각 1회 이상 또는 1배치 3회 이상의 시험규격에 따른 시험성적서\n- 2.  시험규격 설정에 따른 시험 기준 및 방법에 관한 자료와 표준물질이\n사용된 경우, 이에 관한 자료를 제출한다(단, 표준물질에 관한 자료와\n\n- 3.  시험 항목은 품질의 동등성을 입증할 수 있는 항목(민감도, 특이도,\n정밀도 등)을 설정한다.\n\n Ⅶ.  성능시험에 대한 상세사항\n\n- - 65 -\n<!-- PAGE_71 -->\n###### 4\n\n<!-- PAGE_71 -->\n###### 완제품 품질관리 시험에 사용된 표준물질에 관한 자료\n\n- 1.  표준물질 혹은 타사 표준물질을 구매하여 사용한 경우, 아래의 자료를\n- 2.  자사 표준물질을 제작하여 사용할 경우, 다음의 자료를 제출한다.\n",
        "original_sentence": "Ⅶ. "
      }
    },
    {
      "chunk_id": "chunk_636",
      "text": "성능시험에 대한 상세사항\n\n- - 65 -\n<!-- PAGE_71 -->\n###### 4\n\n<!-- PAGE_71 -->\n###### 완제품 품질관리 시험에 사용된 표준물질에 관한 자료\n\n- 1. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 635,
        "window_size": 3,
        "char_count": 110,
        "word_count": 25,
        "page_number": 71,
        "window_text": "시험규격 설정에 따른 시험 기준 및 방법에 관한 자료와 표준물질이\n사용된 경우, 이에 관한 자료를 제출한다(단, 표준물질에 관한 자료와\n\n- 3.  시험 항목은 품질의 동등성을 입증할 수 있는 항목(민감도, 특이도,\n정밀도 등)을 설정한다.\n\n Ⅶ.  성능시험에 대한 상세사항\n\n- - 65 -\n<!-- PAGE_71 -->\n###### 4\n\n<!-- PAGE_71 -->\n###### 완제품 품질관리 시험에 사용된 표준물질에 관한 자료\n\n- 1.  표준물질 혹은 타사 표준물질을 구매하여 사용한 경우, 아래의 자료를\n- 2.  자사 표준물질을 제작하여 사용할 경우, 다음의 자료를 제출한다.\n - 가. ",
        "original_sentence": "성능시험에 대한 상세사항\n\n- - 65 -\n<!-- PAGE_71 -->\n###### 4\n\n<!-- PAGE_71 -->\n###### 완제품 품질관리 시험에 사용된 표준물질에 관한 자료\n\n- 1. "
      }
    },
    {
      "chunk_id": "chunk_637",
      "text": "표준물질 혹은 타사 표준물질을 구매하여 사용한 경우, 아래의 자료를\n- 2. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 636,
        "window_size": 3,
        "char_count": 43,
        "word_count": 11,
        "page_number": 6,
        "window_text": "시험 항목은 품질의 동등성을 입증할 수 있는 항목(민감도, 특이도,\n정밀도 등)을 설정한다.\n\n Ⅶ.  성능시험에 대한 상세사항\n\n- - 65 -\n<!-- PAGE_71 -->\n###### 4\n\n<!-- PAGE_71 -->\n###### 완제품 품질관리 시험에 사용된 표준물질에 관한 자료\n\n- 1.  표준물질 혹은 타사 표준물질을 구매하여 사용한 경우, 아래의 자료를\n- 2.  자사 표준물질을 제작하여 사용할 경우, 다음의 자료를 제출한다.\n - 가.  표준물질의 농도별 설정 기준을 입증할 수 있는 시험 자료 및 결과\n- 1. ",
        "original_sentence": "표준물질 혹은 타사 표준물질을 구매하여 사용한 경우, 아래의 자료를\n- 2. "
      }
    },
    {
      "chunk_id": "chunk_638",
      "text": "자사 표준물질을 제작하여 사용할 경우, 다음의 자료를 제출한다.\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 637,
        "window_size": 3,
        "char_count": 36,
        "word_count": 8,
        "page_number": 32,
        "window_text": "Ⅶ.  성능시험에 대한 상세사항\n\n- - 65 -\n<!-- PAGE_71 -->\n###### 4\n\n<!-- PAGE_71 -->\n###### 완제품 품질관리 시험에 사용된 표준물질에 관한 자료\n\n- 1.  표준물질 혹은 타사 표준물질을 구매하여 사용한 경우, 아래의 자료를\n- 2.  자사 표준물질을 제작하여 사용할 경우, 다음의 자료를 제출한다.\n - 가.  표준물질의 농도별 설정 기준을 입증할 수 있는 시험 자료 및 결과\n- 1.  시험결과를 근거로 하여, 검사에 이용할 수 있는 검체의 취급방법,\n보관조건 및 방법, 사용기간, 주의사항 등에 대하여 기재한다. ",
        "original_sentence": "자사 표준물질을 제작하여 사용할 경우, 다음의 자료를 제출한다.\n"
      }
    },
    {
      "chunk_id": "chunk_639",
      "text": "- 가. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 638,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 74,
        "window_text": "성능시험에 대한 상세사항\n\n- - 65 -\n<!-- PAGE_71 -->\n###### 4\n\n<!-- PAGE_71 -->\n###### 완제품 품질관리 시험에 사용된 표준물질에 관한 자료\n\n- 1.  표준물질 혹은 타사 표준물질을 구매하여 사용한 경우, 아래의 자료를\n- 2.  자사 표준물질을 제작하여 사용할 경우, 다음의 자료를 제출한다.\n - 가.  표준물질의 농도별 설정 기준을 입증할 수 있는 시험 자료 및 결과\n- 1.  시험결과를 근거로 하여, 검사에 이용할 수 있는 검체의 취급방법,\n보관조건 및 방법, 사용기간, 주의사항 등에 대하여 기재한다.  이는\n\n원심분리 조건 등을 포함한 검체 전처리과정 및 냉동 및 해동된\n\n- 2. ",
        "original_sentence": "- 가. "
      }
    },
    {
      "chunk_id": "chunk_640",
      "text": "표준물질의 농도별 설정 기준을 입증할 수 있는 시험 자료 및 결과\n- 1. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 639,
        "window_size": 3,
        "char_count": 42,
        "word_count": 13,
        "page_number": 21,
        "window_text": "표준물질 혹은 타사 표준물질을 구매하여 사용한 경우, 아래의 자료를\n- 2.  자사 표준물질을 제작하여 사용할 경우, 다음의 자료를 제출한다.\n - 가.  표준물질의 농도별 설정 기준을 입증할 수 있는 시험 자료 및 결과\n- 1.  시험결과를 근거로 하여, 검사에 이용할 수 있는 검체의 취급방법,\n보관조건 및 방법, 사용기간, 주의사항 등에 대하여 기재한다.  이는\n\n원심분리 조건 등을 포함한 검체 전처리과정 및 냉동 및 해동된\n\n- 2.  검체 취급 및 보관조건에 대한 시험 결과를 제시한다. ",
        "original_sentence": "표준물질의 농도별 설정 기준을 입증할 수 있는 시험 자료 및 결과\n- 1. "
      }
    },
    {
      "chunk_id": "chunk_641",
      "text": "시험결과를 근거로 하여, 검사에 이용할 수 있는 검체의 취급방법,\n보관조건 및 방법, 사용기간, 주의사항 등에 대하여 기재한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 640,
        "window_size": 3,
        "char_count": 72,
        "word_count": 17,
        "page_number": 33,
        "window_text": "자사 표준물질을 제작하여 사용할 경우, 다음의 자료를 제출한다.\n - 가.  표준물질의 농도별 설정 기준을 입증할 수 있는 시험 자료 및 결과\n- 1.  시험결과를 근거로 하여, 검사에 이용할 수 있는 검체의 취급방법,\n보관조건 및 방법, 사용기간, 주의사항 등에 대하여 기재한다.  이는\n\n원심분리 조건 등을 포함한 검체 전처리과정 및 냉동 및 해동된\n\n- 2.  검체 취급 및 보관조건에 대한 시험 결과를 제시한다.  이는 제시된 시간,\n온도, 습도 등의 항목에 대해 유효하다고 제시된 구간 중 몇 단계에\n\n대해 동일한 검사 결과를 보임을 입증해야 한다. ",
        "original_sentence": "시험결과를 근거로 하여, 검사에 이용할 수 있는 검체의 취급방법,\n보관조건 및 방법, 사용기간, 주의사항 등에 대하여 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_642",
      "text": "이는\n\n원심분리 조건 등을 포함한 검체 전처리과정 및 냉동 및 해동된\n\n- 2. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 641,
        "window_size": 3,
        "char_count": 45,
        "word_count": 13,
        "page_number": 6,
        "window_text": "- 가.  표준물질의 농도별 설정 기준을 입증할 수 있는 시험 자료 및 결과\n- 1.  시험결과를 근거로 하여, 검사에 이용할 수 있는 검체의 취급방법,\n보관조건 및 방법, 사용기간, 주의사항 등에 대하여 기재한다.  이는\n\n원심분리 조건 등을 포함한 검체 전처리과정 및 냉동 및 해동된\n\n- 2.  검체 취급 및 보관조건에 대한 시험 결과를 제시한다.  이는 제시된 시간,\n온도, 습도 등의 항목에 대해 유효하다고 제시된 구간 중 몇 단계에\n\n대해 동일한 검사 결과를 보임을 입증해야 한다.  이 시험은 제시된\n\n구간의 양측 한계치 이상에서 평가된 결과여야 하며, 조건 변화에 따른\n\n결과의 변화를 제시하고 평가에 사용된 만족기준을 함께 기록한다.\n\n",
        "original_sentence": "이는\n\n원심분리 조건 등을 포함한 검체 전처리과정 및 냉동 및 해동된\n\n- 2. "
      }
    },
    {
      "chunk_id": "chunk_643",
      "text": "검체 취급 및 보관조건에 대한 시험 결과를 제시한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 642,
        "window_size": 3,
        "char_count": 30,
        "word_count": 8,
        "page_number": 26,
        "window_text": "표준물질의 농도별 설정 기준을 입증할 수 있는 시험 자료 및 결과\n- 1.  시험결과를 근거로 하여, 검사에 이용할 수 있는 검체의 취급방법,\n보관조건 및 방법, 사용기간, 주의사항 등에 대하여 기재한다.  이는\n\n원심분리 조건 등을 포함한 검체 전처리과정 및 냉동 및 해동된\n\n- 2.  검체 취급 및 보관조건에 대한 시험 결과를 제시한다.  이는 제시된 시간,\n온도, 습도 등의 항목에 대해 유효하다고 제시된 구간 중 몇 단계에\n\n대해 동일한 검사 결과를 보임을 입증해야 한다.  이 시험은 제시된\n\n구간의 양측 한계치 이상에서 평가된 결과여야 하며, 조건 변화에 따른\n\n결과의 변화를 제시하고 평가에 사용된 만족기준을 함께 기록한다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 66 -\n- 3. ",
        "original_sentence": "검체 취급 및 보관조건에 대한 시험 결과를 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_644",
      "text": "이는 제시된 시간,\n온도, 습도 등의 항목에 대해 유효하다고 제시된 구간 중 몇 단계에\n\n대해 동일한 검사 결과를 보임을 입증해야 한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 643,
        "window_size": 3,
        "char_count": 77,
        "word_count": 21,
        "page_number": 3,
        "window_text": "시험결과를 근거로 하여, 검사에 이용할 수 있는 검체의 취급방법,\n보관조건 및 방법, 사용기간, 주의사항 등에 대하여 기재한다.  이는\n\n원심분리 조건 등을 포함한 검체 전처리과정 및 냉동 및 해동된\n\n- 2.  검체 취급 및 보관조건에 대한 시험 결과를 제시한다.  이는 제시된 시간,\n온도, 습도 등의 항목에 대해 유효하다고 제시된 구간 중 몇 단계에\n\n대해 동일한 검사 결과를 보임을 입증해야 한다.  이 시험은 제시된\n\n구간의 양측 한계치 이상에서 평가된 결과여야 하며, 조건 변화에 따른\n\n결과의 변화를 제시하고 평가에 사용된 만족기준을 함께 기록한다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 66 -\n- 3.  시험에 사용된 방법, 검체 수, 검체 범위, 표준 농도, 계산법, 통계처리법,\n허용기준, 결과 등을 요약하여 제시한다.\n\n",
        "original_sentence": "이는 제시된 시간,\n온도, 습도 등의 항목에 대해 유효하다고 제시된 구간 중 몇 단계에\n\n대해 동일한 검사 결과를 보임을 입증해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_645",
      "text": "이 시험은 제시된\n\n구간의 양측 한계치 이상에서 평가된 결과여야 하며, 조건 변화에 따른\n\n결과의 변화를 제시하고 평가에 사용된 만족기준을 함께 기록한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 644,
        "window_size": 3,
        "char_count": 88,
        "word_count": 21,
        "page_number": 33,
        "window_text": "이는\n\n원심분리 조건 등을 포함한 검체 전처리과정 및 냉동 및 해동된\n\n- 2.  검체 취급 및 보관조건에 대한 시험 결과를 제시한다.  이는 제시된 시간,\n온도, 습도 등의 항목에 대해 유효하다고 제시된 구간 중 몇 단계에\n\n대해 동일한 검사 결과를 보임을 입증해야 한다.  이 시험은 제시된\n\n구간의 양측 한계치 이상에서 평가된 결과여야 하며, 조건 변화에 따른\n\n결과의 변화를 제시하고 평가에 사용된 만족기준을 함께 기록한다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 66 -\n- 3.  시험에 사용된 방법, 검체 수, 검체 범위, 표준 농도, 계산법, 통계처리법,\n허용기준, 결과 등을 요약하여 제시한다.\n\n - 1. ",
        "original_sentence": "이 시험은 제시된\n\n구간의 양측 한계치 이상에서 평가된 결과여야 하며, 조건 변화에 따른\n\n결과의 변화를 제시하고 평가에 사용된 만족기준을 함께 기록한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_646",
      "text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 66 -\n- 3. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 645,
        "window_size": 3,
        "char_count": 63,
        "word_count": 14,
        "page_number": 1,
        "window_text": "검체 취급 및 보관조건에 대한 시험 결과를 제시한다.  이는 제시된 시간,\n온도, 습도 등의 항목에 대해 유효하다고 제시된 구간 중 몇 단계에\n\n대해 동일한 검사 결과를 보임을 입증해야 한다.  이 시험은 제시된\n\n구간의 양측 한계치 이상에서 평가된 결과여야 하며, 조건 변화에 따른\n\n결과의 변화를 제시하고 평가에 사용된 만족기준을 함께 기록한다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 66 -\n- 3.  시험에 사용된 방법, 검체 수, 검체 범위, 표준 농도, 계산법, 통계처리법,\n허용기준, 결과 등을 요약하여 제시한다.\n\n - 1.  일반사항\n- 가. ",
        "original_sentence": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 66 -\n- 3. "
      }
    },
    {
      "chunk_id": "chunk_647",
      "text": "시험에 사용된 방법, 검체 수, 검체 범위, 표준 농도, 계산법, 통계처리법,\n허용기준, 결과 등을 요약하여 제시한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 646,
        "window_size": 3,
        "char_count": 68,
        "word_count": 16,
        "page_number": 33,
        "window_text": "이는 제시된 시간,\n온도, 습도 등의 항목에 대해 유효하다고 제시된 구간 중 몇 단계에\n\n대해 동일한 검사 결과를 보임을 입증해야 한다.  이 시험은 제시된\n\n구간의 양측 한계치 이상에서 평가된 결과여야 하며, 조건 변화에 따른\n\n결과의 변화를 제시하고 평가에 사용된 만족기준을 함께 기록한다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 66 -\n- 3.  시험에 사용된 방법, 검체 수, 검체 범위, 표준 농도, 계산법, 통계처리법,\n허용기준, 결과 등을 요약하여 제시한다.\n\n - 1.  일반사항\n- 가.  국내‧외 허가된 체외진단용 의료기기와의 상관성을 확인할 수 있는\n비교시험 성적서를 포함하여야 한다. ",
        "original_sentence": "시험에 사용된 방법, 검체 수, 검체 범위, 표준 농도, 계산법, 통계처리법,\n허용기준, 결과 등을 요약하여 제시한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_648",
      "text": "- 1. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 647,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 21,
        "window_text": "이 시험은 제시된\n\n구간의 양측 한계치 이상에서 평가된 결과여야 하며, 조건 변화에 따른\n\n결과의 변화를 제시하고 평가에 사용된 만족기준을 함께 기록한다.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 66 -\n- 3.  시험에 사용된 방법, 검체 수, 검체 범위, 표준 농도, 계산법, 통계처리법,\n허용기준, 결과 등을 요약하여 제시한다.\n\n - 1.  일반사항\n- 가.  국내‧외 허가된 체외진단용 의료기기와의 상관성을 확인할 수 있는\n비교시험 성적서를 포함하여야 한다.  다만, 측정원리 및 측정항목이\n\n- 나. ",
        "original_sentence": "- 1. "
      }
    },
    {
      "chunk_id": "chunk_649",
      "text": "일반사항\n- 가. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 648,
        "window_size": 3,
        "char_count": 10,
        "word_count": 3,
        "page_number": 3,
        "window_text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 66 -\n- 3.  시험에 사용된 방법, 검체 수, 검체 범위, 표준 농도, 계산법, 통계처리법,\n허용기준, 결과 등을 요약하여 제시한다.\n\n - 1.  일반사항\n- 가.  국내‧외 허가된 체외진단용 의료기기와의 상관성을 확인할 수 있는\n비교시험 성적서를 포함하여야 한다.  다만, 측정원리 및 측정항목이\n\n- 나.  임상적 민감도와 임상적 특이도를 산출하기 위해 시행한 검사에서\n기존검사법(기허가 제품)을 병행하여 검사하였을 경우, 도출된\n\n두 검사 결과를 정리하여 상관성의 자료로 제시할 수 있다. ",
        "original_sentence": "일반사항\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_650",
      "text": "국내‧외 허가된 체외진단용 의료기기와의 상관성을 확인할 수 있는\n비교시험 성적서를 포함하여야 한다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 649,
        "window_size": 3,
        "char_count": 56,
        "word_count": 12,
        "page_number": 1,
        "window_text": "시험에 사용된 방법, 검체 수, 검체 범위, 표준 농도, 계산법, 통계처리법,\n허용기준, 결과 등을 요약하여 제시한다.\n\n - 1.  일반사항\n- 가.  국내‧외 허가된 체외진단용 의료기기와의 상관성을 확인할 수 있는\n비교시험 성적서를 포함하여야 한다.  다만, 측정원리 및 측정항목이\n\n- 나.  임상적 민감도와 임상적 특이도를 산출하기 위해 시행한 검사에서\n기존검사법(기허가 제품)을 병행하여 검사하였을 경우, 도출된\n\n두 검사 결과를 정리하여 상관성의 자료로 제시할 수 있다.  분석적\n\n성능시험 과정에서 기존검사법과의 비교 자료가 있을 경우에도\n\n- 2. ",
        "original_sentence": "국내‧외 허가된 체외진단용 의료기기와의 상관성을 확인할 수 있는\n비교시험 성적서를 포함하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_651",
      "text": "다만, 측정원리 및 측정항목이\n\n- 나. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 650,
        "window_size": 3,
        "char_count": 23,
        "word_count": 6,
        "page_number": 3,
        "window_text": "- 1.  일반사항\n- 가.  국내‧외 허가된 체외진단용 의료기기와의 상관성을 확인할 수 있는\n비교시험 성적서를 포함하여야 한다.  다만, 측정원리 및 측정항목이\n\n- 나.  임상적 민감도와 임상적 특이도를 산출하기 위해 시행한 검사에서\n기존검사법(기허가 제품)을 병행하여 검사하였을 경우, 도출된\n\n두 검사 결과를 정리하여 상관성의 자료로 제시할 수 있다.  분석적\n\n성능시험 과정에서 기존검사법과의 비교 자료가 있을 경우에도\n\n- 2.  시험물질\n- 가. ",
        "original_sentence": "다만, 측정원리 및 측정항목이\n\n- 나. "
      }
    },
    {
      "chunk_id": "chunk_652",
      "text": "임상적 민감도와 임상적 특이도를 산출하기 위해 시행한 검사에서\n기존검사법(기허가 제품)을 병행하여 검사하였을 경우, 도출된\n\n두 검사 결과를 정리하여 상관성의 자료로 제시할 수 있다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 651,
        "window_size": 3,
        "char_count": 103,
        "word_count": 23,
        "page_number": 14,
        "window_text": "일반사항\n- 가.  국내‧외 허가된 체외진단용 의료기기와의 상관성을 확인할 수 있는\n비교시험 성적서를 포함하여야 한다.  다만, 측정원리 및 측정항목이\n\n- 나.  임상적 민감도와 임상적 특이도를 산출하기 위해 시행한 검사에서\n기존검사법(기허가 제품)을 병행하여 검사하였을 경우, 도출된\n\n두 검사 결과를 정리하여 상관성의 자료로 제시할 수 있다.  분석적\n\n성능시험 과정에서 기존검사법과의 비교 자료가 있을 경우에도\n\n- 2.  시험물질\n- 가.  통계적으로 해석 가능한 수의 임상검체를 포함하여 비교시험을\n- 나. ",
        "original_sentence": "임상적 민감도와 임상적 특이도를 산출하기 위해 시행한 검사에서\n기존검사법(기허가 제품)을 병행하여 검사하였을 경우, 도출된\n\n두 검사 결과를 정리하여 상관성의 자료로 제시할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_653",
      "text": "분석적\n\n성능시험 과정에서 기존검사법과의 비교 자료가 있을 경우에도\n\n- 2. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 652,
        "window_size": 3,
        "char_count": 44,
        "word_count": 10,
        "page_number": 6,
        "window_text": "국내‧외 허가된 체외진단용 의료기기와의 상관성을 확인할 수 있는\n비교시험 성적서를 포함하여야 한다.  다만, 측정원리 및 측정항목이\n\n- 나.  임상적 민감도와 임상적 특이도를 산출하기 위해 시행한 검사에서\n기존검사법(기허가 제품)을 병행하여 검사하였을 경우, 도출된\n\n두 검사 결과를 정리하여 상관성의 자료로 제시할 수 있다.  분석적\n\n성능시험 과정에서 기존검사법과의 비교 자료가 있을 경우에도\n\n- 2.  시험물질\n- 가.  통계적으로 해석 가능한 수의 임상검체를 포함하여 비교시험을\n- 나.  임상검체는 기 허가된 방법이거나 여타 검증된 방법으로 검사되어\n- 다. ",
        "original_sentence": "분석적\n\n성능시험 과정에서 기존검사법과의 비교 자료가 있을 경우에도\n\n- 2. "
      }
    },
    {
      "chunk_id": "chunk_654",
      "text": "시험물질\n- 가. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 653,
        "window_size": 3,
        "char_count": 10,
        "word_count": 3,
        "page_number": 32,
        "window_text": "다만, 측정원리 및 측정항목이\n\n- 나.  임상적 민감도와 임상적 특이도를 산출하기 위해 시행한 검사에서\n기존검사법(기허가 제품)을 병행하여 검사하였을 경우, 도출된\n\n두 검사 결과를 정리하여 상관성의 자료로 제시할 수 있다.  분석적\n\n성능시험 과정에서 기존검사법과의 비교 자료가 있을 경우에도\n\n- 2.  시험물질\n- 가.  통계적으로 해석 가능한 수의 임상검체를 포함하여 비교시험을\n- 나.  임상검체는 기 허가된 방법이거나 여타 검증된 방법으로 검사되어\n- 다.  다양한 임상상을 포함하는 검체를 포함하여 비교하도록 한다.\n",
        "original_sentence": "시험물질\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_655",
      "text": "통계적으로 해석 가능한 수의 임상검체를 포함하여 비교시험을\n- 나. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 654,
        "window_size": 3,
        "char_count": 38,
        "word_count": 9,
        "page_number": 33,
        "window_text": "임상적 민감도와 임상적 특이도를 산출하기 위해 시행한 검사에서\n기존검사법(기허가 제품)을 병행하여 검사하였을 경우, 도출된\n\n두 검사 결과를 정리하여 상관성의 자료로 제시할 수 있다.  분석적\n\n성능시험 과정에서 기존검사법과의 비교 자료가 있을 경우에도\n\n- 2.  시험물질\n- 가.  통계적으로 해석 가능한 수의 임상검체를 포함하여 비교시험을\n- 나.  임상검체는 기 허가된 방법이거나 여타 검증된 방법으로 검사되어\n- 다.  다양한 임상상을 포함하는 검체를 포함하여 비교하도록 한다.\n - 라. ",
        "original_sentence": "통계적으로 해석 가능한 수의 임상검체를 포함하여 비교시험을\n- 나. "
      }
    },
    {
      "chunk_id": "chunk_656",
      "text": "임상검체는 기 허가된 방법이거나 여타 검증된 방법으로 검사되어\n- 다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 655,
        "window_size": 3,
        "char_count": 40,
        "word_count": 10,
        "page_number": 33,
        "window_text": "분석적\n\n성능시험 과정에서 기존검사법과의 비교 자료가 있을 경우에도\n\n- 2.  시험물질\n- 가.  통계적으로 해석 가능한 수의 임상검체를 포함하여 비교시험을\n- 나.  임상검체는 기 허가된 방법이거나 여타 검증된 방법으로 검사되어\n- 다.  다양한 임상상을 포함하는 검체를 포함하여 비교하도록 한다.\n - 라.  정량검사의 임상검체는 측정범위 내의 다양한 농도가 포함되도록 하고,\n최소 100개 이상의 검체를 시험하도록 권장한다.\n\n",
        "original_sentence": "임상검체는 기 허가된 방법이거나 여타 검증된 방법으로 검사되어\n- 다. "
      }
    },
    {
      "chunk_id": "chunk_657",
      "text": "다양한 임상상을 포함하는 검체를 포함하여 비교하도록 한다.\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 656,
        "window_size": 3,
        "char_count": 33,
        "word_count": 7,
        "page_number": 33,
        "window_text": "시험물질\n- 가.  통계적으로 해석 가능한 수의 임상검체를 포함하여 비교시험을\n- 나.  임상검체는 기 허가된 방법이거나 여타 검증된 방법으로 검사되어\n- 다.  다양한 임상상을 포함하는 검체를 포함하여 비교하도록 한다.\n - 라.  정량검사의 임상검체는 측정범위 내의 다양한 농도가 포함되도록 하고,\n최소 100개 이상의 검체를 시험하도록 권장한다.\n\n Ⅶ. ",
        "original_sentence": "다양한 임상상을 포함하는 검체를 포함하여 비교하도록 한다.\n"
      }
    },
    {
      "chunk_id": "chunk_658",
      "text": "- 라. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 657,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 74,
        "window_text": "통계적으로 해석 가능한 수의 임상검체를 포함하여 비교시험을\n- 나.  임상검체는 기 허가된 방법이거나 여타 검증된 방법으로 검사되어\n- 다.  다양한 임상상을 포함하는 검체를 포함하여 비교하도록 한다.\n - 라.  정량검사의 임상검체는 측정범위 내의 다양한 농도가 포함되도록 하고,\n최소 100개 이상의 검체를 시험하도록 권장한다.\n\n Ⅶ.  성능시험에 대한 상세사항\n\n- - 67 -\n- 3. ",
        "original_sentence": "- 라. "
      }
    },
    {
      "chunk_id": "chunk_659",
      "text": "정량검사의 임상검체는 측정범위 내의 다양한 농도가 포함되도록 하고,\n최소 100개 이상의 검체를 시험하도록 권장한다.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 658,
        "window_size": 3,
        "char_count": 67,
        "word_count": 14,
        "page_number": 21,
        "window_text": "임상검체는 기 허가된 방법이거나 여타 검증된 방법으로 검사되어\n- 다.  다양한 임상상을 포함하는 검체를 포함하여 비교하도록 한다.\n - 라.  정량검사의 임상검체는 측정범위 내의 다양한 농도가 포함되도록 하고,\n최소 100개 이상의 검체를 시험하도록 권장한다.\n\n Ⅶ.  성능시험에 대한 상세사항\n\n- - 67 -\n- 3.  시험방법\n- 가. ",
        "original_sentence": "정량검사의 임상검체는 측정범위 내의 다양한 농도가 포함되도록 하고,\n최소 100개 이상의 검체를 시험하도록 권장한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_660",
      "text": "Ⅶ. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 659,
        "window_size": 3,
        "char_count": 3,
        "word_count": 1,
        "page_number": 7,
        "window_text": "다양한 임상상을 포함하는 검체를 포함하여 비교하도록 한다.\n - 라.  정량검사의 임상검체는 측정범위 내의 다양한 농도가 포함되도록 하고,\n최소 100개 이상의 검체를 시험하도록 권장한다.\n\n Ⅶ.  성능시험에 대한 상세사항\n\n- - 67 -\n- 3.  시험방법\n- 가.  해당 제품과 측정 원리 및 항목이 가장 유사한 국내 허가 제품 또는\n외국 허가 제품(국내 허가 제품이 없을 시)과의 비교시험을 실시\n\n- 마. ",
        "original_sentence": "Ⅶ. "
      }
    },
    {
      "chunk_id": "chunk_661",
      "text": "성능시험에 대한 상세사항\n\n- - 67 -\n- 3. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 660,
        "window_size": 3,
        "char_count": 29,
        "word_count": 9,
        "page_number": 3,
        "window_text": "- 라.  정량검사의 임상검체는 측정범위 내의 다양한 농도가 포함되도록 하고,\n최소 100개 이상의 검체를 시험하도록 권장한다.\n\n Ⅶ.  성능시험에 대한 상세사항\n\n- - 67 -\n- 3.  시험방법\n- 가.  해당 제품과 측정 원리 및 항목이 가장 유사한 국내 허가 제품 또는\n외국 허가 제품(국내 허가 제품이 없을 시)과의 비교시험을 실시\n\n- 마.  결과가 불일치하는 경우, 다른 검사를 통해 불일치의 원인을 분석하고\n- 4. ",
        "original_sentence": "성능시험에 대한 상세사항\n\n- - 67 -\n- 3. "
      }
    },
    {
      "chunk_id": "chunk_662",
      "text": "시험방법\n- 가. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 661,
        "window_size": 3,
        "char_count": 10,
        "word_count": 3,
        "page_number": 33,
        "window_text": "정량검사의 임상검체는 측정범위 내의 다양한 농도가 포함되도록 하고,\n최소 100개 이상의 검체를 시험하도록 권장한다.\n\n Ⅶ.  성능시험에 대한 상세사항\n\n- - 67 -\n- 3.  시험방법\n- 가.  해당 제품과 측정 원리 및 항목이 가장 유사한 국내 허가 제품 또는\n외국 허가 제품(국내 허가 제품이 없을 시)과의 비교시험을 실시\n\n- 마.  결과가 불일치하는 경우, 다른 검사를 통해 불일치의 원인을 분석하고\n- 4.  결과제시\n- 나. ",
        "original_sentence": "시험방법\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_663",
      "text": "해당 제품과 측정 원리 및 항목이 가장 유사한 국내 허가 제품 또는\n외국 허가 제품(국내 허가 제품이 없을 시)과의 비교시험을 실시\n\n- 마. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 662,
        "window_size": 3,
        "char_count": 80,
        "word_count": 23,
        "page_number": 3,
        "window_text": "Ⅶ.  성능시험에 대한 상세사항\n\n- - 67 -\n- 3.  시험방법\n- 가.  해당 제품과 측정 원리 및 항목이 가장 유사한 국내 허가 제품 또는\n외국 허가 제품(국내 허가 제품이 없을 시)과의 비교시험을 실시\n\n- 마.  결과가 불일치하는 경우, 다른 검사를 통해 불일치의 원인을 분석하고\n- 4.  결과제시\n- 나.  정량검사에 대해서는 기울기, 절편(신뢰구간과 함께), 상관계수 및\n- 다. ",
        "original_sentence": "해당 제품과 측정 원리 및 항목이 가장 유사한 국내 허가 제품 또는\n외국 허가 제품(국내 허가 제품이 없을 시)과의 비교시험을 실시\n\n- 마. "
      }
    },
    {
      "chunk_id": "chunk_664",
      "text": "결과가 불일치하는 경우, 다른 검사를 통해 불일치의 원인을 분석하고\n- 4. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 663,
        "window_size": 3,
        "char_count": 43,
        "word_count": 11,
        "page_number": 6,
        "window_text": "성능시험에 대한 상세사항\n\n- - 67 -\n- 3.  시험방법\n- 가.  해당 제품과 측정 원리 및 항목이 가장 유사한 국내 허가 제품 또는\n외국 허가 제품(국내 허가 제품이 없을 시)과의 비교시험을 실시\n\n- 마.  결과가 불일치하는 경우, 다른 검사를 통해 불일치의 원인을 분석하고\n- 4.  결과제시\n- 나.  정량검사에 대해서는 기울기, 절편(신뢰구간과 함께), 상관계수 및\n- 다.  판정기준치(cut-off value)를 적용한 정성적 검사결과(양성과 음성)에\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 68 -\n<!-- PAGE_74 -->\n# Ⅷ\n\n<!-- PAGE_74 -->\n### 참고문헌\n\n- 1. ",
        "original_sentence": "결과가 불일치하는 경우, 다른 검사를 통해 불일치의 원인을 분석하고\n- 4. "
      }
    },
    {
      "chunk_id": "chunk_665",
      "text": "결과제시\n- 나. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 664,
        "window_size": 3,
        "char_count": 10,
        "word_count": 3,
        "page_number": 74,
        "window_text": "시험방법\n- 가.  해당 제품과 측정 원리 및 항목이 가장 유사한 국내 허가 제품 또는\n외국 허가 제품(국내 허가 제품이 없을 시)과의 비교시험을 실시\n\n- 마.  결과가 불일치하는 경우, 다른 검사를 통해 불일치의 원인을 분석하고\n- 4.  결과제시\n- 나.  정량검사에 대해서는 기울기, 절편(신뢰구간과 함께), 상관계수 및\n- 다.  판정기준치(cut-off value)를 적용한 정성적 검사결과(양성과 음성)에\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 68 -\n<!-- PAGE_74 -->\n# Ⅷ\n\n<!-- PAGE_74 -->\n### 참고문헌\n\n- 1.  CLSI. ",
        "original_sentence": "결과제시\n- 나. "
      }
    },
    {
      "chunk_id": "chunk_666",
      "text": "정량검사에 대해서는 기울기, 절편(신뢰구간과 함께), 상관계수 및\n- 다. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 665,
        "window_size": 3,
        "char_count": 42,
        "word_count": 9,
        "page_number": 33,
        "window_text": "해당 제품과 측정 원리 및 항목이 가장 유사한 국내 허가 제품 또는\n외국 허가 제품(국내 허가 제품이 없을 시)과의 비교시험을 실시\n\n- 마.  결과가 불일치하는 경우, 다른 검사를 통해 불일치의 원인을 분석하고\n- 4.  결과제시\n- 나.  정량검사에 대해서는 기울기, 절편(신뢰구간과 함께), 상관계수 및\n- 다.  판정기준치(cut-off value)를 적용한 정성적 검사결과(양성과 음성)에\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 68 -\n<!-- PAGE_74 -->\n# Ⅷ\n\n<!-- PAGE_74 -->\n### 참고문헌\n\n- 1.  CLSI.  Evaluation of Stability of In Vitro Diagnostic Reagents;\nApproved Guideline. ",
        "original_sentence": "정량검사에 대해서는 기울기, 절편(신뢰구간과 함께), 상관계수 및\n- 다. "
      }
    },
    {
      "chunk_id": "chunk_667",
      "text": "판정기준치(cut-off value)를 적용한 정성적 검사결과(양성과 음성)에\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 68 -\n<!-- PAGE_74 -->\n# Ⅷ\n\n<!-- PAGE_74 -->\n### 참고문헌\n\n- 1. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 666,
        "window_size": 3,
        "char_count": 156,
        "word_count": 30,
        "page_number": 74,
        "window_text": "결과가 불일치하는 경우, 다른 검사를 통해 불일치의 원인을 분석하고\n- 4.  결과제시\n- 나.  정량검사에 대해서는 기울기, 절편(신뢰구간과 함께), 상관계수 및\n- 다.  판정기준치(cut-off value)를 적용한 정성적 검사결과(양성과 음성)에\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 68 -\n<!-- PAGE_74 -->\n# Ⅷ\n\n<!-- PAGE_74 -->\n### 참고문헌\n\n- 1.  CLSI.  Evaluation of Stability of In Vitro Diagnostic Reagents;\nApproved Guideline.  CLSI document EP25-A. ",
        "original_sentence": "판정기준치(cut-off value)를 적용한 정성적 검사결과(양성과 음성)에\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 68 -\n<!-- PAGE_74 -->\n# Ⅷ\n\n<!-- PAGE_74 -->\n### 참고문헌\n\n- 1. "
      }
    },
    {
      "chunk_id": "chunk_668",
      "text": "CLSI. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 667,
        "window_size": 3,
        "char_count": 6,
        "word_count": 1,
        "page_number": 74,
        "window_text": "결과제시\n- 나.  정량검사에 대해서는 기울기, 절편(신뢰구간과 함께), 상관계수 및\n- 다.  판정기준치(cut-off value)를 적용한 정성적 검사결과(양성과 음성)에\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 68 -\n<!-- PAGE_74 -->\n# Ⅷ\n\n<!-- PAGE_74 -->\n### 참고문헌\n\n- 1.  CLSI.  Evaluation of Stability of In Vitro Diagnostic Reagents;\nApproved Guideline.  CLSI document EP25-A.  Wayne, PA: Cinical\n\n- 2.\n",
        "original_sentence": "CLSI. "
      }
    },
    {
      "chunk_id": "chunk_669",
      "text": "Evaluation of Stability of In Vitro Diagnostic Reagents;\nApproved Guideline. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 668,
        "window_size": 3,
        "char_count": 77,
        "word_count": 10,
        "page_number": 14,
        "window_text": "정량검사에 대해서는 기울기, 절편(신뢰구간과 함께), 상관계수 및\n- 다.  판정기준치(cut-off value)를 적용한 정성적 검사결과(양성과 음성)에\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 68 -\n<!-- PAGE_74 -->\n# Ⅷ\n\n<!-- PAGE_74 -->\n### 참고문헌\n\n- 1.  CLSI.  Evaluation of Stability of In Vitro Diagnostic Reagents;\nApproved Guideline.  CLSI document EP25-A.  Wayne, PA: Cinical\n\n- 2.\n CLSI.\n\n",
        "original_sentence": "Evaluation of Stability of In Vitro Diagnostic Reagents;\nApproved Guideline. "
      }
    },
    {
      "chunk_id": "chunk_670",
      "text": "CLSI document EP25-A. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 669,
        "window_size": 3,
        "char_count": 22,
        "word_count": 3,
        "page_number": 6,
        "window_text": "판정기준치(cut-off value)를 적용한 정성적 검사결과(양성과 음성)에\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 68 -\n<!-- PAGE_74 -->\n# Ⅷ\n\n<!-- PAGE_74 -->\n### 참고문헌\n\n- 1.  CLSI.  Evaluation of Stability of In Vitro Diagnostic Reagents;\nApproved Guideline.  CLSI document EP25-A.  Wayne, PA: Cinical\n\n- 2.\n CLSI.\n\n Evaluation\n\nof\n\nPrecision\n\nPerformance\n\nof\n\nQuantitative\n\nMeasurement Methods; Approved Guideline - Second Edition.\n\n",
        "original_sentence": "CLSI document EP25-A. "
      }
    },
    {
      "chunk_id": "chunk_671",
      "text": "Wayne, PA: Cinical\n\n- 2.\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 670,
        "window_size": 3,
        "char_count": 25,
        "word_count": 5,
        "page_number": 6,
        "window_text": "CLSI.  Evaluation of Stability of In Vitro Diagnostic Reagents;\nApproved Guideline.  CLSI document EP25-A.  Wayne, PA: Cinical\n\n- 2.\n CLSI.\n\n Evaluation\n\nof\n\nPrecision\n\nPerformance\n\nof\n\nQuantitative\n\nMeasurement Methods; Approved Guideline - Second Edition.\n\n CLSI document EP5-A2. ",
        "original_sentence": "Wayne, PA: Cinical\n\n- 2.\n"
      }
    },
    {
      "chunk_id": "chunk_672",
      "text": "CLSI.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 671,
        "window_size": 3,
        "char_count": 7,
        "word_count": 1,
        "page_number": 74,
        "window_text": "Evaluation of Stability of In Vitro Diagnostic Reagents;\nApproved Guideline.  CLSI document EP25-A.  Wayne, PA: Cinical\n\n- 2.\n CLSI.\n\n Evaluation\n\nof\n\nPrecision\n\nPerformance\n\nof\n\nQuantitative\n\nMeasurement Methods; Approved Guideline - Second Edition.\n\n CLSI document EP5-A2.  Wayne, PA: Cinical and Laboratory\n\n- 3.\n",
        "original_sentence": "CLSI.\n\n"
      }
    },
    {
      "chunk_id": "chunk_673",
      "text": "Evaluation\n\nof\n\nPrecision\n\nPerformance\n\nof\n\nQuantitative\n\nMeasurement Methods; Approved Guideline - Second Edition.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 672,
        "window_size": 3,
        "char_count": 117,
        "word_count": 13,
        "page_number": 14,
        "window_text": "CLSI document EP25-A.  Wayne, PA: Cinical\n\n- 2.\n CLSI.\n\n Evaluation\n\nof\n\nPrecision\n\nPerformance\n\nof\n\nQuantitative\n\nMeasurement Methods; Approved Guideline - Second Edition.\n\n CLSI document EP5-A2.  Wayne, PA: Cinical and Laboratory\n\n- 3.\n CLSI.\n\n",
        "original_sentence": "Evaluation\n\nof\n\nPrecision\n\nPerformance\n\nof\n\nQuantitative\n\nMeasurement Methods; Approved Guideline - Second Edition.\n\n"
      }
    },
    {
      "chunk_id": "chunk_674",
      "text": "CLSI document EP5-A2. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 673,
        "window_size": 3,
        "char_count": 22,
        "word_count": 3,
        "page_number": 6,
        "window_text": "Wayne, PA: Cinical\n\n- 2.\n CLSI.\n\n Evaluation\n\nof\n\nPrecision\n\nPerformance\n\nof\n\nQuantitative\n\nMeasurement Methods; Approved Guideline - Second Edition.\n\n CLSI document EP5-A2.  Wayne, PA: Cinical and Laboratory\n\n- 3.\n CLSI.\n\n User\n\nProtocol\n\nfor\n\nEvaluation\n\nof\n\nQualitative\n\nTest\n\nPerformance;\n\nApproved\n\nGuideline\n\n- -\nSecond\n\nEdition.\n\n",
        "original_sentence": "CLSI document EP5-A2. "
      }
    },
    {
      "chunk_id": "chunk_675",
      "text": "Wayne, PA: Cinical and Laboratory\n\n- 3.\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 674,
        "window_size": 3,
        "char_count": 40,
        "word_count": 7,
        "page_number": 14,
        "window_text": "CLSI.\n\n Evaluation\n\nof\n\nPrecision\n\nPerformance\n\nof\n\nQuantitative\n\nMeasurement Methods; Approved Guideline - Second Edition.\n\n CLSI document EP5-A2.  Wayne, PA: Cinical and Laboratory\n\n- 3.\n CLSI.\n\n User\n\nProtocol\n\nfor\n\nEvaluation\n\nof\n\nQualitative\n\nTest\n\nPerformance;\n\nApproved\n\nGuideline\n\n- -\nSecond\n\nEdition.\n\n CLSI\n\ndocument EP12-A2. ",
        "original_sentence": "Wayne, PA: Cinical and Laboratory\n\n- 3.\n"
      }
    },
    {
      "chunk_id": "chunk_676",
      "text": "CLSI.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 675,
        "window_size": 3,
        "char_count": 7,
        "word_count": 1,
        "page_number": 74,
        "window_text": "Evaluation\n\nof\n\nPrecision\n\nPerformance\n\nof\n\nQuantitative\n\nMeasurement Methods; Approved Guideline - Second Edition.\n\n CLSI document EP5-A2.  Wayne, PA: Cinical and Laboratory\n\n- 3.\n CLSI.\n\n User\n\nProtocol\n\nfor\n\nEvaluation\n\nof\n\nQualitative\n\nTest\n\nPerformance;\n\nApproved\n\nGuideline\n\n- -\nSecond\n\nEdition.\n\n CLSI\n\ndocument EP12-A2.  Wayne, PA: Cinical and Laboratory Standard\n\n- 4. ",
        "original_sentence": "CLSI.\n\n"
      }
    },
    {
      "chunk_id": "chunk_677",
      "text": "User\n\nProtocol\n\nfor\n\nEvaluation\n\nof\n\nQualitative\n\nTest\n\nPerformance;\n\nApproved\n\nGuideline\n\n- -\nSecond\n\nEdition.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 676,
        "window_size": 3,
        "char_count": 113,
        "word_count": 14,
        "page_number": 14,
        "window_text": "CLSI document EP5-A2.  Wayne, PA: Cinical and Laboratory\n\n- 3.\n CLSI.\n\n User\n\nProtocol\n\nfor\n\nEvaluation\n\nof\n\nQualitative\n\nTest\n\nPerformance;\n\nApproved\n\nGuideline\n\n- -\nSecond\n\nEdition.\n\n CLSI\n\ndocument EP12-A2.  Wayne, PA: Cinical and Laboratory Standard\n\n- 4.  CLSI. ",
        "original_sentence": "User\n\nProtocol\n\nfor\n\nEvaluation\n\nof\n\nQualitative\n\nTest\n\nPerformance;\n\nApproved\n\nGuideline\n\n- -\nSecond\n\nEdition.\n\n"
      }
    },
    {
      "chunk_id": "chunk_678",
      "text": "CLSI\n\ndocument EP12-A2. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 677,
        "window_size": 3,
        "char_count": 24,
        "word_count": 3,
        "page_number": 6,
        "window_text": "Wayne, PA: Cinical and Laboratory\n\n- 3.\n CLSI.\n\n User\n\nProtocol\n\nfor\n\nEvaluation\n\nof\n\nQualitative\n\nTest\n\nPerformance;\n\nApproved\n\nGuideline\n\n- -\nSecond\n\nEdition.\n\n CLSI\n\ndocument EP12-A2.  Wayne, PA: Cinical and Laboratory Standard\n\n- 4.  CLSI.  Protocols for Determination of Limits of Detection and\nLimits\n\nof Quantitation; Approved Guideline.\n\n",
        "original_sentence": "CLSI\n\ndocument EP12-A2. "
      }
    },
    {
      "chunk_id": "chunk_679",
      "text": "Wayne, PA: Cinical and Laboratory Standard\n\n- 4. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 678,
        "window_size": 3,
        "char_count": 49,
        "word_count": 8,
        "page_number": 6,
        "window_text": "CLSI.\n\n User\n\nProtocol\n\nfor\n\nEvaluation\n\nof\n\nQualitative\n\nTest\n\nPerformance;\n\nApproved\n\nGuideline\n\n- -\nSecond\n\nEdition.\n\n CLSI\n\ndocument EP12-A2.  Wayne, PA: Cinical and Laboratory Standard\n\n- 4.  CLSI.  Protocols for Determination of Limits of Detection and\nLimits\n\nof Quantitation; Approved Guideline.\n\n CLSI document\n\nEP17-A. ",
        "original_sentence": "Wayne, PA: Cinical and Laboratory Standard\n\n- 4. "
      }
    },
    {
      "chunk_id": "chunk_680",
      "text": "CLSI. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 679,
        "window_size": 3,
        "char_count": 6,
        "word_count": 1,
        "page_number": 74,
        "window_text": "User\n\nProtocol\n\nfor\n\nEvaluation\n\nof\n\nQualitative\n\nTest\n\nPerformance;\n\nApproved\n\nGuideline\n\n- -\nSecond\n\nEdition.\n\n CLSI\n\ndocument EP12-A2.  Wayne, PA: Cinical and Laboratory Standard\n\n- 4.  CLSI.  Protocols for Determination of Limits of Detection and\nLimits\n\nof Quantitation; Approved Guideline.\n\n CLSI document\n\nEP17-A.  Wayne, PA: Cinical and Laboratory Standard Institute; 2004\n\n- 5. ",
        "original_sentence": "CLSI. "
      }
    },
    {
      "chunk_id": "chunk_681",
      "text": "Protocols for Determination of Limits of Detection and\nLimits\n\nof Quantitation; Approved Guideline.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 680,
        "window_size": 3,
        "char_count": 101,
        "word_count": 13,
        "page_number": 14,
        "window_text": "CLSI\n\ndocument EP12-A2.  Wayne, PA: Cinical and Laboratory Standard\n\n- 4.  CLSI.  Protocols for Determination of Limits of Detection and\nLimits\n\nof Quantitation; Approved Guideline.\n\n CLSI document\n\nEP17-A.  Wayne, PA: Cinical and Laboratory Standard Institute; 2004\n\n- 5.  CLSI. ",
        "original_sentence": "Protocols for Determination of Limits of Detection and\nLimits\n\nof Quantitation; Approved Guideline.\n\n"
      }
    },
    {
      "chunk_id": "chunk_682",
      "text": "CLSI document\n\nEP17-A. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 681,
        "window_size": 3,
        "char_count": 23,
        "word_count": 3,
        "page_number": 6,
        "window_text": "Wayne, PA: Cinical and Laboratory Standard\n\n- 4.  CLSI.  Protocols for Determination of Limits of Detection and\nLimits\n\nof Quantitation; Approved Guideline.\n\n CLSI document\n\nEP17-A.  Wayne, PA: Cinical and Laboratory Standard Institute; 2004\n\n- 5.  CLSI.  Evaluation of the Linearity of Quantitative Measurement\nProcedures: A Statistical Approach; Approved Guideline. ",
        "original_sentence": "CLSI document\n\nEP17-A. "
      }
    },
    {
      "chunk_id": "chunk_683",
      "text": "Wayne, PA: Cinical and Laboratory Standard Institute; 2004\n\n- 5. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 682,
        "window_size": 3,
        "char_count": 65,
        "word_count": 10,
        "page_number": 14,
        "window_text": "CLSI.  Protocols for Determination of Limits of Detection and\nLimits\n\nof Quantitation; Approved Guideline.\n\n CLSI document\n\nEP17-A.  Wayne, PA: Cinical and Laboratory Standard Institute; 2004\n\n- 5.  CLSI.  Evaluation of the Linearity of Quantitative Measurement\nProcedures: A Statistical Approach; Approved Guideline.  CLSI\n\ndocument EP6-A. ",
        "original_sentence": "Wayne, PA: Cinical and Laboratory Standard Institute; 2004\n\n- 5. "
      }
    },
    {
      "chunk_id": "chunk_684",
      "text": "CLSI. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 683,
        "window_size": 3,
        "char_count": 6,
        "word_count": 1,
        "page_number": 74,
        "window_text": "Protocols for Determination of Limits of Detection and\nLimits\n\nof Quantitation; Approved Guideline.\n\n CLSI document\n\nEP17-A.  Wayne, PA: Cinical and Laboratory Standard Institute; 2004\n\n- 5.  CLSI.  Evaluation of the Linearity of Quantitative Measurement\nProcedures: A Statistical Approach; Approved Guideline.  CLSI\n\ndocument EP6-A.  Wayne, PA: Cinical and Laboratory Standard\n\nInstitute; 2003\n\nⅧ. ",
        "original_sentence": "CLSI. "
      }
    },
    {
      "chunk_id": "chunk_685",
      "text": "Evaluation of the Linearity of Quantitative Measurement\nProcedures: A Statistical Approach; Approved Guideline. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 684,
        "window_size": 3,
        "char_count": 112,
        "word_count": 13,
        "page_number": 14,
        "window_text": "CLSI document\n\nEP17-A.  Wayne, PA: Cinical and Laboratory Standard Institute; 2004\n\n- 5.  CLSI.  Evaluation of the Linearity of Quantitative Measurement\nProcedures: A Statistical Approach; Approved Guideline.  CLSI\n\ndocument EP6-A.  Wayne, PA: Cinical and Laboratory Standard\n\nInstitute; 2003\n\nⅧ.  참고문헌\n\n- - 69 -\n- 6. ",
        "original_sentence": "Evaluation of the Linearity of Quantitative Measurement\nProcedures: A Statistical Approach; Approved Guideline. "
      }
    },
    {
      "chunk_id": "chunk_686",
      "text": "CLSI\n\ndocument EP6-A. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 685,
        "window_size": 3,
        "char_count": 22,
        "word_count": 3,
        "page_number": 14,
        "window_text": "Wayne, PA: Cinical and Laboratory Standard Institute; 2004\n\n- 5.  CLSI.  Evaluation of the Linearity of Quantitative Measurement\nProcedures: A Statistical Approach; Approved Guideline.  CLSI\n\ndocument EP6-A.  Wayne, PA: Cinical and Laboratory Standard\n\nInstitute; 2003\n\nⅧ.  참고문헌\n\n- - 69 -\n- 6.  CLSI. ",
        "original_sentence": "CLSI\n\ndocument EP6-A. "
      }
    },
    {
      "chunk_id": "chunk_687",
      "text": "Wayne, PA: Cinical and Laboratory Standard\n\nInstitute; 2003\n\nⅧ. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 686,
        "window_size": 3,
        "char_count": 64,
        "word_count": 9,
        "page_number": 14,
        "window_text": "CLSI.  Evaluation of the Linearity of Quantitative Measurement\nProcedures: A Statistical Approach; Approved Guideline.  CLSI\n\ndocument EP6-A.  Wayne, PA: Cinical and Laboratory Standard\n\nInstitute; 2003\n\nⅧ.  참고문헌\n\n- - 69 -\n- 6.  CLSI.  Method Comparison and Bias Estimation Using Patient\nSamples;\n\nApproved\n\nGuideline\n\n- -\nSecond\n\nEdition\n\n(Interim\n\nRevision). ",
        "original_sentence": "Wayne, PA: Cinical and Laboratory Standard\n\nInstitute; 2003\n\nⅧ. "
      }
    },
    {
      "chunk_id": "chunk_688",
      "text": "참고문헌\n\n- - 69 -\n- 6. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 687,
        "window_size": 3,
        "char_count": 20,
        "word_count": 7,
        "page_number": 35,
        "window_text": "Evaluation of the Linearity of Quantitative Measurement\nProcedures: A Statistical Approach; Approved Guideline.  CLSI\n\ndocument EP6-A.  Wayne, PA: Cinical and Laboratory Standard\n\nInstitute; 2003\n\nⅧ.  참고문헌\n\n- - 69 -\n- 6.  CLSI.  Method Comparison and Bias Estimation Using Patient\nSamples;\n\nApproved\n\nGuideline\n\n- -\nSecond\n\nEdition\n\n(Interim\n\nRevision).  CLSI document EP9-A2-IR. ",
        "original_sentence": "참고문헌\n\n- - 69 -\n- 6. "
      }
    },
    {
      "chunk_id": "chunk_689",
      "text": "CLSI. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 688,
        "window_size": 3,
        "char_count": 6,
        "word_count": 1,
        "page_number": 74,
        "window_text": "CLSI\n\ndocument EP6-A.  Wayne, PA: Cinical and Laboratory Standard\n\nInstitute; 2003\n\nⅧ.  참고문헌\n\n- - 69 -\n- 6.  CLSI.  Method Comparison and Bias Estimation Using Patient\nSamples;\n\nApproved\n\nGuideline\n\n- -\nSecond\n\nEdition\n\n(Interim\n\nRevision).  CLSI document EP9-A2-IR.  Wayne, PA: Cinical and\n\n- 7. ",
        "original_sentence": "CLSI. "
      }
    },
    {
      "chunk_id": "chunk_690",
      "text": "Method Comparison and Bias Estimation Using Patient\nSamples;\n\nApproved\n\nGuideline\n\n- -\nSecond\n\nEdition\n\n(Interim\n\nRevision). ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 689,
        "window_size": 3,
        "char_count": 125,
        "word_count": 16,
        "page_number": 14,
        "window_text": "Wayne, PA: Cinical and Laboratory Standard\n\nInstitute; 2003\n\nⅧ.  참고문헌\n\n- - 69 -\n- 6.  CLSI.  Method Comparison and Bias Estimation Using Patient\nSamples;\n\nApproved\n\nGuideline\n\n- -\nSecond\n\nEdition\n\n(Interim\n\nRevision).  CLSI document EP9-A2-IR.  Wayne, PA: Cinical and\n\n- 7.  CLSI. ",
        "original_sentence": "Method Comparison and Bias Estimation Using Patient\nSamples;\n\nApproved\n\nGuideline\n\n- -\nSecond\n\nEdition\n\n(Interim\n\nRevision). "
      }
    },
    {
      "chunk_id": "chunk_691",
      "text": "CLSI document EP9-A2-IR. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 690,
        "window_size": 3,
        "char_count": 25,
        "word_count": 3,
        "page_number": 6,
        "window_text": "참고문헌\n\n- - 69 -\n- 6.  CLSI.  Method Comparison and Bias Estimation Using Patient\nSamples;\n\nApproved\n\nGuideline\n\n- -\nSecond\n\nEdition\n\n(Interim\n\nRevision).  CLSI document EP9-A2-IR.  Wayne, PA: Cinical and\n\n- 7.  CLSI.  Interference Testing in Clinical Chemistry; Approved\nGuideline - Second Edition. ",
        "original_sentence": "CLSI document EP9-A2-IR. "
      }
    },
    {
      "chunk_id": "chunk_692",
      "text": "Wayne, PA: Cinical and\n\n- 7. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 691,
        "window_size": 3,
        "char_count": 29,
        "word_count": 6,
        "page_number": 14,
        "window_text": "CLSI.  Method Comparison and Bias Estimation Using Patient\nSamples;\n\nApproved\n\nGuideline\n\n- -\nSecond\n\nEdition\n\n(Interim\n\nRevision).  CLSI document EP9-A2-IR.  Wayne, PA: Cinical and\n\n- 7.  CLSI.  Interference Testing in Clinical Chemistry; Approved\nGuideline - Second Edition.  CLSI document EP7-A. ",
        "original_sentence": "Wayne, PA: Cinical and\n\n- 7. "
      }
    },
    {
      "chunk_id": "chunk_693",
      "text": "CLSI. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 692,
        "window_size": 3,
        "char_count": 6,
        "word_count": 1,
        "page_number": 74,
        "window_text": "Method Comparison and Bias Estimation Using Patient\nSamples;\n\nApproved\n\nGuideline\n\n- -\nSecond\n\nEdition\n\n(Interim\n\nRevision).  CLSI document EP9-A2-IR.  Wayne, PA: Cinical and\n\n- 7.  CLSI.  Interference Testing in Clinical Chemistry; Approved\nGuideline - Second Edition.  CLSI document EP7-A.  Wayne, PA:\n\n- 8. ",
        "original_sentence": "CLSI. "
      }
    },
    {
      "chunk_id": "chunk_694",
      "text": "Interference Testing in Clinical Chemistry; Approved\nGuideline - Second Edition. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 693,
        "window_size": 3,
        "char_count": 81,
        "word_count": 10,
        "page_number": 14,
        "window_text": "CLSI document EP9-A2-IR.  Wayne, PA: Cinical and\n\n- 7.  CLSI.  Interference Testing in Clinical Chemistry; Approved\nGuideline - Second Edition.  CLSI document EP7-A.  Wayne, PA:\n\n- 8.  Guidance for Industry and FDA Staff: In Vitro Diagnostic (IVD)\n- 9. ",
        "original_sentence": "Interference Testing in Clinical Chemistry; Approved\nGuideline - Second Edition. "
      }
    },
    {
      "chunk_id": "chunk_695",
      "text": "CLSI document EP7-A. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 694,
        "window_size": 3,
        "char_count": 21,
        "word_count": 3,
        "page_number": 14,
        "window_text": "Wayne, PA: Cinical and\n\n- 7.  CLSI.  Interference Testing in Clinical Chemistry; Approved\nGuideline - Second Edition.  CLSI document EP7-A.  Wayne, PA:\n\n- 8.  Guidance for Industry and FDA Staff: In Vitro Diagnostic (IVD)\n- 9.  Guidance for industry and FDA staff/ Format for traditional and\n- 10. ",
        "original_sentence": "CLSI document EP7-A. "
      }
    },
    {
      "chunk_id": "chunk_696",
      "text": "Wayne, PA:\n\n- 8. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 695,
        "window_size": 3,
        "char_count": 17,
        "word_count": 4,
        "page_number": 14,
        "window_text": "CLSI.  Interference Testing in Clinical Chemistry; Approved\nGuideline - Second Edition.  CLSI document EP7-A.  Wayne, PA:\n\n- 8.  Guidance for Industry and FDA Staff: In Vitro Diagnostic (IVD)\n- 9.  Guidance for industry and FDA staff/ Format for traditional and\n- 10.  Linnet, K and Kondratovich, M. A Partly Noparametric Approach\nfor Determination of the Llimit of Detection. ",
        "original_sentence": "Wayne, PA:\n\n- 8. "
      }
    },
    {
      "chunk_id": "chunk_697",
      "text": "Guidance for Industry and FDA Staff: In Vitro Diagnostic (IVD)\n- 9. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 696,
        "window_size": 3,
        "char_count": 68,
        "word_count": 12,
        "page_number": 14,
        "window_text": "Interference Testing in Clinical Chemistry; Approved\nGuideline - Second Edition.  CLSI document EP7-A.  Wayne, PA:\n\n- 8.  Guidance for Industry and FDA Staff: In Vitro Diagnostic (IVD)\n- 9.  Guidance for industry and FDA staff/ Format for traditional and\n- 10.  Linnet, K and Kondratovich, M. A Partly Noparametric Approach\nfor Determination of the Llimit of Detection.  Clinical Chemistry\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 70 -\n<!-- PAGE_76 -->\n# Ⅸ\n\n<!-- PAGE_76 -->\n### 부록\n\n<!-- PAGE_76 -->\n###### 1. ",
        "original_sentence": "Guidance for Industry and FDA Staff: In Vitro Diagnostic (IVD)\n- 9. "
      }
    },
    {
      "chunk_id": "chunk_698",
      "text": "Guidance for industry and FDA staff/ Format for traditional and\n- 10. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 697,
        "window_size": 3,
        "char_count": 70,
        "word_count": 12,
        "page_number": 14,
        "window_text": "CLSI document EP7-A.  Wayne, PA:\n\n- 8.  Guidance for Industry and FDA Staff: In Vitro Diagnostic (IVD)\n- 9.  Guidance for industry and FDA staff/ Format for traditional and\n- 10.  Linnet, K and Kondratovich, M. A Partly Noparametric Approach\nfor Determination of the Llimit of Detection.  Clinical Chemistry\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 70 -\n<!-- PAGE_76 -->\n# Ⅸ\n\n<!-- PAGE_76 -->\n### 부록\n\n<!-- PAGE_76 -->\n###### 1.  뇌나트륨이뇨펩티드 제품 국내 제조 및 수입 현황\n\n면역분석법\n\nRoche CARDIAC proBNP+\n\nRoche\n\nGermany\n\nAQT90 FLEX NT-proBNP\n\nRadiometer\n\nDenmark\n\nⅨ. ",
        "original_sentence": "Guidance for industry and FDA staff/ Format for traditional and\n- 10. "
      }
    },
    {
      "chunk_id": "chunk_699",
      "text": "Linnet, K and Kondratovich, M. A Partly Noparametric Approach\nfor Determination of the Llimit of Detection. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 698,
        "window_size": 3,
        "char_count": 108,
        "word_count": 16,
        "page_number": 14,
        "window_text": "Wayne, PA:\n\n- 8.  Guidance for Industry and FDA Staff: In Vitro Diagnostic (IVD)\n- 9.  Guidance for industry and FDA staff/ Format for traditional and\n- 10.  Linnet, K and Kondratovich, M. A Partly Noparametric Approach\nfor Determination of the Llimit of Detection.  Clinical Chemistry\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 70 -\n<!-- PAGE_76 -->\n# Ⅸ\n\n<!-- PAGE_76 -->\n### 부록\n\n<!-- PAGE_76 -->\n###### 1.  뇌나트륨이뇨펩티드 제품 국내 제조 및 수입 현황\n\n면역분석법\n\nRoche CARDIAC proBNP+\n\nRoche\n\nGermany\n\nAQT90 FLEX NT-proBNP\n\nRadiometer\n\nDenmark\n\nⅨ.  부록\n\n- - 71 -\n<!-- PAGE_77 -->\n###### 3. ",
        "original_sentence": "Linnet, K and Kondratovich, M. A Partly Noparametric Approach\nfor Determination of the Llimit of Detection. "
      }
    },
    {
      "chunk_id": "chunk_700",
      "text": "Clinical Chemistry\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 70 -\n<!-- PAGE_76 -->\n# Ⅸ\n\n<!-- PAGE_76 -->\n### 부록\n\n<!-- PAGE_76 -->\n###### 1. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 699,
        "window_size": 3,
        "char_count": 152,
        "word_count": 29,
        "page_number": 76,
        "window_text": "Guidance for Industry and FDA Staff: In Vitro Diagnostic (IVD)\n- 9.  Guidance for industry and FDA staff/ Format for traditional and\n- 10.  Linnet, K and Kondratovich, M. A Partly Noparametric Approach\nfor Determination of the Llimit of Detection.  Clinical Chemistry\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 70 -\n<!-- PAGE_76 -->\n# Ⅸ\n\n<!-- PAGE_76 -->\n### 부록\n\n<!-- PAGE_76 -->\n###### 1.  뇌나트륨이뇨펩티드 제품 국내 제조 및 수입 현황\n\n면역분석법\n\nRoche CARDIAC proBNP+\n\nRoche\n\nGermany\n\nAQT90 FLEX NT-proBNP\n\nRadiometer\n\nDenmark\n\nⅨ.  부록\n\n- - 71 -\n<!-- PAGE_77 -->\n###### 3.  미국 FDA에 등록되어 있는 뇌나트륨이뇨펩티드(NT-proBNP,\n\n<!-- PAGE_77 -->\n###### BNP) 제품 목록 (2013년 9월 현재)\n\n**[표 시작]**\n\n**Document**\n| K051265 | 06/13/2005 | approved |\n**K092649**\n| K043584 | LIQUICHEK BNP CONTROL |\n| K073091 | VIDAS NT-PROBNP ASSAY | BIOMERIEUX, | INC. ",
        "original_sentence": "Clinical Chemistry\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 70 -\n<!-- PAGE_76 -->\n# Ⅸ\n\n<!-- PAGE_76 -->\n### 부록\n\n<!-- PAGE_76 -->\n###### 1. "
      }
    },
    {
      "chunk_id": "chunk_701",
      "text": "뇌나트륨이뇨펩티드 제품 국내 제조 및 수입 현황\n\n면역분석법\n\nRoche CARDIAC proBNP+\n\nRoche\n\nGermany\n\nAQT90 FLEX NT-proBNP\n\nRadiometer\n\nDenmark\n\nⅨ. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 700,
        "window_size": 3,
        "char_count": 120,
        "word_count": 19,
        "page_number": 14,
        "window_text": "Guidance for industry and FDA staff/ Format for traditional and\n- 10.  Linnet, K and Kondratovich, M. A Partly Noparametric Approach\nfor Determination of the Llimit of Detection.  Clinical Chemistry\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 70 -\n<!-- PAGE_76 -->\n# Ⅸ\n\n<!-- PAGE_76 -->\n### 부록\n\n<!-- PAGE_76 -->\n###### 1.  뇌나트륨이뇨펩티드 제품 국내 제조 및 수입 현황\n\n면역분석법\n\nRoche CARDIAC proBNP+\n\nRoche\n\nGermany\n\nAQT90 FLEX NT-proBNP\n\nRadiometer\n\nDenmark\n\nⅨ.  부록\n\n- - 71 -\n<!-- PAGE_77 -->\n###### 3.  미국 FDA에 등록되어 있는 뇌나트륨이뇨펩티드(NT-proBNP,\n\n<!-- PAGE_77 -->\n###### BNP) 제품 목록 (2013년 9월 현재)\n\n**[표 시작]**\n\n**Document**\n| K051265 | 06/13/2005 | approved |\n**K092649**\n| K043584 | LIQUICHEK BNP CONTROL |\n| K073091 | VIDAS NT-PROBNP ASSAY | BIOMERIEUX, | INC.  | 02/29/2008 |\n| K072189 | PATHFAST NTPROBNP AND | D-DIMER TESTS | helen landicho | 02/05/2008 |\n**K060632**\n| K060964 | ARCHITECT BNP ASSAY | diana l wolaniuk | 05/25/2006 |\n| DADE BEHRING, | INC. ",
        "original_sentence": "뇌나트륨이뇨펩티드 제품 국내 제조 및 수입 현황\n\n면역분석법\n\nRoche CARDIAC proBNP+\n\nRoche\n\nGermany\n\nAQT90 FLEX NT-proBNP\n\nRadiometer\n\nDenmark\n\nⅨ. "
      }
    },
    {
      "chunk_id": "chunk_702",
      "text": "부록\n\n- - 71 -\n<!-- PAGE_77 -->\n###### 3. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 701,
        "window_size": 3,
        "char_count": 40,
        "word_count": 10,
        "page_number": 77,
        "window_text": "Linnet, K and Kondratovich, M. A Partly Noparametric Approach\nfor Determination of the Llimit of Detection.  Clinical Chemistry\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 70 -\n<!-- PAGE_76 -->\n# Ⅸ\n\n<!-- PAGE_76 -->\n### 부록\n\n<!-- PAGE_76 -->\n###### 1.  뇌나트륨이뇨펩티드 제품 국내 제조 및 수입 현황\n\n면역분석법\n\nRoche CARDIAC proBNP+\n\nRoche\n\nGermany\n\nAQT90 FLEX NT-proBNP\n\nRadiometer\n\nDenmark\n\nⅨ.  부록\n\n- - 71 -\n<!-- PAGE_77 -->\n###### 3.  미국 FDA에 등록되어 있는 뇌나트륨이뇨펩티드(NT-proBNP,\n\n<!-- PAGE_77 -->\n###### BNP) 제품 목록 (2013년 9월 현재)\n\n**[표 시작]**\n\n**Document**\n| K051265 | 06/13/2005 | approved |\n**K092649**\n| K043584 | LIQUICHEK BNP CONTROL |\n| K073091 | VIDAS NT-PROBNP ASSAY | BIOMERIEUX, | INC.  | 02/29/2008 |\n| K072189 | PATHFAST NTPROBNP AND | D-DIMER TESTS | helen landicho | 02/05/2008 |\n**K060632**\n| K060964 | ARCHITECT BNP ASSAY | diana l wolaniuk | 05/25/2006 |\n| DADE BEHRING, | INC.  | 04/06/2006 |\n**K060548**\n| K051596 | NANOGEN, INC. ",
        "original_sentence": "부록\n\n- - 71 -\n<!-- PAGE_77 -->\n###### 3. "
      }
    },
    {
      "chunk_id": "chunk_703",
      "text": "미국 FDA에 등록되어 있는 뇌나트륨이뇨펩티드(NT-proBNP,\n\n<!-- PAGE_77 -->\n###### BNP) 제품 목록 (2013년 9월 현재)\n\n**[표 시작]**\n\n**Document**\n| K051265 | 06/13/2005 | approved |\n**K092649**\n| K043584 | LIQUICHEK BNP CONTROL |\n| K073091 | VIDAS NT-PROBNP ASSAY | BIOMERIEUX, | INC. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 702,
        "window_size": 3,
        "char_count": 252,
        "word_count": 43,
        "page_number": 77,
        "window_text": "Clinical Chemistry\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 70 -\n<!-- PAGE_76 -->\n# Ⅸ\n\n<!-- PAGE_76 -->\n### 부록\n\n<!-- PAGE_76 -->\n###### 1.  뇌나트륨이뇨펩티드 제품 국내 제조 및 수입 현황\n\n면역분석법\n\nRoche CARDIAC proBNP+\n\nRoche\n\nGermany\n\nAQT90 FLEX NT-proBNP\n\nRadiometer\n\nDenmark\n\nⅨ.  부록\n\n- - 71 -\n<!-- PAGE_77 -->\n###### 3.  미국 FDA에 등록되어 있는 뇌나트륨이뇨펩티드(NT-proBNP,\n\n<!-- PAGE_77 -->\n###### BNP) 제품 목록 (2013년 9월 현재)\n\n**[표 시작]**\n\n**Document**\n| K051265 | 06/13/2005 | approved |\n**K092649**\n| K043584 | LIQUICHEK BNP CONTROL |\n| K073091 | VIDAS NT-PROBNP ASSAY | BIOMERIEUX, | INC.  | 02/29/2008 |\n| K072189 | PATHFAST NTPROBNP AND | D-DIMER TESTS | helen landicho | 02/05/2008 |\n**K060632**\n| K060964 | ARCHITECT BNP ASSAY | diana l wolaniuk | 05/25/2006 |\n| DADE BEHRING, | INC.  | 04/06/2006 |\n**K060548**\n| K051596 | NANOGEN, INC.  03/13/2006 |\n\n**[표 끝]**\n\nK052789\n\nTRIAGE BNP TEST FOR\n\nBECKMAN COULTER\n\nIMMUNOASSAY SYSTEMS\n\nBIOSITE\n\nINCORPORATED 01/23/2006\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 72 -\nK051787\n\nTRIAGE BNP TEST\n\nBIOSITE\n\nINCORPORATED 09/22/2005\n\nADVIA IMMUNO MODULAR\n\nSYSTEM (IMS) B-TYPE\n\nNATRIURETIC PEPTIDE (BNP)\n\nASSAY\n\nⅨ. ",
        "original_sentence": "미국 FDA에 등록되어 있는 뇌나트륨이뇨펩티드(NT-proBNP,\n\n<!-- PAGE_77 -->\n###### BNP) 제품 목록 (2013년 9월 현재)\n\n**[표 시작]**\n\n**Document**\n| K051265 | 06/13/2005 | approved |\n**K092649**\n| K043584 | LIQUICHEK BNP CONTROL |\n| K073091 | VIDAS NT-PROBNP ASSAY | BIOMERIEUX, | INC. "
      }
    },
    {
      "chunk_id": "chunk_704",
      "text": "| 02/29/2008 |\n| K072189 | PATHFAST NTPROBNP AND | D-DIMER TESTS | helen landicho | 02/05/2008 |\n**K060632**\n| K060964 | ARCHITECT BNP ASSAY | diana l wolaniuk | 05/25/2006 |\n| DADE BEHRING, | INC. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 703,
        "window_size": 3,
        "char_count": 198,
        "word_count": 37,
        "page_number": 6,
        "window_text": "뇌나트륨이뇨펩티드 제품 국내 제조 및 수입 현황\n\n면역분석법\n\nRoche CARDIAC proBNP+\n\nRoche\n\nGermany\n\nAQT90 FLEX NT-proBNP\n\nRadiometer\n\nDenmark\n\nⅨ.  부록\n\n- - 71 -\n<!-- PAGE_77 -->\n###### 3.  미국 FDA에 등록되어 있는 뇌나트륨이뇨펩티드(NT-proBNP,\n\n<!-- PAGE_77 -->\n###### BNP) 제품 목록 (2013년 9월 현재)\n\n**[표 시작]**\n\n**Document**\n| K051265 | 06/13/2005 | approved |\n**K092649**\n| K043584 | LIQUICHEK BNP CONTROL |\n| K073091 | VIDAS NT-PROBNP ASSAY | BIOMERIEUX, | INC.  | 02/29/2008 |\n| K072189 | PATHFAST NTPROBNP AND | D-DIMER TESTS | helen landicho | 02/05/2008 |\n**K060632**\n| K060964 | ARCHITECT BNP ASSAY | diana l wolaniuk | 05/25/2006 |\n| DADE BEHRING, | INC.  | 04/06/2006 |\n**K060548**\n| K051596 | NANOGEN, INC.  03/13/2006 |\n\n**[표 끝]**\n\nK052789\n\nTRIAGE BNP TEST FOR\n\nBECKMAN COULTER\n\nIMMUNOASSAY SYSTEMS\n\nBIOSITE\n\nINCORPORATED 01/23/2006\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 72 -\nK051787\n\nTRIAGE BNP TEST\n\nBIOSITE\n\nINCORPORATED 09/22/2005\n\nADVIA IMMUNO MODULAR\n\nSYSTEM (IMS) B-TYPE\n\nNATRIURETIC PEPTIDE (BNP)\n\nASSAY\n\nⅨ.  부록\n\n문\n\n의\n\n처\n\n(우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187.\n\n",
        "original_sentence": "| 02/29/2008 |\n| K072189 | PATHFAST NTPROBNP AND | D-DIMER TESTS | helen landicho | 02/05/2008 |\n**K060632**\n| K060964 | ARCHITECT BNP ASSAY | diana l wolaniuk | 05/25/2006 |\n| DADE BEHRING, | INC. "
      }
    },
    {
      "chunk_id": "chunk_705",
      "text": "| 04/06/2006 |\n**K060548**\n| K051596 | NANOGEN, INC. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 704,
        "window_size": 3,
        "char_count": 53,
        "word_count": 9,
        "page_number": 6,
        "window_text": "부록\n\n- - 71 -\n<!-- PAGE_77 -->\n###### 3.  미국 FDA에 등록되어 있는 뇌나트륨이뇨펩티드(NT-proBNP,\n\n<!-- PAGE_77 -->\n###### BNP) 제품 목록 (2013년 9월 현재)\n\n**[표 시작]**\n\n**Document**\n| K051265 | 06/13/2005 | approved |\n**K092649**\n| K043584 | LIQUICHEK BNP CONTROL |\n| K073091 | VIDAS NT-PROBNP ASSAY | BIOMERIEUX, | INC.  | 02/29/2008 |\n| K072189 | PATHFAST NTPROBNP AND | D-DIMER TESTS | helen landicho | 02/05/2008 |\n**K060632**\n| K060964 | ARCHITECT BNP ASSAY | diana l wolaniuk | 05/25/2006 |\n| DADE BEHRING, | INC.  | 04/06/2006 |\n**K060548**\n| K051596 | NANOGEN, INC.  03/13/2006 |\n\n**[표 끝]**\n\nK052789\n\nTRIAGE BNP TEST FOR\n\nBECKMAN COULTER\n\nIMMUNOASSAY SYSTEMS\n\nBIOSITE\n\nINCORPORATED 01/23/2006\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 72 -\nK051787\n\nTRIAGE BNP TEST\n\nBIOSITE\n\nINCORPORATED 09/22/2005\n\nADVIA IMMUNO MODULAR\n\nSYSTEM (IMS) B-TYPE\n\nNATRIURETIC PEPTIDE (BNP)\n\nASSAY\n\nⅨ.  부록\n\n문\n\n의\n\n처\n\n(우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n",
        "original_sentence": "| 04/06/2006 |\n**K060548**\n| K051596 | NANOGEN, INC. "
      }
    },
    {
      "chunk_id": "chunk_706",
      "text": "03/13/2006 |\n\n**[표 끝]**\n\nK052789\n\nTRIAGE BNP TEST FOR\n\nBECKMAN COULTER\n\nIMMUNOASSAY SYSTEMS\n\nBIOSITE\n\nINCORPORATED 01/23/2006\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 72 -\nK051787\n\nTRIAGE BNP TEST\n\nBIOSITE\n\nINCORPORATED 09/22/2005\n\nADVIA IMMUNO MODULAR\n\nSYSTEM (IMS) B-TYPE\n\nNATRIURETIC PEPTIDE (BNP)\n\nASSAY\n\nⅨ. ",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 705,
        "window_size": 3,
        "char_count": 325,
        "word_count": 46,
        "page_number": 6,
        "window_text": "미국 FDA에 등록되어 있는 뇌나트륨이뇨펩티드(NT-proBNP,\n\n<!-- PAGE_77 -->\n###### BNP) 제품 목록 (2013년 9월 현재)\n\n**[표 시작]**\n\n**Document**\n| K051265 | 06/13/2005 | approved |\n**K092649**\n| K043584 | LIQUICHEK BNP CONTROL |\n| K073091 | VIDAS NT-PROBNP ASSAY | BIOMERIEUX, | INC.  | 02/29/2008 |\n| K072189 | PATHFAST NTPROBNP AND | D-DIMER TESTS | helen landicho | 02/05/2008 |\n**K060632**\n| K060964 | ARCHITECT BNP ASSAY | diana l wolaniuk | 05/25/2006 |\n| DADE BEHRING, | INC.  | 04/06/2006 |\n**K060548**\n| K051596 | NANOGEN, INC.  03/13/2006 |\n\n**[표 끝]**\n\nK052789\n\nTRIAGE BNP TEST FOR\n\nBECKMAN COULTER\n\nIMMUNOASSAY SYSTEMS\n\nBIOSITE\n\nINCORPORATED 01/23/2006\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 72 -\nK051787\n\nTRIAGE BNP TEST\n\nBIOSITE\n\nINCORPORATED 09/22/2005\n\nADVIA IMMUNO MODULAR\n\nSYSTEM (IMS) B-TYPE\n\nNATRIURETIC PEPTIDE (BNP)\n\nASSAY\n\nⅨ.  부록\n\n문\n\n의\n\n처\n\n(우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n",
        "original_sentence": "03/13/2006 |\n\n**[표 끝]**\n\nK052789\n\nTRIAGE BNP TEST FOR\n\nBECKMAN COULTER\n\nIMMUNOASSAY SYSTEMS\n\nBIOSITE\n\nINCORPORATED 01/23/2006\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 72 -\nK051787\n\nTRIAGE BNP TEST\n\nBIOSITE\n\nINCORPORATED 09/22/2005\n\nADVIA IMMUNO MODULAR\n\nSYSTEM (IMS) B-TYPE\n\nNATRIURETIC PEPTIDE (BNP)\n\nASSAY\n\nⅨ. "
      }
    },
    {
      "chunk_id": "chunk_707",
      "text": "부록\n\n문\n\n의\n\n처\n\n(우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187.\n\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 706,
        "window_size": 3,
        "char_count": 54,
        "word_count": 13,
        "page_number": 6,
        "window_text": "| 02/29/2008 |\n| K072189 | PATHFAST NTPROBNP AND | D-DIMER TESTS | helen landicho | 02/05/2008 |\n**K060632**\n| K060964 | ARCHITECT BNP ASSAY | diana l wolaniuk | 05/25/2006 |\n| DADE BEHRING, | INC.  | 04/06/2006 |\n**K060548**\n| K051596 | NANOGEN, INC.  03/13/2006 |\n\n**[표 끝]**\n\nK052789\n\nTRIAGE BNP TEST FOR\n\nBECKMAN COULTER\n\nIMMUNOASSAY SYSTEMS\n\nBIOSITE\n\nINCORPORATED 01/23/2006\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 72 -\nK051787\n\nTRIAGE BNP TEST\n\nBIOSITE\n\nINCORPORATED 09/22/2005\n\nADVIA IMMUNO MODULAR\n\nSYSTEM (IMS) B-TYPE\n\nNATRIURETIC PEPTIDE (BNP)\n\nASSAY\n\nⅨ.  부록\n\n문\n\n의\n\n처\n\n(우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n",
        "original_sentence": "부록\n\n문\n\n의\n\n처\n\n(우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187.\n\n"
      }
    },
    {
      "chunk_id": "chunk_708",
      "text": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n",
      "metadata": {
        "source": "(안내서-0638-02)체외진단용_시약_중_뇌나트륨이뇨펩티드_검사제품의_허가·심사_가이드라인.pdf",
        "chunk_index": 707,
        "window_size": 3,
        "char_count": 48,
        "word_count": 8,
        "page_number": 8,
        "window_text": "| 04/06/2006 |\n**K060548**\n| K051596 | NANOGEN, INC.  03/13/2006 |\n\n**[표 끝]**\n\nK052789\n\nTRIAGE BNP TEST FOR\n\nBECKMAN COULTER\n\nIMMUNOASSAY SYSTEMS\n\nBIOSITE\n\nINCORPORATED 01/23/2006\n\n체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n\n- - 72 -\nK051787\n\nTRIAGE BNP TEST\n\nBIOSITE\n\nINCORPORATED 09/22/2005\n\nADVIA IMMUNO MODULAR\n\nSYSTEM (IMS) B-TYPE\n\nNATRIURETIC PEPTIDE (BNP)\n\nASSAY\n\nⅨ.  부록\n\n문\n\n의\n\n처\n\n(우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187.\n\n 체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n",
        "original_sentence": "체외진단용 의료기기 중 심질환표지자 뇌나트륨이뇨펩티드 검사제품의 허가․심사 가이드라인\n"
      }
    }
  ],
  "chunking_analysis": {
    "total_chunks": 708,
    "avg_chunk_length": 83.12570621468926,
    "min_chunk_length": 3,
    "max_chunk_length": 889,
    "total_characters": 58853,
    "total_words": 13317,
    "window_size": 3
  },
  "statistics": {
    "total_text_blocks": 2732,
    "heading_count": 133,
    "paragraph_count": 890,
    "list_item_count": 217,
    "table_cell_count": 1492,
    "tables_detected": 9,
    "chunks_generated": 708
  }
}